PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Toms, AV; Kinsland, C; McCloskey, DE; Pegg, AE; Ealick, SE				Toms, AV; Kinsland, C; McCloskey, DE; Pegg, AE; Ealick, SE			Evolutionary links as revealed by the structure of Thermotoga maritima S-adenosylmethionine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT HISTIDINE-DECARBOXYLASE; ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; METHANOCOCCUS-JANNASCHII; PUTRESCINE STIMULATION; ESTER INTERMEDIATE; CRYSTAL-STRUCTURE; GENE DUPLICATION; PYRUVOYL ENZYMES; POLYAMINES	S-adenosylmethionine decarboxylase (AdoMetDC) is a critical regulatory enzyme of the polyamine biosynthetic pathway and belongs to a small class of pyruvoyl-dependent amino acid decarboxylases. Structural elucidation of the prokaryotic AdoMetDC is of substantial interest in order to determine the relationship between the eukaryotic and prokaryotic forms of the enzyme. Although both forms utilize pyruvoyl groups, there is no detectable sequence similarity except at the site of pyruvoyl group formation. The x-ray structure of the Thermatoga maritima AdoMetDC proenzyme reveals a dimeric protein fold that is remarkably similar to the eukaryotic AdoMetDC protomer, suggesting an evolutionary link between the two forms of the enzyme. Three key active site residues (Ser(55), His(68), and Cys(83)) involved in substrate binding, catalysis or proenzyme processing that were identified in the human and potato AdoMet-DCs are structurally conserved in the T. maritima AdoMetDC despite very limited primary sequence identity. The role of Ser(55), His(68), and Cys(83) in the self-processing reaction was investigated through site-directed mutagenesis. A homology model for the Escherichia coli AdoMetDC was generated based on the structures of the T. maritima and human AdoMetDCs.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ealick, SE (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	see3@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA018138, R37CA018138] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NCI NIH HHS [CA18138] Funding Source: Medline; NCRR NIH HHS [RR15301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albert A, 1998, NAT STRUCT BIOL, V5, P289, DOI 10.1038/nsb0498-289; Bennett EM, 2002, BIOCHEMISTRY-US, V41, P14509, DOI 10.1021/bi026710u; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Compaan DM, 2003, J EXP BIOL, V206, P1545, DOI 10.1242/jeb.00299; DIAZ E, 1991, BIOCHEMISTRY-US, V30, P4078, DOI 10.1021/bi00230a037; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; Ekstrom JL, 2001, BIOCHEMISTRY-US, V40, P9495, DOI 10.1021/bi010736o; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Franceschetti M, 2001, BIOCHEM J, V353, P403, DOI 10.1042/0264-6021:3530403; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HACKERT ML, 1997, COMPREHENSIVE BIOL C, P201; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Illingworth C, 2003, FEBS LETT, V549, P26, DOI 10.1016/S0014-5793(03)00756-7; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim AD, 2000, J BACTERIOL, V182, P6667, DOI 10.1128/JB.182.23.6667-6672.2000; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Li YF, 2001, P NATL ACAD SCI USA, V98, P10578, DOI 10.1073/pnas.181341198; Liu LJ, 2002, FEBS LETT, V528, P114, DOI 10.1016/S0014-5793(02)03264-7; MARKHAM GD, 1982, J BIOL CHEM, V257, P2063; MARTIRENOM MA, 2002, COMP PROTEIN STRUCTU; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schmitzberger F, 2003, EMBO J, V22, P6193, DOI 10.1093/emboj/cdg575; Sekowska A, 2000, MOL MICROBIOL, V36, P1135, DOI 10.1046/j.1365-2958.2000.01930.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tolbert WD, 2003, STRUCTURE, V11, P285, DOI 10.1016/S0969-2126(03)00026-1; Tolbert WD, 2003, BIOCHEMISTRY-US, V42, P2386, DOI 10.1021/bi0268854; Tolbert WD, 2001, BIOCHEMISTRY-US, V40, P9484, DOI 10.1021/bi010735w; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Xiong HS, 1999, J BIOL CHEM, V274, P35059, DOI 10.1074/jbc.274.49.35059; Xiong HS, 1997, J BIOL CHEM, V272, P28342, DOI 10.1074/jbc.272.45.28342; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	44	30	34	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33837	33846		10.1074/jbc.M403369200	http://dx.doi.org/10.1074/jbc.M403369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15150268	hybrid			2022-12-27	WOS:000223039700093
J	Hemonnot, B; Cartier, C; Gay, B; Rebuffat, S; Bardy, M; Devaux, C; Boyer, V; Briant, L				Hemonnot, B; Cartier, C; Gay, B; Rebuffat, S; Bardy, M; Devaux, C; Boyer, V; Briant, L			The host cell MAP kinase ERK-2 regulates viral assembly and release by phosphorylating the p6(gag) protein of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; GAG PROTEIN; MATRIX PROTEIN; NUCLEAR IMPORT; PARTICLE-SIZE; HUMAN HOMOLOG; POL PROTEINS; DOMAIN; INFECTIVITY	The host cell MAP kinase ERK-2 incorporated within human immunodeficiency virus type 1 particles plays a critical role in virus infectivity by phosphorylating viral proteins. Recently, a fraction of the virus incorporated late (L) domain-containing p6(gag) protein, which has an essential function in the release of viral particles from the cell surface, was reported to be phosphorylated by an unknown virus-associated cellular protein kinase (Muller, B., Patschinsky, T., and Krausslich, H. G. (2002) J. Virol. 76, 1015-1024). The present study demonstrates the contribution of the MAP kinase ERK-2 in p6(gag) phosphorylation. According to mutational analysis, a single ERK-2-phosphorylated threonine residue, belonging to a highly conserved phosphorylation MAP kinase consensus site, was identified at position 23 within p6(gag). Substitution by an alanine of the Thr(23) phosphorylable residue within the pNL4.3 molecular clone was found to decrease viral release from various cell types. As observed from electron microscopy experiments, most virions produced from this molecular clone remained incompletely separated from the host cell membrane with an immature morphology and displayed a reduced infectivity in single round infection experiments. Analysis of protein processing by Western blotting experiments revealed an incomplete Pr55(gag) maturation and a reduction in the virion-associated reverse transcriptase proteins was observed that was not related to differences in intracellular viral protein expression. Altogether, these data suggest that phosphorylation of p6(gag) protein by virus-associated ERK-2 is involved in the budding stage of HIV-1 life cycle.	Univ Montpellier I, Inst Biol, Lab Infect Retrovirales & Signalisat Cellulaire, CNRS,UMR 5121, F-34960 Montpellier 2, France; CHU La Tronche, INSERM EMI0108, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm)	Boyer, V (corresponding author), Univ Montpellier I, Inst Biol, Lab Infect Retrovirales & Signalisat Cellulaire, CNRS,UMR 5121, 4 Bd Henri IV,CS89508, F-34960 Montpellier 2, France.	laurence.briant@univ-montp1.fr	Briant, Laurence/AAB-9281-2021; Boyer, Veronique/E-6122-2017	Briant, Laurence/0000-0002-1995-3501; FAUVEL, Benedicte/0000-0003-1166-8391; Rebuffat, Sandra/0000-0002-1102-4935				Agostini I, 2000, EXP CELL RES, V259, P398, DOI 10.1006/excr.2000.4992; BRADAC J, 1984, VIROLOGY, V138, P260, DOI 10.1016/0042-6822(84)90350-7; Briant L, 1998, J IMMUNOL, V160, P1875; Briant L, 1996, J VIROL, V70, P5213, DOI 10.1128/JVI.70.8.5213-5220.1996; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; Bukrinskaya AG, 1996, P NATL ACAD SCI USA, V93, P367, DOI 10.1073/pnas.93.1.367; Cartier C, 1999, J BIOL CHEM, V274, P19434, DOI 10.1074/jbc.274.27.19434; Cartier C, 2003, J BIOL CHEM, V278, P35211, DOI 10.1074/jbc.M301257200; Cartier C, 1997, J VIROL, V71, P4832, DOI 10.1128/JVI.71.6.4832-4837.1997; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; CHARRET R, 1967, J MICROSC-PARIS, V6, P1063; Cimarelli A, 1999, J VIROL, V73, P5388, DOI 10.1128/JVI.73.7.5388-5401.1999; CLINTON GM, 1979, VIROLOGY, V99, P84, DOI 10.1016/0042-6822(79)90039-4; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Dettenhofer M, 1999, J VIROL, V73, P4696, DOI 10.1128/JVI.73.6.4696-4704.1999; Franke EK, 1996, VIROLOGY, V222, P279, DOI 10.1006/viro.1996.0421; FU XY, 1995, J GEN VIROL, V76, P3171, DOI 10.1099/0022-1317-76-12-3171; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Garnier L, 1999, J VIROL, V73, P2309, DOI 10.1128/JVI.73.3.2309-2320.1999; Garnier L, 1998, J VIROL, V72, P4667, DOI 10.1128/JVI.72.6.4667-4677.1998; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gupta K, 2000, J VIROL, V74, P11811, DOI 10.1128/JVI.74.24.11811-11824.2000; Gurer C, 2002, J VIROL, V76, P4666, DOI 10.1128/JVI.76.9.4666-4670.2002; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Hui EKW, 2002, CELL MOL LIFE SCI, V59, P920, DOI 10.1007/s00018-002-8479-6; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KUIKEN CL, 1999, HUMAN RETROVIRUSES A; Lama J, 1998, J VIROL, V72, P1671, DOI 10.1128/JVI.72.2.1671-1676.1998; Liu BD, 1999, J VIROL, V73, P2901, DOI 10.1128/JVI.73.4.2901-2908.1999; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; LUUKKONEN BGM, 1995, VIROLOGY, V206, P854, DOI 10.1006/viro.1995.1008; Martin-Serrano J, 2003, J VIROL, V77, P12373, DOI 10.1128/JVI.77.22.12373-12377.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Muller B, 2002, J VIROL, V76, P1015, DOI 10.1128/JVI.76.3.1015-1024.2002; Ott DE, 1998, J VIROL, V72, P2962, DOI 10.1128/JVI.72.4.2962-2968.1998; Ott DE, 2002, REV MED VIROL, V12, P359, DOI 10.1002/rmv.367; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; Peytavi R, 1999, J BIOL CHEM, V274, P1635, DOI 10.1074/jbc.274.3.1635; Radding W, 2000, AIDS RES HUM RETROV, V16, P1519, DOI 10.1089/088922200750006047; Rey O, 1996, VIROLOGY, V220, P530, DOI 10.1006/viro.1996.0343; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; SEN A, 1977, CELL, V10, P489; SEN A, 1977, CELL, V10, P91, DOI 10.1016/0092-8674(77)90143-X; Sherry B, 1998, P NATL ACAD SCI USA, V95, P1758, DOI 10.1073/pnas.95.4.1758; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tang Y, 1999, J VIROL, V73, P10508, DOI 10.1128/JVI.73.12.10508-10513.1999; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TRAUGER RJ, 1994, J INFECT DIS, V169, P1256, DOI 10.1093/infdis/169.6.1256; Tremblay MJ, 1998, IMMUNOL TODAY, V19, P346, DOI 10.1016/S0167-5699(98)01286-9; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wilk T, 1999, J VIROL, V73, P1931, DOI 10.1128/JVI.73.3.1931-1940.1999; Wilson SA, 1999, BIOCHEM J, V342, P97, DOI 10.1042/0264-6021:3420097; Yu XF, 1998, J VIROL, V72, P3412, DOI 10.1128/JVI.72.4.3412-3417.1998; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	64	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32426	32434		10.1074/jbc.M313137200	http://dx.doi.org/10.1074/jbc.M313137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155723	hybrid			2022-12-27	WOS:000222849700056
J	Yamasaki, M; Moriwaki, S; Miyake, O; Hashimoto, W; Murata, K; Mikami, B				Yamasaki, M; Moriwaki, S; Miyake, O; Hashimoto, W; Murata, K; Mikami, B			Structure and function of a hypothetical Pseudomonas aeruginosa protein PA1167 classified into family PL-7 - A novel alginate lyase with a beta-sandwich fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; CORYNEBACTERIUM SP; SEQUENCE-ANALYSIS; DIFFRACTION DATA; GENE; PURIFICATION; ACID	Structural and functional analyses of alginate lyases are important in the clarification of the biofilm-dependent ecosystem in Pseudomonas aeruginosa and in the development of therapeutic agents for bacterial disease. Most alginate lyases are classified into polysaccharide lyase (PL) family-5 and -7 based on their primary structures. Family PL-7 enzymes are still poorly characterized especially in structural properties. Among family PL-7, a gene coding for a hypothetical protein (PA1167) homologous to Sphingomonas alginate lyase A1-II was found to be present in the P. aeruginosa genome. PA1167 overexpressed in Escherichia coli cleaved glycosidic bonds in alginate and released unsaturated saccharides, indicating that PA1167 is an alginate lyase catalyzing a beta-elimination reaction. The enzyme acted preferably on heteropolymeric regions endolytically and worked most efficiently at pH 8.5 and 40 degreesC. The specific activity of PA1167, however, was much weaker than that of the known alginate lyase AlgL, suggesting that AlgL plays a main role in alginate depolymerization in P. aeruginosa. In addition to this specific activity, differences were found between PA1167 and AlgL in enzyme properties such as molecular mass, optimum pH, salt effect, and substrate specificity. The first crystal structure of the family PL-7 alginate lyase was determined at 2.0 Angstrom resolution. PA1167 was found to form a glove-like beta-sandwich composed of 15 beta-strands and 3 alpha-helices. The structural difference between the beta-sandwich PA1167 of family PL-7 and alpha/alpha-barrel AlgL of family PL-5 may be responsible for the enzyme characteristics. Crystal structures of polysaccharide lyases determined so far indicate that they can be assigned to three folding groups having parallel beta-helix, alpha/alpha-barrel, and alpha/alpha-barrel + antiparallel beta-sheet structures as basic frames. PA1167 is the fourth novel folding structure found among polysaccharide lyases.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Murata, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6110011, Japan.	kmurata@kais.kyoto-u.ac.jp						Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; BARON JS, 1994, BIOGEOCHEMISTRY, V27, P61, DOI 10.1007/BF00002571; BAYER AS, 1991, INFECT IMMUN, V59, P302, DOI 10.1128/IAI.59.1.302-308.1991; BODEY GP, 1983, REV INFECT DIS, V5, P279; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; BOYD A, 1994, APPL ENVIRON MICROB, V60, P2355, DOI 10.1128/AEM.60.7.2355-2359.1994; BOYD A, 1993, GENE, V131, P1, DOI 10.1016/0378-1119(93)90662-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; CHITNIS CE, 1993, MOL MICROBIOL, V8, P583, DOI 10.1111/j.1365-2958.1993.tb01602.x; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; DUNNE WM, 1985, APPL ENVIRON MICROB, V50, P562, DOI 10.1128/AEM.50.3.562-567.1985; EFTEKHAR F, 1988, INFECT IMMUN, V56, P2788, DOI 10.1128/IAI.56.11.2788-2793.1988; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GACESA P, 1988, CARBOHYD POLYM, V8, P161, DOI 10.1016/0144-8617(88)90001-X; Hamelryck TW, 1999, J MOL BIOL, V286, P1161, DOI 10.1006/jmbi.1998.2534; Hardalo C, 1997, CRIT REV MICROBIOL, V23, P47, DOI 10.3109/10408419709115130; Hashimoto W, 2003, J BIOL CHEM, V278, P7663, DOI 10.1074/jbc.M208100200; Hashimoto W, 1998, J FERMENT BIOENG, V86, P236, DOI 10.1016/S0922-338X(98)80120-7; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Jenkins J, 2004, J BIOL CHEM, V279, P9139, DOI 10.1074/jbc.M311390200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULCZYCKI LL, 1978, JAMA-J AM MED ASSOC, V240, P30, DOI 10.1001/jama.240.1.30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; LINKER A, 1984, J BACTERIOL, V159, P958, DOI 10.1128/JB.159.3.958-964.1984; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MALISSARD M, 1993, FEMS MICROBIOL LETT, V110, P101, DOI 10.1016/0378-1097(93)90249-2; Matsubara Y, 1998, J PROTEIN CHEM, V17, P29, DOI 10.1023/A:1022534429792; Matsubara Y, 2000, J BIOSCI BIOENG, V89, P199, DOI 10.1016/S1389-1723(00)88738-1; MAY TB, 1991, CLIN MICROBIOL REV, V4, P191, DOI 10.1128/CMR.4.2.191-206.1991; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Monday SR, 1996, J BACTERIOL, V178, P625, DOI 10.1128/jb.178.3.625-632.1996; Onsoyen E, 1996, CARBOHYDR EUR, V46, P26; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rehm BHA, 1997, APPL MICROBIOL BIOT, V48, P281, DOI 10.1007/s002530051051; Sakakibara H, 2002, J PHARM SCI, V91, P1191, DOI 10.1002/jps.10110; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILLER NL, 1993, J BACTERIOL, V175, P4780, DOI 10.1128/JB.175.15.4780-4789.1993; Schurks N, 2002, INT J BIOL MACROMOL, V30, P105, DOI 10.1016/S0141-8130(02)00002-8; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; Sugimura I, 2000, MAR BIOTECHNOL, V2, P65; Tsai LC, 2003, J MOL BIOL, V330, P607, DOI 10.1016/S0022-2836(03)00630-2; WARREN L, 1960, NATURE, V186, P237, DOI 10.1038/186237a0; WEISSBACH A, 1959, J BIOL CHEM, V234, P705; Wong TY, 2000, ANNU REV MICROBIOL, V54, P289, DOI 10.1146/annurev.micro.54.1.289; Yamasaki M, 2003, ACTA CRYSTALLOGR D, V59, P1499, DOI 10.1107/S0907444903012836; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; Yoon HJ, 2000, PROTEIN EXPRES PURIF, V19, P84, DOI 10.1006/prep.2000.1226; Yoon HJ, 1999, J MOL BIOL, V290, P505, DOI 10.1006/jmbi.1999.2883; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	61	102	108	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31863	31872		10.1074/jbc.M402466200	http://dx.doi.org/10.1074/jbc.M402466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15136569	hybrid			2022-12-27	WOS:000222726800113
J	Miranda, M; Sorkina, T; Grammatopoulos, TN; Zawada, WM; Sorkin, A				Miranda, M; Sorkina, T; Grammatopoulos, TN; Zawada, WM; Sorkin, A			Multiple molecular determinants in the carboxyl terminus regulate dopamine transporter export from endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER MICROSCOPY; RAT GABA TRANSPORTER-1; SEROTONIN TRANSPORTER; CYSTIC-FIBROSIS; LIVING CELLS; G-PROTEIN; TRAFFICKING; ER; DOMAIN; SIGNAL	The plasma membrane dopamine transporter (DAT) has an essential role in terminating dopaminergic neurotransmission by reuptake of dopamine into the presynaptic neurons. Therefore, the amount of DAT at the cell surface is a critical determinant of DAT function. In this study, we examined the role of the carboxyl terminus of DAT in trafficking of the transporter through the biosynthetic pathway to the plasma membrane. Live cell fluorescence microscopy and cell surface biotinylation were used to study the effects of systematic deletions and alanine substitutions in the carboxyl terminus on DAT localization. It was found that alanine substitutions of Lys-590 and Asp-600 significantly delayed the delivery of DAT to the plasma membrane because of retention of DAT in the endoplasmic reticulum (ER). Most surprising, mutation of Gly-585 to alanine completely blocked the exit of DAT from the ER and surface expression of the transporter. The effect of these three mutations on ER export of DAT was demonstrated in porcine aortic endothelial cells and the immortalized neuronal cell line 1RB(3)AN(27). In primary cultures of rat embryonic midbrain neurons, DAT G585A, K590A, and D600A mutants were restricted to the cell soma and did not traffic to the dendrites or axonal processes. These data are consistent with the model whereby the local conformation and/or intramolecular interactions of the sequences of the DAT carboxyl terminus proximal to the last transmembrane domain are essential for the ER export of the transporter.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Div Clin Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.	alexander.sorkin@uchsc.edu		Sorkin, Alexander/0000-0002-4446-1920; Grammatopoulos, Tom/0000-0001-7175-051X	NIDA NIH HHS [DA14204] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014204] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Bauman PA, 2002, ARCH BIOCHEM BIOPHYS, V404, P80, DOI 10.1016/S0003-9861(02)00232-1; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clarkson ED, 1998, P NATL ACAD SCI USA, V95, P1265, DOI 10.1073/pnas.95.3.1265; Cohen J, 2002, CURR OPIN NEUROBIOL, V12, P223, DOI 10.1016/S0959-4388(02)00314-8; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horton AC, 2003, NEURON, V40, P277, DOI 10.1016/S0896-6273(03)00629-9; Lee FJS, 1996, J BIOL CHEM, V271, P20885, DOI 10.1074/jbc.271.34.20885; Lin ZC, 2000, MOL PHARMACOL, V58, P1581, DOI 10.1124/mol.58.6.1581; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Nirenberg MJ, 1997, J NEUROSCI, V17, P5255; Nirenberg MJ, 1997, J NEUROSCI, V17, P6899; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Zawada WM, 2001, BRAIN RES, V891, P185; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	40	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30760	30770		10.1074/jbc.M312774200	http://dx.doi.org/10.1074/jbc.M312774200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128747	hybrid			2022-12-27	WOS:000222531900107
J	Pischon, N; Darbois, LM; Palamakumbura, AH; Kessler, E; Trackman, PC				Pischon, N; Darbois, LM; Palamakumbura, AH; Kessler, E; Trackman, PC			Regulation of collagen deposition and lysyl oxidase by tumor necrosis factor-alpha in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; BONE MORPHOGENETIC PROTEIN-1; SMOOTH-MUSCLE CELLS; TERMINAL PROTEINASE; ENHANCER PROTEIN; CROSS-LINKS; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; FLUOROMETRIC ASSAY; FORMATION INVITRO	Tumor necrosis factor-alpha (TNF-alpha) inhibits osteoblast function in vitro by inhibiting collagen deposition. Studies generally support that TNF-alpha does not inhibit collagen biosynthesis by osteoblasts but that collagen deposition is in some way diminished. The study investigated TNF-alpha regulation of biosynthetic enzymes and proteins crucial for posttranslational extracellular collagen maturation in osteoblasts including procollagen C-proteinases, procollagen C-proteinase enhancer, and lysyl oxidase. The working hypothesis is that such regulation could inhibit collagen deposition by osteoblasts. We report that in phenotypically normal MC3T3-E1 osteoblasts, TNF-alpha decreases collagen deposition without decreasing collagen mRNA levels or procollagen protein synthesis. Analyses of the cell layers revealed that TNF-alpha diminished the levels of mature collagen cross-links, pyridinoline and deoxypyridinoline. Further analyses revealed that the mRNA expression for lysyl oxidase, the determining enzyme required for collagen cross-linking, is down-regulated by TNF-alpha in a concentration- and time-dependent manner by up to 50%. The decrease was accompanied by a significant reduction of lysyl oxidase protein levels and enzyme activity. By contrast, Northern and Western blotting studies revealed that procollagen C-proteinases bone morphogenic protein-1 and mammalians Tolloid and procollagen C-proteinase enhancer were expressed in MC3T3-E1 cells and not down-regulated. The data together demonstrate that TNF-alpha does not inhibit collagen synthesis but does inhibit the expression and activity of lysyl oxidase in osteoblasts, thereby contributing to perturbed collagen cross-linking and accumulation. These studies identify a novel mechanism in which proinflammatory cytokine modulation of an extracellular biosynthetic enzyme plays a determining role in the control of collagen accumulation by osteoblasts.	Boston Univ, Div Oral Biol, Goldman Sch Dent Med, Dept Oral Biol, Boston, MA 02118 USA; Tel Aviv Univ, Sackler Fac Med, Maurice & Gabriela Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel	Boston University; Tel Aviv University; Sackler Faculty of Medicine	Trackman, PC (corresponding author), Boston Univ, Div Oral Biol, Goldman Sch Dent Med, Dept Oral Biol, 700 Albany St,W-210, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NIDCR NIH HHS [DE14066, DE12209] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012209] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahsan T, 1999, J ORTHOPAED RES, V17, P850, DOI 10.1002/jor.1100170610; BAILEY AJ, 1993, CONNECT TISSUE RES, V29, P119, DOI 10.3109/03008209309014239; BELDEKAS JC, 1981, BIOCHEMISTRY-US, V20, P2162, DOI 10.1021/bi00511a014; Bernocco S, 2003, J BIOL CHEM, V278, P7199, DOI 10.1074/jbc.M210857200; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BEUTLER B, 1988, ENDOCR REV, V9, P57, DOI 10.1210/edrv-9-1-57; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; Chou DHI, 1996, J IMMUNOL, V156, P4354; Delmas Pierre D., 1995, P319; DERENZIS FA, 1973, STAIN TECHNOL, V48, P135, DOI 10.3109/10520297309116602; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144; Gacheru SN, 1997, J CELL BIOCHEM, V65, P395, DOI 10.1002/(SICI)1097-4644(19970601)65:3<395::AID-JCB9>3.0.CO;2-N; Geiger BJ, 1933, J NUTR, V6, P427, DOI 10.1093/jn/6.5.427; GERSTENFELD LC, 1993, J BONE MINER RES, V8, P1031; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Graves DT, 1999, CLIN INFECT DIS, V28, P482, DOI 10.1086/515178; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Hong HH, 2004, J CELL PHYSIOL, V200, P53, DOI 10.1002/jcp.10476; Hong HH, 1999, LAB INVEST, V79, P1655; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004; Kostenuik PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE1133; Lathyrism Selye H, 1957, REV CAN BIOL, V16, P3; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LORENZO JA, 1992, MATRIX, V12, P282, DOI 10.1016/S0934-8832(11)80080-6; Mizutani A, 2001, J BONE MINER RES, V16, P2043, DOI 10.1359/jbmr.2001.16.11.2043; MohamedAli H, 1996, CELL TISSUE RES, V284, P509, DOI 10.1007/s004410050613; Ogata I, 1997, HEPATOLOGY, V26, P611, DOI 10.1002/hep.510260312; Oxlund H, 1996, BONE, V19, P479, DOI 10.1016/S8756-3282(96)00283-9; OXLUND H, 1995, BONE, V17, pS365, DOI 10.1016/8756-3282(95)00328-B; Pacifici R, 1996, J BONE MINER RES, V11, P1043; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; PANAGAKOS FS, 1994, INFLAMMATION, V18, P267, DOI 10.1007/BF01534268; PANAGAKOS FS, 1994, INFLAMMATION, V18, P243, DOI 10.1007/BF01534267; Panagakos FS, 1996, MOL CELL BIOCHEM, V158, P81; PANAGAKOS FS, 1995, INFLAMMATION, V19, P423, DOI 10.1007/BF01534577; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Scott IC, 1999, GENOMICS, V55, P229, DOI 10.1006/geno.1998.5663; Seyedin SM, 1990, CURR OPIN CELL BIOL, V2, P914, DOI 10.1016/0955-0674(90)90092-S; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Uchida M, 2000, J CELL PHYSIOL, V185, P207, DOI 10.1002/1097-4652(200011)185:2<207::AID-JCP5>3.0.CO;2-J; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VYTASEK R, 1982, ANAL BIOCHEM, V120, P243, DOI 10.1016/0003-2697(82)90342-6	60	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30060	30065		10.1074/jbc.M404208200	http://dx.doi.org/10.1074/jbc.M404208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138266	hybrid			2022-12-27	WOS:000222531900025
J	Nagata, R; Nishio, Y; Sekine, O; Nagai, Y; Maeno, Y; Ugi, S; Maegawa, H; Kashiwagi, A				Nagata, R; Nishio, Y; Sekine, O; Nagai, Y; Maeno, Y; Ugi, S; Maegawa, H; Kashiwagi, A			Single nucleotide polymorphism (-468 gly to ala) at the promoter region of sterol regulatory element-binding protein-1c associates with genetic defect of fructose-induced hepatic lipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; RAT HEPATOCYTES; TRANSGENIC MICE; CULTURED-CELLS; MESSENGER-RNA; EXPRESSION; TRANSCRIPTION; SREBP-1C; GLUCOSE; TISSUE	To evaluate the genetic susceptibility to metabolic disorders induced by high fructose diet, we investigated the metabolic characteristics in 10 strains of inbred mice and found that they were separated into CBA and DBA groups according to the response to high fructose diet. The hepatic mRNA expression of the sterol regulatory element-binding protein-1 (SREBP-1) in CBA/JN was remarkably enhanced by high fructose diet but not in DBA/2N. Similar results were observed in primary hepatocytes after exposure to fructose. The nucleotide sequence at - 468 bp from the putative starting point of the SREBP-1c gene was adenine in the DBA group while it was guanine in the CBA group. In hepatocytes from CBA/JN, the activity of CBA-SREBP-1c promoter was significantly increased by 2.4- and 2.2-fold, in response to 30 mM fructose or 10 nM insulin, respectively, whereas the activity of DBA-SREBP-1c promoter responded to insulin but not to fructose. In hepatocytes from DBA/2N, both types of SREBP-1c promoter activities in response to insulin were attenuated. Furthermore, electrophoretic mobility shift assay revealed an unidentified nuclear protein bound to the oligonucleotides made from the region between - 453 to - 480 bp of the SREBP-1c promoter of CBA/JN but not to the probe from DBA/2N. Thus, in DBA/2N, the reduced mRNA expression of SREBP-1 after fructose refeeding appeared to associate with two independent mechanisms, 1) loss of binding of unidentified proteins to the region between - 453 to - 480 bp of the SREBP-1c promoter and 2) impaired insulin stimulation of SREBP-1c promoter activity.	Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan	Shiga University of Medical Science	Nishio, Y (corresponding author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan.	nishio@belle.shiga-med.ac.jp	Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; Koya D, 1999, FASEB J, V13, P2329, DOI 10.1096/fasebj.13.15.2329; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001; Nishio Y, 1998, DIABETES, V47, P1318, DOI 10.2337/diabetes.47.8.1318; NISHIO Y, 1995, J CLIN INVEST, V96, P1759, DOI 10.1172/JCI118221; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Sekine M, 1997, J BIOL CHEM, V272, P27246, DOI 10.1074/jbc.272.43.27246; Sekine M, 2002, J BIOCHEM, V132, P387, DOI 10.1093/oxfordjournals.jbchem.a003234; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Shinozaki K, 1999, DIABETES, V48, P2437, DOI 10.2337/diabetes.48.12.2437; Shinozaki K, 2000, CIRC RES, V87, P566, DOI 10.1161/01.RES.87.7.566; SLEDER J, 1980, METABOLISM, V29, P303, DOI 10.1016/0026-0495(80)90001-3; STEINEGER HH, 1994, EUR J BIOCHEM, V225, P967, DOI 10.1111/j.1432-1033.1994.0967b.x; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; TENENHOUSE HS, 1995, AM J PHYSIOL-RENAL, V268, pF1062, DOI 10.1152/ajprenal.1995.268.6.F1062; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	29	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29031	29042		10.1074/jbc.M309449200	http://dx.doi.org/10.1074/jbc.M309449200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123654	hybrid			2022-12-27	WOS:000222445300026
J	Wang, HB; Faucette, S; Moore, R; Sueyoshi, T; Negishi, M; LeCluyse, E				Wang, HB; Faucette, S; Moore, R; Sueyoshi, T; Negishi, M; LeCluyse, E			Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY HUMAN HEPATOCYTES; RESPONSIVE ENHANCER MODULE; DRUG-METABOLISM; NUCLEAR TRANSLOCATION; XENOBIOTIC INDUCTION; PRIMARY CULTURE; MOUSE-LIVER; CAR; CYTOCHROME-P450; ACTIVATION	Compared with its rodent orthologs, little is known about the chemical specificity of human constitutive androstane receptor (hCAR) and its regulation of hepatic enzyme expression. Phenytoin (PHY), a widely used antiepileptic drug, is a potent inducer of CYP2B6 in primary human hepatocytes, but does not activate human pregnane X receptor (PXR) significantly in cell-based transfection assays at the same concentrations associated with potent induction of CYP2B6. Based on this observation, we hypothesized that PHY may be a selective activator of hCAR. In primary human hepatocytes, expression of CYP2B6 reporter genes containing phenobarbital-responsive enhancer module (PBREM) or PBREM/xenobiotic- responsive enhancer module (XREM) response elements were activated up to 14- and 28-fold, respectively, by 50 muM PHY. By contrast, parallel experiments in HepG2 cell lines co-transfected with an hPXR expression vector did not show increased reporter activity. These results indicated that a PXR-independent pathway, which is retained in primary hepatocytes, is responsible for PHY induction of CYP2B6. Further experiments revealed that PHY effectively translocates hCAR from the cytoplasm into the nucleus in both primary human hepatocytes and CAR(-/-) mice. Compared with vehicle controls, PHY administration significantly increased CYP2B6 reporter gene expression, when this reporter construct was delivered together with hCAR expression vector into CAR(-/-) mice. However, PHY did not increase reporter gene expression in CAR(-/-) mice in the absence of hCAR vector, implying that CAR is essential for mediating PHY induction of CYP2B6 gene expression. Taken together, these observations demonstrate that, in contrast to most of the known CYP2B6 inducers, PHY is a selective activator of CAR in humans.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	LeCluyse, E (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	ed_lecluyse@unc.edu	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; LeCluyse, Edward/0000-0002-2149-8990	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005, Z01ES080040] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK061652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bajpai M, 1996, DRUG METAB DISPOS, V24, P1401; Chang TKH, 1997, CANCER RES, V57, P1946; Ducharme MP, 1997, CANCER CHEMOTH PHARM, V40, P531, DOI 10.1007/s002800050698; Faucette SR, 2004, DRUG METAB DISPOS, V32, P348, DOI 10.1124/dmd.32.3.348; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Hamilton GA, 2001, CELL TISSUE RES, V306, P85; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Kakizaki S, 2003, BBA-GEN SUBJECTS, V1619, P239, DOI 10.1016/S0304-4165(02)00482-8; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Klaassen SL, 1998, ANN PHARMACOTHER, V32, P1295, DOI 10.1345/aph.17296; KOBAYASHI K, 2000, MOL PHARMACOL, V64, P1069; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Li AP, 1997, CHEM-BIOL INTERACT, V107, P5, DOI 10.1016/S0009-2797(97)00070-7; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; Makinen JM, 2002, MOL PHARMACOL, V62, P366, DOI 10.1124/mol.62.2.366; MANONESPAILLAT R, 1991, EPILEPSIA, V32, P96, DOI 10.1111/j.1528-1157.1991.tb05619.x; Maurel P, 1996, ADV DRUG DELIVER REV, V22, P105, DOI 10.1016/S0169-409X(96)00417-6; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; MOOTS PL, 1995, ARCH NEUROL-CHICAGO, V52, P717, DOI 10.1001/archneur.1995.00540310091021; Muangmoonchai R, 2001, BIOCHEM J, V355, P71, DOI 10.1042/0264-6021:3550071; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Patsalos PN, 2002, EPILEPSIA, V43, P365, DOI 10.1046/j.1528-1157.2002.13001.x; Raucy JL, 2003, DRUG METAB DISPOS, V31, P533, DOI 10.1124/dmd.31.5.533; Relling MV, 2000, LANCET, V356, P285, DOI 10.1016/S0140-6736(00)02503-4; Sahi J, 2000, XENOBIOTICA, V30, P273, DOI 10.1080/004982500237668; SPATZENEGGER M, 1995, DRUG METAB REV, V27, P397, DOI 10.3109/03602539508998329; Strom SC, 1996, METHOD ENZYMOL, V272, P388, DOI 10.1016/S0076-6879(96)72044-X; Sueyoshi T, 2002, METHOD ENZYMOL, V357, P205; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Ueda A, 2002, MOL PHARMACOL, V61, P1284, DOI 10.1124/mol.61.6.1284; Vecht CJ, 2003, LANCET NEUROL, V2, P404, DOI 10.1016/S1474-4422(03)00435-6; Wang HB, 2003, DRUG METAB DISPOS, V31, P620, DOI 10.1124/dmd.31.5.620; Wang HB, 2003, J BIOL CHEM, V278, P14146, DOI 10.1074/jbc.M212482200; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Williams ML, 1999, CHIRALITY, V11, P569; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Yoshinari K, 2001, MOL PHARMACOL, V59, P278, DOI 10.1124/mol.59.2.278; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001; Zelko I, 2000, BIOCHEM BIOPH RES CO, V277, P1, DOI 10.1006/bbrc.2000.3557	41	119	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29295	29301		10.1074/jbc.M400580200	http://dx.doi.org/10.1074/jbc.M400580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123723	Green Published, hybrid			2022-12-27	WOS:000222445300059
J	Kang, PJ; Lee, BY; Park, HO				Kang, PJ; Lee, BY; Park, HO			Specific residues of the GDP/GTP exchange factor Bud5p are involved in establishment of the cell type-specific budding pattern in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SELECTION; SACCHAROMYCES-CEREVISIAE; SPATIAL LANDMARK; GTPASE; PROTEINS; POLARITY; GENE; RAS; BUD1/RSR1; STRAINS	Cells of the budding yeast undergo oriented cell division by choosing a specific site for growth depending on their cell type. Haploid a and alpha cells bud in an axial pattern whereas diploid a/alpha cells bud in a bipolar pattern. The Ras-like GTPase Rsr1p/Bud1p, its GDP-GTP exchange factor Bud5p, and its GTPase- activating protein Bud2p are essential for selecting the proper site for polarized growth in all cell types. Here we showed that specific residues at the N terminus and the C terminus of Bud5p were important for bipolar budding, while some residues were involved in both axial and bipolar budding. These bipolar-specific mutations of BUD5 disrupted proper localization of Bud5p in diploid a/alpha cells without affecting Bud5p localization in haploid alpha cells. In contrast, Bud5p expressed in the bud5 mutants defective in both budding patterns failed to localize in all cell types. Thus, these results identify specific residues of Bud5p that are likely to be involved in direct interaction with spatial landmarks, which recruit Bud5p to the proper bud site. Finally, we found a new start codon of BUD5, which extends the open reading frame to 210 bp upstream of the previously estimated start site, thus encoding a polypeptide of 608 amino acid residues. Bud5p with these additional N-terminal residues interacted with Bud8p, a potential bipolar landmark, suggesting that the N-terminal region is necessary for recognition of the spatial cues.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Ohio State University	Park, HO (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12th Ave, Columbus, OH 43210 USA.	park.294@osu.edu		Park, Hay-Oak/0000-0001-5782-2257	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056997] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056997-05, R01 GM 56997, R01 GM056997] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Harkins HA, 2001, MOL BIOL CELL, V12, P2497, DOI 10.1091/mbc.12.8.2497; HICKS JB, 1977, GENETICS, V85, P373; Kang PJ, 2001, SCIENCE, V292, P1376, DOI 10.1126/science.1060360; Kozminski KG, 2003, MOL BIOL CELL, V14, P4958, DOI 10.1091/mbc.E03-06-0426; Marston AL, 2001, CURR BIOL, V11, P803, DOI 10.1016/S0960-9822(01)00230-5; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Schenkman LR, 2002, J CELL BIOL, V156, P829, DOI 10.1083/jcb.200107041; SIKORSKI RS, 1989, GENETICS, V122, P19; Taheri N, 2000, EMBO J, V19, P6686, DOI 10.1093/emboj/19.24.6686; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	22	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27980	27985		10.1074/jbc.C400175200	http://dx.doi.org/10.1074/jbc.C400175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15136576	hybrid			2022-12-27	WOS:000222265400020
J	Zhou, ZW; Yamamoto, Y; Sugai, F; Yoshida, K; Kishima, Y; Sumi, H; Nakamura, H; Sakoda, S				Zhou, ZW; Yamamoto, Y; Sugai, F; Yoshida, K; Kishima, Y; Sumi, H; Nakamura, H; Sakoda, S			Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; CHROMATIN PROTEIN; NEURITE OUTGROWTH; CELL-GROWTH; GENE FAMILY; SURVIVAL; BINDING; DNA; PROLIFERATION; AMPHOTERIN	Hepatoma-derived growth factor ( HDGF) is a heparin-binding proliferating factor originally isolated from conditioned medium of the hepatoma-derived cell line HuH-7. HDGF has greatest homology in an amino acid sequence with high mobility group 1 (HMG1), which has been characterized as a DNA-binding, inflammatory, and potent neurite outgrowth molecule. HDGF is reported to be widely expressed and act as a growth factor in many kinds of cells. However, it has not been investigated in the nervous system. Here, we show by Western blot analysis that HDGF is present in the mouse brain from the embryonic period until adulthood. In situ hybridization and immunohistochemical analyses revealed that HDGF was expressed mainly in neurons, and HDGF protein was localized to the nucleus. HDGF and high mobility group 1 were secreted under physiological conditions and released extracellularly in necrotic conditions. Furthermore, we showed that exogenously supplied HDGF had a neurotrophic effect and was able to partially prevent the cell death of neurons in which endogenous HDGF was suppressed. Therefore, we propose that HDGF is a novel type of neurotrophic factor, on account of its localization in the nucleus and its potential to function in an autocrine manner under both physiological and pathological conditions throughout life.	Osaka Univ, Dept Neurol, Grad Sch Med, Osaka 5650871, Japan; Osaka Univ, Dept Mol Med, Grad Sch Med, Osaka 5650871, Japan; Hyogo Med Univ, Div Hepatobiliary & Pancreat Med, Dept Internal Med, Nishinomiya, Hyogo 6638501, Japan	Osaka University; Osaka University; Hyogo College of Medicine; University of Hyogo	Yamamoto, Y (corresponding author), Osaka Univ, Dept Neurol, Grad Sch Med, D4,2-2 Yamada Oka, Osaka 5650871, Japan.	yamamoto@neurol.med.osaka-u.ac.jp						Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Black IB, 1999, J NEUROBIOL, V41, P108, DOI 10.1002/(SICI)1097-4695(199910)41:1<108::AID-NEU14>3.0.CO;2-U; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; Crossin KL, 1997, P NATL ACAD SCI USA, V94, P2687, DOI 10.1073/pnas.94.6.2687; deLapeyriere O, 1997, CURR OPIN GENET DEV, V7, P642, DOI 10.1016/S0959-437X(97)80012-3; Dietz F, 2002, BIOCHEM J, V366, P491, DOI 10.1042/BJ20011811; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Enomoto H, 2002, HEPATOLOGY, V36, P1519, DOI 10.1053/jhep.2002.36935; Everett AD, 2000, J CLIN INVEST, V105, P567, DOI 10.1172/JCI7497; Everett AD, 2001, J BIOL CHEM, V276, P37564, DOI 10.1074/jbc.M105109200; Everett AD, 2001, DEV DYNAM, V222, P450, DOI 10.1002/dvdy.1204; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Giehl KM, 2001, REV NEUROSCIENCE, V12, P79; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 2002, CANCER RES, V62, P4805; Ikegame K, 1999, BIOCHEM BIOPH RES CO, V266, P81, DOI 10.1006/bbrc.1999.1733; Izumoto Y, 1997, BIOCHEM BIOPH RES CO, V238, P26, DOI 10.1006/bbrc.1997.7233; Jankowsky JL, 1999, MOL CELL NEUROSCI, V14, P273, DOI 10.1006/mcne.1999.0792; Kishima Y, 2002, HEPATO-GASTROENTEROL, V49, P1639; Kishima Y, 2002, J BIOL CHEM, V277, P10315, DOI 10.1074/jbc.M111122200; Kuroda T, 1999, BIOCHEM BIOPH RES CO, V262, P433, DOI 10.1006/bbrc.1999.1115; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; NAKAMURA H, 1994, J BIOL CHEM, V269, P25143; Oliver JA, 1998, J CLIN INVEST, V102, P1208, DOI 10.1172/JCI785; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; Passalacqua M, 1997, FEBS LETT, V400, P275, DOI 10.1016/S0014-5793(96)01402-0; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Siegel GJ, 2000, BRAIN RES REV, V33, P199, DOI 10.1016/S0165-0173(00)00030-8; Singh DP, 2000, BIOCHEM BIOPH RES CO, V267, P373, DOI 10.1006/bbrc.1999.1979; Singh DP, 1999, INVEST OPHTH VIS SCI, V40, P1444; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Thoenen H, 2000, PROG BRAIN RES, V128, P183; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HC, 1999, SURGERY, V126, P389, DOI 10.1016/S0039-6060(99)70182-0; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Yamada K, 2002, LIFE SCI, V70, P735, DOI 10.1016/S0024-3205(01)01461-8; Yamamoto Y, 1997, DEVELOPMENT, V124, P2903	52	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27320	27326		10.1074/jbc.M308650200	http://dx.doi.org/10.1074/jbc.M308650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15140875	hybrid			2022-12-27	WOS:000222120400062
J	Jin, ZY; McDonald, ER; Dicker, DT; El-Deiry, WS				Jin, ZY; McDonald, ER; Dicker, DT; El-Deiry, WS			Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECOY RECEPTORS; MELANOMA-CELLS; KAPPA-B; FAMILY; DOMAIN; MEMBER; IDENTIFICATION; CLONING; METASTASIS; KILLER/DR5	Many tumor cell types are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- induced apoptosis. Incubation of TRAIL-sensitive cells with TRAIL invariably leads to resistant survivors even when high doses of TRAIL are used. Because the emergence of resistance to apoptosis is a major concern in successful treatment of cancer, and TRAIL survivors may contribute to therapeutic failure, we investigated potential resistance mechanisms. We selected TRAIL-resistant SW480 human colon adenocarcinoma cells by repeatedly treating them with high and/or low doses of TRAIL. The resulting TRAIL-resistant clones were not cross-resistant to Fas or paclitaxel. Expression of modulators of apoptosis was not changed in the resistant cells, including TRAIL receptors, cFLIP, Bax, Bid, or IAP proteins. Surprisingly, we found that DISC formation was deficient in multiple selected TRAIL-resistant clones. DR4 was not recruited to the DISC upon TRAIL treatment, and caspase-8 was not activated at the DISC. Although total cellular DR4 mRNA and protein were virtually identical in TRAIL-sensitive parental and TRAIL-resistant clones, DR4 protein expression on the cell surface was essentially undetectable in the TRAIL-resistant clones. Moreover, exogenous DR4 and KILLER/DR5 were not properly transported to the cell surface in the TRAIL-resistant cells. Interestingly, TRAIL-resistant cells were resensitized to TRAIL by tunicamycin pretreatment, which increased cell surface expression of DR4 and KILLER/DR5. Our data suggest that tumor cells may become resistant to TRAIL through regulation of the death receptor cell surface transport and that resistance to TRAIL may be overcome by the glycosylation inhibitor/endoplasmic reticulum stress-inducing agent tunicamycin.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Abramson Canc Ctr, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Dept Med, 415 Curie Blvd,CRB 437A, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Burns TF, 2001, J BIOL CHEM, V276, P37879; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Gaeta ML, 2000, LAB INVEST, V80, P1185, DOI 10.1038/labinvest.3780126; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Kim KH, 2000, CLIN CANCER RES, V6, P335; Lamothe B, 2002, J INTERF CYTOK RES, V22, P269, DOI 10.1089/107999002753536248; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; McDonald ER, 2001, J BIOL CHEM, V276, P14939, DOI 10.1074/jbc.M100399200; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang GQ, 2001, J BIOL CHEM, V276, P3610, DOI 10.1074/jbc.M006222200; WANG S, 2004, P NATL ACAD SCI USA, V100, P12095; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961	35	187	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35829	35839		10.1074/jbc.M405538200	http://dx.doi.org/10.1074/jbc.M405538200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15155747	hybrid			2022-12-27	WOS:000223303400084
J	Strom, CS; Liu, XY; Jia, ZC				Strom, CS; Liu, XY; Jia, ZC			Antifreeze protein-induced morphological modification mechanisms linked to ice binding surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM DIHYDROGEN PHOSPHATE; GRAPH-THEORETIC CONSTRUCTION; WINTER FLOUNDER ANTIFREEZE; PERIODIC BOND CHAINS; X-RAY-DIFFRACTION; CRYSTAL MORPHOLOGY; SOLVENT INTERACTION; STRUCTURAL BASIS; NUCLEATION; GROWTH	The mechanisms by which the antifreeze protein (AFP) modifies the ice morphology are identified precisely as surface poisoning by the ice binding surface (IBS) of insect AFPs and as bridge-induced surface reconstruction by the IBS of fish AFPs and antifreeze glycoproteins. The primary surfaces of hexagonal ice have predetermined face indices. The "two-dimensional" insect type IBS has regularly spaced binding intervals in two directions. It causes surface poisoning by matching and reinforcing simultaneously intersecting strong bonding directions on the primary ice surfaces. The secondary ice surfaces have variable face indices. The "one-dimensional" and "irregular" IBS variants of fish AFPs and antifreeze glycoproteins are either linearly extended with regular ice binding intervals or have ice binding sites lacking spacing regularity. These variants can bridge transversely lattice periods or shorter oxygen-oxygen distances between parallel adjacent strong bonding directions that do not intersect. Thus, one-dimensional and irregular IBS variants induce supplementary bridges cross-wise on selected secondary surfaces by mimicking strong bonding directions that are not present in the ice structure. These proteins cause surfaces with variable face indices, which in the absence of the AFPs would not grow flat, to appear in the morphology. Whereas for the primary ice surfaces it is only the morphological importance that is determined by the experimental conditions, for the secondary ice surfaces it is the face indices themselves that become adjusted in the process of maximizing the AFP-substrate interaction through attainment of the best structural match. The growth morphology of the AFP-ice system is derived from various factors, including the face indices, surface molecular compositions, relative growth rates, and the mechanisms responsible for that morphology. The theoretical formulation agrees with experiments over a wide range and resolves these, to date, unexplained phenomena.	Natl Univ Singapore, Fac Sci, Dept Phys, Biophys & Micronanostruct Lab, Singapore 117542, Singapore; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	National University of Singapore; Queens University - Canada	Liu, XY (corresponding author), Natl Univ Singapore, Fac Sci, Dept Phys, Biophys & Micronanostruct Lab, 2 Sci Dr 3, Singapore 117542, Singapore.	phyliuxy@nus.edu.sg	Zhou, Weiqian/B-8991-2011; Li, Jingliang/A-6039-2011; Liu, XY/E-5090-2010	Li, Jingliang/0000-0003-0709-2246; Liu, XY/0000-0002-4747-1251; Liu, Xiang-Yang/0000-0002-5592-6885				Antson AA, 2001, J MOL BIOL, V305, P875, DOI 10.1006/jmbi.2000.4336; Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Baardsnes J, 2002, BBA-PROTEINS PROTEOM, V1601, P49, DOI 10.1016/S1570-9639(02)00431-4; Dalal P, 2001, PHYSCHEMCOMM, DOI 10.1039/b101331i; Dalal P, 2000, J CHEM INF COMP SCI, V40, P1276, DOI 10.1021/ci000449b; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; Du N, 2003, J BIOL CHEM, V278, P36000, DOI 10.1074/jbc.M305222200; Ewart KV, 1996, J BIOL CHEM, V271, P16627, DOI 10.1074/jbc.271.28.16627; Graether SP, 2000, NATURE, V406, P325, DOI 10.1038/35018610; Graham LA, 1997, NATURE, V388, P727, DOI 10.1038/41908; HARTMAN P, 1956, ACTA CRYSTALLOGR, V9, P569, DOI 10.1107/S0365110X56001583; HARTMAN P, 1958, ACTA CRYSTALLOGR, V11, P365, DOI 10.1107/S0365110X58000967; Haymet ADJ, 1998, FEBS LETT, V430, P301, DOI 10.1016/S0014-5793(98)00652-8; Haymet ADJ, 2001, FEBS LETT, V491, P285, DOI 10.1016/S0014-5793(01)02213-X; Houston ME, 1998, J BIOL CHEM, V273, P11714, DOI 10.1074/jbc.273.19.11714; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; Knight CA, 2001, CRYST GROWTH DES, V1, P429, DOI 10.1021/cg015531t; KNIGHT CA, 1994, J CRYST GROWTH, V143, P301, DOI 10.1016/0022-0248(94)90071-X; Liu XY, 2004, J BIOL CHEM, V279, P6124, DOI 10.1074/jbc.M310487200; Miura K, 2001, J BIOL CHEM, V276, P1304, DOI 10.1074/jbc.M007902200; Mutaftschiev B., 1993, HDB CRYSTAL GROWTH, VI, P189; Ning D, 2002, APPL PHYS LETT, V81, P445, DOI 10.1063/1.1492849; Strom CS, 2000, J PHYS CHEM B, V104, P9638, DOI 10.1021/jp000883g; Strom CS, 2001, J CRYST GROWTH, V222, P298, DOI 10.1016/S0022-0248(00)00908-8; STROM CS, 1989, ACTA CRYSTALLOGR A, V45, P371, DOI 10.1107/S0108767389000395; STROM CS, 1980, Z KRISTALLOGR, V153, P99, DOI 10.1524/zkri.1980.0009; STROM CS, 1985, Z KRISTALLOGR, V172, P11, DOI 10.1524/zkri.1985.172.1-2.11; STROM CS, 1981, Z KRISTALLOGR, V154, P31, DOI 10.1524/zkri.1981.154.1-2.31; Strom CS, 1999, J PHYS CHEM B, V103, P11339, DOI 10.1021/jp992652j; STROM CS, 1999, MOL MODELING APPL CR, P228; VANDERVOORT E, 1991, J CRYST GROWTH, V112, P445, DOI 10.1016/0022-0248(91)90321-U; Wathen B, 2003, J AM CHEM SOC, V125, P729, DOI 10.1021/ja0267932; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; Wierzbicki A, 1997, J CHEM INF COMP SCI, V37, P1006, DOI 10.1021/ci9702353; Wilson PW, 2002, CRYOBIOLOGY, V44, P240, DOI 10.1016/S0011-2240(02)00028-7; WILSON PW, 1995, BIOPHYS J, V68, P2098, DOI 10.1016/S0006-3495(95)80389-9; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; Zhang W, 1999, FEBS LETT, V455, P372, DOI 10.1016/S0014-5793(99)00906-0	39	21	24	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32407	32417		10.1074/jbc.M401712200	http://dx.doi.org/10.1074/jbc.M401712200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15140895	hybrid			2022-12-27	WOS:000222849700054
J	Anest, V; Cogswell, PC; Baldwin, AS				Anest, V; Cogswell, PC; Baldwin, AS			I kappa B kinase alpha and p65/Re1A contribute to optimal epidermal growth factor-induced c-fos gene expression independent of I kappa B alpha degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; HISTONE H3; IKK-ALPHA; TRANSCRIPTIONAL ACTIVATION; COVALENT MODIFICATIONS; PHOSPHORYLATION; ELK-1; PHOSPHOACETYLATION; CELL	Mitogenic activation of expression of immediate-early genes, such as c-fos, is controlled through signal-induced phosphorylation of constitutively bound transcription factors that is correlated with a nucleosomal response that involves inducible chromatin modifications, such as histone phosphorylation and acetylation. Here we have explored a potential role for the transcription factor NF-kappaB and its associated signaling components in mediating induction of c-fos gene expression downstream of epidermal growth factor (EGF)-dependent signaling. Here we show that EGF treatment of quiescent fibroblast does not induce the classical pathway of NF-kappaB activation through IkappaB kinase (IKK)-directed IkappaBalpha phosphorylation. Interestingly, efficient induction of c-fos transcription requires IKKalpha, one of the subunits of the IkappaB kinase complex. The NF-kappaB subunit, p65/RelA, is found constitutively associated with the c-fos promoter, and knock-out of this transcription factor significantly reduces c-fos gene expression. Importantly, EGF induces the recruitment of IKKalpha to the c-fos promoter to regulate promoter-specific histone H3 Ser(10) phosphorylation in a manner that is independent of p65/RelA. Collectively, our data demonstrate that IKKalpha and p65/RelA contribute significantly to EGF-induced c-fos gene expression in a manner independent of the classical, IkappaBalpha degradation, p65/RelA nuclear accumulation response pathway.	Univ N Carolina, Lineberger Comprehens Canc Ctr 22 000, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr 22 000, Curriculum Genet & Mol Biol, CB 7295, Chapel Hill, NC 27599 USA.	jhall@med.unc.edu			NATIONAL CANCER INSTITUTE [R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73756] Funding Source: Medline; NIAID NIH HHS [R01 AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Murai K, 2002, MOL CELL BIOL, V22, P7083, DOI 10.1128/MCB.22.20.7083-7092.2002; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamauchi T, 2002, MOL CANCER THER, V1, P287; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	34	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31183	31189		10.1074/jbc.M404380200	http://dx.doi.org/10.1074/jbc.M404380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155743	Green Published, hybrid			2022-12-27	WOS:000222726800036
J	Morgan, K; Obici, S; Rossetti, L				Morgan, K; Obici, S; Rossetti, L			Hypothalamic responses to long-chain fatty acids are nutritionally regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6-PHOSPHATASE GENE-EXPRESSION; FOOD-INTAKE; BODY-WEIGHT; INSULIN-RESISTANCE; DIETARY OBESITY; GLUCOSE-PRODUCTION; LEPTIN ACTION; RATS; INHIBITION; LIVER	Central administration of the long-chain fatty acid oleic acid inhibits food intake and glucose production in rats. Here we examined whether short term changes in nutrient availability can modulate these metabolic and behavioral effects of oleic acid. Rats were divided in three groups receiving a highly palatable energy-dense diet at increasing daily caloric levels ( below, similar, or above the average of rats fed standard chow). Following 3 days on the assigned diet regimen, rats were tested for acute biological responses to the infusion of oleic acid in the third cerebral ventricle. Three days of overfeeding virtually obliterated the metabolic and anorectic effects of the central administration of oleic acid. Furthermore, the infusion of oleic acid in the third cerebral ventricle failed to decrease the expression of neuropeptide Y in the hypothalamus and of glucose-6-phosphatase in the liver following short term overfeeding. The lack of hypothalamic responses to oleic acid following short term overfeeding is likely to contribute to the rapid onset of weight gain and hepatic insulin resistance in this animal model.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, R01DK045024, R37DK048321, R29DK045024, R01DK048321] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20541, DK 45024, DK 48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSMAN LM, 1981, AM J PHYSIOL, V241, pR316, DOI 10.1152/ajpregu.1981.241.5.R316; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; BERTHOUD HR, 1979, ENDOCRINOLOGY, V105, P146, DOI 10.1210/endo-105-1-146; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; BRIEF DJ, 1984, BRAIN RES BULL, V12, P571, DOI 10.1016/0361-9230(84)90174-6; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; CLORE JN, 1995, J CLIN INVEST, V96, P1967, DOI 10.1172/JCI118243; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 2003, SCIENCE, V299, P856, DOI 10.1126/science.1079856; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; GOTO M, 1971, P SOC EXP BIOL MED, V136, P1294; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HALL JE, 1995, HYPERTENSION, V25, P994, DOI 10.1161/01.HYP.25.5.994; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; INOUE S, 1977, ENDOCRINOLOGY, V100, P108, DOI 10.1210/endo-100-1-108; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; Kopelman PG, 1998, LANCET, V352, P5; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MILLER JC, 1987, J NEUROCHEM, V49, P1507, DOI 10.1111/j.1471-4159.1987.tb01021.x; Neel JV, 1999, NUTR REV, V57, pS2, DOI 10.1111/j.1753-4887.1999.tb01782.x; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2002, J CLIN INVEST, V109, P1599, DOI 10.1172/JCI0215258; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Pagliassotti MJ, 1997, ANN NY ACAD SCI, V827, P431, DOI 10.1111/j.1749-6632.1997.tb51853.x; PITHA J, 1994, J PHARM SCI, V83, P833, DOI 10.1002/jps.2600830615; Porte D, 1998, DIABETOLOGIA, V41, P863, DOI 10.1007/s001250051002; Qi KM, 2002, CURR OPIN CLIN NUTR, V5, P133, DOI 10.1097/00075197-200203000-00003; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rapoport SI, 2001, J MOL NEUROSCI, V16, P243, DOI 10.1385/JMN:16:2-3:243; Rapoport SI, 1996, LIPIDS, V31, pS97, DOI 10.1007/BF02637059; Ravussin E, 1999, INT J OBESITY, V23, P37, DOI 10.1038/sj.ijo.0800793; REBRIN K, 1995, DIABETES, V44, P1038, DOI 10.2337/diabetes.44.9.1038; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; ROMSOS DR, 1978, P SOC EXP BIOL MED, V157, P528, DOI 10.3181/00379727-157-40090; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; SCHEMMEL R, 1970, J NUTR, V100, P1041; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SCLAFANI A, 1976, PHYSIOL BEHAV, V17, P461, DOI 10.1016/0031-9384(76)90109-8; SHIMAZU T, 1978, BRAIN RES, V144, P343, DOI 10.1016/0006-8993(78)90159-2; Shimazu T, 1996, NUTRITION, V12, P65; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786; Wang Q, 1997, DIABETES, V46, P335, DOI 10.2337/diabetes.46.3.335; WEST DB, 1995, AM J PHYSIOL-REG I, V268, pR658, DOI 10.1152/ajpregu.1995.268.3.R658; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; Widdowson PS, 1997, DIABETES, V46, P1782, DOI 10.2337/diabetes.46.11.1782; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; YAKSH TL, 1991, LIFE SCI, V48, P623, DOI 10.1016/0024-3205(91)90537-L; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	71	152	157	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31139	31148		10.1074/jbc.M400458200	http://dx.doi.org/10.1074/jbc.M400458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155754	hybrid			2022-12-27	WOS:000222726800030
J	Thomas, D; Blakqori, G; Wagner, V; Banholzer, M; Kessler, N; Elliott, RM; Haller, O; Weber, F				Thomas, D; Blakqori, G; Wagner, V; Banholzer, M; Kessler, N; Elliott, RM; Haller, O; Weber, F			Inhibition of RNA polymerase II phosphorylation by a viral interferon antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN NSS; INFLUENZA-A VIRUS; C-TERMINAL DOMAIN; VESICULAR STOMATITIS-VIRUS; NF-KAPPA-B; GENE-EXPRESSION; TRANSCRIPTION FACTOR; BINDING-PROTEIN; MATRIX PROTEIN; MOSQUITO CELLS	Many viruses subvert the cellular interferon (IFN) system with so-called IFN antagonists. Bunyamwera virus (BUNV) belongs to the family Bunyaviridae and is transmitted by arthropods. We have recently identified the nonstructural protein NSs of BUNV as a virulence factor that inhibits IFN-beta gene expression in the mammalian host. Here, we demonstrate that NSs targets the RNA polymerase II ( RNAP II) complex. The C-terminal domain (CTD) of RNAP II consists of 52 repeats of the consensus sequence YSPTSPS. Phosphorylation at serine 5 is required for efficient initiation of transcription, and subsequent phosphorylation at serine 2 is required for mRNA elongation and 3'-end processing. In BUNV-infected mammalian cells, serine 5 phosphorylation occurred normally. Furthermore, RNAP II was able to bind to the IFN-beta gene promoter as revealed by chromatin immunoprecipitation analysis, indicating that the initiation of transcription was not disturbed by NSs. However, NSs prevented CTD phosphorylation at serine 2, suggesting a block in transition from initiation to elongation. Surprisingly, no interference with CTD phosphorylation was observed in insect cells. Our results indicate that BUNV uses an unconventional mechanism to block IFN synthesis in the mammalian host by directly dysregulating RNAP II. Moreover, by inducing a general transcriptional block, NSs may contribute to the lytic infection observed in mammalian cells as opposed to persistent infection in the insect host.	Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany; Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland	University of Freiburg; University of Glasgow	Weber, F (corresponding author), Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany.	fweber@UKL.uni-freiburg.de	Weber, Friedemann/AAB-3425-2019; Thomas-Rüddel, Daniel/B-4380-2013	Thomas-Rüddel, Daniel/0000-0001-9143-8566; Weber, Friedemann/0000-0001-9737-337X				Ahmed M, 2003, J VIROL, V77, P4646, DOI 10.1128/JVI.77.8.4646-4657.2003; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001; Bridgen A, 2001, P NATL ACAD SCI USA, V98, P664, DOI 10.1073/pnas.98.2.664; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; CLARK ME, 1993, MOL CELL BIOL, V13, P1232, DOI 10.1128/MCB.13.2.1232; Colon-Ramos DA, 2003, MOL BIOL CELL, V14, P4162, DOI 10.1091/mbc.E03-03-0139; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; ELLIOTT RM, 1999, ENCY VIROLOGY, P212; Fong N, 2003, EMBO J, V22, P4274, DOI 10.1093/emboj/cdg396; FORTES P, 1994, EMBO J, V13, P704, DOI 10.1002/j.1460-2075.1994.tb06310.x; Gonzalez-Scarano F, 1996, VIROLOGY, P1473; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; HACKER D, 1989, J VIROL, V63, P5166, DOI 10.1128/JVI.63.12.5166-5174.1989; Han ZB, 2003, CURR BIOL, V13, P1921, DOI 10.1016/j.cub.2003.10.035; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; Hoque M, 2003, MOL CELL BIOL, V23, P1688, DOI 10.1128/MCB.23.5.1688-1702.2003; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P10096, DOI 10.1073/pnas.152327499; Kim MK, 1999, MOL CELL BIOL, V19, P6833; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Kohl A, 2003, J VIROL, V77, P7999, DOI 10.1128/JVI.77.14.7999-8008.2003; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KRUG RM, 1989, INFLUENZA VIRUSES, P89; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Le May N, 2004, CELL, V116, P541, DOI 10.1016/S0092-8674(04)00132-1; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; Ludwig S, 2002, J VIROL, V76, P11166, DOI 10.1128/JVI.76.21.11166-11171.2002; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Patturajan M, 1999, J BIOL CHEM, V274, P27823, DOI 10.1074/jbc.274.39.27823; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; RAJU R, 1988, J VIROL, V62, P27, DOI 10.1128/JVI.62.1.27-32.1988; ROSSIER C, 1988, VIROLOGY, V165, P539, DOI 10.1016/0042-6822(88)90598-3; SCALLAN MF, 1992, J GEN VIROL, V73, P53, DOI 10.1099/0022-1317-73-1-53; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; WATRET GE, 1985, J GEN VIROL, V66, P473, DOI 10.1099/0022-1317-66-3-473; Weber F, 2003, J INTERF CYTOK RES, V23, P209, DOI 10.1089/107999003765027410; Weber F, 2002, J VIROL, V76, P7949, DOI 10.1128/JVI.76.16.7949-7955.2002; Weber F, 2002, VIRUS RES, V88, P129, DOI 10.1016/S0168-1702(02)00125-9; Weber F, 2001, VIROLOGY, V281, P67, DOI 10.1006/viro.2000.0774; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yuan H, 1998, VIROLOGY, V251, P383, DOI 10.1006/viro.1998.9413; Zhang F, 2003, GENE DEV, V17, P748, DOI 10.1101/gad.1068203	61	101	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31471	31477		10.1074/jbc.M400938200	http://dx.doi.org/10.1074/jbc.M400938200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150262	hybrid			2022-12-27	WOS:000222726800069
J	Palomba, L; Persichini, T; Mazzone, V; Colasanti, M; Cantoni, O				Palomba, L; Persichini, T; Mazzone, V; Colasanti, M; Cantoni, O			Inhibition of nitric-oxide synthase-I (NOS-I)-dependent nitric oxide production by lipopolysaccharide plus interferon-gamma is mediated by arachidonic acid - Effects on NF kappa B activation and late inducible NOS expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); CELL-LINE; PROTECTS; BINDING; PHOSPHORYLATION; PATHWAY	Previous results have indicated that lipopolysaccharide (LPS) plus interferon-gamma (IFNgamma) inhibits nitric-oxide synthase (NOS)-I activity in glial cells. We report here that arachidonic acid ( AA) plays a pivotal role in this response, which was consistently reproduced in different glial cell lines and in primary rat astrocytes. This notion was established using pharmacological inhibitors of phospholipase A(2) (PLA(2)), cytosolic PLA(2) (cPLA(2)) antisense oligonucleotides, and AA add-back experiments. This approach not only allowed the demonstration that AA promotes inhibition of NOS-I activity but also produced novel experimental evidence that LPS/IFNgamma itself is a potential stimulus for NOS-I. Indeed, LPS/IFNgamma fails to generate nitric oxide (NO) via NOS-I activation simply because it activates the AA-dependent signal that impedes NOS-I activity. Otherwise, LPS/IFNgamma promotes NO formation, sensitive to exogenous AA, in cells in which cPLA(2) is pharmacologically inhibited or genetically depleted. Because NO suppresses the NFkappaB-dependent NOS-II expression, inactivation of NOS-I by the LPS/IFNgamma-induced AA pathway provides optimal conditions for NFkappaB activation and subsequent NOS-II expression. Inhibition of cPLA(2) activity, while reducing the availability of AA, consistently inhibited NFkappaB activation and NOS-II mRNA induction and delayed NO formation. These responses were promptly re-established by addition of exogenous AA. Finally, we have demonstrated that the LPS/IFNgamma-dependent tyrosine phosphorylation of NOS-I and inhibition of its activity are mediated by endogenous AA.	Univ Roma Tre, Dipartimento Biol, I-00146 Rome, Italy; Univ Urbino Carlo Bo, Ist Farmacol & Farmacognosia, I-61029 Urbino, Italy	Roma Tre University; University of Urbino	Colasanti, M (corresponding author), Univ Roma Tre, Dipartimento Biol, Viale Marconi 446, I-00146 Rome, Italy.	colasant@uniroma3.it	COLASANTI, MARCO/A-5616-2010	COLASANTI, MARCO/0000-0002-5752-4943; PERSICHINI, TIZIANA/0000-0001-8291-6706				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciani E, 2002, J BIOL CHEM, V277, P49896, DOI 10.1074/jbc.M206177200; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Colasanti M, 1998, BIOCHEM BIOPH RES CO, V246, P453, DOI 10.1006/bbrc.1998.8642; Colasanti M, 1999, J BIOL CHEM, V274, P9915, DOI 10.1074/jbc.274.15.9915; Colasanti M, 1997, J BIOL CHEM, V272, P7582, DOI 10.1074/jbc.272.12.7582; Colasanti M, 2000, BRAIN RES BULL, V52, P155, DOI 10.1016/S0361-9230(00)00262-8; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; DUGAN LL, 1995, J NEUROSCI, V15, P4545; GOLDRING CEP, 1995, BIOCHEM BIOPH RES CO, V209, P73, DOI 10.1006/bbrc.1995.1472; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MONCADA S, 1991, PHARMACOL REV, V43, P109; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Palomba L, 2004, FREE RADICAL BIO MED, V36, P319, DOI 10.1016/j.freeradbiomed.2003.10.026; Robb SJ, 2002, ANN NY ACAD SCI, V962, P93, DOI 10.1111/j.1749-6632.2002.tb04059.x; Rose K., 1992, METHODS TOXICOLOGY, V1, P46, DOI DOI 10.1371/J0URNAL.P0NE.0006591; Suzuki H, 2001, CIRCULATION, V103, pE81; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Visnjic D, 1997, BLOOD, V89, P81, DOI 10.1182/blood.V89.1.81.81_81_91; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	24	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29895	29901		10.1074/jbc.M312768200	http://dx.doi.org/10.1074/jbc.M312768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15148326	hybrid, Green Published			2022-12-27	WOS:000222531900005
J	Puig, S; Lau, M; Thiele, DJ				Puig, S; Lau, M; Thiele, DJ			Cti6 is an Rpd3-Sin3 histone deacetylase-associated protein required for growth under iron-limiting conditions in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; IN-VIVO; SCHIZOSACCHAROMYCES-POMBE; INTEGRAL COMPONENT; SIDEROPHORE UPTAKE; COPPER TRANSPORT; PHD DOMAIN; CELL-WALL; YEAST	Iron and copper are redox active metals essential for life. In the budding yeast Saccharomyces cerevisiae, expression of iron and copper genes involved in metal acquisition and utilization is tightly regulated at the transcriptional level. In addition iron and copper metabolism are inextricably linked because of the dependence on copper as a co-factor for iron uptake or mobilization. To further identify genes that function in iron and copper homeostasis, we screened for novel yeast mutants defective for iron limiting growth and thereby identified the CTI6 gene. Cti6 is a PHD finger-containing protein that has been shown to participate in the interaction of the Ssn6-Tup1 co-repressor with the Gcn5-containing SAGA chromatin-remodeling complex. In this report we show that CTI6 mRNA levels are increased under iron-limiting conditions, and that cti6 mutants display a growth defect under conditions of iron deprivation. Furthermore, we demonstrate that Cti6 is a nuclear protein that functionally associates with the Rpd3-Sin3 histone deacetylase complex involved in transcriptional repression. Cti6 demonstrates Rpd3-dependent transcriptional repression, and cti6 mutants exhibit an enhanced silencing of telomeric, rDNA and HMR loci, similar to mutants in genes encoding other Rpd3-Sin3-associated proteins. Microarray experiments with cti6 mutants grown under iron-limiting conditions show a down-regulation of telomeric genes and an up-regulation of Aft1 and Tup1 target genes involved in iron and oxygen regulation. Taken together, these data suggest a specific role for Cti6 in the regulation of gene expression under conditions of iron limitation.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA	University of Michigan System; University of Michigan; Duke University	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dennis.thiele@duke.edu	Puig, Sergi/E-4788-2010	Puig, Sergi/0000-0002-1856-490X	NIGMS NIH HHS [GM48140] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Abramova NE, 2001, GENETICS, V157, P1169; Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; Dorland S, 2000, GENETICS, V154, P573; Ducker CE, 2000, EMBO J, V19, P400, DOI 10.1093/emboj/19.3.400; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Fragiadakis GS, 2004, EMBO J, V23, P333, DOI 10.1038/sj.emboj.7600043; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Georgatsou E, 1999, YEAST, V15, P573, DOI 10.1002/(SICI)1097-0061(199905)15:7<573::AID-YEA404>3.3.CO;2-Z; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Lesuisse E, 2002, YEAST, V19, P329, DOI 10.1002/yea.840; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2002, BIOCHEM J, V362, P119, DOI 10.1042/bj3620119; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Protchenko O, 2003, J BIOL CHEM, V278, P36582, DOI 10.1074/jbc.M306584200; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rachidi N, 2000, MOL MICROBIOL, V35, P1421, DOI 10.1046/j.1365-2958.2000.01807.x; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stubble J, 2003, CURR OPIN CHEM BIOL, V7, P183, DOI 10.1016/S1367-5931(03)00025-5; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wright R, 2003, YEAST, V20, P881, DOI 10.1002/yea.994; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1; Znaidi S, 2004, J BIOL CHEM, V279, P9462, DOI 10.1074/jbc.M312787200	61	33	34	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30298	30306		10.1074/jbc.M313463200	http://dx.doi.org/10.1074/jbc.M313463200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133041	hybrid			2022-12-27	WOS:000222531900055
J	Rouanet, C; Reverchon, S; Rodionov, DA; Nasser, W				Rouanet, C; Reverchon, S; Rodionov, DA; Nasser, W			Definition of a consensus DNA-binding site for PecS, a global regulator of virulence gene expression in Erwinia chrysanthemi and identification of new members of the PecS regulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-ANTIBIOTIC-RESISTANCE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; PECTINOLYSIS GENES; PECTATE LYASES; BLUE PIGMENT; REPRESSOR; TRANSCRIPTION	In Erwinia chrysanthemi, production of pectic enzymes is modulated by a complex network involving several regulators. One of them, PecS, which belongs to the MarR family, also controls the synthesis of various other virulence factors, such as cellulases and indigoidine. Here, the PecS consensus-binding site is defined by combining a systematic evolution of ligands by an exponential enrichment approach and mutational analyses. The consensus consists of a 23-base pair palindromic-like sequence (C(-11)G(-10)A(-9)N(-8)W(-7)T(-6)C(-5)G(-4) T(-3)A(-2))T(-1)A(0)T(1)(T(2)A(3)C(4)G(5)A(6)N(7)N(8)N(9)C(10)G(11)). Mutational experiments revealed that (i) the palindromic organization is required for the binding of PecS, (ii) the very conserved part of the consensus (-6 to 6) allows for a specific interaction with PecS, but the presence of the relatively degenerated bases located apart significantly increases PecS affinity, (iii) the four bases G(-4), A(-2), T-2, and C-4 are required for efficient binding of PecS, and (iv) the presence of several binding sites on the same promoter increases the affinity of PecS. This consensus is detected in the regions involved in PecS binding on the previously characterized target genes. This variable consensus is in agreement with the observation that the members of the MarR family are able to bind various DNA targets as dimers by means of a winged helix DNA-binding motif. Binding of PecS on a promoter region containing the defined consensus results in a repression of gene transcription in vitro. Preliminary scanning of the E. chrysanthemi genome sequence with the consensus revealed the presence of strong PecS-binding sites in the intergenic region between fliE and fliFGHIJKLMNOPQR which encode proteins involved in the biogenesis of flagellum. Accordingly, PecS directly represses fliE expression. Thus, PecS seems to control the synthesis of virulence factors required for the key steps of plant infection.	Univ Lyon 1, Inst Natl Sci Appl, CNRS, Unite Mixte Rech 5122,Unite Microbiol & Genet, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Nasser, W (corresponding author), Univ Lyon 1, Inst Natl Sci Appl, CNRS, Unite Mixte Rech 5122,Unite Microbiol & Genet, F-69622 Villeurbanne, France.	William.nasser@insa-lyon.fr	NASSER, William/C-9611-2019; Sylvie, Reverchon/P-7932-2016; Rodionov, Dmitry/V-2688-2018	NASSER, William/0000-0001-9848-3597; Sylvie, Reverchon/0000-0002-0478-3474; Rouanet, Carine/0000-0001-9105-1855; Rodionov, Dmitry/0000-0002-0939-390X				Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; BAILEY TL, 1994, ISMB, V2, P28; BAUER DW, 1994, MOL PLANT MICROBE IN, V7, P573, DOI 10.1094/MPMI-7-0573; Buchmeier N, 1997, INFECT IMMUN, V65, P3725, DOI 10.1128/IAI.65.9.3725-3730.1997; Chesnokova O, 1997, MOL MICROBIOL, V23, P579, DOI 10.1046/j.1365-2958.1997.d01-1875.x; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Claret L, 2002, J MOL BIOL, V321, P185, DOI 10.1016/S0022-2836(02)00600-9; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; Condemine G, 1999, MOL PLANT MICROBE IN, V12, P45, DOI 10.1094/MPMI.1999.12.1.45; ELHASSOUNI ME, P NATL ACAD SCI US, V96, P887; Evans K, 1998, J BACTERIOL, V180, P5443, DOI 10.1128/JB.180.20.5443-5447.1998; EXPERT D, 1985, J BACTERIOL, V163, P221, DOI 10.1128/JB.163.1.221-227.1985; Hugouvieux-Cotte-Pattat N, 2002, J BACTERIOL, V184, P2664, DOI 10.1128/JB.184.10.2664-2673.2002; HugouvieuxCottePattat N, 1996, ANNU REV MICROBIOL, V50, P213, DOI 10.1146/annurev.micro.50.1.213; Josenhans C, 2002, INT J MED MICROBIOL, V291, P605, DOI 10.1078/1438-4221-00173; LAZARUS LR, 1993, EMBO J, V12, P2483, DOI 10.1002/j.1460-2075.1993.tb05903.x; Lim D, 2002, J BIOL CHEM, V277, P29253, DOI 10.1074/jbc.M111381200; Lopez-Solanilla E, 1998, PLANT CELL, V10, P917, DOI 10.1105/tpc.10.6.917; MARTIN RG, 1995, P NATL ACAD SCI USA, V92, P5456, DOI 10.1073/pnas.92.12.5456; Miller PF, 1996, MOL MICROBIOL, V21, P441, DOI 10.1111/j.1365-2958.1996.tb02553.x; Mironov A. A., 2000, Molekulyarnaya Biologiya (Moscow), V34, P253; MULHOLLAND V, 1993, MOL MICROBIOL, V9, P343, DOI 10.1111/j.1365-2958.1993.tb01695.x; Nagel G, 2001, MOL MICROBIOL, V41, P1249, DOI 10.1046/j.1365-2958.2001.02522.x; NASSER W, 1994, J MOL BIOL, V236, P427, DOI 10.1006/jmbi.1994.1155; Nasser W, 2002, MOL MICROBIOL, V43, P733, DOI 10.1046/j.1365-2958.2002.02782.x; Nasser W, 1999, MOL MICROBIOL, V34, P641, DOI 10.1046/j.1365-2958.1999.01609.x; Nasser W, 1997, MOL MICROBIOL, V26, P1071, DOI 10.1046/j.1365-2958.1997.6472020.x; Nomura K, 1998, P NATL ACAD SCI USA, V95, P14034, DOI 10.1073/pnas.95.24.14034; Praillet T, 1997, MOL MICROBIOL, V24, P803, DOI 10.1046/j.1365-2958.1997.3901755.x; Praillet T, 1996, MOL MICROBIOL, V20, P391, DOI 10.1111/j.1365-2958.1996.tb02626.x; Revell PA, 2000, MOL MICROBIOL, V35, P677, DOI 10.1046/j.1365-2958.2000.01740.x; Reverchon S, 1997, J BACTERIOL, V179, P3500, DOI 10.1128/jb.179.11.3500-3508.1997; REVERCHON S, 1994, MOL MICROBIOL, V11, P1127, DOI 10.1111/j.1365-2958.1994.tb00389.x; Reverchon S, 1998, MOL MICROBIOL, V29, P1407, DOI 10.1046/j.1365-2958.1998.01023.x; Reverchon S, 2002, J BACTERIOL, V184, P654, DOI 10.1128/JB.184.3.654-665.2002; Rouanet C, 1999, J BACTERIOL, V181, P5948, DOI 10.1128/JB.181.19.5948-5957.1999; Santos R, 2001, MOL PLANT MICROBE IN, V14, P758, DOI 10.1094/MPMI.2001.14.6.758; Stapleton MR, 2002, J BIOL CHEM, V277, P17630, DOI 10.1074/jbc.M110178200; Surgey N, 1996, J BACTERIOL, V178, P1593, DOI 10.1128/jb.178.6.1593-1599.1996; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wu RY, 2003, J BIOL CHEM, V278, P20240, DOI 10.1074/jbc.M300292200	42	37	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30158	30167		10.1074/jbc.M403343200	http://dx.doi.org/10.1074/jbc.M403343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140891	hybrid			2022-12-27	WOS:000222531900037
J	Torregrossa, P; Buhl, L; Bancila, M; Durbec, P; Schafer, C; Schachner, M; Rougon, G				Torregrossa, P; Buhl, L; Bancila, M; Durbec, P; Schafer, C; Schachner, M; Rougon, G			Selection of poly-alpha 2,8-sialic acid mimotopes from a random phage peptide library and analysis of their bioactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; CAPSULAR POLYSACCHARIDE; DISPLAYED PEPTIDES; CROSS-REACTIVITY; NERVOUS-SYSTEM; N-CAM; EXPRESSION; PLASTICITY; MIGRATION	Poly-alpha2-8 sialic acid (PSA), attached to the neural cell adhesion molecule, is a permissive determinant for numerous morphogenetic and neural plasticity processes, making it a potential therapeutic target. Here, using a monoclonal antibody specific for PSA, we screened a phage-display library and identified two cyclic nine-amino acid peptides (p1, p2) that are PSA epitope analogues. We evaluated their bioactivity in vitro and in vivo. In culture, micromolar concentrations of the peptides promoted axon growth, defasciculation, and migration of neural progenitors. When injected into developing chicken retina, the peptides modified the trajectory of retinal ganglion cell axons. Moreover, they enhanced migration of grafted neuroblasts in mouse brain. These effects were selective and dependent upon the presence of PSA on transplanted cells. Our results demonstrate the feasibility and therapeutic potential of enhancing PSA biological activity.	Univ Mediterranee, Inst Dev Biol, Lab Neurogenese & Morphogenese Dev & Chez Adulte, CNRS,Unite Mixte Rech 6156, F-13288 Marseille 9, France; Schafer N Fruebjergen, DK-2100 Copenhagen, Denmark; Univ Hamburg, Zentrum Mol Neurobiol, D-20251 Hamburg, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Hamburg; University Medical Center Hamburg-Eppendorf	Rougon, G (corresponding author), Univ Mediterranee, Inst Dev Biol, Lab Neurogenese & Morphogenese Dev & Chez Adulte, CNRS,Unite Mixte Rech 6156, Parc Sci Luminy, F-13288 Marseille 9, France.	rougon@ibdm.univ-mrs.fr		ROUGON, Genevieve/0000-0003-1316-8200				Aubert I, 1998, J COMP NEUROL, V399, P1; Beenhouwer DO, 2002, J IMMUNOL, V169, P6992, DOI 10.4049/jimmunol.169.12.6992; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; Charter NW, 2002, J BIOL CHEM, V277, P9255, DOI 10.1074/jbc.M111619200; Chazal G, 2000, J NEUROSCI, V20, P1446; Coquillat D, 2001, INFECT IMMUN, V69, P7130, DOI 10.1128/IAI.69.11.7130-7139.2001; Decker L, 2000, MOL CELL NEUROSCI, V16, P422, DOI 10.1006/mcne.2000.0885; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Felici F, 1996, METHOD ENZYMOL, V267, P116; FIGARELLABRANGER D, 1990, J NEUROL SCI, V98, P21, DOI 10.1016/0022-510X(90)90179-Q; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; HAYRINEN J, 1989, VACCINE, V7, P217, DOI 10.1016/0264-410X(89)90232-6; Hayrinen J, 2002, MOL IMMUNOL, V39, P399, DOI 10.1016/S0161-5890(02)00202-X; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; Le Belle JE, 2002, BIODRUGS, V16, P389, DOI 10.2165/00063030-200216060-00001; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Marx M, 2001, DEVELOPMENT, V128, P4949; Meloen RH, 2000, J MOL RECOGNIT, V13, P352, DOI 10.1002/1099-1352(200011/12)13:6<352::AID-JMR509>3.0.CO;2-C; Monnier PP, 2001, DEV BIOL, V229, P1, DOI 10.1006/dbio.2000.9970; Muller D, 2000, P NATL ACAD SCI USA, V97, P4315, DOI 10.1073/pnas.070022697; MULLER D, 1994, NEUROSCIENCE, V61, P441, DOI 10.1016/0306-4522(94)90424-3; ONO K, 1994, NEURON, V13, P395; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Pincus SH, 1998, J IMMUNOL, V160, P293; ROUGON G, 1993, EUR J CELL BIOL, V61, P197; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; ROUGON G, 1993, POLYSIALIC ACID MICR, P323; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Seki T, 1998, J NEUROSCI, V18, P3757; Shin JS, 2002, J IMMUNOL, V168, P6273, DOI 10.4049/jimmunol.168.12.6273; Simon-Haldi M, 2002, J NEUROCHEM, V83, P1380, DOI 10.1046/j.1471-4159.2002.01247.x; Stuermer CAO, 2000, PROG NEUROBIOL, V62, P197, DOI 10.1016/S0301-0082(00)00012-5; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; Theodosis DT, 1999, J NEUROSCI, V19, P10228; Toikka J, 1998, J BIOL CHEM, V273, P28557, DOI 10.1074/jbc.273.44.28557; Vutskits L, 2001, EUR J NEUROSCI, V13, P1391, DOI 10.1046/j.0953-816x.2001.01516.x; Zhang H, 2004, J CELL SCI, V117, P93, DOI 10.1242/jcs.00827	40	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30707	30714		10.1074/jbc.M403935200	http://dx.doi.org/10.1074/jbc.M403935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131117	hybrid			2022-12-27	WOS:000222531900101
J	Xing, Y; Liu, D; Zhang, RG; Joachimiak, A; Songyang, Z; Xu, WQ				Xing, Y; Liu, D; Zhang, RG; Joachimiak, A; Songyang, Z; Xu, WQ			Structural basis of membrane targeting by the phox homology domain of cytokine-independent survival kinase (CISK-PX)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; MEDIATED INTERACTION; CRYSTAL-STRUCTURE; FYVE DOMAIN; SH3 DOMAINS; BINDING; ACTIVATION; P40(PHOX)	The cytokine-independent survival kinase (CISK) in the serum and glucocorticoid-regulated kinase family plays an important role in mediating cell growth and survival. N-terminal to its catalytic kinase domain, CISK contains a phox homology (PX) domain, a phosphoinositide-binding motif that directs the membrane localization of CISK and regulates CISK activity. We have determined the crystal structures of the mouse CISK-PX domain to unravel the structural basis of membrane targeting of CISK. In addition to the specific interactions conferred by the phosphoinositide-binding pocket, the structure suggests that a hydrophobic loop region and a hydrophilic beta-turn contribute to the interactions with the membrane. Furthermore, biochemical studies reveal that CISK-PX dimerizes in the presence of the linker between the PX domain and kinase domain, suggesting a multivalent mechanism in membrane localization of CISK.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Argonne Natl Lab, Struct Biol Ctr, Biosci Div, Argonne, IL 60439 USA	University of Washington; University of Washington Seattle; Baylor College of Medicine; United States Department of Energy (DOE); Argonne National Laboratory	Xu, WQ (corresponding author), Univ Washington, Dept Biol Struct, 1959 NE Pacific St, Seattle, WA 98195 USA.	wxu@u.washington.edu		Xu, Wenqing/0000-0002-2884-3101	NCI NIH HHS [CA84208] Funding Source: Medline; NIGMS NIH HHS [GM69572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lang F, 2001, SCI STKE, V2001; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Xing Y, 2003, ACTA CRYSTALLOGR D, V59, P1816, DOI 10.1107/S0907444903015567; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zhou CZ, 2003, J BIOL CHEM, V278, P50371, DOI 10.1074/jbc.M304392200	49	49	51	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30662	30669		10.1074/jbc.M404107200	http://dx.doi.org/10.1074/jbc.M404107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15126499	hybrid			2022-12-27	WOS:000222531900096
J	Hong, SS; Morrow, TJ; Paulson, PE; Isom, LL; Wiley, JW				Hong, SS; Morrow, TJ; Paulson, PE; Isom, LL; Wiley, JW			Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SENSORY NEURONS; MECHANICAL HYPERALGESIA; ACTION-POTENTIALS; PURKINJE NEURONS; ALDOSE REDUCTASE; IONIC CURRENTS; GROWTH-FACTOR; DRG NEURONS; EXPRESSION	Diabetic neuropathy is a common form of peripheral neuropathy, yet the mechanisms responsible for pain in this disease are poorly understood. Alterations in the expression and function of voltage-gated tetrodotoxin-resistant (TTX-R) sodium channels have been implicated in animal models of neuropathic pain, including models of diabetic neuropathy. We investigated the expression and function of TTX-sensitive (TTX-S) and TTX-R sodium channels in dorsal root ganglion (DRG) neurons and the responses to thermal hyperalgesia and mechanical allodynia in streptozotocin-treated rats between 4-8 weeks after onset of diabetes. Diabetic rats demonstrated a significant reduction in the threshold for escape from innocuous mechanical pressure ( allodynia) and a reduction in the latency to withdrawal from a noxious thermal stimulus ( hyperalgesia). Both TTX-S and TTX-R sodium currents increased significantly in small DRG neurons isolated from diabetic rats. The voltage-dependent activation and steady-state inactivation curves for these currents were shifted negatively. TTX-S currents induced by fast or slow voltage ramps increased markedly in neurons from diabetic rats. Immunoblots and immunofluorescence staining demonstrated significant increases in the expression of Na(v)1.3 (TTX-S) and Na(v)1.7 (TTX-S) and decreases in the expression of Na(v)1.6 (TTX-S) and Na(v)1.8 (TTX-R) in diabetic rats. The level of serine/threonine phosphorylation of Na(v)1.6 and Na(v)1.8 increased in response to diabetes. In addition, increased tyrosine phosphorylation of Na(v)1.6 and Na(v)1.7 was observed in DRGs from diabetic rats. These results suggest that both TTX-S and TTX-R sodium channels play important roles and that differential phosphorylation of sodium channels involving both serine/threonine and tyrosine sites contributes to painful diabetic neuropathy.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Wiley, JW (corresponding author), Univ Michigan Hosp, Dept Internal Med, A7007 UH,Box 0108,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	jwiley@med.umich.edu		Isom, Lori/0000-0002-9479-6729	NIDDK NIH HHS [R01 DK52387, DK 45820] Funding Source: Medline; NIMH NIH HHS [R01 MH059980] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052387, R29DK045820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahlgren SC, 1997, NEUROSCIENCE, V76, P285; AHLGREN SC, 1993, NEUROSCIENCE, V52, P1049, DOI 10.1016/0306-4522(93)90551-P; AHLGREN SC, 1994, J NEUROPHYSIOL, V72, P684, DOI 10.1152/jn.1994.72.2.684; Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Amaya F, 2000, MOL CELL NEUROSCI, V15, P331, DOI 10.1006/mcne.1999.0828; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Black JA, 1999, J NEUROPHYSIOL, V82, P2776, DOI 10.1152/jn.1999.82.5.2776; Black JA, 2002, MOL BRAIN RES, V105, P19, DOI 10.1016/S0169-328X(02)00385-6; Blackburn-Munro G, 1999, NEUROSCIENCE, V90, P153, DOI 10.1016/S0306-4522(98)00415-1; Blair NT, 2002, J NEUROSCI, V22, P10277; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; Calcutt NA, 1996, PAIN, V68, P293, DOI 10.1016/S0304-3959(96)03201-0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; Craner MJ, 2002, ANN NEUROL, V52, P786, DOI 10.1002/ana.10364; Cummins TR, 1998, J NEUROSCI, V18, P9607; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; Djouhri L, 2003, J PHYSIOL-LONDON, V546, P565, DOI 10.1113/jphysiol.2002.026559; Djouhri L, 1998, J PHYSIOL-LONDON, V513, P857, DOI 10.1111/j.1469-7793.1998.857ba.x; Fitzgerald EM, 1999, J PHYSIOL-LONDON, V516, P433, DOI 10.1111/j.1469-7793.1999.0433v.x; Fox A, 1999, PAIN, V81, P307, DOI 10.1016/S0304-3959(99)00024-X; GALLEGO R, 1983, J PHYSIOL-LONDON, V342, P591, DOI 10.1113/jphysiol.1983.sp014870; Gold MS, 1998, J NEUROSCI, V18, P10345; Gould HJ, 2000, BRAIN RES, V854, P19, DOI 10.1016/S0006-8993(99)02216-7; Grieco TM, 2004, J NEUROSCI, V24, P35, DOI 10.1523/JNEUROSCI.3807-03.2004; Hall KE, 2001, J NEUROPHYSIOL, V86, P760, DOI 10.1152/jn.2001.86.2.760; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hilborn MD, 1998, J NEUROSCI, V18, P590; Hirade M, 1999, NEUROSCIENCE, V90, P933, DOI 10.1016/S0306-4522(98)00486-2; Isom LL, 2002, NOVART FDN SYMP, V241, P124; Kerr BJ, 2001, NEUROREPORT, V12, P3077, DOI 10.1097/00001756-200110080-00019; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; Kral MG, 1999, PAIN, V81, P15, DOI 10.1016/S0304-3959(98)00264-4; Lai J, 2004, ANNU REV PHARMACOL, V44, P371, DOI 10.1146/annurev.pharmtox.44.101802.121627; Lyu YS, 2000, BRAIN RES, V871, P98, DOI 10.1016/S0006-8993(00)02451-3; Malcangio M, 1998, PAIN, V76, P151, DOI 10.1016/S0304-3959(98)00037-2; Moller KA, 1998, J NEUROSCI METH, V84, P41, DOI 10.1016/S0165-0270(98)00083-1; Novakovic SD, 1998, J NEUROSCI, V18, P2174; Ogata N, 2002, JPN J PHARMACOL, V88, P365, DOI 10.1254/jjp.88.365; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Raman IM, 1997, NEURON, V19, P881, DOI 10.1016/S0896-6273(00)80969-1; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Renganathan M, 2001, J NEUROPHYSIOL, V86, P629, DOI 10.1152/jn.2001.86.2.629; ROY ML, 1992, J NEUROSCI, V12, P2104; Said G, 1996, J NEUROL, V243, P431, DOI 10.1007/BF00900495; Spruce MC, 2003, DIABETIC MED, V20, P88, DOI 10.1046/j.1464-5491.2003.00852.x; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; STEVENS MJ, 1994, J CLIN INVEST, V94, P853, DOI 10.1172/JCI117406; Tate S, 1998, NAT NEUROSCI, V1, P653, DOI 10.1038/3652; Vijayaragavan K, 2004, J NEUROPHYSIOL, V91, P1556, DOI 10.1152/jn.00676.2003; Wada A, 2004, FRONT BIOSCI-LANDMRK, V9, P1954, DOI 10.2741/1314; Wang YG, 2003, PFLUG ARCH EUR J PHY, V446, P485, DOI 10.1007/s00424-003-1061-8; Waxman SG, 1999, PAIN, pS133, DOI 10.1016/S0304-3959(99)00147-5; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207	55	206	231	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29341	29350		10.1074/jbc.M404167200	http://dx.doi.org/10.1074/jbc.M404167200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123645	Green Submitted, hybrid, Green Accepted			2022-12-27	WOS:000222445300065
J	He, L; Simmen, FA; Ronis, MJJ; Badger, TM				He, L; Simmen, FA; Ronis, MJJ; Badger, TM			Post-transcriptional regulation of sterol regulatory element-binding protein-1 by ethanol induces class I alcohol dehydrogenase in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; MESSENGER-RNA; TRANSCRIPTION; ACTIVATION; EXPRESSION; GENE; SREBP-1C; INSULIN; CHOLESTEROL; INDUCTION	Members of the sterol regulatory element-binding protein ( SREBP) family of transcription factors control the synthesis and uptake of cholesterol, fatty acids, triglycerides, and phospholipids. Continuous intragastric infusion of ethanol-containing diets as part of total enteral nutrition generates well defined 6-day cycles ( pulses) of urine ethanol concentrations (UECs) in rats. Pulsatile UECs are the result of cyclical expression and activity of the principal alcohol-metabolizing enzyme, hepatic Class I alcohol dehydrogenase (ADH), and this mechanism involves regulated CCAAT/enhancer-binding protein-beta expression and binding to the ADH promoter. In this study, we further explore the molecular mechanism for ethanol-induced ADH expression during the UEC pulse in adult male rats fed ethanol by total enteral nutrition for 21 - 30 days. In hypophysectomized rats, in which the ADH protein increased by similar to6-fold, the nuclear form of SREBP-1 decreased by similar to7-fold. Because the ADH promoter contains two canonical sterol response element (SRE) sites ( - 63 to - 53 and - 52 to - 40 relative to the transcription start site), electrophoretic mobility shift assays were conducted using an ADH- specific SRE site. Hepatic nuclear protein binding decreased by 2.4-fold on the ascending limbs and by 3.6-fold on the descending limbs of UEC pulses ( p < 0.05). The specificity of nuclear protein binding to the ADH- SRE site was confirmed using antibody and UV cross-link assays. The in vivo binding status of SREBP-1 to ADH- SRE sites, as measured by the chromatin immunoprecipitation assay, had a pattern very similar to the electrophoretic mobility shift assay results. Functional analysis of the ADH- SREs demonstrated these sites to be essential for ADH transcription. In vitro transcription assays demonstrated that depletion of the SREBP-1 protein from nuclear extracts increased transcription activity by similar to 5-fold and that the liver X receptor agonist T0901317 ( a known activator of SREBP-1c transcription) reduced in vitro expression of ADH mRNA by 2-fold. We conclude that SREBP-1 is a negative regulator of the ADH gene and may work in concert with the CCAAT/enhancer-binding proteins to mediate ethanol induction of ADH in vivo.	Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72202 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Badger, TM (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, 1120 Marshall St, Little Rock, AR 72202 USA.	badgerthomasm@uams.edu	Simmen, Frank A/J-9464-2012	Simmen, Frank/0000-0001-6842-7754				BADGER TM, 1993, J PHARMACOL EXP THER, V264, P938; BADGER TM, 1993, J PHARMACOL EXP THER, V264, P438; Badger TM, 2000, BIOCHEM BIOPH RES CO, V274, P684, DOI 10.1006/bbrc.2000.3186; BOLEDA MD, 1992, BIOCHEM PHARMACOL, V43, P1555, DOI 10.1016/0006-2952(92)90214-4; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUETLER TM, 1995, TOXICOL APPL PHARM, V135, P45, DOI 10.1006/taap.1995.1207; Chen GF, 1999, XENOBIOTICA, V29, P437, DOI 10.1080/004982599238461; Cheng JZ, 2003, GASTROENTEROLOGY, V124, pA14, DOI 10.1016/S0016-5085(03)80068-9; CORTESE JF, 1994, J BIOL CHEM, V269, P21898; CRABB DW, 1987, PHARMACOL THERAPEUT, V34, P59, DOI 10.1016/0163-7258(87)90092-1; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; Eliasson E, 1996, MOL PHARMACOL, V50, P573; FELDER MR, 1988, J BIOL CHEM, V263, P14531; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; He L, 2002, J BIOL CHEM, V277, P43572, DOI 10.1074/jbc.M204535200; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; KEEGAN A, 1995, J HEPATOL, V23, P591, DOI 10.1016/0168-8278(95)80067-0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kono H, 1999, AM J PHYSIOL-GASTR L, V277, pG1259, DOI 10.1152/ajpgi.1999.277.6.G1259; Korourian S, 1999, TOXICOL SCI, V47, P110, DOI 10.1093/toxsci/47.1.110; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LIEBER CS, 1969, J LIPID RES, V10, P283; McGehee RE, 1997, DNA CELL BIOL, V16, P725, DOI 10.1089/dna.1997.16.725; MEZEY E, 1990, ARCH BIOCHEM BIOPHYS, V280, P390, DOI 10.1016/0003-9861(90)90347-2; MEZEY E, 1993, ARCH BIOCHEM BIOPHYS, V225, P787; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; POTTER JJ, 1993, BIOCHEM BIOPH RES CO, V191, P1040, DOI 10.1006/bbrc.1993.1322; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; POTTER JJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P246, DOI 10.1016/0003-9861(91)90356-N; QULALI M, 1991, ARCH BIOCHEM BIOPHYS, V288, P406, DOI 10.1016/0003-9861(91)90213-3; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Ronis MJJ, 2004, J NUTR, V134, P904, DOI 10.1093/jn/134.4.904; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Simon FR, 2002, AM J PHYSIOL-GASTR L, V283, pG646, DOI 10.1152/ajpgi.00438.2001; TSUKAMOTO H, 1985, ALCOHOL CLIN EXP RES, V9, P31, DOI 10.1111/j.1530-0277.1985.tb05046.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; You M, 2002, J BIOL CHEM, V277, P29342, DOI 10.1074/jbc.M202411200	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28113	28121		10.1074/jbc.M400906200	http://dx.doi.org/10.1074/jbc.M400906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123720	hybrid			2022-12-27	WOS:000222265400037
J	Panicker, S; Cruz, H; Arrabit, C; Suen, KF; Slesinger, PA				Panicker, S; Cruz, H; Arrabit, C; Suen, KF; Slesinger, PA			Minimal structural rearrangement of the cytoplasmic pore during activation of the 5-HT3A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION-CHANNEL; FRONTAL-LOBE EPILEPSY; CHARGED AMINO-ACIDS; X-RAY STRUCTURES; GABA(A) RECEPTOR; AFFECTS DESENSITIZATION; NEUROBLASTOMA-CELLS; MUTATIONAL ANALYSIS; SELECTIVITY FILTER	Ligand-gated ion channel receptors mediate the response of fast neurotransmitters by opening in less than a millisecond. Here, we investigated the activation mechanism of a serotonin-gated receptor (5-HT3A) by systematically introducing cysteine substitutions throughout the pore-lining M1-M2 loop and M2 transmembrane domain. We hypothesized that multiple cysteines in the narrowest region of the pore, which together can form a high affinity binding site for metal cations, would reveal changes in pore structure during gating. Using cadmium (Cd2+) as a probe, two cysteine substitutions in the cytoplasmic selectivity filter, S2'C and, to a lesser extent, G-2'C, showed high affinity inhibition with Cd2+ when applied extracellularly in the open state. Cd2+ inhibition in S2'C was attenuated if applied in the presence of an open-channel inhibitor and showed voltage-dependent recovery, indicating a direct effect of Cd2+ in the pore. When applied intracellularly, Cd2+ appeared to bind S2'C receptors in the closed state. The ability of cysteine side chains at the 2' and -2' positions to coordinate Cd2+ in both the native open and closed states of the channel suggests that the cytoplasmic selectivity filter of 5-HT3A receptors maintains a narrow pore during channel gating.	Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Neurosci, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	Slesinger, PA (corresponding author), Salk Inst Biol Studies, Peptide Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	slesinger@salk.edu		Panicker, Sandip/0000-0001-7901-2730				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; Benning MM, 2001, BIOCHEMISTRY-US, V40, P2712, DOI 10.1021/bi002661e; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; CamposCaro A, 1996, P NATL ACAD SCI USA, V93, P6118, DOI 10.1073/pnas.93.12.6118; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; Dudev T, 2002, J AM CHEM SOC, V124, P6759, DOI 10.1021/ja012620l; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; FORSTER I, 1995, P ROY SOC B-BIOL SCI, V260, P139, DOI 10.1098/rspb.1995.0071; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V522, P187, DOI 10.1111/j.1469-7793.2000.00187.x; Gunthorpe MJ, 1999, J PHYSIOL-LONDON, V519, P713, DOI 10.1111/j.1469-7793.1999.0713n.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 2001, ION CHANNELS EXCITAB, P170; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Hsiao B, 2001, J NEUROSCI, V21, P1848, DOI 10.1523/JNEUROSCI.21-06-01848.2001; Hubbard PC, 2000, EUR J PHARMACOL, V394, P189, DOI 10.1016/S0014-2999(00)00143-6; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Kandel E., 2000, PRINCIPLES NEURAL SC; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; Kuryatov A, 1997, J NEUROSCI, V17, P9035; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; Laube B, 2000, J PHYSIOL-LONDON, V522, P215, DOI 10.1111/j.1469-7793.2000.t01-1-00215.x; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; LOVINGER DM, 1991, J NEUROPHYSIOL, V66, P1329, DOI 10.1152/jn.1991.66.4.1329; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Palma E, 1998, P NATL ACAD SCI USA, V95, P10246, DOI 10.1073/pnas.95.17.10246; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Phillips HA, 2001, AM J HUM GENET, V68, P225, DOI 10.1086/316946; Rauser WE, 1999, CELL BIOCHEM BIOPHYS, V31, P19, DOI 10.1007/BF02738153; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; Rothberg BS, 2003, J GEN PHYSIOL, V122, P501, DOI 10.1085/jgp.200308928; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Sobolevsky AI, 2004, NEURON, V41, P367, DOI 10.1016/S0896-6273(04)00008-X; Thompson AJ, 2003, BRIT J PHARMACOL, V140, P359, DOI 10.1038/sj.bjp.0705424; UEYAMA N, 1988, INORG CHEM, V27, P741, DOI 10.1021/ic00277a031; Uki M, 1996, ARCH TOXICOL, V70, P652, DOI 10.1007/s002040050325; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177; ZHU ZW, 1994, BIOCHEMISTRY-US, V33, P8858, DOI 10.1021/bi00196a002	62	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28149	28158		10.1074/jbc.M403545200	http://dx.doi.org/10.1074/jbc.M403545200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15131114	hybrid			2022-12-27	WOS:000222265400042
J	Unkles, SE; Wang, RC; Wang, Y; Glass, ADM; Crawford, NM; Kinghorn, JR				Unkles, SE; Wang, RC; Wang, Y; Glass, ADM; Crawford, NM; Kinghorn, JR			Nitrate reductase activity is required for nitrate uptake into fungal but not plant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; IDENTIFICATION; TRANSPORTER; PROTEINS; CHLORATE; INVITRO; NITRITE; ROOTS; GENES	The ability to transport net nitrate was conferred upon transformant cells of the non-nitrate-assimilating yeast Pichia pastoris after the introduction of two genes, one encoding nitrate reductase and the other nitrate transport. It was observed that cells of this lower eukaryote transformed with the nitrate transporter gene alone failed to display net nitrate transport despite having the ability to produce the protein. In addition, loss-of-function nitrate reductase mutants isolated from several nitrate-assimilating fungi appeared to be unable to accumulate nitrate. Uptake assays using the tracer (NO3-)-N-13 showed that nitrate influx is negligible in cells of a nitrate reductase null mutant. In parallel studies using a higher eukaryotic plant, Arabidopsis thaliana, loss-of-function nitrate reductase strains homozygous for both NIA1 insertion and NIA2 deletion were found to have no detectable nitrate reductase mRNA or nitrate reductase activity but retained the ability to transport nitrate. The reasons for these fundamental differences in nitrate transport into the cells of representative members of these two eukaryotic kingdoms are discussed.	Univ St Andrews, Sch Biol, St Andrews KY16 9TH, Fife, Scotland; Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada	University of St Andrews; University of California System; University of California San Diego; University of British Columbia	Kinghorn, JR (corresponding author), Univ St Andrews, Sch Biol, St Andrews KY16 9TH, Fife, Scotland.	jrk@st-andrews.ac.uk			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040672, R01GM040672] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40672] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWNLEE AG, 1983, J BACTERIOL, V155, P1138, DOI 10.1128/JB.155.3.1138-1146.1983; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COVE DJ, 1976, HEREDITY, V36, P191, DOI 10.1038/hdy.1976.24; Crawford NM, 1998, TRENDS PLANT SCI, V3, P389, DOI 10.1016/S1360-1385(98)01311-9; Daniel-Vedele F, 1998, CURR OPIN PLANT BIOL, V1, P235, DOI 10.1016/S1369-5266(98)80110-6; Garcia-Mata C, 2003, TRENDS PLANT SCI, V8, P20, DOI 10.1016/S1360-1385(02)00009-2; GARRETT RH, 1976, MOL GEN GENET, V149, P179, DOI 10.1007/BF00332887; KAMPHAKE LJ, 1967, WATER RES, V1, P205, DOI 10.1016/0043-1354(67)90011-5; KING BJ, 1992, PLANT PHYSIOL, V99, P1582, DOI 10.1104/pp.99.4.1582; KRAMER S, 1984, ARCH BIOCHEM BIOPHYS, V233, P821, DOI 10.1016/0003-9861(84)90511-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Machin F, 2004, YEAST, V21, P265, DOI 10.1002/yea.1075; Parinov S, 1999, PLANT CELL, V11, P2263, DOI 10.1105/tpc.11.12.2263; Scheible WR, 1997, PLANT J, V11, P671, DOI 10.1046/j.1365-313X.1997.11040671.x; SCHLOEMER RH, 1974, J BACTERIOL, V118, P258; Siddiqi MY, 2002, PLANT CELL ENVIRON, V25, P1211, DOI 10.1046/j.1365-3040.2002.00927.x; SIDDIQI MY, 1992, PLANT PHYSIOL, V100, P644, DOI 10.1104/pp.100.2.644; Skipper L, 2001, J BIOL CHEM, V276, P26995, DOI 10.1074/jbc.M100356200; Su WP, 1997, PLANT PHYSIOL, V115, P1135, DOI 10.1104/pp.115.3.1135; Su WP, 1996, PLANT CELL, V8, P519, DOI 10.1105/tpc.8.3.519; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Unkles SE, 1999, J BIOL CHEM, V274, P19286, DOI 10.1074/jbc.274.27.19286; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; Unkles SE, 2001, EMBO J, V20, P6246, DOI 10.1093/emboj/20.22.6246; Vidmar JJ, 2000, PLANT PHYSIOL, V123, P307, DOI 10.1104/pp.123.1.307; Wang RC, 2003, PLANT PHYSIOL, V132, P556, DOI 10.1104/pp.103.021253; WILKINSON JQ, 1991, PLANT CELL, V3, P461, DOI 10.1105/tpc.3.5.461; Williams LE, 2001, ANNU REV PLANT PHYS, V52, P659, DOI 10.1146/annurev.arplant.52.1.659; WRAY JL, 1989, MOL GENETICAL ASPECT; Zhang HM, 2000, J EXP BOT, V51, P51, DOI 10.1093/jexbot/51.342.51	30	37	38	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28182	28186		10.1074/jbc.M403974200	http://dx.doi.org/10.1074/jbc.M403974200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123642	hybrid			2022-12-27	WOS:000222265400046
J	Rasia, RM; Vila, AJ				Rasia, RM; Vila, AJ			Structural determinants of substrate binding to Bacillus cereus metallo-beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; BACTEROIDES-FRAGILIS; ACTIVE-SITE; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; COORDINATION GEOMETRY; ANGSTROM RESOLUTION; CARBOXYPEPTIDASE-A; POTENT INHIBITORS; D-CAPTOPRIL	Binding and hydrolysis of the beta-lactams cefotaxime, cephapirin, imipenem, and benzylpenicillin by the metallo-beta-lactamase from Bacillus cereus were studied by presteady state kinetic measurements. In all cases, the substrate was unmodified in the most populated reaction intermediate, and no chemically modified substrate species accumulated to a detectable amount. The cephalosporins tested showed similar formation rate constants for this intermediate, and they differed mostly in their decay rates. Formation of a non-productive enzyme . substrate complex was detected for imipenem. The substrate binding differences can be accounted for by considering the structural features of each substrate. The apoenzyme could not bind any of the substrates, but binding was restored when the apoenzyme was reconstituted with Zn(II), revealing that the metal ions are the main determinants of substrate binding. This evidence is in line with the lack of an optimized substrate recognition patch in B1 and B3 metallo-beta-lactamases that provides a broad substrate spectrum.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Area Biofis, RA-2000 Rosario, Santa Fe, Argentina; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Mol & Celular Rosario, RA-2000 Rosario, Santa Fe, Argentina	National University of Rosario; National University of Rosario	Vila, AJ (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Area Biofis, Suipacha 531,S2002LRK, RA-2000 Rosario, Santa Fe, Argentina.	vila@arnet.com.ar		Vila, Alejandro/0000-0002-7978-3233; Rasia, Rodolfo/0000-0003-3940-067X				AULD DS, 1972, BIOCHEMISTRY-US, V11, P4994, DOI 10.1021/bi00776a019; AULD DS, 1974, BIOCHEMISTRY-US, V13, P4355, DOI 10.1021/bi00718a018; BICKNELL R, 1986, BIOCHEMISTRY-US, V25, P7208, DOI 10.1021/bi00370a066; BICKNELL R, 1985, BIOCHEMISTRY-US, V24, P6876, DOI 10.1021/bi00345a021; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Bush K, 1999, CURR PHARM DESIGN, V5, P839; Carenbauer AL, 2002, BMC BIOCHEM, V3; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CHRISTIANSON DW, 1989, J BIOL CHEM, V264, P12849; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Cricco JA, 1999, CURR PHARM DESIGN, V5, P915; Dal Peraro M, 2004, PROTEINS, V54, P412, DOI 10.1002/prot.10554; DAVIES RB, 1975, BIOCHEM J, V145, P409, DOI 10.1042/bj1450409; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; Diaz N, 2001, J AM CHEM SOC, V123, P9867, DOI 10.1021/ja0113246; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Fast W, 2001, BIOCHEMISTRY-US, V40, P1640, DOI 10.1021/bi001860v; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P192, DOI 10.1128/AAC.39.1.192; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Haruta S, 2001, FEMS MICROBIOL LETT, V197, P85, DOI 10.1111/j.1574-6968.2001.tb10587.x; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Kaminskaia NV, 2001, J AM CHEM SOC, V123, P6555, DOI 10.1021/ja002699e; Krum JG, 2002, BIOCHEMISTRY-US, V41, P5005, DOI 10.1021/bi0255221; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; McCall KA, 2000, ANAL BIOCHEM, V284, P307, DOI 10.1006/abio.2000.4706; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Moali C, 2003, CHEM BIOL, V10, P319, DOI 10.1016/S1074-5521(03)00070-X; Montoya-Pelaez PJ, 2002, INORG CHEM, V41, P309, DOI 10.1021/ic011005f; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Page M. I., 1992, CHEM BETA LACTAMS; Paul-Soto R, 1998, FEBS LETT, V438, P137, DOI 10.1016/S0014-5793(98)01289-7; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Prosperi-Meys C, 2002, CELL MOL LIFE SCI, V59, P2136, DOI 10.1007/s000180200013; Rasia RM, 2003, ARKIVOC, P507, DOI 10.3998/ark.5550190.0004.a47; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; SENY D, 2002, BIOCHEM J, V363, P687; Siemann S, 2002, BBA-GEN SUBJECTS, V1571, P190, DOI 10.1016/S0304-4165(02)00258-1; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; Suarez D, 2002, J COMPUT CHEM, V23, P1587, DOI 10.1002/jcc.10157; TANAKA M, 1968, INORG CHEM, V7, P573, DOI 10.1021/ic50061a038; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Varon-Castellanos R., 1995, COMPUTERIZED DERIVAT; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	60	53	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26046	26051		10.1074/jbc.M311373200	http://dx.doi.org/10.1074/jbc.M311373200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15140877	hybrid			2022-12-27	WOS:000222003000016
J	Sowa, H; Kaji, H; Hendy, GN; Canaff, L; Komori, T; Sugimoto, T; Chihara, K				Sowa, H; Kaji, H; Hendy, GN; Canaff, L; Komori, T; Sugimoto, T; Chihara, K			Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; P300/CBP TRANSCRIPTIONAL COACTIVATORS; ALKALINE-PHOSPHATASE ACTIVITY; COLLAGEN GENE-EXPRESSION; TGF-BETA; CLEIDOCRANIAL DYSPLASIA; OSTEOCALCIN GENE; TYPE-1 GENE; CELL-LINE; PROTEIN	Menin, the product of the multiple endocrine neoplasia type 1 (MEN1) gene, is required for commitment of multipotential mesenchymal stem cells to the osteoblast lineage, however, it inhibits their later differentiation (Sowa, H., Kaji, H., Canaff, L., Hendy, G. N., Tsukamoto, T., Yamaguchi, T., Miyazono, K., Sugimoto, T., and Chihara, K. ( 2003) J. Biol. Chem. 278, 21058 - 21069). Here, we have examined the mechanism of action of menin in regulating osteoblast differentiation using the mouse bone marrow stromal ST2 and osteoblast MC3T3-E1 cell lines. In ST2 cells, reduced menin expression achieved by transfection of menin antisense DNA ( AS) antagonized bone morphogenetic protein (BMP)-2-induced alkaline phosphatase activity and osteocalcin and Runx2 mRNA expression. Menin was co-immunoprecipitated with Smad1/5 in ST2 and MC3T3-E1 cells, and inactivation of menin antagonized BMP-2-induced transcriptional activity of Smad1/5 in ST2 cells, but not MC3T3-E1 cells. Menin was co-immunoprecipitated with the key osteoblast regulator, Runx2, and AS antagonized Runx2 transcriptional activity and the ability of Runx2 to stimulate alkaline phosphatase activity only in ST2 cells but not in MC3T3-E1 cells. In the osteoblast MC3T3-E1 cells, transforming growth factor-beta and its signaling molecule, Smad3, negatively regulated Runx2 transcriptional activity. Menin and Smad3 were co-immunoprecipitated, and combined menin and Smad3 overexpression antagonized, whereas menin and the dominant-negative Smad3DeltaC together enhanced BMP-2-induced transcriptional activity of Smad1/5 and Runx2. Smad3 alone had no effect. Therefore, menin interacts physically and functionally with Runx2 in uncommitted mesenchymal stem cells, but not in well differentiated osteoblasts. In osteoblasts the interaction of menin and the transforming growth factor-beta/Smad3 pathway negatively regulates the BMP-2/Smad1/5- and Runx2-induced transcriptional activities leading to inhibition of late-tage differentiation.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol, Kobe, Hyogo 6500017, Japan; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A1, Canada; Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka 565, Japan	Kobe University; McGill University; McGill University; McGill University; Osaka University	Sugimoto, T (corresponding author), Shimane Univ, Sch Med, Dept Endocrinol Metab & Hematol Oncol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.	sugimoto@med.shimane-u.ac.jp	Kaji, Hiroshi/AAI-5628-2020					Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Atkinson BL, 1997, J CELL BIOCHEM, V65, P325, DOI 10.1002/(SICI)1097-4644(19970601)65:3<325::AID-JCB3>3.0.CO;2-U; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Ikeo Y, 2000, LAB INVEST, V80, P797, DOI 10.1038/labinvest.3780084; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Karsenty G, 2000, NAT MED, V6, P970, DOI 10.1038/79655; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Lopez-Egido JR, 2002, EXP CELL RES, V278, P175, DOI 10.1006/excr.2002.5575; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MCCABE LR, 1995, EXP CELL RES, V218, P255, DOI 10.1006/excr.1995.1154; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776-003-0702-2; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190; Sowa H, 2003, J BIOL CHEM, V278, P52240, DOI 10.1074/jbc.M302566200; Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; Sukhodolets KE, 2003, MOL CELL BIOL, V23, P493, DOI 10.1128/MCB.23.2.493-509.2003; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1990, J CELL SCI, P149; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F	56	114	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40267	40275		10.1074/jbc.M401312200	http://dx.doi.org/10.1074/jbc.M401312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15150273	hybrid			2022-12-27	WOS:000223916800006
J	Beringue, V; Vilette, D; Mallinson, G; Archer, F; Kaisar, M; Tayebi, M; Jackson, GS; Clarke, AR; Laude, H; Collinge, J; Hawke, S				Beringue, V; Vilette, D; Mallinson, G; Archer, F; Kaisar, M; Tayebi, M; Jackson, GS; Clarke, AR; Laude, H; Collinge, J; Hawke, S			PrPSc binding antibodies are potent inhibitors of prion replication in cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; SCRAPIE AGENT; MONOCLONAL-ANTIBODIES; PROTEIN; ACCUMULATION; PROPAGATION; RESISTANT; DISEASE; PRECURSOR; INFECTION	Conversion of the cellular alpha-helical prion protein (PrPC) into a disease-associated isoform (PrPSc) is central to the pathogenesis of prion diseases. Molecules targeting either normal or disease-associated isoforms may be of therapeutic interest, and the antibodies binding PrPC have been shown to inhibit prion accumulation in vitro. Here we investigate whether antibodies that additionally target disease-associated isoforms such as PrPSc inhibit prion replication in ovine PrP-inducible scrapie-infected Rov cells. We conclude from these experiments that antibodies exclusively binding PrPC were relatively inefficient inhibitors of ScRov cell PrPSc accumulation compared with antibodies that additionally targeted disease-associated PrP isoforms. Although the mechanism by which these monoclonal antibodies inhibit prion replication is unclear, some of the data suggest that antibodies might actively increase PrPSc turnmover. Thus antibodies that bind to both normal and disease-associated isoforms represent very promising anti-prion agents.	Univ London Imperial Coll Sci Technol & Med, Fac Med, CNS Infect & Immunol Grp, Dept Neurogenet, London W2 1PG, England; INRA, Unite Virol & Immunol Mol, F-78352 Jouy En Josas, France; Inst Neurol, MRC, Prion Unit, London WC1N 3BG, England; Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England	Imperial College London; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of London; University College London; University of London; University College London	Hawke, S (corresponding author), Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2006, Australia.	s.hawke@imperial.ac.uk	TAYEBI, MOURAD/F-7404-2010; Archer, Fabienne/E-9371-2010	Archer, Fabienne/0000-0002-8175-866X; Jackson, Graham/0000-0002-3125-2011; Kaisar, Maria/0000-0002-0712-9937; TAYEBI, MOURAD/0000-0001-8664-6918				Archer F, 2004, J VIROL, V78, P482, DOI 10.1128/JVI.78.1.482-490.2004; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Beringue V, 2000, J VIROL, V74, P5432, DOI 10.1128/JVI.74.12.5432-5440.2000; Beringue V, 2003, BRAIN, V126, P2065, DOI 10.1093/brain/awg205; Brown P, 2002, NEUROLOGY, V58, P1720, DOI 10.1212/WNL.58.12.1720; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Clarke AR, 2001, PHILOS T ROY SOC B, V356, P185, DOI 10.1098/rstb.2000.0764; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Ghani AC, 2000, NATURE, V406, P583, DOI 10.1038/35020688; Heppner FL, 2001, NAT MED, V7, P976, DOI 10.1038/nm0901-976; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Oesch B, 1991, Curr Top Microbiol Immunol, V172, P109; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Sabuncu E, 2003, J VIROL, V77, P2696, DOI 10.1128/JVI.77.4.2696-2700.2003; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998	32	51	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39671	39676		10.1074/jbc.M402270200	http://dx.doi.org/10.1074/jbc.M402270200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15133046	hybrid, Green Published			2022-12-27	WOS:000223791500058
J	Sun, Y; Li, TY; Chen, H; Zhang, K; Zheng, KY; Mu, Y; Yan, GL; Li, W; Shen, JC; Luo, GM				Sun, Y; Li, TY; Chen, H; Zhang, K; Zheng, KY; Mu, Y; Yan, GL; Li, W; Shen, JC; Luo, GM			Selenium-containing 15-mer peptides with high glutathione peroxidase-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ANTIBODY; EBSELEN; GENERATION; ISCHEMIA; FAILURE	Glutathione peroxidase (GPX) is one of the most crucial antioxidant enzymes in a variety of organisms. Here we described a new strategy for generating a novel GPX mimic by combination of a phage-displayed random 15-mer peptide library followed by computer-aided rational design and chemical mutation. The novel GPX mimic is a homodimer consisting of a 15-mer selenopeptide with an appropriate catalytic center, a specific binding site for substrates, and high catalytic efficiency. Its steady state kinetics was also studied, and the values of k(cat)/K-mGSH and k(cat)/K-mH2O2 were found to be similar to that of native GPX and the highest among the existing GPX mimics. Moreover, the novel GPX mimic was confirmed to have a strong antioxidant ability to inhibit lipid peroxidation by measuring the content of malondialdehyde, cell viability, and lactate dehydrogenase activity. Importantly, the novel GPX mimic can penetrate into the cell membrane because of its small molecular size. These characteristics endue the novel mimic with potential perspective for pharmaceutical applications.	Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China; Jilin Univ, Minist Educ, Key Lab Supramol Struct & Mat, Changchun 130023, Peoples R China; Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China	Jilin University; Jilin University; Jilin University	Luo, GM (corresponding author), Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, 2519 Jiefang Rd, Changchun 130023, Peoples R China.	gmluo@mail.jlu.edu.cn		Sun, Ye/0000-0002-7674-9056				Babizhayev MA, 1996, BBA-MOL BASIS DIS, V1315, P87, DOI 10.1016/0925-4439(95)00091-7; BELL IM, 1993, BIOCHEMISTRY-US, V32, P3754, DOI 10.1021/bi00065a030; Burke MP, 2002, MED SCI LAW, V42, P10, DOI 10.1177/002580240204200103; CHRISTOPHERSEN BO, 1968, BIOCHIM BIOPHYS ACTA, V164, P35, DOI 10.1016/0005-2760(68)90068-4; COTGREAVE IA, 1992, BIOCHEM PHARMACOL, V43, P793, DOI 10.1016/0006-2952(92)90245-E; Davis Randall L, 2002, Int J Exp Diabetes Res, V3, P185, DOI 10.1080/15604280214279; DAWSON DA, 1995, NEUROSCI LETT, V185, P65, DOI 10.1016/0304-3940(94)11226-9; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; DOWLING EJ, 1989, J LEUKOCYTE BIOL, V46, P336; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; Forgione MA, 2002, CIRCULATION, V106, P1154, DOI 10.1161/01.CIR.0000026820.87824.6A; HOSHIDA S, 1994, AM J PHYSIOL-HEART C, V267, pH2342, DOI 10.1152/ajpheart.1994.267.6.H2342; JOLLEY ME, 1974, CARBOHYD RES, V33, P377, DOI 10.1016/S0008-6215(00)82819-0; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; Lahiri D K, 1997, Ann N Y Acad Sci, V826, P416, DOI 10.1111/j.1749-6632.1997.tb48495.x; LITTLE C, 1968, BIOCHEM BIOPH RES CO, V31, P145, DOI 10.1016/0006-291X(68)90721-3; Liu JQ, 1998, BIOCHEM BIOPH RES CO, V247, P397, DOI 10.1006/bbrc.1998.8545; Liu JQ, 2000, BBA-PROTEIN STRUCT M, V1481, P222, DOI 10.1016/S0167-4838(00)00130-8; Liu JQ, 1999, CHEM COMMUN, P199, DOI 10.1039/a808347i; Liu JQ, 1999, MAT SCI ENG C-BIO S, V10, P131, DOI 10.1016/S0928-4931(99)00095-8; LUO GM, 1994, BIOCHEM BIOPH RES CO, V198, P1240, DOI 10.1006/bbrc.1994.1175; Madesh M, 1997, MOL CELL BIOCHEM, V167, P81, DOI 10.1023/A:1006871622049; MILLS GC, 1957, J BIOL CHEM, V229, P189; Ren XJ, 2001, ARCH BIOCHEM BIOPHYS, V387, P250, DOI 10.1006/abbi.2000.2238; Ren XJ, 2001, BIOCHEM J, V359, P369, DOI 10.1042/0264-6021:3590369; Romero FJ, 1998, ENVIRON HEALTH PERSP, V106, P1229, DOI 10.2307/3433990; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; SITU ZQ, 1996, CELL CULTURE, P90; Su D, 2001, ARCH BIOCHEM BIOPHYS, V395, P177, DOI 10.1006/abbi.2001.2551; Sun Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P90, DOI 10.1016/S0003-9861(03)00006-7; WILSON SR, 1989, J AM CHEM SOC, V111, P5936, DOI 10.1021/ja00197a065; WU ZP, 1990, J AM CHEM SOC, V112, P5647, DOI 10.1021/ja00170a043; Yamaguchi T, 1998, STROKE, V29, P12, DOI 10.1161/01.STR.29.1.12	36	43	43	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37235	37240		10.1074/jbc.M403032200	http://dx.doi.org/10.1074/jbc.M403032200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15148324	hybrid			2022-12-27	WOS:000223554600007
J	Cabedo, H; Carteron, C; Ferrer-Montiel, A				Cabedo, H; Carteron, C; Ferrer-Montiel, A			Oligomerization of the sensory and motor neuron-derived factor prevents protein O-glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CELL-SURFACE; RECEPTORS; NEUREGULINS; DIFFERENTIATION; HEREGULIN	The sensory and motor neuron-derived factor (SMDF) is a neuregulin that promotes Schwann cell proliferation and differentiation. Hence, understanding axon myelination is important to unveil the mechanisms involved in SMDF biogenesis, membrane delivery, and compartmentalization. SMDF is a type II membrane protein expressed as two distinct polypeptides of similar to40 and 83 kDa. Whether the 83-kDa polypeptide results from posttranslational modifications of the protein monomers or protein dimerization remains unknown. Here we have addressed this question and shown that the 83-kDa polypeptide is an O-glycosylated form of the protein. Deletion of the N-terminal domain fully abrogates the SMDF O-glycosylation, indicating that incorporation of O-glycans occurs in the intracellular domain of the protein. Notably, O-glycosylated forms are excluded from partitioning into lipid raft microdomains. In addition, we found that heterologously expressed SMDF monomers interact in intact living cells as evidenced from fluorescence resonance energy transfer of cyan fluorescent protein/ yellow fluorescent protein . SMDF fusion proteins. A stepwise deletion approach demonstrated that SMDF self-association is primarily determined by its transmembrane segment. Notably, biochemical analysis revealed that SMDF multimers are exclusively composed of the 40-kDa polypeptide. Collectively, these findings indicate that the 40-kDa form corresponds to unmodified SMDF, which may be present as multimers, whereas the 83-kDa polypeptide is a monomeric O-glycosylated form of the protein. Furthermore, our observations imply a role for oligomerization as a potential modulator of the distribution in membrane domains and O-glycosylation of the protein.	Univ Miguel Hernandez, Consejo Super Invest Cient, Inst Neurociencias, Alicante 03550, Spain; Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain; Hosp St Joan Alacant, Unidad Invest, Alicante 03550, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universidad Miguel Hernandez de Elche	Cabedo, H (corresponding author), Univ Miguel Hernandez, Consejo Super Invest Cient, Inst Neurociencias, Alicante 03550, Spain.	hugo.cabedo@umh.es	Ferrer-Montiel, Antonio/C-3072-2015; Cabedo, Hugo/F-9404-2016	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Cabedo, Hugo/0000-0002-1322-6290				Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cabedo H, 2002, J BIOL CHEM, V277, P19905, DOI 10.1074/jbc.M201587200; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; El-Husseini AE, 2001, J BIOL CHEM, V276, P44984, DOI 10.1074/jbc.M103049200; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Jiang MS, 1997, J BIOL CHEM, V272, P2421; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Leimeroth R, 2002, DEV BIOL, V246, P245, DOI 10.1006/dbio.2002.0670; Longart M, 2002, REV NEUROLOGIA, V34, P91, DOI 10.33588/rn.3401.2001446; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Panchal RG, 2003, P NATL ACAD SCI USA, V100, P15936, DOI 10.1073/pnas.2533915100; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; Schroering A, 1998, J BIOL CHEM, V273, P30643, DOI 10.1074/jbc.273.46.30643; Stein RA, 2000, J MOL EVOL, V50, P397, DOI 10.1007/s002390010043; Van den Steen PE, 2000, TRENDS GLYCOSCI GLYC, V12, P35, DOI 10.4052/tigg.12.35; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	26	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33623	33629		10.1074/jbc.M401962200	http://dx.doi.org/10.1074/jbc.M401962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159404	hybrid			2022-12-27	WOS:000223039700071
J	Coronella-Wood, J; Terrand, J; Sun, HP; Chen, QM				Coronella-Wood, J; Terrand, J; Sun, HP; Chen, QM			c-Fos phosphorylation induced by H2O2 prevents proteasomal degradation of c-Fos in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; HYDROGEN-PEROXIDE GENERATION; CARDIAC MYOCYTE HYPERTROPHY; PROTEIN-KINASE-C; OXIDATIVE STRESS; SIGNALING PATHWAYS; HEART-FAILURE; TRANSCRIPTIONAL ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; OKADAIC ACID	Oxidants cause activation of the AP-1 transcription factor in cardiomyocytes. c-Fos, a component of the AP-1 transcription factor, is transiently induced by H2O2 and the induction is sensitive to the protein synthesis inhibitor cycloheximide. With high percentage gel electrophoresis, multiple c-Fos bands were resolved by Western blot analyses, indicating post-translational modification of newly synthesized c-Fos protein after H2O2 exposure. Treatment of immunoprecipitated c-Fos protein with the type 2 serine/threonine phosphatase A (PP2A) and immunoblotting of c-Fos protein with antibodies against phosphorylated serine or threonine demonstrated that c-Fos was phosphorylated at serine residues. A pharmacological inhibitor of JNKs inhibited the formation of multiple c-Fos bands without affecting c-fos transcription. The proteasomal inhibitor MG132 and Proteasome Inhibitor I extended the time course of c-Fos protein elevation. An increase in ubiquitin was detectable in c-Fos protein from H2O2-treated cells. Interestingly, treating the whole cell lysates with PP2A, but not calcineurin (i.e. PP2B), resulted in disappearance of c-Fos protein and MG132 was able to prevent this loss. H2O2 caused an elevation of PP2B and total phosphatase activity. The phosphatase inhibitor okadaic acid, but not PP2B inhibiter cypermethrin, extended the time course of c-Fos protein elevation after H2O2 exposure. These data suggest that JNK-mediated phosphorylation of newly synthesized c-Fos protects the protein from being degraded by the proteasome. PP2B independent dephosphorylation contributes to degradation of c-Fos protein during oxidative stress response of cardiomyocytes.	Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona	Chen, QM (corresponding author), Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA.	qchen@email.arizona.edu	Sun, Haipeng/E-8854-2010	Terrand, jerome/0000-0002-8169-7713; Sun, Haipeng/0000-0003-2128-3209	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010826] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL076530] Funding Source: Medline; NIEHS NIH HHS [R01 ES010826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acquaviva C, 2002, ANN NY ACAD SCI, V973, P426, DOI 10.1111/j.1749-6632.2002.tb04677.x; Acquaviva C, 2001, ONCOGENE, V20, P942, DOI 10.1038/sj.onc.1204155; AMSTAD P, 1990, B CANCER, V77, P501; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; Buetler TM, 2000, TRENDS PHARMACOL SCI, V21, P288, DOI 10.1016/S0165-6147(00)01508-X; Chen Q M, 2001, Cardiovasc Toxicol, V1, P267, DOI 10.1385/CT:1:4:267; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 2000, ARCH BIOCHEM BIOPHYS, V373, P242, DOI 10.1006/abbi.1999.1558; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; COPPER G, 1997, ANNU REV MED, V48, P13; CURRAN T, 1987, ONCOGENE, V2, P79; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dounay AB, 2002, CURR MED CHEM, V9, P1939, DOI 10.2174/0929867023368791; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Force T, 1999, GENE EXPRESSION, V7, P337; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FRANCIS GS, 1995, AM J CARDIOL, V75, pA11, DOI 10.1016/S0002-9149(99)80378-6; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Homcy CJ, 1998, CIRCULATION, V97, P1890, DOI 10.1161/01.CIR.97.19.1890; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Lijnen P, 1999, J MOL CELL CARDIOL, V31, P949, DOI 10.1006/jmcc.1999.0934; MARTIN B, 1985, J BIOL CHEM, V260, P4932; McCluskey A, 2002, J MED CHEM, V45, P1151, DOI 10.1021/jm010066k; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sawyer DB, 2000, CIRC RES, V86, P119, DOI 10.1161/01.RES.86.2.119; SHLAFER M, 1987, J MOL CELL CARDIOL, V19, P1195, DOI 10.1016/S0022-2828(87)80530-8; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SINGH N, 1995, MOL CELL BIOCHEM, V147, P77, DOI 10.1007/BF00944786; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Sugden PH, 2001, ANN MED, V33, P611; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Tu VC, 2002, J PHARMACOL EXP THER, V300, P1101, DOI 10.1124/jpet.300.3.1101; Tu Victoria C, 2003, Cardiovasc Toxicol, V3, P119, DOI 10.1385/CT:3:2:119; VANDEPLASSCHE G, 1989, J MOL CELL CARDIOL, V21, P383, DOI 10.1016/0022-2828(89)90649-4; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; ZHU H, 1997, MYOCARDIUM, P33	66	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33567	33574		10.1074/jbc.M404013200	http://dx.doi.org/10.1074/jbc.M404013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15136564	hybrid			2022-12-27	WOS:000223039700065
J	Duncan, RE; El-Sohemy, A; Archer, MC				Duncan, RE; El-Sohemy, A; Archer, MC			Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; COENZYME-A REDUCTASE; RAT MAMMARY TUMORIGENESIS; CHOLESTEROL-METABOLISM; DIETARY-CHOLESTEROL; STEROL SYNTHESIS; CORONARY EVENTS; MOUSE LUNG; STATIN USE; G1 ARREST	Malignant cells are known to have elevated rates of mevalonate synthesis because of increased levels and catalytic efficiency of 3-hydroxy-3-methylglutaryl-CoA reductase. Whether this increased mevalonate synthesis occurs as a consequence of increased requirements for a mevalonate-derived metabolite in response to rapid growth or whether mevalonate promotes the growth of tumor cells is unknown. To address this question, we administered mevalonate via miniosmotic pumps to nude mice inoculated with MDA-MB-435 human cancer cells. After 13 weeks of growth, tumors in mevalonate-treated mice were significantly larger than tumors in saline-treated, control mice (1.52 +/- 0.26 g versus 0.81 +/- 0.27 g respectively, p < 0.05). The cancer cells treated in culture with mevalonate also demonstrated increased proliferation rates associated with accelerated entry of cells into S phase. These cells had enhanced total and cyclin A-immunoprecipitable cyclin-dependent kinase-2 (CDK-2) activity, increased activating phosphorylation of CDK-2, and decreased inhibitory binding of CDK-2 to p21(Cip1). Our findings demonstrate that mevalonate promotes tumor growth and suggest that an increase in mevalonate synthesis in extrahepatic tissues following cholesterol-lowering therapy may explain the elevated risk of cancer shown in some studies.	Univ Toronto, Dept Nutr Sci, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	Archer, MC (corresponding author), Univ Toronto, Dept Nutr Sci, FitzGerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	m.archer@utoronto.ca	Duncan, Robin/AAH-7465-2021	El-Sohemy, Ahmed/0000-0002-8877-6414				Alonso DF, 1998, BREAST CANCER RES TR, V50, P83, DOI 10.1023/A:1006058409974; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Beck P, 2003, J CLIN EPIDEMIOL, V56, P280, DOI 10.1016/S0895-4356(02)00614-5; BENNIS F, 1993, INT J CANCER, V55, P640, DOI 10.1002/ijc.2910550421; BROWN MS, 1980, J LIPID RES, V21, P505; Calvert RJ, 2003, BIOCHEM PHARMACOL, V66, P393, DOI 10.1016/S0006-2952(03)00211-9; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Clutterbuck RD, 1998, BRIT J HAEMATOL, V102, P522, DOI 10.1046/j.1365-2141.1998.00783.x; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connolly JM, 1997, NUTR CANCER, V29, P48, DOI 10.1080/01635589709514601; Connolly JM, 1996, NUTR CANCER, V25, P231, DOI 10.1080/01635589609514447; Coogan PF, 2002, EPIDEMIOLOGY, V13, P262, DOI 10.1097/00001648-200205000-00005; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; DUNCAN RE, 2004, IN PRESS J PHARM TOX; El-Sohemy A, 2000, CARCINOGENESIS, V21, P827, DOI 10.1093/carcin/21.4.827; Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294; ElSohemy A, 1996, NUTR CANCER, V25, P111, DOI 10.1080/01635589609514433; ElSohemy A, 1996, CARCINOGENESIS, V17, P159, DOI 10.1093/carcin/17.1.159; ENDO A, 1979, BIOCHIM BIOPHYS ACTA, V575, P266; Feleszko W, 1998, EUR J CANCER, V34, P406, DOI 10.1016/S0959-8049(97)10034-X; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998; GEBHARDT A, 1995, J CANCER RES CLIN, V121, P343, DOI 10.1007/BF01225686; Ghosh PM, 1999, J CELL BIOCHEM, V74, P532; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165-6147(97)01147-4; HARPER JW, 1993, CELL, V75, P805; HARWOOD HJ, 1991, J LIPID RES, V32, P1237; Hawk MA, 1996, CANCER LETT, V109, P217, DOI 10.1016/S0304-3835(96)04465-5; KAWATA S, 1990, CANCER RES, V50, P3270; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kikuchi T, 1997, J NEURO-ONCOL, V34, P233, DOI 10.1023/A:1005753523949; KOGA T, 1990, BIOCHIM BIOPHYS ACTA, V1045, P115, DOI 10.1016/0005-2760(90)90139-O; Krause BR, 1998, ATHEROSCLEROSIS, V140, P15, DOI 10.1016/S0021-9150(98)00141-5; Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; Mater P, 1998, CANCER BIOTHER RADIO, V13, P387, DOI 10.1089/cbr.1998.13.387; MELHEM MF, 1987, BRIT J CANCER, V56, P45, DOI 10.1038/bjc.1987.150; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; NARISAWA T, 1994, CARCINOGENESIS, V15, P2045, DOI 10.1093/carcin/15.9.2045; Narisawa T, 1996, JPN J CANCER RES, V87, P798, DOI 10.1111/j.1349-7006.1996.tb02103.x; Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3; PRICE JE, 1990, CANCER RES, V50, P717; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; RAO KN, 1988, J NATL CANCER I, V80, P1248, DOI 10.1093/jnci/80.15.1248; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Reimann FM, 1996, ATHEROSCLEROSIS, V125, P63, DOI 10.1016/0021-9150(96)05848-0; ROSE DP, 1991, JNCI-J NATL CANCER I, V83, P1491, DOI 10.1093/jnci/83.20.1491; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; Seeger H, 2003, EXP CLIN ENDOCR DIAB, V111, P47, DOI 10.1055/s-2003-37501; SHAND JH, 1995, LIPIDS, V30, P917, DOI 10.1007/BF02537483; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE BG, 1989, J LIPID RES, V30, P1943; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Ukomadu C, 2003, J BIOL CHEM, V278, P4840, DOI 10.1074/jbc.M208658200; VANVLIET AK, 1995, BBA-LIPID LIPID MET, V1254, P105, DOI 10.1016/0005-2760(94)00176-Y; WEJDE J, 1992, ANTICANCER RES, V12, P317; YACHNIN S, 1982, ONCODEV BIOL MED, V3, P111	65	90	94	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33079	33084		10.1074/jbc.M400732200	http://dx.doi.org/10.1074/jbc.M400732200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155733	hybrid			2022-12-27	WOS:000223039700009
J	Alonso, A; Narisawa, S; Bogetz, J; Tautz, L; Hadzic, R; Huynh, H; Williams, S; Gjorloff-Wingren, A; Bremer, MCD; Holsinger, LJ; Millan, JL; Mustelin, T				Alonso, A; Narisawa, S; Bogetz, J; Tautz, L; Hadzic, R; Huynh, H; Williams, S; Gjorloff-Wingren, A; Bremer, MCD; Holsinger, LJ; Millan, JL; Mustelin, T			VHY, a novel myristoylated testis-restricted dual specificity protein phosphatase related to VHX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE-PHOSPHATASE; KINASE PHOSPHATASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; EYES ABSENT; IDENTIFICATION; MYRISTYLATION; LOCALIZATION	The human DUSP15 gene encodes an uncharacterized 235-amino acid member of the subfamily of small dual specificity protein phosphatases related to the Vaccinia virus VH1 phosphatase. Similar to VHR-related MKPX (VHX) (DUSP22), the predicted protein has an N-terminal myristoylation recognition sequence, and we show here that both are indeed modified by the attachment of a myristate to Gly-2. In recognition of this relatedness to VHX, we refer to the DUSP15-encoded protein as VH1-related member Y (VHY). We report that VHY is expressed at high levels in the testis and barely detectable levels in the brain, spinal cord, and thyroid. A VHY-specific antiserum detected a protein with an apparent molecular mass of 26 kDa, and histochemical analysis showed that VHY was readily detectable in pachytene spermatocytes (midstage of meiotic division I) and round spermatids and weakly in Leydig cells ( somatic cells outside of the seminiferous tubules). When expressed in 293T or NIH-3T3 cells, VHY was concentrated at the plasma membrane with some staining of vesicular structures in the Golgi region. Mutation of the myristoylation site Gly-2 abrogated membrane location. Finally, we demonstrate that VHY is an active phosphatase in vitro. We conclude that VHY is a new member of a subgroup of myristoylated VH1-like small dual specificity phosphatases.	Burnham Inst, Canc Res Ctr, Program Signal Transduct, La Jolla, CA 92037 USA; Burnham Inst, Canc Res Ctr, Program Stem Cell Biol, La Jolla, CA 92037 USA; Lund Univ, Dept Med Microbiol, SE-20502 Malmo, Sweden; SUGEN Inc, San Francisco, CA 94602 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Lund University; Pfizer	Mustelin, T (corresponding author), Burnham Inst, Canc Res Ctr, Program Signal Transduct, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham.org	Millan, Jose Luis/B-6580-2008; Bogetz, Jori F./U-2258-2019; Alonso, Andrés/L-7523-2014; Tautz, Lutz/M-9989-2014	Alonso, Andrés/0000-0001-8674-9378; Mustelin, Tomas/0000-0001-5912-8840; Tautz, Lutz/0000-0002-4075-6238	NCI NIH HHS [CA96949] Funding Source: Medline; NIAID NIH HHS [AI48032, AI53585, AI55741, AI35603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048032, R01AI035603, R01AI053585, R01AI055741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Hood KL, 2002, BIOCHEM BIOPH RES CO, V298, P545, DOI 10.1016/S0006-291X(02)02488-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Mustelin GS, 2002, FRONT BIOSCI, V7, P85; Mustelin T, 2003, IMMUNOL REV, V191, P139, DOI 10.1034/j.1600-065X.2003.00014.x; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Nakamura K, 1999, BIOCHEM J, V344, P819, DOI 10.1042/0264-6021:3440819; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200; Zama T, 2002, J BIOL CHEM, V277, P23919, DOI 10.1074/jbc.M200838200; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	47	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32586	32591		10.1074/jbc.M403442200	http://dx.doi.org/10.1074/jbc.M403442200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15138252	hybrid			2022-12-27	WOS:000222849700075
J	Dassa, B; Haviv, H; Amitai, G; Pietrokovski, S				Dassa, B; Haviv, H; Amitai, G; Pietrokovski, S			Protein splicing and auto-cleavage of bacterial intein-like domains lacking a C '-flanking nucleophilic residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOPROCESSING DOMAIN; HEDGEHOG; MECHANISM; EVOLUTION; PROTEASOME; GLUTAMINE; SEQUENCE; TERMINUS; ELEMENT; SYSTEM	Bacterial intein-like (BIL) domains are newly identified homologs of intein protein-splicing domains. The two known types of BIL domains together with inteins and hedgehog (Hog) auto-processing domains form the Hog/intein (HINT) superfamily. BIL domains are distinct from inteins and Hogs in sequence, phylogenetic distribution, and host protein type, but little is known about their biochemical activity. Here we experimentally study the auto-processing activity of four BIL domains. An A-type BIL domain from Clostridium thermocellum showed both protein-splicing and auto-cleavage activities. The splicing is notable, because this domain has a native Ala C'-flanking residue rather than a nucleophilic residue, which is absolutely necessary for intein protein splicing. B-type BIL domains from Rhodobacter sphaeroides and Rhodobacter capsulatus cleaved their N' or C' ends. We propose an alternative protein-splicing mechanism for the A-type BIL domains. After an initial N-S acyl shift, creating a thioester bond at the N' end of the domain, the C' end of the domain is cleaved by Asn cyclization. The resulting amino end of the C'-flank attacks the thioester bond next at the N' end of the domain. This aminolysis step splices the two flanks of the domain. The B-type BIL domain cleavage activity is explained in the context of the canonical intein protein-splicing mechanism. Our results suggest that the different HINT domains have related biochemical activities of proteolytic cleavages, ligation and splicing. Yet the predominant reactions diverged in each HINT type according to their specific biological roles. We suggest that the BIL domain cleavage and splicing reactions are mechanisms for post-translationally generating protein variability, particularly in extracellular bacterial proteins.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Pietrokovski, S (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	shmuel.pietrokovski@weizmann.ac.il		Pietrokovski, Shmuel/0000-0001-8573-5863				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amitai G, 2004, J BIOL CHEM, V279, P3121, DOI 10.1074/jbc.M311343200; Amitai G, 2003, MOL MICROBIOL, V47, P61, DOI 10.1046/j.1365-2958.2003.03283.x; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Burglin TR, 1996, CURR BIOL, V6, P1047, DOI 10.1016/S0960-9822(02)70659-3; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; CLARKE ND, 1994, P NATL ACAD SCI USA, V91, P11084, DOI 10.1073/pnas.91.23.11084; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; DONG WY, 1998, J BACTERIOL, V180, P4102; Farazi TA, 2001, BIOCHEMISTRY-US, V40, P6335, DOI 10.1021/bi0101401; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; HENIKOFF S, 1995, GENE, V163, P17; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; MEHLMAN T, 2002, P 50 C AM SOC MASS S; Mills KV, 2004, J BIOL CHEM, V279, P20685, DOI 10.1074/jbc.M400887200; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Perler FB, 2000, CURR OPIN BIOTECH, V11, P377, DOI 10.1016/S0958-1669(00)00113-0; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Pietrokovski S, 2001, TRENDS GENET, V17, P465, DOI 10.1016/S0168-9525(01)02365-4; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Romanelli A, 2004, P NATL ACAD SCI USA, V101, P6397, DOI 10.1073/pnas.0306616101; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; Southworth MW, 2000, EMBO J, V19, P5019, DOI 10.1093/emboj/19.18.5019; Southworth MW, 2004, BIOCHEM SOC T, V32, P250, DOI 10.1042/BST0320250; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; Wood DW, 1999, NAT BIOTECHNOL, V17, P889, DOI 10.1038/12879; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	37	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32001	32007		10.1074/jbc.M404562200	http://dx.doi.org/10.1074/jbc.M404562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15150275	hybrid			2022-12-27	WOS:000222849700003
J	Izumi, M; Yatagai, F; Hanaoka, F				Izumi, M; Yatagai, F; Hanaoka, F			Localization of human Mcm10 is spatially and temporally regulated during the S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC DNA-REPLICATION; PROTEIN; COMPLEX; INITIATION; CHROMATIN; ORIGINS; PROTEOLYSIS; BINDING; CDC45; PHOSPHORYLATION	Mcm10 (Dna43) is an essential protein for the initiation of DNA replication in Saccharomyces cerevisiae. Recently, we identified a human Mcm10 homolog and found that it is regulated by proteolysis and phosphorylation in a cell cycle-dependent manner and that it binds chromatin exclusively during the S phase of the cell cycle. However, the precise roles that Mcm10 plays are still unknown. To study the localization dynamics of human Mcm10, we established HeLa cell lines expressing green fluorescent protein (GFP)-tagged Mcm10. From early to mid-S phase, GFP-Mcm10 appeared in discrete nuclear foci. In early S phase, several hundred foci appeared throughout the nucleus. In mid-S phase, the foci appeared at the nuclear periphery and nucleolar regions. In the late S and G(2) phases, GFP-Mcm10 was localized to nucleoli. Although the distributions of GFP-Mcm10 during the S phase resembled those of replication foci, GFP-Mcm10 foci did not colocalize with sites of DNA synthesis in most cases. Furthermore, the transition of GFP-Mcm10 distribution patterns preceded changes in replication foci patterns or proliferating cell nuclear antigen foci patterns by 30-60 min. These results suggest that human Mcm10 is temporarily recruited to the replication sites 30-60 min before they replicate and that it dissociates from chromatin after the activation of the prereplication complex.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; RIKEN, Cyclotron Ctr, Radioisotope Technol Div, Wako, Saitama 3510198, Japan; RIKEN, Discovery Res Inst, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; RIKEN; RIKEN; Japan Science & Technology Agency (JST)	Hanaoka, F (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.	fhanaoka@fbs.osaka-u.ac.jp						Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Christensen TW, 2003, MOL BIOL CELL, V14, P2206, DOI 10.1091/mbc.E02-11-0706; Cook CR, 2003, J BIOL CHEM, V278, P36051, DOI 10.1074/jbc.M306049200; DEPAMPHILIS ML, 1999, CONCEPTS EUKARYOTIC; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Gregan J, 2003, MOL BIOL CELL, V14, P3876, DOI 10.1091/mbc.E03-02-0090; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Homesley L, 2000, GENE DEV, V14, P913; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; Izumi M, 2000, J CELL BIOCHEM, V76, P280, DOI 10.1002/(SICI)1097-4644(20000201)76:2<280::AID-JCB11>3.0.CO;2-0; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Izumi M, 2000, MOL BIOL CELL, V11, P4323, DOI 10.1091/mbc.11.12.4323; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	33	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32569	32577		10.1074/jbc.M314017200	http://dx.doi.org/10.1074/jbc.M314017200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15136575	hybrid			2022-12-27	WOS:000222849700073
J	Wurzer, WJ; Ehrhardt, C; Pleschka, S; Berberich-Siebelt, F; Wolff, T; Walczak, H; Planz, O; Ludwig, S				Wurzer, WJ; Ehrhardt, C; Pleschka, S; Berberich-Siebelt, F; Wolff, T; Walczak, H; Planz, O; Ludwig, S			NF-kappa B-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-3; GENE-EXPRESSION REQUIRES; DOUBLE-STRANDED-RNA; NS1 PROTEIN; TRANSCRIPTION FACTORS; SIGNALING PATHWAY; FAS-LIGAND; CELL-DEATH; ENDOTHELIAL-CELLS; KINASE COMPLEX	Activation of the transcription factor NF-kappaB is a hallmark of infections by viral pathogens including influenza viruses. Because gene expression of many proinflammatory and antiviral cytokines is controlled by this factor, the concept emerged that NF-kappaB and its upstream regulator IkappaB kinase are essential components of the innate antiviral immune response to infectious pathogens. In contrast to this common view we report here that NF-kappaB activity promotes efficient influenza virus production. On a molecular level this is due to NF-kappaB-dependent viral induction of the proapoptotic factors tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and FasL, which enhance virus propagation in an autocrine and paracrine fashion. Thus, NF-kappaB acts both proapoptotically and provirally in the context of an influenza virus infection.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Giessen, Inst Med Virol, D-35392 Giessen, Germany; Univ Wurzburg, Inst Pathol, D-97078 Wurzburg, Germany; Robert Koch Inst, D-13353 Berlin, Germany; Deutsch Krebsforschungszentrum, Tumor Immunol Program, Div Apoptosis Regulat, D-69120 Heidelberg, Germany; Bundesforsch Anstalt Viruskrankheiten Tiere, D-72076 Tubingen, Germany	Heinrich Heine University Dusseldorf; University of Wurzburg; Justus Liebig University Giessen; University of Wurzburg; Robert Koch Institute; Helmholtz Association; German Cancer Research Center (DKFZ)	Ludwig, S (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.	Stephan.Ludwig@uni-duesseldorf.de	Pleschka, Stephan/HGU-9354-2022; Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591; Ludwig, Stephan/0000-0003-4490-3052; Pleschka, Stephan/0000-0002-7372-7089				Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Delhase M, 1999, COLD SPRING HARB SYM, V64, P491, DOI 10.1101/sqb.1999.64.491; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; Ehrhardt C, 2004, FEBS LETT, V567, P230, DOI 10.1016/j.febslet.2004.04.069; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; Fujimoto I, 1998, CELL DEATH DIFFER, V5, P426, DOI 10.1038/sj.cdd.4400362; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Geiss GK, 2002, P NATL ACAD SCI USA, V99, P10736, DOI 10.1073/pnas.112338099; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; HINSHAW VS, 1994, J VIROL, V68, P3667, DOI 10.1128/JVI.68.6.3667-3673.1994; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Ludwig S, 1999, VIRAL IMMUNOL, V12, P175, DOI 10.1089/vim.1999.12.175; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Ludwig S, 2002, J VIROL, V76, P11166, DOI 10.1128/JVI.76.21.11166-11171.2002; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; Majde JA, 2000, J INTERF CYTOK RES, V20, P259, DOI 10.1089/107999000312397; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsui K, 1998, J IMMUNOL, V161, P3469; Mundt B, 2002, FASEB J, V16, P94, DOI 10.1096/fj.02-0537fje; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; RAZVI ES, 1995, ADV VIRUS RES, V45, P1, DOI 10.1016/S0065-3527(08)60057-3; Sedger LM, 1999, J IMMUNOL, V163, P920; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000; Washburn B, 2003, J IMMUNOL, V170, P1814, DOI 10.4049/jimmunol.170.4.1814; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhirnov OP, 2002, J VIROL, V76, P1617, DOI 10.1128/JVI.76.4.1617-1625.2002	60	187	205	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30931	30937		10.1074/jbc.M403258200	http://dx.doi.org/10.1074/jbc.M403258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143063	hybrid			2022-12-27	WOS:000222726800005
J	Das, I; Craig, C; Funahashi, Y; Jung, KM; Kim, TW; Byers, R; Weng, AP; Kutok, JL; Aster, JC; Kitajewski, J				Das, I; Craig, C; Funahashi, Y; Jung, KM; Kim, TW; Byers, R; Weng, AP; Kutok, JL; Aster, JC; Kitajewski, J			Notch Oncoproteins depend on gamma-secretase/presenilin activity for processing and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DOMAIN; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; MAMMALIAN NOTCH; NEOPLASTIC TRANSFORMATION; INTRAMEMBRANE PROTEOLYSIS; NUCLEAR TRANSLOCATION; SECRETASE INHIBITORS; ACTIVATED NOTCH4; PLASMA-MEMBRANE	During normal development Notch receptor signaling is important in regulating numerous cell fate decisions. Mutations that truncate the extracellular domain of Notch receptors can cause aberrant signaling and promote unregulated cell growth. We have examined two types of truncated Notch oncoproteins that arise from proviral insertion into the Notch4 gene (Notch4/int-3) or a chromosomal translocation involving the Notch1 gene (TAN-1). Both Notch4/int-3 and TAN-1 oncoproteins lack most or all of their ectodomain. Normal Notch signaling requires gamma-secretase/presenilin-mediated proteolytic processing, but whether Notch oncoproteins are also dependent on gamma-secretase/presenilin activity is not known. We demonstrate that Notch4/int-3-induced activation of the downstream transcription factor, CSL, is abrogated in cells deficient in presenilins or treated with a pharmacological inhibitor of gamma-secretase/presenilins. Furthermore, we find that both Notch4/int-3 and TAN-1 accumulate at the cell surface, where presenilin-dependent cleavage occurs, when gamma-secretase/presenilin activity is inhibited. gamma-Secretase/presenilin inhibition effectively blocks cellular responses to Notch4/int-3, but not TAN-1, apparently because some TAN-1 polypeptides lack transmembrane domains and do not require gamma-secretase/presenilin activity for nuclear access. These studies highlight potential uses and limitations of gamma-secretase/presenilin inhibitors in targeted therapy of Notch-related neoplasms.	Columbia Univ Coll Phys & Surg, Dept Pathol & Obstet Gynecol, New York, NY 10032 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Columbia University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kitajewski, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol & Obstet Gynecol, 630 W 168th St, New York, NY 10032 USA.	jkk9@columbia.edu	Aster, Jon C/B-6857-2009; Weng, Andrew P/I-5015-2014; Jung, Kwang-Mook/F-1035-2018	Jung, Kwang-Mook/0000-0003-4096-6953; Byers, Richard/0000-0003-0796-0365; craig, colleen/0000-0003-1308-6440; Weng, Andrew/0000-0001-7394-5425	NHLBI NIH HHS [HL-32454] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; ASTER JC, 1995, COLD SPRING HARB SYM, V49, P125; Berechid BE, 2002, J BIOL CHEM, V277, P8154, DOI 10.1074/jbc.M108238200; Berechid BE, 1999, CURR BIOL, V9, P1493, DOI 10.1016/S0960-9822(00)80121-9; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen FS, 2003, J BIOL CHEM, V278, P19974, DOI 10.1074/jbc.M210049200; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Krebs LT, 2000, GENE DEV, V14, P1343; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lauring AS, 2000, MOL CELL, V6, P939, DOI 10.1016/S1097-2765(05)00084-5; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Rohn JL, 1998, J VIROL, V72, P2686, DOI 10.1128/JVI.72.4.2686-2696.1998; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shirayoshi Y, 1997, GENES CELLS, V2, P213, DOI 10.1046/j.1365-2443.1997.d01-310.x; SMITH SD, 1989, BLOOD, V73, P2182; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Uyttendaele H, 2000, MICROVASC RES, V60, P91, DOI 10.1006/mvre.2000.2254; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	67	63	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30771	30780		10.1074/jbc.M309252200	http://dx.doi.org/10.1074/jbc.M309252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123653	hybrid			2022-12-27	WOS:000222531900108
J	Gopalakrishnan, B; Wang, WM; Greenspan, DS				Gopalakrishnan, B; Wang, WM; Greenspan, DS			Biosynthetic processing of the pro-alpha 1(V)pro-alpha 2(V)pro-alpha 3(V) procollagen heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; EHLERS-DANLOS-SYNDROME; ALPHA-1(V)-ALPHA-2(V)-ALPHA-3(V) COLLAGEN MOLECULE; AMINO-TERMINAL PROPEPTIDE; ARGININE-RICH PROTEIN; V COLLAGEN; XI COLLAGEN; NH2-TERMINAL DOMAIN; FIBRILLAR COLLAGEN; SCHWANN-CELLS	Type V collagen is a quantitatively minor fibrillar collagen comprised of different chain compositions in different tissues. The most widely distributed form, an alpha1(V)(2)alpha2(V) heterotrimer, regulates the physical properties of type I/V heterotypic collagen fibrils via partially processed NH2-terminal globular sequences. A less characterized alpha1(V)alpha2(V)alpha3(V) heterotrimer has a much more limited distribution of expression and unknown function(s). We characterized the biosynthetic processing of pro-alpha1(V)(2)pro-alpha2(V) procollagen previously and showed it to differ in important ways from biosynthetic processing of the major fibrillar procollagens I-III. Here we have successfully produced recombinant pro-alpha1(V)pro-2(V)pro-alpha3(V) heterotrimers. We use these, and mouse embryo fibroblasts doubly homozygous null for the Bmp1 gene, which encodes the metalloproteinase bone morphogenetic protein-1 (BMP-1), and for a gene encoding the closely related metalloproteinase mammalian Tolloid-like 1, to characterize biosynthetic processing of pro-alpha1(V)pro-alpha2(V)pro-alpha3(V) heterotrimers, thus completing characterization of type V collagen biosynthetic processing. Whereas pro-alpha1(V) and pro-alpha2(V) processing in pro-alpha1(V)pro-alpha2(V)pro-alpha3(V) heterotrimers is similar to that which occurs in pro-alpha1(V)(2)pro-alpha2(V) heterotrimers, the processing of pro-alpha3(V) by BMP-1 occurs at an unexpected site within NH2-terminal globular sequences. We also demonstrate that, despite similarities in NH2-terminal domain structures, pro-alpha2(V) NH2-terminal globular sequences are not cleaved by ADAMTS-2, the metalloproteinase that cleaves the N-propeptides of the major fibrillar procollagen chains.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave,MSC 5675, Madison, WI 53706 USA.			Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM63471] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR047746, R01AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063471] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEDIN MZ, 1982, BIOSCIENCE REP, V2, P493, DOI 10.1007/BF01115247; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BROEK DL, 1985, J BIOL CHEM, V260, P555; BROWN RA, 1978, BIOCHEM BIOPH RES CO, V80, P866, DOI 10.1016/0006-291X(78)91324-4; Chanut-Delalande H, 2001, J BIOL CHEM, V276, P24352, DOI 10.1074/jbc.M101182200; Chernousov MA, 2000, J BIOL CHEM, V275, P28208; Chernousov MA, 1999, J NEUROSCI RES, V56, P284, DOI 10.1002/(SICI)1097-4547(19990501)56:3<284::AID-JNR8>3.3.CO;2-H; Chernousov MA, 1996, J BIOL CHEM, V271, P13844, DOI 10.1074/jbc.271.23.13844; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Eyre D, 1987, STRUCTURE FUNCTION C, P261; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; GREENSPAN DS, 2005, IN PRESS TOP CURR CH; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KUHN K, 1987, STRUCTURE FUNCTION C, P1; KUMAMOTO CA, 1981, J BIOL CHEM, V256, P7053; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LEE ST, 1988, J BIOL CHEM, V263, P13414; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NIYIBIZI C, 1994, EUR J BIOCHEM, V224, P943, DOI 10.1111/j.1432-1033.1994.00943.x; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; RHODES RK, 1981, COLLAGEN REL RES, V1, P337; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SAGE H, 1979, BIOCHEMISTRY-US, V18, P3815, DOI 10.1021/bi00584a027; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TAKAHARA K, 1995, GENOMICS, V29, P588, DOI 10.1006/geno.1995.9961; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	69	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30904	30912		10.1074/jbc.M402252200	http://dx.doi.org/10.1074/jbc.M402252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136578	hybrid			2022-12-27	WOS:000222531900125
J	Becker, HM; Deitmer, JW				Becker, HM; Deitmer, JW			Voltage dependence of H+ buffering mediated by sodium bicarbonate cotransport expressed in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROGENIC NA+-HCO3-COTRANSPORTER; LEECH GLIAL-CELLS; INTRACELLULAR PH; LAEVIS OOCYTES; CLONING; STOICHIOMETRY; TRANSPORTERS; BRAIN; NBC	The electrogenic sodium bicarbonate cotransporter (NBCe1) is expressed in many epithelial cells and, in the brain, in glial cells. Little is known about the physiological significance of the NBCe1 for proton homeostasis and for other acid/base-coupled transporters in these cells. We have measured the voltage-dependent transport activity of an NBC from human kidney, type hkNBCe1, expressed in oocytes of the frog Xenopus laevis, by recording membrane current and the changes in intracellular pH and sodium at different membrane potentials between - 20 and - 100 mV. The apparent intracellular buffer capacity was increased and became dependent upon membrane voltage when the NBCe1 was expressed; the measured buffer capacity increased by up to 7 mM/10 mV of membrane depolarization. Lactate transport by the electroneutral monocarboxylate transporter became enhanced and dependent upon membrane potential, when the monocarboxylate transporter ( isoform 1) was co-expressed with NBCe1 in oocytes. Our results indicate that the electrogenic NBCe1 renders the cell membrane potential an effective regulator of intracellular H+ buffering and acid/base-coupled metabolite transport.	Tech Univ Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, D-67653 Kaiserslautern, Germany	University of Kaiserslautern	Deitmer, JW (corresponding author), Tech Univ Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, Postfach 3049, D-67653 Kaiserslautern, Germany.	deitmer@rhrk.uni-kl.de	Becker, Holger/AAB-4322-2020					Amara SG, 2002, NEUROCHEM INT, V41, P313, DOI 10.1016/S0197-0186(02)00018-9; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; BROER S, 1997, J BIOL CHEM, V272, P3096; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; Deitmer JW, 2000, BIOESSAYS, V22, P747, DOI 10.1002/1521-1878(200008)22:8<747::AID-BIES8>3.3.CO;2-S; DEITMER JW, 1995, J PHYSIOL-LONDON, V485, P157, DOI 10.1113/jphysiol.1995.sp020720; Deitmer JW, 2002, J NEUROCHEM, V80, P721, DOI 10.1046/j.0022-3042.2002.00765.x; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; Gross E, 2001, J PHYSIOL-LONDON, V531, P597, DOI 10.1111/j.1469-7793.2001.0597h.x; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Heyer M, 1999, PFLUG ARCH EUR J PHY, V438, P322, DOI 10.1007/s004240050916; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MUNSCH T, 1994, J PHYSIOL-LONDON, V474, P43, DOI 10.1113/jphysiol.1994.sp020001; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Schousboe A, 2000, NEUROCHEM RES, V25, P1241, DOI 10.1023/A:1007692012048; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; Soleimani M, 2001, J MEMBRANE BIOL, V183, P71, DOI 10.1007/s00232-001-0055-8; THOMAS RC, 1991, NATURE, V350, P564, DOI 10.1038/350564b0	21	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28057	28062		10.1074/jbc.M402401200	http://dx.doi.org/10.1074/jbc.M402401200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123668	hybrid			2022-12-27	WOS:000222265400030
J	Luo, BH; Strokovich, K; Walz, T; Springer, TA; Takagi, J				Luo, BH; Strokovich, K; Walz, T; Springer, TA; Takagi, J			Allosteric beta(1) integrin antibodies that stabilize the low affinity state by preventing the swing-out of the hybrid domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN MONOCLONAL-ANTIBODY; FIBRONECTIN RECEPTOR; CONFORMATIONAL-CHANGES; REGULATORY REGION; BINDING SITES; CELL-ADHESION; ACTIVATION; SUBUNIT; EPITOPE; IDENTIFICATION	The ligand binding function of integrins can be modulated by various monoclonal antibodies by both direct and indirect mechanisms. We have characterized an anti-beta(1) antibody, SG/19, that had been reported to inhibit the function of the beta(1) integrin on the cell surface. SG/19 recognized the wild type beta(1) subunit that exists in a conformational equilibrium between the high and low affinity states but bound poorly to a mutant beta(1) integrin that had been locked in a high affinity state. Epitope mapping of SG/19 revealed that Thr(82) in the beta(1) subunit, located at the outer face of the boundary between the I-like and hybrid domains, was the key binding determinant for this antibody. Direct visualization of the alpha(5)beta(1) headpiece fragment in complex with SG/19 Fab with electron microscopy confirmed the location of the binding surface and showed that the ligand binding site is not occluded by the bound Fab. Surface plasmon resonance showed that alpha(5)beta(1) integrin bound by SG/19 maintained a low affinity toward its physiological ligand fibronectin (Fn) whereas binding by function-blocking anti-alpha(5) antibodies resulted in a complete loss of fibronectin binding. Thus a class of the anti-beta antibodies represented by SG/19 attenuate the ligand binding function by restricting the conformational shift to the high affinity state involving the swing-out of the hybrid domain without directly interfering with ligand docking.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Osaka Univ, Inst Prot Res, Lab Prot Synth & Express, Osaka 5650871, Japan	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Osaka University	Takagi, J (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA.	takagi@protein.osaka-u.ac.jp		Walz, Thomas/0000-0003-2606-2835	NHLBI NIH HHS [HL48675] Funding Source: Medline; NIGMS NIH HHS [GM62580] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM062580] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Billheimer JT, 2002, BLOOD, V99, P3540, DOI 10.1182/blood.V99.10.3540; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; LUO BH, 2004, IN PRESS PLOS BIOL; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MIYAKE K, 1994, INT IMMUNOL, V6, P1221, DOI 10.1093/intimm/6.8.1221; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Mould AP, 1996, J CELL SCI, V109, P2613; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PETRUZZELLI L, 1995, LEUCOCYTE TYPING, V5, P1581; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tsuchida J, 1998, J CELL SCI, V111, P1759; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881	37	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27466	27471		10.1074/jbc.M404354200	http://dx.doi.org/10.1074/jbc.M404354200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123676	Green Published, hybrid			2022-12-27	WOS:000222120400078
J	Golemi-Kotra, D; Meroueh, SO; Kim, C; Vakulenko, SB; Bulychev, A; Stemmler, AJ; Stemmler, TL; Mobashery, S				Golemi-Kotra, D; Meroueh, SO; Kim, C; Vakulenko, SB; Bulychev, A; Stemmler, AJ; Stemmler, TL; Mobashery, S			The importance of a critical protonation state and the fate of the catalytic steps in class A beta-lactamases and penicillin-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ULTRAHIGH-RESOLUTION STRUCTURE; ESCHERICHIA-COLI; THERMODYNAMIC CONSEQUENCES; STAPHYLOCOCCUS-AUREUS; CHEMICAL-MODIFICATION; IMPROVED SENSITIVITY; SECONDARY STRUCTURE; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE	beta-Lactamases and penicillin-binding proteins are bacterial enzymes involved in antibiotic resistance to beta-lactam antibiotics and biosynthetic assembly of cell wall, respectively. Members of these large families of enzymes all experience acylation by their respective substrates at an active site serine as the first step in their catalytic activities. A Ser-X-X-Lys sequence motif is seen in all these proteins, and crystal structures demonstrate that the side-chain functions of the serine and lysine are in contact with one another. Three independent methods were used in this report to address the question of the protonation state of this important lysine (Lys-73) in the TEM-1 beta-lactamase from Escherichia coli. These techniques included perturbation of the pK(a) of Lys-73 by the study of the gamma-thialysine-73 variant and the attendant kinetic analyses, investigation of the protonation state by titration of specifically labeled proteins by nuclear magnetic resonance, and by computational treatment using the thermodynamic integration method. All three methods indicated that the pK(a) of Lys-73 of this enzyme is attenuated to 8.0 - 8.5. It is argued herein that the unique ground-state ion pair of Glu-166 and Lys-73 of class A beta-lactamases has actually raised the pK(a) of the active site lysine to 8.0 - 8.5 from that of the parental penicillin-binding protein. Whereas we cannot rule out that Glu-166 might activate the active site water, which in turn promotes Ser-70 for the acylation event, such as proposed earlier, we would like to propose as a plausible alternative for the acylation step the possibility that the ion pair would reconfigure to the protonated Glu-166 and unprotonated Lys-73. As such, unprotonated Lys-73 could promote serine for acylation, a process that should be shared among all active-site serine beta-lactamases and penicillin-binding proteins.	Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48202 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Wayne State University; University of Notre Dame	Stemmler, TL (corresponding author), Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48202 USA.	tstemmle@med.wayne.edu; mobashery@nd.edu	/N-6611-2013	/0000-0003-1299-6987; Kim, Choon/0000-0003-0306-8935	NIAID NIH HHS [AI 33170, R01 AI033170] Funding Source: Medline; NIDDK NIH HHS [R01 DK068139] Funding Source: Medline; NIGMS NIH HHS [R01 GM061629, GM 61629] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061629] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ACC INC, 2000, FEL ND SPECTR PROC S; Atanasov BP, 2000, P NATL ACAD SCI USA, V97, P3160, DOI 10.1073/pnas.060027897; Bush K, 1998, ADV EXP MED BIOL, V456, P71; CASE DA, 2002, AMBER; Chen CC, 1996, BIOCHEMISTRY-US, V35, P12251, DOI 10.1021/bi961153v; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Damblon C, 1996, P NATL ACAD SCI USA, V93, P1747, DOI 10.1073/pnas.93.5.1747; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; GIBSON RM, 1990, BIOCHEM J, V272, P613, DOI 10.1042/bj2720613; Golemi D, 2001, P NATL ACAD SCI USA, V98, P14280, DOI 10.1073/pnas.241442898; Golemi-Kotra D, 2003, J BIOL CHEM, V278, P18419, DOI 10.1074/jbc.M300611200; Gouda H, 2003, BIOPOLYMERS, V68, P16, DOI 10.1002/bip.10270; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; HERMANN P, 1968, H-S Z PHYSIOL CHEM, V349, P390, DOI 10.1515/bchm2.1968.349.1.390; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; Hopkins CE, 2002, PROTEIN SCI, V11, P1591, DOI 10.1110/ps.3900102; Ishiguro M, 1996, J MED CHEM, V39, P2207, DOI 10.1021/jm9506027; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KELLY JA, 1982, SCIENCE, V218, P479, DOI 10.1126/science.7123246; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; Kotra L P., 2002, BACTERIAL RESISTANCE, P123; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; Lamotte-Brasseur J, 1999, PROTEIN SCI, V8, P404; LAMOTTEBRASSEUR J, 1991, BIOCHEM J, V279, P213, DOI 10.1042/bj2790213; LEUNG YC, 1994, BIOCHEM J, V299, P671, DOI 10.1042/bj2990671; Lietz EJ, 2000, BIOCHEMISTRY-US, V39, P4971, DOI 10.1021/bi992681k; MADGWICK PJ, 1987, BIOCHEM J, V248, P657, DOI 10.1042/bj2480657; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Massova I, 2002, J COMPUT CHEM, V23, P1559, DOI 10.1002/jcc.10129; Maveyraud L, 1996, J AM CHEM SOC, V118, P7435, DOI 10.1021/ja9609718; Maveyraud L, 2002, J AM CHEM SOC, V124, P2461, DOI 10.1021/ja016736t; MERZ KM, 1991, J AM CHEM SOC, V113, P3572, DOI 10.1021/ja00009a053; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Nukaga M, 2003, J MOL BIOL, V328, P289, DOI 10.1016/S0022-2836(03)00210-9; Paetzel M, 1997, J BIOL CHEM, V272, P9994; PLANAS A, 1991, BIOCHEMISTRY-US, V30, P8268, DOI 10.1021/bi00247a023; RAMESH V, 1994, EUR J BIOCHEM, V225, P601, DOI 10.1111/j.1432-1033.1994.00601.x; Rao BG, 1996, J COMPUT AID MOL DES, V10, P23, DOI 10.1007/BF00124462; Raquet X, 1997, BIOPHYS J, V73, P2416, DOI 10.1016/S0006-3495(97)78270-5; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; SMITH HB, 1988, J BIOL CHEM, V263, P4921; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Sun T, 2003, PROTEIN SCI, V12, P82, DOI 10.1110/ps.0224303; SWAREN P, 1995, STRUCTURE, V3, P603, DOI 10.1016/S0969-2126(01)00194-0; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; Vakulenko S, 2002, ANTIMICROB AGENTS CH, V46, P646, DOI 10.1128/AAC.46.3.646-653.2002; Vakulenko SB, 1998, ANTIMICROB AGENTS CH, V42, P1542, DOI 10.1128/AAC.42.7.1542; Vanhove M, 1997, BIOCHEM J, V321, P413, DOI 10.1042/bj3210413; YAMAZAKI T, 1991, BIOCHEMISTRY-US, V30, P6036, DOI 10.1021/bi00238a030	58	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34665	34673		10.1074/jbc.M313143200	http://dx.doi.org/10.1074/jbc.M313143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15152012	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000223134800071
J	Hansson, K; Ma, XS; Eliasson, L; Czerwiec, E; Furie, B; Furie, BC; Rorsman, P; Stenflo, J				Hansson, K; Ma, XS; Eliasson, L; Czerwiec, E; Furie, B; Furie, BC; Rorsman, P; Stenflo, J			The first gamma-carboxyglutamic acid-containing contryphan - A selective L-type calcium ion channel blocker isolated from the venom of conus marmoreus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC-ACID; K-DEPENDENT CARBOXYLASE; VITAMIN-K; CONANTOKIN-G; GLUTAMYL CARBOXYLASE; CONTAINING CONOTOXIN; RECOGNITION SITE; CA2+ CHANNELS; AMINO-ACIDS; METAL-FREE	Contryphans constitute a group of conopeptides that are known to contain an unusual density of post-translational modifications including tryptophan bromination, amidation of the C-terminal residue, leucine, and tryptophan isomerization, and proline hydroxylation. Here we report the identification and characterization of a new member of this family, glacontryphan-M from the venom of Conus marmoreus. This is the first known example of a contryphan peptide carrying glutamyl residues that have been post-translationally carboxylated to gamma-carboxyglutamyl (Gla) residues. The amino acid sequence of glacontryphan-M was determined using automated Edman degradation and electrospray ionization mass spectrometry. The amino acid sequence of the peptide is: Asn-Gla-Ser-Gla-Cys-Pro-D-Trp-His-Pro-Trp-Cys. As with most other contryphans, glacontryphan-M is amidated at the C terminus and maintains the five-residue intercysteine loop. The occurrence of a D-tryptophan residue was confirmed by chemical synthesis and HPLC elution profiles. Using fluorescence spectroscopy we demonstrated that the Gla-containing peptide binds calcium with a K-D of 0.63 mM. Cloning of the full-length cDNA encoding glacontryphan-M revealed that the primary translation product carries an N-terminal signal/propeptide sequence that is homologous to earlier reported contryphan signal/propeptide sequences up to 10 amino acids preceding the toxin region. Electrophysiological experiments, carried out on mouse pancreatic B-cells, showed that glacontryphan-M blocks L-type voltage-gated calcium ion channel activity in a calcium-dependent manner. Glacontryphan-M is the first contryphan reported to modulate the activity of L-type calcium ion channels.	Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden; Marine Biol Lab, Woods Hole, MA 02543 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis & Vasc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England	Lund University; Skane University Hospital; Lund University; Marine Biological Laboratory - Woods Hole; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; University of Oxford	Hansson, K (corresponding author), Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.	Karin.Hansson@klkemi.mas.lu.se	Rorsman, Patrik/A-4331-2016; Eliasson, Lena/E-9294-2012	Rorsman, Patrik/0000-0001-7578-0767; Eliasson, Lena/0000-0002-6467-5029				Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Barg S, 2001, BIOPHYS J, V81, P3308, DOI 10.1016/S0006-3495(01)75964-4; Barg S, 2000, DIABETES, V49, P1500, DOI 10.2337/diabetes.49.9.1500; Begley GS, 2000, J BIOL CHEM, V275, P36245, DOI 10.1074/jbc.M003944200; Blandl T, 2000, FEBS LETT, V470, P139, DOI 10.1016/S0014-5793(00)01309-0; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; CAIRNS JR, 1991, ANAL BIOCHEM, V199, P93, DOI 10.1016/0003-2697(91)90274-W; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHEN Z, 1998, J BIOL CHEM, V26, P16248; Czerwiec E, 2002, EUR J BIOCHEM, V269, P6162, DOI 10.1046/j.1432-1033.2002.03335.x; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Fainzilber M, 1996, BIOCHEMISTRY-US, V35, P8748, DOI 10.1021/bi9602674; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; Fainzilber M, 1998, BIOCHEMISTRY-US, V37, P1470, DOI 10.1021/bi971571f; FERNLUND P, 1975, J BIOL CHEM, V250, P6125; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; Grant MA, 2004, J BIOL CHEM, V279, P32464, DOI 10.1074/jbc.M313826200; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HAUSCHKA PV, 1988, CURRENT ADV VITAMIN, P237; Jacobsen R, 1998, J PEPT RES, V51, P173; Jacobsen RB, 1999, J PEPT RES, V54, P93, DOI 10.1034/j.1399-3011.1999.00093.x; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; Jimenez EC, 2001, TOXICON, V39, P803, DOI 10.1016/S0041-0101(00)00210-5; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; Kalume DE, 2000, J MASS SPECTROM, V35, P145, DOI 10.1002/(SICI)1096-9888(200002)35:2<145::AID-JMS922>3.0.CO;2-I; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; Lirazan MB, 2000, BIOCHEMISTRY-US, V39, P1583, DOI 10.1021/bi9923712; Massilia GR, 2003, BIOCHEM BIOPH RES CO, V303, P238, DOI 10.1016/S0006-291X(03)00331-0; Massilia GR, 2001, BIOCHEM BIOPH RES CO, V288, P908, DOI 10.1006/bbrc.2001.5833; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; Miles LA, 2002, J BIOL CHEM, V277, P43033, DOI 10.1074/jbc.M206690200; Nakamura T, 1996, PROTEIN SCI, V5, P524; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Prorok M, 1998, J BIOL CHEM, V273, P19573, DOI 10.1074/jbc.273.31.19573; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P15677, DOI 10.1021/bi9718550; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; TAO L, 2000, J BIOL CHEM, V275, P18291; Walker CS, 2001, J BIOL CHEM, V276, P7769, DOI 10.1074/jbc.M009576200; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Zhou LM, 1996, J NEUROCHEM, V66, P620	58	61	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32453	32463		10.1074/jbc.M313825200	http://dx.doi.org/10.1074/jbc.M313825200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155730	hybrid, Green Published			2022-12-27	WOS:000222849700059
J	Isas, JM; Langen, R; Hubbell, WL; Haigler, HT				Isas, JM; Langen, R; Hubbell, WL; Haigler, HT			Structure and dynamics of a helical hairpin that mediates calcium-dependent membrane binding of annexin B12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; PHOSPHOLIPID-VESICLES; FLUIDITY GRADIENT; C2 DOMAIN; SPIN; BILAYERS; FLUORESCENCE; DIFFUSION; PROTEINS	A wealth of high-resolution structural data has accumulated for soluble annexins, but only limited information is available for the biologically important membrane-bound proteins. To investigate the structural and dynamic changes that occur upon membrane binding, we analyzed the electron paramagnetic resonance (EPR) mobility and accessibility parameters of a continuous 30-residue nitroxide scan encompassing helices D and E in repeat 2 of annexin B12 (residues 134-163) while the protein was bound to phospholipid vesicles in the presence of Ca2+. A comparison of these data to those from a previously published study of the protein in solution (Isas, J. M., Langen, R., Haigler, H. T., and Hubbell, W. L. (2002) Biochemistry 41, 1464-1473) showed that the overall backbone fold for the scanned region did not change upon membrane binding. However, side-chains in the loop between the D and E helices were highly dynamic in solution but became essentially frozen in the EPR time scale upon binding to membranes. Accessibility measurements clearly established that side-chains in this loop were exposed to the hydrophobic core of the bilayer and provide the first evidence that a D-E loop directly participates in the Ca2+-dependent binding of annexins to membranes. Other localized changes showed that the D-helix became much less dynamic after membrane binding and identified quaternary contact sites in the membrane-bound homo-trimer. Finally, immobilization of the D-E loop upon contact with phospholipid suggests that the bilayer, which is normally very mobile on the EPR time scale, is immobilized in the head-group region by the annexin B12. This suggests that annexin B12 alters membrane structure in a manner that may be biologically significant.	Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Irvine; University of Southern California; University of California System; University of California Los Angeles	Haigler, HT (corresponding author), Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.	langen@usc.edu; hhaigler@uci.edu	Haigler, Harry/C-3788-2011		NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063915, R01GM055651] Funding Source: NIH RePORTER; NEI NIH HHS [EY05216] Funding Source: Medline; NIGMS NIH HHS [GM55651, GM63915] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DEVAUX P, 1972, J AM CHEM SOC, V94, P4475, DOI 10.1021/ja00768a600; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GILMANSHIN R, 1994, BIOCHEMISTRY-US, V33, P8225, DOI 10.1021/bi00193a008; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; Isas JM, 2003, J BIOL CHEM, V278, P30227, DOI 10.1074/jbc.M301228200; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; Kaetzel MA, 2001, BIOCHEMISTRY-US, V40, P4192, DOI 10.1021/bi002507s; Kohout SC, 2003, BIOCHEMISTRY-US, V42, P1254, DOI 10.1021/bi026596f; Ladokhin AS, 2002, BIOCHEMISTRY-US, V41, P13617, DOI 10.1021/bi0264418; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Liemann S, 1997, CELL MOL LIFE SCI, V53, P516, DOI 10.1007/s000180050065; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Malmberg NJ, 2003, BIOCHEMISTRY-US, V42, P13227, DOI 10.1021/bi035119+; MCHAOURAB HS, 1996, BIOCHEMISTRY-US, V273, P810; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; Megli FM, 1998, BIOCHEMISTRY-US, V37, P10540, DOI 10.1021/bi9801255; Megli FM, 2000, BIOCHEMISTRY-US, V39, P5534, DOI 10.1021/bi992779z; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Patel DR, 2001, BIOCHEMISTRY-US, V40, P7054, DOI 10.1021/bi010345+; Peng S, 2004, BIOPHYS J, V86, P145, DOI 10.1016/S0006-3495(04)74092-8; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Reviakine I, 2000, J STRUCT BIOL, V131, P234, DOI 10.1006/jsbi.2000.4286; Saurel O, 1998, BIOCHEMISTRY-US, V37, P1403, DOI 10.1021/bi971484n; Seaton B. A., 1996, ANNEXINS MOL STRUCTU; Sopkova J, 1998, BIOCHEMISTRY-US, V37, P11962, DOI 10.1021/bi980773o; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281	33	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32492	32498		10.1074/jbc.M402568200	http://dx.doi.org/10.1074/jbc.M402568200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15143059	hybrid			2022-12-27	WOS:000222849700063
J	McIntosh, DB; Clausen, JD; Woolley, DG; MacLennan, DH; Vilsen, B; Andersen, JP				McIntosh, DB; Clausen, JD; Woolley, DG; MacLennan, DH; Vilsen, B; Andersen, JP			Roles of conserved P domain residues and Mg2+ in ATP binding in the ground and Ca2+-activated states of sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; CONFORMATIONAL-CHANGES; PHOSPHORYLATION LOOP; CRYSTAL-STRUCTURE; MGATP BINDING; CALCIUM-PUMP; CA-2+-ATPASE; SITE; INTERMEDIATE; EFFICIENCY	Residues in conserved motifs (625)TGD, (676)FARXXPXXK, and (701)TGDGVND in domain P of sarcoplasmic reticulum Ca2+-ATPase, as well as in motifs (DPPR)-D-601 and (359)NQR(/K)MSV in the hinge segments connecting domains N and P, were examined by mutagenesis to assess their roles in nucleotide and Mg2+ binding and stabilization of the Ca2+-activated transition state for phosphoryl transfer. In the absence of Mg2+, mutations removing the charges of domain P residues Asp(627), Lys(684), Asp(703), and Asp(707) increased the affinity for ATP and 2', 3'-O-(2,4,6-trinitrophenyl)-8-azidoadenosine 5'-triphosphate. These mutations, as well as Gly(626)-->Ala, were inhibitory for ATP binding in the presence of Mg2+ and for tight binding of the beta, gamma-bidentate chromium(III) complex of ATP. The hinge mutations had pronounced, but variable, effects on ATP binding only in the presence of Mg2+. The data demonstrate an unfavorable electrostatic environment for binding of negatively charged nucleotide in domain P and show that Mg2+ is required to anchor the phosphoryl group of ATP at the phosphorylation site. Mutants Gly(626) --> Ala, Lys(684) --> Met, Asp(703) --> Ala/Ser/Cys, and mutants with alteration to Asp(707) exhibited very slow or negligible phosphorylation, making it possible to measure ATP binding in the pseudo-transition state attained in the presence of both Mg2+ and Ca2+. Under these conditions, ATP binding was almost completely blocked in Gly(626) --> Ala and occurred with 12- and 7-fold reduced affinities in Asp(703) --> Ala and Asp(707) --> Cys, respectively, relative to the situation in the presence of Mg2+ without Ca2+, whereas in Lys(684) --> Met and Asp(707) --> Ser/Asn the affinity was enhanced 14- and 3-5-fold, respectively. Hence, Gly(626) and Asp(703) seem particularly critical for mediating entry into the transition state for phosphoryl transfer upon Ca2+ binding at the transport sites.	Univ Cape Town, Fac Hlth Sci, Dept Clin Lab Sci, ZA-7925 Cape Town, South Africa; Groote Schuur Hosp, Natl Hlth Lab Serv, ZA-7925 Cape Town, South Africa; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	University of Cape Town; University of Cape Town; University of Toronto; Aarhus University	McIntosh, DB (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Clin Lab Sci, ZA-7925 Cape Town, South Africa.	davidmci@chempath.uct.ac.za; jpa@fi.au.dk		Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Lee SY, 2001, J BIOL CHEM, V276, P16425, DOI 10.1074/jbc.M101002200; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8	25	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32515	32523		10.1074/jbc.M403242200	http://dx.doi.org/10.1074/jbc.M403242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15133025	Green Published, hybrid			2022-12-27	WOS:000222849700066
J	Guan, RJ; Malchiodi, EL; Wang, Q; Schuck, P; Mariuzza, RA				Guan, RJ; Malchiodi, EL; Wang, Q; Schuck, P; Mariuzza, RA			Crystal structure of the C-terminal peptidoglycan-binding domain of human peptidoglycan recognition protein I alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; IMMUNE-RESPONSE; DROSOPHILA TOLL; GENE; ACTIVATION; AMIDASE; INFECTION; AFFINITY; SYSTEM; FAMILY	Peptidoglycan recognition proteins (PGRPs) are pattern recognition receptors of the innate immune system that bind, and in some cases hydrolyze, peptidoglycans (PGNs) on bacterial cell walls. These molecules, which are highly conserved from insects to mammals, participate in host defense against both Gram-positive and Gram-negative bacteria. We report the crystal structure of the C-terminal PGN-binding domain of human PGRP-Ialpha in two oligomeric states, monomer and dimer, to resolutions of 2.80 and 1.65 Angstrom, respectively. In contrast to PGRPs with PGN-lytic amidase activity, no zinc ion is present in the PGN-binding site of human PGRP-Ialpha. The structure reveals that PGRPs exhibit extensive topological variability in a large hydrophobic groove, located opposite the PGN-binding site, which may recognize host effector proteins or microbial ligands other than PGN. We also show that full-length PGRP-Ialpha comprises two tandem PGN-binding domains. These domains differ at most potential PGN-contacting positions, implying different fine specificities. Dimerization of PGRP-Ialpha, which occurs through three-dimensional domain swapping, is mediated by specific binding of sodium ions to a flexible hinge loop, stabilizing the conformation found in the dimer. We further demonstrate sodium-dependent dimerization of PGRP-Ialpha in solution, suggesting a possible mechanism for modulating PGRP activity through the formation of multivalent adducts.	Univ Maryland, Biotechnol Inst, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, Rockville, MD 20850 USA; UBA, FFyB, CONICET, IDEHU,Catedra Inmunol, Buenos Aires, DF, Argentina; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; National Institutes of Health (NIH) - USA	Mariuzza, RA (corresponding author), Univ Maryland, Biotechnol Inst, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	mariuzza@carb.nist.gov	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966; Malchiodi, Emilio/0000-0001-7501-3330	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047900] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Cole JL, 1996, BIOCHEMISTRY-US, V35, P15601, DOI 10.1021/bi961719f; DEPAUW P, 1995, PROTEIN EXPRES PURIF, V6, P371, DOI 10.1006/prep.1995.1049; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DUMAS P, 1994, EMBO J, V13, P2483, DOI 10.1002/j.1460-2075.1994.tb06535.x; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Larsen TM, 2001, HANDBOOK ON METALLOPROTEINS, P9; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee MH, 2004, J BIOL CHEM, V279, P3218, DOI 10.1074/jbc.M309821200; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Mizuno H, 1997, NAT STRUCT BIOL, V4, P438, DOI 10.1038/nsb0697-438; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pili-Floury S, 2004, J BIOL CHEM, V279, P12848, DOI 10.1074/jbc.M313324200; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Saint-Jean AP, 1998, BIOCHEMISTRY-US, V37, P10345, DOI 10.1021/bi980868q; Sashchenko LP, 2004, J BIOL CHEM, V279, P2117, DOI 10.1074/jbc.M307513200; SCHUCK P, 2000, CURRENT PROTOCOLS IM; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schymkowitz JWH, 2001, NAT STRUCT BIOL, V8, P888, DOI 10.1038/nsb1001-888; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772	50	45	52	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31873	31882		10.1074/jbc.M404920200	http://dx.doi.org/10.1074/jbc.M404920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140887	hybrid			2022-12-27	WOS:000222726800114
J	Mol, CD; Dougan, DR; Schneider, TR; Skene, RJ; Kraus, ML; Scheibe, DN; Snell, GP; Zou, H; Sang, BC; Wilson, KP				Mol, CD; Dougan, DR; Schneider, TR; Skene, RJ; Kraus, ML; Scheibe, DN; Snell, GP; Zou, H; Sang, BC; Wilson, KP			Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC DOMAIN MUTATIONS; WW-LIKE DOMAIN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; PDGF RECEPTOR; CDNA CLONING; WILD-TYPE; JUXTAMEMBRANE; STI571; GENE	The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers. The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known. We report the 1.9-Angstrom resolution crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase. Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure. A 1.6-Angstrom crystal structure of c-Kit in complex with STI-571 ( Imatinib(R) or Gleevec(R)) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state. Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.	Syrrx Inc, San Diego, CA 92121 USA; Italian Fdn Canc Res, Inst Mol Oncol, I-20139 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology	Mol, CD (corresponding author), Syrrx Inc, San Diego, CA 92121 USA.	clifford.mol@syrrx.com	Schneider, Thomas/B-7442-2011	Schneider, Thomas/0000-0001-6955-7374; Skene, Robert/0000-0002-1482-6546				BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Frost MJ, 2002, MOL CANCER THER, V1, P1115; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hosfield D, 2003, J STRUCT BIOL, V142, P207, DOI 10.1016/S1047-8477(03)00051-0; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 2002, CURR OPIN STRUC BIOL, V12, P735, DOI 10.1016/S0959-440X(02)00383-4; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Ilsley JL, 2002, CELL SIGNAL, V14, P183, DOI 10.1016/S0898-6568(01)00236-4; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Irusta PM, 2002, J BIOL CHEM, V277, P38627, DOI 10.1074/jbc.M204890200; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; Kitamura Y, 2001, MUTAT RES-FUND MOL M, V477, P165, DOI 10.1016/S0027-5107(01)00117-8; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Li SQ, 2003, J BIOL CHEM, V278, P26007, DOI 10.1074/jbc.M302425200; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; O'Dwyer ME, 2003, CANCER INVEST, V21, P429, DOI 10.1081/CNV-120018235; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P195, DOI 10.1107/S0907444901019291; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Till JH, 2002, STRUCTURE, V10, P1187, DOI 10.1016/S0969-2126(02)00814-6; Ueda S, 2002, INT J HEMATOL, V76, P427, DOI 10.1007/BF02982808; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	52	475	509	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31655	31663		10.1074/jbc.M403319200	http://dx.doi.org/10.1074/jbc.M403319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123710	hybrid			2022-12-27	WOS:000222726800090
J	Sobczak, I; Lolkema, JS				Sobczak, I; Lolkema, JS			Alternating access and a pore-loop structure in the Na+-citrate transporter CitS of Klebsiella pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; ESCHERICHIA-COLI; MUTAGENESIS REVEALS; MEMBRANE TOPOLOGY; CYTOPLASMIC LOOP; REENTRANT LOOP; MALATE MLEP; CARRIER; ACCESSIBILITY; INSERTION	CitS of Klebsiella pneumoniae is a secondary transporter that transports citrate in symport with 2 Na+ ions. Reaction of Cys-398 and Cys-414, which are located in a cytoplasmic loop of the protein that is believed to be involved in catalysis, with thiol reagents resulted in significant inhibition of uptake activity. The reactivity of the two residues was determined in single Cys mutants in different catalytic states of the transporter and from both sides of the membrane. The single Cys mutants were shown to have the same transport stoichiometry as wild type CitS, but the C398S mutation was responsible for a 10-fold loss of affinity for Na+. Both cysteine residues were accessible from the periplasmic as well as from the cytoplasmic side of the membrane by the membrane-impermeable thiol reagent [2-(trimethylammonium) ethyl] methanethiosulfonate bromide ( MTSET) suggesting that the residues are part of the translocation site. Binding of citrate to the outward facing binding site of the transporter resulted in partial protection against inactivation by N-ethylmaleimide, whereas binding to the inward facing binding site resulted in essentially complete protection. A 10-fold higher concentration of citrate was required at the cytoplasmic rather than at the periplasmic side of the membrane to promote protection. Only marginal effects of citrate binding were seen on reactivity with MTSET. Binding of Na+ at the periplasmic side of the transporter protected both Cys-398 and Cys-414 against reaction with the thiol reagents, whereas binding at the cytoplasmic side was less effective and discriminated between Cys-398 and Cys-414. A model is presented in which part of the cytoplasmic loop containing Cys-398 and Cys-414 folds back into the translocation pore as a pore-loop structure. The loop protrudes into the pore beyond the citrate-binding site that is situated at the membrane-ytoplasm interface.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Lolkema, JS (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	j.s.lolkema@biol.rug.nl						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bandell M, 2000, BIOCHEMISTRY-US, V39, P13059, DOI 10.1021/bi0011882; Bandell M, 1997, J BIOL CHEM, V272, P18140, DOI 10.1074/jbc.272.29.18140; Bandell M, 2000, J BIOL CHEM, V275, P39130, DOI 10.1074/jbc.M005940200; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Ding PZ, 2004, BBA-BIOMEMBRANES, V1660, P106, DOI 10.1016/j.bbamem.2003.11.005; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; Krom BP, 2003, BIOCHEMISTRY-US, V42, P467, DOI 10.1021/bi026874a; Lambert G, 2001, J GEN PHYSIOL, V117, P533, DOI 10.1085/jgp.117.6.533; LOLKEMA JS, 1994, EUR J BIOCHEM, V220, P469, DOI 10.1111/j.1432-1033.1994.tb18645.x; LOLKEMA JS, 1996, HDB BIOL PHYSICS, P229; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Pirch T, 2003, J BIOL CHEM, V278, P42942, DOI 10.1074/jbc.M308253200; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; Pos KM, 1996, BIOCHEMISTRY-US, V35, P1018, DOI 10.1021/bi951609t; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Sobczak I, 2003, BIOCHEMISTRY-US, V42, P9789, DOI 10.1021/bi034683h; van Geest M, 2000, BBA-BIOMEMBRANES, V1466, P328, DOI 10.1016/S0005-2736(00)00185-1; van Geest M, 1999, J BIOL CHEM, V274, P29705, DOI 10.1074/jbc.274.42.29705; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200	35	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31113	31120		10.1074/jbc.M404283200	http://dx.doi.org/10.1074/jbc.M404283200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148311	hybrid, Green Published			2022-12-27	WOS:000222726800027
J	Colvin, RA; Campanella, GSV; Sun, JT; Luster, AD				Colvin, RA; Campanella, GSV; Sun, JT; Luster, AD			Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ALPHA CHEMOATTRACTANT; CHEMOKINE RECEPTOR CXCR3; HIGH-AFFINITY BINDING; IFN-GAMMA; BETA-ARRESTIN; T-CELLS; DIFFERENTIAL EXPRESSION; ACTIVATION; INTERNALIZATION; PROTEIN	The chemokine receptor CXCR3 is a G protein-coupled receptor found predominantly on T cells that is activated by three ligands as follows: CXCL9 (Mig), CXCL10 (IP-10), and CXCL11 (I-TAC). Previously, we have found that of the three ligands, CXCL11 is the most potent inducer of CXCR3 internalization and is the physiologic inducer of CXCR3 internalization after T cell contact with activated endothelial cells. We have therefore hypothesized that these three ligands transduce different signals to CXCR3. In light of this hypothesis, we sought to determine whether regions of CXCR3 are differentially required for CXCL9, CXCL10, and CXCL11 function. Here we identified two distinct domains that contributed to CXCR3 internalization. The carboxyl-terminal domain and beta-arrestin1 were predominantly required by CXCL9 and CXCL10, and the third intracellular loop was predominantly required by CXCL11. Chemotaxis and calcium mobilization induced by all three CXCR3 ligands were dependent on the CXCR3 carboxyl terminus and the DRY sequence in the third trans-membrane domain. Our findings demonstrate that distinct domains of CXCR3 mediate its functions and suggest that the differential requirement of these domains contributes to the complexity of the chemokine system.	Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital	Luster, AD (corresponding author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 149 13th St,Rm 8031, Charlestown, MA 02129 USA.	aluster@partners.org	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NCI NIH HHS [R01 CA69212] Funding Source: Medline; NIAID NIH HHS [K08 AI50147] Funding Source: Medline; NIDDK NIH HHS [P01 DK50305] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Amichay D, 1996, J IMMUNOL, V157, P4511; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Campanella GSV, 2003, J BIOL CHEM, V278, P17066, DOI 10.1074/jbc.M212077200; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; El-Sawy T, 2002, CURR OPIN IMMUNOL, V14, P562, DOI 10.1016/S0952-7915(02)00382-5; Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Feniger-Barish R, 1999, CYTOKINE, V11, P996, DOI 10.1006/cyto.1999.0510; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; Khan IA, 2000, IMMUNITY, V12, P483, DOI 10.1016/S1074-7613(00)80200-9; Kobayashi H, 2002, TRANSPLANTATION, V74, P387, DOI 10.1097/00007890-200208150-00016; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; Miura M, 2001, J IMMUNOL, V167, P3494, DOI 10.4049/jimmunol.167.6.3494; MORO O, 1993, J BIOL CHEM, V268, P6862; Murdoch C, 2000, BLOOD, V95, P3032; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Richardson RM, 2003, J IMMUNOL, V170, P2904, DOI 10.4049/jimmunol.170.6.2904; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; Sauty A, 2001, J IMMUNOL, V167, P7084, DOI 10.4049/jimmunol.167.12.7084; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Xanthou G, 2003, EUR J IMMUNOL, V33, P2927, DOI 10.1002/eji.200324235; Zhang Z, 2002, J IMMUNOL, V168, P3205, DOI 10.4049/jimmunol.168.7.3205	52	186	197	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30219	30227		10.1074/jbc.M403595200	http://dx.doi.org/10.1074/jbc.M403595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150261	hybrid			2022-12-27	WOS:000222531900045
J	Matyash, A; Chung, HR; Jackle, H				Matyash, A; Chung, HR; Jackle, H			Genome-wide mapping of in vivo targets of the Drosophila transcription factor Kruppel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GAP GENES; POSTERIOR REGION; MODIFIER SCREEN; BINDING-SITES; PROTEIN; ACTIVATION; REPRESSION; KNIRPS; SEQUENCE	Kruppel (Kr), a member of the gap class of Drosophila segmentation genes, encodes a DNA binding zinc finger-type transcription factor. In addition to its segmentation function at the blastoderm stage, Kruppel also plays a critical role in organ formation during later stages of embryogenesis. To systematically identify in vivo target genes of Kruppel, we isolated DNA fragments from the Kruppel-associated portion of chromatin and used them to find and map Kruppel-dependent cis-acting regulatory sites in the Drosophila genome. We show that Kruppel binding sites are not enriched in Kruppel-associated chromatin and that the clustering of Kruppel binding sites, as found in the cis-acting elements of Kruppel-dependent segmentation genes used for in silico searches of Kruppel target genes, is not a prerequisite for the in vivo binding of Kruppel to its regulatory elements. Results obtained with the newly identified target gene ken and barbie (ken) indicate that Kruppel represses transcription and thereby restricts the spatial expression pattern of ken during blastoderm and gastrulation.	Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37070 Gottingen, Germany	Max Planck Society	Jackle, H (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37070 Gottingen, Germany.	hjaeckl@gwdg.de						Abrell S, 2000, CHROMOSOMA, V109, P334, DOI 10.1007/s004120000092; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bashaw GJ, 2001, J CELL BIOL, V155, P1117, DOI 10.1083/jcb.200110077; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; Carrera P, 1998, P NATL ACAD SCI USA, V95, P10779, DOI 10.1073/pnas.95.18.10779; CASARES F, 1995, DEVELOPMENT, V121, P1855; CASTRILLON DH, 1993, GENETICS, V135, P489; Cavalli G, 1999, PRACT APPROACH SER, P20; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Fujioka M, 1999, DEVELOPMENT, V126, P2527; GAUL U, 1989, P NATL ACAD SCI USA, V86, P4599, DOI 10.1073/pnas.86.12.4599; Gaul U, 1990, Adv Genet, V27, P239; GUTJAHR T, 1993, DEVELOPMENT, V117, P609; Hader T, 1998, MECH DEVELOP, V71, P177, DOI 10.1016/S0925-4773(98)00014-8; Hartmann C, 1997, DEV GENES EVOL, V207, P186, DOI 10.1007/s004270050106; Hartmann C, 1997, EMBO J, V16, P5299, DOI 10.1093/emboj/16.17.5299; Henegariu O, 1997, BIOTECHNIQUES, V23, P504, DOI 10.2144/97233rr01; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOCH M, 1990, EMBO J, V9, P2587, DOI 10.1002/j.1460-2075.1990.tb07440.x; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; HOSHIZAKI DK, 1995, GENOME, V38, P497, DOI 10.1139/g95-065; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; Kotarski MA, 1998, GENOME, V41, P295, DOI 10.1139/gen-41-2-295; KRAUT R, 1991, DEVELOPMENT, V111, P611; Kuhnlein RP, 1998, MECH DEVELOP, V79, P161, DOI 10.1016/S0925-4773(98)00183-X; La Rosee-Borggreve A, 1999, MECH DEVELOP, V89, P133, DOI 10.1016/S0925-4773(99)00219-1; LANGELAND JA, 1994, DEVELOPMENT, V120, P2945; LaRosee A, 1997, EMBO J, V16, P4403, DOI 10.1093/emboj/16.14.4403; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; Liu XJ, 2000, DEV BIOL, V221, P419, DOI 10.1006/dbio.2000.9689; Michaut L, 2003, P NATL ACAD SCI USA, V100, P4024, DOI 10.1073/pnas.0630561100; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajewsky N, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-30; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; Sanchez D, 2000, INT J DEV BIOL, V44, P349; Sanson B, 2001, EMBO REP, V2, P1083, DOI 10.1093/embo-reports/kve255; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAUER F, 1995, EMBO J, V14, P4773, DOI 10.1002/j.1460-2075.1995.tb00159.x; Sauer F, 1996, PHILOS T ROY SOC B, V351, P579, DOI 10.1098/rstb.1996.0057; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; Shimell MJ, 2000, DEV BIOL, V218, P38, DOI 10.1006/dbio.1999.9576; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DB, 1993, NUCLEIC ACIDS RES, V21, P359, DOI 10.1093/nar/21.2.359; Solano PJ, 2003, DEVELOPMENT, V130, P1243, DOI 10.1242/dev.00348; Thummel CS, 1992, DROS INF SERV, V71, P150; Tolias PP, 1998, DEV GENES EVOL, V208, P274, DOI 10.1007/s004270050182; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	64	10	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30689	30696		10.1074/jbc.M403345200	http://dx.doi.org/10.1074/jbc.M403345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131112	Green Published, hybrid			2022-12-27	WOS:000222531900099
J	Wei, J; Sherman, F				Wei, J; Sherman, F			Sue1p is required for degradation of labile forms of altered cytochromes c in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; AMINO-ACID REPLACEMENTS; SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; SYNTHETIC OLIGONUCLEOTIDES; PHYSIOLOGICAL PARTNERS; ISO-1-CYTOCHROME C; ESCHERICHIA-COLI; HEME LYASE; IN-VIVO	Previous studies on certain altered holo-isocytochromes c revealed a rho(-)-dependent degradation (RDD) phenotype, in which certain altered holo-iso-1-cytochromes c are at normal or nearly normal levels in rho(+) strains, but are at low levels or absent in rho(-) strains, although wild-type holo-iso-1-cytochrome c is present at normal levels in both rho(+) and related rho(-) strains. The diminished levels of altered holo-iso-1-cytochrome c are due to the rapid degradation that is carried out by a novel proteolytic pathway in the IMS of mitochondria. SUE1, a nuclear gene that encodes a mitochondrial protein, was identified with a genetic screen for mutants that diminish RDD. The levels of RDD and certain other types of altered holo-iso-1-cytochrome c were elevated in rho(-) sue1 strains. Also, rho(+) sue1 strains containing certain altered holo- iso-1-cytochromes c grew better on non-fermentable carbon sources than the corresponding rho(+) SUE1 strains. These results indicate that Sue1p may play an important role in the degradation of abnormal holo-iso-1-cytochrome c in the mitochondria.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Sherman, F (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, POB 712, Rochester, NY 14642 USA.	Fred_Sherman@urmc.rochester.edu			NIGMS NIH HHS [GM12702] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DOWNIE JA, 1977, J MOL BIOL, V113, P369, DOI 10.1016/0022-2836(77)90147-4; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Goldberg AL, 1997, BIOL CHEM, V378, P131; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Huang HC, 2001, J BIOL CHEM, V276, P3920, DOI 10.1074/jbc.M002937200; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Lee DH, 1996, MOL CELL BIOL, V16, P4773; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7103, DOI 10.1021/bi00021a023; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7094, DOI 10.1021/bi00021a022; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; MATNER RR, 1982, J BIOL CHEM, V257, P9811; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; MOERSCHELL RP, 1988, P NATL ACAD SCI USA, V85, P524, DOI 10.1073/pnas.85.2.524; Pearce DA, 1998, ARCH BIOCHEM BIOPHYS, V352, P85, DOI 10.1006/abbi.1998.0591; Pearce DA, 1997, J BIOL CHEM, V272, P31829, DOI 10.1074/jbc.272.50.31829; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; Porankiewicz J, 1999, MOL MICROBIOL, V32, P449, DOI 10.1046/j.1365-2958.1999.01357.x; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SHERMAN F, 1968, J BIOL CHEM, V243, P5446; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1974, GENETICS, V77, P255; Sitte N, 1998, J BIOCHEM, V123, P408; SMITH M, 1979, CELL, V16, P753, DOI 10.1016/0092-8674(79)90091-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAMAMOTO T, 1992, YEAST, V8, P935, DOI 10.1002/yea.320081104; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	41	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30449	30458		10.1074/jbc.M403742200	http://dx.doi.org/10.1074/jbc.M403742200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123691	hybrid			2022-12-27	WOS:000222531900072
J	Calderwood, DA; Tai, V; Di Paolo, G; De Camilli, P; Ginsberg, MH				Calderwood, DA; Tai, V; Di Paolo, G; De Camilli, P; Ginsberg, MH			Competition for talin results in trans-dominant inhibition of integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL PHOSPHATE KINASE; BETA CYTOPLASMIC DOMAINS; FUNCTION-ASSOCIATED ANTIGEN-1; AMINO-ACID MOTIFS; TYROSINE PHOSPHORYLATION; LIGAND-BINDING; CELL-MIGRATION; GPIIB-IIIA; ADHESION; SUPPRESSION	The ability of integrin adhesion receptors to undergo rapid changes in affinity for their extracellular ligands ( integrin activation) is essential for the development and function of multicellular animals and is dependent on interactions between the integrin beta subunit-cytoplasmic tail and the cytoskeletal protein talin. Cross-talk among different integrins and between integrins and other receptors impacts many cellular processes including adhesion, spreading, migration, clot retraction, proliferation, and differentiation. One form of integrin cross-talk, transdominant inhibition of integrin activation, occurs when ligand binding to one integrin inhibits the activation of a second integrin. This may be relevant clinically in a number of settings such as during platelet adhesion, leukocyte trans-migration, and angiogenesis. Here we report that competition for talin underlies the trans-dominant inhibition of integrin activation. This conclusion is based on our observations that ( i) beta tails selectively defective in talin binding are unable to mediate trans-dominant inhibition, (ii) trans-dominant inhibition can be reversed by overexpression of integrin binding and activating fragments of talin, and (iii) expression of another non-integrin talin-binding protein, phosphatidylinositol phosphate kinase type Igamma-90, also inhibits integrin activation. Thus, the sequestration of talin by the suppressive species is both necessary and sufficient for trans-dominant inhibition of integrin activation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA	Scripps Research Institute; Yale University; Howard Hughes Medical Institute; Yale University	Calderwood, DA (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	david.calderwood@yale.edu	Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NHLBI NIH HHS [HL31950] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NIGMS NIH HHS [GM68600] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Bodeau AL, 2001, J CELL SCI, V114, P2795; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Cram EJ, 2003, J CELL SCI, V116, P3871, DOI 10.1242/jcs.00705; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fujimoto TT, 2003, BLOOD, V102, P4044, DOI 10.1182/blood-2003-06-1773; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Ginsberg MH, 2001, J BIOL CHEM, V276, P22514, DOI 10.1074/jbc.M101915200; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Keller RS, 2001, AM J PATHOL, V158, P1079, DOI 10.1016/S0002-9440(10)64055-2; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; Ly DP, 2003, J BIOL CHEM, V278, P21878, DOI 10.1074/jbc.M212538200; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; Mastrangelo AM, 1999, J CELL SCI, V112, P217; McDowall A, 2003, J CLIN INVEST, V111, P51, DOI 10.1172/JCI200314076; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PACIFICI R, 1994, J IMMUNOL, V153, P2222; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; Rey-Ladino JA, 1998, J IMMUNOL, V160, P3494; Riederer MA, 2002, THROMB HAEMOSTASIS, V88, P858, DOI 10.1055/s-0037-1613314; Rose DM, 2000, BLOOD, V95, P602, DOI 10.1182/blood.V95.2.602; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Rose DM, 2001, J IMMUNOL, V167, P2824, DOI 10.4049/jimmunol.167.5.2824; Schmeissner PJ, 2001, J IMMUNOL, V167, P3715, DOI 10.4049/jimmunol.167.7.3715; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shiraga M, 1999, J CELL BIOL, V147, P1419, DOI 10.1083/jcb.147.7.1419; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; TAPLEY P, 1989, ONCOGENE, V4, P325; Valencik ML, 2002, J CARD FAIL, V8, P262, DOI 10.1054/jcaf.2002.127335; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059	65	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28889	28895		10.1074/jbc.M402161200	http://dx.doi.org/10.1074/jbc.M402161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15143061	hybrid			2022-12-27	WOS:000222445300009
J	Kono, M; Mi, YD; Liu, YJ; Sasaki, T; Allende, ML; Wu, YP; Yamashita, T; Proia, RL				Kono, M; Mi, YD; Liu, YJ; Sasaki, T; Allende, ML; Wu, YP; Yamashita, T; Proia, RL			The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE RECEPTOR; VASCULAR MATURATION; MOLECULAR-CLONING; MICE LACKING; FAMILY; S1P(1); LYSOPHOSPHOLIPIDS; DIFFERENTIATION; EXPRESSION	Sphingosine-1-phosphate (S1P) elicits diverse cellular responses through a family of G-protein-coupled receptors. We have shown previously that genetic disruption of the S1P(1) receptor, the most widely expressed of the family, results in embryonic lethality because of its key role within endothelial cells in regulating the coverage of blood vessels by vascular smooth muscle cells. To understand the physiologic functions of the two other widely expressed S1P receptors, we generated S1P(2) and S1P(3) null mice. Neither the S1P(2) null mice nor the S1P3 null mice exhibited significant embryonic lethality or obvious phenotypic abnormalities. To unmask possible overlapping or collaborative functions between the S1P(1), S1P(2), and S1P(3) receptors, we examined embryos with multiple S1P receptor mutations. We found that S1P(1) S1P(2) double null and S1P(1) S1P(2) S1P(3) triple null embryos displayed a substantially more severe vascular phenotype than did embryos with only S1P(1) deleted. We also found partial embryonic lethality and vascular abnormalities in S1P(2) S1P(3) double null embryos. Our results indicate that the S1P(1), S1P(2), and S1P(3) receptors have redundant or cooperative functions for the development of a stable and mature vascular system during embryonic development.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bldg 10,Rm 9N-314,10 Ctr Dr MSC 1821, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270; Kono, Mari/0000-0003-2447-4350	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chae SS, 2004, DEV BIOL, V268, P441, DOI 10.1016/j.ydbio.2004.01.001; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Ignatov A, 2003, BIOCHEM BIOPH RES CO, V311, P329, DOI 10.1016/j.bbrc.2003.10.006; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Lindahl P, 1998, CURR OPIN LIPIDOL, V9, P407, DOI 10.1097/00041433-199810000-00004; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Liu YJ, 1999, J CLIN INVEST, V103, P497, DOI 10.1172/JCI5542; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McGiffert C, 2002, FEBS LETT, V531, P103, DOI 10.1016/S0014-5793(02)03404-X; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Niedernberg A, 2003, CELL SIGNAL, V15, P435, DOI 10.1016/S0898-6568(02)00119-5; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	40	309	325	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29367	29373		10.1074/jbc.M403937200	http://dx.doi.org/10.1074/jbc.M403937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15138255	hybrid			2022-12-27	WOS:000222445300068
J	Rosado, JA; Lopez, JJ; Harper, AGS; Harper, MT; Redondo, PC; Pariente, JA; Sage, SO; Salido, GM				Rosado, JA; Lopez, JJ; Harper, AGS; Harper, MT; Redondo, PC; Pariente, JA; Sage, SO; Salido, GM			Two pathways for store-mediated calcium entry differentially dependent on the actin cytoskeleton in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CA2+ ENTRY; FARNESYLCYSTEINE ANALOGS; CELLS; INHIBITION; THAPSIGARGIN; INVOLVEMENT; ACTIVATION; MAINTENANCE; GENERATION	A major pathway for stimulated Ca2+ entry in non-excitable cells is activated following depletion of intracellular Ca2+ stores. Secretion-like coupling between elements in the plasma membrane (PM) and Ca2+ stores has been proposed as the most likely mechanism to activate this store-mediated Ca2+ entry (SMCE) in several cell types. Here we identify two mechanisms for SMCE in human platelets activated by depletion of two independent Ca2+ pools, which are differentially modulated by the actin cytoskeleton. Ca2+ entry induced by depletion of a 2,5-di-(tert-butyl)-1,4-hydroquinone (TBHQ)sensitive pool is increased by disassembly of the actin cytoskeleton and that induced by a TBHQ-insensitive pool is reduced. Stabilization of the actin cytoskeleton prevented Ca2+ entry by both mechanisms. We propose that the membrane-associated actin network prevents constitutive Ca2+ entry via both pathways. Reorganization of the actin cytoskeleton permits the activation of Ca2+ entry via both mechanisms, but only SMCE activated by the TBHQ-insensitive pool requires new actin polymerization, which may support membrane trafficking toward the PM.	Univ Extremadura, Dept Physiol, Caceres 10071, Spain; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	Universidad de Extremadura; University of Cambridge	Rosado, JA (corresponding author), Univ Extremadura, Dept Physiol, Caceres 10071, Spain.	jarosado@unex.es	Liberal, Pedro C Redondo/F-4592-2016; Rosado, Juan A/H-3488-2015; Salido, Gines M/A-4292-2009; Lopez, Jose J/F-4602-2016; Harper, Matthew T/G-5630-2013; Harper, Alan/AFR-9139-2022	Liberal, Pedro C Redondo/0000-0002-2067-2627; Rosado, Juan A/0000-0002-9749-2325; Salido, Gines M/0000-0002-8687-2445; Lopez, Jose J/0000-0002-5234-1478; Harper, Matthew T/0000-0002-4740-637X; Harper, Alan/0000-0003-2413-4823; Sage, Stewart/0000-0001-8578-3558; PARIENTE, JOSE ANTONIO/0000-0002-9094-9943				BIRD GS, 1993, J BIOL CHEM, V268, P21486; CAVALLINI L, 1995, BIOCHEM J, V310, P449, DOI 10.1042/bj3100449; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heemskerk JWM, 1997, EUR J BIOCHEM, V249, P547, DOI 10.1111/j.1432-1033.1997.00547.x; Kovacs T, 1997, BRIT J HAEMATOL, V97, P192, DOI 10.1046/j.1365-2141.1997.9982639.x; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; PAPP B, 1991, J BIOL CHEM, V266, P14593; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Redondo PC, 2003, BIOCHEM J, V370, P255, DOI 10.1042/BJ20021505; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2004, J BIOL CHEM, V279, P1665, DOI 10.1074/jbc.M307963200; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Rosado JA, 2001, AM J PHYSIOL-CELL PH, V280, pC1636, DOI 10.1152/ajpcell.2001.280.6.C1636; Tiffert T, 1997, J PHYSIOL-LONDON, V500, P139, DOI 10.1113/jphysiol.1997.sp022005; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; Xu YJ, 1996, MOL PHARMACOL, V50, P1495	22	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29231	29235		10.1074/jbc.M403509200	http://dx.doi.org/10.1074/jbc.M403509200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15136566	hybrid			2022-12-27	WOS:000222445300051
J	Zhang, QL; Dickson, A; Doupnik, CA				Zhang, QL; Dickson, A; Doupnik, CA			G beta gamma-activated inwardly rectifying K+ (GIRK) channel activation kinetics via G alpha(i) and G alpha(o)-coupled receptors are determined by G alpha-specific interdomain interactions that affect GDP release rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN REGULATION; NUCLEOTIDE EXCHANGE; ACUTE DESENSITIZATION; MEDIATED ACTIVATION; GTP HYDROLYSIS; RGS PROTEINS; SUBUNITS; POTASSIUM; REGULATOR; BINDING	Gbetagamma-activated inwardly rectifying K+ (GIRK) channels have distinct gating properties when activated by receptors coupled specifically to Galpha(o) versus Galpha(i) subunit isoforms, with Galpha(o)-coupled currents having similar to3-fold faster agonist-evoked activation kinetics. To identify the molecular determinants in Galpha subunits mediating these kinetic differences, chimeras were constructed using pertussis toxin (PTX)-insensitive Galpha(oA) and Galpha(i2) mutant subunits (Galpha(oA(C351G)) and Galpha(i2(C352G))) and examined in PTX-treated Xenopus oocytes expressing muscarinic m2 receptors and Kir3.1/3.2a channels. These experiments revealed that the alpha-helical N-terminal region (amino acids 1 - 161) and the switch regions of Galpha(i2) ( amino acids 162 - 262) both partially contribute to slowing the GIRK activation time course when compared with the Galpha(oA(C351G))-coupled response. When present together, they fully reproduce Galpha(i2(C352G))- coupled GIRK kinetics. The Galpha(i2) C-terminal region (amino acids 263-355) had no significant effect on GIRK kinetics. Complementary responses were observed with chimeras substituting the Galpha(o) switch regions into the Galpha(i2(C352G)) subunit, which partially accelerated the GIRK activation rate. The Galpha(oA)/Galpha(i2) chimera results led us to examine an interaction between the alpha-helical domain and the Ras-like domain previously implicated in mediating a 4-fold slower in vitro basal GDP release rate in Galpha(i1) compared with Galpha(o). Mutations disrupting the interdomain contact in Galpha(i2(C352G)) at either the alphaD-alphaE loop (R145A) or the switch III loop (L233Q/A236H/E240T/ M241T), significantly accelerated the GIRK activation kinetics consistent with the Galpha(i2) interdomain interface regulating receptor-catalyzed GDP release rates in vivo. We propose that differences in Galpha(i) versus Galpha(o)-coupled GIRK activation kinetics are due to intrinsic differences in receptor-catalyzed GDP release that rate-limit Gbetagamma production and is attributed to heterogeneity in Galpha(i) and Galpha(o) interdomain contacts.	Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Doupnik, CA (corresponding author), Univ S Florida, Coll Med, Dept Physiol & Biophys, 12901 Bruce B Downs Blvd,MDC8, Tampa, FL 33612 USA.	cdoupnik@hsc.usf.edu	Doupnik, Craig A/I-3617-2012	Doupnik, Craig A/0000-0002-7314-0747				Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Benians A, 2003, J BIOL CHEM, V278, P10851, DOI 10.1074/jbc.M212299200; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Cavalli A, 2000, J BIOL CHEM, V275, P23693, DOI 10.1074/jbc.M910395199; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; Doupnik CA, 2004, METHOD ENZYMOL, V389, P131; Doupnik CA, 2001, BBA-GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167-4781(01)00342-6; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Greif GJ, 2000, J NEUROPHYSIOL, V83, P1010, DOI 10.1152/jn.2000.83.2.1010; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Lutz LB, 2000, J BIOL CHEM, V275, P41512, DOI 10.1074/jbc.M006757200; Marin EP, 2001, J BIOL CHEM, V276, P23873, DOI 10.1074/jbc.M101197200; Marsh SR, 1998, MOL PHARMACOL, V53, P981; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Remmers AE, 1999, BIOCHEMISTRY-US, V38, P13795, DOI 10.1021/bi990887f; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Sheng YL, 2001, CURR BIOL, V11, P405, DOI 10.1016/S0960-9822(01)00123-3; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stanfield PR, 2002, REV PHYSIOL BIOCH P, V145, P47, DOI 10.1007/BFb0116431; Stuhmer W., 1995, SINGLE CHANNEL RECOR, P341, DOI DOI 10.1007/978-1-4419-1229-9_15; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976; Yamada M, 1998, PHARMACOL REV, V50, P723; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151; Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200	41	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29787	29796		10.1074/jbc.M403359200	http://dx.doi.org/10.1074/jbc.M403359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123672	hybrid			2022-12-27	WOS:000222445300115
J	Weljie, AM; Vogel, HJ				Weljie, AM; Vogel, HJ			Unexpected structure of the Ca2+-regulatory region from soybean calcium-dependent protein kinase-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-LIKE DOMAIN; TROPONIN-C; NMR-SPECTROSCOPY; SKELETAL-MUSCLE; MACROMOLECULAR STRUCTURES; INTRAMOLECULAR BINDING; CONFORMATIONAL-CHANGES; ANGSTROM RESOLUTION; REGULATORY DOMAINS; CRYSTAL-STRUCTURE	Calcium-dependent protein kinases (CDPKs) are an extensive class of multidomain Ca2+-regulated enzymes from plants and protozoa. In vivo the so-called calmodulin-like domain (CLD) of CDPK binds intramolecularly to the junction domain (JD), which exhibits both kinase-inhibitory and CLD binding properties. Here we report the high resolution solution structure of the calcium-regulatory region from soybean CDPK-alpha determined in the presence of a peptide encompassing the JD. The structure of both lobes of CLD resembles that of related helix-loop-helix Ca2+-binding proteins. NMR chemical shift mapping studies demonstrate that the JD induces significant structural changes in isolated Ca2+-CLD, particularly the C-terminal domain, although a stable complex is not formed. A CLD solution structure calculated on the basis of NMR data and long range fluorescence resonance energy transfer distances reveals an activated state with both lobes positioned side by side, similar to calcineurin B rather than calmodulin, highlighting the possible pitfall of assigning function purely from sequence information.	Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca	Weljie, Aalim M/B-6203-2012; Weljie, Aalim/V-6952-2019	Weljie, Aalim/0000-0002-7145-4494				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; Christodoulou J, 2002, J BIOMOL NMR, V23, P249, DOI 10.1023/A:1019875822571; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demene H, 2002, J BIOMOL NMR, V22, P47, DOI 10.1023/A:1013821123201; Evans NH, 2001, CURR OPIN PLANT BIOL, V4, P415, DOI 10.1016/S1369-5266(00)00194-1; Fallon JL, 2003, STRUCTURE, V11, P1303, DOI 10.1016/j.str.2003.09.004; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; Gagne SM, 1998, BIOCHEM CELL BIOL, V76, P302, DOI 10.1139/bcb-76-2-3-302; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HARMON AC, 1994, BIOCHEMISTRY-US, V33, P7278, DOI 10.1021/bi00189a032; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARMON AC, 2001, NEW PHYTOL, V151, P175, DOI DOI 10.1046/j.1469-8137.2001.00171.x; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Hrabak EM, 2000, ADV BOT RES, V32, P185, DOI 10.1016/S0065-2296(00)32025-0; Huang JF, 1996, BIOCHEMISTRY-US, V35, P13222, DOI 10.1021/bi960498a; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kohno T, 1998, J BIOMOL NMR, V12, P109, DOI 10.1023/A:1008254603368; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JY, 1998, BIOCHEMISTRY-US, V37, P6801, DOI 10.1021/bi980062q; Lee SY, 2000, BIOCHEMISTRY-US, V39, P4225, DOI 10.1021/bi992697a; Luan S, 2002, PLANT CELL, V14, pS389, DOI 10.1105/tpc.001115; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Nagae M, 2003, J BIOL CHEM, V278, P42240, DOI 10.1074/jbc.M303630200; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Romeis T, 2001, EMBO J, V20, P5556, DOI 10.1093/emboj/20.20.5556; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Rudd JJ, 2001, NEW PHYTOL, V151, P7, DOI 10.1046/j.1469-8137.2001.00173.x; Sanders D, 2002, PLANT CELL, V14, pS401, DOI 10.1105/tpc.002899; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; Vitart V, 2000, BIOCHEMISTRY-US, V39, P12102, DOI 10.1021/bi005113+; Weljie AM, 2003, J BIOL CHEM, V278, P43764, DOI 10.1074/jbc.M306799200; Weljie AM, 2003, PROTEIN SCI, V12, P228, DOI 10.1110/ps.0226203; Weljie AM, 2000, PROTEINS, V39, P343, DOI 10.1002/(SICI)1097-0134(20000601)39:4<343::AID-PROT70>3.0.CO;2-2; Wishart DS, 1998, BIOCHEM CELL BIOL, V76, P153, DOI 10.1139/bcb-76-2-3-153; Yoo BC, 1996, BIOCHEMISTRY-US, V35, P12029, DOI 10.1021/bi9606612; Yoshino H, 1996, BIOCHEMISTRY-US, V35, P2388, DOI 10.1021/bi952121v; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zhang XRS, 2001, J MOL EVOL, V53, P214, DOI 10.1007/s002390010211; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	58	22	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35494	35502		10.1074/jbc.M311520200	http://dx.doi.org/10.1074/jbc.M311520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15155727	hybrid			2022-12-27	WOS:000223303400043
J	Brown, J; Theisler, C; Silberman, S; Magnuson, D; Gottardi-Littell, N; Lee, JM; Yager, D; Crowley, J; Sambamurti, K; Rahman, MM; Reiss, AB; Eckman, CB; Wolozin, B				Brown, J; Theisler, C; Silberman, S; Magnuson, D; Gottardi-Littell, N; Lee, JM; Yager, D; Crowley, J; Sambamurti, K; Rahman, MM; Reiss, AB; Eckman, CB; Wolozin, B			Differential expression of cholesterol hydroxylases in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; LIPID RAFTS; PLASMA 24S-HYDROXYCHOLESTEROL; NEUROFIBRILLARY TANGLES; URSODEOXYCHOLIC ACID; IN-VIVO; CELLS; BRAIN; NEURONS	Cholesterol is eliminated from neurons by oxidization, which generates oxysterols. Cholesterol oxidation is mediated by the enzymes cholesterol 24-hydroxylase (CYP46A1) and cholesterol 27-hydroxylase (CYP27A1). Immunocytochemical studies show that CYP46A1 and CYP27A1 are expressed in neurons and some astrocytes in the normal brain, and CYP27A1 is present in oligodendrocytes. In Alzheimer's disease ( AD), CYP46A1 shows prominent expression in astrocytes and around amyloid plaques, whereas CYP27A1 expression decreases in neurons and is not apparent around amyloid plaques but increases in oligodendrocytes. Although previous studies have examined the effects of synthetic oxysterols on the processing of amyloid precursor protein (APP), the actions of the naturally occurring oxysterols have yet to be examined. To understand the role of cholesterol oxidation in AD, we compared the effects of 24(S)- and 27-hydroxycholesterol on the processing of APP and analyzed the cell-specific expression patterns of the two cholesterol hydroxylases in the human brain. Both oxysterols inhibited production of Abeta in neurons, but 24(S)-hydroxycholesterol was similar to1000-fold more potent than 27-hydroxycholesterol. The IC50 of 24( S)-hydroxycholesterol for inhibiting Abeta secretion was similar to1 nM. Both oxysterols induced ABCA1 expression with IC50 values similar to that for inhibition of Abeta secretion, suggesting the involvement of liver X receptor. Oxysterols also inhibited protein kinase C activity and APP secretion following stimulation of protein kinase C. The selective expression of CYP46A1 around neuritic plaques and the potent inhibition of APP processing in neurons by 24( S)- hydroxycholesterol suggests that CYP46A1 affects the pathophysiology of AD and provides insight into how polymorphisms in the CYP46A1 gene might influence the pathophysiology of this prevalent disease.	Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA; Washington Univ, Dept Med, Mass Spectrometry Facil, St Louis, MO 63110 USA; Northwestern Univ, Med Ctr, Dept Pathol, Chicago, IL 60611 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA	Loyola University Chicago; Loyola University Chicago; Mayo Clinic; Washington University (WUSTL); Northwestern University; New York University; Medical University of South Carolina	Wolozin, B (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, 715 Albany St,L-603, Boston, MA 02118 USA.	bwolozin@bu.edu	Sambamurti, Kumar/A-1620-2012; Messier, Claude/A-2322-2008	Sambamurti, Kumar/0000-0001-9507-9214; Messier, Claude/0000-0002-4791-1763; Reiss, Allison B/0000-0002-4478-2441	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042192, R01NS041786, R01NS048554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017485] Funding Source: NIH RePORTER; NIA NIH HHS [AG/NS 17485-01A2] Funding Source: Medline; NINDS NIH HHS [NS 41786-01, NS 048554-01, NS 042192-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Bu BT, 2002, NEUROBIOL DIS, V11, P285, DOI 10.1006/nbdi.2002.0551; Burns M, 2003, J NEUROSCI, V23, P5645; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CALLAHAN LM, 1995, NEUROBIOL AGING, V16, P311, DOI 10.1016/0197-4580(95)00035-D; Chang JY, 1998, BRAIN RES BULL, V45, P615, DOI 10.1016/S0361-9230(97)00461-9; Chang JY, 1998, NEUROCHEM RES, V23, P7, DOI 10.1023/A:1022437000893; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Javitt NB, 2002, BIOCHEM BIOPH RES CO, V292, P1147, DOI 10.1006/bbrc.2001.2013; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Kolsch H, 2002, MOL PSYCHIATR, V7, P899, DOI 10.1038/sj.mp.4001109; Kolsch H, 2001, J NEURAL TRANSM, V108, P475, DOI 10.1007/s007020170068; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 2000, J LIPID RES, V41, P195; Marlow L, 2003, J MOL NEUROSCI, V20, P233, DOI 10.1385/JMN:20:3:233; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Palacino JJ, 2000, J BIOL CHEM, V275, P215, DOI 10.1074/jbc.275.1.215; Papassotiropoulos A, 2003, ARCH NEUROL-CHICAGO, V60, P29, DOI 10.1001/archneur.60.1.29; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Papassotiropoulos A, 2000, NEUROREPORT, V11, P1959, DOI 10.1097/00001756-200006260-00030; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sola S, 2003, J BIOL CHEM, V278, P48831, DOI 10.1074/jbc.M300468200; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tun H, 2002, J MOL NEUROSCI, V19, P31, DOI 10.1007/s12031-002-0007-5; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yuan H, 1999, J NEUROSCI METH, V88, P45, DOI 10.1016/S0165-0270(99)00011-4	41	208	215	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34674	34681		10.1074/jbc.M402324200	http://dx.doi.org/10.1074/jbc.M402324200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15148325	hybrid			2022-12-27	WOS:000223134800072
J	Diederichs, S; Baumer, N; Ji, P; Metzelder, SK; Idos, GE; Cauvet, T; Wang, WB; Moller, M; Pierschalski, S; Gromoll, J; Schrader, MG; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C				Diederichs, S; Baumer, N; Ji, P; Metzelder, SK; Idos, GE; Cauvet, T; Wang, WB; Moller, M; Pierschalski, S; Gromoll, J; Schrader, MG; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C			Identification of interaction partners and substrates of the cyclin A1-CDK2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACTIVATED C-KINASE; CELL-CYCLE; MAMMALIAN-CELLS; DNA-REPAIR; DEPENDENT KINASES; MESSENGER-RNA; GERM-CELLS; G-PROTEINS; BETA-SUBUNIT	The CDK2-associated cyclin A1 is essential for spermatogenesis and contributes to leukemogenesis. The detailed molecular functions of cyclin A1 remain unclear, since the molecular networks involving cyclin A1-CDK2 have not been elucidated. Here, we identified novel cyclin A1/CDK2 interaction partners in a yeast triple-hybrid approach. Several novel proteins (INCA1, KARCA1, and PROCA1) as well as the known proteins GPS2 (G-protein pathway suppressor 2), Ku70, receptor for activated protein kinase C1/guanine nucleotide-binding protein beta-2-like-1, and mRNA-binding motif protein 4 were identified as interaction partners. These proteins link the cyclin A1-CDK2 complex to diverse cellular processes such as DNA repair, signaling, and splicing. Interactions were confirmed by GST pull-down assays and co-immunoprecipitation. We cloned and characterized the most frequently isolated unknown gene, which we named INCA1 ( inhibitor of CDK interacting with cyclin A1). The nuclear INCA1 protein is evolutionarily conserved and lacks homology to any known gene. This novel protein and two other interacting partners served as substrates for the cyclin A1-CDK2 kinase complex. Cyclin A1 and all interaction partners were highly expressed in testis with varying degrees of tissue specificity. The highest expression levels were observed at different time points during testis maturation, whereas expression levels in germ cell cancers and infertile testes decreased. Taken together, we identified testicular interaction partners of the cyclin A1-CDK2 complex and studied their expression pattern in normal organs, testis development, and testicular malignancies. Thereby, we establish a new basis for future functional analyses of cyclin A1. We provide evidence that the cyclin A1-CDK2 complex plays a role in several signaling pathways important for cell cycle control and meiosis.	Univ Munster, Dept Med Hematol Oncol, D-48129 Munster, Germany; Univ Munster, Inst Reprod Med, D-48129 Munster, Germany; Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Hosp Benjamin Franklin, Dept Urol, D-12200 Berlin, Germany	University of Munster; University of Munster; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muller-Tidow, C (corresponding author), Univ Munster, Dept Med Hematol Oncol, Domagkstr 3, D-48129 Munster, Germany.	muellerc@uni-muenster.de	Gromoll, Joerg/AAB-2146-2019; Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018; Diederichs, Sven/J-6237-2012	Gromoll, Joerg/0000-0002-7788-8138; Müller-Tidow, Carsten/0000-0002-7166-5232; Diederichs, Sven/0000-0001-7901-4752				BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Forsburg SL, 2000, NAT GENET, V25, P263, DOI 10.1038/77015; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herrmann CH, 2001, J CELL SCI, V114, P1491; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Hsia KT, 2003, DEVELOPMENT, V130, P369, DOI 10.1242/dev.00221; Jackson FB, 1997, GENOMICS, V41, P444, DOI 10.1006/geno.1997.4704; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Kishimoto T, 2003, CURR OPIN CELL BIOL, V15, P654, DOI 10.1016/j.ceb.2003.10.010; Lai MC, 2003, EMBO J, V22, P1359, DOI 10.1093/emboj/cdg126; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu D, 2000, DEV BIOL, V224, P388, DOI 10.1006/dbio.2000.9776; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Muller-Tidow C, 2003, CANCER LETT, V190, P89, DOI 10.1016/S0304-3835(02)00582-7; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Ravnik SE, 1999, DEV BIOL, V207, P408, DOI 10.1006/dbio.1998.9156; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schrader M, 2002, HUM REPROD, V17, P2338, DOI 10.1093/humrep/17.9.2338; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; Sherr CJ, 2000, CANCER RES, V60, P3689; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Sweeney C, 1996, DEVELOPMENT, V122, P53; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; Um JH, 2003, MECH AGEING DEV, V124, P967, DOI 10.1016/S0047-6374(03)00169-6; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	63	50	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33727	33741		10.1074/jbc.M401708200	http://dx.doi.org/10.1074/jbc.M401708200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159402	hybrid			2022-12-27	WOS:000223039700082
J	Wang, L; Kwak, JH; Kim, SI; He, YJ; Choi, ME				Wang, L; Kwak, JH; Kim, SI; He, YJ; Choi, ME			Transforming growth factor-beta 1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38 alpha and p38 delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; FACTOR VEGF; SIGNAL-TRANSDUCTION; FACTOR-BETA; P38 MAPK; MECHANICAL STRETCH; FACTOR EXPRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; RECEPTORS	Transforming growth factor-beta1 (TGF-beta1) is a potent inducer of extracellular matrix synthesis leading to progressive glomerular fibrosis. The intracellular signaling mechanisms involved in this process remain incompletely understood. The p38 mitogen-activated protein kinase ( MAPK) is a major stress signal transducing pathway that is rapidly activated by TGF-beta1 in mesangial cells. We have previously demonstrated MKK3 as the immediate upstream MAPK kinase required for selective activation of p38 MAPK isoforms, p38alpha and p38delta, and stimulation of pro-alpha1( I) collagen by TGF-beta1 in murine mesangial cells. In this study, we further sought to determine MAPK kinase 3 ( MKK3)-dependent TGF-beta1 responses by gene expression profiling analysis utilizing mesangial cells isolated from Mkk3(-/-) mice compared with Mkk3(+/+) controls. Interestingly, vascular endothelial growth factor ( VEGF) was identified as a TGF-beta1-induced gene affected by deletion of Mkk3. VEGF is a well known endothelial mitogen, whose actions in nonendothelial cell types are still not well understood. We confirmed that TGF-beta1 increased VEGF mRNA and protein synthesis of VEGF(164) and VEGF(188) isoforms in wild-type mesangial cells. However, in the Mkk3(-/-) mesangial cells, both TGF-beta1-induced VEGF mRNA and VEGF(164) protein expression were inhibited, whereas TGF-beta1-induced VEGF(188) protein expression was unaffected. Furthermore, transfection of dominant negative mutants of p38alpha and p38delta resulted in marked inhibition of TGF-beta1-induced VEGF(164) expression but not VEGF(188), and treatment with recombinant mouse VEGF(164) increased collagen and fibronectin mRNA expression in mesangial cells. Taken together, our findings suggest a critical role for the MKK3-p38alpha and p38delta MAPK pathway in mediating VEGF(164) isoform-specific stimulation by TGF-beta1 in mesangial cells. Further, VEGF(164) stimulates collagen and fibronectin expression in mesangial cells and thus in turn enhances TGF-beta1-induced extracellular matrix and may play an important role in progressive glomerular fibrosis.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, ME (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, E1158 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	choim@pitt.edu			NIDDK NIH HHS [R01 DK57661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ancelin M, 2002, P NATL ACAD SCI USA, V99, P6023, DOI 10.1073/pnas.082110999; Bailey E, 1999, J CLIN PATHOL, V52, P735, DOI 10.1136/jcp.52.10.735; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Benckert C, 2003, CANCER RES, V63, P1083; Bokemeyer D, 1998, KIDNEY INT, V54, pS189, DOI 10.1046/j.1523-1755.1998.06743.x; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Chin BY, 2001, AM J PHYSIOL-RENAL, V280, pF495, DOI 10.1152/ajprenal.2001.280.3.F495; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Cooper ME, 1999, DIABETES, V48, P2229, DOI 10.2337/diabetes.48.11.2229; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Dunlop ME, 2000, KIDNEY INT, V57, P464, DOI 10.1046/j.1523-1755.2000.t01-1-00866.x; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gruden G, 1997, P NATL ACAD SCI USA, V94, P12112, DOI 10.1073/pnas.94.22.12112; Gruden G, 1999, J AM SOC NEPHROL, V10, P730; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hovey RC, 2001, MOL ENDOCRINOL, V15, P819, DOI 10.1210/me.15.5.819; IIJIMA K, 1993, KIDNEY INT, V44, P959, DOI 10.1038/ki.1993.337; IRUELAARISPE L, 1995, AM J PATHOL, V147, P1715; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Ju HS, 2002, J PHARMACOL EXP THER, V301, P15, DOI 10.1124/jpet.301.1.15; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kim NH, 2000, J ENDOCRINOL, V165, P617, DOI 10.1677/joe.0.1650617; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuoka H, 2002, AM J PHYSIOL-LUNG C, V283, pL103, DOI 10.1152/ajplung.00187.2001; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ning W, 2002, AM J PHYSIOL-LUNG C, V283, pL1094, DOI 10.1152/ajplung.00151.2002; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Robinson CJ, 2001, J CELL SCI, V114, P853; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Spector JA, 2001, AM J PHYSIOL-CELL PH, V280, pC72, DOI 10.1152/ajpcell.2001.280.1.C72; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Thomas S, 2000, J AM SOC NEPHROL, V11, P1236, DOI 10.1681/ASN.V1171236; Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200; Wada T, 2000, J AM SOC NEPHROL, V11, P1534, DOI 10.1681/ASN.V1181534; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Yamamoto T, 2001, J CELL BIOCHEM, V82, P591, DOI 10.1002/jcb.1179; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	52	53	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33213	33219		10.1074/jbc.M403758200	http://dx.doi.org/10.1074/jbc.M403758200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15143069	hybrid			2022-12-27	WOS:000223039700026
J	Kumar, DP; Tiwari, A; Bhat, R				Kumar, DP; Tiwari, A; Bhat, R			Effect of pH on the stability and structure of yeast hexokinase A - Acidic amino acid residues in the cleft region are critical for the opening and the closing of the structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSPHEROCYTIC HEMOLYTIC-ANEMIA; MOLTEN GLOBULE; FLUORESCENT-PROBE; SUBUNIT STRUCTURE; D-GLUCOSE; PROTEINS; MECHANISM; BINDING; SALT; DENATURATION	pH and salts have a marked effect on the stability, structure, and function of many globular proteins due to their ability to influence the electrostatic interactions. In this work, calorimetry, CD, and fluorescence studies have been carried out to understand the pH-dependent conformational changes of the two-domain protein yeast hexokinase A. In conjunction with the crystal structural data available, the present results have enabled the complete characterization and analysis of the pH-dependent conformational changes of the enzyme that have strong implications in understanding its structure-function relationship. The calorimetric profiles show a single thermal transition in the acidic pH range, whereas two independent transitions were observed in the alkaline pH range, suggesting the structural merger of the domains at the acidic pH. Comparison of the thermal transitions at pH 8.5 studied by different techniques suggests that the first transition corresponds to the smaller domain, and the second transition corresponds to the larger domain. The acid-denatured state of hexokinase A has high secondary structure content with little or no tertiary interactions and binds to the hydrophobic dye 8-anilinonaphthalene-1-sulfonic acid, suggesting that it is a molten globule-like state, whereas the alkali-denatured state is less structured than the acid-denatured state but more structured than the urea-denatured state, suggestive of a pre-molten globule-like state. Structural analysis using the published hexokinase B structure as well as the hexokinase A structure with the revised amino acid sequence in conjunction with the results obtained by us suggests that the ionization state of the acidic residues at the active site could regulate domain movements that are responsible for the opening and the closure of the cleft between the two domains and in turn affect the structure and function of the enzyme.	Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi	Bhat, R (corresponding author), Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India.	rajivbhat@mail.jnu.ac.in	Tiwari, Ashutosh/A-7458-2008	Tiwari, Ashutosh/0000-0001-7373-349X				ABE Y, 1995, J BIOCHEM-TOKYO, V118, P946, DOI 10.1093/jb/118.5.946; ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BARRIE SE, 1979, RES COMMUN CHEM PATH, V23, P375; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; Catanzano F, 1997, J BIOCHEM-TOKYO, V121, P568; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; FELDMAN I, 1978, BIOCHEMISTRY-US, V17, P1541, DOI 10.1021/bi00601a029; Filfil R, 2003, FEBS LETT, V554, P351, DOI 10.1016/S0014-5793(03)01187-6; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; Frommer WB, 2003, SCIENCE, V300, P261, DOI 10.1126/science.1084120; GarciaMoreno B, 1995, METHOD ENZYMOL, V259, P512; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GROUSELLE M, 1973, EUR J BIOCHEM, V39, P431, DOI 10.1111/j.1432-1033.1973.tb03141.x; KENAR KT, 1995, PROTEIN SCI, V4, P1934, DOI 10.1002/pro.5560040929; Kuser PR, 2000, J BIOL CHEM, V275, P20814, DOI 10.1074/jbc.M910412199; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MAGNANI M, 1985, BLOOD, V66, P690; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Neet KE, 2002, MOL CELL PROTEOMICS, V1, P415, DOI 10.1074/mcp.R200003-MCP200; OHNING GV, 1983, BIOCHEMISTRY-US, V22, P2986, DOI 10.1021/bi00281a031; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; PETERS BA, 1978, J BIOL CHEM, V253, P6826; Peters LL, 2001, BLOOD CELL MOL DIS, V27, P850, DOI 10.1006/bcmd.2001.0454; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rami BR, 2002, BIOCHEMISTRY-US, V41, P1710, DOI 10.1021/bi0120300; RAND RP, 1993, BIOCHEMISTRY-US, V32, P5925, DOI 10.1021/bi00074a001; SCHMIDT JJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P458, DOI 10.1016/0003-9861(73)90537-7; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170; SOLS A, 1958, BIOCHIM BIOPHYS ACTA, V30, P92; SORBI S, 1990, NEUROSCI LETT, V117, P165, DOI 10.1016/0304-3940(90)90138-Y; STEITZ TA, 1971, J MOL BIOL, V61, P695, DOI 10.1016/0022-2836(71)90073-8; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P4693, DOI 10.1021/bi00519a026; VIOLA RE, 1978, BIOCHEMISTRY-US, V17, P4111, DOI 10.1021/bi00613a001; WOMACK FC, 1973, ARCH BIOCHEM BIOPHYS, V158, P451, DOI 10.1016/0003-9861(73)90536-5	42	29	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32093	32099		10.1074/jbc.M313449200	http://dx.doi.org/10.1074/jbc.M313449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145950	hybrid			2022-12-27	WOS:000222849700014
J	Gasol, E; Jimenez-Vidal, M; Chillaron, J; Zorzano, A; Palacin, M				Gasol, E; Jimenez-Vidal, M; Chillaron, J; Zorzano, A; Palacin, M			Membrane topology of system x(c)(-) light subunit reveals a re-entrant loop with substrate-restricted accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; HUMAN XCT; GLUTAMATE; CYSTINE; EXPRESSION; RESIDUES; CHANNEL; CLONING; IDENTIFICATION	Heteromeric amino acid transporters are composed of a heavy and a light subunit linked by a disulfide bridge. 4F2hc/xCT elicits sodium-independent exchange of anionic L-cysteine and L-glutamate (system x(c)(-)). Based on the accessibility of single cysteines to 3-(N-maleimidylpropionyl) biocytin, we propose a topological model for xCT of 12 transmembrane domains with the N and C termini located inside the cell. This location of N and C termini was confirmed by immunofluorescence. Studies of biotinylation and accessibility to sulfhydryl reagents revealed a re-entrant loop within intracellular loops 2 and 3. Residues His(110) and Thr(112), facing outside, are located at the apex of the re-entrant loop. Biotinylation of H110C was blocked by xCT substrates, by the nontransportable inhibitor (S)-4-carboxyphenylglycine, and by the impermeable reagent (2-sulfonatoethyl) methanethiosulfonate, which produced an inactivation of H110C that was protected by L-glutamate and L-cysteine with an IC50 similar to the K-m. Protection was temperature-independent. The data indicate that His110 may lie close to the substrate binding/permeation pathway of xCT. The membrane topology of xCT could serve as a model for other light subunits of heteromeric amino acid transporters.	Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Inst Recerca Oncol, Med & Mol Genet Ctr, E-08028 Barcelona, Spain	University of Barcelona	Palacin, M (corresponding author), Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Avda Diagonal 645, E-08028 Barcelona, Spain.	mpalacin@bio.ub.es	Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Chillaron, Josep/ABF-7663-2021	Chillaron, Josep/0000-0003-3068-7598; Palacin, Manuel/0000-0002-8670-293X				Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; BANNAI S, 1989, J BIOL CHEM, V264, P18480; Barger SW, 2001, J NEUROCHEM, V76, P846, DOI 10.1046/j.1471-4159.2001.00075.x; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; Boado RJ, 2003, J NEUROCHEM, V84, P1322, DOI 10.1046/j.1471-4159.2003.01622.x; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Fenczik CA, 2001, J BIOL CHEM, V276, P8746, DOI 10.1074/jbc.M011239200; Fernandez E, 2002, AM J PHYSIOL-RENAL, V283, pF540, DOI 10.1152/ajprenal.00071.2002; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Jimenez-Vidal M, 2004, J BIOL CHEM, V279, P11214, DOI 10.1074/jbc.M309866200; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Krom BP, 2003, BIOCHEMISTRY-US, V42, P467, DOI 10.1021/bi026874a; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; Lopez-Corcuera B, 2001, J BIOL CHEM, V276, P43463, DOI 10.1074/jbc.M107438200; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Patel SA, 2004, NEUROPHARMACOLOGY, V46, P273, DOI 10.1016/j.neuropharm.2003.08.006; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; PIANI D, 1994, J IMMUNOL, V152, P3578; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2000, ANTIOXID REDOX SIGN, V2, P665, DOI 10.1089/ars.2000.2.4-665; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Shigekawa M, 2002, ANN NY ACAD SCI, V976, P19; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Wang HY, 2003, BIOCHEM BIOPH RES CO, V305, P611, DOI 10.1016/S0006-291X(03)00808-8	41	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31228	31236		10.1074/jbc.M402428200	http://dx.doi.org/10.1074/jbc.M402428200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15151999	hybrid			2022-12-27	WOS:000222726800042
J	Hua, W; Zhang, L; Liang, SP; Jones, RL; Lu, YT				Hua, W; Zhang, L; Liang, SP; Jones, RL; Lu, YT			A tobacco calcium/calmodulin-binding protein kinase functions as a negative regulator of flowering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN ISOFORMS; CALCIUM-CALMODULIN; FLORAL INITIATION; SENSITIVE METHOD; DNA METHYLATION; TARGET GENES; ARABIDOPSIS; PLANT; TIME; EXPRESSION	A tobacco calcium/calmodulin-binding protein kinase (NtCBK1) was isolated and identified. The predicted NtCBK1 protein has 599 amino acids, an N-terminal kinase domain, and shares high homology with other calmodulin (CaM)-related kinases. Whereas NtCBK1 phosphorylates itself and substrates such as histone IIIS and syntide-2 in the absence of CaM, its kinase activity can be stimulated by tobacco CaMs. However, unlike another tobacco protein kinase designated NtCBK2, NtCBK1 was not differentially regulated by the different CaM isoforms tested. The CaM-binding domain of NtCBK1 was located between amino acids 436 and 455, and this domain was shown to be necessary for CaM modulation of kinase activity. RNA in situ hybridization showed that NtCBK1 was highly regulated in the transition to flowering. Whereas NtCBK1 mRNA was accumulated in the shoot apical meristem during vegetative growth, its expression was dramatically decreased in the shoot apical meristem after floral determination, and in young flower primordia. The expression of NtCBK1 was up-regulated to high levels in floral organ primordia. Fluctuations in NtCBK1 expression were verified by analysis of tobacco plants expressing green fluorescent protein under the control of the NtCBK1 promoter, suggesting a role of NtCBK1 in the transition to flowering. This conclusion was confirmed by overexpressing NtCBK1 in transgenic tobacco plants, where maintenance of high levels of NtCBK1 in the shoot apical meristem delayed the switch to flowering and extended the vegetative phase of growth. Further work indicated that overexpression of NtCBK1 in transgenic tobacco did not affect the expression of NFL, a tobacco homologue of the LFY gene that controls meristem initiation and floral structure in tobacco. In addition, the promotion of tobacco flowering time by DNA demethylation cannot be blocked by the overexpression of NtCBK1.	Wuhan Univ, Coll Life Sci, Key Lab MOE Plant Dev Biol, Wuhan 430072, Peoples R China; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	Wuhan University; University of California System; University of California Berkeley	Lu, YT (corresponding author), Wuhan Univ, Coll Life Sci, Key Lab MOE Plant Dev Biol, Wuhan 430072, Peoples R China.	yingtlu@whu.edu.cn						Ahearn KP, 2001, PLANT CELL PHYSIOL, V42, P1130, DOI 10.1093/pcp/pce143; Aitken A, 2002, PROTEIN PROTOCOLS HD, P41; Amaya I, 1999, PLANT CELL, V11, P1405, DOI 10.1105/tpc.11.8.1405; Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; Blazquez MA, 2000, NATURE, V404, P889, DOI 10.1038/35009125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Choi JY, 2002, J BIOL CHEM, V277, P21630, DOI 10.1074/jbc.M110803200; DREWS GN, 1995, FIXATION EMBEDDING I; Finnegan EJ, 1998, P NATL ACAD SCI USA, V95, P5824, DOI 10.1073/pnas.95.10.5824; Finnegan EJ, 2000, CURR OPIN GENET DEV, V10, P217, DOI 10.1016/S0959-437X(00)00061-7; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HEMPEL FD, 1995, PLANT J, V8, P725, DOI 10.1046/j.1365-313X.1995.08050725.x; Higo K, 1999, NUCLEIC ACIDS RES, V27, P297, DOI 10.1093/nar/27.1.297; Hua W, 2003, BIOCHEM J, V376, P291, DOI 10.1042/BJ20030736; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liang SP, 2001, SCI CHINA SER C, V44, P506, DOI 10.1007/BF02882393; LINDZEN E, 1995, PLANT MOL BIOL, V28, P785, DOI 10.1007/BF00042065; Liu BF, 2001, J CHROMATOGR A, V918, P401, DOI 10.1016/S0021-9673(01)00741-5; Liu ZH, 1998, PLANT MOL BIOL, V38, P889, DOI 10.1023/A:1006019001200; Lizal P, 2001, PHYSIOL PLANTARUM, V113, P121, DOI 10.1034/j.1399-3054.2001.1130116.x; LU YT, 1994, PLANT PHYSIOL BIOCH, V32, P413; Lu YT, 1996, PLANTA, V199, P18; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McDaniel CN, 1996, J EXP BOT, V47, P465, DOI 10.1093/jxb/47.4.465; MCDANIEL CN, 1989, AM J BOT, V76, P403, DOI 10.2307/2444610; Mouradov A, 2002, PLANT CELL, V14, pS111, DOI 10.1105/tpc.001362; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Pandey S, 2001, J EXP BOT, V52, P691, DOI 10.1093/jexbot/52.357.691; Pnueli L, 2001, PLANT CELL, V13, P2687, DOI 10.1105/tpc.13.12.2687; Poovaiah BW, 1999, PLANTA, V209, P161, DOI 10.1007/s004250050618; Ramachandiran S, 1997, J BIOCHEM-TOKYO, V121, P984; Reddy VS, 1999, J BIOL CHEM, V274, P31727, DOI 10.1074/jbc.274.44.31727; Reddy VS, 2002, J BIOL CHEM, V277, P9840, DOI 10.1074/jbc.M111626200; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; SINGER SR, 1987, P NATL ACAD SCI USA, V84, P2790, DOI 10.1073/pnas.84.9.2790; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Sugano S, 1999, P NATL ACAD SCI USA, V96, P12362, DOI 10.1073/pnas.96.22.12362; Sugano S, 1998, P NATL ACAD SCI USA, V95, P11020, DOI 10.1073/pnas.95.18.11020; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Wang L, 2001, PLANTA, V213, P556, DOI 10.1007/s004250100540; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; Yamakawa H, 2001, EUR J BIOCHEM, V268, P3916, DOI 10.1046/j.1432-1327.2001.02301.x; Yanovsky MJ, 2003, NAT REV MOL CELL BIO, V4, P265, DOI 10.1038/nrm1077; Zhang L, 2003, TRENDS PLANT SCI, V8, P123, DOI 10.1016/S1360-1385(03)00013-X; Zhang L, 2002, BIOCHEM J, V368, P145, DOI 10.1042/BJ20020780	57	31	36	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31483	31494		10.1074/jbc.M402861200	http://dx.doi.org/10.1074/jbc.M402861200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138273	hybrid			2022-12-27	WOS:000222726800071
J	Ohtaki, A; Mizuno, M; Tonozuka, T; Sakano, Y; Kamitori, S				Ohtaki, A; Mizuno, M; Tonozuka, T; Sakano, Y; Kamitori, S			Complex structures of Thermoactinomyces vulgaris R-47 alpha-amylase 2 with acarbose and cyclodextrins demonstrate the multiple substrate recognition mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURES; ALPHA-AMYLASE; 3-DIMENSIONAL STRUCTURE; MALTOGENIC AMYLASE; CRYSTAL-STRUCTURE; KINETIC ANALYSES; BINDING; TVAII; ENZYME; CYCLOMALTODEXTRINASE	Thermoactinomyces vulgaris R-47 alpha-amylase 2 (TVAII) has the unique ability to hydrolyze cyclodextrins (CDs), with various sized cavities, as well as starch. To understand the relationship between structure and substrate specificity, x-ray structures of a TVAII-acarbose complex and inactive mutant TVAII (D325N/D421N)/alpha-, beta- and gamma-CDs complexes were determined at resolutions of 2.9, 2.9, 2.8, and 3.1 Angstrom, respectively. In all complexes, the interactions between ligands and enzymes at subsites - 1, - 2, and - 3 were almost the same, but striking differences in the catalytic site structure were found at subsites + 1 and + 2, where Trp(356) and Tyr(374) changed the conformation of the side chain depending on the structure and size of the ligands. Trp(356) and Tyr(374) are thought to be responsible for the multiple substrate-recognition mechanism of TVAII, providing the unique substrate specificity. In the beta-CD complex, the beta-CD maintains a regular conical structure, making it difficult for Glu(354) to protonate the O-4 atom at the hydrolyzing site as a previously proposed hydrolyzing mechanism of alpha-amylase. From the x-ray structures, it is suggested that the protonation of the O-4 atom is possibly carried out via a hydrogen atom of the inter-glucose hydrogen bond at the hydrolyzing site.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan; Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Tokyo 1838509, Japan	Tokyo University of Agriculture & Technology; Tokyo University of Agriculture & Technology	Kamitori, S (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Tokyo 1848588, Japan.	kamitori@cc.tuat.ac.jp	Tonozuka, Takashi/D-2268-2013	Tonozuka, Takashi/0000-0002-5422-7548; Kamitori, Shigehiro/0000-0002-3950-3372				Abe A, 2004, J MOL BIOL, V335, P811, DOI 10.1016/j.jmb.2003.10.078; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Fritzsche HB, 2003, EUR J BIOCHEM, V270, P2332, DOI 10.1046/j.1432-1033.2003.03603.x; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hondoh H, 2003, J MOL BIOL, V326, P177, DOI 10.1016/S0022-2836(02)01402-X; Ichikawa K, 2000, BIOSCI BIOTECH BIOCH, V64, P2692, DOI 10.1271/bbb.64.2692; IMBERTY A, 1988, J MOL BIOL, V201, P365, DOI 10.1016/0022-2836(88)90144-1; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Kamitori S, 2002, J MOL BIOL, V318, P443, DOI 10.1016/S0022-2836(02)00111-0; Kim JS, 1999, J BIOL CHEM, V274, P26279, DOI 10.1074/jbc.274.37.26279; Kondo S, 2001, J BIOCHEM, V129, P423, DOI 10.1093/oxfordjournals.jbchem.a002873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee HS, 2002, J BIOL CHEM, V277, P21891, DOI 10.1074/jbc.M201623200; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; Machius M, 1996, J MOL BIOL, V260, P409, DOI 10.1006/jmbi.1996.0410; MANOR PC, 1974, J AM CHEM SOC, V96, P3630, DOI 10.1021/ja00818a042; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Ohtaki A, 2001, CARBOHYD RES, V334, P309, DOI 10.1016/S0008-6215(01)00190-2; Park KH, 2000, BBA-PROTEIN STRUCT M, V1478, P165, DOI 10.1016/S0167-4838(00)00041-8; Qian MX, 2001, BIOCHEMISTRY-US, V40, P7700, DOI 10.1021/bi0102050; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Ramasubbu N, 2003, J MOL BIOL, V325, P1061, DOI 10.1016/S0022-2836(02)01326-8; Schmidt AK, 1998, BIOCHEMISTRY-US, V37, P5909, DOI 10.1021/bi9729918; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; TONOZUKA T, 1993, BIOSCI BIOTECH BIOCH, V57, P395, DOI 10.1271/bbb.57.395; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235	35	23	24	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31033	31040		10.1074/jbc.M404311200	http://dx.doi.org/10.1074/jbc.M404311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138257	hybrid			2022-12-27	WOS:000222726800017
J	Pokidysheva, E; Milbradt, AG; Meier, S; Renner, C; Haussinger, D; Bachinger, HP; Moroder, L; Grzesiek, S; Holstein, TW; Ozbek, S; Engel, J				Pokidysheva, E; Milbradt, AG; Meier, S; Renner, C; Haussinger, D; Bachinger, HP; Moroder, L; Grzesiek, S; Holstein, TW; Ozbek, S; Engel, J			The structure of the Cys-rich terminal domain of hydra minicollagen, which is involved in disulfide networks of the nematocyst wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; IV COLLAGEN; PROTEIN; BONDS; LINKAGE; SYSTEM; SWITCH; CORAL	The minicollagens found in the nematocysts of Hydra constitute a family of invertebrate collagens with unusual properties. They share a common modular architecture with a central collagen sequence ranging from 14 to 16 Gly-X-Y repeats flanked by polyproline/hydroxyproline stretches and short terminal domains that show a conserved cysteine pattern (CXXXCXXXCXXXCXXXCC). The minicollagen cysteine-rich domains are believed to function in a switch of the disulfide connectivity from intra- to intermolecular bonds during maturation of the capsule wall. The solution structure of the C-terminal fragment including a minicollagen cysteine-rich domain of minicollagen-1 was determined in two independent groups by H-1 NMR. The corresponding peptide comprising the last 24 residues of the molecule was produced synthetically and refolded by oxidation under low protein concentrations. Both presented structures are identical in their fold and disulfide connections (Cys(2)-Cys(18), Cys(6)-Cys(14), and Cys(10)-Cys(19)) revealing a robust structural motif that is supposed to serve as the polymerization module of the nematocyst capsule.	Univ Basel, Dept Biol Struct, Biozentrum, CH-4051 Basel, Switzerland; Univ Basel, Dept Biophys Chem, Biozentrum, CH-4051 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Shriners Hosp Children, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Tech Univ Darmstadt, Inst Zool, D-64287 Darmstadt, Germany	University of Basel; University of Basel; Max Planck Society; Oregon Health & Science University; Technical University of Darmstadt	Grzesiek, S (corresponding author), Univ Basel, Dept Biol Struct, Biozentrum, Klingelbergstr 70, CH-4051 Basel, Switzerland.	stephan.grzesiek@unibas.ch; suat.oezbek@unibas.ch	Özbek, Suat/D-3701-2014; Meier, Sebastian/A-4279-2015; Häussinger, Daniel/C-6617-2016	Meier, Sebastian/0000-0003-3761-3217; Häussinger, Daniel/0000-0002-4798-0072; Holstein, Thomas/0000-0003-0480-4674; Moroder, Luis/0000-0001-9570-5713; Grzesiek, Stephan/0000-0003-1998-4225; Ozbek, Suat/0000-0003-2569-3942				Barth D, 2003, CHEM-EUR J, V9, P3703, DOI 10.1002/chem.200304918; BATEMAN JF, 1996, MOL COMPONENTS INTER, V2; BLANQUET R, 1966, SCIENCE, V154, P152, DOI 10.1126/science.154.3745.152; Boudko SP, 2004, J MOL BIOL, V335, P1289, DOI 10.1016/j.jmb.2003.11.054; BRUCKNER P, 1978, EUR J BIOCHEM, V90, P595, DOI 10.1111/j.1432-1033.1978.tb12640.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Creighton TE, 1997, BIOL CHEM, V378, P731; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785; Engel U, 2001, EMBO J, V20, P3063, DOI 10.1093/emboj/20.12.3063; ENGEL U, 2002, J CELL SCI, V115; FAINZILBER M, 1995, BIOCHEMISTRY-US, V34, P8649, DOI 10.1021/bi00027a014; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9; HOLSTEIN T, 1984, SCIENCE, V223, P830, DOI 10.1126/science.6695186; Housset D, 2000, ACTA CRYSTALLOGR D, V56, P151, DOI 10.1107/S0907444999014948; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUHN K, 1995, MATRIX BIOL, V14, P439, DOI 10.1016/0945-053X(95)90001-2; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; Laederach A, 2002, BIOCHEMISTRY-US, V41, P12359, DOI 10.1021/bi026185z; LENHOFF HM, 1957, BIOCHIM BIOPHYS ACTA, V26, P204, DOI 10.1016/0006-3002(57)90074-4; Li PP, 2002, P NATL ACAD SCI USA, V99, P1353, DOI 10.1073/pnas.032668699; Mandard N, 2002, EUR J BIOCHEM, V269, P1190, DOI 10.1046/j.0014-2956.2002.02760.x; MEIER S, 2004, IN PRESS FEBS LETT; Milbradt AG, 2003, BIOCHEMISTRY-US, V42, P2404, DOI 10.1021/bi020628h; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Ozbek S, 2002, J BIOL CHEM, V277, P49200, DOI 10.1074/jbc.M209401200; Ozbek S, 2002, J STRUCT BIOL, V137, P11, DOI 10.1006/jsbi.2002.4436; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Vollmer SV, 2002, SCIENCE, V296, P2023, DOI 10.1126/science.1069524; WAGNER DD, 1987, BLOOD, V69, P27; WANG WQ, 1995, GENE, V152, P195, DOI 10.1016/0378-1119(95)00644-L; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Welker E, 2001, BIOCHEMISTRY-US, V40, P9059, DOI 10.1021/bi010409g; Wieringa R, 2003, J VIROL, V77, P12996, DOI 10.1128/JVI.77.24.12996-13004.2003; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG RM, 1989, J BIOL CHEM, V264, P18472	44	27	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30395	30401		10.1074/jbc.M403734200	http://dx.doi.org/10.1074/jbc.M403734200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123641	hybrid			2022-12-27	WOS:000222531900065
J	Macao, B; Olsson, M; Elias, P				Macao, B; Olsson, M; Elias, P			Functional properties of the herpes simplex virus type I origin-binding protein are controlled by precise interactions with the activated form of the origin of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; VIRAL ORIGIN; CRYSTAL-STRUCTURES; HELICASE; UL9; RECOMBINATION; DOMAIN; INITIATION; COMPLEXES; RESIDUES	The herpes simplex virus, type I origin-binding protein, OBP, is a superfamily II DNA helicase encoded by the UL9 gene. OBP binds in a sequence-specific and cooperative way to the viral origin of replication oriS. OBP may unwind partially and introduce a hairpin into the double-stranded origin of replication. The formation of the novel conformation referred to as oriS* also requires the single-stranded DNA-binding protein, ICP8, and ATP hydrolysis. OBP forms a stable complex with oriS*. The hairpin in oriS* provides a site for sequence-specific attachment, and a single-stranded region triggers ATP hydrolysis. Here we use Escherichia coli exonuclease I to map the binding of the C-terminal domain of OBP to the hairpin and the helicase domains to the single-stranded tail. The helicase domains cover a stretch of 23 nucleotides of single-stranded DNA. Using streptavidin-coated magnetic beads, we show that OBP may bind two copies of double-stranded DNA (one biotin-labeled and the other one radioactively labeled) but only one copy of oriS*. It is the length of the single-stranded tail that determines the stoichiometry of OBP.DNA complexes. OBP interacts with the bases of the single-stranded tail, and ATP hydrolysis is triggered by position-specific interactions between OBP and bases in the single-stranded tail of oriS*.	Univ Gothenburg, Dept Med Biochem, S-40530 Gothenburg, Sweden	University of Gothenburg	Elias, P (corresponding author), Univ Gothenburg, Dept Med Biochem, Box 440, S-40530 Gothenburg, Sweden.	per.elias@medkem.gu.se						Aslani A, 2000, J BIOL CHEM, V275, P5880, DOI 10.1074/jbc.275.8.5880; Aslani A, 2002, J BIOL CHEM, V277, P41204, DOI 10.1074/jbc.M208270200; Aslani A, 2001, P NATL ACAD SCI USA, V98, P7194, DOI 10.1073/pnas.121177198; Boehmer PE, 2003, IUBMB LIFE, V55, P13, DOI 10.1080/1521654031000070645; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; He XD, 2001, P NATL ACAD SCI USA, V98, P3024, DOI 10.1073/pnas.061028298; Jackson SA, 2003, P NATL ACAD SCI USA, V100, P7871, DOI 10.1073/pnas.1230643100; JACOB RJ, 1979, J VIROL, V29, P448, DOI 10.1128/JVI.29.2.448-457.1979; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Le Gac NT, 2002, J BIOL CHEM, V277, P5660, DOI 10.1074/jbc.M108316200; Lee SSK, 1999, J BIOL CHEM, V274, P18613, DOI 10.1074/jbc.274.26.18613; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Makhov AM, 2003, P NATL ACAD SCI USA, V100, P898, DOI 10.1073/pnas.0237171100; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; Marintcheva B, 2003, J VIROL, V77, P2477, DOI 10.1128/JVI.77.4.2477-2488.2003; Marintcheva B, 2001, J BIOL CHEM, V276, P6605, DOI 10.1074/jbc.M007743200; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; Nimonkar AV, 2003, P NATL ACAD SCI USA, V100, P10201, DOI 10.1073/pnas.1534569100; Reuven NB, 2003, J VIROL, V77, P7425, DOI 10.1128/JVI.77.13.7425-7433.2003; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; Simonsson S, 1998, J BIOL CHEM, V273, P24633, DOI 10.1074/jbc.273.38.24633; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; Wilkinson DE, 2003, IUBMB LIFE, V55, P451, DOI 10.1080/15216540310001612237; Yao XD, 1997, J VIROL, V71, P6842, DOI 10.1128/JVI.71.9.6842-6849.1997; Yao XD, 2001, J BIOL CHEM, V276, P2905, DOI 10.1074/jbc.M005627200	42	14	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29211	29217		10.1074/jbc.M400371200	http://dx.doi.org/10.1074/jbc.M400371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133043	hybrid			2022-12-27	WOS:000222445300048
J	Shi, H; Wang, HZ; Yang, BF; Xu, DH; Wang, ZG				Shi, H; Wang, HZ; Yang, BF; Xu, DH; Wang, ZG			The M-3 receptor-mediated K+ current (I-KM3), a G(q) protein-coupled K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; FUNCTIONAL M-3-MUSCARINIC RECEPTORS; ATRIAL-FIBRILLATION; HUMAN HEART; MULTIPLE SUBTYPES; PHOSPHOLIPASE-C; MOLECULAR-BASIS; CA2+ RELEASE; ACTIVATION; EXPRESSION	Stimulation of muscarinic acetylcholine receptors ( mAChRs) can activate an inward rectifier K+ current ( I-KACh), which is mediated by the M-2 subtype of mAChR in cardiac myocytes. Recently, a novel delayed rectifier-like K+ current mediated by activation of the cardiac M-3 receptors ( designated I-KM3) was identified, which is distinct from I-KACh and other known K+ currents. While I-KACh is known to be a G(i) protein- gated K+ channel, the signal transduction mechanisms for I-KM3 activation remained unexplored. We studied I-KM3 with whole- cell patch clamp and macropatch clamp techniques. Whole cell I-KM3 activated by choline persisted with minimal rundown over 2 h in presence of internal GTP. When GTP was replaced by guanyl-5'-yl thiophosphate, I-KM3 demonstrated rapid and extensive rundown. While I-KACh ( induced by ACh) was markedly reduced in cells pretreated with pertussis toxin, I-KM3 was unaltered. Intracellular application of antibodies targeting alpha-subunit of G(i/o) protein suppressed I-KACh without affecting I-KM3. Antibodies targeting the N and the C terminus, respectively, of G(q) protein alpha-subunit substantially depressed I-KM3 but failed to alter I-KACh. The antibody against beta-subunits of G proteins inhibited both I-KACh and I-KM3. I-KM3 activated by choline in the cell- attached mode of macropatches persisted in the cell- free configuration. Application of purified G(q) protein alpha-subunit or betagamma-subunit of G proteins or guanosine 5'-O-( thiotriphosphate) to the internal solution activated I-KM3- like currents in inside- out patches. Our findings revealed a novel aspect of receptor- channel signal transduction mechanisms, and I-KM3 represents the first G(q) protein- coupled K+ channel. We propose that the G protein- coupled K+ channel family could be divided into two subfamilies: G(i) protein- coupled K+ channel subfamily and G(q) protein-coupled K+ channel subfamily.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Harbin Med Univ, Heilongjiang 150086, Peoples R China; Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China	Universite de Montreal; Universite de Montreal; Harbin Medical University; Sun Yat Sen University	Wang, ZG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1C8, Canada.	wangz@icm.umontreal.ca	Wang, Zhiguo/GRS-4339-2022; wang, zhiguo/AAN-4182-2021	Wang, Zhiguo/0000-0002-0811-2045; 				Bian JS, 2001, CIRC RES, V89, P1168, DOI 10.1161/hh2401.101375; BIRNBAUMER L, 1989, RECENT PROG HORM RES, V45, P121; BLUML K, 1994, J BIOL CHEM, V269, P11537; Brundel BJJM, 2001, CIRCULATION, V103, P684; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; Dobrev D, 2002, CARDIOVASC RES, V54, P397, DOI 10.1016/S0008-6363(01)00555-7; Dobrev D, 2001, CIRCULATION, V104, P2551, DOI 10.1161/hc4601.099466; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; Hellgren I, 2000, CELL MOL LIFE SCI, V57, P175, DOI 10.1007/s000180050507; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Morel JL, 1997, BRIT J PHARMACOL, V121, P451, DOI 10.1038/sj.bjp.0701157; Oberhauser V, 2001, CIRCULATION, V103, P1638, DOI 10.1161/01.CIR.103.12.1638; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Ponicke K, 2003, BRIT J PHARMACOL, V138, P156, DOI 10.1038/sj.bjp.0704997; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Schotten U, 2001, CIRCULATION, V103, P691; Shi H, 2004, CELL PHYSIOL BIOCHEM, V14, P31, DOI 10.1159/000076924; Shi H, 1999, J MEMBRANE BIOL, V169, P55, DOI 10.1007/PL00005901; Shi H, 2003, CELL PHYSIOL BIOCHEM, V13, P59, DOI 10.1159/000070250; Shi H, 1999, MOL PHARMACOL, V55, P497; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; Wang HZ, 2001, MOL PHARMACOL, V59, P1029, DOI 10.1124/mol.59.5.1029; Wang HZ, 1999, BRIT J PHARMACOL, V126, P1725, DOI 10.1038/sj.bjp.0702486; Wang JX, 2004, BRIT J PHARMACOL, V141, P586, DOI 10.1038/sj.bjp.0705646; Wang YX, 1997, AM J PHYSIOL-CELL PH, V273, pC500, DOI 10.1152/ajpcell.1997.273.2.C500; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Willmy-Matthes P, 2003, N-S ARCH PHARMACOL, V368, P316, DOI 10.1007/s00210-003-0796-2; Yamada M, 1998, PHARMACOL REV, V50, P723; Yue LX, 1999, J PHYSIOL-LONDON, V516, P385, DOI 10.1111/j.1469-7793.1999.0385v.x	34	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21774	21778		10.1074/jbc.C400100200	http://dx.doi.org/10.1074/jbc.C400100200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15140874	hybrid			2022-12-27	WOS:000221417100013
J	Stuehr, DJ; Santolini, J; Wang, ZQ; Wei, CC; Adak, S				Stuehr, DJ; Santolini, J; Wang, ZQ; Wei, CC; Adak, S			Update on mechanism and catalytic regulation in the NO synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NITRIC-OXIDE SYNTHASE; ELECTRON-TRANSFER; SPECTROSCOPIC CHARACTERIZATION; COMPLEX-FORMATION; HEME REDUCTION; L-ARGININE; TETRAHYDROBIOPTERIN; BINDING; INTERMEDIATE; OXIDATION		Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org		Wei, Chin-Chuan/0000-0001-6453-9409; Santolini, Jerome/0000-0001-8919-112X				Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; Dmochowski IJ, 2002, METHOD ENZYMOL, V357, P120; Elayan IM, 2000, J NEUROPHYSIOL, V83, P2022, DOI 10.1152/jn.2000.83.4.2022; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Greif DM, 2002, BIOCHEMISTRY-US, V41, P15845, DOI 10.1021/bi026732g; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hendrich MP, 2002, BIOCHEMISTRY-US, V41, P4603, DOI 10.1021/bi011332z; Huang H, 2001, J AM CHEM SOC, V123, P2674, DOI 10.1021/ja005900u; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; JONES DP, 1978, J BIOL CHEM, V253, P4874; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P149, DOI 10.1016/S1089-8603(02)00111-8; Mansuy D, 2002, DRUG METAB REV, V34, P593, DOI 10.1081/DMR-120005661; Moller JKS, 2002, CHEM REV, V102, P1167, DOI 10.1021/cr000078y; Nedvetsky PI, 2002, P NATL ACAD SCI USA, V99, P16510, DOI 10.1073/pnas.262701999; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Newton DC, 2003, J BIOL CHEM, V278, P636, DOI 10.1074/jbc.M209988200; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Ost TWB, 2003, J AM CHEM SOC, V125, P15010, DOI 10.1021/ja035731o; Porasuphatana S, 2001, BBA-GEN SUBJECTS, V1526, P95, DOI 10.1016/S0304-4165(01)00114-3; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Rudolf M, 2002, BIOCHEM SOC T, V30, P649, DOI 10.1042/BST0300649; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Wang ZQ, 2004, J BIOL CHEM, V279, P19018, DOI 10.1074/jbc.M311663200; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350	48	392	400	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36167	36170		10.1074/jbc.R400017200	http://dx.doi.org/10.1074/jbc.R400017200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15133020	hybrid			2022-12-27	WOS:000223453600001
J	Gaude, N; Tippmann, H; Flemetakis, E; Katinakis, P; Udvardi, M; Dormann, P				Gaude, N; Tippmann, H; Flemetakis, E; Katinakis, P; Udvardi, M; Dormann, P			The galactolipid digalactosyldiacylglycerol accumulates in the peribacteroid membrane of nitrogen-fixing nodules of soybean and Lotus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-COMPOSITION; SYMBIOTIC MEMBRANES; SYNTHASE GENES; LEGUME; EXPRESSION; BIOSYNTHESIS; PHOSPHORUS; NODULIN-26; DEFICIENT; JAPONICUS	The peribacteroid membrane (PBM) surrounding nitrogen fixing rhizobia in the nodules of legumes is crucial for the exchange of ammonium and nutrients between the bacteria and the host cell. Digalactosyldiacylglycerol (DGDG), a galactolipid abundant in chloroplasts, was detected in the PBM of soybean (Glycine max) and Lotus japonicus. Analyses of membrane marker proteins and of fatty acid composition confirmed that DGDG represents an authentic PBM lipid of plant origin and is not derived from the bacteria or from plastid contamination. In Arabidopsis, DGDG is known to accumulate in extraplastidic membranes during phosphate deprivation. However, the presence of DGDG in soybean PBM was not restricted to phosphate limiting conditions. Complementary DNA sequences corresponding to the two DGDG synthases, DGD1 and DGD2 from Arabidopsis, were isolated from soybean and Lotus. The two genes were expressed during later stages of nodule development in infected cells and in cortical tissue. Because nodule development depends on the presence of high amounts of phosphate in the growth medium, the accumulation of the non-phosphorus galactolipid DGDG in the PBM might be important to save phosphate for other essential processes, i.e. nucleic acid synthesis in bacteroids and host cells.	Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany; Agr Univ Athens, Dept Agr Biotechnol, Athens 11855, Greece	Max Planck Society; Agricultural University of Athens	Dormann, P (corresponding author), Max Planck Inst Mol Plant Physiol, Muhlenberg 1, D-14476 Golm, Germany.	Doermann@mpimp-golm.mpg.de	Udvardi, Michael/GPX-4653-2022	Udvardi, Michael/0000-0001-9850-0828; Flemetakis, Emmanouil/0000-0003-2530-9592				Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; Awai K, 2001, P NATL ACAD SCI USA, V98, P10960, DOI 10.1073/pnas.181331498; Becher M, 2004, PLANT J, V37, P251, DOI 10.1046/j.1365-313X.2003.01959.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boumahdi M, 1999, J APPL MICROBIOL, V87, P611, DOI 10.1046/j.1365-2672.1999.00860.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brewin N J, 1993, Semin Cell Biol, V4, P149, DOI 10.1006/scel.1993.1018; Brewin N. J., 1990, The plant plasma membrane., P351; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; Day DA, 2001, AUST J PLANT PHYSIOL, V28, P667, DOI 10.1071/PP01028; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; Dormann P, 2002, TRENDS PLANT SCI, V7, P112, DOI 10.1016/S1360-1385(01)02216-6; Essigmann B, 1998, P NATL ACAD SCI USA, V95, P1950, DOI 10.1073/pnas.95.4.1950; Flemetakis E, 2003, BBA-GENE STRUCT EXPR, V1628, P186, DOI 10.1016/S0167-4781(03)00142-8; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; GEIGER O, 1998, RHIZOBIACEAE MOL BIO, P56; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hernandez LE, 1996, PHYTOCHEMISTRY, V42, P341, DOI 10.1016/0031-9422(96)00063-5; ISRAEL DW, 1987, PLANT PHYSIOL, V84, P835, DOI 10.1104/pp.84.3.835; Jiang QY, 1997, MOL PLANT MICROBE IN, V10, P59, DOI 10.1094/MPMI.1997.10.1.59; Jorasch P, 1998, MOL MICROBIOL, V29, P419, DOI 10.1046/j.1365-2958.1998.00930.x; Kelly AA, 2003, PLANT CELL, V15, P2694, DOI 10.1105/tpc.016675; Kelly AA, 2002, J BIOL CHEM, V277, P1166, DOI 10.1074/jbc.M110066200; Kelly AA, 2004, CURR OPIN PLANT BIOL, V7, P262, DOI 10.1016/j.pbi.2004.03.009; Leidi EO, 2000, NEW PHYTOL, V147, P337, DOI 10.1046/j.1469-8137.2000.00703.x; Lodwig EM, 2003, NATURE, V422, P722, DOI 10.1038/nature01527; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Long SR, 2001, PLANT PHYSIOL, V125, P69, DOI 10.1104/pp.125.1.69; MIAO GH, 1993, PLANT CELL, V5, P781, DOI 10.1105/tpc.5.7.781; MILLER KJ, 1990, CURR MICROBIOL, V21, P205, DOI 10.1007/BF02092123; ORGAMBIDE GG, 1994, J BACTERIOL, V176, P4338, DOI 10.1128/jb.176.14.4338-4347.1994; Panter S, 2000, MOL PLANT MICROBE IN, V13, P325, DOI 10.1094/MPMI.2000.13.3.325; PAVKOVSKY R, 1988, PHYSIOL PLANTARUM, V72, P733; PRICE GD, 1987, J PLANT PHYSIOL, V130, P157, DOI 10.1016/S0176-1617(87)80219-5; RAE AL, 1992, PLANT J, V2, P385, DOI 10.1111/j.1365-313X.1992.00385.x; Reiter WD, 1997, PLANT J, V12, P335, DOI 10.1046/j.1365-313X.1997.12020335.x; SCHERES B, 1990, CELL, V60, P281, DOI 10.1016/0092-8674(90)90743-X; Schultze M, 1998, ANNU REV GENET, V32, P33, DOI 10.1146/annurev.genet.32.1.33; Stougaard J, 2000, PLANT PHYSIOL, V124, P531, DOI 10.1104/pp.124.2.531; SULLIVAN JT, 1995, P NATL ACAD SCI USA, V92, P8985, DOI 10.1073/pnas.92.19.8985; TAN Y, 1997, GLYCOBIOLOGY, V7, P935; Udvardi Michael K., 2001, Molecular Plant-Microbe Interactions, V14, P6, DOI 10.1094/MPMI.2001.14.1.6; Udvardi MK, 1997, ANNU REV PLANT PHYS, V48, P493, DOI 10.1146/annurev.arplant.48.1.493; Verma DPS, 1996, TRENDS MICROBIOL, V4, P364, DOI 10.1016/0966-842X(96)10053-6; VERMA DPS, 1992, PLANT CELL, V4, P373, DOI 10.1105/tpc.4.4.373; Weissenmayer B, 2000, MOL PLANT MICROBE IN, V13, P666, DOI 10.1094/MPMI.2000.13.6.666; Whitehead LF, 1997, PHYSIOL PLANTARUM, V100, P30, DOI 10.1034/j.1399-3054.1997.1000103.x; WIESLANDER A, 1980, BIOCHEMISTRY-US, V19, P3650, DOI 10.1021/bi00557a002	51	69	76	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34624	34630		10.1074/jbc.M404098200	http://dx.doi.org/10.1074/jbc.M404098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15159398	hybrid			2022-12-27	WOS:000223134800067
J	Tomzig, A; Spassov, S; Friedrich, M; Naumann, D; Beekes, M				Tomzig, A; Spassov, S; Friedrich, M; Naumann, D; Beekes, M			Discriminating scrapie and bovine spongiform encephalopathy isolates by infrared spectroscopy of pathological prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; NATURAL SHEEP SCRAPIE; SECONDARY STRUCTURE; MOLECULAR ANALYSIS; STRAIN VARIATION; VARIANT CJD; BSE; PRPSC; MICE; CONFORMATIONS	For the surveillance of transmissible spongiform encephalopathies (TSEs) in animals and humans, the discrimination of different TSE strains causing scrapie, BSE, or Creutzfeldt-Jakob disease constitutes a substantial challenge. We addressed this problem by Fourier transform-infrared (FT-IR) spectroscopy of pathological prion protein PrP27-30. Different isolates of hamster-adapted scrapie (263K, 22A-H, and ME7-H) and BSE (BSE-H) were passaged in Syrian hamsters. Two of these agents, 22A-H and ME7-H, caused TSEs with indistinguishable clinical symptoms, neuropathological changes, and electrophoretic mobilities and glycosylation patterns of PrP27-30. However, FT-IR spectroscopy revealed that PrP27-30 of all four isolates featured different characteristics in the secondary structure, allowing a clear distinction between the passaged TSE agents. FT-IR analysis showed that phenotypic information is mirrored in beta-sheet and other secondary structure elements of PrP27-30, also in cases where immunobiochemical typing failed to detect structural differences. If the findings of this study hold true for nonexperimental TSEs in animals and humans, FT-IR characterization of PrP27-30 may provide a versatile tool for molecular strain typing without antibodies and without restrictions to specific TSEs or mammalian species.	Robert Koch Inst, D-13353 Berlin, Germany	Robert Koch Institute	Beekes, M (corresponding author), Robert Koch Inst, P26,Nordufer 20, D-13353 Berlin, Germany.	BeekesM@rki.de	Beekes, Michael/S-1975-2018; Spassov, Sashko/C-2105-2013	Beekes, Michael/0000-0002-6454-6657; Spassov, Sashko/0000-0002-3585-3682				BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; Baron TGM, 1999, J CLIN MICROBIOL, V37, P3701, DOI 10.1128/JCM.37.11.3701-3704.1999; Baron TGM, 2000, NEUROSCI LETT, V284, P175, DOI 10.1016/S0304-3940(00)01047-8; BEEKES M, 1995, J GEN VIROL, V76, P2567, DOI 10.1099/0022-1317-76-10-2567; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Biacabe AG, 2004, EMBO REP, V5, P110, DOI 10.1038/sj.embor.7400054; Bradshaw R., 2004, P 11 ACM C COMP COMM, P146, DOI DOI 10.1145/1030083.1030104; Bruce ME, 2003, BRIT MED BULL, V66, P99, DOI 10.1093/bmb/66.1.99; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Cousens SN, 1999, LANCET, V353, P18, DOI 10.1016/S0140-6736(98)08062-3; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; Diringer H, 1997, INTERVIROLOGY, V40, P238, DOI 10.1159/000150553; FABIAN H, 2000, ENCY ANAL CHEM, P5779; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hope J, 1999, J GEN VIROL, V80, P1, DOI 10.1099/0022-1317-80-1-1; JACKSON M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P231, DOI 10.1016/0167-4838(91)90563-F; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Kuczius T, 1999, MOL MED, V5, P406, DOI 10.1007/BF03402129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lezmi S, 2004, J VIROL, V78, P3654, DOI 10.1128/JVI.78.7.3654-3662.2004; Lucassen R, 2003, BIOCHEMISTRY-US, V42, P4127, DOI 10.1021/bi027218d; Madec JY, 1997, ARCH VIROL, V142, P1603, DOI 10.1007/s007050050183; McBride PA, 2001, J VIROL, V75, P9320, DOI 10.1128/JVI.75.19.9320-9327.2001; Notari S, 2004, J BIOL CHEM, V279, P16797, DOI 10.1074/jbc.M313220200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Schulz-Schaeffer WJ, 2000, AM J PATHOL, V156, P51, DOI 10.1016/S0002-9440(10)64705-0; Scott MR, 1999, P NATL ACAD SCI USA, V96, P15137, DOI 10.1073/pnas.96.26.15137; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; Stack MJ, 2002, ACTA NEUROPATHOL, V104, P279, DOI 10.1007/s00401-002-0556-2; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Thuring CMA, 2004, J CLIN MICROBIOL, V42, P972, DOI 10.1128/JCM.42.3.972-980.2004; Yamada N, 1998, J AM CHEM SOC, V120, P12192, DOI 10.1021/ja981363q	48	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33847	33854		10.1074/jbc.M403730200	http://dx.doi.org/10.1074/jbc.M403730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155741	hybrid			2022-12-27	WOS:000223039700094
J	Page, MLD; Hamel, PP; Gabilly, ST; Zegzouti, H; Perea, JV; Alonso, JM; Ecker, JR; Theg, SM; Christensen, SK; Merchant, S				Page, MLD; Hamel, PP; Gabilly, ST; Zegzouti, H; Perea, JV; Alonso, JM; Ecker, JR; Theg, SM; Christensen, SK; Merchant, S			A homolog of prokaryotic thiol disulfide transporter CcdA is required for the assembly of the cytochrome b(6)f complex in Arabidopsis chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROME; ESCHERICHIA-COLI; CHLAMYDOMONAS-REINHARDTII; ALKALINE-PHOSPHATASE; GENETIC-ANALYSIS; HEME ATTACHMENT; BIOGENESIS; PROTEIN; BIOSYNTHESIS; MEMBRANE	The c-type cytochromes are defined by the occurrence of heme covalently linked to the polypeptide via thioether bonds between heme and the cysteine sulfhydryls in the CXXCH motif of apocytochrome. Maintenance of apocytochrome sulfhydryls in a reduced state is a prerequisite for covalent ligation of heme to the CXXCH motif. In bacteria, a thiol disulfide transporter and a thioredoxin are two components in a thio-reduction pathway involved in c-type cytochrome assembly. We have identified in photosynthetic eukaryotes nucleus-encoded homologs of a prokaryotic thiol disulfide transporter, CcdA, which all display an N-terminal extension with respect to their bacterial counterparts. The extension of Arabidopsis CCDA functions as a targeting sequence, suggesting a plastid site of action for CCDA in eukaryotes. Using PhoA and LacZ as topological reporters, we established that Arabidopsis CCDA is a polytopic protein with within-membrane strictly conserved cysteine residues. Insertional mutants in the Arabidopsis CCDA gene were identified, and loss-of-function alleles were shown to impair photosynthesis because of a defect in cytochrome b(6)f accumulation, which we attribute to a block in the maturation of holocytochrome f, whose heme binding domain resides in the thylakoid lumen. We postulate that plastid cytochrome c maturation requires CCDA, thioredoxin HCF164, and other molecules in a membrane-associated trans-thylakoid thiol-reducing pathway.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Salk Inst Biol Studies, Genom Anal Lab, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Davis; Salk Institute	Merchant, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.	merchant@chem.ucla.edu	Ecker, Joseph R/B-9144-2008; Alonso, Jose M/K-6826-2014	Ecker, Joseph R/0000-0001-5799-5895; Alonso, Jose M/0000-0001-7087-1571; Zegzouti, Hicham/0000-0002-0989-6195	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064584] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48350, GM64584] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JWA, 2003, J BIOL CHEM, V278, P52075, DOI 10.1074/jbc.M307196200; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Bardischewsky F, 2001, J BACTERIOL, V183, P257, DOI 10.1128/JB.183.1.257-263.2001; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Beckett CS, 2000, MOL MICROBIOL, V38, P465, DOI 10.1046/j.1365-2958.2000.02174.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Cocherel S, 1996, PLANT MOL BIOL, V30, P539, DOI 10.1007/BF00049330; Deshmukh M, 2000, MOL MICROBIOL, V35, P123, DOI 10.1046/j.1365-2958.2000.01683.x; Dreyfuss BW, 2003, J BIOL CHEM, V278, P2604, DOI 10.1074/jbc.M208652200; DREYFUSS BW, 1999, P 1 INT C PHOT, V4, P3139; Dubreucq B, 2000, PLANT J, V23, P643, DOI 10.1046/j.1365-313x.2000.00829.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; Erlendsson LS, 2003, J BIOL CHEM, V278, P17852, DOI 10.1074/jbc.M300103200; Erlendsson LS, 2002, J BACTERIOL, V184, P1423, DOI 10.1128/JB.184.5.1423-1429.2002; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Ferguson SJ, 2001, BIOCHEM SOC T, V29, P629, DOI 10.1042/0300-5127:0290629; GREVELDING C, 1993, PLANT MOL BIOL, V23, P847, DOI 10.1007/BF00021539; Gupta R, 2002, NATURE, V417, P567, DOI 10.1038/417567a; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hamel PP, 2003, J BIOL CHEM, V278, P2593, DOI 10.1074/jbc.M208651200; Hofmann NR, 2003, PLANT MOL BIOL, V53, P643, DOI 10.1023/B:PLAN.0000019065.31490.06; HOWE G, 1994, J BIOL CHEM, V269, P5824; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; Inoue K, 1997, J BIOL CHEM, V272, P31747, DOI 10.1074/jbc.272.50.31747; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Katzen F, 2003, P NATL ACAD SCI USA, V100, P10471, DOI 10.1073/pnas.1334136100; Kimball RA, 2003, J MOL MICROB BIOTECH, V5, P133, DOI 10.1159/000070263; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Kranz RG, 2002, RES MICROBIOL, V153, P1, DOI 10.1016/S0923-2508(01)01278-5; KRANZ RG, 1985, GENE, V40, P203, DOI 10.1016/0378-1119(85)90043-5; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Le Brun NE, 2000, MOL MICROBIOL, V36, P638, DOI 10.1046/j.1365-2958.2000.01883.x; Lennartz K, 2001, PLANT CELL, V13, P2539, DOI 10.1105/tpc.13.11.2539; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Lukowitz W, 2000, PLANT PHYSIOL, V123, P795, DOI 10.1104/pp.123.3.795; Martienssen RA, 1998, P NATL ACAD SCI USA, V95, P2021, DOI 10.1073/pnas.95.5.2021; Methe BA, 2003, SCIENCE, V302, P1967, DOI 10.1126/science.1088727; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Monika EM, 1997, J MOL BIOL, V271, P679, DOI 10.1006/jmbi.1997.1227; Nakamoto SS, 2000, BIOCHIMIE, V82, P603, DOI 10.1016/S0300-9084(00)00605-2; Nakamura Y, 2003, DNA RES, V10, P137, DOI 10.1093/dnares/10.4.137; NUNBERG JH, 1980, CELL, V19, P355, DOI 10.1016/0092-8674(80)90510-3; O'Brian MR, 2002, ADV MICROB PHYSIOL, V46, P257, DOI 10.1016/S0065-2911(02)46006-7; Ortenberg R, 2003, ANTIOXID REDOX SIGN, V5, P403, DOI 10.1089/152308603768295140; PAGE MD, 1989, MOL MICROBIOL, V3, P653, DOI 10.1111/j.1365-2958.1989.tb00213.x; Pollock MA, 1999, BIOTECHNIQUES, V26, P254, DOI 10.2144/99262bm16; Quinn JM, 1998, METHOD ENZYMOL, V297, P263; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SARSERO JP, 1995, J BACTERIOL, V177, P297, DOI 10.1128/jb.177.2.297-306.1995; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Schiott T, 1997, J BACTERIOL, V179, P1962, DOI 10.1128/jb.179.6.1962-1973.1997; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; Tabata S, 2000, NATURE, V408, P823, DOI 10.1038/35048507; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Tissier C, 2002, EUR J BIOCHEM, V269, P3131, DOI 10.1046/j.1432-1033.2002.02943.x; Weigel M, 2003, TRENDS PLANT SCI, V8, P513, DOI 10.1016/j.tplants.2003.09.009; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Xie ZY, 1996, J BIOL CHEM, V271, P4632; Xie ZY, 1998, GENETICS, V148, P681	71	75	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32474	32482		10.1074/jbc.M404285200	http://dx.doi.org/10.1074/jbc.M404285200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159384	hybrid			2022-12-27	WOS:000222849700061
J	Rosenkilde, MM; McLean, KA; Holst, PJ; Schwartz, TW				Rosenkilde, MM; McLean, KA; Holst, PJ; Schwartz, TW			The CXC chemokine receptor encoded by herpesvirus saimiri, ECRF3, shows ligand-regulated signaling through G(i), G(q), and G(12/13) proteins but constitutive signaling only through G(i) and G(12/13) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; NF-KAPPA-B; GRANULOCYTE CHEMOTACTIC PROTEIN-2; COUPLED RECEPTOR; INVERSE AGONISTS; INTERFERON-GAMMA; IL-8 RECEPTORS; ACTIVATION; INTERLEUKIN-8; IDENTIFICATION	Open reading frame 74 (ORF74) of many gamma(2)-herpesviruses encodes a CXC chemokine receptor. The molecular pharmacological profile of ORF74 from herpesvirus saimiri, ECRF3, is characterized here and compared with that of the well known ORF74 from human herpesvirus 8 (HHV8). The ECRF3 receptor bound the so-called ELR (Glu-Leu-Arg) CXC chemokines I-125-CXCL1/GROalpha, I-125-CXCL6/GCP-2, and I-125-CXCL8/interleukin-8 with high affinity; but in contrast to ORF74 from HHV8, it did not bind the non-ELR CXC chemokine I-125-CXCL10/IP10. Interestingly, the B-max value for CXCL6/GCP-2 was 3-fold higher than the capacity for maximal binding of CXCL1/GROalpha to ECRF3 and 85-fold higher than that of CXCL8/interleukin-8, despite similar affinities. Like ORF74 from HHV8, ECRF3 activated a broad range of pathways (G(q), G(i), and G(12/13) as well as the cAMP response element-binding protein, NF-kappaB, NFAT, and serum response element transcription factors) in a ligand-regulated manner, with CXCL6/GCP-2 being the most potent and efficacious agonist. ECRF3 signaled constitutively through G(i) and G(12/13), but surprisingly not through G(q). At the level of transcription factor activation, the serum response element was activated constitutively by ECRF3, whereas cAMP response element-binding protein, NFAT, and NF-kappaB were only ligand-regulated. The maximal signaling capacities were similar for the two receptors; however, the ligand-regulated signaling was responsible for the major part of the total ECRF3 signaling and only for a minor part of the total HHV8 ORF74 signaling. The activation pattern of ECRF3 with constitutive activation of some ( but not all) of the employed pathways has not been seen before in endogenous or virus-encoded chemokine receptors. The results suggest that the unique ligand selectivity of ECRF3 among ORF74 receptors could reflect differences in the cellular tropism of the gamma(2)-herpesviruses.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Rosenkilde, MM (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, Bldg 18-6,Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	rosenkilde@molpharm.dk		Holst, Peter Johannes/0000-0002-1279-304X; Schwartz, Thue W./0000-0002-0261-6904; Rosenkilde, Mette Marie/0000-0001-9600-3254				Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Alewijnse AE, 1998, J NEUROCHEM, V71, P799; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Casarosa P, 2003, J BIOL CHEM, V278, P50010, DOI 10.1074/jbc.M306530200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen G, 1999, J PHARMACOL TOX MET, V42, P199, DOI 10.1016/S1056-8719(00)00075-7; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Feniger-Barish R, 1999, CYTOKINE, V11, P996, DOI 10.1006/cyto.1999.0510; Feniger-Barish R, 2000, BLOOD, V95, P1551, DOI 10.1182/blood.V95.5.1551.005a36_1551_1559; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GAO JL, 1994, J BIOL CHEM, V269, P28539; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Hill Stephen J., 2001, Current Opinion in Pharmacology, V1, P526, DOI 10.1016/S1471-4892(01)00091-1; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lee BJ, 2003, J IMMUNOL, V170, P243, DOI 10.4049/jimmunol.170.1.243; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Liu Bo, 2003, V237, P145; Liu YQ, 2004, FASEB J, V18, P457, DOI 10.1096/fj.03-0948com; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Moorman NJ, 2003, VIROLOGY, V307, P179, DOI 10.1016/S0042-6822(02)00023-5; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Rabin RL, 1999, J IMMUNOL, V162, P3840; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; ROSENKILDE MM, 2004, HDB CELL SIGNALING; SCHWARTZ TW, 2003, TXB RECEPTOR PHARM, P81; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Sodhi A, 2000, CANCER RES, V60, P4873; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Verzijl D, 2004, J VIROL, V78, P3343, DOI 10.1128/JVI.78.7.3343-3351.2004; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Wolf M, 1998, EUR J IMMUNOL, V28, P164, DOI 10.1002/(SICI)1521-4141(199801)28:01<164::AID-IMMU164>3.0.CO;2-S; Wong SKF, 2003, NEUROSIGNALS, V12, P1, DOI 10.1159/000068914; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1992, J BIOL CHEM, V267, P1811; Wuyts A, 1998, EUR J BIOCHEM, V255, P67, DOI 10.1046/j.1432-1327.1998.2550067.x; Wuyts A, 2003, LAB INVEST, V83, P23, DOI 10.1097/01.LAB.0000048719.53282.00; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	68	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32524	32533		10.1074/jbc.M313392200	http://dx.doi.org/10.1074/jbc.M313392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155729	hybrid			2022-12-27	WOS:000222849700067
J	Toogood, HS; van Thiel, A; Basran, J; Sutcliffe, MJ; Scrutton, NS; Leys, D				Toogood, HS; van Thiel, A; Basran, J; Sutcliffe, MJ; Scrutton, NS; Leys, D			Extensive domain motion and electron transfer in the human electron transferring flavoprotein center dot medium chain acyl-CoA dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ACID BETA-OXIDATION; MOLECULAR PATHOGENESIS; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; CROSS-LINKING; DEFICIENCY; MUTATIONS; GENE	The crystal structure of the human electron transferring flavoprotein (ETF).medium chain acyl-CoA dehydrogenase ( MCAD) complex reveals a dual mode of protein-protein interaction, imparting both specificity and promiscuity in the interaction of ETF with a range of structurally distinct primary dehydrogenases. ETF partitions the functions of partner binding and electron transfer between (i) the recognition loop, which acts as a static anchor at the ETF.MCAD interface, and (ii) the highly mobile redox active FAD domain. Together, these enable the FAD domain of ETF to sample a range of conformations, some compatible with fast interprotein electron transfer. Disorders in amino acid or fatty acid catabolism can be attributed to mutations at the protein-protein interface. Crucially, complex formation triggers mobility of the FAD domain, an induced disorder that contrasts with general models of protein-protein interaction by induced fit mechanisms. The subsequent interfacial motion in the MCAD.ETF complex is the basis for the interaction of ETF with structurally diverse protein partners. Solution studies using ETF and MCAD with mutations at the protein-protein interface support this dynamic model and indicate ionic interactions between MCAD Glu(212) and ETF Argalpha(249) are likely to transiently stabilize productive conformations of the FAD domain leading to enhanced electron transfer rates between both partners.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Leys, D (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	dl37@le.ac.uk		Toogood, Helen/0000-0003-4797-0293; Sutcliffe, Mike/0000-0003-0414-1700				Bartlett K, 2004, EUR J BIOCHEM, V271, P462, DOI 10.1046/j.1432-1033.2003.03947.x; BECKMANN JD, 1983, J BIOL CHEM, V258, P7563; Busquets C, 2000, PEDIATR RES, V48, P315, DOI 10.1203/00006450-200009000-00009; Busquets C, 2000, MOL GENET METAB, V71, P535, DOI 10.1006/mgme.2000.3082; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; Chohan KK, 2001, J BIOL CHEM, V276, P34142, DOI 10.1074/jbc.M101341200; Collins ES, 2002, J MOL BIOL, V318, P787, DOI 10.1016/S0022-2836(02)00036-0; Corydon MJ, 2001, PEDIATR RES, V49, P18; Curcoy A, 2003, MOL GENET METAB, V78, P247, DOI 10.1016/S1096-7192(03)00024-6; DWYER TM, 1997, BIOCHIM BIOPHYS ACTA, V1433, P139; Feng CJ, 2002, BIOCHEMISTRY-US, V41, P5816, DOI 10.1021/bi016059f; FRERMAN FE, 1980, J BIOL CHEM, V255, P2199; Goodman SI, 2002, MOL GENET METAB, V77, P86, DOI 10.1016/S1096-7192(02)00138-5; Gregersen N, 1998, HUM MOL GENET, V7, P619, DOI 10.1093/hmg/7.4.619; Gregersen N, 2004, EUR J BIOCHEM, V271, P470, DOI 10.1046/j.1432-1033.2003.03949.x; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Gutierrez A, 2002, BIOCHEMISTRY-US, V41, P4626, DOI 10.1021/bi0159433; Hoard-Fruchey HM, 2004, J BIOL CHEM, V279, P13786, DOI 10.1074/jbc.M313914200; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; Jacobs DM, 2003, J BIOL CHEM, V278, P26174, DOI 10.1074/jbc.M300796200; Kim JJP, 2004, EUR J BIOCHEM, V271, P483, DOI 10.1046/j.1432-1033.2003.03948.x; Kim JJP, 2002, CURR OPIN STRUC BIOL, V12, P721, DOI 10.1016/S0959-440X(02)00390-1; Knofel T, 2001, J MOL BIOL, V309, P255, DOI 10.1006/jmbi.2001.4657; Koeller DM, 2002, HUM MOL GENET, V11, P347, DOI 10.1093/hmg/11.4.347; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; Leys D, 2003, EMBO J, V22, P4038, DOI 10.1093/emboj/cdg395; Liu JF, 2002, J MOL BIOL, V322, P53, DOI 10.1016/S0022-2836(02)00736-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OKAMURAIKEDA K, 1985, J BIOL CHEM, V260, P1338; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; Parker AR, 2003, MOL CELL BIOCHEM, V254, P91, DOI 10.1023/A:1027349303797; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; Salazar D, 1997, J BIOL CHEM, V272, P26425, DOI 10.1074/jbc.272.42.26425; STEENKAMP DJ, 1988, BIOCHEM J, V255, P869, DOI 10.1042/bj2550869; STEENKAMP DJ, 1987, BIOCHEM J, V243, P519, DOI 10.1042/bj2430519; Takusa Y, 2002, MOL GENET METAB, V75, P227, DOI 10.1006/mgme.2002.3297; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	48	75	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32904	32912		10.1074/jbc.M404884200	http://dx.doi.org/10.1074/jbc.M404884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159392	hybrid			2022-12-27	WOS:000222849700110
J	Chen, XM; Splinter, PL; Tietz, PS; Huang, BQ; Billadeau, DD; LaRusso, NF				Chen, XM; Splinter, PL; Tietz, PS; Huang, BQ; Billadeau, DD; LaRusso, NF			Phosphatidylinositol 3-kinase and frabin mediate Cryptosporidium parvum cellular invasion via activation of Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; SMALL G-PROTEIN; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; MICROSPIKE FORMATION; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; BINDING; BILIARY; RAC	Cryptosporidium parvum invades target epithelia via a mechanism that involves host cell actin reorganization. We previously demonstrated that C. parvum activates the Cdc42/neural Wiskott-Aldrich syndrome protein network in host cells resulting in actin remodeling at the host cell-parasite interface, thus facilitating C. parvum cellular invasion. Here, we tested the role of phosphatidylinositol 3-kinase (PI3K) and frabin, a guanine nucleotide exchange factor specific for Cdc42 in the activation of Cdc42 during C. parvum infection of biliary epithelial cells. We found that C. parvum infection of cultured human biliary epithelial cells induced the accumulation of PI3K at the host cell-parasite interface and resulted in the activation of PI3K in infected cells. Frabin also was recruited to the host cell-parasite interface, a process inhibited by two PI3K inhibitors, wortmannin and LY294002. The cellular expression of either a dominant negative mutant of PI3K (PI3K-Deltap85) or functionally deficient mutants of frabin inhibited C. parvum-induced Cdc42 accumulation at the host cell-parasite interface. Moreover, LY294002 abolished C. parvum-induced Cdc42 activation in infected cells. Inhibition of PI3K by cellular overexpression of PI3K-Deltap85 or by wortmannin or LY294002, as well as inhibition of frabin by various functionally deficient mutants, decreased C. parvum-induced actin accumulation and inhibited C. parvum cellular invasion. In contrast, the overexpression of the p85 subunit of PI3K promoted C. parvum invasion. Our data suggest that an important component of the complex process of C. parvum invasion of target epithelia results from the ability of the organism to trigger host cell PI3K/frabin signaling to activate the Cdc42 pathway, resulting in host cell actin remodeling at the host cell-parasite interface.	Mayo Med Sch Clin & Fdn, Div Gastroenterol & Hepatol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Med Sch Clin & Fdn, Dept Immunol, Div Oncol Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	LaRusso, NF (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.	larusso.nicholas@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024031, R37DK024031, R01DK057993] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK24031, DK57993] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen XM, 2000, GASTROENTEROLOGY, V118, P368, DOI 10.1016/S0016-5085(00)70219-8; Chen XM, 2004, INFECT IMMUN, V72, P3011, DOI 10.1128/IAI.72.5.3011-3021.2004; Chen XM, 2002, NEW ENGL J MED, V346, P1723, DOI 10.1056/NEJMra013170; Chen XM, 2003, GASTROENTEROLOGY, V125, P216, DOI 10.1016/S0016-5085(03)00662-0; Clark DP, 1999, CLIN MICROBIOL REV, V12, P554, DOI 10.1128/CMR.12.4.554; Coombes BK, 2002, CELL MICROBIOL, V4, P447, DOI 10.1046/j.1462-5822.2002.00203.x; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Elliott DA, 2001, INFECT IMMUN, V69, P5940, DOI 10.1128/IAI.69.9.5940-5942.2001; Elliott DA, 2000, INFECT IMMUN, V68, P2315, DOI 10.1128/IAI.68.4.2315-2322.2000; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Forney JR, 1999, INFECT IMMUN, V67, P844, DOI 10.1128/IAI.67.2.844-852.1999; GRUBMAN SA, 1994, AM J PHYSIOL, V266, pG1060, DOI 10.1152/ajpgi.1994.266.6.G1060; Gruenheid S, 2003, NATURE, V422, P775, DOI 10.1038/nature01603; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Ikeda W, 2001, ONCOGENE, V20, P3457, DOI 10.1038/sj.onc.1204463; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Jackson TR, 1996, J CELL SCI, V109, P289; Kwok T, 2002, INFECT IMMUN, V70, P2108, DOI 10.1128/IAI.70.4.2108-2120.2002; Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002-220682; Martinez JJ, 2002, CELL MICROBIOL, V4, P19, DOI 10.1046/j.1462-5822.2002.00166.x; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tzipori S, 1998, ADV PARASIT, V40, P5, DOI 10.1016/S0065-308X(08)60116-5; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; Wilkowsky SE, 2001, EXP CELL RES, V264, P211, DOI 10.1006/excr.2000.5123; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	39	46	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31671	31678		10.1074/jbc.M401592200	http://dx.doi.org/10.1074/jbc.M401592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133042	hybrid			2022-12-27	WOS:000222726800092
J	Golabek, AA; Wujek, P; Walus, M; Bieler, S; Soto, C; Wisniewski, KE; Kida, E				Golabek, AA; Wujek, P; Walus, M; Bieler, S; Soto, C; Wisniewski, KE; Kida, E			Maturation of human tripeptidyl-peptidase I in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PEPSTATIN-INSENSITIVE PROTEINASE; HUMAN PROCATHEPSIN-B; LYSOSOMAL PH; GENE-PRODUCT; CELLS; ACIDIFICATION; PROPEPTIDE; ENZYMES; CLN2	Tripeptidyl-peptidase I (TPP I, CLN2 protein) is a lysosomal aminopeptidase that cleaves off tripeptides from the free N termini of oligopeptides and also shows minor endopeptidase activity. TPP I is synthesized as a preproenzyme. Its proenzyme autoactivates under acidic conditions in vitro, resulting in a rapid conversion into the mature form. In this study, we examined the process of maturation in vitro of recombinant latent human TPP I purified to homogeneity from secretions of Chinese hamster ovary cells overexpressing TPP I cDNA. Autoprocessing of TPP I proenzyme was carried out at a wide pH range, from similar to 2.0 to 6.0, albeit with different efficiencies depending on the pH and the type of buffer. However, the acquisition of enzymatic activity in the same buffer took place in a narrower pH "window," usually in the range of 3.6 - 4.2. N-terminal sequencing revealed that mature, inactive enzyme generated during autoactivation at higher pH contained N-terminal extensions ( starting at 6 and 14 amino acid residues upstream of the prosegment/mature enzyme junction), which could contribute to the lack of activity of TPP I generated in this manner. Autoprocessing was not associated with any major changes of the secondary structure of the proenzyme, as revealed by CD spectroscopy. Both the activation and proteolytic processing of the recombinant TPP I precursor were primarily concentration-independent. The addition of the mature enzyme did not accelerate the processing of the proenzyme. In addition, the maturation of the proenzyme was not affected by the presence of glycerol. Finally, the proenzyme with the active site mutated (S475L) was not processed in the presence of the wild-type enzyme. All of these findings indicate a primarily intramolecular (unimolecular) mechanism of TPP I activation and autoprocessing and suggest that in vivo mature enzyme does not significantly participate in its own generation from the precursor.	New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA; Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA	Institute for Basic Research in Developmental Disabilities; University of Texas System; University of Texas Medical Branch Galveston	Golabek, AA (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	a.golabek@att.net						Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BUTOR C, 1995, J CELL SCI, V108, P2213; Chen CS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-21; Comellas-Bigler M, 2002, STRUCTURE, V10, P865, DOI 10.1016/S0969-2126(02)00772-4; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; Golabek AA, 2003, J BIOL CHEM, V278, P7135, DOI 10.1074/jbc.M211872200; Golabek AA, 2000, MOL GENET METAB, V70, P203, DOI 10.1006/mgme.2000.3006; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu ZX, 1996, J BIOL CHEM, V271, P3375; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; Junaid MA, 2000, J NEUROCHEM, V74, P287, DOI 10.1046/j.1471-4159.2000.0740287.x; Junaid MA, 2000, INT J BIOL MARKER, V15, P129, DOI 10.1177/172460080001500201; Khan AR, 1998, PROTEIN SCI, V7, P815; Kida E, 2001, ADV GENET, V45, P35, DOI 10.1016/S0065-2660(01)45003-6; Kida E, 2001, J NEUROPATH EXP NEUR, V60, P280, DOI 10.1093/jnen/60.3.280; Kurachi Y, 2001, ACTA NEUROPATHOL, V102, P20; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; Li YY, 1996, J MOL BIOL, V262, P591, DOI 10.1006/jmbi.1996.0537; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Liu CG, 1998, GENOMICS, V50, P206, DOI 10.1006/geno.1998.5328; MACH L, 1994, J BIOL CHEM, V269, P13030; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MONTCOURRIER P, 1994, J CELL SCI, V107, P2381; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; TAKEDAEZAKI M, 1993, ARCH BIOCHEM BIOPHYS, V304, P352, DOI 10.1006/abbi.1993.1361; Tomkinson B, 1999, TRENDS BIOCHEM SCI, V24, P355, DOI 10.1016/S0968-0004(99)01435-8; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; VANDYKE RW, 1992, BIOCHEM BIOPH RES CO, V184, P300, DOI 10.1016/0006-291X(92)91192-S; Vergne I, 1998, ANAL BIOCHEM, V255, P127, DOI 10.1006/abio.1997.2466; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Wisniewski K E, 2001, Eur J Paediatr Neurol, V5 Suppl A, P73, DOI 10.1053/ejpn.2000.0439; Wisniewski KE, 2001, ADV GENET, V45, P1, DOI 10.1016/S0065-2660(01)45002-4; Wisniewski KE, 1999, MOL GENET METAB, V66, P248, DOI 10.1006/mgme.1999.2814; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wlodawer A, 2001, NAT STRUCT BIOL, V8, P442, DOI 10.1038/87610; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	47	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31058	31067		10.1074/jbc.M400700200	http://dx.doi.org/10.1074/jbc.M400700200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143070	hybrid			2022-12-27	WOS:000222726800020
J	Jeon, HK; Jin, HS; Lee, DH; Choi, WS; Moon, CK; Oh, YJ; Lee, TH				Jeon, HK; Jin, HS; Lee, DH; Choi, WS; Moon, CK; Oh, YJ; Lee, TH			Proteome analysis associated with cadmium adaptation in U937 cells - Identification of calbindin-D-28k as a secondary cadmium-responsive protein that confers resistance to cadmium-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; EPITHELIAL-CELLS; OXIDANT RESISTANCE; BINDING PROTEIN; PC12 CELLS; EXPRESSION; DEATH; EXPOSURE; INHIBITION; ACTIVATION	Cadmium is a well known environmental toxicant and carcinogen. To identify proteins involved in cellular adaptive responses to cadmium, we established cadmium-adapted U937 cells that exhibit resistance to cadmium-induced apoptosis, and we performed comparative proteome analysis of these cells with parental cells that were either untreated or treated with cadmium. Newly identified proteins that were changed in expression level in both adapted cells and cadmium-treated parental cells included proteins implicated in cell proliferation and malignant transformation. Most interesting, a calcium-binding protein calbindin-D-28k was increased only in the adapted cells but not in cadmium-exposed parental cells. The level of calbindin-D-28k increased by the degree of cadmium adaptation and was stably maintained without selective pressure of cadmium. Cadmium-adapted U937 cells were resistant to the toxic effects of cytosolic calcium rise by cadmium treatment and by depletion of intracellular calcium stores, suggesting that enhanced calcium buffering by up-regulated calbindin-D-28k may be responsible for acquiring resistance to cadmium-induced apoptosis. We demonstrated that overexpression of calbindin-D-28k in MN9D neuronal cells resulted in reduced cadmium-induced apoptosis. Our study documents for the first time that cells respond to long term cadmium exposure by increasing calbindin-D-28k expression, thereby attenuating cadmium-induced apoptosis.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea; Seoul Natl Univ, Coll Pharm, Seoul 110799, South Korea	Yonsei University; Yonsei University; Seoul National University (SNU)	Lee, TH (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, 134 Shinchon Dong, Seoul 120749, South Korea.	thlee@yonsei.ac.kr		jin, hyung-seung/0000-0002-3186-3488				Achanzar WE, 2002, PROSTATE, V52, P236, DOI 10.1002/pros.10106; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Castro CY, 2000, MODERN PATHOL, V13, P808, DOI 10.1038/modpathol.3880141; Choi WS, 2001, BIOCHEM BIOPH RES CO, V287, P656, DOI 10.1006/bbrc.2001.5649; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; ELAZZOUZI B, 1994, TOXICOLOGY, V88, P127; Eneman JD, 2000, TOXICOLOGY, V147, P215, DOI 10.1016/S0300-483X(00)00215-8; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Habeebu SSM, 1998, TOXICOL APPL PHARM, V149, P203, DOI 10.1006/taap.1997.8334; Hampton MB, 1996, FEBS LETT, V399, P277, DOI 10.1016/S0014-5793(96)01341-5; HART BA, 1995, TOXICOLOGY, V98, P1, DOI 10.1016/0300-483X(94)02949-U; Hart BA, 1995, TOXICOL LETT, V81, P131, DOI 10.1016/0378-4274(95)03417-X; Hart BA, 1999, TOXICOLOGY, V133, P43, DOI 10.1016/S0300-483X(99)00013-X; INGERSOLL RJ, 1971, J BIOL CHEM, V246, P2808; Ishido Masami, 1995, Life Sciences, V56, P351; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Joseph P, 2001, TOXICOL SCI, V61, P295, DOI 10.1093/toxsci/61.2.295; Joseph P, 2002, CANCER RES, V62, P703; Joseph P, 2002, J BIOL CHEM, V277, P6131, DOI 10.1074/jbc.M109373200; Kanthasamy AG, 1995, TOXICOL LETT, V81, P151, DOI 10.1016/0378-4274(95)03425-0; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kim MS, 2000, TOXICOLOGY, V145, P27, DOI 10.1016/S0300-483X(99)00176-6; Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200; Lopez E, 2003, BRIT J PHARMACOL, V138, P901, DOI 10.1038/sj.bjp.0705111; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; McMahon A, 1998, MOL BRAIN RES, V54, P56, DOI 10.1016/S0169-328X(97)00305-7; Misra UK, 2003, CELL SIGNAL, V15, P1059, DOI 10.1016/S0898-6568(03)00117-7; Misra UK, 2002, CELL SIGNAL, V14, P327, DOI 10.1016/S0898-6568(01)00268-6; MORSELT AFW, 1991, TOXICOLOGY, V70, P1; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, P1; PETERS JM, 1995, TOXICOLOGY, V99, P11, DOI 10.1016/0300-483X(94)02989-8; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; Rabinovitch A, 2001, ENDOCRINOLOGY, V142, P3649, DOI 10.1210/en.142.8.3649; Rintoul GL, 2001, CELL CALCIUM, V29, P277, DOI 10.1054/ceca.2000.0190; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Shen HM, 2001, TOXICOL APPL PHARM, V171, P12, DOI 10.1006/taap.2000.9092; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tsangaris GT, 1998, TOXICOLOGY, V128, P143, DOI 10.1016/S0300-483X(98)00032-8; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; Waisberg M, 2003, TOXICOLOGY, V192, P95, DOI 10.1016/S0300-483X(03)00305-6; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; Wright JL, 2003, EUR RESPIR J, V22, P77, DOI 10.1183/09031936.03.00095703; Xu CY, 1996, TOXICOLOGY, V107, P1, DOI 10.1016/0300-483X(95)03195-L	49	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31575	31583		10.1074/jbc.M400823200	http://dx.doi.org/10.1074/jbc.M400823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152011	hybrid			2022-12-27	WOS:000222726800080
J	Rocheleau, JV; Head, WS; Piston, DW				Rocheleau, JV; Head, WS; Piston, DW			Quantitative NAD(P)H/flavoprotein autofluorescence imaging reveals metabolic mechanisms of pancreatic islet pyruvate response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED ANAPLEROSIS; STIMULATED INSULIN-SECRETION; RAT-LIVER MITOCHONDRIA; BETA-CELLS; FLUORESCENT FLAVOPROTEINS; METHYL PYRUVATE; MALONYL-COA; DEHYDROGENASE; SHUTTLE; NADH	Glucose-stimulated insulin secretion is a multistep process dependent on beta-cell metabolic flux. Our previous studies on intact pancreatic islets used two-photon NAD(P)H imaging as a quantitative measure of the combined redox signal from NADH and NADPH ( referred to as NAD( P) H). These studies showed that pyruvate, a non-secretagogue, enters beta-cells and causes a transient rise in NAD( P) H. To further characterize the metabolic fate of pyruvate, we have now developed one-photon flavoprotein microscopy as a simultaneous assay of lipoamide dehydrogenase (LipDH) autofluorescence. This flavoprotein is in direct equilibrium with mitochondrial NADH. Hence, a comparison of LipDH and NAD( P) H autofluorescence provides a method to distinguish the production of NADH, NADPH, or both. Using this method, the glucose dose response is consistent with an increase in both NADH and NADPH. In contrast, the transient rise in NAD( P) H observed with pyruvate stimulation is not accompanied by a significant change in LipDH, which indicates that pyruvate raises cellular NADPH without raising NADH. In comparison, methyl pyruvate stimulated a robust NADH and NADPH response. These data provide new evidence that exogenous pyruvate does not induce a significant rise in mitochondrial NADH. This inability likely results in its failure to produce the ATP necessary for stimulated secretion of insulin. Overall, these data are consistent with either a restricted pyruvate dehydrogenase-dependent metabolism or a buffering of the NADH response by other metabolic mechanisms.	Vanderbilt Univ, Nashville, TN 37232 USA	Vanderbilt University	Piston, DW (corresponding author), Vanderbilt Univ, 702 Light Hall, Nashville, TN 37232 USA.	David.Piston@vanderbilt.edu		Rocheleau, Jonathan/0000-0002-1760-2564	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK059737, R01DK053434] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59737, DK53434] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkhammar Per O. G., 1998, Methods in Cell Science, V19, P255, DOI 10.1023/A:1009712630494; Bennett BD, 1996, J BIOL CHEM, V271, P3647; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; CHANCE B, 1979, J BIOL CHEM, V254, P4764; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Dufer M, 2002, BIOCHEM J, V368, P817, DOI 10.1042/BJ20020657; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; HALL CL, 1975, J BIOL CHEM, V250, P3476; HASSINEN I, 1968, BIOCHEM BIOPH RES CO, V31, P895, DOI 10.1016/0006-291X(68)90536-6; Huang SH, 2002, BIOPHYS J, V82, P2811, DOI 10.1016/S0006-3495(02)75621-X; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; KUNZ WS, 1986, FEBS LETT, V195, P92, DOI 10.1016/0014-5793(86)80137-5; KUNZ WS, 1993, BIOCHEM MED METAB B, V50, P103, DOI 10.1006/bmmb.1993.1051; KUNZ WS, 1985, BIOCHIM BIOPHYS ACTA, V841, P237, DOI 10.1016/0304-4165(85)90064-9; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1993, METABOLISM, V42, P1229, DOI 10.1016/0026-0495(93)90118-8; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MAEDAYORITA K, 1984, J BIOCHEM-TOKYO, V96, P683, DOI 10.1093/oxfordjournals.jbchem.a134886; Malaisse WJ, 1996, ARCH BIOCHEM BIOPHYS, V335, P229, DOI 10.1006/abbi.1996.0504; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PATEL MS, 1995, METHOD ENZYMOL, V252, P186; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; PEUHKURINEN KJ, 1983, BIOCHEM J, V210, P193, DOI 10.1042/bj2100193; Piston DW, 1999, METHOD CELL BIOL, V58, P31; Piston DW, 1999, METHOD ENZYMOL, V307, P351; Ramirez R, 1996, BBA-BIOENERGETICS, V1273, P263, DOI 10.1016/0005-2728(95)00156-5; Rocheleau JV, 2002, J BIOL CHEM, V277, P30914, DOI 10.1074/jbc.M202314200; SCHARP DW, 1973, TRANSPLANTATION, V16, P686, DOI 10.1097/00007890-197312000-00028; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; VOLTTI H, 1978, Journal of Bioenergetics and Biomembranes, V10, P45, DOI 10.1007/BF00743226; Wagnieres GA, 1998, PHOTOCHEM PHOTOBIOL, V68, P603; Zhang QH, 2002, SCIENCE, V295, P1895	38	159	161	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31780	31787		10.1074/jbc.M314005200	http://dx.doi.org/10.1074/jbc.M314005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148320	hybrid			2022-12-27	WOS:000222726800104
J	Singh, CR; He, H; Ii, M; Yamamoto, Y; Asano, K				Singh, CR; He, H; Ii, M; Yamamoto, Y; Asano, K			Efficient incorporation of eukaryotic initiation factor 1 into the multifactor complex is critical for formation of functional ribosomal preinitiation complexes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; YEAST; SUBUNITS; EIF5; RNA; BINDING; PROTEIN; RECOGNITION; ROLES	Eukaryotic initiation factor 1 (eIF1) is a low molecular weight factor critical for stringent AUG selection in eukaryotic translation. It is recruited to the 43 S complex in the multifactor complex (MFC) with eIF2, eIF3, and eIF5 via multiple interactions with the MFC constituents. Here we show that FLAG epitope tagging of eIF1 at either terminus abolishes its in vitro interactions with eIF5 and eIF2beta but not that with eIF3c. Nevertheless, both forms of FLAG-eIF1 fail to bind eIF3 and are incorporated into the 43 S complex inefficiently in vivo. C-terminal FLAG tagging of eIF1 is lethal; overexpression of C-terminal FLAG-eIF1 severely impedes 43 S complex formation and derepresses GCN4 translation due to limiting of eIF2 . GTP . Met-tRNA(i)(Met) ternary complex binding to the ribosome. Furthermore, N-terminal FLAG-eIF1 overexpression reduces eIF2 binding to the ribosome and moderately derepresses GCN4 translation. Our results provide the first in vivo evidence that eIF1 plays an important role in promoting 43 S complex formation as a core of factor interactions. We propose that the coordinated recruitment of eIF1 to the 40 S ribosome in the MFC is critical for the production of functional 40 S preinitiation complex.	Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Manhattan, KS 66506 USA	Kansas State University	Asano, K (corresponding author), Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Ackert Hall, Manhattan, KS 66506 USA.	kasano@ksu.edu			NCRR NIH HHS [1 P20 RR15563] Funding Source: Medline; NIGMS NIH HHS [R01GM64781] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064781] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 2002, METHOD ENZYMOL, V351, P221; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; He H, 2003, MOL CELL BIOL, V23, P5431, DOI 10.1128/MCB.23.15.5431-5445.2003; HE H, 2003, THESIS KANSAS STATE; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Maag D, 2003, J MOL BIOL, V330, P917, DOI 10.1016/S0022-2836(03)00665-X; Majumdar R, 2003, J BIOL CHEM, V278, P6580, DOI 10.1074/jbc.M210357200; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; Qiu HF, 2000, MOL CELL BIOL, V20, P2505, DOI 10.1128/MCB.20.7.2505-2516.2000; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS A, 1980, FEBS LETT, V116, P67, DOI 10.1016/0014-5793(80)80530-8; Valasek L, 2003, GENE DEV, V17, P786, DOI 10.1101/gad.1065403; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; von der Haar T, 2002, MOL MICROBIOL, V46, P531, DOI 10.1046/j.1365-2958.2002.03172.x; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	31	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31910	31920		10.1074/jbc.M313940200	http://dx.doi.org/10.1074/jbc.M313940200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145951	hybrid			2022-12-27	WOS:000222726800118
J	Bouhss, A; Crouvoisier, M; Blanot, D; Mengin-Lecreulx, D				Bouhss, A; Crouvoisier, M; Blanot, D; Mengin-Lecreulx, D			Purification and characterization of the bacterial MraY translocase catalyzing the first membrane step of peptidoglycan biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLMURAMYL-PENTAPEPTIDE-TRANSLOCASE; ESCHERICHIA-COLI; OVER-PRODUCTION; D-GLUTAMATE; L-ALANINE; GENE; TUNICAMYCIN; TRANSFERASE; INHIBITION; PHOSPHATE	The MraY translocase catalyzes the first membrane step of bacterial cell wall peptidoglycan synthesis (i.e. the transfer of the phospho-N-acetylmuramoyl-pentapeptide motif onto the undecaprenyl phosphate carrier lipid), a reversible reaction yielding undecaprenyl-pyrophosphoryl-N-acetylmuramoyl-pentapeptide ( lipid intermediate I). This essential integral membrane protein, which is considered as a very promising target for the search of new antibacterial compounds, has thus far been clearly underexploited due to its intrinsic refractory nature to overexpression and purification. We here report conditions for the high level overproduction and for the first time the purification to homogeneity of milligram quantities of MraY protein. The kinetic parameters and effects of pH, salts, cations, and detergents on enzyme activity are described, taking the Bacillus subtilis MraY translocase as a model.	Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, UMR 8619, CNRS, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bouhss, A (corresponding author), Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, UMR 8619, CNRS, Bat 430, F-91405 Orsay, France.	ahmed.bouhss@ebp.u-psud.fr		Muriel, CROUVOISIER/0000-0003-2281-5326; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Auger G, 1998, PROTEIN EXPRES PURIF, V13, P23, DOI 10.1006/prep.1997.0850; Bernhardt TG, 2000, P NATL ACAD SCI USA, V97, P4297, DOI 10.1073/pnas.97.8.4297; BLANOT D, 1994, CARBOHYD RES, V252, P107; Bouhss A, 1999, MOL MICROBIOL, V34, P576, DOI 10.1046/j.1365-2958.1999.01623.x; Boyle DS, 1998, J BACTERIOL, V180, P6429; Brandish PE, 1996, J BIOL CHEM, V271, P7609, DOI 10.1074/jbc.271.13.7609; Brandish PE, 1996, ANTIMICROB AGENTS CH, V40, P1640, DOI 10.1128/AAC.40.7.1640; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; Crouvoisier M, 1999, FEBS LETT, V449, P289, DOI 10.1016/S0014-5793(99)00412-3; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Dementin S, 2001, EUR J BIOCHEM, V268, P5800, DOI 10.1046/j.0014-2956.2001.02524.x; Dini C, 2000, BIOORG MED CHEM LETT, V10, P1839, DOI 10.1016/S0960-894X(00)00349-8; ELBEIN AD, 1979, ARCH BIOCHEM BIOPHYS, V196, P311, DOI 10.1016/0003-9861(79)90583-6; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Gordon E, 2001, J BIOL CHEM, V276, P10999, DOI 10.1074/jbc.M009835200; Gruber G, 2002, BIOCHEM BIOPH RES CO, V298, P383, DOI 10.1016/S0006-291X(02)02468-3; HAROLD FM, 1996, ESCHERICHIA COLI SAL, V1, P283; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; Hyland SA, 2003, ANAL BIOCHEM, V317, P156, DOI 10.1016/S0003-2697(03)00088-5; IKEDA M, 1991, J BACTERIOL, V173, P1021, DOI 10.1128/jb.173.3.1021-1026.1991; LIGER D, 1995, EUR J BIOCHEM, V230, P80, DOI 10.1111/j.1432-1033.1995.0080i.x; McDonald LA, 2002, J AM CHEM SOC, V124, P10260, DOI 10.1021/ja017748h; MENGINLECREULX D, 1990, NUCLEIC ACIDS RES, V18, P2810, DOI 10.1093/nar/18.9.2810; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1989, J BACTERIOL, V171, P6126, DOI 10.1128/jb.171.11.6126-6134.1989; Miller J.H., 1972, EXPT MOL GENETICS; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nanninga N, 1998, MICROBIOL MOL BIOL R, V62, P110, DOI 10.1128/MMBR.62.1.110-129.1998; NEUHAUS FC, 1971, ACCOUNTS CHEM RES, V4, P297, DOI 10.1021/ar50045a001; PIGEON RP, 1994, MOL MICROBIOL, V14, P871, DOI 10.1111/j.1365-2958.1994.tb01323.x; PLESS DD, 1973, J BIOL CHEM, V248, P1568; Rogers H.J., 1980, MICROBIAL CELL WALLS, P239; Sambrook J., 2002, MOL CLONING LAB MANU; Stachyra T, 2004, ANTIMICROB AGENTS CH, V48, P897, DOI 10.1128/AAC.48.3.897-902.2004; Thanassi JA, 2002, NUCLEIC ACIDS RES, V30, P3152, DOI 10.1093/nar/gkf418; UMBREIT JN, 1972, J BACTERIOL, V112, P1306, DOI 10.1128/JB.112.3.1306-1309.1972; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219	39	128	131	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29974	29980		10.1074/jbc.M314165200	http://dx.doi.org/10.1074/jbc.M314165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131133	hybrid			2022-12-27	WOS:000222531900014
J	Kim, SY; Kim, HI; Kim, TH; Im, SS; Park, SK; Lee, IK; Kim, KS; Ahn, YH				Kim, SY; Kim, HI; Kim, TH; Im, SS; Park, SK; Lee, IK; Kim, KS; Ahn, YH			SREBP-1c mediates the insulin-dependent hepatic glucokinase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; LIPOGENIC ENZYME GENES; REGULATORY PROTEIN; TRANSCRIPTION FACTOR; GLUCOSE-HOMEOSTASIS; STEROL REGULATION; LIVER-CELLS; PROMOTER; ACID; MICE	The regulation of hepatic glucose metabolism is important in glucose homeostasis, and liver glucokinase (LGK) plays a central role in this process. Hepatic glucokinase expression is known to be regulated by insulin. Recently it has been suggested that sterol regulatory element binding protein-1c (SREBP-1c) mediates the action of insulin on LGK transcription; however, the precise mechanism is not, to date, well known. In the present study, we identified two functional SREBP-1c response elements, SREa and SREb, in the rat LGK promoter. SREBP-1c could bind to these SREs and activate the LGK promoter, and insulin activated the LGK promoter in Alexander cells. The physical interaction between the protein and SREs of the LGK promoter in vivo was also confirmed. Insulin selectively increased SREBP-1c and LGK expression in primary hepatocytes. Adenoviral expression of SREBP-1c stimulated LGK expression, and the dominant negative mutant of SREBP-1c blocked the increased gene expression of LGK by insulin and SREBP-1c. A chromatin immunoprecipitation assay using primary hepatocytes showed increased binding of SREBP-1 to SREs of the LGK promoter by insulin.	Dept Biochem & Mol Biol, Seoul 120752, South Korea; Brain Korea 21 Project Med Sci, Seoul 120752, South Korea; Ctr Chron Metab Dis Res, Seoul 120752, South Korea; Inst Genet Sci, Seoul 120752, South Korea; Keimyung Univ, Sch Med, Dept Internal Med, Taegu, South Korea	Keimyung University	Ahn, YH (corresponding author), Dept Biochem & Mol Biol, 134 Shinchon Dong, Seoul 120752, South Korea.	yha111@yumc.yonsei.ac.kr	Kim, Hail/C-1849-2011; Kim, So-Youn/H-4368-2016; AHN, Yong Ho/H-6712-2017	Kim, Hail/0000-0002-6652-1349; Kim, So-Youn/0000-0003-1013-6852; Kim, Kyung-sup/0000-0001-8483-8537; AHN, Yong Ho/0000-0002-4133-0757				Becard D, 2001, DIABETES, V50, P2425, DOI 10.2337/diabetes.50.11.2425; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Cha JY, 2000, J BIOL CHEM, V275, P18358, DOI 10.1074/jbc.M909536199; Choi YK, 2003, GENE THER, V10, P559, DOI 10.1038/sj.gt.3301926; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Kim H, 2000, DIABETES, V49, P1517, DOI 10.2337/diabetes.49.9.1517; Kim HI, 2002, DIABETES, V51, P676, DOI 10.2337/diabetes.51.3.676; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim JW, 1998, BIOCHEM J, V336, P83, DOI 10.1042/bj3360083; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Magana MM, 1997, J LIPID RES, V38, P1630; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Matschinsky FM, 2000, FRONT DIABETES, V15, P99; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Moon YA, 2000, J BIOL CHEM, V275, P30280, DOI 10.1074/jbc.M001066200; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Oh SY, 2003, J BIOL CHEM, V278, P28410, DOI 10.1074/jbc.M300553200; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691	33	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30823	30829		10.1074/jbc.M313223200	http://dx.doi.org/10.1074/jbc.M313223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123649	hybrid			2022-12-27	WOS:000222531900114
J	Bednarski, JJ; Lyssiotis, CA; Roush, R; Boitano, AE; Glick, GD; Opipari, AW				Bednarski, JJ; Lyssiotis, CA; Roush, R; Boitano, AE; Glick, GD; Opipari, AW			A novel benzodiazepine increases the sensitivity of B cells to receptor stimulation with synergistic effects on calcium signaling and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; MONOCLONAL-ANTIBODIES; DEPENDENT APOPTOSIS; AUTOIMMUNE-DISEASE; SUPEROXIDE ANION; SURFACE IGM; LYMPHOCYTES; ACTIVATION; RELEASE; LYMPHOMA	Bz-423 is a 1,4-benzodiazepine with selective lymphotoxic properties and potent therapeutic activity against lupus-like disease in autoimmune mice. In NZB/W lupus-prone mice, Bz-423 specifically kills germinal center B cells, which are the cells that drive disease both in this model and in human systemic lupus erythematosus. In this report, the mechanistic basis for the selective action of Bz-423 is investigated. We show that Bz-423-induces superoxide as an immediate early response and that this reactive oxygen species is more effective as a second messenger death signal in B cells activated by B cell receptor stimulation compared with resting cells. As a result, low [Bz-423] that are not cytotoxic to non-stimulated cells kill stimulated cells in synergy with anti-immunoglobulin M antibodies. Subsequent experiments demonstrated that Bz-423 extends the rise in intracellular calcium that accompanies anti-immunoglobulin M stimulation, and this effect mediates the synergistic death response. Because B cell hyperactivation and altered calcium signaling is a distinguishing feature of autoreactive lymphocytes in lupus, the mechanism by which Bz-423 induces apoptosis preferentially targets disease-causing cells on the basis of their activation state. Thus, molecules like Bz-423 could form the basis for new and selective anti-lupus agents.	Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Opipari, AW (corresponding author), Univ Michigan, Dept Obstet & Gynecol, 1500 E Med Ctr Dr,L4602 WH, Ann Arbor, MI 48109 USA.	aopipari@umich.edu	Bednarski, Jeff/GLN-6651-2022; Lyssiotis, Costas A/AAI-1923-2019	Lyssiotis, Costas A/0000-0001-9309-6141	NCI NIH HHS [CA104561] Funding Source: Medline; NIAID NIH HHS [AI47450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047450, R01AI047450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Bednarski JJ, 2003, ARTHRITIS RHEUM-US, V48, P757, DOI 10.1002/art.10968; BIJSTERBOSCH MK, 1986, BIOCHEM BIOPH RES CO, V137, P500, DOI 10.1016/0006-291X(86)91238-6; Blatt NB, 2002, J CLIN INVEST, V110, P1123, DOI 10.1172/JCI200216029; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; BUNIN BA, 1994, P NATL ACAD SCI USA, V91, P4708, DOI 10.1073/pnas.91.11.4708; BURTON KP, 1990, J MOL CELL CARDIOL, V22, P1035, DOI 10.1016/0022-2828(90)91043-7; Cai S, 1997, J MEMBRANE BIOL, V158, P147, DOI 10.1007/s002329900252; Cheng Genhong, 2002, Curr Dir Autoimmun, V5, P51; Chinn P, 2003, CANCER IMMUNOL IMMUN, V52, P257, DOI 10.1007/s00262-002-0347-6; Choi YS, 1997, IMMUNOL RES, V16, P161, DOI 10.1007/BF02786360; Cragg MS, 1999, BRIT J CANCER, V79, P850, DOI 10.1038/sj.bjc.6690136; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DIAMOND B, 1992, ANNU REV IMMUNOL, V10, P731, DOI 10.1146/annurev.iy.10.040192.003503; DiPolo R, 2002, PROG BIOPHYS MOL BIO, V80, P43, DOI 10.1016/S0079-6107(02)00014-7; Dixon F J, 1978, Arthritis Rheum, V21, pS64, DOI 10.1002/art.1780210909; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Donjerkovic D, 2000, CELL RES, V10, P179, DOI 10.1038/sj.cr.7290047; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Grafton G, 1997, CELL IMMUNOL, V182, P45, DOI 10.1006/cimm.1997.1205; GUSKOVA RA, 1984, BIOCHIM BIOPHYS ACTA, V778, P579, DOI 10.1016/0005-2736(84)90409-7; Guzman-Rojas L, 2002, IMMUNOLOGY, V107, P167, DOI 10.1046/j.1365-2567.2002.01494.x; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hirst RA, 1999, METH MOL B, V114, P31; Jeulin C, 2002, PFLUG ARCH EUR J PHY, V443, P574, DOI 10.1007/s00424-001-0733-5; Kim D, 2002, HUM IMMUNOL, V63, P576, DOI 10.1016/S0198-8859(02)00405-6; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; Kozono Y, 1996, J IMMUNOL, V156, P4498; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; RUBIN LA, 1985, Q J MED, V55, P87; Shlomchik MJ, 2001, NAT REV IMMUNOL, V1, P147, DOI 10.1038/35100573; Takano T, 2002, ANTIOXID REDOX SIGN, V4, P533, DOI 10.1089/15230860260196335; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645	43	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29615	29621		10.1074/jbc.M403507200	http://dx.doi.org/10.1074/jbc.M403507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123639	hybrid			2022-12-27	WOS:000222445300097
J	Meshorer, E; Toiber, D; Zurel, D; Sahly, I; Dori, A; Cagnano, E; Schreiber, L; Grisaru, D; Tronche, F; Soreq, H				Meshorer, E; Toiber, D; Zurel, D; Sahly, I; Dori, A; Cagnano, E; Schreiber, L; Grisaru, D; Tronche, F; Soreq, H			Combinatorial complexity of 5 ' alternative acetylcholinesterase transcripts and protein products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCLEAVED SIGNAL PEPTIDE; ANOMALOUS MOLECULAR-FORM; TERMINAL T-PEPTIDE; MESSENGER-RNA; MOUSE ACETYLCHOLINESTERASE; ALZHEIMERS-DISEASE; MEMBRANE ANCHOR; EXPRESSION; GENE; PROMOTER	To explore the scope and significance of alternate promoter usage and its putative inter-relationship to alternative splicing, we searched expression sequence tags for the 5' region of acetylcholinesterase ( ACHE) genes. Three and five novel first exons were identified in human and mouse ACHE genes, respectively. Reverse transcription-PCR and in situ hybridization validated most of the predicted transcripts, and sequence analyses of the corresponding genomic DNA regions suggest evolutionarily conserved promoters for each of the novel exons identified. Distinct tissue specificity and stress-related expression patterns of these exons predict combinatorial complexity with known 3' alternative AChE mRNA transcripts. Unexpectedly one of the 5' exons encodes an extended N terminus in-frame with the known AChE sequence, extending the increased complexity to the protein level. The resultant membrane variant(s), designated N-AChE, is developmentally regulated in human brain neurons and blood mononuclear cells. Alternative promoter usage combined with alternative splicing may thus lead to stress-dependent combinatorial complexity of AChE mRNA transcripts and their protein products.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Israel Ctr Neuronal Computat, IL-91904 Jerusalem, Israel; Coll France, Inst Biol, CNRS FRE2401, F-75231 Paris 5, France; Soroka Univ Med Ctr, Dept Pathol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sourasky Med Ctr, Dept Pathol, IL-84105 Tel Aviv, Israel; Tel Aviv Univ, Sourasky Med Ctr, Dept Obstet & Gynecol, IL-84105 Tel Aviv, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; UDICE-French Research Universities; PSL Research University Paris; College de France; Ben Gurion University; Soroka Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il	TRONCHE, François/F-3895-2011; Dori, Amir/E-5623-2013	Meshorer, Eran/0000-0003-4777-986X; Soreq, Hermona/0000-0002-0955-526X; Dori, Amir/0000-0003-4633-1481				Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Belbeoc'h S, 2003, EMBO J, V22, P3536, DOI 10.1093/emboj/cdg360; Ben Aziz-Aloya R, 1993, Prog Brain Res, V98, P147; Brenner T, 2003, FASEB J, V17, P214, DOI 10.1096/fj.02-0609com; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Darreh-Shori T, 2004, J NEUROCHEM, V88, P1102, DOI 10.1046/j.1471-4159.2003.02230.x; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kawashima K, 2000, PHARMACOL THERAPEUT, V86, P29, DOI 10.1016/S0163-7258(99)00071-6; LI Y, 1991, J BIOL CHEM, V266, P23083; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; McKiernan CJ, 1999, J BIOL CHEM, V274, P38177, DOI 10.1074/jbc.274.53.38177; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Morel N, 2001, J BIOL CHEM, V276, P37379, DOI 10.1074/jbc.M103192200; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NAVARATNAM DS, 1991, LANCET, V337, P447, DOI 10.1016/0140-6736(91)93391-L; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; Perrier NA, 2003, EUR J NEUROSCI, V18, P1837, DOI 10.1046/j.1460-9568.2003.02914.x; PICK M, 2004, IN PRESS INT J DEV N; PODLESKI T, 1967, SCIENCE, V157, P1579, DOI 10.1126/science.157.3796.1579; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shen ZX, 1997, NEUROREPORT, V8, P3229, DOI 10.1097/00001756-199710200-00009; Sorek R, 2003, NUCLEIC ACIDS RES, V31, P1067, DOI 10.1093/nar/gkg170; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1; Wilson MD, 2001, NUCLEIC ACIDS RES, V29, P1352, DOI 10.1093/nar/29.6.1352; Xie HQ, 2002, GENOMICS, V80, P326, DOI 10.1006/geno.2002.6841	40	99	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29740	29751		10.1074/jbc.M402752200	http://dx.doi.org/10.1074/jbc.M402752200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123727	hybrid			2022-12-27	WOS:000222445300110
J	Robson-Dixon, ND; Garcia-Blanco, MA				Robson-Dixon, ND; Garcia-Blanco, MA			MAZ elements alter transcription elongation and silencing of the fibroblast growth factor receptor 2 exon IIIb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SPLICE-SITE SELECTION; TRACT BINDING-PROTEIN; MESSENGER-RNA; HNRNP-H; ALTERNATIVE EXON; IN-VITRO; PAUSE SITE; TERMINATION; GENE	The fibroblast growth factor receptor 2 (FGFR2) gene exons IIIb and IIIc are alternatively spliced in a mutually exclusive and cell type-specific manner. FGFR2 exon choice depends on both activation and silencing. Exon IIIb silencing requires cis-acting elements upstream and downstream of the exon. To examine the influence of transcription on exon IIIb silencing, the putative RNA polymerase II (RNAPII)-pausing MAZ4 element was inserted at different positions within the FGFR2 minigene construct. MAZ4 insertions 5' to the upstream silencing elements or between exon IIIb and downstream silencing elements result in decreased silencing. An insertion 3' of the downstream silencing elements, however, has no effect on splicing. An RT-PCR elongation assay shows that the MAZ4 site in these constructs is likely to be a RNAPII pause site. Insertion of another RNAPII pause site into the minigene has a similar effect on exon IIIb silencing. Transfection of in vitro transcribed RNA demonstrates that the cell type specificity of FGFR2 alternative splicing requires co-transcriptional splicing. Additionally, changing the promoter alters both FGFR2 minigene splicing and the MAZ4 effect. We propose that RNAPII pauses at the MAZ4 elements resulting in a change in the transcription elongation complex that influences alternative splicing decisions downstream.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	garci001@mc.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM067466, R01GM063090] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM063090, 1 F32 GM067466-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DWARKI VJ, 1993, METHOD ENZYMOL, V217, P644; ENRIQUEZHARRIS P, 1991, EMBO J, V10, P1833, DOI 10.1002/j.1460-2075.1991.tb07709.x; Fogel BL, 2000, J BIOL CHEM, V275, P32371, DOI 10.1074/jbc.M005000200; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Furger A, 2002, GENE DEV, V16, P2792, DOI 10.1101/gad.983602; Ghosh S, 2000, RNA, V6, P1325, DOI 10.1017/S1355838200992537; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; Goldstrohm AC, 2001, MOL CELL BIOL, V21, P7617, DOI 10.1128/MCB.21.22.7617-7628.2001; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; GRAESSMANN M, 1982, EMBO J, V1, P1081, DOI 10.1002/j.1460-2075.1982.tb01300.x; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; GREENBERG ME, 1998, CURRENT PROTOCOLS MO, V1; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; Harju S, 2001, BIOTECHNIQUES, V30, P1198, DOI 10.2144/01306bm02; Hastings ML, 2001, RNA, V7, P859, DOI 10.1017/S1355838201002084; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; Howe KJ, 2003, RNA, V9, P993, DOI 10.1261/rna.5390803; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; Peterson ML, 2002, MOL CELL BIOL, V22, P5606, DOI 10.1128/MCB.22.15.5606-5615.2002; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Rosonina E, 2003, J BIOL CHEM, V278, P43034, DOI 10.1074/jbc.M307289200; STRUHL K, 1998, CURRENT PROTOCOLS MO, V2; Sune C, 1999, MOL CELL BIOL, V19, P4719; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Taylor A, 1997, GENET RES, V69, P101, DOI 10.1017/S0016672397002681; Tian HC, 2001, FEBS LETT, V509, P282, DOI 10.1016/S0014-5793(01)03188-X; Wagner EJ, 2003, RNA, V9, P1552, DOI 10.1261/rna.5840803; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Yonaha M, 1999, MOL CELL, V3, P593, DOI 10.1016/S1097-2765(00)80352-4	59	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29075	29084		10.1074/jbc.M312747200	http://dx.doi.org/10.1074/jbc.M312747200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126509	hybrid			2022-12-27	WOS:000222445300031
J	van der Horst, A; Tertoolen, LGJ; de Vries-Smits, LMM; Frye, RA; Medema, RH; Burgering, BMT				van der Horst, A; Tertoolen, LGJ; de Vries-Smits, LMM; Frye, RA; Medema, RH; Burgering, BMT			FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; PROMOTES CELL-SURVIVAL; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; LIFE-SPAN; KINASE-B; GROWTH; DAF-16; P53; AFX	FOXO transcription factors have important roles in metabolism, cellular proliferation, stress tolerance, and aging. FOXOs are negatively regulated by protein kinase B/c-Akt-mediated phosphorylation. Here we show that FOXO factors are also subject to regulation by reversible acetylation. We provide evidence that the acetyltransferase CREB-binding protein (CBP) binds FOXO resulting in acetylation of FOXO. This acetylation inhibits FOXO transcriptional activity. Binding of CBP and acetylation are induced after treatment of cells with peroxide stress. Deacetylation of FOXOs involves binding of the NAD-dependent deacetylase hSir2(SIRT1). Accordingly, hSir2(SIRT1)-mediated deacetylation precludes FOXO inhibition through acetylation and thereby prolongs FOXO-dependent transcription of stress-regulating genes. These data demonstrate that acetylation functions in a second pathway of negative control for FOXO factors and provides a novel mechanism whereby hSir2(SIRT1) can promote cellular survival and increase lifespan.	Univ Med Ctr Utrecht, Ctr Biomed Genet, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Pittsburgh, Dept Pathol, Pittsburgh Vet Affairs Med Ctr 132L, Pittsburgh, PA 15240 USA; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Netherlands Cancer Institute	Burgering, BMT (corresponding author), Univ Med Ctr Utrecht, Ctr Biomed Genet, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands.	B.M.T.Burgering@med.uu.nl	Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381				Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Goodman RH, 2000, GENE DEV, V14, P1553; GOTTLIEB S, 1994, GENETICS, V137, P107; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kaestner KH, 2000, GENE DEV, V14, P142; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Murakami S, 1996, GENETICS, V143, P1207; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095	33	442	452	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28873	28879		10.1074/jbc.M401138200	http://dx.doi.org/10.1074/jbc.M401138200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126506	hybrid			2022-12-27	WOS:000222445300007
J	Wang, XY; Wang, RH; Li, WM; Xu, XL; Hollander, MC; Fornace, AJ; Deng, CX				Wang, XY; Wang, RH; Li, WM; Xu, XL; Hollander, MC; Fornace, AJ; Deng, CX			Genetic interactions between Brca1 and Gadd45a in centrosome duplication, genetic stability, and neural tube closure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; NEK2 PROTEIN-KINASE; FULL-LENGTH ISOFORM; DNA-DAMAGE REPAIR; CANCER SUSCEPTIBILITY; APOPTOSIS; MOUSE; MICE; INSTABILITY; P53	GADD45a is a transcription target of the breast tumor suppressor gene BRCA. It was recently shown that mouse embryonic fibroblast cells carrying a targeted deletion of exon 11 of Brca1 (Brca1(Delta11/Delta11)) or a Gadd45A-null mutation (Gadd45a(-/-)) suffer centrosome amplification. To study genetic interactions between these genes during centrosome duplication, we generated Brca1(Delta11/Delta11)Gadd45a(-/-) mice by crossing each mutant. We found that all Brca1(Delta11/Delta11)Gadd45a(-/-) embryos at embryonic days 9.5-10.5 were exencephalic and exhibited a high incidence of apoptosis accompanied by altered levels of BAX, BCL-2, and p53. The trigger for these events is likely the genetic instability arising from centrosome amplification that is associated, at least in part, with decreased expression of the NIMA-related kinase NEK2. We demonstrate that small interfering RNA-mediated suppression of Brca1 decreased Nek2 more dramatically in Gadd45a(-/-) cells than in wild-type cells and, conversely, that overexpression of Brca1 and/or Gadd45a up-regulated transcription of Nek2. Furthermore, we show that overexpression of Nek2 in Brca1-specific small interfering RNA-treated wild-type and Gadd45a(-/-) cells repressed abnormal centrosome amplification. These observations suggest that NEK2 plays a role in mediating the actions of BRCA1 and GADD45a in regulating centrosome duplication and in maintaining genetic stability.	NIDDK, GDDB, NIH, Bethesda, MD 20892 USA; NCI, Gene Response Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), NIDDK, GDDB, NIH, Bldg 10,Rm 9N105,10 Ctr Dr, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	Fornace, Albert J/A-7407-2008; deng, chuxia/N-6713-2016	Fornace, Albert J/0000-0001-9695-085X; 	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Bachelier R, 2003, ONCOGENE, V22, P528, DOI 10.1038/sj.onc.1206208; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Carrier F, 1999, MOL CELL BIOL, V19, P1673; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; Copp Andrew J., 1994, Current Opinion in Pediatrics, V6, P624, DOI 10.1097/00008480-199412000-00002; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edmonds L D, 1990, MMWR CDC Surveill Summ, V39, P19; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Juriloff DM, 2000, HUM MOL GENET, V9, P993, DOI 10.1093/hmg/9.6.993; Kovalsky O, 2001, J BIOL CHEM, V276, P39330, DOI 10.1074/jbc.M105115200; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Pihan GA, 1998, CANCER RES, V58, P3974; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SHAW GM, 1994, TERATOLOGY, V49, P143, DOI 10.1002/tera.1420490210; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Xu XL, 2003, DEVELOPMENT, V130, P2001, DOI 10.1242/dev.00410; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	51	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29606	29614		10.1074/jbc.M312279200	http://dx.doi.org/10.1074/jbc.M312279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123655	hybrid			2022-12-27	WOS:000222445300096
J	Fuchs, C; Heib, V; Kiger, L; Haberkamp, M; Roesner, A; Schmidt, M; Hamdane, D; Marden, MC; Hankeln, T; Burmester, T				Fuchs, C; Heib, V; Kiger, L; Haberkamp, M; Roesner, A; Schmidt, M; Hamdane, D; Marden, MC; Hankeln, T; Burmester, T			Zebrafish reveals different and conserved features of vertebrate neuroglobin gene structure, expression pattern, and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; HEXACOORDINATE HEMOGLOBIN; GLOBIN FAMILY; TELEOST FISH; DANIO-RERIO; PROTEIN; CYTOGLOBIN; BRAIN; GILLS	Neuroglobin has been identified as a respiratory protein that is primarily expressed in the mammalian nervous system. Here we present the first detailed analysis of neuroglobin from a non-mammalian vertebrate, the zebrafish Danio rerio. The zebrafish neuroglobin gene reveals a mammalian-type exon-intron pattern in the coding region (B12.2, E11.0, and G7.0), plus an additional 5'-non-coding exon. Similar to the mammalian neuroglobin, the zebrafish protein displays a hexacoordinate deoxybinding scheme. Flash photolysis kinetics show the competitive binding on the millisecond timescale of external ligands and the distal histidine, resulting in an oxygen affinity of 1 torr. Western blotting, immune staining, and mRNA in situ hybridization demonstrate neuroglobin expression in the fish central nervous system and the retina but also in the gills. Neurons containing neuroglobin have a widespread distribution in the brain but are also present in the olfactory system. In the fish retina, neuroglobin is mainly present in the inner segments of the photoreceptor cells. In the gills, the chloride cells were identified to express neuroglobin. Neuroglobin appears to be associated with mitochondria-rich cell types and thus oxygen consumption rates, suggesting a myoglobin-like function of this protein in facilitated oxygen diffusion.	Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany; INSERM, U473, F-94276 Le Kremlin Bicetre, France	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Institut National de la Sante et de la Recherche Medicale (Inserm)	Burmester, T (corresponding author), Univ Mainz, Inst Zool, Saarstr 21, D-55099 Mainz, Germany.	burmeste@uni-mainz.de	Marden, Michael C/G-3139-2012; Burmester, Thorsten/I-7225-2013; Kiger, Laurent/Q-1686-2018; Marden, Michael/AAA-5923-2020	Marden, Michael C/0000-0002-5254-6385; Burmester, Thorsten/0000-0002-5772-7863; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; Benton M.J., 1990, VERTEBRATE PALEONTOL; BLANCHETOT A, 1986, EUR J BIOCHEM, V159, P469, DOI 10.1111/j.1432-1033.1986.tb09909.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; BURMESTER T, 2004, IN PRESS NEWS PHYSL; BURNSIDE B, 1978, J CELL BIOL, V78, P227, DOI 10.1083/jcb.78.1.227; Claiborne JB, 2002, J EXP ZOOL, V293, P302, DOI 10.1002/jez.10125; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; Douglas RH, 1998, VISION RES, V38, P2697, DOI 10.1016/S0042-6989(98)00021-2; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; JOHANSEN K, 1981, RESP PHYSIOL, V44, P277, DOI 10.1016/0034-5687(81)90023-2; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8; LAUFS T, 2004, IN PRESS NEUROSCI LE; LYNDON AR, 1994, J FISH BIOL, V44, P707, DOI 10.1111/j.1095-8649.1994.tb01246.x; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Marshall WS, 2002, J EXP ZOOL, V293, P264, DOI 10.1002/jez.10127; Merx Marc W., 2001, FASEB Journal, V15, P1077; Nakatani K, 2004, LAB INVEST, V84, P91, DOI 10.1038/labinvest.3700013; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Perry SF, 1997, ANNU REV PHYSIOL, V59, P325, DOI 10.1146/annurev.physiol.59.1.325; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Rombough P, 2002, J EXP BIOL, V205, P1787; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Schmidt M, 2004, J BIOL CHEM, V279, P8063, DOI 10.1074/jbc.M310540200; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Wenger RH, 1997, BIOL CHEM, V378, P609; Wittbrodt J, 2002, NAT REV GENET, V3, P53, DOI 10.1038/nrg704; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; WITTENBERG JB, 1975, COMP BIOCHEM PHYS A, V51, P425, DOI 10.1016/0300-9629(75)90390-4; Wullimann MF, 1996, NEUROANATOMY ZEBRAFI, DOI 10.1007/978-3-0348-8979-7_6; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; WYSTUB S, 2004, IN PRESS CYTOGENET G; [No title captured]	53	66	71	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24116	24122		10.1074/jbc.M402011200	http://dx.doi.org/10.1074/jbc.M402011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140880	hybrid			2022-12-27	WOS:000221702500034
J	Podsiadlo, P; Komiyama, T; Fuller, RS; Blum, O				Podsiadlo, P; Komiyama, T; Fuller, RS; Blum, O			Furin inhibition by compounds of copper and zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; KEX2 PROTEASE; PROTEINASE-K; COMPLEXES; SPECIFICITY; EMBRYOGENESIS; PARAMETERS; PATHWAY; MERCURY	Furin, a human subtilisin-related proprotein convertase (SPC), is emerging as an important pharmaceutical target because it processes vital proteins of many aggressive pathogens. Furin inhibitors reported as yet are peptide derivatives and proteins, with the exception of andrographolides, which are natural compounds. Here we report that the small and highly stable compounds M(chelate)Cl-2 (M is copper or zinc) inhibit furin and Kex2, with Cu(TTP)Cl-2 and Zn(TTP)Cl-2 as the most efficient inhibitors. (TTP is 4'-[p-tolyl]-2,2':6',2'-terpyridine.) Inhibition is irreversible, competitive with substrate, and affected by substituents on the chelate. The free chelates are not inhibitors. Solvated Zn2+ is less potent than its complexes. This is true also for copper and Kex2. However, solvated Cu2+ (k(on) of 25,000 +/- 2,500 s(-1)) is more potent than Cu(TTP)Cl-2 (k(on) = 140 +/- 13 s(-1)) and allows recovery of furin activity prior to a second inhibition phase. A mechanism that involves coordination to the catalytic histidine is proposed for all inhibitors. Target specificity is indicated by the fact that these metal chelate inhibitors are much less potent toward Kex2, the yeast homologue of furin. For example, kon with Zn(TTP)Cl-2 is 120 +/- 20 s(-1) for furin, but only 1.2 +/- 0.1 s(-1) for Kex2.	Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Technion Israel Institute of Technology	Blum, O (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.	oferblum@tx.technion.ac.il			NIGMS NIH HHS [GM 39667] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambundo EA, 1999, INORG CHEM, V38, P4233, DOI 10.1021/ic990334t; Basak A, 1999, BIOCHEM J, V338, P107, DOI 10.1042/0264-6021:3380107; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; Brinkerhoff CJ, 2002, CHEMBIOCHEM, V3, P1141, DOI 10.1002/1439-7633(20021104)3:11<1141::AID-CBIC1141>3.0.CO;2-7; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; CONSTABLE EC, 1990, INORG CHIM ACTA, V178, P47, DOI 10.1016/S0020-1693(00)88132-3; CORNILSEN BC, 1974, J INORG NUCL CHEM, V36, P2467, DOI 10.1016/0022-1902(74)80455-0; FUGERE M, CURR PHARM DES, V8, P125; HARRIS CM, 1970, AUST J CHEM, V23, P673, DOI 10.1071/CH9700673; Hathaway B.J., 1987, COMPREHENSIVE COORDI, P533; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hill MG, 1996, INORG CHEM, V35, P4585, DOI 10.1021/ic960137j; Hitomi Y, 2001, J AM CHEM SOC, V123, P8614, DOI 10.1021/ja016146v; Holyoak T, 2003, BIOCHEMISTRY-US, V42, P6709, DOI 10.1021/bi034434t; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; KEIM W, 1994, BIOINORGANIC CHEM IN, P20; KEIM W, 1994, BIOINORGANIC CHEM IN, P6; Komiyama T, 2003, P NATL ACAD SCI USA, V100, P8205, DOI 10.1073/pnas.1032865100; Komiyama T, 2000, BIOCHEMISTRY-US, V39, P15156, DOI 10.1021/bi001907c; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; KUNJAPPU JT, 1991, J PHOTOCH PHOTOBIO A, V56, P365, DOI 10.1016/1010-6030(91)80036-H; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P21; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; MULLER A, 1993, J BIOL CHEM, V268, P26150; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Ohta T, 2000, INORG CHEM, V39, P4358, DOI 10.1021/ic000018a; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Saxena AK, 1996, PROTEINS, V25, P195, DOI 10.1002/(SICI)1097-0134(199606)25:2<195::AID-PROT5>3.0.CO;2-H; SCHMIDT KH, 1975, INORG CHEM, V14, P2183, DOI 10.1021/ic50151a031; Steiner D. F., 2002, ENZYMES, V22, P163; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	36	31	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36219	36227		10.1074/jbc.M400338200	http://dx.doi.org/10.1074/jbc.M400338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15140896	hybrid			2022-12-27	WOS:000223453600009
J	Lee, SP; So, CH; Rashid, AJ; Varghese, G; Cheng, R; Lanca, AJ; O'Dowd, BF; George, SR				Lee, SP; So, CH; Rashid, AJ; Varghese, G; Cheng, R; Lanca, AJ; O'Dowd, BF; George, SR			Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-OPIOID RECEPTORS; LOCOMOTOR-ACTIVITY; RAT; STIMULATION; EXPRESSION; GENE; D-2; HOMODIMERIZATION; MODULATION; STRIATUM	Although dopamine D1 and D2 receptors belong to distinct subfamilies of dopamine receptors, several lines of evidence indicate that they are functionally linked. However, a mechanism for this linkage has not been elucidated. In this study, we demonstrate that agonist stimulation of co-expressed D1 and D2 receptors resulted in an increase of intracellular calcium levels via a signaling pathway not activated by either receptor alone or when only one of the co-expressed receptors was activated by a selective agonist. Calcium signaling by D1-D2 receptor co-activation was abolished following treatment with a phospholipase C inhibitor but not with pertussis toxin or inhibitors of protein kinase A or protein kinase C, indicating coupling to the G(q) pathway. We also show, by co-immunoprecipitation from rat brain and from cells co-expressing the receptors, that D1 and D2 receptors are part of the same heteromeric protein complex and, by immunohistochemistry, that these receptors are co-expressed and co-localized within neurons of human and rat brain. This demonstration that D1 and D2 receptors have a novel cellular function when co-activated in the same cell represents a significant step toward elucidating the mechanism of the functional link observed between these two receptors in brain.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	George, SR (corresponding author), Univ Toronto, Dept Pharmacol, Rm 4358,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	s.george@utoronto.ca	George, Susan/W-7494-2019; George, Susan R/P-9669-2018					Aizman O, 2000, NAT NEUROSCI, V3, P226, DOI 10.1038/72929; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K; Charles AC, 2003, MOL PHARMACOL, V63, P89, DOI 10.1124/mol.63.1.89; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DREHER JK, 1989, BRAIN RES, V487, P267, DOI 10.1016/0006-8993(89)90831-7; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Gerfen CR, 1995, J NEUROSCI, V15, P8167; Kita K, 1999, EUR NEUROPSYCHOPHARM, V9, P1, DOI 10.1016/S0924-977X(97)00098-9; LaHoste GJ, 2000, J NEUROSCI, V20, P6666, DOI 10.1523/JNEUROSCI.20-17-06666.2000; LANCA AJ, 1994, NEUROSCIENCE, V58, P359, DOI 10.1016/0306-4522(94)90043-4; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lidow MS, 2003, BRAIN RES REV, V43, P70, DOI 10.1016/S0165-0173(03)00203-0; LIN CW, 1995, MOL PHARMACOL, V47, P131; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MEADORWOODRUFF JH, 1991, NEUROPSYCHOPHARMACOL, V5, P231; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Neumeyer JL, 2003, EUR J PHARMACOL, V474, P137, DOI 10.1016/S0014-2999(03)02008-9; Pacheco MA, 1997, J NEUROCHEM, V69, P639; PEDERSEN UB, 1994, EUR J PHARM-MOLEC PH, V267, P85, DOI 10.1016/0922-4106(94)90228-3; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Svenningsson P, 2000, NEUROSCIENCE, V98, P749, DOI 10.1016/S0306-4522(00)00155-X; UNDIE AS, 1990, J PHARMACOL EXP THER, V253, P987; Yu PY, 1996, J BIOL CHEM, V271, P19503, DOI 10.1074/jbc.271.32.19503; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zhuang XX, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-16-j0001.2000	39	352	362	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35671	35678		10.1074/jbc.M401923200	http://dx.doi.org/10.1074/jbc.M401923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15159403	hybrid			2022-12-27	WOS:000223303400064
J	Reinhart, GJ; Xie, Q; Liu, XJ; Zhu, YF; Fan, J; Chen, C; Struthers, RS				Reinhart, GJ; Xie, Q; Liu, XJ; Zhu, YF; Fan, J; Chen, C; Struthers, RS			Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GNRH RECEPTOR; MOLECULAR-MECHANISMS; BINDING; POTENT; ACTIVATION; AGONIST; DESIGN; SITE; IDENTIFICATION; SENSITIVITY	Efforts to develop orally available gonadotropin-releasing hormone (GnRH) receptor antagonists have led to the discovery of several classes of potent nonpeptide antagonists. Here we investigated molecular interactions of three classes of nonpeptide antagonists with human, rat, and macaque GnRH receptors. Although all are high affinity ligands of the human receptor (K-i < 5 nM), these compounds show reduced affinity for the macaque receptor and bind only weakly (K-i > 1 muM) to the rat receptor. To identify residues responsible for this selectivity, a series of chimeric receptors and mutant receptors was constructed and evaluated for nonpeptide binding. Surprisingly, 4 key residues located in the amino terminus (Met-24) and extracellular loops II (Ser-203, Gln-208) and III (Leu-300) of the GnRH receptor appear to be primarily responsible for species-selective binding. Comparisons of reciprocal mutations suggest that these may not be direct contacts but rather may be involved in organizing extracellular portions of the receptor. These data are novel because most previous reports of residues involved in binding of nonpeptide ligands to peptide-activated G protein-coupled receptors, including the GnRH receptor as well as mono-amine receptors, have identified binding sites in the transmembrane regions.	Neuroendocrine Biosci Inc, Dept Endocrinol, San Diego, CA 92121 USA; Neuroendocrine Biosci Inc, Dept Peptide Chem, San Diego, CA 92121 USA; Neuroendocrine Biosci Inc, Dept Med Chem, San Diego, CA 92121 USA; Neuroendocrine Biosci Inc, Dept Mol Biol, San Diego, CA 92121 USA	Neurocrine Biosciences; Neurocrine Biosciences; Neurocrine Biosciences; Neurocrine Biosciences	Struthers, RS (corresponding author), Neuroendocrine Biosci Inc, Dept Endocrinol, 10555 Sci Ctr Dr, San Diego, CA 92121 USA.	sstruthers@neurocrine.com			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD038625, R44HD038625] Funding Source: NIH RePORTER; NICHD NIH HHS [1R43 HD 38625-01, 2R44 HD 38625-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Assefa D, 1999, MOL CELL ENDOCRINOL, V156, P179, DOI 10.1016/S0303-7207(99)00123-9; BURGUS R, 1972, P NATL ACAD SCI USA, V69, P278, DOI 10.1073/pnas.69.1.278; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cho NB, 1998, J MED CHEM, V41, P4190, DOI 10.1021/jm9803673; Cui JS, 2000, MOL ENDOCRINOL, V14, P671, DOI 10.1210/me.14.5.671; Davidson JS, 1997, BIOCHEMISTRY-US, V36, P12881, DOI 10.1021/bi971377t; Escrieut C, 2002, J BIOL CHEM, V277, P7546, DOI 10.1074/jbc.M108563200; Feighner SD, 1998, MOL ENDOCRINOL, V12, P137, DOI 10.1210/mend.12.1.0051; Fromme BJ, 2001, MOL PHARMACOL, V60, P1280, DOI 10.1124/mol.60.6.1280; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gross TD, 2002, BIOORG MED CHEM LETT, V12, P2185, DOI 10.1016/S0960-894X(02)00371-2; Guo ZQ, 2003, BIOORG MED CHEM LETT, V13, P3311, DOI 10.1016/S0960-894X(03)00620-6; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; Hunyady L, 1998, MOL PHARMACOL, V54, P427, DOI 10.1124/mol.54.2.427; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; Labbe-Jullie C, 1998, J BIOL CHEM, V273, P16351, DOI 10.1074/jbc.273.26.16351; LIMONTA P, 1985, CONTRACEPTION, V32, P75, DOI 10.1016/0010-7824(85)90117-9; LUNENFELD B, 1999, GNRH ANALOGUES STATE; MATSUO H, 1971, BIOCHEM BIOPH RES CO, V43, P1334, DOI 10.1016/S0006-291X(71)80019-0; Millar RP, 2000, BRIT MED BULL, V56, P761, DOI 10.1258/0007142001903346; Ott TR, 2002, MOL ENDOCRINOL, V16, P1079, DOI 10.1210/me.16.5.1079; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Renzetti AR, 1999, J PHARMACOL EXP THER, V290, P487; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; THAU RB, 1985, J STEROID BIOCHEM, V23, P811, DOI 10.1016/S0022-4731(85)80020-0; Thibonnier M, 2000, J PHARMACOL EXP THER, V294, P195; Tokita K, 2001, J BIOL CHEM, V276, P495, DOI 10.1074/jbc.M006059200; Wilcoxen KM, 2002, BIOORG MED CHEM LETT, V12, P2179, DOI 10.1016/S0960-894X(02)00370-0; Zhu YF, 2002, BIOORG MED CHEM LETT, V12, P399, DOI 10.1016/S0960-894X(01)00779-X; Zhu YF, 2003, J MED CHEM, V46, P1769, DOI 10.1021/jm0205402	30	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34115	34122		10.1074/jbc.M404474200	http://dx.doi.org/10.1074/jbc.M404474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15155770	hybrid			2022-12-27	WOS:000223134800008
J	Misiaszek, R; Crean, C; Joffe, A; Geacintov, NE; Shafirovich, V				Misiaszek, R; Crean, C; Joffe, A; Geacintov, NE; Shafirovich, V			Oxidative DNA damage associated with combination of guanine and superoxide radicals and repair mechanisms via radical trapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-ELECTRON OXIDATION; DOUBLE-STRANDED DNA; AQUEOUS-SOLUTION; MAJOR PRODUCT; PHOTOSENSITIZED OXIDATION; TRANSFORMATION REACTIONS; REDUCTION POTENTIALS; HYDANTOIN PRODUCTS; NITROGEN-DIOXIDE; REACTIVE OXYGEN	In living tissues under inflammatory conditions, superoxide radicals (O-2(-.).) are generated and are known to cause oxidative DNA damage. However, the mechanisms of action are poorly understood. It is shown here that the combination of O-2(-.) with guanine neutral radicals, G(-H)(.) in single- or double-stranded oligodeoxyribonucleotides (rate constant of 4.7 +/- 1.0 x 10(8) M-1 s(-1) in both cases), culminates in the formation of oxidatively modified guanine bases (major product, imidazolone; minor product, 8-oxo-7,8-dihydroguanine). The G(-H)(.) and O-2(-.) radicals were generated by intense 308 nm excimer laser pulses resulting in the one-electron oxidation and deprotonation of guanine in the 5'-d(CC[2AP]-TCGCTACC) strands and the trapping of the ejected electrons by molecular oxygen (Shafirovich, V., Dourandin, A., Huang, W., Luneva, N. P., and Geacintov, N. E. (2000) Phys. Chem. Chem. Phys. 2, 4399-4408). The addition of Cu,Zn-superoxide dismutase, known to react rapidly with superoxide, dramatically enhances the lifetimes of guanine radicals from 4 to 7 ms to 0.2-0.6 s in the presence of 5 muM superoxide dismutase. Oxygen-18 isotope labeling experiments reveal two pathways of 8-oxo-7,8-dihydroguanine formation including either addition of O-2(-.) to the C-8 position of G(-H)(.) (in the presence of oxygen), or the hydration of G(-H)(.) (in the absence of oxygen). The formation of the guanine lesions via combination of guanine and superoxide radicals is greatly reduced in the presence of typical antioxidants such as trolox and catechol that rapidly regenerate guanine by the reductive "repair" of G(-H)(.) radicals. The mechanistic aspects of the radical reactions that either regenerate undamaged guanine in DNA or lead to oxidatively modified guanine bases are discussed.	NYU, Dept Chem, New York, NY 10003 USA; NYU, Radiat & Solid State Lab, New York, NY 10003 USA	New York University; New York University	Shafirovich, V (corresponding author), NYU, Dept Chem, 31 Washington Pl, New York, NY 10003 USA.	vs5@nyu.edu	Crean, Conor/A-6609-2010		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011589] Funding Source: NIH RePORTER; NIEHS NIH HHS [5R01ES11589] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adam W, 2002, ORG LETT, V4, P537, DOI 10.1021/ol017138m; ALSHEIKHLY M, 1994, RADIAT PHYS CHEM, V44, P297, DOI 10.1016/0969-806X(94)90007-8; BERGER M, 1990, J LIQ CHROMATOGR, V13, P929, DOI 10.1080/01483919008049222; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BIELSKI BHJ, 1978, PHOTOCHEM PHOTOBIOL, V28, P645, DOI 10.1111/j.1751-1097.1978.tb06986.x; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; Cadet J, 2002, BIOL CHEM, V383, P933, DOI 10.1515/BC.2002.100; CADET J, 1994, J AM CHEM SOC, V116, P7403, DOI 10.1021/ja00095a052; Candeias LP, 2000, CHEM-EUR J, V6, P475, DOI 10.1002/(SICI)1521-3765(20000204)6:3<475::AID-CHEM475>3.0.CO;2-E; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Douki T, 1999, INT J RADIAT BIOL, V75, P571; Duarte V, 2000, J AM CHEM SOC, V122, P12622, DOI 10.1021/ja002218r; Flyunt R, 2003, J PHYS CHEM B, V107, P7242, DOI 10.1021/jp022455b; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Gasparutto D, 1998, J AM CHEM SOC, V120, P10283, DOI 10.1021/ja980674y; Grisham MB, 2000, ALIMENT PHARM THERAP, V14, P3, DOI 10.1046/j.1365-2036.2000.014s1003.x; Halliwell B, 1999, MUTAT RES-GEN TOX EN, V443, P37, DOI 10.1016/S1383-5742(99)00009-5; HILDENBRAND K, 1990, FREE RADICAL RES COM, V11, P195, DOI 10.3109/10715769009088916; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; ITO K, 1993, J BIOL CHEM, V268, P13221; Joffe A, 2003, CHEM RES TOXICOL, V16, P1528, DOI 10.1021/tx034142t; Joffe A, 2003, CHEM RES TOXICOL, V16, P966, DOI 10.1021/tx025578w; JONSSON M, 1993, J PHYS CHEM-US, V97, P8229, DOI 10.1021/j100133a018; JOVANOVIC SV, 1989, BIOCHIM BIOPHYS ACTA, V1008, P39, DOI 10.1016/0167-4781(89)90167-X; Kang P, 2002, J AM CHEM SOC, V124, P4865, DOI 10.1021/ja012038x; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; KLUG D, 1972, J BIOL CHEM, V247, P4839; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Luo WC, 2001, ORG LETT, V3, P2801, DOI 10.1021/ol0161763; Luo WC, 2001, CHEM RES TOXICOL, V14, P927, DOI 10.1021/tx010072j; Luo WC, 2000, ORG LETT, V2, P613, DOI 10.1021/ol9913643; Martinez GR, 2002, BIOL CHEM, V383, P607, DOI 10.1515/BC.2002.063; Mestre B, 1998, CR ACAD SCI II C, V1, P725, DOI 10.1016/S1387-1609(99)80030-9; Niles JC, 2001, ORG LETT, V3, P963, DOI 10.1021/ol006993n; RAOUL S, 1996, J CHEM SOC P2, V2, P371; Ravanat JL, 2000, ARCH BIOCHEM BIOPHYS, V374, P118, DOI 10.1006/abbi.1999.1610; Ravanat JL, 2003, J AM CHEM SOC, V125, P2030, DOI 10.1021/ja028608q; RAVANAT JL, 1992, PHOTOCHEM PHOTOBIOL, V55, P809, DOI 10.1111/j.1751-1097.1992.tb08528.x; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; Seguy C, 2001, CHEM COMMUN, P2116, DOI 10.1039/b106799k; Shafirovich V, 2001, J BIOL CHEM, V276, P24621, DOI 10.1074/jbc.M101131200; Shafirovich V, 2000, PHYS CHEM CHEM PHYS, V2, P4399, DOI 10.1039/b004896h; Shafirovich V, 1999, J PHYS CHEM B, V103, P10924, DOI 10.1021/jp992002f; Shafirovich V, 2002, CHEM RES TOXICOL, V15, P591, DOI 10.1021/tx015593l; Shafirovich V, 2001, J PHYS CHEM B, V105, P8431, DOI 10.1021/jp0044734; Shafirovich V, 2001, CHEM RES TOXICOL, V14, P233, DOI 10.1021/tx000204t; Simic M. G., 1986, MECH DNA DAMAGE REPA, V38, P39; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; Steenken S, 1997, BIOL CHEM, V378, P1293; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Steenken S, 2000, J AM CHEM SOC, V122, P2373, DOI 10.1021/ja993508e; STEENKEN S, 1982, J PHYS CHEM-US, V86, P3661, DOI 10.1021/j100215a033; Valentine JS, 1999, ADV EXP MED BIOL, V448, P193; VONSONNTAG C, 1994, INT J RADIAT BIOL, V66, P485, DOI 10.1080/09553009414551501; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843	58	172	172	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32106	32115		10.1074/jbc.M313904200	http://dx.doi.org/10.1074/jbc.M313904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15152004	hybrid			2022-12-27	WOS:000222849700016
J	Arimura, A; van Peer, M; Schroder, AJ; Rothman, PB				Arimura, A; van Peer, M; Schroder, AJ; Rothman, PB			The transcriptional co-activator p/CIP (NCoA-3) is up-regulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; CREB-BINDING PROTEIN; KAPPA-B; TRANSACTIVATION DOMAIN; LXXLL MOTIF; IL-4; CBP; IGE; INTERLEUKIN-4; COMPLEX	Transcriptional activation by signal transducer and activator of transcription 6 (STAT6) has been shown to require the direct interaction not only with co-activators such as p300 and cAMP-responsive element-binding protein-binding protein (CBP) but also with nuclear coactivator 1, a member of the p160/steroid receptor coactivator family. Among the p160/steroid receptor coactivators, only p/CIP ( nuclear co-activator 3) has been shown to be up-regulated by interleukin (IL)-4 in B cells through a STAT-6-dependent mechanism using Gene-hip analysis. In this study, we have investigated the function of p/CIP in the transcriptional activation by STAT6. We found that p/CIP indirectly interacted with STAT6 via p300, and overexpression of the CBP-interacting domain of p/CIP (p/CIP947-1084) prevented the interaction of p/CIP with STAT6 by blocking the binding of p/CIP to p300. Whereas expression of p/CIP947-1084 resulted in a marked reduction of STAT6-mediated transactivation, overexpression of wild type p/CIP resulted in significant enhancement of it. In addition, p/CIP947-1084 markedly reduced CD23 expression on B cells stimulated with IL-4, whereas overexpression of wild type p/CIP enhanced it. Chromatin immunoprecipitations demonstrate that IL-4 increases the interaction of p/CIP with the murine immunoglobulin heavy chain germ line epsilon promoter in B cells. These results suggest that p/CIP positively regulates STAT6 transcriptional activation through formation of a STAT6, p300/ CBP, and p/CIP complex.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Rothman, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 630 W 168 St,Box 91, New York, NY 10032 USA.	pbr3@columbia.edu		Schroder, Andreas/0000-0002-3568-1358				Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Curiel RE, 1997, EUR J IMMUNOL, V27, P1982, DOI 10.1002/eji.1830270823; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deVries JE, 1995, CURR OPIN IMMUNOL, V7, P771, DOI 10.1016/0952-7915(95)80046-8; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Hein K, 1998, J EXP MED, V188, P2369, DOI 10.1084/jem.188.12.2369; HUUSKONEN J, 2004, ARTERIOSCLER THROMB, P703; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Litterst CM, 2002, J BIOL CHEM, V277, P36052, DOI 10.1074/jbc.M203556200; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Messner B, 1997, J IMMUNOL, V159, P3330; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Newton AL, 2000, J BIOL CHEM, V275, P15128, DOI 10.1074/jbc.M910396199; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; Schroder AJ, 2002, J IMMUNOL, V168, P996, DOI 10.4049/jimmunol.168.3.996; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tinnell SB, 1998, INT IMMUNOL, V10, P1529, DOI 10.1093/intimm/10.10.1529; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yasuda J, 2004, CANCER SCI, V95, P52, DOI 10.1111/j.1349-7006.2004.tb03170.x; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000	52	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31105	31112		10.1074/jbc.M404428200	http://dx.doi.org/10.1074/jbc.M404428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145939	hybrid			2022-12-27	WOS:000222726800026
J	Beard, WA; Shock, DD; Wilson, SH				Beard, WA; Shock, DD; Wilson, SH			Influence of DNA structure on DNA polymerase beta active site function - Extension of mutagenic DNA intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; REVERSE-TRANSCRIPTASE; NUCLEOTIDE INCORPORATION; CATALYTIC EFFICIENCY; DYNAMICS SIMULATIONS; REPLICATION FIDELITY; MISMATCH EXTENSION; CRYSTAL-STRUCTURES; TERNARY COMPLEXES; BINDING	In the ternary substrate complex of DNA polymerase (pol) beta, the nascent base pair (templating and incoming nucleotides) is sandwiched between the duplex DNA terminus and polymerase. To probe molecular interactions in the dNTP-binding pocket, we analyzed the kinetic behavior of wild-type pol beta on modified DNA substrates that alter the structure of the DNA terminus and represent mutagenic intermediates. The DNA substrates were modified to 1) alter the sequence of the duplex terminus ( matched and mismatched), 2) introduce abasic sites near the nascent base pair, and 3) insert extra bases in the primer or template strands to mimic frameshift intermediates. The results indicate that the nucleotide insertion efficiency (k(cat)/K-m, dGTP-dC) is highly dependent on the sequence identity of the matched (i.e. Watson-Crick base pair) DNA terminus (template/primer, G/C similar to A/T > T/A similar to C/G). Mismatches at the primer terminus strongly diminish correct nucleotide insertion efficiency but do not affect DNA binding affinity. Transition intermediates are generally extended more easily than transversions. Most mismatched primer termini decrease the rate of insertion and binding affinity of the incoming nucleotide. In contrast, the loss of catalytic efficiency with homopurine mismatches at the duplex DNA terminus is entirely due to the inability to insert the incoming nucleotide, since K-d(dGTP) is not affected. Abasic sites and extra nucleotides in and around the duplex terminus decrease catalytic efficiency and are more detrimental to the nascent base pair binding pocket when situated in the primer strand than the equivalent position in the template strand.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050158, ZIAES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; Beard WA, 2003, STRUCTURE, V11, P489, DOI 10.1016/S0969-2126(03)00051-0; Beard WA, 2002, J BIOL CHEM, V277, P8235, DOI 10.1074/jbc.M107286200; Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; BEARD WA, 1995, HIV PRACTICAL APPROA, V2, P15; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gelfand CA, 1998, BIOCHEMISTRY-US, V37, P7321, DOI 10.1021/bi9803372; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Kraynov VS, 1997, BIOCHEM J, V323, P103, DOI 10.1042/bj3230103; Kraynov VS, 2000, BIOCHEMISTRY-US, V39, P16008, DOI 10.1021/bi0008480; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Kuzmic P, 2003, ANAL BIOCHEM, V319, P272, DOI 10.1016/S0003-2697(03)00248-3; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Osheroff WP, 2000, J BIOL CHEM, V275, P28033; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Shah AM, 2003, BIOCHEMISTRY-US, V42, P10709, DOI 10.1021/bi034885d; Skandalis A, 2001, NUCLEIC ACIDS RES, V29, P2418, DOI 10.1093/nar/29.11.2418; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Vaisman A, 2001, J BIOL CHEM, V276, P18999, DOI 10.1074/jbc.M007805200; Washington MT, 2001, J BIOL CHEM, V276, P2263, DOI 10.1074/jbc.M009049200; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Yang LJ, 2002, J MOL BIOL, V321, P459, DOI 10.1016/S0022-2836(02)00617-4; Yang LJ, 2004, BIOPHYS J, V86, P3392, DOI 10.1529/biophysj.103.036012	46	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31921	31929		10.1074/jbc.M404016200	http://dx.doi.org/10.1074/jbc.M404016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145936	hybrid			2022-12-27	WOS:000222726800119
J	Jokinen, J; Dadu, E; Nykvist, P; Kapyla, J; White, DJ; Ivaska, J; Vehvilainen, P; Reunanen, H; Larjava, H; Hakkinen, L; Heino, J				Jokinen, J; Dadu, E; Nykvist, P; Kapyla, J; White, DJ; Ivaska, J; Vehvilainen, P; Reunanen, H; Larjava, H; Hakkinen, L; Heino, J			Integrin-mediated cell adhesion to type I collagen fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL COLLAGEN; BINDING-SITE; ALPHA-1-BETA-1 INTEGRIN; CRYSTAL-STRUCTURE; GEL CONTRACTION; LIGAND-BINDING; A-DOMAIN; ALPHA-2-BETA-1; ALPHA(2)BETA(1); EXPRESSION	In the integrin family, the collagen receptors form a structurally and functionally distinct subgroup. Two members of this subgroup, alpha(1)beta(1) and alpha(2)beta(1) integrins, are known to bind to monomeric form of type I collagen. However, in tissues type I collagen monomers are organized into large fibrils immediately after they are released from cells. Here, we studied collagen fibril recognition by integrins. By an immunoelectron microscopy method we showed that integrin alpha(2)I domain is able to bind to classical D-banded type I collagen fibrils. However, according to the solid phase binding assay, the collagen fibril formation appeared to reduce integrin alpha(1)I and alpha(2)I domain avidity to collagen and to lower the number of putative alphaI domain binding sites on it. Respectively, cellular alpha(1)beta(1) integrin was able to mediate cell spreading significantly better on monomeric than on fibrillar type I collagen matrix, whereas alpha(2)beta(1) integrin appeared still to facilitate both cell spreading on fibrillar type I collagen matrix and also the contraction of fibrillar type I collagen gel. Additionally, alpha(2)beta(1) integrin promoted the integrin-mediated formation of long cellular projections typically induced by fibrillar collagen. Thus, these findings suggest that alpha(2)beta(1) integrin is a functional cellular receptor for type I collagen fibrils, whereas alpha(1)beta(1) integrin may only effectively bind type I collagen monomers. Furthermore, when the effect of soluble alphaI domains on type I collagen fibril formation was tested in vitro, the observations suggest that integrin type collagen receptors might guide or even promote pericellular collagen fibrillogenesis.	Univ Turku, Dept Biochem & Food Chem, FI-20014 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, FI-40014 Jyvaskyla, Finland; Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ Turku, Ctr Biotechnol, VTT Med Biotechnol, FI-20520 Turku, Finland	University of Turku; University of Jyvaskyla; University of British Columbia; University of Turku; VTT Technical Research Center Finland	Jokinen, J (corresponding author), Univ Turku, Dept Biochem & Food Chem, FI-20014 Turku, Finland.	jyrki.heino@utu.fi	Larjava, Hannu/GRO-4325-2022; white, daniel J/G-1159-2012; Hakkinen, Lari/B-2228-2016	white, daniel J/0000-0003-4233-0166; Dadu, Elina/0000-0001-5200-8256; Kapyla, Jarmo/0000-0003-3036-713X; Ruuhilehto, Elina/0000-0003-1450-1175; Ivaska, Johanna/0000-0002-6295-6556				BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Cooke ME, 2000, J CELL SCI, V113, P2375; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002-9440(10)61124-8; Emsley J, 2004, J MOL BIOL, V335, P1019, DOI 10.1016/j.jmb.2003.11.030; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Gardner H, 1999, J CELL SCI, V112, P263; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; Grundstrom G, 2003, EXP CELL RES, V291, P463, DOI 10.1016/j.yexcr.2003.07.010; Hulmes DJS, 2002, J STRUCT BIOL, V137, P2, DOI 10.1006/jsbi.2002.4450; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Kadler KE, 1996, BIOCHEM J, V316, P1; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Kuznetsova N, 1999, J BIOL CHEM, V274, P36083, DOI 10.1074/jbc.274.51.36083; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Pozzi M, 1998, J CELL BIOL, V142, P587; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Racine-Samson L, 1997, J BIOL CHEM, V272, P30911, DOI 10.1074/jbc.272.49.30911; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RIIKONEN T, 1995, J BIOL CHEM, V270, P376, DOI 10.1074/jbc.270.1.376; Sato K, 2003, CELL STRUCT FUNCT, V28, P229, DOI 10.1247/csf.28.229; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; White DJ, 2004, INT J BIOCHEM CELL B, V36, P1405, DOI 10.1016/j.biocel.2003.08.016; WOOD GC, 1960, BIOCHEM J, V75, P605, DOI 10.1042/bj0750605; WOOD GC, 1960, BIOCHEM J, V75, P598, DOI 10.1042/bj0750598; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	54	266	289	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31956	31963		10.1074/jbc.M401409200	http://dx.doi.org/10.1074/jbc.M401409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145957	hybrid			2022-12-27	WOS:000222726800124
J	Leonard, PM; Grogan, G				Leonard, PM; Grogan, G			Structure of 6-oxo camphor hydrolase H122A mutant bound to its natural product, (2S,4S)-alpha-campholinic acid - Mutant structure suggests an atypical mode of transition state binding for a crotonase homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRO-CLAISEN REACTION; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ENZYME; COENZYME; DESYMMETRIZATION; SUPERFAMILY; REFINEMENT; MOLSCRIPT; PROGRAM	The crotonase homolog, 6-oxo camphor hydrolase (OCH), catalyzes the desymmetrization of bicyclic beta-diketones to optically active keto acids via an enzymatic retro-Claisen reaction, resulting in the cleavage of a carbon-carbon bond. We have previously reported the structure of OCH (Whittingham, J. L., Turkenburg, J. P., Verma, C. S., Walsh, M. A., and Grogan, G. ( 2003) J. Biol. Chem. 278, 1744 - 1750), which suggested the involvement of five residues, His-45, His-122, His-145, Asp-154, and Glu-244, in catalysis. Here we report mutation studies on OCH that reveal that H145A and D154N mutants of OCH have greatly reduced values of k(cat)/K-m derived from a very large increase in K-m for the native substrate, 6-oxo camphor. In addition, H122A has a greatly reduced value of k(cat), and its K-m is five times that of the wildtype. The location of the active site is confirmed by the 1.9-Angstrom structure of the H122A mutant of OCH complexed with the minor diastereoisomer of (2S, 4S)-alpha-campholinic acid, the natural product of the enzyme. This shows the pendant acetate of the product hydrogen bonded to a His-145/Asp-154 dyad and the endocyclic carbonyl of the cyclopentane ring hydrogen bonded to Trp-40. The results are suggestive of a base-catalyzed mechanism of C-C bond cleavage and provide clues to the origin of prochiral selectivity by the enzyme and to the recruitment of the crotonase fold for alternate modes of transition state stabilization to those described for other crotonase superfamily members.	Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England	University of York - UK	Grogan, G (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	gg12@york.ac.uk		Leonard, Philip/0000-0002-2988-5557				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; CHAPMAN PJ, 1966, J AM CHEM SOC, V88, P618, DOI 10.1021/ja00955a049; Eberhard ED, 2002, BIOCHEMISTRY-US, V41, P8978; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Grogan G, 2002, J MOL CATAL B-ENZYM, V19, P73, DOI 10.1016/S1381-1177(02)00153-4; Grogan G, 2001, ANGEW CHEM INT EDIT, V40, P1111, DOI 10.1002/1521-3773(20010316)40:6<1111::AID-ANIE11110>3.0.CO;2-2; Grogan G, 2001, J BIOL CHEM, V276, P12565, DOI 10.1074/jbc.M011538200; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mursula AM, 2001, J MOL BIOL, V309, P845, DOI 10.1006/jmbi.2001.4671; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelletier DA, 1998, J BACTERIOL, V180, P2330, DOI 10.1128/JB.180.9.2330-2336.1998; Schoffers E, 1996, TETRAHEDRON, V52, P3769, DOI 10.1016/S0040-4020(95)01021-1; Schultz LW, 1998, BIOCHEMISTRY-US, V37, P8886, DOI 10.1021/bi972766q; Shimao M, 2000, MICROBIOL-UK, V146, P649, DOI 10.1099/00221287-146-3-649; Straganz G, 2002, BIOCHEM BIOPH RES CO, V297, P232, DOI 10.1016/S0006-291X(02)02182-4; Truglio JJ, 2003, J BIOL CHEM, V278, P42352, DOI 10.1074/jbc.M307399200; Whittingham JL, 2003, J BIOL CHEM, V278, P1744, DOI 10.1074/jbc.M211188200	30	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31312	31317		10.1074/jbc.M403514200	http://dx.doi.org/10.1074/jbc.M403514200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138275	hybrid			2022-12-27	WOS:000222726800051
J	Ooshio, T; Irie, K; Morimoto, K; Fukuhara, A; Imai, T; Takai, Y				Ooshio, T; Irie, K; Morimoto, K; Fukuhara, A; Imai, T; Takai, Y			Involvement of LMO7 in the association of two cell-cell adhesion molecules, nectin and E-cadherin, through afadin and alpha-actinin in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERENS JUNCTIONS; BINDING PROTEIN; TIGHT JUNCTIONS; INTERCELLULAR-JUNCTIONS; DIFFERENTIAL BEHAVIOR; CANDIDATE GENES; ROLES; POLARITY; DOMAIN; MUSCLE	Nectins are Ca2+-independent immunoglobulin-like cell-cell adhesion molecules that are involved in formation of cadherin-based adherens junctions (AJs). The nectin-based cell-cell adhesion induces activation of Cdc42 and Rac small G proteins, which eventually enhances the formation of AJs through reorganization of the actin cytoskeleton. Although evidence has accumulated that nectins recruit cadherins to the nectin-based cell-cell adhesion sites through their cytoplasm-associated proteins, afadin and catenins, it is not fully understood how nectins are physically associated with cadherins. Here we identified a rat counterpart of the human LIM domain only 7 (LMO7) as an afadin- and alpha-actinin-binding protein. Rat LMO7 has two splice variants, LMO7a and LMO7b, consisting of 1,729 and 1,395 amino acids, respectively. LMO7 has calponin homology, PDZ, and LIM domains. Western blotting revealed that LMO7 was expressed ubiquitously in various rat tissues. Immunofluorescence and immunoelectron microscopy revealed that LMO7 localized at cell-cell AJs, where afadin localized, in epithelial cells of rat gallbladder. In addition, LMO7 localized at the cytoplasmic faces of apical membranes in the same epithelial cells. We furthermore revealed that LMO7 bound alpha-actinin, an actin filament-bundling protein, which bound to alpha-catenin. Immunoprecipitation analysis revealed that LMO7 was associated with both the nectin-afadin and E-cadherin-catenin systems. LMO7 was assembled at the cell-cell adhesion sites after both the nectin-afadin and E-cadherin-catenin systems had been assembled. These results indicate that LMO7 is an afadin- and alpha-actinin-binding protein that connects the nectin-afadin and E-cadherin-catenin systems through alpha-actinin.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	; Fukuhara, Atsunori/A-9601-2018	Ooshio, Takako/0000-0001-6508-8152; Fukuhara, Atsunori/0000-0002-6289-3778				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; James P, 1996, GENETICS, V144, P1425; Kaiser C., 1994, METHODS YEAST GENETI; Kawabe H, 2001, J BIOL CHEM, V276, P48350, DOI 10.1074/jbc.M107335200; Kurihara LJ, 2002, GENOMICS, V79, P154, DOI 10.1006/geno.2002.6692; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Putilina T, 1998, BIOCHEM BIOPH RES CO, V252, P433, DOI 10.1006/bbrc.1998.9656; Rozenblum E, 2002, HUM GENET, V110, P111, DOI 10.1007/s00439-001-0646-6; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Semenova E, 2003, HUM MOL GENET, V12, P1301, DOI 10.1093/hmg/ddg140; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CURR OPIN NEUROBIOL, V13, P520, DOI 10.1016/j.conb.2003.09.003; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	43	111	115	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31365	31373		10.1074/jbc.M401957200	http://dx.doi.org/10.1074/jbc.M401957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140894	hybrid			2022-12-27	WOS:000222726800057
J	Morand, S; Agnandji, D; Noel-Hudson, MS; Nicolas, V; Buisson, S; Macon-Lemaitre, L; Gnidehou, S; Kaniewski, J; Ohayon, R; Virion, A; Dupuy, C				Morand, S; Agnandji, D; Noel-Hudson, MS; Nicolas, V; Buisson, S; Macon-Lemaitre, L; Gnidehou, S; Kaniewski, J; Ohayon, R; Virion, A; Dupuy, C			Targeting of the dual oxidase 2 N-terminal region to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; NADPH OXIDASE; H2O2 GENERATOR; INTRACELLULAR TRAFFICKING; CONGENITAL GOITER; PROTEINS; THYROGLOBULIN; EXPRESSION; HEME; THYROPEROXIDASE	Dual oxidase 2 (Duox2) is a cell surface glycoprotein that probably provides thyroperoxidase with the H2O2 required to catalyze thyroid hormone synthesis. No functional H2O2-generating system has yet been obtained after transfecting Duox2 into non-thyroid cell lines, because it is retained in the endoplasmic reticulum ( ER). We investigated the level of maturation of various Duox2 truncated proteins in an attempt to identify the region of Duox2 responsible for its remaining in the ER. Duox2-Q686X mutant, corresponding to the N-terminal ectodomain including the first putative transmembrane domain, was expressed in different cell lines. Carbohydrate content analysis revealed that complex type-specific Golgi apparatus (GA) oligosaccharides were present on pig Duox2-Q686X, whereas human truncated Duox2 carried only high mannose-type sugar chains characteristic of the ER. Further characterization using surface biotinylation and flow cytometry assays indicated that pig Duox2-Q686X was present at the plasma membrane, whereas human Duox2-Q686X remained inside the cell. The replacement of the last 90 residues of the human Duox2-Q686X with the pig equivalent region allowed the chimerical peptide to reach the Golgi apparatus. Pig mutants containing the complete first intracellular loop with or without the second transmembrane domain accumulated in the ER. These findings show that 1) the human Duox2-Q686X region encompassing residues 596-685 prevents mutant exportation from the ER and 2) there is a pig Duox2 retention domain in the first intracellular loop. In addition, missense mutations of four cysteines (Cys-351, -370, -568, or -582) completely inhibited the emergence of pig Duox2-Q686X from the ER compartment, indicating their importance in Duox2 maturation.	Univ Paris 11, Fac Pharm, INSERM, U468, F-92296 Chatenay Malabry, France; Univ Paris 11, Fac Pharm, Imagerie Cellulaire IFR75 ISIT, F-92296 Chatenay Malabry, France; Univ Paris 11, Fac Pharm, Equipe Accueil 3545, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Morand, S (corresponding author), Univ Paris 11, Fac Pharm, INSERM, U468, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	stanislas.morand@cep.u-psud.fr						Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; De Deken X, 2002, EXP CELL RES, V273, P187, DOI 10.1006/excr.2001.5444; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DEME D, 1994, BIOCHEM J, V301, P75, DOI 10.1042/bj3010075; Dupuy C, 2000, BIOCHEM BIOPH RES CO, V277, P287, DOI 10.1006/bbrc.2000.3671; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; DUPUY C, 1991, J BIOL CHEM, V266, P3739; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Gorin Y, 1997, BIOCHEM J, V321, P383, DOI 10.1042/bj3210383; Hishinuma A, 1999, J CLIN ENDOCR METAB, V84, P1438, DOI 10.1210/jc.84.4.1438; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KLUG J, 1991, NUCLEIC ACIDS RES, V19, P2793, DOI 10.1093/nar/19.10.2793; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; Morand S, 2003, ENDOCRINOLOGY, V144, P1241, DOI 10.1210/en.2002-220981; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; NAKAMURA Y, 1990, J ENDOCRINOL, V26, P283; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Taurog AM, 2000, WERNER INGBARS THYRO, P61; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288	29	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30244	30251		10.1074/jbc.M405406200	http://dx.doi.org/10.1074/jbc.M405406200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150274	hybrid			2022-12-27	WOS:000222531900048
J	Rave-Harel, N; Givens, ML; Nelson, SB; Duong, HA; Coss, D; Clark, ME; Hall, SB; Kamps, MP; Mellon, PL				Rave-Harel, N; Givens, ML; Nelson, SB; Duong, HA; Coss, D; Clark, ME; Hall, SB; Kamps, MP; Mellon, PL			TALE homeodomain proteins regulate gonadotropin-releasing hormone gene expression independently and via interactions with Oct-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC ENHANCER; GLUCOCORTICOID RESPONSE ELEMENT; BINDING TRANSCRIPTION FACTORS; GNRH GENE; PROTOONCOGENE PBX1; OLFACTORY PLACODE; PROMOTER ACTIVITY; MESSENGER-RNA; SUBUNIT GENE; IN-VIVO	Gonadotropin-releasing hormone ( GnRH) is the central regulator of reproductive function. Expression of the GnRH gene is confined to a rare population of neurons scattered throughout the hypothalamus. Restricted expression of the rat GnRH gene is driven by a multicomponent enhancer and an evolutionarily conserved promoter. Oct-1, a ubiquitous POU homeodomain transcription factor, was identified as an essential factor regulating GnRH transcription in the GT1-7 hypothalamic neuronal cell line. In this study, we conducted a two-hybrid interaction screen in yeast using a GT1-7 cDNA library to search for specific Oct-1 cofactors. Using this approach, we isolated Pbx1b, a TALE homeodomain transcription factor that specifically associates with Oct-1. We show that heterodimers containing Pbx/Prep1 or Pbx/Meis1 TALE homeodomain proteins bind to four functional elements within the GnRH regulatory region, each in close proximity to an Oct-1-binding site. Cotransfection experiments indicate that TALE proteins are essential for GnRH promoter activity in the GT1-7 cells. Moreover, Pbx1 and Oct-1, as well as Prep1 and Oct-1, form functional complexes that enhance GnRH gene expression. Finally, Pbx1 is expressed in GnRH neurons in embryonic as well as mature mice, suggesting that the associations between TALE homeodomain proteins and Oct-1 regulate neuron-specific expression of the GnRH gene in vivo.	Univ Calif San Diego, Dept Reprod Med, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Mellon, PL (corresponding author), Univ Calif San Diego, Dept Reprod Med, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pmellon@ucsd.edu		Coss, Djurdjica/0000-0003-0692-1612	NIA NIH HHS [T32 AG00216] Funding Source: Medline; NICHD NIH HHS [P50 HD012303, F32 HD041301, R01 HD072754, F32 HD041301-01, F32 HD41301, F32 HD041301-02] Funding Source: Medline; NIDA NIH HHS [DA07315] Funding Source: Medline; NIDDK NIH HHS [R01 DK44838, R01 DK044838, R01 DK044838-17A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P50HD012303, R01HD072754] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD041301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000216] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bailey JS, 2004, MOL ENDOCRINOL, V18, P1158, DOI 10.1210/me.2003-0442; Belsham DD, 2000, MOL ENDOCRINOL, V14, P212, DOI 10.1210/me.14.2.212; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Carrier JS, 2000, BIOCHEM BIOPH RES CO, V272, P616, DOI 10.1006/bbrc.2000.2795; Chandran UR, 1999, J BIOL CHEM, V274, P2372, DOI 10.1074/jbc.274.4.2372; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; Coss D, 2004, J BIOL CHEM, V279, P152, DOI 10.1074/jbc.M304697200; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; Di Rocco G, 2001, J BIOL CHEM, V276, P20506, DOI 10.1074/jbc.M011175200; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; ERALY SA, 1995, MOL ENDOCRINOL, V9, P848, DOI 10.1210/me.9.7.848; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Herzig S, 2000, J BIOL CHEM, V275, P27989; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kelley CG, 2000, MOL ENDOCRINOL, V14, P1246, DOI 10.1210/me.14.8.1246; Kelley CG, 2002, MOL ENDOCRINOL, V16, P2413, DOI 10.1210/me.2002-0189; Kim SK, 2002, NAT GENET, V30, P430, DOI 10.1038/ng860; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Lawson MA, 1996, MOL CELL BIOL, V16, P3596; Lawson MA, 1998, MOL ENDOCRINOL, V12, P364, DOI 10.1210/me.12.3.364; Lawson MA, 2002, ENDOCRINOLOGY, V143, P1404, DOI 10.1210/en.143.4.1404; LU QA, 1995, MOL CELL BIOL, V15, P3786; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mayer CM, 2003, BIOCHEM BIOPH RES CO, V307, P847, DOI 10.1016/S0006-291X(03)01289-0; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Palazzolo M, 2000, EUR J BIOCHEM, V267, P5427, DOI 10.1046/j.1432-1327.2000.01604.x; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schnabel CA, 2003, DEV BIOL, V254, P262, DOI 10.1016/S0012-1606(02)00038-6; Schnabel CA, 2001, MECH DEVELOP, V100, P131, DOI 10.1016/S0925-4773(00)00516-5; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; SCHWANZELFUKUDA M, 1992, ENDOCR REV, V13, P623, DOI 10.1210/er.13.4.623; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Selleri L, 2001, DEVELOPMENT, V128, P3543; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; Subramaniam N, 2003, BIOCHEM J, V370, P1087, DOI 10.1042/BJ20020471; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Turgeon D, 2000, J MOL BIOL, V295, P489, DOI 10.1006/jmbi.1999.3374; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467; Wierman ME, 1997, MOL CELL BIOL, V17, P1652, DOI 10.1128/MCB.17.3.1652; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Wolfe A, 2002, MOL ENDOCRINOL, V16, P435, DOI 10.1210/me.16.3.435; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132	61	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30287	30297		10.1074/jbc.M402960200	http://dx.doi.org/10.1074/jbc.M402960200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138251	Green Accepted, hybrid			2022-12-27	WOS:000222531900054
J	Chen, C; Koh, AJ; Datta, NS; Zhang, J; Keller, ET; Xiao, GZ; Franceschi, RT; D'Silva, NJ; McCauley, LK				Chen, C; Koh, AJ; Datta, NS; Zhang, J; Keller, ET; Xiao, GZ; Franceschi, RT; D'Silva, NJ; McCauley, LK			Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA LEVELS; CYCLIC-AMP; MAP KINASE; CELL-PROLIFERATION; INTERLEUKIN-6 PROMOTER; TRANSCRIPTION FACTORS; PTH/PTHRP RECEPTOR; REGULATED KINASE; MC3T3-E1 CELLS	Parathyroid hormone-related protein ( PTHrP) regulates proliferation and differentiation of osteoblastic cells via binding to the parathyroid hormone receptor (PTH-1R). The cAMP-dependent protein kinase A pathway governs the majority of these effects, but recent evidence also implicates the MAPK pathway. MC3T3-E1 subclone 4 cells (MC4) were treated with the MAPK inhibitor U0126 and PTHrP. In differentiated MC4 cells, osteocalcin and bone sialoprotein gene expression were both down-regulated by PTHrP and also by inhibition of the MAPK pathway. PTHrP-mediated down-regulation of PTH-1R mRNA and up-regulation of c-fos mRNA were MAPK-independent, whereas PTHrP stimulation of fra-2 and interleukin-6 (IL-6) mRNA was MAPK-dependent. Luciferase promoter assays revealed that regulation of IL-6 involved the cAMP-dependent protein kinase A and MAPK pathways with a potential minor role of the protein kinase C pathway, and a promoter region containing an activator protein-1 site was necessary for PTHrP-induced IL-6 gene transcription. An alternative pathway, through cAMP/Epac/Rap1/MAPK, mediated ERK phosphorylation but was not sufficient for IL-6 promoter activation. Phosphorylation of the transcription factor CREB was also necessary but not sufficient for PTHrP-mediated IL-6 promoter activity. Most interesting, a bidirectional effect was found with PTHrP increasing phosphorylated ERK in undifferentiated MC4 cells but decreasing phosphorylated ERK in differentiated cells. These data indicate that inactivation of the MAPK pathway shows differential regulation of PTHrP-stimulated activator protein-1 members, blocks PTHrP-stimulated IL-6, and synergistically down-regulates certain osteoblastic markers associated with differentiation. These novel findings indicate that the MAPK pathway plays a selective but important role in the actions of PTHrP.	Univ Michigan, Dept Periodont Prevent Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Oral Med Pathol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	McCauley, LK (corresponding author), Univ Michigan, Dept Periodont Prevent Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	mccauley@umich.edu	ZHANG, JIAN/Q-6334-2018; D'Silva, Nisha J/B-4734-2013; Keller, Evan T/M-1446-2016	Keller, Evan T/0000-0002-7592-7535	NATIONAL CANCER INSTITUTE [R01CA098513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053904] Funding Source: NIH RePORTER; NCI NIH HHS [CA098513] Funding Source: Medline; NIDDK NIH HHS [DK53904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Baccam M, 2003, J IMMUNOL, V170, P3099, DOI 10.4049/jimmunol.170.6.3099; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Carpio L, 2001, AM J PHYSIOL-ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; Chan GK, 2001, ENDOCRINOLOGY, V142, P4900, DOI 10.1210/en.142.11.4900; Chaudhary LR, 1998, MOL CELL BIOCHEM, V178, P59, DOI 10.1023/A:1006807221545; Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fujita T, 2002, J BIOL CHEM, V277, P22191, DOI 10.1074/jbc.M110364200; FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hershko DD, 2002, AM J PHYSIOL-REG I, V283, pR1140, DOI 10.1152/ajpregu.00161.2002; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kaiser E, 2003, BIOCHEM BIOPH RES CO, V305, P573, DOI 10.1016/S0006-291X(03)00820-9; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Keller ET, 1996, J BIOL CHEM, V271, P26267, DOI 10.1074/jbc.271.42.26267; Klinger M, 2002, J BIOL CHEM, V277, P32490, DOI 10.1074/jbc.M200556200; Koh AJ, 1999, ENDOCRINOLOGY, V140, P3154, DOI 10.1210/en.140.7.3154; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McCauley LK, 1997, ENDOCRINOLOGY, V138, P5427, DOI 10.1210/en.138.12.5427; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; MCCAULEY LK, 1994, MOL CELL ENDOCRINOL, V101, P331, DOI 10.1016/0303-7207(94)90250-X; McCauley LK, 1996, J CELL BIOCHEM, V61, P638, DOI 10.1002/(SICI)1097-4644(19960616)61:4<638::AID-JCB18>3.0.CO;2-B; MCCAULEY LK, 1995, J BONE MINER RES, V10, P1243, DOI 10.1002/jbmr.5650100815; Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200; Motomura T, 1998, J BONE MINER RES, V13, P1084, DOI 10.1359/jbmr.1998.13.7.1084; Nagy Z, 2001, J BONE MINER RES, V16, P1220, DOI 10.1359/jbmr.2001.16.7.1220; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Onyia JE, 1997, J CELL BIOCHEM, V67, P265, DOI 10.1002/(SICI)1097-4644(19971101)67:2<265::AID-JCB12>3.0.CO;2-E; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Radeff JM, 2001, EXP CELL RES, V268, P179, DOI 10.1006/excr.2001.5283; RENKAWITZ R, 1979, MOL GEN GENET, V173, P1, DOI 10.1007/BF00267685; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; VERHEIJEN MH, 1997, J BIOL CHEM, V271, P7508; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; YOUNG MF, 1994, MAMM GENOME, V5, P108, DOI 10.1007/BF00292337; Zhang J, 2001, ANTIOXID REDOX SIGN, V3, P493, DOI 10.1089/15230860152409121; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	62	60	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29121	29129		10.1074/jbc.M313000200	http://dx.doi.org/10.1074/jbc.M313000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128746	hybrid			2022-12-27	WOS:000222445300037
J	Dutkiewicz, R; Schilke, B; Cheng, S; Knieszner, H; Craig, EA; Marszalek, J				Dutkiewicz, R; Schilke, B; Cheng, S; Knieszner, H; Craig, EA; Marszalek, J			Sequence-specific interaction between mitochondrial Fe-S scaffold protein Isu and Hsp70 Ssq1 is essential for their in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; HSC66-HSC20 CHAPERONE SYSTEM; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; DNAK CHAPERONE; ISCU; BIOGENESIS; IDENTIFICATION; BIOSYNTHESIS	Isu, the scaffold for assembly of Fe-S clusters in the yeast mitochondrial matrix, is a substrate protein for the Hsp70 Ssq1 and the J-protein Jac1 in vitro. As expected for an Hsp70-substrate interaction, the formation of a stable complex between Isu and Ssq1 requires Jac1 in the presence of ATP. Here we report that a conserved tripeptide, PVK, of Isu is critical for interaction with Ssq1 because amino acid substitutions in this tripeptide inhibit both the formation of the Isu-Ssq1 complex and the ability of Isu to stimulate the ATPase activity of Ssq1. These biochemical defects correlate well with the growth defects of cells expressing mutant Isu proteins. We conclude that the Ssq1-Isu substrate interaction is critical for Fe-S cluster biogenesis in vivo. The ability of Jac1 and mutant Isu proteins to cooperatively stimulate the ATPase activity of Ssq1 was also measured. Increasing the concentration of Jac1 and mutant Isu together but not individually partially overcame the effect of the reduced affinity of the Isu mutant proteins for Ssq1. These results, along with the observation that overexpression of Jac1 was able to suppress the growth defect of an ISU mutant, support the hypothesis that Isu is "targeted" to Ssq1 by Jac1, with a preformed Jac1-Isu complex interacting with Ssq1.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Gdansk, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	University of Wisconsin System; University of Wisconsin Madison; Fahrenheit Universities; University of Gdansk	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, 441E Biochem Addit,433 Babcock Dr, Madison, WI 53706 USA.	ecraig@wisc.edu	Marszalek, Jaroslaw/F-5824-2011; Dutkiewicz, Rafal/F-5956-2011; Dutkiewicz, Rafal/ABE-6979-2020	Dutkiewicz, Rafal/0000-0003-4150-0450; Marszalek, Jaroslaw/0000-0002-6978-1189	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM27870] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Nuth M, 2002, J AM CHEM SOC, V124, P8774, DOI 10.1021/ja0264596; PFUND C, 2001, MOL CHAPERONES CELL, P119; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	38	77	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29167	29174		10.1074/jbc.M402947200	http://dx.doi.org/10.1074/jbc.M402947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123690	hybrid			2022-12-27	WOS:000222445300043
J	Fu, MF; Rao, M; Wu, KM; Wang, CG; Zhang, XP; Hessien, M; Yeung, YG; Gioeli, D; Weber, MJ; Pestell, RG				Fu, MF; Rao, M; Wu, KM; Wang, CG; Zhang, XP; Hessien, M; Yeung, YG; Gioeli, D; Weber, MJ; Pestell, RG			The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE-A; PROSTATE-CANCER CELLS; HISTONE H3; TERMINAL DOMAIN; BINDING DOMAIN; IN-VITRO; DEPENDENT TRANSCRIPTION; PHOSPHORYLATION SITES; INDUCED APOPTOSIS	The androgen receptor (AR) regulates ligand-dependent gene transcription upon binding specific DNA sequences. The AR conveys both trans-activation and trans-repression functions, which together contribute to prostate cellular growth, differentiation, and apoptosis. Like histone H3, the AR is post-translationally modified by both acetylation and phosphorylation. The histone acetyltransferase p300 transactivates the AR and directly acetylates the AR in vitro at a conserved motif. Point mutations of the AR acetylation motif that abrogate acetylation reduce trans-activation by p300 without affecting the trans-repression function of the AR. The current studies assessed the functional relationship between acetylation and phosphorylation of the AR. Herein trans-activation of the AR acetylation site mutants were enhanced by the p42/p44 MAPK pathway but were defective in regulation by protein kinase A (PKA) signaling. PKA inhibition augmented ARwt activity but not AR acetylation mutant gene reporter activity and association at an androgen response element in chromatin immunoprecipitation assays. Mutations of the lysine residues at the AR acetylation site reduced trichostatin A (TSA) responsiveness and ligand-induced phosphorylation of the AR. The AR acetylation site mutant formed ligand-induced phosphorylation-dependent isoforms with distinguishable characteristics from wild type AR as determined with two-dimensional electrophoresis. Conversely, point mutation of a subset of AR phosphorylation sites reduced trichostatin A responsiveness and trans-activation by histone acetyltransferases. Together these studies suggest that acetylation and phosphorylation of the AR are linked events and that the conserved AR lysine motif contributes to a select subset of pathways governing AR activity.	Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA	Georgetown University; Yeshiva University; Albert Einstein College of Medicine; University of Virginia; University of Virginia	Pestell, RG (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Res Bldg,Rm E501,3970 Reservoir Rd NW,Box 571468, Washington, DC 20057 USA.	pestell@georgetown.edu		Hessien, Mohamed/0000-0002-3782-1633	NCI NIH HHS [R01CA93596-01, R01CA75503, R01CA70896, P30CA51008-14, P01CA 76465, P01CA 40042, CA26504, R01CA86072] Funding Source: Medline; NIDDK NIH HHS [R21 DK0652201-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R01CA026504, P30CA051008, R01CA086072, R37CA026504, R01CA070896, R01CA075503, P01CA076465, R01CA093596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Alen P, 1999, MOL CELL BIOL, V19, P6085; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Ben Abdelkhalek M, 1999, BIOCHEM BIOPH RES CO, V266, P15, DOI 10.1006/bbrc.1999.1764; Bergel M, 2000, J BIOL CHEM, V275, P11514, DOI 10.1074/jbc.275.15.11514; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Chiarugi V, 1998, ONCOL RES, V10, P55; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marhefka CA, 2001, J MED CHEM, V44, P1729, DOI 10.1021/jm0005353; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; NAKAO M, 1992, ARCH BIOCHEM BIOPHYS, V298, P340, DOI 10.1016/0003-9861(92)90420-2; Nakashio A, 2000, CANCER RES, V60, P5303; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; O'Farrell P H, 1977, Methods Cell Biol, V16, P407; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Poukka H, 2000, J CELL SCI, V113, P2991; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rana S, 1999, J MOL BIOL, V286, P669, DOI 10.1006/jmbi.1998.2505; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schreihofer DA, 2001, ENDOCRINOLOGY, V142, P3361, DOI 10.1210/en.142.8.3361; STAMATIADIS D, 1992, J STEROID BIOCHEM, V41, P43, DOI 10.1016/0960-0760(92)90223-6; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wang LG, 1998, BIOCHEM PHARMACOL, V55, P1427, DOI 10.1016/S0006-2952(97)00657-6; Wang LG, 1999, BIOCHEM BIOPH RES CO, V259, P21, DOI 10.1006/bbrc.1999.0655; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; Yang L, 2003, BIOCHEM BIOPH RES CO, V305, P462, DOI 10.1016/S0006-291X(03)00792-7; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhong SP, 2003, ONCOGENE, V22, P5291, DOI 10.1038/sj.onc.1206507	68	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29436	29449		10.1074/jbc.M313466200	http://dx.doi.org/10.1074/jbc.M313466200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123687	hybrid			2022-12-27	WOS:000222445300076
J	Gange, CT; Quinn, JMW; Zhou, H; Kartsogiannis, V; Gillespie, MT; Ng, KW				Gange, CT; Quinn, JMW; Zhou, H; Kartsogiannis, V; Gillespie, MT; Ng, KW			Characterization of sugar binding by osteoclast inhibitory lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; CARBOHYDRATE-RECOGNITION DOMAIN; KILLER-CELL RECEPTOR; CHONDROITIN SULFATES; CRYSTAL-STRUCTURE; LIGAND-BINDING; PROTEIN; TISSUES; FAMILY; RAT	Osteoclast inhibitory lectin (OCIL) is a membrane-bound C-type lectin that blocks osteoclast differentiation and, via binding to its cognate receptor NKRP1D, inhibits natural killer cell-mediated cytotoxicity. OCIL is a member of the natural killer cell receptor C-type lectin group that includes CD69 and NKRP1D. We investigated carbohydrate binding of soluble recombinant human and mouse OCIL in enzyme-linked immunosorbent assay-based assays. OCIL bound immobilized high molecular weight sulfated glycosaminoglycans, including fucoidan, lambda-carrageenan, and dextran sulfate, but not unsulfated dextran or sialated hyaluronic acid. Carbohydrate binding was Ca2+-independent. Binding of immobilized low molecular weight glycosaminoglycans, including chondroitin sulfate ( A, B, and C forms) and heparin, was not observed. However, the soluble forms of these low molecular weight glycosaminoglycans competed for OCIL binding of immobilized fucoidan ( as did soluble fucoidan, dextran sulfate, and lambda-carrageenan), indicating that OCIL does recognize these carbohydrates. Inhibition constants for chondroitin sulfate A and heparin binding were 380 and 5 nM, respectively. Immobilized and soluble monosaccharides did not bind OCIL. The presence of saturating levels of fucoidan, dextran sulfate, and lambda-carrageenan did not affect OCIL inhibition of osteoclast formation. The fucoidan-binding lectins Ulex europaeus agglutinin I and Anguilla anguilla agglutinin did not block osteoclast formation or affect the inhibitory action of OCIL. Although the osteoclast inhibitory action of OCIL is independent of sugar recognition, we have found that OCIL, a lectin widely distributed, but notably localized in bone, skin, and other connective tissues, binds a range of physiologically important glycosaminoglycans, and this property may modulate OCIL actions upon other cells.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; St Vincents Hosp, Dept Endocrinol & Diabet, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne	Quinn, JMW (corresponding author), St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	j.quinn@medicine.unimelb.edu.au		Gillespie, Matthew/0000-0001-6543-8909; Zhou, Hong/0000-0001-5899-9660				Bali JP, 2001, SEMIN ARTHRITIS RHEU, V31, P58, DOI 10.1053/sarh.2000.24874; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BRENNAN J, 1995, J BIOL CHEM, V270, P9691, DOI 10.1074/jbc.270.17.9691; Childs RA, 1999, BIOCHEM BIOPH RES CO, V266, P19, DOI 10.1006/bbrc.1999.1762; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; FULLER K, 1991, J CELL PHYSIOL, V147, P208, DOI 10.1002/jcp.1041470204; HAGIWARA H, 1995, HISTOCHEM CELL BIOL, V103, P213, DOI 10.1007/BF01454026; Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915; Hu YS, 2004, J BONE MINER RES, V19, P89, DOI 10.1359/JBMR.0301215; Iizuka K, 2003, NAT IMMUNOL, V4, P801, DOI 10.1038/ni954; Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756-3282(99)00214-8; Katsu Y, 2003, ENDOCRINOLOGY, V144, P2597, DOI 10.1210/en.2002-220980; Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; Natarajan K, 1999, IMMUNITY, V11, P591, DOI 10.1016/S1074-7613(00)80134-X; Plougastel B, 2001, IMMUNOGENETICS, V53, P209, DOI 10.1007/s002510100319; PRINCE CW, 1984, BIOCHEM J, V224, P941, DOI 10.1042/bj2240941; SANCHEZMATEOS P, 1989, IMMUNOLOGY, V68, P72; Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; Zhou H, 2001, J BIOL CHEM, V276, P14916, DOI 10.1074/jbc.M011554200; Zhou H, 2002, J BIOL CHEM, V277, P48808, DOI 10.1074/jbc.M209059200	27	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29043	29049		10.1074/jbc.M312518200	http://dx.doi.org/10.1074/jbc.M312518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123656	hybrid			2022-12-27	WOS:000222445300027
J	Akache, B; MacPherson, S; Sylvain, MA; Turcotte, B				Akache, B; MacPherson, S; Sylvain, MA; Turcotte, B			Complex interplay among regulators of drug resistance genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ZINC CLUSTER PROTEINS; MULTIDRUG-RESISTANCE; DNA-BINDING; PLEIOTROPIC DRUG; TRANSCRIPTIONAL ACTIVATION; INDUCED EXPRESSION; CRYSTAL-STRUCTURE; ENCODING GENE; ABC PROTEINS	The Gal4p family of yeast zinc cluster proteins comprises regulators of multidrug resistance genes. For example, Pdr1p and Pdr3p bind as homo- or heterodimers to pleiotropic drug response elements (PDREs) found in promoters of target genes. Other zinc cluster activators of multidrug resistance genes include Stb5p and Yrr1p. To better understand the interplay among these activators, we have performed native co-immunoprecipitation experiments using strains expressing tagged zinc cluster proteins from their natural chromosomal locations. Interestingly, Stb5p is found predominantly as a Pdr1p heterodimer and shows little homodimerization. No interactions of Stb5p with Pdr3p or Yrr1p could be detected in our assays. In contrast to Stb5p, Yrr1p is only detected as a homodimer. Similar results were obtained using glutathione S-transferase pull-down assays. Importantly, the purified DNA binding domains of Stb5p and Pdr1p bound to a PDRE as heterodimers in vitro. These results suggest that the DNA binding domains of Pdr1p and Stb5p are sufficient for heterodimerization. Our data demonstrate a complex interplay among these activators and suggest that Pdr1p is a master drug regulator involved in recruiting other zinc cluster proteins to fine tune the regulation of multidrug resistance genes.	McGill Univ, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Microbiol & Immunol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada.	bernard.turcotte@mcgill.ca		Akache, Bassel/0000-0002-5377-7193				ADAMS A, 1997, METHODS YEAST GENETI, P145; Akache B, 2002, J BIOL CHEM, V277, P21254, DOI 10.1074/jbc.M202566200; Akache B, 2001, NUCLEIC ACIDS RES, V29, P2181, DOI 10.1093/nar/29.10.2181; Alarco AM, 1997, J BIOL CHEM, V272, P19304, DOI 10.1074/jbc.272.31.19304; Amar N, 2000, MOL CELL BIOL, V20, P2087, DOI 10.1128/MCB.20.6.2087-2097.2000; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Brachmann CB, 1998, YEAST, V14, P115; BRICMONT PA, 1991, MOL CELL BIOL, V11, P1161, DOI 10.1128/MCB.11.2.1161; Broco N, 1999, YEAST, V15, P1595; COORNAERT D, 1991, GENE, V97, P163, DOI 10.1016/0378-1119(91)90048-G; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Hellauer K, 2002, J BIOL CHEM, V277, P17671, DOI 10.1074/jbc.M201637200; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; King DA, 1999, NAT STRUCT BIOL, V6, P64; Kolaczkowska A, 1999, DRUG RESIST UPDATE, V2, P403, DOI 10.1054/drup.1999.0113; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Lucau-Danila A, 2003, J BIOL CHEM, V278, P52641, DOI 10.1074/jbc.M309580200; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mamnun YM, 2004, FEBS LETT, V559, P111, DOI 10.1016/S0014-5793(04)00046-8; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; Nourani A, 1997, MOL CELL BIOL, V17, P5453, DOI 10.1128/MCB.17.9.5453; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; TALIBI D, 1995, NUCLEIC ACIDS RES, V23, P550, DOI 10.1093/nar/23.4.550; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; Walters KJ, 1997, NAT STRUCT BIOL, V4, P744, DOI 10.1038/nsb0997-744; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; WU AL, 1993, J BIOL CHEM, V268, P18850; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	53	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27855	27860		10.1074/jbc.M403487200	http://dx.doi.org/10.1074/jbc.M403487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123673	hybrid			2022-12-27	WOS:000222265400006
J	Oestergaard, VH; Giangiacomo, L; Bjergbaek, L; Knudsen, BR; Andersen, AH				Oestergaard, VH; Giangiacomo, L; Bjergbaek, L; Knudsen, BR; Andersen, AH			Hindering the strand passage reaction of human topoisomerase II alpha without disturbing DNA cleavage, ATP hydrolysis, or the operation of the N-terminal clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GYRASE-B-PROTEIN; DROSOPHILA-MELANOGASTER; BINDING-SITE; DOMAIN; MECHANISM; SUBUNIT; FRAGMENT	DNA topoisomerase II is an essential enzyme that releases a topological strain in DNA by introduction of transient breaks in one DNA helix through which another helix is passed. While changing DNA topology, ATP is required to drive the enzyme through a series of conformational changes dependent on interdomain communication. We have characterized a human topoisomerase IIalpha enzyme with a two-amino acid insertion at position 351 in the transducer domain. The mutation specifically abolishes the DNA strand passage event of the enzyme, probably because of a sterical hindrance of T-segment transport. Thus, the enzyme fails to decatenate and relax DNA, even though it is fully capable of ATP hydrolysis, closure of the N-terminal clamp, and DNA cleavage. The cleavage activity is increased, suggesting that the transducer domain has a role in regulating DNA cleavage. Furthermore, the enzyme has retained a tendency to increase DNA cleavage upon nucleotide binding and also responds to DNA with elevated ATP hydrolysis. However, the DNA-mediated increase in ATP hydrolysis is lower than that obtained with the wild-type enzyme but similar to that of a cleavage-deficient topoisomerase IIalpha enzyme. Our results strongly suggest that the strand passage event is required for efficient DNA stimulation of topoisomerase II-mediated ATP hydrolysis, whereas the stimulation occurs independent of the DNA cleavage reaction per se. A comparison of the strand passage deficient-enzyme described here and the cleavage-deficient enzyme may have applications in other studies where a clear distinction between strand passage and topoisomerase II-mediated DNA cleavage is desirable.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Aarhus Univ, Dept Mol Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	aha@mb.au.dk	Andersen, Anni/O-1162-2017; Oestergaard, Vibe Hallundbæk/B-7254-2015; Bjergbæk, Lotte/AAW-6302-2021	Oestergaard, Vibe Hallundbæk/0000-0002-1633-0560; Bjergbaek, Lotte/0000-0002-8233-3356; Knudsen, Birgitta Ruth/0000-0002-3484-3802; Andersen, Anni/0000-0001-7194-3258				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Corbett KD, 2003, EMBO J, V22, P151, DOI 10.1093/emboj/cdg008; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21335; DeLano W, 2002, PYMOL 0 99; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen S, 1996, MOL CELL BIOL, V16, P3866; Lamour V, 2002, J BIOL CHEM, V277, P18947, DOI 10.1074/jbc.M111740200; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Oestergaard VH, 2004, J BIOL CHEM, V279, P28100, DOI 10.1074/jbc.M402119200; Oestergaard VH, 2004, J BIOL CHEM, V279, P1684, DOI 10.1074/jbc.M309624200; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; Skouboe C, 2003, J BIOL CHEM, V278, P5768, DOI 10.1074/jbc.M210332200; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Williams NL, 1999, BIOCHEMISTRY-US, V38, P14157, DOI 10.1021/bi991478m; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	29	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28093	28099		10.1074/jbc.M402120200	http://dx.doi.org/10.1074/jbc.M402120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123700	hybrid			2022-12-27	WOS:000222265400034
J	Du, XO; Zhang, HL; Lopes, C; Mirshahi, T; Rohacs, T; Logothetis, DE				Du, XO; Zhang, HL; Lopes, C; Mirshahi, T; Rohacs, T; Logothetis, DE			Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of Kir channels by diverse modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECTIFIER K+ CHANNELS; RECTIFYING POTASSIUM CHANNEL; XENOPUS-OOCYTES; ATP CHANNELS; PHOSPHOLIPASE-C; ACETYLCHOLINE-RECEPTOR; DIRECT ACTIVATION; INTRACELLULAR PH; ROMK1 CHANNEL	The activity of specific inwardly rectifying potassium (Kir) channels is regulated by any of a number of different modulators, such as protein kinase C, G(q)-coupled receptor stimulation, pH, intracellular Mg2+ or the betagamma-subunits of G proteins. Phosphatidylinositol 4,5-bisphosphate (PIP2) is an essential factor for maintenance of the activity of all Kir channels. Here, we demonstrate that the strength of channel-PIP2 interactions determines the sensitivity of Kir channels to regulation by the various modulators. Furthermore, our results suggest that differences among Kir channels in their specific regulation by a given modulator may reflect differences in their apparent affinity of interactions with PIP2.	Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China; NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Hebei Medical University; Icahn School of Medicine at Mount Sinai; New York University	Logothetis, DE (corresponding author), Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China.	diomedes.logothetis@mssm.edu			NHLBI NIH HHS [HL59949] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BENNDORF K, 1990, PFLUGERS ARCH, V416, P207; Brown AM, 1997, TRENDS CARDIOVAS MED, V7, P118, DOI 10.1016/S1050-1738(97)00002-9; Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Chanchevalap S, 2000, J BIOL CHEM, V275, P7811, DOI 10.1074/jbc.275.11.7811; Chuang HH, 1997, CELL, V89, P1121, DOI 10.1016/S0092-8674(00)80299-8; Collins A, 2002, J BIOL CHEM, V277, P35815, DOI 10.1074/jbc.M206032200; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Haruna T, 2002, CIRC RES, V91, P232, DOI 10.1161/01.RES.0000029971.60214.49; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Hibino H, 1997, J NEUROSCI, V17, P4711; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Ishii M, 1997, J NEUROSCI, V17, P7725; Karle CA, 2002, CIRCULATION, V106, P1493, DOI 10.1161/01.CIR.0000029747.53262.5C; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; MADUH EU, 1990, TOXICOL APPL PHARM, V106, P201, DOI 10.1016/0041-008X(90)90240-U; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; OKITANI N, 2002, AM J PHYSIOL, V282, pH757; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; Qu ZQ, 2000, J BIOL CHEM, V275, P31573, DOI 10.1074/jbc.M003473200; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Ruppersberg JP, 2000, PFLUG ARCH EUR J PHY, V441, P1, DOI 10.1007/s004240000380; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schulze D, 2003, J BIOL CHEM, V278, P10500, DOI 10.1074/jbc.M208413200; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Stevens EB, 1999, MOL PHARMACOL, V55, P1020, DOI 10.1124/mol.55.6.1020; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Thorneloe KS, 2002, J PHYSIOL-LONDON, V541, P65, DOI 10.1113/jphysiol.2002.018101; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33; Zeng WZ, 2003, J BIOL CHEM, V278, P16852, DOI 10.1074/jbc.M300619200; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang LY, 2004, J BIOL CHEM, V279, P7037, DOI 10.1074/jbc.M307323200; Zhu GY, 1999, J BIOL CHEM, V274, P11643, DOI 10.1074/jbc.274.17.11643	52	147	157	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37271	37281		10.1074/jbc.M403413200	http://dx.doi.org/10.1074/jbc.M403413200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15155739	hybrid			2022-12-27	WOS:000223554600011
J	Balasubramanyam, K; Altaf, M; Varier, RA; Swaminathan, V; Ravindran, A; Sadhale, PP; Kundu, TK				Balasubramanyam, K; Altaf, M; Varier, RA; Swaminathan, V; Ravindran, A; Sadhale, PP; Kundu, TK			Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; ACTIVATION; P300; PCAF; DEACETYLASES; CBP/P300; MUSCLE; CANCER; ROLES; CELLS	Histone acetylation is a diagnostic feature of transcriptionally active genes. The proper recruitment and function of histone acetyltransferases (HATs) and deacetylases (HDACs) are key regulatory steps for gene expression and cell cycle. Functional defects of either of these enzymes may lead to several diseases, including cancer. HATs and HDACs thus are potential therapeutic targets. Here we report that garcinol, a polyisoprenylated benzophenone derivative from Garcinia indica fruit rind, is a potent inhibitor of histone acetyltransferases p300 (IC50 approximate to 7 muM) and PCAF (IC50 approximate to5 muM) both in vitro and in vivo. The kinetic analysis shows that it is a mixed type of inhibitor with an increased affinity for PCAF compared with p300. HAT activity-dependent chromatin transcription was strongly inhibited by garcinol, whereas transcription from DNA template was not affected. Furthermore, it was found to be a potent inducer of apoptosis, and it alters ( predominantly downregulates) the global gene expression in HeLa cells.	Jawaharlal Nehru Ctr Adv Sci Res, Transcript & Dis Lab, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India; Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Kundu, TK (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Transcript & Dis Lab, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India.	tapas@jncasr.ac.in	Sadhale, PArag/A-7799-2009	Kundu, Tapas/0000-0001-7790-214X; Varier, Radhika/0000-0003-1302-3159; Venkatesh, Swaminathan/0000-0001-9837-1501; Ravindran, Aarti/0000-0001-7558-4627				An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Cebrat M, 2003, BIOORGAN MED CHEM, V11, P3307, DOI 10.1016/S0968-0896(03)00265-7; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CULLIS PM, 1982, J BIOL CHEM, V257, P2165; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Ito C, 2003, J NAT PROD, V66, P206, DOI 10.1021/np020372g; Kaehlcke K, 2003, MOL CELL, V12, P167, DOI 10.1016/S1097-2765(03)00245-4; Kagoshima M, 2003, BIOCHEM SOC T, V31, P60, DOI 10.1042/bst0310060; Kalkhoven E, 2003, HUM MOL GENET, V12, P441, DOI 10.1093/hmg/ddg039; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Matsumoto K, 2003, BIOL PHARM BULL, V26, P569, DOI 10.1248/bpb.26.569; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pan MH, 2001, J AGR FOOD CHEM, V49, P1464, DOI 10.1021/jf001129v; Pillai B, 2001, CURR SCI INDIA, V81, P574; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; PRES V, 2002, EMBO J, V21, P6811; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Quivy V, 2002, J VIROL, V76, P11091, DOI 10.1128/JVI.76.21.11091-11103.2002; Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; RYAN CA, 2001, CURRENT PROTOCOLS MO; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Shaiu WL, 1998, MOL CELL BIOL, V18, P4358, DOI 10.1128/MCB.18.7.4358; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SPACER TE, 1997, NATURE, V389, P194; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; Wolffe A, 1998, CHROMATIN - STRUCTURE AND FUNCTION, 3RD EDITION, P1, DOI 10.1016/B978-012761914-9/50003-9; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Yamaguchi F, 2000, J AGR FOOD CHEM, V48, P2320, DOI 10.1021/jf990908c; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	46	415	437	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33716	33726		10.1074/jbc.M402839200	http://dx.doi.org/10.1074/jbc.M402839200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155757	hybrid			2022-12-27	WOS:000223039700081
J	Kamei, D; Yamakawa, K; Takegoshi, Y; Mikami-Nakanishi, M; Nakatani, Y; Oh-ishi, S; Yasui, H; Azuma, Y; Hirasawa, N; Ohuchi, K; Kawaguchi, H; Ishikawa, Y; Ishii, T; Uematsu, S; Akira, S; Murakami, M; Kudo, I				Kamei, D; Yamakawa, K; Takegoshi, Y; Mikami-Nakanishi, M; Nakatani, Y; Oh-ishi, S; Yasui, H; Azuma, Y; Hirasawa, N; Ohuchi, K; Kawaguchi, H; Ishikawa, Y; Ishii, T; Uematsu, S; Akira, S; Murakami, M; Kudo, I			Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED ARTHRITIS; E-2 SYNTHASE; OSTEOCLAST DIFFERENTIATION; HISTIDINE DECARBOXYLASE; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; PROSTANOID RECEPTORS; GRANULATION-TISSUE; DUCTUS-ARTERIOSUS; FACTOR EXPRESSION	We examined the in vivo role of membrane-bound prostaglandin E synthase (mPGES)-1, a terminal enzyme in the PGE(2)-biosynthetic pathway, using mPGES-1 knockout (KO) mice. Comparison of PGES activity in the membrane fraction of tissues from mPGES-1 KO and wild-type (WT) mice indicated that mPGES-1 accounted for the majority of lipopolysaccharide (LPS)-inducible PGES in WT mice. LPS-stimulated production of PGE(2), but not other PGs, was impaired markedly in mPGES-1-null macrophages, although a low level of cyclooxygenase-2-dependent PGE(2) production still remained. Pain nociception, as assessed by the acetic acid writhing response, was reduced significantly in KO mice relative to WT mice. This phenotype was particularly evident when these mice were primed with LPS, where the stretching behavior and the peritoneal PGE(2) level of KO mice were far less than those of WT mice. Formation of inflammatory granulation tissue and attendant angiogenesis in the dorsum induced by subcutaneous implantation of a cotton thread were reduced significantly in KO mice compared with WT mice. Moreover, collagen antibody-induced arthritis, a model for human rheumatoid arthritis, was milder in KO mice than in WT mice. Collectively, our present results provide unequivocal evidence that mPGES-1 contributes to the formation of PGE(2) involved in pain hypersensitivity and inflammation.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Univ Tokyo, Fac Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138655, Japan; Teijin Pharma Ltd, Inst Biomed Biochem, Pharmaceut Discovery Res Labs, Hino, Tokyo 1918512, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pathophysiol Biochem, Aoba Ku, Sendai, Miyagi 9808578, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan	Showa University; University of Tokyo; Teijin Pharma Limited; Tohoku University; Osaka University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	kudo@pharm.showa-u.ac.jp	Akira, Shizuo/C-3134-2009	Hirasawa, Noriyasu/0000-0002-8062-4838				Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Azuma Y, 1998, J PHARMACOL EXP THER, V286, P128; Ballou LR, 2000, P NATL ACAD SCI USA, V97, P10272, DOI 10.1073/pnas.180319297; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Bensen W, 2002, RHEUMATOLOGY, V41, P1008, DOI 10.1093/rheumatology/41.9.1008; Besse A, 1999, BBA-MOL CELL RES, V1450, P444, DOI 10.1016/S0167-4889(99)00048-8; Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; Bonner JC, 2002, AM J PATHOL, V161, P459, DOI 10.1016/S0002-9440(10)64202-2; Chikazu D, 2001, J BONE MINER RES, V16, P2074, DOI 10.1359/jbmr.2001.16.11.2074; Claveau D, 2003, J IMMUNOL, V170, P4738, DOI 10.4049/jimmunol.170.9.4738; Desplat V, 2000, EXP HEMATOL, V28, P741, DOI 10.1016/S0301-472X(00)00180-6; Engblom D, 2003, NAT NEUROSCI, V6, P1137, DOI 10.1038/nn1137; Filion F, 2001, J BIOL CHEM, V276, P34323, DOI 10.1074/jbc.M103709200; Ghosh AK, 2002, J EXP MED, V195, P973, DOI 10.1084/jem.20011782; Ghosh AK, 2000, J PHARMACOL EXP THER, V295, P802; Guan YF, 2001, AM J PHYSIOL-RENAL, V281, pF1173, DOI 10.1152/ajprenal.0116.2001; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Hegen M, 2003, J EXP MED, V197, P1297, DOI 10.1084/jem.20030016; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Lader CS, 1998, ENDOCRINOLOGY, V139, P3157, DOI 10.1210/en.139.7.3157; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; Lorenz M, 1999, EXP HEMATOL, V27, P1494, DOI 10.1016/S0301-472X(99)00087-9; Manabe N, 1999, RHEUMATOLOGY, V38, P714, DOI 10.1093/rheumatology/38.8.714; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Matsumoto AK, 2002, J RHEUMATOL, V29, P1623; Matsumoto H, 1998, EUR J PHARMACOL, V352, P47, DOI 10.1016/S0014-2999(98)00340-9; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; MEHINDATE K, 1995, J IMMUNOL, V155, P3570; Morteau O, 2000, J CLIN INVEST, V105, P469, DOI 10.1172/JCI6899; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Myers LK, 2000, ARTHRITIS RHEUM-US, V43, P2687, DOI 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9; Nakashima K, 2003, BBA-MOL CELL BIOL L, V1633, P96, DOI 10.1016/S1388-1981(03)00092-1; Naraba H, 1998, J IMMUNOL, V160, P2974; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Norwood VF, 2000, KIDNEY INT, V58, P2291, DOI 10.1046/j.1523-1755.2000.00413.x; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Rocca B, 1999, J CLIN INVEST, V103, P1469, DOI 10.1172/JCI6400; Saegusa M, 2003, J CELL PHYSIOL, V197, P348, DOI 10.1002/jcp.10356; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; Schuligoi R, 2003, NEUROSCIENCE, V116, P1043, DOI 10.1016/S0306-4522(02)00783-2; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Siegle I, 1998, ARTHRITIS RHEUM-US, V41, P122, DOI 10.1002/1529-0131(199801)41:1<122::AID-ART15>3.3.CO;2-#; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Soruri A, 2003, J IMMUNOL, V171, P2631, DOI 10.4049/jimmunol.171.5.2631; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Stock JL, 2001, J CLIN INVEST, V107, P325, DOI 10.1172/JCI6749; Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; Takeda H, 2003, CANCER RES, V63, P4872; Tanaka S, 1998, J BIOL CHEM, V273, P8177, DOI 10.1074/jbc.273.14.8177; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2003, BIOCHEM BIOPH RES CO, V303, P1018, DOI 10.1016/S0006-291X(03)00470-4; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; TERATO K, 1992, J IMMUNOL, V148, P2103; Terato K, 1995, AUTOIMMUNITY, V22, P137, DOI 10.3109/08916939508995311; Thoren S, 2003, J BIOL CHEM, V278, P22199, DOI 10.1074/jbc.M303227200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Udagawa N, 2002, ARTHRITIS RES, V4, P281, DOI 10.1186/ar431; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ueno A, 2001, BIOCHEM PHARMACOL, V62, P157, DOI 10.1016/S0006-2952(01)00654-2; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; WOOLEY PH, 1981, J EXP MED, V154, P688, DOI 10.1084/jem.154.3.688; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001	75	256	266	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33684	33695		10.1074/jbc.M400199200	http://dx.doi.org/10.1074/jbc.M400199200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15140897	hybrid			2022-12-27	WOS:000223039700078
J	Egawa, T; Hishiki, T; Ichikawa, Y; Kanamori, Y; Shimada, H; Takahashi, S; Kitagawa, T; Ishimura, Y				Egawa, T; Hishiki, T; Ichikawa, Y; Kanamori, Y; Shimada, H; Takahashi, S; Kitagawa, T; Ishimura, Y			Refolding processes of cytochrome P450(cam) from ferric and ferrous acid forms to the native conformation - Formations of folding intermediates with non-native heme coordination state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; LIVER-MICROSOMES; LOW-PH; HORSERADISH-PEROXIDASE; CIRCULAR-DICHROISM; HIGH-PRESSURE; NITRIC-OXIDE	Changes in heme coordination state and protein conformation of cytochrome P450(cam) (P450(cam)), a b-type heme protein, were investigated by employing pH jump experiments coupled with time-resolved optical absorption, fluorescence, circular dichroism, and resonance Raman techniques. We found a partially unfolded form ( acid form) of ferric P450(cam) at pH 2.5, in which a Cys(-)-heme coordination bond in the native conformation was ruptured. When the pH was raised to pH 7.5, the acid form refolded to the native conformation through a distinctive intermediate. Formations of similar acid and intermediate forms were also observed for ferrous P450(cam). Both the ferric and ferrous forms of the intermediate were found to have an unidentified axial ligand of the heme at the 6th coordination sphere, which is vacant in the high spin ferric and ferrous forms at the native conformation. For the ferrous form, it was also indicated that the 5th axial ligand is different from the native cysteinate. The folding intermediates identified in this study demonstrate occurrences of non-native coordination state of heme during the refolding processes of the large b-type heme protein, being akin to the well known folding intermediates of cytochromes c, in which c-type heme is covalently attached to a smaller protein.	Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan; Osaka Univ, Inst Prot Res, Div Phys Chem, Suita, Osaka 5650871, Japan; Okazaki Natl Res Inst, Inst Mol Sci, Okazaki, Aichi 4448585, Japan	Keio University; Osaka University; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB)	Egawa, T (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	tegawa@aecom.yu.edu						ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; Antonini E., 1971, FRONT BIOL, P13; ASAKURA T, 1974, J BIOL CHEM, V249, P4495; CHAMPION PM, 1978, J AM CHEM SOC, V100, P3743, DOI 10.1021/ja00480a015; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; Chen EF, 1999, J AM CHEM SOC, V121, P3811, DOI 10.1021/ja983169+; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHING T, 1973, J BIOL CHEM, V248, P2889; CREIGHTON TE, 1994, NAT STRUCT BIOL, V1, P135, DOI 10.1038/nsb0394-135; Davydov DR, 1999, BIOCHEMISTRY-US, V38, P751, DOI 10.1021/bi981397a; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; Dyer RB, 1998, ACCOUNTS CHEM RES, V31, P709, DOI 10.1021/ar970343a; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; FREIRE E, 1995, ANNU REV BIOPH BIOM, V24, P141, DOI 10.1146/annurev.bb.24.060195.001041; GRIFFIN BW, 1972, BIOCHEMISTRY-US, V11, P4740, DOI 10.1021/bi00775a017; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HASHIMOTOYUTSUDO C, 1980, J BIOCHEM-TOKYO, V88, P505, DOI 10.1093/oxfordjournals.jbchem.a132997; Hishiki T, 2000, J BIOCHEM, V128, P965, DOI 10.1093/oxfordjournals.jbchem.a022848; HOA GHB, 1989, BIOCHEMISTRY-US, V28, P651; HOA GHB, 1990, BIOCHEMISTRY-US, V29, P6810, DOI 10.1021/bi00481a008; ICHIKAWA Y, 1967, BIOCHIM BIOPHYS ACTA, V131, P490, DOI 10.1016/0005-2728(67)90008-4; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; IMAI Y, 1974, J BIOCHEM-TOKYO, V75, P689, DOI 10.1093/oxfordjournals.jbchem.a130441; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KITAGAWA T, 1976, J AM CHEM SOC, V98, P5169, DOI 10.1021/ja00433a019; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; Lamb DC, 1998, J AM CHEM SOC, V120, P2981, DOI 10.1021/ja973781l; MONTELIONE GT, 1989, ACCOUNTS CHEM RES, V22, P70, DOI 10.1021/ar00158a004; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; OZAKI Y, 1978, BIOCHEMISTRY-US, V17, P5826, DOI 10.1021/bi00619a033; Parker MJ, 1998, BIOCHEMISTRY-US, V37, P2538, DOI 10.1021/bi972459k; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; Plaxco KW, 1996, CURR OPIN STRUC BIOL, V6, P630, DOI 10.1016/S0959-440X(96)80029-7; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; Prasad S, 2002, BIOCHEMISTRY-US, V41, P14499, DOI 10.1021/bi026379e; PRUSAKOV VE, 1985, FEBS LETT, V186, P158, DOI 10.1016/0014-5793(85)80700-6; REMBA RD, 1979, BIOCHEMISTRY-US, V18, P2280, DOI 10.1021/bi00578a023; RODER H, 1989, METHOD ENZYMOL, V176, P446; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; Rothwarf DM, 1998, BIOCHEMISTRY-US, V37, P3760, DOI 10.1021/bi972822n; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; Simmons DA, 2002, BIOCHEMISTRY-US, V41, P1906, DOI 10.1021/bi011697j; SMITH ML, 1991, P NATL ACAD SCI USA, V88, P882, DOI 10.1073/pnas.88.3.882; Smulevich G, 1997, BIOCHEMISTRY-US, V36, P640, DOI 10.1021/bi960427b; SONO M, 1985, J BIOL CHEM, V260, P5530; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; SPIRO TG, 1974, J AM CHEM SOC, V96, P338, DOI 10.1021/ja00809a004; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; Telford JR, 1998, ACCOUNTS CHEM RES, V31, P755, DOI 10.1021/ar970078t; TERAOKA J, 1980, J PHYS CHEM-US, V84, P1928, DOI 10.1021/j100452a013; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Wittung-Stafshede P, 1999, P NATL ACAD SCI USA, V96, P6587, DOI 10.1073/pnas.96.12.6587; Wittung-Stafshede P, 2002, ACCOUNTS CHEM RES, V35, P201, DOI 10.1021/ar010106e; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; YONETANI T, 1987, J BIOL CHEM, V262, P9547; Yoshioka S, 2001, EUR J BIOCHEM, V268, P252, DOI 10.1046/j.1432-1033.2001.01872.x; YU CA, 1974, J BIOL CHEM, V249, P102; YU CA, 1974, J BIOL CHEM, V249, P107	67	7	7	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32008	32017		10.1074/jbc.M310810200	http://dx.doi.org/10.1074/jbc.M310810200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15128748	hybrid			2022-12-27	WOS:000222849700004
J	Sanz-Rodriguez, F; Guerrero-Esteo, M; Botella, LM; Banville, D; Vary, CPH; Bernabeu, C				Sanz-Rodriguez, F; Guerrero-Esteo, M; Botella, LM; Banville, D; Vary, CPH; Bernabeu, C			Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; ZYXIN-RELATED PROTEIN; HUMAN ENDOTHELIAL-CELLS; NUCLEAR EXPORT SIGNAL; SMOOTH-MUSCLE-CELLS; MOLECULAR CHARACTERIZATION; STIMULATED PHOSPHOPROTEIN; LISTERIA-MONOCYTOGENES; CELLULAR-RESPONSES	Endoglin is a component of the transforming growth factor-beta receptor complex abundantly expressed at the surface of endothelial cells and plays an important role in cardiovascular development and vascular remodeling. By using the cytoplasmic domain of endoglin as a bait for screening protein interactors, we have identified ZRP-1 (zyxin-related protein 1), a 476-amino acid member that belongs to a family of LIM containing proteins that includes zyxin and lipoma-preferred partner. The endoglin interacting region was mapped within the three double zinc finger LIM domains of the ZRP-1 C terminus. Analysis of the subcellular distribution of ZRP-1 demonstrated that in the absence of endoglin, ZRP-1 mainly localizes to focal adhesion sites, whereas in the presence of endoglin ZRP-1 is found along actin stress fibers. Because the LIM family of proteins has been shown to associate with the actin cytoskeleton, we investigated the possibility of a regulatory role for endoglin with regard to this structure. Expression of endoglin resulted in a dramatic reorganization of the actin cytoskeleton. In the absence of endoglin, F-actin was localized to dense aggregates of bundles, whereas in the presence of endoglin, expressed in endothelial cells, F-actin was in stress fibers and colocalized with ZRP-1. Furthermore, small interfering RNA-mediated suppression of endoglin or ZRP-1, or clustering of endoglin in endothelial cells, led to mislocalization of F-actin fibers. These results suggest a regulatory role for endoglin, via its interaction with ZRP-1, in the actin cytoskeletal organization.	CSIC, Ctr Invest Biol, Madrid 28040, Spain; Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); National Research Council Canada; Maine Medical Center	Sanz-Rodriguez, F (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maetzu 9, Madrid 28040, Spain.	francisco.sanz@uam.es	Bernabeu, Carmelo/L-3226-2014; Botella, Luisa M/L-1392-2014; Bernabeu, Carmelo/P-4662-2019; Sanz-Rodriguez, Francisco/AAK-8388-2020	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15555] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Cuppen E, 2000, EUR J CELL BIOL, V79, P283, DOI 10.1078/S0171-9335(04)70031-X; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Golsteyn RM, 1997, J CELL SCI, V110, P1893; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Holt MR, 1998, INT J BIOCHEM CELL B, V30, P307, DOI 10.1016/S1357-2725(97)00101-5; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; MA K, 2000, ARTERIOSCLER THROMB, V20, P2546; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; Munster AK, 2002, J BIOL CHEM, V277, P19688, DOI 10.1074/jbc.M201093200; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; van der Gaag EJ, 2002, J INVEST DERMATOL, V118, P246, DOI 10.1046/j.0022-202x.2001.01657.x; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; Wang Y, 1999, GENE, V234, P403, DOI 10.1016/S0378-1119(99)00168-7; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; Wang Y, 2003, BBA-MOL CELL RES, V1593, P115, DOI 10.1016/S0167-4889(02)00349-X; Williams G, 1998, INDEX CENSORSHIP, V27, P186, DOI 10.1080/03064229808536405; Xu J, 2003, J BIOL CHEM, V278, P38104; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; Zhao MK, 1999, GENE EXPRESSION, V8, P207; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	60	111	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32858	32868		10.1074/jbc.M400843200	http://dx.doi.org/10.1074/jbc.M400843200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15148318	Green Published, hybrid			2022-12-27	WOS:000222849700106
J	Almaguer, C; Cheng, W; Nolder, C; Patton-Vogt, J				Almaguer, C; Cheng, W; Nolder, C; Patton-Vogt, J			Glycerophosphoinositol, a novel phosphate source whose transport is regulated by multiple factors in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; FUNCTIONAL-CHARACTERIZATION; YEAST; GENE; INOSITOL; PERMEASE; PHOSPHATIDYLINOSITOL; ACCUMULATION; DEGRADATION; STARVATION	Git1p mediates the transport of the phospholipid metabolite, glycerophosphoinositol, into Saccharomyces cerevisiae. We report that phosphate limitation and inositol limitation affect GIT1 expression and Git1p transport activity via distinct mechanisms that involve multiple transcription factors. GIT1 transcript levels and Git1p activity are greater in cells starved for phosphate, with or without inositol limitation, than in cells only limited for inositol. Furthermore, the kinetics of GIT1 transcript accumulation and Git1p activity upon transfer of cells to phosphate starvation media are different from those obtained upon transfer of cells to inositol-free media. Pho2p and Pho4p are required for GIT1 expression and for Git1p transport activity under all growth conditions tested. In contrast, Ino2p and Ino4p are required for full GIT1 expression when inositol is limiting, with or without phosphate limitation, but not when only phosphate is limiting. Greatly reduced transport activity was detected in ino2Delta and ino4Delta cells under all growth conditions. A 300-base pair region of the GIT1 promoter containing potential Pho4p binding sites was shown to be required for full GIT1 expression. Git1p appears to act as a H+-symporter, and neither inositol nor phosphate effectively compete with glycerophosphoinositol for transport by Git1p. Glycerophosphoinositol was shown previously to support the growth of an inositol auxotroph. Remarkably, we now report that glycerophosphoinositol can act as the sole source of phosphate for the cell, providing functional relevance for the regulation of Git1p transport activity by phosphate.	Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA	Duquesne University	Patton-Vogt, J (corresponding author), Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA.	pattonvogt@duq.edu			NIGMS NIH HHS [GM59817] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059817] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almaguer C, 2003, EUKARYOT CELL, V2, P729, DOI 10.1128/EC.2.4.729-736.2003; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Carroll AS, 2001, P NATL ACAD SCI USA, V98, P12578, DOI 10.1073/pnas.211195798; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graves JA, 2000, GENETICS, V154, P1485; Hama H, 2000, METHODS, V20, P465, DOI 10.1006/meth.2000.0959; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Naumov GI, 1998, CAN J MICROBIOL, V44, P1045, DOI 10.1139/cjm-44-11-1045; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; PATTON JL, 1995, J BACTERIOL, V177, P3379, DOI 10.1128/jb.177.12.3379-3385.1995; Patton-Vogt JL, 1998, GENETICS, V149, P1707; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Persson BL, 2003, CURR GENET, V43, P225, DOI 10.1007/s00294-003-0400-9; Pinson B, 1996, EUR J BIOCHEM, V239, P439, DOI 10.1111/j.1432-1033.1996.0439u.x; Robinson KA, 2000, NUCLEIC ACIDS RES, V28, P1499, DOI 10.1093/nar/28.7.1499; Robinson KA, 2000, NUCLEIC ACIDS RES, V28, P4460, DOI 10.1093/nar/28.22.4460; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wykoff DD, 2001, GENETICS, V159, P1491	28	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31937	31942		10.1074/jbc.M403648200	http://dx.doi.org/10.1074/jbc.M403648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145930	hybrid			2022-12-27	WOS:000222726800121
J	Bzymek, KP; Holz, RC				Bzymek, KP; Holz, RC			The catalytic role of glutamate 151 in the leucine aminopeptidase from Aeromonas proteolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED-ACIDIC DIPEPTIDASE; CRYSTAL-STRUCTURE; ZINC; INHIBITION; BINDING; BRAIN; NAALADASE; MECHANISM; ANALOG; INVOLVEMENT	Glutamate 151 has been proposed to act as the general acid/base during the peptide hydrolysis reaction catalyzed by the co-catalytic metallohydrolase from Aeromonas proteolytica (AAP). However, to date, no direct evidence has been reported for the role of Glu-151 during catalytic turnover by AAP. In order to elucidate the catalytic role of Glu-151, altered AAP enzymes have been prepared in which Glu-151 has been substituted with a glutamine, an alanine, and an aspartate. The Michaelis constant ( Km) does not change upon substitution to aspartate or glutamine, but the rate of the reaction changes drastically in the following order: glutamate (100% activity), aspartate (0.05%), glutamine (0.004%), and alanine (0%). Examination of the pH dependence of the kinetic constants k(cat) and K-m revealed a change in the pK(a) of a group that ionizes at pH 4.8 in recombinant leucine aminopeptidase (rAAP) to 4.2 for E151D-AAP. The remaining pK(a) values at 5.2, 7.5, and 9.9 do not change. Proton inventory studies indicate that one proton is transferred in the rate-limiting step of the reaction at pH 10.50 for both rAAP and E151D-AAP, but at pH 6.50 two protons and general solvation effects are responsible for the observed effects in the reaction catalyzed by rAAP and E151D-AAP, respectively. Based on these data, Glu-151 is intrinsically involved in the peptide hydrolysis reaction catalyzed by AAP and can be assigned the role of a general acid and base.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Holz, RC (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.	rholz@cc.usu.edu						Albery W. J., 1975, PROTON TRANSFER REAC, P263; BAKER JO, 1983, BIOCHEMISTRY-US, V22, P5322, DOI 10.1021/bi00292a011; BAKER JO, 1985, BIOCHEM BIOPH RES CO, V130, P1154, DOI 10.1016/0006-291X(85)91736-X; Barinka C, 2002, J NEUROCHEM, V80, P477, DOI 10.1046/j.0022-3042.2001.00715.x; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Bennett B, 1997, BIOCHEMISTRY-US, V36, P9837, DOI 10.1021/bi970735p; Bennett B, 1997, J AM CHEM SOC, V119, P1923, DOI 10.1021/ja963021v; Bienvenue DL, 2002, BIOCHEMISTRY-US, V41, P3712, DOI 10.1021/bi011752o; Bienvenue DL, 2002, J BIOL INORG CHEM, V7, P129, DOI 10.1007/s007750100280; BOYEN A, 1992, GENE, V116, P1, DOI 10.1016/0378-1119(92)90621-U; Chen GJ, 1997, BIOCHEMISTRY-US, V36, P4278, DOI 10.1021/bi9618676; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; D'souza VM, 2000, BIOCHEMISTRY-US, V39, P3817, DOI 10.1021/bi9925827; De Paola CC, 1999, BIOCHEMISTRY-US, V38, P9048, DOI 10.1021/bi9900572; Desmarais WT, 2002, STRUCTURE, V10, P1063, DOI 10.1016/S0969-2126(02)00810-9; DIXON M, 1979, ENZYMES, P140; ELROD JP, 1980, J AM CHEM SOC, V102, P3917, DOI 10.1021/ja00531a039; Elstner M, 2003, J COMPUT CHEM, V24, P565, DOI 10.1002/jcc.10201; Holz RC, 2002, COORDIN CHEM REV, V232, P5, DOI 10.1016/S0010-8545(01)00470-2; Holz RC, 2003, CURR OPIN CHEM BIOL, V7, P197, DOI 10.1016/S1367-5931(03)00033-4; Holz RC, 1998, J AM CHEM SOC, V120, P6329, DOI 10.1021/ja971589d; Huntington KM, 1999, BIOCHEMISTRY-US, V38, P15587, DOI 10.1021/bi991283e; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; MAKINEN KK, 1982, EUR J BIOCHEM, V128, P257; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; Prescott J M, 1976, Methods Enzymol, V45, P530; PRESCOTT JM, 1983, BIOCHEM BIOPH RES CO, V114, P646, DOI 10.1016/0006-291X(83)90829-X; PRESCOTT JM, 1985, BIOCHEMISTRY-US, V24, P5350, DOI 10.1021/bi00341a012; PRESCOTT JM, 1971, J BIOL CHEM, V246, P1756; Pulido-Cejudo G, 1997, ANTIVIR RES, V36, P167, DOI 10.1016/S0166-3542(97)00052-1; Remaut H, 2001, NAT STRUCT BIOL, V8, P674, DOI 10.1038/90380; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; SEGEL IH, 1975, ENZYME KINETICS BEHA, P847; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Slusher BS, 2001, SYNAPSE, V41, P22, DOI 10.1002/syn.1056; Stamper C, 2001, BIOCHEMISTRY-US, V40, P7035, DOI 10.1021/bi0100891; Thomas AG, 1999, BRAIN RES, V843, P48, DOI 10.1016/S0006-8993(99)01879-X; Tiffany CW, 1999, PROSTATE, V39, P28; Ustynyuk L, 1999, BIOCHEMISTRY-US, V38, P11433, DOI 10.1021/bi991090r; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1993, P NATL ACAD SCI USA, V90, P2715, DOI 10.1073/pnas.90.7.2715; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; Velasco AM, 2002, J MOL EVOL, V55, P445, DOI 10.1007/s00239-002-2340-2; VENKATASUBBAN KS, 1984, CRC CR REV BIOCH MOL, V17, P1, DOI 10.3109/10409238409110268; WINZOR DJ, 1995, QUANTITATIVE CHARACT; Witkin JM, 2002, NEUROPHARMACOLOGY, V43, P348, DOI 10.1016/S0028-3908(02)00124-7; Zhang ZZ, 2000, BIOCHEM J, V350, P671, DOI 10.1042/0264-6021:3500671	50	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31018	31025		10.1074/jbc.M404035200	http://dx.doi.org/10.1074/jbc.M404035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138277	hybrid, Green Published			2022-12-27	WOS:000222726800015
J	Inesi, G; Ma, HL; Lewis, D; Xu, C				Inesi, G; Ma, HL; Lewis, D; Xu, C			Ca2+ occlusion and gating function of Glu(309) in the ADP-fluoroaluminate analog of the Ca2+-ATPase phosphoenzyme intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; ATPASE; BINDING; PHOSPHORYLATION; DISSOCIATION; ACTIVATION; MECHANISM; SITES	In the absence of ATP the sarcoplasmic reticulum ATPase (SERCA) binds two Ca2+ with high affinity. The two bound Ca2+ rapidly undergo reverse dissociation upon addition of EGTA, but can be distinguished by isotopic exchange indicating fast exchange at a superficial site ( site II), and retardation of exchange at a deeper site ( site I) by occupancy of site II. Site II mutations that allow high affinity binding to site I, but only low affinity binding to site II, show that retardation of isotopic exchange requires higher Ca2+ concentrations with the N796A mutant, and is not observed with the E309Q mutant even at millimolar Ca2+. Fluoroaluminate forms a complex at the catalytic site yielding stable analogs of the phosphoenzyme intermediate, with properties similar to E2-P or E1-P.Ca2. Mutational analysis indicates that Asp(351), Lys(352), Thr(353), Asp(703), Asn(706), Asp(707), Thr(625), and Lys(684) participate in stabilization of fluoroaluminate and Mg2+ at the phosphorylation site. In the presence of fluoroaluminate and Ca2+, ADP ( or AMP-PCP) favors formation of a stable ADP . E1- P . Ca-2 analog. This produces strong occlusion of Ca2+ bound to both sites ( I and II), whereby dissociation occurs very slowly even following addition of EGTA. Occlusion by fluoraluminate and ADP is not observed with the E309Q mutant, suggesting a gating function of Glu(309) at the mouth of a binding cavity with a single path of entry. This phenomenon corresponds to the earliest step of the catalytic cycle following utilization of ATP. Experiments on limited proteolysis reveal that a long range conformational change, involving displacement of headpiece domains and transmembrane helices, plays a mechanistic role.	Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA.	ginesi@umaryland.edu			NHLBI NIH HHS [R01 HL69830] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069830] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen JP, 1998, ACTA PHYSIOL SCAND, V163, P45; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Chen BW, 2004, BIOCHEMISTRY-US, V43, P4366, DOI 10.1021/bi0356350; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; Einholm AP, 2004, J BIOL CHEM, V279, P15888, DOI 10.1074/jbc.M400158200; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; Gadsby DC, 2004, NATURE, V427, P795, DOI 10.1038/427795a; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; INESI G, 1987, J BIOL CHEM, V262, P16338; Inesi G, 2002, BIOPHYS J, V83, P2327, DOI 10.1016/S0006-3495(02)75247-8; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TOYOSHIMA C, 2004, IN PRESS NATURE; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m	34	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31629	31637		10.1074/jbc.M403211200	http://dx.doi.org/10.1074/jbc.M403211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150270	hybrid			2022-12-27	WOS:000222726800087
J	Ling, KKY; Siow, NL; Choi, RCY; Ting, AKL; Kong, LW; Tsim, KWK				Ling, KKY; Siow, NL; Choi, RCY; Ting, AKL; Kong, LW; Tsim, KWK			ATP potentiates agrin-induced AChR aggregation in cultured myotubes - Activation of RhoA in P2Y1 nucleotide receptor signaling at vertebrate neuromuscular junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTORS; EXPRESSION; MUSCLE; P2Y(1); MUSK; CALCIUM; KINASE; RAPSYN; ROLES; NERVE	At vertebrate neuromuscular junctions, ATP is known to stabilize acetylcholine in the synaptic vesicles and to be co-released with it. We have shown previously that a nucleotide receptor, P2Y(1) receptor, is localized at the nmjs, and we propose that this mediates a trophic role for synaptic ATP there. In cultured myotubes, the activation of P2Y(1) receptors modulated agrin-induced acetylcholine receptor ( AChR) aggregation in a potentiation manner. This potentiation effect in agrin-induced AChR aggregation was reduced by antagonizing the P2Y(1) receptors. The guanosine triphosphatase RhoA was shown to be responsible for this P2Y(1)-potentiated effect. The localization of RhoA in rat and chicken skeletal muscles was restricted at the neuromuscular junctions. Application of P2Y(1) agonists in cultured myotubes induced RhoA activation, which showed an additive effect with agrin-induced RhoA activation. Over-expression of dominant-negative mutant of RhoA in cultured myotubes diminished the agrin-induced AChR aggregation, as well as the potentiation effect of P2Y(1)-specific agonist. Application of UTP in the cultures also triggered similar responses as did 2-methylthioadenosine 5'diphosphate, suggesting the involvement of other subtypes of P2Y receptors. These results demonstrate that RhoA could serve as a downstream mediator of signaling mediated by P2Y(1) receptor and agrin, which therefore synergizes the effects of the two neuron-derived trophic factors in modulating the formation and/or maintenance of post-synaptic apparatus at the neuromuscular junctions.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Cleary Water Bay Rd, Hong Kong, Hong Kong, Peoples R China.	botsim@ust.hk		Tsim, Karl/0000-0003-4808-1674				Borges LS, 2002, J NEUROBIOL, V50, P69, DOI 10.1002/neu.10020; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheung KK, 2003, DEV DYNAM, V228, P254, DOI 10.1002/dvdy.10378; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 2003, J NEUROSCI, V23, P4445; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DESCHENES MR, 1993, J NEUROCYTOL, V22, P603, DOI 10.1007/BF01181487; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fu WM, 1997, EUR J NEUROSCI, V9, P676, DOI 10.1111/j.1460-9568.1997.tb01416.x; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Jones MA, 2004, MOL CELL NEUROSCI, V25, P195, DOI 10.1016/j.mcn.2003.10.013; Jones MA, 2000, MOL CELL NEUROSCI, V16, P649, DOI 10.1006/mcne.2000.0901; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; Luo Z, 2003, NEURON, V40, P703, DOI 10.1016/S0896-6273(03)00695-0; Luo ZG, 2002, NEURON, V35, P489, DOI 10.1016/S0896-6273(02)00783-3; Megeath LJ, 2003, NEUROSCIENCE, V122, P659, DOI 10.1016/S0306-4522(03)00602-X; Megeath LJ, 1998, J NEUROSCI, V18, P672; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Moore D, 2000, J COMP NEUROL, V421, P374, DOI 10.1002/(SICI)1096-9861(20000605)421:3<374::AID-CNE6>3.0.CO;2-Z; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; OMalley JP, 1997, J CELL BIOL, V138, P159, DOI 10.1083/jcb.138.1.159; Pun S, 1997, MOL CELL NEUROSCI, V10, P87, DOI 10.1006/mcne.1997.0637; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sauzeau V, 2000, AM J PHYSIOL-HEART C, V278, pH1751, DOI 10.1152/ajpheart.2000.278.6.H1751; Silinsky EM, 1996, J PHYSIOL-LONDON, V492, P815, DOI 10.1113/jphysiol.1996.sp021348; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; Smith CL, 2001, J NEUROSCI, V21, P3151, DOI 10.1523/JNEUROSCI.21-09-03151.2001; Strochlic L, 2001, J CELL BIOL, V153, P1127, DOI 10.1083/jcb.153.5.1127; Tsim KWK, 2003, J NEUROCYTOL, V32, P603, DOI 10.1023/B:NEUR.0000020613.25367.78; Tsim KWK, 2002, NEUROSIGNALS, V11, P58, DOI 10.1159/000057322; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; WALLACE BG, 1986, J CELL BIOL, V102, P783, DOI 10.1083/jcb.102.3.783; Watty A, 2000, P NATL ACAD SCI USA, V97, P4585, DOI 10.1073/pnas.080061997; Webb TE, 1996, MOL PHARMACOL, V50, P258; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Weston C, 2000, J CELL BIOL, V150, P205, DOI 10.1083/jcb.150.1.205; Weston C, 2003, J BIOL CHEM, V278, P6450, DOI 10.1074/jbc.M210249200	47	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31081	31088		10.1074/jbc.M403316200	http://dx.doi.org/10.1074/jbc.M403316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145960	hybrid			2022-12-27	WOS:000222726800023
J	Tahiri-Alaoui, A; Gill, AC; Disterer, P; James, W				Tahiri-Alaoui, A; Gill, AC; Disterer, P; James, W			Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant - Implications for disease susceptibility to Creutzfeldt-Jakob disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BIOLOGY; SPONGIFORM ENCEPHALOPATHIES; TRANSITION-STATE; STRAIN VARIATION; NMR STRUCTURE; GENE; PRP; POLYMORPHISM; MUTATIONS; CLASSIFICATION	The human PrP gene (PRNP) has two common alleles that encode either methionine or valine at codon 129. This polymorphism modulates disease susceptibility and phenotype of human transmissible spongiform encyphalopathies, but the molecular mechanism by which these effects are mediated remains unclear. Here, we compared the misfolding pathway that leads to the formation of beta-sheet-rich oligomeric isoforms of the methionine 129 variant of PrP to that of the valine 129 variant. We provide evidence for differences in the folding behavior between the two variants at the early stages of oligomer formation. We show that Met(129) has a higher propensity to form beta-sheet-rich oligomers, whereas Val(129) has a higher tendency to fold into alpha-helical-rich monomers. An equimolar mixture of both variants displayed an intermidate folding behavior. We show that the oligomers of both variants are initially a mixture of alpha- and beta-rich conformers that evolve with time to an increasingly homogeneous beta-rich form. This maturation process, which involves no further change in proteinase K resistance, occurs more rapidly in the Met(129) form than the Val(129) form. Although the involvement of such beta-rich oligomers in prion pathogenesis is speculative, the misfolding behavior could, in part, explain the higher susceptibility of individuals that are methionine homozygote to both sporadic and variant Creutzfeldt-Jakob disease.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Inst Anim Hlth, Newbury RG20 7NN, Berks, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Tahiri-Alaoui, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	abdou.tahiri-alaoui@path.ox.ac.uk	Gill, ANdrew/GRO-1248-2022; Gill, Andrew C/A-5219-2009; james, william/H-4289-2013; Disterer, Petra/C-9709-2014	Gill, Andrew C/0000-0001-5201-9473; james, william/0000-0002-2506-1198; Disterer, Petra/0000-0001-9702-9974	Biotechnology and Biological Sciences Research Council [BBS/E/I/00000973, BBS/E/I/00000877] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alonso DOV, 2001, P NATL ACAD SCI USA, V98, P2985, DOI 10.1073/pnas.061555898; BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Cervenakova L, 1998, P NATL ACAD SCI USA, V95, P13239, DOI 10.1073/pnas.95.22.13239; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Croes EA, 2003, ANN NEUROL, V54, P275, DOI 10.1002/ana.10658; Dermaut B, 2003, ANN NEUROL, V53, P409, DOI 10.1002/ana.10507; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; FASMAN GD, 1989, TRENDS BIOCHEM SCI, V14, P295, DOI 10.1016/0968-0004(89)90068-6; Gill AC, 2000, EMBO J, V19, P5324, DOI 10.1093/emboj/19.20.5324; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Hauw JJ, 2000, NEUROLOGY, V54, P1641, DOI 10.1212/WNL.54.8.1641; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; Landon, 1977, Methods Enzymol, V47, P145; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lu BY, 2001, EUR J BIOCHEM, V268, P3767, DOI 10.1046/j.1432-1327.2001.02283.x; Lu BY, 2001, BIOCHEMISTRY-US, V40, P13390, DOI 10.1021/bi011111t; MATOUSCHEK A, 1989, NATURE, V340, P122, DOI 10.1038/340122a0; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Santini S, 2003, PROTEINS, V51, P258, DOI 10.1002/prot.10348; Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; Tahiri-Alaoui A, 2003, PROTEIN SCI, V12, P600, DOI 10.1110/ps.0236703; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; Wong KB, 2000, J MOL BIOL, V296, P1257, DOI 10.1006/jmbi.2000.3523; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	53	56	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31390	31397		10.1074/jbc.M401754200	http://dx.doi.org/10.1074/jbc.M401754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131108	hybrid, Green Accepted			2022-12-27	WOS:000222726800060
J	Cheng, LL; Jia, HY; Lohr, M; Bagherzadeh, A; Holmes, DIR; Selwood, D; Zachary, I				Cheng, LL; Jia, HY; Lohr, M; Bagherzadeh, A; Holmes, DIR; Selwood, D; Zachary, I			Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SENSORY NEURONS; STIMULATES AXONAL OUTGROWTH; PROTEIN-KINASE-C; CELL PROLIFERATION; FACTOR VEGF; IN-VITRO; PROSTACYCLIN PRODUCTION; PROSTAGLANDIN E(2); NERVOUS-SYSTEM; SEMAPHORIN-III	Vascular endothelial growth factor (VEGF) displays neurotrophic and neuroprotective activities, but the mechanisms underlying these effects have not been defined. Neuropilin-1 (NP-1) is a receptor for VEGF(165) and placental growth factor-2 (PlGF-2), but the role of NP-1 in VEGF-dependent neurotrophic actions is unclear. Dorsal root ganglion (DRG) neurons expressed high levels of NP-1 mRNA and protein, much lower levels of KDR, and no detectable Flt-1. VEGF(165) and PlGF-2 promoted DRG growth cone formation with an effect similar to that of nerve growth factor, whereas the Flt-1-specific ligand, PlGF-1, and the KDR/Flt-4 ligand, VEGF-D, had no effect. The chemorepellent NP-1 ligand, semaphorin 3A, antagonized the response to VEGF and PlGF-2. The specific KDR inhibitor, SU5614, did not affect the anti-chemorepellent effects of VEGF and PlGF-2, whereas a novel, specific antagonist of VEGF binding to NP-1, called EG3287, prevented inhibition of growth cone collapse. VEGF stimulated prostacyclin and prostaglandin E(2) production in DRG cultures that was blocked by inhibitors of cyclooxygenases; the anti-chemorepellent activities of VEGF and PlGF-2 were abrogated by cyclooxygenase inhibitors, and a variety of prostacyclin analogues and prostaglandins strikingly inhibited growth cone collapse. These findings support a specific role for NP-1 in mediating neurotrophic actions of VEGF family members and also identify a novel role for prostanoids in the inhibition of neuronal chemorepulsion.	UCL, Rayne Inst, Dept Med, London WC1E 6JJ, England; UCL, Rayne Inst, Ark Therapeut Ltd, London WC1E 6JJ, England; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; King's College London; University College London; University of London; King's College London; University College London; University of London; University College London	Zachary, I (corresponding author), UCL, Rayne Inst, Dept Med, 5 Univ St, London WC1E 6JJ, England.	i.zachary@ucl.ac.uk	Selwood, David/C-1571-2008	Selwood, David/0000-0002-6817-5064; Holmes, David/0000-0002-4560-3572				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Cai HB, 1999, J NEUROSCI, V19, P6519; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cheng LL, 1996, NEURON, V16, P309, DOI 10.1016/S0896-6273(00)80049-5; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.immunol.2.1.335; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fujisawa H, 1997, CELL TISSUE RES, V290, P465, DOI 10.1007/s004410050954; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; HINGTGEN CM, 1995, J NEUROSCI, V15, P5411; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; NEGREAMINOU P, 1993, J NEUROCHEM, V60, P1126, DOI 10.1111/j.1471-4159.1993.tb03263.x; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOL GD, 1994, J PHYSIOL-LONDON, V480, P485, DOI 10.1113/jphysiol.1994.sp020377; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; Rowlands DK, 2001, BRIT J PHARMACOL, V133, P13, DOI 10.1038/sj.bjp.0704028; SELWOOD D, 2003, Patent No. 03082918; Smith JAM, 1998, BRIT J PHARMACOL, V124, P513, DOI 10.1038/sj.bjp.0701853; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; VASKO MR, 1994, J NEUROSCI, V14, P4987; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	52	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30654	30661		10.1074/jbc.M402488200	http://dx.doi.org/10.1074/jbc.M402488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15126502	hybrid			2022-12-27	WOS:000222531900095
J	El Ghachi, M; Bouhss, A; Blanot, D; Mengin-Lecreulx, D				El Ghachi, M; Bouhss, A; Blanot, D; Mengin-Lecreulx, D			The bacA gene of Escherichia coli encodes an undecaprenyl pyrophosphate phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CELL-WALLS; C55-ISOPRENOID ALCOHOL PHOSPHOKINASE; BACITRACIN ABC TRANSPORTER; STAPHYLOCOCCUS-AUREUS; PEPTIDOGLYCAN SYNTHESIS; BACILLUS-LICHENIFORMIS; DIPHOSPHATE SYNTHASE; RESISTANCE; MEMBRANE; PURIFICATION	The bacA gene, the overexpression of which results in bacitracin resistance, was inactivated and shown to be non-essential for growth of Escherichia coli. It was proposed earlier that the bacA gene product may confer resistance to the antibiotic by phosphorylation of undecaprenol (Cain, B. D., Norton, P. J., Eubanks, W., Nick, H. S., and Allen, C. M. (1983) J. Bacteriol. 175, 3784-3789). In the present work, this extremely hydrophobic membrane protein was overproduced and purified to near homogeneity. The analysis of its catalytic properties clearly demonstrated that the purified BacA protein exhibited undecaprenyl pyrophosphate phosphatase activity but not undecaprenol phosphokinase activity. This finding was perfectly consistent with the mechanism of action of bacitracin that consists in the sequestration of undecaprenyl pyrophosphate, the BacA enzyme substrate. The level of undecaprenyl pyrophosphate phosphatase was increased by 280-fold in cells carrying bacA on a multicopy expression plasmid. It was decreased by similar to75% but was not completely abolished in a bacA disruption mutant, suggesting that BacA is the main E. coli undecaprenyl pyrophosphate phosphatase but that other protein(s) exhibiting such an activity should exist to account for the residual activity and viability of the mutant strain. This is the first gene encoding undecaprenyl pyrophosphate phosphatase identified to date. Considering its newly identified function, we propose to rename the bacA gene uppP.	Univ Paris 11, Lab Enveloppes Bacteriennes & Antibiot, Inst Biochim & Biophys Mol & Cellulaire, CNRS,UMR 8619, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mengin-Lecreulx, D (corresponding author), Univ Paris 11, Lab Enveloppes Bacteriennes & Antibiot, Inst Biochim & Biophys Mol & Cellulaire, CNRS,UMR 8619, Batiment 430, F-91405 Orsay, France.	dominique.mengin-lecreulx@ebp.u-psud.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275				ALLEN CM, 1985, METHOD ENZYMOL, V110, P281; ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Bouhss A, 1999, MOL MICROBIOL, V34, P576, DOI 10.1046/j.1365-2958.1999.01623.x; BOUHSS A, 2004, IN PRESS J BIOL CHEM, V279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; CAIN BD, 1993, J BACTERIOL, V175, P3784, DOI 10.1128/JB.175.12.3784-3789.1993; Cao M, 2002, J BACTERIOL, V184, P6123, DOI 10.1128/JB.184.22.6123-6129.2002; Chalker AF, 2000, MICROBIOL-SGM, V146, P1547, DOI 10.1099/00221287-146-7-1547; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; FIEDLER W, 1988, J BIOL CHEM, V263, P14684; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; GOLDMAN R, 1972, J BIOL CHEM, V247, P5116; Gruber G, 2002, BIOCHEM BIOPH RES CO, V298, P383, DOI 10.1016/S0006-291X(02)02468-3; Harel YM, 1999, J BACTERIOL, V181, P6176, DOI 10.1128/JB.181.19.6176-6178.1999; HIGASHI Y, 1970, J BIOL CHEM, V245, P3697; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; KALIN JR, 1979, BIOCHIM BIOPHYS ACTA, V574, P112, DOI 10.1016/0005-2760(79)90090-0; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Miller J. H., 1972, EXPT MOL GENETICS, P431; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; PODLESEK Z, 1995, MOL MICROBIOL, V16, P969, DOI 10.1111/j.1365-2958.1995.tb02322.x; Podlesek Z, 2000, FEMS MICROBIOL LETT, V188, P103, DOI 10.1111/j.1574-6968.2000.tb09176.x; POLLOCK TJ, 1994, J BACTERIOL, V176, P6229, DOI 10.1128/jb.176.20.6229-6237.1994; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rick P, 1996, ESCHERICHIA COLI SAL, P104; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERMA.H, 1971, P NATL ACAD SCI USA, V68, P2441, DOI 10.1073/pnas.68.10.2441; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; STORM DR, 1973, J BIOL CHEM, V248, P3940; TOSCANO WA, 1987, ANTIBIOTIC INHIBITOR, P101; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; WILLOUGHBY E, 1972, J BIOL CHEM, V247, P5113; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	142	147	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30106	30113		10.1074/jbc.M401701200	http://dx.doi.org/10.1074/jbc.M401701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138271	hybrid			2022-12-27	WOS:000222531900031
J	Viard, T; Cossard, R; Duguet, M; de la Tour, CB				Viard, T; Cossard, R; Duguet, M; de la Tour, CB			Thermotoga maritima-Escherichia coli chimeric topoisomerases - Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE GYRASE; MECHANISM; CLEAVAGE; TEMPERATURE; BACTERIAL; FRAGMENT; CLONING; COMPLEX	Bacterial topoisomerases I are generally composed of two domains as follows: a core domain, which contains all the conserved motifs involved in the trans-esterification reactions, and a carboxyl-terminal domain, highly variable in size and sequence. In the present work, we have addressed the question of the respective roles of the two domains in the different steps of the topoisomerization cycle. For this purpose, we prepared various recombinant topoisomerases from two model enzymes: topoisomerase I from the hyperthermophilic bacterium Thermotoga maritima and topoisomerase I from Escherichia coli. We compared the properties of the two core domains to that of the topoisomerases formed by combining the core domain of one enzyme to the carboxyl-terminal domain of the other. We found that, contrary to E. coli (Lima, C. D., Wang, J. C., and Mondragon, A. (1993) J. Mol. Biol. 232, 1213-1216), the core domain from T. maritima (TmTop65) is able to sustain by itself a complete topoisomerization cycle, although with low efficiency. Fusion of TmTop65 to the entire carboxyl-terminal domain from E. coli considerably increases binding efficiency, thermal stability, and DNA relaxation activity. Moreover, the chimera predominantly acquires the cleavage specificity of E. coli full-length topoisomerase. For the chimera obtained by fusion of the T. maritima carboxyl-terminal domain to the core EcTop67, very low DNA relaxation activity and binding are recovered, but formation of a covalent DNA adduct is impaired. Taken together, our results show that the presence and the nature of the carboxyl-terminal domain of bacterial topoisomerases I strongly determine their DNA binding efficiency and cleavage specificity but is not strictly required for strand passage.	Univ Paris 11, Ctr Orsay, CNRS,UMR 8621, Inst Genet & Microbiol,Lab Enzymol Acides Nucl, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	de la Tour, CB (corresponding author), Univ Paris 11, Ctr Orsay, CNRS,UMR 8621, Inst Genet & Microbiol,Lab Enzymol Acides Nucl, Batiment 400, F-91405 Orsay, France.	bouthier@igmors.u-psud.fr						Ahumada A, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-13; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; DEAN FB, 1985, J BIOL CHEM, V260, P4984; Dekker NH, 2003, J MOL BIOL, V329, P271, DOI 10.1016/S0022-2836(03)00320-6; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; delaTour CB, 1995, BBA-GENE STRUCT EXPR, V1264, P279, DOI 10.1016/0167-4781(96)83596-2; Grishin NV, 2000, J MOL BIOL, V299, P1165, DOI 10.1006/jmbi.2000.3841; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Jaxel C, 1999, EUR J BIOCHEM, V260, P103, DOI 10.1046/j.1432-1327.1999.00128.x; Kaltoum H, 1997, SYST APPL MICROBIOL, V20, P505, DOI 10.1016/S0723-2020(97)80019-7; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; Li ZY, 2001, MOL CELL, V7, P301, DOI 10.1016/S1097-2765(01)00178-2; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIMA CD, 1993, J MOL BIOL, V232, P1213, DOI 10.1006/jmbi.1993.1474; Mondragon A, 1999, STRUCTURE, V7, P1373, DOI 10.1016/S0969-2126(00)80027-1; Perry K, 2003, STRUCTURE, V11, P1349, DOI 10.1016/j.str.2003.09.013; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Serre MC, 2003, PROG NUCLEIC ACID RE, V74, P37, DOI 10.1016/S0079-6603(03)01010-9; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; Viard T, 2001, J BIOL CHEM, V276, P46495, DOI 10.1074/jbc.M107714200; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Zhang HL, 1996, J BIOL CHEM, V271, P9039, DOI 10.1074/jbc.271.15.9039; ZHU CX, 1995, J MOL BIOL, V250, P609, DOI 10.1006/jmbi.1995.0402; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	27	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30073	30080		10.1074/jbc.M309692200	http://dx.doi.org/10.1074/jbc.M309692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140883	hybrid			2022-12-27	WOS:000222531900027
J	Guidi, BW; Bjornsdottir, G; Hopkins, DC; Lacomis, L; Erdjument-Bromage, H; Tempst, P; Myers, LC				Guidi, BW; Bjornsdottir, G; Hopkins, DC; Lacomis, L; Erdjument-Bromage, H; Tempst, P; Myers, LC			Mutual targeting of mediator and the TFIIH kinase Kin28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; CYCLIN-DEPENDENT KINASES; FACTOR TF IIE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATION; REPEAT DOMAIN; YEAST MEDIATOR; PHOSPHORYLATION; COMPLEX	In Saccharomyces cerevisiae, Kin28 is a member of the cyclin-dependent kinase family. Kin28 is a subunit of the basal transcription factor holo-TFIIH and its trimeric sub-complex TFIIK. Kin28 is the primary kinase that phosphorylates the RNA polymerase II (RNA pol II) C-terminal domain (CTD) within a transcription initiation complex. Mediator, a global transcriptional co-activator, dramatically enhances the phosphorylation of the CTD of RNA pol II by holo-TFIIH in vitro. Using purified proteins we have determined that the subunits of TFIIK are sufficient for Mediator to enhance Kin28 CTD kinase activity and that Mediator enhances phosphorylation of a glutathione S-transferase-CTD fusion protein, despite the absence of multiple Mediator and/or TFIIH interactions with polymerase. Mediator does not stimulate the activity of several other CTD kinases, suggesting that the specific enhancement of TFIIH kinase activity results in Kin28 being the primary CTD kinase at initiation. In addition, we have found that Kin28 phosphorylates Mediator subunit Med4 in an assay, including purified holo-TFIIH, and either Mediator or recombinant Med4 alone. Furthermore, Kin28 appears to be, at least in part, responsible for the phosphorylation of Med4 in vivo. We have identified Thr-237 as the site of phosphorylation of Med4 by Kin28 in vitro. The mutation of Thr-237 to Ala has no effect on the growth of a yeast strain under normal conditions but confirms that Thr-237 is also the site of Med4 phosphorylation in vivo.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Dartmouth College; Memorial Sloan Kettering Cancer Center	Myers, LC (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	larry.myers@dartmouth.edu		Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062483] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA08748] Funding Source: Medline; NIGMS NIH HHS [R01 GM062483, GM62483] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Balciunas D, 2003, J BIOL CHEM, V278, P3831, DOI 10.1074/jbc.M206946200; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Cooper KF, 1999, GENE EXPRESSION, V8, P43; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Hallberg M, 2004, P NATL ACAD SCI USA, V101, P3370, DOI 10.1073/pnas.0400221101; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; NONET ML, 1989, GENETICS, V123, P715; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Sakurai H, 1998, J BIOL CHEM, V273, P9534, DOI 10.1074/jbc.273.16.9534; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; SERIZAWA H, 1994, J BIOL CHEM, V269, P20750; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; SIKORSKI RS, 1989, GENETICS, V122, P19; Spahr H, 2000, J BIOL CHEM, V275, P1351, DOI 10.1074/jbc.275.2.1351; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Takagi Y, 2003, J BIOL CHEM, V278, P43897, DOI 10.1074/jbc.C300417200; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	52	39	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29114	29120		10.1074/jbc.M404426200	http://dx.doi.org/10.1074/jbc.M404426200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126497	hybrid			2022-12-27	WOS:000222445300036
J	Li, WQ; Jiang, Q; Khaled, AR; Keller, JR; Durum, SK				Li, WQ; Jiang, Q; Khaled, AR; Keller, JR; Durum, SK			Interleukin-7 inactivates the pro-apoptotic protein bad promoting T cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-DEFICIENT MICE; DEFECTIVE LYMPHOID DEVELOPMENT; MITOCHONDRIAL APOPTOSIS; GAMMA-CHAIN; BCL-2; PHOSPHORYLATION; KINASE; DEATH; CYTOKINE; IL-7	Interleukin-7 (IL-7) is a cytokine that is required for T cell development and survival. The anti-apoptotic function of IL-7 is partly through induction of Bcl-2 synthesis and cytosolic retention of Bax. Here we show that the Bcl-2 homology 3 domain-only protein, Bad, is involved in cell death following IL-7 withdrawal from D1 cells, an IL-7-dependent murine thymocyte cell line. IL-7 stimulation resulted in the inactivation of Bad by phosphorylation at Ser-112, -136, and -155. The phosphoinositide 3-kinase (PI3K)/Akt pathway has been implicated previously in Bad phosphorylation. In response to IL-7, the PI3K/Akt pathway induced phosphorylation at Ser-136 and -155, but Ser-112 was partly independent of the PI3K/Akt pathway, indicating an as yet unknown pathway in this response. Following IL-7 withdrawal, dephosphorylated Bad translocated from cytosol to mitochondria, bound to Bcl-2, and accelerated cell death. Thus, the inactivation of Bad contributes to the survival function of IL-7.	NCI, Mol Immunoregulat Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Durum, SK (corresponding author), NCI, Mol Immunoregulat Lab, Ctr Canc Res, NIH, Rm 31-71,Bldg 560, Frederick, MD 21702 USA.	durums@mail.ncifcrf.gov	Keller, Jonathan R./O-6677-2018	durum, scott/0000-0003-1307-9582	NATIONAL CANCER INSTITUTE [Z01BC010001, ZIABC009287, Z01BC009287, ZIABC010001] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; Khaled AR, 2002, IMMUNITY, V17, P561, DOI 10.1016/S1074-7613(02)00450-8; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim K, 1998, J IMMUNOL, V160, P5735; Kim K, 2003, J IMMUNOL METHODS, V274, P177, DOI 10.1016/S0022-1759(02)00513-6; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Nakajima H, 1999, J IMMUNOL, V162, P782; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wang JL, 2000, CANCER RES, V60, P1498; Williams O, 1998, J EXP MED, V188, P1125, DOI 10.1084/jem.188.6.1125; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	43	77	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29160	29166		10.1074/jbc.M401656200	http://dx.doi.org/10.1074/jbc.M401656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123689	hybrid			2022-12-27	WOS:000222445300042
J	Li, Q; Luo, X; Muallem, S				Li, Q; Luo, X; Muallem, S			Functional mapping of Ca2+ signaling complexes in plasma membrane microdomains of polarized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; SALIVARY-GLAND CELLS; INOSITOL TRISPHOSPHATE; WAVES; OSCILLATIONS; CALCIUM; PROPAGATION; INITIATION; EXPRESSION; SECRETION	Many cells cluster signaling complexes in plasma membrane microdomains. Polarized secretory cells cluster all Ca2+ signaling proteins, including GPCRs, at the apical pole. The functional significance of such an arrangement is not known because of a lack of techniques for functional mapping of signaling complexes at plasma membrane patches. In the present work, we developed such a technique based on the use of two patch pipettes, a recording and a stimulating pipette (SP). Including 20% glycerol in the SP solution increased the viscosity and the hydrophobicity to prevent leakage and formation of tight seals on the plasma membrane. This allowed moving the SP between sites to stimulate multiple patches of the same cell and with the same agonist concentrations. Functional mapping of Ca2+ signaling in pancreatic acinar cells revealed that the M3, cholecystokinin, and bombesin signaling complexes at the apical pole are much more sensitive to stimulation than those at the basal pole. Furthermore, at physiological agonist concentrations, Ca2+ signals could be evoked only by stimulation of membrane patches at the apical pole. [Ca2+](i) imaging revealed that Ca2+ waves were invariably initiated at the site of apical membrane patch stimulation, suggesting that long range diffusion of second messengers is not obligatory to initiate and propagate apical-to-basal Ca2+ waves. The present studies reveal a remarkable heterogeneity in responsiveness of Ca2+ signaling complexes at membrane microdomains, with the most responsive complexes confined to the apical pole, probably to restrict the Ca2+ signals to the site of exocytosis and allow the polarized functions of secretory cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	SHMUEL.MUALLEM@utsouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 12902] Funding Source: Medline; NIDDK NIH HHS [DK 38938] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Ashby MC, 2003, J BIOL CHEM, V278, P20860, DOI 10.1074/jbc.M302599200; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; Park MK, 2004, CELL CALCIUM, V35, P367, DOI 10.1016/j.ceca.2003.10.003; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; Rios JD, 1999, INVEST OPHTH VIS SCI, V40, P1102; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Yule DI, 1996, AM J PHYSIOL-CELL PH, V271, pC1285, DOI 10.1152/ajpcell.1996.271.4.C1285; Yule DI, 1997, J BIOL CHEM, V272, P9093; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520	23	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27837	27840		10.1074/jbc.C400184200	http://dx.doi.org/10.1074/jbc.C400184200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123684	hybrid			2022-12-27	WOS:000222265400002
J	Meissner, B; Boll, M; Daniel, H; Baumeister, R				Meissner, B; Boll, M; Daniel, H; Baumeister, R			Deletion of the intestinal peptide transporter affects insulin and TOR signaling in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; DIETARY RESTRICTION; OXIDATIVE STRESS; KINASE; DROSOPHILA; RECEPTOR; GENE; PHOSPHORYLATION; THERMOTOLERANCE; METABOLISM	The mammalian intestinal peptide transporter PEPT1 mediates the uptake of di- and tripeptides from the gut lumen into intestinal epithelial cells and acts in parallel with amino acid transporters. Here we address the importance of the PEPT1 orthologue PEP-2 for the assimilation of dietary protein and for overall protein nutrition in Caenorhabditis elegans. pep-2 is expressed specifically along the apical membrane of the intestinal cells, and in pep-2 deletion mutant animals, uptake of intact peptides from the gut lumen is abolished. The consequences are a severely retarded development, reduced progeny and body size, and increased stress tolerance. We show here that pep-2 cross-talks with both the C. elegans target of rapamycin (TOR) and the DAF2/insulin-signaling pathways. The pep-2 mutant enhances the developmental and longevity phenotypes of daf-2, resulting, among other effects, in a pronounced increase in adult life span. Moreover, all aspects of a weak let-363/TOR RNA interference phenotype are intensified by pep-2 deletion, indicating that pep-2 function upstream of TOR-mediated nutrient sensing. Our findings provide evidence for a predominant role of the intestinal peptide transporter for the delivery of bulk quantities of amino acids for growth and development, which consequently affects signaling pathways that regulate metabolism and aging.	Univ Freiburg, Bio3, D-79104 Freiburg, Germany; Univ Munich, Adolph Butenandt Inst Mol Neurogenet, D-80336 Munich, Germany; Tech Univ Munich, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany	University of Freiburg; University of Munich; Technical University of Munich	Baumeister, R (corresponding author), Univ Freiburg, Bio3, Schaenzlestr 1, D-79104 Freiburg, Germany.	baumeister@celegans.de	Daniel, Hannelore/B-8982-2009					Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; AVERY L, 1997, FEEDING DEFECATION C, V2; BAI JPF, 1992, PHARM RES-DORDR, V9, P969, DOI 10.1023/A:1015885823793; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Daniel H, 1996, J MEMBRANE BIOL, V154, P197, DOI 10.1007/s002329900144; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Doring F, 2002, J MEMBRANE BIOL, V186, P55, DOI 10.1007/s00232-001-0135-9; Fei YJ, 1998, BIOCHEM J, V332, P565, DOI 10.1042/bj3320565; GANAPATHY ME, 1995, J BIOL CHEM, V270, P25672, DOI 10.1074/jbc.270.43.25672; Gems D, 2001, CURR OPIN GENET DEV, V11, P287, DOI 10.1016/S0959-437X(00)00192-1; Gems D, 1998, GENETICS, V150, P129; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; Groneberg DA, 2001, AM J PHYSIOL-GASTR L, V281, pG697, DOI 10.1152/ajpgi.2001.281.3.G697; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nehrke K, 2003, J BIOL CHEM, V278, P44657, DOI 10.1074/jbc.M307351200; RAIZEN DM, 1995, GENETICS, V141, P1365; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Rubio-Aliaga I, 2000, BIOCHEM BIOPH RES CO, V276, P734, DOI 10.1006/bbrc.2000.3546; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; Takenaka A, 2000, J NUTR, V130, P2910, DOI 10.1093/jn/130.12.2910; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; WONG A, 1995, GENETICS, V139, P1247; Yasuda K, 1999, J GERONTOL A-BIOL, V54, pB47, DOI 10.1093/gerona/54.2.B47; YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	48	140	148	2	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36739	36745		10.1074/jbc.M403415200	http://dx.doi.org/10.1074/jbc.M403415200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15155758	hybrid			2022-12-27	WOS:000223453600074
J	Briancon, N; Bailly, A; Clotman, F; Jacquemin, P; Lemaigre, FP; Weiss, MC				Briancon, N; Bailly, A; Clotman, F; Jacquemin, P; Lemaigre, FP; Weiss, MC			Expression of the alpha 7 isoform of hepatocyte nuclear factor (HNF) 4 is activated by HNF6/OC-2 and HNF1 and repressed by HNF4 alpha 1 in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTORS; PHENYLALANINE-HYDROXYLASE GENE; FACTOR 4-ALPHA; VISCERAL ENDODERM; ONECUT CLASS; DNA-BINDING; HOMEODOMAIN PROTEINS; MAMMALIAN MEMBER; MOUSE EMBRYO; CELL	The hepatocyte nuclear factor (HNF) 4alpha gene possesses two promoters, proximal P1 and distal P2, whose use results in HNF4alpha1 and HNF4alpha7 transcripts, respectively. Both isoforms are expressed in the embryonic liver, whereas HNF4alpha1 is almost exclusively in the adult liver. A 516-bp fragment, encompassing a DNase I-hypersensitive site associated with P2 activity that is still retained in adult liver, contains functional HNF1 and HNF6 binding sites and confers full promoter activity in transient transfections. We demonstrate a critical role of the Onecut factors in P2 regulation using site-directed mutagenesis and embryos doubly deficient for HNF6 and OC-2 that show reduced hepatic HNF4alpha7 transcript levels. Transient transgenesis showed that a 4-kb promoter region is sufficient to drive expression of a reporter gene in the stomach, intestine, and pancreas, but not the liver, for which additional activating sequences may be required. Quantitative PCR analysis revealed that throughout liver development HNF4alpha7 transcripts are lower than those of HNF4alpha1. HNF4alpha1 represses P2 activity in transfection assays and as deduced from an increase in P2-derived transcript levels in recombinant mice in which HNF4alpha1 has been deleted and replaced by HNF4alpha7. We conclude that although HNF6/OC-2 and perhaps HNF1 activate the P2 promoter in the embryo, increasing HNF4alpha1 expression throughout development causes a switch to essentially exclusive P1 promoter activity in the adult liver.	Inst Pasteur, Dept Dev Biol, CNRS,URA 2578, Unite Genet Differenciat, F-75724 Paris 15, France; Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Univ Catholique Louvain, B-1200 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite Catholique Louvain	Weiss, MC (corresponding author), Inst Pasteur, Dept Dev Biol, CNRS,URA 2578, Unite Genet Differenciat, 25 Rue Dr Roux, F-75724 Paris 15, France.	mweiss@pasteur.fr	Jacquemin, Patrick/ABA-7932-2021	Lemaigre, Frederic/0000-0002-3609-434X	NIDDK NIH HHS [1 U01 DK63588-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK063588] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; ANGRAND PO, 1990, CELL GROWTH DIFFER, V1, P519; [Anonymous], 2001, NUCL RECEPTORS GENET; Bailly A, 1998, J CELL SCI, V111, P2411; Bailly A, 2001, NUCLEIC ACIDS RES, V29, P3495, DOI 10.1093/nar/29.17.3495; Barbacci E, 1999, DEVELOPMENT, V126, P4795; Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou WC, 2003, MOL BIOL CELL, V14, P1279, DOI 10.1091/mbc.E02-07-0375; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clotman F, 2002, DEVELOPMENT, V129, P1819; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; COON HG, 1969, P NATL ACAD SCI USA, V62, P852, DOI 10.1073/pnas.62.3.852; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Duncan SA, 2003, MECH DEVELOP, V120, P19, DOI 10.1016/S0925-4773(02)00328-3; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Duncan SA, 1997, DEVELOPMENT, V124, P279; Eeckhoute J, 2004, NUCLEIC ACIDS RES, V32, P2586, DOI 10.1093/nar/gkh581; Eeckhoute J, 2003, ENDOCRINOLOGY, V144, P1686, DOI 10.1210/en.2002-0024; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Faust DM, 1996, MOL CELL BIOL, V16, P3125; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gellon G, 1998, BIOESSAYS, V20, P116, DOI 10.1002/(SICI)1521-1878(199802)20:2<116::AID-BIES4>3.3.CO;2-N; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GREENGARD O, 1972, J CELL BIOL, V52, P261, DOI 10.1083/jcb.52.2.261; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hansen SK, 2002, J CLIN INVEST, V110, P827, DOI 10.1172/JCI200215085; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 2003, GENE EXPR PATTERNS, V3, P639, DOI 10.1016/S1567-133X(03)00110-8; Jacquemin P, 1999, J BIOL CHEM, V274, P2665, DOI 10.1074/jbc.274.5.2665; Jiang GQ, 1997, J BIOL CHEM, V272, P1218, DOI 10.1074/jbc.272.2.1218; Ktistaki E, 1997, SCIENCE, V277, P109, DOI 10.1126/science.277.5322.109; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; Li JX, 2000, GENE DEV, V14, P464; Maeda Y, 2002, MOL ENDOCRINOL, V16, P402, DOI 10.1210/me.16.2.402; Maestro MA, 2003, HUM MOL GENET, V12, P3307, DOI 10.1093/hmg/ddg355; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Nakhei H, 1998, NUCLEIC ACIDS RES, V26, P497, DOI 10.1093/nar/26.2.497; NICOLAS JF, 1976, CANCER RES, V36, P4224; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; Parrado A, 2001, NUCLEIC ACIDS RES, V29, P4901, DOI 10.1093/nar/29.24.4901; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Parviz F, 2002, GENESIS, V32, P130, DOI 10.1002/gene.10058; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Pontoglio M, 1997, MOL CELL BIOL, V17, P4948, DOI 10.1128/MCB.17.9.4948; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; SZPIRER C, 1975, DIFFERENTIATION, V4, P85, DOI 10.1111/j.1432-0436.1975.tb01446.x; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; Torres-Padilla ME, 2002, J BIOL CHEM, V277, P44677, DOI 10.1074/jbc.M207545200; Torres-Padilla ME, 2001, MECH DEVELOP, V109, P183, DOI 10.1016/S0925-4773(01)00521-4; TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO, V1, P5; Vanhorenbeeck V, 2002, BIOCHEM BIOPH RES CO, V292, P848, DOI 10.1006/bbrc.2002.6760; Watt AJ, 2003, HEPATOLOGY, V37, P1249, DOI 10.1053/jhep.2003.50273; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Zhang SSM, 2002, MOL NEUROBIOL, V26, P137, DOI 10.1385/MN:26:2-3:137; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	85	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33398	33408		10.1074/jbc.M405312200	http://dx.doi.org/10.1074/jbc.M405312200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159395	hybrid			2022-12-27	WOS:000223039700047
J	Ralston, KJ; Hird, SL; Zhang, XH; Scott, JL; Jin, BQ; Thorne, RF; Brendt, MC; Boyd, AW; Burns, GF				Ralston, KJ; Hird, SL; Zhang, XH; Scott, JL; Jin, BQ; Thorne, RF; Brendt, MC; Boyd, AW; Burns, GF			The LFA-1-associated molecule PTA-1 (CD226) on T cells forms a dynamic molecular complex with protein 4.1G and human discs large	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; INTERCELLULAR-ADHESION MOLECULE-3; GTPASE-ACTIVATING PROTEIN; IMMUNOLOGICAL SYNAPSE; HUMAN HOMOLOG; STRUCTURAL BASIS; LIPID RAFTS; FUNCTIONAL ASSOCIATION; RAP1-INDUCED ADHESION; POTASSIUM CHANNELS	Clustering of the T cell integrin, LFA-1, at specialized regions of intercellular contact initiates integrin-mediated adhesion and downstream signaling, events that are necessary for a successful immunological response. But how clustering is achieved and sustained is not known. Here we establish that an LFA-1-associated molecule, PTA-1, is localized to membrane rafts and binds the carboxyl-terminal domain of isoforms of the actin-binding protein 4.1G. Protein 4.1 is known to associate with the membrane-associated guanylate kinase homologue, human discs large. We show that the carboxyl-terminal peptide of PTA-1 also can bind human discs large and that the presence or absence of this peptide greatly influences binding between PTA-1 and different isoforms of 4.1G. T cell stimulation with phorbol ester or PTA-1 cross-linking induces PTA-1 and 4.1G to associate tightly with the cytoskeleton, and the PTA-1 from such activated cells now can bind to the amino-terminal region of 4.1G. We propose that these dynamic associations provide the structural basis for a regulated molecular adhesive complex that serves to cluster and transport LFA-1 and associated molecules.	Univ Newcastle, Sch Biomed Sci, Canc Res Unit, Callaghan, NSW 2308, Australia; 4th Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Royal Brisbane Hosp PO, Queensland Inst Med Res, Div Canc & Cell Biol, Brisbane, Qld 4029, Australia	University of Newcastle; Air Force Military Medical University; Monash University; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Burns, GF (corresponding author), Univ Newcastle, Sch Biomed Sci, Canc Res Unit, Univ Dr, Callaghan, NSW 2308, Australia.	Gordon.Burns@newcastle.edu.au	Boyd, Andrew/G-2083-2010	Thorne, Rick/0000-0001-7882-7081				Adey NB, 2000, CANCER RES, V60, P35; Alonso MA, 2001, J CELL SCI, V114, P3957; ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; Asaba N, 2003, J BIOL CHEM, V278, P8395, DOI 10.1074/jbc.M210362200; Baldari Cosima T., 2000, EMBO (European Molecular Biology Organization) Journal, V19, P4857, DOI 10.1093/emboj/19.18.4857; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BURNS GF, 1985, J EXP MED, V161, P1063, DOI 10.1084/jem.161.5.1063; Calderwood DA, 2003, NAT CELL BIOL, V5, P694, DOI 10.1038/ncb0803-694; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; CHEN LK, 1986, EUR J IMMUNOL, V16, P767, DOI 10.1002/eji.1830160709; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; Delon J, 2000, CURR BIOL, V10, pR923, DOI 10.1016/S0960-9822(00)00870-8; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Galjart N, 2003, CURR OPIN CELL BIOL, V15, P48, DOI 10.1016/S0955-0674(02)00007-8; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hanada T, 2003, J BIOL CHEM, V278, P34445, DOI 10.1074/jbc.M305209200; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Hoover KB, 2000, CURR OPIN CELL BIOL, V12, P229, DOI 10.1016/S0955-0674(99)00080-0; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Jia W, 2000, HYBRIDOMA, V19, P489, DOI 10.1089/027245700750053986; JIN B, 1989, IMMUNOLOGY, V66, P570; JUAN M, 1994, J EXP MED, V179, P1747, DOI 10.1084/jem.179.6.1747; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; Leclerc E, 1998, EUR J BIOCHEM, V258, P567, DOI 10.1046/j.1432-1327.1998.2580567.x; Leitinger B, 2002, J CELL SCI, V115, P963; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Liddington RC, 2000, EXP CELL RES, V261, P37, DOI 10.1006/excr.2000.5058; Lu CF, 1997, J IMMUNOL, V159, P268; Lu DC, 2004, BIOCHEM J, V377, P51, DOI 10.1042/BJ20030952; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Miceli MC, 2001, SEMIN IMMUNOL, V13, P115, DOI 10.1006/smim.2000.0303; Montoya MC, 2002, NAT IMMUNOL, V3, P159, DOI 10.1038/ni753; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Panyi G, 2003, P NATL ACAD SCI USA, V100, P2592, DOI 10.1073/pnas.0438057100; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Porter JC, 2002, J IMMUNOL, V168, P6330, DOI 10.4049/jimmunol.168.12.6330; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Roy BC, 2002, GENES CELLS, V7, P607; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SCOTT JL, 1989, J BIOL CHEM, V264, P13475; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Shaw AS, 2001, IMMUNITY, V15, P683, DOI 10.1016/S1074-7613(01)00237-0; Sherrington PD, 1997, J BIOL CHEM, V272, P21735, DOI 10.1074/jbc.272.35.21735; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya A, 1998, J IMMUNOL, V161, P1671; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Tohyama Y, 2003, MOL BIOL CELL, V14, P2570, DOI 10.1091/mbc.E02-09-0615; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	84	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33816	33828		10.1074/jbc.M401040200	http://dx.doi.org/10.1074/jbc.M401040200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15138281	hybrid			2022-12-27	WOS:000223039700091
J	Stanhope-Baker, P; Kessler, PM; Li, WL; Agarwal, ML; Williams, BRG				Stanhope-Baker, P; Kessler, PM; Li, WL; Agarwal, ML; Williams, BRG			The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR EPITHELIAL-CELL; P53-STABILIZING COMPOUND; FUNCTIONAL INTERACTION; ACTIN CYTOSKELETON; LIVING CELLS; WT1 GENE; PROTEIN; CP-31398; IDENTIFICATION; APOPTOSIS	Wilms tumors are a heterogeneous class of tumors in which Wilms tumor suppressor-1 (WT1) and the p53 tumor suppressor may be variously inactivated by mutation, reduced in expression, or even overexpressed in the wild-type state. The downstream transcriptional targets of WT1 and p53 that are critical for mediating their roles in Wilms tumorigenesis are not well defined. The WiT49 cell line is characteristic of anaplastic Wilms tumors that are refractory to treatment and expresses wild-type WT1 and mutant p53. We have used the small molecule compound CP- 31398 ( Pfizer) to restore wildtype p53 function to the codon 248 mutant p53 present in WiT49 cells. In these cells, CP- 31398 activated transcription of p53-regulated promoters and enhanced UV light-induced apoptosis without altering the overall p53 protein level. These phenotypes were accompanied by restored binding of the p53 protein to promoter sequences in vivo. Gene expression profiling of CP-31398-treated WiT49 cells revealed subsets of putative p53 target genes that were up- or down-regulated. A preferred target of p53-mediated repression in this system is the podocalyxin (PODXL) gene. PODXL is also transcriptionally regulated by WT1 and has roles in cell adhesion and anti-adhesion. Our results show that PODXL is a bona fide target of p53-mediated transcriptional repression while being positively regulated by WT1. We propose that inappropriate expression of PODXL due to changes in WT1 and/or p53 activity may contribute to Wilms tumorigenesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Genet, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB40,9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Birch JM, 2001, ONCOGENE, V20, P4621, DOI 10.1038/sj.onc.1204621; BONADIO JF, 1985, J CLIN ONCOL, V3, P513, DOI 10.1200/JCO.1985.3.4.513; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Doyonnas R, 2001, J EXP MED, V194, P13, DOI 10.1084/jem.194.1.13; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELBAHTIMI R, 1996, MODERN PATHOL, V9, P233; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Guo JK, 2002, HUM MOL GENET, V11, P651, DOI 10.1093/hmg/11.6.651; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; HARTLEY AL, 1993, CANCER GENET CYTOGEN, V67, P133, DOI 10.1016/0165-4608(93)90166-J; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; Kershaw DB, 1997, J BIOL CHEM, V272, P15708, DOI 10.1074/jbc.272.25.15708; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Loeb DM, 2002, INT J HEMATOL, V76, P117, DOI 10.1007/BF02982573; Luu Y, 2002, J INVEST DERMATOL, V119, P1207, DOI 10.1046/j.1523-1747.2002.19517.x; Luu Y, 2003, ANTICANCER RES, V23, P99; Luu Y, 2002, EXP CELL RES, V276, P214, DOI 10.1006/excr.2002.5526; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Orlando RA, 2001, J AM SOC NEPHROL, V12, P1589, DOI 10.1681/ASN.V1281589; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; SCHNABEL E, 1989, EUR J CELL BIOL, V48, P313; Schopperle WM, 2003, BIOCHEM BIOPH RES CO, V300, P285; Senderowicz AM, 2002, ONCOLOGIST, V7, P12; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Takeda T, 2000, MOL BIOL CELL, V11, P3219, DOI 10.1091/mbc.11.9.3219; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Teruyama K, 2001, FEBS LETT, V504, P1, DOI 10.1016/S0014-5793(01)02724-7; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; Yaoita E, 2001, CELL TISSUE RES, V304, P339; ZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7	46	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33575	33585		10.1074/jbc.M404787200	http://dx.doi.org/10.1074/jbc.M404787200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155752	hybrid			2022-12-27	WOS:000223039700066
J	Banno, T; Gazel, A; Blumenberg, M				Banno, T; Gazel, A; Blumenberg, M			Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MATRIX METALLOPROTEINASES; ADHESION MOLECULES; INDUCED APOPTOSIS; EXPRESSION; RECEPTOR; IDENTIFICATION; LOCALIZATION; LIPOXYGENASE; MODULATION	Identification of tumor necrosis factor-alpha (TNFalpha) as the key agent in inflammatory disorders, e. g. rheumatoid arthritis, Crohn's disease, and psoriasis, led to TNFalpha-targeting therapies, which, although avoiding many of the side-effects of previous drugs, nonetheless causes other side-effects, including secondary infections and cancer. By controlling gene expression, TNFalpha orchestrates the cutaneous responses to environmental damage and inflammation. To define TNFalpha action in epidermis, we compared the transcriptional profiles of normal human keratinocytes untreated and treated with TNFalpha for 1, 4, 24, and 48 h by using oligonucleotide microarrays. We found that TNFalpha regulates not only immune and inflammatory responses but also tissue remodeling, cell motility, cell cycle, and apoptosis. Specifically, TNFalpha regulates innate immunity and inflammation by inducing a characteristic large set of chemokines, including newly identified TNFalpha targets, that attract neutrophils, macrophages, and skin-specific memory T-cells. This implicates TNFalpha in the pathogenesis of psoriasis, fixed drug eruption, atopic and allergic contact dermatitis. TNFalpha promotes tissue repair by inducing basement membrane components and collagen-degrading proteases. Unexpectedly, TNFalpha induces actin cytoskeleton regulators and integrins, enhancing keratinocyte motility and attachment, effects not previously associated with TNFalpha. Also unanticipated was the influence of TNFalpha upon keratinocyte cell fate by regulating cell-cycle and apoptosis-associated genes. Therefore, TNFalpha initiates not only the initiation of inflammation and responses to injury, but also the subsequent epidermal repair. The results provide new insights into the harmful and beneficial TNFalpha effects and define the mechanisms and genes that achieve these outcomes, both of which are important for TNFalpha-targeted therapies.	NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA; Univ Tsukuba, Dept Dermatol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan	New York University; New York University; New York University; University of Tsukuba; University of Tsukuba	Blumenberg, M (corresponding author), NYU, Sch Med, Dept Dermatol, 550 1st Ave, New York, NY 10016 USA.	blumem01@med.nyu.edu		Blumenberg, Miroslav/0000-0002-8672-7774	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041850] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41850] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS152; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Banno T, 2003, ANTIVIR THER, V8, P541; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baugh J A, 2001, Curr Opin Drug Discov Devel, V4, P635; Becke FM, 2001, EUR CYTOKINE NETW, V12, P45; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; ETTEHADI P, 1994, CLIN EXP IMMUNOL, V96, P146, DOI 10.1111/j.1365-2249.1994.tb06244.x; FOGH K, 1987, ARCH DERMATOL RES, V279, P504, DOI 10.1007/BF00413280; Fong WF, 2001, BBA-GENE STRUCT EXPR, V1517, P250, DOI 10.1016/S0167-4781(00)00287-6; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; GRIFFITHS CEM, 1991, BRIT J DERMATOL, V124, P519, DOI 10.1111/j.1365-2133.1991.tb04943.x; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; Kondo T, 1996, INT J LEGAL MED, V108, P231, DOI 10.1007/BF01369816; KONO T, 1990, Journal of Dermatology (Tokyo), V17, P409; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mahlknecht U, 2002, BIOCHEM BIOPH RES CO, V293, P182, DOI 10.1016/S0006-291X(02)00193-6; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McDermott MF, 2001, CELL MOL BIOL, V47, P619; McNamara RK, 2002, DEV NEUROSCI-BASEL, V24, P485, DOI 10.1159/000069359; Moses MA, 1996, J CELL BIOCHEM, V60, P379, DOI 10.1002/(SICI)1097-4644(19960301)60:3<379::AID-JCB9>3.0.CO;2-T; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Muller I, 2003, FASEB J, V17, P476, DOI 10.1096/fj.02-0574fje; Murakami T, 2000, J Atheroscler Thromb, V7, P39; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nahar IK, 2003, ANN PHARMACOTHER, V37, P1256, DOI 10.1345/aph.1C039; Neely AN, 1999, WOUND REPAIR REGEN, V7, P166, DOI 10.1046/j.1524-475X.1999.00166.x; Palecek SP, 1998, J CELL SCI, V111, P929; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PILLAI S, 1989, J CLIN INVEST, V83, P816, DOI 10.1172/JCI113963; Quensel C, 2002, J CELL BIOCHEM, V85, P403, DOI 10.1002/jcb.10143; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Romer J, 1996, NAT MED, V2, P725, DOI 10.1038/nm0796-725a; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sallenave JM, 2003, INFECT IMMUN, V71, P3766, DOI 10.1128/IAI.71.7.3766-3774.2003; SALO T, 1994, LAB INVEST, V70, P176; Schilham MW, 1998, SEMIN IMMUNOL, V10, P127, DOI 10.1006/smim.1998.0114; Shakhov AN, 2000, J LEUKOCYTE BIOL, V68, P151; SHAM RL, 1993, BLOOD, V82, P2546; Shiohara T, 2002, CURR OPIN ALLERGY CL, V2, P317, DOI 10.1097/00130832-200208000-00005; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TERAKI Y, 1994, AM J PATHOL, V145, P550; Urieli-Shoval S, 2002, BLOOD, V99, P1224, DOI 10.1182/blood.V99.4.1224; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; WAKEFIELD PE, 1991, J AM ACAD DERMATOL, V24, P675, DOI 10.1016/0190-9622(91)70102-8; Wolf R, 2002, CLIN DERMATOL, V20, P522, DOI 10.1016/S0738-081X(02)00273-0; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	66	235	244	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32633	32642		10.1074/jbc.M400642200	http://dx.doi.org/10.1074/jbc.M400642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145954	hybrid			2022-12-27	WOS:000222849700081
J	Michel, G; Pojasek, K; Li, YG; Sulea, T; Linhardt, RJ; Raman, R; Prabhakar, V; Sasisekharan, R; Cygler, M				Michel, G; Pojasek, K; Li, YG; Sulea, T; Linhardt, RJ; Raman, R; Prabhakar, V; Sasisekharan, R; Cygler, M			The structure of chondroitin B lyase complexed with glycosaminoglycan oligosaccharides unravels a calcium-dependent catalytic machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRANOSE RING FLEXIBILITY; CRYSTAL-STRUCTURE; PECTATE LYASE; FLAVOBACTERIUM-HEPARINUM; DERMATAN SULFATE; AC LYASE; IOTA-CARRAGEENAN; BINDING SITES; ACTIVE-SITE; BETA-HELIX	Chondroitinase B from Pedobacter heparinus is the only known enzyme strictly specific for dermatan sulfate and is a widely used enzymatic tool for the structural characterization of glycosaminoglycans. This beta-helical polysaccharide lyase belongs to family PL-6 and cleaves the beta(1,4) linkage of dermatan sulfate in a random manner, yielding 4,5-unsaturated dermatan sulfate disaccharides as the product. The previously reported structure of its complex with a dermatan sulfate disaccharide product identified the -1 and -2 subsites of the catalytic groove. We present here the structure of chondroitinase B complexed with several dermatan sulfate and chondroitin sulfate oligosaccharides. In particular, the soaking of chondroitinase B crystals with a dermatan sulfate hexasaccharide results in a complex with two dermatan sulfate disaccharide reaction products, enabling the identification of the +2 and +1 subsites. Unexpectedly, this structure revealed the presence of a calcium ion coordinated by sequence-conserved acidic residues and by the carboxyl group of the L-iduronic acid at the +1 subsite. Kinetic and site-directed mutagenesis experiments have subsequently demonstrated that chondroitinase B absolutely requires calcium for its activity, indicating that the protein-Ca2+-oligosaccharide complex is functionally relevant. Modeling of an intact tetrasaccharide in the active site of chondroitinase B provided a better understanding of substrate specificity and the role of Ca2+ in enzymatic activity. Given these results, we propose that the Ca2+ ion neutralizes the carboxyl moiety of the L-iduronic acid at the cleavage site, whereas the conserved residues Lys-250 and Arg-271 act as Bronsted base and acid, respectively, in the lytic degradation of dermatan sulfate by chondroitinase B.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; MIT, Biol Engn Div, Cambridge, MA 02139 USA; Rensselaer Polytech Inst, Dept Chem & Biol Chem, Troy, NY 12180 USA	National Research Council Canada; Massachusetts Institute of Technology (MIT); Rensselaer Polytechnic Institute	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	MICHEL, Gurvan/B-3490-2008	MICHEL, Gurvan/0000-0002-3009-6205	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060, R01GM057073, R37GM057073] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL052622-07, R01 HL062244, HL62244, R01 HL052622-08, R01 HL062244-05A1, R01 HL062244-06, HL52622, R01 HL052622] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060, R01 GM038060-16A2, R01 GM038060-17, R01 GM057073, R37 GM057073, GM38060, GM57073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguiar JAK, 2003, BIOTECHNOL APPL BIOC, V37, P115, DOI 10.1042/BA20020089; Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson V. E., 1998, COMPREHENSIVE BIOL C; ARNOTT S, 1974, J MOL BIOL, V90, P253, DOI 10.1016/0022-2836(74)90371-4; Berces A, 2001, TETRAHEDRON, V57, P477, DOI 10.1016/S0040-4020(00)01019-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; CORNELL WD, 1993, J AM CHEM SOC, V115, P9620, DOI 10.1021/ja00074a030; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Coutinho PM, 1999, ROY SOC CH, P3; Das SK, 2001, CHEM-EUR J, V7, P4821; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1998, J AM CHEM SOC, V120, P2099, DOI 10.1021/ja972185o; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; GU KN, 1995, BIOCHEM J, V312, P569, DOI 10.1042/bj3120569; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; Herron SR, 2003, J BIOL CHEM, V278, P12271, DOI 10.1074/jbc.M209306200; HOPWOOD JJ, 1981, CARBOHYD RES, V91, P165, DOI 10.1016/S0008-6215(00)86029-2; Howard MB, 2003, J BACTERIOL, V185, P3352, DOI 10.1128/JB.185.11.3352-3360.2003; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Janaswamy S, 2002, CARBOHYD RES, V337, P523, DOI 10.1016/S0008-6215(02)00017-4; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kuwaba K, 2002, J DERMATOL SCI, V29, P185, DOI 10.1016/S0923-1811(02)00023-3; Larsson AM, 2003, STRUCTURE, V11, P1111, DOI 10.1016/S0969-2126(03)00147-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YG, 1999, ACTA CRYSTALLOGR D, V55, P1055, DOI 10.1107/S0907444999002097; Liu DF, 1999, J BIOL CHEM, V274, P4089, DOI 10.1074/jbc.274.7.4089; Lunin VV, 2004, J MOL BIOL, V337, P367, DOI 10.1016/j.jmb.2003.12.071; Manning G.S., 1974, LIMITING LAWS EQUILI, P9, DOI 10.1007/978-94-010-2185-2_2; Michel G, 2003, J MOL BIOL, V334, P421, DOI 10.1016/j.jmb.2003.09.056; Michel G, 2001, J BIOL CHEM, V276, P40202, DOI 10.1074/jbc.M100670200; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; MICHELACCI YM, 1974, BIOCHEM BIOPH RES CO, V56, P973, DOI 10.1016/S0006-291X(74)80284-6; MITRA AK, 1983, J MOL BIOL, V169, P873, DOI 10.1016/S0022-2836(83)80141-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pojasek K, 2002, J BIOL CHEM, V277, P31179, DOI 10.1074/jbc.M201552200; Pojasek K, 2001, BIOCHEM BIOPH RES CO, V286, P343, DOI 10.1006/bbrc.2001.5380; Rye CS, 2002, J ORG CHEM, V67, P4505, DOI 10.1021/jo020089m; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Scott JE, 2001, PATHOL BIOL, V49, P284, DOI 10.1016/S0369-8114(01)00152-3; Shimizu T, 2002, BIOCHEMISTRY-US, V41, P6651, DOI 10.1021/bi025541a; Shriver Z, 1999, J BIOL CHEM, V274, P4082, DOI 10.1074/jbc.274.7.4082; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Steyn PL, 1998, INT J SYST BACTERIOL, V48, P165, DOI 10.1099/00207713-48-1-165; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Tkalec AL, 2000, APPL ENVIRON MICROB, V66, P29, DOI 10.1128/AEM.66.1.29-35.2000; Valla S, 2001, BIOCHIMIE, V83, P819, DOI 10.1016/S0300-9084(01)01313-X; VENKATARAMAN G, 1994, P NATL ACAD SCI USA, V91, P6171, DOI 10.1073/pnas.91.13.6171; VYAS NK, 1991, J BIOL CHEM, V266, P5226; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200; WOODS RJ, 1995, J PHYS CHEM-US, V99, P3832, DOI 10.1021/j100011a061; Yang HO, 2000, GLYCOBIOLOGY, V10, P1033, DOI 10.1093/glycob/10.10.1033; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	68	77	81	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32882	32896		10.1074/jbc.M403421200	http://dx.doi.org/10.1074/jbc.M403421200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155751	Green Accepted, hybrid			2022-12-27	WOS:000222849700108
J	Chen, SF; Yakunin, AF; Kuznetsova, E; Busso, D; Pufan, R; Proudfoot, M; Kim, R; Kim, SH				Chen, SF; Yakunin, AF; Kuznetsova, E; Busso, D; Pufan, R; Proudfoot, M; Kim, R; Kim, SH			Structural and functional characterization of a novel phosphodiesterase from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE ACID-PHOSPHATASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEINS; ENZYME; CRYSTALLOGRAPHY; DATABASE; SITE	Methanococcus jannaschii MJ0936 is a hypothetical protein of unknown function with over 50 homologs found in many bacteria and Archaea. To help define the molecular ( biochemical and biophysical) function of MJ0936, we determined its crystal structure at 2.4-Angstrom resolution and performed a series of biochemical screens for catalytic activity. The overall fold of this single domain protein consists of a four-layered structure formed by two beta-sheets flanked by alpha-helices on both sides. The crystal structure suggested its biochemical function to be a nuclease, phosphatase, or nucleotidase, with a requirement for some metal ions. Crystallization in the presence of Ni2+ or Mn2+ produced a protein containing a binuclear metal center in the putative active site formed by a cluster of conserved residues. Analysis of MJ0936 against a panel of general enzymatic assays revealed catalytic activity toward bis-p-nitrophenyl phosphate, an indicator substrate for phosphodiesterases and nucleases. Significant activity was also found with two other phosphodiesterase substrates, thymidine 5'-monophosphate p-nitrophenyl ester and p-nitrophenylphosphorylcholine, but no activity was found for cAMP or cGMP. Phosphodiesterase activity of MJ0936 had an absolute requirement for divalent metal ions with Ni2+] and Mn2+ being most effective. Thus, our structural and enzymatic studies have identified the biochemical function of MJ0936 as that of a novel phosphodiesterase.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley Struct Genom Ctr, Berkeley, CA 94720 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Toronto	Kim, SH (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	shkim@lbl.gov	Yakunin, Alexander/J-1519-2014	Yakunin, Alexander/0000-0003-0813-6490	NIGMS NIH HHS [GM 62412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Frishman D, 2003, NUCLEIC ACIDS RES, V31, P207, DOI 10.1093/nar/gkg005; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLEY RL, 1988, METHOD ENZYMOL, V161, P307; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIOKA S, 1976, ANAL BIOCHEM, V75, P281, DOI 10.1016/0003-2697(76)90078-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sanishvili R, 2003, J BIOL CHEM, V278, P26039, DOI 10.1074/jbc.M303867200; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Yang ZR, 2003, J BIOL CHEM, V278, P8804, DOI 10.1074/jbc.M211892200	29	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31854	31862		10.1074/jbc.M401059200	http://dx.doi.org/10.1074/jbc.M401059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15128743	hybrid			2022-12-27	WOS:000222726800112
J	Park, SJ; Ciccone, SLM; Beck, BD; Hwang, B; Freie, B; Clapp, DW; Lee, SH				Park, SJ; Ciccone, SLM; Beck, BD; Hwang, B; Freie, B; Clapp, DW; Lee, SH			Oxidative stress/damage induces multimerization and interaction of Fanconi anemia proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; REDOX REGULATION; YEAST 2-HYBRID; CELL-CYCLE; DAMAGE; COMPLEX; REPAIR; FAA; FANCG/XRCC9; PROTECTION	Fanconi anemia (FANC) is a heterogeneous genetic disorder characterized by a hypersensitivity to DNA-damaging agents, chromosomal instability, and defective DNA repair. Eight FANC genes have been identified so far, and five of them (FANCA, -C, -E, -F, and -G) assemble in a multinuclear complex and function at least in part in a complex to activate FANCD2 by monoubiquitination. Here we show that FANCA and FANCG are redox-sensitive proteins that are multimerized and/or form a nuclear complex in response to oxidative stress/damage. Both FANCA and FANCG proteins exist as monomers under non-oxidizing conditions, whereas they become multimers following H2O2 treatment. Treatment of cells with oxidizing agent not only triggers the multimeric complex of FANCA and FANCG in vivo but also induces the interaction between FANCA and FANCG. N-Ethylmaleimide treatment abolishes multimerization and interaction of FANCA and FANCG in vitro. Taken together, our results lead us to conclude that FANCA and FANCG uniquely respond to oxidative damage by forming complex(es) via intermolecular disulfide linkage(s), which may be crucial in forming such complexes and in determining their function.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Lee, SH (corresponding author), Indiana Univ, Canc Res Inst, 1044 W Walnut St,Rm 153, Indianapolis, IN 46202 USA.	slee@iupui.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020167] Funding Source: NIH RePORTER; NCI NIH HHS [CA92111] Funding Source: Medline; NIGMS NIH HHS [F32 GM20167-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Busch DB, 1996, MUTAT RES-DNA REPAIR, V363, P209, DOI 10.1016/0921-8777(96)00014-6; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Fortini P, 2003, MUTAT RES-FUND MOL M, V531, P127, DOI 10.1016/j.mrfmmm.2003.07.004; Futaki M, 2002, CARCINOGENESIS, V23, P67, DOI 10.1093/carcin/23.1.67; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huber PAJ, 2000, BIOCHEM BIOPH RES CO, V268, P73, DOI 10.1006/bbrc.1999.2055; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kelley MR, 2001, MUTAT RES-DNA REPAIR, V485, P107, DOI 10.1016/S0921-8777(00)00067-7; Kruyt FAE, 1999, J BIOL CHEM, V274, P34212, DOI 10.1074/jbc.274.48.34212; Kruyt FAE, 1998, BLOOD, V92, P2229, DOI 10.1182/blood.V92.7.2229.2229_2229_2236; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu N, 1997, P NATL ACAD SCI USA, V94, P9232, DOI 10.1073/pnas.94.17.9232; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Naf D, 1998, MOL CELL BIOL, V18, P5952; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; OKUNO H, 1993, ONCOGENE, V8, P695; Opstelten DJE, 1998, J VIROL, V72, P6537, DOI 10.1128/JVI.72.8.6537-6545.1998; Pagano G, 2003, BIOESSAYS, V25, P589, DOI 10.1002/bies.10283; Park JS, 1999, J BIOL CHEM, V274, P29075, DOI 10.1074/jbc.274.41.29075; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Reuter T, 2000, BLOOD, V95, P719, DOI 10.1182/blood.V95.2.719; Saadatzadeh MR, 2004, J BIOL CHEM, V279, P16805, DOI 10.1074/jbc.M313721200; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; You JS, 2003, J BIOL CHEM, V278, P7476, DOI 10.1074/jbc.M210603200; Zunino A, 2001, MUTAGENESIS, V16, P283, DOI 10.1093/mutage/16.3.283	42	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30053	30059		10.1074/jbc.M403527200	http://dx.doi.org/10.1074/jbc.M403527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138265	hybrid			2022-12-27	WOS:000222531900024
J	Bjorklund, M; Heikkila, P; Koivunen, E				Bjorklund, M; Heikkila, P; Koivunen, E			Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; UROKINASE RECEPTOR; SURFACE ASSOCIATION; FIBROSARCOMA CELLS; EPITHELIAL-CELLS; GELATINASE-B; INTEGRIN; ANGIOGENESIS; BINDING; VITRONECTIN	Migration of invasive cells appears to be dependent on matrix metalloproteinases (MMPs) anchored on the cell surface through integrins. We have previously demonstrated an interaction between the integrin alpha-subunit I domain and the catalytic domain of MMP-9. We now show that there is also an interaction between the integrin beta subunit and MMP-9. Using phage display, we have developed MMP-9 inhibitors that bind either to the MMP-9 catalytic domain, the collagen binding domain, or the C-terminal hemopexin-like domain. The C-terminal domain-binding peptide mimics an activation epitope in the stalk of the integrin beta chain and inhibits the association of MMP-9 C-terminal domain with alpha(V)beta(5) integrin. Unlike other MMP-9 binding peptides, it does not directly inhibit catalytic activity of MMP-9, but still prevents proenzyme activation and cell migration in vitro and tumor xenograft growth in vivo. We also find an association between MMP-9 and urokinase-plasminogen activator receptor and find that urokinase-plasminogen activator receptor is cleaved by MMP-9. Collectively, we have defined molecular details for several interactions mediated by the different MMP-9 domains.	Viikki Bioctr, Dept Biol & Environm Sci, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Oral & Maxillofacial Dis, Inst Dent, FIN-00014 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Koivunen, E (corresponding author), Viikki Bioctr, Dept Biol & Environm Sci, Viikinkaari 5D, Helsinki, Finland.	erkki.koivunen@helsinki.fi	Bjorklund, Mikael/AAA-2894-2020; Björklund, Mikael/D-3362-2009	Björklund, Mikael/0000-0002-2176-681X; Koivunen, Erkki/0000-0002-6443-9595				Andolfo A, 2002, THROMB HAEMOSTASIS, V88, P298; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; BEHRENDT N, 1993, METHOD ENZYMOL, V223, P207; Bjorklund M, 2003, COMB CHEM HIGH T SCR, V6, P29; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Carriero MV, 1999, CANCER RES, V59, P5307; Cha HJ, 2002, J MOL BIOL, V320, P1065, DOI 10.1016/S0022-2836(02)00558-2; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Festuccia C, 2002, EXP CELL RES, V280, P1, DOI 10.1006/excr.2002.5609; Filardo EJ, 1996, J CELL SCI, V109, P1615; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Koivunen E, 1999, METH MOL B, V129, P3; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Montuori N, 2002, J BIOL CHEM, V277, P46932, DOI 10.1074/jbc.M207494200; Myohanen H, 2001, BIOL CHEM, V382, P1563, DOI 10.1515/BC.2001.191; Nyberg P, 2003, J BIOL CHEM, V278, P22404, DOI 10.1074/jbc.M210325200; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; PASQUALINI R, 1993, J CELL SCI, V105, P101; Pedersen TL, 2000, ULTRASTRUCT PATHOL, V24, P175, DOI 10.1080/01913120050132912; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; ROLLI M, 2003, P NATL ACAD SCI USA, V21, P21; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; Stefanidakis M, 2004, J IMMUNOL, V172, P7060, DOI 10.4049/jimmunol.172.11.7060; Stefanidakis M, 2003, J BIOL CHEM, V278, P34674, DOI 10.1074/jbc.M302288200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; Toth M, 1997, CANCER RES, V57, P3159; Trexler M, 2003, J BIOL CHEM, V278, P12241, DOI 10.1074/jbc.M210116200; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WANG XQ, 2003, J BIOL CHEM, V30, P30; Xue W, 1997, CANCER RES, V57, P1682; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	48	66	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29589	29597		10.1074/jbc.M401601200	http://dx.doi.org/10.1074/jbc.M401601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123665	hybrid			2022-12-27	WOS:000222445300094
J	Christodoulou, J; Malmendal, A; Harper, JF; Chazin, WJ				Christodoulou, J; Malmendal, A; Harper, JF; Chazin, WJ			Evidence for differing roles for each lobe of the calmodulin-like domain in a calcium-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE SCATTERING; INTRAMOLECULAR BINDING; TARGET RECOGNITION; NMR-SPECTROSCOPY; CA2+ BINDING; ACTIVATION; PEPTIDE; AFFINITY; COMPLEX; N-15	Calcium-dependent protein kinases (CDPKs) are structurally unique Ser/Thr kinases found in plants and certain protozoa. They are distinguished by a calmodulin-like regulatory apparatus (calmodulin-like domain (CaM-LD)) that is joined via a junction (J) region to the C-terminal end of the kinase catalytic domain. Like CaM, the CaM-LD is composed of two globular EF structural domains (N-lobe,C-lobe), each containing a pair of Ca2+ binding sites. Spectroscopic analysis shows that the CaM-LD is comprised of helical elements, but the isolated CaM-LD does not form a conformationally homogeneous tertiary structure in the absence of Ca2+. The addition of substoichiometric amounts of Ca2+ is sufficient to stabilize the C-terminal lobe in a construct containing J and CaM-LD (JC) but not in the CaM-LD alone. Moreover, as J is titrated into Ca2+-saturated CaM-LD, interactions are stronger with the C-lobe than the N-lobe of the CaM-LD. Measurements of Ca2+ affinity for JC reveal two cooperatively interacting high affinity binding sites (K-d,(mean) = 5.6 nM at 20 mM KCl) in the C-lobe and two weaker sites in the N-lobe (K-d,K-mean = 110 nM at 20 mM KCl). The corresponding Ca2+ binding constants in the isolated CaM-LD are lower by more than 2 orders of magnitude, which indicates that the J region has an essential role in stabilizing the structure of the CDPK regulatory apparatus. The large differential affinity between the two domains together with previous studies on a plasmodium CDPK (Zhao, Y., Pokutta, S., Maurer, P., Lindt, M., Franklin, R. M., and Kappes, B. (1994) Biochemistry 33, 3714-3721) suggests a model whereby even at normally low cytosolic levels of Ca2+, the C-lobe interacts with the junction, but the kinase remains in an autoinhibited state. Activation then occurs when Ca2+ levels rise to fill the two weaker affinity binding sites in the N-lobe, thereby triggering a conformational change that leads to release of the autoinhibitory region.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Phys, Nashville, TN 37232 USA; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Aarhus Univ, Dept Chem, NMR Ctr, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Chem, Interdisciplinary Nanosci Ctr, DK-8000 Aarhus, Denmark	Scripps Research Institute; Scripps Research Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Cambridge; Aarhus University; Aarhus University	Harper, JF (corresponding author), Scripps Res Inst, Dept Cell Biol, BCC 283, La Jolla, CA 92037 USA.	harper@scripps.edu	Malmendal, Anders/F-1198-2017; Malmendal, Anders/S-2014-2019	Malmendal, Anders/0000-0002-8413-9717; Malmendal, Anders/0000-0002-8413-9717; Christodoulou, John/0000-0002-6710-3843	NIGMS NIH HHS [GM 40120] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040120, R29GM040120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Biekofsky RR, 1998, BIOCHEMISTRY-US, V37, P7617, DOI 10.1021/bi9800449; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Christodoulou J, 2002, J BIOMOL NMR, V23, P249, DOI 10.1023/A:1019875822571; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; Fersht A., 1999, STRUCTURE MECH PROTE; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARPER JF, 1993, BIOCHEMISTRY-US, V32, P3282, DOI 10.1021/bi00064a010; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Huang JF, 1996, BIOCHEMISTRY-US, V35, P13222, DOI 10.1021/bi960498a; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P17810, DOI 10.1021/bi981656w; Lee JY, 1998, BIOCHEMISTRY-US, V37, P6801, DOI 10.1021/bi980062q; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; LINSE S, 1991, J BIOL CHEM, V266, P8050; Martin SR, 1996, BIOCHEMISTRY-US, V35, P3508, DOI 10.1021/bi952522a; MARTIN SR, 1986, BIOCHEM J, V238, P485, DOI 10.1042/bj2380485; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Peersen OB, 1997, PROTEIN SCI, V6, P794; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rutschmann F, 2002, PLANT PHYSIOL, V129, P156, DOI 10.1104/pp.000869; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; SUEN KL, 1991, PLANT MOL BIOL, V17, P581, DOI 10.1007/BF00037045; Vitart V, 2000, BIOCHEMISTRY-US, V39, P4004, DOI 10.1021/bi992373m; Weljie AM, 2003, PROTEIN SCI, V12, P228, DOI 10.1110/ps.0226203; Weljie AM, 2000, PROTEINS, V39, P343, DOI 10.1002/(SICI)1097-0134(20000601)39:4<343::AID-PROT70>3.0.CO;2-2; Yoo BC, 1996, BIOCHEMISTRY-US, V35, P12029, DOI 10.1021/bi9606612; ZHAO Y, 1992, EUR J BIOCHEM, V207, P305, DOI 10.1111/j.1432-1033.1992.tb17051.x; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031	35	53	59	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29092	29100		10.1074/jbc.M401297200	http://dx.doi.org/10.1074/jbc.M401297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126505	hybrid			2022-12-27	WOS:000222445300033
J	Rundle, DR; Gorbsky, G; Tsiokas, L				Rundle, DR; Gorbsky, G; Tsiokas, L			PKD2 interacts and co-localizes with mDia1 to mitotic spindles of dividing cells - Role of mDia1 in PKD2 localization to mitotic spindles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; ACTIN CYTOSKELETON; MAMMALIAN HOMOLOG; GENE-PRODUCT; SMALL GTPASE; 2ND GENE; PROTEIN; RHO; ACTIVATION; DROSOPHILA	Mutations in pkd2 result in the type 2 form of autosomal dominant polycystic kidney disease, which accounts for similar to15% of all cases of the disease. PKD2, the protein product of pkd2, belongs to the transient receptor potential superfamily of cation channels, and it can function as a mechanosensitive channel in the primary cilium of kidney cells, an intracellular Ca2+ release channel in the endoplasmic reticulum, and/or a nonselective cation channel in the plasma membrane. We have identified mDia1/Drf1 ( mammalian Diaphanous or Diaphanous-related formin 1 protein) as a PKD2-interacting protein by yeast two-hybrid screen. mDia1 is a member of the RhoA GTPase-binding formin homology protein family that participates in cytoskeletal organization, cytokinesis, and signal transduction. We show that mDia1 and PKD2 interact in native and in transfected cells, and binding is mediated by the cytoplasmic C terminus of PKD2 binding to the mDia1 N terminus. The interaction is more prevalent in dividing cells in which endogenous PKD2 and mDia1 co-localize to the mitotic spindles. RNA interference experiments reveal that endogenous mDia1 knockdown in HeLa cells results in the loss of PKD2 from mitotic spindles and alters intracellular Ca2+ release. Our results suggest that mDia1 facilitates the movement of PKD2 to a centralized position during cell division and has a positive effect on intracellular Ca2+ release during mitosis. This may be important to ensure equal segregation of PKD2 to the daughter cell to maintain a necessary level of channel activity. Alternatively, PKD2 channel activity may be important in the cell division process or in cell fate decisions after division.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Mol Cell & Dev Biol Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Tsiokas, L (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.	leonidas-tsiokas@ouhsc.edu		Gorbsky, Gary/0000-0003-3076-4725; Tsiokas, Leonidas/0000-0002-3659-1813	NIDDK NIH HHS [DK59599] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK059599, R01DK059599] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Arnould T, 1999, MOL CELL BIOL, V19, P3423; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; BELL PE, 1988, KIDNEY INT, V34, P683, DOI 10.1038/ki.1988.233; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; CARONE FA, 1995, KIDNEY INT, V47, P861, DOI 10.1038/ki.1995.129; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Gachet Y, 1999, J CELL SCI, V112, P1257; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Kato T, 2001, J CELL SCI, V114, P775; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Kramer J, 2003, NAT CELL BIOL, V5, P261, DOI 10.1038/ncb944; Krebs A, 2001, J CELL SCI, V114, P3663; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Ma R, 2003, J BIOL CHEM, V278, P52763, DOI 10.1074/jbc.M309610200; MARTINEZ JR, 1995, DM-DIS MON, V41, P698, DOI 10.1016/S0011-5029(05)80007-0; Mitsuyama F, 2001, INT J DEV BIOL, V45, P861; Mitsuyama F, 1999, DEV BIOL, V214, P160, DOI 10.1006/dbio.1999.9416; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Vicente-Manzanares M, 2003, J IMMUNOL, V171, P1023, DOI 10.4049/jimmunol.171.2.1023; VOLPI M, 1988, J CELL BIOL, V107, P2533, DOI 10.1083/jcb.107.6.2533; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25	50	88	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29728	29739		10.1074/jbc.M400544200	http://dx.doi.org/10.1074/jbc.M400544200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123714	hybrid			2022-12-27	WOS:000222445300109
J	Sherrill, KW; Byrd, MP; Van Eden, ME; Lloyd, RE				Sherrill, KW; Byrd, MP; Van Eden, ME; Lloyd, RE			BCL-2 translation is mediated via internal ribosome entry during cell stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRES-DEPENDENT TRANSLATION; EUKARYOTIC MESSENGER-RNAS; 5' NONTRANSLATED REGION; ENDOPLASMIC-RETICULUM; FOLLICULAR LYMPHOMA; APOPTOSIS PROTEIN; X-L; EXPRESSION; GENE; INITIATION	The cellular response to stress involves a rapid inhibition of cap-dependent translation via multiple mechanisms, yet some translation persists. This residual translation may include proteins critical to the cellular stress response. BCL-2 is a key inhibitor of intrinsic apoptotic signaling. Its primary transcript contains a 1.45-kb 5'-untranslated region (UTR) including 10 upstream AUGs that may restrict translation initiation via cap-dependent ribosome scanning. Thus, we hypothesized that this 5'-UTR may contain an internal ribosome entry site (IRES) that facilitates BCL-2 translation, particularly during cell stress. Here we show that the BCL-2 5'-UTR demonstrated IRES activity both when translated in vitro and also when m(7)G-capped and polyadenylated mRNA was transiently transfected into 293T cells. The activity of this IRES in unstressed cells was similar to6% the strength of the hepatitis C virus IRES but was induced 3-6-fold in a dose-dependent manner following short term treatment with either etoposide or sodium arsenite. Thus, the IRES-mediated translation of BCL-2 may enable the cell to replenish levels of this critical protein during cell stress, when cap-dependent translation is repressed, thereby maintaining the balance between pro-and anti-apoptotic BCL-2 family members in the cell and preventing unwarranted induction of apoptosis.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Lloyd, RE (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Rm 860E,1 Baylor Plaza, Houston, TX 77030 USA.	rlloyd@bcm.tmc.edu			NIAID NIH HHS [T32 AI0747-7/10, AI 50237] Funding Source: Medline; NIGMS NIH HHS [GM 59803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000747, R01AI050237, R56AI050237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059803] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BORNER C, 1994, BIOCHEM CELL BIOL, V72, P463, DOI 10.1139/o94-062; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; GLISSON BS, 1984, BIOCHIM BIOPHYS ACTA, V783, P74, DOI 10.1016/0167-4781(84)90080-0; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Haile S, 2003, RNA, V9, P1491, DOI 10.1261/rna.5940703; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Harigai M, 1996, ONCOGENE, V12, P1369; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Kim YK, 2003, RNA, V9, P599, DOI 10.1261/rna.2185603; Koev G, 2002, VIROLOGY, V297, P195, DOI 10.1006/viro.2002.1455; Koh DCY, 2003, J BIOL CHEM, V278, P20565, DOI 10.1074/jbc.M210212200; KONDO E, 1992, BLOOD, V80, P2044; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Liang Y, 2002, MOL PHARMACOL, V61, P142, DOI 10.1124/mol.61.1.142; Lin H, 2000, EXP CELL RES, V261, P180, DOI 10.1006/excr.2000.5036; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Ravazoula P, 2002, ANTICANCER RES, V22, P1799; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Saleh H A, 1999, Pathol Oncol Res, V5, P273, DOI 10.1053/paor.1999.0231; SATO T, 1994, GENE, V140, P291, DOI 10.1016/0378-1119(94)90561-4; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tu YP, 1996, BLOOD, V88, P1805, DOI 10.1182/blood.V88.5.1805.bloodjournal8851805; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; Van Eden ME, 2004, RNA, V10, P469, DOI 10.1261/rna.5156804; van Hoof A, 2002, CURR BIOL, V12, pR285, DOI 10.1016/S0960-9822(02)00802-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Yamagiwa Y, 2004, CANCER RES, V64, P1293, DOI 10.1158/0008-5472.CAN-03-2517; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	60	117	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29066	29074		10.1074/jbc.M402727200	http://dx.doi.org/10.1074/jbc.M402727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123638	hybrid			2022-12-27	WOS:000222445300030
J	Harrison, CA; Gray, PC; Fischer, WH; Donaldson, C; Choe, S; Vale, W				Harrison, CA; Gray, PC; Fischer, WH; Donaldson, C; Choe, S; Vale, W			An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; VERTEBRATE DEVELOPMENT; BIOLOGICAL-ACTIVITY; BETA; IDENTIFICATION; COMPLEX; CELL; FOLLISTATIN; INHIBIN; LIGAND	Activins control many physiologic and pathophysiologic processes in multiple tissues and, like other TGF-beta superfamily members, signal via type II (ActRII/IIB) and type I (ALK4) receptor serine kinases. ActRII/IIB are promiscuous receptors known to bind at least a dozen TGF-beta superfamily ligands including activins, myostatin, several BMPs, and nodal. Here we utilize a new screening procedure to rapidly identify activin-A mutants with loss of signaling activity. Our goal was to identify activin-A mutants able to bind ActRII but unable to bind ALK4 and which would be, therefore, candidate type II activin receptor antagonists. Using the structure of BMP-2 bound to its type I receptor (ALK3) as a guide, we introduced mutations in the context of the inhibin betaA cDNA and assessed the signaling activity of the resulting mutant proteins. We identified several mutants in the finger ( M91E, I105E, M108A) and wrist ( activin A/activin C chimera, S60P, I63P) regions of activin-A with reduced signaling activity. Of these the M108A mutant displayed the lowest signaling activity while retaining wild-type-like affinity for ActRII. Unlike wild-type activin-A, the M108A mutant was unable to form a cross-linked complex with ALK4 in the presence of ActRII indicating that its ability to bind ALK4 was disrupted. This data suggested that the M108A mutant might be capable of modulating signaling of activin and related ligands. Indeed, the M108A mutant antagonized activin-A and myostatin, but not TGF-beta, signaling in 293T cells, indicating it may be generally capable of blocking ligands that signal via ActRII/IIB.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute	Vale, W (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vale@salk.edu		Harrison, Craig/0000-0003-1059-3682	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 13527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BILEZIKJIAN LM, 1993, ENDOCRINOLOGY, V133, P2554, DOI 10.1210/en.133.6.2554; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Chabicovsky M, 2003, ENDOCRINOLOGY, V144, P3497, DOI 10.1210/en.2003-0388; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Coerver KA, 1996, MOL ENDOCRINOL, V10, P534, DOI 10.1210/me.10.5.534; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Harrison CA, 2003, J BIOL CHEM, V278, P21129, DOI 10.1074/jbc.M302015200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Mellor SL, 2000, J CLIN ENDOCR METAB, V85, P4851, DOI 10.1210/jc.85.12.4851; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Pernasetti F, 2001, ENDOCRINOLOGY, V142, P2284, DOI 10.1210/en.142.6.2284; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Takabe K, 2003, HEPATOLOGY, V38, P1107, DOI 10.1053/jhep.2003.50483; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VALE W, 1988, LAUR HORM C REC PROG, P1; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; Wankell M, 2003, ANN NY ACAD SCI, V995, P48, DOI 10.1111/j.1749-6632.2003.tb03209.x; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	39	58	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28036	28044		10.1074/jbc.M402782200	http://dx.doi.org/10.1074/jbc.M402782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123686	hybrid			2022-12-27	WOS:000222265400027
J	Shibata, R; Ouchi, N; Kihara, S; Sato, K; Funahashi, T; Walsh, K				Shibata, R; Ouchi, N; Kihara, S; Sato, K; Funahashi, T; Walsh, K			Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; PLASMA-PROTEIN; INSULIN-RESISTANCE; METABOLIC SYNDROME; GLUCOSE-TRANSPORT; ENDOTHELIAL-CELLS; GLOBULAR DOMAIN; GROWTH-FACTOR; NITRIC-OXIDE; ASSOCIATION	Obesity is a risk factor for the development of cardiovascular diseases that are associated with impaired angiogenesis. Adiponectin is an adipocyte-specific adipocytokine with anti-atherogenic and anti-diabetic properties, and its plasma levels are reduced in association with obesity-linked diseases. Here, we investigated whether adiponectin regulates angiogenesis in response to tissue ischemia using adiponectin knock-out ( KO) mice. Angiogenic repair of ischemic hind limbs was impaired in adiponectin-KO mice compared with wildtype (WT) mice as evaluated by laser Doppler flow method and capillary density analyses. Adenovirus-mediated supplement of adiponectin accelerated angiogenic repair in both adiponectin-KO and WT mice. Intramuscular injection of an adenovirus encoding dominant-negative AMP-activated kinase diminished the improvement in limb perfusion seen in WT mice and abolished the adiponectin-induced enhancement of perfusion. These data indicate that adiponectin can function to stimulate angiogenesis in response to ischemic stress by promoting AMP-activated kinase signaling. Therefore, adiponectin may be useful in the treatment for obesity-related vascular deficiency diseases.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan	Boston University; Osaka University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu	OUCHI, Noriyuki/I-7306-2014		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R01AG017241, R37AG015052] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 40197] Funding Source: Medline; NIA NIH HHS [AG 15052, AG 17241] Funding Source: Medline; PHS HHS [HE 23641] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brakenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Grundy SM, 2004, ARTERIOSCL THROM VAS, V24, pE13, DOI 10.1161/01.ATV.0000111245.75752.C6; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; LIND L, 1993, AM HEART J, V125, P1494, DOI 10.1016/0002-8703(93)90446-G; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Noon JP, 1997, J CLIN INVEST, V99, P1873, DOI 10.1172/JCI119354; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2003, HYPERTENSION, V42, P231, DOI 10.1161/01.HYP.0000083488.67550.B8; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Sata M, 2004, HYPERTENSION, V43, P1214, DOI 10.1161/01.HYP.0000126186.29571.41; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; WARLEY A, 1995, DIABETOLOGIA, V38, P413, DOI 10.1007/s001250050300; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; YILMAZ MB, 2003, INT J OBESITY, V27, P15451	34	260	295	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28670	28674		10.1074/jbc.M402558200	http://dx.doi.org/10.1074/jbc.M402558200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123726	hybrid			2022-12-27	WOS:000222265400103
J	Yu, MK; Moos, PJ; Cassidy, P; Wade, M; Fitzpatrick, FA				Yu, MK; Moos, PJ; Cassidy, P; Wade, M; Fitzpatrick, FA			Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase - Modulation of selenoproteins by lipoxygenase enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER CELLS; ACTIVATED RECEPTOR-GAMMA; DRUG-INDUCED APOPTOSIS; MOLECULAR TARGET; COLON-CANCER; SUICIDE INACTIVATION; ARACHIDONIC-ACID; CARCINOMA-CELLS; GENE-EXPRESSION; LINOLEIC-ACID	The selenoenzyme thioredoxin reductase regulates redox-sensitive proteins involved in inflammation and carcinogenesis, including ribonucleotide reductase, p53, NFkappaB, and others. Little is known about endogenous cellular factors that modulate thioredoxin reductase activity. Here we report that several metabolites of 15-lipoxygenase-1 inhibit purified thioredoxin reductase in vitro. 15(S)-Hydroperoxy-5,8,11-cis-13-trans-eicosatetraenoic acid, a metastable hydroperoxide generated by 15-lipoxygenase-1, and 4-hydroxy-2-nonenal, its non-enzymatic rearrangement product inhibit thioredoxin reductase with IC50 = 13 +/- 1.5 muM and 1 +/- 0.2 muM, respectively. Endogenously generated metabolites of 15-lipoxygenase- 1 also inhibit thioredoxin reductase in HEK-293 cells that harbor a 15-LOX-1 gene under the control of an inducible promoter complex. Conditional, highly selective induction of 15-lipoxygenase- 1 caused an inhibition of ribonucleotide reductase activity, cell cycle arrest in G(1), impairment of anchorage-independent growth, and accumulation of the pro-apoptotic protein BAX. All of these responses are consistent with inhibition of thioredoxin reductase via 15-lipoxygenase- 1 overexpression. In contrast, metabolites of 5-lipoxygenase were poor inhibitors of isolated thioredoxin reductase, and the overexpression of 5-lipoxygenase did not inhibit thioredoxin reductase or cause a G(1) cell cycle arrest. The influences of 15-lipoxygenase- 1 on inflammation, cell growth, and survival may be attributable, in part, to inhibition of thioredoxin reductase and several redox-sensitive processes subordinate to thioredoxin reductase.	Univ Utah Hlth Sci, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah Hlth Sci, Huntsman Canc Inst, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Utah Hlth Sci, Huntsman Canc Inst, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Utah Hospital; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Utah Hospital; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Utah Hospital	Fitzpatrick, FA (corresponding author), Univ Utah Hlth Sci, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA.	frank.fitzpatrick@hci.utah.edu		Moos, Philip/0000-0002-8223-442X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 26730] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; BAUER KD, 1993, CLIN FLOW CYTOMETRY, P44; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Bortuzzo C, 1996, BBA-LIPID LIPID MET, V1300, P240, DOI 10.1016/0005-2760(96)00003-3; Bosch-Morell F, 1999, FREE RADICAL BIO MED, V26, P1383, DOI 10.1016/S0891-5849(98)00335-9; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; Burcham PC, 1998, MUTAGENESIS, V13, P287, DOI 10.1093/mutage/13.3.287; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cenas N, 2004, J BIOL CHEM, V279, P2583, DOI 10.1074/jbc.M310292200; Chen GG, 2003, INT J CANCER, V107, P837, DOI 10.1002/ijc.11447; GARDNER HW, 1975, J AGR FOOD CHEM, V23, P129, DOI 10.1021/jf60198a012; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Hawcroft G, 2002, CARCINOGENESIS, V23, P107, DOI 10.1093/carcin/23.1.107; Hsi LC, 2001, J BIOL CHEM, V276, P34545, DOI 10.1074/jbc.M100280200; Ikawa H, 1999, CANCER RES, V59, P360; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kelavkar Uddhav, 2002, Curr Urol Rep, V3, P207, DOI 10.1007/s11934-002-0066-8; Kelavkar UP, 2000, CARCINOGENESIS, V21, P1777; Kelavkar UP, 2001, CARCINOGENESIS, V22, P1765, DOI 10.1093/carcin/22.11.1765; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Mariadason JM, 2000, CANCER RES, V60, P4561; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Powis G, 1997, ONCOL RES, V9, P303; Profita M, 2002, J PHARMACOL EXP THER, V300, P868, DOI 10.1124/jpet.300.3.868; Saez E, 2000, P NATL ACAD SCI USA, V97, P14512, DOI 10.1073/pnas.260499497; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Shappell SB, 2001, CANCER RES, V61, P497; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 2000, CANCER RES, V60, P6846; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Stewart ZA, 1999, CANCER RES, V59, P3831; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; TANG S, 2000, J BIOL CHEM, V277, P16189; Valderrama B, 2002, CHEM BIOL, V9, P555, DOI 10.1016/S1074-5521(02)00149-7; Wu G, 2001, J BIOL CHEM, V276, P19879, DOI 10.1074/jbc.M100628200; YEH YC, 1978, J BIOL CHEM, V253, P1323; Zhang ZH, 2000, GASTROENTEROLOGY, V118, P1012, DOI 10.1016/S0016-5085(00)70352-0	52	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28028	28035		10.1074/jbc.M313939200	http://dx.doi.org/10.1074/jbc.M313939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123685	hybrid			2022-12-27	WOS:000222265400026
J	Harvey, BP; Banga, SS; Ozer, HL				Harvey, BP; Banga, SS; Ozer, HL			Regulation of the multifunctional Ca2+/calmodulin-dependent protein kinase II by the PP2C phosphatase PPM1F in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; EXTRACELLULAR CALCIUM; PYRAMIDAL NEURONS; OKADAIC-ACID; 2A ACTIVITY; 3Y1 CELLS; CALMODULIN; AUTOPHOSPHORYLATION; ACTIVATION; GROWTH	The regulation of the multifunctional calcium/calmodulin dependent protein kinase II (CaMKII) by serine/threonine protein phosphatases has been extensively studied in neuronal cells; however, this regulation has not been investigated previously in fibroblasts. We cloned a cDNA from SV40-transformed human fibroblasts that shares 80% homology to a rat calcium/calmodulin-dependent protein kinase phosphatase that encodes a PPM1F protein. By using extracts from transfected cells, PPM1F, but not a mutant (R326A) in the conserved catalytic domain, was found to dephosphorylate in vitro a peptide corresponding to the autoinhibitory region of CaMKII. Further analyses demonstrated that PPM1F specifically dephosphorylates the phospho-Thr-286 in autophosphorylated CaMKII substrate and thus deactivates the CaMKII in vitro. Coimmunoprecipitation of CaMKII with PPM1F indicates that the two proteins can interact intracellularly. Binding of PPM1F to CaMKII involves multiple regions and is not dependent on intact phosphatase activity. Furthermore, overexpression of PPM1F in fibroblasts caused a reduction in the CaMKII-specific phosphorylation of the known substrate vimentin(Ser-82) following induction of the endogenous CaM kinase. These results identify PPM1F as a CaM kinase phosphatase within fibroblasts, although it may have additional functions intracellularly since it has been presented elsewhere as POPX2 and hFEM-2. We conclude that PPM1F, possibly together with the other previously described protein phosphatases PP1 and PP2A, can regulate the activity of CaMKII. Moreover, because PPM1F dephosphorylates the critical autophosphorylation site of CaMKII, we propose that this phosphatase plays a key role in the regulation of the kinase intracellularly.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07101 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ozer, HL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave,MSB,Rm C-671, Newark, NJ 07101 USA.	ozerhl@umdnj.edu			NCI NIH HHS [T32 CA09665] Funding Source: Medline; NIA NIH HHS [AG04821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aplin AE, 1999, J CELL SCI, V112, P695; Bennecib M, 2001, FEBS LETT, V490, P15, DOI 10.1016/S0014-5793(01)02127-5; BOYNTON AL, 1977, J CELL PHYSIOL, V92, P241, DOI 10.1002/jcp.1040920212; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; Cai XA, 2002, J BIOL CHEM, V277, P36553, DOI 10.1074/jbc.M203752200; Chang BH, 1998, P NATL ACAD SCI USA, V95, P10890, DOI 10.1073/pnas.95.18.10890; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DERMODY JJ, 1986, MOL CELL BIOL, V6, P4594, DOI 10.1128/MCB.6.12.4594; Dhavan R, 2002, J NEUROSCI, V22, P7879; DURKIN JP, 1981, BIOCHEM BIOPH RES CO, V103, P233, DOI 10.1016/0006-291X(81)91684-3; Easom RA, 1998, BIOCHEM J, V329, P283; Enns L, 1999, BRIT J CANCER, V81, P959, DOI 10.1038/sj.bjc.6690793; Famulski KS, 1999, FEBS LETT, V453, P183, DOI 10.1016/S0014-5793(99)00664-X; Fladmark KE, 2002, J BIOL CHEM, V277, P2804, DOI 10.1074/jbc.M109049200; Fukunaga K, 2000, J NEUROCHEM, V74, P807, DOI 10.1046/j.1471-4159.2000.740807.x; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; Gardoni F, 2001, J BIOL CHEM, V276, P7609, DOI 10.1074/jbc.M009922200; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GORELICK FS, 1988, J BIOL CHEM, V263, P17209; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; He H, 2001, J BIOL CHEM, V276, P26741, DOI 10.1074/jbc.C100229200; Hwang J, 1996, BIOCHEM BIOPH RES CO, V225, P520, DOI 10.1006/bbrc.1996.1205; Ishida A, 1998, BIOCHEM BIOPH RES CO, V253, P159, DOI 10.1006/bbrc.1998.9771; Ishida A, 2002, ARCH BIOCHEM BIOPHYS, V408, P229, DOI 10.1016/S0003-9861(02)00592-1; Ishida A, 1998, J BIOL CHEM, V273, P1904, DOI 10.1074/jbc.273.4.1904; JHA KK, 1978, J CELL PHYSIOL, V97, P147, DOI 10.1002/jcp.1040970203; Kameshita I, 1997, ANAL BIOCHEM, V245, P149, DOI 10.1006/abio.1996.9945; Kitani A, 1998, J IMMUNOL, V161, P4931; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; KLUG M, 1991, CELL BIOL INT REP, V15, P907, DOI 10.1016/0309-1651(91)90141-5; Koh CG, 2002, CURR BIOL, V12, P317, DOI 10.1016/S0960-9822(02)00652-8; LOU LL, 1989, J NEUROSCI, V9, P2020; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Menegon A, 2002, J NEUROSCI, V22, P7016; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Mishra-Gorur K, 2002, AM J PATHOL, V161, P1893, DOI 10.1016/S0002-9440(10)64465-3; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; Nomura K, 2003, J NEUROSCI RES, V72, P198, DOI 10.1002/jnr.10563; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Ofek P, 2003, J BIOL CHEM, V278, P14299, DOI 10.1074/jbc.M211699200; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; OHTA Y, 1988, J BIOL CHEM, V263, P11540; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; Pardinas J, 1997, J CELL PHYSIOL, V171, P325, DOI 10.1002/(SICI)1097-4652(199706)171:3<325::AID-JCP11>3.0.CO;2-9; Scholz WK, 1998, J NEUROCHEM, V71, P580; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; Strack S, 1997, J NEUROCHEM, V68, P2119; Tan KML, 2001, J BIOL CHEM, V276, P44193, DOI 10.1074/jbc.M105880200; TERASAWA M, 1991, J BIOCHEM-TOKYO, V110, P417, DOI 10.1093/oxfordjournals.jbchem.a123596; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; Tombes RM, 1999, BBA-MOL CELL RES, V1452, P1, DOI 10.1016/S0167-4889(99)00113-5; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Wang N, 2002, J MUSCLE RES CELL M, V23, P535, DOI 10.1023/A:1023470709071; YATSUNAMI J, 1991, BIOCHEM BIOPH RES CO, V177, P1165, DOI 10.1016/0006-291X(91)90662-Q; Yoshimura Y, 1999, FEBS LETT, V446, P239, DOI 10.1016/S0014-5793(99)00226-4; Zhang S, 2003, CIRCULATION, V107, P1539, DOI 10.1161/01.CIR.0000056766.45109.C1; Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200	64	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24889	24898		10.1074/jbc.M400656200	http://dx.doi.org/10.1074/jbc.M400656200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140879	hybrid			2022-12-27	WOS:000221702500121
J	Jang, HD; Yoon, K; Shin, YJ; Kim, J; Lee, SY				Jang, HD; Yoon, K; Shin, YJ; Kim, J; Lee, SY			PIAS3 suppresses NF-kappa B-mediated transcription by interacting with the p65/RelA subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INHIBITOR; STAT3 INHIBITOR; GENE ACTIVATION; BINDING; PHOSPHORYLATION; REQUIRES; CANCER; DOMAIN; ASSOCIATION; CONJUGATION	Nuclear factor-kappaB (NF-kappaB) is a transcription factor critical for key cellular processes, including immune response, apoptosis, and cell cycle progression. A yeast two-hybrid screening, using the Rel homology domain (RHD) of the p65 subunit (RelA) of NF-kappaB as bait, led to the isolation of PIAS3, previously identified as a specific inhibitor of STAT3. We show that PIAS3 can directly associate with p65 using an in vitro pull-down and in vivo coimmunoprecipitation assays. When overexpressed, PIAS3 inhibits NF-kappaB-dependent transcription induced by treatment with tumor necrosis factor alpha (TNF-alpha) or interleukin-1beta or by overexpression of TNF family receptors such as RANK, TNFR1, and CD30 or signal transducers of TNF receptor-associated factors (TRAFs), including TRAF2, TRAF5, and TRAF6. Down-regulation of PIAS3 by RNA interference reverses its effect on TNF-alpha-mediated NF-kappaB activation. We found that an N-terminal region of PIAS3 is necessary for both the interaction with p65 and the transcriptional suppression activity. In addition, we found that an LXXLL coregulator signature motif located within the N-terminal region of PIAS3 is the minimal requirement for the interaction with p65. Furthermore, we demonstrate that PIAS3 interferes with p65 binding to the CBP coactivator, thereby resulting in a decreased NF-kappaB-dependent transcription. Taken together, these data suggest that PIAS3 may function in vivo as a modulator in suppressing the transcriptional activity of p65.	Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea	Ewha Womans University; Ewha Womans University	Lee, SY (corresponding author), Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea.	leesy@ewha.ac.kr						Alen P, 1999, MOL CELL BIOL, V19, P6085; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bours V, 2000, TOXICOLOGY, V153, P27, DOI 10.1016/S0300-483X(00)00302-4; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Chung YM, 2001, BIOCHEM BIOPH RES CO, V284, P15, DOI 10.1006/bbrc.2001.4936; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Foo SY, 1999, TRENDS GENET, V15, P229; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Jimenez-Lara AM, 2002, FEBS LETT, V526, P142, DOI 10.1016/S0014-5793(02)03154-X; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P667, DOI 10.1073/pnas.012317299; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Levy C, 2002, J BIOL CHEM, V277, P1962, DOI 10.1074/jbc.M109236200; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; SCHDEV S, 2001, GENE DEV, V15, P3088; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	45	85	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24873	24880		10.1074/jbc.M313018200	http://dx.doi.org/10.1074/jbc.M313018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140884	hybrid			2022-12-27	WOS:000221702500119
J	Swingle, MR; Honkanen, RE; Ciszak, EM				Swingle, MR; Honkanen, RE; Ciszak, EM			Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; TRANSITION-STATE; CALCINEURIN; SUBUNIT; IDENTIFICATION; PHOSPHORYL; ISOTOPE; PP5	Serine/threonine protein phosphatase-5 (PP5) affects many signaling networks that regulate cell growth and cellular responses to stress. Here we report the crystal structure of the PP5 catalytic domain (PP5c) at a resolution of 1.6 Angstrom. From this structure we propose a mechanism for PP5-mediated hydrolysis of phosphoprotein substrates, which requires the precise positioning of two metal ions within a conserved Asp(271)-M-1: M-2-W-1-His(427)-His(304)-Asp(274) catalytic motif (where M-1 and M-2 are metals and W-1 is a water molecule). The structure of PP5c provides a structural basis for explaining the exceptional catalytic proficiency of protein phosphatases, which are among the most powerful known catalysts. Resolution of the entire C terminus revealed a novel subdomain, and the structure of the PP5c should also aid development of type-specific inhibitors.	NASA, George C Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35812 USA; Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; Univ Alabama, Struct Biol Lab, Huntsville, AL 35812 USA	National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; University of South Alabama; University of Alabama System; University of Alabama Huntsville	Ciszak, EM (corresponding author), NASA, George C Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35812 USA.	ewa.m.ciszak@nasa.gov			NCI NIH HHS [CA 60750, R01 CA060750] Funding Source: Medline; NHLBI NIH HHS [HL 59154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060750, R29CA060750] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baes C.R., 1976, HYDROLYSIS CATIONS, P219; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bertini I., 1994, BIOINORG CHEM, P37; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Hengge AC, 2002, ACCOUNTS CHEM RES, V35, P105, DOI 10.1021/ar000143q; Hengge AC, 2001, FEBS LETT, V501, P99, DOI 10.1016/S0014-5793(01)02638-2; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P10185, DOI 10.1021/bi9706374; Hoff RH, 1999, J AM CHEM SOC, V121, P6382, DOI 10.1021/ja990667p; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Jackson MD, 2001, CHEM REV, V101, P2313, DOI 10.1021/cr000247e; Kang H, 2001, BIOCHEMISTRY-US, V40, P10485, DOI 10.1021/bi010999i; KING MM, 1984, J BIOL CHEM, V259, P8847; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; Lad C, 2003, P NATL ACAD SCI USA, V100, P5607, DOI 10.1073/pnas.0631607100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MARTIN BL, 1986, J BIOL CHEM, V261, P4545; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mertz P, 1997, J BIOL CHEM, V272, P21296, DOI 10.1074/jbc.272.34.21296; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myles T, 2001, BIOCHEM J, V357, P225, DOI 10.1042/0264-6021:3570225; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; RAJCA A, 1987, J AM CHEM SOC, V109, P4189, DOI 10.1021/ja00248a011; Reiter TA, 2002, BIOCHEMISTRY-US, V41, P15404, DOI 10.1021/bi026317o; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Rusnak F, 1996, J BIOL INORG CHEM, V1, P388, DOI 10.1007/s007750050070; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Smoukov SK, 2002, J AM CHEM SOC, V124, P2595, DOI 10.1021/ja003169l; Ullrich V, 2003, TOXICOL LETT, V139, P107, DOI 10.1016/S0378-4274(02)00424-1; Urban G, 2003, J BIOL CHEM, V278, P9747, DOI 10.1074/jbc.M210993200; Urban G, 2001, J BIOL CHEM, V276, P27638, DOI 10.1074/jbc.M103512200; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WYNNE CJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P133, DOI 10.1006/abbi.1995.1275; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yu L, 1997, BIOCHEMISTRY-US, V36, P10727, DOI 10.1021/bi970519g; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; Zhang LF, 1997, BIOCHEMISTRY-US, V36, P8209, DOI 10.1021/bi9704865; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	70	88	90	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33992	33999		10.1074/jbc.M402855200	http://dx.doi.org/10.1074/jbc.M402855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155720	hybrid			2022-12-27	WOS:000223039700110
J	Petrakis, TG; Wittschieben, BO; Svejstrup, JQ				Petrakis, TG; Wittschieben, BO; Svejstrup, JQ			Molecular architecture, structure-function relationship, and importance of the Elp3 subunit for the RNA binding of holo-elongator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; SACCHAROMYCES-CEREVISIAE ELONGATOR; KLUYVEROMYCES-LACTIS ZYMOCIN; IN-VIVO; HISTONE ACETYLTRANSFERASE; COMPLEX; PROTEIN; YEAST; ACETYLATION; GENES	The molecular architecture of six-subunit yeast holo-Elongator complex was investigated by the use of immunoprecipitation, two-hybrid interaction mapping, and in vitro studies of binary interactions between individual subunits. Surprisingly, Elp2 is dispensable for the integrity of the holo-Elongator complex, and a purified five-subunit elp2Delta Elongator complex retains histone acetyltransferase activity in vitro. These results indicate that the WD40 repeats in Elp2 are required neither for subunit-subunit interactions within Elongator nor for Elongator interaction with histones during catalysis. Elp2 and Elp4 were largely dispensable for the association of Elongator with nascent RNA transcript in vivo. In contrast, Elongator-RNA interaction requires the Elp3 protein. Together, these data shed light on the structure-function relationship of the Elongator complex.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Svejstrup, JQ (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk		Svejstrup, Jesper/0000-0003-4964-6147				Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; Fichtner L, 2003, MOL MICROBIOL, V49, P1297, DOI 10.1046/j.1365-2958.2003.03632.x; Fichtner L, 2002, MOL MICROBIOL, V45, P817, DOI 10.1046/j.1365-2958.2002.03055.x; Fichtner L, 2002, MOL MICROBIOL, V43, P783, DOI 10.1046/j.1365-2958.2002.02794.x; Formosa T, 2002, GENETICS, V162, P1557; Frohloff F, 2003, J BIOL CHEM, V278, P956, DOI 10.1074/jbc.M210060200; Frohloff F, 2001, EMBO J, V20, P1993, DOI 10.1093/emboj/20.8.1993; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; Jona G, 2001, GENE, V267, P31, DOI 10.1016/S0378-1119(01)00389-4; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Krogan NJ, 2001, MOL CELL BIOL, V21, P8203, DOI 10.1128/MCB.21.23.8203-8212.2001; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Li Y, 2001, J BIOL CHEM, V276, P29628, DOI 10.1074/jbc.C100274200; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Van Mullem V, 2002, J BIOL CHEM, V277, P10220, DOI 10.1074/jbc.M107207200; Vermaak D, 1999, MOL CELL BIOL, V19, P5847; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Winkler GS, 2002, P NATL ACAD SCI USA, V99, P3517, DOI 10.1073/pnas.022042899; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	23	30	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32087	32092		10.1074/jbc.M403361200	http://dx.doi.org/10.1074/jbc.M403361200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15138274	hybrid			2022-12-27	WOS:000222849700013
J	Golestaneh, N; Fan, JG; Fariss, RN; Lo, WK; Zelenka, PS; Chepelinsky, AB				Golestaneh, N; Fan, JG; Fariss, RN; Lo, WK; Zelenka, PS; Chepelinsky, AB			Lens major intrinsic Protein (MIP)/aquaporin expression in rat lens epithelia explants requires fibroblast growth factor-induced ERK and JNK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER CELL-DIFFERENTIATION; CATARACTOUS HUMAN LENSES; TRANSGENIC MICE; OCULAR LENS; MOUSE LENS; MIP; PROLIFERATION; GENE; AQUAPORIN-0; DISRUPTION	Lens major intrinsic protein (MIP), exclusive to the vertebrate lens, otherwise known as MIP26 and Aquaporin 0, is abundantly expressed as a lens fiber membrane protein. Although relatively less efficient compared with other aquaporins, MIP is suggested to function as a water channel, as an adhesion molecule, and is required for lens transparency. Because MIP is specifically expressed in lens fiber cells, we investigated in this study the activation of Mip expression after triggering differentiation of rat lens epithelia explants by fibroblast growth factor (FGF)-2. Here, we show that Mip expression in the lens cells is regulated by FGF-2. Using Real time PCR we demonstrate that endogenous Mip levels in the explants were up-regulated upon FGF-2 stimulation, in a concentration-dependent manner. Up-regulation of Mip at the transcriptional level was simultaneous with the activation of the FGF downstream signaling components, ERK1/2 and JNK. Specific inhibitors, UO126 for ERK1/2 and SP600125 for JNK, abrogated Mip expression in response to FGF-2 in the explants. This inhibition pattern was recapitulated in reporter assays for transfection of the rat lens epithelia explants, driven by the Mip promoter ( -1648/ +44). Our studies show that ERK1/2 and JNK signaling pathways are required for Mip expression in lens epithelia explants induced to differentiate by FGF-2.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Morehouse Sch Med, Dept Anat & Neurobiol, Atlanta, GA 30310 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Morehouse School of Medicine	Chepelinsky, AB (corresponding author), NEI, Mol & Dev Biol Lab, NIH, 7 Mem Dr,MSC 0704 Bldg 7,Rm 105, Bethesda, MD 20892 USA.		Fariss, Robert/ABI-1771-2020	Fariss, Robert/0000-0003-3227-7170	NATIONAL EYE INSTITUTE [Z01EY000238, ZIAEY000238, Z01EY000253] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Belecky-Adams TL, 2002, DEVELOPMENT, V129, P3795; Berry V, 2000, NAT GENET, V25, P15, DOI 10.1038/75538; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Boyle DL, 1999, EXP EYE RES, V68, P41, DOI 10.1006/exer.1998.0579; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; Chamberlain CG, 1989, GROWTH FACTORS, V1, P125, DOI 10.3109/08977198909029122; Chepelinsky AB, 2003, J EXP ZOOL PART A, V300A, P41, DOI 10.1002/jez.a.10307; Chow RL, 1995, DEVELOPMENT, V121, P4383; DePianto DJ, 2003, MOL VIS, V9, P288; Dunia I, 1998, J CELL SCI, V111, P2109; EGWUAGU CE, 1994, DEV BIOL, V166, P557, DOI 10.1006/dbio.1994.1337; Faber SC, 2002, DEVELOPMENT, V129, P3727; Fotiadis D, 2000, J MOL BIOL, V300, P779, DOI 10.1006/jmbi.2000.3920; Francis P, 2000, HUM MOL GENET, V9, P2329, DOI 10.1093/oxfordjournals.hmg.a018925; Gong XH, 2001, INVEST OPHTH VIS SCI, V42, P539; Grey AC, 2003, EXP EYE RES, V77, P567, DOI 10.1016/S0014-4835(03)00192-1; Klok EJ, 1998, EXP EYE RES, V67, P425, DOI 10.1006/exer.1998.0534; Kok A, 2002, GROWTH FACTORS, V20, P27, DOI 10.1080/08977190290022202; Lang RA, 1999, INVEST OPHTH VIS SCI, V40, P3075; Le ACN, 2001, DEV BIOL, V233, P394, DOI 10.1006/dbio.2001.0194; Leenders WPJ, 1997, MECH DEVELOP, V67, P193, DOI 10.1016/S0925-4773(97)00121-4; Lovicu FJ, 2001, DEVELOPMENT, V128, P5075; Lovicu FJ, 1998, DEVELOPMENT, V125, P3365; McAvoy JW, 1999, EYE, V13, P425, DOI 10.1038/eye.1999.117; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; MICHEA LF, 1995, EXP EYE RES, V61, P293, DOI 10.1016/S0014-4835(05)80124-1; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; Ochi H, 2003, J BIOL CHEM, V278, P537, DOI 10.1074/jbc.M208380200; Ohtaka-Maruyama C, 1998, DEV BIOL, V202, P125, DOI 10.1006/dbio.1998.8997; Okamura T, 2003, GENOMICS, V81, P361, DOI 10.1016/S0888-7543(03)00029-6; Potts JD, 1998, DEV BIOL, V204, P277, DOI 10.1006/dbio.1998.9077; Robinson ML, 1995, DEVELOPMENT, V121, P3959; Robinson ML, 1998, DEV BIOL, V198, P13, DOI 10.1016/S0012-1606(98)80026-2; Saika S, 2001, EXP EYE RES, V72, P679, DOI 10.1006/exer.2001.1002; SAX CM, 1995, EXP EYE RES, V61, P125, DOI 10.1016/S0014-4835(95)80066-2; Seth RK, 2001, INVEST OPHTH VIS SCI, V42, P3239; Shiels A, 2000, FASEB J, V14, P2207, DOI 10.1096/fj.99-1071com; Shiels A, 2001, PHYSIOL GENOMICS, V7, P179, DOI 10.1152/physiolgenomics.00078.2001; Sidjanin DJ, 2001, GENOMICS, V74, P313, DOI 10.1006/geno.2001.6509; STEVEN ZD, 2002, EXP EYE RES, V75, P177; Stolen CM, 1997, DEVELOPMENT, V124, P4009; Stolen CM, 2000, DEV BIOL, V217, P205, DOI 10.1006/dbio.1999.9557; Tan FG, 2004, INVEST OPHTH VIS SCI, V45, P863, DOI 10.1167/iovs.03-0708; Varadaraj K, 1999, J MEMBRANE BIOL, V170, P191, DOI 10.1007/s002329900549; Verkman AS, 2003, EXP EYE RES, V76, P137, DOI 10.1016/S0014-4835(02)00303-2; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; Wride MA, 1996, DIFFERENTIATION, V61, P77, DOI 10.1046/j.1432-0436.1996.6120077.x; Yu XS, 2004, J CELL SCI, V117, P871, DOI 10.1242/jcs.00945; Zatechka DS, 2002, EXP EYE RES, V74, P703, DOI 10.1006/exer.2002.1168	49	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31813	31822		10.1074/jbc.M403473200	http://dx.doi.org/10.1074/jbc.M403473200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145928	hybrid			2022-12-27	WOS:000222726800108
J	Hleb, M; Murphy, S; Wagner, EF; Hanna, NN; Sharma, N; Park, J; Li, XC; Strom, TB; Padbury, JF; Tseng, YT; Sharma, S				Hleb, M; Murphy, S; Wagner, EF; Hanna, NN; Sharma, N; Park, J; Li, XC; Strom, TB; Padbury, JF; Tseng, YT; Sharma, S			Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; CELL-CYCLE; CYCLOSPORINE-A; DOWN-REGULATION; MESSENGER-RNA; IMMUNOSUPPRESSANT RAPAMYCIN; RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; GROWTH-INHIBITION; MAMMALIAN TARGET	The immunosuppressant rapamycin has been shown to inhibit G(1)/S transition of the cell cycle. This inhibition is thought to be mediated by maintenance of the threshold levels of cyclin-dependent kinase (CDK) inhibitor p27(Kip1) (p27) and inhibition of p70 s6 kinase (p70(s6k)). However, recent evidence suggests that cells still remain sensitive to rapamycin in the absence of functional p27 or p70(s6k). Here, we show that rapamycin represses cyclin D3 levels in activated human T lymphocytes with no inhibitory effects on cyclin D2. Furthermore, rapamycin elicits similar cyclin D3 modulatory effects in B lymphocytes. The overall effect of rapamycin on cyclin D3 leads to impaired formation of active complexes with Cdk4 or Cdk6 and subsequent inhibition of cyclin D3/CDK kinase activity. Decrease in cyclin D3 protein levels is due to translational repression and not due to attenuated transcription of the cyclin D3 gene. Importantly, stable overexpression of cyclin D3 ( 2 - 2.5 fold) in Jurkat T cell transfectants renders them resistant to lower doses ( 1 - 10 ng/ml) of rapamycin. These results point to a critical role of cyclin D3 in rapamycin-mediated immunosuppressive effects in T cells and cell cycle regulation in lymphocytes in general.	Women & Infants Hosp Rhode Isl, Brown Med Sch, Dept Pediat, Providence, RI 02905 USA; Women & Infants Hosp Rhode Isl, Brown Med Sch, Dept Pathol, Providence, RI 02905 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Immunol, Boston, MA 02215 USA	Brown University; Women & Infants Hospital Rhode Island; Brown University; Women & Infants Hospital Rhode Island; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Sharma, S (corresponding author), Women & Infants Hosp Rhode Isl, Brown Med Sch, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA.	ssharma@wihri.org	Hanna, Nazeeh/W-1996-2019; Strom, Terry B./E-9268-2010	Strom, Terry B./0000-0002-7570-0736; hanna, nazeeh/0000-0003-2167-5712; Li, Xian Chang/0000-0002-5981-2762	NCRR NIH HHS [1P20 RR018728-01] Funding Source: Medline; NIAID NIH HHS [AI/GF41521, AI42298, P01 AI041521] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042298, P01AI041521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BIERER BE, 1995, P ASSOC AM PHYSICIAN, V107, P28; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Combadiere B, 1998, IMMUNITY, V9, P305, DOI 10.1016/S1074-7613(00)80613-5; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dumont F J, 1996, Life Sci, V58, P373; DUMONT FJ, 1994, J IMMUNOL, V152, P992; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Juan G, 1996, CELL PROLIFERAT, V29, P259, DOI 10.1046/j.1365-2184.1996.01000.x; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kuchiki H, 2000, INT J CANCER, V85, P113, DOI 10.1002/(SICI)1097-0215(20000101)85:1<113::AID-IJC20>3.0.CO;2-3; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Marx SO, 1999, MOL CELL BIOL, V19, P6041; Materna T, 1998, ANAL BIOCHEM, V255, P161, DOI 10.1006/abio.1997.2464; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; Nagasawa M, 1997, J IMMUNOL, V158, P5146; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Piva R, 1999, J NEUROPATH EXP NEUR, V58, P691, DOI 10.1097/00005072-199907000-00002; Powell JD, 1999, J IMMUNOL, V162, P2775; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Suthanthiran M, 1997, PEDIATR NEPHROL, V11, P651, DOI 10.1007/s004670050359; Takahama Y, 1996, J IMMUNOL, V157, P1508; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; Wagner EF, 1998, J IMMUNOL, V161, P1123; Watson DS, 1999, ONCOLOGY-BASEL, V56, P66, DOI 10.1159/000011932	68	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31948	31955		10.1074/jbc.M400638200	http://dx.doi.org/10.1074/jbc.M400638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131122	hybrid			2022-12-27	WOS:000222726800123
J	Johnson, E; Theisen, CS; Johnson, KR; Wheelock, MJ				Johnson, E; Theisen, CS; Johnson, KR; Wheelock, MJ			R-cadherin influences cell motility via Rho family GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CADHERIN; P120 CATENIN; VE-CADHERIN; ACTIN CYTOSKELETON; CONTACT FORMATION; CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL EXPRESSION; ENDOTHELIAL-CELLS; CARCINOMA-CELLS	Classical cadherins are the transmembrane proteins of the adherens junction and mediate cell-cell adhesion via homotypic interactions in the extracellular space. In addition, they mediate connections to the cytoskeleton by means of their association with catenins. Decreased cadherin-mediated adhesion has been implicated as an important component of tumorigenesis. Cadherin switching is central to the epithelial to mesenchymal transitions that drive normal developmental processes. Cadherin switching has also been implicated in tumorigenesis, particularly in metastasis. Recently, cadherins have been shown to be engaged in cellular activities other than adhesion, including motility, invasion, and signaling. In this study, we show that inappropriate expression of R-cadherin in tumor cells results in decreased expression of endogenous cadherins ( cadherin switching) and sustained signaling through Rho GTPases. In addition, we show that R-cadherin induces cell motility when expressed in epithelial cells and that this increased motility is dependent upon Rho GTPase activity.	Univ Nebraska, Med Ctr 987696, Dept Oral Biol, Coll Dent, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wheelock, MJ (corresponding author), Univ Nebraska, Med Ctr 987696, Dept Oral Biol, Coll Dent, 600 S 42nd St, Omaha, NE 68198 USA.	mwheelock@unmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051188] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR018759] Funding Source: Medline; NIDCR NIH HHS [R01-DE12308] Funding Source: Medline; NIGMS NIH HHS [R01-GM51188] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Giroldi Laurence A., 2000, Morphologie, V84, P31; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Grignani F, 1998, CANCER RES, V58, P14; Grosheva I, 2001, J CELL SCI, V114, P695; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; INUZUKA H, 1991, DEVELOPMENT, V113, P959; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Jaggi M, 2002, CELL COMMUN ADHES, V9, P103, DOI 10.1080/15419060214150; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; MATSUNAMI H, 1993, J CELL SCI, V106, P401; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nieman MT, 1999, J CELL SCI, V112, P1621; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pishvaian MJ, 1999, CANCER RES, V59, P947; Redfield A, 1997, J CELL BIOL, V138, P1323, DOI 10.1083/jcb.138.6.1323; REDIES C, 1993, J COMP NEUROL, V333, P398, DOI 10.1002/cne.903330307; Rosenberg P, 1997, DEV BIOL, V187, P55, DOI 10.1006/dbio.1997.8602; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomita K, 2000, CANCER RES, V60, P3650; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wong AST, 1999, INT J CANCER, V81, P180; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	55	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31041	31049		10.1074/jbc.M400024200	http://dx.doi.org/10.1074/jbc.M400024200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143071	hybrid			2022-12-27	WOS:000222726800018
J	Lin, HH; Chang, GW; Davies, JQ; Stacey, M; Harris, J; Gordon, S				Lin, HH; Chang, GW; Davies, JQ; Stacey, M; Harris, J; Gordon, S			Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LATROTOXIN CIRL; 3-DIMENSIONAL STRUCTURE; EGF-TM7 FAMILY; AUTOPROTEOLYSIS; DOMAIN; 7-TRANSMEMBRANE; ACTIVATION; THREONINE; REQUIRES; FURIN	Post-translational cleavage at the G protein-coupled receptor proteolytic site (GPS) has been demonstrated in many class B2 G protein-coupled receptors as well as other cell surface proteins such as polycystin-1. However, the mechanism of the GPS proteolysis has never been elucidated. Here we have characterized the cleavage of the human EMR2 receptor and identified the molecular mechanism of the proteolytic process at the GPS. Proteolysis at the highly conserved His-Leu down arrow Ser(518) cleavage site can occur inside the endoplasmic reticulum compartment, resulting in two protein subunits that associate noncovalently as a heterodimer. Site-directed mutagenesis of the P+1 cleavage site (Ser(518)) shows an absolute requirement of a Ser, Thr, or Cys residue for efficient proteolysis. Substitution of the P-2 His residue to other amino acids produces slow processing precursor proteins, which spontaneously hydrolyze in a defined cell-free system. Further biochemical characterization indicates that the GPS proteolysis is mediated by an autocatalytic intramolecular reaction similar to that employed by the N-terminal nucleophile hydrolases, which are known to activate themselves by self-catalyzed cis-proteolysis. We propose here that the autoproteolytic cleavage of EMR2 represents a paradigm for the other GPS motif-containing proteins and suggest that these GPS proteins belong to a cell surface receptor subfamily of N-terminal nucleophile hydrolases.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Lin, HH (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	hsi-hsien.lin@path.ox.ac.uk	LIN, Hsi-Hsien/N-1488-2015	Harris, James/0000-0002-5634-9637				Abe J, 2002, J BIOL CHEM, V277, P23391, DOI 10.1074/jbc.M110877200; Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Aronson NN, 1999, BBA-MOL BASIS DIS, V1455, P139, DOI 10.1016/S0925-4439(99)00076-9; Boker C, 1997, J CELL SCI, V110, P1023; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chang GW, 2003, FEBS LETT, V547, P145, DOI 10.1016/S0014-5793(03)00695-1; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; Gray JX, 1996, J IMMUNOL, V157, P5438; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Harmar AJ, 2001, GENOME BIOL, V2; Hauri HP, 2000, J CELL SCI, V113, P587; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; Kisselev AF, 2000, J BIOL CHEM, V275, P14831, DOI 10.1074/jbc.275.20.14831; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Kwakkenbos MJ, 2002, J LEUKOCYTE BIOL, V71, P854; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Obermann H, 2003, MOL REPROD DEV, V64, P13, DOI 10.1002/mrd.10220; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Stacey M, 2003, BLOOD, V102, P2916, DOI 10.1182/blood-2002-11-3540; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Suzuki H, 2002, J BIOL CHEM, V277, P43536, DOI 10.1074/jbc.M207680200; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; TRIMMER JS, 1986, P NATL ACAD SCI USA, V83, P9055, DOI 10.1073/pnas.83.23.9055; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Wang YM, 2003, J BIOL CHEM, V278, P3210, DOI 10.1074/jbc.M210431200; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	61	153	155	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31823	31832		10.1074/jbc.M402974200	http://dx.doi.org/10.1074/jbc.M402974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150276	hybrid			2022-12-27	WOS:000222726800109
J	Schultz, A; Ling, M; Larsson, C				Schultz, A; Ling, M; Larsson, C			Identification of an amino acid residue in the protein kinase CC1b domain crucial for its localization to the Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHORBOL ESTER RECEPTORS; C-DELTA; REGULATORY DOMAIN; NEURITE OUTGROWTH; CATALYTIC DOMAIN; BINDING-SITES; C1B DOMAIN; APOPTOSIS; COMPLEX	Protein kinase C (PKC) isoforms have been reported to be targeted to the Golgi complex via their C1 domains. We have shown recently that the regulatory domain of PKCtheta induces apoptosis in neuroblastoma cells and that this effect is correlated to Golgi localization via the C1b domain. This study was designed to identify specific residues in the C1 domains that mediate Golgi localization. We demonstrate that the isolated C1b domains from PKCalpha, -delta, -epsilon, -eta, and -theta are targeted to the Golgi complex, whereas the corresponding C1a domains localize throughout the cell. Sequence alignment showed that amino acid residues corresponding to Glu-246 and Met-267 in PKCtheta are conserved among C1b but absent from C1a domains. Mutation of Met-267, but not of Glu-246, to glycine abolished the Golgi localization of the isolated C1b domain and the regulatory domain of PKCtheta. The mutated PKCtheta regulatory domain constructs lacking Golgi localization were unable to induce apoptosis, suggesting a direct correlation between Golgi localization and apoptotic activity of PKCtheta regulatory domain. Mutation of analogous residues in the C1b domain of PKCepsilon abrogated its Golgi localization, demonstrating that this effect is not restricted to one PKC isoform. The abolished Golgi localization did not affect neurite induction by PKCepsilon. However, the PKCepsilon mutant did not relocate to the Golgi network in response to ceramide and ceramide did not suppress the neurite-inducing capacity of the protein. Thus, the specific mutations in the C1b domain influence both the localization and function of full-length PKCepsilon.	Lund Univ, Dept Lab Med, S-20502 Malmo, Sweden	Lund University	Larsson, C (corresponding author), UMAS, Entrance 78,3rd Floor, S-20502 Malmo, Sweden.	christer.larsson@molmed.mas.lu.se						AKITA Y, 1994, J BIOL CHEM, V269, P4653; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; CARRASCO S, 2004, MOL BIOL CELL; Chen D, 2004, J BIOL CHEM, V279, P4829, DOI 10.1074/jbc.M311196200; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DE MR, 1997, SCIENCE, V277, P1652; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; HUBBARD SR, 1991, SCIENCE, V254, P1776; Hurley JH, 1997, PROTEIN SCI, V6, P477; Imam A, 2001, FASEB J, V15, P28; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Maceyka M, 1997, J CELL BIOL, V139, P1411, DOI 10.1083/jcb.139.6.1411; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Schultz A, 2004, J NEUROCHEM, V89, P1427, DOI 10.1111/j.1471-4159.2004.02431.x; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; Wang SM, 1996, J MED CHEM, V39, P2541, DOI 10.1021/jm950403n; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	42	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31750	31760		10.1074/jbc.M313017200	http://dx.doi.org/10.1074/jbc.M313017200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145947	hybrid			2022-12-27	WOS:000222726800101
J	Tombline, G; Bartholomew, LA; Urbatsch, IL; Senior, AE				Tombline, G; Bartholomew, LA; Urbatsch, IL; Senior, AE			Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; ADENOSINE-TRIPHOSPHATASE; CONSERVED WALKER; SER RESIDUES; MOTOR DOMAIN; SITES; CYCLE; TRANSPORTER; MECHANISM; HYDROLYSIS	Combined mutation of "catalytic carboxylates" in both nucleotide binding domains (NBDs) of P-glycoprotein generates a conformation capable of tight binding of 8-azido-ADP ( Sauna, Z. E., Muller, M., Peng, X. H., and Ambudkar, S. V. ( 2002) Biochemistry 41, 13989 - 14000). Here we characterized this conformation using pure mouse MDR3 P-glycoprotein and natural MgATP and MgADP. Mutants E552A/E1197A, E552Q/E1197Q, E552D/ E1197D, and E552K/E1197K had low but real ATPase activity in the order Ala > Gln > Asp > Lys, emphasizing the requirement for Glu stereochemistry. Mutant E552A/ E1197A bound MgATP and MgADP ( 1 mol/mol) with K-d 9.2 and 92 muM, showed strong temperature sensitivity of MgATP binding and equal dissociation rates for MgATP and MgADP. With MgATP as the added ligand, 80% of bound nucleotide was in the form of ATP. None of these parameters was vanadate-sensitive. The other mutants showed lower stoichiometry of MgATP and MgADP binding, in the order Ala > Gln > Asp > Lys. We conclude that the E552A/ E1197A mutation arrests the enzyme in a conformation, likely a stabilized NBD dimer, which occludes nucleotide, shows preferential binding of ATP, does not progress to a normal vanadate-sensitive transition state, but hydrolyzes ATP and releases ADP slowly. Impairment of turnover is primarily due to inability to form the normal transition state rather than to slow ADP release. The Gln, Asp, and Lys mutants are less effective at stabilizing the occluded nucleotide, putative dimeric NBD, conformation. We envisage that in wild-type the occluded nucleotide conformation occurs transiently after MgATP binds to both NBDs with associated dimerization, and before progression to the transition state.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NATIONAL CANCER INSTITUTE [T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09363] Funding Source: Medline; NIGMS NIH HHS [GM50156] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Tombline G, 2004, J BIOL CHEM, V279, P5363, DOI 10.1074/jbc.M311964200; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503	38	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31212	31220		10.1074/jbc.M404689200	http://dx.doi.org/10.1074/jbc.M404689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159388	hybrid			2022-12-27	WOS:000222726800040
J	Webb, GC; Dey, A; Wang, J; Stein, J; Milewski, M; Steiner, DF				Webb, GC; Dey, A; Wang, J; Stein, J; Milewski, M; Steiner, DF			Altered proglucagon processing in an alpha-cell line derived from prohormone convertase 2 null mouse islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC2; GLUCAGON; EXPRESSION; PEPTIDE; FURIN; IDENTIFICATION; BIOSYNTHESIS; INSULIN; PROTEIN; GENE	The endoproteolytic processing of proproteins in the secretory pathway depends on the expression of selected members of a family of subtilisin-like endoproteases known as the prohormone convertases (PCs). The main PC family members expressed in mammalian neuroendocrine cells are PC2 and PC1/3. The differential processing of proglucagon in pancreatic alpha-cells and intestinal L cells leads to production of distinct hormonal products with opposing physiological effects from the same precursor. Here we describe the establishment and characterization of a novel alpha-cell line (alphaTC-DeltaPC2) derived from PC2 homozygous null animals. The alphaTC-DeltaPC2 cells are shown to be similar to the well characterized alphaTC1-6 cell line in both morphology and overall gene expression. However, the absence of PC2 activity in alphaTC-DeltaPC2 leads to a complete block in the production of mature glucagon. Surprisingly, alphaTC-DeltaPC2 cells are able to efficiently cleave the interdomain site in proglucagon (KR 70 - 71). Further analysis reveals that alphaTC-DeltaPC2 cells, unlike alphaTC1-6 cells, express low levels of PC1/3 that lead to the generation of glicentin as well as low amounts of oxyntomodulin, GLP-1, truncated GLP-1, and N-terminally extended GLP-2. We conclude that alphaTC-DeltaPC2 cells provide additional evidence for PC2 as the major convertase in alpha-cells leading to mature glucagon production and provide a robust model for further analysis of the mechanisms of proprotein processing by the prohormone convertases.	Univ Chicago, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Comm Human Nutr & Nutr Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Steiner, DF (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Biochem & Mol Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	dfsteine@midway.uchicago.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R37DK013914, R01DK013914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13914, DK-20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbero P, 1998, J BIOL CHEM, V273, P25339, DOI 10.1074/jbc.273.39.25339; Cain BM, 2001, PEPTIDES, V22, P1271, DOI 10.1016/S0196-9781(01)00451-X; Cameron A., 2001, ENZYMES, V22, P291; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Dey A, 2004, ENDOCRINOLOGY, V145, P1961, DOI 10.1210/en.2003-1472; Dey A, 2003, J BIOL CHEM, V278, P15007, DOI 10.1074/jbc.M212128200; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; Fortenberry Y, 1999, J NEUROCHEM, V73, P994, DOI 10.1046/j.1471-4159.1999.0730994.x; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Furuta M, 2001, J BIOL CHEM, V276, P27197, DOI 10.1074/jbc.M103362200; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; HU ZX, 1994, BIOCHEMISTRY-US, V33, P562, DOI 10.1021/bi00168a022; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Lee YC, 1999, MOL CELL ENDOCRINOL, V155, P27, DOI 10.1016/S0303-7207(99)00119-7; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nie Y, 2000, J CLIN INVEST, V105, P955, DOI 10.1172/JCI7456; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; Rouille Y, 1997, J BIOL CHEM, V272, P32810, DOI 10.1074/jbc.272.52.32810; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER DF, 1967, SCIENCE, V157, P697, DOI 10.1126/science.157.3789.697; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STEINER DF, 1974, FED PROC, V33, P2105; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ugleholdt R, 2004, ENDOCRINOLOGY, V145, P1349, DOI 10.1210/en.2003-0801; Viale A, 1999, J BIOL CHEM, V274, P6536, DOI 10.1074/jbc.274.10.6536; Vincent M, 2003, ENDOCRINOLOGY, V144, P4061, DOI 10.1210/en.2003-0088; Wang J, 2003, P NATL ACAD SCI USA, V100, P12660, DOI 10.1073/pnas.1735286100; Webb GC, 2002, DIABETES, V51, P398, DOI 10.2337/diabetes.51.2.398; Webb GC, 2001, DIABETES, V50, pS135, DOI 10.2337/diabetes.50.2007.S135; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Wilson ME, 2002, MECH DEVELOP, V115, P171, DOI 10.1016/S0925-4773(02)00118-1; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10299, DOI 10.1073/pnas.162352799; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	50	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31068	31075		10.1074/jbc.M404110200	http://dx.doi.org/10.1074/jbc.M404110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143067	hybrid			2022-12-27	WOS:000222726800021
J	Xu, XF; Tan, YW; Lam, L; Hackett, J; Zhang, MJ; Mok, YK				Xu, XF; Tan, YW; Lam, L; Hackett, J; Zhang, MJ; Mok, YK			NMR structure of a Type IVb pilin from Salmonella typhi and its assembly into pilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROTOXIGENIC ESCHERICHIA-COLI; TORSION ANGLE DYNAMICS; R64 THIN-PILUS; PSEUDOMONAS-AERUGINOSA; RECEPTOR-BINDING; X-RAY; PAK; PROTEINS; SEQUENCE; PROGRAM	The structure of the N-terminal-truncated Type IVb structural pilin (t-PilS) from Salmonella typhi was determined by NMR. Although topologically similar to the recently determined x-ray structure of pilin from Vibrio cholerae toxin-coregulated pilus, the only Type IVb pilin with known structure, t-PilS contains many distinct structural features. The protein contains an extra pair of beta-strands in the N-terminal alphabeta loop that align with the major beta-strands to form a continuous 7-stranded antiparallel beta-sheet. The C-terminal disulfide-bonded region of t-PilS is only half the length of that of toxin-coregulated pilus pilin. A model of S. typhi pilus has been proposed and mutagenesis studies suggested that residues on both the alphabeta loop and the C-terminal disulfide-bonded region of PilS might be involved in binding specificity of the pilus. This model structure reveals an exposed surface between adjacent subunits of PilS that could be a potential binding site for the cystic fibrosis transmembrane conductance regulator.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	National University of Singapore; Hong Kong University of Science & Technology	Mok, YK (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.	dbsmokh@nus.edu.sg	Mok, Yu Keung/H-8019-2012; Xu, Xingfu/A-1359-2015	Mok, Yu Keung/0000-0002-2829-4878; Xu, Xingfu/0000-0001-6231-269X; Zhang, Mingjie/0000-0001-9404-0190				Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114; Campbell AP, 1995, BIOCHEMISTRY-US, V34, P16255, DOI 10.1021/bi00050a005; CAmpbell AP, 1997, BIOCHEMISTRY-US, V36, P12791, DOI 10.1021/bi9709304; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Craig L, 2003, MOL CELL, V11, P1139, DOI 10.1016/S1097-2765(03)00170-9; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Giron JA, 1997, GENE, V192, P39, DOI 10.1016/S0378-1119(97)00039-5; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hahn HP, 1997, GENE, V192, P99, DOI 10.1016/S0378-1119(97)00116-9; Hazes B, 2000, J MOL BIOL, V299, P1005, DOI 10.1006/jmbi.2000.3801; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Keizer DW, 2001, J BIOL CHEM, V276, P24186, DOI 10.1074/jbc.M100659200; Kim SR, 1997, J BACTERIOL, V179, P3594, DOI 10.1128/jb.179.11.3594-3603.1997; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Manning PA, 1997, GENE, V192, P63, DOI 10.1016/S0378-1119(97)00036-X; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pier GB, 1998, NATURE, V393, P79, DOI 10.1038/30006; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; Sakai D, 2002, J BACTERIOL, V184, P444, DOI 10.1128/JB.184.2.444-451.2002; Sakellaris H, 1999, P NATL ACAD SCI USA, V96, P12828, DOI 10.1073/pnas.96.22.12828; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsui ISM, 2003, INFECT IMMUN, V71, P6049, DOI 10.1128/IAI.71.10.6049-6050.2003; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Zaidi TS, 1999, INFECT IMMUN, V67, P1481, DOI 10.1128/IAI.67.3.1481-1492.1999; Zhang XL, 2000, INFECT IMMUN, V68, P3067, DOI 10.1128/IAI.68.6.3067-3073.2000; Zhang XL, 1997, GENE, V202, P139, DOI 10.1016/S0378-1119(97)00466-6	37	26	27	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31599	31605		10.1074/jbc.M404727200	http://dx.doi.org/10.1074/jbc.M404727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159389	hybrid			2022-12-27	WOS:000222726800083
J	Drummer, HE; Poumbourios, P				Drummer, HE; Poumbourios, P			Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK-BORNE ENCEPHALITIS; ENVELOPE PROTEIN-E; SCAVENGER RECEPTOR; CELL ENTRY; FUSION; BINDING; CD81; COMPLEXES; LOCALIZATION; CONFORMATION	The E1 and E2 glycoproteins of hepatitis C virus form a noncovalently associated heterodimer that mediates viral entry. Glycoprotein E2 comprises a receptor-binding domain (residues 384-661) that is connected to the transmembrane domain (residues 716-746) via a highly conserved sequence containing a hydrophobic heptad repeat (residues 675-699). Alanine- and proline-scanning mutagenesis of the E2 heptad repeat revealed that Leu(675), Ser(678), Leu(689), and Leu(692) are important for E1E2 heterodimerization. Furthermore, Pro and Ala substitution of all but one heptad repeat residue (Ser(678)) blocked the entry of E1E2-HIV-1 pseudotypes into Huh7 cells, irrespective of an effect on heterodimerization. Two conserved prolines (Pro(676) and Pro(683)), occupying consecutive b positions of the heptad, were not required for E1E2 heterodimerization; however, Pro(683) was critical for viral entry. Thus, disruption of the predicted alpha-helical structure by proline at position 683 is important for E2 function. The inability of mutants to mediate viral entry was not explained by a loss of receptor binding function, because all mutants were able to interact with a recombinant form of the CD81 large extracellular loop. Chimeras formed between the E1 and E2 ectodomains and the transmembrane domains of flavivirus prM and E glycoproteins, respectively, were able to heterodimerize, although with lower efficiency in comparison with wild type E1E2. The heptad repeat of E2 therefore requires the native transmembrane domain for full heterodimerization and viral entry function. Our data indicate that the membrane-proximal heptad repeat of E2 is functionally homologous to the stem of flavivirus E glycoproteins. We propose that E2 has mechanistic features in common with class II fusion proteins.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Drummer, HE (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	heidid@ariel.its.unimelb.edu.au		Drummer, Heidi/0000-0002-0042-6277				Allison SL, 1999, J VIROL, V73, P5605, DOI 10.1128/JVI.73.7.5605-5612.1999; Allison SL, 2001, J VIROL, V75, P4268, DOI 10.1128/JVI.75.9.4268-4275.2001; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; Drummer HE, 2002, J VIROL, V76, P11143, DOI 10.1128/JVI.76.21.11143-11147.2002; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Ferlenghi I, 2001, MOL CELL, V7, P593, DOI 10.1016/S1097-2765(01)00206-4; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Lorenz IC, 2002, J VIROL, V76, P5480, DOI 10.1128/JVI.76.11.5480-5491.2002; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Molenkamp R, 2003, J VIROL, V77, P1644, DOI 10.1128/JVI.77.2.1644-1648.2003; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Yagnik AT, 2000, PROTEINS, V40, P355, DOI 10.1002/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004	30	66	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30066	30072		10.1074/jbc.M405098200	http://dx.doi.org/10.1074/jbc.M405098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136562	hybrid			2022-12-27	WOS:000222531900026
J	Knowles, LM; Axelrod, F; Browne, CD; Smith, JW				Knowles, LM; Axelrod, F; Browne, CD; Smith, JW			A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; SERINE HYDROLASE ACTIVITIES; DEPENDENT KINASE; PROTEIN PALMITOYLATION; ANTITUMOR-ACTIVITY; CERULENIN ANALOGS; COMPLEX PROTEOMES; INHIBITOR P27; EXPRESSION; FAS	In eukaryotes, fatty acid synthase (FAS) is the enzyme responsible for synthesis of palmitate, the precursor of long-chain nonessential fatty acids. FAS is up-regulated in a wide range of cancers and has been suggested as a relevant drug target. Here, two independent approaches are taken toward knocking down FAS and then probing its connection to tumor cell proliferation. In one approach, Orlistat, a drug approved for treating obesity, is used as a potent inhibitor of the thioesterase function of FAS. In a separate strategy, the expression of FAS is suppressed by targeted knock-down with small interfering RNA. In both circumstances, the ablation of FAS activity causes a dramatic down-regulation of Skp2, a component of the E3 ubiquitin ligase that controls the turnover of p27(Kip1). These effects ultimately tie into the retinoblastoma protein pathway and lead to a cell-cycle arrest at the G(1)/S boundary. Altogether, the findings of the study reveal unappreciated links between fatty acid synthase and ubiquitin-dependent proteolysis of cell-cycle regulatory proteins.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jsmith@burnham.org		Knowles, Lynn/0000-0002-6250-9289	NATIONAL CANCER INSTITUTE [R01CA069306, P30CA030199] Funding Source: NIH RePORTER; NCI NIH HHS [CA30199, CA6982713, CA69306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108; Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Alo PL, 2001, AM J CLIN PATHOL, V116, P129; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chirala SS, 2001, P NATL ACAD SCI USA, V98, P3104, DOI 10.1073/pnas.051635998; De Vos ML, 2001, BIOCHEM PHARMACOL, V62, P985, DOI 10.1016/S0006-2952(01)00739-0; Furuya Y, 1997, ANTICANCER RES, V17, P4589; HADVARY P, 1991, J BIOL CHEM, V266, P2021; Harvey S, 2001, PHYSIOL GENOMICS, V5, P129, DOI 10.1152/physiolgenomics.2001.5.3.129; HAUPTMAN JB, 1992, AM J CLIN NUTR, V55, P309; Heiligtag SJ, 2002, CELL DEATH DIFFER, V9, P1017, DOI 10.1038/sj.cdd.4401055; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; Kidd D, 2001, BIOCHEMISTRY-US, V40, P4005, DOI 10.1021/bi002579j; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lawrence DS, 1999, J MED CHEM, V42, P4932, DOI 10.1021/jm980591s; Li JN, 2001, CANCER RES, V61, P1493; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; MATTICK JS, 1983, J BIOL CHEM, V258, P5300; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Pizer ES, 1996, CANCER RES, V56, P745; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Rank KB, 2000, BIOCHEM BIOPH RES CO, V271, P469, DOI 10.1006/bbrc.2000.2648; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; Wang Y, 2001, CANCER LETT, V167, P99, DOI 10.1016/S0304-3835(01)00464-5; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; Yang G, 2002, CLIN CANCER RES, V8, P3419	38	109	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30540	30545		10.1074/jbc.M405061200	http://dx.doi.org/10.1074/jbc.M405061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138278	hybrid			2022-12-27	WOS:000222531900083
J	Guo, Q; Shen, YQ; Zhukovskaya, NL; Florian, J; Tang, WJ				Guo, Q; Shen, YQ; Zhukovskaya, NL; Florian, J; Tang, WJ			Structural and kinetic analyses of the interaction of anthrax adenylyl cyclase toxin with reaction products cAMP and pyrophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY DNA-POLYMERASE; P-SITE INHIBITION; EDEMA FACTOR; BACILLUS-ANTHRACIS; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; X-RAY; CALMODULIN; COMPLEX; BINDING	Anthrax edema factor (EF) raises host intracellular cAMP to pathological levels through a calcium-calmodulin (CaM)-dependent adenylyl cyclase activity. Here we report the structure of EF.CaM in complex with its reaction products, cAMP and PPi. Mutational analysis confirmed the interaction of EF with cAMP and PPi as depicted in the structural model. While both cAMP and PPi have access to solvent channels to exit independently, PPi is likely released first. EF can synthesize ATP from cAMP and PPi, and the estimated rate constants of this reaction at two physiologically relevant calcium concentrations were similar to those of adenylyl cyclase activity of EF. Comparison of the conformation of adenosine in the structures of EF.CaM.cAMP.PPi with EF.CaM.3' dATP revealed about 160 rotation in the torsion angle of N-glycosyl bond from the +anti conformation in 3' dATP to -syn in cAMP; such a rotation could serve to distinguish against substrates with the N-2 amino group of purine. The catalytic rate of EF for ITP was about 2 orders of magnitude better than that for GTP, supporting the potential role of this rotation in substrate selectivity of EF. The anomalous difference Fourier map revealed that two ytterbium ions (Yb3+) could bind the catalytic site of EF.CaM in the presence of cAMP and PPi, suggesting the presence of two magnesium ions at the catalytic site of EF. We hypothesize that EF could use a "histidine and two-metal ion" hybrid mechanism to facilitate the cyclization reaction.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA; Loyola Univ, Dept Chem, Chicago, IL 60626 USA	University of Chicago; University of Chicago; Loyola University Chicago	Tang, WJ (corresponding author), Univ Chicago, Ben May Inst Canc Res, 924 E 57th St, Chicago, IL 60637 USA.	wtang@uchicago.edu	Florian, Jan/E-1554-2012	Florian, Jan/0000-0003-2669-4293; Tang, Wei-Jen/0000-0002-8267-8995				Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Brautigam CA, 1999, CHEM BIOL, V6, P901, DOI 10.1016/S1074-5521(00)80009-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Drum CL, 2001, ACTA CRYSTALLOGR D, V57, P1881, DOI 10.1107/S0907444901014937; Drum CL, 2000, J BIOL CHEM, V275, P36334, DOI 10.1074/jbc.M004778200; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; FARNDALE RW, 1992, SIGNAL TRANSDUCTION, P75; Florian J, 1998, J PHYS CHEM B, V102, P719, DOI 10.1021/jp972182y; Florian J, 2003, J AM CHEM SOC, V125, P8163, DOI 10.1021/ja028997o; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Garcia-Viloca M, 2004, SCIENCE, V303, P186, DOI 10.1126/science.1088172; GERLT JA, 1980, J BIOL CHEM, V255, P331; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kraut DA, 2003, ANNU REV BIOCHEM, V72, P517, DOI 10.1146/annurev.biochem.72.121801.161617; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; Linder JU, 2003, CELL SIGNAL, V15, P1081, DOI 10.1016/S0898-6568(03)00130-X; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; MUNIER H, 1992, J BIOL CHEM, V267, P9816; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shen Y, 2004, BIOCHEM BIOPH RES CO, V317, P309, DOI 10.1016/j.bbrc.2004.03.046; Shen YQ, 2004, P NATL ACAD SCI USA, V101, P3242, DOI 10.1073/pnas.0306552101; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; Soelaiman S, 2003, J BIOL CHEM, V278, P25990, DOI 10.1074/jbc.M301232200; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tesmer JJG, 2000, BIOCHEMISTRY-US, V39, P14464, DOI 10.1021/bi0015562; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Ulmer TS, 2003, J BIOL CHEM, V278, P29261, DOI 10.1074/jbc.M302837200; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899	40	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29427	29435		10.1074/jbc.M402689200	http://dx.doi.org/10.1074/jbc.M402689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131111	hybrid			2022-12-27	WOS:000222445300075
J	Diebold, BA; Fowler, B; Lu, J; Dinauer, MC; Bokoch, GM				Diebold, BA; Fowler, B; Lu, J; Dinauer, MC; Bokoch, GM			Antagonistic cross-talk between Rac and Cdc42 GTPases regulates generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL RESPIRATORY BURST; NADPH OXIDASE; SUPEROXIDE-PRODUCTION; EFFECTOR REGION; INSERT REGION; ACTIVATION; RHO; BINDING; PROTEIN; DOMAIN	Cross-talk between Rho GTPase family members (Rho, Rac, and Cdc42) plays important roles in modulating and coordinating downstream cellular responses resulting from Rho GTPase signaling. The NADPH oxidase of phagocytes and nonphagocytic cells is a Rac GTPase-regulated system that generates reactive oxygen species (ROS) for the purposes of innate immunity and intracellular signaling. We recently demonstrated that NADPH oxidase activation involves sequential interactions between Rac and the flavocytochrome b(558) and p67(phox) oxidase components to regulate electron transfer from NADPH to molecular oxygen. Here we identify an antagonistic interaction between Rac and the closely related GTPase Cdc42 at the level of flavocytochrome b558 that regulates the formation of ROS. Cdc42 is unable to stimulate ROS formation by NADPH oxidase, but Cdc42, like Rac1 and Rac2, was able to specifically bind to flavocytochrome b(558) in vitro. Cdc42 acted as a competitive inhibitor of Rac1- and Rac2- mediated ROS formation in a recombinant cell-free oxidase system. Inhibition was dependent on the Cdc42 insert domain but not the Switch I region. Transient expression of Cdc42Q61L inhibited ROS formation induced by constitutively active Rac1 in an NADPH oxidase-expressing Cos7 cell line. Inhibition of Cdc42 activity by transduction of the Cdc42-binding domain of Wiscott-Aldrich syndrome protein into human neutrophils resulted in an enhanced fMetLeuPhe-induced oxidative response, consistent with inhibitory cross-talk between Rac and Cdc42 in activated neutrophils. We propose here a novel antagonism between Rac and Cdc42 GTPases at the level of the Nox proteins that modulates the generation of ROS used for host defense, cell signaling, and transformation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Scripps Research Institute; Scripps Research Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol & Cell Biol, IMM-14,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu			NCRR NIH HHS [M01 RR 00833] Funding Source: Medline; NHLBI NIH HHS [HL 48008, HL 45635] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008, R01HL045635] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; Burridge K, 1999, SCIENCE, V283, P2028, DOI 10.1126/science.283.5410.2028; Catz SD, 1996, J LEUKOCYTE BIOL, V59, P591, DOI 10.1002/jlb.59.4.591; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Gruenheid S, 2003, NATURE, V422, P775, DOI 10.1038/nature01603; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Han HS, 2003, J EXP MED, V197, P63, DOI 10.1084/jem.20021638; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Leverrier Y, 2001, J IMMUNOL, V166, P4831, DOI 10.4049/jimmunol.166.8.4831; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Rabiet MJ, 2002, BLOOD, V100, P1835, DOI 10.1182/blood-2001-12-0193; Ridley AJ, 2001, J CELL SCI, V114, P2713; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Thrasher AJ, 2002, NAT REV IMMUNOL, V2, P635, DOI 10.1038/nri884; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042	55	68	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28136	28142		10.1074/jbc.M313891200	http://dx.doi.org/10.1074/jbc.M313891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123662	hybrid			2022-12-27	WOS:000222265400040
J	Fu, T; Mukhopadhyay, D; Davidson, NO; Borensztajn, J				Fu, T; Mukhopadhyay, D; Davidson, NO; Borensztajn, J			The peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice - Effects on plasma lipoproteins and the development of atherosclerotic lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; TRANSGENIC MICE; APO-B; CHOLESTEROL; OVEREXPRESSION; MOUSE; HYPERCHOLESTEROLEMIA; EXPRESSION; SECRETION; CLEARANCE	Low density lipoprotein receptor (LDLR)-deficient mice fed a chow diet have a mild hypercholesterolemia caused by the abnormal accumulation in the plasma of apolipoprotein B (apoB)-100- and apoB-48-carrying intermediate density lipoproteins (IDL) and low density lipoproteins (LDL). Treatment of LDLR-deficient mice with ciprofibrate caused a marked decrease in plasma apoB-48-carrying IDL and LDL but at the same time caused a large accumulation of triglyceride-depleted apoB-100-carrying IDL and LDL, resulting in a significant increase in plasma cholesterol levels. These plasma lipoprotein changes were associated with an increase in the hepatic secretion of apoB-100-carrying very low density lipoproteins ( VLDL) and a decrease in the secretion of apoB-48-carrying VLDL, accompanied by a significant decrease in hepatic apoB mRNA editing. Hepatic apobec-1 complementation factor mRNA and protein abundance were significantly decreased, whereas apobec-1 mRNA and protein abundance remained unchanged. No changes in apoB mRNA editing occurred in the intestine of the treated animals. After 150 days of treatment with ciprofibrate, consistent with the increased plasma accumulation of apoB-100-carrying IDL and LDL, the LDLR-deficient mice displayed severe atherosclerotic lesions in the aorta. These findings demonstrate that ciprofibrate treatment decreases hepatic apoB mRNA editing and alters the pattern of hepatic lipoprotein secretion toward apoB-100-associated VLDL, changes that in turn lead to increased atherosclerosis.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Washington Univ, Dept Internal Med, St Louis, MO 63110 USA	Northwestern University; Feinberg School of Medicine; Washington University (WUSTL)	Borensztajn, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jbb@northwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 52574] Funding Source: Medline; PHS HHS [DL 56260] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anant S, 2002, TRENDS CARDIOVAS MED, V12, P311, DOI 10.1016/S1050-1738(02)00180-9; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; BORENSZTAJN J, 1976, BIOCHEM J, V156, P539, DOI 10.1042/bj1560539; Covey SD, 2003, ARTERIOSCL THROM VAS, V23, P1589, DOI 10.1161/01.ATV.0000083343.19940.A0; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Duez H, 2002, J BIOL CHEM, V277, P48051, DOI 10.1074/jbc.M206966200; Fruchart J C, 2001, Curr Atheroscler Rep, V3, P83, DOI 10.1007/s11883-001-0015-x; Fu T, 2003, J BIOL CHEM, V278, P52559, DOI 10.1074/jbc.M310892200; Fu T, 2003, BIOCHEM J, V373, P941, DOI 10.1042/BJ20030105; Havel RJ, 1998, ATHEROSCLEROSIS, V141, pS1; HAYASHI H, 1990, AM J PHYSIOL, V259, pG709, DOI 10.1152/ajpgi.1990.259.5.G709; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Krause BR, 1998, ATHEROSCLEROSIS, V140, P15, DOI 10.1016/S0021-9150(98)00141-5; Li XH, 1996, J LIPID RES, V37, P210; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; Linton M F, 2000, Curr Atheroscler Rep, V2, P29, DOI 10.1007/s11883-000-0092-2; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Mukhopadhyay D, 2003, ENDOCRINOLOGY, V144, P711, DOI 10.1210/en.2002-220741; Okochi E, 1999, BBA-MOL CELL BIOL L, V1437, P393, DOI 10.1016/S1388-1981(99)00024-4; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Rubins HB, 2000, EUR HEART J, V21, P1113, DOI 10.1053/euhj.1999.2024; Smith JD, 1997, J INTERN MED, V242, P99, DOI 10.1046/j.1365-2796.1997.00197.x; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Veniant MM, 1998, J CLIN INVEST, V102, P1559, DOI 10.1172/JCI4164; Veniant MM, 2000, J CLIN INVEST, V106, P1501, DOI 10.1172/JCI10695; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 2002, J LIPID RES, V43, P1421, DOI 10.1194/jlr.M200026-JLR200	31	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28662	28669		10.1074/jbc.M403271200	http://dx.doi.org/10.1074/jbc.M403271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123680	hybrid			2022-12-27	WOS:000222265400102
J	Peng, Y; Jiang, BH; Yang, PH; Cao, ZX; Shi, XL; Lin, MCM; He, ML; Kung, HF				Peng, Y; Jiang, BH; Yang, PH; Cao, ZX; Shi, XL; Lin, MCM; He, ML; Kung, HF			Phosphatidylinositol 3-kinase signaling is involved in neurogenesis during Xenopus embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; NF-KAPPA-B; SERINE-THREONINE KINASE; NITRIC-OXIDE SYNTHASE; HOMEOBOX GENE; PHOSPHOINOSITIDE 3-KINASE; DEPENDENT PHOSPHORYLATION; ENDOTHELIAL-CELLS; CORTICAL ROTATION; NEURAL INDUCTION	Phosphatidylinositol 3-kinase (PI3K) has numerous cellular functions, including cell survival and proliferation. In this study, we demonstrated that the expression of the active form of PI3K induced dorsal differentiation and axis duplication and strongly induced the expression of neural markers. In contrast, the inhibition of PI3K activity by its dominant negative mutant induced the phenotype of losing posterior structures and the expression of ventral markers. Akt is an essential target of PI3K for neurogenesis. The expression of the active form of Akt induced axis duplication and increased the expression of neural markers. Inhibition of the Akt activity abolished the PI3K-induced double heads and axes. This signal transmits through its target, glycogen synthase kinase 3beta, which is known to mediate Wnt signaling for Xenopus development. These results identify a new function of PI3K/Akt signaling in axis formation and neurogenesis during Xenopus embryonic development and provide a direct link between growth factor-mediated PI3K/Akt signaling and Wnt signaling during embryonic development.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; First Mil Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou 510515, Peoples R China; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; Chinese Acad Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	University of Hong Kong; Southern Medical University - China; West Virginia University; Chinese Academy of Sciences	Kung, HF (corresponding author), Univ Hong Kong, Inst Mol Biol, 8-F,Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	hkung@hkucc.hku.hk	HE, Ming-Liang/AAG-3397-2022; HE, Ming-Liang/AFK-4738-2022; Shi, Xianglin/B-8588-2012	He, Ming-Liang/0000-0002-4317-2836; HE, Mingliang/0000-0002-9942-9151; Jiang, Bing-Hua/0000-0003-4526-2031	NCRR NIH HHS [RR 16440] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BLITZ IL, 1995, DEVELOPMENT, V121, P993; Carballada R, 2001, DEVELOPMENT, V128, P35; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DEL PL, 1997, SCIENCE, V278, P687; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dominguez I, 2000, DEVELOPMENT, V127, P861; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GERHART J, 1989, DEVELOPMENT, V107, P37; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Izuhara K, 1996, BLOOD, V88, P3910, DOI 10.1182/blood.V88.10.3910.bloodjournal88103910; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Ozes ON, 1999, NATURE, V401, P82; PANNESE M, 1995, DEVELOPMENT, V121, P707; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225; Xu RH, 1997, MOL CELL BIOL, V17, P436, DOI 10.1128/MCB.17.1.436; Xu RH, 1997, J NEUROSCI, V17, P6892	48	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28509	28514		10.1074/jbc.M402294200	http://dx.doi.org/10.1074/jbc.M402294200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123704	Green Published, hybrid			2022-12-27	WOS:000222265400086
J	McCarty, EA; Titus, SA; Taylor, SM; Jackson-Cook, C; Moran, RG				McCarty, EA; Titus, SA; Taylor, SM; Jackson-Cook, C; Moran, RG			A mutation inactivating the mitochondrial inner membrane folate transporter creates a glycine requirement for survival of Chinese hamster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BROWN FAT MITOCHONDRIA; ADP ATP TRANSLOCASE; CARRIER PROTEIN; SERINE HYDROXYMETHYLTRANSFERASE; STRUCTURAL RELATIONSHIP; UNCOUPLING PROTEIN; PHOSPHATE CARRIER; SEQUENCE; COMPLEMENTATION	A mutant Chinese hamster ovary cell line, glyB, that required exogenous glycine for survival and growth was reported previously (Kao, F., Chasin, L., and Puck, T. T. (1969) Proc. Natl. Acad. Sci. U. S. A. 64, 1284 - 1291). We now report that the defect in glyB cells causative of this phenotype is a point mutation in an inner mitochondrial membrane protein required for transport of folates into mitochondria. The CHO mitochondrial folate transporter (mft) was sequenced and compared with that from glyB cells. The hamster sequence was nearly identical to that of the recently reported human mitochondrial folate transporter. The corresponding cDNA from glyB cells contained a single nucleotide change that introduced a glutamate in place of the glycine in wild-type hamster MFT at codon 192 in a predicted transmembrane domain. Transfection of the wild-type hamster cDNA into glyB cells allowed cell survival in the absence of glycine and the accumulation of folates in mitochondria, whereas transfection of the Glu-192 cDNA did not. Genomic sequence analysis and fluorescence in situ hybridization demonstrated a single mutated allele of the mft gene in glyB cells, whereas there were two alleles in CHO cells. We conclude that we have defined the cause of the glyB auxotrophy and that the glyB mft mutation identified a region of this mitochondrial folate carrier vital to its transport function.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Pathol & Human Genet, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Moran, RG (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus,1101 E Marshall St, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu			NATIONAL CANCER INSTITUTE [R01CA104279, R01CA027605] Funding Source: NIH RePORTER; NCI NIH HHS [CA-27605, CA-104279] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; CAPOBIANCO L, 1995, FEBS LETT, V357, P297, DOI 10.1016/0014-5793(94)01379-F; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; COOK RJ, 1979, BIOCHEM J, V178, P651, DOI 10.1042/bj1780651; DIXON KH, 1994, J BIOL CHEM, V269, P17; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JacksonCook C, 1996, CANCER GENET CYTOGEN, V87, P14, DOI 10.1016/0165-4608(95)00232-4; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAO FT, 1975, GENETICS, V79, P343; KAO FT, 1969, P NATL ACAD SCI USA, V64, P1284, DOI 10.1073/pnas.64.4.1284; Kaplan RS, 2001, J MEMBRANE BIOL, V179, P165, DOI 10.1007/s002320010046; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; Titus SA, 2000, J BIOL CHEM, V275, P36811, DOI 10.1074/jbc.M005163200; WANG FK, 1967, BIOCHEM Z, V346, P458; WORTON RG, 1977, SOMAT CELL GENET, V3, P27, DOI 10.1007/BF01550985	33	44	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33829	33836		10.1074/jbc.M403677200	http://dx.doi.org/10.1074/jbc.M403677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15140890	hybrid			2022-12-27	WOS:000223039700092
J	Aoki, M; Yamashita, T; Tohyama, M				Aoki, M; Yamashita, T; Tohyama, M			EphA receptors direct the differentiation of mammalian neural precursor cells through a mitogen-activated protein kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAP1; MORPHOLOGY; ADHESION; RHO	Ephrins are cell surface-associated ligands for Eph receptor tyrosine kinases and are implicated in repulsive axon guidance and cell migration. EphA2, 3, and 4 receptors and one of their cognate ligands, ephrin-A2, are expressed by cells in the subventricular zone and ganglionic eminence of the embryonic day 14.5 telencephalon and by neural precursor cells in vitro. Activation of EphA receptors in dissociated neural precursor cells in vitro facilitates the commitment to neuronal fates. The majority of ephrin-A1-induced neurons is immunoreactive for tyrosine hydroxylase. Blocking the signal by the extracellular domain of EphA in forebrain slices results in a decrease in neurogenesis. Extracellular signal-regulated kinase is activated by the ligand binding to EphA receptors and is involved in the neurogenesis through EphA receptors. Rap1, but not Ras, is activated in response to ephrin-A1. Our results identify EphA receptors as positive regulators of the mitogen-activated protein kinase pathway that exerts neurogenesis of neural precursor cells from the developing central nervous system.	Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, Chiba 2608670, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan	Chiba University; Osaka University	Yamashita, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	t-yamashita@faculty.chiba-u.jp		Yamashita, Toshihide/0000-0003-4559-7018				Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rajan P, 1998, J NEUROSCI, V18, P3620; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	23	66	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32643	32650		10.1074/jbc.M313247200	http://dx.doi.org/10.1074/jbc.M313247200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145949	hybrid			2022-12-27	WOS:000222849700082
J	Karbat, I; Frolow, F; Froy, O; Gilles, N; Cohen, L; Turkov, M; Gordon, D; Gurevitz, M				Karbat, I; Frolow, F; Froy, O; Gilles, N; Cohen, L; Turkov, M; Gordon, D; Gurevitz, M			Molecular basis of the high insecticidal potency of scorpion alpha-toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; LEIURUS-QUINQUESTRIATUS-HEBRAEUS; ANDROCTONUS-AUSTRALIS HECTOR; CIS PEPTIDE-BONDS; RECEPTOR-SITE; NA+-CHANNELS; RAT-BRAIN; DIFFERENTIALLY INTERACT; BINDING; NEUROTOXIN	Scorpion alpha-toxins are similar in their mode of action and three-dimensional structure but differ considerably in affinity for various voltage-gated sodium channels (NaChs). To clarify the molecular basis of the high potency of the alpha-toxin LqhalphaIT ( from Leiurus quinquestriatus hebraeus) for insect NaChs, we identified by mutagenesis the key residues important for activity. We have found that the functional surface is composed of two distinct domains: a conserved "Core-domain" formed by residues of the loops connecting the secondary structure elements of the molecule core and a variable "NC-domain" formed by a five-residue turn ( residues 8 - 12) and a C-terminal segment ( residues 56 - 64). We further analyzed the role of these domains in toxin activity on insects by their stepwise construction onto the scaffold of the anti-mammalian alpha-toxin, Aah2 ( from Androctonus australis hector). The chimera harboring both domains, Aah2(LqhalphaIT(face)), was as active to insects as LqhalphaIT. Structure determination of Aah2(LqhalphaIT(face)) by x-ray crystallography revealed that the NC-domain deviates from that of Aah2 and forms an extended protrusion off the molecule core as appears in LqhalphaIT. Notably, such a protrusion is observed in all alpha-toxins active on insects. Altogether, the division of the functional surface into two domains and the unique configuration of the NC-domain illuminate the molecular basis of alpha-toxin specificity for insects and suggest a putative binding mechanism to insect NaChs.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; CEA, CE Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	Tel Aviv University; Tel Aviv University; Hebrew University of Jerusalem; CEA; UDICE-French Research Universities; Universite Paris Saclay	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	dgordon@post.tau.ac.il; mamgur@post.tau.ac.il	Frolow, Felix/A-1760-2013; Froy, Oren/C-3550-2009					Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Cestele S, 1999, EUR J NEUROSCI, V11, P975, DOI 10.1046/j.1460-9568.1999.00505.x; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chen HJ, 2002, EUR J NEUROSCI, V16, P767, DOI 10.1046/j.1460-9568.2002.02142.x; Chen HJ, 2000, PFLUG ARCH EUR J PHY, V439, P423, DOI 10.1007/s004240050959; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; DARBON H, 1983, INT J PEPT PROT RES, V22, P179; ELAYEB M, 1986, BIOCHEMISTRY-US, V25, P6671, DOI 10.1021/bi00369a052; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; Gilles N, 2002, EUR J BIOCHEM, V269, P1500, DOI 10.1046/j.1432-1033.2002.02799.x; Gilles N, 2001, BIOCHEMISTRY-US, V40, P14576, DOI 10.1021/bi010973r; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; Gilles N, 2000, EUR J NEUROSCI, V12, P2823, DOI 10.1046/j.1460-9568.2000.00168.x; Gilles N, 1999, J NEUROSCI, V19, P8730, DOI 10.1523/JNEUROSCI.19-20-08730.1999; GORDON D, 1993, FEBS LETT, V315, P125, DOI 10.1016/0014-5793(93)81147-R; Gordon D, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P215; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Gordon D, 1997, TOXINS SIGNAL TRANSD, P119; GUREVITZ M, 1991, TOXICON, V29, P1270, DOI 10.1016/0041-0101(91)90200-B; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; He XL, 1999, J MOL BIOL, V292, P125, DOI 10.1006/jmbi.1999.3036; He XL, 2000, ACTA CRYSTALLOGR D, V56, P25, DOI 10.1107/S0907444999014614; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Karbat I, 2004, FASEB J, V18, P683, DOI 10.1096/fj.03-0733com; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Little MJ, 1998, J BIOL CHEM, V273, P27076, DOI 10.1074/jbc.273.42.27076; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Menez A, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P175; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Sautiere P, 1998, TOXICON, V36, P1141, DOI 10.1016/S0041-0101(98)00080-4; Smith GD, 1997, ACTA CRYSTALLOGR D, V53, P551, DOI 10.1107/S0907444997005386; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang CG, 2003, BIOCHEMISTRY-US, V42, P4699, DOI 10.1021/bi0270438; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	56	85	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31679	31686		10.1074/jbc.M402048200	http://dx.doi.org/10.1074/jbc.M402048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133045	hybrid			2022-12-27	WOS:000222726800093
J	Lu, R; Niida, H; Nakanishi, M				Lu, R; Niida, H; Nakanishi, M			Human SAD1 kinase is involved in UV-induced DNA damage checkpoint function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; NIM1/CDR1 MITOTIC INDUCER; FISSION YEAST; MAP KINASE; S-PHASE; WEE1; CHK1; P53; PATHWAY	Checkpoint activation by DNA damage during G(2) prevents activation of cyclin B/Cdc2 complexes, and as a consequence, mitotic entry is blocked. Although initiation and maintenance of G2 arrest are known to be regulated by at least two distinct signaling pathways, including those of p38MAPK and ataxia-telangiectasiamutated (ATM)- and Rad3-related (ATR)-Chk1 in higher eukaryotes, the actual number of signaling pathways involved in this regulation is still elusive. In the present study, we identified human SAD1 (hsSAD1) by searching a sequence data base. The predicted hsSAD1 protein comprises 778 amino acids and shares significant homology with the fission yeast Cdr2, a mitosis-regulatory kinase, and Caenorhabditis elegans SAD1, a neuronal cell polarity regulator. HsSAD1 transcript was expressed ubiquitously with the highest levels of expression in brain and testis. HsSAD1 specifically phosphorylated Wee1A, Cdc25-C, and - B on Ser-642, Ser-216, and Ser-361 in vitro, respectively. Overexpression of hsSAD1 resulted in an increased phosphorylation of Cdc25C on Ser-216 in vivo. DNA damage induced by UV or methyl methane sulfonate but not by IR enhanced endogenous hsSAD1 kinase activity in a caffeine-sensitive manner and caused translocation of its protein from cytoplasm to nucleus. Overexpression of wild-type hsSAD1 induced G(2)/M arrest in HeLa S2 cells. Furthermore, UV-induced G(2)/M arrest was partially abrogated by the reduced expression of hsSAD1 using small interfering RNA. These results suggest that hsSAD1 acts as checkpoint kinase upon DNA damage induced by UV or methyl methane sulfonate. The identification of this new kinase suggests the existence of an alternative checkpoint pathway other than those of ATR-Chk1 and p38MAPK.	Nagoya City Univ, Grad Sch Med Sci, Dept Biochem & Cell Biol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Nakanishi, M (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Biochem & Cell Biol, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	mkt-naka@med.nagoya-cu.ac.jp						Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Crump JG, 2001, NEURON, V29, P115, DOI 10.1016/S0896-6273(01)00184-2; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu QH, 2000, GENE DEV, V14, P1448; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Prives C, 1999, J PATHOL, V187, P112; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Takai H, 2000, GENE DEV, V14, P1439; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang SW, 1999, J CELL SCI, V112, P927; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	47	43	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31164	31170		10.1074/jbc.M404728200	http://dx.doi.org/10.1074/jbc.M404728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150265	hybrid			2022-12-27	WOS:000222726800033
J	Jones, AL; Hulett, MD; Parish, CR				Jones, AL; Hulett, MD; Parish, CR			Histidine-rich glycoprotein binds to cell-surface heparan sulfate via its N-terminal domain following Zn2+ chelation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IGG; ANTITHROMBIN; SERUM; MODULATION; INHIBITOR; MECHANISM; SEQUENCE; PROLINE; PROTEIN; GLYCOSAMINOGLYCANS	Histidine-rich glycoprotein (HRG) is an alpha(2)-glycoprotein found in mammalian plasma at high concentrations (similar to150 mug/ml) and is distinguished by its high content of histidine and proline. Structurally, HRG is a modular protein consisting of an N-terminal cystatin-like domain (N1N2), a central histidine-rich region (HRR) flanked by proline-rich sequences, and a C-terminal domain. HRG binds to cell surfaces and numerous ligands such as plasminogen, fibrinogen, thrombospondin, C1q, heparin, and IgG, suggesting that it may act as an adaptor protein either by targeting ligands to cell surfaces or by cross-linking soluble ligands. Despite the suggested functional importance of HRG, the cell-binding characteristics of the molecule are poorly defined. In this study, HRG was shown to bind to most cell lines in a Zn2+-dependent manner, but failed to interact with the Chinese hamster ovary cell line pgsA-745, which lacks cell-surface glycosaminoglycans (GAGs). Subsequent treatment of GAG-positive Chinese hamster ovary cells with mammalian heparanase or bacterial heparinase III, but not chondroitinase ABC, abolished HRG binding. Furthermore, blocking studies with various GAG species indicated that only heparin was a potent inhibitor of HRG binding. These data suggest that heparan sulfate is the predominate cell-surface ligand for HRG and that mammalian heparanase is a potential regulator of HRG binding. Using recombinant forms of full-length HRG and the N-terminal N1N2 domain, it was shown that the N1N2 domain bound specifically to immobilized heparin and cell-surface heparan sulfate. In contrast, synthetic peptides corresponding to the Zn2+-binding HRR of HRG did not interact with cells. Furthermore, the binding of full-length HRG, but not the N1N2 domain, was greatly potentiated by physiological concentrations of Zn2+. Based on these data, we propose that the N1N2 domain binds to cell-surface heparan sulfate and that the interaction of Zn2+ with the HRR can indirectly enhance cell-surface binding.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, GPO Box 4, Canberra, ACT 2601, Australia.	christopher.parish@anu.edu.au	Hulett, Mark D/C-4160-2012	Parish, Christopher/0000-0001-7740-0430; Hulett, Mark/0000-0003-2072-5968				AKTULGA A, 1974, RECENT ADV BASIC RES, P185; Borza DB, 1996, BIOCHEMISTRY-US, V35, P1925, DOI 10.1021/bi952061t; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BURCH MK, 1987, BIOCHEMISTRY-US, V26, P7477, DOI 10.1021/bi00397a042; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG NS, 1992, IMMUNOLOGY, V77, P532; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Gorgani NN, 1999, J BIOL CHEM, V274, P29633, DOI 10.1074/jbc.274.42.29633; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Gorgani NN, 1999, INT IMMUNOL, V11, P1275, DOI 10.1093/intimm/11.8.1275; Gorgani NN, 2002, J IMMUNOL, V169, P4745, DOI 10.4049/jimmunol.169.9.4745; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; GUTHANS SL, 1982, ARCH BIOCHEM BIOPHYS, V218, P320, DOI 10.1016/0003-9861(82)90350-2; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; ICHINOSE A, 1984, THROMB RES, V33, P401, DOI 10.1016/0049-3848(84)90079-3; KAZAMA Y, 1992, THROMB HAEMOSTASIS, V67, P50; KOIDE T, 1987, FEBS LETT, V216, P17, DOI 10.1016/0014-5793(87)80748-2; KOIDE T, 1986, FEBS LETT, V194, P242, DOI 10.1016/0014-5793(86)80092-8; KOIDE T, 1982, FEBS LETT, V141, P222, DOI 10.1016/0014-5793(82)80052-5; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; KOIDE T, 1985, J BIOCHEM-TOKYO, V98, P1191, DOI 10.1093/oxfordjournals.jbchem.a135385; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; MORGAN WT, 1978, BIOCHIM BIOPHYS ACTA, V535, P319, DOI 10.1016/0005-2795(78)90098-3; MORGAN WT, 1981, BIOCHEMISTRY-US, V20, P1054, DOI 10.1021/bi00508a002; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; Olsen HM, 1996, IMMUNOLOGY, V88, P198, DOI 10.1111/j.1365-2567.1996.tb00005.x; Olsson AK, 2004, CANCER RES, V64, P599, DOI 10.1158/0008-5472.CAN-03-1941; PARISH CR, 1984, J CELL SCI, V67, P145; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; RYLATT DB, 1981, EUR J BIOCHEM, V119, P641, DOI 10.1111/j.1432-1033.1981.tb05655.x; SAIGO K, 1989, J BIOL CHEM, V264, P8249; Schedin-Weiss S, 2002, BIOCHEMISTRY-US, V41, P12369, DOI 10.1021/bi020406j; Simantov R, 2001, J CLIN INVEST, V107, P45, DOI 10.1172/JCI9061	38	58	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30114	30122		10.1074/jbc.M401996200	http://dx.doi.org/10.1074/jbc.M401996200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138272	hybrid			2022-12-27	WOS:000222531900032
J	Paetzel, M; Goodall, JJ; Kania, M; Dalbey, RE; Page, MGP				Paetzel, M; Goodall, JJ; Kania, M; Dalbey, RE; Page, MGP			Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with a lipopeptide-based inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; CATALYTICALLY ACTIVE FORM; STREPTOMYCES SP TU-6075; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ARYLOMYCIN-A; PROTEIN; PROGRAM; SERINE; MECHANISM	We report here the crystallographic and biophysical analysis of a soluble, catalytically active fragment of the Escherichia coli type I signal peptidase (SPase Delta2-75) in complex with arylomycin A(2). The 2.5-Angstrom resolution structure revealed that the inhibitor is positioned with its COOH-terminal carboxylate oxygen (O45) within hydrogen bonding distance of all the functional groups in the catalytic center of the enzyme (Ser(90) O-gamma, Lys(145) N-zeta, and Ser(88) O-gamma) and that it makes beta-sheet type interactions with the beta-strands that line each side of the binding site. Ligand binding studies, calorimetry, fluorescence spectroscopy, and stopped-flow kinetics were also used to analyze the binding mode of this unique non-covalently bound inhibitor. The crystal structure was solved in the space group P4(3)2(1)2. A detailed comparison is made to the previously published acyl-enzyme inhibitor complex structure (space group: P2(1)2(1)2) and the apo-enzyme structure (space group: P4(1)2(1)2). Together this work provides insights into the binding of pre-protein substrates to signal peptidase and will prove helpful in the development of novel antibiotics.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Basilea Pharmaceut Ltd, CH-4058 Basel, Switzerland; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	Simon Fraser University; Basilea Pharmaceutica Ltd.; University System of Ohio; Ohio State University	Paetzel, M (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, S Sci Bldg,8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	mpaetzel@sfu.ca		Paetzel, Mark/0000-0002-7408-5487				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARKOCYGALLAGHER GA, 1992, J BIOL CHEM, V267, P1231; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; Black MT, 1998, CURR PHARM DESIGN, V4, P133; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruton G, 2003, EUR J MED CHEM, V38, P351, DOI 10.1016/S0223-5234(03)00040-0; Bullock TL, 1996, J MOL BIOL, V255, P714, DOI 10.1006/jmbi.1996.0058; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Carlos J. L., 2001, ENZYMES, V22, P27; Carlos JL, 2000, BIOCHEMISTRY-US, V39, P7276, DOI 10.1021/bi000301l; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DATE T, 1981, P NATL ACAD SCI-BIOL, V78, P6106, DOI 10.1073/pnas.78.10.6106; Davies JS, 2003, J PEPT SCI, V9, P471, DOI 10.1002/psc.491; Holtzel A, 2002, J ANTIBIOT, V55, P571; Hubbard BK, 2000, CHEM BIOL, V7, P931, DOI 10.1016/S1074-5521(00)00043-0; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanwar R, 2000, BIOCHEMISTRY-US, V39, P14976, DOI 10.1021/bi0008579; KIM YT, 1995, EUR J BIOCHEM, V234, P358, DOI 10.1111/j.1432-1033.1995.358_c.x; KIM YT, 1995, J BIOCHEM-TOKYO, V117, P535, DOI 10.1093/oxfordjournals.jbchem.a124741; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO D, 1994, BIOCHEMISTRY-US, V33, P8347, DOI 10.1021/bi00193a023; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; Kurz M, 1996, BIOCHEMISTRY-US, V35, P12570, DOI 10.1021/bi961017q; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Loll PJ, 1997, J AM CHEM SOC, V119, P1516, DOI 10.1021/ja963566p; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Paetzel M, 1999, PROTEIN SCI, V8, P2533; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PAETZEL M, 1995, PROTEINS, V23, P122, DOI 10.1002/prot.340230115; Paetzel M, 2000, PHARMACOL THERAPEUT, V87, P27, DOI 10.1016/S0163-7258(00)00064-4; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Schafer M, 1996, STRUCTURE, V4, P1509, DOI 10.1016/S0969-2126(96)00156-6; Schimana J, 2002, J ANTIBIOT, V55, P565, DOI 10.7164/antibiotics.55.565; SUNG M, 1992, J BIOL CHEM, V267, P13154; TSCHANTZ WR, 1995, BIOCHEMISTRY-US, V34, P3935, DOI 10.1021/bi00012a010; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TSCHANTZ WR, 1994, METHOD ENZYMOL, V244, P285; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; WICKNER W, 1987, J BACTERIOL, V169, P3821, DOI 10.1128/jb.169.8.3821-3822.1987; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593; [No title captured]	58	76	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30781	30790		10.1074/jbc.M401686200	http://dx.doi.org/10.1074/jbc.M401686200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136583	Green Submitted, hybrid			2022-12-27	WOS:000222531900109
J	Schulze, PC; Yoshioka, J; Takahashi, T; He, ZH; King, GL; Lee, RT				Schulze, PC; Yoshioka, J; Takahashi, T; He, ZH; King, GL; Lee, RT			Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UP-REGULATED PROTEIN-1; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; MAMMALIAN THIOREDOXIN; DEPENDENT ACTIVATION; ENDOTHELIAL-CELLS; NAD(P)H OXIDASE; GENE-EXPRESSION; KINASE-C; SUPEROXIDE	Increased intracellular reactive oxygen species (ROS) contribute to vascular disease and pro-atherosclerotic effects of diabetes mellitus may be mediated by oxidative stress. Several ROS-scavenging systems tightly control cellular redox balance; however, their role in hyperglycemia-induced oxidative stress is unclear. A ubiquitous antioxidative mechanism for regulating cellular redox balance is thioredoxin, a highly conserved thiol reductase that interacts with an endogenous inhibitor, thioredoxin-interacting protein (Txnip). Here we show that hyperglycemia inhibits thioredoxin ROS-scavenging function through p38 MAPK-mediated induction of Txnip. Overexpression of Txnip increased oxidative stress, while Txnip gene silencing restored thioredoxin activity in hyperglycemia. Diabetic animals exhibited increased vascular expression of Txnip and reduced thioredoxin activity, which normalized with insulin treatment. These results provide evidence for the impairment of a major ROS-scavenging system in hyperglycemia. These studies implicate reduced thioredoxin activity through interaction with Txnip as an important mechanism for vascular oxidative stress in diabetes mellitus.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Cambridge, MA 02139 USA; Joslin Diabet Ctr, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Joslin Diabetes Center, Inc.; Harvard University	Lee, RT (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, 65 Landsdowne St, Cambridge, MA 02139 USA.	rlee@rics.bwh.harvard.edu	Schulze, Christian/AGJ-7744-2022	Schulze, Christian/0000-0001-9442-7141				Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Ceriello A, 1996, DIABETES, V45, P471, DOI 10.2337/diabetes.45.4.471; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Griendling KK, 1997, CIRCULATION, V96, P3264; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hink HU, 2002, ARTERIOSCL THROM VAS, V22, P1402, DOI 10.1161/01.ATV.0000027524.86752.02; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kobayashi T, 2003, KIDNEY INT, V64, P1632, DOI 10.1046/j.1523-1755.2003.00263.x; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pekkari K, 2003, FEBS LETT, V539, P143, DOI 10.1016/S0014-5793(03)00214-X; Prieto-Alamo MJ, 2000, J BIOL CHEM, V275, P13398, DOI 10.1074/jbc.275.18.13398; Rosen P, 2001, DIABETES-METAB RES, V17, P189, DOI 10.1002/dmrr.196; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; Shalev A, 2002, ENDOCRINOLOGY, V143, P3695, DOI 10.1210/en.2002-220564; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Szocs K, 2002, ARTERIOSCL THROM VAS, V22, P21, DOI 10.1161/hq0102.102189; Tanudji M, 2003, AM J PHYSIOL-CELL PH, V284, pC1272, DOI 10.1152/ajpcell.00521.2002; Wang YL, 2002, J BIOL CHEM, V277, P26496, DOI 10.1074/jbc.M202133200; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	39	292	313	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30369	30374		10.1074/jbc.M400549200	http://dx.doi.org/10.1074/jbc.M400549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128745	hybrid			2022-12-27	WOS:000222531900062
J	Tanaka, T; Fukui, T; Fujiwara, S; Atomi, H; Imanaka, T				Tanaka, T; Fukui, T; Fujiwara, S; Atomi, H; Imanaka, T			Concerted action of diacetylchitobiose deacetylase and exo-beta-D-glucosaminidase in a novel chitinolytic pathway in the hyperthermophilic archaeon Thermococcus kodakaraensis KOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PIG-L; CHITINASE; CLONING; N,N'-DIACETYLCHITOBIOSE; DISACCHARIDE	The hyperthermophilic archaeon Thermococcus kodakaraensis KOD1 possesses chitinase (Tk-ChiA) and exo-beta-D-glucosaminidase (Tk-GlmA) for chitin degradation; the former produces diacetylchitobiose (GlcNAc(2)) from chitin, and the latter hydrolyzes chitobiose (GlcN(2)) to glucosamine ( GlcN). To identify the enzyme that physiologically links these two activities, here we focused on the deacetylase that provides the substrate for Tk-GlmA from GlcNAc2. The deacetylase could be detected in and partially purified from T. kodakaraensis cells, and the corresponding gene (Tk-dac) was identified on the genome. The deduced amino acid sequence was classified into the LmbE protein family including N-acetylglucosaminylphosphatidylinositol de-N-acetylases and 1-D-myo-inosityl-2-acetamido-2-deoxy-alpha-D-glucopyranoside deacetylase. Recombinant Tk-Dac showed deacetylase activity toward N-acetylchitooligosaccharides (GlcNAc(2-5)), and the deacetylation site was revealed to be specific at the nonreducing GlcNAc residue. The enzyme also deacetylated GlcNAc monomer. In T. kodakaraensis cells, the transcription of Tk-dac, Tk-glmA, Tk-chiA, and the clustered genes were induced by GlcNAc(2), suggesting the function of this gene cluster in chitin catabolism in vivo. These results have revealed a unique chitin catabolic pathway in T. kodakaraensis, in which GlcNAc(2) produced from chitin is degraded by the concerted action of Tk-Dac and Tk-GlmA. That is, GlcNAc(2) is site-specifically deacetylated to GlcN-GlcNAc by Tk-Dac and then hydrolyzed to GlcN and GlcNAc by Tk-GlmA followed by a second deacetylation step of the remaining GlcNAc by Tk-Dac to form GlcN. This is the first elucidation of an archaeal chitin catabolic pathway and defines a novel mechanism for dimer processing using a combination of deacetylation and cleavage, distinct from any previously known pathway.	Kyoto Univ, Dept Synthet Chem & Biol Chem, Grad Sch Engn, Nishikyo Ku, Kyoto 6158510, Japan; Kwansei Gakuin Univ, Dept Biosci, Nanobiotechnol Res Ctr, Sch Sci & Technol, Sanda 6691337, Japan	Kyoto University; Kwansei Gakuin University	Imanaka, T (corresponding author), Kyoto Univ, Dept Synthet Chem & Biol Chem, Grad Sch Engn, Nishikyo Ku, Kyoto 6158510, Japan.	imanaka@sbchem.kyoto-u.ac.jp	Fujiwara, Shinsuke/CAE-9955-2022; Tanaka, Takeshi/C-2921-2012; Fukui, Toshiaki/S-6882-2019; 福居, 俊昭/K-5056-2012	Tanaka, Takeshi/0000-0001-7547-7928; Fukui, Toshiaki/0000-0003-4557-6284; 福居, 俊昭/0000-0003-4557-6284; Atomi, Haruyuki/0000-0001-9687-6426				Andronopoulou E, 2003, EXTREMOPHILES, V7, P43, DOI 10.1007/s00792-002-0294-3; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; Ezaki S, 1999, J BIOSCI BIOENG, V88, P130, DOI 10.1016/S1389-1723(99)80190-X; Gao J, 2003, APPL ENVIRON MICROB, V69, P3119, DOI 10.1128/AEM.69.6.3119-3128.2003; Gooday Graham W., 1994, P279; Handa N, 2003, PROTEIN SCI, V12, P1621, DOI 10.1110/gad.03104003; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Newton GL, 2000, J BACTERIOL, V182, P6958, DOI 10.1128/JB.182.24.6958-6963.2000; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; Sambrook J., 2001, MOL CLONING LAB MANU; Tanaka T, 1999, APPL ENVIRON MICROB, V65, P5338; Tanaka T, 2003, J BACTERIOL, V185, P5175, DOI 10.1128/JB.185.17.5175-5181.2003; Tanaka T, 2001, J BIOL CHEM, V276, P35629, DOI 10.1074/jbc.M105919200; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tsigos I, 2000, TRENDS BIOTECHNOL, V18, P305, DOI 10.1016/S0167-7799(00)01462-1; Watanabe R, 1999, BIOCHEM J, V339, P185, DOI 10.1042/0264-6021:3390185	20	68	75	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30021	30027		10.1074/jbc.M314187200	http://dx.doi.org/10.1074/jbc.M314187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136574	hybrid			2022-12-27	WOS:000222531900020
J	Terrones, O; Antonsson, B; Yamaguchi, H; Wang, HG; Liu, JH; Lee, RM; Herrmann, A; Basanez, G				Terrones, O; Antonsson, B; Yamaguchi, H; Wang, HG; Liu, JH; Lee, RM; Herrmann, A; Basanez, G			Lipidic pore formation by the concerted action of proapoptotic BAX and tBID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBER; CONFORMATIONAL-CHANGE; MITOCHONDRIAL-MEMBRANES; PROTEIN; CELL; APOPTOSIS; BH3; OLIGOMERIZATION; ACTIVATION	BCL-2 homology 3 (BH3)-only proteins of the BCL-2 family such as tBID and BIMEL assist BAX-type proteins to breach the permeability barrier of the outer mitochondrial membrane, thereby allowing cytoplasmic release of cytochrome c and other active inducers of cell death normally confined to the mitochondrial intermembrane space. However, the exact mechanism by which tBID and BIMEL aid BAX and its close homologues in this mitochondrial protein release remains enigmatic. Here, using pure lipid vesicles, we provide evidence that tBID acts in concert with BAX to 1) form large membrane openings through both BH3-dependent and BH3-independent mechanisms, 2) cause lipid trans-bilayer movement concomitant with membrane permeabilization, and 3) disrupt the lipid bilayer structure of the membrane by promoting positive monolayer curvature stress. None of these effects were observed with BAX when BIMEL was substituted for tBID. Based on these data, we propose a novel model in which tBID assists BAX not only via protein-protein but also via protein-lipid interactions to form lipidic pore-type nonbilayer structures in the outer mitochondrial membrane through which intermembrane prodeath molecules exit mitochondria during apoptosis.	Univ Basque Country, Euskal Herriko Unibertsitatea, Ctr Mixto, CSIC,Unidad Biofis, E-48080 Bilbao, Spain; Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Humboldt Univ, Inst Biol Mol Biophys, D-10115 Berlin, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; Merck & Company; Serono International S.A.; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Humboldt University of Berlin	Basanez, G (corresponding author), Univ Basque Country, Euskal Herriko Unibertsitatea, Ctr Mixto, CSIC,Unidad Biofis, POB 644, E-48080 Bilbao, Spain.	gbzbaasg@lg.ehu.es	Basanez, Gorka/L-9509-2014; Terrones, Oihana/AAA-8903-2019; Wang, Hong-Gang/A-3018-2015; Terrones, Oihana/I-4023-2015	Basanez, Gorka/0000-0002-7475-7861; Wang, Hong-Gang/0000-0003-0551-0571; Terrones, Oihana/0000-0001-7421-6486				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Basanez G, 2002, FEBS LETT, V532, P115, DOI 10.1016/S0014-5793(02)03651-7; Basanez G, 2002, CELL MOL LIFE SCI, V59, P1478, DOI 10.1007/s00018-002-8523-6; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cristea IM, 2004, CHEM PHYS LIPIDS, V129, P133, DOI 10.1016/j.chemphyslip.2004.02.002; CULLIS PR, 1999, MEMBRANE FUSION, P35; DEJONG D, 1994, CANCER RES, V54, P256; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DUFOURCQ J, 1986, BIOCHIM BIOPHYS ACTA, V859, P33, DOI 10.1016/0005-2736(86)90315-9; Epand RF, 2003, BIOCHEMISTRY-US, V42, P14576, DOI 10.1021/bi035348w; Epand RF, 2004, BIOCHEM J, V377, P509, DOI 10.1042/BJ20030938; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Festjens N, 2003, ACTA HAEMATOL-BASEL, V111, P7, DOI 10.1159/000074483; Fuller N, 2001, BIOPHYS J, V81, P243, DOI 10.1016/S0006-3495(01)75695-0; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; LIU J, 2004, IN PRESS APOPTOSIS; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Malisan F, 2003, CURR MED CHEM, V10, P1573, DOI 10.2174/0929867033457188; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Menestrina G, 2001, TOXICON, V39, P1661, DOI 10.1016/S0041-0101(01)00153-2; Montessuit S, 1999, PROTEIN EXPRES PURIF, V15, P202, DOI 10.1006/prep.1998.1010; Mouhamad S, 2004, J IMMUNOL, V172, P2084, DOI 10.4049/jimmunol.172.4.2084; Muller P, 2000, CHEM PHYS LIPIDS, V106, P89, DOI 10.1016/S0009-3084(00)00134-1; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Polster BM, 2003, J NEUROSCI, V23, P2735; Polster BM, 2001, J BIOL CHEM, V276, P37887; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; SHEAU YH, 1998, MOL ENDOCRINOL, V12, P1432; SORICE M, 2004, IN PRESS CELL DEATH; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Szule JA, 2002, BIOPHYS J, V83, P977, DOI 10.1016/S0006-3495(02)75223-5; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; WANG K, 1999, GENE DEV, V15, P2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhai DY, 2001, EUR J BIOCHEM, V268, P48, DOI 10.1046/j.1432-1327.2001.01841.x; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	78	194	198	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30081	30091		10.1074/jbc.M313420200	http://dx.doi.org/10.1074/jbc.M313420200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138279	hybrid			2022-12-27	WOS:000222531900028
J	Vougier, S; Mary, J; Dautin, N; Vinh, J; Friguet, B; Ladant, D				Vougier, S; Mary, J; Dautin, N; Vinh, J; Friguet, B; Ladant, D			Essential role of methionine residues in calmodulin binding to Bordetella pertussis adenylate cyclase, as probed by selective oxidation and repair by the peptide methionine sulfoxide reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA-ATPASE; OXIDIZED CALMODULIN; CALCIUM SENSOR; EXPRESSION; ACTIVATION; PROTEINS; CLONING; TOXIN; MUTAGENESIS; ABILITY	Bordetella pertussis, the causative agent of whooping cough, secretes among other virulence factors an adenylate cyclase (AC) toxin that is able to enter into eukaryotic cells where it is activated upon binding to endogenous calmodulin (CaM) and synthesizes supraphysiological cAMP levels. In vivo, the AC toxin, through its specific interaction with the CD11b/CD18 integrin, primarily targets phagocytic cells such as neutrophils and macrophages. Because neutrophil priming and activation result in the production of reactive oxygen species that may cause intracellular oxidation, we have examined the biological consequences of the oxidation of CaM methionines upon its interaction with AC. We show here that the interaction of CaM with AC is dependent on the reduced state of methionines, because oxidation of all methionine residues of CaM dramatically decreases its affinity for AC. Peptide methionine sulfoxide reductases A (MsrA) and B (MsrB) were able to partially reduce the oxidized CaM, and these partially "repaired" forms could interact with AC nearly as efficiently as the native protein. We further showed that the CaM.AC complex is resistant to oxidation with tert-butylhydroperoxide, and we identified methionine residues 109, 124, and 145 as critical for binding to AC. The resistance of the AC.CaM complex to oxidation and the ability of AC to be efficiently activated by partially oxidized CaM molecules should allow the toxin to exert its cytotoxic effects on activated neutrophils and contribute to the host colonization.	Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, EA 3106, IFR 117, F-75005 Paris, France; Inst Pasteur, Dept Biol Struct & Chim, CNRS, URA 2185,Unite Biochim Interact Macromol, F-75015 Paris, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, Lab Neurobiol & Divers Cellulaire, F-75005 Paris, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Friguet, B (corresponding author), Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, EA 3106, IFR 117, 2 Pl Jussieu, F-75005 Paris, France.	bfriguet@paris7.jussieu.fr; ladant@pasteur.fr	Mary, Jean/H-2344-2011; Vinh, Joelle/K-1347-2015	Mary, Jean/0000-0002-2438-8383; Vinh, Joelle/0000-0001-7184-2668; Friguet, Bertrand/0000-0001-8085-1961; LADANT, Daniel/0000-0003-1955-548X				Balog EM, 2003, J BIOL CHEM, V278, P15615, DOI 10.1074/jbc.M209180200; Bartlett RK, 2003, BIOCHEMISTRY-US, V42, P3231, DOI 10.1021/bi026956z; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; GILLES AM, 1990, BIOCHEMISTRY-US, V29, P8126, DOI 10.1021/bi00487a020; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; Harvill ET, 1999, INFECT IMMUN, V67, P1493, DOI 10.1128/IAI.67.3.1493-1500.1999; Jung S, 2002, FEBS LETT, V527, P91, DOI 10.1016/S0014-5793(02)03171-X; Keck RG, 1996, ANAL BIOCHEM, V236, P56, DOI 10.1006/abio.1996.0131; Kondo R, 1999, J BIOL CHEM, V274, P36213, DOI 10.1074/jbc.274.51.36213; Kryukov GV, 2002, P NATL ACAD SCI USA, V99, P4245, DOI 10.1073/pnas.072603099; Kuschel L, 1999, FEBS LETT, V456, P17, DOI 10.1016/S0014-5793(99)00917-5; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LADANT D, 1992, J BIOL CHEM, V267, P2244; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Levine RL, 1999, MECH AGEING DEV, V107, P323, DOI 10.1016/S0047-6374(98)00152-3; Michaelis ML, 1996, LIFE SCI, V59, P405, DOI 10.1016/0024-3205(96)00319-0; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mock M, 1993, Trends Microbiol, V1, P187, DOI 10.1016/0966-842X(93)90089-A; Montgomery HJ, 2003, BIOCHEMISTRY-US, V42, P7759, DOI 10.1021/bi027097h; Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664; WOLFF J, 1986, BIOCHEMISTRY-US, V25, P7950, DOI 10.1021/bi00372a025; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841; Yin D, 2000, CHEM RES TOXICOL, V13, P103, DOI 10.1021/tx990142a	36	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30210	30218		10.1074/jbc.M400604200	http://dx.doi.org/10.1074/jbc.M400604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15148319	hybrid			2022-12-27	WOS:000222531900044
J	Mayasundari, A; Whittemore, NA; Serpersu, EH; Peterson, CB				Mayasundari, A; Whittemore, NA; Serpersu, EH; Peterson, CB			The solution structure of the N-terminal domain of human vitronectin - Proximal sites that regulate fibrinolysis and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SOMATOMEDIN-B-DOMAIN; UROKINASE RECEPTOR; NMR-SPECTROSCOPY; BREAST-CANCER; CYSTINE KNOT; IN-VIVO; EXTRACELLULAR-MATRIX; DISTANCE GEOMETRY; INTEGRIN FUNCTION	The three-dimensional structure of an N-terminal fragment comprising the first 51 amino acids from human plasma vitronectin, the somatomedin B (SMB) domain, has been determined by two-dimensional NMR approaches. An average structure was calculated, representing the overall fold from a set of 20 minimized structures. The core residues (18-41) overlay with a root mean square deviation of 2.29 +/- 0.62 Angstrom. The N- and C-terminal segments exhibit higher root mean square deviations, reflecting more flexibility in solution and/or fewer long-range NOEs for these regions. Residues 26-30 form a unique single-turn alpha-helix, the locus where plasminogen activator inhibitor type-1 (PAI-1) is bound. This structure of this helix is highly homologous with that of a recombinant SMB domain solved in a co-crystal with PAI-1 (Zhou, A., Huntington, J. A., Pannu, N. S., Carrell, R. W., and Read, R. J. (2003) Nat. Struct. Biol. 10, 541-544), although the remainder of the structure differs. Significantly, the pattern of disulfide cross-links observed in this material isolated from human plasma is altogether different from the disulfides proposed for recombinant forms. The NMR structure reveals the relative orientation of binding sites for cell surface receptors, including an integrin-binding site at residues 45 47, which was disordered and did not diffract in the co-crystal, and a site for the urokinase receptor, which overlaps with the PAI-1-binding site.	Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Excellence Struct Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.	cynthia-peterson@utk.edu		Serpersu, Engin H./0000-0003-1420-455X	NHLBI NIH HHS [HL50676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaboe M, 2003, BBA-MOL BASIS DIS, V1638, P72, DOI 10.1016/S0925-4439(03)00059-0; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; BenMenahem D, 1997, J BIOL CHEM, V272, P6827, DOI 10.1074/jbc.272.11.6827; Carreiras F, 1999, GYNECOL ONCOL, V72, P312, DOI 10.1006/gyno.1998.5262; Carriero MV, 1999, CANCER RES, V59, P5307; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; De Prada NA, 2002, EUR J BIOCHEM, V269, P184, DOI 10.1046/j.0014-2956.2002.02639.x; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Eitzman DT, 1996, BLOOD, V87, P4718; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Gutierrez LS, 2000, CANCER RES, V60, P5839; HEITZ A, 1989, BIOCHEMISTRY-US, V28, P2392, DOI 10.1021/bi00432a009; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Jang YC, 2000, SURGERY, V127, P696, DOI 10.1067/msy.2000.105858; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jensen JK, 2004, FEBS LETT, V556, P175, DOI 10.1016/S0014-5793(03)01405-4; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Kamikubo Y, 2002, J BIOL CHEM, V277, P27109, DOI 10.1074/jbc.M200354200; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; KOBAYASHI Y, 1991, BIOPOLYMERS, V31, P1213, DOI 10.1002/bip.360311009; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Podor TJ, 2002, J BIOL CHEM, V277, P7520, DOI 10.1074/jbc.M109677200; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REDFIELD C, 1993, NMR MACROMOLECULES P, P71; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wilcox-Adelman SA, 2000, CELL ADHES COMMUN, V7, P477, DOI 10.3109/15419060009040305; WILLIAMSON PM, 1985, J MOL BIOL, P295; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Xu D, 2001, PROTEINS, V44, P312, DOI 10.1002/prot.1096; Xue W, 1997, CANCER RES, V57, P1682; Yoneda A, 1998, BIOCHEMISTRY-US, V37, P6351, DOI 10.1021/bi972247n; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	65	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29359	29366		10.1074/jbc.M401279200	http://dx.doi.org/10.1074/jbc.M401279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123712	hybrid			2022-12-27	WOS:000222445300067
J	Silletti, S; Yebra, M; Perez, B; Cirulli, V; McMahon, M; Montgomery, AMP				Silletti, S; Yebra, M; Perez, B; Cirulli, V; McMahon, M; Montgomery, AMP			Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NEURITE OUTGROWTH; INTEGRIN ALPHA(V)BETA(3); CATHEPSINS-B; MIGRATION; MELANOMA; BINDING; GROWTH; MOUSE; CASCADE	The cell adhesion molecule L1 has been implicated in a variety of motile processes, including neurite extension, cerebellar cell migration, extravasation, and metastasis. Homophilic or heterophilic L1 binding and concomitant signaling have been shown to promote cell motility in the short term. In this report, L1 is also shown to induce and maintain a motile and invasive phenotype by promoting gene transcription. In the presence of serum or platelet-derived growth factor, L1 promotes heightened and sustained activation of the extracellular signal-regulated kinase pathway. Activation of this pathway then induces the expression of motility- and invasion-associated gene products, including the beta(3)-integrin subunit, small GTPases, and the cysteine proteases cathepsin-L and - B. Induction of integrin alpha(v)beta(3) and rac-1 is shown to contribute directly to L1-dependent haptotaxis, whereas induction of cathepsins-L and - B promotes matrix invasion. This study provides a novel translational mechanism to account for the association between L1 expression and motile processes involved in metastasis and development.	Univ Calif San Diego, Whittier Inst, Dept Pediat, La Jolla, CA 92037 USA; Univ Calif San Diego, Moores Comprehens Canc Ctr, La Jolla, CA 92037 USA; Univ Calif San Francisco, Mt Zion Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; UCSF Medical Center at Mount Zion	Montgomery, AMP (corresponding author), Univ Calif San Diego, Whittier Inst, Dept Pediat, 9894 Genesee Ave, La Jolla, CA 92037 USA.	ammontgo@ucsd.edu			NCI NIH HHS [R01 CA69112-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL62477-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK55183, R01 DK55183S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069112] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBELDA SM, 1990, CANCER RES, V50, P6757; ALTETSEE C, 2001, AUDIOL NEURO-OTOL, V2, P57; Balaian LB, 2000, EUR J IMMUNOL, V30, P938; Bartsch U, 2003, FRONT BIOSCI-LANDMRK, V8, pD477, DOI 10.2741/1028; Bednarski E, 1997, J NEUROSCI, V17, P4006; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; Calvo A, 2002, CANCER RES, V62, P5325; CROSSIN KL, 1990, EXP NEUROL, V109, P6, DOI 10.1016/S0014-4886(05)80004-4; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Debiec H, 1998, J CELL BIOL, V143, P2067, DOI 10.1083/jcb.143.7.2067; Demyanenko GP, 1999, J NEUROSCI, V19, P4907; Di Sciullo G, 1998, J EXP MED, V187, P1953, DOI 10.1084/jem.187.12.1953; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Hangan D, 1997, CANCER RES, V57, P3812; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Islam R, 2004, MOL BIOL CELL, V15, P2003, DOI 10.1091/mbc.e03-05-0333; Ivins JK, 2000, J NEUROSCI, V20, P6551, DOI 10.1523/JNEUROSCI.20-17-06551.2000; Izumoto S, 1996, CANCER RES, V56, P1440; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jessen U, 2001, J NEUROCHEM, V79, P1149, DOI 10.1046/j.1471-4159.2001.00636.x; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Koistinen P, 2002, J BIOL CHEM, V277, P24835, DOI 10.1074/jbc.M203149200; Kolkova K, 2000, J NEUROSCI, V20, P2238; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINNEMANN D, 1989, INT J CANCER, V43, P709, DOI 10.1002/ijc.2910430428; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA M, 1992, J BIOL CHEM, V267, P10752; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Moses S, 2001, ARCH BIOCHEM BIOPHYS, V396, P133, DOI 10.1006/abbi.2001.2578; Nayeem N, 1999, J CELL SCI, V112, P4739; Nolte C, 1999, CELL TISSUE RES, V298, P261, DOI 10.1007/s004419900063; Pancook JD, 1997, J IMMUNOL, V158, P4413; Petitclerc E, 1999, CANCER RES, V59, P2724; Primiano T, 2003, CANCER CELL, V4, P415, DOI 10.1016/S1535-6108(03)00274-5; RELVAS JB, 2001, CURR BIOL, V6, P1445; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schmid RS, 2000, J NEUROSCI, V20, P4177; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Thies A, 2002, EUR J CANCER, V38, P1708, DOI 10.1016/S0959-8049(02)00105-3; Thompson RD, 2000, J IMMUNOL, V165, P426, DOI 10.4049/jimmunol.165.1.426; THOR G, 1987, EMBO J, V6, P2581, DOI 10.1002/j.1460-2075.1987.tb02548.x; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Welch DR, 2000, CANCER RES, V60, P1552; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Yip PM, 1998, MOL BIOL CELL, V9, P277, DOI 10.1091/mbc.9.2.277; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	61	126	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28880	28888		10.1074/jbc.M404075200	http://dx.doi.org/10.1074/jbc.M404075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128735	hybrid			2022-12-27	WOS:000222445300008
J	Yang, RY; Hsu, DK; Yu, L; Chen, HY; Liu, FT				Yang, RY; Hsu, DK; Yu, L; Chen, HY; Liu, FT			Galectin-12 is required for adipogenic signaling and adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CLONAL EXPANSION; BINDING-PROTEIN-BETA; SMALL INTERFERING RNAS; C/EBP-ALPHA; PPAR-GAMMA; ADIPOSE-TISSUE; MAMMALIAN-CELLS; KINASE-B; TRANSCRIPTIONAL REGULATION; MOLECULAR REGULATION	Galectin-12 is a member of the galectin family consisting of beta-galactoside-binding proteins with conserved carbohydrate recognition domains. This protein is preferentially expressed in peripheral blood leukocytes and adipocytes. We previously showed that galectin-12 is induced by cell cycle block at the G(1) phase and causes G(1) arrest when overexpressed ( Yang, R.-Y., Hsu, D. K., Yu, L., Ni, J., and Liu, F.- T. ( 2001) J. Biol. Chem. 276, 20252 20260). Here, we show that the galectin-12 gene is expressed in mouse preadipocytes and is up-regulated when preadipocytes undergo cell cycle arrest, concomitant with acquisition of the competence to undergo differentiation in response to adipogenic hormone stimulation. Following a brief down-regulation 1 day after adipogenic treatment, its expression was once again markedly elevated when cells underwent terminal differentiation. Down-regulation of endogenous galectin-12 expression by RNA interference greatly reduced the expression of the adipogenic transcription factors CCAAT/enhancer-binding protein-beta and -alpha and peroxisome proliferator-activated receptor-gamma and severely suppressed adipocyte differentiation as a result of defective adipogenic signaling. We conclude that galectin-12 is required for signal transduction that conveys hormone stimulation to the induction of adipogenic factors essential for adipocyte differentiation. The findings suggest that galectin-12 is a major regulator of adipose tissue development.	Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA	University of California System; University of California Davis	Yang, RY (corresponding author), Univ Calif Davis, Sch Med, Dept Dermatol, Res 3 Bldg,Rm 3100C,4645 2nd Ave, Sacramento, CA 95817 USA.	ryyang@ucdavis.edu	Yang, Riyao/R-7593-2019; Liu, FU-TONG/A-5749-2019	Yang, Riyao/0000-0002-0278-4385; Liu, FU-TONG/0000-0002-3354-1001	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020958, R01AI039620] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI20958, R01 AI39620] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Akahani S, 1997, CANCER RES, V57, P5272; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; Calkhoven CF, 2000, GENE DEV, V14, P1920; CATALANO RA, 1975, STAIN TECHNOL, V50, P297, DOI 10.3109/10520297509117078; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Fasshauer M, 2002, EUR J ENDOCRINOL, V147, P553, DOI 10.1530/eje.0.1470553; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410; Hikita C, 2000, J CELL BIOL, V151, P1235, DOI 10.1083/jcb.151.6.1235; Hotta K, 2001, J BIOL CHEM, V276, P34089, DOI 10.1074/jbc.M105097200; Janderova L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Koopman R, 2001, HISTOCHEM CELL BIOL, V116, P63; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; LIU FT, 1995, AM J PATHOL, V147, P1016; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Mehul B, 1997, J CELL SCI, V110, P1169; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Reichert M, 1999, ONCOGENE, V18, P459, DOI 10.1038/sj.onc.1202308; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; SEVE AP, 1994, EXP CELL RES, V213, P191, DOI 10.1006/excr.1994.1190; Sorisky A, 1999, CRIT REV CL LAB SCI, V36, P1, DOI 10.1080/10408369991239169; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Worrall DS, 2002, MOL ENDOCRINOL, V16, P378, DOI 10.1210/me.16.2.378; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; Yang RY, 2001, J BIOL CHEM, V276, P20252, DOI 10.1074/jbc.M010914200; Zhang JW, 2004, J BIOL CHEM, V279, P4471, DOI 10.1074/jbc.M311327200	70	54	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29761	29766		10.1074/jbc.M401303200	http://dx.doi.org/10.1074/jbc.M401303200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131127	hybrid			2022-12-27	WOS:000222445300112
J	Chen, ZL; Katzenellenbogen, BS; Katzenellenbogen, JA; Zhao, HM				Chen, ZL; Katzenellenbogen, BS; Katzenellenbogen, JA; Zhao, HM			Directed evolution of human estrogen receptor variants with significantly enhanced androgen specificity and affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; LIGAND-BINDING DOMAIN; STEROID-RECEPTOR; ALPHA; TRANSCRIPTION; SUPERFAMILY; PROTEINS; YEAST; BETA; GENE	Human estrogen receptor alpha (hERalpha) and human androgen receptor exhibit exquisite ligand specificity, which underlies their remarkable ability to effect ligand-regulated gene transcription in a highly distinctive and specific manner. Here we used a directed evolution approach to create hERalpha variants with enhanced androgen specificity and affinity with the goal to better understand the molecular basis of ER ligand specificity and the evolutionary mechanism of nuclear receptors. We developed a sensitive yeast two-hybrid system to screen for hERalpha variants with increased transactivation potency toward testosterone. After two rounds of directed evolution, we identified five hERalpha variants with dramatically improved transactivation potency toward testosterone in both yeast and mammalian cells. These variants showed up to 7,600-fold improvement in the binding affinity for testosterone and only slightly reduced affinity toward 17beta-estradiol. Detailed analysis of these evolved variants and a few site-directed mutants generated de novo led to several unexpected findings including the following. 1) Only two beneficial mutations were needed to create hERalpha variants with near nanomolar affinity for testosterone. 2) Some beneficial mutations were synergistic, context-dependent, or nonadditive. 3) Of the five identified beneficial mutations, four of them were not in the ER ligand binding pocket and yet exerted important action on ligand specificity. 4) The single ligand-contacting mutation E353Q plays a dominant role in discriminating androgens and estrogens. These results, viewed in conjunction with the ligand exploitation model of nuclear receptor evolution, suggest that the mutation E353Q may represent a key event in the evolution of androgen receptors from an ancestral estrogen receptor and that ligand promiscuity may play an important role in the creation of new nuclear receptors via divergent evolution.	Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem Engn & Biomol Engn, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Zhao, HM (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.	zhao5@uiuc.edu			NCI NIH HHS [CA18119] Funding Source: Medline; NIDDK NIH HHS [DK15556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015556, R37DK015556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen ZL, 2003, GENE, V306, P127, DOI 10.1016/S0378-1119(03)00431-1; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Ekena K, 1998, J BIOL CHEM, V273, P693, DOI 10.1074/jbc.273.2.693; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Katzenellenbogen JA, 1996, CHEM BIOL, V3, P529, DOI 10.1016/S1074-5521(96)90143-X; KATZENELLENBOGEN JA, 1973, BIOCHEMISTRY-US, V12, P4085, DOI 10.1021/bi00745a010; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCPHAUL MJ, 1991, FASEB J, V5, P2910, DOI 10.1096/fasebj.5.14.1752359; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Muthyala RS, 2003, J MED CHEM, V46, P1589, DOI 10.1021/jm0204800; Nettles KW, 2004, MOL CELL, V13, P317, DOI 10.1016/S1097-2765(04)00054-1; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Schmidt-Dannert C, 2001, BIOCHEMISTRY-US, V40, P13125, DOI 10.1021/bi011310c; Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941; Tenbaum S, 1997, INT J BIOCHEM CELL B, V29, P1325, DOI 10.1016/S1357-2725(97)00087-3; Thornton JW, 2003, SCIENCE, V301, P1714, DOI 10.1126/science.1086185; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Toth I, 1995, PHARMACOL RES, V32, P217, DOI 10.1016/S1043-6618(05)80025-8; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Zhao CQ, 2003, J BIOL CHEM, V278, P27278, DOI 10.1074/jbc.M303840200; Zhao H., 1999, MANUAL IND MICROBIOL, P597; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	30	43	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33855	33864		10.1074/jbc.M402118200	http://dx.doi.org/10.1074/jbc.M402118200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159406	hybrid			2022-12-27	WOS:000223039700095
J	Deng, L; Markova, SV; Vysotski, ES; Liu, ZJ; Lee, J; Rose, J; Wang, BC				Deng, L; Markova, SV; Vysotski, ES; Liu, ZJ; Lee, J; Rose, J; Wang, BC			Crystal structure of a Ca2+-discharged photoprotein - Implications for mechanisms of the calcium trigger and bioluminescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIOLET BIOLUMINESCENCE; W92F OBELIN; AEQUORIN; LIGHT; SEQUENCE; LUMINESCENCE; EVOLUTION; EMISSION; PROTEINS; CLONING	Ca2+-regulated photoproteins are members of the EF-hand calcium-binding protein family. The addition of Ca2+ produces a blue bioluminescence by triggering a decarboxylation reaction of protein-bound hydroperoxycoelenterazine to form the product, coelenteramide, in an excited state. Based on the spatial structures of aequorin and several obelins, we have postulated mechanisms for the Ca2+ trigger and for generation of the different excited states that are the origin of the different colors of bioluminescence. Here we report the crystal structure of the Ca2+-discharged photoprotein obelin at 1.96-Angstrom resolution. The results lend support to the proposed mechanisms and provide new structural insight into details of these processes. Global conformational changes caused by Ca2+ association are typical of the class of calcium signal modulators within the EF-hand protein superfamily. Accommodation of the Ca2+ ions into the loops of the EF-hands is seen to propagate into the active site of the protein now occupied by the coelenteramide where there is a significant repositioning and flipping of the His-175 imidazole ring as crucially required in the trigger hypothesis. Also the H-bonding between His-22 and the coelenterazine found in the active photoprotein is preserved at the equivalent position of coelenteramide, confirming the proposed rapid excited state proton transfer that would lead to the excited state of the phenolate ion pair, which is responsible for the blue emission of bioluminescence.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Russian Acad Sci, Inst Biophys, Siberian Branch, Krasnoyarsk 660036, Russia	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Russian Academy of Sciences; Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences; Biophysics Institute, Siberian Branch, Russian Academy of Sciences	Lee, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	jlee@uga.edu	Liu, Zhi-Jie/A-3946-2012; Deng, Lu/AAE-1635-2021; Vysotski, Eugene/I-1761-2013; Markova, Svetlana V./AAT-7574-2020	Liu, Zhi-Jie/0000-0001-7279-2893; Vysotski, Eugene/0000-0002-5884-3081; Markova, Svetlana V./0000-0001-5702-1193				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BREHM P, 1989, NEURON, V3, P191, DOI 10.1016/0896-6273(89)90032-9; CHARBONNEAU H, 1985, BIOCHEMISTRY-US, V24, P6762, DOI 10.1021/bi00345a006; Deng L, 2004, ACTA CRYSTALLOGR D, V60, P512, DOI 10.1107/S090744490302852X; Deng L, 2001, FEBS LETT, V506, P281, DOI 10.1016/S0014-5793(01)02937-4; Head JF, 2000, NATURE, V405, P372, DOI 10.1038/35012659; ILLARIONOV BA, 1995, GENE, V153, P273, DOI 10.1016/0378-1119(94)00797-V; Imai Y, 2001, J PHOTOCH PHOTOBIO A, V146, P95, DOI 10.1016/S1010-6030(01)00554-8; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; Jeffery G.A., 1997, INTRO HYDROGEN BONDI; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee J., 2001, BIOLUMINESCENCE CHEM, P99; Liu ZJ, 2003, BIOCHEM BIOPH RES CO, V311, P433, DOI 10.1016/j.bbrc.2003.09.231; Liu ZJ, 2000, PROTEIN SCI, V9, P2085, DOI 10.1110/ps.9.11.2085; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Malikova NP, 2003, FEBS LETT, V554, P184, DOI 10.1016/S0014-5793(03)01166-9; Markova SV, 2002, BIOCHEMISTRY-US, V41, P2227, DOI 10.1021/bi0117910; MCCAPRA F, 1967, CHEM COMMUN, P1011, DOI 10.1039/c19670001011; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Morin J.G., 1974, pUnpaginated; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; OHMIYA Y, 1993, FEBS LETT, V320, P267, DOI 10.1016/0014-5793(93)80600-Y; Ohmiya Y, 1996, CHEM BIOL, V3, P337, DOI 10.1016/S1074-5521(96)90116-7; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; SHIMOMURA O, 1988, BIOCHEM J, V251, P405, DOI 10.1042/bj2510405; Shimomura O, 2000, LUMINESCENCE, V15, P51, DOI 10.1002/(SICI)1522-7243(200001/02)15:1<51::AID-BIO555>3.0.CO;2-J; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Vysotski ES, 2003, BIOCHEMISTRY-US, V42, P6013, DOI 10.1021/bi027258h	31	49	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33647	33652		10.1074/jbc.M402427200	http://dx.doi.org/10.1074/jbc.M402427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155735	hybrid			2022-12-27	WOS:000223039700074
J	Grant, MA; Hansson, K; Furie, BC; Furie, B; Stenflo, J; Rigby, AC				Grant, MA; Hansson, K; Furie, BC; Furie, B; Stenflo, J; Rigby, AC			The metal-free and calcium-bound structures of a gamma-carboxyglutamic acid-containing contryphan from Conus marmoreus, glacontryphan-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; NMR CHEMICAL-SHIFTS; BLOOD-COAGULATION; CONANTOKIN-T; FACTOR-IX; PROTEIN-STRUCTURE; MEMBRANE-BINDING; MOLECULAR-BASIS; D-TRYPTOPHAN; AMINO-ACIDS	Glacontryphan-M, a novel calcium-dependent inhibitor of L-type voltage-gated Ca2+ channels expressed in mouse pancreatic beta-cells, was recently isolated from the venom of the cone snail Conus marmoreus (Hansson, K., Ma, X., Eliasson, L., Czerwiec, E., Furie, B., Furie, B. C., Rorsman, P., and Stenflo, J. ( 2004) J. Biol. Chem. 278, 32453-32463). The conserved disulfide-bonded loop of the contryphan family of conotoxins including a D-Trp is present; however, unique to glacontryphan-M is a histidine within the intercysteine-loop and two gamma-carboxy-glutamic acid (Gla) residues, formed by post-translational modification of glutamic acid. The two calcium-binding Gla residues are located in a four residue N-terminal extension of this contryphan. To better understand the structural and functional significance of these residues, we have determined the structure of glacontryphan-M using two-dimensional H-1 NMR spectroscopy in the absence and presence of calcium. Comparisons of the glacontryphan-M structures reveal that calcium binding induces structural perturbations within the Gla-containing N terminus and the Cys(11)-Cys(5)-Pro(6) region of the intercysteine loop. The backbone of N-terminal residues perturbed by calcium, Gla(2) and Ser(3), moves away from the His(8) and Trp(10) aromatic rings and the alignment of the D-Trp(7) and His(8) aromatic rings with respect to the Trp(10) rings is altered. The blockage of L-type voltage-gated Ca2+ channel currents by glacontryphan-M requires calcium binding to N-terminal Gla residues, where presumably histidine and tryptophan may be accessible for interaction with the channel. The backbone Calpha conformation of the intercysteine loop of calcium-bound glacontryphan-M superimposes on known structures of contryphan-R and Vn (0.83 and 0.66 Angstrom, respectively). Taken together these data identify that glacontryphan-M possesses the canonical contryphan intercysteine loop structure, yet possesses critical determinants necessary for a calcium-induced functionally required conformation.	Beth Israel Deaconess Med Ctr, Ctr Hemostasis Thrombosis & Vasc Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Marine Biol Lab, Woods Hole, MA 02543 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Lund University; Skane University Hospital; Marine Biological Laboratory - Woods Hole	Rigby, AC (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Hemostasis Thrombosis & Vasc Biol, 330 Brookline Ave, Boston, MA 02215 USA.	arigby@bidmc.harvard.edu						BARSUKOV IL, 1993, NMR MACROMOLECULES P, P315; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Blandl T, 1999, J PEPT RES, V53, P453, DOI 10.1034/j.1399-3011.1999.00042.x; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAACK JA, 1990, J BIOL CHEM, V265, P6025; Hansson K, 2004, J BIOL CHEM, V279, P32453, DOI 10.1074/jbc.M313825200; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; Huang MD, 2004, J BIOL CHEM, V279, P14338, DOI 10.1074/jbc.M314011200; Huang MD, 2003, NAT STRUCT BIOL, V10, P751, DOI 10.1038/nsb971; Jacobsen RB, 1999, J PEPT RES, V54, P93, DOI 10.1034/j.1399-3011.1999.00093.x; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; Jimenez EC, 2001, TOXICON, V39, P803, DOI 10.1016/S0041-0101(00)00210-5; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; Massilia GR, 2003, BIOCHEM BIOPH RES CO, V303, P238, DOI 10.1016/S0006-291X(03)00331-0; Massilia GR, 2001, BIOCHEM BIOPH RES CO, V288, P908, DOI 10.1006/bbrc.2001.5833; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; Mitterdorfer J, 1998, J BIOENERG BIOMEMBR, V30, P319, DOI 10.1023/A:1021933504909; Nakamura T, 1996, PROTEIN SCI, V5, P524; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAIN R, 1996, PROTOCOLS PROTEIN SC; Pallaghy PK, 1999, BIOCHEMISTRY-US, V38, P11553, DOI 10.1021/bi990685j; Pallaghy PK, 2000, BIOPOLYMERS, V54, P173, DOI 10.1002/1097-0282(200009)54:3<173::AID-BIP30>3.3.CO;2-1; Pallaghy PK, 2000, BIOCHEMISTRY-US, V39, P12845, DOI 10.1021/bi0010930; PASTORE A, 1990, J MAGN RESON, V90, P165, DOI 10.1016/0022-2364(90)90375-J; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARZ R, 1978, BIOPOLYMERS, V17, P2133, DOI 10.1002/bip.1978.360170908; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P15677, DOI 10.1021/bi9718550; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; STENFLO J, 2001, MOL BASIS BLOOD DIS, P579; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Woody RW, 1996, CIRCULAR DICHROISM C, P109; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	39	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32464	32473		10.1074/jbc.M313826200	http://dx.doi.org/10.1074/jbc.M313826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155731	Green Published, hybrid			2022-12-27	WOS:000222849700060
J	Bluher, M; Wilson-Fritch, L; Leszyk, J; Laustsen, PG; Corvera, S; Kahn, CR				Bluher, M; Wilson-Fritch, L; Leszyk, J; Laustsen, PG; Corvera, S; Kahn, CR			Role of insulin action and cell size on protein expression patterns in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; MICE LACKING; GLUCOSE; RECEPTOR; OBESITY; CLATHRIN; DISRUPTION; METABOLISM; MEMBRANES; STRESS	Mice with a fat-specific insulin receptor knock-out (FIRKO) exhibit a polarization of white adipose tissue into two populations of cells, one small ( diameter < 50 mu m) and one large ( diameter > 100 mum), accompanied by changes in insulin-stimulated glucose uptake, triglyceride synthesis, and lipolysis. To characterize these subclasses of adipocytes, we have used a proteomics approach in which isolated adipocytes from FIRKO and control (IR lox/lox) mice were separated by size, fractionated into cytosolic and membrane subfractions, and analyzed by sucrose gradient, SDS-PAGE, and mass spectrometry. A total of 27 alterations in protein expression at key steps in lipid and energy metabolism could be defined, which were coordinately regulated by adipocyte cell size, impaired insulin signaling, or both. Nine proteins, including vimentin, EH-domain-containing protein 2, elongation factor 2, glucose-regulated protein 78, transketolase, and succinyl-CoA transferase were primarily affected by presence or absence of insulin signaling, whereas 21 proteins, including myosin non-muscle form A, annexin 2, annexin A6, and Hsp47 were regulated in relation to adipocyte size. Of these 27 alterations in protein expression, 14 changes correlated with altered levels of mRNA, whereas the remaining 13 were the result of changes in protein translation or turnover. These data suggest an intrinsic heterogeneity in adipocytes with differences in protein expression patterns caused by transcriptional and post-transcriptional alterations related to insulin action and cellular lipid accumulation.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Kahn, CR (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 30136] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Barnes JA, 2000, ANAT EMBRYOL, V202, P67, DOI 10.1007/s004290000090; Bluher M, 2004, J BIOL CHEM, V279, P31891, DOI 10.1074/jbc.M404569200; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CORVERA S, 1990, J BIOL CHEM, V265, P2413; CUSHMAN SW, 1978, J LIPID RES, V19, P269; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; Lieber JG, 1996, J CELL SCI, V109, P3047; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LYNCH CJ, 1993, AM J PHYSIOL, V264, pE621, DOI 10.1152/ajpendo.1993.264.4.E621; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Saltiel AR, 2001, NAT MED, V7, P887, DOI 10.1038/90911; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Seri M, 2000, NAT GENET, V26, P103; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; TeichertKuliszewska K, 1996, INT J OBESITY, V20, pS108; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	30	84	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31902	31909		10.1074/jbc.M404570200	http://dx.doi.org/10.1074/jbc.M404570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131120	hybrid			2022-12-27	WOS:000222726800117
J	Gauthier, BR; Brun, T; Sarret, EJ; Ishihara, H; Schaad, O; Descombes, P; Wollheim, CB				Gauthier, BR; Brun, T; Sarret, EJ; Ishihara, H; Schaad, O; Descombes, P; Wollheim, CB			Oligonucleotide microarray analysis reveals PDX1 as an essential regulator of mitochondrial metabolism in rat islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; STIMULATED INSULIN-SECRETION; TYPE-2 DIABETES-MELLITUS; FACTOR-I GENE; TRANSCRIPTION FACTOR; PROMOTER FACTOR-1; UBIQUINONE OXIDOREDUCTASE; TRANSGENIC MICE; COMPLEX-I; EXPRESSION	Mutations in the transcription factor IPF1/PDX1 have been associated with type 2 diabetes. To elucidate beta-cell dysfunction, PDX1 was suppressed by transduction of rat islets with an adenoviral construct encoding a dominant negative form of PDX1. After 2 days, there was a marked inhibition of insulin secretion in response to glucose, leucine, and arginine. Increasing cAMP levels with forskolin and isobutylmethylxanthine restored glucose-stimulated insulin secretion, indicating normal capacity for exocytosis. To identify molecular targets implicated in the altered metabolism secretion coupling, DNA microarray analysis was performed on PDX1-deficient and control islets. Of the 2640 detected transcripts, 70 were up-regulated and 56 were down-regulated. Transcripts were subdivided into 12 clusters; the most prevalent were associated with metabolism. Quantitative reverse transcriptase-CR confirmed increases in succinate dehydrogenase and ATP synthase mRNAs as well as pyruvate carboxylase and the transcript for the malate shuttle. In parallel there was a 50% reduction in mRNA levels for the mitochondrially encoded nd1 gene, a subunit of the NADH dehydrogenase comprising complex I of the mitochondrial respiratory chain. As a consequence, total cellular ATP concentration was drastically decreased by 75%, and glucose failed to augment cytosolic ATP, explaining the blunted glucose-stimulated insulin secretion. Rotenone, an inhibitor of complex I, mimicked this effect. Surprisingly, TFAM, a nuclear-encoded transcription factor important for sustaining expression of mitochondrial genes, was down-regulated in islets expressing DN79PDX1. In conclusion, loss of PDX1 function alters expression of mitochondrially encoded genes through regulation of TFAM leading to impaired insulin secretion.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; Univ Geneva, Natl Ctr Competence Res Frontiers Genet, CH-1211 Geneva 4, Switzerland; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metab & Diabet, Sendai, Miyagi 980, Japan	University of Geneva; University of Geneva; Tohoku University	Gauthier, BR (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland.	benoit.gauthier@medecine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486; BRUN, Thierry/0000-0002-1659-4283				Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; BROWN MD, 1992, GENETICS, V130, P163; Cardozo AK, 2001, J BIOL CHEM, V276, P48879, DOI 10.1074/jbc.M108658200; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; Collins CL, 1998, BIOTECHNIQUES, V24, P803, DOI 10.2144/98245st04; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Forman HJ, 2003, BIOFACTORS, V17, P1, DOI 10.1002/biof.5520170101; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; Gauthier BR, 2002, MOL ENDOCRINOL, V16, P170, DOI 10.1210/me.16.1.170; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hansen L, 2000, J CLIN ENDOCR METAB, V85, P1323, DOI 10.1210/jc.85.3.1323; Hart AW, 2000, NATURE, V408, P864, DOI 10.1038/35048589; Hattori Y, 2003, DIABETES CARE, V26, P952, DOI 10.2337/diacare.26.3.952; Hirai M, 1996, BIOCHEM BIOPH RES CO, V219, P951, DOI 10.1006/bbrc.1996.0324; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lottmann H, 2001, J MOL MED-JMM, V79, P321, DOI 10.1007/s001090100229; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; MAJANDER A, 1991, PEDIATR RES, V30, P327, DOI 10.1203/00006450-199110000-00007; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Odawara M, 1999, J MED GENET, V36, P934; Offield MF, 1996, DEVELOPMENT, V122, P983; OHTA M, 1990, J BIOL CHEM, V265, P17525; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Schwitzgebel VM, 2003, J CLIN ENDOCR METAB, V88, P4398, DOI 10.1210/jc.2003-030046; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Smith PA, 1997, J PHYSIOL-LONDON, V499, P625, DOI 10.1113/jphysiol.1997.sp021955; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044	54	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31121	31130		10.1074/jbc.M405030200	http://dx.doi.org/10.1074/jbc.M405030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15151993	hybrid			2022-12-27	WOS:000222726800028
J	Gu, BJ; Sluyter, R; Skarratt, KK; Shemon, AN; Dao-Ung, LP; Fuller, SJ; Barden, JA; Clarke, AL; Petrou, S; Wiley, JS				Gu, BJ; Sluyter, R; Skarratt, KK; Shemon, AN; Dao-Ung, LP; Fuller, SJ; Barden, JA; Clarke, AL; Petrou, S; Wiley, JS			An Arg(307) to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X(7) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; PHAGOSOME-LYSOSOME FUSION; HUMAN-LYMPHOCYTES; EXTRACELLULAR ATP; PURINERGIC RECEPTORS; NUCLEOTIDE RECEPTOR; STRUCTURAL MOTIF; ALA POLYMORPHISM; PORE FORMATION; B-LYMPHOCYTES	The P2X(7) receptor is a ligand-gated channel that is highly expressed on mononuclear cells of the immune system and that mediates ATP-induced apoptosis. Wide variations in the function of the P2X(7) receptor have been observed, explained in part by loss-of-function polymorphisms that change Glu(496) to Ala (E496A) and Ile(568) to Asn (I568N). In this study, a third polymorphism, which substitutes an uncharged glutamine for the highly positively charged Arg(307) (R307Q), has been found in heterozygous dosage in 12 of 420 subjects studied. P2X(7) function was measured by ATP-induced fluxes of Rb+, Ba2+, and ethidium(+) into peripheral blood monocytes or various lymphocyte subsets and was either absent or markedly decreased. Transfection experiments showed that P2X(7) carrying the R307Q mutation lacked either channel or pore function despite robust protein synthesis and surface expression of the receptor. The monoclonal antibody (clone L4) that binds to the extracellular domain of wild type P2X(7) and blocks P2X(7) function failed to bind to the R307Q mutant receptor. Differentiation of monocytes to macrophages up-regulated P2X(7) function in cells heterozygous for the R307Q to a value 10 - 40% of that for wild type macrophages. However, macrophages from a subject who was double heterozygous for R307Q/I568N remained totally non-functional for P2X(7), and lymphocytes from the same subject also lacked ATP-stimulated phospholipase D activity. These data identify a third loss-of-function polymorphism affecting the human P2X(7) receptor, and since the affected Arg(307) is homologous to those amino acids essential for ATP binding to P2X(1) and P2X(2), it is likely that this polymorphism abolishes the binding of ATP to the extracellular domain of P2X(7).	Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2750, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia	Nepean Hospital; University of Sydney; University of Sydney; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Wiley, JS (corresponding author), Univ Sydney, Nepean Hosp, Dept Med, Level 5,S Block, Penrith, NSW 2750, Australia.	wileyj@medicine.usyd.edu.au	Skarratt, Kristy/AAN-1479-2020; Sluyter, Ronald/B-5798-2009; Fuller, Stephen/W-6646-2019; Petrou, Steven/M-8332-2013	Sluyter, Ronald/0000-0003-4909-686X; Fuller, Stephen/0000-0003-4637-7391; Petrou, Steven/0000-0002-4960-6375; Wiley, James/0000-0001-9421-4154; Skarratt, Kristy/0000-0003-4971-2773; Gu, Ben/0000-0001-5500-4453				Boldt W, 2003, AM J PHYSIOL-CELL PH, V284, pC749, DOI 10.1152/ajpcell.00042.2002; BRETSCHNEIDER F, 1995, PFLUG ARCH EUR J PHY, V429, P691, DOI 10.1007/BF00373990; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Coutinho-Silva R, 2003, IMMUNITY, V19, P403, DOI 10.1016/S1074-7613(03)00235-8; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Fairbairn IP, 2001, J IMMUNOL, V167, P3300, DOI 10.4049/jimmunol.167.6.3300; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Freist W, 1998, FEBS LETT, V434, P61, DOI 10.1016/S0014-5793(98)00958-2; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Hansen MA, 1997, BIOCHEM BIOPH RES CO, V236, P670, DOI 10.1006/bbrc.1997.6815; HICKMAN SE, 1994, BLOOD, V84, P2452; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Jamieson GP, 1996, J CELL PHYSIOL, V166, P637, DOI 10.1002/(SICI)1097-4652(199603)166:3<637::AID-JCP19>3.0.CO;2-3; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Klapperstuck M, 2001, J PHYSIOL-LONDON, V534, P25, DOI 10.1111/j.1469-7793.2001.00025.x; Kusner DJ, 2001, J IMMUNOL, V167, P3308, DOI 10.4049/jimmunol.167.6.3308; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; NAUMOV AP, 1995, J PHYSIOL-LONDON, V486, P323, DOI 10.1113/jphysiol.1995.sp020815; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Saunders BM, 2003, J IMMUNOL, V171, P5442, DOI 10.4049/jimmunol.171.10.5442; Sluyter R, 2002, INT IMMUNOL, V14, P1415, DOI 10.1093/intimm/dxf111; Sluyter R, 2001, CELL TISSUE RES, V304, P231, DOI 10.1007/s004410100372; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; Wen LT, 2003, MOL PHARMACOL, V63, P706, DOI 10.1124/mol.63.3.706; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T; WILEY JS, 1993, ARCH BIOCHEM BIOPHYS, V305, P54, DOI 10.1006/abbi.1993.1392; Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7	43	109	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31287	31295		10.1074/jbc.M313902200	http://dx.doi.org/10.1074/jbc.M313902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15123679	hybrid			2022-12-27	WOS:000222726800048
J	Heiz, M; Grunberg, J; Schubiger, PA; Novak-Hofer, I				Heiz, M; Grunberg, J; Schubiger, PA; Novak-Hofer, I			Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1 - Role of the L1 cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CARCINOMA CELLS; PROSTATE-CANCER; ANKYRIN-BINDING; FACTOR RECEPTOR; EXPRESSION; TYROSINE; SERUM; PHOSPHORYLATION; NEUROBLASTOMA; KINASE	The L1 cell adhesion molecule and its soluble form are tumor-associated proteins and potential markers for tumor staging as well as targets for therapeutic intervention. Soluble L1 is produced by metalloprotease-mediated ectodomain shedding of L1. We investigated effects of hepatocyte growth factor (HGF), a growth factor shown to increase invasiveness of renal carcinoma cells, on ectodomain shedding of L1 from these cells. All of the tested L1-positive renal carcinoma cell lines released a 180-kDa form of L1 into the medium. In the presence of serum, addition of HGF led to a dose-dependent increase in L1 shedding with a maximum reached at 5 ng/ml. In contrast, L1 shedding was inhibited by glial cell line-derived neurotrophic factor ( GDNF). The tyrosine kinase inhibitor Genistein reduced basal and HGF-stimulated L1 shedding, indicating that protein phosphorylation is involved. To investigate the role of the L1 intracellular domain, two mutants of the L1 cytoplasmic part were constructed. L1trun lacking the complete intracellular domain showed enhanced basal shedding. In a L1YH mutant, containing the mutation tyrosine 1229 to histidine that deletes the ankyrin binding motif of L1, basal shedding was reduced. Disruption of actin assembly by cytochalasin D also reduced shedding of L1. These results indicate that the cytoplasmic domain regulates basal shedding of L1, and association with the cytoskeleton through the L1 ankyrin binding site is involved. HGF stimulated L1 shedding in both mutants, indicating that receptor-mediated phosphorylation in the L1 cytoplasmic domain is not required for HGF-stimulated shedding.	Paul Scherrer Inst, ETH, PSI,USZ, Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland	ETH Zurich; Paul Scherrer Institute	Novak-Hofer, I (corresponding author), Paul Scherrer Inst, ETH, PSI,USZ, Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland.	ilse.novak@psi.ch						AMSTUTZ H, 1993, INT J CANCER, V53, P147, DOI 10.1002/ijc.2910530127; Beer S, 1999, J CELL SCI, V112, P2667; CANTLEY LG, 1994, AM J PHYSIOL, V267, pF271, DOI 10.1152/ajprenal.1994.267.2.F271; Davies G, 2001, CLIN CANCER RES, V7, P3289; Davies J, 2001, J ANAT, V198, P257, DOI 10.1046/j.1469-7580.2000.19830257.x; Debiec H, 1998, J CELL BIOL, V143, P2067, DOI 10.1083/jcb.143.7.2067; Debiec H, 2002, NEPHROL DIAL TRANSPL, V17, P42, DOI 10.1093/ndt/17.suppl_9.42; Dihne M, 2003, J NEUROSCI, V23, P6638; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; El-Ghoneimi A, 2002, J UROLOGY, V168, P2624, DOI 10.1016/S0022-5347(05)64231-0; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Gil OD, 2003, J CELL BIOL, V162, P719, DOI 10.1083/jcb.200211011; Grunberg J, 2003, BIOTECHNIQUES, V34, P968, DOI 10.2144/03345st02; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hoefnagel CA, 2001, EUR J NUCL MED, V28, P359, DOI 10.1007/s002590000454; Holzer G, 2003, MED PEDIATR ONCOL, V40, P64, DOI 10.1002/mpo.10058; Horie S, 1999, J UROLOGY, V161, P990, DOI 10.1016/S0022-5347(01)61834-2; Islam R, 2004, MOL BIOL CELL, V15, P2003, DOI 10.1091/mbc.e03-05-0333; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kenwrick S, 2000, HUM MOL GENET, V9, P879, DOI 10.1093/hmg/9.6.879; LEDERMANN JA, 1994, INT J CANCER, P49; Lee DCW, 2002, ONCOGENE, V21, P5582, DOI 10.1038/sj.onc.1205741; Lynch DF, 1997, PROSTATE, V32, P214, DOI 10.1002/(SICI)1097-0045(19970801)32:3<214::AID-PROS8>3.0.CO;2-K; McCulloch DR, 2004, CLIN CANCER RES, V10, P314, DOI 10.1158/1078-0432.CCR-0846-3; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meli ML, 1999, INT J CANCER, V83, P401, DOI 10.1002/(SICI)1097-0215(19991029)83:3<401::AID-IJC17>3.0.CO;2-A; Miyata Y, 2003, BIOCHEM BIOPH RES CO, V302, P892, DOI 10.1016/S0006-291X(03)00281-X; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nakamura T, 2001, ONCOGENE, V20, P7610, DOI 10.1038/sj.onc.1204975; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Needham LK, 2001, J NEUROSCI, V21, P1490, DOI 10.1523/JNEUROSCI.21-05-01490.2001; Oh RR, 2002, APMIS, V110, P229, DOI 10.1034/j.1600-0463.2002.100305.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RICHTERLANDSBERG C, 1984, J NEUROCHEM, V43, P841, DOI 10.1111/j.1471-4159.1984.tb12807.x; Roselli M, 2003, ONCOLOGY-BASEL, V65, P132, DOI 10.1159/000072338; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Sambrook J., 2001, MOL CLONING LAB MANU; Sandler B, 1999, ANTICANCER RES, V19, P4229; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; Yokota A, 1999, HEMATOL ONCOL, V17, P161, DOI 10.1002/(SICI)1099-1069(199912)17:4<161::AID-HON646>3.0.CO;2-Y	43	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31149	31156		10.1074/jbc.M403587200	http://dx.doi.org/10.1074/jbc.M403587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15151998	Green Published, hybrid			2022-12-27	WOS:000222726800031
J	Pfeffer, LM; Kim, JG; Pfeffer, SR; Carrigan, DJ; Baker, DP; Wei, L; Homayouni, R				Pfeffer, LM; Kim, JG; Pfeffer, SR; Carrigan, DJ; Baker, DP; Wei, L; Homayouni, R			Role of nuclear factor-kappa B in the antiviral action of interferon and interferon-regulated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; PROTEIN-KINASE; ALPHA; ACTIVATION; TRANSCRIPTION; INDUCTION; INHIBITOR; CYTOKINES; PATHWAYS; STAT3	Interferons (IFNs) play critical roles in host defense by modulating the expression of various genes via tyrosine phosphorylation of STAT transcription factors. IFN-alpha/beta activates another important transcription factor, nuclear factor-kappaB (NF-kappaB), but its role in IFN-mediated activity is poorly understood. Sensitivity to the antiviral and gene-inducing effects of IFN was examined in normal fibroblasts and in NF-kappaB knockout fibroblasts from p50- and p65-null mice. Antiviral assays demonstrated that NF-kappaB knockout fibroblasts were sensitized to the antiviral action of IFN. Moreover, analysis of IFN-stimulated gene expression by real-time PCR demonstrated selective effects of NF-kappaB on gene expression. Our results demonstrate that a subset of IFN-stimulated genes is regulated through an NF-kappaB-dependent pathway and that NF-kappaB may regulate the sensitivity of cells to IFN-mediated antiviral activity.	Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN 38103 USA; Biogen Idec Inc, Cambridge, MA 02142 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Biogen	Pfeffer, LM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Rm 530,930 Madison Ave, Memphis, TN 38103 USA.	lpfeffer@utmem.edu	Homayouni, Ramin/U-2837-2019; Homayouni, Ramin/B-3547-2009; Wei, Lai/D-1088-2014	Homayouni, Ramin/0000-0003-0186-5076; Homayouni, Ramin/0000-0003-0186-5076; Pfeffer, Lawrence/0000-0003-2809-1234	NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI048216] Funding Source: NIH RePORTER; NCI NIH HHS [CA73753] Funding Source: Medline; NIAID NIH HHS [AI48216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arduini RM, 2004, PROTEIN EXPRES PURIF, V34, P229, DOI 10.1016/j.pep.2003.11.004; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chen J, 2000, J BIOL CHEM, V275, P36278, DOI 10.1074/jbc.M006975200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; Jin HK, 1998, BIOCHEM GENET, V36, P311, DOI 10.1023/A:1018741312058; LARNER AC, 1986, J BIOL CHEM, V261, P453; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; Naschberger E, 2004, BIOCHEM J, V379, P409, DOI 10.1042/BJ20031873; Pfeffer LM, 1998, CANCER RES, V58, P2489; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIMON A, 1991, J VIROL, V65, P968, DOI 10.1128/JVI.65.2.968-971.1991; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Valanciute A, 2004, J IMMUNOL, V172, P688, DOI 10.4049/jimmunol.172.1.688; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397	27	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31304	31311		10.1074/jbc.M308975200	http://dx.doi.org/10.1074/jbc.M308975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131130	hybrid			2022-12-27	WOS:000222726800050
J	Billecke, SS; Draganov, DI; Morishima, Y; Murphy, PJM; Dunbar, AY; Pratt, WB; Osawa, Y				Billecke, SS; Draganov, DI; Morishima, Y; Murphy, PJM; Dunbar, AY; Pratt, WB; Osawa, Y			The role of hsp90 in heme-dependent activation of apo-neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; HSP90/HSP70-BASED CHAPERONE MACHINERY; RAT GLUCOCORTICOID RECEPTORS; 7-AMINO ACID SEQUENCE; STEROID-BINDING; LIGAND-BINDING; CONFORMATIONAL-CHANGES; MOLECULAR CHAPERONE; AMINO-TERMINUS; PROTEIN	Like other nitric-oxide synthase (NOS) enzymes, neuronal NOS (nNOS) turnover and activity are regulated by the ubiquitous protein chaperone hsp90. We have shown previously that nNOS expressed in Sf9 cells where endogenous heme levels are low is activated from the apo- to the holo-enzyme by addition of exogenous heme to the culture medium, and this activation is inhibited by radicicol, a specific inhibitor of hsp90 (Billecke, S. S., Bender, A. T., Kanelakis, K. C., Murphy, P. J. M., Lowe, E. R., Kamada, Y., Pratt, W. B., and Osawa, Y. (2002) J. Biol. Chem. 278, 15465-15468). In this work, we examine heme binding by apo-nNOS to form the active enzyme in a cell-free system. We show that cytosol from Sf9 cells facilitates heme-dependent apo- nNOS activation by promoting functional heme insertion into the enzyme. Sf9 cytosol also converts the glucocorticoid receptor (GR) to a state where the hydrophobic ligand binding cleft is open to access by steroid. Both cell-free heme activation of purified nNOS and activation of steroid binding activity of the immunopurified GR are inhibited by radicicol treatment of Sf9 cells prior to cytosol preparation, and addition of purified hsp90 to cytosol partially overcomes this inhibition. Although there is an hsp90-dependent machinery in Sf9 cytosol that facilitates heme binding by apo- nNOS, it is clearly different from the machinery that facilitates steroid binding by the GR. hsp90 regulation of apo- nNOS heme activation is very dynamic and requires higher concentrations of radicicol for its inhibition, whereas GR steroid binding is determined by assembly of stable GR.hsp90 heterocomplexes that are formed by a purified five-chaperone machinery that does not activate apo- nNOS.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	osawa@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIEHS NIH HHS [ES08365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Dikalov S, 2002, J BIOL CHEM, V277, P25480, DOI 10.1074/jbc.M203271200; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gee AC, 2001, MOL ENDOCRINOL, V15, P421, DOI 10.1210/me.15.3.421; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hemmens B, 1998, BIOCHEM J, V332, P337, DOI 10.1042/bj3320337; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; Kanelakis KC, 2003, METHOD ENZYMOL, V364, P159; Kanelakis KC, 2002, J BIOL CHEM, V277, P33698, DOI 10.1074/jbc.M204164200; Kaul S, 2002, J BIOL CHEM, V277, P36223, DOI 10.1074/jbc.M206748200; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Ou JS, 2004, AM J PHYSIOL-HEART C, V286, pH561, DOI 10.1152/ajpheart.00736.2003; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918	42	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30252	30258		10.1074/jbc.M403864200	http://dx.doi.org/10.1074/jbc.M403864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15155759	hybrid			2022-12-27	WOS:000222531900049
J	Fulton, D; Babbitt, R; Zoelllner, S; Fontana, J; Acevedo, L; McCabe, TJ; Iwakiri, Y; Sessa, WC				Fulton, D; Babbitt, R; Zoelllner, S; Fontana, J; Acevedo, L; McCabe, TJ; Iwakiri, Y; Sessa, WC			Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT ENOS ACTIVATION; PROTEIN INTERACTIONS; ESTROGEN-RECEPTOR; S-NITROSYLATION; GROWTH-FACTOR; PHOSPHORYLATION; PALMITOYLATION; DOMAIN; CELLS; LOCALIZATION	The heterogeneous localization of endothelial nitric-oxide synthase (eNOS) on the Golgi complex versus the plasma membrane has made it difficult to dissect the regulation of each pool of enzyme. Here, we generated fusion proteins that specifically target the plasma membrane or cytoplasmic aspects of the Golgi complex and have assessed eNOS activation. Plasma membrane-targeted eNOS constructs were constitutively active, phosphorylated, and responsive to transmembrane calcium fluxes, yet were insensitive to further activation by Akt-mediated phosphorylation. In contrast, cis-Golgi complex-targeted eNOS behaved similarly to wild-type eNOS and was less sensitive to calcium-dependent activation and highly responsive to Akt-dependent phosphorylation compared with plasma membrane versions. In plasma membrane- and Golgi complex-targeted constructs, Ser(1179) is critical for NO production. This study provides clear evidence for functional roles of plasma membrane- and Golgi complex-localized eNOS and supports the concept that proteins thought to be regulated and to function exclusively in the plasma membrane of cells can indeed signal and be regulated in internal Golgi membranes.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Program Vasc Cell Signaling & Therapeut, New Haven, CT 06536 USA; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA	Yale University; Yale University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave, New Haven, CT 06536 USA.	william.sessa@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061371, R37HL061371, R01HL074279, R01HL064793, R01HL057665] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64793, HL61371, HL074279-01, R01 HL57665] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andries LJ, 1998, CIRC RES, V82, P195; Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; Bauersachs J, 1997, HYPERTENSION, V30, P1598, DOI 10.1161/01.HYP.30.6.1598; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; Boo YC, 2003, FREE RADICAL BIO MED, V35, P729, DOI 10.1016/S0891-5849(03)00397-6; Brown DL, 2001, TRAFFIC, V2, P336, DOI 10.1034/j.1600-0854.2001.002005336.x; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dedio J, 2001, FASEB J, V15, P79, DOI 10.1096/fj.00-0078com; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Govers R, 2002, BIOCHEM J, V361, P193, DOI 10.1042/0264-6021:3610193; Govers R, 2002, J HISTOCHEM CYTOCHEM, V50, P779, DOI 10.1177/002215540205000604; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Jobin CM, 2003, BIOCHEMISTRY-US, V42, P11716, DOI 10.1021/bi035066w; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; OBRIEN AJ, 1995, HISTOCHEM CELL BIOL, V103, P221, DOI 10.1007/BF01454027; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SINGER HA, 1982, HYPERTENSION, V4, P19, DOI 10.1161/01.HYP.4.3_Pt_2.19; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; STANBOLI A, 1994, NEUROSCI LETT, V171, P209, DOI 10.1016/0304-3940(94)90641-6; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; van Haperen R, 2003, AM J PATHOL, V163, P1677, DOI 10.1016/S0002-9440(10)63524-9; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; Zimmermann K, 2002, P NATL ACAD SCI USA, V99, P17167, DOI 10.1073/pnas.252345399	65	107	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30349	30357		10.1074/jbc.M402155200	http://dx.doi.org/10.1074/jbc.M402155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136572	hybrid			2022-12-27	WOS:000222531900060
J	Lusetti, SL; Voloshin, ON; Inman, RB; Camerini-Otero, RD; Cox, MM				Lusetti, SL; Voloshin, ON; Inman, RB; Camerini-Otero, RD; Cox, MM			The DinI protein stabilizes RecA protein filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-RECA; SINGLE-STRANDED-DNA; NUCLEOSIDE TRIPHOSPHATE; COPROTEASE ACTIVITIES; STABLE COMPLEXES; BINDING-PROTEIN; IN-VITRO; EXCHANGE; LEXA; INHIBITION	When DinI is present at concentrations that are stoichiometric with those of RecA or somewhat greater, DinI has a substantial stabilizing effect on RecA filaments bound to DNA. Exchange of RecA between free and bound forms was almost entirely suppressed, and highly stable filaments were documented with several different experimental methods. DinI-mediated stabilization did not affect RecA-mediated ATP hydrolysis and LexA co-protease activities. Initiation of DNA strand exchange was affected in a DNA structure-dependent manner, whereas ongoing strand exchange was not affected. Destabilization of RecA filaments occurred as reported in earlier work but only when DinI protein was present at very high concentrations, generally super-stoichiometric, relative to the RecA protein concentration. DinI did not facilitate RecA filament formation but stabilized the filaments only after they were formed. The interaction between the RecA protein and DinI was modulated by the C terminus of RecA. We discuss these results in the context of a new hypothesis for the role of DinI in the regulation of recombination and the SOS response.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NIGMS NIH HHS [GM52725] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; Haruta N, 2003, J BIOL CHEM, V278, P52710, DOI 10.1074/jbc.M308563200; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; LEWIS LK, 1994, J MOL BIOL, V241, P507, DOI 10.1006/jmbi.1994.1528; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; Mustard JA, 2000, J BACTERIOL, V182, P1659, DOI 10.1128/JB.182.6.1659-1670.2000; REGISTER JC, 1986, P NATL ACAD SCI USA, V83, P624, DOI 10.1073/pnas.83.3.624; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Walker GC, 2000, BACTERIAL STRESS RESPONSES, P131; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; WILLIAMS JGK, 1981, J BIOL CHEM, V256, P7573; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yasuda T, 1996, J BACTERIOL, V178, P3854, DOI 10.1128/jb.178.13.3854-3859.1996; Yoshimasu M, 2003, NUCLEIC ACIDS RES, V31, P1735, DOI 10.1093/nar/gkg256	41	74	78	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30037	30046		10.1074/jbc.M403064200	http://dx.doi.org/10.1074/jbc.M403064200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138263	hybrid			2022-12-27	WOS:000222531900022
J	Richter, W; Conti, M				Richter, W; Conti, M			The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING; PROTEIN-KINASE; MAP KINASE; ACTIVATION; PHOSPHORYLATION; DOMAINS; PDE4D3; (R)-ROLIPRAM; DIMERIZATION	PDE4 splice variants are classified into long and short forms depending on the presence or absence of two unique N-terminal domains termed upstream conserved regions 1 and 2 (UCR1 and -2). We have shown previously that the UCR module mediates dimerization of PDE4 long forms, whereas short forms, which lack UCR1, behave as monomers. In the present study, we demonstrate that dimerization is an essential structural element that determines the regulatory properties and inhibitor sensitivities of PDE4 enzymes. Comparing the properties of the dimeric wild type PDE4D3 with several monomeric mutant PDE4D3 constructs revealed that disruption of dimerization ablates the activation of PDE4 long forms by either protein kinase A phosphorylation or phosphatidic acid binding. Moreover, the analysis of heterodimers consisting of a catalytically active and a catalytically inactive PDE4D3 subunit indicates that protein kinase A phosphorylation of both subunits is essential to fully activate PDE4 enzymes. In addition to affecting enzyme regulation, disruption of dimerization reduces the sensitivity of the enzymes toward the prototypical PDE4 inhibitor rolipram. Parallel binding assays indicated that this shift in rolipram sensitivity is likely mediated by a decrease in the number of inhibitor binding sites in the high affinity rolipram binding state. Thus, although dimerization is not a requirement for high affinity rolipram binding, it functions to stabilize PDE4 long forms in their high affinity rolipram binding conformation. Taken together, our data indicate that dimerization defines the properties of PDE4 enzymes and suggest a common structural and functional organization for all PDEs.	Stanford Univ, Sch Med, Div Reprod Biol, Dept Obstet & Gynecol, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Div Reprod Biol, Dept Obstet & Gynecol, 300 Pasteur Dr, Stanford, CA 94305 USA.	marco.conti@stanford.edu		Richter, Wito/0000-0001-5588-9060	NICHD NIH HHS [HD20788] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baillie GS, 2000, BRIT J PHARMACOL, V131, P811, DOI 10.1038/sj.bjp.0703636; Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; Kovala T, 1997, BIOCHEMISTRY-US, V36, P2968, DOI 10.1021/bi9613483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laliberte F, 2000, BIOCHEMISTRY-US, V39, P6449, DOI 10.1021/bi992432w; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; Liu S, 2001, BIOCHEMISTRY-US, V40, P10179, DOI 10.1021/bi010096p; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Muradov KG, 2003, J BIOL CHEM, V278, P10594, DOI 10.1074/jbc.M208456200; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200; Rocque WJ, 1997, BIOCHEMISTRY-US, V36, P14250, DOI 10.1021/bi971112e; Rocque WJ, 1997, PROTEIN EXPRES PURIF, V9, P191, DOI 10.1006/prep.1996.0683; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P18271; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; TENOR H, 1999, PROG INFLAM RES, P87; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; WADA H, 1987, J BIOL CHEM, V262, P5139; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAN C, 1995, P NATL ACAD SCI USA, V92, P9677, DOI 10.1073/pnas.92.21.9677	37	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30338	30348		10.1074/jbc.M312687200	http://dx.doi.org/10.1074/jbc.M312687200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131123	hybrid			2022-12-27	WOS:000222531900059
J	Shintani, T; Klionsky, DJ				Shintani, T; Klionsky, DJ			Cargo proteins facilitate the formation of transport vesicles in the cytoplasm to vacuole targeting pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-AUTOPHAGOSOMAL STRUCTURE; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; AMINOPEPTIDASE-I; YEAST; REQUIRES; COMPLEX; COMPONENTS; INDUCTION; MECHANISM	Selective incorporation of cargo proteins into the forming vesicle is an important aspect of protein targeting via vesicular trafficking. Based on the current paradigm of cargo selection in vesicular transport, proteins to be sorted to other organelles are condensed at the vesicle budding site in the donor organelle, a process that is mediated by the interaction between cargo and coat proteins, which constitute part of the vesicle forming machinery. The cytoplasm to vacuole targeting (Cvt) pathway is an unconventional vesicular trafficking pathway in yeast, which is topologically and mechanistically related to autophagy. Aminopeptidase I (Ape1) is the major cargo protein of the Cvt pathway. Unlike the situation in conventional vesicular transport, precursor Ape1, along with its receptor Atg19/Cvt19, is packed into a huge complex, termed a Cvt complex, independent of the vesicle formation machinery. The Cvt complex is subsequently incorporated into the forming Cvt vesicle. The deletion of APE1 or ATG19 compromised the organization of the pre-autophagosomal structure ( PAS), a site that is thought to play a critical role in Cvt vesicle/autophagosome formation. The proper organization of the PAS also required Atg11/Cvt9, a protein that localizes the cargo complex at the PAS. Accordingly, the deletion of APE1, ATG19, or ATG11 affected the formation of Cvt vesicles. These observations suggest a unique concept; in the case of the Cvt pathway, the cargo proteins facilitate receptor recruitment and vesicle formation rather than the situation with most vesicular transport, in which the forming vesicle concentrates the cargo proteins.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Klionsky, DJ (corresponding author), Univ Michigan, Inst Life Sci, 210 Washtenaw Ave,Rm 6036, Ann Arbor, MI 48109 USA.	klionsky@umich.edu	SHINTANI, Takahiro/ABE-1267-2020	Shintani, Takahiro/0000-0001-6630-5892	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053396, GM53396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; Hamasaki M, 2003, CELL STRUCT FUNCT, V28, P49; Hettema EH, 2003, EMBO J, V22, P548, DOI 10.1093/emboj/cdg062; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Nice DC, 2002, J BIOL CHEM, V277, P30198, DOI 10.1074/jbc.M204736200; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Reggiori F, 2004, DEV CELL, V6, P79, DOI 10.1016/S1534-5807(03)00402-7; Reggiori F, 2004, MOL BIOL CELL, V15, P2189, DOI 10.1091/mbc.E03-07-0479; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200	34	288	299	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29889	29894		10.1074/jbc.M404399200	http://dx.doi.org/10.1074/jbc.M404399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138258	hybrid, Green Accepted			2022-12-27	WOS:000222531900004
J	Zhu, H; Larade, K; Jackson, TA; Xie, JX; Ladoux, A; Acker, H; Berchner-Pfannschmidt, U; Fandrey, J; Cross, AR; Lukat-Rodgers, GS; Rodgers, KR; Bunn, HF				Zhu, H; Larade, K; Jackson, TA; Xie, JX; Ladoux, A; Acker, H; Berchner-Pfannschmidt, U; Fandrey, J; Cross, AR; Lukat-Rodgers, GS; Rodgers, KR; Bunn, HF			NCB5OR is a novel soluble NAD(P)H reductase localized in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(5) REDUCTASE; RESONANCE RAMAN; ELECTRON-TRANSFER; NITRATE REDUCTASE; GOLGI-APPARATUS; BINDING DOMAIN; HEME PROTEIN; OXYGEN; IDENTIFICATION; STABILITY	The NAD(P)H cytochrome b(5) oxidoreductase, Ncb5or (previously named b(5) + b5R), is widely expressed in human tissues and broadly distributed among the animal kingdom. NCB5OR is the first example of an animal flavohemoprotein containing cytochrome b(5) and cytochrome b(5) reductase domains. We initially reported human NCB5OR to be a 487-residue soluble protein that reduces cytochrome c, methemoglobin, ferricyanide, and molecular oxygen in vitro. Bioinformatic analysis of genomic sequences suggested the presence of an upstream start codon. We confirm that endogenous NCB5OR indeed has additional NH2-terminal residues. By performing fractionation of subcellular organelles and confocal microscopy, we show that NCB5OR colocalizes with calreticulin, a marker for endoplasmic reticulum. Recombinant NCB5OR is soluble and has stoichiometric amounts of heme and flavin adenine dinucleotide. Resonance Raman spectroscopy of NCB5OR presents typical signatures of a six-coordinate low-spin heme similar to those found in other cytochrome b(5) proteins. Kinetic measurements showed that full-length and truncated NCB5OR reduce cytochrome c actively in vitro. However, both full-length and truncated NCB5OR produce superoxide from oxygen with slow turnover rates: k(cat) = similar to0.05 and similar to1 s(-1), respectively.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA; Max Planck Inst Mol Physiol, Lab Opt Syst Physiol, D-44227 Dortmund, Germany; Univ Klinikum Essen, Inst Physiol, D-45122 Essen, Germany; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; N Dakota State Univ, Dept Chem, Fargo, ND 58105 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Max Planck Society; University of Duisburg Essen; Scripps Research Institute; North Dakota State University Fargo	Zhu, H (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, 221 Longwood Ave, Boston, MA 02115 USA.	haozhu@rics.bwh.harvard.edu; HFBunn@rics.bwh.harvard.edu	Acker, Helmut Anton Josef/AAS-6841-2020; LADOUX, ANNIE/S-2077-2019; Fandrey, Joachim/AAA-3524-2021; LADOUX, ANNIE/O-4267-2016	Acker, Helmut Anton Josef/0000-0001-5589-5508; LADOUX, ANNIE/0000-0003-3857-2621; LADOUX, ANNIE/0000-0003-3857-2621; Fandrey, Joachim/0000-0001-9585-0531	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059901, R01DK056050] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015566] Funding Source: Medline; NIAID NIH HHS [R01 AI024838, R01 AI24838] Funding Source: Medline; NIDDK NIH HHS [K01 DK059901-02, R01 DK56050, K01 DK059901-03, R01 DK056050, K01 DK59901] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; BARKER PD, 1993, P NATL ACAD SCI USA, V90, P6542, DOI 10.1073/pnas.90.14.6542; BENDIAK B, 1990, BIOCHEM BIOPH RES CO, V170, P879, DOI 10.1016/0006-291X(90)92173-W; Borgese N, 1996, J CELL BIOL, V135, P1501, DOI 10.1083/jcb.135.6.1501; BRUNT CE, 1992, BIOCHEM J, V283, P87, DOI 10.1042/bj2830087; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; Cohen JD, 1997, ARCH BIOCHEM BIOPHYS, V341, P321, DOI 10.1006/abbi.1997.9987; Cross AR, 1999, BIOCHEM J, V341, P251, DOI 10.1042/0264-6021:3410251; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; Curry BJ, 2004, GENOMICS, V83, P425, DOI 10.1016/j.ygeno.2003.08.020; Davis CA, 2002, ARCH BIOCHEM BIOPHYS, V400, P63, DOI 10.1006/abbi.2002.2783; DESBOIS A, 1989, BIOCHEMISTRY-US, V28, P8011, DOI 10.1021/bi00446a007; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; FUJII H, 1995, J BIOL CHEM, V270, P12685, DOI 10.1074/jbc.270.21.12685; Garcia-Ranea JA, 2002, FEBS LETT, V529, P162, DOI 10.1016/S0014-5793(02)03321-5; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GUILLEMETTE JG, 1994, BIOCHIMIE, V76, P592, DOI 10.1016/0300-9084(94)90136-8; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; HURST JK, 1991, J BIOL CHEM, V266, P1627; ISOGAI Y, 1995, J BIOL CHEM, V270, P7853, DOI 10.1074/jbc.270.14.7853; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Kawano M, 1998, BIOCHEM BIOPH RES CO, V245, P666, DOI 10.1006/bbrc.1998.8502; KITAGAWA T, 1982, BIOCHEMISTRY-US, V21, P1680, DOI 10.1021/bi00536a032; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lukat-Rodgers GS, 2000, BIOCHEMISTRY-US, V39, P9984, DOI 10.1021/bi0006870; NORTHRUP SH, 1993, BIOCHEMISTRY-US, V32, P6613, DOI 10.1021/bi00077a014; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Porwol T, 1998, EUR J BIOCHEM, V256, P16, DOI 10.1046/j.1432-1327.1998.2560016.x; Ratnam K, 1997, J BIOL CHEM, V272, P2122; Seetharaman R, 1996, BIOCHEMISTRY-US, V35, P12455, DOI 10.1021/bi9529723; SILVESTRINI MC, 1986, EUR J BIOCHEM, V161, P465, DOI 10.1111/j.1432-1033.1986.tb10467.x; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; SUGIYAMA T, 1985, BIOCHEMISTRY-US, V24, P3012, DOI 10.1021/bi00333a031; Sun YL, 1999, J MOL BIOL, V285, P347, DOI 10.1006/jmbi.1998.2295; Suokas M, 2003, BIOCHEM J, V370, P913, DOI 10.1042/BJ20021533; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Voet D., 1995, BIOCHEMISTRY; Wang ZQ, 2000, BIOPHYS CHEM, V83, P3, DOI 10.1016/S0301-4622(99)00119-2; WOOD PM, 1988, BIOCHEM J, V253, P287, DOI 10.1042/bj2530287; Xue LL, 1999, BIOCHEMISTRY-US, V38, P11961, DOI 10.1021/bi990893b; ZANDER R, 1989, J CLIN CHEM CLIN BIO, V27, P185; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9; Zhu H, 1999, P NATL ACAD SCI USA, V96, P14742, DOI 10.1073/pnas.96.26.14742; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	54	34	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30316	30325		10.1074/jbc.M402664200	http://dx.doi.org/10.1074/jbc.M402664200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131110	Green Accepted, hybrid			2022-12-27	WOS:000222531900057
J	Zhu, QS; Qian, B; Levy, D				Zhu, QS; Qian, B; Levy, D			CCAAT/enhancer-binding protein alpha (C/EBP alpha) activates transcription of the human microsomal epoxide hydrolase gene (EPHX1) through the interaction with DNA-bound NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID TRANSPORT; NUCLEAR-FACTOR-Y; C-MYC; HISTONE ACETYLTRANSFERASE; TOPOLOGICAL ORIENTATIONS; FUNCTIONAL EXPRESSION; MOLECULAR-BIOLOGY; BETA-RECEPTOR; CCAAT BOXES; RAT-LIVER	Microsomal epoxide hydrolase (mEH) plays a central role in xenobiotic metabolism as well as mediating the sodium-dependent uptake of bile acids into the liver, where these compounds regulate numerous biological processes such as cholesterol metabolism and hepatocyte signaling pathways. Little is known, however, about the factors that control the constitutive and inducible expression of the mEH gene (EPHX1) that is altered during development and in response to numerous xenobiotics. In previous studies we have established that GATA-4 binding to the EPHX1 core promoter is critical for EPHX1 expression. The -80/+25 bp core promoter also contained a reversed CCAAT box (-5/-1 bp), integrity of which was required for maximal basal EPHX1 transcription in HepG2 cells. Transient transfection of CCAAT/enhancer-binding protein alpha (C/EBPalpha) substantially stimulated EPHX1 promoter activity. Electrophoretic mobility shift assays, however, revealed that nuclear factor Y (NF-Y), but not C/EBPalpha, directly bound to this site although increased expression of NF-Y had no effect on EPHX1 promoter activity. These results suggested that C/EBPalpha activated EPHX1 expression through its interaction with NF-Y bound to the CCAAT box. The existence of a C/EBPalpha[NF-Y] complex was supported by electrophoretic mobility shift assays using antibodies against NF-Y and C/EBPalpha as well as by the ability of a dominant-negative NF-Y expression vector to inhibit promoter activity. The interaction between these transcription factors was established by co-immunoprecipitation analysis and glutathione S-transferase pull-down assays, whereas the association of the two factors and the interaction of NF-Y with the CCAAT box in vivo was confirmed by chromatin immunoprecipitation assays. C/EBPalpha-dependent EPHX1 activation was also supported by reconstitution studies in HeLa cells that lack this protein. These results establish that EPHX1 expression is regulated by C/EBPalpha interacting with DNA-bound NF-Y.	Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Levy, D (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, 2011 Zonal Ave, Los Angeles, CA 90033 USA.	dlevy@usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025836] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 25836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVES C, 1993, J BIOL CHEM, V268, P20148; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; Cortessis V, 2001, CANCER RES, V61, P2381; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dinic S, 2000, CELL BIOL INT, V24, P691, DOI 10.1006/cbir.2000.0531; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fretland AJ, 2000, CHEM-BIOL INTERACT, V129, P41, DOI 10.1016/S0009-2797(00)00197-6; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Hackzell A, 2002, J BIOL CHEM, V277, P39769, DOI 10.1074/jbc.M204483200; HASSETT C, 1994, GENOMICS, V23, P433, DOI 10.1006/geno.1994.1520; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Izumi H, 2001, J CELL SCI, V114, P1533; Jackson SM, 1998, J LIPID RES, V39, P767; Jacobs SBR, 2003, MOL ENDOCRINOL, V17, P1470, DOI 10.1210/me.2002-0286; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kim IS, 1996, MOL CELL BIOL, V16, P4003; KIM SG, 1992, MOL PHARMACOL, V42, P273; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; OMIECINSKI CJ, 1994, J PHARMACOL EXP THER, V269, P417; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; ROSSI AM, 1987, MUTAT RES, V182, P75, DOI 10.1016/0165-1161(87)90056-2; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Tomizawa M, 1998, BIOCHEM BIOPH RES CO, V249, P1, DOI 10.1006/bbrc.1998.8999; Ueda A, 1998, J BIOL CHEM, V273, P19339, DOI 10.1074/jbc.273.30.19339; VONDIPPE P, 1993, AM J PHYSIOL, V264, pG528, DOI 10.1152/ajpgi.1993.264.3.G528; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; VONDIPPE P, 1983, J BIOL CHEM, V258, P8890; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; VONDIPPE P, 1990, J BIOL CHEM, V265, P5942; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251; Zhu QS, 1999, J BIOL CHEM, V274, P27898, DOI 10.1074/jbc.274.39.27898; Zhu QS, 2004, BBA-GENE STRUCT EXPR, V1676, P251, DOI 10.1016/j.bbaexp.2004.01.002; Zhu QS, 2003, BBA-MOL BASIS DIS, V1638, P208, DOI 10.1016/S0925-4439(03)00085-1	49	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29902	29910		10.1074/jbc.M400438200	http://dx.doi.org/10.1074/jbc.M400438200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150264	hybrid			2022-12-27	WOS:000222531900006
J	Boukis, LA; Liu, N; Furuyama, S; Bruzik, JP				Boukis, LA; Liu, N; Furuyama, S; Bruzik, JP			Ser/Arg-rich protein-mediated communication between U1 and U2 small nuclear ribonucleoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; 3' SPLICE-SITE; SR PROTEINS; 5-SPLICE-SITE RECOGNITION; PREMESSENGER RNA; LEADER ADDITION; FACTOR SF1; SELECTION; CAENORHABDITIS; ENHANCERS	Previous work demonstrated that U1 small nuclear ribonucleoprotein particle ( snRNP), bound to a downstream 5' splice site, can positively influence utilization of an upstream 3' splice site via exon definition in both trans- and cis-splicing systems. Although exon definition results in the enhancement of splicing of an upstream intron, the nature of the factors involved has remained elusive. We assayed the interaction of U1 snRNP as well as the positive effect of a downstream 5' splice site on trans- splicing in nematode extracts containing either inactive ( early in development) or active ( later in development) serine/arginine-rich splicing factors (SR proteins). We have determined that U1 snRNP interacts with the 5' splice site in the downstream exon even in the absence of active SR proteins. In addition, we determined that U1 snRNP-directed loading of U2 snRNP onto the branch site as well as efficient transsplicing in these inactive extracts could be rescued upon the addition of active SR proteins. Identical results were obtained when we examined the interaction of U1 snRNP as well as the requirement for SR proteins in communication across a cis-spliced intron. Weakening of the 3' splice site uncovered distinct differences, however, in the ability of U1 snRNP to promote U2 addition, dependent upon its position relative to the branch site. These results demonstrate that SR proteins are required for communication between U1 and U2 snRNPs whether this interaction is across introns or exons.	Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, Cleveland, OH 44106 USA	Case Western Reserve University	Bruzik, JP (corresponding author), Case Western Reserve Univ, Sch Med, Ctr RNA Mol Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxb83@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054204] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM R01 54204] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; Boukis LA, 2001, RNA, V7, P793, DOI 10.1017/S1355838201010524; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Das R, 2000, MOL CELL, V5, P779, DOI 10.1016/S1097-2765(00)80318-4; Denker JA, 1996, RNA, V2, P746; Denker JA, 2002, NATURE, V417, P667, DOI 10.1038/nature00783; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; Furuyama S, 2002, MOL CELL BIOL, V22, P5337, DOI 10.1128/MCB.22.15.5337-5346.2002; FURUYAMA S, 2003, ENCY HUMAN GENOME, V5, P623; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Kashima T, 2003, NAT GENET, V34, P460, DOI 10.1038/ng1207; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lam BJ, 2002, RNA, V8, P1233, DOI 10.1017/S1355838202028030; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Maquat LE, 2001, NAT GENET, V27, P5, DOI 10.1038/83759; Maroney PA, 1996, RNA, V2, P735; Maroney PA, 2000, RNA, V6, P1905, DOI 10.1017/S1355838200001308; Mazroui R, 1999, RNA, V5, P1615, DOI 10.1017/S1355838299991872; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; NILSEN TW, 1997, EUKARYOTIC MRNA PROC, P310; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Page-McCaw PS, 1999, RNA, V5, P1548, DOI 10.1017/S1355838299991938; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; Romfo CM, 2001, RNA, V7, P785, DOI 10.1017/S1355838201010263; Sanford JR, 1999, GENE DEV, V13, P1513, DOI 10.1101/gad.13.12.1513; Sanford JR, 1999, RNA, V5, P918, DOI 10.1017/S1355838299990234; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Stover NA, 2001, P NATL ACAD SCI USA, V98, P5693, DOI 10.1073/pnas.101049998; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; Van Buskirk C, 2002, DEV CELL, V2, P343, DOI 10.1016/S1534-5807(02)00128-4; Vandenberghe AE, 2001, GENE DEV, V15, P294, DOI 10.1101/gad.865401; VANDOREN K, 1988, NATURE, V335, P556; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; WANG Z, 1995, RNA, V1, P21; WILL CL, 1997, EUKARYOTIC MRNA PROC, P130; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	64	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29647	29653		10.1074/jbc.M313209200	http://dx.doi.org/10.1074/jbc.M313209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131126	hybrid			2022-12-27	WOS:000222445300101
J	Nigam, S; Patabhiraman, S; Ciccoli, R; Ishdorj, G; Schwarz, K; Petrucev, B; Kuhn, H; Haeggstrom, JZ				Nigam, S; Patabhiraman, S; Ciccoli, R; Ishdorj, G; Schwarz, K; Petrucev, B; Kuhn, H; Haeggstrom, JZ			The rat leukocyte-type 12-lipoxygenase exhibits an intrinsic hepoxilin A(3) synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; POSITIONAL SPECIFICITY; PRIMARY DETERMINANT; INHIBITION; LIPOXIN; PHENYLALANINE; METABOLISM; PRODUCTS; APLYSIA; CALCIUM	Hepoxilins are biologically relevant eicosanoids formed via the 12-lipoxygenase pathway of the arachidonic acid cascade. Although these eicosanoids exhibit a myriad of biological activities, their biosynthetic mechanism has not been investigated in detail. We examined the arachidonic acid metabolism of RINm5F rat insulinoma cells and found that they constitutively express a leukocyte-type 12S-lipoxygenase. Moreover, we observed that RINm5F cells exhibit an active hepoxilin A(3) synthase that converts exogenous 12S-HpETE (12S-5Z, 8Z, 10E, 14Z-12-hydro(pero)xy-eicosa-5,8,10,14-tetraenoic acid) or arachidonic acid predominantly to hepoxilin A(3). 12S-lipoxygenase and hepoxilin A(3) synthase activities were co-localized in the cytosol; immunoprecipitation with an anti-12S-lipoxygenase antibody co-precipitated the two catalytic activities. These data suggested that hepoxilin A(3) synthase activity may be considered an intrinsic catalytic property of the leukocyte-type 12S-lipoxygenase. To test this hypothesis we cloned the leukocytetype 12S-LOX from RINm5F cells, expressed it in Pichia pastoris, and found that the recombinant enzyme exhibited both 12S-lipoxygenase and hepoxilin A(3) synthase activities. The recombinant human platelet-type 12S-lipoxygenase and the porcine leukocyte-type 12S-lipoxygenase also exhibited hepoxilin A(3) synthase activity. In contrast, the native rabbit reticulocyte-type 15S-lipoxygenase did not convert 12S-HpETE to hepoxilin isomers. These data suggest that the positional specificity of lipoxygenases may be crucial for this catalytic function. This hypothesis was confirmed by site-directed mutagenesis studies that altered the positional specificity of the rat leukocyte-type 12S- and the rabbit reticulocyte-type 15-lipoxygenase. In summary, it may be concluded that naturally occurring 12S- lipoxygenases exhibit an intrinsic hepoxilin A(3) synthase activity that is minimal in lipoxygenase isoforms with different positional specificity.	Free Univ Berlin, Univ Med Ctr Berlin, Eicosanoid & Lipid Res Div, D-12200 Berlin, Germany; Free Univ Berlin, Univ Med Ctr Berlin, Ctr Expt Gynecol & Breast Res, D-12200 Berlin, Germany; Humboldt Univ, Univ Med Ctr Berlin, Inst Biochem, D-10098 Berlin, Germany; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Karolinska Institutet	Nigam, S (corresponding author), Free Univ Berlin, Univ Med Ctr Berlin, Eicosanoid & Lipid Res Div, Campus Benjamin Franklin, D-12200 Berlin, Germany.	nigam@zedat.fu-berlin.de						BELARDETTI F, 1989, NEURON, V3, P497, DOI 10.1016/0896-6273(89)90208-0; Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BRYANT RW, 1979, PROSTAGLANDINS, V17, P9, DOI 10.1016/0090-6980(79)90071-6; DEMIN P, 1995, ANAL BIOCHEM, V226, P252, DOI 10.1006/abio.1995.1222; DHO S, 1990, BIOCHEM J, V266, P63, DOI 10.1042/bj2660063; GARSSEN GJ, 1976, EUR J BIOCHEM, V62, P33, DOI 10.1111/j.1432-1033.1976.tb10094.x; Ivanov I, 2001, BIOCHEMISTRY-US, V40, P10223, DOI 10.1021/bi010700w; KUHN H, 1986, FEBS LETT, V208, P248, DOI 10.1016/0014-5793(86)81026-2; LANEUVILLE O, 1993, BIOCHEM J, V295, P393, DOI 10.1042/bj2950393; MARGALIT A, 1993, P NATL ACAD SCI USA, V90, P2589, DOI 10.1073/pnas.90.7.2589; Moody JS, 2002, BIOCHEMISTRY-US, V41, P10297, DOI 10.1021/bi020320q; NIGAM S, 1990, BIOCHEM BIOPH RES CO, V171, P944, DOI 10.1016/0006-291X(90)90775-I; PACEASCIAK CR, 1995, J LIPID MEDIAT CELL, V12, P307, DOI 10.1016/0929-7855(95)00036-P; PACEASCIAK CR, 1995, LIPIDS, V30, P107, DOI 10.1007/BF02538262; PACEASCIAK CR, 1983, J BIOL CHEM, V258, P6835; PACEASCIAK CR, 1984, PROSTA LEUKOTR MED, V16, P173, DOI 10.1016/0262-1746(84)90069-6; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P1721, DOI 10.1073/pnas.86.5.1721; REYNAUD D, 1994, J NEUROCHEM, V62, P126; Richards KM, 1999, BIOCHEMISTRY-US, V38, P16529, DOI 10.1021/bi991336s; ROMANO M, 1993, BIOCHEM J, V296, P127, DOI 10.1042/bj2960127; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; Schwarz K, 2000, BIOCHEMISTRY-US, V39, P14515, DOI 10.1021/bi001447n; Serhan CN, 1999, CLIN CHEM LAB MED, V37, P299, DOI 10.1515/CCLM.1999.052; Shankaranarayanan P, 2003, FEBS LETT, V538, P107, DOI 10.1016/S0014-5793(03)00151-0; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; Walther M, 2001, CHEM BIOL, V8, P779, DOI 10.1016/S1074-5521(01)00050-3; WATANABE T, 1993, BIOCHEM BIOPH RES CO, V192, P1023, DOI 10.1006/bbrc.1993.1519	30	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29023	29030		10.1074/jbc.M307576200	http://dx.doi.org/10.1074/jbc.M307576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123652	hybrid			2022-12-27	WOS:000222445300025
J	Vorberg, I; Raines, A; Priola, SA				Vorberg, I; Raines, A; Priola, SA			Acute formation of protease-resistant prion protein does not always lead to persistent scrapie infection in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; CELL-FREE FORMATION; NEUROBLASTOMA-CELLS; STRAIN VARIATION; AGENT PROTEIN; MICE; PRP; PROPAGATION; BSE; CONFORMATIONS	Transmissible spongiform encephalopathies are accompanied by the accumulation of a pathologic isoform of a host-encoded protein, termed prion protein (PrP). Despite the widespread distribution of the cellular isoform of PrP (protease-sensitive PrP; PrP-sen), the disease-associated isoform (protease-resistant PrP; PrP-res) appears to be primarily restricted to cells of the nervous and lymphoreticular systems. In order to study why scrapie infection appears to be restricted to certain cells, we followed acute and persistent PrP-res formation upon exposure of cells to different scrapie agents. We found that, independent of the cell type and scrapie strain, initial PrP-res formation occurred rapidly in cells. However, sustained generation of PrP-res and persistent infection did not necessarily follow acute PrP-res formation. Persistent PrP-res formation and scrapie infection was restricted to one cell line inoculated with the mouse scrapie strain 22L. In contrast to cells that did not become scrapie-infected, the level of PrP-res in the 22L-infected cells rapidly increased in the absence of a concomitant increase in the number of PrP-resproducing cells. Furthermore, the protein banding pattern of PrP-res in these cells changed over time as the cells became chronically infected. Thus, our results suggest that the events leading to the initial formation of PrP-res may differ from those required for sustained PrP-res formation and infection. This may, at least in part, explain the observation that not all PrP-sen-expressing cells appear to support transmissible spongiform encephalopathy agent replication.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Priola, SA (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.	spriola@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000752, ZIAAI000752] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; BENDHEIM PE, 1988, J INFECT DIS, V158, P1198, DOI 10.1093/infdis/158.6.1198; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; Bruce Moira E., 1996, P223; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; DICKINSON AG, 1972, NATURE-NEW BIOL, V237, P244, DOI 10.1038/newbio237244a0; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Gonzalez L, 2003, J GEN VIROL, V84, P1339, DOI 10.1099/vir.0.18800-0; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Kanu N, 2002, CURR BIOL, V12, P523, DOI 10.1016/S0960-9822(02)00722-4; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 2000, J GEN VIROL, V81, P2555, DOI 10.1099/0022-1317-81-10-2555; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Mulcahy ER, 2004, J BIOL CHEM, V279, P1643, DOI 10.1074/jbc.M307844200; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Pammer J, 1999, LANCET, V354, P1702, DOI 10.1016/S0140-6736(99)02800-7; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; RUBENSTEIN R, 1992, J GEN VIROL, V73, P3027, DOI 10.1099/0022-1317-73-11-3027; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Schatzl HM, 1997, J VIROL, V71, P8821; SKLAVIADIS T, 1993, P NATL ACAD SCI USA, V90, P5713, DOI 10.1073/pnas.90.12.5713; Soto C, 2002, TRENDS NEUROSCI, V25, P390, DOI 10.1016/S0166-2236(02)02195-1; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Vorberg I, 2004, J INFECT DIS, V189, P431, DOI 10.1086/381166; Vorberg I, 2002, J BIOL CHEM, V277, P36775, DOI 10.1074/jbc.M206865200; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377	44	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29218	29225		10.1074/jbc.M402576200	http://dx.doi.org/10.1074/jbc.M402576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133048	hybrid			2022-12-27	WOS:000222445300049
J	Walker, JB; Bajzar, L				Walker, JB; Bajzar, L			The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; SOLUBLE FIBRIN; DEGRADATION-PRODUCTS; PROCARBOXYPEPTIDASE-B; THERMAL-STABILITY; TAFI; PLASMA; THROMBOMODULIN; PURIFICATION; MECHANISM	Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is intrinsically unstable, a property that complicates the study of its role in regulating fibrinolysis. To investigate the effect of basic carboxypeptidases on fibrinolysis under conditions of constant carboxypeptidase activity, we employed pancreatic carboxypeptidase B (CPB), a homologous, stable basic carboxypeptidase, as a surrogate for TAFIa. Clots formed from TAFI-depleted plasma or from purified components were supplemented with tissue-type plasminogen activator and either CPB or TAFIa. The clot lysis data indicate that the down-regulation of fibrinolysis mediated by basic carboxypeptidases involves a threshold mechanism. At carboxypeptidase concentrations above the threshold, plasminogen activation is maintained in a fully down-regulated state; experiments in plasma showed that fibrinolysis is essentially halted by saturating concentrations of TAFIa and that fibrinolysis can be prolonged more than 45-fold by a stable carboxypeptidase. The threshold carboxypeptidase concentration was dependent on tissue-type plasminogen activator and antiplasmin concentrations, indicating that the threshold is determined by the steady-state plasmin concentration. Although obvious with CPB, the threshold was masked by the intrinsic instability of TAFIa and became apparent only when the effect of TAFIa was investigated over the picomolar concentration range. Because of the threshold effect and the instability of TAFIa, exponential increases in TAFIa concentration generate linear increases in lysis time. A model relating lysis time to TAFIa concentration, TAFIa half-life, and the threshold concentration of TAFIa is provided. The threshold effect has potentially important implications regarding the role of TAFIa and the regulation of clot lysis in vivo.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada	McMaster University	Bajzar, L (corresponding author), Henderson Res Ctr, 711 Consess St, Hamilton, ON L8V 1C3, Canada.	lbajzar@thrombosis.hhscr.org						ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1998, J BIOL CHEM, V273, P2792, DOI 10.1074/jbc.273.5.2792; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; EATON DL, 1991, J BIOL CHEM, V266, P21833; Frank PS, 2003, BIOCHEMISTRY-US, V42, P1078, DOI 10.1021/bi026917n; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; Komura H, 2002, MICROBIOL IMMUNOL, V46, P217, DOI 10.1111/j.1348-0421.2002.tb02689.x; KOSHLAND DE, 1987, TRENDS BIOCHEM SCI, V12, P225, DOI 10.1016/0968-0004(87)90114-9; Leurs J, 2004, J THROMB HAEMOST, V2, P416, DOI 10.1111/j.1538-7836.2004.00605.x; LEURS J, 2003, J THROMB HAEMOST, V1, pOC66; LEWIS J, 1977, J THEOR BIOL, V65, P579, DOI 10.1016/0022-5193(77)90216-8; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Marx PF, 2004, J BIOL CHEM, V279, P6620, DOI 10.1074/jbc.M307337200; Marx PF, 2002, BIOCHEMISTRY-US, V41, P6688, DOI 10.1021/bi015982e; Mosnier LO, 2001, THROMB HAEMOSTASIS, V86, P1035; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Ries M, 2003, BLOOD COAGUL FIBRIN, V14, P203, DOI 10.1097/00001721-200302000-00014; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; Schneider M, 2004, J BIOL CHEM, V279, P13333, DOI 10.1074/jbc.M313164200; Schneider M, 2004, J BIOL CHEM, V279, P13340, DOI 10.1074/jbc.M313211200; Schneider M, 2003, J THROMB HAEMOST, V1, P147, DOI 10.1046/j.1538-7836.2003.00028.x; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; SUENSON E, 1986, BIOCHIM BIOPHYS ACTA, V870, P510, DOI 10.1016/0167-4838(86)90260-8; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; THORSEN S, 1984, BIOCHEM J, V223, P179, DOI 10.1042/bj2230179; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Walker JB, 2003, J BIOL CHEM, V278, P8913, DOI 10.1074/jbc.M205006200; Walker JB, 2001, J BIOL CHEM, V276, P3138, DOI 10.1074/jbc.M005876200; WALKER JB, 2003, J THROMB HAEMOSTA S1, V1, pOC65; Wang HY, 2003, EUR J BIOCHEM, V270, P2023, DOI 10.1046/j.1432-1033.2003.03578.x; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229; YAMAMOTO KK, 1992, J BIOL CHEM, V267, P2575	44	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27896	27904		10.1074/jbc.M401027200	http://dx.doi.org/10.1074/jbc.M401027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15128744	hybrid			2022-12-27	WOS:000222265400011
J	Cordente, AG; Lopez-Vinas, E; Vazquez, MI; Swiegers, JH; Pretorius, IS; Gomez-Puertas, P; Hegardt, FG; Asins, G; Serra, D				Cordente, AG; Lopez-Vinas, E; Vazquez, MI; Swiegers, JH; Pretorius, IS; Gomez-Puertas, P; Hegardt, FG; Asins, G; Serra, D			Redesign of carnitine acetyltransferase specificity by protein engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITOYLTRANSFERASE-I; SUBSTRATE-SPECIFICITY; AUTOMATED DOCKING; STRUCTURAL MODEL; SWISS-MODEL; MALONYL-COA; OCTANOYLTRANSFERASE; ACYLTRANSFERASES; PURIFICATION; DEFICIENCY	In eukaryotes, L-carnitine is involved in energy metabolism by facilitating beta-oxidation of fatty acids. Carnitine acetyltransferases (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to acetylcarnitine and free CoA. To redesign the specificity of rat CrAT toward its substrates, we mutated Met(564). The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA. Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates. In the reverse case, mutation of the orthologous glycine (Gly(553)) to methionine in carnitine octanoyltransferase ( COT) decreased activity toward its natural substrates, medium- and long-chain acyl-CoAs, and increased activity toward short-chain acyl-CoAs. Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results. We conclude that Met(564) blocks the entry of medium- and long-chain acyl-CoAs to the catalytic site of CrAT. Three-dimensional models of wild-type and mutated CrAT and COT support this hypothesis. We show for the first time that a single amino acid is able to determine the substrate specificity of CrAT and COT.	Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; CSIC, Ctr Astrobiol, Bioinformat Lab, E-28850 Madrid, Spain; Australian Wine Res Inst, Glen Osmond, SA 5064, Australia	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); Australian Wine Research Institute	Hegardt, FG (corresponding author), Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, Diagonal 643, E-08028 Barcelona, Spain.	fgarciaheg@ub.edu	López-Viñas, Eduardo/AAT-1124-2021; Serra, Dolors/L-3657-2014; Gomez-Puertas, Paulino/G-8821-2014; Pretorius, Isak/C-1213-2012	Serra, Dolors/0000-0002-4936-4206; Gomez-Puertas, Paulino/0000-0003-3131-729X; Pretorius, Isak/0000-0001-9127-3175; Swiegers, Jan Hendrik/0000-0002-4721-3797; Cordente, Toni/0000-0001-9166-9073				BIEBER LL, 1981, ARCH BIOCHEM BIOPHYS, V211, P599, DOI 10.1016/0003-9861(81)90494-X; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BLOISI W, 1990, EUR J BIOCHEM, V189, P539, DOI 10.1111/j.1432-1033.1990.tb15520.x; BREVETTI G, 1991, CIRCULATION, V84, P1490, DOI 10.1161/01.CIR.84.4.1490; BROWN NF, 1994, J BIOL CHEM, V269, P19157; Brunner S, 1997, BIOCHEM J, V322, P403, DOI 10.1042/bj3220403; CHASE JFA, 1967, BIOCHEM J, V104, P510, DOI 10.1042/bj1040510; COLUCCI WJ, 1988, BIOORG CHEM, V16, P307, DOI 10.1016/0045-2068(88)90018-1; CORTI O, 1994, BIOCHEM J, V303, P37, DOI 10.1042/bj3030037; DIDONATO S, 1979, NEUROLOGY, V29, P1578, DOI 10.1212/WNL.29.12.1578; ESSER V, 1993, J BIOL CHEM, V268, P5817; FARRELL SO, 1984, J BIOL CHEM, V259, P3089; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; Govindasamy L, 2004, J STRUCT BIOL, V146, P416, DOI 10.1016/j.jsb.2004.01.011; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hassett RP, 2000, ANAL BIOCHEM, V287, P176, DOI 10.1006/abio.2000.4799; He M, 2003, J BIOL CHEM, V278, P37974, DOI 10.1074/jbc.M306882200; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; KALARIA RN, 1992, ANN NEUROL, V32, P583, DOI 10.1002/ana.410320417; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lopez-Romero P, 2004, PRINC PRACT, P319; MAKAR TK, 1995, NEUROCHEM RES, V20, P705, DOI 10.1007/BF01705539; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Melegh B, 1999, J INHERIT METAB DIS, V22, P827, DOI 10.1023/A:1005562209034; MIYAZAWA S, 1983, J BIOCHEM, V93, P439, DOI 10.1093/oxfordjournals.jbchem.a134198; MIYAZAWA S, 1983, J BIOCHEM, V94, P529, DOI 10.1093/oxfordjournals.jbchem.a134384; Morillas M, 2004, BIOCHEM J, V379, P777, DOI 10.1042/BJ20031373; Morillas M, 2003, J BIOL CHEM, V278, P9058, DOI 10.1074/jbc.M209999200; Morillas M, 2000, FEBS LETT, V466, P183, DOI 10.1016/S0014-5793(99)01788-3; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; Schmitt J, 2002, PROTEIN ENG, V15, P595, DOI 10.1093/protein/15.7.595; Souri M, 1998, EUR J BIOCHEM, V257, P592, DOI 10.1046/j.1432-1327.1998.2570592.x; Swiegers JH, 2001, YEAST, V18, P585, DOI 10.1002/yea.712; van der Leij FR, 2000, MOL GENET METAB, V71, P139, DOI 10.1006/mgme.2000.3055; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yang J, 2002, PROTEIN ENG, V15, P147, DOI 10.1093/protein/15.2.147; Zammit VA, 1999, PROG LIPID RES, V38, P199, DOI 10.1016/S0163-7827(99)00002-8	47	28	31	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33899	33908		10.1074/jbc.M402685200	http://dx.doi.org/10.1074/jbc.M402685200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155769	hybrid			2022-12-27	WOS:000223039700100
J	Bucciantini, M; Calloni, G; Chiti, F; Formigli, L; Nosi, D; Dobson, CM; Stefani, M				Bucciantini, M; Calloni, G; Chiti, F; Formigli, L; Nosi, D; Dobson, CM; Stefani, M			Prefibrillar amyloid protein aggregates share common features of cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ALPHA-SYNUCLEIN; CELL-DEATH; MISFOLDING DISEASES; PARKINSONS-DISEASE; PRION PROTEIN; A-BETA; MECHANISM; TOXICITY	The intracellular free Ca2+ concentration and redox status of murine fibroblasts exposed to prefibrillar aggregates of the HypF N-terminal domain have been investigated in vitro and in vivo using a range of fluorescent probes. Aggregate entrance into the cytoplasm is followed by an early rise of reactive oxygen species and free Ca2+ levels and eventually by cell death. Such changes correlate directly with the viability of the cells and are not observed when cell are cultured in the presence of reducing agents or in Ca2+-free media. In addition, moderate cell stress following exposure to the aggregates was found to be fully reversible. The results show that the cytotoxicity of prefibrillar aggregates of HypF-N, a protein not associated with clinical disease, has the same fundamental origin as that produced by similar types of aggregates of proteins linked with specific amyloidoses. These findings suggest that misfolded proteinaceous aggregates stimulate generic cellular responses as a result of the exposure of regions of the structure ( such as hydrophobic residues and the polypeptide main chain) that are buried in the normally folded proteins. They also support the idea that a higher number of degenerative pathologies than previously known might be considered as protein deposition diseases.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy; Univ Florence, Ctr Excellence Mol & Clin Studies Chron Inflammat, I-50134 Florence, Italy; Univ Florence, Dept Anat Histol & Forens Med, I-50134 Florence, Italy	University of Cambridge; University of Florence; University of Florence; University of Florence	Stefani, M (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	stefani@scibio.unifi.it		Calloni, Giulia/0000-0002-7216-929X; bucciantini, monica/0000-0002-5243-9301; STEFANI, MASSIMO/0000-0002-4490-1922				Abe K, 1996, J NEUROCHEM, V67, P2074; Andersson K, 2002, BIOCHEM BIOPH RES CO, V294, P309, DOI 10.1016/S0006-291X(02)00465-5; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Gillmore JD, 2001, LANCET, V358, P24, DOI 10.1016/S0140-6736(00)05252-1; Gillmore JD, 1997, BRIT J HAEMATOL, V99, P245, DOI 10.1046/j.1365-2141.1997.303194.x; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Hirakura Y, 2001, AMYLOID, V8, P94, DOI 10.3109/13506120109007350; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; KANSKI J, 2001, BIOCHIM BIOPHYS ACTA, V1586, P190; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Keller JN, 2000, NEUROSCIENCE, V98, P149, DOI 10.1016/S0306-4522(00)00067-1; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Kourie JI, 2002, CLIN EXP PHARMACOL P, V29, P741, DOI 10.1046/j.1440-1681.2002.03737.x; Kranenburg O, 2003, FEBS LETT, V539, P149, DOI 10.1016/S0014-5793(03)00218-7; Kruman II, 1999, EXP NEUROL, V160, P28, DOI 10.1006/exnr.1999.7190; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; Mattson MP, 2002, NEUROMOL MED, V2, P215, DOI 10.1385/NMM:2:2:215; Mattson MP, 1999, METHOD ENZYMOL, V309, P733; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PACIFICI M, 1988, J BIOL CHEM, V263, P2483; Relini A, 2004, J MOL BIOL, V338, P943, DOI 10.1016/j.jmb.2004.03.054; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sousa MM, 2001, AM J PATHOL, V159, P1993; Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Svanborg C, 2003, ADV CANCER RES, V88, P1; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Tweten RK, 2001, CURR TOP MICROBIOL, V257, P15; Velez-Pardo C, 2001, J ALZHEIMERS DIS, V3, P409, DOI 10.3233/JAD-2001-3408; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang LM, 2002, P NATL ACAD SCI USA, V99, P15947, DOI 10.1073/pnas.252508399; WATT JA, 1994, BRAIN RES, V661, P147, DOI 10.1016/0006-8993(94)91191-6; Weatherall DJ, 1995, OXFORD TXB MED, V2, P1512; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905	58	314	324	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31374	31382		10.1074/jbc.M400348200	http://dx.doi.org/10.1074/jbc.M400348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133040	hybrid			2022-12-27	WOS:000222726800058
J	Kaniuk, NA; Vinogradov, E; Li, JJ; Monteiro, MA; Whitfield, C				Kaniuk, NA; Vinogradov, E; Li, JJ; Monteiro, MA; Whitfield, C			Chromosomal and plasmid-encoded enzymes are required for assembly of the R3-type core oligosaccharide in the lipopolysaccharide of Escherichia coli O157 : H7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; COMPLETE GENOME SEQUENCE; LARGE VIRULENCE PLASMID; COMPLETE DNA-SEQUENCE; RFB GENE-CLUSTER; D-GALACTAN-I; SALMONELLA-ENTERICA; STRUCTURAL-ANALYSIS; OUTER-MEMBRANE; SHIGELLA-FLEXNERI	The type R3 core oligosaccharide predominates in the lipopolysaccharides from enterohemorrhagic Escherichia coli isolates including O157: H7. The R3 core biosynthesis (waa) genetic locus contains two genes, waaD and waaJ, that are predicted to encode glycosyltransferases involved in completion of the outer core. Through determination of the structures of the lipopolysaccharide core in precise mutants and biochemical analyses of enzyme activities, WaaJ was shown to be a UDP-glucose:( galactosyl) lipopolysaccharide alpha-1,2-glucosyltransferase, and WaaD was shown to be a UDP-glucose:( glucosyl) lipopolysaccharide alpha- 1,2-glucosyltransferase. The residue added by WaaJ was identified as the ligation site for O polysaccharide, and this was confirmed by determination of the structure of the linkage region in serotype O157 lipopolysaccharide. The initial O157 repeat unit begins with an N-acetylgalactosamine residue in a beta-anomeric configuration, whereas the biological repeat unit for O157 contains alpha-linked N-acetylgalactosamine residues. With the characterization of WaaJ and WaaD, the activities of all of the enzymes encoded by the R3 waa locus are either known or predicted from homology data with a high level of confidence. However, when core oligosaccharide structure is considered, the origin of an additional alpha-1,3-linked N-acetylglucosamine residue in the outer core is unknown. The gene responsible for a nonstoichiometric alpha-1,7-linked N-acetylglucosamine substituent in the heptose ( inner core) region was identified on the large virulence plasmids of E. coli O157 and Shigella flexneri serotype 2a. This is the first plasmid-encoded core oligosaccharide biosynthesis enzyme reported in E. coli.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca		Vinogradov, Evgeny/0000-0002-5364-1376				Amor K, 2000, INFECT IMMUN, V68, P1116, DOI 10.1128/IAI.68.3.1116-1124.2000; Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; APPELMELK B, 1987, MICROB PATHOGENESIS, V2, P391, DOI 10.1016/0882-4010(87)90080-5; APPELMELK BJ, 1994, MICROBIOL-UK, V140, P1119, DOI 10.1099/13500872-140-5-1119; APPELMELK BJ, 1988, J MED MICROBIOL, V26, P107, DOI 10.1099/00222615-26-2-107; APPELMELK BJ, 1993, J GEN MICROBIOL, V139, P2641, DOI 10.1099/00221287-139-11-2641; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BINOTTO J, 1991, CAN J MICROBIOL, V37, P474, DOI 10.1139/m91-078; Buchrieser C, 2000, MOL MICROBIOL, V38, P760, DOI 10.1046/j.1365-2958.2000.02179.x; Burland V, 1998, NUCLEIC ACIDS RES, V26, P4196, DOI 10.1093/nar/26.18.4196; Chart H, 2002, J MED MICROBIOL, V51, P1050, DOI 10.1099/0022-1317-51-12-1050; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; CLARKE BR, 1992, J BACTERIOL, V174, P4614, DOI 10.1128/JB.174.14.4614-4621.1992; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Currie CG, 1999, FEMS IMMUNOL MED MIC, V24, P57, DOI 10.1016/S0928-8244(99)00007-3; Currie CG, 2001, J MED MICROBIOL, V50, P345, DOI 10.1099/0022-1317-50-4-345; Czeczulin JR, 1999, INFECT IMMUN, V67, P2692, DOI 10.1128/IAI.67.6.2692-2699.1999; d'Hauteville H, 2002, J IMMUNOL, V168, P5240, DOI 10.4049/jimmunol.168.10.5240; DASGUPTA T, 1994, INFECT IMMUN, V62, P809, DOI 10.1128/IAI.62.3.809-817.1994; DIPADOVA FE, 1993, INFECT IMMUN, V61, P3863, DOI 10.1128/IAI.61.9.3863-3872.1993; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; Frirdich E, 2003, J BACTERIOL, V185, P1659, DOI 10.1128/JB.185.5.1659-1671.2003; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GAMIAN A, 1992, CARBOHYD RES, V236, P195, DOI 10.1016/0008-6215(92)85016-S; GIBB AP, 1992, J INFECT DIS, V166, P1051, DOI 10.1093/infdis/166.5.1051; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; HOLST O, 1992, BACTERIAL ENDOTOXIC, P136; Hull S., 1997, P145; Inagaki M, 2003, FEMS MICROBIOL LETT, V226, P221, DOI 10.1016/S0378-1097(03)00601-3; Jin Q, 2002, NUCLEIC ACIDS RES, V30, P4432, DOI 10.1093/nar/gkf566; Joiner K A, 1985, Curr Top Microbiol Immunol, V121, P99; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; Kaniuk NA, 2002, MOL MICROBIOL, V46, P1305, DOI 10.1046/j.1365-2958.2002.03243.x; Kim SH, 2004, INFECT IMMUN, V72, P1174, DOI 10.1128/IAI.72.2.1174-1180.2004; KJAER M, 1994, METHODS ENZYMOL, V239, P288; MACLACHLAN PR, 1991, J BACTERIOL, V173, P7151, DOI 10.1128/jb.173.22.7151-7163.1991; Makino K, 1998, DNA Res, V5, P1, DOI 10.1093/dnares/5.1.1; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; MENG AM, 1994, BIOTECHNIQUES, V17, P72; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Muller-Loennies S, 2003, J BIOL CHEM, V278, P25618, DOI 10.1074/jbc.M302904200; Muller-Loennies S, 2002, EUR J BIOCHEM, V269, P5982, DOI 10.1046/j.1432-1033.2002.03322.x; NAKATA N, 1992, MOL MICROBIOL, V6, P2387, DOI 10.1111/j.1365-2958.1992.tb01413.x; Olsthoorn MA, 2000, EUR J BIOCHEM, V267, P2014, DOI 10.1046/j.1432-1327.2000.01205.x; Olsthoorn MMA, 1998, J BIOL CHEM, V273, P3817, DOI 10.1074/jbc.273.7.3817; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; PERRY MB, 1986, BIOCHEM CELL BIOL, V64, P21, DOI 10.1139/o86-004; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT G, 1970, EUR J BIOCHEM, V14, P357, DOI 10.1111/j.1432-1033.1970.tb00297.x; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Shibayama K, 1998, J BACTERIOL, V180, P5313, DOI 10.1128/JB.180.20.5313-5318.1998; Thibault P, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P439; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Venkatesan MM, 2001, INFECT IMMUN, V69, P3271, DOI 10.1128/IAI.69.5.3271-3285.2001; Vinogradov E, 2002, CARBOHYD RES, V337, P1285, DOI 10.1016/S0008-6215(02)00160-X; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999; Wei J, 2003, INFECT IMMUN, V71, P2775, DOI 10.1128/IAI.71.5.2775-2786.2003; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; XIANG SH, 1994, J BACTERIOL, V176, P4357, DOI 10.1128/jb.176.14.4357-4365.1994; Yethon JA, 2000, J BACTERIOL, V182, P5620, DOI 10.1128/JB.182.19.5620-5623.2000; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310; Yethon JA, 2001, J BIOL CHEM, V276, P5498, DOI 10.1074/jbc.M008255200; Yoon JW, 2004, MOL MICROBIOL, V51, P419, DOI 10.1046/j.1365-2958.2003.03827.x; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	78	28	29	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31237	31250		10.1074/jbc.M401879200	http://dx.doi.org/10.1074/jbc.M401879200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155763	hybrid			2022-12-27	WOS:000222726800043
J	Hu, Y; Riesland, L; Paterson, AJ; Kudlow, JE				Hu, Y; Riesland, L; Paterson, AJ; Kudlow, JE			Phosphorylation of mouse glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2) by cAMP-dependent protein kinase increases the enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; O-GLCNAC TRANSFERASE; BETA-CELL; GLUCOSAMINE-6-PHOSPHATE SYNTHASE; HEXOSAMINE BIOSYNTHESIS; N-ACETYLGLUCOSAMINE; INSULIN-RESISTANCE; GLUCOSE; APOPTOSIS; GLUTAMINE	A protein encoded by a new gene with approximately 75% homology to glutamine-fructose-6-phosphate amidotransferase (GFAT) was termed GFAT2 on the basis of this similarity. The mouse GFAT2 cDNA was cloned, and the protein was expressed with either an N-terminal glutathione S-transferase or His tag. The purified protein expressed in mammalian cells had GFAT activity. The K-m values for the two substrates of reaction, fructose 6-phosphate and glutamine, were determined to be 0.8 mM for fructose 6-phosphate and 1.2 mM for glutamine, which are within the ranges determined for GFAT1. The protein sequence around the serine 202 of GFAT2 was conserved to the serine 205 of GFAT1, whereas the serine at 235 in GFAT1 was not present in GFAT2. Previously we showed that phosphorylation of serine 205 in GFAT1 by the catalytic subunit of cAMP-dependent protein kinase (PKA) inhibits its activity. Like GFAT1, GFAT2 was phosphorylated by PKA, but GFAT2 activity increased approximately 2.2-fold by this modification. When serine 202 of GFAT2 was mutated to an alanine, the enzyme not only became resistant to phosphorylation, but also the increase in activity in response to PKA also was blocked. These results indicated that the phosphorylation of serine 202 was necessary and sufficient for these alterations by PKA. GFAT2 was modestly inhibited (15%) by UDP-GlcNAc but not through detectable O-glycosylation. GFAT2 is, therefore, an isoenzyme of GFAT1, but its regulation by cAMP is the opposite, allowing differential regulation of the hexosamine pathway in specialized tissues.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA.	kudlow@uab.edu						AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Broschat KO, 2002, J BIOL CHEM, V277, P14764, DOI 10.1074/jbc.M201056200; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; Chang Q, 2000, J BIOL CHEM, V275, P21981, DOI 10.1074/jbc.M001049200; Drucker DJ, 2003, ENDOCRINOLOGY, V144, P5145, DOI 10.1210/en.2003-1147; Graack HR, 2001, BIOCHEM J, V360, P401, DOI 10.1042/0264-6021:3600401; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han I, 2000, BIOCHEM J, V350, P109, DOI 10.1042/0264-6021:3500109; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Li YZ, 2003, J BIOL CHEM, V278, P471, DOI 10.1074/jbc.M209423200; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Liu K, 2004, J NEUROCHEM, V89, P1044, DOI 10.1111/j.1471-4159.2004.02389.x; Liu K, 2002, MOL CELL ENDOCRINOL, V194, P135, DOI 10.1016/S0303-7207(02)00155-7; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; Milewski S, 1999, J BIOL CHEM, V274, P4000, DOI 10.1074/jbc.274.7.4000; Milewski S, 2002, BBA-PROTEIN STRUCT M, V1597, P173, DOI 10.1016/S0167-4838(02)00318-7; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; Oki T, 1999, GENOMICS, V57, P227, DOI 10.1006/geno.1999.5785; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Teplyakov A, 2001, J MOL BIOL, V313, P1093, DOI 10.1006/jmbi.2001.5094; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhou JX, 1998, DIABETES, V47, P1836, DOI 10.2337/diabetes.47.12.1836	31	59	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29988	29993		10.1074/jbc.M401547200	http://dx.doi.org/10.1074/jbc.M401547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133036	hybrid			2022-12-27	WOS:000222531900016
J	Kasahara, T; Ishiguro, M; Kasahara, M				Kasahara, T; Ishiguro, M; Kasahara, M			Comprehensive chimeric analysis of amino acid residues critical for high affinity glucose transport by Hxt2 of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE RECOGNITION; ESCHERICHIA-COLI; GAL2; MECHANISM; PROTEINS; FAMILY	Chimeras of Hxt2 and Hxt1, high affinity and low affinity glucose transporters, respectively, of Saccharomyces cerevisiae, were previously constructed by random replacement of each of the 12 transmembrane segments (TMs) of Hxt2 with the corresponding region of Hxt1. Characterization of these chimeras revealed that at least TMs 1, 5, 7, and 8 of Hxt2 are required for high affinity transport activity. To determine which amino acid residues in these TMs are important for high affinity glucose transport, we systematically shuffled all of the 20 residues in these regions that differ between Hxt2 and Hxt1. Analysis of 60 independent mutant strains identified as expressing high affinity and high capacity glucose transport activity by selection on glucose-limited agar plates revealed that Leu-201 in TM5 of Hxt2 is most important for such activity and that either Cys-195 or Phe-198 is also required for maximal activity.	Teikyo Univ, Sch Med, Biophys Lab, Tokyo 1920395, Japan; Teikyo Univ, Genome Res Ctr, Tokyo 1920395, Japan; Suntory Inst Bioorgan Res, Osaka 6188503, Japan	Teikyo University; Teikyo University; Suntory Holdings Ltd	Kasahara, M (corresponding author), Teikyo Univ, Sch Med, Biophys Lab, Tokyo 1920395, Japan.	kasahara@main.teikyo-u.ac.jp						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Berg JM, 2002, BIOCHEMISTRY-US, V5th; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Heymann JAW, 2003, J STRUCT BIOL, V144, P320, DOI 10.1016/j.jsb.2003.09.002; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kasahara M, 1998, J BIOL CHEM, V273, P29106, DOI 10.1074/jbc.273.44.29106; Kasahara T, 2003, BIOCHEM J, V372, P247, DOI 10.1042/BJ20030044; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Kasahara T, 2000, J BIOL CHEM, V275, P4422, DOI 10.1074/jbc.275.6.4422; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Saraceni-Richards CA, 2000, J BIOL CHEM, V275, P6101, DOI 10.1074/jbc.275.9.6101; Ye L, 1999, J BACTERIOL, V181, P4673, DOI 10.1128/JB.181.15.4673-4675.1999	16	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30274	30278		10.1074/jbc.M403762200	http://dx.doi.org/10.1074/jbc.M403762200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128737	hybrid			2022-12-27	WOS:000222531900052
J	Malliri, A; van Es, S; Huveneers, S; Collard, JG				Malliri, A; van Es, S; Huveneers, S; Collard, JG			The Rac exchange factor Tiam1 is required for the establishment and maintenance of cadherin-based adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; EPITHELIAL-CELLS; SMALL GTPASES; NEGATIVE MODULATION; TUMOR PROGRESSION; ADENOVIRUS-5 E1A; DROSOPHILA CTBP; RHO ACTIVITY; MDCK CELLS; C-TERMINUS	Rho family proteins are essential for the formation of adherens junctions, which are required for the maintenance of epithelial integrity. Activated Rac and the Rac exchange factor Tiam1 have been shown to promote the formation of adherens junctions and the accompanying induction of an epithelioid phenotype in a number of cell lines. Here we show that Madin-Darby canine kidney II cells in which Tiam1 was down-regulated using short interfering RNA disassembled their cadherin-based adhesions and acquired a flattened, migratory, and mesenchymal morphology. In addition, the expression of E1A in mesenchymal V12Ras-transformed Madin-Darby canine kidney II cells led simultaneously to the up-regulation of the Tiam1 protein, the activation of Rac, the formation of cadherin-based adhesions, and reversion to an epithelial phenotype. This finding suggests that E1A induces an epithelial morphology through the up-regulation of Tiam1 and, thereby, the activation of Rac and the formation of cadherin-based adhesions. Indeed, we found that E1A is able to induce an epithelial-like morphology accompanied by the formation of cadherin-based adhesions only in wild-type but not in Tiam1-deficient primary mouse embryonic fibroblasts. These studies indicate that the Rac activator Tiam1 is essential for the formation as well as the maintenance of cadherin-based adhesions.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Collard, JG (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.collard@nki.nl		Huveneers, Stephan/0000-0002-1091-475X; Malliri, Angeliki/0000-0001-6848-090X				BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Drews R, 1998, MUTAT RES-FUND MOL M, V421, P9, DOI 10.1016/S0027-5107(98)00149-3; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; HABETS GGM, 1995, CYTOGENET CELL GENET, V70, P48, DOI 10.1159/000133989; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	35	104	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30092	30098		10.1074/jbc.M401192200	http://dx.doi.org/10.1074/jbc.M401192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138270	hybrid			2022-12-27	WOS:000222531900029
J	Letzelter, C; Duguet, M; Serre, MC				Letzelter, C; Duguet, M; Serre, MC			Mutational analysis of the archaeal tyrosine recombinase SSV1 integrase suggests a mechanism of DNA cleavage in trans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; HOLLIDAY JUNCTION COMPLEX; HUMAN TOPOISOMERASE-I; LAMBDA-INTEGRASE; FLP RECOMBINASE; ACTIVE-SITE; VACCINIA TOPOISOMERASE; INT FAMILY; FUNCTIONAL-ANALYSIS; COVALENT CATALYSIS	The only tyrosine recombinase so far studied in archaea, the SSV1 integrase, harbors several changes in the canonical residues forming the catalytic pocket of this family of recombinases. This raised the possibility of a different mechanism for archaeal tyrosine recombinase. The residues of Int(SSV) tentatively involved in catalysis were modified by site-directed mutagenesis, and the properties of the corresponding mutants were studied. The results show that all of the targeted residues are important for activity, suggesting that the archaeal integrase uses a mechanism similar to that of bacterial or eukaryotic tyrosine recombinases. In addition, we show that Int(SSV) exhibits a type IB topoisomerase activity because it is able to relax both positive and negative supercoils. Interestingly, in vitro complementation experiments between the inactive integrase mutant Y314F and all other inactive mutants restore in all cases enzymatic activity. This suggests that, as for the yeast Flp recombinase, the active site is assembled by the interaction of the tyrosine from one monomer with the other residues from another monomer. The shared active site paradigm of the eukaryotic Flp protein may therefore be extended to the archaeal tyrosine recombinase Int(SSV).	Univ Paris 11, Inst Genet & Microbiol, Lab Enzymol Acides Nucleiques, F-91405 Orsay, France	UDICE-French Research Universities; Universite Paris Saclay	Serre, MC (corresponding author), Univ Paris 11, Inst Genet & Microbiol, Lab Enzymol Acides Nucleiques, Batiment 400, F-91405 Orsay, France.	serre@igmors.u-psud.fr	Serre, Marie-Claude/B-4159-2008	SERRE, Marie-Claude/0000-0002-7899-9833				ABREMSKI K, 1986, J BIOL CHEM, V261, P391; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; Blakely GW, 1996, MOL MICROBIOL, V20, P234, DOI 10.1111/j.1365-2958.1996.tb02505.x; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; CHEN JW, 1992, MOL CELL BIOL, V12, P3757, DOI 10.1128/MCB.12.9.3757; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Chen Y, 2003, J BIOL CHEM, V278, P24800, DOI 10.1074/jbc.M300853200; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Conway AB, 2003, J MOL BIOL, V326, P425, DOI 10.1016/S0022-2836(02)01370-0; Cornet F, 1997, J BIOL CHEM, V272, P21927, DOI 10.1074/jbc.272.35.21927; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; Edgcomb SP, 2002, PROTEINS, V49, P1, DOI 10.1002/prot.10177; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Grainge I, 2001, J MOL BIOL, V314, P717, DOI 10.1006/jmbi.2001.5194; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HAN YPW, 1994, J MOL BIOL, V235, P908, DOI 10.1006/jmbi.1994.1048; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; JAYARAM M, 1995, TRENDS GENET, V11, P432, DOI 10.1016/S0168-9525(00)89140-4; Jayaram M., 2002, MOBILE DNA, P192; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; Lee J, 1999, EMBO J, V18, P784, DOI 10.1093/emboj/18.3.784; LEE J, 1992, J MOL BIOL, V228, P1091, DOI 10.1016/0022-2836(92)90317-D; Mondragon A, 1997, NAT STRUCT BIOL, V4, P427, DOI 10.1038/nsb0697-427; MUSKHELISHVILI G, 1994, SYST APPL MICROBIOL, V16, P605; MUSKHELISHVILI G, 1993, MOL GEN GENET, V237, P334, DOI 10.1007/BF00279436; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; REDDER P, 2002, MOBILE DNA, V2, P1060; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; REITER WD, 1989, NUCLEIC ACIDS RES, V17, P1907, DOI 10.1093/nar/17.5.1907; Serre MC, 2003, PROG NUCLEIC ACID RE, V74, P37, DOI 10.1016/S0079-6603(03)01010-9; SERRE MC, 1992, J MOL BIOL, V225, P643, DOI 10.1016/0022-2836(92)90391-V; Serre MC, 2002, J BIOL CHEM, V277, P16758, DOI 10.1074/jbc.M200707200; Shaikh AC, 2000, J MOL BIOL, V302, P27, DOI 10.1006/jmbi.2000.3967; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; STARK WM, 1995, TRENDS GENET, V11, P121; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200	60	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28936	28944		10.1074/jbc.M403971200	http://dx.doi.org/10.1074/jbc.M403971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123675	hybrid			2022-12-27	WOS:000222445300015
J	Sanokawa-Akakura, R; Dai, HC; Akakura, S; Weinstein, D; Fajardo, JE; Lang, SE; Wadsworth, S; Siekierka, J; Birge, RB				Sanokawa-Akakura, R; Dai, HC; Akakura, S; Weinstein, D; Fajardo, JE; Lang, SE; Wadsworth, S; Siekierka, J; Birge, RB			A novel role for the immunophilin FKBP52 in copper transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PROGESTERONE-RECEPTOR; ISOMERASE ACTIVITY; TERMINAL DOMAIN; PROTEIN; FK506; EXPRESSION; GENE; REGENERATION; HOMEOSTASIS	FK506-binding protein 52 (FKBP52) is an immunophilin that possesses peptidylprolyl cis/trans-isomerase (PPIase) activity and is a component of a subclass of steroid hormone receptor complexes. Several recent studies indicate that immunophilins can regulate neuronal survival and nerve regeneration although the molecular mechanisms are poorly understood. To investigate the function of FKBP52 in the nervous system, we employed a yeast two-hybrid strategy using the PPIase domain ( domain I) as bait to screen a neonatal rat dorsal root ganglia cDNA expression library. We identified an interaction between FKBP52 domain I and Atox1, a copper-binding metallochaperone. Atox1 interacts with Menkes disease protein and Wilson disease protein (WD) and functions in copper efflux. The interaction between FKBP52 and Atox1 was observed in both glutathione S-transferase pull-down experiments and when proteins were ectopically expressed in human embryonic kidney (HEK) 293T cells and was sensitive to FK506. Interestingly, the FKBP52/Atox1 interaction was enhanced when HEK 293T cells were cultured in copper-supplemented medium and decreased in the presence of the copper chelator, bathocuproine disulfate, suggesting that the interaction is regulated in part by intracellular copper. Overexpression of FKBP52 increased rapid copper efflux in Cu-64-loaded cells, as did the overexpression of WD transporter. Taken together, our present findings suggest that FKBP52 is a component of the copper efflux machinery, and in so, may also promote neuroprotection from copper toxicity.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; GliaMed Inc, New York, NY 10032 USA; Rockefeller Univ, New York, NY 10021 USA; Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rockefeller University; Johnson & Johnson; Johnson & Johnson USA	Birge, RB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	birgera@umdnj.edu			NCI NIH HHS [R24 CA 86307] Funding Source: Medline; NIGMS NIH HHS [GM 55760] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Birge RB, 2004, NEUROSCIENCE, V124, P351, DOI 10.1016/j.neuroscience.2003.10.013; Brecht S, 2003, NEUROSCIENCE, V120, P1037, DOI 10.1016/S0306-4522(03)00404-4; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Goel M, 2001, J BIOL CHEM, V276, P38762, DOI 10.1074/jbc.M104125200; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; GOLD BG, 1994, NEUROSCI LETT, V176, P123, DOI 10.1016/0304-3940(94)90886-9; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Li PY, 2003, ACTA CRYSTALLOGR D, V59, P16, DOI 10.1107/S0907444902017523; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Marks PW, 1998, J CELL SCI, V111, P2129; Muller T, 1999, Eur J Med Res, V4, P293; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Qing KY, 2001, J VIROL, V75, P8968, DOI 10.1128/JVI.75.19.8968-8976.2001; Railson JE, 2001, J MOL CELL CARDIOL, V33, P1209, DOI 10.1006/jmcc.2001.1384; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SMITH DF, 1993, J BIOL CHEM, V268, P18365; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; Tapiero H, 2003, BIOMED PHARMACOTHER, V57, P386, DOI 10.1016/S0753-3322(03)00012-X; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; Udina E, 2003, EXP NEUROL, V183, P220, DOI 10.1016/S0014-4886(03)00173-0; Wu BL, 2003, ACTA CRYSTALLOGR D, V59, P2269, DOI 10.1107/S090744490301970X	32	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27845	27848		10.1074/jbc.C400118200	http://dx.doi.org/10.1074/jbc.C400118200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15133031	hybrid			2022-12-27	WOS:000222265400004
J	Liu, YT; Flanagan, JJ; Barlowe, C				Liu, YT; Flanagan, JJ; Barlowe, C			Sec22p export from the endoplasmic reticulum is independent of SNARE pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; COPII VESICLES; RETROGRADE TRANSPORT; RAB GTPASE; PROTEINS; GOLGI; COMPLEX; FUSION; ER	Molecularly distinct sets of SNARE proteins localize to specific intracellular compartments and catalyze membrane fusion events. Although their central role in membrane fusion is appreciated, little is known about the mechanisms by which individual SNARE proteins are targeted to specific organelles. Here we investigated functional domains in Sec22p that direct this SNARE protein to the endoplasmic reticulum ( ER), to Golgi membranes, and into SNARE complexes with Bet1p, Bos1p, and Sed5p. A series of Sec22p deletion mutants were monitored in COPII budding assays, subcellular fractionation gradients, and SNARE complex immunoprecipitations. We found that the N-terminal " profilin-like" domain of Sec22p was required but not sufficient for COPII-dependent export of Sec22p from the ER. Interestingly, versions of Sec22p that lacked the N-terminal domain were assembled into ER/Golgi SNARE complexes. Analyses of Sec22p SNARE domain mutants revealed a second signal within the SNARE motif ( between layers -4 and -1) that was required for efficient ER export. Other SNARE domain mutants that contained this signal were efficiently packaged into COPII vesicles but failed to assemble into SNARE complexes. Together these results indicated that SNARE complex formation is neither required nor sufficient for Sec22p packaging into COPII transport vesicles and subsequent targeting to the Golgi complex. We propose that the COPII budding machinery has a preference for unassembled ER/Golgi SNARE proteins.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Barlowe, C (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Biochem HB 7200, Hanover, NH 03755 USA.	barlowe@dartmouth.edu						Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Bhattacharya S, 2002, P NATL ACAD SCI USA, V99, P13867, DOI 10.1073/pnas.202335999; Burri L, 2003, P NATL ACAD SCI USA, V100, P9873, DOI 10.1073/pnas.1734000100; Calero M, 2002, FEBS LETT, V515, P89, DOI 10.1016/S0014-5793(02)02442-0; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Dilcher M, 2003, EMBO J, V22, P3664, DOI 10.1093/emboj/cdg339; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Hasegawa H, 2003, MOL BIOL CELL, V14, P698, DOI 10.1091/mbc.E02-09-0556; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Joglekar AP, 2003, J BIOL CHEM, V278, P14121, DOI 10.1074/jbc.M300659200; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Liu YT, 2002, MOL BIOL CELL, V13, P3314, DOI 10.1091/mbc.E02-04-0204; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Munson M, 2002, J BIOL CHEM, V277, P9375, DOI 10.1074/jbc.M111729200; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Tsui MMK, 2000, J CELL SCI, V113, P145; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	50	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27225	27232		10.1074/jbc.M312122200	http://dx.doi.org/10.1074/jbc.M312122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123693	hybrid			2022-12-27	WOS:000222120400050
J	Apuzzo, S; Abdelhakim, A; Fortin, AS; Gros, P				Apuzzo, S; Abdelhakim, A; Fortin, AS; Gros, P			Cross-talk between the paired domain and the homeodomain of Pax3 - DNA binding by each domain causes a structural change in the other domain, supporting interdependence for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR ALVEOLAR RHABDOMYOSARCOMA; INDUCED CONFORMATIONAL-CHANGES; SPLOTCH MUTANT MOUSE; NUCLEOTIDE-BINDING; P-GLYCOPROTEIN; WAARDENBURG-SYNDROME; CRYSTAL-STRUCTURE; TERMINAL SUBDOMAIN; ESCHERICHIA-COLI; PBX HOMEODOMAIN	The Pax3 protein has two DNA binding domains, a Paired domain (PD) and a paired-type Homeo domain (HD). Although the PD and HD can bind to cognate DNA sequences when expressed individually, genetic and biochemical data indicate that the two domains are functionally interdependent in intact Pax3. The mechanistic basis of this functional interdependence is unknown and was studied by protease sensitivity. Pax3 was modified by the creation of Factor Xa cleavage sites at discrete locations in the PD, the HD, and in the linker segment joining the PD and the HD (Xa172, Xa189, and Xa216) in individual Pax3 mutants. The effect of Factor Xa insertions on protein stability and on DNA binding by the PD and the HD was measured using specific target site sequences. Independent insertions at position 100 in the linker separating the first from the second helix-turn-helix motif of the PD and at position 216 immediately upstream of the HD were found to be readily accessible to Factor Xa cleavage. The effect of DNA binding by the PD or the HD on accessibility of Factor Xa sites inserted in the same or in the other domain was monitored and quantitated for multiple mutants bearing different numbers of Xa sites at each position. In general, DNA binding reduced accessibility of all sites, suggesting a more compact and less solvent-exposed structure of DNA-bound versus DNA-free Pax3. Results of dose response and time course experiments were consistent and showed that DNA binding by the PD not only caused a local structural change in the PD but also caused a conformational change in the HD (P3OPT binding to Xa216 mutants); similarly, DNA binding by the HD also caused a conformational change in the PD (P2 binding to Xa100 mutants). These results provide a structural basis for the functional interdependence of the two DNA binding domains of Pax3.	McGill Univ, Dept Biochem, Quebec City, PQ H1E 1S9, Canada; McGill Univ, McGill Canc Ctr, Quebec City, PQ H1E 1S9, Canada	McGill University; McGill University	Gros, P (corresponding author), McGill Univ, Dept Biochem, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	sapuzz@po-box.mcgill.ca; philippe.gros@mcgill.ca						Apuzzo S, 2002, BIOCHEMISTRY-US, V41, P12076, DOI 10.1021/bi0260583; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALDWIN CT, 1995, AM J MED GENET, V58, P115, DOI 10.1002/ajmg.1320580205; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Beechey CV, 1986, MOUSE NEWS LETT, V75, P28; Bendall AJ, 1999, DEVELOPMENT, V126, P4965; BOBER E, 1994, DEVELOPMENT, V120, P603; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CLARKE ND, 1994, PROTEIN SCI, V3, P1779, DOI 10.1002/pro.5560031018; COX M, 1995, J BIOMOL NMR, V6, P23, DOI 10.1007/BF00417488; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fortin AS, 1998, NUCLEIC ACIDS RES, V26, P4574, DOI 10.1093/nar/26.20.4574; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; FRANZ T, 1989, ANAT EMBRYOL, V180, P457, DOI 10.1007/BF00305120; FRANZ T, 1990, ACTA ANAT, V138, P246; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HE MG, 1993, J PROTEIN CHEM, V12, P1, DOI 10.1007/BF01024906; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Jabet C, 1999, J MOL BIOL, V291, P521, DOI 10.1006/jmbi.1999.2983; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Jun S, 1996, DEVELOPMENT, V122, P2639; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; MENEZES ME, 1990, P NATL ACAD SCI USA, V87, P1638, DOI 10.1073/pnas.87.5.1638; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; QIAN YQ, 1994, P NATL ACAD SCI USA, V91, P4091, DOI 10.1073/pnas.91.9.4091; Rothman A, 1997, BIOCHEMISTRY-US, V36, P14572, DOI 10.1021/bi971800y; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Sprules T, 2000, BIOCHEMISTRY-US, V39, P9943, DOI 10.1021/bi0001067; Sprules T, 2003, J BIOL CHEM, V278, P1053, DOI 10.1074/jbc.M207504200; Stout JG, 1998, BIOCHEMISTRY-US, V37, P14860, DOI 10.1021/bi9812930; STUART ET, 1994, ANNU REV GENET, V28, P219, DOI 10.1146/annurev.ge.28.120194.001251; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Torres M, 1995, DEVELOPMENT, V121, P4057; TREISMAN J, 1989, CELL, V59, P553; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; Vogan KJ, 1997, J BIOL CHEM, V272, P28289, DOI 10.1074/jbc.272.45.28289; Walmsley AR, 1999, J BIOL CHEM, V274, P16153, DOI 10.1074/jbc.274.23.16153; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1993, J BIOL CHEM, V268, P20126; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731	69	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33601	33612		10.1074/jbc.M402949200	http://dx.doi.org/10.1074/jbc.M402949200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15148315	hybrid			2022-12-27	WOS:000223039700069
J	Marchetti, L; Klein, M; Schlett, K; Pfizenmaier, K; Eisel, ULM				Marchetti, L; Klein, M; Schlett, K; Pfizenmaier, K; Eisel, ULM			Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation - Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; ZETA-PKC; EXPRESSION; SURVIVAL; SUBUNIT; AKT; PATHOGENESIS; INHIBITORS; APOPTOSIS	We have previously shown that two tumor necrosis factor (TNF) receptors (TNFR) exhibit antagonistic functions during neurodegenerative processes in vivo with TNFR1 aggravating and TNFR2 reducing neuronal cell loss, respectively. To elucidate the neuroprotective signaling pathways of TNFR2, we investigated glutamate-induced excitotoxicity in primary cortical neurons. TNF-expressing neurons from TNF-transgenic mice were found to be strongly protected from glutamate-induced apoptosis. Neurons from wild type and TNFR1(-/-) mice prestimulated with TNF or agonistic TNFR2-specific antibodies were also resistant to excitotoxicity, whereas TNFR2(-/-) neurons died upon glutamate and/or TNF exposures. Both protein kinase B/Akt and nuclear factor-kappaB (NF-kappaB) activation were apparent upon TNF treatment. Both TNFR1 and TNFR2 induced the NF-kappaB pathway, yet with distinguishable kinetics and upstream activating components, TNFR1 only induced transient NF-kappaB activation, whereas TNFR2 facilitated long term phosphatidylinositol 3-kinase-dependent NF-kappaB activation strictly. Glutamate-induced triggering of the ionotropic N-methyl-D-aspartate receptor was required for the enhanced and persistent phosphatidylinositol 3-kinase-dependent NF-kappaB activation by TNFR2, indicating a positive cooperation of TNF and neurotransmitter-induced signal pathways. TNFR2-induced persistent NF-kappaB activity was essential for neuronal survival. Thus, the duration of NF-kappaB activation is a critical determinant for sensitivity toward excitotoxic stress and is dependent on a differential upstream signal pathway usage of the two TNFRs.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Xantos Biomed AG, D-82152 Martinsried, Germany; Eotvos Lorand Univ, Dept Physiol & Neurobiol, H-1117 Budapest, Hungary; Univ Groningen, Dept Mol Neurobiol, NL-9750 AA Haren, Netherlands	University of Stuttgart; Eotvos Lorand University; University of Groningen	Pfizenmaier, K (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	klaus.pfizenmaier@izi.uni-stuttgart.de	Schlett, Katalin/AAF-1952-2020	Schlett, Katalin/0000-0001-9265-4236; Eisel, Ulrich/0000-0003-4178-0384				Akassoglou K, 1997, J IMMUNOL, V158, P438; Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Clark WM, 2001, EXPERT OPIN BIOL TH, V1, P227, DOI 10.1517/14712598.1.2.227; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; EISEL U, 1993, EMBO J, V12, P3365, DOI 10.1002/j.1460-2075.1993.tb06010.x; Eisel ULM, 2002, CURR TOP MICROBIOL, V265, P49; ESKANDARI MK, 1990, IMMUNOL INVEST, V19, P69, DOI 10.3109/08820139009042026; Fleischmann R, 2002, DRUG SAFETY, V25, P173, DOI 10.2165/00002018-200225030-00004; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GREEN S, 1982, J NATL CANCER I, V68, P997; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Kassiotis G, 1999, EUR J IMMUNOL, V29, P912, DOI 10.1002/(SICI)1521-4141(199903)29:03<912::AID-IMMU912>3.0.CO;2-G; Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; Klein M, 1998, GENE, V208, P259, DOI 10.1016/S0378-1119(98)00005-5; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller C, 2002, IMMUNOLOGY, V105, P1, DOI 10.1046/j.1365-2567.2002.01329.x; Ozes ON, 1999, NATURE, V401, P82; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Petegnief V, 2001, NEUROSCIENCE, V104, P223, DOI 10.1016/S0306-4522(01)00046-X; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Probert L, 2001, GLIA, V36, P212, DOI 10.1002/glia.1110; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sandra F, 2002, CELL SIGNAL, V14, P771, DOI 10.1016/S0898-6568(02)00025-6; Sasner M, 1996, J BIOL CHEM, V271, P21316, DOI 10.1074/jbc.271.35.21316; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Tacchini-Cottier F, 1998, J IMMUNOL, V160, P6182; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; WATANABE M, 1993, J COMP NEUROL, V338, P377, DOI 10.1002/cne.903380305; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002	54	330	347	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32869	32881		10.1074/jbc.M311766200	http://dx.doi.org/10.1074/jbc.M311766200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155767	Green Published, hybrid			2022-12-27	WOS:000222849700107
J	Sorger, D; Athenstaedt, K; Hrastnik, C; Daum, G				Sorger, D; Athenstaedt, K; Hrastnik, C; Daum, G			A yeast strain lacking lipid particles bears a defect in ergosterol formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE GENE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SQUALENE EPOXIDASE; CHOLESTEROL ACYLTRANSFERASE; FUNCTIONAL EXPRESSION; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; BIOSYNTHESIS	Lipid particles of the yeast Saccharomyces cerevisiae are storage compartments for triacylglycerols (TAG) and steryl esters (STE). Four gene products, namely the TAG synthases Dga1p and Lro1p, and the STE synthases Are1p and Are2p contribute to storage lipid synthesis. A yeast strain lacking the four respective genes is devoid of lipid particles thus providing a valuable tool to study the physiological role of storage lipids and lipid particles. Using a dga1lro1are1are2 quadruple mutant transformed with plasmids bearing inducible DGA1, LRO1, or ARE2 we demonstrate that TAG synthesis contributes more efficiently to lipid particle proliferation than synthesis of STE. Moreover, we show that proteins typically located to lipid particles in wild type such as Erg1p, Erg6p, Erg7p, and Ayr1p are refined to microsomal fractions of the dga1lro1are1are2 quadruple mutant. This result confirms the close relationship between lipid particles and endoplasmic reticulum. Most interestingly, the amount of the squalene epoxidase Erg1p, which is dually located in lipid particles and endoplasmic reticulum of wild type, is decreased in the quadruple mutant, whereas amounts of other lipid particle proteins tested were not reduced. This decrease is not caused by downregulation of ERG1 transcription but by the low stability of Erg1p in the quadruple mutant. Because a similar effect was also observed in are1are2 mutants this finding can be mainly attributed to the lack of STE. The quadruple mutant, however, was more sensitive to terbinafine, an inhibitor of Erg1p, than the are1are2 strain suggesting that the presence of TAG and/or intact lipid particles has an additional protective effect. In a strain lacking the two STE synthases, Are1p and Are2p, incorporation of ergosterol into the plasma membrane was reduced, although the total cellular amount of free ergosterol was higher in the mutant than in wild type. Thus, an esterification/deacylation mechanism appears to contribute to the supply of ergosterol to the plasma membrane.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Graz University of Technology	Daum, G (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at		Athenstaedt, Karin/0000-0001-7198-3989				Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; Daum G, 1999, YEAST, V15, P601, DOI 10.1002/(SICI)1097-0061(199905)15:7<601::AID-YEA390>3.0.CO;2-N; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hobbs DH, 1999, FEBS LETT, V452, P145, DOI 10.1016/S0014-5793(99)00646-8; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; Lacey DJ, 1999, PLANT J, V17, P397, DOI 10.1046/j.1365-313X.1999.00387.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; LEBER R, 1995, BBA-BIOMEMBRANES, V1234, P119, DOI 10.1016/0005-2736(94)00270-Y; Leber R, 2001, EUR J BIOCHEM, V268, P914, DOI 10.1046/j.1432-1327.2001.01940.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MBAYA B, 1989, LIPIDS, V24, P1020, DOI 10.1007/BF02544072; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Quail M A, 1996, Methods Mol Biol, V53, P123; Routaboul JM, 1999, PLANT PHYSIOL BIOCH, V37, P831, DOI 10.1016/S0981-9428(99)00115-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; Shibata N, 2001, P NATL ACAD SCI USA, V98, P2244, DOI 10.1073/pnas.041620398; SIBORSKI RS, 1989, GENETICS, V122, P19; Sorger D, 2003, APPL MICROBIOL BIOT, V61, P289, DOI 10.1007/s00253-002-1212-4; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; Zou JT, 1999, PLANT J, V19, P645, DOI 10.1046/j.1365-313x.1999.00555.x; Zweytick D, 2000, EUR J BIOCHEM, V267, P1075, DOI 10.1046/j.1432-1327.2000.01103.x; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	42	93	96	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31190	31196		10.1074/jbc.M403251200	http://dx.doi.org/10.1074/jbc.M403251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155725	hybrid			2022-12-27	WOS:000222726800037
J	Kathuria, H; Cao, YX; Ramirez, MI; Williams, MC				Kathuria, H; Cao, YX; Ramirez, MI; Williams, MC			Transcription of the caveolin-1 gene is differentially regulated in lung type I epithelial and endothelial cell lines - A role for ETS proteins in epithelial cell expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR PROGRESSION; MESSENGER-RNA; PROMOTER; IDENTIFICATION; ACTIVATION; BINDING; TRAFFICKING; ASSOCIATION; SEQUENCES; REPRESSOR	In the lung, caveolin-1 is expressed in both type I alveolar epithelial and endothelial cells where it is hypothesized to modulate molecular signaling activities and progression of tumorigenesis. Developmentally, caveolin-1alpha is expressed in fetal lung endothelial, but not epithelial, cells; in adult lung, both cell types express caveolin-1alpha. To test the hypothesis that caveolin-1 transcription is differentially regulated in type I and endothelial cells, we characterized the proximal promoter of the mouse caveolin-1 gene in lung cell lines to identify factors that control its cell-specific expression. We show that caveolin-1 expression is regulated by an Ets cis-element in a lung epithelial cell line, but not a lung endothelial cell line, and that three ETS family members, ETS-1, PEA3, and ERM, recognize and bind the Ets site in the epithelial cell line. Based on these findings, we have identified the Ets cis-element as a region that accounts for differential transcriptional regulation of caveolin-1 in lung epithelial and endothelial cells.	Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Anat, Boston, MA 02118 USA	Boston University; Boston University	Kathuria, H (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 80 E Concord St, Boston, MA 02118 USA.	hasmeena.kathuria@bmc.org	Kathuria, Hasmeena/I-4169-2019	Kathuria, Hasmeena/0000-0002-9062-409X; Cao, Yu-Xia/0000-0001-7396-9988; Ramirez, Maria Isabel/0000-0001-6294-4419	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL073605] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073605] Funding Source: Medline; PHS HHS [47049] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akeson AL, 2000, DEV DYNAM, V217, P11, DOI 10.1002/(SICI)1097-0177(200001)217:1<11::AID-DVDY2>3.0.CO;2-L; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Bonner AE, 2004, ONCOGENE, V23, P1166, DOI 10.1038/sj.onc.1207234; Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; Cao YX, 2003, J CELL BIOCHEM, V89, P887, DOI 10.1002/jcb.10555; CAO YX, 2001, AM J RESP CRIT CARE, V163, P575; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Chen YH, 2003, J BIOL CHEM, V278, P39572, DOI 10.1074/jbc.M308179200; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DING W, 2003, GENE, V332, P175; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; Fuchs S, 2003, CELL TISSUE RES, V311, P31, DOI 10.1007/s00441-002-0653-5; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Horiuchi S, 2003, J PATHOL, V200, P568, DOI 10.1002/path.1387; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Liu YR, 2003, DEV BIOL, V261, P10, DOI 10.1016/S0012-1606(03)00359-2; Lu Z, 2003, BIOCHEM BIOPH RES CO, V303, P190, DOI 10.1016/S0006-291X(03)00314-0; Maier H, 2003, MOL CELL BIOL, V23, P1946, DOI 10.1128/MCB.23.6.1946-1960.2003; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Marjomaki V, 2002, J VIROL, V76, P1856, DOI 10.1128/JVI.76.4.1856-1865.2002; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Martin CSS, 2004, J VIROL, V78, P2310, DOI 10.1128/JVI.78.5.2310-2318.2004; Marx J, 2001, SCIENCE, V294, P1862, DOI 10.1126/science.294.5548.1862; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Park DS, 2003, BIOCHEMISTRY-US, V42, P15124, DOI 10.1021/bi0356348; Parton RG, 2001, SCIENCE, V293, P2404, DOI 10.1126/science.1065677; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Perez A, 2003, J BIOL CHEM, V278, P36942, DOI 10.1074/jbc.M300264200; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; Powell CA, 2003, AM J RESP CELL MOL, V29, P157, DOI 10.1165/rcmb.2002-0183RC; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ramirez MI, 1997, J BIOL CHEM, V272, P26285, DOI 10.1074/jbc.272.42.26285; Ramirez MI, 2002, J HISTOCHEM CYTOCHEM, V50, P33, DOI 10.1177/002215540205000104; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Richards AA, 2002, MOL BIOL CELL, V13, P1750, DOI 10.1091/mbc.01-12-0592; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Takanami I, 2001, TUMOR BIOL, V22, P205, DOI 10.1159/000050617; TAKEFUMI S, 2003, CANCER, V97, P1225; Tsokos GC, 2003, ANN NY ACAD SCI, V987, P240, DOI 10.1111/j.1749-6632.2003.tb06054.x; Tugores A, 2001, J BIOL CHEM, V276, P20397, DOI 10.1074/jbc.M010930200; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	56	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30028	30036		10.1074/jbc.M402236200	http://dx.doi.org/10.1074/jbc.M402236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138262	hybrid			2022-12-27	WOS:000222531900021
J	Song, JJ; Lee, YJ				Song, JJ; Lee, YJ			Tryptophan 621 and serine 667 residues of Daxx regulate its nuclear export during glucose deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN DAXX; TRANSCRIPTIONAL REPRESSION; INDUCED APOPTOSIS; SIGNAL; CRM1; PHOSPHORYLATION; BINDING; ACTIVATION; PML; IDENTIFICATION	The cellular target responsible for the nuclear export of Daxx has been identified as chromosomal region maintenance 1 (CRM1), which is a carrier protein for nuclear export and a receptor for the nuclear export signal (NES) of Daxx. Binding of Daxx to CRM1 was increased early during glucose deprivation and then gradually decreased. This interaction was inhibited by leptomycin B, a specific inhibitor of CRM1-dependent nuclear export. Substitution of the serine 667 amino acid residue of Daxx with alanine reduced the interaction with CRM1 during glucose deprivation, suggesting that the phosphorylation of Ser-667 is required for its binding to CRM1 and for its subsequent nuclear export. Data from coupled transcription-translation studies reveal that the NES (amino acids 565-575) of Daxx is a binding site for CRM1. Interestingly, constitutive export of Daxx has occurred by replacement of the tryptophan 621 Daxx residue with alanine. These results suggest that this tryptophan residue plays a key role in masking the NES of Daxx from its receptor, CRM1, in the resting state, whereas phosphorylation of serine 667 would release the NES, which could then be recognized by the CRM1.	Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, 5117 Ctr Ave,Room G-5A, Pittsburgh, PA 15213 USA.	leeyj@msx.upmc.edu		Song, Jae/0000-0001-8183-9550	NCI NIH HHS [CA95191, CA96989, CA48000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095191, R01CA048000, R01CA096989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; FISHER U, 1995, CELL, V82, P475; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	27	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30573	30578		10.1074/jbc.M404512200	http://dx.doi.org/10.1074/jbc.M404512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128734	hybrid			2022-12-27	WOS:000222531900087
J	Srivastava, KK; Batra, S; Sassano, A; Li, YZ; Majchrzak, B; Kiyokawa, H; Altman, A; Fish, EN; Platanias, LC				Srivastava, KK; Batra, S; Sassano, A; Li, YZ; Majchrzak, B; Kiyokawa, H; Altman, A; Fish, EN; Platanias, LC			Engagement of protein kinase C-theta in interferon signaling in T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES TYROSINE PHOSPHORYLATION; STAT1 SERINE PHOSPHORYLATION; VAV PROTOONCOGENE PRODUCT; JUN NH2-TERMINAL KINASE; P70 S6 KINASE; I INTERFERONS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; MAP KINASE; IFN-GAMMA	Protein kinase C-theta (PKC-theta) plays important roles in the activation and survival of lymphocytes and is the predominant PKC isoform expressed in T-cells. Interferons regulate T-cell function and activation, but the precise signaling mechanisms by which they mediate such effects have not been elucidated. We determined whether PKC-theta is engaged in interferon (INF) signaling in T-cells. Both Type I (alpha, beta) and Type II (gamma) IFNs induced phosphorylation of PKC-theta in human T-cell lines and primary human T-lymphocytes. Such phosphorylation of PKC-theta resulted in activation of its kinase domain, suggesting that this kinase plays a functional role in interferon signaling. Consistent with this, inhibition of PKC-theta protein expression using small interfering RNAs (siRNA) abrogated IFN-alpha- and IFN-gamma-dependent gene transcription via GAS elements. Similarly, blocking of PKC-theta kinase activity by overexpression of a dominant-negative PKC-theta mutant also blocked GAS-driven transcription, further demonstrating a requirement for PKC-theta in IFN-dependent transcriptional activation. The effects of PKC-theta on IFN-dependent gene transcription were not mediated by regulation of the IFN-activated STAT pathway, as siRNA-mediated PKC-theta knockdown had no effects on STAT1 phosphorylation and binding of STAT1-containing complexes to SIE/GAS elements. On the other hand, siRNA-mediated PKC-theta inhibition blocked phosphorylation/activation of MKK4, suggesting that interferon-dependent PKC-theta activation regulates downstream engagement of MAP kinase pathways. Altogether, these findings demonstrate that PKC-theta is an interferon-inducible kinase and strongly suggest that it plays an important role in the generation of interferon-responses in T-cells.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Lakeside Vet Adm Med Ctr, Chicago, IL 60611 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Univ Toronto, Div Cell & Mol Biol, Toronto Res Inst, Univ Network, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; La Jolla Institute for Immunology; University of Toronto; University of Toronto	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks Ave,Olson Pavil 8250, Chicago, IL 60611 USA.	1-platanias@northwestern.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NCI NIH HHS [CA94079, CA77816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816, R01CA094079] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Altman A, 2003, IMMUNOL REV, V192, P53, DOI 10.1034/j.1600-065X.2003.00027.x; Altman A, 2002, J BIOCHEM, V132, P841, DOI 10.1093/oxfordjournals.jbchem.a003295; Arendt CW, 2002, CURR OPIN IMMUNOL, V14, P323, DOI 10.1016/S0952-7915(02)00346-1; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Langer J, 1996, BIOTHERAPY, V8, P163, DOI 10.1007/BF01877201; Lekmine F, 2004, EXP CELL RES, V295, P173, DOI 10.1016/j.yexcr.2003.12.021; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Micouin A, 2000, ONCOGENE, V19, P387, DOI 10.1038/sj.onc.1203314; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pestka S, 2000, BIOPOLYMERS, V55, P254, DOI 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1; Pestka Sidney, 1997, Seminars in Oncology, V24, P18; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Schnaper HW, 2000, PEDIATR NEPHROL, V14, P254, DOI 10.1007/s004670050050; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; WEN Z, 1995, CELL, V28, P241; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; Yu F, 1997, EXP CELL RES, V234, P240, DOI 10.1006/excr.1997.3621; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	64	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29911	29920		10.1074/jbc.M401997200	http://dx.doi.org/10.1074/jbc.M401997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150272	hybrid			2022-12-27	WOS:000222531900007
J	Thomae, TL; Glover, E; Bradfield, CA				Thomae, TL; Glover, E; Bradfield, CA			A maternal Ahr null genotype sensitizes embryos to chemical teratogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; EPITHELIAL-CELL DIFFERENTIATION; PATENT DUCTUS-VENOSUS; CLEFT-PALATE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN TCDD; DEVELOPMENTAL TOXICITY; EXTRACELLULAR-MATRIX; NUCLEAR TRANSLOCATOR; AROMATIC-HYDROCARBON; DEFICIENT MICE	The aryl hydrocarbon receptor (encoded by the Ahr locus) is a ligand-activated transcription factor that mediates the toxicology and teratology of 2,3,7,8-tetrachlorodibenzo-p-dioxin ( dioxin). In an effort to understand the role of the maternal compartment in dioxin teratology, we designed a breeding strategy that allowed us to compare the teratogenic response in embryos from Ahr(-/-) (null) and Ahr(+/+) (wild-type) dams. Using this strategy, we demonstrate that embryos from the Ahr(-/-) dams are 5-fold more sensitive to dioxin-induced cleft palate and hydronephrosis as compared with embryos from an Ahr(+/+) dam. Moreover, this increased teratogenic sensitivity extends beyond dioxin, because embryos from Ahr(-/-) dams exhibited a 9-fold increase in their sensitivity to the fetotoxic effects of the glucocorticoid, dexamethasone. In searching for an explanation for this increased sensitivity, we found that more dioxin and dexamethasone reached the embryos from Ahr(-/-) dams as compared with embryos from Ahr(+/+) dams. We propose that increased deposition of teratogens/fetotoxicants to the embryonic compartment is the result of porto-systemic shunting and/or blocked P4501A induction in Ahr(+/+) dams. In addition to demonstrating the importance of maternal AHR in teratogenesis, these data may have implications that reach beyond the mechanism of action of dioxin. In this regard, the Ahr(-/-) mouse may provide a system that allows pharmacological agents and toxicants to be more easily studied in a model where first pass clearance is a significant obstacle.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	Bradfield@oncology.wisc.edu			NIEHS NIH HHS [R01 ES006883] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006883] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1987, TERATOLOGY, V35, P329, DOI 10.1002/tera.1420350307; ABBOTT BD, 1989, TOXICOL APPL PHARM, V100, P119, DOI 10.1016/0041-008X(89)90096-3; ABBOTT BD, 1987, TERATOLOGY, V35, P335, DOI 10.1002/tera.1420350308; Abbott BD, 1996, TOXICOL APPL PHARM, V141, P256; ABBOTT BD, 1989, TOXICOL APPL PHARM, V99, P276, DOI 10.1016/0041-008X(89)90010-0; Andreola F, 1997, CANCER RES, V57, P2835; BEER AE, 1986, MEAD JOHNSON S PERIN, V24, P20; BENESOVA O, 1989, NEUROPHARMACOLOGY, V28, P89, DOI 10.1016/0028-3908(89)90073-7; BIRNBAUM LS, 1985, TOXICOL APPL PHARM, V77, P292, DOI 10.1016/0041-008X(85)90329-1; Bittencourt M A, 2000, Braz Dent J, V11, P117; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P682; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P229; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Burczynski ME, 2000, CANCER RES, V60, P908; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; CHAN WK, 1994, J BIOL CHEM, V269, P26464; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; Cummings AM, 1996, TOXICOL APPL PHARM, V138, P131, DOI 10.1006/taap.1996.0106; Dao D, 1998, HUM MOL GENET, V7, P597, DOI 10.1093/hmg/7.4.597; DEWAAL EJ, 1992, TOXICOL APPL PHARM, V115, P80, DOI 10.1016/0041-008X(92)90370-8; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; EMA M, 1994, J BIOL CHEM, V269, P27337; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; EPA, 2002, TEST METH EV SOL WAS, P1; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOLDMAN AS, 1978, NATURE, V272, P464, DOI 10.1038/272464a0; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; Hansen DK, 1999, TOXICOL SCI, V48, P230, DOI 10.1093/toxsci/48.2.230; Jacob S, 1999, GUT, V45, P442, DOI 10.1136/gut.45.3.442; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Knutson J. C., 1981, TOXICITY HALOGENATED, P187; KRAUTH J, 1983, J NEUROSCI METH, V9, P269, DOI 10.1016/0165-0270(83)90058-4; Kulkarni AP, 2001, CURR PHARM DESIGN, V7, P833, DOI 10.2174/1381612013397735; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Luch A, 1998, CHEM RES TOXICOL, V11, P686, DOI 10.1021/tx970236p; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Montenegro MA, 1998, J CRAN GENET DEV BIO, V18, P100; MOSIER HD, 1981, TERATOLOGY, V23, P15, DOI 10.1002/tera.1420230105; NATSUME N, 1986, INT J ORAL MAX SURG, V15, P752, DOI 10.1016/S0300-9785(86)80117-X; NAU H, 1981, TOXICOLOGY, V20, P299, DOI 10.1016/0300-483X(81)90037-8; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; Pisano MM, 2000, METH MOL B, V137, P267; POLAND A, 1989, MOL PHARMACOL, V36, P121; POLAND A, 1989, MOL PHARMACOL, V36, P113; POLAND A, 1980, MOL PHARMACOL, V17, P86; POLAND AP, 1974, J BIOL CHEM, V249, P5599; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; SAUERBIER I, 1986, DRUG CHEM TOXICOL, V9, P25, DOI 10.3109/01480548609042827; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Taya Y, 1999, DEVELOPMENT, V126, P3869; Uchino T, 1996, GASTROENTEROLOGY, V110, P1964, DOI 10.1053/gast.1996.v110.pm8964424; WEBER H, 1985, TOXICOL LETT, V26, P159, DOI 10.1016/0378-4274(85)90161-4; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574	60	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30189	30194		10.1074/jbc.M403690200	http://dx.doi.org/10.1074/jbc.M403690200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15145931	hybrid			2022-12-27	WOS:000222531900041
J	Wu, CA; Tsujita, M; Hayashi, M; Yokoyama, S				Wu, CA; Tsujita, M; Hayashi, M; Yokoyama, S			Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER A1; TANGIER-DISEASE; CELLULAR CHOLESTEROL; EXTRACELLULAR DOMAIN; PEST SEQUENCE; APOA-I; EFFLUX; MUTATIONS; ATHEROSCLEROSIS; PHOSPHORYLATION	Probucol has been shown to inhibit the release of cellular lipid by helical apolipoprotein and thereby to reduce plasma high density lipoprotein. We attempted to explore the underlying mechanism for this effect in human fibroblast WI-38. Probucol inhibited the apoA-I-mediated cellular lipid release and binding of apoA-I to the cells in a dose-dependent manner. It did not influence cellular uptake of low density lipoprotein, transport of cholesterol to the cell surface whether de novo synthesized or delivered as low density lipoprotein, and overall cellular content of cholesterol, although biosynthesis of lipids from acetate was somewhat increased. Probucol did not affect the mRNA level of ABCA1, and ABCA1 was recovered along with marker proteins for plasma membrane regardless of the presence of probucol. However, the protein level of ABCA1 increased, and the rate of its decay in the presence of cycloheximide was slower in the probucol-treated cells. ABCA1 in the probucol-treated cells was resistant to digestion by calpain but not by trypsin. We concluded that probucol inactivates ABCA1 in the plasma membrane with respect to its function in mediating binding of and lipid release by apolipoprotein and with respect to proteolytic degradation by calpain.	Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.	syokoyam@med.nagoya-cu.ac.jp		TSUJITA, MAKI/0000-0003-1108-621X				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2004, J BIOL CHEM, V279, P6217, DOI 10.1074/jbc.C300553200; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Costet P, 2000, J BIOL CHEM, V275, P28240; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GOTOH N, 1992, BIOCHIM BIOPHYS ACTA, V1128, P147, DOI 10.1016/0005-2760(92)90300-K; HARA H, 1991, J BIOL CHEM, V266, P3080; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; KUZUYA M, 1993, FREE RADICAL BIO MED, V14, P67, DOI 10.1016/0891-5849(93)90510-2; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; NISHIKAWA O, 1986, J BIOCHEM, V99, P295, DOI 10.1093/oxfordjournals.jbchem.a135473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PORN MI, 1993, J LIPID RES, V34, P1385; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SATONIN DK, 1986, J CHROMATOGR, V380, P401, DOI 10.1016/S0378-4347(00)83670-1; SCHAEFER EJ, 1981, J LIPID RES, V22, P217; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; STANBRIDGE E, 1969, EXP CELL RES, V57, P397, DOI 10.1016/0014-4827(69)90166-9; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Tomimoto S, 2001, ARTERIOSCL THROM VAS, V21, P394, DOI 10.1161/01.ATV.21.3.394; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Tsujita M, 2000, BBA-MOL CELL BIOL L, V1485, P199, DOI 10.1016/S1388-1981(00)00061-5; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; YAMAMOTO A, 1986, AM J CARDIOL, V57, pH29, DOI 10.1016/0002-9149(86)90434-0; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811; YOKOYAMA S, 1988, ATHEROSCLEROSIS, V70, P179, DOI 10.1016/0021-9150(88)90114-1; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	48	81	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30168	30174		10.1074/jbc.M403765200	http://dx.doi.org/10.1074/jbc.M403765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140889	hybrid			2022-12-27	WOS:000222531900038
J	Kolli, S; Zito, CI; Mossink, MH; Wiemer, EAC; Bennett, AM				Kolli, S; Zito, CI; Mossink, MH; Wiemer, EAC; Bennett, AM			The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE-RELATED PROTEIN; KSR-1 GENE ENCODES; DRUG-RESISTANCE; FACTOR RECEPTOR; RIBONUCLEOPROTEIN-PARTICLES; PHOSPHOTYROSINE PHOSPHATASE; CELL-ADHESION; BREAST-CANCER; C-ELEGANS; ACTIVATION	The catalytic activity of the Src homology 2 (SH2) domain-containing tyrosine phosphatase, SHP-2, is required for virtually all of its signaling effects. Elucidating the molecular mechanisms of SHP-2 signaling, therefore, rests upon the identification of its target substrates. In this report, we have used SHP-2 substrate-trapping mutants to identify the major vault protein (MVP) as a putative SHP-2 substrate. MVP is the predominant component of vaults that are cytoplasmic ribonucleoprotein complexes of unknown function. We show that MVP is dephosphorylated by SHP-2 in vitro and it forms an enzyme-substrate complex with SHP-2 in vivo. In response to epidermal growth factor (EGF), SHP-2 associates via its SH2 domains with tyrosyl-phosphorylated MVP. MVP also interacts with the activated form of the extracellular-regulated kinases (Erks) in response to EGF and a constitutive complex between tyrosyl-phosphorylated MVP, SHP-2, and the Erks was detected in MCF-7 breast cancer cells. Using MVP-deficient fibroblasts, we demonstrate that MVP cooperates with Ras for optimal EGF-induced Elk-1 activation and is required for cell survival. We propose that MVP functions as a novel scaffold protein for both SHP-2 and Erk. The regulation of MVP tyrosyl phosphorylation by SHP-2 may play an important role in cell survival signaling.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Erasmus Med Ctr, Dept Med Oncol, NL-3000 DR Rotterdam, Netherlands	Yale University; Erasmus University Rotterdam; Erasmus MC	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM-B 226D,333 Cedar St, New Haven, CT 06520 USA.	anton.bennett@yale.edu		Bennett, Anton/0000-0001-5187-7599; Wiemer, Erik/0000-0002-0673-7236	NATIONAL CANCER INSTITUTE [T32CA009085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046504] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09085] Funding Source: Medline; NIAMS NIH HHS [R01-AR46504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams A, 2000, J BIOL CHEM, V275, P27414; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHUGANI DC, 1993, J CELL SCI, V106, P23; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1611; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Herrmann C, 1996, J BIOL CHEM, V271, P13908, DOI 10.1074/jbc.271.23.13908; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Linn SC, 1997, INT J CANCER, V71, P787, DOI 10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; Morrison DK, 2001, J CELL SCI, V114, P1609; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Mossink MH, 2002, CANCER RES, V62, P7298; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Pohl G, 1999, ANTICANCER RES, V19, P5051; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Suprenant KA, 2002, BIOCHEMISTRY-US, V41, P14447, DOI 10.1021/bi026747e; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; van Zon A, 2001, J BIOL CHEM, V276, P37715, DOI 10.1074/jbc.M106055200; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	59	107	111	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29374	29385		10.1074/jbc.M313955200	http://dx.doi.org/10.1074/jbc.M313955200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133037	hybrid			2022-12-27	WOS:000222445300069
J	Hua, G; Jurat-Fuentes, JL; Adang, MJ				Hua, G; Jurat-Fuentes, JL; Adang, MJ			Bt-R-1a extracellular cadherin repeat 12 mediates Bacillus thuringiensis Cry1Ab binding and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANDUCA-SEXTA AMINOPEPTIDASE; BRUSH-BORDER MEMBRANE; DROSOPHILA S2 CELLS; HELIOTHIS-VIRESCENS; TOXIN BINDING; SPODOPTERA-FRUGIPERDA; DELTA-ENDOTOXIN; PORE FORMATION; DOMAIN-II; RECEPTOR	The cadherin protein Bt-R-1a is a receptor for Bacillus thuringiensis Cry1A toxins in Manduca sexta. Cry1Ab toxin is reported to bind specific epitopes located in extracellular cadherin repeat (CR) 7 and CR11 on Bt-R-1 (Gomez, B., Miranda-Rios, J., Riudino-Pinera, E., Oltean, D. I., Gill, S. S., Bravo, A., and Soberon, M. ( 2002) J. Biol. Chem. 277, 30137 - 30143; Dorsch, J. A., Candas, M., Griko, N., Maaty, W., Midboe, E., Vadlamudi, R., and Bulla, L. ( 2002) Insect Biochem. Mol. Biol. 32, 1025 - 1036). We transiently expressed CR domains of Bt-R-1a in Drosophila melanogaster Schneider 2 (S2) cells as fusion peptides between a signal peptide and a terminal region that included membrane-proximal, membrane-spanning, and cytoplasmic domains. A domain consisting of CR11 and 12 was the minimal I-125-Cry1Ab binding region detected under denaturing conditions. Only CR12 was essential for Cry1Ab binding and cytotoxicity to S2 cells when tested under native conditions. Under these conditions expressed CR12 bound I-125-Cry1Ab with high affinity (K-com = 2.9 nM). Flow cytometry assays showed that expression of CR12 conferred susceptibility to Cry1Ab in S2 cells. Derivatives of Bt-R-1a with separate deletions of CR7, 11, and 12 were expressed in S2 cells. Only deletion of CR12 caused loss of Cry1Ab binding and cytotoxicity. These results demonstrate that CR12 is the essential Cry1Ab binding component on Bt-R-1a that mediates Cry1Ab-induced cytotoxicity.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Adang, MJ (corresponding author), Univ Georgia, Dept Entomol, Rm 413, Athens, GA 30602 USA.	adang@uga.edu	Jurat-Fuentes, Juan Luis/A-5104-2014	Jurat-Fuentes, Juan Luis/0000-0002-8945-1814	NIAID NIH HHS [R01 AI 29092-09] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banks DJ, 2003, INSECT BIOCHEM MOLEC, V33, P499, DOI 10.1016/S0965-1748(03)00022-5; Betz FS, 2000, REGUL TOXICOL PHARM, V32, P156, DOI 10.1006/rtph.2000.1426; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Daniel A, 2002, APPL ENVIRON MICROB, V68, P2106, DOI 10.1128/AEM.68.5.2106-2112.2002; Dorsch JA, 2002, INSECT BIOCHEM MOLEC, V32, P1025, DOI 10.1016/S0965-1748(02)00040-1; Francis BR, 1997, INSECT BIOCHEM MOLEC, V27, P541, DOI 10.1016/S0965-1748(97)00029-5; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; Gomez I, 2003, BIOCHEMISTRY-US, V42, P10482, DOI 10.1021/bi034440p; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Gomez I, 2002, J BIOL CHEM, V277, P30137, DOI 10.1074/jbc.M203121200; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; Hua G, 2004, INSECT BIOCHEM MOLEC, V34, P193, DOI 10.1016/j.ibmb.2003.10.006; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MK, 1996, BIOCHEM BIOPH RES CO, V220, P575, DOI 10.1006/bbrc.1996.0445; Luo K, 1999, APPL ENVIRON MICROB, V65, P457; MASSON L, 1990, BIOCHEM J, V269, P507, DOI 10.1042/bj2690507; Miranda R, 2001, INSECT BIOCHEM MOLEC, V31, P1155, DOI 10.1016/S0965-1748(01)00061-3; Morin S, 2003, P NATL ACAD SCI USA, V100, P5004, DOI 10.1073/pnas.0831036100; Nagamatsu Y, 1998, BIOSCI BIOTECH BIOCH, V62, P718, DOI 10.1271/bbb.62.718; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; Sangadala S, 2001, INSECT BIOCHEM MOLEC, V32, P97, DOI 10.1016/S0965-1748(01)00086-8; Schwartz JL, 1997, FEBS LETT, V412, P270, DOI 10.1016/S0014-5793(97)00801-6; Thomson JM, 1998, BIOTECHNIQUES, V24, P922, DOI 10.2144/98246bm04; Tsuda Y, 2003, BIOCHEM J, V369, P697, DOI 10.1042/BJ20021401; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	29	83	95	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28051	28056		10.1074/jbc.M400237200	http://dx.doi.org/10.1074/jbc.M400237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123702	hybrid			2022-12-27	WOS:000222265400029
J	Kang, D; Mariash, E; Kim, D				Kang, D; Mariash, E; Kim, D			Functional expression of TRESK-2, a new member of the tandem-pore K+ channel family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; POTASSIUM CHANNEL; CLONING; PH; ANESTHETICS; SUBUNITS; TWIK-1; TASK	A new member of the tandem-pore K+ (K-2P) channel family has been isolated from mouse testis complementary DNA. The new K-2P channel was named TRESK-2, as its amino acid sequence shares 65% identity with that of TRESK-1. Mouse TRESK-2 is a 394-amino acid protein and possesses four putative transmembrane segments and two pore-forming domains. TRESK-2 has a long cytoplasmic domain joining the second and third transmembrane segments and a short carboxyl terminus. In the rat, TRESK-2 mRNA transcripts were expressed abundantly in the thymus and spleen and at low levels in many other tissues, including heart, small intestine, skeletal muscle, uterus, testis, and placenta, as judged by Northern blot analysis. TRESK-2 mRNA was also expressed in mouse and human tissues. In COS-7 cells transfected with TRESK-2 DNA, a time-independent and noninactivating K+-selective current was recorded. TRESK-2 was insensitive to 1 mM tetraethylammonium, 100 nM apamin, 1 mM 4-aminopyridine, and 10 muM glybenclamide. TRESK-2 was inhibited by 10 muM quinidine, 20 muM arachidonate and acid ( pH 6.3) at 49, 43, and 23%, respectively. Single channel openings of TRESK-2 showed marked open channel noise. In symmetrical 150 mM KCl, the current-voltage relationship of TRESK-2 was slightly inwardly rectifying, with the single channel conductance 13 picosiemens (pS) at +60 mV and 16 pS at - 60 mV. In inside-out patches, TRESK-2 was unaffected by the intracellular application of 10 muM guanosine 5'-O( thiotriphosphate). These results show that TRESK-2 is a functional member of the K2P channel family and contributes to the background K+ conductance in many types of cells.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Physiol & Biophys, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Kim, D (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Physiol & Biophys, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	donghee.kim@Rosalindfranklin.edu						Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Czirjak B, 2004, J BIOL CHEM, V279, P18550, DOI 10.1074/jbc.M312229200; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Girard C, 2001, BIOCHEM BIOPH RES CO, V282, P249, DOI 10.1006/bbrc.2001.4562; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Han J, 2003, AM J PHYSIOL-CELL PH, V285, pC529, DOI 10.1152/ajpcell.00601.2002; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008; Kim D, 2001, BIOCHEM BIOPH RES CO, V284, P923, DOI 10.1006/bbrc.2001.5064; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 2000, J BIOL CHEM, V275, P28398, DOI 10.1074/jbc.M002822200; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Patel AJ, 2000, J BIOL CHEM, V275, P28722, DOI 10.1074/jbc.M003755200; Pountney DJ, 1999, FEBS LETT, V450, P191, DOI 10.1016/S0014-5793(99)00495-0; Rajan S, 2001, J BIOL CHEM, V276, P7302, DOI 10.1074/jbc.M008985200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Sano Y, 2003, J BIOL CHEM, V278, P27406, DOI 10.1074/jbc.M206810200; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	31	71	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28063	28070		10.1074/jbc.M402940200	http://dx.doi.org/10.1074/jbc.M402940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123670	hybrid			2022-12-27	WOS:000222265400031
J	Ueda, K; Nakamura, K; Hayashi, T; Inagaki, N; Takahashi, M; Arimura, T; Morita, H; Higashiuesato, Y; Hirano, Y; Yasunami, M; Takishita, S; Yamashina, A; Ohe, T; Sunamori, M; Hiraoka, M; Kimura, A				Ueda, K; Nakamura, K; Hayashi, T; Inagaki, N; Takahashi, M; Arimura, T; Morita, H; Higashiuesato, Y; Hirano, Y; Yasunami, M; Takishita, S; Yamashina, A; Ohe, T; Sunamori, M; Hiraoka, M; Kimura, A			Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; PACEMAKER CHANNELS; I-KR; MOLECULAR CHARACTERIZATION; VENTRICULAR-FIBRILLATION; ACTION-POTENTIALS; SINOATRIAL NODE; SODIUM-CHANNEL; SYNDROME GENES; SCN5A	Hyperpolarization-activated cyclic nucleotide-gated channel 4 gene HCN4 is a pacemaker channel that plays a key role in automaticity of sinus node in the heart, and an HCN4 mutation was reported in a patient with sinus node dysfunction. Expression of HCN4 in the heart is, however, not confined to the sinus node cells but is found in other tissues, including cells of the conduction system. On the other hand, mutations in another cardiac ion channel gene, SCN5A, also cause sinus node dysfunction as well as other cardiac arrhythmias, including long QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, and progressive cardiac conduction disturbance. These observations imply that HCN4 abnormalities may be involved in the pathogenesis of various arrhythmias, similar to the SCN5A mutations. In this study, we analyzed patients suffering from sinus node dysfunction, progressive cardiac conduction disease, and idiopathic ventricular fibrillation for mutations in HCN4. A missense mutation, D553N, was found in a patient with sinus node dysfunction who showed recurrent syncope, QT prolongation in electrocardiogram, and polymorphic ventricular tachycardia, torsade de pointes. In vitro functional study of the D553N mutation showed a reduced membranous expression associated with decreased If currents because of a trafficking defect of the HCN4 channel in a dominant-negative manner. These data suggest that the loss of function of HCN4 is associated with sinus nodal dysfunction and that a consequence of pacemaker channel abnormality might underlie clinical features of QT prolongation and polymorphic ventricular tachycardia developed under certain conditions.	Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pathogenesis, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Lab Genome Divers, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Inst Med Res, Dept Cardiovasc Dis, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Thorac & Cardiovasc Surg, Tokyo 1010062, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Cardiovasc Med, Okayama 7008558, Japan; Tokyo Med Univ, Dept Internal Med 2, Tokyo 1608402, Japan; Univ Ryukyus, Fac Med, Dept Internal Med 3, Okinawa 9030215, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Okayama University; Tokyo Medical University; University of the Ryukyus	Kimura, A (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pathogenesis, Chiyoda Ku, 2-3-10 Kandasurugadai, Tokyo 1010062, Japan.	akitis@mri.tmd.ac.jp	Kimura, Akinori/I-5989-2018; Arimura, Takuro/AAA-2745-2022	Kimura, Akinori/0000-0002-4933-2132; Arimura, Takuro/0000-0002-0929-3140				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Akai J, 2000, FEBS LETT, V479, P29, DOI 10.1016/S0014-5793(00)01875-5; Benson DW, 2003, J CLIN INVEST, V112, P1019, DOI 10.1172/JCI200318062; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; BRACHMANN J, 1983, CIRCULATION, V68, P846, DOI 10.1161/01.CIR.68.4.846; Bucchi A, 2002, J GEN PHYSIOL, V120, P1, DOI 10.1085/jgp.20028593; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; KURITA T, 1992, AM J CARDIOL, V69, P628, DOI 10.1016/0002-9149(92)90154-Q; Lees-Miller JP, 2003, MOL CELL BIOL, V23, P1856, DOI 10.1128/MCB.23.6.1856-1862.2003; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Marban E, 2002, NATURE, V415, P213, DOI 10.1038/415213a; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; NISHI H, 1992, BIOCHEM BIOPH RES CO, V188, P379, DOI 10.1016/0006-291X(92)92396-F; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Priori SG, 2001, CIRCULATION, V103, P196; RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857; Schulze-Bahr E, 2003, J CLIN INVEST, V111, P1537, DOI 10.1172/JCI200316387; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Thollon C, 1997, EUR J PHARMACOL, V339, P43, DOI 10.1016/S0014-2999(97)01364-2; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Zaza A, 1997, J PHYSIOL-LONDON, V505, P677, DOI 10.1111/j.1469-7793.1997.677ba.x; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	37	160	176	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27194	27198		10.1074/jbc.M311953200	http://dx.doi.org/10.1074/jbc.M311953200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15123648	hybrid			2022-12-27	WOS:000222120400046
J	Toledo, MS; Suzuki, E; Handa, K; Hakomori, S				Toledo, MS; Suzuki, E; Handa, K; Hakomori, S			Cell growth regulation through GM3-enriched microdomain (glycosynapse) in human lung embryonal fibroblast WI38 and its oncogenic transformant VA13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDE-MEDIATED MODULATION; DENSITY-DEPENDENT REGULATION; METASTASIS SUPPRESSOR GENE; PROTEIN-TYROSINE KINASE; CAVEOLAE-LIKE DOMAINS; MELANOMA B16 CELLS; SIGNAL-TRANSDUCTION; BETA-CATENIN; GM3 GANGLIOSIDE; DOWN-REGULATION	Cell growth control mechanisms were studied based on organization of components in glycosphingolipid-enriched microdomain ( GEM) in WI38 cells versus their oncogenic transformant VA13 cells. Levels of fibroblast growth factor receptor ( FGFR) and cSrc were 4 times and 2 - 3 times higher, respectively, in VA13 than in WI38 GEM, whereas the level of tetraspanin CD9/CD81 was 3 - 5 times higher in WI38 than in VA13 GEM. Csk, the physiological inhibitor of cSrc, was present in WI38 but not in VA13 GEM. Functional association of GEM components in control of cell growth in WI38 is indicated by several lines of evidence. (i) Confluent, growth-inhibited WI38 showed a lower degree of FGF-induced MAPK activation than actively growing cells in sparse culture. (ii) The level of inactive cSrc ( with Tyr-527 phosphate) was higher in confluent cells than in actively growing cells. Both processes i and ii were inhibited by GM3 since they were enhanced by GM3 depletion with D-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4). (iii) The high level of inactive cSrc associated with growth-inhibited cells was caused by coexisting Csk in WI38 GEM. (iv) Interaction of GM3 with FGFR was demonstrated by binding of GM3 to FGFR in the GEM fraction, as probed with GM3-coated beads, and by confocal microscopy. In contrast to WI38, both cSrc and MAPK in VA13 were strongly activated regardless of FGF stimulation or GM3 depletion by P4. Continuous, constitutive activation of both cSrc and MAPK was due to ( i) a much higher level of cSrc and FGFR in VA13 than in WI38 GEM, ( ii) their close association/ interaction in VA13 GEM as indicated by clear coimmunoprecipitation between cSrc and FGFR, and ( iii) the absence of Csk in VA13 GEM, making GEM incapable of inhibiting cSrc activation.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu	de Toledo, Marcos Sergio/M-7185-2019; Suzuki, Erika/B-3456-2008; Toledo, Marcos S/B-6243-2008	de Toledo, Marcos Sergio/0000-0002-6605-0874; Suzuki, Erika/0000-0002-4010-8716; 	NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 80054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; ABERCROMBIE M, 1962, CANCER RES, V22, P525; Anderson RGW, 2003, TRENDS CELL BIOL, V13, P534, DOI 10.1016/j.tcb.2003.08.007; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bagnato C, 2003, J BIOL CHEM, V278, P52203, DOI 10.1074/jbc.M305760200; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; Gagnoux-Palacios L, 2003, J CELL BIOL, V162, P1189, DOI 10.1083/jcb.200305006; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; Gospodarowicz D, 1979, Recent Prog Horm Res, V35, P375; GRANZER E, 1964, H-S Z PHYSIOL CHEM, V337, P52, DOI 10.1515/bchm2.1964.337.1.52; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAKOMORI SI, 1970, P NATL ACAD SCI USA, V67, P1741, DOI 10.1073/pnas.67.4.1741; Handa K, 2001, BIOCHEM BIOPH RES CO, V285, P788, DOI 10.1006/bbrc.2001.5225; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HOLLEY RW, 1977, P NATL ACAD SCI USA, V74, P5046, DOI 10.1073/pnas.74.11.5046; HOLLEY RW, 1972, P NATL ACAD SCI USA, V69, P2840, DOI 10.1073/pnas.69.10.2840; Hollmann CA, 2001, ONCOGENE, V20, P7645, DOI 10.1038/sj.onc.1204980; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Loo BM, 2002, J BIOL CHEM, V277, P32616, DOI 10.1074/jbc.M204961200; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ono M, 1999, CANCER RES, V59, P2335; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; SAKIYAMA H, 1972, P NATL ACAD SCI USA, V69, P872, DOI 10.1073/pnas.69.4.872; Satoh M, 2001, INT J ONCOL, V19, P723; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sekimoto H, 2003, ENDOCRINOLOGY, V144, P2546, DOI 10.1210/en.2003-0187; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Sorice M, 1997, J LIPID RES, V38, P969; Trembacz H, 2002, CELL MOL BIOL LETT, V7, P1047; Vukelic Z, 2001, GLYCOCONJUGATE J, V18, P429, DOI 10.1023/A:1016066816457; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x; Zhang LF, 2002, CARCINOGENESIS, V23, P1251, DOI 10.1093/carcin/23.7.1251	63	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34655	34664		10.1074/jbc.M403857200	http://dx.doi.org/10.1074/jbc.M403857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15143068	hybrid			2022-12-27	WOS:000223134800070
J	Schweinitz, A; Steinmetzer, T; Banke, IJ; Arlt, MJE; Sturzebecher, A; Schuster, O; Geissler, A; Giersiefen, H; Zeslawska, E; Jacob, U; Kruger, A; Sturzebecher, J				Schweinitz, A; Steinmetzer, T; Banke, IJ; Arlt, MJE; Sturzebecher, A; Schuster, O; Geissler, A; Giersiefen, H; Zeslawska, E; Jacob, U; Kruger, A; Sturzebecher, J			Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITORS; SMALL-MOLECULE INHIBITORS; THROMBIN INHIBITORS; TUMOR INVASION; GROWTH-FACTOR; CANCER-CELLS; METASTASIS; RECEPTOR; BINDING; SYSTEM	The serine protease urokinase-type plasminogen activator (uPA) interacts with a specific receptor ( uPAR) on the surface of various cell types, including tumor cells, and plays a crucial role in pericellular proteolysis. High levels of uPA and uPAR often correlate with poor prognosis of cancer patients. Therefore, the specific inhibition of uPA with small molecule active-site inhibitors is one strategy to decrease the invasive and metastatic activity of tumor cells. We have developed a series of highly potent and selective uPA inhibitors with a C-terminal 4-amidinobenzylamide residue. Optimization was directed toward reducing the fast elimination from circulation that was observed with initial analogues. The x-ray structures of three inhibitor/uPA complexes have been solved and were used to improve the inhibition efficacy. One of the most potent and selective derivatives, benzylsulfonyl-D-Ser-Ser- 4-amidinobenzylamide ( inhibitor 26), inhibits uPA with a K-i of 20 nM. This inhibitor was used in a fibrosarcoma model in nude mice using lacZ-tagged human HT1080 cells, to prevent experimental lung metastasis formation. Compared with control (100%), an inhibitor dose of 2 x 1.5 mg/kg/day reduced the number of experimental metastases to 4.6 +/- 1%. Under these conditions inhibitor 26 also significantly prolonged survival. All mice from the control group died within 43 days after tumor cell inoculation, whereas 50% of mice from the inhibitor-treated group survived more than 117 days. This study demonstrates that the specific inhibition of uPA by these inhibitors may be a useful strategy for the treatment of cancer to prevent metastasis.	Curacyte Chem GmbH, D-07745 Jena, Germany; Tech Univ Munich, Inst Expt Onkol & Therapieforsch, D-81675 Munich, Germany; Curacyte AG, D-80339 Munich, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Univ Jena Klinikum, Zentrum Vaskulare Biol & Med, D-99089 Erfurt, Germany	Technical University of Munich; Max Planck Society; Friedrich Schiller University of Jena	Steinmetzer, T (corresponding author), Curacyte Chem GmbH, Winzerlaer Str 2, D-07745 Jena, Germany.	torsten.steinmetzer@curacyte.com		Zeslawska, Ewa/0000-0003-1946-9370				Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; ARNOLD RT, 1948, J AM CHEM SOC, V70, P2590, DOI 10.1021/ja01187a088; Banke IJ, 2003, BIOL CHEM, V384, P1515, DOI 10.1515/BC.2003.168; Collen D, 2001, Hematology Am Soc Hematol Educ Program, P1; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Dullweber F, 2001, J MOL BIOL, V313, P593, DOI 10.1006/jmbi.2001.5062; Edwards DR, 1996, EXP GERONTOL, V31, P207, DOI 10.1016/0531-5565(95)02010-1; Eriksson H, 1999, THROMB HAEMOSTASIS, V81, P358; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; Gustafsson D, 1998, THROMB HAEMOSTASIS, V79, P110; Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T; Harbeck Nadia, 2002, Clin Breast Cancer, V3, P196, DOI 10.3816/CBC.2002.n.023; Hauptmann J, 2002, PHARM RES-DORDR, V19, P1027, DOI 10.1023/A:1016426724831; Jankun J, 2001, INT J MOL MED, V8, P365; Judkins BD, 1996, SYNTHETIC COMMUN, V26, P4351, DOI 10.1080/00397919608003838; KAISER B, 1987, PHARMAZIE, V42, P119; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KIRCHHEIMER JC, 1989, EUR J BIOCHEM, V181, P103, DOI 10.1111/j.1432-1033.1989.tb14699.x; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; Klinghofer V, 2001, BIOCHEMISTRY-US, V40, P9125, DOI 10.1021/bi010186u; Kruger A, 1998, CANCER METAST REV, V17, P285, DOI 10.1023/A:1006066706040; Kunzel S, 2002, BIOORG MED CHEM LETT, V12, P645, DOI 10.1016/S0960-894X(01)00815-0; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Mammoto T, 2002, CANCER LETT, V184, P165, DOI 10.1016/S0304-3835(02)00210-0; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Ossowski L, 1996, BRAZ J MED BIOL RES, V29, P1099; Pallottini V, 2002, IUBMB LIFE, V54, P301, DOI 10.1080/15216540215672; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Praus M, 2002, INT J CANCER, V102, P584, DOI 10.1002/ijc.10767; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Renwinkel JBM, 1999, CURR PHARM DESIGN, V5, P1043; Reuning U, 2003, BIOL CHEM, V384, P1119, DOI 10.1515/BC.2003.125; Reuning U, 1998, INT J ONCOL, V13, P893; Rockway TW, 2003, EXPERT OPIN THER PAT, V13, P773, DOI 10.1517/eotp.13.6.773.23017; Rockway TW, 2002, CURR PHARM DESIGN, V8, P2541, DOI 10.2174/1381612023392676; ROWLAND M, 1995, CLIN PHARMACOKINET, P315; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schmitt M, 2000, FIBRINOLYSIS PROTEOL, V14, P114, DOI 10.1054/fipr.2000.0079; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Sier CFM, 1998, CANCER RES, V58, P1843; Steinmetzer T, 2001, EXPERT OPIN INV DRUG, V10, P845, DOI 10.1517/13543784.10.5.845; Steinmetzer T, 2003, IDRUGS, V6, P138; Sturzebecher J, 1999, BIOORG MED CHEM LETT, V9, P3147, DOI 10.1016/S0960-894X(99)00541-7; Sturzebecher J, 1997, J MED CHEM, V40, P3091, DOI 10.1021/jm960668h; Tucker TJ, 1997, J MED CHEM, V40, P830, DOI 10.1021/jm960762y; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Zeslawska E, 2000, J MOL BIOL, V301, P465, DOI 10.1006/jmbi.2000.3966; Zeslawska E, 2003, J MOL BIOL, V328, P109, DOI 10.1016/S0022-2836(03)00267-5; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	55	119	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33613	33622		10.1074/jbc.M314151200	http://dx.doi.org/10.1074/jbc.M314151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15150279	hybrid			2022-12-27	WOS:000223039700070
J	Palaniyar, N; Nadesalingam, J; Clark, H; Shih, MJ; Dodds, AW; Reid, KBM				Palaniyar, N; Nadesalingam, J; Clark, H; Shih, MJ; Dodds, AW; Reid, KBM			Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannose-binding lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-DNA; BRONCHOALVEOLAR LAVAGE; CYSTIC-FIBROSIS; IN-VITRO; ASPERGILLUS-FUMIGATUS; CRYSTAL-STRUCTURE; APOPTOTIC CELLS; CPG MOTIFS; CLEARANCE; C1Q	Collectins are a family of innate immune proteins that contain fibrillar collagen-like regions and globular carbohydrate recognition domains (CRDs). The CRDs of these proteins recognize various microbial surface-specific carbohydrate patterns, particularly hexoses. We hypothesized that collectins, such as pulmonary surfactant proteins (SPs) SP-A and SP-D and serum protein mannose-binding lectin, could recognize nucleic acids, pentose-based anionic phosphate polymers. Here we show that collectins bind DNA from a variety of origins, including bacteria, mice, and synthetic oligonucleotides. Pentoses, such as arabinose, ribose, and deoxyribose, inhibit the interaction between SP-D and mannan, one of the well-studied hexose ligands for SP-D, and biologically relevant D-forms of the pentoses are better competitors than the L-forms. In addition, DNA and RNA polymer-related compounds, such as nucleotide diphosphates and triphosphates, also inhibit the carbohydrate binding ability of SP-D, or similar to60 kDa trimeric recombinant fragments of SP-D that are composed of the alpha-helical coiled-coil neck region and three CRDs (SP-D(n/CRD)) or SP-D(n/CRD) with eight GXY repeats (SPD(GXY)(8)(n/CRD)). Direct binding and competition studies suggest that collectins bind nucleic acid via their CRDs as well as by their collagen-like regions, and that SP-D binds DNA more effectively than do SP-A and mannose-binding lectin at physiological salt conditions. Furthermore, the SP-D(GXY)(8)(n/CRD) fragments co-localize with DNA, and the protein competes the interaction between propidium iodide, a DNA-binding dye, and apoptotic cells. In conclusion, we show that collectins are a new class of proteins that bind free DNA and the DNA present on apoptotic cells by both their globular CRDs and collagen-like regions. Collectins may therefore play an important role in decreasing the inflammation caused by DNA in lungs and other tissues.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Hosp Sick Children, Res Inst, Lung Biol Res Program, Toronto, ON M5G 1X8, Canada	University of Oxford; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Palaniyar, N (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	Nades@bioch.ox.ac.uk		Dodds, Alister William/0000-0003-3396-1257; Clark, Howard/0000-0001-7354-2028; Palaniyar, Nades/0000-0002-2170-8548				Allen MJ, 2001, INFECT IMMUN, V69, P2037, DOI 10.1128/IAI.69.4.2037-2044.2001; Clark H, 2002, J IMMUNOL, V169, P2892, DOI 10.4049/jimmunol.169.6.2892; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; Holmskov UL, 2000, APMIS, V108, P7; JIANG HX, 1992, J BIOL CHEM, V267, P25597; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; Liacos C, 2001, CRIT CARE MED, V29, P2310, DOI 10.1097/00003246-200112000-00013; Lu J, 1993, Behring Inst Mitt, P6; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; McLachlan G, 2000, GENE THER, V7, P384, DOI 10.1038/sj.gt.3301097; Nadesalingam J, 2003, J BIOL CHEM, V278, P25678, DOI 10.1074/jbc.M210186200; Noah TL, 2003, AM J RESP CRIT CARE, V168, P685, DOI 10.1164/rccm.200301-005OC; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Palaniyar N, 1999, J MOL BIOL, V287, P9, DOI 10.1006/jmbi.1999.2586; Palaniyar N, 1998, J STRUCT BIOL, V122, P297, DOI 10.1006/jsbi.1998.4004; Palaniyar N, 1998, BIOCHEM BIOPH RES CO, V250, P131, DOI 10.1006/bbrc.1998.9284; Palaniyar N, 2003, ANN NY ACAD SCI, V1010, P471, DOI 10.1196/annals.1299.085; Palaniyar N, 2003, ANN NY ACAD SCI, V1010, P467, DOI 10.1196/annals.1299.084; Palaniyar N, 2002, IMMUNOBIOLOGY, V205, P575, DOI 10.1078/0171-2985-00156; Palaniyar N, 2000, BIOCHEMISTRY-US, V39, P6310, DOI 10.1021/bi992793b; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; PERSSON A, 1990, J BIOL CHEM, V265, P5755; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; REID KBM, 1982, METHOD ENZYMOL, V82, P319; Ruiz FE, 2001, HUM GENE THER, V12, P751, DOI 10.1089/104303401750148667; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Strong P, 1998, J IMMUNOL METHODS, V220, P139, DOI 10.1016/S0022-1759(98)00160-4; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; Tseng M, 1999, J BIOL CHEM, V274, P21637, DOI 10.1074/jbc.274.31.21637; van de Wetering JK, 2001, J INFECT DIS, V184, P1143, DOI 10.1086/323746; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Whitchurch CB, 2002, SCIENCE, V295, P1487, DOI 10.1126/science.295.5559.1487	48	129	141	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32728	32736		10.1074/jbc.M403763200	http://dx.doi.org/10.1074/jbc.M403763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145932	hybrid			2022-12-27	WOS:000222849700092
J	Valentijn, AJ; Gilmore, AP				Valentijn, AJ; Gilmore, AP			Translocation of full-length bid to mitochondria during anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; FOCAL ADHESION KINASE; PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; CASPASE ACTIVATION; SUBCELLULAR-LOCALIZATION; CONFORMATIONAL-CHANGE; BCL-2 FAMILY; BAX; SURVIVAL	Epithelial cells require adhesion to the extracellular matrix for survival, and in the absence of adhesion they undergo apoptosis (anoikis). This is distinct from apoptosis induced by extracellular death ligands, such as tumor necrosis factor, which result in direct activation of caspase 8. Bid is a member of the BH3-only subfamily of the Bcl-2 proteins and is important for most cell types to apoptose in response to Fas and tumor necrosis factor receptor activation. Caspase 8 cleaves full-length Bid, resulting in truncated p15 tBid. p15 tBid is potently apoptotic and activates the multidomain Bcl-2 protein, Bax, resulting in release of cytochrome c from mitochondria. We have previously shown that Bax rapidly translocates from the cytosol to mitochondria following loss of adhesion and that this is required for anoikis. We have now examined the role of Bid in anoikis. Bid translocates to mitochondria with identical kinetics as Bax. Although Bid is required for anoikis, it does not require proteolytic cleavage by caspase 8. Furthermore, it does not require Bid to interact directly with other Bcl-2 family proteins, such as Bax. Our data indicate that Bid is important for regulating apoptosis via the intrinsic pathway and has implications for how Bid may fulfill that role.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Gilmore, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, A-3034 Smith Bldg, Manchester M13 9PT, Lancs, England.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bouillet P, 2002, J CELL SCI, V115, P1567; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Ilic D, 1998, J CELL BIOL, V143, P547; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rehm M, 2003, J CELL BIOL, V162, P1031, DOI 10.1083/jcb.200303123; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	54	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32848	32857		10.1074/jbc.M313375200	http://dx.doi.org/10.1074/jbc.M313375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15148322	hybrid			2022-12-27	WOS:000222849700105
J	Yin, P; Xu, QJ; Duan, CM				Yin, P; Xu, QJ; Duan, CM			Paradoxical actions of endogenous and exogenous insulin-like growth factor-binding protein-5 revealed by RNA interference analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; SMOOTH-MUSCLE-CELLS; HORMONE-RELATED PROTEIN; FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; INCREASED EXPRESSION; PROSTATE REGRESSION; MOLECULAR-CLONING; INDUCED APOPTOSIS; EPITHELIAL-CELLS	Insulin-like growth factor-binding protein-5 (IGFBP5) is abundantly expressed in bone cells. To determine the physiological role(s) of endogenous IGFBP-5 in regulating bone cell growth, differentiation, and survival, we used short double-stranded RNA ( siRNA) to trigger RNA interference of IGFBP-5 in human osteosarcoma cells. The IGFBP-5 siRNA, targeting against a sequence unique to the IGFBP-5 middle domain, efficiently reduced IGFBP-5 mRNA and protein levels. The IGFBP-5 siRNA did not change the levels of IGFBP-4, a structurally related protein, or glyceraldehyde-3-phosphate dehydrogenase, a housekeeping gene. Knock-down of IGFBP-5 resulted in a significant increase in the number of transferase-mediated dUTP nick end labeling-positive cells and a decrease in a bone differentiation parameter (alkaline phosphatase activity) but had little effect on basal or insulin-like growth factor I-induced proliferation. Overexpression of a siRNA-resistant IGFBP-5 mutant in the IGFBP-5 knock-down cells restored the levels of survival to the control level; overexpression of IGFBP-4 or wild type IGFBP-5 had no such effect. Paradoxically, the addition of exogenous IGFBP5 not only failed to rescue IGFBP-5 knock-down-induced apoptosis, it caused a further increase in apoptosis. Furthermore, the addition of exogenous IGFBP-5 alone increased apoptosis. This pro-apoptotic action of exogenous IGFBP-5 was abolished when IGF-I was added in excess, suggesting that exogenous IGFBP-5 increases apoptosis by binding to and inhibiting the activities of insulin-like growth factors. These results indicate that endogenous and exogenous IGFBP-5 exhibits opposing biological actions on cell survival and underscore the necessity and utility of studying IGFBP functions through loss-of-function approaches.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu	Xu, Qijin/B-2680-2009	Xu, Qijin/0000-0003-0521-9039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL60679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Andress DL, 2001, AM J PHYSIOL-ENDOC M, V281, pE283, DOI 10.1152/ajpendo.2001.281.2.E283; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; Cobb LJ, 2004, J CELL SCI, V117, P1737, DOI 10.1242/jcs.01028; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; Devlin RD, 2002, ENDOCRINOLOGY, V143, P3955, DOI 10.1210/en.2002-220129; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; Duan CM, 1999, P NATL ACAD SCI USA, V96, P15274, DOI 10.1073/pnas.96.26.15274; Duan CM, 1996, J BIOL CHEM, V271, P4280; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Flint DJ, 1997, J MAMMARY GLAND BIOL, V2, P41, DOI 10.1023/A:1026321529451; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; JAMES PL, 1993, J BIOL CHEM, V268, P22305; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KOU K, 1994, GENOMICS, V20, P412, DOI 10.1006/geno.1994.1195; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Massfelder T, 2001, FASEB J, V15, P707, DOI 10.1096/fj.00-0053com; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; McCaig C, 2002, J CELL BIOCHEM, V84, P784, DOI 10.1002/jcb.10093; Meadows KA, 2000, J CELL PHYSIOL, V183, P330, DOI 10.1002/(SICI)1097-4652(200006)183:3<330::AID-JCP5>3.0.CO;2-N; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nickerson T, 1999, UROLOGY, V54, P1120, DOI 10.1016/S0090-4295(99)00421-5; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Nickerson T, 1999, J ENDOCRINOL, V160, P223, DOI 10.1677/joe.0.1600223; OKAZAKI R, 1995, J BONE MINER RES, V10, P788; Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680; Perks CM, 1999, J CELL BIOCHEM, V75, P652, DOI 10.1002/(SICI)1097-4644(19991215)75:4<652::AID-JCB11>3.0.CO;2-0; Richman C, 1999, ENDOCRINOLOGY, V140, P4699, DOI 10.1210/en.140.10.4699; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schmid C., 1995, Progress in Growth Factor Research, V6, P167, DOI 10.1016/0955-2235(95)00037-2; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Schneider MR, 2001, BIOCHEM BIOPH RES CO, V288, P435, DOI 10.1006/bbrc.2001.5785; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; Shimizu M, 2003, GEN COMP ENDOCR, V132, P103, DOI 10.1016/S0016-6480(03)00052-2; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 2000, ADV EXP MED BIOL, V480, P45; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Xu QJ, 2004, CIRC RES, V94, pE46, DOI 10.1161/01.RES.0000124761.62846.DF; Xu QJ, 2004, J BIOL CHEM, V279, P4269, DOI 10.1074/jbc.M311586200	49	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32660	32666		10.1074/jbc.M401378200	http://dx.doi.org/10.1074/jbc.M401378200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155755	hybrid			2022-12-27	WOS:000222849700084
J	Anderson, KA; Noeldner, PK; Reece, K; Wadzinski, BE; Means, AR				Anderson, KA; Noeldner, PK; Reece, K; Wadzinski, BE; Means, AR			Regulation and function of the calcium/calmodulin-dependent protein kinase IV/protein serine/threonine phosphatase 2A signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; MOLECULAR-CLONING; ACTIVATION; CALMODULIN; IV; CALCIUM; PHOSPHORYLATION; IDENTIFICATION; TRANSCRIPTION; EXPRESSION	Calcium/calmodulin-dependent protein kinase IV (CaMKIV) is a member of the broad substrate specificity class of Ca2+/calmodulin (CaM)-dependent protein kinases and functions as a potent stimulator of Ca2+-dependent gene expression. Activation of CaMKIV is a transient, tightly regulated event requiring both Ca2+/ CaM binding and phosphorylation of the kinase on T200 by an upstream CaMK kinase ( CaMKK). Previously, CaMKIV was shown to stably associate with protein serine/ threonine phosphatase 2A (PP2A), which was proposed to play a role in negatively regulating the kinase. Here we report that the Ca2+/CaM binding-autoinhibitory domain of CaMKIV is required for association of the kinase with PP2A and that binding of PP2A and Ca2+/ CaM appears to be mutually exclusive. We demonstrate that inhibition of the CaMKIV/PP2A association in cells results in enhanced CaMKIV-mediated gene transcription that is independent of Ca2+/CaM. The enhanced transcriptional activity correlates with the elevated level of phospho-T200 that accumulates when CaMKIV is prevented from interacting with PP2A. Collectively, these data suggest a molecular basis for the sequential activation and inactivation of CaMKIV. First, in response to an increase in intracellular Ca2+, CaMKIV binds Ca2+/CaM and becomes phosphorylated on T200 by CaMKK. These events result in the generation of autonomous activity required for CaMKIV-mediated transcriptional regulation. The CaMKIV-associated PP2A then dephosphorylates CaMKIV T200, thereby terminating autonomous activity and CaMKIV-mediated gene transcription.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Duke University; Vanderbilt University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	means001@mc.duke.edu			NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM-51366, GM-33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R56GM051366, R01GM033976] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Anderson KA, 2002, MOL CELL BIOL, V22, P23, DOI 10.1128/MCB.22.1.23-29.2002; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Anderson KA, 1998, BIOMETALS, V11, P331, DOI 10.1023/A:1009276932076; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Boudreau RTM, 2002, J BIOL CHEM, V277, P5322, DOI 10.1074/jbc.M108623200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Heist EK, 1998, CELL CALCIUM, V23, P103; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; Pawson T, 2000, GENE DEV, V14, P1027; Raman V, 2001, J IMMUNOL, V167, P6270, DOI 10.4049/jimmunol.167.11.6270; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Wu JY, 2001, MOL CELL BIOL, V21, P6066, DOI 10.1128/MCB.21.17.6066-6070.2001; Yokoyama N, 2003, ARCH BIOCHEM BIOPHYS, V417, P87, DOI 10.1016/S0003-9861(03)00333-3	40	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31708	31716		10.1074/jbc.M404523200	http://dx.doi.org/10.1074/jbc.M404523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143065	hybrid			2022-12-27	WOS:000222726800096
J	Itoh, T; Akao, S; Hashimoto, W; Mikami, B; Murata, K				Itoh, T; Akao, S; Hashimoto, W; Mikami, B; Murata, K			Crystal structure of unsaturated glucuronyl hydrolase, responsible for the degradation of glycosaminoglycan, from Bacillus sp GL1 at 1.8 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN AC LYASE; POLYSACCHARIDE DEPOLYMERIZATION; HYALURONATE LYASE; MICROBIAL SYSTEM; DIFFRACTION DATA; ENZYMATIC ROUTE; COMPLEX; FAMILY; GLUCOAMYLASE; MECHANISM	Unsaturated glucuronyl hydrolase (UGL) is a novel glycosaminoglycan hydrolase that releases unsaturated D-glucuronic acid from oligosaccharides produced by polysaccharide lyases. The x-ray crystallographic structure of UGL from Bacillus sp. GL1 was first determined by multiple isomorphous replacement (mir) and refined at 1.8 Angstrom resolution with a final R-factor of 16.8% for 25 to 1.8 Angstrom resolution data. The refined UGL structure consists of 377 amino acid residues and 478 water molecules, four glycine molecules, two dithiothreitol (DTT) molecules, and one 2-methyl-2,4-pentanediol (MPD) molecule. UGL includes an alpha(6)/alpha(6)-barrel, whose structure is found in the six-hairpin enzyme superfamily of an alpha/alpha-toroidal fold. One side of the UGL alpha(6)/ alpha(6)-barrel structure consists of long loops containing three short beta-sheets and contributes to the formation of a deep pocket. One glycine molecule and two DTT molecules surrounded by highly conserved amino acid residues in UGLs were found in the pocket, suggesting that catalytic and substrate-binding sites are located in this pocket. The overall UGL structure, with the exception of some loops, very much resembled that of the Bacillus subtilis hypothetical protein Yter, whose function is unknown and which exhibits little amino acid sequence identity with UGL. In the active pocket, residues possibly involved in substrate recognition and catalysis by UGL are conserved in UGLs and Yter. The most likely candidate catalytic residues for glycosyl hydrolysis are Asp(88) and Asp(149). This was supported by site-directed mutagenesis studies in Asp(88) and Asp(149).	Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Mikami, B (corresponding author), Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Kyoto 6110011, Japan.	mikami@kais.kyoto-u.ac.jp						Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Aleshin AE, 1996, BIOCHEMISTRY-US, V35, P8319, DOI 10.1021/bi960321g; Aleshin AE, 2003, J MOL BIOL, V327, P61, DOI 10.1016/S0022-2836(03)00084-6; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOULNOIS GJ, 1992, J GEN MICROBIOL, V138, P249, DOI 10.1099/00221287-138-2-249; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Hashimoto W, 1997, ARCH BIOCHEM BIOPHYS, V339, P17, DOI 10.1006/abbi.1996.9851; Hashimoto W, 2003, J BIOL CHEM, V278, P7663, DOI 10.1074/jbc.M208100200; Hashimoto W, 1999, ARCH BIOCHEM BIOPHYS, V368, P367, DOI 10.1006/abbi.1999.1305; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Itoh T, 2000, J MOL BIOL, V303, P733, DOI 10.1006/jmbi.2000.4188; JANSSON PE, 1983, CARBOHYD RES, V124, P135, DOI 10.1016/0008-6215(83)88361-X; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINKER A, 1955, J BIOL CHEM, V213, P237; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mori S, 2003, PROTEIN EXPRES PURIF, V29, P77, DOI 10.1016/S1046-5928(03)00019-6; Mori S, 2003, ACTA CRYSTALLOGR D, V59, P946, DOI 10.1107/S0907444903005912; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nankai H, 1999, APPL ENVIRON MICROB, V65, P2520; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsiegla G, 2000, BIOCHEMISTRY-US, V39, P11238, DOI 10.1021/bi001139p; Parsiegla G, 2002, BIOCHEMISTRY-US, V41, P11134, DOI 10.1021/bi025816m; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; Sawitzky D, 1996, MED MICROBIOL IMMUN, V184, P155, DOI 10.1007/BF02456129; SCOTT JE, 1995, J ANAT, V187, P259; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P854, DOI 10.1107/S0907444998002005; Van Petegem F, 2003, J BIOL CHEM, V278, P7531, DOI 10.1074/jbc.M206862200; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; Yoon HJ, 1999, J MOL BIOL, V290, P505, DOI 10.1006/jmbi.1999.2883	53	33	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31804	31812		10.1074/jbc.M403288200	http://dx.doi.org/10.1074/jbc.M403288200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148314	hybrid			2022-12-27	WOS:000222726800107
J	Kato, T; Sakamoto, E; Kutsuna, H; Kimura-Eto, A; Hato, F; Kitagawa, S				Kato, T; Sakamoto, E; Kutsuna, H; Kimura-Eto, A; Hato, F; Kitagawa, S			Proteolytic conversion of STAT3 alpha to STAT3 gamma in human neutrophils - Role of granule-derived serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MYELOID-LEUKEMIA BLASTS; SIGNAL TRANSDUCER; G-CSF; GRANULOCYTIC DIFFERENTIATION; POLYMORPHONUCLEAR LEUKOCYTES; TRANSCRIPTION PROTEINS; HUMAN MONOCYTES; STAT3; ALPHA	Four isoforms (alpha, beta, gamma, and delta) have been identified for signal transducer and activator of transcription 3 (STAT3). It has been reported that STAT3gamma, which is derived from STAT3alpha by limited proteolysis during granulocytic differentiation, is a major STAT3 isoform expressed in human neutrophils. We confirmed that STAT3gamma was a major STAT3 isoform detected in human neutrophil lysates prepared with the conventional lysis buffer. The enzymes capable of converting STAT3alpha to STAT3gamma in vitro were localized in neutrophil granule fraction and were released into the medium upon ionomycin stimulation. The enzyme activity was strongly inhibited by phenylmethylsulfonyl fluoride, CuSO4, and ONO-5046 ( a specific inhibitor of neutrophil elastase), but not by aprotinin, leupeptin, benzamidine, and EDTA. STAT3gamma was effectively generated in vitro from STAT3alpha by limited proteolysis with human neutrophil elastase or proteinase 3 but not cathepsin G. The converting activity in neutrophil lysates was reduced by immunodepletion of elastase but not proteinase 3. Unexpectedly, STAT3gamma was undetected in the lysates of neutrophil-derived cytoplasts, which lack granules, and the cytosol fraction prepared by nitrogen cavitation. The STAT3 isoform detected in these preparations was primarily STAT3alpha. STAT3gamma was also undetected in the lysates of PMSF-pretreated neutrophils and was markedly decreased in the lysates of ionomycin-pretreated neutrophils. These findings indicate that, in contrast to the previous reports, STAT3alpha, but not STAT3gamma, is primarily expressed in human neutrophils, and STAT3gamma is rapidly generated from STAT3alpha by limited proteolysis with granule-derived serine proteases during preparation of neutrophil lysates with the conventional lysis buffer.	Osaka City Univ, Sch Med, Dept Physiol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Sch Med, Dept Dermatol, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University; Osaka Metropolitan University	Kitagawa, S (corresponding author), Osaka City Univ, Sch Med, Dept Physiol, Abeno Ku, Asahi Machi, Osaka 5458585, Japan.	kitagawas@med.osaka-cu.ac.jp						Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BRITZ ML, 1981, AUST J EXP BIOL MED, V59, P63, DOI 10.1038/icb.1981.3; Chakraborty A, 1998, J LEUKOCYTE BIOL, V64, P675, DOI 10.1002/jlb.64.5.675; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Hevehan DL, 2002, BLOOD, V99, P1627, DOI 10.1182/blood.V99.5.1627; KAWABATA K, 1991, BIOCHEM BIOPH RES CO, V177, P814, DOI 10.1016/0006-291X(91)91862-7; Kjeldsen L, 1999, J IMMUNOL METHODS, V232, P131, DOI 10.1016/S0022-1759(99)00171-4; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; Nishiki S, 2004, AM J PHYSIOL-CELL PH, V286, pC1302, DOI 10.1152/ajpcell.00387.2003; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; Sakamoto C, 2003, INT J HEMATOL, V77, P60, DOI 10.1007/BF02982604; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Suzuki K, 1999, BLOOD, V93, P341, DOI 10.1182/blood.V93.1.341.401k09_341_349; Suzuki K, 2001, J IMMUNOL, V166, P1185, DOI 10.4049/jimmunol.166.2.1185; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Xia Z, 2001, CANCER RES, V61, P1747; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; YUO A, 1992, BLOOD, V79, P1553	24	31	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31076	31080		10.1074/jbc.M400637200	http://dx.doi.org/10.1074/jbc.M400637200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145953	hybrid			2022-12-27	WOS:000222726800022
J	Lefevre, G; Glotin, AL; Calipel, A; Mouriaux, F; Tran, T; Kherrouche, Z; Maurage, CA; Auclair, C; Mascarelli, F				Lefevre, G; Glotin, AL; Calipel, A; Mouriaux, F; Tran, T; Kherrouche, Z; Maurage, CA; Auclair, C; Mascarelli, F			Roles of stem cell factor/c-kit and effects of Glivec (R)/STI571 in human uveal melanoma cell tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE INHIBITOR; OF-FUNCTION MUTATIONS; C-KIT; LUNG-CANCER; BRAF GENE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; AUTOCRINE GROWTH; PROTEIN-KINASES	The B-Raf(V599E)-mediated constitutive activation of ERK1/2 is involved in establishing the transformed phenotype of some uveal melanoma cells (Calipel, A., Lefevre, G., Pouponnot, C., Mouriaux, F., Eychene, A., and Mascarelli, F. (2003) J. Biol. Chem. 278, 42409 42418). We have shown that stem cell factor (SCF) is involved in the proliferation of normal uveal melanocytes and that c-Kit is expressed in 75% of primary uveal melanomas. This suggests that the acquisition of autonomous growth during melanoma progression may involve the SCF/c-Kit axis. We used six human uveal melanoma tumor-derived cell lines and normal uveal melanocytes to characterize the SCF/c-Kit system and to assess its specific role in transformation. We investigated the possible roles of activating mutations in c-KIT, the overexpression of this gene, and ligand-dependent c-Kit overactivation in uveal melanoma cell tumorigenesis. Four cell lines (92.1, SP6.5, Mel270, and TP31) expressed both SCF and c-Kit, and none harbored the c-KIT mutations in exons 9, 11, 13, and 17 that have been shown to induce SCF-independent c-Kit activation. Melanoma cell proliferation was strongly inhibited by small interfering RNA-mediated depletion of c-Kit in these cells, despite the presence of B-V599E-Raf in SP6.5 and TP31 cells. We characterized the signaling pathways involved in SCF/c-Kit-mediated cell growth and survival in normal and tumoral melanocytes and found that constitutive ERK1/2 activation played a key role in both the SCF/c-Kit autocrine loop and the gain of function of (EB)-E-V599-Raf for melanoma cell proliferation and transformation. We also provide the first evidence that Glivec(R)/STI571, a c-Kit tyrosine kinase inhibitor, could be used to treat uveal melanomas.	INSERM, U598, Inst Biomed Cordeliers, F-75006 Paris, France; CHU Caen, Serv Ophtalmol, F-14000 Caen, France; AB Sci, F-75008 Paris, France; CNRS, Inst Biol, F-59000 Lille, France; Fac Med, Serv Anat Pathol, F-59000 Lille, France; Fac Med, Serv Commun Morphol Cellulaire, F-59000 Lille, France; CNRS, ENS, UMR 8113, F-94235 Cachan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay	Mascarelli, F (corresponding author), INSERM, U598, Inst Biomed Cordeliers, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	KHERROUCHE, Zoulika/L-6549-2019; Mascarelli, Frederic/L-8916-2018; KHERROUCHE, Zoulika/HHN-0213-2022; Mouriaux, Frederic/T-1440-2019					Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brose MS, 2002, CANCER RES, V62, P6997; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Chui X, 1996, BRIT J CANCER, V73, P1233, DOI 10.1038/bjc.1996.236; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DiPaola RS, 1997, CANCER GENE THER, V4, P176; Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919; Fabbro D, 2002, CURR OPIN DRUG DISC, V5, P701; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fiorentini G, 2003, ANN ONCOL, V14, P805, DOI 10.1093/annonc/mdg192; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Heinrich MC, 2002, HUM PATHOL, V33, P484, DOI 10.1053/hupa.2002.124124; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JOURIAUX F, 2003, MELANOMA RES, V13, P161; Kishore K, 1996, AM J OPHTHALMOL, V121, P561, DOI 10.1016/S0002-9394(14)75431-5; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Krystal GW, 1996, CANCER RES, V56, P370; Lefevre G, 2003, ONCOGENE, V22, P8813, DOI 10.1038/sj.onc.1207099; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MATSUDA R, 1993, AM J PATHOL, V142, P339; McGary EC, 2002, CLIN CANCER RES, V8, P3584; Merbs SL, 1999, INVEST OPHTH VIS SCI, V40, P779; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mouriaux F, 2001, EXP EYE RES, V73, P151, DOI 10.1006/exer.2001.1017; Pache M, 2003, VIRCHOWS ARCH, V443, P741, DOI 10.1007/s00428-003-0883-2; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Satyamoorthy K, 2003, CANCER RES, V63, P756; Singh AD, 1996, SEMIN ONCOL, V23, P768; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wardelmann E, 2002, MODERN PATHOL, V15, P125, DOI 10.1038/modpathol.3880504; Weber A, 2003, LAB INVEST, V83, P1771, DOI 10.1097/01.LAB.0000101732.89463.29; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	56	71	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31769	31779		10.1074/jbc.M403907200	http://dx.doi.org/10.1074/jbc.M403907200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145934	hybrid			2022-12-27	WOS:000222726800103
J	Banno, F; Kaminaka, K; Soejima, K; Kokame, K; Miyata, T				Banno, F; Kaminaka, K; Soejima, K; Kokame, K; Miyata, T			Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; VONWILLEBRAND-FACTOR MULTIMERS; MUTATIONS; CLEAVAGE; FAMILY; DOMAIN; PURIFICATION; PROTEOLYSIS; EXPRESSION; INSERTION	Human ADAMTS13 was recently identified as a gene encoding von Willebrand factor-cleaving protease, hADAMTS13. Both congenital and acquired defects in this enzyme can cause thrombotic thrombocytopenic purpura. hADAMTS13 consists of 1,427 amino acid residues and is composed of multiple structural domains including thrombospondin type 1 motifs and CUB domains. To analyze the functional roles of these domains in vivo, we determined the cDNA sequence of the mouse ortholog, mADAMTS13. Unexpectedly, two forms of the mouse Adamts13 gene were isolated that differed in the insertion of an intracisternal A particle (IAP) retrotransposon including a premature stop codon. The IAP insertion was found in BALB/c, C3H/He, C57BL/6, and DBA/2 strains but not in the 129/Sv strain. The outbred ICR strain had either the IAP-free or IAP-inserted allele or both. IAP-free Adamts13 encoded mADAMTS13L, a protein of 1,426 amino acid residues with the same domain organization as hADAMTS13. In contrast, IAP-inserted Adamts13 encoded a C-terminally truncated enzyme, mADAMTS13S, that is comprised of only 1,037 amino acid residues and lacking the C-terminal two thrombospondin type 1 motifs and two CUB domains. Strain specificity was also confirmed by reverse transcription-PCR and Northern blot analyses. Both recombinant mADAMTS13L and mADAMTS13S exhibited von Willebrand factor cleaving activities in vitro. The natural variation in mouse ADAMTS13 should allow for the determination of hitherto unknown functions of its C-terminal domains in vivo.	Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Chemoserotherapeut Res Inst, Res Dept 1, Kumamoto 8691298, Japan	National Cerebral & Cardiovascular Center - Japan	Miyata, T (corresponding author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Osaka 5658565, Japan.	miyata@ri.ncvc.go.jp		Kokame, Koichi/0000-0002-9654-6299				Antoine G, 2003, BRIT J HAEMATOL, V120, P821, DOI 10.1046/j.1365-2141.2003.04183.x; BERNARDO A, 2003, J THROMB HAEMOST, V1, pA405; DENT JA, 1991, J CLIN INVEST, V88, P774, DOI 10.1172/JCI115376; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; Dupressoir A, 1999, J BIOL CHEM, V274, P31068, DOI 10.1074/jbc.274.43.31068; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1996, ANN HEMATOL, V72, P341, DOI 10.1007/s002770050184; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Gwynn B, 1998, MOL CELL BIOL, V18, P6474, DOI 10.1128/MCB.18.11.6474; Johnson KR, 1999, HUM MOL GENET, V8, P645, DOI 10.1093/hmg/8.4.645; KALAFATIS M, 1987, BLOOD, V70, P1577; KESHET E, 1991, ADV CANCER RES, V56, P215; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LAMB BT, 1992, MOL CELL BIOL, V12, P4824, DOI 10.1128/MCB.12.11.4824; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Matsumoto M, 2004, BLOOD, V103, P1305, DOI 10.1182/blood-2003-06-1796; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pimanda JE, 2004, BLOOD, V103, P627, DOI 10.1182/blood-2003-04-1346; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Schneppenheim R, 2003, BLOOD, V101, P1845, DOI 10.1182/blood-2002-08-2399; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Vasicek TJ, 1997, GENETICS, V147, P777; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	33	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30896	30903		10.1074/jbc.M314184200	http://dx.doi.org/10.1074/jbc.M314184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136581	hybrid			2022-12-27	WOS:000222531900124
J	Klenotic, PA; Munier, FL; Marmorstein, LY; Anand-Apte, B				Klenotic, PA; Munier, FL; Marmorstein, LY; Anand-Apte, B			Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) - Implications for macular degenerations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORSBYS-FUNDUS-DYSTROPHY; MUTATION; EXPRESSION; LOCALIZATION; ANGIOGENESIS; ACCUMULATION; PHENOTYPE; GENE	Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a matrix-bound inhibitor of matrix metalloproteinases. Mutations in the Timp-3 gene cause Sorsby fundus dystrophy (SFD), a hereditary macular degenerative disease. The pathogenic mechanisms responsible for the disease phenotype are unknown. In an in vivo quest for binding partners of the TIMP-3 protein in the subretina, we identified epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1, also known as fibulin 3) as a strong interacting protein. The COOH-terminal end of TIMP-3 was involved in the interaction. Interestingly, a missense mutation in EFEMP1 is responsible for another hereditary macular degenerative disease, Malattia Leventinese (ML). Both SFD and ML have strong similarities to age-related macular degeneration (AMD), a major cause of blindness in the elderly population of the Western hemisphere. Our results were supported by significant accumulation and expression overlap of both TIMP-3 and EFEMP1 between the retinal pigment epithelia and Bruch membrane in the eyes of ML and AMD patients. These results provide the first link between two different macular degenerative disease genes and imply the possibility of a common pathogenic mechanism behind different forms of macular degeneration.	Univ Arizona, Dept Ophthalmol & Cell Biol, Tucson, AZ 85711 USA; Cleveland Clin Fdn, Dept Ophthalm Res, Cole Eye Inst, Cleveland, OH 44195 USA; Jules Gonin Eye Hosp, Oculognet Unit, CH-1004 Lausanne, Switzerland; Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	University of Arizona; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Marmorstein, LY (corresponding author), Univ Arizona, Dept Ophthalmol & Cell Biol, Tucson, AZ 85711 USA.	lmarmorstein@oacs01.eyes.arizona.edu; anandab@ccf.org			NATIONAL EYE INSTITUTE [R29EY012109, R01EY016490, R01EY013847] Funding Source: NIH RePORTER; NEI NIH HHS [R29 EY012109, R01 EY016490, R01EY13847, 1 R29 EY12109-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; Blackburn J, 2003, INVEST OPHTH VIS SCI, V44, P4613, DOI 10.1167/iovs.03-0112; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Langton KP, 2000, J BIOL CHEM, V275, P27027; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200; Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361; Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285; Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/PL00008707; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	30	125	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30469	30473		10.1074/jbc.M403026200	http://dx.doi.org/10.1074/jbc.M403026200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123717	hybrid			2022-12-27	WOS:000222531900074
J	Kock, MA; Hew, BE; Bammert, H; Fritzinger, DC; Vogel, CW				Kock, MA; Hew, BE; Bammert, H; Fritzinger, DC; Vogel, CW			Structure and function of recombinant cobra venom factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-ACTIVATING PROTEIN; N-LINKED OLIGOSACCHARIDES; ALTERNATIVE PATHWAY; 3RD COMPONENT; FACTOR-B; BIOCHEMICAL-CHARACTERIZATION; BETA-1H GLOBULIN; C3-C5 CONVERTASE; C3B INACTIVATOR; EXPRESSION	Cobra venom factor (CVF) is the complement-activating protein from cobra venom. It is a structural and functional analog of complement component C3. CVF functionally resembles C3b, the activated form of C3. Like C3b, CVF binds factor B, which is subsequently cleaved by factor D to form the bimolecular complex CVF, Bb. CVF, Bb is a C3/C5 convertase that cleaves both complement components C3 and C5. CVF is a three-chain protein that structurally resembles the C3b degradation product C3c, which is unable to form a C3/C5 convertase. Both C3 and CVF are synthesized as single-chain prepro-proteins. This study reports the recombinant expression of pro-CVF in two insect cell expression systems (baculovirus-infected Sf9 Spodoptera frugiperda cells and stably transfected S2 Drosophila melanogaster cells). In both expression systems pro-CVF is synthesized initially as a single-chain pro-CVF molecule that is subsequently proteolytically processed into a two-chain form of pro-CVF that structurally resembles C3. The C3-like form of pro-CVF can be further proteolytically processed into another two-chain form of pro-CVF that structurally resembles C3b. Unexpectedly, all three forms of pro-CVF exhibit functional activity of mature, natural CVF. Recombinant pro-CVF supports the activation of factor B in the presence of factor D and Mg2+ and depletes serum complement activity like natural CVF. The bimolecular convertase pro-CVF, Bb exhibits both C3 cleaving and C5 cleaving activity. The activity of pro-CVF and the resulting C3/C5 convertase is indistinguishable from CVF and the CVF, Bb convertase. The ability to produce active forms of pro-CVF recombinantly ensures the continued availability of an important research reagent for complement depletion because cobra venom as the source for natural CVF will be increasingly difficult to obtain as the Indian cobra is on the list of endangered species. Experimental systems to express pro-CVF recombinantly will also be invaluable for studies to delineate the structure and function relationship of CVF and its differences from C3 as well as to generate human C3 derivatives with CVF-like function for therapeutic complement depletion ("humanized CVF").	Univ Hawaii Manoa, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA; Univ Hamburg, Dept Biochem & Mol Biol, D-20146 Hamburg, Germany	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Hamburg	Vogel, CW (corresponding author), Univ Hawaii Manoa, Canc Res Ctr Hawaii, 1236 Lauhala St, Honolulu, HI 96813 USA.	cvogel@crch.hawaii.edu	Fritzinger, David C/E-5259-2012					ALPER CA, 1976, SCIENCE, V191, P1275, DOI 10.1126/science.56780; Bambai B, 1998, MOL IMMUNOL, V35, P408, DOI 10.1016/S0161-5890(98)90843-4; BROWN TL, 1981, J BIOL CHEM, V256, P743; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COCHRANE CG, 1970, J IMMUNOL, V105, P55; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DUNCKER BP, 1994, BIOCHEM BIOPH RES CO, V203, P1851, DOI 10.1006/bbrc.1994.2403; EGGERTSEN G, 1981, MOL IMMUNOL, V18, P125, DOI 10.1016/0161-5890(81)90078-X; FRITZINGER DC, 1994, P NATL ACAD SCI USA, V91, P12775, DOI 10.1073/pnas.91.26.12775; Fritzinger DC, 2003, MOL IMMUNOL, V40, P199; FRITZINGER DC, 1992, J IMMUNOL, V149, P3554; GOWDA DC, 1992, MOL IMMUNOL, V29, P335, DOI 10.1016/0161-5890(92)90020-X; Gowda DC, 2001, GLYCOBIOLOGY, V11, P195, DOI 10.1093/glycob/11.3.195; GOWDA DC, 1994, J IMMUNOL, V152, P2977; GRIER AH, 1987, J IMMUNOL, V139, P1245; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HAUGEN TH, 1979, P NATL ACAD SCI USA, V76, P2689, DOI 10.1073/pnas.76.6.2689; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENSLEY P, 1986, J BIOL CHEM, V261, P1038; Hew BE, 2004, MOL IMMUNOL, V41, P244; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; ISAAC L, 1992, J BIOL CHEM, V267, P10062; Iwanaga S., 1979, SNAKE VENOMS, P61; KIRKPATRICK RB, 1995, J BIOL CHEM, V270, P19800, DOI 10.1074/jbc.270.34.19800; KRESS LF, 1983, BIOCHIM BIOPHYS ACTA, V745, P113, DOI 10.1016/0167-4838(83)90039-0; LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109; LAO ZG, 1994, J IMMUNOL METHODS, V176, P127; LESAVRE PH, 1979, J IMMUNOL, V123, P529; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; NAGAKI K, 1978, INT ARCH ALLER A IMM, V57, P221, DOI 10.1159/000232106; OKEEFE MC, 1988, J BIOL CHEM, V263, P12690; PANGBURN MK, 1992, J BIOL CHEM, V267, P8584; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETRELLA EC, 1987, J IMMUNOL METHODS, V104, P159, DOI 10.1016/0022-1759(87)90500-X; Petrella EC, 1991, COMPLEMENT INFLAMM, V9, P210; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SMITH CA, 1984, J EXP MED, V159, P324, DOI 10.1084/jem.159.1.324; SMITH CA, 1982, J BIOL CHEM, V257, P9879; Vogel C.-W., 1991, HDB NATURAL TOXINS, P147; VOGEL CW, 1984, J IMMUNOL METHODS, V73, P203, DOI 10.1016/0022-1759(84)90045-0; Vogel CW, 1996, ADV EXP MED BIOL, V391, P97; VOGEL CW, 1982, J BIOL CHEM, V257, P8292; VOGEL CW, 1984, J IMMUNOL, V133, P3235; VOGT W, 1974, H-S Z PHYSIOL CHEM, V355, P171, DOI 10.1515/bchm2.1974.355.1.171; Wehrhahn Daniel, 2000, Immunopharmacology, V49, P94, DOI 10.1016/S0162-3109(00)80281-7; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; Wuster W, 1996, TOXICON, V34, P399, DOI 10.1016/0041-0101(95)00139-5	55	47	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30836	30843		10.1074/jbc.M403196200	http://dx.doi.org/10.1074/jbc.M403196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131128	hybrid			2022-12-27	WOS:000222531900116
J	Murphy, PJM; Galigniana, MD; Morishima, Y; Harrell, JM; Kwok, RPS; Ljungman, M; Pratt, WB				Murphy, PJM; Galigniana, MD; Morishima, Y; Harrell, JM; Kwok, RPS; Ljungman, M; Pratt, WB			Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLPROLYL ISOMERASE DOMAIN; HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; INDUCED APOPTOSIS; HSP90-BINDING IMMUNOPHILINS; DYNEIN INTERACTION; MOVEMENT; MUTANT; DEATH; MICE	Pifithrin-alpha (PFTalpha) was originally thought to be a specific inhibitor of signaling by the tumor suppressor protein p53. However, the laboratory that discovered pifithrin recently reported that the compound also inhibits heat shock and glucocorticoid receptor (GR) signaling, and they suggested that PFTalpha targets a factor common to all three signal transduction pathways, such as the hsp90/hsp70-based chaperone machinery (Komarova, E. A., Neznanov, N., Komarov, P. G., Chernov, M. V., Wang, K., and Gudkov, A. V. ( 2003) J. Biol. Chem. 278, 15465-15468). Because it is important for the mechanistic study of this machinery to identify unique inhibitors of chaperone action, we have examined the effect of PFTalpha on transcriptional activation, the hsp90 heterocomplex assembly, and hsp90-dependent nuclear translocation for both p53 and the GR. At concentrations where PFTalpha blocks p53-mediated induction of p21/Waf-1 in human embryonic kidney cells, we observed no inhibition of GR-mediated induction of a chloramphenicol acetyl transferase reporter in LMCAT cells. PFTalpha did, however, cause a left shift in the dexamethasone dose response curve by increasing intracellular dexamethasone concentration, apparently by competing for dexamethasone efflux from the cell. The assembly of p53 or GR heterocomplexes with hsp90 and immunophilins was not affected by PFTalpha either in vivo or in vitro and did not affect the nuclear translocation of either transcription factor. Thus, we conclude that PFTalpha does not inhibit GR-mediated induction or the function of the chaperone machinery, and, as originally thought, it may specifically inhibit p53 signaling by acting at a stage after p53 translocation to the nucleus.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem & Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	pjmurphy@umich.edu		GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL CANCER INSTITUTE [R01CA082376, R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010, CA82376] Funding Source: Medline; NIDDK NIH HHS [P60DK20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; GANNON JV, 1991, NATURE, V349, P802; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2001, BIOCHEM PHARMACOL, V62, P657, DOI 10.1016/S0006-2952(01)00733-X; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu XW, 2004, AM J PHYSIOL-HEART C, V286, pH933, DOI 10.1152/ajpheart.00759.2003; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; Merchant AK, 1996, ONCOGENE, V13, P2631; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; NING YM, 1993, J BIOL CHEM, V268, P6073; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Schafer T, 2003, FASEB J, V17, P660, DOI 10.1096/fj.02-0774com; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Zhang M, 2003, NEUROSCIENCE, V120, P191, DOI 10.1016/S0306-4522(03)00286-0	34	95	98	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30195	30201		10.1074/jbc.M403539200	http://dx.doi.org/10.1074/jbc.M403539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15145929	Green Published, hybrid			2022-12-27	WOS:000222531900042
J	Pudi, R; Srinivasan, P; Das, S				Pudi, R; Srinivasan, P; Das, S			La protein binding at the GCAC site near the initiator AUG facilitates the ribosomal assembly on the hepatitis C virus RNA to influence internal ribosome entry site-mediated translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-INDEPENDENT TRANSLATION; 5' NONTRANSLATED REGIONS; STEM-LOOP; POLYMERASE-III; SS-B; AUTOANTIGEN; POLIOVIRUS; ELEMENT; GENOME; CODON	Human La autoantigen has been shown to influence internal initiation of translation of hepatitis C virus (HCV) RNA. Previously, we have demonstrated that, among the three RRMs of La protein, the RRM2 interacts with HCV internal ribosome entry site (IRES) around the GCAC motif near the initiator AUG present in the stem region of stem-loop IV (SL IV) (Pudi, R., Abhiman, S., Srinivasan, N., and Das S. (2003) J. Biol. Chem. 278, 12231-12240). Here, we have demonstrated that the mutations in the GCAC motif, which altered the binding to RRM2, had drastic effect on HCV IRES-mediated translation, both in vitro and in vivo. The results indicated that the primary sequence of the stem region of SL IV plays an important role in mediating internal initiation. Furthermore, we have shown that the mutations also altered the ability to bind to ribosomal protein S5 (p25), through which 40 S ribosomal subunit is known to contact the HCV IRES RNA. Interestingly, binding of La protein to SL IV region induced significant changes in the circular dichroism spectra of the HCV RNA indicating conformational alterations that might assist correct positioning of the initiation complex. Finally, the ribosome assembly analysis using sucrose gradient centrifugation implied that the mutations within SL IV of HCV IRES impair the formation of functional ribosomal complexes. These observations strongly support the hypothesis that La protein binding near the initiator AUG facilitates the interactions with ribosomal protein S5 and 48 S ribosomal assembly and influences the formation of functional initiation complex on the HCV IRES RNA to mediate efficient internal initiation of translation.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Das, S (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Sir CV Raman Ave, Bangalore 560012, Karnataka, India.	sdas@mcbl.iisc.ernet.in		Limgala, Renuka/0000-0001-6957-6284				ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; Das S, 1998, J VIROL, V72, P5638, DOI 10.1128/JVI.72.7.5638-5647.1998; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; Fouraux MA, 2002, RNA, V8, P1428, DOI 10.1017/S1355838202021076; Fukushi S, 1997, J VIROL, V71, P1662, DOI 10.1128/JVI.71.2.1662-1666.1997; Fukushi S, 2001, VIRUS RES, V73, P67, DOI 10.1016/S0168-1702(00)00228-8; Fukushi S, 2001, J BIOL CHEM, V276, P20824, DOI 10.1074/jbc.C100206200; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HARDIN CC, 1993, BIOCHEMISTRY-US, V32, P5870, DOI 10.1021/bi00073a021; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Honda M, 1996, RNA, V2, P955; Honda M, 1996, VIROLOGY, V222, P31, DOI 10.1006/viro.1996.0395; Huhn P, 1997, NUCLEIC ACIDS RES, V25, P410, DOI 10.1093/nar/25.2.410; Izumi RE, 2004, J VIROL, V78, P3763, DOI 10.1128/JVI.78.7.3763-3776.2004; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; Kieft JS, 2001, RNA, V7, P194, DOI 10.1017/S1355838201001790; Lemon SM, 1997, SEMIN VIROL, V8, P274, DOI 10.1006/smvy.1997.0129; Lu HH, 1996, P NATL ACAD SCI USA, V93, P1412, DOI 10.1073/pnas.93.4.1412; McKnight KL, 2003, VIROLOGY, V317, P345, DOI 10.1016/j.virol.2003.08.033; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Pestova TV, 1999, VIROLOGY, V258, P249, DOI 10.1006/viro.1999.9741; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Ray PS, 2004, NUCLEIC ACIDS RES, V32, P1678, DOI 10.1093/nar/gkh328; Ray PS, 2002, NUCLEIC ACIDS RES, V30, P4500, DOI 10.1093/nar/gkf583; Reynolds JE, 1996, RNA, V2, P867; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schultz DE, 1996, J BIOL CHEM, V271, P14134, DOI 10.1074/jbc.271.24.14134; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412	41	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29879	29888		10.1074/jbc.M403417200	http://dx.doi.org/10.1074/jbc.M403417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138264	hybrid			2022-12-27	WOS:000222531900003
J	Xu, YH; Liu, YW; Lou, ZY; Qin, L; Li, X; Bai, ZH; Pang, H; Tien, P; Gao, GF; Rao, Z				Xu, YH; Liu, YW; Lou, ZY; Qin, L; Li, X; Bai, ZH; Pang, H; Tien, P; Gao, GF; Rao, Z			Structural basis for coronavirus-mediated membrane fusion - Crystal structure of mouse hepatitis virus spike protein fusion core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-CELL FUSION; ENVELOPE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; EBOLA-VIRUS; CONFORMATIONAL-CHANGE; HIV-1 ENTRY; COILED-COIL; HYDROPHOBIC REGIONS; POTENT INHIBITORS; ATOMIC-STRUCTURE	The surface transmembrane glycoprotein is responsible for mediating virion attachment to cell and subsequent virus-cell membrane fusion. However, the molecular mechanisms for the viral entry of coronaviruses remain poorly understood. The crystal structure of the fusion core of mouse hepatitis virus S protein, which represents the first fusion core structure of any coronavirus, reveals a central hydrophobic coiled coil trimer surrounded by three helices in an oblique, antiparallel manner. This structure shares significant similarity with both the low pH-induced conformation of influenza hemagglutinin and fusion core of HIV gp41, indicating that the structure represents a fusion-active state formed after several conformational changes. Our results also indicate that the mechanisms for the viral fusion of coronaviruses are similar to those of influenza virus and HIV. The coiled coil structure has unique features, which are different from other viral fusion cores. Highly conserved heptad repeat 1 (HR1) and HR2 regions in coronavirus spike proteins indicate a similar three-dimensional structure among these fusion cores and common mechanisms for the viral fusion. We have proposed the binding regions of HR1 and HR2 of other coronaviruses and a structure model of their fusion core based on our mouse hepatitis virus fusion core structure and sequence alignment. Drug discovery strategies aimed at inhibiting viral entry by blocking hairpin formation may be applied to the inhibition of a number of emerging infectious diseases, including severe acute respiratory syndrome.	Tsing Hua Univ, Struct Biol Lab, Sch Life Sci & Engn, Beijing 100084, Peoples R China; Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Microbiol, Beijing 100080, Peoples R China; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Microbiology, CAS; University of Oxford	Rao, Z (corresponding author), Tsing Hua Univ, Struct Biol Lab, Sch Life Sci & Engn, Beijing 100084, Peoples R China.	raozh@xtal.tsinghua.edu.cn	Bai, Zhihui/O-5303-2019; Rao, Zihe/HCH-6944-2022; Gao, George Fu/ABD-5229-2021; Li, Xu/A-7108-2013	Bai, Zhihui/0000-0002-3818-527X; 				Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Damico RL, 1998, P NATL ACAD SCI USA, V95, P2580, DOI 10.1073/pnas.95.5.2580; DAVIES HA, 1979, ARCH VIROL, V59, P25, DOI 10.1007/BF01317891; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hernandez LD, 1997, J CELL BIOL, V139, P1455, DOI 10.1083/jcb.139.6.1455; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999; Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wool-Lewis RJ, 1999, J VIROL, V73, P1419, DOI 10.1128/JVI.73.2.1419-1426.1999; Yamada YK, 1997, VIROLOGY, V227, P215, DOI 10.1006/viro.1996.8313; Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197	51	104	113	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30514	30522		10.1074/jbc.M403760200	http://dx.doi.org/10.1074/jbc.M403760200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123674	hybrid, Green Published			2022-12-27	WOS:000222531900080
J	Bjerkan, TM; Bender, CL; Ertesvag, H; Drablos, F; Fakhr, MK; Preston, LA; Skjak-Braek, G; Valla, S				Bjerkan, TM; Bender, CL; Ertesvag, H; Drablos, F; Fakhr, MK; Preston, LA; Skjak-Braek, G; Valla, S			The pseudomonas syringae genome encodes a combined mannuronan C-5-epimerase and O-acetylhydrolase, which strongly enhances the predicted gel-forming properties of alginates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL GROUPS; GENE-CLUSTER; ALGINIC ACID; SEQUENCE; SECRETION; PROTEIN; EXPRESSION; FLUORESCENS; FAMILY; ALGG	Alginates are industrially important, linear copolymers of beta-D-mannuronic acid (M) and its C-5-epimer alpha-L-guluronic acid ( G). The G residues originate from a post-polymerization reaction catalyzed by mannuronan C-5-epimerases (MEs), leading to extensive variability in M/G ratios and distribution patterns. Alginates containing long continuous stretches of G residues ( G blocks) can form strong gels, a polymer type not found in alginate-producing bacteria belonging to the genus Pseudomonas. Here we show that the Pseudomonas syringae genome encodes a Ca2+-dependent ME (PsmE) that efficiently forms such G blocks in vitro. The deduced PsmE protein consists of 1610 amino acids and is a modular enzyme related to the previously characterized family of Azotobacter vinelandii ME (AlgE1-7). A- and R-like modules with sequence similarity to those in the AlgE enzymes are found in PsmE, and the A module of PsmE (PsmEA) was found to be sufficient for epimerization. Interestingly, an R module from AlgE4 stimulated PsmEA activity. PsmE contains two regions designated M and RTX, both presumably involved in the binding of Ca2+. Bacterial alginates are partly acetylated, and such modified residues cannot be epimerized. Based on a detailed computer-assisted analysis and experimental studies another PsmE region, designated N, was found to encode an acetylhydrolase. By the combined action of N and A PsmE was capable of redesigning an extensively acetylated alginate low in G from a non gel-forming to a gel-forming state. Such a property has to our knowledge not been previously reported for an enzyme acting on a polysaccharide.	Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway; Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA; Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Oklahoma State University System; Oklahoma State University - Stillwater; Norwegian University of Science & Technology (NTNU)	Valla, S (corresponding author), Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway.	Svein.Valla@biotech.ntnu.no	Heggeset, Tonje Marita Bjerkan/I-9077-2019; Drablos, Finn/L-4970-2019	Drablos, Finn/0000-0001-5794-828X; Heggeset, Tonje/0000-0002-1221-8598; Ertesvag, helga/0000-0001-9437-9469	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043311] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BARTA TM, 1992, J BACTERIOL, V174, P3021, DOI 10.1128/JB.174.9.3021-3029.1992; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BJERKAN TM, 2004, IN PRESS BIOCH J; Buchanan SK, 2001, TRENDS BIOCHEM SCI, V26, P3, DOI 10.1016/S0968-0004(00)01733-3; Budde IP, 2000, MOL PLANT MICROBE IN, V13, P951, DOI 10.1094/MPMI.2000.13.9.951; Buell CR, 2003, P NATL ACAD SCI USA, V100, P10181, DOI 10.1073/pnas.1731982100; COTE GL, 1988, CARBOHYD RES, V181, P143, DOI 10.1016/0008-6215(88)84030-8; DAVIDSON IW, 1977, J GEN MICROBIOL, V98, P603, DOI 10.1099/00221287-98-2-603; Dickens NJ, 2002, CURR BIOL, V12, pR197, DOI 10.1016/S0960-9822(02)00748-0; DUONG F, 1992, GENE, V121, P47, DOI 10.1016/0378-1119(92)90160-Q; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; Ertesvag H, 1999, J BACTERIOL, V181, P3033; Ertesvag H, 1999, METH BIOTEC, V10, P71; Ertesvag H, 1999, METAB ENG, V1, P262, DOI 10.1006/mben.1999.0130; FRANKLIN MJ, 1994, J BACTERIOL, V176, P1821, DOI 10.1128/JB.176.7.1821-1830.1994; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Gimmestad M, 2003, J BACTERIOL, V185, P3515, DOI 10.1128/JB.185.12.3515-3523.2003; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; GORIN PAJ, 1966, CAN J CHEMISTRY, V44, P993, DOI 10.1139/v66-147; GOVAN JRW, 1981, J GEN MICROBIOL, V125, P217; GRASDALEN H, 1981, CARBOHYD RES, V89, P179, DOI 10.1016/S0008-6215(00)85243-X; GRASDALEN H, 1983, CARBOHYD RES, V118, P255, DOI 10.1016/0008-6215(83)88053-7; Hartmann M, 2002, BBA-GEN SUBJECTS, V1570, P104, DOI 10.1016/S0304-4165(02)00195-2; HAUG A, 1967, ACTA CHEM SCAND, V21, P768, DOI 10.3891/acta.chem.scand.21-0768; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; Ho YS, 1999, PROTEIN ENG, V12, P693, DOI 10.1093/protein/12.8.693; Hoidal HK, 1999, J BIOL CHEM, V274, P12316, DOI 10.1074/jbc.274.18.12316; Jaroszewski L, 2000, PROTEIN SCI, V9, P1487, DOI 10.1110/ps.9.8.1487; JONES JDG, 1987, GENE, V61, P299, DOI 10.1016/0378-1119(87)90193-4; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Keith RC, 2003, MICROBIOL-SGM, V149, P1127, DOI 10.1099/mic.0.26109-0; KEITH RC, 2002, EXPRESSION ALGINATE; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lally ET, 1999, TRENDS MICROBIOL, V7, P356, DOI 10.1016/S0966-842X(99)01530-9; LETOFFE S, 1992, J BACTERIOL, V174, P4920; LETOFFE S, 1994, J BACTERIOL, V176, P5372; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; LINKER A, 1984, J BACTERIOL, V159, P958, DOI 10.1128/JB.159.3.958-964.1984; LINKER A, 1964, NATURE, V204, P187, DOI 10.1038/204187a0; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; McMullen TWP, 2000, PROTEIN ENG, V13, P865, DOI 10.1093/protein/13.12.865; MICHELL RE, 1982, PHYSL PLANT PATHOL, V20, P83; Molgaard A, 2000, STRUCTURE, V8, P373, DOI 10.1016/S0969-2126(00)00118-0; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; OSMAN SF, 1986, J BACTERIOL, V166, P66, DOI 10.1128/jb.166.1.66-71.1986; PALMER DA, 1993, APPL ENVIRON MICROB, V59, P1619, DOI 10.1128/AEM.59.5.1619-1626.1993; PenalozaVazquez A, 1997, J BACTERIOL, V179, P4464, DOI 10.1128/jb.179.14.4464-4472.1997; Ramstad MV, 1999, ENZYME MICROB TECH, V24, P636, DOI 10.1016/S0141-0229(98)00148-3; Rehm BH, 1996, J BACTERIOL, V178, P5884, DOI 10.1128/jb.178.20.5884-5889.1996; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; Sambrook J., 2001, MOL CLONING LAB MANU, Vthird edition; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheffield PJ, 2001, PROTEIN ENG, V14, P513, DOI 10.1093/protein/14.7.513; Skjak-Braek G, 1996, CARBOHYDR EUR, V14, P19; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; SKJAKBRAEK G, 1985, CARBOHYD RES, V145, P169; Smidsrod O., 1996, CARBOHYDR EUR, V14, P6; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; Sutton JM, 1996, MOL PLANT MICROBE IN, V9, P671, DOI 10.1094/MPMI-9-0671; Svanem BIG, 2001, J BIOL CHEM, V276, P31542, DOI 10.1074/jbc.M102562200; Svanem BIG, 1999, J BACTERIOL, V181, P68, DOI 10.1128/JB.181.1.68-77.1999; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ullrich MS, 2000, MICROBIOL-SGM, V146, P2457, DOI 10.1099/00221287-146-10-2457; Valla S, 2001, BIOCHIMIE, V83, P819, DOI 10.1016/S0300-9084(01)01313-X; WASSIF C, 1995, J BACTERIOL, V177, P5790, DOI 10.1128/jb.177.20.5790-5798.1995; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; YOUNG JM, 1988, INT COLLECTION MICRO; Yu J, 1999, MOL MICROBIOL, V33, P712, DOI 10.1046/j.1365-2958.1999.01516.x	72	15	16	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28920	28929		10.1074/jbc.M313293200	http://dx.doi.org/10.1074/jbc.M313293200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123694	hybrid			2022-12-27	WOS:000222445300013
J	Fischer, OM; Giordano, S; Comoglio, PM; Ullrich, A				Fischer, OM; Giordano, S; Comoglio, PM; Ullrich, A			Reactive oxygen species mediate met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; C-MET; BETA-CATENIN; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; CROSS-TALK; TYROSINE PHOSPHORYLATION; SCATTER-FACTOR; ACTIVATION; GENERATION	Cross-communication between the Met receptor tyrosine kinase and the epidermal growth factor receptor ( EGFR) has been proposed to involve direct association of both receptors and EGFR kinase-dependent phosphorylation. Here, we demonstrate that in human hepatocellular and pancreatic carcinoma cells the Met receptor becomes tyrosine phosphorylated not only upon EGF stimulation but also in response to G protein-coupled receptor ( GPCR) agonists. Whereas specific inhibition of the EGFR kinase activity blocked EGF- but not GPCR agonist-induced Met receptor transactivation, it was abrogated in the presence of a reducing agent or treatment of cells with a NADPH oxidase inhibitor. Both GPCR ligands and EGF are further shown to increase the level of reactive oxygen species within the cell. Interestingly, stimulation of the Met receptor by either GPCR agonists, EGF or its cognate ligand HGF, resulted in release of Met-associated beta-catenin and in its Met-dependent translocation into the nucleus, as analyzed by small interfering RNA-mediated knockdown of the Met receptor. Our results provide a new molecular explanation for cell surface receptor cross-talk involving the Met receptor and thereby link the wide diversity of GPCRs and the EGFR to the oncogenic potential of Met signaling in human carcinoma cells.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Turin, Italy	Max Planck Society; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de	Giordano, Silvia/J-9858-2018; Fischer, Oliver/V-7641-2019	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328				Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daveau M, 2003, MOL CARCINOGEN, V36, P130, DOI 10.1002/mc.10103; De Palma M, 2002, METHOD ENZYMOL, V346, P514; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Gschwind A, 2002, CANCER RES, V62, P6329; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Herynk MH, 2003, CLIN EXP METASTAS, V20, P291, DOI 10.1023/A:1024024218529; Hiscox S, 1999, ANTICANCER RES, V19, P509; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Holland JA, 1998, ENDOTHELIUM-NEW YORK, V6, P113, DOI 10.3109/10623329809072198; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Miura Y, 2003, BIOCHEM BIOPH RES CO, V305, P160, DOI 10.1016/S0006-291X(03)00725-3; Monga SPS, 2002, CANCER RES, V62, P2064; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nath D, 2001, J CELL SCI, V114, P1213; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Peghini PL, 2002, CLIN CANCER RES, V8, P2273; Perner A, 2003, GUT, V52, P231, DOI 10.1136/gut.52.2.231; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAMSBY ML, 1994, ELECTROPHORESIS, V15, P265, DOI 10.1002/elps.1150150146; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rhee S G, 2000, Sci STKE, V2000, ppe1; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Scheving LA, 2002, BIOCHEM BIOPH RES CO, V290, P197, DOI 10.1006/bbrc.2001.6157; Schiavo G, 2001, NAT REV MOL CELL BIO, V2, P530, DOI 10.1038/35080089; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	61	93	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28970	28978		10.1074/jbc.M402508200	http://dx.doi.org/10.1074/jbc.M402508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123705	hybrid			2022-12-27	WOS:000222445300019
J	Fukuda, M; Itoh, T				Fukuda, M; Itoh, T			Slac2-a/melanophilin contains multiple PEST-like sequences that are highly sensitive to proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLP HOMOLOGY DOMAIN; MYOSIN-VA; GRISCELLI-SYNDROME; MELANOSOME TRANSPORT; BINDING DOMAIN; C2 DOMAINS; SYNAPTOTAGMIN FAMILY; CRITICAL DETERMINANT; MISSENSE MUTATIONS; RAB EFFECTOR	The synaptotagmin-like protein homologue lacking C2 domains-a (Slac2-a)/melanophilin was recently identified as the "missing link" between the small GTPase Rab27A and the actin-based motor protein myosin Va. Although formation of a tripartite protein complex by three molecules had been shown to be required for proper melanosome distribution in melanocytes (Kuroda, T. S., Ariga, H., and Fukuda, M. ( 2003) Mol. Cell. Biol. 23, 5245-5255), the regulatory mechanisms of the complex (i.e. assembly and disassembly of the complex) had never been elucidated. In this study, we discovered that Slac2-a and a closely related isoform, Slac2-c/MyRIP, contain multiple PEST-like sequences ( potential signals for rapid protein degradation) in the myosin Va- and actin-binding domains at the C terminus. We found that the C-terminal domain of Slac2-a is highly sensitive to low concentrations of proteases, such as trypsin and calpain, in vitro, whereas the N-terminal Rab27A-binding domain is highly resistant to these proteases. We further found that endogenous calpains selectively cleave Slac2-a, but not Rab27A or myosin Va, in melanocytes. A mutant Slac2-a lacking one of the PEST-like sequences located at the interface between the myosin Va- and actin-binding domains (DeltaPEST; amino acids 399-405) is more stable than the wild-type protein, both in vitro and in melanocytes. Expression of the mutant Slac2-a-DeltaPEST with an N-terminal green fluorescence protein tag often induced perinuclear aggregation of melanosomes (similar to40% of the transfected cells) compared with the wild-type Slac2-a. Our findings suggest that protein degradation of Slac2-a is an essential process for proper melanosome distribution in melanocytes.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bizario JCD, 2002, CELL MOTIL CYTOSKEL, V51, P57, DOI 10.1102/cmc.10010; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2004, J BIOL CHEM, V279, P13065, DOI 10.1074/jbc.M306812200; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 2004, J CELL SCI, V117, P583, DOI 10.1242/jcs.00891; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, J BIOL CHEM, V276, P41112, DOI 10.1074/jbc.M106209200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; FUKUDA M, 2002, RRD NEUROCHEMISTRY, V5, P297; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Huang JD, 1998, GENETICS, V148, P1963; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Imai A, 2004, J CELL SCI, V117, P1945, DOI 10.1242/jcs.01048; Ishikawa K, 2003, J CELL BIOL, V160, P887, DOI 10.1083/jcb.200210139; Jimbow K, 2000, PIGM CELL RES, V13, P222, DOI 10.1034/j.1600-0749.2000.130403.x; Karcher RL, 2001, SCIENCE, V293, P1317, DOI 10.1126/science.1061086; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, J CLIN INVEST, V112, P450, DOI 10.1172/JCI200318264; Menasche G, 2003, BLOOD, V101, P2736, DOI 10.1182/blood-2002-09-2789; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCHOLLMEYER JE, 1986, EXP CELL RES, V163, P413, DOI 10.1016/0014-4827(86)90072-8; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Tang FS, 2003, NATURE, V422, P87, DOI 10.1038/nature01453; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	53	48	50	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22314	22321		10.1074/jbc.401791200	http://dx.doi.org/10.1074/jbc.401791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15145961	Bronze			2022-12-27	WOS:000221417100079
J	Pop, M; Aktories, K; Schmidt, G				Pop, M; Aktories, K; Schmidt, G			Isotype-specific degradation of Rac activated by the cytotoxic necrotizing factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO GTPASES; PROTEIN; COMPLEX; CDC42; TOXIN; CELLS; TRANSFORMATION; LOCALIZATION; DEAMIDATION; POLYAMINES	The cytotoxic necrotizing factor 1 (CNF1) from Escherichia coli activates members of the Rho family by deamidation of glutamine 61/63. Because this amino acid is crucial for GTP hydrolysis, deamidation of glutamine 61/63 results in constitutively active Rho proteins. Recently, it was shown that the level of CNF1-activated Rac is rapidly diminished in CNF1-treated cells by proteolytic degradation. Here, we studied the requirements for CNF1-induced Rac degradation. By overexpressing His-tagged activated Rac mutants we show that constitutive activation is necessary for degradation of Rac. However, permanent activation is not sufficient for degradation, because Rac that is constitutively activated by transamidation at glutamine 61 by the Bordetella dermonecrotic toxin is not degraded. Overexpression of His-tagged Rac mutants deficient in interaction with GTPase-activating protein (Rac(N92D) and Rac(Y64H)) and guanosine nucleotide dissociation inhibitor (Rac(H103E)) were degraded after activation by CNF1, whereas Rac(Y40C), which is not able to interact with CRIB domain effectors or plenty of SH3, was not degraded. Isoprenylation and the presence of a putative mitotic destruction box are essential for CNF-induced degradation. In contrast to Rac1, Rac2, and Rac3 were not degraded following constitutive activation by CNF1. Using site-directed mutagenesis, we defined the polybasic region and amino acids 90, 107, 147, and 151 as responsible for isotype-specific degradation.	Univ Freiburg, Inst Expt, D-79104 Freiburg, Germany; Univ Freiburg, Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Schmidt, G (corresponding author), Univ Freiburg, Inst Expt, Albert Str 25, D-79104 Freiburg, Germany.	Gudula.Schmidt@uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Karnoub AE, 2001, MOL CELL BIOL, V21, P2847, DOI 10.1128/MCB.21.8.2847-2857.2001; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lerm M, 2000, FEMS MICROBIOL LETT, V188, P1; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Masuda M, 2000, EMBO J, V19, P521, DOI 10.1093/emboj/19.4.521; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Owen D, 2003, J BIOL CHEM, V278, P50578, DOI 10.1074/jbc.M304313200; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schmidt G, 1999, J BIOL CHEM, V274, P31875, DOI 10.1074/jbc.274.45.31875; Schmidt G, 2001, INFECT IMMUN, V69, P7663, DOI 10.1128/IAI.69.12.7663-7670.2001; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; van Hennik PB, 2003, J BIOL CHEM, V278, P39166, DOI 10.1074/jbc.M307001200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021	28	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35840	35848		10.1074/jbc.M404346200	http://dx.doi.org/10.1074/jbc.M404346200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15143066	hybrid			2022-12-27	WOS:000223303400085
J	Rozan, L; Krysan, DJ; Rockwell, NC; Fuller, RS				Rozan, L; Krysan, DJ; Rockwell, NC; Fuller, RS			Plasticity of extended subsites facilitates divergent substrate recognition by Kex2 and furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROHORMONE-PROCESSING ENZYME; SUBTILISIN BPN'; CRYSTAL-STRUCTURE; PROTEASE KEX2; SPECIFICITY; ENDOPROTEASE; INHIBITOR; YEAST; CLEAVAGE	Yeast Kex2 and human furin are subtilisin-related proprotein convertases that function in the late secretory pathway and exhibit similar though distinguishable patterns of substrate recognition. Although both enzymes prefer Arg at P-1 and basic residues at P-2, the two differ in recognition of P-4 and P-6 residues. To probe P-4 and P-6 recognition by Kex2p, furin-like substitutions were made in the putative S-4 and S-6 subsites of Kex2. T252D and Q283E mutations were introduced to increase the preference for Arg at P-4 and P-6, respectively. Glu(255) was replaced with Ile to limit recognition of P-4 Arg. The effects of putative S-4 and S-6 mutations were determined by examining the cleavage by purified mutant enzymes of a series of fluorogenic substrates with systematic changes in P-4 and/or P-6. Whereas wild type Kex2 exhibited little preference for Arg at P-6, the T252D mutant and T252D/Q283E double mutant exhibited clear interactions with P-6 Arg. Moreover, the T252D and T252D/Q283E substitutions altered the influence of the P-6 residue on P-4 recognition. We infer that cross-talk between S-4 and S-6, not seen in furin, allows wild type and mutant forms of Kex2 to adapt their subsites for altered modes of recognition. This apparent plasticity may allow the subsites to rearrange their local environment to interact with different substrates in a productive manner. E255I-Kex2 exhibited significantly decreased recognition of P-4 Arg in a tetrapeptide substrate with Lys at P-1, although the general pattern of selectivity for aliphatic residues at P-4 remained unchanged.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, CS Mott Childrens Hosp, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fuller, RS (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	bfuller@umich.edu		Krysan, Damian/0000-0001-6330-3365	NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039697, R55GM039697] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA46592] Funding Source: Medline; NIGMS NIH HHS [GM 39697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; BALLINGER MD, 1995, BIOCHEMISTRY-US, V34, P13312, DOI 10.1021/bi00041a006; Ballinger MD, 1996, BIOCHEMISTRY-US, V35, P13579, DOI 10.1021/bi961543h; BECH LM, 1993, BIOCHEMISTRY-US, V32, P2845, DOI 10.1021/bi00062a016; BECH LM, 1992, EUR J BIOCHEM, V209, P869, DOI 10.1111/j.1432-1033.1992.tb17359.x; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; BEVAN A, 1997, THESIS STANFORD U; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRENNER C, 1994, METHOD ENZYMOL, V244, P152; Constam DB, 2000, DEVELOPMENT, V127, P245; Constam DB, 2000, GENE DEV, V14, P1146; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GRON H, 1992, BIOCHEMISTRY-US, V31, P6011, DOI 10.1021/bi00141a008; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holyoak T, 2004, BIOCHEMISTRY-US, V43, P2412, DOI 10.1021/bi035849h; Holyoak T, 2003, BIOCHEMISTRY-US, V42, P6709, DOI 10.1021/bi034434t; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Komiyama T, 2000, BIOCHEMISTRY-US, V39, P15156, DOI 10.1021/bi001907c; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Legendre D, 2000, J MOL BIOL, V296, P87, DOI 10.1006/jmbi.1999.3437; MCPHALEN CA, 1985, P NATL ACAD SCI USA, V82, P7242, DOI 10.1073/pnas.82.21.7242; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; RHEINNECKER M, 1993, BIOCHEMISTRY-US, V32, P1199, DOI 10.1021/bi00056a001; RHEINNECKER M, 1994, BIOCHEMISTRY-US, V33, P221, DOI 10.1021/bi00167a029; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rockwell NC, 1998, BIOCHEMISTRY-US, V37, P3386, DOI 10.1021/bi972534r; Rockwell NC, 2001, J BIOL CHEM, V276, P38394, DOI 10.1074/jbc.M105782200; Rockwell NC, 2001, BIOCHEMISTRY-US, V40, P3657, DOI 10.1021/bi0020877; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEIZEN RJ, 1994, EUR J BIOCHEM, V222, P255; SEIZEN RJ, 1997, PROTEIN SCI, V6, P501; Siekhaus DE, 1999, J NEUROSCI, V19, P6942, DOI 10.1523/JNEUROSCI.19-16-06942.1999; SORENSON SB, 1993, BIOCHEMISTRY-US, V32, P8894; TAKEUCHI Y, 1991, J MOL BIOL, V221, P309, DOI 10.1016/0022-2836(91)80221-F; Thacker C, 2000, BIOESSAYS, V22, P545, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;545::AID-BIES7&gt;3.0.CO;2-F	48	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35656	35663		10.1074/jbc.M405362200	http://dx.doi.org/10.1074/jbc.M405362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15159396	hybrid			2022-12-27	WOS:000223303400062
J	Ammanamanchi, S; Brattain, MG				Ammanamanchi, S; Brattain, MG			Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; I RECEPTOR; REDUCED EXPRESSION; SP3; PROMOTER; CARCINOMA; GENE; ACETYLTRANSFERASE; ACTIVATION; P300	The loss of transforming growth factor-beta (TGF-beta) response due to the dysregulation of TGF-beta receptors type I (RI) and type II (RII) is well known for its contribution to oncogenesis. Estrogen receptor-expressing breast cancer cells are refractory to TGF-beta-mediated growth control because of the reduced expression of TGF-beta receptors. Although RII is required for the binding of TGF-beta to RI, RI is responsible for directly transducing TGF-beta signals through the Smad protein family. Treatment of estrogen receptor-expressing MCF-7L and ZR75 breast cancer cells with the histone deacetylase ( HDAC) inhibitor suberoylanilide hydroxamic acid ( SAHA) led to a dramatic induction of RI. Accumulation of acetylated histones H3 and H4 was observed in the SAHA-treated cells. Chromatin immunoprecipitation analysis followed by PCR with RI promoter-specific primers indicated an accumulation of acetylated histones in chromatin associated with the RI gene, suggesting that histone deacetylation was involved in the transcriptional inactivation of RI. SAHA treatment stimulated RI promoter activity through the inhibition of Sp1/Sp3-associated HDAC activity. Histone acetyltransferase p300 stimulated RI promoter activity, thus further confirming the involvement of HDAC activity in the transcriptional repression of RI. Significantly, SAHA-mediated RI regeneration restored the TGF-beta response in breast cancer cells.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Ammanamanchi, S (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	sudhakar.ammanamanchi@roswellpark.org; michael.brattain@roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056, R01CA072001, R37CA038173, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72001, CA 38173, CA 16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Chen T, 2001, CANCER RES, V61, P4679; Chen TP, 1998, CANCER RES, V58, P4805; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fukai Y, 2003, INT J CANCER, V104, P161, DOI 10.1002/ijc.10929; Kaklamani VG, 2003, J CLIN ONCOL, V21, P3236, DOI 10.1200/JCO.2003.11.524; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Knobloch TJ, 2001, MUTAT RES-FUND MOL M, V479, P131, DOI 10.1016/S0027-5107(01)00157-9; Lee BI, 2001, CANCER RES, V61, P931; Marks PA, 2001, CLIN CANCER RES, V7, P759; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Pinto M, 2003, J PATHOL, V200, P32, DOI 10.1002/path.1327; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Tokunaga H, 1999, CLIN CANCER RES, V5, P2520; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Zhang HT, 2003, LUNG CANCER-J IASLC, V40, P281, DOI 10.1016/S0169-5002(03)00121-1	27	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32620	32625		10.1074/jbc.M402691200	http://dx.doi.org/10.1074/jbc.M402691200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155736	hybrid			2022-12-27	WOS:000222849700079
J	Pangas, SA; Jorgez, CJ; Matzuk, MM				Pangas, SA; Jorgez, CJ; Matzuk, MM			Growth differentiation factor 9 regulates expression of the bone morphogenetic protein antagonist gremlin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; GRANULOSA-CELLS; OSTEOGENIC PROTEIN-1; FOLLISTATIN; OOCYTE; RECEPTOR; NOGGIN; OVULATION; DEFECTS; INDUCE	Growth differentiation factor 9 (GDF9) is an oocyte-expressed member of the transforming growth factor beta (TGF-beta) superfamily and is required for normal ovarian follicle development and female fertility. GDF9 acts as a paracrine factor and affects granulosa cell physiology. Only a few genes regulated by GDF9 are known. Our microarray analysis has identified gremlin as one of the genes up-regulated by GDF9 in cultures of granulosa cells. Gremlin is a known member of the DAN family of bone morphogenetic protein (BMP) antagonists, but its expression and function in the ovary are unknown. We have investigated the regulation of gremlin in mouse granulosa cells by GDF9 as well as other members of the TGF-beta superfamily. GDF9 and BMP4 induce gremlin, but TGF-beta does not. In addition, in cultures of granulosa cells, gremlin negatively regulates BMP4 signaling but not GDF9 activity. The expression of gremlin in the ovary was also examined by in situ hybridization. A distinct change in gremlin mRNA compartmentalization occurs during follicle development and ovulation, indicating a highly regulated expression pattern during folliculogenesis. We propose that gremlin modulates the cross-talk between GDF9 and BMP signaling that is necessary during follicle development because both ligands use components of the same signaling pathway.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu	xu, huanfang/I-4315-2012	Pangas, Stephanie/0000-0001-5748-5844				Albrecht U, 1997, MOL CELLULAR METHODS, P23; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Durlinger ALL, 2002, REPRODUCTION, V124, P601, DOI 10.1530/reprod/124.5.601; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1018, DOI 10.1210/me.13.6.1018; Elvin JA, 2000, P NATL ACAD SCI USA, V97, P10288, DOI 10.1073/pnas.180295197; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Erickson Gregory F, 2003, Reprod Biol Endocrinol, V1, P9, DOI 10.1186/1477-7827-1-9; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; GHIGLIERI C, 1995, HUM REPROD, V10, P2115, DOI 10.1093/oxfordjournals.humrep.a136245; Groppe J, 2003, J BONE JOINT SURG AM, V85A, P52, DOI 10.2106/00004623-200300003-00010; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Jorgez CJ, 2004, MOL ENDOCRINOL, V18, P953, DOI 10.1210/me.2003-0301; Joyce IM, 2001, ENDOCRINOLOGY, V142, P3187, DOI 10.1210/en.142.7.3187; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lee WS, 2001, BIOL REPROD, V65, P994, DOI 10.1095/biolreprod65.4.994; MICHEL U, 1992, J MOL ENDOCRINOL, V9, P147, DOI 10.1677/jme.0.0090147; Moore RK, 2003, J BIOL CHEM, V278, P304, DOI 10.1074/jbc.M207362200; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nilsson EE, 2003, BIOL REPROD, V69, P1265, DOI 10.1095/biolreprod.103.018671; Otsuka F, 2001, BIOCHEM BIOPH RES CO, V289, P961, DOI 10.1006/bbrc.2001.6103; Pereira RC, 2000, ENDOCRINOLOGY, V141, P4558, DOI 10.1210/en.141.12.4558; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Shi W, 2001, AM J PHYSIOL-LUNG C, V280, pL1030, DOI 10.1152/ajplung.2001.280.5.L1030; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimasaki S, 1999, P NATL ACAD SCI USA, V96, P7282, DOI 10.1073/pnas.96.13.7282; Shimasaki S, 2004, ENDOCR REV, V25, P72, DOI 10.1210/er.2003-0007; TANO M, 1995, MOL CELL ENDOCRINOL, V109, P167, DOI 10.1016/0303-7207(95)03499-W; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Valve E, 1997, BIOCHEM BIOPH RES CO, V232, P173, DOI 10.1006/bbrc.1997.6256; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Vitt UA, 2002, BIOL REPROD, V67, P473, DOI 10.1095/biolreprod67.2.473; Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600-0722.1998.tb02170.x; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zhuo LS, 2001, CELL STRUCT FUNCT, V26, P189, DOI 10.1247/csf.26.189; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	51	91	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32281	32286		10.1074/jbc.M403212200	http://dx.doi.org/10.1074/jbc.M403212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15133038	hybrid			2022-12-27	WOS:000222849700037
J	Tikhonova, EB; Zgurskaya, HI				Tikhonova, EB; Zgurskaya, HI			AcrA, AcrB, and TolC of Escherichia coli form a stable intermembrane multidrug efflux complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION PROTEIN; OUTER-MEMBRANE; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; ANTIBIOTIC-RESISTANCE; CRYSTAL-STRUCTURE; CHANNEL-TUNNEL; PUMP; EXPORT; SYSTEM	Many transporters of Gram-negative bacteria involved in the extracellular secretion of proteins and the efflux of toxic molecules operate by forming intermembrane complexes. These complexes are proposed to span both inner and outer membranes and create a bridge across the periplasm. In this study, we analyzed interactions between the inner and outer membrane components of the tri-partite multidrug efflux pump AcrAB-TolC from Escherichia coli. We found that, once assembled, the intermembrane AcrAB-TolC complex is stable during the separation of the inner and outer membranes and subsequent purification. All three components of the complex co-purify when the affinity tag is attached to either of the proteins suggesting bi-partite interactions between AcrA, AcrB, and TolC. We show that antibiotics, the substrates of AcrAB-TolC, stabilize interactions within the complex. However, the formation of the AcrAB-TolC complex does not require an input of energy.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Zgurskaya, HI (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval,Rm 208, Norman, OK 73019 USA.	elenaz@ou.edu	Tikhonova, Elena/P-2515-2015	Tikhonova, Elena/0000-0002-7892-9173; Zgurskaya, Helen/0000-0001-8929-4727	NIAID NIH HHS [1-R01-AI052293-01A1, R01 AI052293] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052293] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen C, 2001, CURR OPIN CELL BIOL, V13, P412, DOI 10.1016/S0955-0674(00)00229-5; Avila-Sakar AJ, 2001, J STRUCT BIOL, V136, P81, DOI 10.1006/jsbi.2001.4418; Balakrishnan L, 2001, J MOL BIOL, V313, P501, DOI 10.1006/jmbi.2001.5038; Borges-Walmsley MI, 2003, J BIOL CHEM, V278, P12903, DOI 10.1074/jbc.M209457200; Buchanan SK, 2001, TRENDS BIOCHEM SCI, V26, P3, DOI 10.1016/S0968-0004(00)01733-3; Chen JC, 2002, J BACTERIOL, V184, P695, DOI 10.1128/JB.184.3.695-705.2002; Elkins CA, 2002, J BACTERIOL, V184, P6490, DOI 10.1128/JB.184.23.6490-6499.2002; Fasman G. D., 1975, HDB BIOCH MOL BIOL; Fralick JA, 1996, J BACTERIOL, V178, P5803, DOI 10.1128/jb.178.19.5803-5805.1996; German GJ, 2001, J MOL BIOL, V308, P579, DOI 10.1006/jmbi.2001.4578; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; Ip H, 2003, J BIOL CHEM, V278, P50474, DOI 10.1074/jbc.M305152200; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; Jones HE, 2003, BBA-BIOMEMBRANES, V1612, P90, DOI 10.1016/S0005-2736(03)00082-8; Koch AL, 1998, CRIT REV MICROBIOL, V24, P23, DOI 10.1080/10408419891294172; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 1997, MOL MICROBIOL, V23, P617, DOI 10.1046/j.1365-2958.1997.d01-1880.x; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; Lomovskaya O, 1999, ANTIMICROB AGENTS CH, V43, P1340, DOI 10.1128/AAC.43.6.1340; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; Ma JX, 1997, BIOCHEMISTRY-US, V36, P11298, DOI 10.1021/bi9709710; Maseda H, 2002, MOL MICROBIOL, V46, P677, DOI 10.1046/j.1365-2958.2002.03197.x; Matsuo E, 2003, MOL GENET GENOMICS, V268, P808, DOI 10.1007/s00438-003-0803-9; Miyamae S, 2001, ANTIMICROB AGENTS CH, V45, P3341, DOI 10.1128/AAC.45.12.3341-3346.2001; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Possot OM, 1997, MOL MICROBIOL, V24, P457, DOI 10.1046/j.1365-2958.1997.3451726.x; SCHULEIN R, 1994, MOL GEN GENET, V245, P203; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Tikhonova EB, 2002, J BACTERIOL, V184, P6499, DOI 10.1128/JB.184.23.6499-6507.2002; YAMANE K, 1987, J BIOL CHEM, V262, P2358; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000; Zgurskaya HI, 1999, J MOL BIOL, V285, P409, DOI 10.1006/jmbi.1998.2313; Zgurskaya HI, 2002, INT J MED MICROBIOL, V292, P95, DOI 10.1078/1438-4221-00195; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	39	197	203	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32116	32124		10.1074/jbc.M402230200	http://dx.doi.org/10.1074/jbc.M402230200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155734	hybrid			2022-12-27	WOS:000222849700017
J	Mochizuki, T; Miyazaki, H; Hara, T; Furuya, T; Imamura, T; Watabe, T; Miyazono, K				Mochizuki, T; Miyazaki, H; Hara, T; Furuya, T; Imamura, T; Watabe, T; Miyazono, K			Roles for the MH2 domain of Smad7 in the specific inhibition of transforming growth factor-beta superfamily signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN; SPEMANNS ORGANIZER; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; XENOPUS-EMBRYOS; CELL-MEMBRANE; PROMOTER; RECEPTOR; TRANSCRIPTION; DEGRADATION	Signals by cytokines of the transforming growth factor-beta( TGF-beta) superfamily are negatively regulated by inhibitory Smads ( I-Smads). Smad7 inhibits signaling by both TGF-beta and bone morphogenetic proteins (BMPs), whereas Smad6 inhibits TGF-beta signals less effectively. I-Smads have amino-terminal N domains and carboxyl-terminal Mad homology 2 (MH2) domains. The N domains are essential for specific inhibition of TGF-beta signaling by Smad7, whereas the MH2 domains of I-Smads are involved in the inhibition of TGF-beta superfamily signals through interaction with type I receptors. Here, we have identified four basic amino acid residues (Lys-312, Lys-316, Lys-401, and Arg-409) in the basic surface of the Smad7 MH2 domain that play important roles in interaction with type I receptors. Mutations of the four basic amino acid residues to acidic residues (K312E, K316E, K401E, and R409E) abolished the interaction of Smad7 with TGF-beta type I receptors, inhibition of Smad2 phosphorylation and transcriptional responses induced by TGF-beta, and induction of target genes of endogenous activin/Nodal signals in Xenopus early embryos. The K401E and R409E mutants of Smad7 were also unable to interact with BMP type I receptors ( BMPR-I), repress the Smad5 phosphorylation and transcription induced by BMP, and effectively inhibit endogenous BMP signals in Xenopus early embryos. However, the K312E and K316E mutants were able to interact with BMPR-I and retained the ability to inhibit BMP signaling. Thus, the MH2 domain of Smad7 plays important roles in specific inhibition of TGF-beta superfamily signals through differential interaction with type I receptors.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo 1130033, Japan; PharmaDesign Inc, Tokyo 1040032, Japan	Japanese Foundation for Cancer Research; University of Tokyo; University of Tokyo	Miyazono, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	miyazono-ind@umin.ac.jp						Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bhushan A, 1998, DEV BIOL, V200, P260, DOI 10.1006/dbio.1998.8965; Casellas R, 1998, DEV BIOL, V198, P1; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mochizuki T, 2000, DEV BIOL, V224, P470, DOI 10.1006/dbio.2000.9778; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakayama T, 1998, DEVELOPMENT, V125, P857; Nakayama T, 2001, MECH DEVELOP, V100, P251, DOI 10.1016/S0925-4773(00)00533-5; Osada SI, 2003, DEVELOPMENT, V130, P1783, DOI 10.1242/dev.00401; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Zhao JS, 2000, J BIOL CHEM, V275, P23992, DOI 10.1074/jbc.M002433200	38	51	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31568	31574		10.1074/jbc.M313977200	http://dx.doi.org/10.1074/jbc.M313977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148321	hybrid			2022-12-27	WOS:000222726800079
J	Niu, SL; Mitchell, DC; Lim, SY; Wen, ZM; Kim, HY; Salem, N; Litman, BJ				Niu, SL; Mitchell, DC; Lim, SY; Wen, ZM; Kim, HY; Salem, N; Litman, BJ			Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC ACID; TERM INFANTS; METARHODOPSIN-II; VISUAL-ACUITY; DISK MEMBRANES; BRAIN; PHOSPHOLIPIDS; ACTIVATION; RATS	The fatty acid ( FA) docosahexaenoic acid ( DHA, 22: 6n-3) is highly enriched in membrane phospholipids of the central nervous system and retina. Loss of DHA because of n-3 FA deficiency leads to suboptimal function in learning, memory, olfactory-based discrimination, spatial learning, and visual acuity. G protein-coupled receptor (GPCR) signal transduction is a common signaling motif in these neuronal pathways. Here we investigated the effect of n-3 FA deficiency on GPCR signaling in retinal rod outer segment (ROS) membranes isolated from rats raised on n-3-adequate or -deficient diets. ROS membranes of second generation n-3 FA-deficient rats had similar to 80% less DHA than n-3-adequate rats. DHA was replaced by docosapentaenoic acid ( 22: 5n-6), an n-6 FA. This replacement correlated with desensitization of visual signaling in n-3 FA-deficient ROS, as evidenced by reduced rhodopsin activation, rhodopsin-ransducin (G(t)) coupling, cGMP phosphodiesterase activity, and slower formation of metarhodopsin II (MII) and the MII-G(t) complex relative to n-3 FA-adequate ROS. ROS membranes from n-3 FA-deficient rats exhibited a higher degree of phospholipid acyl chain order relative to n-3 FA-adequate rats. These findings reported here provide an explanation for the reduced amplitude and delayed response of the electroretinogram a-wave observed in n-3 FA deficiency in rodents and nonhuman primates. Because members of the GPCR family are widespread in signaling pathways in the nervous system, the effect of reduced GPCR signaling due to the loss of membrane DHA may serve as an explanation for the suboptimal neural signaling observed in n-3 FA deficiency.	NIAAA, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Litman, BJ (corresponding author), NIAAA, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA.	litman@helix.nih.gov		Lim, Sun Young/0000-0002-8091-3496	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000080, Z01AA000080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGOSTONI C, 1995, PEDIATR RES, V38, P262, DOI 10.1203/00006450-199508000-00021; BIRCH DG, 1992, INVEST OPHTH VIS SCI, V33, P2365; Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311; BIRCH EE, 1992, INVEST OPHTH VIS SCI, V33, P3242; BOURRE JM, 1989, J NUTR, V119, P1880, DOI 10.1093/jn/119.12.1880; Carlson SE, 1996, PEDIATR RES, V39, P882, DOI 10.1203/00006450-199605000-00024; Catalan J, 2002, BEHAV NEUROSCI, V116, P1022, DOI 10.1037//0735-7044.116.6.1022; Champoux M, 2002, PEDIATR RES, V51, P273, DOI 10.1203/00006450-200203000-00003; CONNOR WE, 1988, BIOL MEMBRANES ABERR, P275; Eldho NV, 2003, J AM CHEM SOC, V125, P6409, DOI 10.1021/ja029029o; Frances H, 1996, EUR J PHARMACOL, V298, P217, DOI 10.1016/0014-2999(95)00825-X; GALLI C, 1971, BIOCHIM BIOPHYS ACTA, V248, P449, DOI 10.1016/0005-2760(71)90233-5; Greiner RS, 2001, PHYSIOL BEHAV, V72, P379, DOI 10.1016/S0031-9384(00)00437-6; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Jeffrey BG, 2002, LIPIDS, V37, P839, DOI 10.1007/s11745-002-0969-0; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KIM HY, 1994, ANAL CHEM, V66, P3977, DOI 10.1021/ac00094a020; Koenig BW, 1997, BIOPHYS J, V73, P1954, DOI 10.1016/S0006-3495(97)78226-2; LAMPTEY MS, 1976, J NUTR, V106, P86, DOI 10.1093/jn/106.1.86; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; MAKRIDES M, 1993, PEDIATR RES, V33, P425; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; MILLER JL, 1987, BIOCHIM BIOPHYS ACTA, V898, P81, DOI 10.1016/0005-2736(87)90111-8; MILLS DE, 1988, NUTR RES, V8, P273, DOI 10.1016/S0271-5317(88)80045-9; Mitchell DC, 1998, BIOPHYS J, V74, P879, DOI 10.1016/S0006-3495(98)74011-1; Mitchell DC, 2001, J BIOL CHEM, V276, P42801, DOI 10.1074/jbc.M105772200; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; Niu SL, 2001, J BIOL CHEM, V276, P42807, DOI 10.1074/jbc.M105778200; Niu SL, 2002, J BIOL CHEM, V277, P20139, DOI 10.1074/jbc.M200594200; ORGANISCIAK DT, 1982, EXP EYE RES, V34, P401, DOI 10.1016/0014-4835(82)90086-0; Pawlosky RJ, 1997, AM J CLIN NUTR, V65, P465, DOI 10.1093/ajcn/65.2.465; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; SALEM N, 1989, CURRENT TOPICS NUTRI, V22, P109; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; Wainwright P E, 1998, Nutr Neurosci, V1, P281, DOI 10.1080/1028415X.1998.11747238; Weisinger HS, 2002, LIPIDS, V37, P759, DOI 10.1007/s11745-002-0958-3; Weisinger HS, 1996, ANN NUTR METAB, V40, P91, DOI 10.1159/000177900; Werkman SH, 1996, LIPIDS, V31, P91, DOI 10.1007/BF02522417; WHEELER TG, 1975, SCIENCE, V188, P1312, DOI 10.1126/science.1145197; YAMAMOTO N, 1991, J GERONTOL, V46, P17; YEE R, 1978, J BIOL CHEM, V253, P8902	44	190	197	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31098	31104		10.1074/jbc.M404376200	http://dx.doi.org/10.1074/jbc.M404376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145938	hybrid			2022-12-27	WOS:000222726800025
J	Roosterman, D; Cottrell, GS; Schmidlin, F; Steinhoff, M; Bunnett, NW				Roosterman, D; Cottrell, GS; Schmidlin, F; Steinhoff, M; Bunnett, NW			Recycling and resensitization of the neurokinin 1 receptor - Influence of agonist concentration and Rab GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SUBSTANCE-P RECEPTOR; BETA-ARRESTIN; ENDOCYTIC PATHWAY; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; INDUCED TRAFFICKING; EPITHELIAL-CELLS; PLASMA-MEMBRANE; EARLY ENDOSOMES	Substance P (SP) induces endocytosis and recycling of the neurokinin 1 receptor (NK1R) in endothelial cells and spinal neurons at sites of inflammation and pain, and it is thus important to understand the mechanism and function of receptor trafficking. We investigated how the SP concentration affects NK1R trafficking and determined the role of Rab GTPases in trafficking. NK1R trafficking was markedly influenced by the SP concentration. High SP (10 nM) induced translocation of the NK1R and beta-arrestin 1 to perinuclear sorting endosomes containing Rab5a, where NK1R remained for >60 min. Low SP (1 nM) induced translocation of the NK1R to early endosomes located immediately beneath the plasma membrane that also contained Rab5a and beta-arrestin 1, followed by rapid recycling of the NK1R. Overexpression of Rab5a promoted NK1R translocation to perinuclear sorting endosomes, whereas the GTP binding-deficient mutant Rab5aS34N caused retention of the NK1R in superficial early endosomes. NK1R translocated from superficial early endosomes to recycling endosomes containing Rab4a and Rab11a, and Rab11aS25N inhibited NK1R recycling. Rapid NK1R recycling coincided with resensitization of SP-induced Ca2+ mobilization and with the return of surface SP binding sites. Resensitization was minimally affected by inhibition of vacuolar H+-ATPase and phosphatases but was markedly suppressed by disruption of Rab4a and Rab11a. Thus, whereas beta-arrestins mediate NK1R endocytosis, Rab5a regulates translocation between early and sorting endosomes, and Rab4a and Rab11a regulate trafficking through recycling endosomes. We have thus identified a new function of Rab5a as a control protein for directing concentration-dependent trafficking of the NK1R into different intracellular compartments and obtained evidence that Rab4a and Rab11a contribute to G-protein-coupled receptor recycling from early endosomes.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.	nigelb@itsa.ucsf.edu	Steinhoff, Martin/F-6312-2013	Steinhoff, Martin/0000-0002-7090-2187; Cottrell, Graeme/0000-0001-9098-7627; Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK39957, DK43207] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039957, R01DK043207, R56DK043207, R37DK039957] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bohm SK, 1997, J BIOL CHEM, V272, P2363; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUNNETT NW, 1995, PEPTIDES, V16, P733, DOI 10.1016/0196-9781(95)00042-I; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dery O, 2001, AM J PHYSIOL-CELL PH, V280, pC1097, DOI 10.1152/ajpcell.2001.280.5.C1097; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; MOORE RH, 1995, J CELL SCI, V108, P2983; Nishimura K, 1998, BIOCHEMISTRY-US, V37, P1192, DOI 10.1021/bi972302s; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Roosterman D, 2003, AM J PHYSIOL-CELL PH, V284, pC1319, DOI 10.1152/ajpcell.00540.2002; Roush ED, 1999, MOL PHARMACOL, V55, P855; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Schmidlin F, 2003, AM J PHYSIOL-CELL PH, V285, pC945, DOI 10.1152/ajpcell.00541.2002; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VIGNA SR, 1994, J NEUROSCI, V14, P834; Vigna SR, 1999, J NEUROCHEM, V73, P1925; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; VON ZM, 1992, J BIOL CHEM, V267, P3530; Warabi K, 2002, FEBS LETT, V521, P140, DOI 10.1016/S0014-5793(02)02858-2	46	70	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30670	30679		10.1074/jbc.M402479200	http://dx.doi.org/10.1074/jbc.M402479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128739	hybrid			2022-12-27	WOS:000222531900097
J	Yeh, M; Gharavi, NM; Choi, J; Hsieh, X; Reed, E; Mouillesseaux, KP; Cole, AL; Reddy, ST; Berliner, JA				Yeh, M; Gharavi, NM; Choi, J; Hsieh, X; Reed, E; Mouillesseaux, KP; Cole, AL; Reddy, ST; Berliner, JA			Oxidized phospholipids increase interleukin 8 (IL-8) synthesis by activation of the c-src/signal transducers and activators of transcription (STAT)3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; MONOCYTE CHEMOTACTIC PROTEIN-1; LOW-DENSITY-LIPOPROTEIN; ENDOTHELIAL-CELLS; OXIDATION-PRODUCTS; TYROSINE KINASE; GENE-EXPRESSION; V-SRC; STAT3	Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (Ox-PAPC) and its component phospholipids 1-palmitoyl-2-epoxyisoprostane-sn-glycero-3-phosphorylcholine (PEIPC) and 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine induce endothelial cells to synthesize chemotactic factors, such as interleukin 8 (IL-8). We have shown recently that Ox-PAPC-mediated induction of IL-8 transcription is independent of NF-kappaB activation, a major transcription factor utilized by cytokines and lipopolysaccharide for the induction of IL-8 transcription. In this study, we provide evidence for the role of c-src in Ox-PAPC and, specifically, PEIPC-mediated IL-8 induction. Ox-PAPC and its component phospholipids induced a rapid and transient phosphorylation of c-src Tyr(418), a hallmark of c-src activation, in human aortic endothelial cells ( HAEC). Ox-PAPC-mediated IL-8 protein synthesis in HAEC was inhibited by Src family kinase inhibitors, PP1 and PP2, but not by an inactive analog, PP3. Transient expression of plasmids containing C-terminal Src kinase or kinase-deficient dominant-negative c-src resulted in a 72 and 50% reduction in Ox-PAPC- induced IL-8 promoter activation in human microvascular endothelial cells, respectively. In contrast, overexpression of v-src kinase resulted in a 4-fold increase in IL-8 promoter activation, without inducing NF-kappaB promoter activation. Furthermore, treatment of HAEC with Ox-PAPC and its component PEIPC induced the activation of STAT3 by phosphorylating Tyr(705), a feature of STAT3 activation. STAT3 is a known downstream effector of c-src. Ox-PAPC- induced activation of STAT3 resulted in the translocation of STAT3 from the cytoplasm of HAEC into their nuclear compartment. Transient expression of a dominant-negative STAT3beta construct in HMEC strongly inhibited IL-8 induction by Ox-PAPC. Taken together, these data demonstrate the role of the c-src kinase/STAT3 pathway in Ox-PAPC- mediated IL-8 expression in endothelial cells.	Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Berliner, JA (corresponding author), 13-239 CHS Pathol,650 Charles E Young Dr S, Los Angeles, CA 90095 USA.	myeh@mednet.ucla.edu	Gharavi, Nima/AAN-7890-2020					Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6; Blaber R, 2003, J AM SOC NEPHROL, V14, P116, DOI 10.1097/01.ASN.0000040595.35207.62; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Cole AL, 2003, ARTERIOSCL THROM VAS, V23, P1384, DOI 10.1161/01.ATV.0000081215.45714.71; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Debets R, 2001, J IMMUNOL, V167, P1440, DOI 10.4049/jimmunol.167.3.1440; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EICHER DM, 1994, J IMMUNOL, V152, P2710; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Fujimoto J, 2003, J BIOMED SCI, V10, P320, DOI 10.1159/000070097; Funakoshi-Tago M, 2003, EUR J BIOCHEM, V270, P1257, DOI 10.1046/j.1432-1033.2003.03487.x; Hazeki K, 2003, EUR J IMMUNOL, V33, P740, DOI 10.1002/eji.200323375; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Lee H, 2000, CIRC RES, V87, P516; Liu R, 2001, J LEUKOCYTE BIOL, V70, P961; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masamune A, 2002, J PHARMACOL EXP THER, V302, P36, DOI 10.1124/jpet.302.1.36; Maziere C, 1999, FEBS LETT, V448, P49, DOI 10.1016/S0014-5793(99)00324-5; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Myers SJ, 1999, ATHEROSCLEROSIS, V143, P389, DOI 10.1016/S0021-9150(98)00331-1; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; SCHMID P, 1993, ARCH DERMATOL RES, V285, P334, DOI 10.1007/BF00371833; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Shih PT, 1999, J CLIN INVEST, V103, P613, DOI 10.1172/JCI5710; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Vaingankar SM, 1998, J BIOL CHEM, V273, P5226, DOI 10.1074/jbc.273.9.5226; Velichko S, 2002, J BIOL CHEM, V277, P35635, DOI 10.1074/jbc.M204578200; Vink A, 2002, CIRCULATION, V106, P1985, DOI 10.1161/01.CIR.0000032146.75113.EE; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; Walton KA, 2003, ARTERIOSCL THROM VAS, V23, P1197, DOI 10.1161/01.ATV.0000079340.80744.B8; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573; Yeh M, 2001, ARTERIOSCL THROM VAS, V21, P1585, DOI 10.1161/hq1001.097027; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	45	105	107	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30175	30181		10.1074/jbc.M312198200	http://dx.doi.org/10.1074/jbc.M312198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15143062	hybrid			2022-12-27	WOS:000222531900039
J	Liu, HB; Holm, M; Xie, XQ; Wolf-Watz, M; Grundstrom, T				Liu, HB; Holm, M; Xie, XQ; Wolf-Watz, M; Grundstrom, T			AML1/Runx1 recruits calcineurin to regulate granulocyte macrophage colony-stimulating factor by Ets1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE-BINDING-FACTOR; T-CELL-RECEPTOR; GM-CSF PROMOTER; NF-KAPPA-B; DNA-BINDING; TRANSCRIPTION FACTOR; PHOSPHATASE CALCINEURIN; NEGATIVE REGULATION; PROTEIN INTERFERES; SIGNALING PATHWAYS	Acute myeloid leukemia 1 (AML1), also denoted Runx1, is a transcription factor essential for hematopoiesis, and the AML1 gene is the most common target of chromosomal translocations in human leukemias. AML1 binds to sequences present in the regulatory regions of a number of hematopoiesis-specific genes, including certain cytokines such as granulocyte macrophage colony-stimulating factor (GM-CSF) up-regulated after T cell receptor stimulation. Here we show that both subunits of the Ca2+/calmodulin-dependent protein phosphatase calcineurin (CN), which is activated upon T cell receptor stimulation, interact directly with the N-terminal runt homology domain-containing part of AML1. The regulatory CN subunit binds AML1 with a higher affinity and in addition also interacts with the isolated runt homology domain. The related Runx2 transcription factor, which is essential for bone formation, also interacts with CN. A constitutively active derivative of CN is shown to activate synergistically the GM-CSF promoter/enhancer together with AML1 or Runx2. We also provide evidence that relief of the negative effect of the AML1 sites is important for Ca2+ activation of the GM-CSF promoter/enhancer and that AML1 overexpression increases this Ca2+ activation. Both subunits of CN interact with AML1 in coimmunoprecipitation analyses, and confocal microscopy analysis of cells expressing fluorescence-tagged protein derivatives shows that CN can be recruited to the nucleus by AML1 in vivo. Mutant analysis of the GM-CSF promoter shows that the Ets1 binding site of the promoter is essential for the synergy between AML1 and CN in Jurkat T cells. Analysis of the effects of inhibitors of the protein kinase glycogen synthase kinase-beta and in vitro phosphorylation/dephosphorylation analysis of Ets1 suggest that glycogen synthase kinase-3beta-phosphorylated Ets1 is a target of AML1-recruited CN phosphatase at the GM-CSF promoter.	Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden	Umea University	Grundstrom, T (corresponding author), Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden.	thomas.grundstrom@molbiol.umu.se	Holm, Magnus/B-8932-2008					Backstrom S, 2002, J MOL BIOL, V322, P259, DOI 10.1016/S0022-2836(02)00702-7; BAE SC, 1993, ONCOGENE, V8, P809; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Benschop RJ, 2001, J IMMUNOL, V167, P4172, DOI 10.4049/jimmunol.167.8.4172; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GAJEWSKI TF, 1994, J EXP MED, V179, P481, DOI 10.1084/jem.179.2.481; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; LARS N, 1993, INT IMMUNOL, V5, P271, DOI 10.1093/intimm/5.3.271; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Liles W C, 2001, Semin Respir Infect, V16, P11; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; LU J, 1995, MOL CELL BIOL, V15, P1651; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; McKinlay LH, 1998, J IMMUNOL, V161, P4098; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Okuda T, 2001, INT J HEMATOL, V74, P252, DOI 10.1007/BF02982057; Perry C, 2002, LEUKEMIA RES, V26, P221, DOI 10.1016/S0145-2126(01)00128-X; PISTOIA V, 1995, STEM CELLS, V13, P487, DOI 10.1002/stem.5530130506; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1991, MOL CELL BIOL, V11, P5671, DOI 10.1128/MCB.11.11.5671; Shang C, 1999, INT IMMUNOL, V11, P1945, DOI 10.1093/intimm/11.12.1945; Shannon MF, 1997, CRIT REV IMMUNOL, V17, P301, DOI 10.1615/CritRevImmunol.v17.i3-4.30; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SloanLancaster J, 1996, J EXP MED, V184, P1525, DOI 10.1084/jem.184.4.1525; Speck NA, 2001, CURR OPIN HEMATOL, V8, P192, DOI 10.1097/00062752-200107000-00002; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; THORNELL A, 1993, J BIOL CHEM, V268, P21946; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; TRUNEH A, 1985, J IMMUNOL, V135, P2262; UEKI K, 1992, BIOCHEM BIOPH RES CO, V187, P537, DOI 10.1016/S0006-291X(05)81527-X; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	78	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29398	29408		10.1074/jbc.M403173200	http://dx.doi.org/10.1074/jbc.M403173200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123671	hybrid			2022-12-27	WOS:000222445300072
J	Nouet, S; Amzallag, N; Li, JM; Louis, S; Seitz, I; Cui, TX; Alleaume, AM; Di Benedetto, M; Boden, C; Masson, M; Strosberg, AD; Horiuchi, M; Couraud, PO; Nahmias, C				Nouet, S; Amzallag, N; Li, JM; Louis, S; Seitz, I; Cui, TX; Alleaume, AM; Di Benedetto, M; Boden, C; Masson, M; Strosberg, AD; Horiuchi, M; Couraud, PO; Nahmias, C			Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; TYPE-2 RECEPTOR; COUPLED RECEPTORS; INDEPENDENT ACTIVATION; SHP-1; AT(2); TRANSACTIVATION; LOCALIZATION; ASSOCIATION; INHIBITION	Negative regulation of mitogenic pathways is a fundamental process that remains poorly characterized. The angiotensin II AT2 receptor is a rare example of a 7-transmembrane domain receptor that negatively cross-talks with receptor tyrosine kinases to inhibit cell growth. In the present study, we report the molecular cloning of a novel protein, ATIP1 (AT2-interacting protein), which interacts with the C-terminal tail of the AT2 receptor, but not with those of other receptors such as angiotensin AT1, bradykinin BK2, and adrenergic beta(2) receptor. ATIP1 defines a family of at least four members that possess the same domain of interaction with the AT2 receptor, contain a large coiled-coil region, and are able to dimerize. Ectopic expression of ATIP1 in eukaryotic cells leads to inhibition of insulin, basic fibroblast growth factor, and epidermal growth factor-induced ERK2 activation and DNA synthesis, and attenuates insulin receptor autophosphorylation, in the same way as the AT2 receptor. The inhibitory effect of ATIP1 requires expression, but not ligand activation, of the AT2 receptor and is further increased in the presence of Ang II, indicating that ATIP1 cooperates with AT2 to transinactivate receptor tyrosine kinases. Our findings therefore identify ATIP1 as a novel early component of growth inhibitory signaling cascade.	Inst Cochin Genet Mol, Dept Cell Biol, CNRS, UMR8104,INSERM,U567, F-75014 Paris, France; Univ Melbourne, Clin Pharmacol Unit, Austin Hlth, Heidelberg, Vic 3084, Australia; Ehime Univ, Sch Med, Dept Med Biochem, Shigenobu, Ehime 7910295, Japan; Mol Engines Labs, F-75011 Paris, France; Deutsch Herzzentrum Munich, D-80636 Munich, Germany; Hybrigenics SA, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Ehime University; German Heart Centre Munich	Nahmias, C (corresponding author), Inst Cochin Genet Mol, Dept Cell Biol, CNRS, UMR8104,INSERM,U567, 22 Rue Mechain, F-75014 Paris, France.	nahmias@cochin.inserm.fr	Di Benedetto, Melanie MD/C-1512-2018	Di Benedetto, Melanie MD/0000-0003-1119-3752; Alleaume, Anne-Marie/0000-0001-7881-1880; Cui, Taixing/0000-0002-9528-7299				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Cui TX, 2002, MOL ENDOCRINOL, V16, P2113, DOI 10.1210/me.2001-0284; Cui TX, 2001, CARDIOVASC RES, V49, P863, DOI 10.1016/S0008-6363(00)00299-6; Cui TX, 2000, BIOCHEM BIOPH RES CO, V279, P938, DOI 10.1006/bbrc.2000.4055; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; De Paolis P, 2002, J HYPERTENS, V20, P693, DOI 10.1097/00004872-200204000-00027; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Di Liberto G, 2003, AM J PHYSIOL-CELL PH, V285, pC599, DOI 10.1152/ajpcell.00040.2003; Elbaz N, 2000, MOL ENDOCRINOL, V14, P795, DOI 10.1210/me.14.6.795; Feng YH, 2002, P NATL ACAD SCI USA, V99, P12049, DOI 10.1073/pnas.192404199; Gallinat S, 2000, AM J PHYSIOL-ENDOC M, V278, pE357, DOI 10.1152/ajpendo.2000.278.3.E357; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Horiuchi M, 1999, TRENDS ENDOCRIN MET, V10, P391, DOI 10.1016/S1043-2760(99)00191-5; Knowle D, 2000, REGUL PEPTIDES, V87, P73, DOI 10.1016/S0167-0115(99)00111-1; LAZARD D, 1994, RECEPTOR CHANNEL, V2, P271; Lehtonen JYA, 1999, MOL ENDOCRINOL, V13, P1051, DOI 10.1210/me.13.7.1051; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; Matsubara H, 2001, BIOCHEM BIOPH RES CO, V282, P1085, DOI 10.1006/bbrc.2001.4695; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; NAHMIAS C, 1995, BIOCHEM J, V306, P87, DOI 10.1042/bj3060087; Nouet S, 2000, TRENDS ENDOCRIN MET, V11, P1, DOI 10.1016/S1043-2760(99)00205-2; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pulakat L, 2002, FEBS LETT, V524, P73, DOI 10.1016/S0014-5793(02)03005-3; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Shibasaki Y, 2001, HYPERTENSION, V38, P367, DOI 10.1161/01.HYP.38.3.367; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Stoll M, 2001, REGUL PEPTIDES, V99, P175, DOI 10.1016/S0167-0115(01)00246-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Volpe M, 2003, J HYPERTENS, V21, P1429, DOI 10.1097/00004872-200308000-00001; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	41	135	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28989	28997		10.1074/jbc.M403880200	http://dx.doi.org/10.1074/jbc.M403880200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123706	hybrid			2022-12-27	WOS:000222445300021
J	Sato, O; White, HD; Inoue, A; Belknap, B; Ikebe, R; Ikebe, M				Sato, O; White, HD; Inoue, A; Belknap, B; Ikebe, R; Ikebe, M			Human deafness mutation of myosin VI (C442Y) accelerates the ADP dissociation rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; MOTOR DOMAIN DETERMINES; LIGHT-CHAIN KINASE; ACTIN-BASED MOTOR; UNCONVENTIONAL MYOSIN; KINETIC MECHANISM; SNELLS-WALTZER; INNER-EAR; 2-HEADED STRUCTURE	The missense mutation of Cys(442) to Tyr of myosin VI causes progressive postlingual sensorineural deafness. Here we report the affects of the C442Y mutation on the kinetics of the actomyosin ATP hydrolysis mechanism and motor function of myosin VI. The largest changes in the kinetic mechanism of ATP hydrolysis produced by the C442Y mutation are about 10-fold increases in the rate of ADP dissociation from both myosin VI and actomyosin VI. The rates of ADP dissociation from acto-C442Y myosin VI-ADP and C442Y myosin VI-ADP are 20 - 40 times more rapid than the steady state rates and cannot be the rate-limiting steps of the hydrolysis mechanism in the presence or absence of actin. The 2-fold increase in the actin gliding velocity of C442Y compared with wild type (WT) may be explained at least in part by the more rapid rate of ADP dissociation. The C442Y myosin VI has a significant increase (similar to 10-fold) in the steady state ATPase rate in the absence of actin relative to WT myosin VI. The steady state rate of actin-activated ATP hydrolysis is unchanged by the C442Y mutation at low (< 10(-7) M) calcium but is calcium-sensitive with a 1.6-fold increase at high ( similar to 10(-4) M) calcium that does not occur with WT. The actin gliding velocity of the C442Y mutant decreases significantly at low surface density of myosin VI, suggesting that the mutation hampers the processive movement of myosin VI.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23507 USA	University of Massachusetts System; University of Massachusetts Worcester; Eastern Virginia Medical School	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu			NIAMS NIH HHS [AR 48526, AR41653] Funding Source: Medline; NIBIB NIH HHS [EB00209] Funding Source: Medline; NIGMS NIH HHS [GM 55834] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048526, R01AR041653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000209] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; Bohrmann J, 1997, CELL MOL LIFE SCI, V53, P652, DOI 10.1007/s000180050084; Buss F, 2001, FEBS LETT, V508, P295, DOI 10.1016/S0014-5793(01)03065-4; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; DEOL MS, 1966, GENET RES, V8, P339, DOI 10.1017/S0016672300010193; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Friedman TB, 1999, AM J MED GENET, V89, P147, DOI 10.1002/(SICI)1096-8628(19990924)89:3<147::AID-AJMG5>3.0.CO;2-6; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; HEINTZELMAN MB, 1994, J CELL SCI, V107, P3535; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1987, J BIOL CHEM, V262, P13828; KAMM KE, 1987, AM REV RESPIR DIS, V136, pS12, DOI 10.1164/ajrccm/136.4_Pt_2.S12; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 2000, BIOCHEMISTRY-US, V39, P2254, DOI 10.1021/bi9924617; Li XD, 2003, J BIOL CHEM, V278, P29435, DOI 10.1074/jbc.M301784200; Li XD, 1998, J BIOL CHEM, V273, P27404, DOI 10.1074/jbc.273.42.27404; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Melchionda S, 2001, AM J HUM GENET, V69, P635, DOI 10.1086/323156; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424; Sellers J. R., 1999, MYOSINS; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; TAYLOR EW, 1977, BIOCHEMISTRY-US, V16, P732, DOI 10.1021/bi00623a027; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITE HD, 1993, J BIOL CHEM, V268, P10039; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	59	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28844	28854		10.1074/jbc.M314332200	http://dx.doi.org/10.1074/jbc.M314332200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123708	hybrid			2022-12-27	WOS:000222445300004
J	Wang, Q; Liu, M; Kozasa, T; Rothstein, JD; Sternweis, PC; Neubig, RR				Wang, Q; Liu, M; Kozasa, T; Rothstein, JD; Sternweis, PC; Neubig, RR			Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; G(12) FAMILY; KINASE; LARG; PHOSPHORYLATION; IDENTIFICATION; G-ALPHA(13); EXPRESSION	Thrombin and lysophosphatidic acid (LPA) receptors play important roles in vascular biology, development, and cancer. These receptors activate rho via G(12/13) family heterotrimeric G proteins, which are known to directly activate three distinct rho guanine nucleotide exchange factors ( rhoGEFs) that contain a regulator of G protein signaling (RGS) domain (RGS-rhoGEFs). However, it is not known which, if any, of these RGS-rhoGEFs ( LARG (leukemia-associated rhoGEF), p115rhoGEF, or PDZrhoGEF) plays a role in G protein-coupled receptor-stimulated rho signaling. Using oligonucleotide small interfering RNAs that suppress specific RGS-rhoGEF expression, we show that thrombin receptor stimulation of rho is primarily mediated by LARG in HEK293T and PC-3 prostate cancer cell lines. In contrast, the LPA-stimulated rho response in PC-3 cells is dependent on PDZrhoGEF expression. Suppression of p115rhoGEF had no effect. Thus different rhoGEFs ( LARG and PDZrhoGEF) mediate downstream rho signaling by the thrombin and LPA receptors.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Neubig, RR (corresponding author), Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA.	rneubig@umich.edu	rothstein, jeffrey d/C-9470-2013	Neubig, Richard/0000-0003-0501-0008	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, R01GM061454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954, GM39561, GM61454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; Cooper CR, 2003, CANCER-AM CANCER SOC, V97, P739, DOI 10.1002/cncr.11181; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Huang YQ, 2001, THROMB HAEMOSTASIS, V86, P1094; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Liu J, 2003, UROL RES, V31, P163, DOI 10.1007/s00240-003-0309-2; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; WANG Q, 2004, IN PRESS METHODS ENZ, V389; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200	29	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28831	28834		10.1074/jbc.C400105200	http://dx.doi.org/10.1074/jbc.C400105200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15143072	hybrid			2022-12-27	WOS:000222445300002
J	Divinski, I; Mittelman, L; Gozes, I				Divinski, I; Mittelman, L; Gozes, I			A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; DEPENDENT NEUROTROPHIC FACTOR; NEUROPROTECTIVE PEPTIDE; HEAD-INJURY; DIPHTHERIA-TOXIN; NAP; VIP; TOXICITY; CELLS; BRAIN	An octapeptide was previously described that protects neurons against a wide variety of insults directly and indirectly as a result of interactions (at femtomolar concentrations) with supporting glial cells. The current study set out to identify the octapeptide binding molecules so as to understand the high affinity mechanisms of cellular protection. Studies utilizing affinity chromatography of brain extracts identified tubulin, the brain major protein, as the octapeptide-binding ligand. Dot blot analysis with pure tubulin and the biotinylated octapeptide verified this finding. When added to cerebral cortical astrocytes, the octapeptide (10(-15)-10(-10) M) induced a rapid microtubule reorganization into distinct microtubular structures that were stained by monoclonal tubulin antibodies and visualized by confocal microscopy. Fluorescein-labeled octapeptide induced a similar change and was detected in the intracellular milieu, even when cells were incubated at 4 degreesC or at low pH. In a cell-free system, the octapeptide stimulated tubulin assembly into microtubules. Furthermore, treatment of astrocytes with zinc chloride resulted in microtubule disassembly and cell death that was protected by the octapeptide. In conclusion, the results suggest that the octapeptide crosses the plasma membrane and interacts directly with tubulin, the microtubule subunit, to induce microtubule reorganization and improved survival. Because microtubules are the key component of the neuronal and glial cytoskeleton that regulates cell division, differentiation, and efficiency of the cellular protective capacities of the octapeptide.	Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Interdepartmental Core Facil, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Gozes, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il						Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Ashur-Fabian O, 2003, PEPTIDES, V24, P1413, DOI 10.1016/j.peptides.2003.08.005; Ashur-Fabian O, 2001, NEUROSCI LETT, V307, P167, DOI 10.1016/S0304-3940(01)01954-1; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brenneman DE, 2004, J PHARMACOL EXP THER, V309, P1190, DOI 10.1124/jpet.103.063891; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Brenneman DE, 1998, J PHARMACOL EXP THER, V285, P619; Brenneman DE, 2000, BIOCHEM SOC T, V28, P452, DOI 10.1042/0300-5127:0280452; Brion JP, 2001, BIOCHEM SOC SYMP, V67, P81; Chen CJ, 2003, J NEUROCHEM, V85, P443, DOI 10.1046/j.1471-4159.2003.01691.x; Cribbs DH, 1997, J BIOL CHEM, V272, P7431, DOI 10.1074/jbc.272.11.7431; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; GOTTLIEB P, 1982, EUR J BIOCHEM, V125, P631, DOI 10.1111/j.1432-1033.1982.tb06729.x; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; GOZES I, 1982, NEUROCHEM INT, V4, P101, DOI 10.1016/0197-0186(82)90003-1; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; GOZES I, 1981, NATURE, V294, P477, DOI 10.1038/294477a0; Gozes I, 2002, J MOL NEUROSCI, V19, P167, DOI 10.1007/s12031-002-0028-0; GOZES I, 1978, NATURE, V276, P411, DOI 10.1038/276411a0; GOZES I, 1982, P NATL ACAD SCI-BIOL, V79, P2579, DOI 10.1073/pnas.79.8.2579; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; Gozes I, 2000, J MOL NEUROSCI, V14, P61, DOI 10.1385/JMN:14:1-2:061; Hamel E, 2002, BIOPOLYMERS, V66, P142, DOI 10.1002/bip.10255; Islam K, 1997, AM J PATHOL, V151, P265; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Li GB, 2003, J NEUROCHEM, V84, P347, DOI 10.1046/j.1471-4159.2003.01526.x; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Loring JF, 2001, DNA CELL BIOL, V20, P683, DOI 10.1089/10445490152717541; Martin A, 2002, J VIROL, V76, P4961, DOI 10.1128/JVI.76.10.4961-4970.2002; MAXWELL IH, 1992, LEUKEMIA LYMPHOMA, V7, P457, DOI 10.3109/10428199209049802; Moscarello MA, 2002, MULT SCLER J, V8, P130, DOI 10.1191/1352458502ms776oa; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Petrova PS, 2004, PROG BRAIN RES, V146, P167, DOI 10.1016/S0079-6123(03)46012-3; PIZZA M, 1990, J BIOL CHEM, V265, P17759; Plassart-Schiess E, 2001, BRAIN RES REV, V37, P133, DOI 10.1016/S0165-0173(01)00113-8; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; SARIS P, 1990, FEMS MICROBIOL LETT, V68, P143; SEBO P, 1995, INFECT IMMUN, V63, P3851, DOI 10.1128/IAI.63.10.3851-3857.1995; Sigalov E, 2000, J MOL NEUROSCI, V15, P147, DOI 10.1385/JMN:15:3:147; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; Steingart RA, 2000, J MOL NEUROSCI, V15, P137, DOI 10.1385/JMN:15:3:137; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; Terry RD, 1998, J NEURAL TRANSM-SUPP, P141; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; Yoshiyama Y, 2003, J NEUROSCI, V23, P10662; Zaltzman R, 2003, NEUROREPORT, V14, P481, DOI 10.1097/01.wnr.0000058036.29600.ff; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1	51	124	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28531	28538		10.1074/jbc.M403197200	http://dx.doi.org/10.1074/jbc.M403197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123709	hybrid			2022-12-27	WOS:000222265400089
J	Yoon, T; Cowan, JA				Yoon, T; Cowan, JA			Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUSTER BIOSYNTHESIS; FRIEDREICH ATAXIA; ENZYME; DEFICIENT; HOMODIMER; PROTEINS; BINDING; FORMS	Human ferrochelatase, a mitochondrial membrane-associated protein, catalyzes the terminal step of heme biosynthesis by insertion of ferrous iron into protoporphyrin IX. The recently solved x-ray structure of human ferrochelatase identifies a potential binding site for an iron donor protein on the matrix side of the homodimer. Herein we demonstrate Hs holofrataxin to be a high affinity iron binding partner for Hs ferrochelatase that is capable of both delivering iron to ferrochelatase and mediating the terminal step in mitochondrial heme biosynthesis. A general regulatory mechanism for mitochondrial iron metabolism is described that defines frataxin involvement in both heme and iron-sulfur cluster biosyntheses. In essence, the distinct binding affinities of holofrataxin to the target proteins, ferrochelatase ( heme synthesis) and ISU (iron-sulfur cluster synthesis), allows discrimination between the two major iron-dependent pathways and facilitates targeted heme biosynthesis following down-regulation of frataxin.	Ohio State Univ, Evans Lab Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Cowan, JA (corresponding author), Ohio State Univ, Evans Lab Chem, 100 W 18th Ave, Columbus, OH 43210 USA.	cowan@chemistry.ohio-state.edu						Becker EM, 2002, BLOOD, V99, P3813, DOI 10.1182/blood.V99.10.3813; Burden AE, 1999, BBA-PROTEIN STRUCT M, V1435, P191, DOI 10.1016/S0167-4838(99)00196-X; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Cavadini P, 2000, J BIOL CHEM, V275, P41469, DOI 10.1074/jbc.M006539200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Grzybowska E, 2002, ARCH BIOCHEM BIOPHYS, V398, P170, DOI 10.1006/abbi.2001.2730; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Musco G, 2000, STRUCTURE, V8, P695, DOI 10.1016/S0969-2126(00)00158-1; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Sellers VM, 2001, BIOCHEMISTRY-US, V40, P9821, DOI 10.1021/bi010012c; Wu CK, 2001, NAT STRUCT BIOL, V8, P156, DOI 10.1038/84152; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i	18	226	237	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25943	25946		10.1074/jbc.C400107200	http://dx.doi.org/10.1074/jbc.C400107200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15123683	hybrid			2022-12-27	WOS:000222003000003
J	Behrmann, I; Smyczek, T; Heinrich, PC; Schmitz-Van de Leur, H; Komyod, W; Giese, B; Muller-Newen, G; Haan, S; Haan, C				Behrmann, I; Smyczek, T; Heinrich, PC; Schmitz-Van de Leur, H; Komyod, W; Giese, B; Muller-Newen, G; Haan, S; Haan, C			Janus kinase (Jak) subcellular localization revisited - The exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak center dot receptor complex to be equivalent to a receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; SIGNAL TRANSDUCER GP130; PROTEIN-KINASE; FERM DOMAIN; ENDOPLASMIC-RETICULUM; NUCLEAR-LOCALIZATION; INTERFERON RESPONSES; N-TERMINUS; TYK2; INTERLEUKIN-6	The Janus kinases are considered to be cytoplasmic kinases that constitutively associate with the cytoplasmic region of cytokine receptors, and the Janus kinases (Jaks) are crucial for cytokine signal transduction. We investigated Jak1 localization using subcellular fractionation techniques and fluorescence microscopy (immunofluorescence and yellow fluorescent protein-tagged Jaks). In the different experimental approaches we found Jak1 (as well as Jak2 and Tyk2) predominantly located at membranes. In contrast to previous reports we did not observe Jak proteins in significant amounts within the nucleus or in the cytoplasm. The cytoplasmic localization observed for the Jak1 mutant L80A/Y81A, which is unable to associate with cytokine receptors, indicates that Jak1 does not have a strong intrinsic membrane binding potential and that only receptor binding is crucial for the membrane recruitment. Finally we show that Jak1 remains a membrane-localized protein after cytokine stimulation. These data strongly support the hypothesis that cytokine receptor Janus kinase complexes can be regarded as receptor tyrosine kinases.	Univ Luxembourg, Fac Sci Technol & Commun, Lab Biol & Physiol Integree, L-1511 Luxembourg, Luxembourg; Univ Klinikum Aachen, Inst Biochem, D-52074 Aachen, Germany	University of Luxembourg; RWTH Aachen University; RWTH Aachen University Hospital	Haan, C (corresponding author), Univ Luxembourg, Fac Sci Technol & Commun, Lab Biol & Physiol Integree, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	claude.haan@rwth-aachen.de	Komyod, Waraporn/CAG-9665-2022	Komyod, Waraporn/0000-0001-8020-0026; Behrmann, Iris/0000-0003-3688-3645				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BERNARDS A, 1991, ONCOGENE, V6, P1185; Bork P, 1996, METHOD ENZYMOL, V266, P162; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Cohen J, 1997, BIOCHEM J, V327, P391, DOI 10.1042/bj3270391; Dondi E, 2001, J BIOL CHEM, V276, P47004, DOI 10.1074/jbc.M104316200; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2000, BIOCHEM J, V349, P261, DOI 10.1042/0264-6021:3490261; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Hilkens CMU, 2001, FEBS LETT, V505, P87, DOI 10.1016/S0014-5793(01)02783-1; Hoffner G, 2002, J CELL SCI, V115, P941; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kampa D, 2000, BIOCHEM BIOPH RES CO, V278, P175, DOI 10.1006/bbrc.2000.3757; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Lavoie C, 2000, P NATL ACAD SCI USA, V97, P13637, DOI 10.1073/pnas.240278097; Lobie PE, 1996, ENDOCRINOLOGY, V137, P4037, DOI 10.1210/en.137.9.4037; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2001, J BIOL CHEM, V276, P30812, DOI 10.1074/jbc.M103559200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; SORENSON RL, 1995, ENDOCRINOLOGY, V136, P4092, DOI 10.1210/en.136.9.4092; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Vigouroux C, 2001, J CELL SCI, V114, P4459; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392	48	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35486	35493		10.1074/jbc.M404202200	http://dx.doi.org/10.1074/jbc.M404202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15123646	hybrid			2022-12-27	WOS:000223303400042
J	Ivey, RA; Zhang, YM; Virga, KG; Hevener, K; Lee, RE; Rock, CO; Jackowski, S; Park, HW				Ivey, RA; Zhang, YM; Virga, KG; Hevener, K; Lee, RE; Rock, CO; Jackowski, S; Park, HW			The structure of the pantothenate kinase center dot ADP center dot pantothenate ternary complex reveals the relationship between the binding sites for substrate, allosteric regulator, and antimetabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A; ESCHERICHIA-COLI; ACUTE ENCEPHALOPATHY; CALCIUM HOPANTENATE; CRYSTAL-STRUCTURE; GENE; CLONING; ADENYLYLTRANSFERASE; IDENTIFICATION; MECHANISMS	Pantothenate kinase catalyzes the first step in the biosynthesis of coenzyme A, the major acyl group carrier in biology. In bacteria, regulation of pantothenate kinase activity is a major factor in controlling intracellular coenzyme A levels, and pantothenate analogs are growth-inhibiting antimetabolites. We have extended the structural information on Escherichia coli pantothenate kinase by determining the structure of the enzyme.ADP. pantothenate ternary complex. Pantothenate binding induces a significant conformational change in amino acids 243-263, which form a "lid" that folds over the open pantothenate binding groove. The positioning of the substrates suggests the reaction proceeds by a concerted mechanism that involves a dissociative transition state, although the negative charge neutralization of the gamma-phosphate by Arg-243, Lys-101, and Mg2+ coupled with hydrogen bonding of the C1 of pantothenate to Asp-127 suggests different interpretations of the phosphoryl transfer mechanism of pantothenate kinase. N-alkylpantothenamides are substrates for pantothenate kinase. Modeling these antimetabolites into the pantothenate active site predicts that they bind in the same orientation as pantothenate with their alkyl chains interacting with the hydrophobic dome over the pantothenate pocket, which is also accessed by the beta-mercaptoethylamine moiety of the allosteric regulator, coenzyme A. These structural/biochemical studies illustrate the intimate relationship between the substrate, allosteric regulator, and antimetabolite binding sites on pantothenate kinase and provide a framework for studies of its catalysis and feedback regulation.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Biosci, Memphis, TN 38163 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Park, HW (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	hee-won.park@stjude.org	Lee, Richard/AAX-3996-2021; Hevener, Kirk/AAC-4828-2020; Lee, Richard/J-4997-2013; Jackowski, Suzanne/N-8168-2018	Lee, Richard/0000-0002-2397-0443; Hevener, Kirk/0000-0002-5584-3625; Lee, Richard/0000-0002-2397-0443; Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496, R01GM062896] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIGMS NIH HHS [GM 62896, GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Begley TP, 2001, VITAM HORM, V61, P157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN ID, 1985, ACTA CRYSTALLOGR B, V41, P244, DOI 10.1107/S0108768185002063; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Cleland WW, 1995, FASEB J, V9, P1585, DOI 10.1096/fasebj.9.15.8529838; CLIFTON G, 1970, ARCH BIOCHEM BIOPHYS, V137, P523, DOI 10.1016/0003-9861(70)90470-4; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Madhusudan, 2002, NAT STRUCT BIOL, V9, P273, DOI 10.1038/nsb780; MATSUMOTO M, 1991, J CHROMATOGR-BIOMED, V562, P139, DOI 10.1016/0378-4347(91)80572-T; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Mishra PK, 2000, CHEM REV, V100, P3283, DOI 10.1021/cr990010m; NODA S, 1991, LIVER, V11, P134; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pauling L., 1960, NATURE CHEM BOND; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; SASAKI T, 1991, BRAIN DEV-JPN, V13, P52, DOI 10.1016/S0387-7604(12)80298-1; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Strauss E, 2002, J BIOL CHEM, V277, P48205, DOI 10.1074/jbc.M204560200; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; VALLARI DS, 1985, J BACTERIOL, V162, P1156, DOI 10.1128/JB.162.3.1156-1161.1985; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; Yun M, 2000, J BIOL CHEM, V275, P28093	33	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35622	35629		10.1074/jbc.M403152200	http://dx.doi.org/10.1074/jbc.M403152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15136582	hybrid			2022-12-27	WOS:000223303400058
J	Jaffer, ZM; Chernoff, J				Jaffer, ZM; Chernoff, J			The cross-Rho'ds of cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TUMOR-SUPPRESSOR GENE; SMALL GTPASE RAC; P120 CATENIN; E-CADHERIN; ADHERENS JUNCTIONS; FAMILY GTPASES; ENDOTHELIAL-CELLS; ERM PROTEINS; MERLIN; IQGAP1		Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	J_Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836				Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Angst BD, 2001, J CELL SCI, V114, P629; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Grosheva I, 2001, J CELL SCI, V114, P695; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Noritake J, 2004, MOL BIOL CELL, V15, P1065, DOI 10.1091/mbc.E03-08-0582; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2003, J BIOL CHEM, V278, P17395, DOI 10.1074/jbc.M300998200; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; Takemoto H, 2001, INT J CANCER, V91, P783, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1121>3.0.CO;2-Z; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Turner CE, 2001, CURR BIOL, V11, pR875, DOI 10.1016/S0960-9822(01)00521-8; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Xiao GH, 2003, GENE CHROMOSOME CANC, V38, P389, DOI 10.1002/gcc.10282; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	50	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35123	35126		10.1074/jbc.R400010200	http://dx.doi.org/10.1074/jbc.R400010200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15133033	hybrid			2022-12-27	WOS:000223303400001
J	Vaquero, EC; Edderkaoui, M; Pandol, SJ; Gukovsky, I; Gukovskaya, AS				Vaquero, EC; Edderkaoui, M; Pandol, SJ; Gukovsky, I; Gukovskaya, AS			Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED ENDOTHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; NADPH OXIDASE; HYDROGEN-PEROXIDE; SUPEROXIDE ANION; REGULATES GROWTH; MITOCHONDRIAL; ACTIVATION; DEATH	One reason why pancreatic cancer is so aggressive and unresponsive to treatments is its resistance to apoptosis. We report here that reactive oxygen species (ROS) are a prosurvival, antiapoptotic factor in pancreatic cancer cells. Human pancreatic adenocarcinoma MIA PaCa-2 and PANC-1 cells generated ROS, which was stimulated by growth factors ( serum, insulin-like growth factor I, or fibroblast growth factor-2). Growth factors also stimulated membrane NAD(P) H oxidase activity in these cells. Both intracellular ROS and NAD( P) H oxidase activity were inhibited by antioxidants tiron and N-acetylcysteine and the inhibitor of flavoprotein-dependent oxidases, diphenylene iodonium, but not by inhibitors of various other ROS-generating enzymes. Using Rho(0) cells deficient in mitochondrial DNA, we showed that a nonmitochondrial NAD( P) H oxidase is a major source of growth factor-induced ROS in pancreatic cancer cells. Among proteins that have been implicated in NAD( P) H oxidase activity, MIA PaCa-2 and PANC-1 cells do not express the phagocytic gp91(phox) subunit but express several nonphagocytic oxidase (NOX) isoforms. Transfection with Nox4 antisense oligonucleotide inhibited NAD( P) H oxidase activity and ROS production in MIA PaCa-2 and PANC-1 cells. Inhibiting ROS with the antioxidants, Nox4 antisense, or MnSOD overexpression all stimulated apoptosis in pancreatic cancer cells as measured by internucleosomal DNA fragmentation, phosphatidylserine externalization, cytochrome c release, and effector caspase activation. The results show that growth factor-induced ROS produced by NAD( P) H oxidase ( probably Nox4) protect pancreatic cancer cells from apoptosis. This mechanism may play an important role in pancreatic cancer resistance to treatment and thus represent a novel therapeutic target.	Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, W Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Gukovskaya, AS (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, W Los Angeles Healthcare Ctr, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	agukovsk@ucla.edu		Gukovskaya, Anna/0000-0003-3737-5335; Edderkaoui, Mouad/0000-0002-2549-8242; Vaquero, Eva C./0000-0003-0098-5295	NIDDK NIH HHS [DK 59936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Blinman TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1993, DOI 10.1152/ajpcell.2000.279.6.C1993; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cullen JJ, 2003, CANCER RES, V63, P1297; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Green DR, 2003, MOL CELL, V11, P551, DOI 10.1016/S1097-2765(03)00107-2; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Hail N, 2001, CANCER RES, V61, P6698; Janiszewski M, 2002, FREE RADICAL BIO MED, V32, P446, DOI 10.1016/S0891-5849(01)00828-0; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; King M P, 1996, Methods Enzymol, V264, P339, DOI 10.1016/S0076-6879(96)64032-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kolko M, 2003, NEUROSCI LETT, V338, P164, DOI 10.1016/S0304-3940(02)01385-X; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Lin KI, 1999, J BIOL CHEM, V274, P13650, DOI 10.1074/jbc.274.19.13650; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Mouria M, 2002, INT J CANCER, V98, P761, DOI 10.1002/ijc.10202; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; RAND MJ, 1993, CLIN EXP PHARMACOL P, V20, P141, DOI 10.1111/j.1440-1681.1993.tb01661.x; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Sakamoto T, 1996, BIOCHEM BIOPH RES CO, V220, P643, DOI 10.1006/bbrc.1996.0457; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sorescu D, 2001, FREE RADICAL BIO MED, V30, P603, DOI 10.1016/S0891-5849(00)00507-4; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Taanman JW, 1997, J BIOENERG BIOMEMBR, V29, P151, DOI 10.1023/A:1022638013825; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tong WG, 2002, MOL CANCER THER, V1, P929; Vaquero EC, 2003, GASTROENTEROLOGY, V125, P1188, DOI 10.1016/S0016-5085(03)01203-4; Wanebo HJ, 1996, CANCER-AM CANCER SOC, V78, P580; Wedgwood S, 2003, AM J PHYSIOL-LUNG C, V285, pL305, DOI 10.1152/ajplung.00382.2002; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC	57	287	306	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34643	34654		10.1074/jbc.M400078200	http://dx.doi.org/10.1074/jbc.M400078200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15155719	hybrid			2022-12-27	WOS:000223134800069
J	Salahpour, A; Angers, S; Mercier, JF; Lagace, M; Marullo, S; Bouvier, M				Salahpour, A; Angers, S; Mercier, JF; Lagace, M; Marullo, S; Bouvier, M			Homodimerization of the beta 2-adrenergic receptor as a prerequisite for cell surface targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; OPIOID RECEPTORS; GABA(B) RECEPTOR; POTASSIUM CHANNELS; LIVING CELLS; DIMERIZATION; OLIGOMERIZATION; TRAFFICKING; HETERODIMERIZATION; EXPRESSION	Although homodimerization has been demonstrated for a large number of G protein-coupled receptors (GPCRs), no general role has been attributed to this process. Because it is known that oligomerization plays a key role in the quality control and endoplasmic reticulum ( ER) export of many proteins, we sought to determine if homodimerization could play such a role in GPCR biogenesis. Using the beta2-adrenergic receptor (beta2AR) as a model, cell fractionation studies revealed that receptor homodimerization is an event occurring as early as the ER. Supporting the hypothesis that receptor homodimerization is involved in ER processing, beta2AR mutants lacking an ER-export motif or harboring a heterologous ER-retention signal dimerized with the wild-type receptor and inhibited its trafficking to the cell surface. Finally, in addition to inhibiting receptor dimerization, disruption of the putative dimerization motif, (276)GXXXGXXXL(284), prevented normal trafficking of the receptor to the plasma membrane. Taken together, these data indicate that beta2AR homodimerization plays an important role in ER export and cell surface targeting.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada; Univ Paris 05, CNRS, Dept Cell Biol, Inst Cochin,INSERM, F-75014 Paris, France	Universite de Montreal; Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bouvier, M (corresponding author), Univ Montreal, Dept Biochem, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014; Marullo, Stefano/C-6142-2008; Angers, Stephane/E-1432-2014	Bouvier, Michel/0000-0003-1128-0100; Marullo, Stefano/0000-0001-9604-9973; Angers, Stephane/0000-0001-7241-9044				AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Chapple JP, 2003, J BIOL CHEM, V278, P19087, DOI 10.1074/jbc.M212349200; Chelli M, 2001, J BIOL CHEM, V276, P46975, DOI 10.1074/jbc.M106432200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gimelbrant AA, 2001, J BIOL CHEM, V276, P7285, DOI 10.1074/jbc.M005433200; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Hague C, 2004, J BIOL CHEM, V279, P15541, DOI 10.1074/jbc.M314014200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Papazian DM, 1999, NEURON, V23, P7, DOI 10.1016/S0896-6273(00)80746-1; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2	51	250	252	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33390	33397		10.1074/jbc.M403363200	http://dx.doi.org/10.1074/jbc.M403363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155738	hybrid			2022-12-27	WOS:000223039700046
J	Malik, P; Blackbourn, DJ; Clements, JB				Malik, P; Blackbourn, DJ; Clements, JB			The evolutionarily conserved Kaposi's sarcoma-associated herpesvirus ORF57 protein interacts with REF protein and acts as an RNA export factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CONSTITUTIVE TRANSPORT ELEMENT; NUCLEAR-PORE COMPLEX; VIRAL MESSENGER-RNA; READING FRAME 57; SIMPLEX-VIRUS; GENE-EXPRESSION; REGULATORY PROTEIN; SM PROTEIN; POSTTRANSCRIPTIONAL ACTIVATOR	ORF57 (MTA) one of the earliest Kaposi's sarcoma-associated herpesvirus (KSHV) regulatory proteins to be expressed is essential for virus lytic replication. A counterpart is present in every herpesvirus sequenced, indicating the importance of this signature viral protein and those examined act post-transcriptionally, affecting RNA splicing and transport. In KSHV-infected cells, ORF57 protein was present in a complex with REF (Aly) and TAP (NXF1), factors involved in cellular mRNA export. The ORF57 N-terminal region interacts with REF, whereas both N- and C-terminal domains of REF interact with ORF57. The ORF57-REF interaction was direct, whereas TAP appeared to be recruited via REF. In somatic cells, ectopically expressed ORF57 protein was shown to function as a CRM1-independent nuclear mRNA export factor, promoting export of mRNAs that are poor substrates for splicing. The gamma-herpesvirus ORF57 protein, and its alpha-1 herpesvirus ICP27 counterpart both export RNA through pathways involving REF and TAP proteins, although divergence of these herpesvirus subfamilies occurred some 180-210 million years ago. The TAP-mediated cellular mRNA export pathway is CRM1-independent. However, human immunodeficiency virus type 1 Rev protein-mediated RNA export, which is CRM1-dependent, was considerably inhibited by ORF57, suggesting that Rev and ORF57 compete for a common export component. These data strengthen arguments that TAP and CRM1 pathways converge in accessing similar components of the nuclear pore complex. We propose that ORF57-mediated RNA export may use different export factors to accommodate the KSHV-infected host cell environments, for example, in B-cells or endothelial cells and during the different phases of lytic virus replication.	Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland	University of Glasgow	Clements, JB (corresponding author), Univ Glasgow, Inst Virol, Church St, Glasgow G11 5JR, Lanark, Scotland.	b.clements@vir.gla.ac.uk	Malik, Poonam/A-1756-2008	Malik, Poonam/0000-0002-1733-722X; Blackbourn, David/0000-0002-6703-4497				Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bello LJ, 1999, J GEN VIROL, V80, P3207, DOI 10.1099/0022-1317-80-12-3207; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; Boshoff C, 2001, PHILOS T R SOC B, V356, P517, DOI 10.1098/rstb.2000.0778; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boyer JL, 2002, J VIROL, V76, P9420, DOI 10.1128/JVI.76.18.9420-9433.2002; Boyle SM, 1999, J VIROL, V73, P6872, DOI 10.1128/JVI.73.8.6872-6881.1999; Braun IC, 2002, MOL CELL BIOL, V22, P5405, DOI 10.1128/MCB.22.15.5405-5418.2002; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Bryant HE, 2001, J VIROL, V75, P4376, DOI 10.1128/JVI.75.9.4376-4385.2001; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen IHB, 2002, J VIROL, V76, P12877, DOI 10.1128/JVI.76.24.12877-12889.2002; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Cullen BR, 2003, TRENDS BIOCHEM SCI, V28, P419, DOI 10.1016/S0968-0004(03)00142-7; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; Cunningham C, 2003, J GEN VIROL, V84, P1471, DOI 10.1099/vir.0.19015-0; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Gupta AK, 2000, J VIROL, V74, P1038, DOI 10.1128/JVI.74.2.1038-1044.2000; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; HARDWICKE MA, 1994, J VIROL, V68, P4797, DOI 10.1128/JVI.68.8.4797-4810.1994; Herold A, 2001, RNA, V7, P1768; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; Hiriart E, 2003, J BIOL CHEM, V278, P335, DOI 10.1074/jbc.M208656200; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; Jean S, 2001, VIROLOGY, V283, P273, DOI 10.1006/viro.2001.0902; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Kirshner JR, 2000, J VIROL, V74, P3586, DOI 10.1128/JVI.74.8.3586-3597.2000; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lengyel J, 2002, J VIROL, V76, P11866, DOI 10.1128/JVI.76.23.11866-11879.2002; LIEBERMAN PM, 1986, J VIROL, V60, P140, DOI 10.1128/JVI.60.1.140-148.1986; Longman D, 2003, RNA, V9, P881, DOI 10.1261/rna.5420503; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; MCGEOCH DJ, 1995, J MOL BIOL, V247, P443, DOI 10.1006/jmbi.1995.0152; MCLAUCHLAN J, 1992, J VIROL, V66, P6939, DOI 10.1128/JVI.66.12.6939-6945.1992; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Paulose-Murphy M, 2001, J VIROL, V75, P4843, DOI 10.1128/JVI.75.10.4843-4853.2001; Portman DS, 1997, RNA, V3, P527; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; SANDRIGOLDIN RM, 1992, GENE DEV, V6, P848, DOI 10.1101/gad.6.5.848; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Schmitt I, 2001, J BIOL CHEM, V276, P42355, DOI 10.1074/jbc.M103916200; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Sokolowski M, 2003, J BIOL CHEM, V278, P33540, DOI 10.1074/jbc.M302063200; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tan W, 2000, RNA, V6, P1762, DOI 10.1017/S1355838200000832; Virbasius CMA, 1999, MOL CELL, V4, P219, DOI 10.1016/S1097-2765(00)80369-X; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; Whitehouse A, 1998, J VIROL, V72, P857, DOI 10.1128/JVI.72.1.857-861.1998; Wiegand HL, 2002, MOL CELL BIOL, V22, P245, DOI 10.1128/MCB.22.1.245-256.2002; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zheng ZM, 2003, REV MED VIROL, V13, P173, DOI 10.1002/rmv.387; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	81	90	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					33001	33011		10.1074/jbc.M313008200	http://dx.doi.org/10.1074/jbc.M313008200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155762	hybrid			2022-12-27	WOS:000222849700120
J	McMahon, M; Thomas, N; Itoh, K; Yamamoto, M; Hayes, JD				McMahon, M; Thomas, N; Itoh, K; Yamamoto, M; Hayes, JD			Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; PROTEASOMAL DEGRADATION; CHEMOPREVENTIVE AGENTS; ENDOPLASMIC-RETICULUM; INDUCIBLE EXPRESSION; TUMOR SUPPRESSORS; GOLGI-APPARATUS; GENE-EXPRESSION; UBIQUITIN	The Nrf2 transcription factor is more rapidly turned over in cells grown under homeostatic conditions than in those experiencing oxidative stress. The variable turnover of Nrf2 is accomplished through the use of at least two degrons and its redox-sensitive interaction with the Kelch-repeat protein Keap1. In homeostatic COS1 cells, the Neh2 degron confers on Nrf2 a half-life of less than 10 min. Analyses of deletion mutants of a Gal4(HA) mNeh2 fusion protein and full-length mNrf2 indicate that full redox-sensitive Neh2 destabilizing activity depends upon two separate sequences within this N-terminal domain. The DIDLID element ( amino acids 17 - 32) is indispensable for Neh2 activity and appears necessary to recruit a ubiquitin ligase to the fusion protein. A second motif within Neh2, the ETGE tetrapeptide ( amino acids 79 - 82), allows the redox-sensitive recruitment of Nrf2 to Keap1. This interaction, which occurs only in homeostatic cells, enhances the capacity of the Neh2 degron to direct degradation by functioning downstream of ubiquitination mediated by the DIDLID element. By contrast with the situation under homeostatic conditions, the Neh2 degron is neither necessary nor sufficient to account for the characteristic half-life of Nrf2 in oxidatively stressed cells. Instead, the previously uncharacterized, redox-insensitive Neh6 degron ( amino acids 329 - 379) is essential to ensure that the transcription factor is still appropriately turned over in stressed cells, albeit with an increased half-life of 40 min. A model can now be proposed to explain how the turnover of this protein adapts in response to alterations in cellular redox state.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	University of Dundee; University of Tsukuba; University of Tsukuba	McMahon, M (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	m.j.m.mcmahon@dundee.ac.uk	Yamamoto, Masayuki/A-4873-2010; McMahon, Michael J/A-1702-2008; Itoh, Ken/B-9506-2013; McMahon, Michael J/F-7070-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; McMahon, Michael J/0000-0001-8615-9351; Hayes, John/0000-0002-2927-5548				AN JH, 2003, EMBO J, V17, P1882; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Boevink P, 1998, PLANT J, V15, P441, DOI 10.1046/j.1365-313X.1998.00208.x; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CULLINAN SB, 2003, MOL CELL BIOL, V101, P2040; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jager S, 2001, EMBO J, V20, P4423, DOI 10.1093/emboj/20.16.4423; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Krzywda S, 2004, J BIOL CHEM, V279, P1541, DOI 10.1074/jbc.M310265200; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Rezvani K, 2003, BIOCHEM SOC T, V31, P470, DOI 10.1042/BST0310470; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shimada O, 2003, CELL STRUCT FUNCT, V28, P155; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Walker AK, 2000, J BIOL CHEM, V275, P22166, DOI 10.1074/jbc.M001746200; Wollert T, 2002, J CELL BIOL, V159, P571, DOI 10.1083/jcb.200204065; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003	53	292	324	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31556	31567		10.1074/jbc.M403061200	http://dx.doi.org/10.1074/jbc.M403061200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143058	hybrid			2022-12-27	WOS:000222726800078
J	Verdoucq, L; Moriniere, J; Bevan, DR; Esen, A; Vasella, A; Henrissat, B; Czjzek, M				Verdoucq, L; Moriniere, J; Bevan, DR; Esen, A; Vasella, A; Henrissat, B; Czjzek, M			Structural determinants of substrate specificity in family 1 beta-glucosidases - Novel insights from the crystal structure of sorghum dhurrinase-1, a plant beta-glucosidase with strict specificity, in complex with its natural substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGLYCONE SPECIFICITY; KINETIC-ANALYSIS; ENDOGLUCANASE I; MAIZE; GLYCOSIDASE; MECHANISM; EXPRESSION; DISTORTION	Plant beta-glucosidases play a crucial role in defense against pests. They cleave, with variable specificity, beta-glucosides to release toxic aglycone moieties. The Sorghum bicolor beta-glucosidase isoenzyme Dhr1 has a strict specificity for its natural substrate dhurrin (p-hydroxy-(S)-mandelonitrile- beta-D-glucoside), whereas its close homolog, the maize beta-glucosidase isoenzyme Glu1, which shares 72% sequence identity, hydrolyzes a broad spectrum of substrates in addition to its natural substrate 2-O-beta-D-glucopyranosyl-4- hydroxy-7-methoxy-1,4-benzoxaxin-3-one. Structural data from enzyme . substrate complexes of Dhr1 show that the mode of aglycone binding differs from that previously observed in the homologous maize enzyme. Specifically, the data suggest that Asn(259), Phe(261), and Ser(462), located in the aglycone-binding site of S. bicolor Dhr1, are crucial for aglycone recognition and binding. The tight binding of the aglycone moiety of dhurrin promotes the stabilization of the reaction intermediate in which the glycone moiety is in a deformed S-1(3) conformation within the glycone-binding site, ready for nucleophilic attack to occur. Compared with the broad specificity maize beta-glucosidase, this different binding mode explains the narrow specificity of sorghum dhurrinase-1.	CNRS, F-13402 Marseille 20, France; Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; ETH Hogerberg, Organ Chem Lab, CH-8093 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Czjzek, M (corresponding author), CNRS, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	czjzek@afmb.cnrs-mrs.fr	Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; Bevan, David/0000-0001-9974-1105				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; Burmeister WP, 2000, J BIOL CHEM, V275, P39385, DOI 10.1074/jbc.M006796200; Cicek M, 1998, PLANT PHYSIOL, V116, P1469, DOI 10.1104/pp.116.4.1469; Cicek M, 2000, J BIOL CHEM, V275, P20002, DOI 10.1074/jbc.M001609200; Coutinho PM, 2003, TRENDS PLANT SCI, V8, P563, DOI 10.1016/j.tplants.2003.10.002; Czjzek M, 2001, BIOCHEM J, V354, P37, DOI 10.1042/0264-6021:3540037; Czjzek M, 2000, P NATL ACAD SCI USA, V97, P13555, DOI 10.1073/pnas.97.25.13555; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DAVIES GJ, 1998, BIOCHEMISTRY-US, V37, P15280; DHARMAWARDHANA DP, 1995, PLANT PHYSIOL, V107, P331, DOI 10.1104/pp.107.2.331; Ducros VMA, 2002, ANGEW CHEM INT EDIT, V41, P2824, DOI 10.1002/1521-3773(20020802)41:15<2824::AID-ANIE2824>3.0.CO;2-G; ERMERT P, 1993, CARBOHYD RES, V250, P113, DOI 10.1016/0008-6215(93)84160-8; FALK A, 1995, PLANT PHYSIOL, V108, P1369, DOI 10.1104/pp.108.4.1369; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSEL W, 1987, ARCH BIOCHEM BIOPHYS, V252, P152, DOI 10.1016/0003-9861(87)90019-1; LEAH R, 1995, J BIOL CHEM, V270, P15789, DOI 10.1074/jbc.270.26.15789; Namchuk MN, 1995, BIOCHEMISTRY-US, V34, P16194, DOI 10.1021/bi00049a035; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POULTON JE, 1990, PLANT PHYSIOL, V94, P401, DOI 10.1104/pp.94.2.401; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanz-Aparicio J, 1998, J MOL BIOL, V275, P491, DOI 10.1006/jmbi.1997.1467; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P5902, DOI 10.1021/bi962963+; Sulzenbacher G, 1996, BIOCHEMISTRY-US, V35, P15280, DOI 10.1021/bi961946h; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Varrot A, 2003, ACTA CRYSTALLOGR D, V59, P447, DOI 10.1107/S0907444902023405; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Verdoucq L, 2003, J BIOL CHEM, V278, P25055, DOI 10.1074/jbc.M301978200; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; WANG Q, 1995, BIOCHEMISTRY-US, V34, P14554, DOI 10.1021/bi00044a034; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; Zechel D. L., 1999, COMPREHENSIVE NATURA, V5, P279; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zouhar J, 2001, PLANT PHYSIOL, V127, P973, DOI 10.1104/pp.010712	42	109	115	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31796	31803		10.1074/jbc.M402918200	http://dx.doi.org/10.1074/jbc.M402918200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148317	hybrid			2022-12-27	WOS:000222726800106
J	Rajagopalan, L; Rajarathnam, K				Rajagopalan, L; Rajarathnam, K			Ligand selectivity and affinity of chemokine receptor CXCR1 - Role of N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-STIMULATING ACTIVITY; INTERLEUKIN-8 RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; AMINO-TERMINUS; A RECEPTOR; BINDING; RESIDUES; H-1-NMR; ANALOGS	Glu-Leu-Arg ("ELR") CXC chemokines interleukin-8 (IL-8) and melanoma growth stimulatory activity (MGSA) recruit neutrophils by binding and activating two receptors, CXCR1 and CXCR2. CXCR1 is specific, binding only IL-8 with nanomolar affinity, whereas CXCR2 is promiscuous, binding all ELRCXC chemokines with high affinity. Receptor signaling consists of two events: interactions between the ligand N-terminal loop (N-loop) and receptor N-terminal domain (N-domain) residues ( site I), and between the ligand N-terminal ELR and the receptor juxtamembrane domain (J-domain) residues (site II). It is not known how these interactions mediate ligand affinity and selectivity, and whether binding at one site influences binding and function at the other. Sequence analysis and structure-function studies have suggested that the receptor N-domain plays an important role in ligand selectivity. Here, we report ligand-binding properties and structural characteristics of the CXCR1 N-domain in solution and in detergent micelles that mimic the native membrane environment. We find that IL-8 binds the N-domain with significantly higher affinity in micelles than in solution (similar to1 muM versus similar to20 muM) and that MGSA does not bind the N-domain in solution but does in micelles with appreciable affinity (similar to3 muM). We find that the N-domain is structured in micelles and that the entire N-domain interacts with the micelle in an extended fashion. We conclude that the micellar environment constrains the N-domain, and this conformational restraint influences its ligand-binding properties. Most importantly, our data suggest that for both ligands, site I interaction provides similar affinity and that differential coupling between site I and II interactions is responsible for the observed differences in affinity.	Univ Texas, Dept Human Biol Chem & Genet, Med Branch, Galveston, TX 77555 USA; Univ Texas, Sealy Ctr Struct Biol, Med Branch, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Rajarathnam, K (corresponding author), Univ Texas, Dept Human Biol Chem & Genet, Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	krrajara@utmb.edu						Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Attwood MR, 1996, BIOORG MED CHEM LETT, V6, P1869, DOI 10.1016/0960-894X(96)00331-9; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Baly DL, 1998, J IMMUNOL, V161, P4944; Catusse J, 2003, BIOCHEM PHARMACOL, V65, P813, DOI 10.1016/S0006-2952(02)01619-2; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; Katancik JA, 2000, CYTOKINE, V12, P1480, DOI 10.1006/cyto.2000.0742; KIM KS, 1994, J BIOL CHEM, V269, P32909; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Loetscher P, 2001, J LEUKOCYTE BIOL, V69, P881; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MOSER B, 1993, J BIOL CHEM, V268, P7125; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008; Rajarathnam K, 1999, BIOCHEMISTRY-US, V38, P7653, DOI 10.1021/bi990033v; Rajarathnam K, 1996, FEBS LETT, V399, P43, DOI 10.1016/S0014-5793(96)01277-X; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P6623, DOI 10.1021/bi00187a032; Rajarathnam K, 2002, CURR PHARM DESIGN, V8, P2159, DOI 10.2174/1381612023393233; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Suetomi K, 1999, J BIOL CHEM, V274, P11768, DOI 10.1074/jbc.274.17.11768; SUZUKI H, 1994, J BIOL CHEM, V269, P18263; Vinogradova O, 1998, J BIOMOL NMR, V11, P381, DOI 10.1023/A:1008289624496; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202	49	92	94	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30000	30008		10.1074/jbc.M313883200	http://dx.doi.org/10.1074/jbc.M313883200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133028	hybrid			2022-12-27	WOS:000222531900018
J	Wang, Q; Hurd, TW; Margolis, B				Wang, Q; Hurd, TW; Margolis, B			Tight junction protein Par6 interacts with an evolutionarily conserved region in the amino terminus of PALS1/Stardust	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASYMMETRIC CELL-DIVISION; DISCS LOST; PDZ DOMAIN; KINASE-C; DROSOPHILA STARDUST; EPITHELIAL POLARITY; COMPLEX; CRUMBS; CDC42; NEUROBLASTS	Tight junctions are the structures in mammalian epithelial cells that separate the apical and basolateral membranes and may also be important in the establishment of cell polarity. Two evolutionarily conserved multiprotein complexes, Crumbs-PALS1 (Stardust)-PATJ and Cdc42-Par6-Par3-atypical protein kinase C, have been implicated in the assembly of tight junctions and in polarization of Drosophila melanogaster epithelia. These two complexes have been linked physically and functionally by an interaction between PALS1 and Par6. Here we identify an evolutionarily conserved region in the amino terminus of PALS1 as the Par6 binding site and identify valine and aspartic acid residues in this region as essential for interacting with the PDZ domain of Par6. We have also characterized, in more detail, the amino terminus of Drosophila Stardust and demonstrate that the interaction mechanism between Stardust and Drosophila Par6 is evolutionarily conserved. Par6 interferes with PATJ in binding PALS1, and these two interactions do not appear to function synergistically. Taken together, these results define the molecular mechanisms linking two conserved polarity complexes.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	bmargoli@umich.edu			NIDDK NIH HHS [DK-58208] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058208] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; Harris BZ, 2002, J BIOL CHEM, V277, P34902, DOI 10.1074/jbc.M205856200; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KNUST E, SCIENCE, V298, P1955; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Nam SC, 2003, DEVELOPMENT, V130, P4363, DOI 10.1242/dev.00648; Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200; Peterson FC, 2004, MOL CELL, V13, P665, DOI 10.1016/S1097-2765(04)00086-3; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Pielage J, 2003, DEV CELL, V5, P841, DOI 10.1016/S1534-5807(03)00358-7; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; ROB MH, 2003, AM J PHYSIOL, V285, pF377; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.E03-08-0620; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	30	81	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30715	30721		10.1074/jbc.M401930200	http://dx.doi.org/10.1074/jbc.M401930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140881	hybrid			2022-12-27	WOS:000222531900102
J	Bourguignon, LYW; Singleton, PA; Diedrich, F				Bourguignon, LYW; Singleton, PA; Diedrich, F			Hyaluronan-CD44 interaction with Rac1-dependent protein kinase N-gamma promotes phospholipase C gamma 1 activation, Ca2+ signaling, and cortactin-cytoskeleton function leading to keratinocyte adhesion and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL-MIGRATION; HUMAN EPIDERMAL-KERATINOCYTES; FYN TYROSINE KINASE; CD44 INTERACTION; MOUSE KERATINOCYTES; POTENTIAL EFFECTOR; IP3 RECEPTOR; E-CADHERIN; HUMAN SKIN; IN-VIVO	In this study we have investigated hyaluronan (HA)-CD44 interaction with protein kinase N-gamma (PKNgamma), a small GTPase (Rac1)-activated serine/threonine kinase in human keratinocytes. By using a variety of biochemical and molecular biological techniques, we have determined that CD44 and PKNgamma kinase ( molecular mass similar to 120 kDa) are physically linked in vivo. The binding of HA to keratinocytes promotes PKNgamma kinase recruitment into a complex with CD44 and subsequently stimulates Rac1-mediated PKNgamma kinase activity. The Rac1-activated PKNgamma in turn increases threonine ( but not serine) phosphorylation of phospholipase C ( PLC) gamma1 and upregulates PLCgamma1 activity leading to the onset of intracellular Ca2+ mobilization. HA/CD44-activated Rac1-PKNgamma also phosphorylates the cytoskeletal protein, cortactin, at serine/threonine residues. The phosphorylation of cortactin by Rac1-PKNgamma attenuates its ability to cross-link filamentous actin in vitro. Further analyses indicate that the N-terminal antiparallel coiled-coil (ACC) domains of PKNgamma interact directly with Rac1 in a GTP-dependent manner. The binding of HA to CD44 induces PKNgamma association with endogenous Rac1 and its activity in keratinocytes. Transfection of keratinocytes with PKNgamma-ACCcDNA reduces HA-mediated recruitment of endogenous Rac1 to PKNgamma and blocks PKNgamma activity. These findings suggest that the PKNgamma-ACC fragment acts as a potent competitive inhibitor of endogenous Rac1 binding to PKNgamma in vivo. Most important, the PKNgamma-ACC fragment functions as a strong dominant-negative mutant that effectively inhibits HA/CD44-mediated PKNgamma phosphorylation of PLCgamma1 and cortactin as well as keratinocyte signaling ( e g. Ca2+ mobilization and cortactin-actin binding) and cellular functioning (e.g. cell-cell adhesion and differentiation). Taken together, these findings strongly suggest that hyaluronan-CD44 interaction with Rac1-PKNgamma plays a pivotal role in PLCgamma1-regulated Ca2+ signaling and cortactin-cytoskeleton function required for keratinocyte cell-cell adhesion and differentiation.	Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA66163, R01 CA 78633] Funding Source: Medline; NIAMS NIH HHS [P01 AR39448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Akhtar N, 2000, CELL ADHES COMMUN, V7, P465, DOI 10.3109/15419060009040304; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bolz SS, 2000, CIRCULATION, V102, P2402, DOI 10.1161/01.CIR.102.19.2402; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Bruno S, 2000, CARCINOGENESIS, V21, P893, DOI 10.1093/carcin/21.5.893; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; Dingemans KP, 1999, BRIT J DERMATOL, V140, P17; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DRIMME HU, 1999, BRIT J DERMATOL, V141, P824; Haase I, 1997, J INVEST DERMATOL, V108, P748, DOI 10.1111/1523-1747.ep12292135; HAGGERTY JG, 1992, J INVEST DERMATOL, V99, P374, DOI 10.1111/1523-1747.ep12616087; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heider KH, 1996, CANCER IMMUNOL IMMUN, V43, P245, DOI 10.1007/s002620050329; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, J CELL PHYSIOL, V116, P265, DOI 10.1002/jcp.1041160303; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Koivisto L, 2004, EXP CELL RES, V293, P68, DOI 10.1016/j.yexcr.2003.09.026; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Lesley J, 2000, J BIOL CHEM, V275, P26967; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; Mukai H, 2003, J BIOCHEM, V133, P17, DOI 10.1093/jb/mvg019; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1988, J BIOL CHEM, V263, P5390; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Seiter S, 1996, VIRCHOWS ARCH, V428, P141; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; Simon JC, 1996, EUR J CANCER, V32A, P1394, DOI 10.1016/0959-8049(96)00196-7; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; TAMMI R, 1988, J INVEST DERMATOL, V90, P412, DOI 10.1111/1523-1747.ep12456530; TANG W, 1988, J INVEST DERMATOL, V90, P37, DOI 10.1111/1523-1747.ep12462536; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yoshinaga C, 1999, J BIOCHEM, V126, P475, DOI 10.1093/oxfordjournals.jbchem.a022476	70	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29654	29669		10.1074/jbc.M403608200	http://dx.doi.org/10.1074/jbc.M403608200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123640	hybrid			2022-12-27	WOS:000222445300102
J	Gong, XM; Choi, JY; Franzin, CM; Zhai, DY; Reed, JC; Marassi, FM				Gong, XM; Choi, JY; Franzin, CM; Zhai, DY; Reed, JC; Marassi, FM			Conformation of membrane-associated proapoptotic tBid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; SECONDARY STRUCTURE; STRUCTURAL BASIS; BCL-W; NMR; PROTEIN; BAX; MITOCHONDRIA; FAMILY; DEATH	The proapoptotic Bcl-2 family protein Bid is cleaved by caspase-8 to release the C-terminal fragment tBid, which translocates to the outer mitochondrial membrane and induces massive cytochrome c release and cell death. In this study, we have characterized the conformation of tBid in lipid membrane environments, using NMR and CD spectroscopy with lipid micelle and lipid bilayer samples. In micelles, tBid adopts a unique helical conformation, and the solution NMR H-1/N-15 HSQC spectra have a single well resolved resonance for each of the protein amide sites. In lipid bilayers, tBid associates with the membrane with its helices parallel to the membrane surface and without trans-membrane helix insertion, and the solid-state NMR H-1/N-15 polarization inversion with spin exchange at the magic angle spectrum has all of the amide resonances centered at N-15 chemical shift ( 70 - 90 ppm) and H-1-N-15 dipolar coupling (0 - 5 kHz) frequencies associated with NH bonds parallel to the bilayer surface, with no intensity at frequencies associated with NH bonds in trans-membrane helices. Thus, the cytotoxic activity of tBid at mitochondria may be similar to that observed for antibiotic polypeptides, which bind to the surface of bacterial membranes as amphipathic helices and destabilize the bilayer structure, promoting the leakage of cell contents.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Marassi, FM (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fmarassi@burnham.org			NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI063563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065374, R01GM060554] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA30199, P30 CA030199] Funding Source: Medline; NIAID NIH HHS [R21 AI063563, R21 AI063563-02] Funding Source: Medline; NIBIB NIH HHS [P41 EB002031, P41EB002031] Funding Source: Medline; NIGMS NIH HHS [R01 GM065374-04, R01GM60554, R01 GM065374, R01 GM060554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Denisov AY, 2003, J BIOL CHEM, V278, P21124, DOI 10.1074/jbc.M301798200; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Franzin CM, 2004, MAGN RESON CHEM, V42, P172, DOI 10.1002/mrc.1322; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krueger-Koplin RD, 2004, J BIOMOL NMR, V28, P43, DOI 10.1023/B:JNMR.0000012875.80898.8f; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LEVITT MH, 1986, J CHEM PHYS, V84, P4243, DOI 10.1063/1.450046; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Marassi FM, 2000, J MAGN RESON, V144, P156, DOI 10.1006/jmre.2000.2036; Marassi FM, 2000, J MAGN RESON, V144, P150, DOI 10.1006/jmre.2000.2035; Marassi FM, 2001, BIOPHYS J, V80, P994, DOI 10.1016/S0006-3495(01)76078-X; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; OH KJ, 2004, 5 BIENN STRUCT BIOL; Opella SJ, 2001, METHOD ENZYMOL, V339, P285, DOI 10.1016/S0076-6879(01)39319-9; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tian CL, 2003, PROTEIN SCI, V12, P2597, DOI 10.1110/ps.03168503; Wang J, 2000, J MAGN RESON, V144, P162, DOI 10.1006/jmre.2000.2037; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WU CH, 1994, J MAGN RESON SER A, V109, P270, DOI 10.1006/jmra.1994.1169; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	49	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28954	28960		10.1074/jbc.M403490200	http://dx.doi.org/10.1074/jbc.M403490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123718	Green Accepted, hybrid			2022-12-27	WOS:000222445300017
J	Stewart, SA; Kothapalli, D; Yung, YV; Assoian, RK				Stewart, SA; Kothapalli, D; Yung, YV; Assoian, RK			Antimitogenesis linked to regulation of Skp2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; BOX PROTEIN SKP2; UBIQUITIN LIGASE; PROSTACYCLIN RECEPTOR; CYCLE PROGRESSION; BINDING-PROTEIN; SHEAR-STRESS; G1 PHASE; S-PHASE; P27(KIP1)	Prostacyclin has many effects in the vasculature; one of the less well understood is the ability to block cell cycle progression through G(1) phase. We previously reported that the prostacyclin mimetic, cicaprost, selectively inhibits cyclin E-cyclin-dependent kinase-2 (Cdk2), and now we show that it acts by regulating the expression of Skp2, the F-box protein that targets p27(Kip1) for ubiquitin-mediated proteolysis. First, we show that cicaprost prevents the late G(1) phase down-regulation of p27(Kip1) and that the inhibitory effect of cicaprost on cyclin E-Cdk2 activity and S phase entry is eliminated by deleting p27(Kip1). Levels of the closely related Cdk2 inhibitor, p21(Cip1), are unaffected by cicaprost. Moreover, we show that cicaprost blocks the induction of Skp2 mRNA and that ectopic expression of a Skp2 cDNA overrides the effect of cicaprost on p27(Kip1) levels and S phase entry. Our data show that inhibition of F-box protein gene expression can underlie the effect of a potent antimitogen.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Assoian, RK (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 167 Johnson pavil,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	rka@pharm.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051878] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62250] Funding Source: Medline; NIGMS NIH HHS [GM51878] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; Doroudi R, 2000, BIOCHEM BIOPH RES CO, V269, P257, DOI 10.1006/bbrc.2000.2279; EGAN K, 2000, CIRCULATION, V102, P234; Fink A N, 1999, Heart Dis, V1, P29; Ii M, 2001, CARDIOVASC RES, V52, P500, DOI 10.1016/S0008-6363(01)00411-4; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kothapalli D, 2003, MOL PHARMACOL, V64, P249, DOI 10.1124/mol.64.2.249; Kramer A, 1996, J BIOL CHEM, V271, P6579; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NAMBA T, 1994, J BIOL CHEM, V269, P9986; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takahashi Y, 2000, GENE DEV, V14, P804; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Weber AA, 1998, BASIC RES CARDIOL, V93, P54; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29109	29113		10.1074/jbc.M404271200	http://dx.doi.org/10.1074/jbc.M404271200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126498	hybrid			2022-12-27	WOS:000222445300035
J	Wei, M; Tai, GH; Gao, YG; Li, N; Huang, BQ; Zhou, YF; Hao, S; Zeng, XL				Wei, M; Tai, GH; Gao, YG; Li, N; Huang, BQ; Zhou, YF; Hao, S; Zeng, XL			Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELLS; CARBOHYDRATE INTERACTIONS; ENDOTHELIAL-CELLS; SULFATE; METASTASIS; LIGANDS; PROTEOGLYCANS; AGGREGATION; DESULFATION; EXPRESSION	Accumulating evidence indicates that the formation of tumor cell platelet emboli complexes in the blood stream is a very important step during metastases and that the anti-metastasis effects of heparin are partially due to a blockade of P-selectin on platelets. In this study, heparin and chemically modified heparins were tested as inhibitors of three human colon carcinoma cell lines (COLO320, LS174T, and CW-2) binding to P-selectin, adhering to CHO cells expressing a transfected human P-selectin cDNA, and adhering to surface-anchored platelets expressing P-selectin under static and flow conditions. The aim was to screen for heparin derivatives with high anti-adhesion activity but negligible anticoagulant activity. In this study, four modified heparins with high anti-adhesion activity were identified including RO-heparin, CR-heparin, 2/3ODS-heparin, and N/2/3DS-heparin. NMR analysis proved the reliability of structure of the four modified heparins. Our findings suggested that the 6-O-sulfate group of glucosamine units in heparin is critical for the inhibition of P-selectin-mediated tumor cell adhesion. Heparan sulfate-like proteoglycans on these tumor cell surfaces are implicated in adhesion of the tumor cells to P-selectin. Some chemically modified heparins with low anticoagulant activities, such as 2/3ODS-heparin, may have potential value as therapeutic agents that block P-selectin-mediated cell adhesion and prevent tumor metastasis.	NE Normal Univ, Sch Life Sci, Inst Cytol & Genet, Changchun 130024, Jilin, Peoples R China	Northeast Normal University - China	Zeng, XL (corresponding author), NE Normal Univ, Sch Life Sci, Inst Cytol & Genet, Changchun 130024, Jilin, Peoples R China.	zengx1779@nenu.edu.cn						Aigner S, 1998, FASEB J, V12, P1241, DOI 10.1096/fasebj.12.12.1241; Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; BAI XM, 1994, J HISTOCHEM CYTOCHEM, V42, P1043, DOI 10.1177/42.8.8027524; Baumann H, 1998, CARBOHYD RES, V308, P381, DOI 10.1016/S0008-6215(98)00097-4; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; BUTTRUM SM, 1993, BLOOD, V82, P1165; CASU B, 1986, ARZNEIMITTEL-FORSCH, V36-1, P637; Dardik R, 1997, INT J CANCER, V70, P201, DOI 10.1002/(SICI)1097-0215(19970117)70:2<201::AID-IJC11>3.0.CO;2-L; Dardik R, 1998, BRIT J CANCER, V77, P2069, DOI 10.1038/bjc.1998.349; Fryer A, 1997, J PHARMACOL EXP THER, V282, P208; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; Goetz DJ, 1996, AM J PATHOL, V149, P1661; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; Konstantopoulos K, 1998, CIRCULATION, V98, P873, DOI 10.1161/01.CIR.98.9.873; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; Ma YQ, 2000, J IMMUNOL, V165, P558, DOI 10.4049/jimmunol.165.1.558; MANNORI G, CANC RES, V55, P4425; McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NIERODZIK MLR, 1992, CANCER RES, V52, P3267; Nieswandt B, 1999, CANCER RES, V59, P1295; OLEKSOWICZ L, 1995, THROMB RES, V79, P261, DOI 10.1016/0049-3848(95)00113-6; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Pottratz ST, 1996, AM J PHYSIOL-LUNG C, V271, pL918, DOI 10.1152/ajplung.1996.271.6.L918; Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h; Salmivirta M, 1998, GLYCOBIOLOGY, V8, P1029, DOI 10.1093/glycob/8.10.1029; Sobel M, 2001, J VASC SURG, V33, P587, DOI 10.1067/mva.2001.112696; STONE JP, 1993, J CLIN INVEST, V92, P804, DOI 10.1172/JCI116654; Varki NM, 2002, SEMIN THROMB HEMOST, V28, P53, DOI 10.1055/s-2002-20564; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; Wei M, 2003, PROG BIOCHEM BIOPHYS, V30, P185; WESSEL HP, 1990, CARBOHYD RES, V204, P131, DOI 10.1016/0008-6215(90)84028-S	44	63	70	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29202	29210		10.1074/jbc.M312951200	http://dx.doi.org/10.1074/jbc.M312951200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133030	hybrid			2022-12-27	WOS:000222445300047
J	Yang, YP; Zhang, ZJ; Mukherjee, AB; Linnoila, RI				Yang, YP; Zhang, ZJ; Mukherjee, AB; Linnoila, RI			Increased susceptibility of mice lacking Clara cell 10-kDa protein to lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a potent carcinogen in cigarette smoke	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; BLASTOCYST DEVELOPMENT; TRANSFORMED PHENOTYPE; UTEROGLOBIN GENE; EXPRESSION; TUMORS; CC10; ADENOCARCINOMA; OVEREXPRESSION; POLYMORPHISM	Ninety percent of all human lung cancers are related to cigarette smoking. Both tobacco smoke and lung tumorigenesis are associated with drastically reduced levels of Clara cell 10-kDa protein (CC10), a multifunctional secreted protein, naturally produced by the airway epithelia of virtually all mammals. We previously reported that the expression of CC10 is markedly reduced in animals exposed to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, NNK, a potent carcinogen in tobacco smoke. Furthermore, it has been reported that CC10 expression, induced in certain tumor cells, reverses the transformed phenotype. We demonstrate here that NNK exposure of CC10-knock-out (CC10-KO) mice causes a significantly higher incidence of airway epithelial hyperplasia and lung adenomas compared with wild type (WT) littermates (30% CC10-KO versus 5% WT, p = 0.041). We also found that compared with NNK-treated WT mice, CC10-KO mice manifest increased frequency of K-ras mutation, elevated level of Fas ligand (FasL) expression, and increased MAPK/Erk phosphorylation, all of which are considered predisposing events in NNK-induced lung tumorigenesis. We propose that CC10 has a protective role against NNK-induced lung tumorigenesis mediated via down-regulation of the above-mentioned predisposing events.	NCI, Cell & Canc Biol Branch, Ctr Canc Res, NIH, Rockville, MD 20850 USA; NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yang, YP (corresponding author), NCI, MCGP, POB B,Bldg 560,Rm 32-12, Frederick, MD 21702 USA.	yongpiny@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01SC000167, ZIASC000167] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BELINSKY SA, 1989, CANCER RES, V49, P5305; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BROERS JLV, 1992, LAB INVEST, V66, P337; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; DEVEREUX TR, 1993, MOL CARCINOGEN, V8, P177, DOI 10.1002/mc.2940080308; Gochuico BR, 1998, AM J PHYSIOL-LUNG C, V274, pL444, DOI 10.1152/ajplung.1998.274.3.L444; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646, DOI 10.1164/ajrccm.159.2.9806064; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1998, J BIOL CHEM, V273, P22819, DOI 10.1074/jbc.273.35.22819; Laing IA, 1998, J MED GENET, V35, P463, DOI 10.1136/jmg.35.6.463; LEYTON J, 1994, CANCER RES, V54, P3696; Linnoila RI, 2000, ANN NY ACAD SCI, V923, P249; LINNOILA RI, 1992, AM J CLIN PATHOL, V97, P233, DOI 10.1093/ajcp/97.2.233; Magdaleno SM, 1997, CELL GROWTH DIFFER, V8, P145; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Mango GW, 1998, AM J PHYSIOL-LUNG C, V275, pL348, DOI 10.1152/ajplung.1998.275.2.L348; MATZINGER SA, 1995, CARCINOGENESIS, V16, P2487, DOI 10.1093/carcin/16.10.2487; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; MUKHERJEE AB, 2000, ANN NY ACAD SCI, V923, P348; Peri A, 2000, INT J CANCER, V88, P525, DOI 10.1002/1097-0215(20001115)88:4<525::AID-IJC3>3.0.CO;2-Z; Ramakrishna G, 2002, TOXICOL APPL PHARM, V179, P21, DOI 10.1006/taap.2001.9344; Robledo RF, 2000, AM J PATHOL, V156, P1307, DOI 10.1016/S0002-9440(10)65001-8; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; Shijubo N, 1997, EUR RESPIR J, V10, P1108, DOI 10.1183/09031936.97.10051108; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Singh G, 2000, ANN NY ACAD SCI, V923, P43; Stripp BR, 1996, AM J PHYSIOL-LUNG C, V271, pL656, DOI 10.1152/ajplung.1996.271.4.L656; Szabo E, 1998, CELL GROWTH DIFFER, V9, P475; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408; Zhang ZJ, 1999, P NATL ACAD SCI USA, V96, P3963, DOI 10.1073/pnas.96.7.3963; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	36	49	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29336	29340		10.1074/jbc.C400162200	http://dx.doi.org/10.1074/jbc.C400162200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15148323	hybrid			2022-12-27	WOS:000222445300064
J	Breit, A; Lagace, M; Bouvier, M				Breit, A; Lagace, M; Bouvier, M			Hetero-oligomerization between beta 2-and beta 3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; RESONANCE ENERGY-TRANSFER; BETA(2)-ADRENERGIC RECEPTOR; OPIOID RECEPTORS; LIVING CELLS; BETA(3)-ADRENERGIC RECEPTOR; TRANSFER BRET; KINASE; HETERODIMERIZATION; SUBTYPES	The ability of the closely related beta(2)- and beta(3)-adrenergic receptors (AR) to form hetero-oligomers was assessed by bioluminescence resonance energy transfer. Quantitative bioluminescence resonance energy transfer titration curves revealed that the beta(2)AR has identical propensity to hetero-oligomerize with the beta(3)AR than to form homo-oligomers. To determine the influence of hetero-oligomerization, a HEK293 cell line stably expressing an excess of beta(3)AR over beta(2)AR was generated so that all beta(2)AR are engaged in hetero-oligomerization with beta(3)AR, providing a tool to study the effect of hetero- oligomerization on beta(2)AR function in the absence of any beta(2)AR homo-oligomer. The hetero- oligomerization had no effect on the ligand binding properties of various beta(2)AR ligands and did not affect the potency of isoproterenol to stimulate adenylyl cyclase. Despite the unaltered ligand binding properties of the beta(2/3)AR hetero-oligomer, the stable association of the beta(2)AR with the beta(3)AR completely blocked agonist-stimulated internalization of the beta(2)AR. Given that the beta(3)AR is resistant to agonist-promoted endocytosis, the results indicate that the beta(3)AR acted as a dominant negative of the beta(2)AR endocytosis process. Consistent with this notion, the beta(2/3)AR hetero-oligomer displayed a lower propensity to recruit beta-arrestin-2 than the beta(2)AR. The hetero-oligomerization also led to a change in G protein coupling selectivity. Indeed, in contrast to beta(2)AR and beta(3)AR, which regulate adenylyl cyclase and extracellular signal-regulated kinase activity through a coupling to G(s) and G(i/o), no G(i/o) coupling was observed for the beta(2/3)AR hetero-oligomer. Together, these results demonstrate that hetero- oligomerization between beta(2)AR and beta(3)AR forms a beta-adrenergic signaling unit that possesses unique functional properties.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Bouvier, M (corresponding author), Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Carrillo JJ, 2003, J BIOL CHEM, V278, P42578, DOI 10.1074/jbc.M306165200; Charest PG, 2003, J BIOL CHEM, V278, P41541, DOI 10.1074/jbc.M306589200; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CHUANG DM, 1982, BIOCHEM BIOPH RES CO, V105, P1466, DOI 10.1016/0006-291X(82)90953-6; Chung S, 1999, PFLUG ARCH EUR J PHY, V437, P508, DOI 10.1007/s004240050810; Collins S, 2001, EXP BIOL MED, V226, P982, DOI 10.1177/153537020122601104; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gerhardt CC, 1999, MOL PHARMACOL, V55, P255, DOI 10.1124/mol.55.2.255; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Gong HB, 2000, BRIT J PHARMACOL, V131, P594, DOI 10.1038/sj.bjp.0703591; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Grimm M, 1998, J MOL CELL CARDIOL, V30, P1917, DOI 10.1006/jmcc.1998.0769; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERTEL C, 1985, J BIOL CHEM, V260, P2547; Jockers R, 1998, ENDOCRINOLOGY, V139, P2676, DOI 10.1210/en.139.6.2676; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KENT RS, 1980, MOL PHARMACOL, V17, P14; Klein U, 2001, J BIOL CHEM, V276, P17442, DOI 10.1074/jbc.M009214200; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafontan M., 1997, Human Reproduction (Oxford), V12, P6; LANGIN D, 1991, EUR J PHARMACOL, V199, P291, DOI 10.1016/0014-2999(91)90492-9; Lavoie C, 2003, CAN J PHYSIOL PHARM, V81, P186, DOI 10.1139/Y02-167; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Lee CW, 2002, J BIOL CHEM, V277, P15795, DOI 10.1074/jbc.M111818200; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Lindquist JM, 2000, J BIOL CHEM, V275, P22670, DOI 10.1074/jbc.M909093199; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2001, J CELL SCI, V114, P1265; NANTEL F, 1993, MOL PHARMACOL, V43, P548; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; PIETRIROUXEL F, 1995, FUNDAM CLIN PHARM, V9, P211, DOI 10.1111/j.1472-8206.1995.tb00288.x; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; THILLET J, 1990, FEBS LETT, V269, P450, DOI 10.1016/0014-5793(90)81213-8; VON ZM, 1992, J BIOL CHEM, V267, P3530; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Xu JG, 2003, J BIOL CHEM, V278, P10770, DOI 10.1074/jbc.M207968200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200; Zilberfarb V, 1997, J CELL SCI, V110, P801; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	80	131	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28756	28765		10.1074/jbc.M313310200	http://dx.doi.org/10.1074/jbc.M313310200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123695	hybrid			2022-12-27	WOS:000222265400113
J	Hartman, ME; O'Connor, JC; Godbout, JP; Minor, KD; Mazzocco, VR; Freund, GG				Hartman, ME; O'Connor, JC; Godbout, JP; Minor, KD; Mazzocco, VR; Freund, GG			Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SUBSTRATE-1 TYROSINE PHOSPHORYLATION; GROWTH-FACTOR-I; MURINE PERITONEAL-MACROPHAGES; PROTEIN-KINASE; SERINE/THREONINE PHOSPHORYLATION; MAMMALIAN TARGET; HIGH GLUCOSE; TNF-ALPHA; PHOSPHATIDYLINOSITOL 3'-KINASE	We have shown previously that hyperinsulinemia inhibits interferon-alpha-dependent activation of phosphatidylinositol 3-kinase (PI3-kinase) through mammalian target of rapamycin (mTOR)-induced serine phosphorylation of insulin receptor substrate (IRS)-1. Here we report that chronic insulin and high glucose synergistically inhibit interleukin (IL)-4-dependent activation of PI3-kinase in macrophages via the mTOR pathway. Resident peritoneal macrophages (PerMPhis) from diabetic (db/db) mice showed a 44% reduction in IRS-2-associated PI3-kinase activity stimulated by IL-4 compared with PerMPhis from heterozygote (db/+) control mice. IRS-2 from db/db mouse PerMPhis also showed a 78% increase in Ser/Thr-Pro motif phosphorylation without a difference in IRS-2 mass. To investigate the mechanism of this PI3-kinase inhibition, 12-O-tetradecanoylphorbol-13-acetate-matured U937 cells were treated chronically with insulin ( 1 nM, 18 h) and high glucose (4.5 g/liter, 48 h). In these cells, IL-4-stimulated IRS-2-associated PI3-kinase activity was reduced by 37.5%. Importantly, chronic insulin or high glucose alone did not impact IL-4-activated IRS-2-associated PI3-kinase. Chronic insulin + high glucose did reduce IL-4-dependent IRS-2 tyrosine phosphorylation and p85 association by 54 and 37%, respectively, but did not effect IL-4-activated JAK/STAT signaling. When IRS-2 Ser/Thr-Pro motif phosphorylation was examined, chronic insulin + high glucose resulted in a 92% increase in IRS-2 Ser/Thr-Pro motif phosphorylation without a change in IRS-2 mass. Pretreatment of matured U937 cells with rapamycin blocked chronic insulin + high glucose-dependent IRS-2 Ser/Thr-Pro motif phosphorylation and restored IL-4-dependent IRS-2-associated PI3-kinase activity. Taken together these results indicate that IRS-2-dependent IL-4 signaling in macrophages is impaired in models of type 2 diabetes mellitus through a mechanism that relies on insulin/ glucose-dependent Ser/Thr-Pro motif serine phosphorylation mediated by the mTOR pathway.	Univ Illinois, Coll Med, Dept Pathol, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Freund, GG (corresponding author), Univ Illinois, Coll Med, Dept Pathol, 506 S Mathews, Urbana, IL 61801 USA.	freun@uiuc.edu		Hartman, Matt/0000-0002-6238-1887	NIDDK NIH HHS [DK 064862] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064862] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Bonder CS, 2001, GROWTH FACTORS, V19, P207, DOI 10.3109/08977190109001087; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Buren J, 2003, EUR J ENDOCRINOL, V148, P157, DOI 10.1530/eje.0.1480157; Ceddia MA, 1999, J APPL PHYSIOL, V87, P2253, DOI 10.1152/jappl.1999.87.6.2253; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Cengel KA, 1998, BIOCHEM J, V335, P397, DOI 10.1042/bj3350397; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Deszo EL, 2004, CELL SIGNAL, V16, P271, DOI 10.1016/S0898-6568(03)00137-2; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; GAUTAM S, 1992, J IMMUNOL, V148, P1725; Godbout JP, 1999, CELL SIGNAL, V11, P15, DOI 10.1016/S0898-6568(98)00024-2; Greaves David R., 2001, Trends in Immunology, V22, P180, DOI 10.1016/S1471-4906(00)01848-2; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Haddad TC, 1997, J BIOL CHEM, V272, P19525, DOI 10.1074/jbc.272.31.19525; Hartman ME, 2001, BIOCHEM BIOPH RES CO, V280, P776, DOI 10.1006/bbrc.2000.4214; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Johnston JA, 1996, J LEUKOCYTE BIOL, V60, P441, DOI 10.1002/jlb.60.4.441; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; Kubota T, 2003, CIRCULATION, V107, P3073, DOI 10.1161/01.CIR.0000070937.52035.25; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu BF, 1999, DIABETES, V48, P2074, DOI 10.2337/diabetes.48.10.2074; MARCINKIEWICZ J, 1991, CYTOKINE, V3, P327, DOI 10.1016/1043-4666(91)90501-4; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Minshall C, 1997, J IMMUNOL, V159, P1225; Minshall C, 1999, J IMMUNOL, V162, P4542; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Muller S, 2002, DIABETOLOGIA, V45, P805, DOI 10.1007/s00125-002-0829-2; Nakajima K, 2000, J BIOL CHEM, V275, P20880, DOI 10.1074/jbc.M905410199; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Connor JC, 2003, METABOLISM, V52, P666, DOI 10.1016/S0026-0495(03)00026-X; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; Orchansky PL, 1997, J BIOL CHEM, V272, P22940, DOI 10.1074/jbc.272.36.22940; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Plutzky J, 2002, J DIABETES COMPLICAT, V16, P401, DOI 10.1016/S1056-8727(02)00202-7; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Salt IP, 2003, J BIOL CHEM, V278, P18791, DOI 10.1074/jbc.M210618200; Sartippour MR, 2000, DIABETES, V49, P597, DOI 10.2337/diabetes.49.4.597; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; WAGTEVELD AJ, 1991, LEUKEMIA, V5, P782; Warne JP, 2003, J ENDOCRINOL, V177, P351, DOI 10.1677/joe.0.1770351; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; Winkler G, 1998, DIABETES RES CLIN PR, V42, P169, DOI 10.1016/S0168-8227(98)00109-0; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Withers DJ, 2001, BIOCHEM SOC T, V29, P525, DOI 10.1042/BST0290525; Wurster AL, 2002, MOL CELL BIOL, V22, P117, DOI 10.1128/MCB.22.1.117-126.2002; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YIN TG, 1994, J BIOL CHEM, V269, P26614	76	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28045	28050		10.1074/jbc.M404368200	http://dx.doi.org/10.1074/jbc.M404368200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123681	hybrid			2022-12-27	WOS:000222265400028
J	Kurtev, V; Margueron, R; Kroboth, K; Ogris, E; Cavailles, V; Seiser, C				Kurtev, V; Margueron, R; Kroboth, K; Ogris, E; Cavailles, V; Seiser, C			Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I TRANSCRIPTION; COUP-TF; N-COR; NUCLEAR RECEPTORS; OXYTOCIN GENE; PROTEIN; COMPLEX; PROMOTER; FAMILY; COREPRESSOR	Histone acetyltransferases and deacetylases are recruited by transcription factors and adapter proteins to regulate specific subsets of target genes. We were interested in identifying interaction partners of histone deacetylase 1 (HDAC1) that might be involved in conferring target or substrate specificity. Using the yeast two-hybrid system, we isolated the repressor of estrogen receptor activity ( REA) as a novel HDAC1-associated protein. We demonstrated the in vivo interaction of REA with HDAC1 and characterized the respective domains required for their interaction in vitro. In addition, we found that REA also associates with the class II histone deacetylase HDAC5. In luciferase reporter assays, REA decreased transcription, and this repression was sensitive to the deacetylase inhibitor trichostatin A. Finally, we showed that REA specifically interacts with the chicken ovalbumin upstream binding transcription factors and II. The nuclear receptor chicken ovalbumin upstream binding transcription factor I was found to cooperate with REA and histone deacetylases in the repression of target genes. We, therefore, propose a novel function for REA as a mediator of transcriptional repression by nuclear hormone receptors via recruitment of histone deacetylases.	Med Univ Vienna, Vienna Bioctr, Inst Med Biochem, MAx F Perutz Labs, A-1030 Vienna, Austria; INSERM, U540, F-34090 Montpellier, France	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Seiser, C (corresponding author), Med Univ Vienna, Vienna Bioctr, Inst Med Biochem, MAx F Perutz Labs, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	christian.seiser@univie.ac.at	Cavailles, Vincent/Y-5379-2019; Margueron, Raphael F/B-9996-2015; cavailles, vincent/C-6277-2017	Cavailles, Vincent/0000-0002-7160-3074; Margueron, Raphael F/0000-0002-9093-7977; Ogris, Egon/0000-0001-5950-9264; Seiser, Christian/0000-0002-7046-9352				ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Baker A, 1997, GENE THER, V4, P773, DOI 10.1038/sj.gt.3300471; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; Chu K, 1997, J MOL ENDOCRINOL, V19, P163, DOI 10.1677/jme.0.0190163; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hou SH, 2002, J VIROL, V76, P3212, DOI 10.1128/JVI.76.7.3212-3220.2002; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; KIM KM, 1994, EMBO J, V13, P3793, DOI 10.1002/j.1460-2075.1994.tb06690.x; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kurihara I, 2002, ENDOCR RES, V28, P581, DOI 10.1081/ERC-120016845; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lechner T, 1996, BBA-PROTEIN STRUCT M, V1296, P181, DOI 10.1016/0167-4838(96)00069-6; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Pereira FA, 2000, CELL MOL LIFE SCI, V57, P1388, DOI 10.1007/PL00000624; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Schuettengruber B, 2003, MOL CELL BIOL, V23, P6993, DOI 10.1128/MCB.23.19.6993-7004.2003; SEISER C, 1993, J BIOL CHEM, V268, P13074; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Smirnov DA, 2000, VIROLOGY, V268, P319, DOI 10.1006/viro.1999.0181; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wei LN, 2001, J BIOL CHEM, V276, P16107, DOI 10.1074/jbc.M010185200; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	68	77	85	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24834	24843		10.1074/jbc.M312300200	http://dx.doi.org/10.1074/jbc.M312300200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140878	hybrid			2022-12-27	WOS:000221702500114
J	Marchini, A; Marttila, T; Winter, A; Caldeira, S; Malanchi, I; Blaschke, RJ; Hacker, B; Rao, E; Karperien, M; Wit, JM; Richter, W; Tommasino, M; Rappold, GA				Marchini, A; Marttila, T; Winter, A; Caldeira, S; Malanchi, I; Blaschke, RJ; Hacker, B; Rao, E; Karperien, M; Wit, JM; Richter, W; Tommasino, M; Rappold, GA			The short stature homeodomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENE SHOX; CASEIN KINASE-II; TURNER-SYNDROME; LERI-WEILL; DOMAIN GENE; MUTATIONS; HORMONE; CELLS; DYSCHONDROSTEOSIS; CHONDRODYSPLASIA	Mutations in the homeobox gene SHOX cause growth retardation and the skeletal abnormalities associated with Leri-Weill, Langer, and Turner syndromes. Little is known about the mechanism underlying these SHOX-related inherited disorders of bone formation. Here we demonstrate that SHOX expression in osteogenic stable cell lines, primary oral fibroblasts, and primary chondrocytes leads to cell cycle arrest and apoptosis. These events are associated with alterations in the expression of several cellular genes, including pRB, p53, and the cyclin kinase inhibitors p21(Cip1) and p27(Kip1). A SHOX mutant, such as seen in Leri-Weill syndrome patients, does not display these activities of the wild type protein. We have also shown that endogenous SHOX is mainly expressed in hypertrophic/apoptotic chondrocytes of the growth plate, strongly suggesting that the protein plays a direct role in regulating the differentiation of these cells. This study provides the first insight into the biological function of SHOX as regulator of cellular proliferation and viability and relates these cellular events to the phenotypic consequences of SHOX deficiency.	Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany; Univ Heidelberg, Orthopaed Hosp, D-69118 Heidelberg, Germany; Univ Lisbon, Inst Mol Med, P-1649028 Lisbon, Portugal; WHO, Int Agcy Res Canc, Unit Infect & Canc, F-69372 Lyon 08, France; Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Universidade de Lisboa; World Health Organization; International Agency for Research on Cancer (IARC); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rappold, GA (corresponding author), Univ Heidelberg, Inst Human Genet, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	gudrun_rappold@med.uni-heidelberg.de	Richter, Wiltrud/V-3217-2017; Marchini, Antonio/ABD-3328-2020; Caldeira, Sandra/Y-3652-2019; Marchini, Antonio/AAG-7151-2019; Karperien, Marcel/R-3270-2018	Richter, Wiltrud/0000-0003-4694-2768; Caldeira, Sandra/0000-0002-6057-5979; Karperien, Marcel/0000-0003-0751-0604; Marchini, Antonio/0000-0003-3157-4552				BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; Ballock RT, 2000, ENDOCRINOLOGY, V141, P4552, DOI 10.1210/en.141.12.4552; Belin V, 1998, NAT GENET, V19, P67, DOI 10.1038/ng0198-67; Blaschke RJ, 2000, TRENDS ENDOCRIN MET, V11, P227, DOI 10.1016/S1043-2760(00)00262-9; Boncinelli E, 1997, CURR OPIN GENET DEV, V7, P331, DOI 10.1016/S0959-437X(97)80146-3; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Brunelli S, 1996, NAT GENET, V12, P94, DOI 10.1038/ng0196-94; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; CASCIOLAROSEN L, 1996, J EXP MED, V183, P1947; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Clement-Jones M, 2000, HUM MOL GENET, V9, P695, DOI 10.1093/hmg/9.5.695; DEAR TN, 1995, DEVELOPMENT, V121, P2909; Ellison JW, 1997, HUM MOL GENET, V6, P1341, DOI 10.1093/hmg/6.8.1341; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Kasahara H, 1999, MOL CELL BIOL, V19, P526; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; Quaggin SE, 1997, J CLIN INVEST, V99, P718, DOI 10.1172/JCI119216; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; Rao E, 2001, HUM MOL GENET, V10, P3083, DOI 10.1093/hmg/10.26.3083; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Semina EV, 1998, NAT GENET, V19, P167, DOI 10.1038/527; Shears DJ, 1998, NAT GENET, V19, P70, DOI 10.1038/ng0198-70; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Stewart MC, 1997, CALCIFIED TISSUE INT, V61, P199, DOI 10.1007/s002239900323; Van Der Eerden BCJ, 2000, J BONE MINER RES, V15, P1045, DOI 10.1359/jbmr.2000.15.6.1045; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; Winter A, 2003, ARTHRITIS RHEUM-US, V48, P418, DOI 10.1002/art.10767	38	79	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37103	37114		10.1074/jbc.M307006200	http://dx.doi.org/10.1074/jbc.M307006200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15145945	hybrid			2022-12-27	WOS:000223453600114
J	Newman, E; Spratt, DE; Mosher, J; Cheyne, B; Montgomery, HJ; Wilson, DL; Weinberg, JB; Smith, SME; Salerno, JC; Ghosh, DK; Guillemette, JG				Newman, E; Spratt, DE; Mosher, J; Cheyne, B; Montgomery, HJ; Wilson, DL; Weinberg, JB; Smith, SME; Salerno, JC; Ghosh, DK; Guillemette, JG			Differential activation of nitric-oxide synthase isozymes by calmodulin-troponin C chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; TARGET RECOGNITION; STRUCTURAL BASIS; CALCIUM-BINDING; ELECTRON-TRANSFER; REDUCTASE DOMAIN; CONTROL ELEMENT; PEPTIDE; COMPLEX; MODULATION	The interactions of neuronal nitric-oxide synthase ( nNOS) with calmodulin (CaM) and mutant forms of CaM, including CaM-troponin C chimeras, have been previously reported, but there has been no comparable investigation of CaM interactions with the other constitutively expressed NOS (cNOS), endothelial NOS ( eNOS), or the inducible isoform ( iNOS). The present study was designed to evaluate the role of the four CaM EF hands in the activation of eNOS and iNOS. To assess the role of CaM regions on aspects of enzymatic function, three distinct activities associated with NOS were measured: NADPH oxidation, cytochrome c reduction, and nitric oxide ((NO)-N-.) generation as assessed by the oxyhemoglobin capture assay. CaM activates the cNOS enzymes by a mechanism other than stimulating electron transfer into the oxygenase domain. Interactions with the reductase moiety are dominant in cNOS activation, and EF hand 1 is critical for activation of both nNOS and eNOS. Although the activation patterns for nNOS and eNOS are clearly related, effects of the chimeras on all the reactions are not equivalent. We propose that cytochrome c reduction is a measure of the release of the FMN domain from the reductase complex. In contrast, cytochrome c reduction by iNOS is readily activated by each of the chimeras examined here and may be constitutive. Each of the chimeras were coexpressed with the human iNOS enzyme in Escherichia coli and subsequently purified. Domains 2 and 3 of CaM contain important elements required for the Ca2+/CaM independence of (NO)-N-. production by the iNOS enzyme. The disparity between cytochrome c reduction and (NO)-N-. production at low calcium can be attributed to poor association of heme and FMN domains when the bound CaM constructs are depleted of Ca2+. In general cNOSs are much more difficult to activate than iNOS, which can be attributed to their extra sequence elements, which are adjacent to the CaM-binding site and associated with CaM control.	Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; Duke Univ, Dept Med, Durham, NC 27713 USA; VA Med Ctr, Durham, NC 27713 USA; Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA	University of Waterloo; Duke University; Rensselaer Polytechnic Institute	Ghosh, DK (corresponding author), Duke Univ, Dept Med Hematol Oncol, Durham, NC 27713 USA.	dgx@acpub.duke.edu; jguillem@sciborg.uwaterloo.ca	salerno, john c/A-2595-2014	Spratt, Donald/0000-0002-0699-155X	NIGMS NIH HHS [GM52419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Aoyagi M, 2003, EMBO J, V22, P766, DOI 10.1093/emboj/cdg078; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; da Silva EF, 2002, INT J BIOCHEM CELL B, V34, P657, DOI 10.1016/S1357-2725(01)00170-4; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; George SE, 1996, BIOCHEMISTRY-US, V35, P8307, DOI 10.1021/bi960495y; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Ghosh DK, 2001, P NATL ACAD SCI USA, V98, P10392, DOI 10.1073/pnas.181251298; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Montgomery HJ, 2002, BIOORGAN MED CHEM, V10, P1919, DOI 10.1016/S0968-0896(02)00050-0; Montgomery HJ, 2003, BIOCHEMISTRY-US, V42, P7759, DOI 10.1021/bi027097h; Newton DC, 1998, ARCH BIOCHEM BIOPHYS, V359, P249, DOI 10.1006/abbi.1998.0917; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; WANG S, 1996, BIOCHEMISTRY-US, V37, P14539; Yuan T, 1998, FEBS LETT, V431, P210, DOI 10.1016/S0014-5793(98)00750-9; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901	41	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33547	33557		10.1074/jbc.M403892200	http://dx.doi.org/10.1074/jbc.M403892200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15138276	hybrid			2022-12-27	WOS:000223039700063
J	Giese, KC; Vierling, E				Giese, KC; Vierling, E			Mutants in a small heat shock protein that affect the oligomeric state - Analysis and allele-specific suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; CHAPERONE-LIKE ACTIVITY; GENETIC INTERACTION; ESCHERICHIA-COLI; IN-VITRO; BINDING; TEMPERATURE; PHOSPHORYLATION; MECHANISM; SUBSTRATE	Oligomerization is an essential property of small heat shock proteins (sHSPs) that appears to regulate their chaperone activity. We have examined the role of conserved hydrophobic residues that are postulated to stabilize sHSP oligomers. We identified a mutation of Synechocystis Hsp16.6 that impairs function in vivo and in vitro. The V143A mutation is in the C-terminal extension, a region predicted to form an oligomeric interaction with a hydrophobic region that includes the site of a previously characterized mutation, L66A. Both mutants were dimeric, but V143A had a stronger oligomerization defect than L66A. However, V143A protected a model substrate better than L66A. This suggests that although the two regions both play a role in oligomerization, they are not equivalent. Nevertheless, the addition of either dimeric sHSP enhanced the in vitro chaperone activity of wild type Hsp16.6, consistent with models that the sHSP dimers initiate interactions with substrates. Suppressor analysis of V143A identified mutations in the N terminus that restored activity by restabilizing the oligomer. These mutants were allele-specific and unable to suppress L66A, although they suppressed a dimeric C-terminal truncation of Hsp16.6. Conversely, suppressors of L66A were unable to suppress either V143A or the truncation, although they, like suppressors of V143A, stabilize the Hsp16.6 oligomer. We interpret these data as evidence that the mutations V143A and L66A stabilize two different dimeric structures and as further support that sHSP dimers are active species.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Arizona	Vierling, E (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St, Tucson, AZ 85721 USA.	vierling@email.arizona.edu		Vierling, Elizabeth/0000-0002-0066-4881	NIGMS NIH HHS [R01 GM42762] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; CRAIG WS, 1988, METHOD ENZYMOL, V156, P333; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; GHOSH S, 1988, ANAL BIOCHEM, V169, P227, DOI 10.1016/0003-2697(88)90278-3; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Kelley PB, 2003, MOL CELL BIOCHEM, V252, P273, DOI 10.1023/A:1025568417000; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 2003, P NATL ACAD SCI USA, V100, P8151, DOI 10.1073/pnas.1032940100; Laksanalamai P, 2003, EXTREMOPHILES, V7, P79, DOI 10.1007/s00792-002-0298-z; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Landry SJ, 2003, BIOCHEMISTRY-US, V42, P4926, DOI 10.1021/bi027070y; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; Richardson A, 1999, J BIOL CHEM, V274, P52, DOI 10.1074/jbc.274.1.52; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; Studer S, 2002, EUR J BIOCHEM, V269, P3578, DOI 10.1046/j.1432-1033.2002.03049.x; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	38	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32674	32683		10.1074/jbc.M404455200	http://dx.doi.org/10.1074/jbc.M404455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15152007	hybrid			2022-12-27	WOS:000222849700086
J	Jones, CE; Abdelraheim, SR; Brown, DR; Viles, JH				Jones, CE; Abdelraheim, SR; Brown, DR; Viles, JH			Preferential Cu2+ coordination by His(96) and His(111) induces beta-sheet formation in the unstructured amyloidogenic region of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-BINDING; STRUCTURAL IMPLICATIONS; CIRCULAR-DICHROISM; REPEAT REGION; METAL-BINDING; AMINO-ACIDS; RECOMBINANT; SCRAPIE; DOMAIN; SITES	The prion protein (PrP) is a Cu2+ binding cell surface glycoprotein that can misfold into a beta-sheet-rich conformation to cause prion diseases. The majority of copper binding studies have concentrated on the octarepeat region of PrP. However, using a range of spectroscopic techniques, we show that copper binds preferentially to an unstructured region of PrP between residues 90 and 115, outside of the octarepeat domain. Comparison of recombinant PrP with PrP-(91-115) indicates that this prion fragment is a good model for Cu2+ binding to the full-length protein. In contrast to previous reports we show that Cu2+ binds to this region of PrP with a nano-molar dissociation constant. NMR and EPR spectroscopy indicate a square-planar or square-pyramidal Cu2+ coordination utilizing histidine residues. Studies with PrP analogues show that the high affinity site requires both His(96) and His(111) as Cu2+ ligands, rather than a complex centered on His(96) as has been previously suggested. Our circular dichroism studies indicate a loss of irregular structure on copper coordination with an increase in beta-sheet conformation. It has been shown that this unstructured region, between residues 90 and 120, is vital for prion propagation and different strains of prion disease have been linked with copper binding. The role of Cu2+ in prion misfolding and disease must now be re-evaluated in the light of these findings.	Univ London, Queen Mary, Sch Biol Sci, London E1 4NS, England; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of London; Queen Mary University London; University of Bath	Viles, JH (corresponding author), Univ London, Queen Mary, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	j.viles@qmul.ac.uk	Brown, David/A-4083-2008; Jones, Christopher/C-5725-2014					Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Belosi B, 2004, CHEMBIOCHEM, V5, P349, DOI 10.1002/cbic.200300786; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; Brown DR, 2001, BRAIN RES BULL, V55, P165, DOI 10.1016/S0361-9230(01)00453-1; Brown DR, 2004, J INORG BIOCHEM, V98, P133, DOI 10.1016/j.jinorgbio.2003.09.006; BRYCE GF, 1966, J BIOL CHEM, V241, P1439; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Cui T, 2003, EUR J BIOCHEM, V270, P3368, DOI 10.1046/j.1432-1033.2003.03717.x; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Florio T, 2003, J NEUROCHEM, V85, P62, DOI 10.1046/j.1471-4159.2003.01664.x; Garnett AP, 2003, J BIOL CHEM, V278, P6795, DOI 10.1074/jbc.M209280200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; LAU SJ, 1971, J BIOL CHEM, V246, P5938; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; LENTNER C, 1984, GEIGY SCI TABLES, V3; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Millhauser GL, 2004, ACCOUNTS CHEM RES, V37, P79, DOI 10.1021/ar0301678; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Orfei M, 2003, J INORG BIOCHEM, V97, P299, DOI 10.1016/S0162-0134(03)00283-6; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Rachidi W, 2003, J BIOL CHEM, V278, P14595, DOI 10.1074/jbc.C300092200; Rachidi W, 2003, J BIOL CHEM, V278, P9064, DOI 10.1074/jbc.M211830200; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Ruiz FH, 2000, BIOCHEM BIOPH RES CO, V269, P491, DOI 10.1006/bbrc.2000.2270; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SHIRAISHI N, 2000, BIOCH BIOPHYS RES CO, V267; SIGEL H, 1982, CHEM REV, V82, P385, DOI 10.1021/cr00050a003; Sigurdsson EM, 2003, J BIOL CHEM, V278, P46199, DOI 10.1074/jbc.C300303200; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Thackray AM, 2002, BIOCHEM J, V362, P253, DOI 10.1042/0264-6021:3620253; TSANGARIS JM, 1970, J AM CHEM SOC, V92, P4255, DOI 10.1021/ja00717a020; VALENTINE JS, 1979, P NATL ACAD SCI USA, V76, P4245, DOI 10.1073/pnas.76.9.4245; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; Wong BS, 2000, BIOCHEM BIOPH RES CO, V273, P136, DOI 10.1006/bbrc.2000.2911; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	68	217	220	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32018	32027		10.1074/jbc.M403467200	http://dx.doi.org/10.1074/jbc.M403467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145944	hybrid			2022-12-27	WOS:000222849700005
J	Song, WZ; Liu, ZQ; Tan, JG; Nomura, Y; Dong, K				Song, WZ; Liu, ZQ; Tan, JG; Nomura, Y; Dong, K			RNA editing generates tissue-specific sodium channels with distinct gating properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KNOCKDOWN-RESISTANCE; FUNCTIONAL-ANALYSIS; RECEPTOR CHANNELS; MEMBRANE-PROTEIN; IONIC CURRENTS; MESSENGER-RNAS; DROSOPHILA; BRAIN; GENE; MODULATION	Sodium channels play an essential role in generating the action potential in eukaryotic cells, and their transcripts, especially those in insects, undergo extensive A-to-I RNA editing. The functional consequences of RNA editing of sodium channel transcripts, however, have yet to be determined. We characterized 20 splice variants of the German cockroach sodium channel gene BgNa(v). Functional analysis revealed that these variants exhibited a broad range of voltage-dependent activation and inactivation. Further analysis of two variants, BgNan(v)1-1 and BgNa(v)1-2, which activate at more depolarizing membrane potentials than other variants, showed that RNA editing events were responsible for variant-specific gating properties. Two U-to-C editing sites identified in BgNa(v)1-1 resulted in a Leu to Pro change in segment 1 of domain III (IIIS1) and a Val to Ala change in IVS4. The Leu to Pro change shifted both the voltage dependence of activation and steady-state inactivation in the depolarizing direction. Two A-to-I editing events in BgNa(v)1-2 resulted in a Lys to Arg change in IS2 and an Ile to Met change in IVS3. The Lys to Arg change shifted the voltage dependence of activation in the depolarizing direction. Moreover, these RNA editing events occurred in a tissue-specific and development-specific manner. Our findings provide direct evidence that RNA editing is an important mechanism generating tissue-/cell type-specific functional variants of sodium channels.	Michigan State Univ, Dept Entomol, Ctr Integrated Plant Syst 106, E Lansing, MI 48824 USA; Michigan State Univ, Neurosci Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Dong, K (corresponding author), Michigan State Univ, Dept Entomol, Ctr Integrated Plant Syst 106, E Lansing, MI 48824 USA.	dongk@msu.edu			NIGMS NIH HHS [R01 GM057440, R01 GM057440-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057440] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bass BL, 2001, RNA EDITING; Bell W. J., 1981, LAB COCKROACH; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; BYERLY L, 1988, J NEUROSCI, V8, P4379; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Catterall WA, 2003, PHARMACOL REV, V55, P575, DOI 10.1124/pr.55.4.7; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.ph.58.030196.002025; Dib-Hajj S, 2002, TRENDS NEUROSCI, V25, P253, DOI 10.1016/S0166-2236(02)02150-1; Dietrich PS, 1998, J NEUROCHEM, V70, P2262; Dong K, 1997, INSECT BIOCHEM MOLEC, V27, P93, DOI 10.1016/S0965-1748(96)00082-3; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Grauso M, 2002, GENETICS, V160, P1519; GUSTAFSON TA, 1993, J BIOL CHEM, V268, P18648; Hanrahan CJ, 2000, GENETICS, V155, P1149; Lee Si Hyeock, 2002, Invertebrate Neuroscience, V4, P125, DOI 10.1007/s10158-001-0014-1; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; NAGALLA SR, 1994, MOL ENDOCRINOL, V8, P943, DOI 10.1210/me.8.8.943; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ODOWD DK, 1995, J NEUROSCI, V15, P4005; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; Patton DE, 1997, NEURON, V19, P711, DOI 10.1016/S0896-6273(00)80383-9; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Reenan RA, 2000, NEURON, V25, P139, DOI 10.1016/S0896-6273(00)80878-8; Rosenthal JJC, 2002, NEURON, V34, P743, DOI 10.1016/S0896-6273(02)00701-8; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; Seeburg PH, 2000, NEURON, V25, P261, DOI 10.1016/S0896-6273(00)80891-0; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Seeburg PH, 2002, NEURON, V35, P17, DOI 10.1016/S0896-6273(02)00760-2; Semenov EP, 1999, J NEUROCHEM, V72, P66, DOI 10.1046/j.1471-4159.1999.0720066.x; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Smith L A, 1998, J Neurogenet, V12, P227; Smith RD, 1996, J NEUROSCI, V16, P1965; Smith RD, 1997, J NEUROSCI, V17, P6086; Smith RD, 2000, AM J PHYSIOL-CELL PH, V278, pC638, DOI 10.1152/ajpcell.2000.278.4.C638; Smith TJ, 1997, INSECT BIOCHEM MOLEC, V27, P807, DOI 10.1016/S0965-1748(97)00065-9; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Tan J, 2002, INSECT BIOCHEM MOLEC, V32, P445, DOI 10.1016/S0965-1748(01)00122-9; Tan JG, 2002, J NEUROSCI, V22, P5300; THACKERAY JR, 1995, GENETICS, V141, P203; THACKERAY JR, 1994, J NEUROSCI, V14, P2569; Villegas J, 2002, NUCLEIC ACIDS RES, V30, P1895, DOI 10.1093/nar/30.9.1895; Warmke JW, 1997, J GEN PHYSIOL, V110, P119, DOI 10.1085/jgp.110.2.119; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207	49	82	90	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32554	32561		10.1074/jbc.M402392200	http://dx.doi.org/10.1074/jbc.M402392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15136570	hybrid, Green Accepted			2022-12-27	WOS:000222849700071
J	Armesilla, AL; Williams, JC; Buch, MH; Pickard, A; Emerson, M; Cartwright, EJ; Oceandy, D; Vos, MD; Gillies, S; Clark, GJ; Neyses, L				Armesilla, AL; Williams, JC; Buch, MH; Pickard, A; Emerson, M; Cartwright, EJ; Oceandy, D; Vos, MD; Gillies, S; Clark, GJ; Neyses, L			Novel functional interaction between the plasma membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; ION MOTIVE ATPASES; CALCIUM-PUMP; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; KINASE FAMILY; CA-2+ PUMP; ISOFORM 4B; PROTEIN; IDENTIFICATION	Plasma membrane calmodulin-dependent calcium ATPases (PMCAs) are enzymatic systems implicated in the extrusion of calcium from the cell. We and others have previously identified molecular interactions between the cytoplasmic COOH-terminal end of PMCA and PDZ domain-containing proteins. These interactions suggested a new role for PMCA as a modulator of signal transduction pathways. The existence of other intracellular regions in the PMCA molecule prompted us to investigate the possible participation of other domains in interactions with different partner proteins. A two-hybrid screen of a human fetal heart cDNA library, using the region 652 - 840 of human PMCA4b ( located in the catalytic, second intracellular loop) as bait, revealed a novel interaction between PMCA4b and the tumor suppressor RASSF1, a Ras effector protein involved in H-Ras-mediated apoptosis. Immunofluorescence co-localization, immunoprecipitation, and glutathione S-transferase pull-down experiments performed in mammalian cells provided further confirmation of the physical interaction between the two proteins. The interaction domain has been narrowed down to region 74 - 123 of RASSF1C ( 144 - 193 in RASSF1A) and 652 - 748 of human PMCA4b. The functionality of this interaction was demonstrated by the inhibition of the epidermal growth factor-dependent activation of the Erk pathway when PMCA4b and RASSF1 were co-expressed. This inhibition was abolished by blocking PMCA/ RASSSF1 association with an excess of a green fluorescent protein fusion protein containing the region 50 - 123 of RASSF1C. This work describes a novel protein-protein interaction involving a domain of PMCA other than the COOH terminus. It suggests a function for PMCA4b as an organizer of macromolecular protein complexes, where PMCA4b could recruit diverse proteins through interaction with different domains. Furthermore, the functional association with RASSF1 indicates a role for PMCA4b in the modulation of Ras-mediated signaling.	Univ Manchester, Div Cardiol, Manchester M13 9PT, Lancs, England; NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA	University of Manchester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neyses, L (corresponding author), Univ Manchester, Div Cardiol, Rm 1-302,Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ludwig.neyses@cmmc.nhs.uk	Oceandy, Delvac/G-9911-2015; Neyses, Ludwig/AGY-7446-2022	Oceandy, Delvac/0000-0002-6242-6491; Armesilla, Angel/0000-0003-3546-5580; pickard, adam/0000-0001-9757-143X; Cartwright, Elizabeth/0000-0002-6836-7795	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010279, Z01SC010359] Funding Source: NIH RePORTER; Medical Research Council [G0200020] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Brown BJ, 1996, BBA-BIOMEMBRANES, V1283, P10, DOI 10.1016/0005-2736(96)00108-3; Chami M, 2003, J BIOL CHEM, V278, P31745, DOI 10.1074/jbc.M304202200; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Goellner GM, 2003, ANN NY ACAD SCI, V986, P461, DOI 10.1111/j.1749-6632.2003.tb07230.x; GREEB J, 1989, J BIOL CHEM, V264, P18569; Hammes A, 1998, CIRC RES, V83, P877; HEIM R, 1992, J BIOL CHEM, V267, P24476; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; JAMES P, 1988, J BIOL CHEM, V263, P2905; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Ko YG, 1999, J IMMUNOL, V162, P7217; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Oxhorn BC, 2003, CELL SIGNAL, V15, P489, DOI 10.1016/S0898-6568(02)00149-3; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PRIOR IA, 2003, BIOCHEMIST, V25, P22; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sasamura S, 2002, JPN J PHARMACOL, V90, P164, DOI 10.1254/jjp.90.164; Schuh K, 2003, J BIOL CHEM, V278, P9778, DOI 10.1074/jbc.M212507200; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Sugden PH, 2000, TRENDS CARDIOVAS MED, V10, P1, DOI 10.1016/S1050-1738(00)00038-4; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Zabe M, 2001, J BIOL CHEM, V276, P14704, DOI 10.1074/jbc.M009850200	46	91	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31318	31328		10.1074/jbc.M307557200	http://dx.doi.org/10.1074/jbc.M307557200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145946	hybrid, Green Published			2022-12-27	WOS:000222726800052
J	Mattera, R; Puertollano, R; Smith, WJ; Bonifacino, JS				Mattera, R; Puertollano, R; Smith, WJ; Bonifacino, JS			The trihelical bundle subdomain of the GGA proteins interacts with multiple partners through overlapping but distinct sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; AMINO-TERMINAL DOMAIN; TRANS-GOLGI NETWORK; EAR HOMOLOGY DOMAIN; GAMMA-ADAPTIN; UBIQUITIN-BINDING; VHS DOMAINS; GAT DOMAIN; MEMBRANE-FUSION; CLATHRIN	The Golgi-localized, gamma-adaptin ear-containing, ARF-binding (GGA) proteins are monomeric clathrin adaptors that mediate the sorting of cargo at the trans-Golgi network and endosomes. The GGAs contain four different domains named Vps27, Hrs, Stam (VHS); GGAs and TOM1 (GAT); hinge; and gamma-adaptin ear (GAE). The VHS domain recognizes transmembrane cargo, whereas the hinge and GAE regions bind clathrin and accessory proteins, respectively. The GAT domain is a polyfunctional module that interacts with various partners including the small GTPase ARF, the endosomal fusion regulator Rabaptin-5, ubiquitin, and the product of the tumor susceptibility gene 101 (TSG101). Previous x-ray crystallographic analyses showed that the GAT region is composed of two subdomains, an N-terminal helix-loop-helix containing the ARF binding site, and a C-terminal triple alpha-helical (trihelical) bundle. In this study, we define the Rabaptin-5 binding site on the GGA1-GAT domain and its relationship to the binding sites for ubiquitin and TSG101. Our observations show that Rabaptin-5, ubiquitin, and TSG101 bind to overlapping but distinct binding sites on the trihelical bundle. The different GAT binding partners engage in both competitive and cooperative interactions that may be important for the function of the GGAs in protein sorting.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Boman AL, 2002, MOL BIOL CELL, V13, P3078, DOI 10.1091/mbc.E02-02-0078; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Mattera R, 2004, J BIOL CHEM, V279, P8018, DOI 10.1074/jbc.M311873200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Seet LF, 2004, J BIOL CHEM, V279, P4670, DOI 10.1074/jbc.M311228200; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Suer S, 2003, P NATL ACAD SCI USA, V100, P4451, DOI 10.1073/pnas.0831133100; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; Zhai P, 2003, BIOCHEMISTRY-US, V42, P13901, DOI 10.1021/bi035392b; Zhu GY, 2003, BIOCHEMISTRY-US, V42, P6392, DOI 10.1021/bi034334n; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	45	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31409	31418		10.1074/jbc.M402183200	http://dx.doi.org/10.1074/jbc.M402183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143060	hybrid			2022-12-27	WOS:000222726800062
J	Witt, S; Zieseniss, A; Fock, U; Jockusch, BM; Illenberger, S				Witt, S; Zieseniss, A; Fock, U; Jockusch, BM; Illenberger, S			Comparative biochemical analysis suggests that vinculin and metavinculin cooperate in muscular adhesion sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN-BINDING; SMOOTH-MUSCLE; META-VINCULIN; INTRAMOLECULAR ASSOCIATION; SKELETAL-MUSCLE; TAIL DOMAIN; DILATED CARDIOMYOPATHY; ACIDIC PHOSPHOLIPIDS; JUNCTIONAL COMPLEX; ALPHA-CATENIN	Metavinculin, the muscle-specific splice variant of the cell adhesion protein vinculin, is characterized by a 68-amino acid insert within the C-terminal tail domain. The findings that mutations within this region correlate with hereditary idiopathic dilated cardiomyopathy in man suggest a specific contribution of metavinculin to the molecular architecture of muscular actin-membrane attachment sites, the nature of which, however, is still unknown. In mice, metavinculin is expressed in smooth and skeletal muscle, where it co-localizes with vinculin in dense plaques and costameres, respectively, but is of conspicuously low abundance in the heart. Immunoprecipitates suggest that both isoforms are present in the same complex. On the molecular level, both vinculin isoforms are regulated via an intramolecular head-tail interaction, with the metavinculin tail domain having a lower affinity for the head as compared with the vinculin tail. In addition, metavinculin displays impaired binding to acidic phospholipids and reduced homodimerization. Only in the presence of phospholipidactivated vinculin tail, the metavinculin tail domain is readily incorporated into heterodimers. Mutational analysis revealed that the metavinculin insert significantly alters binding of the C-terminal hairpin loop to acidic phospholipids. In summary, our data lead to a model in which unfurling of the metavinculin tail domain is impaired by the negative charges of the 68-amino acid insert, thus requiring vinculin to fully activate the metavinculin molecule. As a consequence, microfilament anchorage may be modulated at muscular adhesion sites through heterodimer formation.	Tech Univ Braunschweig, Inst Zool, Bioctr, D-38092 Braunschweig, Germany	Braunschweig University of Technology	Illenberger, S (corresponding author), Tech Univ Braunschweig, Inst Zool, Bioctr, Spielmannstr 7, D-38092 Braunschweig, Germany.							Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; BELKIN AM, 1988, J CELL BIOL, V107, P545, DOI 10.1083/jcb.107.2.545; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Chopard A, 2002, PFLUG ARCH EUR J PHY, V444, P627, DOI 10.1007/s00424-002-0872-3; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DANOWSKI BA, 1992, J CELL BIOL, V118, P1411, DOI 10.1083/jcb.118.6.1411; DARSZON A, 1980, P NATL ACAD SCI-BIOL, V77, P239, DOI 10.1073/pnas.77.1.239; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 2001, J CELL BIOL, V155, P775, DOI 10.1083/jcb.200105044; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; ITO S, 1983, J BIOL CHEM, V258, P4626; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kainulainen T, 2002, J BIOL CHEM, V277, P21998, DOI 10.1074/jbc.M200715200; KOTELIANSKY VE, 1992, EUR J BIOCHEM, V204, P767, DOI 10.1111/j.1432-1033.1992.tb16692.x; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Laine RO, 1997, J CELL BIOL, V138, P1255, DOI 10.1083/jcb.138.6.1255; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; Moulder GL, 1996, MOL BIOL CELL, V7, P1181, DOI 10.1091/mbc.7.8.1181; Olson TM, 2002, CIRCULATION, V105, P431, DOI 10.1161/hc0402.102930; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; Rudiger M, 1998, FEBS LETT, V431, P49, DOI 10.1016/S0014-5793(98)00723-6; SAGA S, 1985, EXP CELL RES, V156, P45, DOI 10.1016/0014-4827(85)90260-5; SAITO Y, 1988, BIOCHEM BIOPH RES CO, V154, P85, DOI 10.1016/0006-291X(88)90653-5; SILICIANO JD, 1986, METHOD ENZYMOL, V134, P78; Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Xu WM, 1998, DEVELOPMENT, V125, P327; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	52	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31533	31543		10.1074/jbc.M314245200	http://dx.doi.org/10.1074/jbc.M314245200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159399	hybrid			2022-12-27	WOS:000222726800076
J	Seshasayee, D; Wang, H; Lee, WP; Gribling, P; Ross, J; Van Bruggen, N; Carano, R; Grewal, IS				Seshasayee, D; Wang, H; Lee, WP; Gribling, P; Ross, J; Van Bruggen, N; Carano, R; Grewal, IS			A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; TNF FAMILY-MEMBER; T-CELLS; FACTOR RECEPTOR; LYMPHOCYTE DEVELOPMENT; HUMORAL HYPERCALCEMIA; MONOCLONAL-ANTIBODIES; CD40; CYTOKINE	Osteoprotegerin Ligand (OPGL) is a member of the tumor necrosis factor ligand superfamily and has been shown to be involved in interactions between T cells and dendritic cells. Its role in monocyte effector function, however, has not been defined. In the present study a role for OPGL in activating monocytes/macrophages has been characterized. OPGL was found to up-regulate receptor activator of NF-kappaB (RANK) receptor expression on monocytes, regulate their effector function by inducing cytokine and chemokine secretion, activate antigen presentation through up-regulation of co-stimulatory molecule expression, and promote survival. This activation is mediated through the MAPK pathway as evidenced by activation of p38 and p42/44 MAPK and upregulation of BCL-XL protein levels. A physiological role for OPGL in monocyte activation and effector function was tested in a model of lipopolysaccharide-induced endotoxic shock. Administration of receptor activator of NF-kappaB (RANK)-Fc to block OPGL activity in vivo was able to protect mice from death induced by sepsis, indicating a hitherto undescribed role for OPGL in monocyte function and in mediating inflammatory response. This was further tested in an animal model of inflammation-mediated arthritis. Treatment with RANK-Fc significantly ameliorated disease development and attenuated bone destruction. Thus, our study strongly suggests that administration of receptor fusion proteins to specifically block OPGL activity in vivo may result in blocking development of monocyte/macrophage-mediated diseases.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Grewal, IS (corresponding author), Genentech Inc, Dept Immunol, 1 DNA Way,MS 34, San Francisco, CA 94080 USA.	iqbal@gene.com		Grewal, Iqbal S/0000-0002-4775-055X				Akatsu T, 1998, BONE, V23, P495, DOI 10.1016/S8756-3282(98)00141-0; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Capparelli C, 2000, CANCER RES, V60, P783; Clark LB, 1996, ADV IMMUNOL, V63, P43; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Genant HK, 1998, ARTHRITIS RHEUM, V41, P1583, DOI 10.1002/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Josien R, 1999, J IMMUNOL, V162, P2562; KIENER PA, 1995, J IMMUNOL, V155, P4917; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440-1711.1999.00815.x; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Malik N, 1996, J IMMUNOL, V156, P3952; Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498; Ravirajan C T, 1999, Int Rev Immunol, V18, P563, DOI 10.3109/08830189909088499; Ross FP, 2000, J CLIN INVEST, V105, P555, DOI 10.1172/JCI9557; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Stout RD, 1996, J IMMUNOL, V156, P8; Suttles J, 1999, J BIOL CHEM, V274, P5835, DOI 10.1074/jbc.274.9.5835; Suttles J, 1996, J LEUKOCYTE BIOL, V60, P651, DOI 10.1002/jlb.60.5.651; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; TERATO K, 1992, J IMMUNOL, V148, P2103; Terato K, 1995, AUTOIMMUNITY, V22, P137, DOI 10.3109/08916939508995311; TIAN LC, 1995, EUR J IMMUNOL, V25, P306, DOI 10.1002/eji.1830250152; VanKooten C, 1996, ADV IMMUNOL, V61, P1; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	39	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30202	30209		10.1074/jbc.M403968200	http://dx.doi.org/10.1074/jbc.M403968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15145935	hybrid			2022-12-27	WOS:000222531900043
J	Sze, CI; Su, M; Pugazhenthi, S; Jambal, P; Hsu, LJ; Heath, J; Schultz, L; Chang, NS				Sze, CI; Su, M; Pugazhenthi, S; Jambal, P; Hsu, LJ; Heath, J; Schultz, L; Chang, NS			Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro - A potential role in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PAIRED HELICAL FILAMENTS; NEUROBLASTOMA CELL-LINE; TUMOR-SUPPRESSOR GENE; PROLYL ISOMERASE PIN1; N-TERMINAL KINASE; NEUROFIBRILLARY TANGLES; BINDING-PROTEIN; ESTROGEN; APOPTOSIS	Numerous enzymes hyperphosphorylate Tau in vivo, leading to the formation of neurofibrillary tangles (NFTs) in the neurons of Alzheimer's disease ( AD). Compared with age-matched normal controls, we demonstrated here that the protein levels of WW domain-containing oxidoreductase WOX1 ( also known as WWOX or FOR), its Tyr(33)-phosphorylated form, and WOX2 were significantly down-regulated in the neurons of AD hippocampi. Remarkably knock-down of WOX1 expression by small interfering RNA in neuroblastoma SK-N-SH cells spontaneously induced Tau phosphorylation at Thr(212)/Thr(231) and Ser(515)/Ser(516), enhanced phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) and ERK, and enhanced NFT formation. Also an increased binding of phospho-GSK-3beta with phospho-Tau was observed in these WOX1 knock-down cells. In comparison, increased phosphorylation of Tau, GSK-3beta, and ERK, as well as NFT formation, was observed in the AD hippocampi. Activation of JNK1 by anisomycin further increased Tau phosphorylation, and SP600125 (a JNK inhibitor) and PD-98059 (an MEK1/2 inhibitor) blocked Tau phosphorylation and NFT formation in these WOX1 knock-down cells. Ectopic or endogenous WOX1 colocalized with Tau, JNK1, and GSK-3beta in neurons and cultured cells. 17beta-Estradiol, a neuronal protective hormone, increased the binding of WOX1 and GSK-3beta with Tau. Mapping analysis showed that WOX1 bound Tau via its COOH-terminal short-chain alcohol dehydrogenase/reductase domain. Together WOX1 binds Tau via its short-chain alcohol dehydrogenase/reductase domain and is likely to play a critical role in regulating Tau hyper-phosphorylation and NFT formation in vivo.	Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Chang, NS (corresponding author), Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA.	chang_nanshan@guthrie.org	Hsu, Li-Jin/G-7822-2011					Allen B, 2002, J NEUROSCI, V22, P9340; Ba F, 2004, NEUROCHEM INT, V44, P401, DOI 10.1016/j.neuint.2003.08.004; Bednarek AK, 2001, CANCER RES, V61, P8068; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonnefort AB, 1998, FEBS LETT, V441, P220, DOI 10.1016/S0014-5793(98)01552-X; CASANOVA MF, 1993, PSYCHIAT RES, V49, P41, DOI 10.1016/0165-1781(93)90029-G; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2002, INT J MOL MED, V9, P19; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chen ST, 2004, NEUROSCIENCE, V124, P831, DOI 10.1016/j.neuroscience.2003.12.036; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Ferrer I, 2001, J NEURAL TRANSM, V108, P1397, DOI 10.1007/s007020100016; Fukutani Y, 2000, PSYCHIAT CLIN NEUROS, V54, P523, DOI 10.1046/j.1440-1819.2000.00747.x; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Greenfield JP, 2002, J BIOL CHEM, V277, P12128, DOI 10.1074/jbc.M110009200; Holzer M, 2002, ACTA NEUROPATHOL, V104, P471, DOI 10.1007/s00401-002-0581-1; Jellinger KA, 2001, J CELL MOL MED, V5, P1, DOI 10.1111/j.1582-4934.2001.tb00134.x; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Kitamura Y, 1997, BIOCHEM BIOPH RES CO, V232, P418, DOI 10.1006/bbrc.1997.6301; Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001; LEW GM, 1993, GEN PHARMACOL, V24, P1383, DOI 10.1016/0306-3623(93)90423-U; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; Lu PJ, 1999, NATURE, V399, P784; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; Mailliot C, 2000, ANN NY ACAD SCI, V920, P107; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Morishima-Kawashima M, 2002, J NEUROSCI RES, V70, P392, DOI 10.1002/jnr.10355; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Okazawa Hitohi, 2002, Am J Alzheimers Dis Other Demen, V17, P79, DOI 10.1177/153331750201700209; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Pei JJ, 2001, J ALZHEIMERS DIS, V3, P41, DOI 10.3233/JAD-2001-3107; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Ramakrishnan P, 2003, NEUROBIOL DIS, V14, P251, DOI 10.1016/S0969-9961(03)00109-8; Reyna-Neyra A, 2002, BRAIN RES BULL, V58, P607, DOI 10.1016/S0361-9230(02)00829-8; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shimura H, 2004, J BIOL CHEM, V279, P17957, DOI 10.1074/jbc.M400351200; Takayama N, 2002, NEUROPATHOLOGY, V22, P147, DOI 10.1046/j.1440-1789.2002.00433.x; Tandon A, 2003, J NEUROCHEM, V86, P572, DOI 10.1046/j.1471-4159.2003.01865.x; Tanemura K, 2001, NEUROBIOL DIS, V8, P1036, DOI 10.1006/nbdi.2001.0439; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; Watanabe A, 2003, CANCER RES, V63, P8629; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	59	93	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30498	30506		10.1074/jbc.M401399200	http://dx.doi.org/10.1074/jbc.M401399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15126504	hybrid			2022-12-27	WOS:000222531900078
J	Baxter, TK; Gagnon, SJ; Davis-Harrison, RL; Beck, JC; Binz, AK; Turner, RV; Biddison, WE; Baker, BM				Baxter, TK; Gagnon, SJ; Davis-Harrison, RL; Beck, JC; Binz, AK; Turner, RV; Biddison, WE; Baker, BM			Strategic mutations in the class I major histocompatibility complex HLA-A2 independently affect both peptide binding and T cell receptor recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ANTIGEN (HLA)-A2; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; VIRAL PEPTIDES; VIRUS TYPE-1; TAX PEPTIDE; HTLV-1 TAX; ALPHA-BETA; IMMUNOGENICITY; MOLECULES	Mutational studies of T cell receptor (TCR) contact residues on the surface of the human class I major histocompatibility complex (MHC) molecule HLA-A2 have identified a "functional hot spot" that comprises Arg(65) and Lys(66) and is involved in recognition by most peptide-specific HLA-A2-restricted TCRs. Although there is a significant amount of functional data on the effects of mutations at these positions, there is comparatively little biochemical information that could illuminate their mode of action. Here, we have used a combination of fluorescence anisotropy, functional assays, and Biacore binding experiments to examine the effects of mutations at these positions on the peptide-MHC interaction and TCR recognition. The results indicate that mutations at both position 65 and position 66 influence peptide binding by HLA-A2 to various extents. In particular, mutations at position 66 result in significantly increased peptide dissociation rates. However, these effects are independent of their effects on TCR recognition, and the Arg(65)-Lys(66) region thus represents a true "hot spot" for TCR recognition. We also made the observation that in vitro T cell reactivity does not scale with the half-life of the peptide-MHC complex, as is often assumed. Finally, position 66 is implicated in the "dual recognition" of both peptide and TCR, emphasizing the multiple roles of the class I MHC peptide-binding domain.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Res Ctr, Notre Dame, IN 46556 USA; NINDS, Mol Immunol Sect, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA	University of Notre Dame; University of Notre Dame; Walther Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Baker, BM (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	bbaker2@nd.edu	Baker, Brian/B-4584-2009	Baker, Brian/0000-0002-0864-0964	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002603] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson MW, 2003, J IMMUNOL, V171, P5683, DOI 10.4049/jimmunol.171.11.5683; Arden Bernhard, 1995, Immunogenetics, V42, P455; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; Baker BM, 2001, J EXP MED, V193, P551, DOI 10.1084/jem.193.5.551; Bevington PR, 1992, DATA REDUCTION ERROR; Binz AK, 2003, BIOCHEMISTRY-US, V42, P4954, DOI 10.1021/bi034077m; Bouvier M, 1998, PROTEINS, V33, P97, DOI 10.1002/(SICI)1097-0134(19981001)33:1<97::AID-PROT9>3.0.CO;2-I; Bouvier M, 2003, MOL IMMUNOL, V39, P697, DOI 10.1016/S0161-5890(02)00261-4; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Eyring H, 1935, CHEM REV, V17, P65, DOI 10.1021/cr60056a006; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; Gabdoulline RR, 2002, CURR OPIN STRUC BIOL, V12, P204, DOI 10.1016/S0959-440X(02)00311-1; Gagnon SJ, 2003, J IMMUNOL, V171, P2233, DOI 10.4049/jimmunol.171.5.2233; Gakamsky DM, 2000, BIOCHEMISTRY-US, V39, P11163, DOI 10.1021/bi000763z; Gakamsky DM, 1999, BIOCHEMISTRY-US, V38, P12165, DOI 10.1021/bi9905821; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Hausmann S, 1999, J IMMUNOL, V162, P5389; Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; Holler PD, 2001, J EXP MED, V194, P1043, DOI 10.1084/jem.194.8.1043; Hornell TMC, 1999, J IMMUNOL, V163, P3217; Huard R, 1997, INT IMMUNOL, V9, P1701, DOI 10.1093/intimm/9.11.1701; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kirksey TJ, 1999, J BIOL CHEM, V274, P37259, DOI 10.1074/jbc.274.52.37259; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; MATSUI M, 1994, HUM IMMUNOL, V41, P160, DOI 10.1016/0198-8859(94)90010-8; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Robinson J, 2003, NUCLEIC ACIDS RES, V31, P311, DOI [10.1093/nar/gkg070, 10.1093/nar/GKG070]; Schlueter CJ, 1996, J IMMUNOL, V157, P4478; SETTE A, 1994, J IMMUNOL, V153, P5586; Sharma AK, 2001, J BIOL CHEM, V276, P21443, DOI 10.1074/jbc.M010791200; Sliz P, 2001, J IMMUNOL, V167, P3276, DOI 10.4049/jimmunol.167.6.3276; Springer S, 1998, BIOCHEMISTRY-US, V37, P3001, DOI 10.1021/bi9717441; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Sykulev Y, 1995, P NATL ACAD SCI USA, V92, P11990, DOI 10.1073/pnas.92.26.11990; UTZ U, 1992, J IMMUNOL, V149, P214; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; van der Merwe PA, 2001, IMMUNITY, V14, P665, DOI 10.1016/S1074-7613(01)00155-8; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; Wang ZC, 2002, J IMMUNOL, V169, P3146, DOI 10.4049/jimmunol.169.6.3146; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Zhao R, 1999, J EXP MED, V189, P359, DOI 10.1084/jem.189.2.359	55	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29175	29184		10.1074/jbc.M403372200	http://dx.doi.org/10.1074/jbc.M403372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131131	hybrid			2022-12-27	WOS:000222445300044
J	Jin, YH; Jeon, EJ; Li, QL; Lee, YH; Choi, JK; Kim, WJ; Lee, KY; Bae, SC				Jin, YH; Jeon, EJ; Li, QL; Lee, YH; Choi, JK; Kim, WJ; Lee, KY; Bae, SC			Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; CORE-BINDING FACTOR; T-CELL-RECEPTOR; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; FUNCTIONAL COOPERATION; HISTONE DEACETYLASE-6; DNA-BINDING; AML1	The Runt domain transcription factors (RUNXs) play essential roles in normal development and neoplasias. Genetic analyses of animals and humans have revealed the involvement of RUNX1 in hematopoiesis and leukemia, RUNX2 in osteogenesis and cleidocranial dysplasia, and RUNX3 in the development of T-cells and dorsal root ganglion neurons and in the genesis of gastric cancer. Here we report that RUNX3 is a target of the acetyltransferase activity of p300. The p300-dependent acetylation of three lysine residues protects RUNX3 from ubiquitin ligase Smurf-mediated degradation. The extent of the acetylation is up-regulated by the transforming growth factor-beta signaling pathway and down-regulated by histone deacetylase activities. Our findings demonstrate that the level of RUNX3 protein is controlled by the competitive acetylation and deacetylation of the three lysine residues, revealing a new mechanism for the posttranslational regulation of RUNX3 expression.	Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea; Chungbuk Natl Univ, Sch Med, Dept Urol, Cheongju 361763, South Korea; Chungbuk Natl Univ, Inst Tumor Res, Cheongju 361763, South Korea	Chungbuk National University; Chungbuk National University; Chungbuk National University	Lee, KY (corresponding author), Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea.	ginsenoside@runx3.co.kr; scbae@med.chungbuk.ac.kr	Li, Qinglin/K-2570-2015; jin, yun/GQZ-6618-2022; 高, 雨莉/HGU-8187-2022	Li, Qinglin/0000-0002-4125-1944; 				Bae SC, 1999, HISTOL HISTOPATHOL, V14, P1213, DOI 10.14670/HH-14.1213; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200	38	172	178	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29409	29417		10.1074/jbc.M313120200	http://dx.doi.org/10.1074/jbc.M313120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15138260	hybrid			2022-12-27	WOS:000222445300073
J	Lopez-Rubio, JJ; Padmanabhan, S; Lazaro, JM; Salas, M; Murillo, FJ; Elias-Arnanz, M				Lopez-Rubio, JJ; Padmanabhan, S; Lazaro, JM; Salas, M; Murillo, FJ; Elias-Arnanz, M			Operator design and mechanism for CarA repressor-mediated down-regulation of the photoinducible carB operon in Myxococcus xanthus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-INDUCED CAROTENOGENESIS; OPEN-COMPLEX-FORMATION; MAJOR SIGMA-FACTOR; LAC UV5 PROMOTER; RNA-POLYMERASE; TRANSCRIPTION INITIATION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; BLUE-LIGHT; CAROTENOID SYNTHESIS	The carB operon encodes all except one of the enzymes involved in light-induced carotenogenesis in Myxococcus xanthus. Expression of its promoter (P-B) is repressed in the dark by sequence-specific DNA binding of CarA to a palindrome (pI) located between positions - 47 and - 64 relative to the transcription start site. This promotes subsequent binding of CarA to additional sites that remain to be defined. CarS, produced in the light, interacts physically with CarA, abrogates CarA-DNA binding, and thereby derepresses P-B. In this study, we delineate the operator design that exists for CarA by precisely mapping out the second operator element. For this, we examined how stepwise deletions and site-directed mutagenesis in the region between the palindrome and the transcription start site affect CarA binding around P-B in vitro and expression of P-B in vivo. These revealed the second operator element to be an imperfect interrupted palindrome (pII) spanning positions - 26 to -40. In vitro assays using purified M. xanthus RNA polymerase showed that CarA abolishes P-B-RNA polymerase binding and runoff transcription and that both were restored by CarS, thus rationalizing the observations in vivo. CarA binding to pII ( after association with pI) effectively occludes RNA polymerase from P-B and so provides the operative mechanism for the repression of the carB operon by CarA. The bipartite operator design, whereby transcription is blocked by the low affinity CarA-pII binding and is readily restored by CarS, may have evolved to match the needs for a rapid and an effective response to light.	Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	University of Murcia; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Murillo, FJ (corresponding author), Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain.	araujo@um.es; melias@um.es	Salas, Margarita/J-9873-2014; Padmanabhan, S./E-8943-2017; Elías-Arnanz, Montserrat/H-4707-2015; lopez-rubio, jose juan/A-4509-2014	Salas, Margarita/0000-0001-5939-3441; Elías-Arnanz, Montserrat/0000-0003-1980-3092; Padmanabhan, S./0000-0002-8772-0152; lopez-rubio, jose juan/0000-0002-0555-1122				BALSALOBRE JM, 1987, P NATL ACAD SCI USA, V84, P2359, DOI 10.1073/pnas.84.8.2359; BERTRANDBURGGRAF E, 1987, J MOL BIOL, V193, P293, DOI 10.1016/0022-2836(87)90220-8; Biran D, 1997, MOL MICROBIOL, V25, P463, DOI 10.1046/j.1365-2958.1997.4751843.x; BOTELLA JA, 1995, EUR J BIOCHEM, V233, P238, DOI 10.1111/j.1432-1033.1995.238_1.x; BRETSCHER AP, 1978, J BACTERIOL, V133, P763, DOI 10.1128/JB.133.2.763-768.1978; Browning DF, 2003, MOL MICROBIOL, V48, P237, DOI 10.1046/j.1365-2958.2003.03431.x; Camacho A, 2001, J BIOL CHEM, V276, P28927, DOI 10.1074/jbc.M103738200; Cayuela ML, 2003, J BACTERIOL, V185, P3527, DOI 10.1128/JB.185.12.3527-3537.2003; CHOY H, 1996, ESCHERICHIA COLI SAL, V1, P1287; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; Ciubotaru M, 2003, BIOCHEMISTRY-US, V42, P4253, DOI 10.1021/bi027318j; Courey AJ, 2001, CURR BIOL, V11, pR250, DOI 10.1016/S0960-9822(01)00130-0; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; Elias-Arnanz M, 1999, GENE DEV, V13, P2502, DOI 10.1101/gad.13.19.2502; Fontes M, 2003, MOL MICROBIOL, V47, P561, DOI 10.1046/j.1365-2958.2003.03319.x; FONTES M, 1993, EMBO J, V12, P1265, DOI 10.1002/j.1460-2075.1993.tb05771.x; Gorham HC, 1996, MOL MICROBIOL, V19, P171, DOI 10.1046/j.1365-2958.1996.360888.x; HAWLEY DK, 1985, J BIOL CHEM, V260, P8618; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodgson D, 1993, MYXOBACTERIA, VII, P157; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; INOUYE S, 1990, J BACTERIOL, V172, P80, DOI 10.1128/JB.172.1.80-85.1990; Lee YS, 1997, J BIOL CHEM, V272, P83; Lloyd G, 2001, ESSAYS BIOCHEM, V37, P17, DOI 10.1042/bse0370017; Lopez-Rubio JJ, 2002, J BIOL CHEM, V277, P7262, DOI 10.1074/jbc.M110351200; Martinez-Argudo I, 1998, MOL MICROBIOL, V30, P883, DOI 10.1046/j.1365-2958.1998.01129.x; MARTINEZLABORDA A, 1989, GENETICS, V122, P801; MCGOWAN SJ, 1993, MOL MICROBIOL, V10, P713, DOI 10.1111/j.1365-2958.1993.tb00943.x; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; Moreno AJ, 2001, J BACTERIOL, V183, P557, DOI 10.1128/JB.183.2.557-569.2001; Muller-Hill B, 1998, MOL MICROBIOL, V29, P13, DOI 10.1046/j.1365-2958.1998.00870.x; NICOLAS FJ, 1994, GENE DEV, V8, P2375, DOI 10.1101/gad.8.19.2375; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; Padmanabhan S, 2001, J BIOL CHEM, V276, P41566, DOI 10.1074/jbc.M106352200; PEREZMARIN MC, 2004, J BIOL CHEM     0525; Ptashne M., 1986, A GENETIC SWITCH; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; Rojo F, 1999, J BACTERIOL, V181, P2987, DOI 10.1128/JB.181.10.2987-2991.1999; RUDD KE, 1982, J BACTERIOL, V151, P89, DOI 10.1128/JB.151.1.89-105.1982; RUIZVAZQUEZ R, 1993, MOL MICROBIOL, V10, P25, DOI 10.1111/j.1365-2958.1993.tb00900.x; RUIZVAZQUEZ R, 1984, J BACTERIOL, V160, P818; SAMBROOK J, 2000, MOL CLONING LAB MANU; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; Smith TL, 1996, P NATL ACAD SCI USA, V93, P8868, DOI 10.1073/pnas.93.17.8868; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Whitworth DE, 2001, MOL MICROBIOL, V42, P809, DOI 10.1046/j.1365-2958.2001.02679.x; WILLIAMS DR, 1993, NUCLEIC ACIDS RES, V21, P1141, DOI 10.1093/nar/21.5.1141; Zeng XM, 1999, J BACTERIOL, V181, P1719, DOI 10.1128/JB.181.6.1719-1727.1999; Zeng XM, 2000, J BACTERIOL, V182, P1916, DOI 10.1128/JB.182.7.1916-1922.2000	55	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28945	28953		10.1074/jbc.M403459200	http://dx.doi.org/10.1074/jbc.M403459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123730	hybrid			2022-12-27	WOS:000222445300016
J	Tani, M; Okino, N; Sueyoshi, N; Ito, M				Tani, M; Okino, N; Sueyoshi, N; Ito, M			Conserved amino acid residues in the COOH-terminal tail are indispensable for the correct folding and localization and enzyme activity of neutral ceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PSEUDOMONAS-AERUGINOSA; MEDIATED DEGRADATION; ALKALINE CERAMIDASE; PROTEIN; GENE; PURIFICATION; SECRETION; SPHINGOSINE; APOPTOSIS	Several lines of evidence suggest that neutral ceramidase is involved in the regulation of ceramide-mediated signaling. Recently, the enzymes from mouse and rat were found to be localized at plasma membranes as a type II integral membrane protein, occasionally being detached from the cells after proteolytic processing of the NH2-terminal anchoring region (Tani, M., Iida, H., and Ito, M. (2003) J. Biol. Chem. 278, 10523-10530). We report here that conserved hydrophobic amino acid residues in the COOH-terminal tail are indispensable for the correct folding and localization, and enzyme activity of neutral ceramidase. Truncation of four, but not three, amino acid residues from the COOH terminus of rat neutral ceramidase resulted in a complete loss of enzyme activity as well as cell surface expression in HEK293 cells. Point mutation analysis revealed that Ile(758), the 4th amino acid residue from the COOH terminus, and Phe(756) are essential for the enzyme to function. The truncated and mutated enzymes were found to be retained in the endoplasmic reticulum (ER) and rapidly degraded without transportation to the Golgi apparatus. Treatment of the cells expressing the aberrant COOH-terminal enzyme with MG-132, a specific inhibitor for the proteasome, increased the accumulation of the enzyme in the ER, indicating that the misfolded enzyme was degraded by the proteasome. It was also found that the COOH-terminal tail was indispensable for the enzyme activity and correct folding of the prokaryote ceramidase from Pseudomonas aeruginosa, indicating that the importance of the COOH-terminal tail of the enzyme has been preserved through evolution.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Okino, Nozomu/AAY-2635-2021; Ito, Makoto/Q-6164-2019	Tani, Motohiro/0000-0003-4316-8260; ito, Makoto/0000-0003-3159-7818				Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; CRYSTAL RG, 1989, TRENDS GENET, V5, P411, DOI 10.1016/0168-9525(89)90200-X; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Franzen R, 2002, J BIOL CHEM, V277, P46184, DOI 10.1074/jbc.M204034200; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; GATT S, 1963, J BIOL CHEM, V238, P3131; ITO M, 2003, CERAMIDE SIGNALING, P41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lydakis-Simantiris N, 1999, BIOCHEMISTRY-US, V38, P15528, DOI 10.1021/bi991599m; Maki CG, 1996, CANCER RES, V56, P2649; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Shimada Y, 1999, J BIOL CHEM, V274, P18536, DOI 10.1074/jbc.274.26.18536; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215; Zhang ZJ, 2000, MOL GENET METAB, V70, P301, DOI 10.1006/mgme.2000.3029	30	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29351	29358		10.1074/jbc.M404012200	http://dx.doi.org/10.1074/jbc.M404012200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123644	hybrid			2022-12-27	WOS:000222445300066
J	Ingham, KC; Brew, SA; Erickson, HP				Ingham, KC; Brew, SA; Erickson, HP			Localization of a cryptic binding site for tenascin on fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK MYOTENDINOUS ANTIGEN; HUMAN-PLASMA FIBRONECTIN; CELL-ADHESION; EXTRACELLULAR-MATRIX; DOMAINS; PROTEIN	Fibronectin and tenascin are large extracellular matrix proteins that interact with each other and with integrin receptors to regulate cell growth and movement. They are both modular proteins composed of independently folded domains ( modules) that are arranged in linear fashion. Fibronectin is a covalent dimer and tenascin is a hexamer. The site on tenascin to which fibronectin binds has been localized to type III modules 3 - 5. In this study we use surface plasmon resonance to examine the interaction between various fragments of fibronectin and tenascin to further characterize and localize the binding sites. We found that tenascin fragments that contain type III modules 3 - 5 bind primarily to the N-terminal 29-kDa hep-1/fib-1 domain, which contains the first five type I modules of fibronectin. The dissociation constant, K-d, is approximate to 1 muM. The binding site on fibronectin appears to be cryptic in the whole molecule in solution but is exposed on the proteolytic fragments and probably when fibronectin is in the extended conformation.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Amer Red Cross, Holland Lab, Dept Biochem, Rockville, MD 20896 USA	Duke University; American Red Cross	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	h.erickson@cellbio.duke.edu			NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47056] Funding Source: Medline; NHLBI NIH HHS [HL 21791] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; Chung CY, 1997, J CELL SCI, V110, P1413; Fischer D, 1997, J CELL SCI, V110, P1513; Huang WT, 2001, CANCER RES, V61, P8586; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; INGHAM KC, 1984, J BIOL CHEM, V259, P1901; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; LIGHTNER VA, 1990, ANN NY ACAD SCI, V580, P260, DOI 10.1111/j.1749-6632.1990.tb17935.x; LIGHTNER VA, 1990, J CELL SCI, V95, P263; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; NARASIMHAN C, 1989, BIOCHEMISTRY-US, V28, P5041, DOI 10.1021/bi00438a021; Ohashi T, 1999, P NATL ACAD SCI USA, V96, P2153, DOI 10.1073/pnas.96.5.2153; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; RIOU JF, 1990, DEV BIOL, V137, P305, DOI 10.1016/0012-1606(90)90256-I; ROCCO M, 1983, J BIOL CHEM, V258, P4545; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	21	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28132	28135		10.1074/jbc.M312785200	http://dx.doi.org/10.1074/jbc.M312785200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123658	hybrid			2022-12-27	WOS:000222265400039
J	Kepley, CL; Taghavi, S; Mackay, G; Zhu, DC; Morel, PA; Zhang, K; Ryan, JJ; Satin, LS; Zhang, M; Pandolfi, PP; Saxon, A				Kepley, CL; Taghavi, S; Mackay, G; Zhu, DC; Morel, PA; Zhang, K; Ryan, JJ; Satin, LS; Zhang, M; Pandolfi, PP; Saxon, A			Co-aggregation of Fc gamma RII with Fc epsilon RI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; NEGATIVE REGULATION; TYROSINE PHOSPHORYLATION; PROTEIN P62(DOK); SHIP BINDS; B-CELLS; DOMAIN; IGE; EXPRESSION	Signaling through the high affinity IgE receptor FcepsilonRI on human basophils and rodent mast cells is decreased by co-aggregating these receptors to the low affinity IgG receptor FcgammaRII. We used a recently described fusion protein, GE2, which is composed of key portions of the human gamma1 and the human epsilon heavy chains, to dissect the mechanisms that lead to human mast cell and basophil inhibition through co-aggregation of FcgammaRII and FcepsilonRI. Unstimulated human mast cells derived from umbilical cord blood express the immunoreceptor tyrosine-based inhibitory motif-containing receptor FcgammaRII but not FcgammaRI or FcgammaRIII. Interaction of the mast cells with GE2 alone did not cause degranulation. Co-aggregating FcepsilonRI and FcgammaRII with GE2 1) significantly inhibited IgE-mediated histamine release, cytokine production, and Ca2+ mobilization, 2) reduced the antigen-induced morphological changes associated with mast cell degranulation, 3) reduced the tyrosine phosphorylation of several cellular substrates, and 4) increased the tyrosine phosphorylation of the adapter protein downstream of kinase 1 (p62(dok); Dok), growth factor receptor-bound protein 2 (Grb2), and SH2 domain containing inositol 5-phosphatase (SHIP). Tyrosine phosphorylation of Dok was associated with increased binding to Grb2. Surprisingly, in non-stimulated cells, there were complexes of phosphorylated SHIP-Grb2-Dok that were lost upon IgE receptor activation but retained under conditions of Fcepsilon-Fcgamma co-aggregation. Finally, studies using mast cells from Dok-1 knock-out mice showed that IgE alone triggers degranulation supporting an inhibitory role for Dok degranulation. Our results demonstrate how human FcepsilonRI-mediated responses can be inhibited by co-aggregation with FcgammaRIIB and implicate Dok, SHIP, and Grb2 as key intermediates in regulating antigen-induced mediator release.	Virginia Commonwealth Univ Hlth Syst, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ Hlth Syst, Dept Biol, Richmond, VA 23298 USA; Virginia Commonwealth Univ Hlth Syst, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Univ So Calif, Dept Med, Los Angeles, CA 90033 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Melbourne; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Memorial Sloan Kettering Cancer Center; University of Southern California	Kepley, CL (corresponding author), Virginia Commonwealth Univ Hlth Syst, Dept Internal Med, Div Rheumatol Allergy & Immunol, POB 263,MCV Stn, Richmond, VA 23298 USA.	clkepley@mail1.vcu.edu	Morel, Penelope Anne/AAI-6239-2020	Morel, Penelope Anne/0000-0002-1743-3676; Mackay, Graham/0000-0002-9083-1304; Taghavi, Sharven/0000-0001-6289-2129	FIC NIH HHS [R03 TW00440] Funding Source: Medline; NHLBI NIH HHS [P50 HL56384] Funding Source: Medline; NIAID NIH HHS [R01-AI15251, R01 AI42204] Funding Source: Medline; NIGMS NIH HHS [R01 GM49814] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000440] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042204, R01AI015251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049814] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2002, IMMUNOL LETT, V82, P23, DOI 10.1016/S0165-2478(02)00013-5; Anderson CC, 1998, CRIT REV IMMUNOL, V18, P525, DOI 10.1615/CritRevImmunol.v18.i6.30; BENJAMIN CW, 1994, J BIOL CHEM, V269, P31346; BUDDE P, 1994, J BIOL CHEM, V269, P30636; Chacko GW, 1996, J IMMUNOL, V157, P2234; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Dustin LB, 1999, J IMMUNOL, V162, P2717; DVORAK AM, 1993, INT ARCH ALLERGY IMM, V100, P219, DOI 10.1159/000236415; EGUCHI M, 1991, ELECTRON MICROSC REV, V4, P293, DOI 10.1016/0892-0354(91)90007-Y; Fleming TJ, 1997, J EXP MED, V186, P1307, DOI 10.1084/jem.186.8.1307; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; FURITSU T, 1989, P NATL ACAD SCI USA, V86, P10039, DOI 10.1073/pnas.86.24.10039; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GHOSH J, 1995, MECH AGEING DEV, V80, P171, DOI 10.1016/0047-6374(94)01568-7; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; Kepley CL, 1998, J ALLERGY CLIN IMMUN, V102, P304, DOI 10.1016/S0091-6749(98)70100-9; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2003, CLIN IMMUNOL, V108, P89, DOI 10.1016/S1521-6616(03)00155-4; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; Lesourne R, 2001, J BIOL CHEM, V276, P6327, DOI 10.1074/jbc.M006537200; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Lyden TW, 2001, J IMMUNOL, V166, P3882, DOI 10.4049/jimmunol.166.6.3882; MACGLASHAN D, 1991, J IMMUNOL, V147, P2259; Malbec O, 1998, J IMMUNOL, V160, P1647; Matricardi PM, 2001, CURR OPIN ALLERGY CL, V1, P413, DOI 10.1097/00130832-200110000-00006; Metes D, 1998, BLOOD, V91, P2369, DOI 10.1182/blood.V91.7.2369.2369_2369_2380; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ott VL, 2002, J IMMUNOL, V168, P4430, DOI 10.4049/jimmunol.168.9.4430; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Platts-Mills TAE, 2002, CLIN EXP ALLERGY, V32, P335, DOI 10.1046/j.1365-2222.2002.01352.x; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; RISKE F, 1991, J BIOL CHEM, V266, P11245; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; ROSENFELD SI, 1987, J IMMUNOL, V138, P2869; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Suzuki H, 1997, J IMMUNOL, V159, P5881; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tkaczyk C, 2001, CLIN IMMUNOL, V99, P198, DOI 10.1006/clim.2001.4992; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159; Yamada T, 2003, J BIOL CHEM, V278, P32818, DOI 10.1074/jbc.M304590200; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Yamanashi Y, 2000, GENE DEV, V14, P11; ZHANG K, 2004, IN PRESS J ALLERGY C; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	64	96	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35139	35149		10.1074/jbc.M404318200	http://dx.doi.org/10.1074/jbc.M404318200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15151996	hybrid			2022-12-27	WOS:000223303400004
J	Sancar, A				Sancar, A			Regulation of the mammalian circadian clock by cryptochrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BLUE-LIGHT PHOTORECEPTORS; DNA PHOTOLYASE; GANGLION-CELLS; CRYSTAL-STRUCTURE; ARABIDOPSIS; MELANOPSIN; BLIND; RESPONSES; PHOSPHORYLATION; ENTRAINMENT		Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	Aziz_Sancar@med.unc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031082, R37GM031082] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31082] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Barinaga M, 2002, SCIENCE, V295, P955; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Berson DM, 2003, TRENDS NEUROSCI, V26, P314, DOI 10.1016/S0166-2236(03)00130-9; Bouly JP, 2003, EUR J BIOCHEM, V270, P2921, DOI 10.1046/j.1432-1033.2003.03691.x; Briggs WR, 2002, TRENDS PLANT SCI, V7, P204, DOI 10.1016/S1360-1385(02)02245-8; Cashmore AR, 2003, CELL, V114, P537, DOI 10.1016/j.cell.2003.08.004; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; CZEISLER CA, 1995, NEW ENGL J MED, V332, P6, DOI 10.1056/NEJM199501053320102; EBIHARA S, 1980, PHYSIOL BEHAV, V24, P523, DOI 10.1016/0031-9384(80)90246-2; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; GRESSEL J, 1977, PHOTOCHEM PHOTOBIOL, V48, P11; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hall JC, 2000, CURR OPIN NEUROBIOL, V10, P456, DOI 10.1016/S0959-4388(00)00117-3; Hannibal J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0002.2002; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; Herzog ED, 2003, J NEUROPHYSIOL, V90, P763, DOI 10.1152/jn.00129.2003; Hitomi K, 2001, J BIOL CHEM, V276, P10103, DOI 10.1074/jbc.M008828200; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; Imaizumi T, 2003, NATURE, V426, P302, DOI 10.1038/nature02090; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LI YF, 1993, P NATL ACAD SCI USA, V90, P4389, DOI 10.1073/pnas.90.10.4389; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Miyamoto Y, 1999, MOL BRAIN RES, V71, P238, DOI 10.1016/S0169-328X(99)00192-8; Ozgur S, 2003, BIOCHEMISTRY-US, V42, P2926, DOI 10.1021/bi026963n; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Selby CP, 2000, P NATL ACAD SCI USA, V97, P14697, DOI 10.1073/pnas.260498597; Shalitin D, 2003, PLANT CELL, V15, P2421, DOI 10.1105/tpc.013011; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Thompson CL, 2003, INVEST OPHTH VIS SCI, V44, P4515, DOI 10.1167/iovs.03-0303; Thompson CL, 2004, MOL BRAIN RES, V122, P158, DOI 10.1016/j.molbrainres.2003.12.006; Thompson CL, 2001, P NATL ACAD SCI USA, V98, P11708, DOI 10.1073/pnas.201301498; THOMPSON CL, 2003, THESIS U N CAROLINA; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1999, MUTAT RES, V434, P79; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Van Gelder RN, 2003, TRENDS NEUROSCI, V26, P458, DOI 10.1016/S0166-2236(03)00211-X; Van Gelder RN, 2003, SCIENCE, V299, P222, DOI 10.1126/science.1079536; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Wright KP, 2002, SCIENCE, V297, P571, DOI 10.1126/science.1071697; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	62	110	115	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34079	34082		10.1074/jbc.R400016200	http://dx.doi.org/10.1074/jbc.R400016200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15123698	hybrid, Green Published			2022-12-27	WOS:000223134800001
J	Sandberg, EM; Sayeski, PP				Sandberg, EM; Sayeski, PP			Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ANGIOTENSIN-II; STAT PATHWAY; ACTIVATION; MECHANISMS; EXPRESSION; BAX	In vascular smooth muscle cells, Jak2 tyrosine kinase becomes activated in response to oxidative stress in the form of hydrogen peroxide. Although it has been postulated that hydrogen peroxide-induced Jak2 activation promotes cell survival, this has never been tested. We therefore examined the role that Jak2 plays in vascular smooth muscle cell apoptosis following hydrogen peroxide treatment. Here, we report that Jak2 tyrosine kinase activation by hydrogen peroxide is required for apoptosis of vascular smooth muscle cells. Upon treatment of primary rat aortic smooth muscle cells with hydrogen peroxide, we observed laddering of genomic DNA and nuclear condensation, both hallmarks of apoptotic cells. However, apoptosis was prevented by either the expression of a dominant negative Jak2 protein or by the Jak2 pharmacological inhibitor AG490. Moreover, expression of the proapoptotic Bax protein was induced following hydrogen peroxide treatment. Again, expression of a dominant negative Jak2 protein or treatment of cells with AG490 prevented this Bax induction. Following Bax induction by hydrogen peroxide, mitochondrial membrane integrity was compromised, and caspase-9 became activated. In contrast, in cells expressing a Jak2 dominant negative we observed that mitochondrial membrane integrity was preserved, and no caspase-9 activation occurred. These data demonstrate that the activation of Jak2 tyrosine kinase by hydrogen peroxide is essential for apoptosis of vascular smooth muscle cells. Furthermore, this report identifies Jak2 as a potential therapeutic target in vascular diseases in which vascular smooth muscle cell apoptosis contributes to pathological progression.	Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Sayeski, PP (corresponding author), Univ Florida, Coll Med, Dept Physiol & Funct Genom, POB 100274, Gainesville, FL 32610 USA.	Psayeski@phys.med.ufl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060471] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 67277] Funding Source: Medline; NIDDK NIH HHS [K01 DK 60471] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDBERG EM, 2004, J BIOL CHEM, V279, P1956; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; El-Adawi H, 2003, CARDIOVASC RES, V57, P129, DOI 10.1016/S0008-6363(02)00614-4; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; GENG YJ, 1995, AM J PATHOL, V147, P251; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Li JF, 2003, BRAIN RES BULL, V62, P101, DOI 10.1016/j.brainresbull.2003.08.011; Li PF, 1997, CIRCULATION, V96, P3602; Li PF, 1999, CIRCULATION, V100, P967, DOI 10.1161/01.CIR.100.9.967; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Mascareno E, 2001, CIRCULATION, V104, P325, DOI 10.1161/01.CIR.104.3.325; Naderi J, 2003, APOPTOSIS, V8, P91, DOI 10.1023/A:1021657220843; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Sarosi LAG, 2003, BIOCHEM BIOPH RES CO, V312, P355, DOI 10.1016/j.bbrc.2003.10.133; Sayeski PP, 1999, J BIOL CHEM, V274, P33131, DOI 10.1074/jbc.274.46.33131; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Sotnikova R, 1998, GEN PHARMACOL, V31, P115, DOI 10.1016/S0306-3623(97)00392-3; Yamakawa H, 2000, NEUROL RES, V22, P556	26	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34547	34552		10.1074/jbc.M405045200	http://dx.doi.org/10.1074/jbc.M405045200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15159394	hybrid			2022-12-27	WOS:000223134800058
J	Kanki, H; Kupershmidt, S; Yang, T; Wells, S; Roden, DM				Kanki, H; Kupershmidt, S; Yang, T; Wells, S; Roden, DM			A structural requirement for processing the cardiac K+ channel KCNQ1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; DEFECTIVE PROTEIN TRAFFICKING; POTASSIUM CHANNEL; GABA(B) RECEPTOR; COILED-COILS; GENOMIC ORGANIZATION; MUTATIONAL ANALYSIS; DRUG BLOCK; I-KS; LOCALIZATION	Normal membrane protein function requires trafficking from the endoplasmic reticulum. Here, we studied processing of the KCNQ1 channel mutated in LQT1, the commonest form of the long QT syndrome. Serial C terminus truncations identified a small region ( amino acids (aa) 610-620) required for normal cell surface expression. Non-trafficked truncations assembled as tetramers but were nevertheless retained in the endoplasmic reticulum. Further mutagenesis did not identify specific residues mediating channel processing; cell surface expression was preserved with the mutation of known trafficking motifs in the channel and with alanine scanning across aa 610-620. Structural prediction algorithms place aa 610-620 at the C-terminal end of an alpha-helix (aa 586-618) that includes a leucine zipper and is part of a coiled coil. Mutants disrupting the leucine zipper but preserving the predicted coiled coil reached the cell surface, whereas those disrupting the coil did not. These data suggest that specific protein-protein interactions are required for normal channel processing. Further biochemical studies ruled out three candidate proteins, namely KCNE1, yotiao, and KCNQ1 itself, as effectors of this coiled coil-mediated trafficking. Four LQT1 mutations within this helix generated little or no current and were not expressed on the cell surface, whereas LQT1 mutations in adjacent residues, which produce a milder clinical phenotype, generate only slightly reduced current and are expressed on the cell surface. These data suggest that mutations within this domain cause human disease by interfering with normal channel processing. More generally, we have identified a domain whose structural integrity is required for normal surface expression of the KCNQ1 channel.	Vanderbilt Univ, Div Clin Pharmacol, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Roden, DM (corresponding author), Vanderbilt Univ, Div Clin Pharmacol, Sch Med, Dept Med, 532C Med Res Bldg 1, Nashville, TN 37232 USA.	dan.roden@vanderbilt.edu	Kupershmidt, Sabina/AAO-5464-2021; Roden, Dan/ABD-5412-2021	Kupershmidt, Sabina/0000-0002-8119-2723; 	NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [HL46681, HL49989] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL049989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baroudi G, 2002, CIRC RES, V90, pE11, DOI 10.1161/hh0102.102977; Baroudi G, 2001, CIRC RES, V88, pE78, DOI 10.1161/hh1201.093270; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Chouabe C, 2000, CARDIOVASC RES, V45, P971, DOI 10.1016/S0008-6363(99)00411-3; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Fothergill-Gilmore Linda A., 1993, P467, DOI 10.1007/978-1-59259-438-2_13; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; Grunewald S, 2002, MOL PHARMACOL, V61, P1070, DOI 10.1124/mol.61.5.1070; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; Itoh T, 1998, HUM GENET, V103, P290, DOI 10.1007/s004390050819; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Kammerer RA, 1999, BIOCHEMISTRY-US, V38, P13263, DOI 10.1021/bi991018t; Kawakami K, 2001, J BIOL CHEM, V276, P25114, DOI 10.1074/jbc.M100936200; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lam BCH, 2001, PLANT CELL, V13, P2499, DOI 10.1105/tpc.13.11.2499; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; Monera OD, 1996, J BIOL CHEM, V271, P3995; MYSZKA DG, 1994, BIOCHEMISTRY-US, V33, P2363, DOI 10.1021/bi00175a003; Neyroud N, 1999, CIRC RES, V84, P290, DOI 10.1161/01.RES.84.3.290; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Pagano A, 2001, J NEUROSCI, V21, P1189; Piippo K, 2001, J AM COLL CARDIOL, V37, P562, DOI 10.1016/S0735-1097(00)01124-4; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; Raiborg C, 2001, J CELL SCI, V114, P2255; Schmitt N, 2000, EMBO J, V19, P332, DOI 10.1093/emboj/19.3.332; Seaman MNJ, 2002, MOL BIOL CELL, V13, P2826, DOI 10.1091/mbc.02-05-0064; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Yamashita F, 2001, J MOL CELL CARDIOL, V33, P197, DOI 10.1006/jmcc.2000.1300; Yang P, 2002, CIRCULATION, V105, P1943, DOI 10.1161/01.CIR.0000014448.19052.4C; Yang T, 2003, CIRCULATION, V108, P132, DOI 10.1161/01.CIR.0000082708.86266.B8; Yang T, 2001, J CARDIOVASC PHARM, V38, P737, DOI 10.1097/00005344-200111000-00010; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123	46	65	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33976	33983		10.1074/jbc.M404539200	http://dx.doi.org/10.1074/jbc.M404539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15140888	hybrid			2022-12-27	WOS:000223039700108
J	Ortiz, DF; Moseley, J; Calderon, G; Swift, AL; Li, SH; Arias, IM				Ortiz, DF; Moseley, J; Calderon, G; Swift, AL; Li, SH; Arias, IM			Identification of HAX-1 as a protein that binds bile salt export protein and regulates its abundance in the apical membrane of Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MULTIDRUG-RESISTANCE PROTEIN-2; RAT-LIVER; CANALICULAR MEMBRANE; PLASMA-MEMBRANE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INTRAHEPATIC CHOLESTASIS; FUNCTIONAL EXPRESSION; ABC TRANSPORTERS; P-GLYCOPROTEINS	ATP-binding cassette (ABC)-type proteins are essential for bile formation in vertebrate liver. BSEP, MDR1, MDR2, and MRP2 ABC transporters are targeted to the apical (canalicular) membrane of hepatocytes where they execute ATP-dependent transport of bile acids, drugs, amphipathic cations, phospholipids, and conjugated organic anions, respectively. Changes in activity and abundance of transporters in the canalicular membrane regulate bile flow; however, little is known regarding cellular proteins that bind ABC transporters and regulate their trafficking. A yeast two-hybrid screen identified HAX-1 as a binding partner for BSEP, MDR1, and MDR2. The interactions were validated biochemically by glutathione S-transferase pull-down and co-immunoprecipitation assays. BSEP and HAX-1 were over-represented in rat liver subcellular fractions enriched for canalicular membrane vesicles, microsomes, and clathrin-coated vesicles. HAX-1 was bound to BSEP, MDR1, and MDR2 in canalicular membrane vesicles and co-localized with BSEP and MDR1 in the apical membrane of Madin-Darby canine kidney (MDCK) cells. RNA interference of HAX-1 increased BSEP levels in the apical membrane of MDCK cells by 71%. Pulse-chase studies indicated that HAX-1 depletion did not affect BSEP translation, post-translational modification, delivery to the plasma membrane, or half-life. HAX-1 depletion resulted in an increased peak of metabolically labeled apical membrane BSEP at 4 h and enhanced retention at 6 and 9 h. HAX-1 also interacts with cortactin. Expression of dominant negative cortactin increased steady state levels of BSEP 2-fold in the apical membrane of MDCK cells, as did expression of dominant negative EPS15. These findings suggest that HAX-1 and cortactin participate in BSEP internalization from the apical membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Ortiz, DF (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	daniel.ortiz@tuffs.edu			NIDDK NIH HHS [T32DK07542, R01 DK060719, R01DK35652, P30 DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542, R01DK060719, P30DK034928, R01DK035652] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANIENTO F, 1993, J BIOL CHEM, V268, P10463; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Bond TD, 1998, J PHYSIOL-LONDON, V508, P333, DOI 10.1111/j.1469-7793.1998.333bq.x; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Buchler M, 1996, J BIOL CHEM, V271, P15091; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Cao H, 2001, HEPATOLOGY, V34, p450A; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; Dixon PH, 2000, HUM MOL GENET, V9, P1209, DOI 10.1093/hmg/9.8.1209; Dombrowski F, 2000, BIOCHEM J, V348, P183, DOI 10.1042/0264-6021:3480183; Dufva M, 2001, J GEN VIROL, V82, P1581, DOI 10.1099/0022-1317-82-7-1581; Fischer T, 1999, P NATL ACAD SCI USA, V96, P6722, DOI 10.1073/pnas.96.12.6722; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Harris MJ, 2001, J BIOL CHEM, V276, P20876, DOI 10.1074/jbc.M010566200; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; JOHANSSON I, 1988, BIOCHEMISTRY-US, V27, P1925, DOI 10.1021/bi00406a019; Juvvadi SR, 1997, BIOCHEM BIOPH RES CO, V230, P442, DOI 10.1006/bbrc.1996.5932; Kawaguchi Y, 2000, J VIROL, V74, P10104, DOI 10.1128/JVI.74.21.10104-10111.2000; Keitel V, 2000, HEPATOLOGY, V32, P1317, DOI 10.1053/jhep.2000.19791; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Kocher O, 1999, LAB INVEST, V79, P1161; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Kullak-Ublick GA, 2000, J HEPATOL, V32, P3, DOI 10.1016/S0168-8278(00)80411-0; LIN SH, 1989, J BIOL CHEM, V264, P14403; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Matsuda G, 2003, MICROBIOL IMMUNOL, V47, P91, DOI 10.1111/j.1348-0421.2003.tb02790.x; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Nies AT, 1996, J LIPID RES, V37, P1125; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; RUETZ S, 1994, J BIOL CHEM, V269, P12277; Sai Y, 1999, J CELL SCI, V112, P4535; Sharp TV, 2002, J VIROL, V76, P802, DOI 10.1128/JVI.76.2.802-816.2002; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; SUBRAMANIAM VN, 1992, J BIOL CHEM, V267, P12016; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Suzuki Y, 1997, J IMMUNOL, V158, P2736; Szabo K, 1997, J BIOL CHEM, V272, P23165, DOI 10.1074/jbc.272.37.23165; VREE JMD, 1998, P NATL ACAD SCI USA, V95, P282; Wang L, 2002, J CLIN INVEST, V110, P965, DOI 10.1172/JCI200215968; Yin HL, 2001, CYTOKINE, V15, P122, DOI 10.1006/cyto.2001.0891	53	89	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32761	32770		10.1074/jbc.M404337200	http://dx.doi.org/10.1074/jbc.M404337200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159385	hybrid			2022-12-27	WOS:000222849700095
J	Abdulhussein, R; McFadden, C; Fuentes-Prior, P; Vogel, WF				Abdulhussein, R; McFadden, C; Fuentes-Prior, P; Vogel, WF			Exploring the collagen-binding site of the DDR1 tyrosine kinase receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VIIIC2 DOMAIN; COAGULATION-FACTOR-V; MEMBRANE-BINDING; C2 DOMAIN; IDENTIFICATION; EXPRESSION; PROTEIN; RETINOSCHISIS; C2-DOMAIN; MUTATIONS	Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are tyrosine kinase receptors activated by triple-helical collagens. Aberrant expression and signaling of these receptors have been implicated in several human diseases linked to accelerated matrix degradation and remodeling including tumor invasion, atherosclerosis and liver fibrosis. The objective of this study is to characterize the collagen-binding sites in the discoidin domains of DDR1 and DDR2 at a molecular level. We expressed glutathione S-transferase fusion proteins containing the discoidin and extracellular domains of DDR1 and DDR2 in insect cells and subjected them to a solid-phase collagen-binding assay. We found high affinity binding of the DDR extracellular domains to immobilized type I collagen and confirmed the discoidin-collagen interaction with an enzyme-linked immunosorbent assay-based read-out. Furthermore, we created a three-dimensional model of the DDR1 discoidin domain based on the related domains of blood coagulation factors V and VIII. This model predicts the presence of four neighboring, surface-exposed loops that are topologically equivalent to a major phospholipid-binding site in factors V and VIII. To test the involvement of these loops in collagen binding, we mutated individual amino acid residues to alanine or deleted short sequence stretches within these loops. We found that several residues within loop 1 (Ser-52-Thr-57) and loop 3 (Arg-105-Lys-112) as well as Ser-175 in loop 4 are critically involved in collagen binding. Our structure-function analysis of the DDR discoidin domains provides new insights into this non-integrin-mediated collagen-signaling mechanism and may ultimately lead to the design of small molecule inhibitors that interfere with aberrant DDR function.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Max Planck Inst Biochem, D-82152 Martinsried, Germany; CSIC, Inst Catala Ciencies Cardiovasc, Cardiovasc Res Ctr, Barcelona 08025, Spain	University of Toronto; Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC)	Vogel, WF (corresponding author), 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	w.vogel@utoronto.ca		Fuentes-Prior, Pablo/0000-0002-6618-3204				ALVES F, 1995, ONCOGENE, V10, P609; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Curat CA, 2001, J BIOL CHEM, V276, P45952, DOI 10.1074/jbc.M104360200; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Fraternali F, 2003, FEBS LETT, V544, P21, DOI 10.1016/S0014-5793(03)00433-2; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; Gilbert GE, 2002, J BIOL CHEM, V277, P6374, DOI 10.1074/jbc.M104732200; Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; KANE WH, 1988, BLOOD, V71, P539; Kim SW, 2000, BIOCHEMISTRY-US, V39, P1951, DOI 10.1021/bi992256r; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200; Lewis DA, 2003, BLOOD COAGUL FIBRIN, V14, P361, DOI 10.1097/00001721-200306000-00007; Liu ML, 2000, BLOOD, V96, P979, DOI 10.1182/blood.V96.3.979.015k42a_979_987; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; Mooy CM, 2002, ARCH OPHTHALMOL-CHIC, V120, P979; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Sakamoto O, 2001, EUR RESPIR J, V17, P969, DOI 10.1183/09031936.01.17509690; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Vogel WF, 2001, EUR J DERMATOL, V11, P506; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028	35	51	56	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31462	31470		10.1074/jbc.M400651200	http://dx.doi.org/10.1074/jbc.M400651200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15136580	hybrid			2022-12-27	WOS:000222726800068
J	Cao, JS; Liu, YF; Lockwood, J; Burn, P; Shi, YG				Cao, JS; Liu, YF; Lockwood, J; Burn, P; Shi, YG			A novel cardiolipin-remodeling pathway revealed by a gene encoding an endoplasmic reticulum-associated acyl-CoA : lysocardiolipin acyltransferase (ALCAT1) in mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; MAMMALIAN-CELLS; MONOLYSOCARDIOLIPIN ACYLTRANSFERASE; SPECIES PATTERN; CYTOCHROME-C; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPIDS; APOPTOSIS; LIPIDS; HEART	Cardiolipin is a major membrane polyglycerophospholipid that is required for the reconstituted activity of a number of key mitochondrial enzymes involved in energy metabolism. Cardiolipin is subjected to remodeling subsequent to its de novo biosynthesis to attain appropriate acyl composition for its biological functions. Yet, the enzyme(s) involved in the remodeling process have not been identified. We report here the identification and characterization of a murine gene that encodes an acyl-CoA: lysocardiolipin acyltransferase 1 (ALCAT1). Expression of the ALCAT1 cDNA in either insect or mammalian cells led to a significant increase in acyl-CoA: monolysocardiolipin acyltransferase and acyl-CoA: dilysocardiolipin acyltransferase activities that exhibited a dependence upon ALCAT1 enzyme levels. The recombinant ALCAT1 enzyme recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors. In contrast, no significant increases in acyltransferase activities by the recombinant ALCAT1 were detected against either glycerol-3-phosphate or a variety of other lysophospholipids as substrates, including lysophosphatidylcholine, lysophosphatidylethanolamine, and lysophosphatidylserine. Immunocytohistochemical analysis showed that the ALCAT1 enzyme is localized in the endoplasmic reticulum, which is supported by a significant ALCAT activity in isolated liver and heart microsomes. Northern blot analysis indicates that the mouse ALCAT1 is widely distributed, with the highest expression in heart and liver. In support of a role for ALCAT1 in maintaining heart function, the ALCAT1 gene is conserved among different species of vertebrates, but not in non-atrium organisms. ALCAT1 represents the first identified cardiolipin-remodeling enzyme from any living organism; its identification implies a novel role for the endoplasmic reticulum in cardiolipin metabolism.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, DC 0545, Indianapolis, IN 46285 USA.	shi_yuguang@lilly.com						Berger A, 1993, Adv Food Nutr Res, V37, P259, DOI 10.1016/S1043-4526(08)60118-7; Cao JS, 2004, J BIOL CHEM, V279, P18878, DOI 10.1074/jbc.M313272200; CAO SG, 1995, BBA-LIPID LIPID MET, V1256, P97, DOI 10.1016/0005-2760(95)00002-T; Daum G, 1997, PROG LIPID RES, V36, P103, DOI 10.1016/S0163-7827(97)00006-4; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; EICHBERG J, 1974, J BIOL CHEM, V249, P3423; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; HALLMAN M, 1980, PEDIATR RES, V14, P1250, DOI 10.1203/00006450-198011000-00020; HARDING PGR, 1983, BIOCHIM BIOPHYS ACTA, V750, P373, DOI 10.1016/0005-2760(83)90042-5; Hatch GM, 1998, INT J MOL MED, V1, P33; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOF H, 1970, LIPIDS, V5, P485, DOI 10.1007/BF02531312; HOSTETLER KY, 1975, BIOCHIM BIOPHYS ACTA, V380, P382, DOI 10.1016/0005-2760(75)90106-X; LANDS WEM, 1965, J BIOL CHEM, V240, P1905; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Ma BJ, 1999, J LIPID RES, V40, P1837; MAVIS RD, 1981, BIOCHIM BIOPHYS ACTA, V664, P409, DOI 10.1016/0005-2760(81)90063-1; McMillin JB, 2002, BBA-MOL CELL BIOL L, V1585, P97, DOI 10.1016/S1388-1981(02)00329-3; MCMURRAY WC, 1986, BIOCHEM CELL BIOL, V64, P1115, DOI 10.1139/o86-147; Mutter T, 2000, BIOCHEM J, V346, P403, DOI 10.1042/0264-6021:3460403; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; RUSTOW B, 1989, BIOCHIM BIOPHYS ACTA, V1002, P261, DOI 10.1016/0005-2760(89)90296-8; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1986, BIOCHEM J, V240, P247, DOI 10.1042/bj2400247; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SCHLAME M, 1994, J AM COLL CARDIOL, V42, P1994; Taylor WA, 2003, J BIOL CHEM, V278, P12716, DOI 10.1074/jbc.M210329200; Taylor WA, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-9; Valianpour F, 2002, J PEDIATR-US, V141, P729, DOI 10.1067/mpd.2002.129174; VANCE JE, 1985, BIOCH LIPIDS MEMBRAN; VOELKER DR, 1990, EXPERIENTIA, V46, P569, DOI 10.1007/BF01939695; Xu Y, 2003, J BIOL CHEM, V278, P51380, DOI 10.1074/jbc.M307382200; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003	40	167	182	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31727	31734		10.1074/jbc.M402930200	http://dx.doi.org/10.1074/jbc.M402930200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152008	hybrid			2022-12-27	WOS:000222726800098
J	Daubenspeck, JM; Zeng, HD; Chen, P; Dong, SL; Steichen, CT; Krishna, NR; Pritchard, DG; Turnbough, CL				Daubenspeck, JM; Zeng, HD; Chen, P; Dong, SL; Steichen, CT; Krishna, NR; Pritchard, DG; Turnbough, CL			Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE LIGANDS; GENE-EXPRESSION; SPORES; PROTEINS; CEREUS; SUBTILIS; IDENTIFICATION; BACTERIAL; HYDRAZINOLYSIS; TRANSCRIPTION	Spores of Bacillus anthracis, the causative agent of anthrax, are enclosed by a prominent loose fitting layer called the exosporium. The exosporium consists of a basal layer and an external hairlike nap. The filaments of the nap are composed of a highly immunogenic glycoprotein called BclA, which has a long, central collagen-like region with multiple XXG repeats. Most of the triplet repeats are PTG, and nearly all of the triplet repeats contain a threonine residue, providing multiple potential sites for O-glycosylation. In this study, we demonstrated that two O-linked oligosaccharides, a 715-Da tetrasaccharide and a 324-Da disaccharide, are released from spore- and exosporium-associated BclA by hydrazinolysis. Each oligosaccharide is probably attached to BclA through a GalNAc linker, which was lost during oligosaccharide release. We found that multiple copies of the tetrasaccharide are linked to the collagen-like region of BclA, whereas the disaccharide may be attached outside of this region. Using NMR, mass spectrometry, and other analytical techniques, we determined that the structure of the tetrasaccharide is 2-O-methyl-4-(3-hydroxy-3-methylbutamido)-4,6- dideoxy-beta-D-glucopyranosyl-(1-->3)-alpha-L-rhamnopyranosyl( 1-->3)-alpha-L-rhamnopyranosyl-(1-->2)-L- rhamnopyranose. The previously undescribed nonreducing terminal sugar ( i.e. 2-O-methyl-4-(3-hydroxy- 3-methylbutamido)-4,6-dideoxy-D-glucose) was given the trivial name anthrose. Anthrose was not found in spores of either Bacillus cereus or Bacillus thuringiensis, two species that are the most phylogenetically similar to B. anthracis. Thus, anthrose may be useful for species-specific detection of B. anthracis spores or as a new target for therapeutic intervention.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Turnbough, CL (corresponding author), Univ Alabama, Dept Microbiol, BBRB 409,1530 3rd Ave S, Birmingham, AL 35294 USA.	ChuckT@uab.edu			NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050566] Funding Source: NIH RePORTER; NCI NIH HHS [CA13148] Funding Source: Medline; NIAID NIH HHS [AI50566] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTONA C, 1980, ORG MAGN RESONANCE, V13, P417, DOI 10.1002/mrc.1270130606; Ausubel FM, 1988, MOL REPROD DEV; BEAMAN TC, 1971, J BACTERIOL, V107, P320, DOI 10.1128/JB.107.1.320-324.1971; BHATTI T, 1970, BIOCHIM BIOPHYS ACTA, V222, P339, DOI 10.1016/0304-4165(70)90122-4; DAI ZH, 1995, MOL MICROBIOL, V16, P1171, DOI 10.1111/j.1365-2958.1995.tb02340.x; DISCHE Z, 1948, J BIOL CHEM, V175, P595; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; Fox A, 2003, J MICROBIOL METH, V54, P143, DOI 10.1016/S0167-7012(03)00095-2; FOX A, 1993, J CLIN MICROBIOL, V31, P887, DOI 10.1128/JCM.31.4.887-894.1993; GERHARDT P, 1964, J BACTERIOL, V88, P1774, DOI 10.1128/JB.88.6.1774-1789.1964; GERHARDT P, 1967, FED PROC, V26, P1504; HACHISUKA Y, 1966, J BACTERIOL, V91, P2382, DOI 10.1128/JB.91.6.2382-2384.1966; Henriques AO, 2000, METHODS, V20, P95, DOI 10.1006/meth.1999.0909; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KASAI R, 1979, TETRAHEDRON, V35, P1427, DOI 10.1016/0040-4020(79)85038-3; Knurr J, 2003, APPL ENVIRON MICROB, V69, P6841, DOI 10.1128/AEM.69.11.6841-6847.2003; KOEHLER TM, 1994, J BACTERIOL, V176, P586, DOI 10.1128/jb.176.3.586-595.1994; KRAMER MJ, 1968, CAN J MICROBIOL, V14, P1297, DOI 10.1139/m68-217; Lai EM, 2003, J BACTERIOL, V185, P1443, DOI 10.1128/JB.185.4.1443-1454.2003; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; Liu HB, 2004, J BACTERIOL, V186, P164, DOI 10.1128/JB.186.1.164-178.2004; MATZ LL, 1970, J BACTERIOL, V101, P196, DOI 10.1128/JB.101.1.196-201.1970; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Moens S, 1997, ARCH MICROBIOL, V168, P169, DOI 10.1007/s002030050484; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; Paidhungat M., 2002, BACILLUS SUBTILIS IT, P537, DOI DOI 10.1128/9781555817992.CH37; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; PATEL TP, 1994, METHOD ENZYMOL, V230, P57; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; Priest Fergus G., 1993, P3; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; ROELS S, 1995, J BACTERIOL, V177, P6263, DOI 10.1128/jb.177.21.6263-6275.1995; Saile E, 2002, J BACTERIOL, V184, P370, DOI 10.1128/JB.184.2.370-380.2002; Schmidt MA, 2003, TRENDS MICROBIOL, V11, P554, DOI 10.1016/j.tim.2003.10.004; Steichen C, 2003, J BACTERIOL, V185, P1903, DOI 10.1128/JB.185.6.1903-1910.2003; Suzen S, 1999, J PEPT SCI, V5, P283, DOI 10.1002/(SICI)1099-1387(199906)5:6<283::AID-PSC198>3.0.CO;2-O; Sylvestre P, 2003, J BACTERIOL, V185, P1555, DOI 10.1128/JB.185.5.1555-1563.2003; Sylvestre P, 2002, MOL MICROBIOL, V45, P169, DOI 10.1046/j.1365-2958.2000.03000.x; Todd SJ, 2003, J BACTERIOL, V185, P3373, DOI 10.1128/JB.185.11.3373-3378.2003; Webb GF, 2003, P NATL ACAD SCI USA, V100, P4355, DOI 10.1073/pnas.0830963100; Williams DD, 2004, J BACTERIOL, V186, P566, DOI 10.1128/JB.186.2.566-569.2004; Williams DD, 2003, APPL ENVIRON MICROB, V69, P6288, DOI 10.1128/AEM.69.10.6288-6293.2003	44	165	176	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30945	30953		10.1074/jbc.M401613200	http://dx.doi.org/10.1074/jbc.M401613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152001	hybrid			2022-12-27	WOS:000222726800007
J	Ives, JH; Fung, S; Tiwari, P; Payne, HL; Thompson, CL				Ives, JH; Fung, S; Tiwari, P; Payne, HL; Thompson, CL			Microtubule-associated protein light chain 2 is a stargazin-AMPA receptor complex-interacting protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; MUTANT MOUSE STARGAZER; CHANNEL GAMMA-SUBUNIT; POSTSYNAPTIC DENSITY; REGULATORY PROTEINS; NEUROTROPHIC FACTOR; GABA(A) RECEPTORS; BETA-3 SUBUNITS; CA2+ CHANNEL; RAT-BRAIN	The ataxic mutant mouse stargazer is a null mutant for stargazin, a protein involved in the regulation of cell surface trafficking and synaptic targeting of AMPA receptors. The extreme C terminus of stargazin ( sequence, - TTPV), confers high affinity for PDZ domain-containing proteins e.g. PSD-95. Interaction with PDZ proteins enables stargazin to fulfill its role as an AMPA receptor synaptic targeting molecule but is not essential for its ability to influence AMPA receptor trafficking to the neuronal cell surface. Using the yeast-two hybrid approach we screened for proteins that interact with the intracellular C-terminal tail of stargazin. Positive interactors included PDZ domain-containing proteins e.g. SAP97, SAP102, and PIST. Interestingly, light chain 2 of microtubule-associated protein 1 (LC2), which does not contain a PDZ domain, was also a strong interactor. This was shown to be a direct interaction that occurred upstream of the - TTPV sequence of stargazin. Immunoprecipitations of Triton X-100 soluble cerebellar extracts revealed that LC2 is pulled down not only by anti-stargazin antibodies but also anti-GluR2 antibodies suggesting that stargazin and AMPA receptor subunits associate with LC2. Immunopurified full-length, native stargazin was shown to co-associate not only with GluR2 in vivo but also with full-length, native LC2. Indeed, LC2 co-associates with stargazin when part of a tripartite complex comprising LC2-stargazin-GluR2. Since this complex was extracted using Triton X-100 and was devoid of PSD95, SAP97, and actin we postulate that LC2 is involved in trafficking of AMPA receptors in cerebellar neurons before they are anchored at the synapse.	Univ Durham, Sci Res Labs, Sch Biol & Biomed Sci, Durham DH1 3LE, England	Durham University	Thompson, CL (corresponding author), Univ Durham, Sci Res Labs, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.	C.L.Thompson@durham.ac.uk						Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Brenman JE, 1998, J NEUROSCI, V18, P8805; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen L, 1999, P NATL ACAD SCI USA, V96, P12132, DOI 10.1073/pnas.96.21.12132; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Dakoji S, 2003, NEUROPHARMACOLOGY, V45, P849, DOI 10.1016/S0028-3908(03)00267-3; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Green PJ, 2001, J PHYSIOL-LONDON, V533, P467, DOI 10.1111/j.1469-7793.2001.0467a.x; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Ikeda A, 2002, NAT GENET, V30, P401, DOI 10.1038/ng838; Ives JH, 2000, EUR J NEUROSCI, V12, P45; Ives JH, 2002, J NEUROCHEM, V80, P317, DOI 10.1046/j.0022-3042.2001.00700.x; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mei X, 2000, BRAIN RES BULL, V53, P801, DOI 10.1016/S0361-9230(00)00416-0; Morris JA, 2003, HUM MOL GENET, V12, P1591, DOI 10.1093/hmg/ddg162; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Noiges R, 2002, J NEUROSCI, V22, P2106, DOI 10.1523/JNEUROSCI.22-06-02106.2002; QIAO X, 1998, J NEUROSCI, V16, P640; Qiao XX, 1998, J NEUROSCI, V18, P6990; Rousset M, 2001, J PHYSIOL-LONDON, V532, P583, DOI 10.1111/j.1469-7793.2001.0583e.x; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sharp AH, 2001, NEUROSCIENCE, V105, P599, DOI 10.1016/S0306-4522(01)00220-2; Thompson CL, 1998, MOL BRAIN RES, V60, P282, DOI 10.1016/S0169-328X(98)00205-8; THOMPSON CL, 1994, J NEUROCHEM, V62, P2037; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636	40	29	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31002	31009		10.1074/jbc.M402214200	http://dx.doi.org/10.1074/jbc.M402214200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15136571	hybrid			2022-12-27	WOS:000222726800013
J	Schwamborn, JC; Fiore, R; Bagnard, D; Kappler, J; Kaltschmidt, C; Puschel, AW				Schwamborn, JC; Fiore, R; Bagnard, D; Kappler, J; Kaltschmidt, C; Puschel, AW			Semaphorin 3A stimulates neurite extension and regulates gene expression in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX REGULATION; GROWTH; APOPTOSIS; DIFFERENTIATION; ACTIVATION; REPULSION; RESPONSES; OXIDANTS; PATHWAY; GTPASES	The secreted semaphorin 3A (Sema3A) is a member of a large family of proteins that act as guidance signals for axons and dendrites. While the receptors and signaling pathways that mediate the repulsive effects of semaphorins are beginning to be understood in some detail, the mechanisms that are responsible for the ability of Sema3A to stimulate the extension of dendrites remain to be elucidated. Here we show that PC12 cells, a model widely used to study neuronal differentiation, can be used to dissect this pathway. Sema3A is as effective as nerve growth factor in stimulating the extension of neurites from PC12 cells. We show that Sema3A is able to regulate gene expression and identify mitochondria as a novel target of Sema3A signaling. Pharmacological block of mitochondrial reactive oxygen species production abolishes the extension of neurites in response to Sema3A. These results show that the characterization of transcripts that are regulated by axon guidance signals may help to identify novel components of their signaling pathways.	Univ Munster, Inst Allgemeine Zool & Genet, D-48149 Munster, Germany; Univ Witten Herdecke, Inst Neurobiochem, D-58448 Witten, Germany; Univ Bonn, Inst Physiol Chem, D-53115 Bonn, Germany; Ctr Neurochim, INSERM, U Physiopathol Syst Nerveux 575, Grp Physiol Mol Regenerat Nerveuse, F-67084 Strasbourg, France	University of Munster; Witten Herdecke University; University of Bonn; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Puschel, AW (corresponding author), Univ Munster, Inst Allgemeine Zool & Genet, Schlosspl 5, D-48149 Munster, Germany.	apuschel@uni-muenster.de	Schwamborn, Jens C/F-9395-2011; Bagnard, Dominique/I-6535-2013	Schwamborn, Jens C/0000-0003-4496-0559; Bagnard, Dominique/0000-0002-5261-902X				Atwal JK, 2003, J NEUROSCI, V23, P7602; Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagnard D, 2004, MOL CELL NEUROSCI, V25, P722, DOI 10.1016/j.mcn.2003.12.007; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Campbell DS, 2003, NEURON, V37, P939, DOI 10.1016/S0896-6273(03)00158-2; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Fenstermaker V, 2004, J NEUROBIOL, V58, P403, DOI 10.1002/neu.10304; Fiore R, 2003, FRONT BIOSCI-LANDMRK, V8, pS484, DOI 10.2741/1080; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411; Franken S, 2003, J BIOL CHEM, V278, P3241, DOI 10.1074/jbc.M210181200; Fujioka S, 2003, BIOCHEM BIOPH RES CO, V301, P304, DOI 10.1016/S0006-291X(02)03023-1; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Mikule K, 2002, J NEUROSCI, V22, P4932, DOI 10.1523/JNEUROSCI.22-12-04932.2002; Ming GL, 2002, NATURE, V417, P411, DOI 10.1038/nature745; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666; Schwamborn J, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-46; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Zanata SM, 2002, J NEUROSCI, V22, P471, DOI 10.1523/JNEUROSCI.22-02-00471.2002	31	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30923	30926		10.1074/jbc.C400082200	http://dx.doi.org/10.1074/jbc.C400082200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155748	hybrid			2022-12-27	WOS:000222726800003
J	Bertoli, G; Simmen, T; Anelli, T; Molteni, SN; Fesce, R; Sitia, R				Bertoli, G; Simmen, T; Anelli, T; Molteni, SN; Fesce, R; Sitia, R			Two conserved cysteine triads in human Ero1 alpha cooperate for efficient disulfide bond formation in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ERO1P; ISOMERASE; GENE; ERO1-L-ALPHA; COMPLEXES; YEAST; ERP44; MOTIF; ER	Human Ero1alpha is an endoplasmic reticulum (ER)-resident protein responsible for protein disulfide isomerase (PDI) oxidation. To clarify the molecular mechanisms underlying its function, we generated a panel of cysteine replacement mutants and analyzed their capability of: 1) complementing a temperature-sensitive yeast Ero1 mutant, 2) favoring oxidative folding in mammalian cells, 3) forming mixed disulfides with PDI and ERp44, and 4) adopting characteristic redox-dependent conformations. Our results reveal that two essential cysteine triads (Cys(85)-Cys(94)-Cys(99) and Cys(391)-Cys(394)-Cys(397)) cooperate in electron transfer, with Cys(94) likely forming mixed disulfides with PDI. Dominant negative phenotypes arise when critical residues within the triads are mutated (Cys(394), Cys(397), and to a lesser extent Cys(99)). Replacing the first cysteine in either triad (Cys(85) or Cys(391)) generates mutants with weaker activity. In addition, mutating either Cys(85) or Cys(391), but not Cys(397), reverts the dominant negative phenotype of the C394A mutant. These findings suggest that interactions between the two triads, dependent on Cys(85) and Cys(391), are important for Ero1alpha function, possibly stabilizing a platform for efficient PDI oxidation.	Univ Vita Salute San Raffaele, I-20132 Milan, Italy; San Raffaele Sci Inst, Dept Biol & Technol, Milan, Italy	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Sitia, R (corresponding author), Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.	r.sitia@hsr.it	Bertoli, Gloria/J-6559-2016; fesce, riccardo/A-6317-2008; Sitia, Roberto/AAB-5005-2019; Anelli, Tiziana/AAN-3717-2020	Bertoli, Gloria/0000-0002-5901-4269; Sitia, Roberto/0000-0001-7086-4152; Anelli, Tiziana/0000-0002-9159-9164; fesce, riccardo/0000-0001-9473-896X	Telethon [GP0117Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; CLACKSON T, 1989, NUCLEIC ACIDS RES, V17, P10163, DOI 10.1093/nar/17.24.10163; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pagani M, 2001, FEBS LETT, V508, P117, DOI 10.1016/S0014-5793(01)03034-4; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Woycechowsky KJ, 2003, BIOCHEMISTRY-US, V42, P5387, DOI 10.1021/bi026993q	24	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30047	30052		10.1074/jbc.M403192200	http://dx.doi.org/10.1074/jbc.M403192200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136577	hybrid			2022-12-27	WOS:000222531900023
J	Kumar, P; Rao, AGA; Hariharaputran, S; Chandra, N; Gowda, LR				Kumar, P; Rao, AGA; Hariharaputran, S; Chandra, N; Gowda, LR			Molecular mechanism of dimerization of Bowman-Birk inhibitors - Pivotal role of Asp(76) in the dimerzation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SOYBEAN TRYPSIN-INHIBITORS; GRAM DOLICHOS-BIFLORUS; EYED PEA TRYPSIN; RED KIDNEY BEANS; PROTEINASE-INHIBITOR; CHYMOTRYPSIN-INHIBITOR; PROTEASE INHIBITORS; PHASEOLUS-VULGARIS; CRYSTAL-STRUCTURE	Horsegram (Dolichos biflorus), a protein-rich leguminous pulse, is a crop native to Southeast Asia and tropical Africa. The seeds contain multiple forms of Bowman-Birk type inhibitors. The major inhibitor HGI-III, from the native seed with 76 amino acid residues exists as a dimer. The amino acid sequence of three isoforms of Bowman-Birk inhibitor from germinated horsegram, designated as HGGI-I, HGGI-II, and HGGI-III, have been obtained by sequential Edman analyses of the pyridylethylated inhibitors and peptides derived there from by enzymatic and chemical cleavage. The HGGIs are monomers, comprising of 66, 65, and 60 amino acid residues, respectively. HGGI-III from the germinated seed differs from the native seed inhibitor in the physiological deletion of a dodecapeptide at the amino terminus and a tetrapeptide, -SHDD, at the carboxyl terminus. The study of the state of association of HGI-III, by size-exclusion chromatography and SDS-PAGE in the presence of 1 mM ZnCl2, has revealed the role of charged interactions in the monomer <----> dimer equilibria. Chemical modification studies of Lys and Arg have confirmed the role of charge interactions in the above equilibria. These results support the premise that a unique interaction, which stabilizes the dimer, is the cause of self-association in the inhibitors. This interaction in HGI-III involves the epsilon-amino group of the Lys(24) (P-1 residue) at the first reactive site of one monomer and the carboxyl of an Asp(76) at the carboxyl terminus of the second monomer. Identification of the role of these individual amino acids in the structure and stability of the dimer was accomplished by chemical modifications, multiple sequence alignment of legume Bowman-Birk inhibitors, and homology modeling. The state of association may also influence the physiological and functional role of these inhibitors.	Cent Food Technol Res Inst, Dept Prot Chem & Technol, Mysore 570020, Karnataka, India; Indian Inst Sci, Bioinformat Ctr, Bangalore 560012, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI); Indian Institute of Science (IISC) - Bangalore	Gowda, LR (corresponding author), Cent Food Technol Res Inst, Dept Prot Chem & Technol, Mysore 570020, Karnataka, India.	lrg@cftri.com	Hariharaputran, Sridhar/B-1063-2012; Gowda, Lalitha/C-7644-2009	Hariharaputran, Sridhar/0000-0002-9979-3244; Chandra, Nagasuma/0000-0002-9939-8439				AITKEN A, 1989, PROTEIN SEQUENCING P, P43; Allen G., 1981, LABORATORY TECHNIQUE, V9, P73; ASAO T, 1991, AGR BIOL CHEM TOKYO, V55, P707, DOI 10.1080/00021369.1991.10870641; BERGERON D, 1993, J AGR FOOD CHEM, V41, P1544, DOI 10.1021/jf00034a003; BIRK Y, 1985, INT J PEPT PROT RES, V25, P113, DOI 10.1111/j.1399-3011.1985.tb02155.x; BROWN WE, 1984, BIOCHEMISTRY-US, V23, P3418, DOI 10.1021/bi00310a006; Catalano M, 2003, BIOCHEMISTRY-US, V42, P2836, DOI 10.1021/bi020576w; CHEN P, 1992, J BIOL CHEM, V267, P1990; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; de la Sierra IL, 1999, J MOL BIOL, V285, P1195, DOI 10.1006/jmbi.1998.2351; deFreitas SM, 1997, FEBS LETT, V409, P121, DOI 10.1016/S0014-5793(97)00419-5; Deshimaru M, 2002, BIOSCI BIOTECH BIOCH, V66, P1897, DOI 10.1271/bbb.66.1897; DIXON HBF, 1968, BIOCHEM J, V109, P312, DOI 10.1042/bj1090312; FOARD D E, 1982, Plant Molecular Biology, V1, P227, DOI 10.1007/BF00021034; FUNK A, 1993, Z LEBENSM UNTERS FOR, V196, P343, DOI 10.1007/BF01197933; GENNIS LS, 1976, J BIOL CHEM, V251, P747; GODBOLE SA, 1994, J SCI FOOD AGR, V64, P87, DOI 10.1002/jsfa.2740640113; HARMSRINGDAHL M, 1979, BIOCHEM BIOPH RES CO, V86, P492, DOI 10.1016/0006-291X(79)91741-8; HARRY JB, 1970, EUR J BIOCHEM, V16, P174, DOI 10.1111/j.1432-1033.1970.tb01069.x; HAYNES R, 1967, J BIOL CHEM, V242, P5378; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HWANG DLR, 1977, BIOCHIM BIOPHYS ACTA, V495, P239; Ikenaka T, 1986, PROTEINASE INHIBITOR, P361; JOUBERT FJ, 1984, PHYTOCHEMISTRY, V23, P957, DOI 10.1016/S0031-9422(00)82591-1; JOUBERT FJ, 1979, EUR J BIOCHEM, V97, P85, DOI 10.1111/j.1432-1033.1979.tb13088.x; Kennedy AR, 1998, AM J CLIN NUTR, V68, p1406S, DOI 10.1093/ajcn/68.6.1406S; Koepke J, 2000, J MOL BIOL, V298, P477, DOI 10.1006/jmbi.2000.3677; Kumar P, 2002, PHYTOCHEMISTRY, V60, P581, DOI 10.1016/S0031-9422(02)00178-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN GD, 1993, EUR J BIOCHEM, V212, P549, DOI 10.1111/j.1432-1033.1993.tb17692.x; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; Miles E W, 1977, Methods Enzymol, V47, P431; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; ODANI S, 1977, J BIOCHEM-TOKYO, V82, P1523, DOI 10.1093/oxfordjournals.jbchem.a131846; ODANI S, 1978, J BIOCHEM-TOKYO, V83, P747, DOI 10.1093/oxfordjournals.jbchem.a131968; Prakash B, 1996, J MOL EVOL, V42, P560, DOI 10.1007/BF02352286; RAMASARMA PR, 1995, BBA-PROTEIN STRUCT M, V1248, P35, DOI 10.1016/0167-4838(95)00004-E; Singh RR, 2002, BBA-PROTEIN STRUCT M, V1597, P280, DOI 10.1016/S0167-4838(02)00301-1; Smith E L, 1977, Methods Enzymol, V47, P156; Song HK, 1999, J MOL BIOL, V293, P1133, DOI 10.1006/jmbi.1999.3239; Sreerama YN, 1997, BBA-PROTEIN STRUCT M, V1343, P235, DOI 10.1016/S0167-4838(97)00117-9; Sreerama YN, 1998, J AGR FOOD CHEM, V46, P2596, DOI 10.1021/jf980075a; Sreerama YN, 1997, J FOOD BIOCHEM, V21, P461, DOI 10.1111/j.1745-4514.1997.tb00200.x; SUZUKI A, 1993, J MOL BIOL, V234, P722, DOI 10.1006/jmbi.1993.1622; Tanaka AS, 1996, J PROTEIN CHEM, V15, P553, DOI 10.1007/BF01908537; TANAKA AS, 1996, J BIOL CHEM, V378, P273; TERADA S, 1994, BIOSCI BIOTECH BIOCH, V58, P371, DOI 10.1271/bbb.58.371; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUNOGAE Y, 1986, J BIOCHEM-TOKYO, V100, P1637, DOI 10.1093/oxfordjournals.jbchem.a121872; VENTURA MM, 1981, AN ACAD BRAS CIENC, V53, P195; Voss RH, 1996, EUR J BIOCHEM, V242, P122, DOI 10.1111/j.1432-1033.1996.0122r.x; WERNER MH, 1992, BIOCHEMISTRY-US, V31, P999, DOI 10.1021/bi00119a008; WILSON KA, 1983, PLANT PHYSIOL, V71, P341, DOI 10.1104/pp.71.2.341; WILSON KA, 1973, J BIOL CHEM, V248, P756; WU C, 1990, J AGR FOOD CHEM, V38, P1523, DOI 10.1021/jf00097a021; ZHANG Y, 1982, SCI SIN B-CHEM B A M, V25, P268	59	43	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30425	30432		10.1074/jbc.M402972200	http://dx.doi.org/10.1074/jbc.M402972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123729	hybrid			2022-12-27	WOS:000222531900069
J	Lee, JY; Kim, H; Ryu, CH; Kim, JY; Choi, BH; Lim, Y; Huh, PW; Kim, YH; Lee, KH; Jun, TY; Rha, HK; Kang, JK; Choi, CR				Lee, JY; Kim, H; Ryu, CH; Kim, JY; Choi, BH; Lim, Y; Huh, PW; Kim, YH; Lee, KH; Jun, TY; Rha, HK; Kang, JK; Choi, CR			Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 NEUROFIBROMATOSIS; UNITED-KINGDOM; KINASE PKR; TAR; TRBP; GENE; HIV-1; DOMAIN; MOUSE; ACTIVATION	The neurofibromatosis type 2 gene-encoded protein, merlin, is related to the ERM (ezrin, radixin, and moesin) family of membrane-cytoskeleton-associated proteins. Recent studies suggest that the loss of neurofibromatosis type 2 function contributes to tumor development and metastasis. Although the cellular functions of merlin as a tumor suppressor are relatively well characterized, the cellular mechanism whereby merlin controls cell proliferation from membrane locations is still poorly understood. During our efforts to find potential merlin modulators through protein-protein interactions, we identified transactivation-responsive RNA-binding protein (TRBP) as a merlin-binding protein in a yeast two-hybrid screen. The interaction between TRBP and merlin was confirmed by glutathione S-transferase pull-down assays, co-immunoprecipitation, and co-localization experiments. The carboxyl-terminal regions of each protein were responsible for their interaction. Cells overexpressing TRBP showed enhanced cell growth in cell proliferation assays and also exhibited transformed phenotypes, such as anchorage-independent cell growth and tumor development in mouse xenografts. Merlin efficiently inhibited these oncogenic activities of TRBP in our experiments. These results provide the first clue to the functional interaction between TRBP and merlin and suggest a novel mechanism for the tumor suppressor function of merlin both in vitro and in vivo.	Catholic Univ Korea, Catholic Neurosci Ctr, Seoul 137701, South Korea; Catholic Univ Korea, Dept Neurosurg, Seoul 137701, South Korea; Catholic Univ Korea, Dept Occupat & Environm Med, Seoul 137701, South Korea; Catholic Univ Korea, Dept Pharmacol, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Kim, YH (corresponding author), Catholic Univ Korea, Catholic Neurosci Ctr, Seoul 137701, South Korea.	pedkyh@catholic.ac.kr	Lee, Joo-Yong/AAE-3388-2019	Lee, Joo-Yong/0000-0003-1049-6006				Bannwarth S, 2001, J BIOL CHEM, V276, P48803, DOI 10.1074/jbc.M104645200; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Daher A, 2001, J BIOL CHEM, V276, P33899, DOI 10.1074/jbc.M103584200; Donzeau M, 1997, J VIROL, V71, P2628, DOI 10.1128/JVI.71.4.2628-2635.1997; Duarte M, 2000, J BIOMED SCI, V7, P494; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; Gatignol A, 1996, GENE EXPRESSION, V5, P217; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Giovannini M, 2000, GENE DEV, V14, P1617; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; KOZAK CA, 1995, GENOMICS, V25, P66, DOI 10.1016/0888-7543(95)80110-8; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lee K, 1996, MOL CELL BIOL, V16, P3023; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; Sainio M, 1997, J CELL SCI, V110, P2249; Siffroi JP, 2001, MOL HUM REPROD, V7, P219, DOI 10.1093/molehr/7.3.219; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684; Zhong J, 1998, MAMM GENOME, V9, P413, DOI 10.1007/s003359900786	38	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30265	30273		10.1074/jbc.M312083200	http://dx.doi.org/10.1074/jbc.M312083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123692	hybrid			2022-12-27	WOS:000222531900051
J	Nishitani, H; Lygerou, Z; Nishimoto, T				Nishitani, H; Lygerou, Z; Nishimoto, T			Proteolysis of DNA replication licensing factor Cdt1 in S-phase is performed independently of Geminin through its N-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; ORIGIN RECOGNITION COMPLEX; CELL-CYCLE; BUDDING YEAST; FISSION YEAST; CDK PHOSPHORYLATION; MCM PROTEINS; CHROMATIN ASSOCIATION; MEDIATED PROTEOLYSIS; HELICASE ACTIVITY	Licensing of replication origins is carefully regulated in a cell cycle to maintain genome integrity. Using an in vivo ubiquitination assay and temperature-sensitive cell lines we demonstrate that Cdt1 in mammalian cells is degraded through ubiquitin-dependent proteolysis in S-phase. siRNA experiments for Geminin indicate that Cdt1 is degraded in the absence of Geminin. The N terminus of Cdt1 is required for its nuclear localization, associates with cyclin A, but is dispensable for the association of Cdt1 with Geminin in cells. This region is responsible for proteolysis of Cdt1 in S-phase. On the other hand, the N terminus-truncated Cdt1 is stable in S-phase, and associates with the licensing inhibitor, Geminin. High level expression of this form of Cdt1 brings about cells having higher DNA content. Proteasome inhibitors stabilize Cdt1 in S-phase, and the protein is detected in the nucleus in a complex with Geminin. This form of Cdt1 associates with chromatin as tightly as that of G1-cells, when no Geminin is detected. Our data show that proteolysis and Geminin binding independently inactivate Cdt1 after the onset of S-phase to prevent re-replication.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Univ Patras, Sch Med, Lab Gen Biol, Patras 26500, Greece	Kyushu University; University of Patras	Nishitani, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	hideon@molbiol.med.kyushu-u.ac.jp		Nishitani, Hideo/0000-0001-5907-9380				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Baum B, 1998, EMBO J, V17, P5689, DOI 10.1093/emboj/17.19.5689; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Coverley D, 2000, J CELL SCI, V113, P1929; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; FUJITA M, 1999, FRONT BIOSCI, V4, P816; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Homesley L, 2000, GENE DEV, V14, P913; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1992, BIOCHEM BIOPH RES CO, V184, P1015, DOI 10.1016/0006-291X(92)90692-E; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Noguchi E, 2002, CURR BIOL, V12, P599, DOI 10.1016/S0960-9822(02)00739-X; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Zhang YX, 2002, CELL, V109, P849, DOI 10.1016/S0092-8674(02)00805-X; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	63	93	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30807	30816		10.1074/jbc.M312644200	http://dx.doi.org/10.1074/jbc.M312644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138268	hybrid			2022-12-27	WOS:000222531900112
J	Dubel, SJ; Altier, C; Chaumont, S; Lory, P; Bourinet, E; Nargeot, J				Dubel, SJ; Altier, C; Chaumont, S; Lory, P; Bourinet, E; Nargeot, J			Plasma membrane expression of T-type calcium channel alpha(1) subunits is modulated by high voltage-activated auxiliary subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNEL; BETA-SUBUNIT; FUNCTIONAL-PROPERTIES; MOLECULAR CHARACTERIZATION; ALPHA(2)DELTA SUBUNIT; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE; GAMMA-SUBUNIT; CELL LINE; TRAFFICKING	It has been suggested that the auxiliary subunits of high voltage-activated (HVA) calcium channels modulate T-type, low voltage-activated (LVA) calcium channels. Such a regulation has yet to be documented, especially because there has been no biochemical characterization of T-channels. To monitor total protein levels and plasma membrane expression of T-channels in living cells, external epitopes ( hemagglutinin, FLAG) were introduced into human recombinant Ca(V)3 channels that were also N-terminally fused to green fluorescent protein. Utilizing Western blot techniques, fluorescence flow cytometry, immunofluorescence, luminometry, and electrophysiology, we describe here that beta(1b) and alpha(2)-delta(1) subunits enhance the level of Ca(V)3 proteins as well as their plasma membrane expression in various expression systems. We also report that, in both Xenopus oocytes and mammalian cells, the alpha(2)-delta(1) and beta(1b) subunits increase by at least 2-fold the current density of Ca(V)3 channels with no change in the electrophysiological properties. Altogether, these data indicate that HVA auxiliary subunits modulate Ca(V)3 channel surface expression, suggesting that the membrane targeting of HVA and LVA alpha1 subunits is regulated dynamically through the expression of a common set of regulatory subunits.	Dept Physiol, Lab Genom Fonct, CNRS, Unite Propre Rech 2580, F-34396 Montpellier 01, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Nargeot, J (corresponding author), Dept Physiol, Lab Genom Fonct, CNRS, Unite Propre Rech 2580, 141 Rue Cardonille, F-34396 Montpellier 01, France.	joel.nargeot@igh.cnrs.fr		Chaumont-Dubel, Severine/0000-0001-6860-6891; bourinet, emmanuel/0000-0001-8021-0419; LORY, philippe/0000-0002-1638-7604; Nargeot, Joel/0000-0003-2893-5636				Agueev V, 2000, BIOPHYS J, V78, p457A; Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Baroudi G, 2001, CIRC RES, V88, pE78, DOI 10.1161/hh1201.093270; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; Chen YC, 2003, ANN NEUROL, V54, P239, DOI 10.1002/ana.10607; Cornet V, 2002, EUR J NEUROSCI, V16, P883, DOI 10.1046/j.1460-9568.2002.02168.x; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Garcia R, 2002, J PHYSIOL-LONDON, V545, P407, DOI 10.1113/jphysiol.2002.027433; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; Green PJ, 2001, J PHYSIOL-LONDON, V533, P467, DOI 10.1111/j.1469-7793.2001.0467a.x; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Howard M, 1995, AM J PHYSIOL-CELL PH, V269, pC1565, DOI 10.1152/ajpcell.1995.269.6.C1565; Howard M, 1996, KIDNEY INT, V49, P1642, DOI 10.1038/ki.1996.239; Jones SW, 1998, J BIOENERG BIOMEMBR, V30, P299, DOI 10.1023/A:1021977304001; Kang MG, 2003, J BIOL CHEM, V278, P21315, DOI 10.1074/jbc.R300004200; Klugbauer N, 1999, J NEUROSCI, V19, P684; Kuchenbecker M, 2001, PFLUG ARCH EUR J PHY, V443, P280, DOI 10.1007/s004240100688; Lacinova L, 1999, J PHYSIOL-LONDON, V516, P639, DOI 10.1111/j.1469-7793.1999.0639u.x; Lambert RC, 1997, J NEUROSCI, V17, P6621; Leuranguer V, 1998, NEUROPHARMACOLOGY, V37, P701, DOI 10.1016/S0028-3908(98)00060-4; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200; Monteil A, 2000, J BIOL CHEM, V275, P6090, DOI 10.1074/jbc.275.9.6090; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; WELLING A, 1993, J PHYSIOL-LONDON, V471, P749, DOI 10.1113/jphysiol.1993.sp019926; Wyatt CN, 1998, J PHYSIOL-LONDON, V510, P347, DOI 10.1111/j.1469-7793.1998.347bk.x; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Yunker AMR, 2003, NEUROSCIENCE, V117, P321, DOI 10.1016/S0306-4522(02)00936-3; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976; Zhang Y, 2002, J NEUROSCI, V22, P6362	40	92	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29263	29269		10.1074/jbc.M313450200	http://dx.doi.org/10.1074/jbc.M313450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123697	hybrid			2022-12-27	WOS:000222445300055
J	Ketcham, C; Wang, F; Fisher, SZ; Ercan, A; van der Wel, H; Locke, RD; Sirajud-Doulah, K; Matta, KL; West, CM				Ketcham, C; Wang, F; Fisher, SZ; Ercan, A; van der Wel, H; Locke, RD; Sirajud-Doulah, K; Matta, KL; West, CM			Specificity of a soluble UDP-galactose : fucoside alpha 1,3-galactosyltransferase that modifies the cytoplasmic glycoprotein Skp1 in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCF UBIQUITIN LIGASE; CYTOSOLIC GLYCOPROTEIN; COMPLEX GLYCOSYLATION; GLCNAC-TRANSFERASE; OLIGOSACCHARIDES; FP21; GALACTOSYLTRANSFERASES; GLYCOSYLTRANSFERASES; IDENTIFICATION; PURIFICATION	Skp1 is an adaptor-like protein in E3SCF-ubiquitin ligases and other multiprotein complexes of the cytoplasm and nucleus. In Dictyostelium, Skp1 is modified by an unusual pentasaccharide containing a Galalpha1-Fuc linkage, whose formation is examined here. A cytosolic extract from Dictyostelium was found to yield, after 2400-fold purification, an activity that could transfer Gal from UDP-Gal to both a Fuc-terminated glycoform of Skp1 and synthetic Fuc conjugates in the presence of Mn2+ and dithiothreitol. The microsomal fraction was devoid of activity. The linkage formed was Galalpha1,3Fuc based on co-chromatography with only this synthetic isomer conjugate, and sensitivity to alpha1,3/6-galactosidase. Skp1 exhibited an almost 1000-fold lower K-m and 35-fold higher V-max compared with a simple alpha-fucoside, but this advantage was abolished by denaturation or alkylation of Cys residues. A comparison of a complete series of synthetic glycosides representing the non-reducing terminal mono-, di-, and trisaccharides of Skp1 revealed, surprisingly, that the disaccharide is most active owing primarily to a V-max advantage, but still much less active than Skp1 itself because of a K-m difference. These findings indicate that alpha-GalT1 is a cytoplasmic enzyme whose modification of Skp1 requires proper presentation of the terminal acceptor disaccharide by a folded Skp1 polypeptide, which correlates with previous evidence that the Galalpha1,3Fuc linkage is deficient in expressed mutant Skp1 proteins.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; State University System of Florida; University of Florida; Roswell Park Cancer Institute	West, CM (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd,BMSB 853, Oklahoma City, OK 73104 USA.	Christopher-West@ouhsc.edu	Ercan, Altan/AGO-4238-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Bekiroglu S, 2000, CARBOHYD RES, V328, P409, DOI 10.1016/S0008-6215(00)00104-X; Breton C, 1998, J BIOCHEM, V123, P1000; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; FLOWERS HM, 1979, CARBOHYD RES, V74, P177, DOI 10.1016/S0008-6215(00)84774-6; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Martin-Pastor M, 2000, BIOCHEMISTRY-US, V39, P4674, DOI 10.1021/bi992050q; MATTA KL, 1975, CARBOHYD RES, V43, P299, DOI 10.1016/S0008-6215(00)83494-1; MATTA KL, 1984, CARBOHYD RES, V131, P247, DOI 10.1016/0008-6215(84)85246-5; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Pedersen LL, 2003, CELL MOL LIFE SCI, V60, P259, DOI 10.1007/s000180300021; RANA SS, 1981, CARBOHYD RES, V96, P231, DOI 10.1016/S0008-6215(00)81873-X; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shao L, 2003, CELL MOL LIFE SCI, V60, P241, DOI 10.1007/s000180300019; Taylor SG, 2003, GLYCOBIOLOGY, V13, P327, DOI 10.1093/glycob/cwg030; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Teng-umnuay P, 1999, J BIOL CHEM, V274, P36392, DOI 10.1074/jbc.274.51.36392; TOOMRE DK, 1994, GLYCOBIOLOGY, V4, P653, DOI 10.1093/glycob/4.5.653; van der Wel H, 2002, J BIOL CHEM, V277, P46527, DOI 10.1074/jbc.M208824200; van der Wel H, 2002, J BIOL CHEM, V277, P46328, DOI 10.1074/jbc.M208024200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; Wang F, 2003, J BIOL CHEM, V278, P51395, DOI 10.1074/jbc.M308756200; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 2003, CELL MOL LIFE SCI, V60, P229, DOI 10.1007/s000180300018; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; WEST CM, 2004, BIOCH BIOPHYS ACTA; WONGMADDEN ST, 1995, GLYCOBIOLOGY, V5, P19, DOI 10.1093/glycob/5.1.19; Zhang Y, 1997, GLYCOBIOLOGY, V7, P1153, DOI 10.1093/glycob/7.8.1153; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	37	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29050	29059		10.1074/jbc.M313858200	http://dx.doi.org/10.1074/jbc.M313858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123660	hybrid			2022-12-27	WOS:000222445300028
J	Liekens, S; Hernandez, AI; Ribatti, D; De Clercq, E; Camarasa, MJ; Perez-Perez, MJ; Balzarini, J				Liekens, S; Hernandez, AI; Ribatti, D; De Clercq, E; Camarasa, MJ; Perez-Perez, MJ; Balzarini, J			The nucleoside derivative 5 '-O-trityl-inosine (KIN59) suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; MULTISUBSTRATE ANALOG INHIBITORS; EMBRYO CHORIOALLANTOIC MEMBRANE; HYPOXIA-INDUCED APOPTOSIS; INTRATUMORAL MICROVESSELS; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXPRESSION; 2-DEOXY-D-RIBOSE	Thymidine phosphorylase (TPase) catalyzes the reversible phosphorolysis of pyrimidine deoxynucleosides to 2-deoxy-D-ribose-1-phosphate and their respective pyrimidine bases. The enzymatic activity of TPase was found to be essential for its angiogenesis-stimulating properties. All of the previously described TPase inhibitors are either pyrimidine analogues that interact with the nucleoside-binding site of the enzyme or modified purine derivatives that mimic the pyrimidine structure and either compete with thymidine or act as a multisubstrate (competitive) inhibitor. We now describe the inhibitory activity of the purine riboside derivative KIN59 (5'-O-tritylinosine) against human and bacterial recombinant TPase and TPase-induced angiogenesis. In contrast to previously described TPase inhibitors, KIN59 does not compete with the pyrimidine nucleoside or the phosphate-binding site of the enzyme but noncompetitively inhibits TPase when thymidine or phosphate is used as the variable substrate. In addition, KIN59 was far more active than other TPase inhibitors, previously tested by us, against TPase-induced angiogenesis in the chorioallantoic membrane assay. The observed anti-angiogenic effect of KIN59 was not accompanied by inflammation or any visible toxicity. Inosine did not inhibit the enzymatic or angiogenic activity of the enzyme, indicating that the 5'-O-trityl group in KIN59 is essential for the observed effects. In contrast with current concepts, our data indicate that the angiogenic activity of TPase is not solely directed through its functional nucleoside and phosphate-binding sites. Other regulatory (allosteric) site(s) in TPase may play an important role in the mechanism of TPase-triggered angiogenesis stimulation and apoptosis inhibition. Identification of these site(s) is important to obtain a better insight into the molecular role of TPase in the progression of cancer and angiogenic diseases.	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Dept Human Anat & Histol, I-70124 Bari, Italy; CSIC, Inst Quim Med, E-28006 Madrid, Spain	KU Leuven; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Medica (IQM); CSIC - Instituto de Quimica Organica General (IQOG)	Liekens, S (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	sandra.liekens@rega.kuleuven.ac.be	Camarasa, María-José/N-8845-2019; Higueras, Ana Isabel Hernandez/F-9372-2016; Camarasa, María-José/B-6340-2015; Perez-Perez, Maria-Jesus/O-4580-2014	Camarasa, María-José/0000-0002-4978-6468; Higueras, Ana Isabel Hernandez/0000-0003-2310-3718; Camarasa, María-José/0000-0002-4978-6468; Perez-Perez, Maria-Jesus/0000-0003-1336-7760; De Clercq, Erik/0000-0002-2985-8890				Balzarini J, 2000, FEBS LETT, V483, P181, DOI 10.1016/S0014-5793(00)02101-3; Balzarini J, 1998, FEBS LETT, V438, P91, DOI 10.1016/S0014-5793(98)01271-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Brown NS, 2000, CANCER RES, V60, P6298; Brown NS, 1998, BIOCHEM J, V334, P1; CHU CK, 1989, J ORG CHEM, V54, P2217, DOI 10.1021/jo00270a036; Cole C, 2003, J MED CHEM, V46, P207, DOI 10.1021/jm020964w; DESGRANGES C, 1983, BIOCHEM PHARMACOL, V32, P3583, DOI 10.1016/0006-2952(83)90307-6; Esteban-Gamboa A, 2000, J MED CHEM, V43, P971, DOI 10.1021/jm9911377; Focher F, 2000, J MED CHEM, V43, P2601, DOI 10.1021/jm000037u; HARAGUCHI M, 1994, NATURE, V368, P198, DOI 10.1038/368198a0; Hata K, 1998, ULTRASOUND OBST GYN, V12, P201, DOI 10.1046/j.1469-0705.1998.12030201.x; Hotchkiss KA, 2003, J BIOL CHEM, V278, P19272, DOI 10.1074/jbc.M212670200; Hotchkiss KA, 2003, CANCER RES, V63, P527; Ikeda R, 2003, BIOCHEM BIOPH RES CO, V301, P358, DOI 10.1016/S0006-291X(02)03034-6; Ikeda R, 2002, BIOCHEM BIOPH RES CO, V291, P806, DOI 10.1006/bbrc.2002.6432; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; Kitazono M, 1998, BIOCHEM BIOPH RES CO, V253, P797, DOI 10.1006/bbrc.1998.9852; Klein RS, 2001, BIOCHEM PHARMACOL, V62, P1257, DOI 10.1016/S0006-2952(01)00783-3; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Liekens S, 2002, FEBS LETT, V510, P83, DOI 10.1016/S0014-5793(01)03233-1; Liekens S, 2001, CANCER RES, V61, P5057; Matsushita S, 1999, CANCER RES, V59, P1911; Matsuura T, 1999, CANCER RES, V59, P5037; Mendieta J, 2004, BIOCHEMISTRY-US, V43, P405, DOI 10.1021/bi034793o; MIYADERA K, 1995, CANCER RES, V55, P1687; MOGHADDAM A, 1995, P NATL ACAD SCI USA, V92, P998, DOI 10.1073/pnas.92.4.998; Mori S, 2002, BIOCHEM BIOPH RES CO, V295, P300, DOI 10.1016/S0006-291X(02)00662-9; Norman RA, 2004, STRUCTURE, V12, P75, DOI 10.1016/j.str.2003.11.018; Okamoto E, 2001, PATHOL INT, V51, P158, DOI 10.1046/j.1440-1827.2001.01184.x; Pugmire MJ, 1998, STRUCTURE, V6, P1467, DOI 10.1016/S0969-2126(98)00145-2; Ribatti D, 2002, J CELL MOL MED, V6, P439, DOI 10.1111/j.1582-4934.2002.tb00524.x; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Rick SW, 1999, PROTEINS, V37, P242, DOI 10.1002/(SICI)1097-0134(19991101)37:2<242::AID-PROT9>3.0.CO;2-5; Seki N, 2000, EUR J CANCER, V36, P68, DOI 10.1016/S0959-8049(99)00201-4; Sengupta S, 2003, BRIT J PHARMACOL, V139, P219, DOI 10.1038/sj.bjp.0705216; Stevenson DP, 1998, AM J PATHOL, V152, P1641; TOI M, 1995, INT J CANCER, V64, P79, DOI 10.1002/ijc.2910640202; USUKI K, 1992, BIOCHEM BIOPH RES CO, V184, P1311, DOI 10.1016/S0006-291X(05)80025-7; WALTER MR, 1990, J BIOL CHEM, V265, P14016	40	45	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29598	29605		10.1074/jbc.M402602200	http://dx.doi.org/10.1074/jbc.M402602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123637	Green Published, hybrid			2022-12-27	WOS:000222445300095
J	Marheineke, K; Hyrien, O				Marheineke, K; Hyrien, O			Control of replication origin density and firing time in Xenopus egg extracts - Role of a caffeine-sensitive, ATR-dependent checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC DNA-REPLICATION; RECOGNITION COMPLEX; DAMAGE CHECKPOINT; EARLY EMBRYOS; INITIATION; CHROMATIN; LAEVIS; PROTEIN; PROGRESSION; INHIBITION	A strict control of replication origin density and firing time is essential to chromosomal stability. Replication origins in early frog embryos are located at apparently random sequences, are spaced at close ( similar to 10-kb) intervals, and are activated in clusters that fire at different times throughout a very brief S phase. Using molecular combing of DNA from sperm nuclei replicating in Xenopus egg extracts, we show that the temporal order of origin firing can be modulated by the nucleocytoplasmic ratio and the checkpoint-abrogating agent caffeine in the absence of external challenge. Increasing the concentration of nuclei in the extract increases S phase length. Contrary to a previous interpretation, this does not result from a change in local origin spacing but from a spreading of the time over which distinct origin clusters fire and from a decrease in replication fork velocity. Caffeine addition or ATR inhibition with a specific neutralizing antibody increases origin firing early in S phase, suggesting that a checkpoint controls the time of origin firing during unperturbed S phase. Furthermore, fork progression is impaired when excess forks are assembled after caffeine treatment. We also show that caffeine allows more early origin firing with low levels of aphidicolin treatment but not higher levels. We propose that a caffeine-sensitive, ATR-dependent checkpoint adjusts the frequency of initiation to the supply of replication factors and optimizes fork density for safe and efficient chromosomal replication during normal S phase.	Ecole Normale Super, UMR 8541, Genet Mol Lab, F-75230 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Hyrien, O (corresponding author), Ecole Normale Super, UMR 8541, Genet Mol Lab, 46 Rue Ulm, F-75230 Paris 05, France.	hyrien@wotan.ens.fr	Marheineke, Kathrin/C-1797-2008; Hyrien, Olivier/R-5108-2017	Hyrien, Olivier/0000-0001-8879-675X; Marheineke, Kathrin/0000-0002-1514-0167				Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; CHOI OH, 1988, LIFE SCI, V43, P387, DOI 10.1016/0024-3205(88)90517-6; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Fredholm BB, 1999, PHARMACOL REV, V51, P83; Goren A, 2003, NAT REV MOL CELL BIO, V4, P25, DOI 10.1038/nrm1008; Harvey KJ, 2003, MOL CELL BIOL, V23, P6769, DOI 10.1128/MCB.23.19.6769-6779.2003; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Herrick J, 2000, J MOL BIOL, V300, P1133, DOI 10.1006/jmbi.2000.3930; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; Jun S, 2004, CELL CYCLE, V3, P223; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; LASKEY RA, 1985, J EMBRYOL EXP MORPH, V89, P285; Lucas I, 2000, J MOL BIOL, V296, P769, DOI 10.1006/jmbi.2000.3500; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Marheineke K, 2001, J BIOL CHEM, V276, P17092, DOI 10.1074/jbc.M100271200; Maric C, 1999, J MOL BIOL, V291, P775, DOI 10.1006/jmbi.1999.3017; McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305; Miao H, 2003, J BIOL CHEM, V278, P4295, DOI 10.1074/jbc.M204264200; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; Rippe K, 2001, TRENDS BIOCHEM SCI, V26, P733, DOI 10.1016/S0968-0004(01)01978-8; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sharma K, 2001, GENETICS, V159, P35; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	47	121	125	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28071	28081		10.1074/jbc.M401574200	http://dx.doi.org/10.1074/jbc.M401574200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123715	Green Published, hybrid			2022-12-27	WOS:000222265400032
J	Zhang, L; Keane, MP; Zhu, LX; Sharma, S; Rozengurt, E; Strieter, RM; Dubinett, SM; Huang, M				Zhang, L; Keane, MP; Zhu, LX; Sharma, S; Rozengurt, E; Strieter, RM; Dubinett, SM; Huang, M			Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; GENE-EXPRESSION; MESSENGER-RNA; ACTIVATION; PATHWAY; SMAD3; CELLS; CD40; IL-2	Transforming growth factor-beta (TGF-beta) is a potent fibrogenic factor responsible for promoting synthesis of extracellular matrix. Interleukin-7 (IL-7) inhibits TGF-beta signaling by up-regulating Smad7, a major inhibitor of the Smad family. In a variety of cells, TGF-beta-mediated activation of target genes requires active protein kinase C-delta (PKC-delta) in addition to Smads (1). We determined the role of PKC-delta in the regulation of pulmonary fibroblast collagen synthesis in response to TGF-beta and IL-7 stimulation. Here we show that TGF-beta and IL-7 have opposing effects on PKC-delta; TGF-beta stimulates, while IL-7 inhibits, PKC-delta activity. IL-7 inhibits TGF-beta-induced PKC-delta phosphorylation at Ser-645 and Thr-505. Inhibition of PKC-delta with specific small inhibitory RNA restores TGF-beta-mediated induction of Smad7 and in parallel significantly reduces TGF-beta-mediated collagen synthesis. Thus, PKC-delta may play a critical role in the pathogenesis of pulmonary fibrosis and may serve as a molecular target for therapeutic intervention to suppress fibrosis.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Huang, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.	minhuang@mednet.ucla.edu			NCI NIH HHS [P50 CA 90388, R01 CA 085686] Funding Source: Medline; NHLBI NIH HHS [P50 HL 67665, P01 HL 03906] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388, R01CA085686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067665] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bloor CA, 2001, AM J RESP CRIT CARE, V164, P265, DOI 10.1164/ajrccm.164.2.2003114; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; HUANG M, 1990, ARCH BIOCHEM BIOPHYS, V277, P296, DOI 10.1016/0003-9861(90)90582-J; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jimenez SA, 2001, J CLIN INVEST, V108, P1395, DOI 10.1172/JCI200112347; Kaufman J, 2004, J IMMUNOL, V172, P1862, DOI 10.4049/jimmunol.172.3.1862; Keane MP, 1997, J IMMUNOL, V159, P1437; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI WQ, 1994, J BIOL CHEM, V269, P2349; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Sheppard D, 2001, J CLIN INVEST, V107, P1501, DOI 10.1172/JCI13318; Xiao H, 2002, J BIOL CHEM, V277, P8091, DOI 10.1074/jbc.M106650200; Zhao Y, 2002, BIOCHEM BIOPH RES CO, V294, P319, DOI 10.1016/S0006-291X(02)00471-0	21	49	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28315	28319		10.1074/jbc.C400115200	http://dx.doi.org/10.1074/jbc.C400115200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15133032	hybrid			2022-12-27	WOS:000222265400063
J	Mitchell, SM; Lee, E; Garcia, ML; Stephan, MM				Mitchell, SM; Lee, E; Garcia, ML; Stephan, MM			Structure and function of extracellular loop 4 of the serotonin transporter as revealed by cysteine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER; MEGAPRIMER METHOD; MONOAMINE TRANSPORTERS; TRANSMEMBRANE DOMAIN; EXPRESSION SYSTEM; ESCHERICHIA-COLI; PROLINE RESIDUES; LACTOSE PERMEASE; BINDING; ACID	Residues 386-423 of the rat brain serotonin transporter (SERT) are predicted to form a hydrophilic loop connecting transmembrane spans 7 and 8 (extracellular loop 4 or EL4). EL4 has been hypothesized to play a role in conformational changes associated with substrate translocation. To more fully investigate EL4 structure and function, we performed cysteine-scanning mutagenesis and methanethiosulfonate (MTS) accessibility studies on these 38 residues. Four EL4 mutants (M386C, R390C, G402C, and L405C) showed very low transport activities, low cell surface expression, and strong inhibition by MTS reagents, indicating high structural and functional importance. Twelve mutants were sensitive to very low MTS concentrations, indicating positions highly exposed to the aqueous environment. Eleven mutants were MTS-insensitive, indicating positions that were either buried in EL4 structure or functionally unimportant. The patterns of sensitivity to mutation and MTS reagents were used to produce a structural model of EL4. Positions 386-399 and 409-421 are proposed to form alpha-helices, connected by nine consecutive MTS-sensitive positions, within which four positions, 402-405, may form a turn or hinge. The presence of serotonin changed the MTS accessibility of cysteines at nine positions, while cocaine, a non-transportable blocker, did not affect accessibility. Serotonin-induced accessibility changes required both Na+ and Cl-, indicating that they were associated with active substrate translocation. With the exception of a single mutant, F407C, neither mutation to cysteine nor treatment with MTS reagents affected SERT affinities for serotonin or the cocaine analog beta-CIT. These studies support the role of EL4 in conformational changes occurring during translocation and show that it does not play a direct role in serotonin binding.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Stephan, MM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.	megan.stephan@yale.edu			NIDA NIH HHS [DA12408, DA12586] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012586, P01DA012408] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; BARIK S, 1991, BIOTECHNIQUES, V10, P489; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Burgess KSD, 1999, J NEUROCHEM, V73, P656, DOI 10.1046/j.1471-4159.1999.0730656.x; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chou KC, 2000, ANAL BIOCHEM, V286, P1, DOI 10.1006/abio.2000.4757; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LANGER SZ, 1988, PROG NEURO-PSYCHOPH, V12, P193, DOI 10.1016/0278-5846(88)90037-1; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; MacAulay N, 2003, J BIOL CHEM, V278, P28771, DOI 10.1074/jbc.M213023200; MEINILD AK, 2003, ANN M SOC NEUR NEW O; Norregaard L, 2003, J BIOL CHEM, V278, P30587, DOI 10.1074/jbc.M303854200; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Penado KMY, 1998, J BIOL CHEM, V273, P28098, DOI 10.1074/jbc.273.43.28098; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; Saier MH, 1999, J CELL BIOCHEM, P84; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; TATE CG, 1994, J BIOL CHEM, V269, P26303; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Visiers I, 2000, PROTEIN ENG, V13, P603, DOI 10.1093/protein/13.9.603; Visiers I, 2003, BIOCHEMISTRY-US, V42, P6784, DOI 10.1021/bi0273415; WALL SC, 1993, MOL PHARMACOL, V43, P264; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; Yan BX, 1997, J BIOL CHEM, V272, P3190, DOI 10.1074/jbc.272.6.3190; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	40	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24089	24099		10.1074/jbc.M311173200	http://dx.doi.org/10.1074/jbc.M311173200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140876	hybrid			2022-12-27	WOS:000221702500031
J	Rosen, ML; Edman, M; Sjostrom, M; Wieslander, A				Rosen, ML; Edman, M; Sjostrom, M; Wieslander, A			Recognition of fold and sugar linkage for glycosyltransferases by multivariate sequence analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPORT VECTOR MACHINES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BLOOD-GROUP; GLYCOSIDE HYDROLASES; CATALYTIC DOMAIN; PROTEIN; COMPLEX; BIOSYNTHESIS; PREDICTION	Glycosyltransferases (GTs) are among the largest groups of enzymes found and are usually classified on the basis of sequence comparisons into many families of varying similarity (CAZy systematics). Only two different Rossman-like folds have been detected (GT-A and GT-B) within the small number of established crystal structures. A third uncharacterized fold has been indicated with transmembrane organization (GT-C). We here use a method based on multivariate data analyses (MVDAs) of property patterns in amino acid sequences and can with high accuracy recognize the correct fold in a large data set of GTs. Likewise, a retaining or inverting enzymatic mechanism for attachment of the donor sugar could be properly revealed in the GT-A and GT-B fold group sequences by such analyses. Sequence alignments could be correlated to important variables in MVDA, and the separating amino acid positions could be mapped over the active sites. These seem to be localized to similar positions in space for the alpha/beta/alpha binding motifs in the GT-B fold group structures. Analogous, active-site sequence positions were found for the GT-A fold group. Multivariate property patterns could also easily group most GTs annotated in the genomes of Escherichia coli and Synechocystis to proper fold or organization group, according to bench-marking comparisons at the MetaServer. We conclude that the sequence property patterns revealed by the multivariate analyses seem more conserved than amino acid types for these GT groups, and these patterns are also conserved in the structures. Such patterns may also potentially define substrate preferences.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Umea Univ, Chemometr Res Grp, Dept Chem, SE-90187 Umea, Sweden	Stockholm University; Umea University	Wieslander, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	ake@dbb.su.se						Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Boix E, 2001, J BIOL CHEM, V276, P48608, DOI 10.1074/jbc.M108828200; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Branden C., 1999, INTRO PROTEIN STRUCT; Breton C, 2001, BIOCHIMIE, V83, P713, DOI 10.1016/S0300-9084(01)01298-6; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Cai YD, 2003, PEPTIDES, V24, P159, DOI 10.1016/S0196-9781(02)00289-9; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chou KC, 2002, J BIOL CHEM, V277, P45765, DOI 10.1074/jbc.M204161200; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Edman M, 1999, PROTEINS, V35, P195, DOI 10.1002/(SICI)1097-0134(19990501)35:2<195::AID-PROT6>3.3.CO;2-G; Edman M, 2003, J BIOL CHEM, V278, P8420, DOI 10.1074/jbc.M211492200; Eriksson L, MULTI MEGAVARIATE DA; Franco OL, 2003, GLYCOBIOLOGY, V13, P707, DOI 10.1093/glycob/cwg098; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GEBLER J, 1992, J BIOL CHEM, V267, P12559; Gibson RP, 2004, J BIOL CHEM, V279, P1950, DOI 10.1074/jbc.M307643200; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Heissigerova H, 2003, GLYCOBIOLOGY, V13, P377, DOI 10.1093/glycob/cwg042; HELLBERG S, 1987, J MED CHEM, V30, P1126, DOI 10.1021/jm00390a003; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; HORNE DS, 1988, BIOPOLYMERS, V27, P451, DOI 10.1002/bip.360270308; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Kikuchi N, 2003, BIOCHEM BIOPH RES CO, V310, P574, DOI 10.1016/j.bbrc.2003.09.031; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Mirny LA, 1999, J MOL BIOL, V291, P177, DOI 10.1006/jmbi.1999.2911; Mulichak AM, 2003, P NATL ACAD SCI USA, V100, P9238, DOI 10.1073/pnas.1233577100; Mulichak AM, 2001, STRUCTURE, V9, P547, DOI 10.1016/S0969-2126(01)00616-5; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Rackovsky S, 1998, P NATL ACAD SCI USA, V95, P8580, DOI 10.1073/pnas.95.15.8580; SJOSTROM M, 1995, CHEMOMETR INTELL LAB, V29, P295, DOI 10.1016/0169-7439(95)00059-1; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; Wimmerova M, 2003, BIOCHIMIE, V85, P691, DOI 10.1016/S0300-9084(03)00120-2; Wold S, 1998, ACTA CHEM SCAND, V52, P517, DOI 10.3891/acta.chem.scand.52-0517; WOLD S, 1993, ANAL CHIM ACTA, V277, P239, DOI 10.1016/0003-2670(93)80437-P; Wold S., 2002, ENCY COMPUTATIONAL C, P79, DOI [10.1002/0470845015, 10.1002/0470845015.cpa012, DOI 10.1002/0470845015.CPA012]	47	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38683	38692		10.1074/jbc.M402925200	http://dx.doi.org/10.1074/jbc.M402925200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15148316	hybrid			2022-12-27	WOS:000223684100077
J	Chaudhry, HW; Dashoush, NH; Tang, HY; Zhang, L; Wang, XY; Wu, EX; Wolgemuth, DJ				Chaudhry, HW; Dashoush, NH; Tang, HY; Zhang, L; Wang, XY; Wu, EX; Wolgemuth, DJ			Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-SYNTHESIS; GROWTH-FACTORS; CARDIAC MYOCYTES; ADULT MYOCARDIUM; EXPRESSION; OVEREXPRESSION; DIFFERENTIATION; PROTOONCOGENES; LOCALIZATION	Cell cycle withdrawal limits proliferation of adult mammalian cardiomyocytes. Therefore, the concept of stimulating myocyte mitotic divisions has dramatic implications for cardiomyocyte regeneration and hence, cardiovascular disease. Previous reports describing manipulation of cell cycle proteins have not shown induction of cardiomyocyte mitosis after birth. We now report that cyclin A2, normally silenced in the postnatal heart, induces cardiac enlargement because of cardiomyocyte hyperplasia when constitutively expressed from embryonic day 8 into adulthood. Cardiomyocyte hyperplasia during adulthood was coupled with an increase in cardiomyoctye mitosis, noted in transgenic hearts at all time points examined, particularly during postnatal development. Several stages of mitosis were observed within cardiomyocytes and correlated with the nuclear localization of cyclin A2. Magnetic resonance analysis confirmed cardiac enlargement. These results reveal a previously unrecognized critical role for cyclin A2 in mediating cardiomyocyte mitosis, a role that may significantly impact upon clinical treatment of damaged myocardium.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Chaudhry, HW (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 622 W 168th St, New York, NY 10032 USA.	hwc7@columbia.edu	Wu, Ed/C-1579-2009	Wu, Ed/0000-0001-5581-1546	NHLBI NIH HHS [K08 HL067048] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; BASI G, 1995, MOL CELL BIOL, V15, P2028; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BEINLICH CJ, 1993, MOL CELL BIOCHEM, V119, P3, DOI 10.1007/BF00926846; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Bianchi C, 2001, CIRCULATION, V104, pI319; Brooks G, 1998, CARDIOVASC RES, V39, P301, DOI 10.1016/S0008-6363(98)00125-4; Brooks G, 1997, J MOL CELL CARDIOL, V29, P2261, DOI 10.1006/jmcc.1997.0471; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; JACKSON T, 1990, MOL CELL BIOL, V10, P3709, DOI 10.1128/MCB.10.7.3709; Kajstura J, 2000, AM J PATHOL, V156, P813, DOI 10.1016/S0002-9440(10)64949-8; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Leri A, 2000, J MOL CELL CARDIOL, V32, P385, DOI 10.1006/jmcc.1999.1084; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liao HS, 2001, CIRC RES, V88, P443; MENDEZ J, 1960, METABOLISM, V9, P184; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Poolman RA, 1998, INT J CARDIOL, V67, P133, DOI 10.1016/S0167-5273(98)00320-9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ravnik SE, 1996, DEV BIOL, V173, P69, DOI 10.1006/dbio.1996.0007; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Rumyantsev PP., 1991, GROWTH HYPERPLASIA C; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; Slawson SE, 1998, MAGN RESON MED, V39, P980, DOI 10.1002/mrm.1910390616; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1997, J CLIN INVEST, V99, P2644, DOI 10.1172/JCI119453; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Tang HY, 2000, ANN NY ACAD SCI, V904, P32; Wei L, 2002, DEVELOPMENT, V129, P1705; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wiesmann F, 2000, AM J PHYSIOL-HEART C, V278, pH652, DOI 10.1152/ajpheart.2000.278.2.H652; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	43	143	150	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35858	35866		10.1074/jbc.M404975200	http://dx.doi.org/10.1074/jbc.M404975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15159393	hybrid			2022-12-27	WOS:000223303400087
J	Li, L; Gronning, LM; Anderson, PO; Li, SL; Edvardsen, K; Johnston, J; Kioussis, D; Shepherd, PR; Wang, P				Li, L; Gronning, LM; Anderson, PO; Li, SL; Edvardsen, K; Johnston, J; Kioussis, D; Shepherd, PR; Wang, P			Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE-ACTIVITY; MICE LACKING; GROWTH-HORMONE; CYTOKINE SIGNALING-1; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; P85-ALPHA SUBUNIT; 85-KDA SUBUNIT; BOX MOTIF; SUPPRESSOR	The suppressors of cytokine signaling ( SOCS) family is thought to act largely as a negative regulator of signaling by cytokines and some growth factors. Surprisingly, the SOCS-6 transgenics had no significant defects in the cytokine signaling and hematopoietic system but displayed significant improvements in glucose metabolism. Insulin stimulation of Akt/protein kinase B was also potentiated. Biochemical analysis showed that, after insulin stimulation, SOCS-6 interacted with the monomeric p85 subunit of class-Ia phosphoinositide ( PI) 3-kinase but not with p85/p110 dimers. Furthermore, SOCS-6 expression is transiently increased by serum and insulin in normal fibroblasts. However, both the mRNA and protein of SOCS-6 were rapidly degraded after induction by insulin. The degradation of the SOCS-6 protein was partially inhibited by a proteasome inhibitor, suggesting a proteasome-mediated degradation mechanism. In contrast, SOCS-6- associated p85 was not degraded and could be recruited to the newly synthesized SOCS-6 molecules in the presence of insulin, suggesting that SOCS-6 expression and its interaction with p85, but not the degradation, is regulated by insulin. The phenotype of SOCS-6 transgenic mice bears a striking resemblance to p85 knock-out mouse models in which glucose metabolism stimulated by insulin is significantly improved despite reduced activation of PI 3-kinase. This suggests that monomeric p85 might play a physiologically important role in attenuating signaling through PI 3-kinase-dependent pathways in unstimulated cells. Therefore, our results indicate that SOCS-6 may provide a dynamically regulated mechanism by which insulin can transiently overcome the negative effects that p85 monomers have on signaling via PI 3-kinase-dependent signaling pathways.	St Barts & Rotal London Sch Med, Inst Cell & Mol Sci, Immunol Grp, London EC1A 7ED, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Natl Inst Med Res, Div Mol Immunol, MRC, London NW7 1AA, England; Lund Univ, Dept Tumor Immunol, S-22362 Lund, Sweden; Queens Univ Belfast, Dept Immunol, Belfast BT9 7BL, Antrim, North Ireland	University of London; Queen Mary University London; University of London; University College London; MRC National Institute for Medical Research; Lund University; Queens University Belfast	Wang, P (corresponding author), Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, Immunol Grp, 59 Bartholomews Close, London EC1A 7ED, England.	p.wang@qmul.ac.uk		Wang, Ping/0000-0001-8992-1233; Anderson, Per/0000-0002-0958-7990				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Denson LA, 2003, AM J PHYSIOL-GASTR L, V284, pG646, DOI 10.1152/ajpgi.00178.2002; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dogusan Z, 2000, J NEUROIMMUNOL, V109, P34, DOI 10.1016/S0165-5728(00)00300-3; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Foukas LC, 2004, MOL CELL BIOL, V24, P966, DOI 10.1128/MCB.24.3.966-975.2004; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; Greenhalgh CJ, 2002, J BIOL CHEM, V277, P40181, DOI 10.1074/jbc.C200450200; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Krebs DL, 2000, J CELL SCI, V113, P2813; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Lebel E, 2000, ENDOCRINOLOGY, V141, P3749, DOI 10.1210/en.141.10.3749; Li SL, 2000, J EXP MED, V191, P985, DOI 10.1084/jem.191.6.985; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Philp AJ, 2001, CANCER RES, V61, P7426; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sadowski CL, 2001, J BIOL CHEM, V276, P20703, DOI 10.1074/jbc.M101014200; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Ueki K, 2000, J CLIN INVEST, V105, P1437, DOI 10.1172/JCI7656; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498; ZHANG WG, 1993, P NATL ACAD SCI USA, V90, P11317, DOI 10.1073/pnas.90.23.11317	41	52	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34107	34114		10.1074/jbc.M312672200	http://dx.doi.org/10.1074/jbc.M312672200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15123678	hybrid			2022-12-27	WOS:000223134800007
J	Cen, S; Guo, F; Niu, MJ; Saadatmand, J; Deflassieux, J; Kleiman, L				Cen, S; Guo, F; Niu, MJ; Saadatmand, J; Deflassieux, J; Kleiman, L			The interaction between HIV-1 Gag and APOBEC3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIF PROTEIN BINDS; SOR GENE-PRODUCT; TYPE-1 VIF; CYTIDINE DEAMINASE; HTLV-III/LAV; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; EDITING ENZYME; RNA-BINDING	APOBEC3G, a member of an RNA/DNA cytidine deaminase superfamily, has been identified as a cellular inhibitor of HIV-1 infectivity, possibly through the dC to dU deamination of the first minus strand cDNA synthesized during reverse transcription. Virions incorporate APOBEC3G during viral assembly in non-permissive cells, and this incorporation is inhibited by the viral protein Vif. The mechanism of APOBEC3G incorporation into HIV-1 is examined in this report. In the absence of Vif, cytoplasmic APOBEC3G becomes membrane-bound in cells expressing HIV-1 Gag, and its incorporation into Gag viral-like particles (VLPs) is proportional to the amount of APOBEC3G expressed in the cell. The expression of Vif, or mutant Gag unable to bind to membrane, prevents the APOBEC3G association with membrane. HIV-1 Gag alone among viral proteins is sufficient for packaging of APOBEC3G into Gag VLPs, and this incorporation requires the presence of Gag nucleocapsid. The presence of amino acids 104 - 156 in APOBEC3G, located in the linker region between two zinc coordination motifs, is also required for its incorporation into Gag VLPs. Evidence against an RNA bridge facilitating the Gag/APOBEC3G interaction includes data indicating that 1) the incorporation of APOBEC3G occurs independently of viral genomic RNA, 2) a Gag/APOBEC3G complex is immunoprecipitated from cell lysate after RNase treatment, and 3) the zinc coordination motif, rather than the regions flanking this motif, have been implicated in RNA binding in another family member, APOBEC1.	Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Jewish Gen Hosp, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Cen, S (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	shan.cen@staff.mcgill.ca; Lawrence.Kleiman@mcgill.ca		Guo, Fei/0000-0003-3500-1006				Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; Camaur D, 1996, J VIROL, V70, P6106, DOI 10.1128/JVI.70.9.6106-6111.1996; Cen S, 1999, J VIROL, V73, P4485, DOI 10.1128/JVI.73.5.4485-4488.1999; Cen S, 2004, J VIROL, V78, P1042, DOI 10.1128/JVI.78.2.1042-1049.2004; Chatterji U, 2000, J VIROL, V74, P2533, DOI 10.1128/JVI.74.6.2533-2540.2000; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; Halwani R, 2003, J VIROL, V77, P3973, DOI 10.1128/JVI.77.7.3973-3984.2003; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001; Huvent I, 1998, J GEN VIROL, V79, P1069, DOI 10.1099/0022-1317-79-5-1069; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KAN NC, 1986, SCIENCE, V231, P1553, DOI 10.1126/science.3006245; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kao S, 2003, J VIROL, V77, P1131, DOI 10.1128/JVI.77.2.1131-1140.2003; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Khorchid A, 2002, J VIROL, V76, P4131, DOI 10.1128/JVI.76.8.4131-4137.2002; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LEE TH, 1986, SCIENCE, V231, P1546, DOI 10.1126/science.3006243; Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; Simon JHM, 1999, J VIROL, V73, P2667, DOI 10.1128/JVI.73.4.2667-2674.1999; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244; Sova P, 2001, J VIROL, V75, P5504, DOI 10.1128/JVI.75.12.5504-5517.2001; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	53	214	222	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33177	33184		10.1074/jbc.M402062200	http://dx.doi.org/10.1074/jbc.M402062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159405	hybrid			2022-12-27	WOS:000223039700021
J	Moraczewska, J; Gruszczynska-Biegala, J; Redowicz, MJ; Khaitlina, SY; Strzelecka-Golaszewska, H				Moraczewska, J; Gruszczynska-Biegala, J; Redowicz, MJ; Khaitlina, SY; Strzelecka-Golaszewska, H			The DNase-I binding loop of actin may play a role in the regulation of actin-myosin interaction by tropomyosin/troponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-CLEAVED ACTIN; THIN FILAMENT REGULATION; RAY FIBER DIFFRACTION; F-ACTIN; TROPONIN-TROPOMYOSIN; COOPERATIVE BINDING; SUBDOMAIN 2; ALPHA-TROPOMYOSIN; ENERGY-TRANSFER; CROSS-LINKING	Various lines of evidence suggest that communication between tropomyosin and myosin in the regulation of vertebrate-striated muscle contraction involves yet unknown changes in actin conformation. Possible participation of loop 38 - 52 in this communication has recently been questioned based on unimpaired Ca2+ regulation of myosin interaction, in the presence of the tropomyosin-troponin complex, with actin cleaved by subtilisin between Met(47) and Gly(48). We have compared the effects of actin cleavage by subtilisin and by protease ECP32, between Gly(42) and Val(43), on its interaction with myosin S1 in the presence and absence of tropomyosin or tropomyosin-troponin. Both individual modifications reduced activation of S1 ATPase by actin to a similar extent. The effect of ECP cleavage, but not of subtilisin cleavage, was partially reversed by stabilization of interprotomer contacts with phalloidin, indicating different pathways of signal transmission from the N- and C-terminal parts of loop 38 - 52 to myosin binding sites. ECP cleavage diminished the affinity to tropomyosin and reduced its inhibition of acto-S1 ATPase at low S1 concentrations, but increased the tropomyosin-mediated cooperative enhancement of the ATPase by S1 binding to actin. These effects were reversed by phalloidin. Subtilisin-cleaved actin more closely resembled unmodified actin than the ECP-modified actin. Limited proteolysis of the modified and unmodified F-actins revealed an allosteric effect of ECP cleavage on the conformation of the actin subdomain 4 region that is presumably involved in tropomyosin binding. Our results point to a possible role of the N- terminal part of loop 38 - 52 of actin in communication between tropomyosin and myosin through changes in actin structure.	M Nencki Inst Expt Biol, Dept Muscle Biochem, PL-02093 Warsaw, Poland; Kazimierz Wielki Univ Bydgoszcz, Inst Biol & Environm Protect, PL-85064 Bydgoszcz, Poland; Russian Acad Sci, Inst Cytol, Dept Cell Culture, St Petersburg 194064, Russia	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Kazimierz Wielki University; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Strzelecka-Golaszewska, H (corresponding author), M Nencki Inst Expt Biol, Dept Muscle Biochem, 3 Pasteur St, PL-02093 Warsaw, Poland.	hannas@nencki.gov.pl	Moraczewska, Joanna/AAL-7738-2021; Gruszczynska-Biegala, Joanna/U-4945-2019; Redowicz, Maria Jolanta/R-4083-2016; Redowicz, Maria Jolanta/AAM-8020-2020	Gruszczynska-Biegala, Joanna/0000-0003-3541-2550; Redowicz, Maria Jolanta/0000-0001-5834-471X; Moraczewska, Joanna/0000-0003-4518-3843				BRADFORD M, 1976, ANAL BIOCHEM, V64, P215; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Chalovich JM, 2002, BIOPHYS J, V82, P1679, DOI 10.1016/S0006-3495(02)75519-7; Chen YD, 2001, BIOPHYS J, V80, P2338, DOI 10.1016/S0006-3495(01)76204-2; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; CROSBIE RH, 1994, BIOPHYS J, V67, P1957, DOI 10.1016/S0006-3495(94)80678-2; DABROWSKA R, 1983, J MUSCLE RES CELL M, V4, P143, DOI 10.1007/BF00712027; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; EGELMAN EH, 1995, CURR OPIN STRUC BIOL, V5, P172, DOI 10.1016/0959-440X(95)80072-7; ELSALEH SC, 1984, J BIOL CHEM, V259, P1014; Fiske CH, 1925, J BIOL CHEM, V66, P375; Geeves MA, 2002, BIOPHYS J, V82, P1677, DOI 10.1016/S0006-3495(02)75518-5; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; Gerson JH, 2001, J BIOL CHEM, V276, P18442, DOI 10.1074/jbc.M011070200; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLMES KC, 1995, BIOPHYS J, V68, pS2; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P4512, DOI 10.1021/bi00412a044; Khaitlina S, 2003, BIOPHYS J, V84, p480A; KHAITLINA SY, 1993, EUR J BIOCHEM, V218, P911, DOI 10.1111/j.1432-1033.1993.tb18447.x; KHAITLINA SY, 1991, FEBS LETT, V279, P49, DOI 10.1016/0014-5793(91)80247-Z; Khaitlina SY, 2002, BIOPHYS J, V82, P321, DOI 10.1016/S0006-3495(02)75397-6; Kim E, 1996, BIOPHYS J, V70, P1439, DOI 10.1016/S0006-3495(96)79703-5; Kim E, 1998, BIOCHEMISTRY-US, V37, P17801, DOI 10.1021/bi981286b; Kim E, 2000, BIOPHYS CHEM, V86, P191, DOI 10.1016/S0301-4622(00)00143-5; Kim E, 2000, J MOL BIOL, V299, P421, DOI 10.1006/jmbi.2000.3727; Kim E, 1996, BIOPHYS J, V71, P1914, DOI 10.1016/S0006-3495(96)79390-6; Kim E, 2002, BIOCHEMISTRY-US, V41, P86, DOI 10.1021/bi0113824; Korman VL, 2000, J BIOL CHEM, V275, P22470, DOI 10.1074/jbc.M002939200; Kuznetsova I, 1996, FEBS LETT, V383, P105, DOI 10.1016/0014-5793(96)00238-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MAK AS, 1983, J BIOL CHEM, V258, P4330; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MILLER CJ, 1995, BIOPHYS J, V68, pS50; Moraczewska J, 2000, BIOCHEMISTRY-US, V39, P6891, DOI 10.1021/bi000242b; Moraczewska J, 2003, BIOPHYS J, V84, p246A; Pavlov D, 2003, J BIOL CHEM, V278, P5517, DOI 10.1074/jbc.M210889200; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; RAYMENT I, 1993, SCIENCE, V261, P1; Resetar AM, 2002, BIOPHYS J, V83, P1039, DOI 10.1016/S0006-3495(02)75229-6; Rommelaere H, 2003, STRUCTURE, V11, P1279, DOI 10.1016/j.str.2003.09.002; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; Saeki K, 1996, BIOCHEMISTRY-US, V35, P14465, DOI 10.1021/bi961292c; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Smith DA, 2003, BIOPHYS J, V84, P3155, DOI 10.1016/S0006-3495(03)70040-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Strand J, 2001, J BIOL CHEM, V276, P34832, DOI 10.1074/jbc.M104750200; STRZELECKAGOLASZEWSKA H, 1995, BIOCHEM J, V307, P527, DOI 10.1042/bj3070527; StrzeleckaGolaszewska H, 1996, BIOCHEM J, V316, P713, DOI 10.1042/bj3160713; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; VAHDAT A, 1995, FEBS LETT, V365, P149, DOI 10.1016/0014-5793(95)00446-G; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; YANG YZ, 1979, J BIOL CHEM, V254, P7137	72	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31197	31204		10.1074/jbc.M400794200	http://dx.doi.org/10.1074/jbc.M400794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159400	hybrid			2022-12-27	WOS:000222726800038
J	Zhang, YM; Rock, CO				Zhang, YM; Rock, CO			Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; TEA CAMELLIA-SINENSIS; ESCHERICHIA-COLI; GREEN TEA; THIOLACTOMYCIN RESISTANCE; NATURAL INHIBITOR; ACTIVE-SITE; BIOSYNTHESIS; TRICLOSAN; CATECHINS	Epigallocatechin gallate ( EGCG) is the major component of green tea extracts and possesses antibacterial, antiviral, and antitumor activity. Our study focused on validating the inhibition of the bacterial type II fatty acid synthesis system as a mechanism for the antibacterial effects of EGCG and related plant polyphenols. EGCG and the related tea catechins potently inhibited both the FabG and FabI reductase steps in the fatty acid elongation cycle with IC50 values between 5 and 15 muM. The presence of the galloyl moiety was essential for activity, and EGCG was a competitive inhibitor of FabI and a mixed type inhibitor of FabG demonstrating that EGCG interfered with cofactor binding in both enzymes. EGCG inhibited acetate incorporation into fatty acids in vivo, although it was much less potent than thiolactomycin, a validated fatty acid synthesis inhibitor, and overexpression of FabG, FabI, or both did not confer resistance. A panel of other plant polyphenols was screened for FabG/FabI inhibition and antibacterial activity. Most of these inhibited both reductase steps, possessed antibacterial activity, and inhibited cellular fatty acid synthesis. The ability of the plant secondary metabolites to interfere with the activity of multiple NAD(P)dependent cellular processes must be taken into account when assessing the specificity of their effects.	St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, 332 N Lauderdale St, Memphis, TN 38105 USA.	charles.rock@stjude.org			NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhami VM, 2003, J NUTR, V133, p2417S, DOI 10.1093/jn/133.7.2417S; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Brusselmans K, 2003, INT J CANCER, V106, P856, DOI 10.1002/ijc.11317; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P95; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; De Smet PAGM, 2002, NEW ENGL J MED, V347, P2046, DOI 10.1056/NEJMra020398; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; HAMILTONMILLER JMT, 1995, ANTIMICROB AGENTS CH, V39, P2375, DOI 10.1128/AAC.39.11.2375; HAYASHI T, 1984, J ANTIBIOT, V37, P1456, DOI 10.7164/antibiotics.37.1456; Heath Richard J, 2004, Curr Opin Investig Drugs, V5, P146; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 2002, APPL MICROBIOL BIOT, V58, P695, DOI 10.1007/s00253-001-0918-z; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jackowski S, 2002, ANTIMICROB AGENTS CH, V46, P1246, DOI 10.1128/AAC.46.5.1246-1252.2002; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Laakso JA, 2003, J NAT PROD, V66, P1041, DOI 10.1021/np030046g; Lai CY, 2004, J BACTERIOL, V186, P1869, DOI 10.1128/JB.186.6.1869-1878.2004; Lewis K, 2001, J MOL MICROB BIOTECH, V3, P247; Li BH, 2004, J BIOCHEM, V135, P85, DOI 10.1093/jb/mvh010; Li XC, 2002, J NAT PROD, V65, P1909, DOI 10.1021/np020289t; Mabe K, 1999, ANTIMICROB AGENTS CH, V43, P1788, DOI 10.1128/AAC.43.7.1788; Marrakchi H, 2003, BIOCHEM J, V370, P1055, DOI 10.1042/BJ20021699; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MIYAKAWA S, 1982, J ANTIBIOT, V35, P411, DOI 10.7164/antibiotics.35.411; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Price AC, 2004, STRUCTURE, V12, P417, DOI 10.1016/j.str.2004.02.008; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; Rausher MD, 2001, NATURE, V411, P857, DOI 10.1038/35081193; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; Sivaraman S, 2003, BIOCHEMISTRY-US, V42, P4406, DOI 10.1021/bi0300229; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; Sulavik MC, 2001, ANTIMICROB AGENTS CH, V45, P1126, DOI 10.1128/AAC.45.4.1126-1136.2001; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Tegos G, 2002, ANTIMICROB AGENTS CH, V46, P3133, DOI 10.1128/AAC.46.10.3133-3141.2002; Tian WX, 2004, LIFE SCI, V74, P2389, DOI 10.1016/j.lfs.2003.09.064; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; Verhoef J, 2003, ADV EXP MED BIOL, V531, P301; Wang X, 2003, BIOCHEM PHARMACOL, V66, P2039, DOI 10.1016/S0006-2952(03)00585-9; Wang X, 2001, BIOCHEM BIOPH RES CO, V288, P1200, DOI 10.1006/bbrc.2001.5923; Wright HT, 2004, STRUCTURE, V12, P358, DOI 10.1016/j.str.2004.02.027; Yam TS, 1997, FEMS MICROBIOL LETT, V152, P169, DOI 10.1016/S0378-1097(97)00197-3; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yee YK, 2000, ALIMENT PHARM THER, V14, P635, DOI 10.1046/j.1365-2036.2000.00747.x; Yeh CW, 2003, PHARMACOGENOMICS J, V3, P267, DOI 10.1038/sj.tpj.6500192; Zhang YQ, 2003, J BIOL CHEM, V278, P10417, DOI 10.1074/jbc.M211044200	59	158	169	3	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30994	31001		10.1074/jbc.M403697200	http://dx.doi.org/10.1074/jbc.M403697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133034	hybrid			2022-12-27	WOS:000222726800012
J	Zheng, WJ; Wang, HY; Xue, LX; Zhang, ZY; Tong, TJ				Zheng, WJ; Wang, HY; Xue, LX; Zhang, ZY; Tong, TJ			Regulation of cellular senescence and p16(INK4a) expression by Id1 and E47 proteins in human diploid fibroblast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING; GROWTH-FACTOR; NEGATIVE REGULATOR; G(1) PROGRESSION; DIFFERENTIATION; TRANSCRIPTION; DISTINCT; E2A; EXTRAMACROCHAETAE	Id1, a member of Id family of helix-loop-helix transcriptional regulatory proteins, is implicated in cellular senescence by repressing p16(INK4a) expression, but the mechanisms and cellular effects in human diploid fibroblasts remain unknown. Here we analyzed the patterns of p16(INK4a) and Id1 expression during the lifespan of 2BS cells and presented the inverse correlation between these two proteins. Immunoprecipitation assays demonstrated the presence of endogenous interaction of Id1 and E47 proteins that was strong in young 2BS cells and weakened during replicative senescence and, thereby, influenced the transcription activation of p16(INK4a) by E47. Furthermore, we found that E47 protein could bind to the E-box-containing region in p16(INK4a) promoter in senescent cells by chromatin immunoprecipitation analyses, suggesting that E47 is indeed ultimately involved in the regulation of p16(INK4a) transcription in vivo. Silencing Id1 expression in young cells by RNA interference induced an increased p16(INK4a) level and premature cellular senescence, whereas silencing E47 expression inhibited the expression of p16(INK4a) and delayed the onset of senescent phenotype. The present study demonstrated not only the capacity of Id1 to regulate p16(INK4a) gene expression by E47, but also the phenotypic consequence of the regulation on cellular senescence, moreover, raised the possibility of Id1-specific gene silencing for human cancer therapy.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Capital Univ Med Sci, Beijing Chao Yang Hosp, Beijing 100020, Peoples R China	Peking University; Capital Medical University	Tong, TJ (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	ttj@bjmu.edu.cn						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Barndt RJ, 1999, COLD SPRING HARB SYM, V64, P45, DOI 10.1101/sqb.1999.64.45; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; DEED RW, 1993, ONCOGENE, V8, P599; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1994, J BIOL CHEM, V269, P2139; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LEJOSSIC C, 1994, CANCER RES, V54, P6065; LI JH, 1995, MECH AGEING DEV, V80, P25, DOI 10.1016/0047-6374(94)01557-3; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pagliuca A, 2000, CANCER RES, V60, P1376; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Spector D.I., 1998, CELL LAB MANUAL, V1; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Wadhwa R, 2000, Prog Mol Subcell Biol, V24, P191; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	48	68	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31524	31532		10.1074/jbc.M400365200	http://dx.doi.org/10.1074/jbc.M400365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138269	hybrid			2022-12-27	WOS:000222726800075
J	Aggelidou, E; Iordanidou, P; Tsantili, P; Papadopoulos, G; Hadzopoulou-Cladaras, M				Aggelidou, E; Iordanidou, P; Tsantili, P; Papadopoulos, G; Hadzopoulou-Cladaras, M			Critical role of residues defining the ligand binding pocket in hepatocyte nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRANSCRIPTION FACTOR; APOCIII PROMOTER; GENE-EXPRESSION; HNF-4 GENE; DOMAIN; PROTEIN; ORPHAN; LIVER; TRANSACTIVATION	Hepatocyte nuclear factor-4alpha (HNF-4alpha), a member of the nuclear receptor superfamily, is a crucial regulator of a large number of genes involved in glucose, cholesterol, and fatty acid metabolism. Unlike other members of the superfamily, HNF-4alpha activates transcription in the absence of exogenously added ligand. Recently published crystallographic data show that fatty acids are endogenous ligands for HNF-4. Transcriptional analysis of point mutations of the residues that are located in helices H3, H5, H10, and H11, which have been shown to come in contact with the ligand, resulted in a dramatic decrease in activity, without affecting DNA binding and dimerization. Our results show the importance of residues Ser-181, Met-182 in H3, Leu-219, Leu-220 and Arg-226 in H5, Ile-338 in H10, and Ile-346 in H11 that line the ligand-binding domain pocket in HNF-4alpha and impair its transactivation potential. Structural modeling reveals that the mutations do not cause any large scale structural alterations, and the observed loss in transactivation can be attributed to local changes, demonstrating that these residues play a significant role in maintaining the structural integrity of the HNF-4alpha ligand binding pocket.	Aristotle Univ Thessaloniki, Fac Sci, Sch Biol, Dept Genet Dev & Mol Biol, GR-54124 Thessaloniki, Greece; Univ Thessaly, Dept Biochem & Biotechnol, Thessaly 41221, Greece	Aristotle University of Thessaloniki; University of Thessaly	Hadzopoulou-Cladaras, M (corresponding author), Aristotle Univ Thessaloniki, Fac Sci, Sch Biol, Dept Genet Dev & Mol Biol, GR-54124 Thessaloniki, Greece.	cladaras@bio.auth.gr	Aggelidou, Eleni/GQZ-2215-2022	Papadopoulos, Georgios/0000-0002-2742-8467				[Anonymous], 2001, NUCL RECEPTORS GENET; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CARDOT P, 1993, BIOCHEMISTRY-US, V32, P9080, DOI 10.1021/bi00086a013; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Chou WC, 2003, MOL BIOL CELL, V14, P1279, DOI 10.1091/mbc.E02-07-0375; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Gronemeyer H, 2001, CELL MOL BIOL LETT, V6, P3; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; HADZOPOULOUCLADARAS M, 1993, BIOCHEMISTRY-US, V32, P9657, DOI 10.1021/bi00088a018; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Li JX, 2000, GENE DEV, V14, P464; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; OGAMI K, 1990, J BIOL CHEM, V265, P9808; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	34	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30680	30688		10.1074/jbc.M401120200	http://dx.doi.org/10.1074/jbc.M401120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123688	hybrid			2022-12-27	WOS:000222531900098
J	Duvernay, MT; Zhou, FG; Wu, GY				Duvernay, MT; Zhou, FG; Wu, GY			A conserved motif for the transport of G protein-coupled receptors from the endoplasmic reticulum to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; 3RD INTRACELLULAR LOOP; ER EXPORT; ALPHA(2)-ADRENERGIC RECEPTORS; CARBOXYL-TERMINUS; SECRETORY PATHWAY; CYTOPLASMIC TAIL; C-TERMINUS; EXPRESSION; ENDOCYTOSIS	The structural determinants for the export trafficking of G protein-coupled receptors are poorly defined. In this report, we determined the role of carboxyl termini (CTs) of alpha(2B)-adrenergic receptor (AR) and angiotensin II type 1A receptor (AT1R) in their transport from the endoplasmic reticulum (ER) to the cell surface. The alpha(2B)-AR and AT1R mutants lacking the CTs were completely unable to transport to the cell surface and were trapped in the ER. Alanine-scanning mutagenesis revealed that residues Phe(436) and Ile(443)-Leu(444) in the CT were required for alpha(2B)-AR export. Insertion or deletion between Phe(436) and Ile(443)-Leu(444) as well as Ile(443)-Leu(444) mutation to FF severely disrupted alpha(2B)-AR transport, indicating there is a defined spatial requirement, which is essential for their function as a single motif regulating receptor transport from the ER. Furthermore, the carboxyl-terminally truncated as well as Phe(436) and Ile(443)-Leu(444) mutants were unable to bind ligand and the alpha(2B)-AR CT conferred its transport properties to the AT1R mutant without the CT in a Phe(436)- Ile(443)-Leu(444)-dependent manner. These data suggest that the Phe436 and Ile(443)-Leu(444) may be involved in both proper folding and export from the ER of the receptor. Similarly, residues Phe(309) and Leu(316)-Leu(317) in the CT were identified as essential for AT1R export. The sequence F(X)(6)LL (where X can be any residue, and L is leucine or isoleucine) is highly conserved in the membrane-proximal CTs of many G protein-coupled receptors and may function as a common motif mediating receptor transport from the ER to the cell surface.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wu, GY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	gwu@lsuhsc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018766] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20RR018766] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; HAMAMDZIC D, 1995, AM J PHYSIOL-ENDOC M, V269, pE162, DOI 10.1152/ajpendo.1995.269.1.E162; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Jayadev S, 1999, ENDOCRINOLOGY, V140, P2010, DOI 10.1210/en.140.5.2010; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller KC, 2002, GEOL SOC AM BULL, V114, P497, DOI 10.1130/0016-7606(2002)114<0497:GEFMEA>2.0.CO;2; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2003, J CELL SCI, V116, P4429, DOI 10.1242/jcs.00759; Nufer O, 2002, J CELL SCI, V115, P619; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Olkkonen VM, 2000, NEW ENGL J MED, V343, P1095, DOI 10.1056/NEJM200010123431507; Pankevych H, 2003, J BIOL CHEM, V278, P30283, DOI 10.1074/jbc.M212918200; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Sayeski PP, 1998, REGUL PEPTIDES, V78, P19, DOI 10.1016/S0167-0115(98)00137-2; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Wu GY, 2001, CIRC RES, V89, P1130, DOI 10.1161/hh2401.100427; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yang Q, 1999, MOL PHARMACOL, V56, P651, DOI 10.1124/mol.56.3.651; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	52	128	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30741	30750		10.1074/jbc.M313881200	http://dx.doi.org/10.1074/jbc.M313881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123661	hybrid			2022-12-27	WOS:000222531900105
J	Kutney, SN; Hong, R; Macfarlan, T; Chakravarti, D				Kutney, SN; Hong, R; Macfarlan, T; Chakravarti, D			A signaling role of histone-binding proteins and INHAT subunits pp32 and Set/TAF-I alpha in integrating chromatin hypoacetylation and transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; LYSINE 9; H3; ACETYLATION; METHYLATION; COMPLEX; YEAST; HETEROCHROMATIN; BROMODOMAIN; DEACETYLASE	Various post-translational modifications of histones significantly influence gene transcription. Although un- or hypoacetylated histones are tightly linked to transcriptional repression, the mechanisms and identities of chromatin signal transducer proteins integrating histone hypoacetylation into repression in humans have remained largely unknown. Here we show that the mammalian histone-binding proteins and inhibitor of acetyltransferases (INHAT) complex subunits, Set/template-activating factor-Ibeta (TAF-Ibeta) and pp32, specifically bind to unacetylated, hypoacetylated, and repressively marked histones but not to hyperacetylated histones. Additionally, Set/TAF-Ibeta and pp32 associate with histone deacetylases in vitro and in vivo and repress transcription from a chromatin-integrated template in vivo. Finally, Set/TAF-Ibeta and pp32 associate with an endogenous estrogen receptor-regulated gene, EB1, in the hypoacetylated transcriptionally inactive state but not with the hyperacetylated transcriptionally active form. Together, these data define a novel in vivo mechanistic role for the mammalian Set/TAF-Ibeta and pp32 proteins as transducers of chromatin signaling by integrating chromatin hypoacetylation and transcriptional repression.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Chakravarti, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	debu@pharm.med.upenn.edu	Macfarlan, Todd/S-3750-2017	Macfarlan, Todd/0000-0003-2495-9809; Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065148, R01DK057079, R56DK065148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57079, DK65148, R01 DK057079, R01 DK065148] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM-007229] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brody JR, 2004, AM J PATHOL, V164, P273, DOI 10.1016/S0002-9440(10)63117-3; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	39	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30850	30855		10.1074/jbc.M404969200	http://dx.doi.org/10.1074/jbc.M404969200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136563	hybrid			2022-12-27	WOS:000222531900118
J	Lange, H; Muhlenhoff, U; Denzel, M; Kispal, G; Lill, R				Lange, H; Muhlenhoff, U; Denzel, M; Kispal, G; Lill, R			The heme synthesis defect of mutants impaired in mitochondrial iron-sulfur protein biogenesis is caused by reversible inhibition of ferrochelatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUSTER BIOSYNTHESIS; YEAST FRATAXIN; SACCHAROMYCES-CEREVISIAE; SCAFFOLD PROTEIN; MATURATION; HOMOLOG; DEFICIENCY; FRIEDREICH; ATAXIA; FERREDOXIN	Mitochondria are responsible for the synthesis of both iron-sulfur clusters and heme, but the potential connection between the two major iron-consuming pathways is unknown. Here, we have shown that mutants in the yeast mitochondrial iron-sulfur cluster (ISC) assembly machinery displayed reduced cytochrome levels and diminished activity of the heme-containing cytochrome c oxidase, in addition to iron-sulfur protein defects. In contrast, mutants in components of the mitochondrial ISC export machinery, which are specifically required for maturation of cytosolic iron-sulfur proteins, were not decreased in heme synthesis or cytochrome levels. Heme synthesis does not involve the function of mitochondrial ISC components, because immunological depletion of various ISC proteins from mitochondrial extracts did not affect the formation and amounts of heme. The heme synthesis defects of ISC mutants were found in vivo in isolated mitochondria and in mitochondrial detergent extracts and were confined to an inhibition of ferrochelatase, the enzyme catalyzing the insertion of iron into protoporphyrin IX. In support of these findings, immunopurification of ferrochelatase from ISC mutants restored its activity to wild-type levels. We conclude that the reversible inhibition of ferrochelatase is the molecular reason for the heme deficiency in ISC assembly mutants. This inhibitory mechanism may be used for regulation of iron distribution between the two iron-consuming processes.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Med Sch Pecs, Inst Biochem, H-7624 Pecs, Hungary	Philipps University Marburg; University of Pecs	Lill, R (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 6, D-35033 Marburg, Germany.	Lill@mailer.uni-marburg.de	Denzel, Martin/C-9047-2014	Denzel, Martin/0000-0002-5691-3349; Lill, Roland/0000-0002-8345-6518; Lange, Heike/0000-0002-8222-3448				ABBAS A, 1993, J BIOL CHEM, V268, P8541; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Bekri S, 2000, BLOOD, V96, P3256; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; Cossee M, 2000, HUM MOL GENET, V9, P1219, DOI 10.1093/hmg/9.8.1219; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Crisp RJ, 2003, J BIOL CHEM, V278, P45499, DOI 10.1074/jbc.M307229200; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARLOW E, 1998, USING ANTIBODIES LAB; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; Labbe-Bois Rosine, 1994, V11, P413; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; LILL R, 2003, NORD GUIDE RARE DISO, P374; MORGAN RO, 1979, CAN J NEUROL SCI, V6, P227, DOI 10.1017/S0317167100119699; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sambrook J., 2001, MOL CLONING LAB MANU; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Taketani S, 2000, EUR J BIOCHEM, V267, P4685, DOI 10.1046/j.1432-1327.2000.01519.x; Wilson RB, 2003, J NEUROL SCI, V207, P103, DOI 10.1016/S0022-510X(02)00432-X; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	58	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29101	29108		10.1074/jbc.M403721200	http://dx.doi.org/10.1074/jbc.M403721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128732	hybrid			2022-12-27	WOS:000222445300034
J	Sawchuk, DJ; Mansilla-Soto, J; Alarcon, C; Singha, NC; Langen, H; Bianchi, ME; Lees-Miller, SP; Nussenzweig, MC; Cortes, P				Sawchuk, DJ; Mansilla-Soto, J; Alarcon, C; Singha, NC; Langen, H; Bianchi, ME; Lees-Miller, SP; Nussenzweig, MC; Cortes, P			Ku70/Ku80 and DNA-dependent protein kinase catalytic subunit modulate RAG-mediated cleavage - Implications for the enforcement of the 12/23 rule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; MICE DEFICIENT; IN-VIVO; GENE; REPAIR; COMPLEX; TRANSPOSITION; INSIGHTS; SIGNALS; BINDING	The 12/23 rule is a critical step for regulation of V( D) J recombination. To date, only the RAG proteins and high mobility group protein 1 or 2 have been implicated in 12/23 regulation. Through protein fractionation and biochemical experiments, we find that Ku70/Ku80 and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) modulate RAG-mediated cleavage. Modulation of cleavage by Ku70/80 and DNA-PKcs results in preferential inhibition of 12/12 and 23/23 DNA cleavage, thus increasing 12/23 rule specificity. This observation indicates that DNA repair factors, Ku70/80 and DNA-PKcs, might be present upstream of the DNA cleavage events and not recruited downstream as is currently thought, assigning new nonrepair functions to the DNA-dependent protein kinase.	CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; F Hoffmann La Roche & Co Ltd, Genet, CH-4070 Basel, Switzerland; Univ Vita Salute San Raffaele, I-20132 Milan, Italy; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Roche Holding; Vita-Salute San Raffaele University; University of Calgary	Cortes, P (corresponding author), CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA.	patricia.cortes@mssm.edu	Nussenzweig, Michel/AAE-7292-2019; Bianchi, Marco Emilio/K-3417-2018	Bianchi, Marco Emilio/0000-0002-5329-6445; Lees-Miller, Susan/0000-0001-5809-2516	NIAID NIH HHS [AI45996-05, AI38890] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045996] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aidinis V, 1999, MOL CELL BIOL, V19, P6532; Bertocci B, 2003, IMMUNITY, V19, P203, DOI 10.1016/S1074-7613(03)00203-6; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; ISACKSON PJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P436, DOI 10.1016/0167-4838(83)90190-5; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kim DR, 1998, MOL CELL BIOL, V18, P4679, DOI 10.1128/MCB.18.8.4679; Larijani M, 1999, NUCLEIC ACIDS RES, V27, P2304, DOI 10.1093/nar/27.11.2304; Lee KB, 2000, J MOL BIOL, V304, P135, DOI 10.1006/jmbi.2000.4206; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Lew S, 2000, MOL CELL BIOL, V20, P7170, DOI 10.1128/MCB.20.19.7170-7177.2000; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Mansilla-Soto J, 2003, J EXP MED, V197, P543, DOI 10.1084/jem.20022210; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ono M, 1996, MOL IMMUNOL, V33, P787, DOI 10.1016/0161-5890(96)00030-2; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ronfani L, 2001, DEVELOPMENT, V128, P1265; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Schlissel MS, 2003, NAT REV IMMUNOL, V3, P890, DOI 10.1038/nri1225; Steen SB, 1996, GENES CELLS, V1, P543; Swanson PC, 2002, MOL CELL BIOL, V22, P7790, DOI 10.1128/MCB.22.22.7790-7801.2002; Thai TH, 2002, NAT IMMUNOL, V3, P457, DOI 10.1038/ni788; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; West RB, 1998, MOL CELL BIOL, V18, P6408, DOI 10.1128/MCB.18.11.6408	37	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29821	29831		10.1074/jbc.M403706200	http://dx.doi.org/10.1074/jbc.M403706200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123719	hybrid			2022-12-27	WOS:000222445300119
J	Stern, JC; Anderson, BJ; Owens, TJ; Schildbach, JF				Stern, JC; Anderson, BJ; Owens, TJ; Schildbach, JF			Energetics of the sequence-specific binding of single-stranded DNA by the F factor relaxase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; HEAT-CAPACITY CHANGES; CRYSTAL-STRUCTURE; TELOMERIC DNA; KH DOMAINS; RECOGNITION; SITE; ORIGIN; SSDNA; CLEAVAGE	Transfer of conjugative plasmids between bacteria requires the activity of relaxases or mobilization proteins. These proteins nick the plasmid in a site- and strand-specific manner prior to transfer of the cut strand from donor to recipient. TraI36, the relaxase domain of TraI from plasmid F factor, binds a single-stranded DNA (ssDNA) oligonucleotide containing an F factor sequence with high affinity and sequence specificity. To better understand the energetics of this interaction, we examined the temperature, salt, and pH dependence of TraI36 recognition. Binding is entropically driven below 25 degreesC and enthalpically driven at higher temperatures. van't Hoff analysis yields an estimated DeltaC(P)(0) of binding (-3300 cal mol(-1) K-1) that is larger and more negative than that observed for most double-stranded DNA (dsDNA)-binding proteins. Based on analyses of circular dichroism data and the crystal structure of the unliganded protein, we attribute the DeltaC(P)(0) to both burial of hydrophobic surface area and coupled folding and binding of the protein. The salt dependence of the binding indicates that several ssDNA phosphates are buried in the complex, and the pH dependence of the binding suggests that some of these ssDNA phosphates form ionic interactions with basic residues of the protein. Although data are available for relatively few sequence-specific ssDNA-binding proteins, sufficient differences exist between TraI36 and other proteins to indicate that, like dsDNA-binding proteins, ssDNA-binding proteins use different motifs and combinations of forces to achieve specific recognition.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schildbach, JF (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	joel@jhu.edu		Anderson, Brian/0000-0002-2426-9683; Schildbach, Joel/0000-0002-3038-9745	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackroyd PC, 2001, BIOCHEMISTRY-US, V40, P2911, DOI 10.1021/bi0023854; Anderson EM, 2003, BIOCHEMISTRY-US, V42, P3751, DOI 10.1021/bi027047c; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3842, DOI 10.1021/bi00516a027; Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Campos-Olivas R, 2002, P NATL ACAD SCI USA, V99, P10310, DOI 10.1073/pnas.152342699; Classen S, 2003, BIOCHEMISTRY-US, V42, P9269, DOI 10.1021/bi0273718; Classen S, 2001, J MOL BIOL, V314, P1113, DOI 10.1006/jmbi.2000.5191; Datta S, 2003, STRUCTURE, V11, P1369, DOI 10.1016/j.str.2003.10.001; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Gallagher K, 1998, BIOPHYS J, V75, P769, DOI 10.1016/S0006-3495(98)77566-6; Garvie CW, 2001, MOL CELL, V8, P937, DOI 10.1016/S1097-2765(01)00392-6; Goddard NL, 2000, PHYS REV LETT, V85, P2400, DOI 10.1103/PhysRevLett.85.2400; Guasch A, 2003, NAT STRUCT BIOL, V10, P1002, DOI 10.1038/nsb1017; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Hard T, 1996, BIOPHYS CHEM, V62, P121, DOI 10.1016/S0301-4622(96)02197-7; Harley MJ, 2002, BIOCHEMISTRY-US, V41, P6460, DOI 10.1021/bi011969i; Hickman AB, 2002, MOL CELL, V10, P327, DOI 10.1016/S1097-2765(02)00592-0; Horvath MP, 2001, J MOL BIOL, V310, P367, DOI 10.1006/jmbi.2001.4766; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Jen-Jacobson L, 2000, STRUCTURE, V8, P1015, DOI 10.1016/S0969-2126(00)00501-3; Kozlov AG, 1999, BIOCHEMISTRY-US, V38, P7388, DOI 10.1021/bi990309z; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Mitton-Fry RM, 2004, J MOL BIOL, V338, P241, DOI 10.1016/j.jmb.2004.01.063; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; OLMSTED MC, 1989, P NATL ACAD SCI USA, V86, P7766, DOI 10.1073/pnas.86.20.7766; Peersen OB, 2002, NAT STRUCT BIOL, V9, P182, DOI 10.1038/nsb761; Poon GMK, 2002, BIOCHEMISTRY-US, V41, P2361, DOI 10.1021/bi015572q; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P462; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; Sidorova NY, 2001, J MOL BIOL, V310, P801, DOI 10.1006/jmbi.2001.4781; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stern JC, 2001, BIOCHEMISTRY-US, V40, P11586, DOI 10.1021/bi010877q; Street LM, 2003, BBA-PROTEINS PROTEOM, V1646, P86, DOI 10.1016/S1570-9639(02)00553-8	35	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29155	29159		10.1074/jbc.M402965200	http://dx.doi.org/10.1074/jbc.M402965200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123728	hybrid			2022-12-27	WOS:000222445300041
J	Oestergaard, VH; Knudsen, BR; Andersen, AH				Oestergaard, VH; Knudsen, BR; Andersen, AH			Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; 2-GATE MECHANISM; PROTEIN CLAMP; YEAST; TRANSPORT; ALPHA; BISDIOXOPIPERAZINES; HYPERSENSITIVITY; INHIBITION; EXPRESSION	Topoisomerase II is an essential enzyme that is targeted by a number of clinically valuable anticancer drugs. One class referred to as topoisomerase II poisons works by increasing the cellular level of topoisomerase II-mediated DNA breaks, resulting in apoptosis. Another class of topoisomerase II-directed drugs, the bis-dioxopiperazines, stabilizes the conformation of the enzyme where it attains an inactive salt-stable closed clamp structure. Bis-dioxopiperazines, similar to topoisomerase II poisons, induce cell killing, but the underlying mechanism is presently unclear. In this study, we use three different biochemically well characterized human topoisomerase IIalpha mutant enzymes to dissect the catalytic requirements needed for the enzyme to cause dominant sensitivity in yeast to the bis-dioxopirazine ICRF193 and the topoisomerase II poison m-AMSA. We find that the clamp-closing activity, the DNA cleavage activity, and even both activities together are insufficient for topoisomerase II to cause dominant sensitivity to ICRF193 in yeast. Rather, the strand passage event per se is an absolute requirement, most probably because this involves a simultaneous interaction of the enzyme with two DNA segments. Furthermore, we show that the ability of human topoisomerase IIalpha to cause dominant sensitivity to m-AMSA in yeast does not depend on clamp closure or strand passage but is directly related to the capability of the enzyme to respond to m-AMSA with increased DNA cleavage complex formation.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Aarhus Univ, Dept Mol Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	aha@mb.au.dk	Oestergaard, Vibe Hallundbæk/B-7254-2015; Andersen, Anni/O-1162-2017	Oestergaard, Vibe Hallundbæk/0000-0002-1633-0560; Andersen, Anni/0000-0001-7194-3258; Knudsen, Birgitta Ruth/0000-0002-3484-3802				Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Hajji N, 2003, MUTAT RES-FUND MOL M, V530, P35, DOI 10.1016/S0027-5107(03)00135-0; Hasinoff BB, 1997, BIOCHEM PHARMACOL, V53, P1843, DOI 10.1016/S0006-2952(97)00013-0; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Huang KC, 2001, J BIOL CHEM, V276, P44488, DOI 10.1074/jbc.M104383200; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Jensen S, 1996, MOL CELL BIOL, V16, P3866; Kobayashi M, 2001, CANCER LETT, V166, P71, DOI 10.1016/S0304-3835(01)00447-5; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Oestergaard VH, 2004, J BIOL CHEM, V279, P28093, DOI 10.1074/jbc.M402120200; Oestergaard VH, 2004, J BIOL CHEM, V279, P1684, DOI 10.1074/jbc.M309624200; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; van Hille B, 1999, BRIT J CANCER, V81, P800, DOI 10.1038/sj.bjc.6690767; van Hille B, 1998, CANCER CHEMOTH PHARM, V42, P345, DOI 10.1007/s002800050828; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100	25	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28100	28105		10.1074/jbc.M402119200	http://dx.doi.org/10.1074/jbc.M402119200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123716	hybrid			2022-12-27	WOS:000222265400035
J	Park, SW; Vepachedu, R; Owens, RA; Vivanco, JM				Park, SW; Vepachedu, R; Owens, RA; Vivanco, JM			The N-glycosidase activity of the ribosome-inactivating protein ME1 targets single-stranded regions of nucleic acids independent of sequence or structural motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POKEWEED ANTIVIRAL PROTEIN; RICIN-A-CHAIN; POLYNUCLEOTIDE-ADENOSINE GLYCOSIDASE; CENTRAL CONSERVED REGION; RNA IDENTITY ELEMENTS; IN-VIVO; ALPHA-SARCIN; SYNTHETIC OLIGORIBONUCLEOTIDE; NONSPECIFIC DEADENYLATION; EUKARYOTIC RIBOSOMES	ME1, a type I ribosome-inactivating protein ( RIP), belongs to a family of enzymes long believed to possess rRNA N-glycosidase activity directed solely at the universally conserved residue A4324 in the sarcin/ricin loop of large eukaryotic and prokaryotic rRNAs. We have investigated the effect of modifying the structure of non-ribosomal RNA substrates on their interaction with ME1 and other RIPs. ME1 was shown to depurinate a variety of partially denatured nucleic acids, randomly removing adenine residues from single-stranded regions and, to a lesser extent, guanine residues from wobble base-pairs in hairpin stems. A defined sequence motif was not required for recognition of non-paired adenosines and cleavage of the N-glycosidic bond. Substrate recognition and ME1 activity appeared to depend on the physical availability of nucleotides, and denaturation of nucleic acid substrates increased their interaction with ME1. Pretreatment of mRNA at 75 degreesC rather than 60 degreesC, for example, lowered the apparent K-D from 87.1 to 73.9 nM, making it more vulnerable to depurination by RIPs. Exposure to ME1 in vitro completely abolished the infectivity of partially denatured RNA transcripts of the potato spindle tuber viroid, suggesting that RIPs may target invading nucleic acids before they reach host ribosomes in vivo. Our data suggest that the extensive folding of many potential substrates interferes with their ability to interact with RIPs, thereby blocking their inactivation by ME1 (or other RIPs).	Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA; Colorado State Univ, Cell & Mol Biol Program, Ft Collins, CO 80523 USA; ARS, Mol Plant Pathol Lab, USDA, Beltsville, MD 20705 USA	Colorado State University; Colorado State University; United States Department of Agriculture (USDA)	Vivanco, JM (corresponding author), Colorado State Univ, Dept Hort & Landscape Architecture, Shepardson Bldg,Rm 217, Ft Collins, CO 80523 USA.	j.vivanco@colostate.edu						Antal M, 2002, NUCLEIC ACIDS RES, V30, P912, DOI 10.1093/nar/30.4.912; ARON GM, 1980, ANTIMICROB AGENTS CH, V17, P1032, DOI 10.1128/AAC.17.6.1032; Au TK, 2000, FEBS LETT, V471, P169, DOI 10.1016/S0014-5793(00)01389-2; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1992, BIOCHEM J, V286, P1; Barbieri L, 2000, J BIOCHEM-TOKYO, V128, P883, DOI 10.1093/oxfordjournals.jbchem.a022827; Batey RT, 1998, RNA, V4, P984, DOI 10.1017/S1355838298980426; BAUMSTARK T, 1995, NUCLEIC ACIDS RES, V23, P4246, DOI 10.1093/nar/23.21.4246; Bink HHJ, 2002, P NATL ACAD SCI USA, V99, P13465, DOI 10.1073/pnas.202287499; Bonin M, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf080; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XY, 1998, BIOCHEMISTRY-US, V37, P11605, DOI 10.1021/bi980990p; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; CRESS DE, 1983, NUCLEIC ACIDS RES, V11, P6821, DOI 10.1093/nar/11.19.6821; DOMINGO C, 1994, PLANT MOL BIOL, V24, P725, DOI 10.1007/BF00029854; Draper DE, 1996, NAT STRUCT BIOL, V3, P397, DOI 10.1038/nsb0596-397; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ENDO Y, 1988, J BIOL CHEM, V263, P7917; ENDO Y, 1991, J MOL BIOL, V254, P848; Ferre-d'Amare AR, 1999, ANNU REV BIOPH BIOM, V28, P57, DOI 10.1146/annurev.biophys.28.1.57; GLUCK A, 1994, NUCLEIC ACIDS RES, V22, P321, DOI 10.1093/nar/22.3.321; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; He WJ, 2002, ARCH BIOCHEM BIOPHYS, V399, P181, DOI 10.1006/abbi.2001.2748; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hudak KA, 2000, RNA, V6, P369, DOI 10.1017/S1355838200991337; Hudak KA, 2002, RNA, V8, P1148, DOI 10.1017/S1355838202026638; LODGE JK, 1993, P NATL ACAD SCI USA, V90, P7089, DOI 10.1073/pnas.90.15.7089; MARCHANT A, 1995, J MOL BIOL, V254, P848, DOI 10.1006/jmbi.1995.0660; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; Nicolas E, 1997, FEBS LETT, V406, P162, DOI 10.1016/S0014-5793(97)00267-6; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Nielsen K, 2001, ANNU REV PLANT PHYS, V52, P785, DOI 10.1146/annurev.arplant.52.1.785; Nikolcheva T, 1999, J MOL BIOL, V292, P557, DOI 10.1006/jmbi.1999.3083; Orita M, 1996, NUCLEIC ACIDS RES, V24, P611, DOI 10.1093/nar/24.4.611; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; Panabieres F, 1995, MOL PLANT MICROBE IN, V8, P996, DOI 10.1094/MPMI-8-0996; Park SW, 2002, PLANT PHYSIOL, V130, P164, DOI 10.1104/pp.000794; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; PODLECKIS EV, 1993, J VIROL METHODS, V43, P147, DOI 10.1016/0166-0934(93)90072-Y; Rajamohan F, 1999, BIOCHEM BIOPH RES CO, V263, P419, DOI 10.1006/bbrc.1999.1335; Rajamohan F, 1999, BIOCHEM BIOPH RES CO, V260, P453, DOI 10.1006/bbrc.1999.0922; READY MP, 1986, P NATL ACAD SCI USA, V83, P5053, DOI 10.1073/pnas.83.14.5053; RIESNER D, 1990, SEMIN VIROL, V1, P83; Schrader O, 2003, NUCLEIC ACIDS RES, V31, P988, DOI 10.1093/nar/gkg193; Schroeder R, 2002, CURR OPIN STRUC BIOL, V12, P296, DOI 10.1016/S0959-440X(02)00325-1; SHAW JG, 1986, VIROLOGY, V148, P326, DOI 10.1016/0042-6822(86)90329-6; Steger G., 2003, Viroids, P15; STEIN A, 1976, BIOCHEMISTRY-US, V15, P157, DOI 10.1021/bi00646a024; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; Tang S, 2001, BBA-GENE STRUCT EXPR, V1519, P192, DOI 10.1016/S0167-4781(01)00236-6; Tanner MA, 1996, RNA, V2, P74; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x; Vepachedu R, 2003, PLANTA, V217, P498, DOI 10.1007/s00425-003-1014-7; Vivanco JM, 1999, PLANT PHYSIOL, V119, P1447, DOI 10.1104/pp.119.4.1447; Wassenegger M, 1996, VIROLOGY, V226, P191, DOI 10.1006/viro.1996.0646; Wu XJ, 1997, VIROLOGY, V239, P426, DOI 10.1006/viro.1997.8870; ZAMBONI M, 1989, BIOCHEM J, V259, P639, DOI 10.1042/bj2590639; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; Zhu YL, 2002, PLANT PHYSIOL, V130, P138, DOI 10.1104/pp.006403; Zoubenko O, 2000, PLANT MOL BIOL, V44, P219, DOI 10.1023/A:1006443626864; Zuker M., 1999, V70, P11	69	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34165	34174		10.1074/jbc.M400105200	http://dx.doi.org/10.1074/jbc.M400105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15123667	hybrid			2022-12-27	WOS:000223134800014
J	Cicchillo, RM; Baker, MA; Schnitzer, EJ; Newman, EB; Krebs, C; Booker, SJ				Cicchillo, RM; Baker, MA; Schnitzer, EJ; Newman, EB; Krebs, C; Booker, SJ			Escherichia coli L-serine deaminase requires a [4Fe-4S] cluster in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYASE ACTIVATING ENZYME; IRON-SULFUR PROTEINS; DOUBLE-RESONANCE CHARACTERIZATION; FORMATE-LYASE; PEPTOSTREPTOCOCCUS-ASACCHAROLYTICUS; <4FE-4S>+ CLUSTER; THREONINE DEHYDRATASE; S-ADENOSYLMETHIONINE; INHIBITOR BINDING; ACONITASE	L-Serine deaminases catalyze the deamination of L-serine, producing pyruvate and ammonia. Two families of these proteins have been described and are delineated by the cofactor that each employs in catalysis. These are the pyridoxal 5'-phosphate-dependent deaminases and the deaminases that are activated in vitro by iron and dithiothreitol. In contrast to the enzymes that employ pyridoxal 5'-phosphate, detailed physical and mechanistic characterization of the iron-dependent deaminases is limited, primarily because of their extreme instability. We report here the characterization of L-serine deaminase from Escherichia coli, which is the product of the sdaA gene. When purified anaerobically, the isolated protein contains 1.86 +/- 0.46 eq of iron and 0.670 +/- 0.019 eq of sulfide per polypeptide and displays a UV-visible spectrum that is consistent with a [4Fe-4S] cluster. Reconstitution of the protein with iron and sulfide generates considerably more of the cluster, and treatment of the reconstituted protein with dithionite gives rise to an axial EPR spectrum, displaying g\\ = 2.03 and g(perpendicular to) = 1.93. Mossbauer spectra of the Fe-57-reconstituted protein reveal that the majority of the iron is in the form of [4Fe-4S](2+) clusters, as evidenced by the typical Mossbauer parameters-isomer shift, delta = 0.47 mm/s, quadrupole splitting of DeltaE(Q) = 1.14 mm/s, and a diamagnetic (S = 0) ground state. Treatment of the dithionite-reduced protein with L-serine results in a slight broadening of the feature at g = 2.03 in the EPR spectrum of the protein, and a dramatic loss in signal intensity, suggesting that the amino acid interacts directly with the cluster.	Penn State Univ, Dept Biochem & Mol Biol, S Frear Lab 306, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Concordia Univ, Dept Biol, Montreal, PQ H3G 1M8, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Concordia University - Canada	Booker, SJ (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, S Frear Lab 306, University Pk, PA 16802 USA.	ckrebs@psu.edu; sjb14@psu.edu	Krebs, Carsten/D-4773-2009	Krebs, Carsten/0000-0002-3302-7053	NIGMS NIH HHS [GM-63847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Beinert H, 1978, Methods Enzymol, V54, P435; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EA, 1990, J GEN MICROBIOL, V136, P1017, DOI 10.1099/00221287-136-6-1017; CARTER JE, 1972, J BACTERIOL, V109, P757, DOI 10.1128/JB.109.2.757-763.1972; Chen DW, 2003, J AM CHEM SOC, V125, P11788, DOI 10.1021/ja036120z; Cosper MM, 2002, J AM CHEM SOC, V124, P14006, DOI 10.1021/ja0283044; Davis L., 1972, ENZYMES, V7, P33; DOWHAN W, 1970, J BIOL CHEM, V245, P4629; DOWHAN W, 1970, J BIOL CHEM, V245, P4618; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRABOWSKI R, 1991, EUR J BIOCHEM, V199, P89, DOI 10.1111/j.1432-1033.1991.tb16095.x; GRABOWSKI R, 1993, TRENDS BIOCHEM SCI, V18, P297, DOI 10.1016/0968-0004(93)90040-T; Hesslinger C, 1998, MOL MICROBIOL, V27, P477, DOI 10.1046/j.1365-2958.1998.00696.x; Hofmeister AEM, 1997, J BACTERIOL, V179, P4937, DOI 10.1128/jb.179.15.4937-4941.1997; HOFMEISTER AEM, 1993, EUR J BIOCHEM, V215, P341, DOI 10.1111/j.1432-1033.1993.tb18040.x; HOFMEISTER AEM, 1994, FEBS LETT, V351, P416, DOI 10.1016/0014-5793(94)00901-5; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENT TA, 1985, J BIOL CHEM, V260, P6871; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Krebs C, 2000, J AM CHEM SOC, V122, P12497, DOI 10.1021/ja003335p; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; MEISTER A, 1950, J BIOL CHEM, V184, P117; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; MUDD SH, 1965, BIOCHEM BIOPH RES CO, V19, P665; NEWMAN EB, 1990, BIOCHEM CELL BIOL, V68, P723, DOI 10.1139/o90-104; NEWMAN EB, 1985, J BACTERIOL, V162, P1270, DOI 10.1128/JB.162.3.1270-1275.1985; NEWMAN EB, 1980, CAN J BIOCHEM CELL B, V58, P1292, DOI 10.1139/o80-173; OGAWA H, 1989, J BIOL CHEM, V264, P15818; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; Rao PV, 2004, CHEM REV, V104, P527, DOI 10.1021/cr020615+; SHAO ZQ, 1993, EUR J BIOCHEM, V212, P777, DOI 10.1111/j.1432-1033.1993.tb17718.x; SU HS, 1989, J BACTERIOL, V171, P5095, DOI 10.1128/jb.171.9.5095-5102.1989; SU HS, 1993, EUR J BIOCHEM, V211, P521, DOI 10.1111/j.1432-1033.1993.tb17578.x; TELSER J, 1986, J BIOL CHEM, V261, P4840; UMBARGER HE, 1973, ADV ENZYMOL RAMB, V37, P349; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10533, DOI 10.1021/bi00498a016; YANOFSKY C, 1972, ENZYMES, V7, P1; Zinecker H, 1998, J BASIC MICROB, V38, P147, DOI 10.1002/(SICI)1521-4028(199805)38:2<147::AID-JOBM147>3.0.CO;2-M	47	35	37	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32418	32425		10.1074/jbc.M404381200	http://dx.doi.org/10.1074/jbc.M404381200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155761	hybrid			2022-12-27	WOS:000222849700055
J	Desaint, S; Luriau, S; Aude, JC; Rousselet, G; Toledano, MB				Desaint, S; Luriau, S; Aude, JC; Rousselet, G; Toledano, MB			Mammalian antioxidant Defenses are not inducible by H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; HYDROGEN-PEROXIDE; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; MICROARRAY ANALYSIS; CELLULAR-RESPONSE; REDOX REGULATION; P53; GROWTH; CELLS	As an approach to understanding how mammals regulate H2O2 intracellular concentration to prevent its toxicity, we analyzed the genome-wide mRNA profile changes of human cells after treatment with a non-toxic H2O2 concentration. We identified a large and essentially late H2O2 response of induced and repressed genes that unexpectedly comprise few or no antioxidants but mostly apoptosis and cell cycle control activities. The requirement of the p53 regulator for regulating about a third of this H2O2 stimulon and the lack of an associated enhancement of total cellular H2O2 scavenging activity further suggest that H2O2 elicits a stress antiproliferative/ repair response that does not increase antioxidant defenses. We conclude that mammalian antioxidant defenses are constitutive, a finding that contrasts with the oxidant-inducibility of such defenses in microorganisms. This finding might be important in understanding the role of H2O2 as a key signaling molecule in mammals.	CEA Saclay, Lab Stress Oxydants & Canc, Serv Biol Mol Syst, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, Lab Physiogenom, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Toledano, MB (corresponding author), CEA Saclay, Lab Stress Oxydants & Canc, Serv Biol Mol Syst, F-91191 Gif Sur Yvette, France.	toledano@jonas.saclay.cea.fr	Rousselet, Germain/E-3525-2018; AUDE, Jean-Christophe/C-7111-2011	Rousselet, Germain/0000-0002-1710-1639; AUDE, Jean-Christophe/0000-0002-1755-7417				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chuang YYE, 2002, CANCER RES, V62, P6246; De Nigris F, 2001, ANTIOXID REDOX SIGN, V3, P1119, DOI 10.1089/152308601317203620; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jurado J, 2003, J BIOL CHEM, V278, P45546, DOI 10.1074/jbc.M307866200; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Menendez S, 2003, J BIOL CHEM, V278, P18720, DOI 10.1074/jbc.M211007200; Nakamura Y, 2003, BIOCHEMISTRY-US, V42, P4300, DOI 10.1021/bi0340090; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Schonhoff CM, 2002, BIOCHEMISTRY-US, V41, P13570, DOI 10.1021/bi026262q; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Toledano MB, 2003, TOP CURR GENET, V1, P241; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	37	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31157	31163		10.1074/jbc.M401888200	http://dx.doi.org/10.1074/jbc.M401888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155764	hybrid			2022-12-27	WOS:000222726800032
J	Fabbro, M; Savage, K; Hobson, K; Deans, AJ; Powell, SN; McArthur, GA; Khanna, KK				Fabbro, M; Savage, K; Hobson, K; Deans, AJ; Powell, SN; McArthur, GA; Khanna, KK			BRCA1-BARD1 complexes are required for p53(Ser-15) phosphorylation and a G(1)/S arrest following ionizing radiation-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; TELANGIECTASIA-MUTATED ATM; S-PHASE CHECKPOINT; HISTONE H2AX; CELL-CYCLE; DEPENDENT PHOSPHORYLATION; BRCA1; CHK1; KINASE; CANCER	BRCA1 is a major player in the DNA damage response. This is evident from its loss, which causes cells to become sensitive to a wide variety of DNA damaging agents. The major BRCA1 binding partner, BARD1, is also implicated in the DNA damage response, and recent reports indicate that BRCA1 and BARD1 co-operate in this pathway. In this report, we utilized small interfering RNA to deplete BRCA1 and BARD1 to demonstrate that the BRCA1-BARD1 complex is required for ATM/ ATR (ataxia-telangiectasia-mutated/ATM and Rad3-related)mediated phosphorylation of p53(Ser-15) following IR- and UV radiation-induced DNA damage. In contrast, phosphorylation of a number of other ATM/ ATR targets including H2AX, Chk2, Chk1, and c-jun does not depend on the presence of BRCA1-BARD1 complexes. Moreover, prior ATM/ ATR-dependent phosphorylation of BRCA1 at Ser-1423 or Ser-1524 regulates the ability of ATM/ ATR to phosphorylate p53(Ser-15) efficiently. Phosphorylation of p53(Ser-15) is necessary for an IR-induced G(1)/S arrest via transcriptional induction of the cyclin-dependent kinase inhibitor p21. Consistent with these data, repressing p53(Ser-15) phosphorylation by BRCA1-BARD1 depletion compromises p21 induction and the G(1)/S checkpoint arrest in response to IR but not UV radiation. These findings suggest that BRCA1-BARD1 complexes act as an adaptor to mediate ATM/ ATR-directed phosphorylation of p53, influencing G(1)/S cell cycle progression after DNA damage.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Queensland, Sch Med, Cent Clin Div, Brisbane, Qld 4072, Australia; Peter MacCallum Canc Inst, Oncol Mol Lab, Melbourne 3002, Australia; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Peter Maccallum Cancer Center; Harvard University; Massachusetts General Hospital	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.	kumkumK@qimr.edu.au	Hobson, Keith/Q-9306-2019; Deans, Andrew/U-3515-2019; Deans, Andrew J/E-5817-2011; Khanna, Kum Kum/I-1747-2013	Deans, Andrew/0000-0002-5271-4422; Deans, Andrew J/0000-0002-5271-4422; Savage, Kienan/0000-0002-4898-899X; Khanna, Kum Kum/0000-0001-8650-5381				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Lee JH, 2003, MOL CANCER RES, V1, P674; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu QH, 2000, GENE DEV, V14, P1448; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Okubo E, 2003, J VIROL, V77, P1257, DOI 10.1128/JVI.77.2.1257-1267.2003; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	62	116	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31251	31258		10.1074/jbc.M405372200	http://dx.doi.org/10.1074/jbc.M405372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159397	hybrid			2022-12-27	WOS:000222726800044
J	Gourbal, B; Sonuc, N; Bhattacharjee, H; Legare, D; Sundar, S; Ouellette, M; Rosen, BP; Mukhopadhyay, R				Gourbal, B; Sonuc, N; Bhattacharjee, H; Legare, D; Sundar, S; Ouellette, M; Rosen, BP; Mukhopadhyay, R			Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPLIFIED H-CIRCLE; MOLECULAR CHARACTERIZATION; SODIUM STIBOGLUCONATE; PENTAVALENT ANTIMONY; GENE AMPLIFICATION; TARENTOLAE; ARSENITE; AMASTIGOTES; ACCUMULATION; PURIFICATION	Leishmaniasis is a protozoan parasitic disease that affects 12 million people worldwide. The first line choice for the treatment of this disease is antimonial drugs. In the endemic regions, resistance to this class of drugs is a major impediment to treatment. Microbes often become resistant to drugs by mutation or down-regulation of uptake systems, but the uptake system for the antimonial drugs in Leishmania is unknown. In other organisms, aquaglyceroporins have been shown to facilitate uptake of trivalent metalloids. In this study, we report the identification and characterization of aquaglyceroporins from Leishmania major (LmAQP1) and Leishmania tarentolae (LtAQP1), respectively. These Leishmania proteins have the conserved signature motifs of aquaglyceroporins. Transfection of LmAQP1 into three species of Leishmania, L. tarentolae, Leishmania infantum, and L. major, produced hypersensitivity to both As(III) and Sb(III) in all three strains. Increased production of LmAQP1 was detected by immunoblotting. Drug-resistant parasites with various mutations leading to resistance mechanisms became hypersensitive to both metalloids after expression of LmAQP1. Increased rates of uptake of As( III) or Sb( III) correlated with metalloid sensitivity of the wild type and drug-resistant transfectants. Transfection of LmAQP1 in a Pentostam-resistant field isolate also sensitized the parasite in the macrophage-associated amastigote form. One allele of LmAQP1 was disrupted in L. major, and the resulting cells became 10-fold more resistant to Sb( III). This is the first report of the uptake of a metalloid drug by an aquaglyceroporin in Leishmania, suggesting a strategy to reverse resistance in the field.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Laval, Dept Microbiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Munich, Klinikum Grosshadern, Dept Med 2, D-81377 Munich, Germany; Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India	Wayne State University; Laval University; Laval University; University of Munich; Banaras Hindu University (BHU)	Mukhopadhyay, R (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	rmukhopa@med.wayne.edu	Ouellette, Marc/K-8694-2017; GOURBAL, Benjamin E.F./B-3743-2010	Ouellette, Marc/0000-0002-6743-9646; GOURBAL, Benjamin E.F./0000-0003-2097-2563; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM2216-08] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brochu C, 2003, ANTIMICROB AGENTS CH, V47, P3073, DOI 10.1128/AAC.47.10.3073-3079.2003; Choi Christine M, 2002, Am J Clin Dermatol, V3, P91, DOI 10.2165/00128071-200203020-00003; CROFT SL, 1981, COMP BIOCHEM PHYS C, V68, P95, DOI 10.1016/0306-4492(81)90043-5; SILVA Eduardo Sérgio da, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P145, DOI 10.1590/S0036-46652002000300006; DENTON H, 2004, IN PRESS BIOCH J; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1994, MOL BIOCHEM PARASIT, V67, P49, DOI 10.1016/0166-6851(94)90095-7; Ferreira CD, 2003, BIOMETALS, V16, P441, DOI 10.1023/A:1022823605068; Guerin PJ, 2002, LANCET INFECT DIS, V2, P564, DOI 10.1016/S1473-3099(02)00372-9; Guimond C, 2003, NUCLEIC ACIDS RES, V31, P5886, DOI 10.1093/nar/gkg806; Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0; Haimeur A, 1998, ANTIMICROB AGENTS CH, V42, P1689, DOI 10.1128/AAC.42.7.1689; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lira R, 1999, J INFECT DIS, V180, P564, DOI 10.1086/314896; Liu ZJ, 2004, J BIOL CHEM, V279, P17312, DOI 10.1074/jbc.M314006200; Liu ZJ, 2002, P NATL ACAD SCI USA, V99, P6053, DOI 10.1073/pnas.092131899; MOTTRAM JC, 1985, EXP PARASITOL, V59, P151, DOI 10.1016/0014-4894(85)90067-0; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; Ouellette M, 1998, DRUG RESIST UPDATE, V1, P43, DOI 10.1016/S1368-7646(98)80213-6; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; Ramirez-Solis A, 2004, INORG CHEM, V43, P2954, DOI 10.1021/ic0351592; ROBERTS WL, 1995, ANTIMICROB AGENTS CH, V39, P1234, DOI 10.1128/AAC.39.6.1234; ROBERTS WL, 1993, ANTIMICROB AGENTS CH, V37, P1842, DOI 10.1128/AAC.37.9.1842; Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanders OI, 1997, J BACTERIOL, V179, P3365, DOI 10.1128/jb.179.10.3365-3367.1997; Sereno D, 1998, ANTIMICROB AGENTS CH, V42, P3097, DOI 10.1128/AAC.42.12.3097; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001; Shaked-Mishan P, 2001, J BIOL CHEM, V276, P3971, DOI 10.1074/jbc.M005423200; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Tsukaguchi H, 1999, AM J PHYSIOL-RENAL, V277, pF685, DOI 10.1152/ajprenal.1999.277.5.F685; WHITE TC, 1988, J BIOL CHEM, V263, P16977; Wysocki R, 2001, MOL MICROBIOL, V40, P1391, DOI 10.1046/j.1365-2958.2001.02485.x	37	195	202	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31010	31017		10.1074/jbc.M403959200	http://dx.doi.org/10.1074/jbc.M403959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138256	hybrid			2022-12-27	WOS:000222726800014
J	Morikawa, Y; Goto, T; Momose, F				Morikawa, Y; Goto, T; Momose, F			Human immunodeficiency virus type 1 Gag assembly through assembly intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA-VIRUS; CRYSTAL-STRUCTURE; CAPSID PROTEIN; DELETION MUTANTS; ESCHERICHIA-COLI; PARTICLES; MYRISTOYLATION; PRECURSOR; HIV; IDENTIFICATION	Human immunodeficiency virus Gag protein self-assembles into spherical particles, and recent reports suggest the formation of assembly intermediates during the process. To understand the nature of such assembly intermediates along with the mechanism of Gag assembly, we employed expression in Escherichia coli and an in vitro assembly reaction. When E. coli expression was performed at 37 degreesC, Gag predominantly assembled to a high order of multimer, apparently equivalent to the virus-like particles obtained following Gag expression in eukaryotic cells, through the formation of low orders of multimer characterized with a discreet sedimentation value of 60 S. Electron microscopy confirmed the presence of spherical particles in the E. coli cells. In contrast, expression at 30 degreesC resulted in the production of only the 60 S form of Gag multimer, and crescent-shaped structures or small patches with double electrondense layers were accumulated, but no complete particles. In vitro assembly reactions using purified Gag protein, when performed at 37 degreesC, also produced the high order of Gag multimers with some 60 S multimers, whereas the 30 degreesC reaction produced only the 60 S multimers. However, when the 60 S multimers were crosslinked so as not to allow conformational changes, in vitro assembly reactions at 37 degreesC did not produce any higher order of multimers. ATP depletion did not halt Gag assembly in the E. coli cells, and the addition of GroEL-GroES to in vitro reactions did not facilitate Gag assembly, indicating that conformational changes rather than protein refolding by chaperonins, induced at 37 degreesC, were solely responsible for the Gag assembly observed here. We suggest that Gag assembles to a capsid through the formation of the 60 S multimer, possibly a key intermediate of the assembly process, accompanied with conformational changes in Gag.	Kitasato Univ, Kitasato Inst Life Sci, Minato Ku, Tokyo 1088641, Japan; Kyoto Univ, Coll Med Technol, Sakyo Ku, Kyoto 6068507, Japan	Kitasato University; Kyoto University	Morikawa, Y (corresponding author), Kitasato Univ, Kitasato Inst Life Sci, Minato Ku, Shirokane 5-9-1, Tokyo 1088641, Japan.	morikawa@lisci.kitasato-u.ac.jp						Berthet-Colominas C, 1999, EMBO J, V18, P1124, DOI 10.1093/emboj/18.5.1124; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; Campbell S, 1997, J VIROL, V71, P4425, DOI 10.1128/JVI.71.6.4425-4435.1997; CARRIERE C, 1995, J VIROL, V69, P2366; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Forster MJ, 2000, J MOL BIOL, V298, P841, DOI 10.1006/jmbi.2000.3715; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; Hong S, 2001, J VIROL, V75, P2526, DOI 10.1128/JVI.75.6.2526-2534.2001; HOSHIKAWA N, 1991, J GEN VIROL, V72, P2509, DOI 10.1099/0022-1317-72-10-2509; Kihara A, 1998, J BIOL CHEM, V273, P29770, DOI 10.1074/jbc.273.45.29770; KLIKOVA M, 1995, J VIROL, V69, P1093, DOI 10.1128/JVI.69.2.1093-1098.1995; Lee YM, 1999, J VIROL, V73, P5654, DOI 10.1128/JVI.73.7.5654-5662.1999; Lee YM, 1998, VIROLOGY, V243, P78, DOI 10.1006/viro.1998.9064; Lingappa JR, 1997, J CELL BIOL, V136, P567, DOI 10.1083/jcb.136.3.567; Ma YM, 2004, J VIROL, V78, P52, DOI 10.1128/JVI.78.1.52-60.2004; Ma YM, 2002, J VIROL, V76, P5452, DOI 10.1128/JVI.76.11.5452-5462.2002; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morikawa Y, 1999, J BIOL CHEM, V274, P27997, DOI 10.1074/jbc.274.39.27997; Morikawa Y, 2000, J VIROL, V74, P16, DOI 10.1128/JVI.74.1.16-23.2000; Morikawa Y, 2001, VIROLOGY, V283, P343, DOI 10.1006/viro.2001.0886; Nermut MV, 2003, VIROLOGY, V305, P219, DOI 10.1006/viro.2002.1692; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; Perrin-Tricaud C, 1999, VIROLOGY, V255, P20, DOI 10.1006/viro.1998.9573; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; ROSE JR, 1995, J VIROL, V69, P2751; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; Tritel M, 2000, J VIROL, V74, P5845, DOI 10.1128/JVI.74.13.5845-5855.2000; Tritel M, 2001, J VIROL, V75, P5473, DOI 10.1128/JVI.75.12.5473-5481.2001; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Wang JJ, 2001, APPL IMMUNOHISTO M M, V9, P371, DOI 10.1097/00022744-200112000-00014; Weldon RA, 1998, J VIROL, V72, P3098, DOI 10.1128/JVI.72.4.3098-3106.1998; Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a	48	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31964	31972		10.1074/jbc.M313432200	http://dx.doi.org/10.1074/jbc.M313432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152006	hybrid			2022-12-27	WOS:000222726800125
J	Yun, JS; Tomida, A; Andoh, T; Tsuruo, T				Yun, JS; Tomida, A; Andoh, T; Tsuruo, T			Interaction between glucose-regulated destruction domain of DNA topoisomerase II alpha and MPN domain of Jab1/CSN5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E1A-INDUCED APOPTOSIS; NUCLEAR-LOCALIZATION SIGNALS; CANCER CELL-LINE; COP9 SIGNALOSOME; DEPENDENT REGULATION; UBIQUITIN SYSTEM; DIRECTED DRUGS; SOLID TUMORS; DEGRADATION; RESISTANCE	DNA topoisomerase (topo) IIalpha, an essential enzyme for cell proliferation, is targeted to a proteasome-dependent degradation pathway when human tumor cells are glucose-starved. Here we show that the topo IIalpha destabilization depends on the newly identified domain, GRDD (glucose-regulated destruction domain), which was mapped to the N-terminal 70 - 170 amino acid sequence. Indeed, the deletion of GRDD conferred a stable feature on topo IIalpha, whereas the fusion of GRDD rendered green fluorescent protein unstable under glucose starvation conditions. Nuclear localization was a prerequisite for GRDD function, because the inhibition of nuclear translocation resulted in the suppression of GRDD-mediated topo IIalpha degradation. Further, GRDD was identified as an interactive domain for Jab1/CSN5, which promoted the degradation of topo IIalpha in a manner dependent on the MPN (Mpr1p/ Prd1p N terminus) domain. Depleting Jab1/CSN5 by antisense oligonucleotide and treating cells with the CSN-associated kinase inhibitor, curcumin, inhibited topo IIalpha degradation induced by glucose starvation. These findings demonstrate that GRDD can act as a stress-activated degron for regulating topo IIalpha stability, possibly through interaction with the MPN domain of Jab1/CSN5.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Soka Univ, Fac Engn, Dept Bioengn, Tokyo 1920003, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Soka University; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp						Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Brown JM, 1998, CANCER RES, V58, P1408; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Dingemans AMC, 1998, BBA-GENE STRUCT EXPR, V1400, P275, DOI 10.1016/S0167-4781(98)00141-9; HARKER WG, 1995, CANCER RES, V55, P1707; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; HSIANG YH, 1988, CANCER RES, V48, P3230; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kim HD, 1999, J CELL PHYSIOL, V180, P97, DOI 10.1002/(SICI)1097-4652(199907)180:1<97::AID-JCP11>3.0.CO;2-Y; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Mirski SEL, 1997, EXP CELL RES, V237, P452, DOI 10.1006/excr.1997.3805; MIRSKI SEL, 1995, CANCER RES, V55, P2129; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; NAKAJIMA T, 1995, ONCOGENE, V10, P651; Ogiso Y, 2000, CANCER RES, V60, P2429; Ogiso Y, 2002, CANCER RES, V62, P5008; Salmena L, 2001, BIOCHEM PHARMACOL, V61, P795, DOI 10.1016/S0006-2952(01)00580-9; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SULLIVAN DM, 1987, CANCER RES, V47, P3973; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; VASSETZKY YS, 1995, BIOESSAYS, V17, P767, DOI 10.1002/bies.950170906; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Yu Q, 1997, BIOCHEMISTRY-US, V36, P5868, DOI 10.1021/bi962400y; Yun J, 1995, ONCOL RES, V7, P583	44	27	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31296	31303		10.1074/jbc.M401411200	http://dx.doi.org/10.1074/jbc.M401411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15126503	hybrid			2022-12-27	WOS:000222726800049
J	Abecassis, L; Rogier, E; Vazquez, A; Atfi, A; Bourgeade, MF				Abecassis, L; Rogier, E; Vazquez, A; Atfi, A; Bourgeade, MF			Evidence for a role of MSK1 in transforming growth factor-beta-mediated responses through p38 alpha and Smad signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TGF-BETA; FUNCTIONAL-CHARACTERIZATION; C-JUN; TRANSCRIPTION; MAPK; TRANSDUCTION; EXPRESSION; PROMOTER; ISOFORMS	Smad proteins are central mediators of the transforming growth factor-beta (TGF-beta) superfamily signaling. The mitogen-activated protein kinase (MAPK) p38 is also one of the downstream targets required for TGF-beta-mediated responses. Although the interplay between the p38 and Smad signaling pathways might allow cells to display diverse patterns of responses to TGF-beta, the mechanism of this cross-talk is not well established. We report here that inhibition of the p38alpha isoform suppressed the ability of Smad3 to mediate TGF-beta-induced transcriptional responses. The inhibition of p38 activity blocked TGF-beta-mediated phosphorylation of the MSK1 kinase, a substrate of p38 that plays an important role in the remodeling of chromatin. Moreover, we observed that expression of dominant-interfering mutants of MSK1 blocked the binding of Smad3 to the coactivator p300 in response to TGF-beta signaling. These data reveal a new mechanism whereby the Smad signaling pathway and the p38 cascade are integrated in the nucleus to activate gene expression.	Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, France; Hop St Antoine, INSERM, U482, F-75771 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bourgeade, MF (corresponding author), Hop Paul Brousse, INSERM, U542, Batiment Lavoisier,14 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	bourgeade@vjf.inserm.fr						Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Hale KK, 1999, J IMMUNOL, V162, P4246; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Markou T, 2002, BIOCHEM J, V365, P757, DOI 10.1042/BJ20011828; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2001, J CELL SCI, V114, P4359; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Yue JB, 2000, METH MOL B, V142, P125	20	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30474	30479		10.1074/jbc.M403294200	http://dx.doi.org/10.1074/jbc.M403294200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133024	hybrid			2022-12-27	WOS:000222531900075
J	Chiang, CS; Stacey, G; Tsay, YF				Chiang, CS; Stacey, G; Tsay, YF			Mechanisms and functional properties of two peptide transporters, AtPTR2 and fPTR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED OLIGOPEPTIDE TRANSPORTER; NITRATE TRANSPORTER; PEPTIDE/HISTIDINE TRANSPORTER; TISSUE DISTRIBUTION; EXPRESSION CLONING; LACTOCOCCUS-LACTIS; MOLECULAR-CLONING; ESCHERICHIA-COLI; ARABIDOPSIS; GENE	The Arabidopsis AtPTR2 and fungal fPTR2 genes, which encode H+/dipeptide cotransporters, belong to two different subgroups of the peptide transporter (PTR) (NRT1) family. In this study, the kinetics, substrate specificity, stoichiometry, and voltage dependence of these two transporters expressed in Xenopus oocytes were investigated using the two-microelectrode voltage-clamp method. The results showed that: 1) although AtPTR2 belongs to the same PTR family subgroup as certain H+/nitrate cotransporters, neither AtPTR2 nor fPTR2 exhibited any nitrate transporting activity; 2) AtPTR2 and fPTR2 transported a wide spectrum of dipeptides with apparent affinity constants in the range of 30 muM to 3 mM, the affinity being dependent on the side chain structure of both the N- and C-terminal amino acids; 3) larger maximal currents (I-max) were evoked by positively charged dipeptides in AtPTR2- or fPTR2-injected oocytes; 4) a major difference between AtPTR2 and fPTR2 was that, whereas fPTR2 exhibited low Ala-Asp(-) transporting activity, AtPTR2 transported Ala-Asp(-) as efficiently as some of the positively charged dipeptides; 5) kinetic analysis suggested that both fPTR2 and AtPTR2 transported by a random binding, simultaneous transport mechanism. The results also showed that AtPTR2 and fPTR2 were quite distinct from PepT1 and PepT2, two well characterized animal PTR transporters in terms of order of binding of substrate and proton(s), pH sensitivity, and voltage dependence.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Univ Missouri, Dept Microbiol & Plant Pathol, Columbia, MO 65211 USA	Academia Sinica - Taiwan; University of Missouri System; University of Missouri Columbia	Tsay, YF (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	yftsay@gate.sinica.edu.tw	Tsay, Yi-Fang/ABB-3662-2021	Tsay, Yi-Fang/0000-0003-4271-0687				Amasheh S, 1997, J MEMBRANE BIOL, V155, P247, DOI 10.1007/s002329900177; Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; BASRAI MA, 1995, MICROBIOL-UK, V141, P1147, DOI 10.1099/13500872-141-5-1147; Boll M, 1996, P NATL ACAD SCI USA, V93, P284, DOI 10.1073/pnas.93.1.284; CAO YW, 1992, PLANT CELL, V4, P961, DOI 10.1105/tpc.4.8.961; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; DANIEL H, 1992, J BIOL CHEM, V267, P9565; Fang G, 2000, J BACTERIOL, V182, P2530, DOI 10.1128/JB.182.9.2530-2535.2000; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FROMMER WB, 1994, FEBS LETT, V347, P185, DOI 10.1016/0014-5793(94)00533-8; HAGTING A, 1994, J BIOL CHEM, V269, P11391; Herrera-Ruiz D, 2003, J PHARM SCI-US, V92, P691, DOI 10.1002/jps.10303; Huang NC, 1996, PLANT CELL, V8, P2183, DOI 10.1105/tpc.8.12.2183; Huang NC, 1999, PLANT CELL, V11, P1381, DOI 10.1105/tpc.11.8.1381; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lauter FR, 1996, P NATL ACAD SCI USA, V93, P8139, DOI 10.1073/pnas.93.15.8139; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lin CM, 2000, PLANT PHYSIOL, V122, P379, DOI 10.1104/pp.122.2.379; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Miyamoto K, 1996, BBA-GENE STRUCT EXPR, V1305, P34, DOI 10.1016/0167-4781(95)00208-1; MULDIN I, 1995, PLANT PHYSIOL, V108, P1341; Nakajima H, 1997, APPL ENVIRON MICROB, V63, P2213, DOI 10.1128/AEM.63.6.2213-2217.1997; PAULSEN IT, 1994, TRENDS BIOCHEM SCI, V19, P404, DOI 10.1016/0968-0004(94)90087-6; PERRY JR, 1994, MOL CELL BIOL, V14, P104, DOI 10.1128/MCB.14.1.104; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Roche JP, 1998, J NEUROSCI, V18, P4883; Roman G, 1998, AM J PHYSIOL-CELL PH, V275, pC857, DOI 10.1152/ajpcell.1998.275.3.C857; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; Sakata K, 2001, BIOCHEM J, V356, P53, DOI 10.1042/0264-6021:3560053; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Song W, 1996, PLANT PHYSIOL, V110, P171, DOI 10.1104/pp.110.1.171; Stacey G, 2002, TRENDS PLANT SCI, V7, P257, DOI 10.1016/S1360-1385(02)02249-5; STEINER HY, 1994, PLANT CELL, V6, P1289, DOI 10.1105/tpc.6.9.1289; Steiner HY, 2000, PLANT CELL, V12, P2295; Szczyglowski K, 1997, PLANT PHYSIOL, V114, P1335, DOI 10.1104/pp.114.4.1335; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; West CE, 1998, PLANT J, V15, P221, DOI 10.1046/j.1365-313X.1998.00199.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yamashita T, 1997, J BIOL CHEM, V272, P10205; Zhou JJ, 1998, J BIOL CHEM, V273, P12017, DOI 10.1074/jbc.273.20.12017	43	69	72	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30150	30157		10.1074/jbc.M405192200	http://dx.doi.org/10.1074/jbc.M405192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138259	hybrid			2022-12-27	WOS:000222531900036
J	Gu, Y; Lin, Q; Childress, C; Yang, WN				Gu, Y; Lin, Q; Childress, C; Yang, WN			Identification of the region in Cdc42 that confers the binding specificity to activated Cdc42-associated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONRECEPTOR TYROSINE KINASE; ALDRICH SYNDROME PROTEIN; ACTIN CYTOSKELETON; C-ELEGANS; GTPASE; COMPLEX; DOMAIN; TARGET; EFFECTOR; FAMILY	The Rho family small G-protein Cdc42 has been implicated in a diversity of biological functions. Multiple downstream effectors have been identified. How Cdc42 discriminates the interaction with its multiple downstream effectors is not known. Activated Cdc42-associated tyrosine kinase (ACK) is a very specific effector of Cdc42. To delineate the Cdc42 signaling pathway mediated by ACK, we set about to identify the specific ACK-binding region in Cdc42. We utilized TC10, another member of the Rho family of G-proteins that is 66.7% identical to Cdc42, to construct TC10/Cdc42 chimeras for screening the specific ACK-binding region in Cdc42. A region between switch I and switch II has been identified as the specific ACK-binding ( AB) region. The replacement of the AB region with the corresponding region in TC10 resulted in the complete loss of ACK-binding ability but did not affect the binding to WASP, suggesting that the AB region confers the binding specificity to ACK. On the other hand, replacement of the corresponding region of TC10 with the AB region enabled TC10 to acquire ACK-binding ability. Eight residues are different between the AB region and the corresponding region of TC10. The mutational analysis indicated that all eight residues contribute to the binding to ACK2. The assays for the Cdc42-mediated activation of ACK2 indicated that the AB region is essential for Cdc42 to activate ACK2 in cells. Thus, our studies have defined a specific ACK-binding region in Cdc42 and have provided a molecular basis for generating ACK binding-defective mutants of Cdc42 to delineate ACK-mediated signaling pathway.	Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Yang, WN (corresponding author), Weis Ctr Res, Geisinger Clin, 100 N Acad Ave, Danville, PA 17822 USA.	wyang1@geisinge.edu						Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Coon M, 2002, J CELL BIOCHEM, V84, P655, DOI 10.1002/jcb.10078; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	31	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30507	30513		10.1074/jbc.M313518200	http://dx.doi.org/10.1074/jbc.M313518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123659	hybrid			2022-12-27	WOS:000222531900079
J	Hartman, HL; Bowers, KE; Fierke, CA				Hartman, HL; Bowers, KE; Fierke, CA			Lysine beta 311 of protein geranylgeranyltransferase type I partially replaces magnesium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE BINDING; FARNESYL-TRANSFERASE; FLUORESCENCE ASSAY; METAL REQUIREMENTS; KINETIC MECHANISM; MAMMALIAN-CELLS; FARNESYLTRANSFERASE; RAT; PRENYLTRANSFERASES; PRENYLATION	Protein geranylgeranyltransferase type I (GGTase I) catalyzes the attachment of a geranylgeranyl lipid group near the carboxyl terminus of protein substrates. Unlike protein farnesyltransferase (FTase) and protein geranylgeranyltransferase type II, which require both Zn(II) and Mg(II) for maximal turnover, GGTase I turnover is dependent only on Zn(II). In FTase, the magnesium ion is coordinated by aspartate beta352 and the diphosphate of farnesyl diphosphate to stabilize the developing charge in the transition state (Pickett, J. S., Bowers, K. E., and Fierke, C. A. (2003) J. Biol. Chem. 278, 51243-51250). In GGTase I, lysine beta311 is substituted for this aspartate and is proposed to replace the catalytic function of Mg(II) (Taylor, J. S., Reid, T. S., Terry, K. L., Casey, P. J., and Beese, L. S. (2003) EMBO J. 22, 5963-5974). Here we demonstrate that the prenylation rate constant catalyzed by wild type GGTase I (k(chem) = 0.18 +/- 0.02 s(-1)) is not dependent on Mg(II), is similar to20-fold slower than the maximal rate constant catalyzed by FTase, and has a single pK(a) of 6.4 +/- 0.1, likely reflecting deprotonation of the peptide thiol. Mutation of lysine beta311 in GGTase I to alanine (Kbeta311A) or aspartate (Kbeta311D) decreases the k(chem) in the absence of magnesium 9-41fold without significantly affecting the binding affinity of either substrate. Furthermore, the geranylgeranylation rate constant is enhanced by the addition of Mg(II) for Kbeta311A and Kbeta311D GGTase I 2-5- fold compared with wild type GGTase I with K-Mg of 140 +/- 10 mM and 6.4 +/- 0.8 mM, respectively. These results demonstrate that lysine beta311 of GGTase I partially replaces the catalytic function of Mg(II) observed in FTase.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fierke, CA (corresponding author), Univ Michigan, Dept Chem, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	fierke@umich.edu			NCI NIH HHS [F32CA84757] Funding Source: Medline; NIGMS NIH HHS [GM07767, GM40602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA084757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040602, R29GM040602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bowers KE, 2004, BIOCHEMISTRY-US, V43, P5256, DOI 10.1021/bi049822p; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CASSIDY PB, 1995, METHOD ENZYMOL, V250, P30; Chehade KAH, 2002, J AM CHEM SOC, V124, P8206, DOI 10.1021/ja0124717; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; Grubbs RD, 2002, BIOMETALS, V15, P251, DOI 10.1023/A:1016026831789; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hightower KE, 1998, BIOCHEMISTRY-US, V37, P15555, DOI 10.1021/bi981525v; Huang CC, 2000, BIOCHEMISTRY-US, V39, P2593, DOI 10.1021/bi992356x; Huang CC, 1997, J BIOL CHEM, V272, P20; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Long SB, 2000, STRUCTURE, V8, P209, DOI 10.1016/S0969-2126(00)00096-4; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; Long SB, 2001, P NATL ACAD SCI USA, V98, P12948, DOI 10.1073/pnas.241407898; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Pickett JS, 2003, J BIOL CHEM, V278, P51243, DOI 10.1074/jbc.M309226200; Pickett JS, 2003, BIOCHEMISTRY-US, V42, P9741, DOI 10.1021/bi0346852; PICKETT WC, 1995, ANAL BIOCHEM, V225, P60, DOI 10.1006/abio.1995.1108; POMPLIANO DL, 1992, J AM CHEM SOC, V114, P7945, DOI 10.1021/ja00046a070; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; Rellick LM, 1997, BIOPOLYMERS, V42, P191, DOI 10.1002/(SICI)1097-0282(199708)42:2<191::AID-BIP8>3.0.CO;2-I; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; Saderholm MJ, 2000, BIOCHEMISTRY-US, V39, P12398, DOI 10.1021/bi0011781; SAGAMI H, 1992, ARCH BIOCHEM BIOPHYS, V297, P314, DOI 10.1016/0003-9861(92)90678-P; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEBTI SM, 2001, FARNESYLTRANSFERASE, P21; Tamanoi F, 2001, CELL MOL LIFE SCI, V58, P1636, DOI 10.1007/PL00000802; Taylor JS, 2003, EMBO J, V22, P5963, DOI 10.1093/emboj/cdg571; Wolf Federica I., 2003, Molecular Aspects of Medicine, V24, P11, DOI 10.1016/S0098-2997(02)00088-2; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1992, BIOCHEM SOC T, V20, P489, DOI 10.1042/bst0200489; Yokoyama K, 1997, J BIOL CHEM, V272, P3944, DOI 10.1074/jbc.272.7.3944; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; Zhang FL, 1996, BIOCHEM J, V320, P925, DOI 10.1042/bj3200925; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zimmerman KK, 1998, PROTEIN EXPRES PURIF, V14, P395, DOI 10.1006/prep.1998.0979	55	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30546	30553		10.1074/jbc.M403469200	http://dx.doi.org/10.1074/jbc.M403469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131129	hybrid			2022-12-27	WOS:000222531900084
J	Kato, M; Ito, T; Wagner, G; Ellenberger, T				Kato, M; Ito, T; Wagner, G; Ellenberger, T			A molecular handoff between bacteriophage T7 DNA primase and T7 DNA polymerase initiates DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENE 2.5 PROTEIN; CARBOXYL-TERMINAL DOMAIN; RNA PRIMER SYNTHESIS; BINDING-PROTEIN; TEMPLATE RECOGNITION; CRYSTAL-STRUCTURE; HELICASE-PRIMASE; DEOXYRIBONUCLEIC-ACID; ANGSTROM RESOLUTION	The T7 DNA primase synthesizes tetraribonucleotides that prime DNA synthesis by T7 DNA polymerase but only on the condition that the primase stabilizes the primed DNA template in the polymerase active site. We used NMR experiments and alanine scanning mutagenesis to identify residues in the zinc binding domain of T7 primase that engage the primed DNA template to initiate DNA synthesis by T7 DNA polymerase. These residues cover one face of the zinc binding domain and include a number of aromatic amino acids that are conserved in bacteriophage primases. The phage T7 single-stranded DNA-binding protein gp2.5 specifically interfered with the utilization of tetraribonucleotide primers by interacting with T7 DNA polymerase and preventing a productive interaction with the primed template. We propose that the opposing effects of gp2.5 and T7 primase on the initiation of DNA synthesis reflect a sequence of mutually exclusive interactions that occur during the recycling of the polymerase on the lagging strand of the replication fork.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	tome@hms.harvard.edu	Ito, Takuhiro/N-6893-2015	Ito, Takuhiro/0000-0003-3704-5205	NIGMS NIH HHS [GM55390, P01 GM047467, GM47467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055390, P01GM047467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; FUJIYAMA A, 1981, P NATL ACAD SCI-BIOL, V78, P903, DOI 10.1073/pnas.78.2.903; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200; Higgins D G, 1994, Methods Mol Biol, V25, P307; HILL J, 1979, ANN BOT-LONDON, V43, P449, DOI 10.1093/oxfordjournals.aob.a085655; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Hyland EM, 2003, J BIOL CHEM, V278, P7247, DOI 10.1074/jbc.M210605200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Kato M, 2001, J BIOL CHEM, V276, P21809, DOI 10.1074/jbc.M101470200; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kornberg A., 1992, DNA REPLICATION; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Kusakabe T, 1997, J BIOL CHEM, V272, P5943, DOI 10.1074/jbc.272.9.5943; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lee SJ, 2001, J BIOL CHEM, V276, P49419, DOI 10.1074/jbc.M108443200; Lee SJ, 2002, P NATL ACAD SCI USA, V99, P12703, DOI 10.1073/pnas.202471499; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; OGAWA T, 1980, ANNU REV BIOCHEM, V49, P421, DOI 10.1146/annurev.bi.49.070180.002225; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; ROWEN L, 1978, J BIOL CHEM, V253, P770; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SCHERZINGER E, 1975, MOL GEN GENET, V141, P233, DOI 10.1007/BF00341802; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STUDIER FW, 1982, COLD SPRING HARB SYM, V47, P999, DOI 10.1101/SQB.1983.047.01.114; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	58	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30554	30562		10.1074/jbc.M403485200	http://dx.doi.org/10.1074/jbc.M403485200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133047	hybrid			2022-12-27	WOS:000222531900085
J	Morel, N; Simon, S; Frobert, Y; Volland, H; Mourton-Gilles, C; Negro, A; Sorgato, MC; Creminon, C; Grassi, J				Morel, N; Simon, S; Frobert, Y; Volland, H; Mourton-Gilles, C; Negro, A; Sorgato, MC; Creminon, C; Grassi, J			Selective and efficient immunoprecipitation of the disease-associated form of the prion protein can be mediated by nonspecific interactions between monoclonal antibodies and scrapie-associated fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNIZATION; IMMUNOASSAY; CONVERSION; MOLECULES; HAPTENS; PLASMA; PRPSC	Transmissible spongiform encephalopathies are characterized by the accumulation in brain tissues of an abnormal isoform of the prion protein named PrPsc, which is the only direct marker known for transmissible spongiform encephalopathies. Here we show that PrPsc can be specifically immunoprecipitated by using several monoclonal antibodies (mAbs) of various specificities independently of the properties of their binding site (paratope). These results strongly suggest that a significant proportion of mAbs can interact with PrPsc aggregates through nonspecific paratope-independent interactions allowing selective immunoprecipitation of PrPsc when these mAbs are immobilized on a polydisperse solid phase like microbeads.	CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; Fac Pharm Montpellier, CNRS, UMR 5160, F-34093 Montpellier 5, France; Univ Padua, CRIBI, I-35100 Padua, Italy; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Padua; University of Padua	Grassi, J (corresponding author), CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France.	jacques.grassi@cea.fr	Morel, Nathalie/O-9012-2016; Simon, Stephanie/E-4289-2012	Simon, Stephanie/0000-0002-6071-8255; NEGRO, ALESSANDRO/0000-0003-3142-7632	Telethon [E.0945] Funding Source: Medline	Telethon(Fondazione Telethon)		Andreoletti O, 2000, J GEN VIROL, V81, P3115, DOI 10.1099/0022-1317-81-12-3115; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; BON S, 1987, J NEUROCHEM, V49, P1720, DOI 10.1111/j.1471-4159.1987.tb02429.x; CURIN S, 2004, J BIOL CHEM, V279, P3694; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Grassi J, 1996, CLIN CHEM, V42, P1532; Grassi J, 2000, Arch Virol Suppl, P197; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Krasemann S, 1996, J IMMUNOL METHODS, V199, P109, DOI 10.1016/S0022-1759(96)00165-2; Krasemann S, 1999, J BIOTECHNOL, V73, P119, DOI 10.1016/S0168-1656(99)00115-7; Meggio F, 2000, BIOCHEM J, V352, P191, DOI 10.1042/0264-6021:3520191; Molina F, 1996, PEPTIDE RES, V9, P151; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; PRADELLES P, 1994, ANAL CHEM, V66, P16, DOI 10.1021/ac00073a005; PRADELLES P, 1990, BIOCHEM BIOPH RES CO, V170, P986, DOI 10.1016/0006-291X(90)90489-A; Schonberger O, 2003, BIOCHEM BIOPH RES CO, V312, P473, DOI 10.1016/j.bbrc.2003.10.150; Volland H, 1999, J IMMUNOL METHODS, V228, P37, DOI 10.1016/S0022-1759(99)00097-6; Zou WQ, 2004, P NATL ACAD SCI USA, V101, P1380, DOI 10.1073/pnas.0307825100; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	23	49	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30143	30149		10.1074/jbc.M403896200	http://dx.doi.org/10.1074/jbc.M403896200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140886	hybrid			2022-12-27	WOS:000222531900035
J	Ropers, D; Ayadi, L; Gattoni, R; Jacquenet, S; Damier, L; Branlant, C; Stevenin, J				Ropers, D; Ayadi, L; Gattoni, R; Jacquenet, S; Damier, L; Branlant, C; Stevenin, J			Differential effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HNRNP A/B PROTEINS; MESSENGER-RNA; TAT EXON-2; IN-VITRO; REGULATORY ELEMENTS; SILENCER ELEMENT/; ALTERNATIVE EXON; INFECTED CELLS; BRANCH SITE	Splicing is a crucial step for human immunodeficiency virus, type 1 (HIV-1) multiplication; eight acceptor sites are used in competition to produce the vif, vpu, vpr, nef, env, tat, and rev mRNAs. The effects of SR proteins have only been investigated on a limited number of HIV-1 splicing sites by using small HIV-1 RNA pieces. To understand how SR proteins influence the use of HIV-1 splicing sites, we tested the effects of overproduction of individual SR proteins in HeLa cells on the splicing pattern of an HIV-1 RNA that contained all the splicing sites. The steady state levels of the HIV-1 mRNAs produced were quantified by reverse transcriptase-PCR. For interpretation of the data, transcripts containing one or several of the HIV-1 acceptor sites were spliced in vitro in the presence or the absence of one of the tested SR proteins. Both in vivo and in vitro, acceptor sites A2 and A3 were found to be strongly and specifically regulated by SR proteins. ASF/SF2 strongly activates site A2 and to a lesser extent site A1. As a result, upon ASF/SF2 overexpression, the vpr mRNA steady state level is specifically increased. SC35 and SRp40, but not 9G8, strongly activate site A3, and their overexpression ex vivo induces a dramatic accumulation of the tat mRNA, to the detriment of most of the other viral mRNAs. Here we showed by Western blot analysis that the Nef protein synthesis is strongly decreased by overexpression of SC35, SRp40, and ASF/SF2. Finally, activation by ASF/SF2 and 9G8 was found to be independent of the RS domain. This is the first investigation of the effects of variations of individual SR protein concentrations that is performed ex vivo on an RNA containing a complex set of splicing sites.	Univ Henri Poincare, Lab Maturat ARN & Enzymol Mol, UMAR 7567, CNRS,Fac Sci, F-54506 Vandoeuvre Les Nancy, France; IGBMC, CNRS, INSERM, ULP 7104, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Branlant, C (corresponding author), Univ Henri Poincare, Lab Maturat ARN & Enzymol Mol, UMAR 7567, CNRS,Fac Sci, Blvd Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	Christiane.Branlant@maem.uhp-nancy.fr		Branlant, Christiane/0000-0003-4728-5499; Ropers, Delphine/0000-0003-2659-3003				AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Arora VK, 2002, MICROBES INFECT, V4, P189, DOI 10.1016/S1286-4579(01)01527-1; Azad AA, 2000, BIOCHEM BIOPH RES CO, V267, P677, DOI 10.1006/bbrc.1999.1708; BENKO DM, 1990, J VIROL, V64, P2505, DOI 10.1128/JVI.64.6.2505-2518.1990; Bertsch C, 2002, ARCH VIROL, V147, P1963, DOI 10.1007/s00705-002-0857-8; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Bilodeau PS, 1999, J VIROL, V73, P9764, DOI 10.1128/JVI.73.12.9764-9772.1999; Boris-Lawrie K, 2001, LIFE SCI, V69, P2697, DOI 10.1016/S0024-3205(01)01360-1; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Damier L, 1997, BIOCHEM BIOPH RES CO, V237, P182, DOI 10.1006/bbrc.1997.7091; DAMIER L, 1997, THESIS U H POINCARE; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DYHRMIKKELSEN H, 1995, J BIOL CHEM, V270, P24060, DOI 10.1074/jbc.270.41.24060; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; HIMMELSPACH M, 1995, RNA, V1, P794; Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200; Jacquenet S, 2001, NUCLEIC ACIDS RES, V29, P464, DOI 10.1093/nar/29.2.464; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; Lejeune F, 2001, J BIOL CHEM, V276, P7850, DOI 10.1074/jbc.M009510200; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Maldarelli F, 1998, VIRUS RES, V53, P39, DOI 10.1016/S0168-1702(97)00130-5; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Molin M, 2000, J VIROL, V74, P9002, DOI 10.1128/JVI.74.19.9002-9009.2000; OREILLY MM, 1995, VIROLOGY, V213, P373, DOI 10.1006/viro.1995.0010; Pongoski J, 2002, J VIROL, V76, P5108, DOI 10.1128/JVI.76.10.5108-5120.2002; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Ryo A, 2000, AIDS RES HUM RETROV, V16, P995, DOI 10.1089/08892220050058416; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; Si ZH, 1998, MOL CELL BIOL, V18, P5404, DOI 10.1128/MCB.18.9.5404; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Tang HL, 1999, ANNU REV GENET, V33, P133, DOI 10.1146/annurev.genet.33.1.133; Tange TO, 2001, J MOL BIOL, V312, P649, DOI 10.1006/jmbi.2001.4971; Tange TO, 2001, EMBO J, V20, P5748; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zauli G, 1999, BLOOD, V93, P1000, DOI 10.1182/blood.V93.3.1000.403a12_1000_1010; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	65	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29963	29973		10.1074/jbc.M404452200	http://dx.doi.org/10.1074/jbc.M404452200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123677	hybrid			2022-12-27	WOS:000222531900013
J	Sattlegger, E; Swanson, MJ; Ashcraft, EA; Jennings, JL; Fekete, RA; Link, AJ; Hinnebusch, AG				Sattlegger, E; Swanson, MJ; Ashcraft, EA; Jennings, JL; Fekete, RA; Link, AJ; Hinnebusch, AG			YIH1 is an actin-binding protein that inhibits protein kinase GCN2 and impairs general amino acid control when overexpressed	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCHARGED TRANSFER-RNA; INITIATION FACTOR-II; TRANSLATIONAL ACTIVATOR; SHUTTLE VECTORS; BUDDING YEAST; GI DOMAIN; ASSOCIATION; PHOSPHORYLATION; CYTOSKELETON; EXPRESSION	The general amino acid control (GAAC) enables yeast cells to overcome amino acid deprivation by activation of the alpha subunit of translation initiation factor 2 (eIF2alpha) kinase GCN2 and consequent induction of GCN4, a transcriptional activator of amino acid biosynthetic genes. Binding of GCN2 to GCN1 is required for stimulation of GCN2 kinase activity by uncharged tRNA in starved cells. Here we show that YIH1, when overexpressed, dampens the GAAC response (Gcn(-) phenotype) by suppressing eIF2alpha phosphorylation by GCN2. The overexpressed YIH1 binds GCN1 and reduces GCN1-GCN2 complex formation, and, consistent with this, the Gcn(-) phenotype produced by YIH1 overexpression is suppressed by GCN2 overexpression. YIH1 interacts with the same GCN1 fragment that binds GCN2, and this YIH1-GCN1 interaction requires Arg-2259 in GCN1 in vitro and in full-length GCN1 in vivo, as found for GCN2-GCN1 interaction. However, deletion of YIH1 does not increase eIF2alpha phosphorylation or derepress the GAAC, suggesting that YIH1 at native levels is not a general inhibitor of GCN2 activity. We discovered that YIH1 normally resides in a complex with monomeric actin, rather than GCN1, and that a genetic reduction in actin levels decreases the GAAC response. This Gcn(-) phenotype was partially suppressed by deletion of YIH1, consistent with YIH1-mediated inhibition of GCN2 in actin-deficient cells. We suggest that YIH1 resides in a YIH1-actin complex and may be released for inhibition of GCN2 and stimulation of protein synthesis under specialized conditions or in a restricted cellular compartment in which YIH1 is displaced from monomeric actin.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hinnebusch, AG (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 6A,Rm B1A-13, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov			NCI NIH HHS [CA098131] Funding Source: Medline; NHLBI NIH HHS [HL68744] Funding Source: Medline; NIEHS NIH HHS [ES11993] Funding Source: Medline; NIGMS NIH HHS [GM64779] Funding Source: Medline; NINDS NIH HHS [NS43952] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA098131] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Adams Alison, 1997, P143; Amberg DC, 1998, MOL BIOL CELL, V9, P3259, DOI 10.1091/mbc.9.12.3259; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDMAN E, 1990, MOL MICROBIOL, V4, P2035, DOI 10.1111/j.1365-2958.1990.tb00563.x; GUELMAN R, 2002, BONE, V30, P23; HANNIG EM, 1990, GENETICS, V126, P549; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; Kubota H, 2001, J BIOL CHEM, V276, P17591, DOI 10.1074/jbc.M011793200; Kubota H, 2000, J BIOL CHEM, V275, P20243, DOI 10.1074/jbc.C000262200; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Maniatis T., 1982, MOL CLONING; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Qiu HF, 2002, GENE DEV, V16, P1271, DOI 10.1101/gad.979402; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; Schott D, 2002, CURR OPIN MICROBIOL, V5, P564, DOI 10.1016/S1369-5274(02)00369-7; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIKORSKI RS, 1989, GENETICS, V122, P19; WEK SA, 1995, MOL CELL BIOL, V15, P4497; WERTMAN KF, 1992, GENETICS, V132, P337; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	45	43	46	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29952	29962		10.1074/jbc.M404009200	http://dx.doi.org/10.1074/jbc.M404009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15126500	hybrid			2022-12-27	WOS:000222531900012
J	Shim, KS; Schmutte, C; Tombline, G; Heinen, CD; Fishel, R				Shim, KS; Schmutte, C; Tombline, G; Heinen, CD; Fishel, R			hXRCC2 enhances ADP/ATP processing and strand exchange by hRAD51	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RAD51 PROTEIN; ESCHERICHIA-COLI RECA; HUMAN EXONUCLEASE-I; NUCLEOTIDE EXCHANGE; MISMATCH REPAIR; DNA-REPAIR; BIOCHEMICAL-CHARACTERIZATION; HOMOLOGOUS RECOMBINATION; MOLECULAR SWITCH; ATP HYDROLYSIS	The assembly of bacterial RecA, and its human homolog hRAD51, into an operational ADP/ATP-regulated DNA-protein ( nucleoprotein) filament is essential for homologous recombination repair (HRR). Yet hRAD51 lacks the coordinated ADP/ATP processing exhibited by RecA and is less efficient in HRR reactions in vitro. In this study, we demonstrate that hXRCC2, one of five other poorly understood non-redundant human mitotic RecA homologs (hRAD51B, hRAD51C, hRAD51D, hXRCC2, and hXRCC3), stimulates hRAD51 ATP processing. hXRCC2 also increases hRAD51-mediated DNA unwinding and strand exchange activities that are integral for HRR. Although there does not seem to be a long-lived interaction between hXRCC2 and hRAD51, we detail a strong adenosine nucleotide-regulated interaction between the hXRCC2-hRAD51D heterodimer and hRAD51. These observations begin to elucidate the separate and specialized functions of the human mitotic RecA homologs that enable an efficient nucleoprotein filament required for HRR.	Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, BLSB933,233 S 10th St, Philadelphia, PA 19107 USA.	rfishel@lac.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA056542] Funding Source: NIH RePORTER; NCI NIH HHS [CA56542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; De Zutter SK, 1999, J MOL BIOL, V293, P769, DOI 10.1006/jmbi.1999.3200; Deans B, 2000, EMBO J, V19, P6675, DOI 10.1093/emboj/19.24.6675; Easter J, 2002, MOL CELL, V10, P427, DOI 10.1016/S1097-2765(02)00594-4; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 2000, COLD SPRING HARB SYM, V65, P217, DOI 10.1101/sqb.2000.65.217; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Holmes VF, 2001, NUCLEIC ACIDS RES, V29, P5052, DOI 10.1093/nar/29.24.5052; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JONES NJ, 1995, GENOMICS, V26, P619, DOI 10.1016/0888-7543(95)80187-Q; Kabani M, 2000, MOL CELL BIOL, V20, P6923, DOI 10.1128/MCB.20.18.6923-6934.2000; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kurumizaka H, 2002, J BIOL CHEM, V277, P14315, DOI 10.1074/jbc.M105719200; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SABLIN EP, 2001, CURR OPIN STRUC BIOL, V11, P617; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; THACKER J, 1995, HUM MOL GENET, V4, P113, DOI 10.1093/hmg/4.1.113; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Tombline G, 2002, J BIOL CHEM, V277, P14426, DOI 10.1074/jbc.M109916200; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; Tombline G, 2002, J BIOL CHEM, V277, P14434, DOI 10.1074/jbc.M109917200; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	62	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30385	30394		10.1074/jbc.M306066200	http://dx.doi.org/10.1074/jbc.M306066200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123651	hybrid			2022-12-27	WOS:000222531900064
J	Binet, V; Brajon, C; Le Corre, L; Acher, F; Pin, JP; Prezeau, L				Binet, V; Brajon, C; Le Corre, L; Acher, F; Pin, JP; Prezeau, L			The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; PROTEIN-COUPLED RECEPTOR; B-RECEPTOR; BINDING-SITE; PHARMACOLOGICAL CHARACTERIZATION; MUTATIONAL ANALYSIS; ACID(B) RECEPTORS; GB2 SUBUNITS; C-TERMINI; RHODOPSIN	The gamma-aminobutyric acid, type B (GABA(B)) receptor is well recognized as being composed of two subunits, GABA(B1) and GABA(B2). Both subunits share structural homology with other class-III G-protein-coupled receptors. They are composed of two main domains: a heptahelical domain (HD) typical of all G-protein-coupled receptors and a large extracellular domain (ECD). Although GABA(B1) binds GABA, GABA(B2) is required for GABAB1 to reach the cell surface. However, it is still not demonstrated whether the association of these two subunits is always required for function in the brain. Indeed, GABA(B2) plays a major role in the coupling of the heteromer to G-proteins, such that it is possible that GABA(B2) can transmit a signal in the absence of GABA(B1). Today only ligands interacting with GABA(B1) ECD have been identified. Thus, the compounds acting exclusively on the GABA(B2) subunit will be helpful in analyzing the specific role of this subunit in the brain. Here, we explored the mechanism of action of CGP7930, a compound described as a positive allosteric regulator of the GABA(B) receptor. We showed that it activates the wild type GABA(B) receptor but with a low efficacy. The GABA(B2) HD is necessary for this effect, although one cannot exclude that CGP7930 could also bind to GABA(B1). Of interest, CGP7930 could activate GABA(B2) expressed alone and is the first described agonist of GABA(B2). Finally, we show that CGP7930 retains its agonist activity on a GABA(B2) subunit deleted of its ECD. This demonstrates that the HD of GABA(B2) behaves similar to a rhodopsin-like receptor, because it can reach the cell surface alone, can couple to G-protein, and be activated by agonists. These data open new strategies for studying the mechanism of activation of GABA(B) receptor and examine any possible role of homomeric GABA(B2) receptors.	CNRS, INSERM, Ctr Pharmacol Endocrinol, Lab Funct Genom,Dept Mol Pharmacol,UPR 2580, F-34094 Montpellier 5, France; Univ Paris 05, CNRS, UMR 8601, Lab Pharmacol & Toxicol Chem & Biochem, F-75270 Paris 6, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Prezeau, L (corresponding author), CNRS, INSERM, Ctr Pharmacol Endocrinol, Lab Funct Genom,Dept Mol Pharmacol,UPR 2580, F-34094 Montpellier 5, France.	lprezeau@ccipe.cnrs.fr	Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X				Billinton A, 2001, TRENDS NEUROSCI, V24, P277, DOI 10.1016/S0166-2236(00)01815-4; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Calver AR, 2000, NEUROSCIENCE, V100, P155, DOI 10.1016/S0306-4522(00)00262-1; Calver AR, 2001, J NEUROSCI, V21, P1203; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; Chabre M, 2003, NATURE, V426, P30, DOI 10.1038/426030b; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Franek M, 1999, NEUROPHARMACOLOGY, V38, P1657, DOI 10.1016/S0028-3908(99)00135-5; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; Gasparini F, 2002, CURR OPIN PHARMACOL, V2, P43, DOI 10.1016/S1471-4892(01)00119-9; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Grunewald S, 2002, MOL PHARMACOL, V61, P1070, DOI 10.1124/mol.61.5.1070; Havlickova M, 2002, MOL PHARMACOL, V62, P343, DOI 10.1124/mol.62.2.343; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Johnson MP, 2003, J MED CHEM, V46, P3189, DOI 10.1021/jm034015u; JOLY C, 1995, J NEUROSCI, V15, P3970; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Joubert L, 2002, J BIOL CHEM, V277, P25502, DOI 10.1074/jbc.M202539200; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lavreysen H, 2003, MOL PHARMACOL, V63, P1082, DOI 10.1124/mol.63.5.1082; Litschig S, 1999, MOL PHARMACOL, V55, P453; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Malherbe P, 2003, MOL PHARMACOL, V64, P823, DOI 10.1124/mol.64.4.823; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Marino MJ, 2003, P NATL ACAD SCI USA, V100, P13668, DOI 10.1073/pnas.1835724100; Martin SC, 1999, MOL CELL NEUROSCI, V13, P180, DOI 10.1006/mcne.1999.0741; Mathiesen JM, 2003, BRIT J PHARMACOL, V138, P1026, DOI 10.1038/sj.bjp.0705159; Maurel D, 2004, ANAL BIOCHEM, V329, P253, DOI 10.1016/j.ab.2004.02.013; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; O'Brien JA, 2003, MOL PHARMACOL, V64, P731, DOI 10.1124/mol.64.3.731; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Pagano A, 2001, J NEUROSCI, V21, P1189; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Pin JP, 2001, MOL PHARMACOL, V60, P881, DOI 10.1124/mol.60.5.881; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Schaffhauser H, 2003, MOL PHARMACOL, V64, P798, DOI 10.1124/mol.64.4.798; Urwyler S, 2003, J PHARMACOL EXP THER, V307, P322, DOI 10.1124/jpet.103.053074; Urwyler S, 2001, MOL PHARMACOL, V60, P963, DOI 10.1124/mol.60.5.963; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197	58	164	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29085	29091		10.1074/jbc.M400930200	http://dx.doi.org/10.1074/jbc.M400930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126507	hybrid, Green Submitted, Green Accepted			2022-12-27	WOS:000222445300032
J	Fotia, AB; Ekberg, J; Adams, DJ; Cook, DI; Poronnik, P; Kumar, S				Fotia, AB; Ekberg, J; Adams, DJ; Cook, DI; Poronnik, P; Kumar, S			Regulation of neuronal voltage-gated sodium channels by the ubiquitin-protein ligases Nedd4 and Nedd4-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; WW DOMAINS; INTERNALIZATION; IDENTIFICATION; SPECIFICITY; EXPRESSION	Nedd4 and Nedd4-2 are ubiquitin-protein ligases known to regulate a number of membrane proteins including receptors and ion transporters. Regulation of the epithelial Na+ channel by Nedd4 and Nedd4-2 is mediated via interactions between the PY motifs of the epithelial sodium channel subunits and the Nedd4/Nedd4-2 WW domains. This example serves as a model for the regulation of other PY motif-containing ion channels by Nedd4 and Nedd4-2. We found that the carboxyl termini of the six voltage-gated Na+ (Na-v) channels contain typical PY motifs (PPXY), and a further Na-v contains a PY motif variant (LPXY). Not only did we demonstrate by Far-Western analysis that Nedd4 and Nedd4-2 interact with the PY motif-containing Na-v channels, but we also showed that these channels have conserved WW domain binding specificity. We further showed that the carboxyl termini fusion proteins of one central nervous system and one peripheral nervous system-derived Na+ channel (Na(v)1.2 and Na(v)1.7, respectively) are readily ubiquitinated by Nedd4-2. In Xenopus oocytes, Nedd4-2 strongly inhibited the activities of all three Na(v)s (Na(v)1.2, Na(v)1.7, and Na(v)1.8) tested. Interestingly, Nedd4 suppressed the activity of Na(v)1.2 and Na(v)1.7 but was a poor inhibitor of Na(v)1.8. Our results provide evidence that Nedd4 and Nedd4-2 are likely to be key regulators of specific neuronal Na-v channels in vivo.	Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide; University of Queensland; University of Sydney	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Inst, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Ekberg, Jenny/AAV-2006-2020; Adams, David John/K-3578-2019; Kumar, Sharad/AAX-7787-2020	Adams, David John/0000-0002-7030-2288; Kumar, Sharad/0000-0001-7126-9814; Poronnik, Philip/0000-0002-6246-528X; Ekberg, Jenny/0000-0001-5151-4966				Abriel H, 2000, FEBS LETT, V466, P377, DOI 10.1016/S0014-5793(00)01098-X; Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; DARGENT B, 1994, NEURON, V13, P683, DOI 10.1016/0896-6273(94)90035-3; DARGENT B, 1995, J NEUROCHEM, V65, P407; DARGENT B, 1990, P NATL ACAD SCI USA, V87, P5907, DOI 10.1073/pnas.87.15.5907; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207	20	122	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28930	28935		10.1074/jbc.M402820200	http://dx.doi.org/10.1074/jbc.M402820200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123669	hybrid			2022-12-27	WOS:000222445300014
J	Hanssen, E; Hew, FH; Moore, E; Gibson, MA				Hanssen, E; Hew, FH; Moore, E; Gibson, MA			MAGP-2 has multiple binding regions on fibrillins and has covalent periodic association with fibrillin-containing microfibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; MARFAN-SYNDROME; EXTRACELLULAR MICROFIBRILS; MOLECULAR-CLONING; DEVELOPMENTAL EXPRESSION; GLYCOPROTEIN-1 MAGP-1; TISSUE MICROFIBRILS; RICH MICROFIBRILS; TERNARY COMPLEX; COLLAGEN-VI	The interactions of microfibril-associated glycoprotein (MAGP)-2 have been investigated with fibrillins and fibrillin-containing microfibrils. Solid phase binding assays were conducted with recombinant fragments covering fibrillin-1 and most of fibrillin-2. MAGP-2, and its structure relative MAGP-1, were found to bind two fragments spanning the N-terminal half of fibrillin-1 and an N-terminal fragment of fibrillin-2. Blocking experiments indicated that MAGP-2 had a binding site(s) close to the N terminus of the fibrillin-1 molecule that was distinct from that for MAGP-1 and an additional, more central binding site( s) that may be shared by the two MAGPs. Immunogold labeling of developing nuchal ligament tissue showed that MAGP-2 had regular covalent and periodic (about 56 nm) association with fibrillin-containing microfibrils of elastic fibers in this tissue. Further analysis of isolated microfibrils indicated that MAGP-2 was attached at two points along the microfibril substructure, "site 1" on the "beads" and "site 2" at the "shoulder" of the interbead region close to where the two "arms" fuse. In contrast, MAGP-1 was located only on the beads. Comparison of the MAGP-2 binding data with known fibrillin epitope maps of the microfibrils showed that site 1 correlated with the N-terminal MAGP-2 binding region, and site 2 correlated with the second, more central, MAGP-2 binding region on the fibrillin-1 molecule. Of particular note, immunolabeling at site 2 was markedly decreased, relative to that at site 1, on extended microfibrils with bead-to-bead periods over 90 nm, suggesting that site 2 may move toward the beads when the microfibril is stretched. The study points to MAGP-2 being an integral component of some populations of fibrillin-containing microfibrils. Moreover, the identification of multiple MAGP-binding sequences on fibrillins supports the concept that MAGPs may function as molecular cross-linkers, stabilizing fibrillin monomers in folded conformation within or between the microfibrils, and thus MAGPs may be implicated in the modulation of the elasticity of these structures.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia	University of Adelaide	Gibson, MA (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	mark.gibson@adelaide.edu.au	Hanssen, Eric/A-7217-2013	Hanssen, Eric/0000-0002-4064-1844				ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; Ashworth JL, 1999, J CELL SCI, V112, P4163; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; Charbonneau NL, 2003, J BIOL CHEM, V278, P2740, DOI 10.1074/jbc.M209201200; Cleary E. G., 1996, EXTRACELLULAR MATRIX, V2, P95; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GIBSON MA, 2004, IN PRESS MARFAN SYND; GIBSON MA, 1986, J BIOL CHEM, V26, P11436; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Hanssen E, 2003, J BIOL CHEM, V278, P24334, DOI 10.1074/jbc.M303455200; Hanssen E, 2001, MATRIX BIOL, V20, P77, DOI 10.1016/S0945-053X(01)00122-6; Haston JL, 2003, J BIOL CHEM, V278, P41189, DOI 10.1074/jbc.M212854200; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Kielty CM, 1998, ANAL BIOCHEM, V255, P108, DOI 10.1006/abio.1997.2442; Kielty CM, 2002, J MUSCLE RES CELL M, V23, P581, DOI 10.1023/A:1023479010889; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Penner AS, 2002, J BIOL CHEM, V277, P35044, DOI 10.1074/jbc.M206363200; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Sherratt MJ, 2003, J MOL BIOL, V332, P183, DOI 10.1016/S0022-2836(03)00829-5; Sinha S, 1998, MATRIX BIOL, V17, P529, DOI 10.1016/S0945-053X(98)90106-8; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Werneck CC, 2004, J BIOL CHEM, V279, P23045, DOI 10.1074/jbc.M402656200; Whiteman P, 2003, HUM MOL GENET, V12, P727, DOI 10.1093/hmg/ddg081; YEH H, 1994, GENOMICS, V23, P443, DOI 10.1006/geno.1994.1521; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	55	38	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29185	29194		10.1074/jbc.M313672200	http://dx.doi.org/10.1074/jbc.M313672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131124	hybrid			2022-12-27	WOS:000222445300045
J	Huang, ZH; Gu, DS; Mazzone, T				Huang, ZH; Gu, DS; Mazzone, T			Oleic acid modulates the post-translational glycosylation of macrophage ApoE to increase its secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; RESISTANCE SYNDROME PREDICTS; CORONARY-HEART-DISEASE; HUMAN APOLIPOPROTEIN-E; INSULIN-RESISTANCE; LIPOPROTEIN-LIPASE; CHOLESTEROL EFFLUX; PLASMA-MEMBRANE; CELLULAR UPTAKE; EXPRESSION	There has been increasing interest in a potential role for fatty acids in adversely affecting organismal substrate utilization and contributing to the cardiovascular complications in insulin resistance. Fatty acids have already been implicated in regulating the expression of a number of genes in resident cells of the vessel wall. In the current studies, we evaluated a potential role for fatty acids in the regulation of macrophage apoE expression. Incubation in oleic acid increased the synthesis and secretion of apoE by human monocyte-derived macrophages. Part of this stimulation was mediated at a post-translational locus. Oleic acid increased the secretion of apoE from macrophages that constitutively expressed a human apoE3 cDNA. Incubation in palmitic acid decreased apoE secretion from these cells. The effect of oleic acid on apoE secretion could not be accounted for by the known effect of fatty acid on cellular sterol, because incubation in oleic acid did not suppress the degradation of nascent apoE. Incubation in oleic acid for at least 6 h was required to observe an effect on apoE secretion. Oleic acid altered the glycosylation pattern of cellular and secreted apoE, with a loss of the most heavily sialylated isoform. Oleic acid had no effect on the glycosylation of interleukin 6 secreted from macrophages. Elimination of apoE glycosylation, by substitution of threonine 194 with alanine, eliminated oleic acid-mediated stimulation of apoE secretion. These results indicate that oleic acid increases apoE secretion from macrophages at a locus involving post-translational glycosylation.	Univ Illinois, Dept Med, Sect Diabet & Metab, Chicago, IL 60612 USA; Univ Illinois, Dept Pharmacol, Sect Diabet & Metab, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mazzone, T (corresponding author), Univ Illinois, Dept Med & Pharmacol, Sect Diabet & Metab, M-C 797,1819 W Polk St, Chicago, IL 60612 USA.	tmazzone@uic.edu			NHLBI NIH HHS [HL 39653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASHEERUDDIN K, 1992, J BIOL CHEM, V267, P1219; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; CORR PB, 1984, CIRC RES, V55, P135, DOI 10.1161/01.RES.55.2.135; Cullis P.R., 1996, NEW COMPREHENSIVE BI, V31, P1; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; DORY L, 1993, BIOCHEM J, V292, P105, DOI 10.1042/bj2920105; Du XN, 2001, BIOCHEM J, V357, P275, DOI 10.1042/0264-6021:3570275; Duan HW, 2000, BBA-MOL CELL BIOL L, V1484, P142, DOI 10.1016/S1388-1981(00)00005-6; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; Ghosh P, 2000, AM J CLIN NUTR, V72, P190; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Huang ZH, 2003, BIOCHEMISTRY-US, V42, P3949, DOI 10.1021/bi0269207; Johnson RA, 2003, BIOCHEMISTRY-US, V42, P1637, DOI 10.1021/bi0264465; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; KOTLOFF RM, 1990, AM J RESP CELL MOL, V3, P497, DOI 10.1165/ajrcmb/3.5.497; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Lempiainen P, 1999, CIRCULATION, V100, P123, DOI 10.1161/01.CIR.100.2.123; Lin CY, 1999, J LIPID RES, V40, P1618; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MAZZONE T, 1994, J LIPID RES, V35, P1345; MAZZONE T, 1986, BIOCHIM BIOPHYS ACTA, V875, P393, DOI 10.1016/0005-2760(86)90190-6; McArthur MJ, 1999, J LIPID RES, V40, P1371; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Michaud SE, 2001, DIABETES, V50, P660, DOI 10.2337/diabetes.50.3.660; Nilsson L, 1998, ARTERIOSCL THROM VAS, V18, P1679, DOI 10.1161/01.ATV.18.11.1679; Olsson U, 1999, DIABETES, V48, P616, DOI 10.2337/diabetes.48.3.616; ORITA T, 1994, J BIOCHEM-TOKYO, V115, P345, DOI 10.1093/oxfordjournals.jbchem.a124340; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; Prescott J, 1999, BBA-MOL CELL BIOL L, V1439, P110, DOI 10.1016/S1388-1981(99)00082-7; Pyorala M, 2000, ARTERIOSCL THROM VAS, V20, P538, DOI 10.1161/01.ATV.20.2.538; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; Seo T, 2002, BIOCHEMISTRY-US, V41, P7885, DOI 10.1021/bi011949g; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; ZANNIS VI, 1986, J BIOL CHEM, V261, P3415; Zhao YW, 2000, J BIOL CHEM, V275, P4759, DOI 10.1074/jbc.275.7.4759	46	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29195	29201		10.1074/jbc.M402631200	http://dx.doi.org/10.1074/jbc.M402631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131109	hybrid			2022-12-27	WOS:000222445300046
J	Munro, P; Flatau, G; Doye, A; Boyer, L; Oregioni, O; Mege, JL; Landraud, L; Lemichez, E				Munro, P; Flatau, G; Doye, A; Boyer, L; Oregioni, O; Mege, JL; Landraud, L; Lemichez, E			Activation and proteasomal degradation of rho GTPases by cytotoxic necrotizing factor-1 elicit a controlled inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE-SYSTEM; CHEMOKINES; HOST; INFECTION; BINDING; CELLS; RAC	The CNF1 toxin is produced by uropathogenic and meningitis-causing Escherichia coli. CNF1 penetrates autonomously into cells and confers phagocytic properties to epithelial and endothelial cells. CNF1 acts at the molecular level by constitutively activating Rho GTPases attenuated by their cellular ubiquitin-mediated proteasomal degradation. Here we report the relationship between the ubiquitin-mediated proteasomal degradation of activated Rho and the endothelial cell response to the toxin. The type of cellular response to CNF1 intoxication, first screened by DNA microarray analysis, revealed the launching of a program oriented toward an inflammatory response. Parallel to Rho protein activation by CNF1, we also established the kinetics of production of monocyte chemotactic protein-1 (MCP1), interleukin-8 (IL-8), IL-6, monocyte inflammatory protein-3alpha(MIP-3alpha) and E-selectin. Both the mutation of the catalytic domain of the toxin (CNF1-C866S) and the inhibition of Rho proteins abrogate the CNF1-induced production of the immunomodulators MIP-3alpha, MCP-1, and IL-8. These immunomodulators are also produced upon activation of Cdc42 and Rac preferentially. Our results indicate that, in addition to pathogen molecular pattern recognition by host-receptors, a direct activation of Rho proteins by the CNF1 virulence factor efficiently triggers a cellular reaction of host alert. Consistently, we assume that the CNF1-induced ubiquitin-mediated proteasomal degradation of activated Rho proteins may limit the amplitude of the host cell immune responses.	Fac Med Nice, INSERM, U627, F-06107 Nice 2, France; Univ Mediterranee, Fac Med, Unite Rickettsies, CNRS,UMR 6020, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Lemichez, E (corresponding author), Fac Med Nice, INSERM, U627, 28 Ave Valombrose, F-06107 Nice 2, France.	lemichez@unice.fr	MEGE, JEAN-LOUIS/O-6063-2016; Munro, Patrick/A-6579-2009; BOYER, Laurent/AAH-4543-2021; Landraud, Luce/HGB-1249-2022; Lemichez, Emmanuel/G-3559-2013; Boyer, laurent/F-8921-2015	Munro, Patrick/0000-0003-4283-4671; BOYER, Laurent/0000-0002-1375-1706; Landraud, Luce/0000-0001-8486-1403; Lemichez, Emmanuel/0000-0001-9080-7761; Boyer, laurent/0000-0002-1375-1706				Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boquet P, 2003, TRENDS CELL BIOL, V13, P238, DOI 10.1016/S0962-8924(03)00037-0; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Janeway CA, 2001, P NATL ACAD SCI USA, V98, P7461, DOI 10.1073/pnas.131202998; Khan NA, 2002, J BIOL CHEM, V277, P15607, DOI 10.1074/jbc.M112224200; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Krawczyk C, 2001, TRENDS CELL BIOL, V11, P212, DOI 10.1016/S0962-8924(01)01981-X; Kubori T, 2003, CELL, V115, P333, DOI 10.1016/S0092-8674(03)00849-3; Lemichez E, 1997, MOL MICROBIOL, V24, P1061, DOI 10.1046/j.1365-2958.1997.4151781.x; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Lerm M, 1999, J BIOL CHEM, V274, P28999, DOI 10.1074/jbc.274.41.28999; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Mysorekar IU, 2002, J BIOL CHEM, V277, P7412, DOI 10.1074/jbc.M110560200; Pedron T, 2003, J BIOL CHEM, V278, P33878, DOI 10.1074/jbc.M303749200; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Shapiro SD, 2003, NATURE, V421, P223, DOI 10.1038/421223a; Szyperski T, 1998, P NATL ACAD SCI USA, V95, P2262, DOI 10.1073/pnas.95.5.2262; VANNHIEU GT, 2000, CELL MICROBIOL, V2, P187, DOI DOI 10.1046/J.1462-5822.2000.00046.X; WAKAI Y, 2001, PHYSIOL REV, V81, P153; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wang YX, 2000, J BIOL CHEM, V275, P4687, DOI 10.1074/jbc.275.7.4687; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024	37	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35849	35857		10.1074/jbc.M401580200	http://dx.doi.org/10.1074/jbc.M401580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15152002	hybrid			2022-12-27	WOS:000223303400086
J	Aoki, K; Uchiyama, R; Yamauchi, S; Katayama, T; Itonori, S; Sugita, M; Hada, N; Yamada-Hada, J; Takeda, T; Kumagai, H; Yamamoto, K				Aoki, K; Uchiyama, R; Yamauchi, S; Katayama, T; Itonori, S; Sugita, M; Hada, N; Yamada-Hada, J; Takeda, T; Kumagai, H; Yamamoto, K			Newly discovered neutral glycosphingolipids in Aureobasidin A-resistant Zygomycetes - Identification of a novel family of gala-series glycolipids with core Gal alpha 1-6Gal beta 1-6Gal beta sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID BIOSYNTHESIS; TRANSPLANT RECIPIENT; OLIGOSACCHARIDES; MUCORMYCOSIS; INHIBITION; SUGAR; CELLS; FUNGI	We found for the first time that Zygomycetes species showed resistance to Aureobasidin A, an antifungal agent. A novel family of neutral glycosphingolipids (GSLs) was found in these fungi and isolated from Mucor hiemalis, which is a typical Zygomycetes species. Their structures were completely determined by compositional sugar, fatty acid, and sphingoid analyses, methylation analysis, matrix-assisted laser desorption ionization time-of-flight/mass spectrometry, and H-1 NMR spectroscopy. They were as follows: Galbeta1-6Galbeta1-1Cer (CDS), Galalpha1-6Galbeta1-6Galbeta1-1Cer (CTS), Galalpha1-6Galalpha1-6Galbeta1-6Galbeta1-1Cer (CTeS), and Galalpha1-6Galalpha1-6Galalpha1-6Galbeta1-6Galbeta1-1Cer (CPS). The ceramide moieties of these GSLs consist of 24: 0, 25: 0, and 26: 0 2-hydroxy acids as major fatty acids and 4-hydroxyoctadecasphinganine ( phytosphingosine) as the sole sphingoid. However, the glycosylinositolphosphoceramide families that are the major GSLs components in fungi were not detected in Zygomycetes at all. This seems to be the reason that Aureobasidin A is not effective for Zygomycetes as an antifungal agent. Our results indicate that the biosynthetic pathway for GSLs in Zygomycetes is significantly different from those in other fungi and suggest that any inhibitor of this pathway may be effective for mucormycosis, which is a serious pathogenic disease for humans.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan; Shiga Univ Med Sci, Fac Liberal Arts & Educ, Shiga 5200862, Japan; Kyoritsu Univ Pharm, Minato Ku, Tokyo 1058512, Japan	Kyoto University; Shiga University of Medical Science	Aoki, K (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Oiwake Cho, Kyoto 6068502, Japan.	kaoki@lif.kyoto-u.ac.jp	Aoki, Kazuhiro/H-8283-2014	Katayama, Takane/0000-0003-4009-7874; Aoki, Kazuhiro/0000-0003-0029-4291				Aoki K, 2004, BIOCHEM J, V378, P461, DOI 10.1042/BJ20031307; CARAVEO J, 1977, AM J MED, V62, P404, DOI 10.1016/0002-9343(77)90838-5; Cheng JJ, 2001, MOL CELL BIOL, V21, P6198, DOI 10.1128/MCB.21.18.6198-6209.2001; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dai YQ, 1997, CARBOHYD RES, V304, P1, DOI 10.1016/S0008-6215(97)00195-X; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Fischl AS, 2000, METHOD ENZYMOL, V311, P123; FLORENCE P, 1996, INFECT IMMUN, V64, P3682; FUJINO Y, 1977, BIOCHIM BIOPHYS ACTA, V486, P161; Heidler SA, 2000, BBA-MOL BASIS DIS, V1500, P147, DOI 10.1016/S0925-4439(99)00097-6; IKAI K, 1991, J ANTIBIOT, V44, P925, DOI 10.7164/antibiotics.44.925; Itonori S, 2004, J LIPID RES, V45, P574, DOI 10.1194/jlr.D300030-JLR200; KADOWAKI S, 1990, AGR BIOL CHEM TOKYO, V54, P97, DOI 10.1080/00021369.1990.10869923; KADOWAKI S, 1989, AGR BIOL CHEM TOKYO, V53, P111, DOI 10.1080/00021369.1989.10869270; Kremery V, 1996, SUPPORT CARE CANCER, V4, P39, DOI 10.1007/BF01769874; LESTER RL, 1993, ADV LIPID RES, V26, P253; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NOZIA N, 1996, CHEM PHARM BULL, V44, P895; Oliver MR, 1996, CLIN INFECT DIS, V22, P521, DOI 10.1093/clinids/22.3.521; PERSAT F, 1992, J BIOL CHEM, V267, P8764; Ribes JA, 2000, CLIN MICROBIOL REV, V13, P236, DOI 10.1128/CMR.13.2.236-301.2000; Rother RP, 1996, CELL, V86, P185, DOI 10.1016/S0092-8674(00)80090-2; SUGITA M, 1997, JPN OIL CHEM SOC, V46, P755; TAKESAKO K, 1993, J ANTIBIOT, V46, P1414, DOI 10.7164/antibiotics.46.1414; Tobon AM, 2003, CLIN INFECT DIS, V36, P1488, DOI 10.1086/375075; WANG E, 1991, J BIOL CHEM, V266, P14486; WEITZMAN I, 1993, J CLIN MICROBIOL, V31, P2523, DOI 10.1128/JCM.31.9.2523-2525.1993; YAWEI NI, 2000, CLIN DIAGN LAB IMMUN, V7, P490; Zabel D D, 1997, Del Med J, V69, P459; Zhong WY, 2000, ANTIMICROB AGENTS CH, V44, P651, DOI 10.1128/AAC.44.3.651-653.2000	31	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32028	32034		10.1074/jbc.M312918200	http://dx.doi.org/10.1074/jbc.M312918200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155728	hybrid			2022-12-27	WOS:000222849700006
J	Anneren, C; Cowan, CA; Melton, DA				Anneren, C; Cowan, CA; Melton, DA			The Src family of tyrosine kinases is important for embryonic stem cell self-renewal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; SIGNAL-TRANSDUCTION; ACTIVATION; EXPRESSION; DIFFERENTIATION; PLURIPOTENCY; MAINTENANCE; MAINTAIN; RECEPTOR; STAT3	cYes, a member of the Src family of non-receptor tyrosine kinases, is highly expressed in mouse and human embryonic stem (ES) cells. We demonstrate that cYes kinase activity is regulated by leukemia inhibitory factor (LIF) and serum and is down-regulated when cells differentiate. Moreover, selective chemical inhibition of Src family kinases decreases growth and expression of stem cell genes that mark the undifferentiated state, including Oct3/4, alkaline phosphatase, fibroblast growth factor 4, and Nanog. A synergistic effect on differentiation is observed when ES cells are cultured with an Src family inhibitor and low levels of retinoic acid. Src family kinase inhibition does not interfere with LIF-induced JAK/STAT3 (Janus-associated tyrosine kinases/ signal transducer and activator of transcription 3) or p42/p44 MAPK (mitogen-activated protein kinase) phosphorylation. Together the results suggest that the activation of the Src family is important for maintaining mouse and human ES in an undifferentiated state and may represent a third, independent pathway, downstream of LIF in mouse ES cells.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute	Melton, DA (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	dmelton@mcb.harvard.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Anneren, Cecilia/0000-0003-3600-6650				Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BOULTER CA, 1991, DEVELOPMENT, V111, P357; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rose-John S, 2002, TRENDS BIOTECHNOL, V20, P417, DOI 10.1016/S0167-7799(02)02056-5; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Shen MM, 1997, DEVELOPMENT, V124, P429; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Summy JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS185, DOI 10.2741/1011; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	40	118	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31590	31598		10.1074/jbc.M403547200	http://dx.doi.org/10.1074/jbc.M403547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148312	hybrid			2022-12-27	WOS:000222726800082
J	Kasrayan, A; Birgander, PL; Pappalardo, L; Regnstrom, K; Westman, M; Slaby, A; Gordon, E; Sjoberg, BM				Kasrayan, A; Birgander, PL; Pappalardo, L; Regnstrom, K; Westman, M; Slaby, A; Gordon, E; Sjoberg, BM			Enhancement by effectors and substrate nucleotides of R1-R2 interactions in Escherichia coli class Ia ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; SITE-DIRECTED MUTAGENESIS; DIPHOSPHATE REDUCTASE; ALLOSTERIC REGULATION; SUBUNIT INTERACTION; ELECTRON-TRANSFER; PROTEIN R1; THIOREDOXIN REDUCTASE; COMPREHENSIVE MODEL	Ribonucleotide reductases are a family of essential enzymes that catalyze the reduction of ribonucleotides to their corresponding deoxyribonucleotides and provide cells with precursors for DNA synthesis. The different classes of ribonucleotide reductase are distinguished based on quaternary structures and enzyme activation mechanisms, but the components harboring the active site region in each class are evolutionarily related. With a few exceptions, ribonucleotide reductases are allosterically regulated by nucleoside triphosphates (ATP and dNTPs). We have used the surface plasmon resonance technique to study how allosteric effects govern the strength of quaternary interactions in the class Ia ribonucleotide reductase from Escherichia coli, which like all class I enzymes has a tetrameric alpha(2)beta(2) structure. The alpha(2) component called R1 harbors the active site and two types of binding sites for allosteric effector nucleotides, whereas the beta(2) component called R2 harbors the tyrosyl radical necessary for catalysis. Our results show that only the known allosteric effector nucleotides, but not non-interacting nucleotides, promote a specific interaction between R1 and R2. Interestingly, the presence of substrate together with allosteric effector nucleotide strengthens the complex 2 - 3 times with a similar free energy change as the mutual allosteric effects of substrate and effector nucleotide binding to protein R1 in solution experiments. The dual allosteric effects of dATP as positive allosteric effector at low concentrations and as negative allosteric effector at high concentrations coincided with an almost 100-fold stronger R1-R2 interaction. Based on the experimental setup, we propose that the inhibition of enzyme activity in the E. coli class Ia enzyme occurs in a tight 1: 1 complex of R1 and R2. Most intriguingly, we also discovered that thioredoxin, one of the physiological reductants of ribonucleotide reductases, enhances the R1-R2 interaction 4-fold.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se	Pappalardo, Lucia/ABA-9311-2020	Pappalardo, Lucia/0000-0002-4491-2082; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Berardi MJ, 1999, J MOL BIOL, V292, P151, DOI 10.1006/jmbi.1999.3067; Birgander PL, 2004, J BIOL CHEM, V279, P14496, DOI 10.1074/jbc.M310142200; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Ekberg M, 1998, J BIOL CHEM, V273, P21003, DOI 10.1074/jbc.273.33.21003; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Erickson HK, 2001, BIOCHEMISTRY-US, V40, P9631, DOI 10.1021/bi010651n; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; HANSON E, 1994, J BIOL CHEM, V269, P30999; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Larsson A, 1996, EUR J BIOCHEM, V237, P58, DOI 10.1111/j.1432-1033.1996.0058n.x; LARSSON A, 1966, J BIOL CHEM, V241, P2540; LUNN CA, 1984, J BIOL CHEM, V259, P469; LYCKSELL PO, 1995, FEBS LETT, V368, P441, DOI 10.1016/0014-5793(95)00706-F; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; Reichard P, 2002, ARCH BIOCHEM BIOPHYS, V397, P149, DOI 10.1006/abbi.2001.2637; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; RUSSEL M, 1985, J BACTERIOL, V163, P238, DOI 10.1128/JB.163.1.238-242.1985; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; SJOBERG BM, 2001, ENCY LIFE SCI; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1973, J BIOL CHEM, V248, P4591; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0	44	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31050	31057		10.1074/jbc.M400693200	http://dx.doi.org/10.1074/jbc.M400693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145955	hybrid			2022-12-27	WOS:000222726800019
J	Okochi, M; Nomura, T; Zako, T; Arakawa, T; Iizuka, R; Ueda, H; Funatsu, T; Leroux, M; Yohda, M				Okochi, M; Nomura, T; Zako, T; Arakawa, T; Iizuka, R; Ueda, H; Funatsu, T; Leroux, M; Yohda, M			Kinetics and binding sites for interaction of the prefoldin with a group II chaperonin - Contiguous non-native substrate and chaperonin binding sites in the archaeal prefoldin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOCOCCUS STRAIN KS-1; EUKARYOTIC PREFOLDIN; CYTOSOLIC CHAPERONIN; UNFOLDED PROTEINS; THERMOSOME; POLYPEPTIDE; COMPLEXES; SUBUNITS; TUBULIN; CAVITY	Prefoldin is a jellyfish-shaped hexameric co-chaperone of the group II chaperonins. It captures a protein folding intermediate and transfers it to a group II chaperonin for completion of folding. The manner in which prefoldin interacts with its substrates and cooperates with the chaperonin is poorly understood. In this study, we have examined the interaction between a prefoldin and a chaperonin from hyperthermophilic archaea by immunoprecipitation, single molecule observation, and surface plasmon resonance. We demonstrate that Pyrococcus prefoldin interacts most tightly with its cognate chaperonin, and vice versa, suggesting species specificity in the interaction. Using truncation mutants, we uncovered by kinetic analyses that this interaction is multivalent in nature, consistent with multiple binding sites between the two chaperones. We present evidence that both N- and C-terminal regions of the prefoldin beta subunit are important for molecular chaperone activity and for the interaction with a chaperonin. Our data are consistent with substrate and chaperonin binding sites on prefoldin that are different but in close proximity, which suggests a possible handover mechanism of prefoldin substrates to the chaperonin.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Waseda Univ, Sch Sci & Engn, Dept Phys, Tokyo 1698555, Japan; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Tokyo University of Agriculture & Technology; University of Tokyo; Waseda University; Simon Fraser University	Yohda, M (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Tokyo 1848588, Japan.	yohda@cc.tuat.ac.jp	Ueda, Hiroshi/A-3515-2011; Yohda, Masafumi/A-5149-2013; Funatsu, Takashi/Q-1404-2015; Arakawa, Takatoshi/K-9739-2013; Zako, Tamotsu/C-3004-2012	Ueda, Hiroshi/0000-0001-8849-4217; Yohda, Masafumi/0000-0001-8307-9671; Funatsu, Takashi/0000-0002-9656-8308; Arakawa, Takatoshi/0000-0001-6496-5440; Iizuka, Ryo/0000-0002-9328-5628				Archibald JM, 1999, CURR BIOL, V9, P1053, DOI 10.1016/S0960-9822(99)80457-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; Fenton WA, 1997, PROTEIN SCI, V6, P743; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Gutsche I, 2001, J STRUCT BIOL, V135, P139, DOI 10.1006/jsbi.2001.4373; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Iizuka R, 2003, J BIOL CHEM, V278, P44959, DOI 10.1074/jbc.M305484200; Iizuka R, 2001, BIOCHEM BIOPH RES CO, V289, P1118, DOI 10.1006/bbrc.2001.6139; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Leroux MR, 1999, EMBO J, V18, P6730, DOI 10.1093/emboj/18.23.6730; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Okochi M, 2002, BIOCHEM BIOPH RES CO, V291, P769, DOI 10.1006/bbrc.2002.6523; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Shomura Y, 2004, J MOL BIOL, V335, P1265, DOI 10.1016/j.jmb.2003.11.028; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Simons CT, 2004, J BIOL CHEM, V279, P4196, DOI 10.1074/jbc.M306053200; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220; Yoshida T, 2001, MOL MICROBIOL, V39, P1406, DOI 10.1046/j.1365-2958.2001.02334.x	32	51	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31788	31795		10.1074/jbc.M402889200	http://dx.doi.org/10.1074/jbc.M402889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145959	hybrid			2022-12-27	WOS:000222726800105
J	Velarde, JJ; Nataro, JP				Velarde, JJ; Nataro, JP			Hydrophobic residues of the autotransporter EspP linker domain are important for outer membrane translocation of its passenger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXTRACELLULAR TRANSPORT; SERINE-PROTEASE; SECRETION; PROTEINS; SURFACE; BRKA; DETERMINANTS; SEQUENCE; RELEASE	The autotransporter family of proteins is an important class of Gram-negative secreted virulence factors. Their secretion mechanism comprises entry to the periplasm via the Sec apparatus, followed by formation of an outer membrane beta barrel, which allows the N-terminal passenger domain to pass to the extracellular space. Several groups have identified a region immediately upstream of the beta domain that is important for outer membrane translocation, the so-called linker region. Here we characterize this region in EspP, a prototype of the serine protease autotransporters of enterobacteriaceae. We hypothesized that the folding of this region would be important in the outer membrane translocation process. We tested this hypothesis using a mutagenesis approach in conjunction with a series of nested deletions and found that in the absence of a complete passenger, mutations to the C-terminal helix, but not the upstream linker, significantly decrease secretion efficiency. However, in the presence of the passenger mutations to the amino-terminal region of the linker decrease secretion efficiency. Moreover, amino acids of hydrophobic character play a crucial role in linker function, suggesting the existence of a hydrophobic core or hydrophobic interaction necessary for outer membrane translocation of autotransporter proteins.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Nataro, JP (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, 685 W Baltimore St,HSF 441, Baltimore, MD 21201 USA.	jnataro@medicine.umaryland.edu			NIAID NIH HHS [AI-43615, F31-AI50249] Funding Source: Medline; NIGMS NIH HHS [R25-GM55036] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI050249, R56AI043615, R01AI043615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055036] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Brandon LD, 2003, MOL MICROBIOL, V50, P45, DOI 10.1046/j.1365-2958.2003.03674.x; Brandon LD, 2001, J BACTERIOL, V183, P951, DOI 10.1128/JB.183.3.951-958.2001; Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x; DIEDRICH DL, 1977, J BACTERIOL, V131, P598, DOI 10.1128/JB.131.2.598-607.1977; Djafari S, 1997, MOL MICROBIOL, V25, P771, DOI 10.1046/j.1365-2958.1997.5141874.x; Dutta PR, 2003, J BIOL CHEM, V278, P39912, DOI 10.1074/jbc.M303595200; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; FUKUDA I, 1995, J BACTERIOL, V177, P1719, DOI 10.1128/jb.177.7.1719-1726.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLOW E, 1999, USING ANTIBODIES LAB, P269; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Hendrixson DR, 1997, MOL MICROBIOL, V26, P505, DOI 10.1046/j.1365-2958.1997.5921965.x; Jose J, 1996, GENE, V178, P107, DOI 10.1016/0378-1119(96)00343-5; JOSE J, 1995, MOL MICROBIOL, V18, P378, DOI 10.1111/j.1365-2958.1995.mmi_18020378.x; KLAUSER T, 1990, EMBO J, V9, P1991, DOI 10.1002/j.1460-2075.1990.tb08327.x; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; Konieczny MPJ, 2001, ANTON LEEUW INT J G, V80, P19, DOI 10.1023/A:1012084325728; Loveless BJ, 1997, MOL MEMBR BIOL, V14, P113, DOI 10.3109/09687689709048171; MARSHAK DR, 1996, STRATEGIES PROTEIN P, P373; Maurer J, 1997, J BACTERIOL, V179, P794, DOI 10.1128/jb.179.3.794-804.1997; Maurer J, 1999, J BACTERIOL, V181, P7014, DOI 10.1128/JB.181.22.7014-7020.1999; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P10; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; OHNISHI Y, 1994, J BIOL CHEM, V269, P32800; Oliver DC, 2003, MOL MICROBIOL, V47, P1367, DOI 10.1046/j.1365-2958.2003.03377.x; Oliver DC, 2003, J BACTERIOL, V185, P489, DOI 10.1128/JB.185.2.489-495.2003; Oomen CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/sj.emboj.7600148; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; Purdy GE, 2002, INFECT IMMUN, V70, P6355, DOI 10.1128/IAI.70.11.6355-6364.2002; Roggenkamp A, 2003, J BACTERIOL, V185, P3735, DOI 10.1128/JB.185.13.3735-3744.2003; Sambrook J., 2001, MOL CLONING LAB MANU; Shannon JL, 1999, J BACTERIOL, V181, P5838, DOI 10.1128/JB.181.18.5838-5842.1999; Sheikh J, 2001, MOL MICROBIOL, V41, P983, DOI 10.1046/j.1365-2958.2001.02512.x; Surana NK, 2004, J BIOL CHEM, V279, P14679, DOI 10.1074/jbc.M311496200; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; Tao Bernard Y., 1994, P69; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Veiga E, 1999, MOL MICROBIOL, V33, P1232, DOI 10.1046/j.1365-2958.1999.01571.x; Veiga E, 2004, MOL MICROBIOL, V52, P1069, DOI 10.1111/j.1365-2958.2004.04014.x; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; [No title captured]	47	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31495	31504		10.1074/jbc.M404424200	http://dx.doi.org/10.1074/jbc.M404424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15151995	hybrid			2022-12-27	WOS:000222726800072
J	Crambert, G; Li, CM; Swee, LK; Geering, K				Crambert, G; Li, CM; Swee, LK; Geering, K			FXYD7, mapping of functional sites involved in endoplasmic reticulum export, association with and regulation of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; GAMMA-SUBUNIT; SECRETORY PATHWAY; PROTGF-ALPHA; BETA-SUBUNIT; TRANSPORT; PROTEIN; MEMBRANE; ISOZYMES; LOCALIZATION	The brain-specific FXYD7 is a member of the recently defined FXYD family that associates with the alpha1-beta1 Na,K-ATPase isozyme and induces an about 2-fold decrease in its apparent K+ affinity. By using the Xenopus oocyte as an expression system, we have investigated the role of conserved and FXYD7-specific amino acids in the cellular routing of FXYD7 and in its association with and regulation of Na,K-ATPase. In contrast to FXYD2 and FXYD4, the studies on FXYD7 show that the conserved FXYD motif in the extracytoplasmic domain is not involved in the efficient association of FXYD7 with Na,K-ATPase. On the other hand, the conserved Gly(40) and Gly(29), located on the same face of the transmembrane helix, were found to be implicated both in the association with and the regulation of Na,K-ATPase. Mutational analysis of FXYD7-specific regions revealed the presence of an ER export signal at the end of the cytoplasmic tail. Deletion of a C-terminal valine residue in FXYD7 significantly delayed and decreased its O-glycosylation processing and retarded the rate of its cell surface expression. This result indicates that the C-terminal valine residue is involved in the rapid and selective ER export of FXYD7, which could explain the observed post-translational association of FXYD7 with Na,K-ATPase. In conclusion, our study on FXYD7 provides new information on structural determinants of general importance for FXYD protein action. Moreover, FXYD7 is identified as a new member of proteins with a regulated ER export, which suggests that, among FXYD proteins, FXYD7 has a particular regulatory function in brain.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	kaethi.geering@ipharm.unil.ch		Crambert, Gilles/0000-0001-7065-9124				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cordat E, 2003, TRAFFIC, V4, P642, DOI 10.1034/j.1600-0854.2003.00123.x; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE, V166, pRE1; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Iodice L, 2001, J BIOL CHEM, V276, P28920, DOI 10.1074/jbc.M103558200; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; LODISH HF, 1988, J BIOL CHEM, V263, P2107; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Nufer O, 2002, J CELL SCI, V115, P619; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Urena JM, 1999, J CELL SCI, V112, P773; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	34	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30888	30895		10.1074/jbc.M313494200	http://dx.doi.org/10.1074/jbc.M313494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133029	hybrid			2022-12-27	WOS:000222531900123
J	Yamaguchi, T; Omatsu, N; Matsushita, S; Osumi, T				Yamaguchi, T; Omatsu, N; Matsushita, S; Osumi, T			CGI-58 interacts with perilipin and is localized to lipid droplets - Possible involvement of CGI-58 mislocalization in Chanarin-Dorfman syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; HORMONE-SENSITIVE LIPASE; GENE; EXPRESSION; IDENTIFICATION; LIPOLYSIS; STORAGE; CELLS; OBESITY; TISSUE	Lipid droplets (LDs) are a class of ubiquitous cellular organelles that are involved in lipid storage and metabolism. Although the mechanisms of the biogenesis of LDs are still unclear, a set of proteins called the PAT domain family have been characterized as factors associating with LDs. Perilipin, a member of this family, is expressed exclusively in the adipose tissue and regulates the breakdown of triacylglycerol in LDs via its phosphorylation. In this study, we used a yeast two-hybrid system to examine the potential function of perilipin. We found direct interaction between perilipin and CGI-58, a deficiency of which correlated with the pathogenesis of Chanarin-Dorfman syndrome (CDS). Endogenous CGI-58 was distributed predominantly on the surface of LDs in differentiated 3T3-L1 cells, and its expression increased during adipocyte differentiation. Overexpressed CGI-58 tagged with GFP gathered at the surface of LDs and colocalized with perilipin. This interaction seems physiologically important because CGI-58 mutants carrying an amino acid substitution identical to that found in CDS lost the ability to be recruited to LDs. These mutations significantly weakened the binding of CGI-58 with perilipin, indicating that the loss of this interaction is involved in the etiology of CDS. Furthermore, we identified CGI-58 as a binding partner of ADRP, another PAT domain protein expressed ubiquitously, by yeast two-hybrid assay. GFP-CGI-58 expressed in non-differentiated 3T3-L1 or CHO-K1 cells was colocalized with ADRP, and the CGI-58 mutants were not recruited to LDs carrying ADRP, indicating that CGI-58 may also cooperate with ADRP.	Univ Hyogo, Grad Sch Life Sci, Himeji Inst Technol, Kamigori, Hyogo 6781297, Japan	University of Hyogo	Osumi, T (corresponding author), Univ Hyogo, Grad Sch Life Sci, Himeji Inst Technol, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.	osumi@sci.u-hyogo.ac.jp						Akiyama M, 2003, J INVEST DERMATOL, V121, P1029, DOI 10.1046/j.1523-1747.2003.12520.x; Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; Corsini E, 2003, J INVEST DERMATOL, V121, P337, DOI 10.1046/j.1523-1747.2003.12371.x; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; DORFMAN ML, 1974, ARCH DERMATOL, V110, P261, DOI 10.1001/archderm.110.2.261; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Garcia A, 2004, J BIOL CHEM, V279, P8409, DOI 10.1074/jbc.M311198200; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Haemmerle G, 2002, J BIOL CHEM, V277, P12946, DOI 10.1074/jbc.M108640200; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Krise JP, 2000, J BIOL CHEM, V275, P25188, DOI 10.1074/jbc.M001138200; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; McManaman JL, 2002, J PHYSIOL-LONDON, V545, P567, DOI 10.1113/jphysiol.2002.027185; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Nagai S, 2004, ENDOCRINOLOGY, V145, P2346, DOI 10.1210/en.2003-1180; Nakamura N, 2003, BIOCHEM BIOPH RES CO, V306, P333, DOI 10.1016/S0006-291X(03)00979-3; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Osada S, 1997, GENES CELLS, V2, P315, DOI 10.1046/j.1365-2443.1997.1220319.x; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Rosenbaum SE, 1998, MOL ENDOCRINOL, V12, P1150, DOI 10.1210/me.12.8.1150; ROZENSZAJN L, 1966, BLOOD-J HEMATOL, V28, P258, DOI 10.1182/blood.V28.2.258.258; Schrag JD, 1997, METHOD ENZYMOL, V284, P85; Schultz CJ, 2002, AM J PHYSIOL-LUNG C, V283, pL288, DOI 10.1152/ajplung.00204.2001; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Shimizu M, 2004, MOL CELL BIOL, V24, P1313, DOI 10.1128/MCB.24.3.1313-1323.2004; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Tominaga S, 2002, J BIOCHEM, V132, P881, DOI 10.1093/oxfordjournals.jbchem.a003301; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Yamasaki M, 1999, J BIOL CHEM, V274, P35293, DOI 10.1074/jbc.274.50.35293; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200	49	199	204	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30490	30497		10.1074/jbc.M403920200	http://dx.doi.org/10.1074/jbc.M403920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136565	hybrid			2022-12-27	WOS:000222531900077
J	Horisberger, JD; Kharoubi-Hess, S; Guennoun, S; Michielin, O				Horisberger, JD; Kharoubi-Hess, S; Guennoun, S; Michielin, O			The fourth transmembrane segment of the Na,K-ATPase alpha subunit - A systematic mutagenesis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; CYSTEINE-SCANNING MUTAGENESIS; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; BETA-SUBUNIT; GASTRIC H+,K+-ATPASE; STRUCTURAL-CHANGES; CATION-BINDING; CALCIUM-PUMP; CA2+-ATPASE	The Na,K-ATPase is a major ion-motive ATPase of the P-type family responsible for many aspects of cellular homeostasis. To determine the structure of the pathway for cations across the transmembrane portion of the Na, K-ATPase, we mutated 24 residues of the fourth transmembrane segment into cysteine and studied their function and accessibility by exposure to the sulfhydryl reagent 2-aminoethyl-methanethiosulfonate. Accessibility was also examined after treatment with palytoxin, which transforms the Na, K-pump into a cation channel. Of the 24 tested cysteine mutants, seven had no or a much reduced transport function. In particular cysteine mutants of the highly conserved "PEG" motif had a strongly reduced activity. However, most of the non-functional mutants could still be transformed by palytoxin as well as all of the functional mutants. Accessibility, determined as a 2-aminoethylmethanethiosulfonate- induced reduction of the transport activity or as inhibition of the membrane conductance after palytoxin treatment, was observed for the following positions: Phe(323), Ile(322), Gly(326), Ala(330), Pro(333), Glu(334), and Gly(335). In accordance with a structural model of the Na,K-ATPase obtained by homology modeling with the two published structures of sarcoplasmic and endoplasmic reticulum calcium ATPase ( Protein Data Bank codes 1EUL and 1IWO), the results suggest the presence of a cation pathway along the side of the fourth transmembrane segment that faces the space between transmembrane segments 5 and 6. The phenylalanine residue in position 323 has a critical position at the outer mouth of the cation pathway. The residues thought to form the cation binding site II ((333)PEGL) are also part of the accessible wall of the cation pathway opened by palytoxin through the Na, K-pump.	Univ Lausanne, Inst Pharmacol & Toxicol, Dept Pharmacol & Toxicol, Sch Med, CH-1005 Lausanne, Switzerland; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol Physiol, Newark, NJ 07103 USA; Swiss Inst Bioinformat, CH-1066 Epalinges, Switzerland; Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; CHU Vaudois, Ctr Pluridsiciplinaire Oncol, CH-1011 Lausanne, Switzerland	University of Lausanne; Rutgers State University New Brunswick; Rutgers State University Medical Center; Swiss Institute of Bioinformatics; Ludwig Institute for Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Horisberger, JD (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Dept Pharmacol & Toxicol, Sch Med, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Jean-Daniel.Horisberger@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009; Michielin, Olivier/ABE-7924-2020					ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; Artigas P, 2004, J GEN PHYSIOL, V123, P357, DOI 10.1085/jgp.200308964; Artigas P, 2003, P NATL ACAD SCI USA, V100, P501, DOI 10.1073/pnas.0135849100; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Guennoun S, 2000, FEBS LETT, V482, P144, DOI 10.1016/S0014-5793(00)02050-0; Guennoun S, 2002, FEBS LETT, V513, P277, DOI 10.1016/S0014-5793(02)02323-2; Hermsen HPH, 2001, BIOCHEMISTRY-US, V40, P6527, DOI 10.1021/bi002456z; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1992, J BIOL CHEM, V267, P577; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Jorgensen PL, 2003, ANN NY ACAD SCI, V986, P22, DOI 10.1111/j.1749-6632.2003.tb07135.x; Koenderink JB, 2001, J BIOL CHEM, V276, P11705, DOI 10.1074/jbc.M010804200; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUGER P, 1979, BIOCHIM BIOPHYS ACTA, V552, P143, DOI 10.1016/0005-2736(79)90253-0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Mense M, 2000, J BIOL CHEM, V275, P1749, DOI 10.1074/jbc.275.3.1749; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Qiu LY, 2003, J BIOL CHEM, V278, P47240, DOI 10.1074/jbc.M308833200; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Swarts HGP, 2001, J BIOL CHEM, V276, P36909, DOI 10.1074/jbc.M103945200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wang XY, 1996, MOL PHARMACOL, V50, P687	39	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29542	29550		10.1074/jbc.M400585200	http://dx.doi.org/10.1074/jbc.M400585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123699	hybrid			2022-12-27	WOS:000222445300088
J	Lambers, TT; Weidema, AF; Nilius, B; Hoenderop, JGJ; Bindels, RJM				Lambers, TT; Weidema, AF; Nilius, B; Hoenderop, JGJ; Bindels, RJM			Regulation of the mouse epithelial Ca2+ channel TRPV6 by the Ca2+-sensor calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL; BINDING-SITES; EXPRESSION; IDENTIFICATION; INACTIVATION; INHIBITION; MECHANISM; TERMINUS; SUBUNIT; PROTEIN	TRPV5 and TRPV6 are members of the superfamily of transient receptor potential (TRP) channels and facilitate Ca2+ influx in a variety of epithelial cells. The activity of these Ca2+ channels is tightly controlled by the intracellular Ca2+ concentration in close vicinity to the channel mouth. The molecular mechanism underlying the Ca2+-dependent activity of TRPV5/TRPV6 is, however, still unknown. Here, the putative role of calmodulin (CaM) as the Ca2+ sensor mediating the regulation of channel activity was investigated. Overexpression of Ca2+-insensitive CaM mutants (CaM1234 and CaM34) significantly reduced the Ca2+ as well as the Na+ current of TRPV6- but not that of TRPV5-expressing HEK293 cells. By combining pull-down assays and co-immunoprecipitations, we demonstrated that CaM binds to both TRPV5 and TRPV6 in a Ca2+-dependent fashion. The binding of CaM to TRPV6 was localized to the transmembrane domain (TRPV6(327-577)) and consensus CaM-binding motifs located in the N (1-5-10 motif, TRPV6(88-97)) and C termini ( 1 - 8- 14 motif, TRPV6(643-656)), suggesting a mechanism of regulation involving multiple interaction sites. Subsequently, chimeric TRPV6/TRPV5 proteins, in which the N and/or C termini of TRPV6 were substituted by that of TRPV5, were co-expressed with CaM34 in HEK293 cells. Exchanging, the N and/or the C termini of TRPV6 by that of TRPV5 did not affect the CaM34- induced reduction of the Ca2+ and Na+ currents. These results suggest that CaM positively affects TRPV6 activity upon Ca2+ binding to EF-hands 3 and 4, located in the high Ca2+ affinity CaM C terminus, which involves the N and C termini and the transmembrane domain of TRPV6.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands; Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium	Radboud University Nijmegen; KU Leuven	Bindels, RJM (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Physiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@ncmls.kun.nl	Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014	Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544				Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Hirnet D, 2003, CELL CALCIUM, V33, P509, DOI 10.1016/S0143-4160(03)00066-6; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Peng CH, 2003, J BIOL CHEM, V278, P24617, DOI 10.1074/jbc.M301699200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; WANG CLA, 1985, BIOCHEM BIOPH RES CO, V130, P426, DOI 10.1016/0006-291X(85)90434-6; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	28	101	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28855	28861		10.1074/jbc.M313637200	http://dx.doi.org/10.1074/jbc.M313637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123711	Green Published, hybrid			2022-12-27	WOS:000222445300005
J	Angata, K; Long, JM; Bukalo, O; Lee, W; Dityatev, A; Wynshaw-Boris, A; Schachner, M; Fukuda, M; Marth, JD				Angata, K; Long, JM; Bukalo, O; Lee, W; Dityatev, A; Wynshaw-Boris, A; Schachner, M; Fukuda, M; Marth, JD			Sialyltransferase ST8Sia-II assembles a subset of polysialic acid that directs hippocampal axonal targeting and promotes fear behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CENTRAL-NERVOUS-SYSTEM; LONG-TERM POTENTIATION; MOSSY FIBER SYNAPSES; SYNAPTIC PLASTICITY; MICE DEFICIENT; PSA-NCAM; GENOMIC STRUCTURE; OLFACTORY-BULB; DENTATE GYRUS	Polysialic acid (PSA) is a post-translational protein modification that is widely expressed among neural cell types during development. Found predominantly on the neural cell adhesion molecule ( NCAM), PSA becomes restricted to regions of neurogenesis and neuroplasticity in the adult. In the mammalian genome, two polysialyltransferases termed ST8Sia-II and ST8Sia-IV have been hypothesized to be responsible for the production of PSA in vivo. Approaches to discover PSA function have involved the application of endoneuraminidase-N to remove PSA and genetic manipulations in the mouse to deplete either NCAM or ST8Sia-IV. Here we report the production and characterization of mice deficient in the ST8Sia-II polysialyltransferase. We observed alterations in brain PSA expression unlike those observed in mice lacking ST8Sia-IV. This included a PSA deficit in regions of neurogenesis but without changes in the frequency of mitotic neural progenitor cells. In further contrast with ST8Sia-IV deficiency, loss of ST8Sia-II did not impair hippocampal synaptic plasticity but instead resulted in the misguidance of infrapyramidal mossy fibers and the formation of ectopic synapses in the hippocampus. Consistent with studies of animal models bearing these morphological changes, ST8Sia-II-deficient mice exhibited higher exploratory drive and reduced behavioral responses to Pavlovian fear conditioning. PSA produced by the ST8Sia-II polysialyltransferase modifies memory and behavior processes that are distinct from the neural roles reported for ST8Sia-IV. This genetic partitioning of PSA formation engenders discrete neurological processes and reveals that this post-translational modification forms the predominant basis for the multiple functions attributed to the NCAM glycoprotein.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA.	minoru@burnham-inst.org; jmarth@ucsd.edu	Angata, Kiyohiko/M-2749-2018; Dityatev, Alexander/A-4034-2008	Angata, Kiyohiko/0000-0001-5561-1368; Dityatev, Alexander/0000-0002-0472-0553	NCI NIH HHS [CA33895] Funding Source: Medline; NHLBI NIH HHS [P01-HL57345] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline; NIGMS NIH HHS [GM62116] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMASSARITEULE M, 1991, BRAIN RES, V551, P104, DOI 10.1016/0006-8993(91)90919-M; Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Bagri A, 2003, CELL, V113, P285, DOI 10.1016/S0092-8674(03)00267-8; Becker CG, 1996, J NEUROSCI RES, V45, P143, DOI 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; CLAIBORNE BJ, 1993, HIPPOCAMPUS, V3, P115, DOI 10.1002/hipo.450030202; Corbo JC, 2002, J NEUROSCI, V22, P7548; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cremer H, 1998, P NATL ACAD SCI USA, V95, P13242, DOI 10.1073/pnas.95.22.13242; Cremer H, 2000, INT J DEV NEUROSCI, V18, P213, DOI 10.1016/S0736-5748(99)00090-8; Cremer H, 1997, MOL CELL NEUROSCI, V8, P323, DOI 10.1006/mcne.1996.0588; Crusio WE, 2001, BEHAV BRAIN RES, V125, P127, DOI 10.1016/S0166-4328(01)00280-7; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Eckhardt M, 1998, GLYCOBIOLOGY, V8, P1165, DOI 10.1093/glycob/8.12.1165; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; Evers MR, 2002, J NEUROSCI, V22, P7177; Fanselow MS, 1999, NEURON, V23, P229, DOI 10.1016/S0896-6273(00)80775-8; Franklin K. B. J., 1996, MOUSE BRAIN STEREOTA; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; GAARSKJAER FB, 1986, BRAIN RES REV, V11, P335, DOI 10.1016/0165-0173(86)90004-4; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; Henze DA, 2000, NEUROSCIENCE, V98, P407, DOI 10.1016/S0306-4522(00)00146-9; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Kiss JZ, 2001, BRAIN RES REV, V36, P175, DOI 10.1016/S0165-0173(01)00093-5; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kurosawa N, 1997, J NEUROCHEM, V69, P494; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; Maccaferri G, 1998, SCIENCE, V279, P1368, DOI 10.1126/science.279.5355.1368; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; Marx M, 2001, DEVELOPMENT, V128, P4949; McIlwain KL, 2001, PHYSIOL BEHAV, V73, P705, DOI 10.1016/S0031-9384(01)00528-5; Montag-Sallaz M, 2002, MOL CELL BIOL, V22, P7967, DOI 10.1128/MCB.22.22.7967-7981.2002; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nacher J, 2002, NEUROSCIENCE, V113, P479, DOI 10.1016/S0306-4522(02)00219-1; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; Prior H, 1997, BEHAV BRAIN RES, V87, P183, DOI 10.1016/S0166-4328(97)02282-1; Rodriguez JJ, 1998, EUR J NEUROSCI, V10, P2994, DOI 10.1046/j.1460-9568.1998.00316.x; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; Sandi C, 2003, BIOL PSYCHIAT, V54, P599, DOI 10.1016/S0006-3223(03)00182-3; Sandi C, 2001, NEUROSCIENCE, V102, P329, DOI 10.1016/S0306-4522(00)00484-X; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Seki T, 1998, J NEUROSCI, V18, P3757; SERESS L, 1993, J COMP NEUROL, V337, P208, DOI 10.1002/cne.903370204; Skutella T, 2001, TRENDS NEUROSCI, V24, P107, DOI 10.1016/S0166-2236(00)01717-3; Stork O, 2000, EUR J NEUROSCI, V12, P3291, DOI 10.1046/j.1460-9568.2000.00197.x; Takashima S, 1998, J BIOL CHEM, V273, P7675, DOI 10.1074/jbc.273.13.7675; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VANDAAL JHHM, 1991, BEHAV BRAIN RES, V43, P57, DOI 10.1016/S0166-4328(05)80052-X; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167	66	150	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32603	32613		10.1074/jbc.M403429200	http://dx.doi.org/10.1074/jbc.M403429200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15140899	hybrid			2022-12-27	WOS:000222849700077
J	Lenoir, G; Picard, M; Moller, JV; le Maire, M; Champeil, P; Falson, P				Lenoir, G; Picard, M; Moller, JV; le Maire, M; Champeil, P; Falson, P			Involvement of the L6-7 loop in SERCA1a Ca2+-ATPase activation by Ca2+ (or Sr2+) and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; SITE-DIRECTED MUTAGENESIS; TRANSMEMBRANE SEGMENTS 6; P-TYPE ATPASES; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; INORGANIC-PHOSPHATE; CYTOPLASMIC LOOP; KINETIC CHARACTERIZATION; GLYCOGEN-PHOSPHORYLASE	Wild-type (WT) and the double mutant D813A, D818A (ADA) of the L6-7 loop of SERCA1a were expressed in yeast, purified, and reconstituted into lipids. This allowed us to functionally study these ATPases by both kinetic and spectroscopic means, and to solve previous discrepancies in the published literature about both experimental facts and interpretation concerning the role of this loop in P-type ATPases. We show that in a solubilized state, the ADA mutant experiences a dramatic decrease of its calcium-dependent ATPase activity. On the contrary, reconstituted in a lipid environment, it displays an almost unaltered maximal calcium-dependent ATPase activity at high ( millimolar) ATP, with an apparent affinity for Ca2+ altered only moderately (3-fold). In the absence of ATP, the true affinity of ADA for Ca2+ is, however, more significantly reduced (20-30-fold) compared with WT, as judged from intrinsic (Trp) or extrinsic ( fluorescence isothiocyanate) fluorescence experiments. At low ATP, transient kinetics experiments reveal an overshoot in the ADA phosphorylation level primarily arising from the slowing down of the transition between the nonphosphorylated "E2" and "Ca(2)E1" forms of ADA. At high ATP, this slowing down is only partially compensated for, as ADA turnover remains more sensitive to orthovanadate than WT turnover. ADA ATPase also proved to have a reduced affinity for ATP in studies performed under equilibrium conditions in the absence of Ca2+, highlighting the long range interactions between L6-7 and the nucleotide-binding site. We propose that these mutations in L6-7 could affect protonation-dependent winding and unwinding events in the nearby M6 transmembrane segment.	CEA Saclay, Dept Biol Joliot Curie, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, Sect Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France; Univ Paris 11, Lab Rech Associe 17V, Orsay, France; Univ Paris 11, Inst Federat Rech 46, Orsay, France; Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark	CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Aarhus University	Falson, P (corresponding author), CEA Saclay, Dept Biol Joliot Curie, CNRS, URA 2096, F-91191 Gif Sur Yvette, France.	pierre.falson@cea.fr	Picard, Martin/A-3236-2016; Lenoir, Guillaume/I-4002-2019	Picard, Martin/0000-0002-6518-8900; Lenoir, Guillaume/0000-0002-8759-5179; Falson, Pierre/0000-0002-9760-4577				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 2003, ANN NY ACAD SCI, V986, P72, DOI 10.1111/j.1749-6632.2003.tb07141.x; ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1983, EUR J BIOCHEM, V134, P205, DOI 10.1111/j.1432-1033.1983.tb07552.x; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CARVALHO CAM, 1976, EXPERIENTIA, V32, P428, DOI 10.1007/BF01920776; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Champeil P., 1996, BIOMEMBR, V5, P43; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Costa V, 2003, PROTEINS, V50, P104, DOI 10.1002/prot.10219; CUENDA A, 1994, BBA-BIOMEMBRANES, V1194, P35, DOI 10.1016/0005-2736(94)90200-3; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DEFORESTA B, 1992, EUR J BIOCHEM, V209, P1023, DOI 10.1111/j.1432-1033.1992.tb17378.x; DEFORESTA B, 1994, EUR J BIOCHEM, V223, P359; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1976, J BIOL CHEM, V251, P2055; DRUECKES P, 1995, ANAL BIOCHEM, V230, P173, DOI 10.1006/abio.1995.1453; Duchesne L, 2003, EUR J BIOCHEM, V270, P422, DOI 10.1046/j.1432-1033.2003.03389.x; DUPONT Y, 1988, METHOD ENZYMOL, V157, P206; DUX L, 1987, J BIOL CHEM, V262, P6439; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; Falson P, 2003, ANN NY ACAD SCI, V986, P312, DOI 10.1111/j.1749-6632.2003.tb07198.x; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FORGE V, 1993, J BIOL CHEM, V268, P10953; FORGE V, 1993, J BIOL CHEM, V268, P10961; FUJIMORI T, 1992, J BIOL CHEM, V267, P18466; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Inesi G, 2002, BIOPHYS J, V83, P2327, DOI 10.1016/S0006-3495(02)75247-8; INESI G, 1980, J BIOL CHEM, V255, P3025; KARLISH SJD, 1979, NATURE, V282, P333, DOI 10.1038/282333a0; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LACAPERE JJ, 1993, EUR J BIOCHEM, V211, P117, DOI 10.1111/j.1432-1033.1993.tb19877.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenoir G, 2002, BBA-BIOMEMBRANES, V1560, P67, DOI 10.1016/S0005-2736(01)00458-8; Lenoir G, 2004, J BIOL CHEM, V279, P9156, DOI 10.1074/jbc.M311411200; Lenoir G, 2003, ANN NY ACAD SCI, V986, P333, DOI 10.1111/j.1749-6632.2003.tb07206.x; LUND S, 1989, J BIOL CHEM, V264, P4907; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; Martonosi AN, 2003, ACTA BIOCHIM POL, V50, P337; MEIS LD, 1971, J BIOL CHEM, V246, P4759; Menguy T, 2002, J BIOL CHEM, V277, P13016, DOI 10.1074/jbc.M108899200; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Menguy T, 1998, ANAL BIOCHEM, V264, P141, DOI 10.1006/abio.1998.2854; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; Miras R, 2001, PROTEIN EXPRES PURIF, V22, P299, DOI 10.1006/prep.2001.1436; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLNAR E, 1988, ACTA BIOCHIM BIOPHYS, V23, P63; NAKAMURA Y, 1984, J BIOL CHEM, V259, P8183; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; ORLOWSKI S, 1993, FEBS LETT, V328, P296, DOI 10.1016/0014-5793(93)80947-S; ORTIZ A, 1984, BIOCHEM J, V221, P213, DOI 10.1042/bj2210213; PICK U, 1982, J BIOL CHEM, V257, P6111; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; SAHEKI S, 1985, ANAL BIOCHEM, V148, P277, DOI 10.1016/0003-2697(85)90229-5; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Scarborough GA, 2002, J BIOENERG BIOMEMBR, V34, P235, DOI 10.1023/A:1020211016696; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, INT CONGR SER, V1207, P405; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VIJAYA S, 1984, J INORG BIOCHEM, V20, P247, DOI 10.1016/0162-0134(84)85022-9; VYSKOCIL F, 1980, NATURE, V286, P516, DOI 10.1038/286516a0; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WEBER K, 1969, J BIOL CHEM, V244, P4406; Xu G, 2003, ANN NY ACAD SCI, V986, P96, DOI 10.1111/j.1749-6632.2003.tb07144.x; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	84	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32125	32133		10.1074/jbc.M402934200	http://dx.doi.org/10.1074/jbc.M402934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155750	Green Submitted, hybrid			2022-12-27	WOS:000222849700018
J	Russo, GL; Tosto, M; Mupo, A; Castellano, I; Cuomo, A; Tosti, E				Russo, GL; Tosto, M; Mupo, A; Castellano, I; Cuomo, A; Tosti, E			Biochemical and functional characterization of protein kinase CK2 in ascidian Ciona intestinalis oocytes at fertilization - Cloning and sequence analysis of cDNA for alpha and beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION; CALCIUM OSCILLATIONS; PHOSPHORYLATION SITE; METAPHASE ARREST; P34(CDC2); CKII; IDENTIFICATION; PURIFICATION; EXPRESSION; MEIOSIS	The ubiquitous and pleiotropic dual specificity protein kinase CK2 has been studied and characterized in many organisms, from yeast to mammals. Generally, the enzyme is composed of two catalytic (alpha and/or alpha') and two regulatory (beta) subunits, forming a differently assembled tetramer. Although prone to controversial interpretation, the function of CK2 has been associated with fundamental biological processes such as signal transduction, cell cycle progression, cell growth, apoptosis, and transcription. Less known is the role of CK2 during meiosis and the early phase of embryogenesis. In this work, we studied CK2 activity during oocyte activation, a process occurring at the end of oocyte maturation and triggered by fertilization. In ascidian Ciona intestinalis, an organism whose complete genome has been published recently, CK2 was constitutively active in unfertilized and fertilized oocytes. The enzymatic activity oscillated through meiosis showing three major peaks: soon after fertilization ( metaphase I exit), before metaphase II, and at the exit from metaphase II. Biochemical analysis of CK2 subunit composition in activated oocytes indicated that CK2-alpha was catalytically active as a monomer, independently from its regulatory subunit beta; however, CK2-beta was only detectable in unfertilized oocytes where it was associated with a bona fide identified ascidian mitogen-activated protein kinase. After fertilization, CK2-beta was undetectable, suggesting its rapid degradation. Protein sequence analysis of CK2-alpha and -beta cDNA indicated a high identity compared with vertebrate homologs. In addition, the absence of putative phosphorylation sites for Cdc2 kinase on both alpha and beta subunits suggested an important role for CK2 in regulating meiotic cell cycle in C. intestinalis oocytes.	CNR, Ist Sci Alimentaz, I-83100 Avellino, Italy; Staz Zool Anton Dohrn, I-80121 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); Stazione Zoologica Anton Dohrn di Napoli	Russo, GL (corresponding author), CNR, Ist Sci Alimentaz, Via Roma 52 A-C, I-83100 Avellino, Italy.	glrusso@szn.it	RUSSO, GIAN LUIGI/GQB-0962-2022; Castellano, Immacolata/AAD-5523-2019	Castellano, Immacolata/0000-0002-4274-6738; RUSSO, GIAN LUIGI/0000-0001-9321-1613; Mupo, Annalisa/0000-0002-2771-0462				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BELLE R, 1990, International Journal of Developmental Biology, V34, P111; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Donella-Deana A, 2001, BIOCHEM J, V357, P563, DOI 10.1042/0264-6021:3570563; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Gotz C, 1996, ONCOGENE, V13, P391; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; Hutson SF, 2003, DEV GENES EVOL, V213, P1, DOI 10.1007/s00427-002-0286-4; KANDROR KV, 1989, EUR J BIOCHEM, V180, P441, DOI 10.1111/j.1432-1033.1989.tb14666.x; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 2001, MOL CELL BIOCHEM, V227, P153, DOI 10.1023/A:1013108822847; LEIVA L, 1987, BIOCHEM INT, V14, P707; Levasseur M, 2000, DEVELOPMENT, V127, P631; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LITCHFIELD DW, 1995, BBA-MOL CELL RES, V1269, P69, DOI 10.1016/0167-4889(95)00100-7; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LONGO FJ, 1983, MOLLUSCA, V3, P49; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MARSHAK DR, 1994, CELL MOL BIOL RES, V40, P513; McDougall A, 1998, DEVELOPMENT, V125, P4451; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Nixon VL, 2000, BIOL CELL, V92, P187, DOI 10.1016/S0248-4900(00)01068-6; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OSBORNE HB, 1989, BIOCHEM BIOPH RES CO, V158, P520, DOI 10.1016/S0006-291X(89)80080-4; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; PYERIN W, 1994, ADV ENZYME REGUL, V34, P225, DOI 10.1016/0065-2571(94)90018-3; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; Russo GL, 1997, BIOCHEM BIOPH RES CO, V233, P673, DOI 10.1006/bbrc.1997.6515; Russo GL, 2000, BIOCHEM J, V351, P143, DOI 10.1042/0264-6021:3510143; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Russo GL, 2001, MOL CELL BIOCHEM, V227, P113, DOI 10.1023/A:1013189629207; Russo GL, 1996, DEVELOPMENT, V122, P1995; Russo GL, 1998, SEMIN CELL DEV BIOL, V9, P559, DOI 10.1006/scdb.1998.0250; Sagata N, 1996, TRENDS CELL BIOL, V6, P22, DOI 10.1016/0962-8924(96)81034-8; Sambrook J., 2001, MOL CLONING LAB MANU; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SARDET C, 1989, DEVELOPMENT, V105, P237; Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Satoh N, 2003, NAT REV GENET, V4, P285, DOI 10.1038/nrg1042; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Tosti E, 2004, HUM REPROD UPDATE, V10, P53, DOI 10.1093/humupd/dmh006; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; WILHELM V, 1995, EUR J BIOCHEM, V232, P671, DOI 10.1111/j.1432-1033.1995.tb20859.x; XU Z, 1993, DEV GENET, V14, P424, DOI 10.1002/dvg.1020140604; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; Zhang CJ, 2002, ONCOGENE, V21, P3754, DOI 10.1038/sj.onc.1205467	73	12	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					33012	33023		10.1074/jbc.M401085200	http://dx.doi.org/10.1074/jbc.M401085200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159401	hybrid			2022-12-27	WOS:000222849700121
J	Sierra, OL; Cheng, SL; Loewy, AP; Charlton-Kachigian, N; Towler, DA				Sierra, OL; Cheng, SL; Loewy, AP; Charlton-Kachigian, N; Towler, DA			MINT, the Msx2 interacting nuclear matrix target, enhances Runx2-dependent activation of the osteocalcin fibroblast growth factor response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BONE MORPHOGENETIC PROTEINS; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; SIGNALING PATHWAY; VASCULAR CALCIFICATION; HOMEODOMAIN PROTEINS; BINDING-PROTEIN; TERMINAL DOMAIN	Msx2 promotes osteogenic lineage allocation from mesenchymal progenitors but inhibits terminal differentiation demarcated by osteocalcin (OC) gene expression. Msx2 inhibits OC expression by targeting the fibroblast growth factor responsive element (OCFRE), a 42-bp DNA domain in the OC gene bound by the Msx2 interacting nuclear target protein (MINT) and Runx2/Cbfa1. To better understand Msx2 regulation of the OCFRE, we have studied functional interactions between MINT and Runx2, a master regulator of osteoblast differentiation. In MC3T3E1 osteoblasts ( with endogenous Runx2 and FGFR2), MINT augments transcription driven by the OCFRE that is further enhanced by FGF2 treatment. OCFRE regulation can be reconstituted in the naive CV1 fibroblast cell background. In CV1 cells, MINT synergizes with Runx2 to enhance OCFRE activity in the presence of activated FGFR2. The RNA recognition motif domain of MINT ( which binds the OCFRE) is required. Runx2 structural studies reveal that synergy with MINT uniquely requires Runx2 activation domain 3. In confocal immunofluorescence microscopy, MINT adopts a reticular nuclear matrix distribution that overlaps transcriptionally active osteoblast chromatin, extensively co-localizing with the phosphorylated RNA polymerase II meshwork. MINT only partially co-localizes with Runx2; however, co-localization is enhanced 2.5-fold by FGF2 stimulation. Msx2 abrogates Runx2-MINT OCFRE activation, and MINT-directed RNA interference reduces endogenous OC expression. In chromatin immunoprecipitation assays, Msx2 selectively inhibits Runx2 binding to OC chromatin. Thus, MINT enhances Runx2 activation of multiprotein complexes assembled by the OCFRE. Msx2 targets this complex as a mechanism of transcriptional inhibition. In osteoblasts, MINT may serve as a nuclear matrix platform that organizes and integrates osteogenic transcriptional responses.	Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Internal Med,Div Bone & Mineral Dis, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Internal Med,Div Bone & Mineral Dis, North Campus Box 8301,660 S Euclid Ave, St Louis, MO 63110 USA.	dtowler@im.wustl.edu		Towler, Dwight/0000-0003-2107-7923	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043731] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43731] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Cohen MM, 2000, J CRAN GENET DEV BIO, V20, P19; Demer LL, 2003, ARTERIOSCL THROM VAS, V23, P1739, DOI 10.1161/01.ATV.0000093547.63630.0F; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Franceschi RT, 2003, CALCIFIED TISSUE INT, V72, P638, DOI 10.1007/s00223-002-1053-2; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Garcia-Minaur S, 2003, EUR J HUM GENET, V11, P892, DOI 10.1038/sj.ejhg.5201062; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Goodman RH, 2000, GENE DEV, V14, P1553; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hawkins SM, 2001, J BIOL CHEM, V276, P44472, DOI 10.1074/jbc.M104193200; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; Lin PS, 2002, J BIOL CHEM, V277, P45949, DOI 10.1074/jbc.M208588200; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Mo XM, 2002, MOL CELL BIOL, V22, P8088, DOI 10.1128/MCB.22.22.8088-8099.2002; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; ONATE SA, 1995, SCIENCE, V270, P1354; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Rebay I, 2000, GENETICS, V154, P695; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shannon MF, 2003, NAT GENET, V34, P4, DOI 10.1038/ng0503-4; Shao JS, 2003, J BIOL CHEM, V278, P50195, DOI 10.1074/jbc.M308825200; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Verschure PJ, 1999, J CELL BIOL, V147, P13, DOI 10.1083/jcb.147.1.13; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Wiellette EL, 1999, DEVELOPMENT, V126, P5373; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zaidi SK, 2001, J CELL SCI, V114, P3093; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585	57	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32913	32923		10.1074/jbc.M314098200	http://dx.doi.org/10.1074/jbc.M314098200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15131132	hybrid			2022-12-27	WOS:000222849700111
J	Frick, C; Atanasov, AG; Arnold, P; Ozols, J; Odermatt, A				Frick, C; Atanasov, AG; Arnold, P; Ozols, J; Odermatt, A			Appropriate function of 11 beta-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; ARYLACETAMIDE DEACETYLASE; CHOLESTEROL-METABOLISM; REDUCTASE-ACTIVITY; ER MEMBRANES; HUMAN LIVER; ENZYME; CELLS; MACROPHAGES; OXYSTEROLS	By interconverting glucocorticoids, 11beta-hydroxysteroid dehydrogenase type 1 ( 11beta-HSD1) exerts an important pre-receptor function and is currently considered a promising therapeutic target. In addition, 11beta-HSD1 plays a potential role in 7-ketocholesterol metabolism. Here we investigated the role of the N-terminal region on enzymatic activity and addressed the relevance of 11beta-HSD1 orientation into the endoplasmic reticulum ( ER) lumen. Previous studies revealed that the luminal orientation of 11beta-HSD1 and 50-kDa esterase/ arylacetamide deacetylase (E3) is determined by their highly similar N-terminal transmembrane domains. Substitution of Lys(5) by Ser in 11beta-HSD1, but not of the analogous Lys(4) by Ile in E3, led to an inverted topology in the ER membrane, indicating the existence of a second topological determinant. Here we identified Glu(25)/Glu(26) in 11beta-HSD1 and Asp(25) in E3 as the second determinant for luminal orientation. Our results suggest that the exact location of specific residues rather than net charge distribution on either side of the helix is critical for membrane topology. Analysis of charged residues in the N-terminal domain revealed an essential role of Lys(35)/Lys(36) and Glu(25)/Glu(26) on enzymatic activity, suggesting that these residues are responsible for the observed stabilizing effect of the N-terminal membrane anchor on the catalytic domain of 11beta-HSD1. Moreover, activity measurements in intact cells expressing wildtype 11beta-HSD1, facing the ER lumen, or mutant K5S/ K6S, facing the cytoplasm, revealed that the luminal orientation is essential for efficient oxidation of cortisol. Furthermore, we demonstrate that 11beta-HSD1, but not mutant K5S/ K6S with cytoplasmic orientation, catalyzes the oxoreduction of 7-ketocholesterol. 11beta-HSD1 and E3 constructs with cytosolic orientation of their catalytic moiety should prove useful in future studies addressing the physiological function of these proteins.	Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Bern; University of Connecticut	Odermatt, A (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.	alex.odermatt@dkf1.unibe.ch	Atanasov, Atanas G./C-5535-2013	Atanasov, Atanas G./0000-0003-2545-0967; Odermatt, Alex/0000-0002-6820-2712				Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Arnold P, 2003, MOL CELL ENDOCRINOL, V201, P177, DOI 10.1016/S0303-7207(02)00304-0; BANBEGYI G, 2004, J BIOL CHEM, V279, P27017; Bannenberg G, 2003, CHEM-BIOL INTERACT, V143, P449, DOI 10.1016/S0009-2797(02)00183-7; Barf T, 2002, J MED CHEM, V45, P3813, DOI 10.1021/jm025530f; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; Blum A, 2000, BIOCHEM BIOPH RES CO, V276, P428, DOI 10.1006/bbrc.2000.3491; Blum A, 2003, CHEM-BIOL INTERACT, V143, P469, DOI 10.1016/S0009-2797(02)00224-7; Blum A, 2003, BIOCHEMISTRY-US, V42, P4108, DOI 10.1021/bi027425d; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Bujalska IJ, 2002, J CLIN ENDOCR METAB, V87, P1205, DOI 10.1210/jc.87.3.1205; CHARUK JHM, 1994, AM J PHYSIOL, V266, pF66, DOI 10.1152/ajprenal.1994.266.1.F66; Chrousos GP, 2004, P NATL ACAD SCI USA, V101, P6329, DOI 10.1073/pnas.0401671101; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Gao HB, 1996, ENDOCRINOLOGY, V137, P1714, DOI 10.1210/en.137.5.1714; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Maser E, 2003, CHEM-BIOL INTERACT, V143, P435, DOI 10.1016/S0009-2797(02)00180-1; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Mziaut H, 1999, J BIOL CHEM, V274, P14122, DOI 10.1074/jbc.274.20.14122; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; PROBST MR, 1994, J BIOL CHEM, V269, P21650; Robinzon B, 2003, ARCH BIOCHEM BIOPHYS, V412, P251, DOI 10.1016/S0003-9861(03)00056-0; SampathKumar R, 1997, J STEROID BIOCHEM, V62, P195, DOI 10.1016/S0960-0760(97)00027-7; Sandeep TC, 2004, P NATL ACAD SCI USA, V101, P6734, DOI 10.1073/pnas.0306996101; Schmitz G, 2001, NEUROCHEM RES, V26, P1045, DOI 10.1023/A:1012357106398; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Schweizer RAS, 2004, J BIOL CHEM, V279, P18415, DOI 10.1074/jbc.M313615200; Schweizer RAS, 2003, MOL CELL ENDOCRINOL, V212, P41, DOI 10.1016/j.mce.2003.09.027; Stewart PM, 1999, VITAM HORM, V57, P249; Thieringer R, 2001, J IMMUNOL, V167, P30, DOI 10.4049/jimmunol.167.1.30; Trickett JI, 2001, J BIOL CHEM, V276, P39522, DOI 10.1074/jbc.M101764200; UEDA K, 1992, J BIOL CHEM, V267, P24248; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Wsol V, 2003, CHEM-BIOL INTERACT, V143, P459, DOI 10.1016/S0009-2797(02)00221-1	45	45	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31131	31138		10.1074/jbc.M313666200	http://dx.doi.org/10.1074/jbc.M313666200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152005	hybrid			2022-12-27	WOS:000222726800029
J	Hirano, Y; Yoshinaga, S; Ogura, K; Yokochi, M; Noda, Y; Sumimoto, H; Inagaki, F				Hirano, Y; Yoshinaga, S; Ogura, K; Yokochi, M; Noda, Y; Sumimoto, H; Inagaki, F			Solution structure of atypical protein kinase CPB1 domain and its mode of interaction with ZIP/p62 and MEK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; EPITHELIAL TIGHT JUNCTION; NERVE GROWTH-FACTOR; CELL-POLARITY; NADPH OXIDASE; PB1 DOMAIN; PC MOTIF; MOLECULAR-CLONING; C ZETA; COMPLEX	Atypical protein kinase C ( aPKC) has been implicated in several signaling pathways such as cell polarity, cell survival, and cell differentiation. In contrast to other PKCs, aPKC is unique in having the PB1 ( Phox and Bem 1) domain in the N terminus. The aPKC PB1 domain binds with ZIP/p62, Par6, or MEK5 through a PB1-PB1 domain interaction that controls the localization of aPKC. Here, we determined the three-dimensional structure of the PB1 domain of PKCiota by NMR and found that the PB1 domain adopts a ubiquitin fold. The OPCA (OPR, PC, and AID) motif inserted into the ubiquitin fold was presented as a betabetaalpha fold in which the side chains of conserved Asp residues were oriented to the same direction to form an acidic surface. This structural feature suggested that the acidic surface of the PKCiota PB1 domain interacted with the basic surface of the target PB1 domains, and this was confirmed in the case of the PKCiota-ZIP/p62 complex by mutational analysis. Interestingly, in the PKCiota PB1 domain a conserved lysine residue was located on the side opposite to the OPCA motif-presenting surface, suggesting dual roles for the PKCiota PB1 domain in that it could interact with either the conserved lysine residue or the acidic residues on the OPCA motif of the target PB1 domains.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	Hokkaido University; Kyushu University; Japan Science & Technology Agency (JST)	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, N-12 W-6, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp		Hirano, Yoshinori/0000-0001-9888-1616				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Coligan J.E., 1997, CURRENT PROTOCOLS PR; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Geetha T, 2003, J BIOL CHEM, V278, P4730, DOI 10.1074/jbc.M208468200; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; OLEJNICZAK ET, 1992, J BIOMOL NMR, V2, P655, DOI 10.1007/BF02192854; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Roehrl MHA, 2003, J BIOMOL NMR, V26, P373, DOI 10.1023/A:1024047110957; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Watts JL, 1996, DEVELOPMENT, V122, P3133; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Yoshinaga S, 2003, EMBO J, V22, P4888, DOI 10.1093/emboj/cdg475	51	61	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31883	31890		10.1074/jbc.M403092200	http://dx.doi.org/10.1074/jbc.M403092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143057	hybrid			2022-12-27	WOS:000222726800115
J	Tamura, Y; Osuga, J; Adachi, H; Tozawa, R; Takanezawa, Y; Ohashi, K; Yahagi, N; Sekiya, M; Okazaki, H; Tomita, S; Iizuka, Y; Koizumi, H; Inaba, T; Yagyu, H; Kamada, N; Suzuki, H; Shimano, H; Kadowaki, T; Tsujimoto, M; Arai, H; Yamada, N; Ishibashi, S				Tamura, Y; Osuga, J; Adachi, H; Tozawa, R; Takanezawa, Y; Ohashi, K; Yahagi, N; Sekiya, M; Okazaki, H; Tomita, S; Iizuka, Y; Koizumi, H; Inaba, T; Yagyu, H; Kamada, N; Suzuki, H; Shimano, H; Kadowaki, T; Tsujimoto, M; Arai, H; Yamada, N; Ishibashi, S			Scavenger receptor expressed by endothelial cells I (SREC-I) mediates the uptake of acetylated low density lipoproteins by macrophages stimulated with lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-A; ATHEROSCLEROTIC LESIONS; BACTERIA-BINDING; MICE LACKING; ENDOTOXIN; CLONING; HYPERCHOLESTEROLEMIA; INFLAMMATION; RECOGNITION; INFECTION	Scavenger receptor expressed by endothelial cells I (SREC-I) is a novel endocytic receptor for acetylated low density lipoprotein (LDL). Here we show that SREC-I is expressed in a wide variety of tissues, including macrophages and aortas. Lipopolysaccharide (LPS) robustly stimulated the expression of SREC-I in macrophages. In an initial attempt to clarify the role of SREC-I in the uptake of modified lipoproteins as well as in the development of atherosclerosis, we generated mice with a targeted disruption of the SREC-I gene by homologous recombination in embryonic stem cells. To exclude the overwhelming effect of the type A scavenger receptor (SR-A) on the uptake of Ac-LDL, we further generated mice lacking both SR-A and SREC-I (SR-A(-/-); SREC-I-/-) by cross-breeding and compared the uptake and degradation of Ac-LDL in the isolated macrophages. The contribution of SR-A and SREC-I to the overall degradation of Ac-LDL was 85 and 5%, respectively, in a non-stimulated condition. LPS increased the uptake and degradation of Ac-LDL by 1.8-fold. In this condition, the contribution of SR-A and SREC-I to the overall degradation of Ac-LDL was 90 and 6%, respectively. LPS increased the absolute contribution of SR-A and SREC-I by 1.9- and 2.3-fold, respectively. On the other hand, LPS decreased the absolute contribution of other pathways by 31%. Consistently, LPS did not increase the expression of other members of the scavenger receptor family such as CD36. In conclusion, SREC-I serves as a major endocytic receptor for Ac-LDL in LPS-stimulated macrophages lacking SR-A, suggesting that it has a key role in the development of atherosclerosis in concert with SR-A.	Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, Minami Kawachi, Tochigi 3290498, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; Chugai Res Inst Med Sci Inc, Shizuoka 4128513, Japan; Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Unit Funct Genom, Obihiro, Hokkaido 0808555, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan	Jichi Medical University; University of Tokyo; RIKEN; University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Chugai Research Institute for Medical Science, Inc.; Obihiro University of Agriculture & Veterinary Medicine; University of Tsukuba	Ishibashi, S (corresponding author), Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	ishibash@jichi.ac.jp	Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019	Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572; Takanezawa, Yasukazu/0000-0002-9220-5825				ACTON SL, 1994, J BIOL CHEM, V269, P21003; Adachi H, 2002, J BIOL CHEM, V277, P24014, DOI 10.1074/jbc.M201854200; Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; Babaev VR, 2000, ARTERIOSCL THROM VAS, V20, P2593, DOI 10.1161/01.ATV.20.12.2593; Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002; Becker AE, 2001, ANNU REV MED, V52, P289, DOI 10.1146/annurev.med.52.1.289; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; de Winther MPJ, 2000, INT J TISSUE REACT, V22, P85; de Winther MPJ, 1999, ATHEROSCLEROSIS, V144, P315, DOI 10.1016/S0021-9150(98)00332-3; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Fitzgerald ML, 2000, J IMMUNOL, V164, P2692, DOI 10.4049/jimmunol.164.5.2692; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FUNK JL, 1993, ATHEROSCLEROSIS, V98, P67, DOI 10.1016/0021-9150(93)90224-I; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Ishiguro T, 2001, AM J PATHOL, V158, P179, DOI 10.1016/S0002-9440(10)63956-9; Ishii J, 2002, J BIOL CHEM, V277, P39696, DOI 10.1074/jbc.M206140200; Kamada N, 2001, J Atheroscler Thromb, V8, P1; Khovidhunkit W, 2001, J LIPID RES, V42, P1636; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lehr HA, 2001, CIRCULATION, V104, P914, DOI 10.1161/hc3401.093153; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; LYNN WA, 1995, CLIN INFECT DIS, V20, P143, DOI 10.1093/clinids/20.1.143; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Perrey S, 2001, ATHEROSCLEROSIS, V154, P51, DOI 10.1016/S0021-9150(00)00457-3; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; Sakaguchi H, 1998, LAB INVEST, V78, P423; Sambrook J., 2001, MOL CLONING LAB MANU; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; Vink A, 2002, CIRCULATION, V106, P1985, DOI 10.1161/01.CIR.0000032146.75113.EE; Yagyu H, 2000, J BIOL CHEM, V275, P21324, DOI 10.1074/jbc.M002541200; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	42	55	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30938	30944		10.1074/jbc.M313088200	http://dx.doi.org/10.1074/jbc.M313088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145948	Green Published, hybrid			2022-12-27	WOS:000222726800006
J	Trinidad, JC; Cohen, JB				Trinidad, JC; Cohen, JB			Neuregulin inhibits acetylcholine receptor aggregation in myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMUSCULAR-JUNCTION; TYROSINE-PHOSPHATASE; SYNAPSE ELIMINATION; GENE-EXPRESSION; PROTEIN-KINASE; NERVOUS-SYSTEM; MUSCLE-FIBERS; IN-VIVO; ARIA; ACTIVATION	The high local concentration of acetylcholine receptors (AChRs) at the vertebrate neuromuscular junction results from their aggregation by the agrin/MuSK signaling pathway and their synthetic up-regulation by the neuregulin/ErbB pathway. Here, we show a novel role for the neuregulin/ErbB pathway, the inhibition of AChR aggregation on the muscle surface. Treatment of C2C12 myotubes with the neuregulin epidermal growth factor domain decreased the number of both spontaneous and agrin-induced AChR clusters, in part by increasing the rate of cluster disassembly. Upon cluster disassembly, AChRs were internalized into caveolae ( as identified by caveolin-3). Time-lapse microscopy revealed that individual AChR clusters fragmented into puncta, and application of neuregulin accelerated the rate at which AChR clusters decreased in area without affecting the density of AChRs remaining in individual clusters ( as measured by the fluorescence intensity/unit area). We propose that this novel action of neuregulin regulates synaptic competition at the developing neuromuscular junction.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu	Trinidad, Jonathan/GWR-2077-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018458] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18458] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; Astrow SH, 1996, J NEUROSCI, V16, P5130; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; Bezakova G, 2001, P NATL ACAD SCI USA, V98, P9924, DOI 10.1073/pnas.171539698; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; Culican SM, 1998, J NEUROSCI, V18, P4953; Dai ZS, 1998, J CELL BIOL, V141, P1613, DOI 10.1083/jcb.141.7.1613; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Finn AJ, 2003, NAT NEUROSCI, V6, P717, DOI 10.1038/nn1071; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; Gonzalez M, 1999, NEURON, V24, P567, DOI 10.1016/S0896-6273(00)81113-7; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kim S, 2000, J NEUROBIOL, V42, P22, DOI 10.1002/(SICI)1097-4695(200001)42:1<22::AID-NEU3>3.0.CO;2-#; KO PK, 1977, SCIENCE, V196, P540, DOI 10.1126/science.850796; Li QF, 2001, J BIOL CHEM, V276, P38068; Lin WC, 2000, P NATL ACAD SCI USA, V97, P1299, DOI 10.1073/pnas.97.3.1299; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; McDearmon EL, 2003, J BIOL CHEM, V278, P44868, DOI 10.1074/jbc.M307026200; Meyer D, 1997, DEVELOPMENT, V124, P3575; Mittaud P, 2001, J BIOL CHEM, V276, P14505, DOI 10.1074/jbc.M007024200; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; MOSS BL, 1987, J NEUROBIOL, V18, P101, DOI 10.1002/neu.480180108; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RICH M, 1989, NEURON, V3, P677, DOI 10.1016/0896-6273(89)90236-5; SALPETER MM, 1988, J CELL BIOL, V106, P2087, DOI 10.1083/jcb.106.6.2087; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267; Walsh MK, 2003, NEURON, V37, P67, DOI 10.1016/S0896-6273(02)01142-X; Wells DG, 1999, P NATL ACAD SCI USA, V96, P1112, DOI 10.1073/pnas.96.3.1112; Werle MJ, 1996, J NEUROBIOL, V30, P293, DOI 10.1002/(SICI)1097-4695(199606)30:2<293::AID-NEU10>3.0.CO;2-L; Weston C, 2003, J BIOL CHEM, V278, P6450, DOI 10.1074/jbc.M210249200; Willmann R, 2002, CELL MOL LIFE SCI, V59, P1296, DOI 10.1007/s00018-002-8509-4; Yang JF, 1997, FEBS LETT, V403, P163, DOI 10.1016/S0014-5793(97)00044-6; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2	46	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31622	31628		10.1074/jbc.M400044200	http://dx.doi.org/10.1074/jbc.M400044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155732	hybrid			2022-12-27	WOS:000222726800086
J	Aubol, BE; Ungs, L; Lukasiewicz, R; Ghosh, G; Adams, JA				Aubol, BE; Ungs, L; Lukasiewicz, R; Ghosh, G; Adams, JA			Chemical clamping allows for efficient phosphorylation of the RNA carrier protein Npl3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SRC KINASE; SUBSTRATE-SPECIFICITY; CONFORMATIONAL-CHANGES; KINETIC MECHANISM; STRUCTURAL BASIS; SPLICING FACTORS; DOCKING SITE; C-JUN; INSIGHTS; SKY1P	Protein kinases phosphorylate the appropriate protein substrate by recognizing residues both proximal and distal to the site of phosphorylation. Although these distal contacts may provide excellent binding affinities (low K-m values) through stabilization of the enzyme-substrate complex, these contacts could reduce catalytic turnover (decrease k(cat)) through slow phosphoprotein release. To investigate how protein kinases can overcome this problem and maintain both high substrate affinities and high turnover rates, the phosphorylation of the yeast RNA transport protein Npl3 by its natural protein kinase, Sky1p, was evaluated. Sky1p bound and phosphorylated Npl3 with a K-m that was 2 orders of magnitude lower than a short peptide mimic representing the phosphorylation site and only proximal determinants. Surprisingly, this extraordinary difference is not the result of high affinity Npl3 binding. Rather, Npl3 achieves a low K-m through a rapid and favorable phosphoryl transfer step. This step serves as a chemical clamp that locks the protein substrate in the active site without unduly stabilizing the product phosphoprotein and slowing its release. The chemical clamping mechanism offers an efficient means whereby a protein kinase can simultaneously achieve both high turnover and good substrate binding properties.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Adams, JA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	joeadams@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067969] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 67969, GM 07752] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Aubol BE, 2003, BIOCHEMISTRY-US, V42, P12813, DOI 10.1021/bi035200c; Aubol BE, 2002, BIOCHEMISTRY-US, V41, P10002, DOI 10.1021/bi020233y; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Cohen P, 2001, EUR J BIOCHEM, V268, P5001, DOI 10.1046/j.0014-2956.2001.02473.x; COLE PA, 1994, J BIOL CHEM, V269, P30880; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; Hawkins J, 2000, ARCH BIOCHEM BIOPHYS, V382, P310, DOI 10.1006/abbi.2000.2005; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jan AY, 2000, BIOCHEMISTRY-US, V39, P9786, DOI 10.1021/bi9924922; Johnson KA, 1998, CURR OPIN BIOTECH, V9, P87, DOI 10.1016/S0958-1669(98)80089-X; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOHNSSON MSA, 1992, CRIT REV ORAL BIOL M, V3, P61, DOI 10.1177/10454411920030010601; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Nolen B, 2001, NAT STRUCT BIOL, V8, P176, DOI 10.1038/84178; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Shaffer J, 1999, BIOCHEMISTRY-US, V38, P12072, DOI 10.1021/bi991109q; Shaffer J, 2001, BIOCHEMISTRY-US, V40, P11149, DOI 10.1021/bi011029y; Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440; Sondhi D, 1998, BIOCHEMISTRY-US, V37, P165, DOI 10.1021/bi9722960; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Waas WF, 2003, BIOCHEMISTRY-US, V42, P12273, DOI 10.1021/bi0348617; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Zhou J, 1997, BIOCHEMISTRY-US, V36, P15733, DOI 10.1021/bi971438n; Zhou J, 1997, BIOCHEMISTRY-US, V36, P2977, DOI 10.1021/bi9619132	42	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30182	30188		10.1074/jbc.M402797200	http://dx.doi.org/10.1074/jbc.M402797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15145958	hybrid			2022-12-27	WOS:000222531900040
J	Kanzaki, M; Furukawa, M; Raab, W; Pessin, JE				Kanzaki, M; Furukawa, M; Raab, W; Pessin, JE			Phosphatidylinositol 4,5-bisphosphate regulates adipocyte actin dynamics and GLUT4 vesicle recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RECEPTOR-MEDIATED ENDOCYTOSIS; GLUCOSE-TRANSPORTER GLUT4; CLATHRIN-COATED PITS; PLECKSTRIN HOMOLOGY DOMAINS; ISOLATED RAT ADIPOCYTES; LIPID KINASE FAMILY; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; N-WASP; GOLGI-COMPLEX	To investigate the potential role of phosphatidylinositol 4, 5-bisphosphate (PI(4,5)P-2) in the regulation of actin polymerization and GLUT4 translocation, the type I phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks) were expressed in 3T3L1 adipocytes. In preadipocytes (fibroblasts) PIP5K expression promoted actin polymerization on membrane-bound vesicles to form motile actin comets. In contrast, expression of PIP5K in differentiated 3T3L1 adipocytes resulted in the formation of enlarged vacuole-like structures coated with F-actin, cortactin, dynamin, and N-WASP. Treatment with either latrunculin B (an inhibitor for actin polymerization) or Clostridium difficile toxin B (a general Rho family inhibitor) resulted in a relatively slower disappearance of coated F-actin from these vacuoles, but the vacuoles themselves remained unaffected. Functionally, the increased PI(4,5) P2 levels resulted in an inhibition of transferrin receptor and GLUT4 endocytosis and a slow accumulation of these proteins in the PI(4,5)P-2-enriched vacuoles along with the non-clathrin-derived endosome marker (caveolin) and the AP-2 adaptor complex. However, these structures were devoid of early endosome markers (EEA1, clathrin) and the biosynthetic membrane secretory machinery markers p115 (Golgi) and syntaxin 6 (trans-Golgi Network). Taken together, these data demonstrate that PI(4,5) P2 has distinct morphologic and functional properties depending upon specific cell context. In adipocytes, altered PI(4,5) P2 metabolism has marked effects on GLUT4 endocytosis and intracellular vesicle trafficking due to the derangement of actin dynamics.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kanzaki, M (corresponding author), Tohoku Univ, Biomed Engn Res Org, Grad Sch Med, Aoba Ku, Bldg 1,2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	kanzaki@tubero.tohoku.ac.jp	Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955	NIDDK NIH HHS [DK59291, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK059291, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Barbieri MA, 2001, J BIOL CHEM, V276, P47212, DOI 10.1074/jbc.C100490200; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cremona O, 2001, J CELL SCI, V114, P1041; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; di Campli A, 1999, CELL MOTIL CYTOSKEL, V43, P334, DOI 10.1002/(SICI)1097-0169(1999)43:4<334::AID-CM6>3.0.CO;2-3; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Galiano FJ, 2002, J CELL BIOCHEM, V85, P131, DOI 10.1002/jcb.10100; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hellsten E, 2002, BIOL REPROD, V66, P1522, DOI 10.1095/biolreprod66.5.1522; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; James DJ, 2004, J BIOL CHEM, V279, P20567, DOI 10.1074/jbc.C400096200; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kanzaki M, 2002, MOL BIOL CELL, V13, P2334, DOI 10.1091/mbc.01-10-0490; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2001, J BIOL CHEM, V276, P49331, DOI 10.1074/jbc.M109657200; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Khayat ZA, 2000, J CELL SCI, V113, P279; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lawrence JTR, 2003, P NATL ACAD SCI USA, V100, P13320, DOI 10.1073/pnas.2232129100; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Luna A, 2002, MOL BIOL CELL, V13, P866, DOI 10.1091/mbc.01-12-0579; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Mizutani K, 2004, BIOCHEM BIOPH RES CO, V313, P468, DOI 10.1016/j.bbrc.2003.11.139; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; OKADA T, 1994, J BIOL CHEM, V269, P3568; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Qualmann B, 2002, INT REV CYTOL, V220, P93; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Stamnes M, 2002, CURR OPIN CELL BIOL, V14, P428, DOI 10.1016/S0955-0674(02)00349-6; Suetsugu S, 2003, J BIOL CHEM, V278, P42515, DOI 10.1074/jbc.M302177200; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Valderrama F, 2001, TRAFFIC, V2, P717, DOI 10.1034/j.1600-0854.2001.21006.x; Valderrama F, 1998, EUR J CELL BIOL, V76, P9, DOI 10.1016/S0171-9335(98)80012-5; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Watson RT, 2003, MOL CELL BIOL, V23, P961, DOI 10.1128/MCB.23.3.961-974.2003; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Wong KW, 2003, J EXP MED, V198, P603, DOI 10.1084/jem.20021363; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; YANG J, 1993, J BIOL CHEM, V268, P4600; Ying M, 2003, TRAFFIC, V4, P772, DOI 10.1034/j.1600-0854.2003.00134.x; Yorek M, 1999, ARCH BIOCHEM BIOPHYS, V361, P241, DOI 10.1006/abbi.1998.0982	123	48	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30622	30633		10.1074/jbc.M401443200	http://dx.doi.org/10.1074/jbc.M401443200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123724	hybrid			2022-12-27	WOS:000222531900092
J	Vanden Abeele, F; Lemonnier, L; Thebault, S; Lepage, G; Parys, JB; Shuba, Y; Skryma, R; Prevarskaya, N				Vanden Abeele, F; Lemonnier, L; Thebault, S; Lepage, G; Parys, JB; Shuba, Y; Skryma, R; Prevarskaya, N			Two types of store-operated Ca2+ channels with different activation modes and molecular origin in LNCaP human prostate cancer epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; INTRACELLULAR CA2+; CATION CHANNELS; XENOPUS OOCYTES; MAST-CELLS; DIFFUSIBLE MESSENGER; PHOSPHOLIPASE A(2); SIGNALING COMPLEX	The one or more coupling mechanisms of store-operated channels (SOCs) to endoplasmic reticulum ( ER) Ca2+ store depletion as well as the molecular identity of SOCs per se still remain a mystery. Here, we demonstrate the co-existence of two populations of molecular distinct endogenous SOCs in LNCaP prostate cancer epithelial cells, which are preferentially activated by either active inositol 1,4,5-trisphosphate (IP3)-mediated or passive thapsigargin-facilitated store depletion and have different ER store content sensitivity. The first population, called SOCCC (for "conformational coupling"), is characterized by preferential IP3 receptor-dependent mode of activation, as judged from sensitivity to cytoskeleton modifications, and dominant contribution of transient receptor potential (TRP) TRPC1 within it. The second one, called SOCCIF (for "calcium influx factor"), depends on Ca2+-independent phospholipase A(2) for activation with probable CIF involvement and is mostly represented by TRPC4. The previously identified SOC constituent in LNCaP cells, TRPV6, seems to play equal role in both SOC populations. These results provide new insight into the nature of SOCs and their representation in the single cell type as well as permit reconciliation of current SOC activation hypotheses.	Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM, EMI 0228, F-59655 Villeneuve Dascq, France; Catholic Univ Louvain, Fysiol Lab, B-3000 Louvain, Belgium; Natl Acad Sci Ukraine, Bogomoletz Inst Physiol, UA-01024 Kiev 24, Ukraine	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite Catholique Louvain; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology	Prevarskaya, N (corresponding author), Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM, EMI 0228, Bat SN3, F-59655 Villeneuve Dascq, France.	natacha.prevarskaya@univ-lille1.f	Shuba, Yaroslav/AAT-6758-2021; Lemonnier, Loic/L-7289-2018; Vanden Abeele, Fabien/O-6012-2017; Thébault, Stéphanie/AAD-8350-2019	Lemonnier, Loic/0000-0001-6200-5382; Thebault, Stephanie/0000-0003-3233-282X; Prevarskaya, natacha/0000-0003-0316-197X; Parys, Jan/0000-0002-3591-4967; Vanden Abeele, Fabien/0000-0001-7111-7220				Bakowski D, 2003, J PHYSIOL-LONDON, V553, P387, DOI 10.1113/jphysiol.2003.055335; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; Gusev K, 2003, J GEN PHYSIOL, V122, P81, DOI 10.1085/jgp.200308815; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Itagaki K, 2004, J IMMUNOL, V172, P601, DOI 10.4049/jimmunol.172.1.601; Kahr H, 2004, J PHYSIOL-LONDON, V557, P121, DOI 10.1113/jphysiol.2004.062653; Kinoshita M, 2000, CELL CALCIUM, V28, P151, DOI 10.1054/ceca.2000.0143; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Krause E, 1999, J BIOL CHEM, V274, P36957, DOI 10.1074/jbc.274.52.36957; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143-4160(03)00042-3; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Peng JB, 2003, J PHYSIOL-LONDON, V551, P729, DOI 10.1113/jphysiol.2003.043349; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2003, CELL CALCIUM, V34, P339, DOI 10.1016/S0143-4160(03)00143-X; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; Vanden Abeele F, 2003, CELL CALCIUM, V33, P357, DOI 10.1016/S0143-4160(03)00049-6; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vanlingen S, 2000, BIOCHEM J, V346, P275, DOI 10.1042/0264-6021:3460275; Vanlingen S, 1997, CELL CALCIUM, V22, P475, DOI 10.1016/S0143-4160(97)90075-0; Vanoverberghe K, 2003, CELL CALCIUM, V34, P75, DOI 10.1016/S0143-4160(03)00024-1; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Wilson BS, 1998, MOL BIOL CELL, V9, P1465, DOI 10.1091/mbc.9.6.1465; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	70	86	89	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30326	30337		10.1074/jbc.M400106200	http://dx.doi.org/10.1074/jbc.M400106200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138280	hybrid			2022-12-27	WOS:000222531900058
J	Ivanov, AV; Gable, ME; Askari, A				Ivanov, AV; Gable, ME; Askari, A			Interaction of SDS with Na+/K+-ATPase - SDS-solubilized enzyme retains partial structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSICALLY UNSTRUCTURED PROTEINS; ACTIVATED ADENOSINE-TRIPHOSPHATASE; SODIUM DODECYL-SULFATE; KIDNEY OUTER MEDULLA; MAMMALIAN KIDNEY; GAMMA-SUBUNIT; FXYD PROTEINS; PIG-KIDNEY; OLIGOMERIC STRUCTURE; MEMBRANE-PROTEINS	Because nearly all structure/function studies on Na+/ K+-ATPase have been done on enzymes prepared in the presence of SDS, we have studied previously unrecognized consequences of SDS interaction with the enzyme. When the purified membrane-bound kidney enzyme was solubilized with SDS or TDS concentrations just sufficient to cause complete solubilization, but not at concentrations severalfold higher, the enzyme retained quaternary structure, exhibiting alpha,alpha-, alpha,beta-, beta,beta-, and alpha,gamma- associations as detected by chemical cross-linking. The presence of solubilized oligomers was confirmed by sucrose density gradient centrifugation. This solubilized enzyme had no ATPase activity and was not phosphorylated by ATP, but it retained the ability to occlude Rb+ and Na+. This, and comparison of cross-linking patterns obtained with different reagents, suggested that the transmembrane domains of the enzyme are more resistant to SDS-induced unfolding than its other domains. These findings ( a) indicate that the partially unfolded oligomer(s) retaining partial function is the intermediate in the SDS-induced denaturation of the native membrane enzyme having the minimum oligomeric structure of (alpha, beta, gamma)(2) and (b) suggest potential functions for Na+/K+-ATPase with intrinsically unfolded domains. Mixtures of solubilized/ partially unfolded enzyme and membrane-bound enzyme exhibited cross-linking patterns and Na+ occlusion capacities different from those of either enzyme species, suggesting that the two interact. Formation of the partially unfolded enzyme during standard purification procedure for the preparation of the membrane-bound enzyme was shown, indicating that it is necessary to ensure the separation of the partially unfolded enzyme from the membrane-bound enzyme to avoid the distortion of the properties of the latter.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA		Askari, A (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	mheck@mco.edu			NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2002, AM J PHYSIOL-RENAL, V282, pF393, DOI 10.1152/ajprenal.00146.2001; Askari A, 2000, INT CONGR SER, V1207, P17; Askari A, 1988, Prog Clin Biol Res, V268A, P149; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BLACKBURN MN, 1981, ARCH BIOCHEM BIOPHYS, V212, P162, DOI 10.1016/0003-9861(81)90355-6; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CRAIG WS, 1980, J BIOL CHEM, V255, P6262; Crambert G, 2004, MOL PHARMACOL, V65, P335, DOI 10.1124/mol.65.2.335; Das TK, 1998, EUR J BIOCHEM, V254, P662, DOI 10.1046/j.1432-1327.1998.2540662.x; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; DUNHAM PB, 1970, P NATL ACAD SCI USA, V66, P936, DOI 10.1073/pnas.66.3.936; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; DZHANDZHUGAZYAN KN, 1981, BIOORG KHIM+, V7, P847; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; ESMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1106, P1, DOI 10.1016/0005-2736(92)90214-7; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Geering K, 2003, ANN NY ACAD SCI, V986, P388, DOI 10.1111/j.1749-6632.2003.tb07219.x; Grimsley JK, 1997, BIOCHEMISTRY-US, V36, P14366, DOI 10.1021/bi971596e; Grinberg AV, 2001, EUR J BIOCHEM, V268, P5027, DOI 10.1046/j.0014-2956.2001.02436.x; HANSEN O, 1979, NATURE, V280, P410, DOI 10.1038/280410a0; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; Hasler U, 2001, J BIOL CHEM, V276, P16356, DOI 10.1074/jbc.M008778200; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Ivanov AV, 2002, BIOCHEM J, V364, P293, DOI 10.1042/bj3640293; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P53, DOI 10.1016/0005-2736(74)90293-4; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P366, DOI 10.1016/0005-2736(71)90334-8; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P381, DOI 10.1016/0005-2736(71)90335-X; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Klodos I, 2002, KIDNEY INT, V62, P2097, DOI 10.1046/j.1523-1755.2002.00654.x; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; LIANG SM, 1977, J BIOL CHEM, V252, P8278; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; MIMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1145, P63, DOI 10.1016/0005-2736(93)90382-A; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Ohnishi S, 2001, BBA-BIOMEMBRANES, V1515, P159, DOI 10.1016/S0005-2736(01)00410-2; PARKER W, 1992, BIOPHYS J, V61, P1435, DOI 10.1016/S0006-3495(92)81949-5; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Reynolds J A, 1988, Prog Clin Biol Res, V268A, P137; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; ROBINSON JD, 1980, BIOCHIM BIOPHYS ACTA, V598, P543, DOI 10.1016/0005-2736(80)90034-6; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; Sweadner KJ, 2003, ANN NY ACAD SCI, V986, P382, DOI 10.1111/j.1749-6632.2003.tb07218.x; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Tsuda T, 1998, J BIOL CHEM, V273, P24339, DOI 10.1074/jbc.273.38.24339; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989	60	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29832	29840		10.1074/jbc.M401986200	http://dx.doi.org/10.1074/jbc.M401986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123703	hybrid			2022-12-27	WOS:000222445300120
J	Lewis, DE; Merched-Sauvage, M; Goronzy, JJ; Weyand, CM; Vallejo, AN				Lewis, DE; Merched-Sauvage, M; Goronzy, JJ; Weyand, CM; Vallejo, AN			Tumor necrosis factor-alpha and CD80 modulate CD28 expression through a similar mechanism of T-cell receptor-independent inhibition of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; NUCLEAR FACTOR; GENE; B7-1; REQUIREMENTS; REPERTOIRE; ACTIVATION; INITIATOR; PATHWAYS; DISTINCT	Replicative senescence of human T cells is characterized by the loss of CD28 expression, exemplified by the clonal expansion of CD28(null) T cells during repeated stimulation in vitro as well as in chronic inflammatory and infectious diseases and in the normal course of aging. Because CD28 is the major costimulatory receptor for the induction of T cell-mediated immunity, the mechanism(s) underlying CD28 loss is of paramount interest. Current models of replicative senescence involve protracted procedures to generate CD28(null) cells from CD28(+) precursors; hence, a T-cell line model was used to examine the dynamics of CD28 expression. Here, we show the versatility of the JT and Jtag cell lines in tracking CD28(null) <----> CD28(hi) phenotypic transitions. JT and Jtag cells were CD28(null) and CD28(lo), respectively, but expressed high levels of CD28 when exposed to phorbol 12-myristate 13-acetate. This was a result of the reconstitution of the CD28 gene transcriptional initiator (INR). Tumor necrosis factor-alpha reduced CD28 expression because of the inhibition of INR-driven transcription. Ligation of CD28 by an antibody or by CD80 also down-regulated CD28 transcription through the same mechanism, providing evidence that CD28 can generate a T cell receptor-independent signal with a unique biological outcome. Collectively, these data unequivocally demonstrate the critical role of the INR in the regulation of CD28 expression. T cell lines with transient expression of CD28 are invaluable in the dissection of the biochemical processes involved in the transactivation of the CD28 INR, the silencing of which is a key event in the ontogenesis of senescent T cells.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Emory Univ, Sch Med, Lowance Ctr Human Immunol, Atlanta, GA 30322 USA; Mayo Clin, Dept Med, Div Rheumatol, Rochester, MN 55905 USA	Baylor College of Medicine; Emory University; Mayo Clinic	Vallejo, AN (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Rangos Res Ctr 2122, 3705 5th Ave, Pittsburgh, PA 15213 USA.	abbe.vallejo@chp.edu	Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856	NIAID NIH HHS [R37-AI36682, R21 AI054251] Funding Source: Medline; NIA NIH HHS [R01 AG022379-02, R01-AG15043, R01-AG22379, R01 AG022379] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054251, R37AI036682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022379, R01AG015043] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; Bruunsgaard H, 2002, EUR CYTOKINE NETW, V13, P389; Bryl E, 2001, J IMMUNOL, V167, P3231, DOI 10.4049/jimmunol.167.6.3231; Burastero SE, 1999, J ALLERGY CLIN IMMUN, V103, P1136, DOI 10.1016/S0091-6749(99)70189-2; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Chen HX, 1998, J IMMUNOL, V160, P5045; Cortesini R, 2001, IMMUNOL REV, V182, P201, DOI 10.1034/j.1600-065X.2001.1820116.x; Dutra WO, 1996, SCAND J IMMUNOL, V43, P88, DOI 10.1046/j.1365-3083.1996.d01-9.x; Eck SC, 1997, TRANSPLANTATION, V64, P1497, DOI 10.1097/00007890-199711270-00025; Effros RB, 1997, DEV COMP IMMUNOL, V21, P471, DOI 10.1016/S0145-305X(97)00027-X; Erbe DV, 2002, J BIOL CHEM, V277, P7363, DOI 10.1074/jbc.M110162200; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001; Honda M, 2001, CLIN IMMUNOL, V99, P211, DOI 10.1006/clim.2001.5023; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kariv I, 1996, J IMMUNOL, V157, P29; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984; Kollias G, 2002, CYTOKINE GROWTH F R, V13, P315, DOI 10.1016/S1359-6101(02)00019-9; Lamprecht P, 2001, THORAX, V56, P751, DOI 10.1136/thorax.56.10.751; LEE KP, 1990, J IMMUNOL, V145, P344; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lewis DE, 1999, AIDS, V13, P1029, DOI 10.1097/00002030-199906180-00005; Lewis DE, 1999, CLIN IMMUNOL, V90, P302, DOI 10.1006/clim.1998.4663; Lin CJ, 2001, J IMMUNOL, V166, P6134, DOI 10.4049/jimmunol.166.10.6134; Lloyd TE, 1997, J IMMUNOL, V158, P1551; Luhder F, 2003, J EXP MED, V197, P955, DOI 10.1084/jem.20021024; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; Monteiro J, 1996, J IMMUNOL, V156, P3587; Moosig F, 1998, CLIN EXP IMMUNOL, V114, P113; Nakajima T, 2002, CIRCULATION, V105, P570, DOI 10.1161/hc0502.103348; Namekawa T, 1998, ARTHRITIS RHEUM, V41, P2108; NEIL GA, 1994, DIGEST DIS SCI, V39, P1900, DOI 10.1007/BF02088123; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; Park W, 1997, EUR J IMMUNOL, V27, P1082, DOI 10.1002/eji.1830270507; Paul ME, 2001, J ALLERGY CLIN IMMUN, V108, P258, DOI 10.1067/mai.2001.117179; PELLATDECEUNYNCK C, 1994, BLOOD, V84, P2597, DOI 10.1182/blood.V84.8.2597.bloodjournal8482597; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; Posnett DN, 1999, INT IMMUNOL, V11, P229, DOI 10.1093/intimm/11.2.229; RUGVEIT J, 1997, CLIN EXP IMMUNOL, V110, P104; Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893, DOI 10.4049/jimmunol.168.11.5893; Schirmer M, 2002, ARTHRITIS RES, V4, P71, DOI 10.1186/ar386; Schlienger K, 1998, J IMMUNOL, V161, P2407; Schmidt D, 1996, MOL MED, V2, P608, DOI 10.1007/BF03401644; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Slavik JM, 1999, J BIOL CHEM, V274, P3116, DOI 10.1074/jbc.274.5.3116; Snyder MR, 2002, J IMMUNOL, V168, P3839, DOI 10.4049/jimmunol.168.8.3839; Spaulding C, 1999, EXP GERONTOL, V34, P633, DOI 10.1016/S0531-5565(99)00033-9; Tarazona R, 2000, MECH AGEING DEV, V121, P77; Vallejo AN, 2000, J IMMUNOL, V165, P6301, DOI 10.4049/jimmunol.165.11.6301; Vallejo AN, 1998, J BIOL CHEM, V273, P8119, DOI 10.1074/jbc.273.14.8119; Vallejo AN, 1999, J IMMUNOL, V162, P6572; Vallejo AN, 2004, TRENDS MOL MED, V10, P119, DOI 10.1016/j.molmed.2004.01.002; Vallejo AN, 2002, J BIOL CHEM, V277, P46940, DOI 10.1074/jbc.M207352200; Vallejo AN, 2001, J BIOL CHEM, V276, P2565, DOI 10.1074/jbc.M005503200; Warrington KJ, 2003, BLOOD, V101, P3543, DOI 10.1182/blood-2002-08-2574; Warrington KJ, 2001, ARTHRITIS RHEUM, V44, P13, DOI 10.1002/1529-0131(200101)44:1<13::AID-ANR3>3.0.CO;2-6; Weyand CM, 1998, MECH AGEING DEV, V102, P131, DOI 10.1016/S0047-6374(97)00161-9; ZUPO S, 1993, J CLIN IMMUNOL, V13, P228, DOI 10.1007/BF00919976	64	33	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29130	29138		10.1074/jbc.M402194200	http://dx.doi.org/10.1074/jbc.M402194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128741	hybrid			2022-12-27	WOS:000222445300038
J	Li, J; O'Connor, KL; Hellmich, MR; Greeley, GH; Townsend, CM; Evers, BM				Li, J; O'Connor, KL; Hellmich, MR; Greeley, GH; Townsend, CM; Evers, BM			The role of protein kinase D in neurotensin secretion mediated by protein kinase C-alpha/-delta and Rho/Rho kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GASTROINTESTINAL HORMONES; INSULIN-SECRETION; PHORBOL ESTERS; PKC-ALPHA; CELL; ACTIVATION; RHO; MU; PHOSPHORYLATION	Neurotensin (NT) is a gut peptide that plays an important role in gastrointestinal (GI) secretion, motility, and growth as well as the proliferation of NT receptor positive cancers. Secretion of NT is regulated by phorbol ester-sensitive protein kinase C (PKC) isoforms-alpha and -delta and may involve protein kinase D (PKD). The purpose of our present study was: (i) to define the role of PKD in NT release from BON endocrine cells and (ii) to delineate the upstream signaling mechanisms mediating this effect. Here, we demonstrate that small interfering RNA ( siRNA) targeted against PKD dramatically inhibited both basal and PMA-stimulated NT secretion; NT release is significantly increased by overexpression of PKD. PKC-alpha and -delta siRNA attenuated PKD activity, whereas overexpression of PKC-alpha and -delta enhanced PKD activity. Rho kinase (ROK) siRNA significantly inhibited NT secretion, whereas overexpression of ROKalpha effectively increased NT release. Rho protein inhibitor C3 dramatically inhibited both NT secretion and PKD activity. In conclusion, our results demonstrate that PKD activation plays a central role in NT peptide secretion; upstream regulators of PKD include PKC-alpha and -delta and Rho/ROK. Importantly, our results identify novel signaling pathways, which culminate in gut peptide release.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu	O'Connor, Kathleen L/H-2569-2013; Li, Jing/B-7206-2011	O'Connor, Kathleen L/0000-0002-1088-9734; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058119, P01DK035608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA 10212] Funding Source: Medline; NIA NIH HHS [2R37 AG 10885] Funding Source: Medline; NIDDK NIH HHS [P01 DK 35608, R01 DK 48489, R01 DK 58119] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amin RH, 2003, ENDOCRINOLOGY, V144, P4508, DOI 10.1210/en.2003-0106; ARMSTRONG MJ, 1986, AM J PHYSIOL, V251, pG823, DOI 10.1152/ajpgi.1986.251.6.G823; Barandier C, 2003, BIOCHEM BIOPH RES CO, V304, P714, DOI 10.1016/S0006-291X(03)00668-5; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Buyukafsar K, 2003, BIOCHEM BIOPH RES CO, V303, P777, DOI 10.1016/S0006-291X(03)00422-4; CARRAWAY RE, 1994, REGUL PEPTIDES, V53, P17, DOI 10.1016/0167-0115(94)90155-4; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; CHUNG DH, 1992, GASTROENTEROLOGY, V103, P1254, DOI 10.1016/0016-5085(92)91512-3; Daniel S, 2002, BIOCHEMISTRY-US, V41, P9663, DOI 10.1021/bi025604p; Evers BM, 2002, WORLD J SURG, V26, P799, DOI 10.1007/s00268-002-4055-3; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; EVERS BM, 1992, GASTROENTEROLOGY, V103, P86, DOI 10.1016/0016-5085(92)91099-P; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; Frantz C, 2002, EXP CELL RES, V273, P119, DOI 10.1006/excr.2001.5432; GASMAN S, 2003, MOL BIOL CELL; Gomez DE, 1999, ONCOL REP, V6, P1363; Goodge KA, 2000, SEMIN CELL DEV BIOL, V11, P235, DOI 10.1006/scdb.2000.0172; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Guo YS, 1999, CONT ENDOCRINOL, V8, P189; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hellmich MR, 1999, J BIOL CHEM, V274, P23901, DOI 10.1074/jbc.274.34.23901; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; Holinstat M, 2003, J BIOL CHEM, V278, P28793, DOI 10.1074/jbc.M303900200; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JONES PM, 1989, BIOCHEM SOC T, V17, P61, DOI 10.1042/bst0170061; Just I, 2001, INT J MED MICROBIOL, V291, P243, DOI 10.1078/1438-4221-00127; Kowluru A, 2003, AM J PHYSIOL-ENDOC M, V285, pE669, DOI 10.1152/ajpendo.00196.2003; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Li J, 2002, AM J PHYSIOL-GASTR L, V283, pG1197, DOI 10.1152/ajpgi.00177.2002; Li XY, 2003, ONCOL RES, V13, P323; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Moore EDW, 1999, J BIOL CHEM, V274, P22493, DOI 10.1074/jbc.274.32.22493; Nevins AK, 2003, AM J PHYSIOL-CELL PH, V285, pC698, DOI 10.1152/ajpcell.00093.2003; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Nozu F, 1999, AM J PHYSIOL-GASTR L, V276, pG915, DOI 10.1152/ajpgi.1999.276.4.G915; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; PAREKH D, 1994, PANCREAS, V9, P83, DOI 10.1097/00006676-199401000-00013; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; Sasaki Y, 2003, J PHARMACOL SCI, V93, P35, DOI 10.1254/jphs.93.35; SHIMODA I, 1994, AM J PHYSIOL, V266, pG706, DOI 10.1152/ajpgi.1994.266.4.G706; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; Slater SJ, 2001, BIOCHEMISTRY-US, V40, P4437, DOI 10.1021/bi001654n; Slater SJ, 2003, BIOCHEMISTRY-US, V42, P12105, DOI 10.1021/bi034860e; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; Tan MQ, 2003, J BIOL CHEM, V278, P2824, DOI 10.1074/jbc.M211523200; Thomas RP, 2003, ENDOCR REV, V24, P571, DOI 10.1210/er.2002-0028; THOR K, 1986, GASTROENTEROLOGY, V90, P27, DOI 10.1016/0016-5085(86)90070-3; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; TOWNSEND CM, 1994, SURG TODAY, V24, P772, DOI 10.1007/BF01636304; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; VITALE ML, 1992, NEUROSCIENCE, V51, P463, DOI 10.1016/0306-4522(92)90330-5; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Yaney GC, 2002, AM J PHYSIOL-ENDOC M, V283, pE880, DOI 10.1152/ajpendo.00474.2001; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200; ZHANG T, 1995, ENDOCRINOLOGY, V136, P2252, DOI 10.1210/en.136.5.2252	70	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28466	28474		10.1074/jbc.M314307200	http://dx.doi.org/10.1074/jbc.M314307200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123666	hybrid			2022-12-27	WOS:000222265400081
J	Schmitt, JM; Wayman, GA; Nozaki, N; Soderling, TR				Schmitt, JM; Wayman, GA; Nozaki, N; Soderling, TR			Calcium activation of ERK mediated by calmodulin kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; SYNAPTIC PLASTICITY; GENE-EXPRESSION; NG108-15 CELLS; NEURONAL DIFFERENTIATION; CREB PHOSPHORYLATION; SIGNAL-TRANSDUCTION; NEUROBLASTOMA-CELLS; NMDA RECEPTOR	Elevated intracellular Ca2+ triggers numerous signaling pathways including protein kinases such as the calmodulin-dependent kinases (CaMKs) and the extracellular signal-regulated kinases (ERKs). In the present study we examined Ca2+-dependent" cross-talk" between these two protein kinase families. Using a combination of pharmacological inhibitors and dominant-negative kinases (dnKinase), we identified a requirement for CaMKK acting through CaMKI in the stimulation of ERKs upon depolarization of the neuroblastoma cell line, NG108. Depolarization stimulated prolonged ERK and JNK activation that was blocked by the CaMKK inhibitor, STO-609; this inhibition of ERK activation by STO-609 was rescued by expression of a STO-609-insensitive mutant of CaMKK. However, activation of ERK by epidermal growth factor or carbachol were not suppressed by inhibition of CaMKK, indicating specificity for this "cross-talk." To identify the downstream target of CaMKK that mediated ERK activation upon depolarization, dnKinases were expressed. The dnCaMKI completely suppressed ERK2 activation whereas dnAKT/PKB or nuclear-targeted dnCaMKIV, other substrates for CaMKK, were not inhibitory. ERK activation upon depolarization or transfection with constitutively active (ca) CaMKI was blocked by dnRas. Additionally, depolarization of NG108 cells promoted neurite outgrowth, and this effect was blocked by inhibition of either CaMKK (STO-609) or ERK (UO126). Co-transfection with caCaMKK plus caCaMKI also stimulated neurite outgrowth that was blocked by inhibition of ERK (UO126). These data are the first to suggest that ERK activation and neurite outgrowth in response to depolarization are mediated by CaMKK activation of CaMKI.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA; Kanagawa Dent Coll, Yokosuka, Kanagawa, Japan	Oregon Health & Science University; Oregon Health & Science University; Kanagawa Dental College	Soderling, TR (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, Mailcode L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	soderlit@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK44239, DK007680, T32 DK007680] Funding Source: Medline; NIGMS NIH HHS [R01 GM 41292] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Adams JP, 2000, ACTA NEUROBIOL EXP, V60, P377; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chang BH, 1998, P NATL ACAD SCI USA, V95, P10890, DOI 10.1073/pnas.95.18.10890; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Fan GH, 1997, NEUROPHARMACOLOGY, V36, P1763, DOI 10.1016/S0028-3908(97)00164-0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Gendron L, 1999, MOL ENDOCRINOL, V13, P1615, DOI 10.1210/me.13.9.1615; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hashii M, 2000, BIOCHEM J, V345, P207, DOI 10.1042/0264-6021:3450207; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Illario M, 2003, J BIOL CHEM, V278, P45101, DOI 10.1074/jbc.M305355200; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Komiyama NH, 2002, J NEUROSCI, V22, P9721; Kozireski-Chuback D, 1999, J NEUROSCI RES, V57, P541, DOI 10.1002/(SICI)1097-4547(19990815)57:4<541::AID-JNR14>3.0.CO;2-X; Kutcher LW, 2003, AM J PHYSIOL-CELL PH, V284, pC1334, DOI 10.1152/ajpcell.00510.2002; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; Markus A, 2002, NEURON, V35, P65, DOI 10.1016/S0896-6273(02)00752-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mazzucchelli C, 2002, NEURON, V34, P807, DOI 10.1016/S0896-6273(02)00716-X; Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NORONHABLOB L, 1988, J NEUROCHEM, V50, P1381, DOI 10.1111/j.1471-4159.1988.tb03020.x; OH JS, 2004, J BIOL CHEM; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QIN H, 2003, J BIOL CHEM; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Suizu F, 2002, BIOCHEM J, V367, P335, DOI 10.1042/BJ20020536; Takeuchi Y, 2003, J NEUROCHEM, V85, P729, DOI 10.1046/j.1471-4159.2003.01711.x; Tokumitsu H, 2003, J BIOL CHEM, V278, P10908, DOI 10.1074/jbc.M213183200; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023; Tong JF, 2003, J BIOL CHEM, V278, P6111, DOI 10.1074/jbc.M208972200; Uezu A, 2002, J NEUROCHEM, V82, P585, DOI 10.1046/j.1471-4159.2002.00984.x; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vaudry D, 2002, ANN NY ACAD SCI, V971, P491, DOI 10.1111/j.1749-6632.2002.tb04513.x; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Whitmarsh AJ, 2001, NAT NEUROSCI, V4, P963, DOI 10.1038/nn1001-963; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Wu G, 1998, J NEUROCYTOL, V27, P1, DOI 10.1023/A:1006910001869; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xiao JN, 2003, J NEUROCHEM, V86, P1516, DOI 10.1046/j.1471-4159.2003.01961.x; Xie X, 2002, J NEUROCHEM, V81, P1185, DOI 10.1046/j.1471-4159.2002.00917.x; Yamauchi T, 1998, BRAIN RES PROTOC, V2, P250, DOI 10.1016/S1385-299X(98)00002-6; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	77	124	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24064	24072		10.1074/jbc.M401501200	http://dx.doi.org/10.1074/jbc.M401501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15150258	hybrid, Green Submitted			2022-12-27	WOS:000221702500028
J	Frank, C; Molnar, F; Matilainen, M; Lempiainen, H; Carlberg, C				Frank, C; Molnar, F; Matilainen, M; Lempiainen, H; Carlberg, C			Agonist-dependent and agonist-independent transactivations of the human constitutive androstane receptor are modulated by specific amino acid pairs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ENHANCER MODULE; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; VITAMIN-D-3 RECEPTOR; CYP2B10 GENE; TARGET GENES; CAR; COACTIVATOR; ACTIVATION; SUPERFAMILY	The constitutive androstane receptor ( CAR) is an interesting member of the nuclear receptor superfamily because of its exceptionally high constitutive activity due to ligand-independent interaction of the ligand-binding domain with co-activator proteins. This study compares the agonist- dependent and agonist- independent activities of human CAR with those of mouse CAR and the vitamin D receptor and demonstrates that the constitutive activity of CAR is mediated by at least three contacts between the amino acids of helix 12, partner amino acids in helices 4 and 11, and a charge clamp between helices 12 and 3. The stabilization of helix 12 by a contact between its C terminus and the lysine of helix 4 has the same impact in human and mouse CARs. In addition, the charge clamp between the glutamate in helix 12 and the lysine in helix 3 is also important for the constitutive activity of both receptor orthologs but less critical for the agonist- dependent stabilization of their respective helices 12. Interestingly, Cys-357 in mouse CAR has significantly more impact on the stabilization of helix 12 than does the orthologous position Cys-347 in human CAR. This deficit appears to be compensated by a more dominant role of Ile-330 in human CAR over Leu-340 in mouse CAR because it is more efficient than Cys-347 in controlling the flexibility of helix 12 in the presence of an agonist. The constitutive activity of other members of the nuclear receptor superfamily could be explained by a homologous hydrophobic interaction between large, non-polar amino acids of helices 11 and 12.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Heinaniemi, Merja/AAS-4530-2020; Molnár, Ferdinand/E-2290-2011; Carlberg, Carsten/C-9075-2011; Heinäniemi, Merja/C-5051-2014	Heinaniemi, Merja/0000-0001-6190-3439; Molnár, Ferdinand/0000-0001-9008-4233; Carlberg, Carsten/0000-0003-2633-0684; Heinäniemi, Merja/0000-0001-6190-3439; Lempiainen, Harri/0000-0002-8945-6295				Andersin T, 2003, MOL ENDOCRINOL, V17, P234, DOI 10.1210/me.2002-0263; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Carlberg C, 2003, J CELL BIOCHEM, V88, P274, DOI 10.1002/jcb.10337; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Drocourt L, 2002, J BIOL CHEM, V277, P25125, DOI 10.1074/jbc.M201323200; Dussault I, 2002, MOL CELL BIOL, V22, P5270, DOI 10.1128/MCB.22.15.5270-5280.2002; Frank C, 2003, J BIOL CHEM, V278, P43299, DOI 10.1074/jbc.M305186200; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL PHARMACOL, V53, P597, DOI 10.1124/mol.53.4.597; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Jacobs MN, 2003, J STEROID BIOCHEM, V84, P117, DOI 10.1016/S0960-0760(03)00021-9; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li Y, 2003, STRUCTURE, V11, P741, DOI 10.1016/S0969-2126(03)00133-3; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; Makinen JM, 2002, MOL PHARMACOL, V62, P366, DOI 10.1124/mol.62.2.366; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; ONATE SA, 1995, SCIENCE, V270, P1354; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Toell A, 2002, J CELL BIOCHEM, V85, P72, DOI 10.1002/jcb.10104; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; Vaisanen S, 2002, J MOL BIOL, V315, P229, DOI 10.1006/jmbi.2001.5225; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762	38	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33558	33566		10.1074/jbc.M403946200	http://dx.doi.org/10.1074/jbc.M403946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15151997	hybrid			2022-12-27	WOS:000223039700064
J	Miller, SLH; Malotky, E; O'Bryan, JP				Miller, SLH; Malotky, E; O'Bryan, JP			Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26 S PROTEASOME; DEUBIQUITINATING ENZYME; MULTIUBIQUITIN CHAINS; PROTEIN-DEGRADATION; FAT FACETS; IN-VIVO; DOMAIN; HRS; RECEPTOR; SUBUNIT	The ubiquitin-interacting motif (UIM) is a short peptide motif with the dual function of binding ubiquitin and promoting ubiquitylation. This motif is conserved throughout eukaryotes and is present in numerous proteins involved in a wide variety of cellular processes including endocytosis, protein trafficking, and signal transduction. We previously reported that the UIMs of epsin were both necessary and sufficient for its ubiquitylation. In this study, we found that many, but not all, UIM-containing proteins were ubiquitylated. When expressed as chimeric fusion proteins, most UIMs promoted ubiquitylation of the chimera. In contrast to previous studies, we found that UIMs do not exclusively promote monoubiquitylation but rather a mixture of mono-, multi-, and polyubiquitylation. However, UIM-dependent polyubiquitylation does not lead to degradation of the modified protein. UIMs also bind polyubiquitin chains of varying lengths and to different degrees, and this activity is required for UIM-dependent ubiquitylation. Mutational analysis of the UIM revealed specific amino acids that are important for both polyubiquitin binding and ubiquitin conjugation. Finally we provide evidence that UIM-dependent ubiquitylation inhibits the interaction of UIM-containing proteins with other ubiquitylated cellular proteins. Our results suggest a new model for the ubiquitylation of UIM-containing proteins.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Med, Dept Biomed Engn, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	O'Bryan, JP (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Bldg Rm 101-F336,MD F3-06,POB 12233, Res Triangle Pk, NC 27709 USA.	obryan@niehs.nih.gov	Scappini, Erica/C-7684-2019	Scappini, Erica/0000-0002-9100-0027; O'Bryan, John/0000-0001-5386-1080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Cheetham ME, 1996, BIOCHEM J, V319, P103, DOI 10.1042/bj3190103; Chen H, 2003, P NATL ACAD SCI USA, V100, P14908, DOI 10.1073/pnas.2136625100; Chen X, 2002, GENE DEV, V16, P289, DOI 10.1101/gad.961502; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Valero R, 1999, GENOMICS, V62, P395, DOI 10.1006/geno.1999.6025; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	42	84	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33528	33537		10.1074/jbc.M313097200	http://dx.doi.org/10.1074/jbc.M313097200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155768	Green Published, hybrid			2022-12-27	WOS:000223039700061
J	Verma, S; Shewan, AM; Scott, JA; Helwani, FM; den Elzen, NR; Miki, H; Takenawa, T; Yap, AS				Verma, S; Shewan, AM; Scott, JA; Helwani, FM; den Elzen, NR; Miki, H; Takenawa, T; Yap, AS			Arp2/3 activity is necessary for efficient formation of E-cadherin adhesive contacts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN NUCLEATION; BINDING-ACTIVITY; PLASMA-MEMBRANE; COMPLEX; DYNAMICS; POLYMERIZATION; MORPHOGENESIS; MECHANISMS	Classical cadherin adhesion molecules are fundamental determinants of cell-cell recognition that function in cooperation with the actin cytoskeleton. Productive cadherin-based cell recognition is characterized by a distinct morphological process of contact zone extension, where limited initial points of adhesion are progressively expanded into broad zones of contact. We recently demonstrated that E-cadherin ligation recruits the Arp2/3 actin nucleator complex to the plasma membrane in regions where cell contacts are undergoing protrusion and extension. This suggested that Arp2/3 might generate the protrusive forces necessary for cell surfaces to extend upon one another during contact assembly. We tested this hypothesis in mammalian cells by exogenously expressing the CA region of N-WASP. This fragment, which potently inhibits Arp2/3-mediated actin assembly in vitro, also effectively reduced actin assembly at cadherin adhesive contacts. Blocking Arp2/3 activity by this strategy profoundly reduced the ability of cells to extend cadherin adhesive contacts but did not affect cell adhesiveness. These findings demonstrate that Arp2/3 activity is necessary for cells to efficiently extend and assemble cadherin-based adhesive contacts.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Tokyo, Inst Med Sci, Div Canc Gen, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, PRESTO, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, CREST, Tokyo 1088639, Japan	University of Queensland; University of Queensland; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Yap, AS (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	a.yap@imb.uq.edu.au	Shewan, Annette/B-3251-2011; Yap, Alpha S./J-1554-2014	Shewan, Annette/0000-0003-4936-9207; Yap, Alpha S./0000-0002-1038-8956; Den Elzen, Nicole/0000-0003-0223-4954				Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Ayscough K, 1998, METHOD ENZYMOL, V298, P18, DOI 10.1016/S0076-6879(98)98004-1; Bailly M, 2001, CURR BIOL, V11, P620, DOI 10.1016/S0960-9822(01)00152-X; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; EVANGELISTA M, 2001, NAT CELL BIOL, V4, P260; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Grinnell F, 1978, Int Rev Cytol, V53, P65; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; Helwani FM, 2004, J CELL BIOL, V164, P899, DOI 10.1083/jcb.200309034; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; Kobielak A, 2004, NAT CELL BIOL, V6, P21, DOI 10.1038/ncb1075; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Niessen CM, 2002, J CELL BIOL, V156, P389, DOI 10.1083/jcb.200108040; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sako Y, 1998, J CELL BIOL, V140, P1227, DOI 10.1083/jcb.140.5.1227; Sasaki N, 2000, BIOCHEM BIOPH RES CO, V272, P386, DOI 10.1006/bbrc.2000.2785; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; TROXELLML, 1999, AM J PHYSIOL, V276, pC404; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	38	124	124	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34062	34070		10.1074/jbc.M404814200	http://dx.doi.org/10.1074/jbc.M404814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159390	hybrid			2022-12-27	WOS:000223039700118
J	Wang, YQ; Theriault, JR; He, HY; Gong, JL; Calderwood, SK				Wang, YQ; Theriault, JR; He, HY; Gong, JL; Calderwood, SK			Expression of a dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-1; MOLECULAR CHAPERONES; SPINDLE CHECKPOINT; PROTEIN EXPRESSION; GENE-TRANSCRIPTION; DNA REREPLICATION; MAMMALIAN-CELLS; BREAST-CANCER; C-FOS; ACTIVATION	Recent studies have implicated heat shock proteins (HSP) and heat shock transcription factor 1 (HSF1) in tumor progression. We have examined the role of HSF1 in the malignant phenotype of PC-3 prostate carcinoma cells. We have developed a dominant negative construct of HSF1 that antagonizes transcription from HSP promoters and results in the depletion of intracellular HSP 70. Our studies indicate that expression of DN-HSF1 dramatically alters the DNA content of PC-3 cells ( derived from p53 null prostatic carcinoma) and inhibits aneuploidy in these cells. This effect is due to prolonged expression of DN-HSF1, and transient expression of the dominant negative factor from an inducible promoter failed to cause the effect. Inhibition of aneuploidy in p53 null PC-3 cells by DN-HSF1 expression was recapitulated by expression within the cells of wild type p53. Furthermore, cells expressing DN-HSF1 showed a profound inhibition in the development of aneuploidy when exposed to chemical agents that disrupt the mitotic spindle and prevent progression through metaphase. Inhibition of aneuploidy in PC-3 cells expressing DN-HSF1 was associated with delayed breakdown of cyclin B1 compared with controls, consistent with a role for wild type HSF1 in the regulation of cyclin B1 degradation, a key step in the control of mitosis. Our experiments therefore demonstrate that HSF1 plays a functional role in cancer cells under nonstress conditions and influences cell cycle behavior and progression through mitosis and promotes the development of the aneuploid state.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol,Div Mol & Cellular Biol, 21-27 Burlington Ave,Rm 553B, Boston, MA 02215 USA.			Gong, Jianlin/0000-0003-0910-014X	NCI NIH HHS [CA50642, CA31303, CA47407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047407, P01CA031303, R01CA050642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Bruce JL, 1999, CELL STRESS CHAPERON, V4, P36, DOI 10.1054/csac.1999.0005; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Ciocca Daniel R, 2002, Prog Mol Subcell Biol, V28, P205; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cornford PA, 2000, CANCER RES, V60, P7099; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GREEN M, 1995, MOL CELL BIOL, V15, P3354; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; He HY, 2003, J BIOL CHEM, V278, P35465, DOI 10.1074/jbc.M304663200; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Huang JR, 1997, J BIOL CHEM, V272, P26009, DOI 10.1074/jbc.272.41.26009; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEE KA, 1990, METHOD ENZYMOL, V181, P227; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; LI GC, 1980, CANCER RES, V40, P4501; Li RH, 1997, P NATL ACAD SCI USA, V94, P14506, DOI 10.1073/pnas.94.26.14506; Liang P, 1997, J CELL SCI, V110, P1431; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Matzke MA, 1999, BIOESSAYS, V21, P761, DOI 10.1002/(SICI)1521-1878(199909)21:9&lt;761::AID-BIES7&gt;3.0.CO;2-C; Newton EM, 1996, MOL CELL BIOL, V16, P839; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; RATTNER JB, 1991, EXP CELL RES, V195, P110, DOI 10.1016/0014-4827(91)90505-O; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; Strik HM, 2000, ANTICANCER RES, V20, P4457; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Wigley WC, 1999, J CELL BIOL, V145, P481; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xie Y, 2003, J BIOL CHEM, V278, P4687, DOI 10.1074/jbc.M210189200; Yano M, 1999, CANCER LETT, V137, P45, DOI 10.1016/S0304-3835(98)00338-3; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	63	58	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32651	32659		10.1074/jbc.M401475200	http://dx.doi.org/10.1074/jbc.M401475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15152009	hybrid			2022-12-27	WOS:000222849700083
J	Ahmad, Z; Senior, AE				Ahmad, Z; Senior, AE			Mutagenesis of residue beta Arg-246 in the phosphate-binding subdomain of catalytic sites of Escherichia coli F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACILLUS PS3; MYOSIN MOTOR DOMAIN; ATP SYNTHASE; TRANSITION-STATE; NUCLEOTIDE-BINDING; BETA-SUBUNIT; OXIDATIVE-PHOSPHORYLATION; F1F0-ATP SYNTHASE; ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL ATPASE	Residues responsible for phosphate binding in F1F0-ATP synthase catalytic sites are of significant interest because phosphate binding is believed linked to proton gradient-driven subunit rotation. From x-ray structures, a phosphate-binding subdomain is evident in catalytic sites, with conserved betaArg-246 in a suitable position to bind phosphate. Mutations betaR246Q, betaR246K, and betaR246A in Escherichia coli were found to impair oxidative phosphorylation and to reduce ATPase activity of purified F-1 by 100-fold. In contrast to wild type, ATPase of mutants was not inhibited by MgADP-fluoroaluminate or MgADP-fluoroscandium, showing the Arg side chain is required for wild-type transition state formation. Whereas 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) inhibited wild-type ATPase essentially completely, ATPase in mutants was inhibited maximally by similar to 50%, although reaction still occurred at residue betaTyr-297, proximal to betaArg-246 in the phosphate-binding pocket. Inhibition characteristics supported the conclusion that NBD-Cl reacts in betaE ( empty) catalytic sites, as shown previously by x-ray structure analysis. Phosphate protected against NBD-Cl inhibition in wild type but not in mutants. The results show that phosphate can bind in the betaE catalytic site of E. coli F-1 and that betaArg-246 is an important phosphate-binding residue.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu		Ahmad, Zulfiqar/0000-0001-7306-8151	NIGMS NIH HHS [GM25349, R15 GM085771] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM085771, R01GM025349, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12961, DOI 10.1021/bi971478r; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; Bockmann RA, 2002, NAT STRUCT BIOL, V9, P198, DOI 10.1038/nsb760; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; de Meis L, 1977, Biochemistry, V16, P4455, DOI 10.1021/bi00639a020; DEMEIS L, 1987, FEBS LETT, V213, P333, DOI 10.1016/0014-5793(87)81517-X; Dittrich M, 2003, BIOPHYS J, V85, P2253, DOI 10.1016/S0006-3495(03)74650-5; Dou C, 1998, BIOCHEMISTRY-US, V37, P16757, DOI 10.1021/bi981717q; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P127, DOI 10.1111/j.1432-1033.1975.tb04121.x; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P117, DOI 10.1111/j.1432-1033.1975.tb04120.x; FISCHER S, 1994, EUR J BIOCHEM, V225, P167, DOI 10.1111/j.1432-1033.1994.00167.x; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Masaike T, 2002, J BIOL CHEM, V277, P21643, DOI 10.1074/jbc.M110297200; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nadanaciva S, 2000, BIOCHEMISTRY-US, V39, P9583, DOI 10.1021/bi000941o; Nadanaciva S, 1999, BIOCHEMISTRY-US, V38, P15493, DOI 10.1021/bi9917683; Nadanaciva S, 1999, BIOCHEMISTRY-US, V38, P7670, DOI 10.1021/bi990663x; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; NOUMI T, 1986, J BIOL CHEM, V261, P9196; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ JA, 1986, FEBS LETT, V198, P113, DOI 10.1016/0014-5793(86)81195-4; RAO R, 1988, J BIOL CHEM, V263, P5569; ROSING J, 1977, J BIOL CHEM, V252, P2478; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; SENIOR AE, 1983, BIOCHEM J, V210, P395, DOI 10.1042/bj2100395; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; WEBER J, 1992, J BIOL CHEM, V267, P1712; Weber J, 2004, METHOD ENZYMOL, V380, P132; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Yang W, 2003, P NATL ACAD SCI USA, V100, P874, DOI 10.1073/pnas.0337432100	57	47	49	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31505	31513		10.1074/jbc.M404621200	http://dx.doi.org/10.1074/jbc.M404621200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150266	hybrid			2022-12-27	WOS:000222726800073
J	Mohri, K; Vorobiev, S; Fedorov, AA; Almo, SC; Ono, S				Mohri, K; Vorobiev, S; Fedorov, AA; Almo, SC; Ono, S			Identification of functional residues on Caenorhabditis elegans actin-interacting protein 1 (UNC-78) for disassembly of actin depolymerizing factor/cofilin-bound actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; WD REPEAT; BINDING PROTEINS; COFILIN; DYNAMICS; HOMOLOG; FAMILY; AIP1; UNC-60B; XAIP1	Actin-interacting protein 1 (AIP1) is a WD40 repeat protein that enhances actin filament disassembly in the presence of actin-depolymerizing factor (ADF)/cofilin. AIP1 also caps the barbed end of ADF/cofilin-bound actin filament. However, the mechanism by which AIP1 interacts with ADF/cofilin and actin is not clearly understood. We determined the crystal structure of Caenorhabditis elegans AIP1 ( UNC-78), which revealed 14 WD40 modules arranged in two seven-bladed beta-propeller domains. The structure allowed for the mapping of conserved surface residues, and mutagenesis studies identified five residues that affected the ADF/cofilin-dependent actin filament disassembly activity. Mutations of these residues, which reside in blades 3 and 4 in the N-terminal propeller domain, had significant effects on the disassembly activity but did not alter the barbed end capping activity. These data support a model in which this conserved surface of AIP1 plays a direct role in enhancing fragmentation/depolymerization of ADF/cofilin-bound actin filaments but not in barbed end capping.	Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Synchrotron Biosci, Bronx, NY 10461 USA	Emory University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Ono, S (corresponding author), Emory Univ, Dept Pathol, 615 Michael St,Whitehead Res Bldg,Rm 105N, Atlanta, GA 30322 USA.	sono@emory.edu	Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001979] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41-EB-01979] Funding Source: Medline; NIGMS NIH HHS [GM53807] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa H, 1999, GENES CELLS, V4, P311, DOI 10.1046/j.1365-2443.1999.00262.x; Allwood EG, 2002, PLANT CELL, V14, P2915, DOI 10.1105/tpc.005363; Balcer HI, 2003, CURR BIOL, V13, P2159, DOI 10.1016/S0960-9822(03)00907-2; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Galkin VE, 2003, J CELL BIOL, V163, P1057, DOI 10.1083/jcb.200308144; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; Gerisch G, 2004, CELL MOTIL CYTOSKEL, V57, P18, DOI 10.1002/cm.10150; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Ketelaar T, 2004, CURR BIOL, V14, P145, DOI 10.1016/j.cub.2004.01.004; Konzok A, 1999, J CELL BIOL, V146, P453, DOI 10.1083/jcb.146.2.453; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Maciver SK, 2002, GENOME BIOL, V3; MBERG DC, 1995, NAT STRUCT BIOL, V2, P28; McGough A, 1999, J MOL BIOL, V291, P513, DOI 10.1006/jmbi.1999.2968; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Mohri K, 2003, J CELL SCI, V116, P4107, DOI 10.1242/jcs.00717; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Okada K, 1999, J CELL SCI, V112, P1553; Okada K, 2002, J BIOL CHEM, V277, P43011, DOI 10.1074/jbc.M203111200; Ono K, 2003, J CELL SCI, V116, P2073, DOI 10.1242/jcs.00421; Ono S, 2003, BIOCHEMISTRY-US, V42, P13363, DOI 10.1021/bi034600x; Ono S, 2004, J BIOL CHEM, V279, P14207, DOI 10.1074/jbc.M313418200; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Ono S, 1998, J BIOL CHEM, V273, P3778, DOI 10.1074/jbc.273.6.3778; Ono S, 2001, J CELL BIOL, V152, P1313, DOI 10.1083/jcb.152.6.1313; Ono S, 2001, J BIOL CHEM, V276, P5952, DOI 10.1074/jbc.M007563200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Voegtli WC, 2003, J BIOL CHEM, V278, P34373, DOI 10.1074/jbc.M302773200	42	63	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31697	31707		10.1074/jbc.M403351200	http://dx.doi.org/10.1074/jbc.M403351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150269	hybrid			2022-12-27	WOS:000222726800095
J	Pakneshan, P; Szyf, M; Farias-Eisner, R; Rabbani, SA				Pakneshan, P; Szyf, M; Farias-Eisner, R; Rabbani, SA			Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; IN-VIVO; INHIBITS TUMORIGENESIS; S-ADENOSYLMETHIONINE; EXPRESSION; ANTISENSE; METHYLTRANSFERASE; INVASION; DEMETHYLATION; MECHANISM	Metastasis is a leading cause of mortality and morbidity in cancer. Urokinase (uPA), only expressed by the highly invasive cancer cells, has been implicated in invasion, metastases, and angiogenesis of several malignancies including breast cancer. Because uPA expression is strongly correlated with its hypomethylated state, we utilized the uPA gene in the highly invasive MDA-231 human breast cancer cells as a model system to test the hypothesis that pharmacological reversal of the uPA promoter hypomethylation would result in its silencing and inhibition of metastasis. S-Adenosyl-L-methionine ( AdoMet) has previously been shown to cause hypermethylation and inhibit demethylation. Treatment of MDA-231 cells with AdoMet, but not its unmethylated analogue S-adenosylhomocysteine, significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and metastasis in vivo. The effects of AdoMet on uPA expression were reversed by the demethylating agent 5'-azacytidine, supporting the conclusion that AdoMet effects are caused by hypermethylation. Knockdown of the methyl-binding protein 2 also causes a significant inhibition of uPA expression in vitro and tumor growth and metastasis in vivo. These treatments did not have any effects on estrogen receptor expression, suggesting that inhibition of hypomethylation will not affect genes already silenced by hypermethylation. These data are consistent with the hypothesis that hypomethylation of critical genes like uPA plays a causal role in metastasis. Inhibition of hypomethylation can thus be used as a novel therapeutic approach to silence the pro-metastatic gene uPA and block breast cancer progression into the aggressive and metastatic stages of the disease.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Pharmacol, Montreal, PQ H3A 1A1, Canada; Univ Calif Los Angeles, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA	McGill University; McGill University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med, 687 Pine Ave W,Rm H4-67, Montreal, PQ H3A 1A1, Canada.	shafaat.rabbani@mcgill.ca		rabbani, shafaat/0000-0001-5594-3899				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Campbell PM, 2004, CARCINOGENESIS, V25, P499, DOI 10.1093/carcin/bgh045; Detich N, 2003, J BIOL CHEM, V278, P20812, DOI 10.1074/jbc.M211813200; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fuso A, 2001, FEBS LETT, V508, P337, DOI 10.1016/S0014-5793(01)03030-7; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393; Rabbani SA, 1998, INT J ONCOL, V12, P911; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Ross SA, 2003, ANN NY ACAD SCI, V983, P197, DOI 10.1111/j.1749-6632.2003.tb05974.x; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; SIMILE MM, 1994, CANCER LETT, V79, P9, DOI 10.1016/0304-3835(94)90056-6; Slack A, 2002, J GENE MED, V4, P381, DOI 10.1002/jgm.288; Szyf M, 2003, AGEING RES REV, V2, P299, DOI 10.1016/S1568-1637(03)00012-6; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; van der Westhuyzen J, 1985, Nutr Cancer, V7, P179; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555	30	152	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31735	31744		10.1074/jbc.M401669200	http://dx.doi.org/10.1074/jbc.M401669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150277	hybrid			2022-12-27	WOS:000222726800099
J	Han, JS; Kang, SY; Kim, SH; Ko, MJ; Hwang, DS				Han, JS; Kang, SY; Kim, SH; Ko, MJ; Hwang, DS			Binding of SeqA protein to hemi-methylated GATC sequences enhances their interaction and aggregation properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-REPLICATION; TOPOISOMERASE-IV; BIDIRECTIONAL MIGRATION; CHROMOSOME-REPLICATION; DAM METHYLTRANSFERASE; SEGREGATION; ORIGIN; SEQUESTRATION; INITIATION	The SeqA protein regulates chromosome initiation and is involved in segregation in Escherichia coli. One SeqA protein binds to two hemi-methylated GATC sequences to form a stable SeqA-DNA complex. We found that binding induced DNA bending, which was pronounced when the two sequences were on the same face of the DNA. Two SeqA molecules bound cooperatively to each pair of hemi-methylated sites when the spacing between the sites was less than or equal to30 bp. This cooperative binding was able to stabilize the binding of a wild type to a single hemi-methylated site, or mutant form of SeqA protein to hemi-methylated sites, although such binding did not occur without cooperative interaction. Two cooperatively bound SeqA molecules interacted with another SeqA bound up to 185 bp away from the two bound SeqA proteins, and this was followed by aggregation of free SeqA proteins onto the bound proteins. These results suggest that the stepwise interaction of SeqA proteins with hemi-methylated GATC sites enhances their interaction and leads to the formation of SeqA aggregates. Cooperative interaction followed by aggregation may be the driving force for formation of the SeqA foci that appear to be located behind replication forks.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Hwang, DS (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	dshwang@plaza.snu.ac.kr		Kang, Sukhyun/0000-0002-7567-0231				ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Bach T, 2003, EMBO J, V22, P315, DOI 10.1093/emboj/cdg020; Bae SH, 2003, J BIOL CHEM, V278, P45987, DOI 10.1074/jbc.M306038200; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Boye E, 1996, P NATL ACAD SCI USA, V93, P12206, DOI 10.1073/pnas.93.22.12206; Brendler T, 2000, EMBO J, V19, P6249, DOI 10.1093/emboj/19.22.6249; Brendler T, 1999, EMBO J, V18, P2304, DOI 10.1093/emboj/18.8.2304; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Fossum S, 2003, MOL MICROBIOL, V47, P619, DOI 10.1046/j.1365-2958.2003.t01-1-03329.x; Fujikawa N, 2004, NUCLEIC ACIDS RES, V32, P82, DOI 10.1093/nar/gkh173; Fujikawa N, 2003, BIOCHEM BIOPH RES CO, V300, P699, DOI 10.1016/S0006-291X(02)02891-7; GEIER GE, 1979, J BIOL CHEM, V254, P1408; Guarne A, 2002, NAT STRUCT BIOL, V9, P839, DOI 10.1038/nsb857; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Han JS, 2003, J BIOL CHEM, V278, P34983, DOI 10.1074/jbc.M304923200; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hiraga S, 2000, GENES CELLS, V5, P327, DOI 10.1046/j.1365-2443.2000.00334.x; Hiraga S, 1998, MOL CELL, V1, P381, DOI 10.1016/S1097-2765(00)80038-6; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kang S, 1999, J BIOL CHEM, V274, P11463, DOI 10.1074/jbc.274.17.11463; Kang SH, 2003, J BIOL CHEM, V278, P48779, DOI 10.1074/jbc.M308843200; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KORNBERG A, 1992, DNA REPLICATION, P521; Lee H, 2001, J BIOL CHEM, V276, P34600, DOI 10.1074/jbc.M101339200; Lee H, 2001, MOL GEN GENET, V264, P931, DOI 10.1007/PL00008701; Lee YS, 1997, J BIOL CHEM, V272, P83; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MESSER W, 1996, ESCHERICHIA COLI SAL, P1580; Onogi T, 1999, MOL MICROBIOL, V31, P1775, DOI 10.1046/j.1365-2958.1999.01313.x; Papavassiliou AG., 1994, DNA-protein interactions, P43, DOI 10.1385/0-89603-256-6:43; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sawitzke J, 2001, MOL MICROBIOL, V40, P786, DOI 10.1046/j.1365-2958.2001.02350.x; Slominska M, 2001, MOL MICROBIOL, V40, P1371, DOI 10.1046/j.1365-2958.2001.02480.x; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitao T, 2000, EMBO REP, V1, P494; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	39	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30236	30243		10.1074/jbc.M402612200	http://dx.doi.org/10.1074/jbc.M402612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15151991	hybrid			2022-12-27	WOS:000222531900047
J	Karbowniczek, M; Cash, T; Cheung, M; Robertson, GP; Astrinidis, A; Henske, EP				Karbowniczek, M; Cash, T; Cheung, M; Robertson, GP; Astrinidis, A; Henske, EP			Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEINS; SCLEROSIS GENE; CELL-GROWTH; TSC1 GENE; ACTIVATION; PRODUCT; DROSOPHILA; HAMARTIN; MTOR; COMPLEX	Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome with manifestations that can include seizures, mental retardation, autism, and tumors in the brain, retina, kidney, heart, and skin. The products of the TSC1 and TSC2 genes, hamartin and tuberin, respectively, heterodimerize and inhibit the mammalian target of rapamycin ( mTOR). We found that tuberin expression increases p42/44 MAPK phosphorylation and B-Raf kinase activity. Short interfering RNA down-regulation of tuberin decreased the p42/44 MAPK phosphorylation and B-Raf activity. Expression of Rheb, the target of the GTPase-activating domain of tuberin, inhibited wildtype B-Raf kinase but not activated forms of B-Raf. The interaction of endogenous Rheb with B-Raf was enhanced by serum and by Ras overexpression. A farnesylation-defective mutant of Rheb co-immunoprecipitated with and inhibited B-Raf but did not activate ribosomal protein S6 kinase, indicating that farnesylation is not required for B-Raf inhibition by Rheb and that B-Raf inhibition and S6 kinase activation are separable activities of Rheb. Consistent with this, inhibition of B-Raf and p42/44 MAPK by Rheb was resistant to rapamycin in contrast to Rheb activation of S6 kinase, which is rapamycin-sensitive. Taken together these data demonstrate that inhibition of B-Raf kinase via Rheb is an mTOR-independent function of tuberin.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Henske, EP (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	EP_Henske@fccc.edu	Astrinidis, Aristotelis/A-1396-2010; Astreinidis, Aristotelis/ABA-6715-2021; Astreinidis, Aristotelis/AAK-5137-2020; Robertson, Gavin P./A-6106-2017	Robertson, Gavin P./0000-0003-0152-2997; Astrinidis, Aristotelis/0000-0001-7098-1391	NHLBI NIH HHS [HL 60746] Funding Source: Medline; NIDDK NIH HHS [DK 51052] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051052, R01DK051052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; HIROSE T, 1995, ACTA NEUROPATHOL, V90, P387; HOWE SR, 1995, AM J PATHOL, V146, P1568; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Karbowniczek M, 2003, AM J PATHOL, V162, P491, DOI 10.1016/S0002-9440(10)63843-6; Kenerson HL, 2002, CANCER RES, V62, P5645; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Liu MY, 2002, CANCER RES, V62, P6475; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Yoon HS, 2004, AM J PHYSIOL-RENAL, V286, pF417, DOI 10.1152/ajprenal.00234.2003; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	48	82	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29930	29937		10.1074/jbc.M402591200	http://dx.doi.org/10.1074/jbc.M402591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150271	hybrid			2022-12-27	WOS:000222531900009
J	Landon, C; Thouzeau, C; Labbe, H; Bulet, P; Vovelle, F				Landon, C; Thouzeau, C; Labbe, H; Bulet, P; Vovelle, F			Solution structure of spheniscin, a beta-defensin from the penguin stomach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; ANTIBACTERIAL ACTIVITIES; PROGRAM; SYSTEM; IDENTIFICATION; INFECTION; REVEALS; CHICKEN; FOOD	Recently two beta-defensins, named spheniscins, have been isolated from the stomach content of the king penguin (Aptenodytes patagonicus), which is capable of preserving food for several weeks during egg incubation (Thouzeau, C., Le Maho, Y., Froget, G., Sabatier, L., Le Bohec, C., Hoffmann, J.A., and Bulet, P. (2003) J. Biol. Chem. 278, 51053-51058). It has been proposed that, in combination with other antimicrobial peptides, spheniscins may be involved in this long term preservation of food in the bird's stomach. To draw some structure/function features, the three-dimensional structure in aqueous solution of the most abundant spheniscin (Sphe-2) was determined by two-dimensional NMR and molecular modeling techniques. The overall fold of Sphe-2 includes a three-stranded antiparallel beta-sheet stabilized by three disulfide bridges with a pairing typical of beta-defensins. In addition, the N-terminal segment shows helical features on most structures. Sphe-2 is highly cationic, and its surface displays a hydrophobic patch. Comparative modeling revealed that this patch is preserved in avian defensins. The activity of Sphe-2 against a pathogenic Gram-positive strain was retained in vitro in the conditions of osmolarity found in penguin stomach content and also in different salt concentrations and compositions up to those reported for seawater. Comparison with structurally related mammalian beta-defensins showed that the hydrophobic patch is not preserved in mammalian beta-defensins and that the high cationicity of Sphe-2 is presumably the critical factor for its retained activity in high salt concentrations. Such peculiarities, in addition to a broad activity spectrum, suggest that penguin defensins may represent interesting probes for the design of highly efficient antibiotics to fight off pathogens that develop in relatively salt-rich body fluids.	Univ Orleans, Ctr Biophys Mol, CNRS, UPR 4301, F-45071 Orleans 2, France; CNRS, UPR 9010, Ctr Ecol & Physiol Energet, F-67087 Strasbourg 02, France; Atheris Labs, CH-1233 Geneva, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Orleans; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Vovelle, F (corresponding author), Univ Orleans, Ctr Biophys Mol, CNRS, UPR 4301, Rue Charles Sadron, F-45071 Orleans 2, France.	vovelle@cnrs-orleans.fr	BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				Bateman A, 1996, J BIOL CHEM, V271, P10654, DOI 10.1074/jbc.271.18.10654; Bauer F, 2001, PROTEIN SCI, V10, P2470, DOI 10.1110/ps.ps.24401; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulet P, 2003, INFEC DIS S, P89; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dinulos JGH, 2003, CLIN DIAGN LAB IMMUN, V10, P161, DOI 10.1128/CDLI.10.1.161-166.2003; ECKERT R, 1988, ANIMAL PHYSL MECH AD, P389; Evans EW, 1995, VET MICROBIOL, V47, P295, DOI 10.1016/0378-1135(95)00126-3; EVANS EW, 1994, J LEUKOCYTE BIOL, V56, P661, DOI 10.1002/jlb.56.5.661; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garcia JRC, 2001, CELL TISSUE RES, V306, P257, DOI 10.1007/s004410100433; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; Gauthier-Clerc M, 2000, NATURE, V408, P928, DOI 10.1038/35050163; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HARWIG SSL, 1994, FEBS LETT, V342, P281, DOI 10.1016/0014-5793(94)80517-2; Hetru C, 1997, Methods Mol Biol, V78, P35; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Mandal M, 2002, PEPTIDES, V23, P413, DOI 10.1016/S0196-9781(01)00628-3; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sawai MV, 2001, BIOCHEMISTRY-US, V40, P3810, DOI 10.1021/bi002519d; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Thouzeau C, 2003, POLAR BIOL, V26, P115, DOI 10.1007/s00300-002-0451-2; Thouzeau C, 2003, J BIOL CHEM, V278, P51053, DOI 10.1074/jbc.M306839200; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhao CQ, 2001, INFECT IMMUN, V69, P2684, DOI 10.1128/IAI.69.4.2684-2691.2001	43	36	41	1	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30433	30439		10.1074/jbc.M401338200	http://dx.doi.org/10.1074/jbc.M401338200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123713	hybrid			2022-12-27	WOS:000222531900070
J	Nowikovsky, K; Froschauer, EM; Zsurka, G; Samaj, J; Reipert, S; Kolisek, M; Wiesenberger, G; Schweyen, RJ				Nowikovsky, K; Froschauer, EM; Zsurka, G; Samaj, J; Reipert, S; Kolisek, M; Wiesenberger, G; Schweyen, RJ			The LETM1/YOL027 gene family encodes a factor of the mitochondrial K+ homeostasis with a potential role in the Wolf-Hirschhorn syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; WHS CRITICAL REGION; YEAST MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; NA+/H+ ANTIPORTER; PROTEIN IMPORT; K+/H+ ANTIPORT; TRANSPORT; RECONSTITUTION	The yeast open reading frames YOL027 and YPR125 and their orthologs in various eukaryotes encode proteins with a single predicted trans-membrane domain ranging in molecular mass from 45 to 85 kDa. Hemizygous deletion of their human homolog LETM1 is likely to contribute to the Wolf-Hirschhorn syndrome phenotype. We show here that in yeast and human cells, these genes encode integral proteins of the inner mitochondrial membrane. Deletion of the yeast YOL027 gene (yol027Delta mutation) results in mitochondrial dysfunction. This mutant phenotype is complemented by the expression of the human LETM1 gene in yeast, indicating a functional conservation of LetM1/Yol027 proteins from yeast to man. Mutant yol027Delta mitochondria have increased cation contents, particularly K+ and low-membrane-potential DeltaPsi. They are massively swollen in situ and refractory to potassium acetate-induced swelling in vitro, which is indicative of a defect in K+/H+ exchange activity. Thus, YOL027/LETM1 are the first genes shown to encode factors involved in both K+ homeostasis and organelle volume control.	Univ Vienna, Max F Perutz Labs, Dept Genet & Microbiol, A-1030 Vienna, Austria; Univ Vienna, Dept Biochem & Mol Biol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); University of Vienna	Schweyen, RJ (corresponding author), Univ Vienna, Max F Perutz Labs, Dept Genet & Microbiol, Campus Vienna Bioctr, A-1030 Vienna, Austria.	rudolf.schweyen@univie.ac.at	Samaj, Jozef/AAD-4206-2022; Reipert, Siegfried/A-4406-2014	Samaj, Jozef/0000-0003-4750-2123; Wiesenberger, Gerlinde/0000-0002-3788-7974; Reipert, Siegfried/0000-0002-2043-3562; Nowikovsky, Karin/0000-0001-8435-8410; Zsurka, Gabor/0000-0002-6379-849X				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brett CL, 2002, AM J PHYSIOL-CELL PH, V282, pC1031, DOI 10.1152/ajpcell.00420.2001; BRIERLEY GP, 1988, J BIOENERG BIOMEMBR, V20, P193, DOI 10.1007/BF00768394; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Endele S, 1999, GENOMICS, V60, P218, DOI 10.1006/geno.1999.5881; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; GARLID KD, 1986, J BIOL CHEM, V261, P1529; Godinot C, 1979, Methods Enzymol, V55, P112; Gregan J, 2001, GENE DEV, V15, P2229, DOI 10.1101/gad.201301; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; JEZEK P, 1990, J BIOL CHEM, V265, P10522; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; LI XQ, 1990, J BIOL CHEM, V265, P15316; MANON S, 1992, BIOCHIM BIOPHYS ACTA, V1108, P169, DOI 10.1016/0005-2736(92)90022-E; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Schlickum S, 2004, GENOMICS, V83, P254, DOI 10.1016/j.ygeno.2003.08.013; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; WELIHINDA AA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P367, DOI 10.1016/0005-2728(93)90122-V; WIESENBERGER G, 1992, J BIOL CHEM, V267, P6963; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; Zollino M, 2003, AM J HUM GENET, V72, P590, DOI 10.1086/367925	32	158	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30307	30315		10.1074/jbc.M403607200	http://dx.doi.org/10.1074/jbc.M403607200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138253	hybrid			2022-12-27	WOS:000222531900056
J	Zachara, NE; O'Donnell, N; Cheung, WD; Mercer, JJ; Marth, JD; Hart, GW				Zachara, NE; O'Donnell, N; Cheung, WD; Mercer, JJ; Marth, JD; Hart, GW			Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress - A survival response of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; CAPACITATIVE CALCIUM-ENTRY; HYPOXIA-INDUCED APOPTOSIS; DEPENDENT NUCLEAR IMPORT; 67-KDA POLYPEPTIDE P67; NITRIC-OXIDE SYNTHASE; MUTATIONAL HOT-SPOT; RNA-POLYMERASE-II; CYTOSOLIC PROTEINS; INSULIN-RESISTANCE	Cellular response to environmental, physiological, or chemical stress is key to survival following injury or disease. Here we describe a unique signaling mechanism by which cells detect and respond to stress in order to survive. A wide variety of stress stimuli rapidly increase nucleocytoplasmic protein modification by O-linked beta-N-acetylglucosamine (O-GlcNAc), an essential post-translational modification of Ser and Thr residues of metazoans. Blocking this post-translational modification, or reducing it, renders cells more sensitive to stress and results in decreased cell survival; and increasing O-GlcNAc levels protects cells. O-GlcNAc regulates both the rates and extent of the stress-induced induction of heat shock proteins, providing a molecular basis for these findings.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Calif San Diego, Dept Cellular & Mol Sci, Glycobiol Res & Training Ctr, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Johns Hopkins University; Howard Hughes Medical Institute; University of California System; University of California San Diego	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	gwhart@jhmi.edu		Hart, Gerald/0000-0001-7812-4351	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028180] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NCI NIH HHS [CA42486] Funding Source: Medline; NHLBI NIH HHS [N01-HV-28180] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreoni G, 1997, EXP NEUROL, V148, P281, DOI 10.1006/exnr.1997.6647; BACHMANN M, 1989, MOL CELL BIOCHEM, V85, P103, DOI 10.1007/BF00577106; Barnes K, 2002, J CELL SCI, V115, P2433; Barros LF, 2001, PFLUG ARCH EUR J PHY, V442, P614; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Buse MG, 2002, AM J PHYSIOL-ENDOC M, V283, pE241, DOI 10.1152/ajpendo.00060.2002; CHAKRABORTY A, 1994, INDIAN J BIOCHEM BIO, V31, P236; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DATTA B, 1989, J BIOL CHEM, V264, P20620; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; DUVERGER E, 1993, EXP CELL RES, V207, P197, DOI 10.1006/excr.1993.1181; Duverger E, 1996, GLYCOBIOLOGY, V6, P381, DOI 10.1093/glycob/6.4.381; DUVERGER E, 1995, J CELL SCI, V108, P1325; Dwyer DS, 1999, J CELL PHYSIOL, V178, P93, DOI 10.1002/(SICI)1097-4652(199901)178:1<93::AID-JCP12>3.3.CO;2-L; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; Fiorentini D, 2001, FREE RADICAL BIO MED, V31, P923, DOI 10.1016/S0891-5849(01)00678-5; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Goldberg HJ, 2002, J BIOL CHEM, V277, P33833, DOI 10.1074/jbc.M112331200; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Hall JL, 2000, CIRC RES, V87, P574, DOI 10.1161/01.RES.87.7.574; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han I, 1998, J CELL BIOCHEM, V68, P50, DOI 10.1002/(SICI)1097-4644(19980101)68:1<50::AID-JCB5>3.0.CO;2-V; HART GW, 1995, ADV EXP MED BIOL, V376, P115; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Ikari A, 2002, J BIOL CHEM, V277, P33338, DOI 10.1074/jbc.M200310200; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; Juang YT, 2002, J IMMUNOL, V168, P2865, DOI 10.4049/jimmunol.168.6.2865; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; Kim HJ, 2002, J BIOL CHEM, V277, P23193, DOI 10.1074/jbc.M201007200; Kozlovsky N, 1997, J BIOL CHEM, V272, P33367, DOI 10.1074/jbc.272.52.33367; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Lamarre-Vincent N, 2003, J AM CHEM SOC, V125, P6612, DOI 10.1021/ja028200t; Lefebvre T, 2001, BIOCHEM J, V360, P179, DOI 10.1042/0264-6021:3600179; Lin ZW, 2000, AM J PHYSIOL-ENDOC M, V278, pE958, DOI 10.1152/ajpendo.2000.278.5.E958; Liu WL, 2000, AM J PHYSIOL-ENDOC M, V279, pE782, DOI 10.1152/ajpendo.2000.279.4.E782; Luss H, 2002, CARDIOVASC RES, V54, P140, DOI 10.1016/S0008-6363(02)00232-8; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Mer G, 1996, NAT STRUCT BIOL, V3, P45, DOI 10.1038/nsb0196-45; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Moley KH, 2000, APOPTOSIS, V5, P99, DOI 10.1023/A:1009697908332; Monsigny M, 1999, BIOSCIENCE REP, V19, P125, DOI 10.1023/A:1020114611517; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Pang Y, 2002, DIABETES, V51, P3461, DOI 10.2337/diabetes.51.12.3461; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; PASTERNAK CA, 1991, J CELL PHYSIOL, V149, P324, DOI 10.1002/jcp.1041490221; Pereira C, 2000, EXP NEUROL, V161, P383, DOI 10.1006/exnr.1999.7270; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; Rivera AA, 1995, AM J PHYSIOL-CELL PH, V269, pC1482, DOI 10.1152/ajpcell.1995.269.6.C1482; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; Sumegi M, 2003, BIOCHEM BIOPH RES CO, V312, P1284, DOI 10.1016/j.bbrc.2003.11.074; Sviderskaya EV, 1996, J MEMBRANE BIOL, V149, P133, DOI 10.1007/s002329900014; Vemuri S, 1999, J BIOL CHEM, V274, P20165, DOI 10.1074/jbc.274.29.20165; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Walgren JLE, 2003, AM J PHYSIOL-ENDOC M, V284, pE424, DOI 10.1152/ajpendo.00382.2002; WARREN AP, 1986, J CELL PHYSIOL, V128, P383, DOI 10.1002/jcp.1041280306; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang JZ, 1999, AM J KIDNEY DIS, V34, P189, DOI 10.1016/S0272-6386(99)70131-9	89	423	455	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30133	30142		10.1074/jbc.M403773200	http://dx.doi.org/10.1074/jbc.M403773200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138254	hybrid			2022-12-27	WOS:000222531900034
J	Frew, IJ; Sims, NA; Quinn, JMW; Walkley, CR; Purton, LE; Bowtell, DDL; Gillespie, MT				Frew, IJ; Sims, NA; Quinn, JMW; Walkley, CR; Purton, LE; Bowtell, DDL; Gillespie, MT			Osteopenia in Siah1a mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-FORMATION; TRANSCRIPTIONAL RESPONSES; UBIQUITIN LIGASE; DEGRADATION; P53; GENERATION; DEFICIENT; DECREASE; PATHWAY; CELLS	Siah1a has been implicated in numerous signaling pathways because of its ability to induce ubiquitin-mediated degradation of many protein substrates. Siah1a knockout mice are growth-retarded, exhibit early lethality, and display spermatogenic defects. In this study we identified a striking low bone volume phenotype in these mice (trabecular bone volume was halved compared with wild type mice), linking Siah1a to bone metabolism for the first time. Markers of bone formation, including osteoblast numbers and osteoid volume, were decreased by up to 40%, whereas the number of osteoclasts was more than doubled in Siah1a mutant mice. However, ex vivo osteoclast formation occurs normally and hematopoietic osteoclast progenitor cell types were present in normal numbers in Siah1a mutant mice. Moreover, adoptive transfer of Siah1a mutant bone marrow into wild type mice failed to reproduce the osteopenia or increased osteoclast numbers observed in mutant mice. Although ex vivo osteoblast colony formation was normal in Siah1a mutant mice, mineralization from these cells was elevated in cultures from Siah1a mutant mice, which may explain the reduction in osteoid volume seen in vivo. These findings suggest that although Siah1a is clearly essential for normal bone metabolism, the bone defect in Siah1a mutant mice is not due to cell-autonomous requirements for Siah1a in osteoblast or osteoclast formation. We propose that bone metabolism defects in Siah1a mutant mice are secondary to an alteration in an unidentified systemic, paracrine, or metabolic factor in these mice.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem, Parkville, Vic 3010, Australia	St. Vincent's Institute of Medical Research; Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Melbourne; University of Melbourne	Sims, NA (corresponding author), St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	nsims@unimelb.edu.au	Bowtell, David/H-1007-2016; Walkley, Carl/AAO-6021-2020; Purton, Louise/AAI-8956-2021; Sims, Natalie Ann/A-7192-2012	Bowtell, David/0000-0001-9089-7525; Walkley, Carl/0000-0002-4784-9031; Purton, Louise/0000-0001-6593-3168; Sims, Natalie Ann/0000-0003-1421-8468; Frew, Ian/0000-0003-2735-5509; Gillespie, Matthew/0000-0001-6543-8909				Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Dickins RA, 2002, MOL CELL BIOL, V22, P2294, DOI 10.1128/MCB.22.7.2294-2303.2002; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Frew IJ, 2002, MOL CELL BIOL, V22, P8155, DOI 10.1128/MCB.22.23.8155-8164.2002; Gravallese EM, 2001, ARTHRITIS RES, V3, P6, DOI 10.1186/ar134; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Quinn JMW, 2002, BONE, V30, P164, DOI 10.1016/S8756-3282(01)00654-8; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753; Sims Natalie, 2000, P1; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Yamazaki H, 2001, EXP HEMATOL, V29, P68, DOI 10.1016/S0301-472X(00)00626-3	25	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29583	29588		10.1074/jbc.M312755200	http://dx.doi.org/10.1074/jbc.M312755200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123657	hybrid			2022-12-27	WOS:000222445300093
J	Lum, R; Tkach, JM; Vierling, E; Glover, JR				Lum, R; Tkach, JM; Vierling, E; Glover, JR			Evidence for an unfolding/threading mechanism for protein disaggregation by Saccharomyces cerevisiae Hsp104	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ATPASE DOMAIN; DEPENDENT CLP PROTEASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; PURIFICATION; TRANSLOCATION; YEAST; HSP70	Saccharomyces cerevisiae Hsp104, a hexameric member of the Hsp100/Clp subfamily of AAA+ ATPases with two nucleotide binding domains (NBD1 and 2), refolds aggregated proteins in conjunction with Hsp70 molecular chaperones. Hsp104 may act as a "molecular crowbar" to pry aggregates apart and/or may extract proteins from aggregates by unfolding and threading them through the axial channel of the Hsp104 hexamer. Targeting Tyr-662, located in a Gly-Tyr-Val-Gly motif that forms part of the axial channel loop in NBD2, we created conservative (Phe and Trp) and non-conservative (Ala and Lys) amino acid substitutions. Each of these Hsp104 derivatives was comparable to the wild type protein in their ability to hydrolyze ATP, assemble into hexamers, and associate with heat-shock-induced aggregates in living cells. However, only those with conservative substitutions complemented the thermotolerance defect of a Deltahsp104 yeast strain and promoted refolding of aggregated protein in vitro. Monitoring fluorescence from Trp-662 showed that titration of fully assembled molecules with either ATP or ADP progressively quenches fluorescence, suggesting that nucleotide binding determines the position of the loop within the axial channel. A Glu to Lys substitution at residue 645 in the NBD2 axial channel strongly alters the nucleotide-induced change in fluorescence of Trp-662 and specifically impairs in protein refolding. These data establish that the structural integrity of the axial channel through NBD2 is required for Hsp104 function and support the proposal that Hsp104 and ClpB use analogous unfolding/threading mechanisms to promote disaggregation and refolding that other Hsp100s use to promote protein degradation.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Toronto; University of Arizona	Glover, JR (corresponding author), Univ Toronto, Dept Biochem, Rm 5302,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	john.glover@utoronto.ca		Vierling, Elizabeth/0000-0002-0066-4881				Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Fujita K, 1998, BIOCHEM BIOPH RES CO, V248, P542, DOI 10.1006/bbrc.1998.9008; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Glover JR, 2001, BIOCHEM CELL BIOL, V79, P557, DOI 10.1139/bcb-79-5-557; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hong SW, 2000, P NATL ACAD SCI USA, V97, P4392, DOI 10.1073/pnas.97.8.4392; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Schirmer EC, 1998, METHOD ENZYMOL, V290, P430, DOI 10.1016/S0076-6879(98)90036-2; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; SIKORSKI RS, 1989, GENETICS, V122, P19; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Song HK, 2000, P NATL ACAD SCI USA, V97, P14103, DOI 10.1073/pnas.250491797; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Strub C, 2003, FEBS LETT, V553, P125, DOI 10.1016/S0014-5793(03)00985-2; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Weibezahn J, 2004, MICROB CELL FACT, V3, DOI 10.1186/1475-2859-3-1; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035	40	178	179	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29139	29146		10.1074/jbc.M403777200	http://dx.doi.org/10.1074/jbc.M403777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15128736	hybrid			2022-12-27	WOS:000222445300039
J	O'Brien, PJ; Ellenberger, T				O'Brien, PJ; Ellenberger, T			The Escherichia coli 3-methyladenine DNA glycosylase AlkA has a remarkably versatile active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; CRYSTAL-STRUCTURE; ALKYLATED DNA; N-GLYCOSYLASE; HYPOXANTHINE; PROTEIN; BINDING; ENZYME; 1,N-6-ETHENOADENINE; RECOGNITION	3-Methyladenine DNA glycosylase II (AlkA) from Escherichia coli is induced in response to DNA alkylation, and it protects cells from alkylated nucleobases by catalyzing their excision. In contrast to the highly specific 3-methyladenine DNA glycosylase I (E. coli TAG) that catalyzes the excision of 3-methyl adducts of adenosine and guanosine from DNA, AlkA catalyzes the excision of a wide variety of alkylated bases including N-3 and N-7 adducts of adenosine and guanosine and O-2 adducts of thymidine and cytidine. We have investigated how AlkA can recognize a diverse set of damaged bases by characterizing its discrimination between oligonucleotide substrates in vitro. Similar rate enhancements are observed for the excision of a structurally diverse set of substituted purine bases and of the normal purines adenine and guanine. These results are consistent with a remarkably indiscriminate active site and suggest that the rate of AlkA-catalyzed excision is dictated not by the catalytic recognition of a specific substrate but instead by the reactivity of the N-glycosidic bond of each substrate. Damaged bases with altered base pairing have a modest advantage, as mismatches are processed up to 400-fold faster than stable Watson-Crick base pairs. Nevertheless, AlkA does not effectively exclude undamaged DNA from its active site. The resulting deleterious excision of normal bases is expected to have a substantial cost associated with the expression of AlkA.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	tome@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052504, F32GM065043] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM65043, R01 GM52504] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asaeda A, 2000, BIOCHEMISTRY-US, V39, P1959, DOI 10.1021/bi9917075; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Biswas T, 2002, J MOL BIOL, V320, P503, DOI 10.1016/S0022-2836(02)00519-3; BJELLAND S, 1993, NUCLEIC ACIDS RES, V21, P2045, DOI 10.1093/nar/21.9.2045; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; Deng L, 1997, J AM CHEM SOC, V119, P7865, DOI 10.1021/ja970828u; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; EVENSEN G, 1982, NATURE, V296, P773, DOI 10.1038/296773a0; Gasparutto D, 2002, DNA REPAIR, V1, P437, DOI 10.1016/S1568-7864(02)00016-2; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Kow YW, 2002, FREE RADICAL BIO MED, V33, P886, DOI 10.1016/S0891-5849(02)00902-4; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; LAWLEY PD, 1963, BIOCHEM J, V89, P127, DOI 10.1042/bj0890127; LEONARD GA, 1994, BIOCHEMISTRY-US, V33, P4755, DOI 10.1021/bi00182a002; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Masaoka A, 1999, J BIOL CHEM, V274, P25136, DOI 10.1074/jbc.274.35.25136; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; O'Brien PJ, 2003, BIOCHEMISTRY-US, V42, P12418, DOI 10.1021/bi035177v; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Osborne MR, 2000, CHEM RES TOXICOL, V13, P257, DOI 10.1021/tx990182e; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; Reardon JT, 2003, GENE DEV, V17, P2539, DOI 10.1101/gad.1131003; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; SAMSON L, 1977, NATURE, V267, P281, DOI 10.1038/267281a0; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; Sedgwick B, 2004, NAT REV MOL CELL BIO, V5, P148, DOI 10.1038/nrm1312; Stivers JT, 2001, ARCH BIOCHEM BIOPHYS, V396, P1, DOI 10.1006/abbi.2001.2605; Terato H, 2002, NUCLEIC ACIDS RES, V30, P4975, DOI 10.1093/nar/gkf630; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; Wyatt MD, 2000, CARCINOGENESIS, V21, P901, DOI 10.1093/carcin/21.5.901	39	81	84	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26876	26884		10.1074/jbc.M403860200	http://dx.doi.org/10.1074/jbc.M403860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15126496	hybrid			2022-12-27	WOS:000222120400011
J	Maeda, H; Nagata, S; Wolfgang, CD; Bratthauer, GL; Bera, TK; Pastan, I				Maeda, H; Nagata, S; Wolfgang, CD; Bratthauer, GL; Bera, TK; Pastan, I			The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN-REGULATED GENE; CANCER CELLS; EPITHELIAL-CELLS; MOLECULAR-CLONING; CITRATE METABOLISM; EXPRESSION; MEMBRANE; ANTIGEN; BINDING; TUMORS	We previously showed that mRNA encoding TARP ( T cell receptor gamma chain alternate reading frame protein) is exclusively expressed in the prostate in males and is up-regulated by androgen in LNCaP cells, an androgen-sensitive prostate cancer cell line. We have now developed an anti-TARP monoclonal antibody named TP1, and show that TARP protein is up-regulated by androgen in both LNCaP and MDA-PCa-2b cells. We used TP1 to determine the subcellular localization of TARP by Western blotting following subcellular fractionation and immunocytochemistry. Both methods showed that TARP is localized in the mitochondria of LNCaP cells, MDA-PCa-2b cells, and PC-3 cells transfected with a TARP-expressing plasmid. We also transfected a plasmid encoding TARP fused to green fluorescent protein into LNCaP, MDA-Pca-2b, and PC-3 cells and confirmed its specific mitochondrial localization in living cells. Fractionation of mitochondria shows that TARP is located in the outer mitochondrial membrane. Immunohistochemistry using a human prostate cancer sample showed that TP1 reacted in a dot-like cytoplasmic pattern consistent with the presence of TARP in mitochondria. These data demonstrate that TARP is the first prostate-specific protein localizing in mitochondria and indicate that TARP, an androgen-regulated protein, may act on mitochondria to carry out its biological functions.	NCI, Mol Biol Lab, NIH, Ctr Canc Res, Bethesda, MD 20892 USA; Armed Forces Inst Pathol, Dept Gynecol & Breast Pathol, Washington, DC 20306 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense	Pastan, I (corresponding author), NCI, Mol Biol Lab, NIH, Ctr Canc Res, 37 Convent Dr,Room 5106, Bethesda, MD 20892 USA.	pastani@mail.nih.gov	pastan, ira/P-9319-2019; Nagata, Satoshi/B-5781-2008	pastan, ira/0000-0002-9223-0270; Nagata, Satoshi/0000-0001-9156-5215	NATIONAL CANCER INSTITUTE [ZIABC010298, Z01BC010298] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bander NH, 2003, J UROLOGY, V170, P1717, DOI 10.1097/01.ju.0000091655.77601.0c; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bratthauer G L, 1999, Methods Mol Biol, V115, P203; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chaib H, 2001, CANCER RES, V61, P2390; Costello LC, 1997, UROLOGY, V50, P3, DOI 10.1016/S0090-4295(97)00124-6; Costello LC, 2002, HORM METAB RES, V34, P417, DOI 10.1055/s-2002-33598; Dubbink HJ, 1998, GENOMICS, V51, P434, DOI 10.1006/geno.1998.5393; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Essand M, 1999, P NATL ACAD SCI USA, V96, P9287, DOI 10.1073/pnas.96.16.9287; Evdokimov AG, 2000, ACTA CRYSTALLOGR D, V56, P1676, DOI 10.1107/S0907444900013378; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; HASUMURA S, 1986, BIOCHEMISTRY-US, V25, P7881, DOI 10.1021/bi00372a014; Herness EA, 2003, CANCER RES, V63, P329; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kimura K, 2001, CANCER RES, V61, P5611; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Lin BY, 2000, CANCER RES, V60, P858; Lin BY, 2001, CANCER RES, V61, P1611; Maeda H, 2001, CANCER RES, V61, P5432; Murphy GP, 1999, PROSTATE, V39, P54, DOI 10.1002/(SICI)1097-0045(19990401)39:1<54::AID-PROS9>3.0.CO;2-U; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Nicholson B, 2003, HISTOL HISTOPATHOL, V18, P275, DOI 10.14670/HH-18.275; Nozawa M, 2000, CANCER RES, V60, P1348; Olsson P, 2001, PROSTATE, V48, P231, DOI 10.1002/pros.1102; Qi H, 2002, CANCER RES, V62, P721; Rhodes DR, 2002, CANCER RES, V62, P4427; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Spector D. L., 1998, CELLS LAB MANUAL CUL, V1; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Staack A, 2003, PROSTATE, V54, P212, DOI 10.1002/pros.10179; Stamey TA, 2001, J UROLOGY, V166, P2171, DOI 10.1016/S0022-5347(05)65528-0; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Tsavaler L, 2001, CANCER RES, V61, P3760; Van de Sande T, 2002, CANCER RES, V62, P642; Vasmatzis G, 1998, P NATL ACAD SCI USA, V95, P300, DOI 10.1073/pnas.95.1.300; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; Wolfgang CD, 2001, CANCER RES, V61, P8122; Xu JC, 2001, CANCER RES, V61, P1563; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Xu LL, 2000, CANCER RES, V60, P6568; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhuang LY, 2002, CANCER RES, V62, P2227	46	20	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24561	24568		10.1074/jbc.M402492200	http://dx.doi.org/10.1074/jbc.M402492200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15150260	hybrid			2022-12-27	WOS:000221702500085
J	Butan, C; van der Zandt, H; Tucker, PA				Butan, C; van der Zandt, H; Tucker, PA			Structure and assembly of the RNA binding domain of bluetongue virus non-structural protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED RNA; INCLUSION-BODIES; RECOGNITION; NS2; REFINEMENT; SYNTHETASE; NSP2; CRYSTALLOGRAPHY; PHOSPHOPROTEIN; MULTIMERS	Bluetongue virus non-structural protein 2 belongs to a class of highly conserved proteins found in orbiviruses of the Reoviridae family. Non-structural protein 2 forms large multimeric complexes and localizes to cytoplasmic inclusions in infected cells. It is able to bind single-stranded RNA non-specifically, and it has been suggested that the protein is involved in the selection and condensation of the Bluetongue virus RNA segments prior to genome encapsidation. We have determined the x-ray structure of the N-terminal domain ( sufficient for the RNA binding ability of non-structural protein 2) to 2.4 Angstrom resolution using anomalous scattering methods. Crystals of this apparently insoluble domain were obtained by in situ proteolysis of a soluble construct. The asymmetric unit shows two monomers related by noncrystallographic symmetry, with each monomer folded as a beta sandwich with a unique topology. The crystal structure reveals extensive monomer-monomer interactions, which explain the ability of the protein to self-assemble into large homomultimeric complexes. Of the entire surface area of the monomer, one-third is used to create the interfaces of the curved multimeric assembly observed in the x-ray structure. The structure reported here shows how the N-terminal domain would be able to bind single-stranded RNA non-specifically protecting the bound regions in a heterogeneous multimeric but not polymeric complex.	Deutsch Elektron Synchrotron, European Mol Biol Lab, D-22603 Hamburg, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Tucker, PA (corresponding author), Deutsch Elektron Synchrotron, European Mol Biol Lab, Notkestr 85, D-22603 Hamburg, Germany.	tucker@embl-hamburg.de						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; BROOKES SM, 1993, J GEN VIROL, V74, P525, DOI 10.1099/0022-1317-74-3-525; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Clemons WM, 1998, STRUCT FOLD DES, V6, P429, DOI 10.1016/S0969-2126(98)00045-8; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Deo RC, 2002, CELL, V108, P71, DOI 10.1016/S0092-8674(01)00632-8; DEVANEY MA, 1988, VIRUS RES, V11, P151, DOI 10.1016/0168-1702(88)90040-8; EATON BT, 1990, CURR TOP MICROBIOL, V162, P89; Fillmore GC, 2002, J VIROL, V76, P499, DOI 10.1128/JVI.76.2.499-506.2002; Gillian AL, 2000, J VIROL, V74, P5939, DOI 10.1128/JVI.74.13.5939-5948.2000; Gouet P, 1999, CELL, V97, P481, DOI 10.1016/S0092-8674(00)80758-8; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUISMANS H, 1987, J VIROL, V61, P3589, DOI 10.1128/JVI.61.11.3589-3595.1987; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lymperopoulos K, 2003, J BIOL CHEM, V278, P31722, DOI 10.1074/jbc.M301072200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Taraporewala Z, 1999, J VIROL, V73, P9934, DOI 10.1128/JVI.73.12.9934-9943.1999; Taraporewala ZF, 2002, J VIROL, V76, P7082, DOI 10.1128/JVI.76.14.7082-7093.2002; Taraporewala ZF, 2001, VIROLOGY, V280, P221, DOI 10.1006/viro.2000.0764; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMAS CP, 1990, J GEN VIROL, V71, P2073, DOI 10.1099/0022-1317-71-9-2073; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Wang XQ, 2002, CELL, V110, P501, DOI 10.1016/S0092-8674(02)00873-5; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; ZHAO Y, 1994, J VIROL, V68, P2179, DOI 10.1128/JVI.68.4.2179-2185.1994	40	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37613	37621		10.1074/jbc.M400502200	http://dx.doi.org/10.1074/jbc.M400502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15155766	hybrid			2022-12-27	WOS:000223554600052
J	Akiyoshi, H; Hatakeyama, S; Pitkanen, J; Mouri, Y; Doucas, V; Kudoh, J; Tsurugaya, K; Uchida, D; Matsushima, A; Oshikawa, K; Nakayama, KI; Shimizu, N; Peterson, P; Matsumoto, M				Akiyoshi, H; Hatakeyama, S; Pitkanen, J; Mouri, Y; Doucas, V; Kudoh, J; Tsurugaya, K; Uchida, D; Matsushima, A; Oshikawa, K; Nakayama, KI; Shimizu, N; Peterson, P; Matsumoto, M			Subcellular expression of autoimmune regulator is organized in a spatiotemporal manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE SELECTION; NUCLEAR-BODIES; AIRE; PROTEIN; GENE; LOCALIZATION; ACTIVATION; TOLERANCE; THYMUS; PHD	Autoimmune regulator ( AIRE) is responsible for the development of organ-specific autoimmune disease in a monogenic fashion. Rare and low levels of tissue expression together with the lack of AIRE-expressing cell lines have hampered a detailed analysis of the molecular dynamics of AIRE. Here we have established cell lines stably transfected with AIRE and studied the regulatory mechanisms for its subcellular expression. We found that nuclear body ( NB) formation by AIRE was dependent on the cell cycle. Biochemical fractionation revealed that a significant proportion of AIRE is associated with the nuclear matrix, which directs the functional domains of chromatin to provide sites for gene regulation. Upon proteasome inhibition, AIRE NBs were increased with concomitant reduced expression in the cytoplasm, suggesting that subcellular targeting of AIRE is regulated by a ubiquitin-proteasome pathway. We also found that AIRE NBs compete for cAMP-response element-binding protein-binding protein/p300, a common coactivator of transcription, with the promyelocytic leukemia gene product. These results suggest that the transcriptional regulating activities of AIRE within a cell are controlled and organized in a spatiotemporal manner.	Univ Tokushima, Inst Enzyme Res, Div Mol Immunol, Tokushima 7708503, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Saitama 3320012, Japan; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere 33101, Finland; Inst Jacques Monod, Dept Biol Genomes, F-75251 Paris 05, France; Keio Univ, Sch Med, Dept Mol Biol, Tokyo 1608582, Japan	Tokushima University; Kyushu University; Japan Science & Technology Agency (JST); Tampere University; Tampere University; Tampere University Hospital; UDICE-French Research Universities; Universite Paris Cite; Keio University	Matsumoto, M (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Mol Immunol, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	mitsuru@ier.tokushima-u.ac.jp	Mouri, Yasuhiro/AAF-8953-2021; Peterson, Pärt/A-5788-2009; Hatakeyama, Shigetsugu/C-8333-2012	Peterson, Pärt/0000-0001-6755-791X; Hatakeyama, Shigetsugu/0000-0002-2150-9979				Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Bjorses P, 1999, HUM MOL GENET, V8, P259, DOI 10.1093/hmg/8.2.259; Bjorses P, 1998, HUM MOL GENET, V7, P1547, DOI 10.1093/hmg/7.10.1547; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Doucas V, 2000, BIOCHEM PHARMACOL, V60, P1197, DOI 10.1016/S0006-2952(00)00413-5; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kasai M, 1996, EUR J IMMUNOL, V26, P2101, DOI 10.1002/eji.1830260921; Kumar PG, 2001, J BIOL CHEM, V276, P41357, DOI 10.1074/jbc.M104898200; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nickerson JA, 2001, J CELL SCI, V114, P463; Oshikawa K, 2003, BIOCHEM BIOPH RES CO, V303, P1209, DOI 10.1016/S0006-291X(03)00501-1; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; Pitkanen J, 2003, GENES IMMUN, V4, P12, DOI 10.1038/sj.gene.6363929; Pitkanen J, 2001, J BIOL CHEM, V276, P19597, DOI 10.1074/jbc.M008322200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Ramsey C, 2002, HUM MOL GENET, V11, P3299, DOI 10.1093/hmg/11.26.3299; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; TESTA U, 1994, CANCER RES, V54, P4508; Uchida D, 2004, J EXP MED, V199, P167, DOI 10.1084/jem.20031291; Wandstrat A, 2001, NAT IMMUNOL, V2, P802, DOI 10.1038/ni0901-802; Wilson KL, 2001, CELL, V104, P647, DOI 10.1016/S0092-8674(02)01452-6; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zuklys S, 2000, J IMMUNOL, V165, P1976, DOI 10.4049/jimmunol.165.4.1976	37	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33984	33991		10.1074/jbc.M400702200	http://dx.doi.org/10.1074/jbc.M400702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15150263	hybrid			2022-12-27	WOS:000223039700109
J	Yamazaki, T; Nakano, H; Hayakari, M; Tanaka, M; Mayama, J; Tsuchida, S				Yamazaki, T; Nakano, H; Hayakari, M; Tanaka, M; Mayama, J; Tsuchida, S			Differentiation induction of human keratinocytes by phosphatidylethanolamine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; NERVE GROWTH-FACTOR; RAF KINASE; BOVINE BRAIN; INHIBITOR PROTEIN; 23-KDA PROTEIN; ACTIVATION; PATHWAY; EXPRESSION; SEQUENCE	Phosphatidylethanolamine-binding protein ( PEBP) has been demonstrated to bind to Raf-1 and mitogen-activated protein kinase kinase, components of the extracellular signal-regulated protein kinase (ERK) pathway, thereby inhibiting the pathway and resulting in the suppression of cell proliferation. In the present study, we examined whether PEBP is involved in differentiation induction of human keratinocytes. PEBP expression was immunohistochemically examined in normal human skin and skin cancers with different differentiation properties. PEBP was not expressed in the basal layer of the epidermis but was expressed in the spinous and granular layers of normal skin. The protein was expressed in differentiated but not in undifferentiated carcinoma. PEBP expression was also examined in cultured normal human epidermal keratinocytes in which differentiation was induced by calcium treatment. Involucrin was used as a differentiation marker for spinous and granular cells. Northern blotting analysis indicated that both PEBP and involucrin mRNAs were enhanced 6 h after treatment with 2.0 mM CaCl2. The protein amount of PEBP was also increased by this treatment. To investigate whether PEBP is involved in differentiation induction of keratinocytes, HaCaT keratinocytes were transfected with an expression vector. Fluorescent immunostain revealed that cells expressing PEBP exhibited enlarged and flattened cell shape, and induction of involucrin expression was demonstrated by immunoblot analysis. Although the protein amount of ERK was not altered, phosphorylated ERK levels were decreased and cell proliferation was partly inhibited by PEBP expression. These results indicate that PEBP not only inhibits cell proliferation but also induces differentiation of human keratinocytes.	Hirosaki Univ, Sch Med, Dept Biochem 2, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Sch Med, Dept Dermatol, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Sch Med, Dept Pathol 2, Hirosaki, Aomori 0368562, Japan	Hirosaki University; Hirosaki University; Hirosaki University	Tsuchida, S (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem 2, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	tsuchida@cc.hirosaki-u.ac.jp	Tsuchida, Shigeki/L-3382-2013	Tsuchida, Shigeki/0000-0002-4404-5599				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Apostolidis A, 1997, CELL SIGNAL, V9, P439, DOI 10.1016/S0898-6568(97)00034-X; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BERNIER I, 1986, BIOCHIM BIOPHYS ACTA, V871, P19, DOI 10.1016/0167-4838(86)90128-7; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; BOLLENGIER F, 1989, J NEUROCHEM, V52, P1123, DOI 10.1111/j.1471-4159.1989.tb01856.x; BOS JL, 1989, CANCER RES, V49, P4682; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Deucher A, 2002, J BIOL CHEM, V277, P17032, DOI 10.1074/jbc.M109076200; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; GUTHENBERG C, 1979, BIOCHEM BIOPH RES CO, V86, P1304, DOI 10.1016/0006-291X(79)90258-4; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HORI N, 1994, GENE, V140, P293; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HYDER SM, 1994, BIOTECHNIQUES, V17, P478; KajiharaKano H, 1997, BIOCHEM J, V328, P473, DOI 10.1042/bj3280473; Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Murphy George F., 1997, P5; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEETERS JM, 1989, J IMMUNOL METHODS, V120, P133, DOI 10.1016/0022-1759(89)90298-6; PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	55	23	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32191	32195		10.1074/jbc.M404029200	http://dx.doi.org/10.1074/jbc.M404029200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155742	hybrid			2022-12-27	WOS:000222849700025
J	Tondera, D; Santel, A; Schwarzer, R; Dames, S; Giese, K; Klippel, A; Kaufmann, J				Tondera, D; Santel, A; Schwarzer, R; Dames, S; Giese, K; Klippel, A; Kaufmann, J			Knockdown of MTP18, a novel phosphatidylinositol 3-kinase-dependent protein, affects mitochondrial morphology and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; CELL-GROWTH; FISSION; 3-KINASE; ACTIVATION; CLEAVAGE; DIVISION; PATHWAY; KINASE; BAX	We identified a novel human cDNA encoding a mitochondrial protein, MTP18 ( mitochondrial protein, 18 kDa) as a transcriptional downstream target of phosphatidylinositol ( PI) 3-kinase signaling. We demonstrate that MTP18 mRNA as well as protein expression is dependent on PI 3-kinase activity. Confocal microscopy and biochemical fractionation revealed a mitochondrial localization of MTP18. Loss-of-function analysis employing antisense molecules revealed that MTP18 is essential for cell viability in PC-3 and HaCaT cells. We show that knockdown of MTP18 protein level results in a cytochrome c release from mitochondria and consequently leads to apoptosis. In addition, HaCaT cells with reduced levels of MTP18 become more sensitive to apoptotic stimuli. This effect is accompanied by dramatic subcellular alterations. Reduction of MTP18 impairs mitochondrial morphology resulting in the formation of a highly interconnected mitochondrial reticulum in COS-7 cells. Conversely, overexpression of MTP18 induces a punctuate morphology of mitochondria suggesting also a functional role of MTP18 in maintaining the mitochondrial integrity. Hence, our data indicate an unexpected connection of PI 3-kinase signaling, apoptosis and the morphology of mammalian mitochondria.	Atugen AG, D-13125 Berlin, Germany		Kaufmann, J (corresponding author), Atugen AG, Otto Warburg Haus 80,Robert Rossle Str 10, D-13125 Berlin, Germany.	kaufmann@atugen.com		Schwarzer, Rolf/0000-0002-8934-8788				BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Coffer PJ, 1998, BIOCHEM J, V335, P1; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P670, DOI 10.1093/nar/gkg141; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEL PL, 1997, SCIENCE, V278, P687; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kaufmann J, 2004, BIOCHEM SOC T, V32, P355, DOI 10.1042/BST0320355; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003; Modica-Napolitano Josephine S, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004453; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Santel A, 2001, J CELL SCI, V114, P867; Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Takasawa R, 2003, APOPTOSIS, V8, P291, DOI 10.1023/A:1023629023696; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhu YF, 2002, EXP CELL RES, V280, P97, DOI 10.1006/excr.2002.5621	47	104	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31544	31555		10.1074/jbc.M404704200	http://dx.doi.org/10.1074/jbc.M404704200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155745	hybrid			2022-12-27	WOS:000222726800077
J	Khan, H; Barna, T; Harris, RJ; Bruce, NC; Barsukov, I; Munro, AW; Moody, PCE; Scrutton, NS				Khan, H; Barna, T; Harris, RJ; Bruce, NC; Barsukov, I; Munro, AW; Moody, PCE; Scrutton, NS			Atomic resolution structures and solution Behavior of enzyme-substrate complexes of Enterobacter cloacae PB2 pentaerythritol tetranitrate reductase - Multiple conformational states and implications for the mechanism of nitroaromatic explosive degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL MORPHINONE REDUCTASE; CRYSTAL-STRUCTURE; 2,4,6-TRINITROTOLUENE; SEQUENCE; CRYSTALLOGRAPHY; BINDING	The structure of pentaerythritol tetranitrate (PETN) reductase in complex with the nitroaromatic substrate picric acid determined previously at 1.55 Angstrom resolution indicated additional electron density between the indole ring of residue Trp-102 and the nitro group at C-6 of picrate. The data suggested the presence of an unusual bond between substrate and the tryptophan side chain. Herein, we have extended the resolution of the PETN reductase-picric acid complex to 0.9 Angstrom. This high-resolution analysis indicates that the active site is partially occupied with picric acid and that the anomalous density seen in the original study is attributed to the population of multiple conformational states of Trp-102 and not a formal covalent bond between the indole ring of Trp-102 and picric acid. The significance of any interaction between Trp-102 and nitroaromatic substrates was probed further in solution and crystal complexes with wild-type and mutant (W102Y and W102F) enzymes. Unlike with wild-type enzyme, in the crystalline form picric acid was bound at full occupancy in the mutant enzymes, and there was no evidence for multiple conformations of active site residues. Solution studies indicate tighter binding of picric acid in the active sites of the W102Y and W102F enzymes. Mutation of Trp-102 does not impair significantly enzyme reduction by NADPH, but the kinetics of decay of the hydride-Meisenheimer complex are accelerated in the mutant enzymes. The data reveal that decay of the hydride-Meisenheimer complex is enzyme catalyzed and that the final distribution of reaction products for the mutant enzymes is substantially different from wild-type enzyme. Implications for the mechanism of high explosive degradation by PETN reductase are discussed.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ York, Ctr Novel Agr Prod, Dept Biol, York YO10 5YW, N Yorkshire, England	University of Leicester; University of York - UK	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk	barna, terez/R-1357-2018; Moody, Peter/A-6832-2008; Munro, Andrew/G-5639-2019	Moody, Peter/0000-0003-1762-9238; Munro, Andrew/0000-0002-4642-180X; Bruce, Neil Charles/0000-0003-0398-2997				Barna T, 2002, J BIOL CHEM, V277, P30976, DOI 10.1074/jbc.M202846200; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Basran J, 2003, J BIOL CHEM, V278, P43973, DOI 10.1074/jbc.M305983200; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Khan H, 2002, J BIOL CHEM, V277, P21906, DOI 10.1074/jbc.M200637200; Lario PI, 2003, J MOL BIOL, V326, P1635, DOI 10.1016/S0022-2836(03)00054-8; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pak JW, 2000, APPL ENVIRON MICROB, V66, P4742, DOI 10.1128/AEM.66.11.4742-4750.2000; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; Wang CY, 2003, ENVIRON SCI TECHNOL, V37, P3595, DOI 10.1021/es030010a; Wang CY, 2000, BIOTECHNOL LETT, V22, P15, DOI 10.1023/A:1005663104888; Williams RE, 2001, BIOCHEM SOC SYMP, V68, P143; WILLIAMS RE, 1999, FLAVINS FLAVOPROTEIN, P663; WILLIAMS RE, 2004, IN PRESS APPL ENV MI	25	36	38	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30563	30572		10.1074/jbc.M403541200	http://dx.doi.org/10.1074/jbc.M403541200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128738	hybrid			2022-12-27	WOS:000222531900086
J	Rugles, SW; Fletterick, RJ; Craik, CS				Rugles, SW; Fletterick, RJ; Craik, CS			Characterization of structural determinants of granzyme B reveals potent mediators of extended substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM CRYSTAL-STRUCTURE; SERINE-PROTEASE GENES; CONVERTING TRYPSIN; CASPASE FAMILY; KEY MEDIATORS; HUMAN CHYMASE; ACTIVE-SITE; FACTOR XA; PROTEINASE; CLEAVAGE	Granzymes are trypsin-like serine proteases mediating apoptotic cell death that are composed of two genetically distinct subfamilies: granzyme A-like proteases resemble trypsin in their active site architecture, while granzyme B-like proteases are quite distinct. Granzyme B prefers substrates containing P4 to P1 amino acids Ile/Val, Glu/Met/Gln, Pro/Xaa, and aspartic acid N-terminal to the proteolytic cleavage. By investigating the narrow extended specificity of the granzyme B-like proteases the mediators of their unique specificity are being defined. The foci of this study were the structural determinants Ile(99), Tyr(174), Arg(192), and Asn(218). Even modest mutations of these residues resulted in unique extended specificity profiles as determined using combinatorial substrate libraries and individual fluorogenic substrates. As with other serine proteases, Ile(99) completely defines and predicts P2 specificity, primarily through the binding constant K-m. Asn(218) variants have minor effects alone but in combination with mutations at Arg(192) and Ile(99) alter P2 through P4 extended specificity. For each variant, the activity on its cognate substrate was equal to that of granzyme B for the same substrate. Thus, mutations at these determinants change extended selectivity preferentially over catalytic power. Additionally Asn(218) variants result in increased activity on the wild type substrate, while the N218A/I99A variant disrupts the additivity between P2 and P4 specificity. This defines Asn(218) not only as a determinant of specificity but also as a structural component required for P2 and P4 independence. This study confirms four determinants of granzyme B extended substrate specificity that constitute a canon applicable to the study of the remaining family members.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St,Box 2280, San Francisco, CA 94143 USA.	craik@cgl.ucsf.edu			NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039304] Funding Source: NIH RePORTER; NCI NIH HHS [CA72006] Funding Source: Medline; NIDDK NIH HHS [DK39304] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bell JK, 2003, NAT STRUCT BIOL, V10, P527, DOI 10.1038/nsb944; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Caputo A, 1999, PROTEINS, V35, P415, DOI 10.1002/(SICI)1097-0134(19990601)35:4<415::AID-PROT5>3.0.CO;2-7; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; Case A, 2003, BIOCHEMISTRY-US, V42, P3335, DOI 10.1021/bi020668l; CHAN C, 2000, FMOC SOLID PHASE SYN; Estebanez-Perpina E, 2000, BIOL CHEM, V381, P1203, DOI 10.1515/BC.2000.148; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; HUDIG D, 1987, BIOCHEM BIOPH RES CO, V149, P882, DOI 10.1016/0006-291X(87)90490-6; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; Kam CM, 2000, BBA-PROTEIN STRUCT M, V1477, P307, DOI 10.1016/S0167-4838(99)00282-4; McGrath ME, 1997, BIOCHEMISTRY-US, V36, P14318, DOI 10.1021/bi971403n; Pereira PJB, 1999, J MOL BIOL, V286, P163, DOI 10.1006/jmbi.1998.2462; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; Perona JJ, 1997, BIOCHEMISTRY-US, V36, P5381, DOI 10.1021/bi9617522; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; POE M, 1991, J BIOL CHEM, V266, P98; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; Rezaie AR, 1996, EUR J BIOCHEM, V242, P477, DOI 10.1111/j.1432-1033.1996.477rr.x; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; Rotonda J, 2001, CHEM BIOL, V8, P357, DOI 10.1016/S1074-5521(01)00018-7; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; Sharif-Askari E, 2001, EMBO J, V20, P3101, DOI 10.1093/emboj/20.12.3101; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 2001, GENOME BIOL, V2; VandeCraen M, 1997, EUR J IMMUNOL, V27, P1296, DOI 10.1002/eji.1830270535; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992	42	25	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30751	30759		10.1074/jbc.M400949200	http://dx.doi.org/10.1074/jbc.M400949200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123647	hybrid			2022-12-27	WOS:000222531900106
J	Shibagaki, N; Grossman, AR				Shibagaki, N; Grossman, AR			Probing the function of STAS domains of the Arabidopsis sulfate transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ANION TRANSPORTERS; NA+/H+ EXCHANGER; MUTATIONS; FAMILY; RESIDUES; PROTEIN; BINDING; GENE	Sulfate transporters in plants and animals are structurally conserved and have an amino-terminal domain that functions in transport and a carboxyl-terminal region that has been designated the STAS domain. The STAS domain in sulfate transporters has significant similarity to bacterial anti-sigma factor antagonists. To determine if the STAS domain has a role in controlling the activity of sulfate transporters, their stability, or their localization to the plasma membrane, we examined the effect of deleting or modifying the STAS domain of dominant sulfate transporters in roots of Arabidopsis thaliana. The A. thaliana Sultr1;2 and Sultr1; 1 sulfate transporters rescue the methionine-dependent growth phenotype of the yeast sulfate transporter mutant strain CP154-7B. Constructs of Sultr1; 2 in which the STAS domain was deleted (DeltaSTAS) resulted in synthesis of a truncated polypeptide that was unable to rescue the CP154-7B phenotype. The inability of these constructs to rescue the mutant phenotype probably reflected both low level cellular accumulation of the transporter and the inability of the truncated protein to localize to the plasma membrane. Fusing the STAS domain from other sulfate transporters to Sultr1; 2 DeltaSTAS constructs restored elevated accumulation and plasma membrane localization, although the kinetics of sulfate uptake in the transformants were markedly altered with respect to transformants synthesizing wild-type Sultr1; 2 protein. These results suggest that the STAS domain is essential, either directly or indirectly, for facilitating localization of the transporters to the plasma membrane, but it also appears to influence the kinetic properties of the catalytic domain of transporters.	Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Shibagaki, N (corresponding author), Carnegie Inst Washington, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	snakako@stanford.edu						Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Cherest H, 1997, GENETICS, V145, P627; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Everett LA, 1999, HUM MOL GENET, V8, P1883, DOI 10.1093/hmg/8.10.1883; Fuglsang AT, 2003, J BIOL CHEM, V278, P42266, DOI 10.1074/jbc.M306707200; Hastbacka J, 1996, ANN NY ACAD SCI, V785, P131; Hawkesford MJ, 2003, PHYSIOL PLANTARUM, V117, P155, DOI 10.1034/j.1399-3054.2003.00034.x; Ho MS, 2003, J BIOL CHEM, V278, P20898, DOI 10.1074/jbc.M302305200; Jahn TP, 2002, J BIOL CHEM, V277, P6353, DOI 10.1074/jbc.M109637200; Jones S, 1998, PROTEIN SCI, V7, P233; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; Khurana OK, 2000, FEBS LETT, V477, P118, DOI 10.1016/S0014-5793(00)01783-X; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matulef K, 2003, ANNU REV CELL DEV BI, V19, P23, DOI 10.1146/annurev.cellbio.19.110701.154854; Mitsui K, 2004, J BIOL CHEM, V279, P12438, DOI 10.1074/jbc.M310806200; Pang TX, 2002, J BIOL CHEM, V277, P43771, DOI 10.1074/jbc.M208313200; Rose MD., 1990, METHODS YEAST GENETI; Saito K, 2000, CURR OPIN PLANT BIOL, V3, P188, DOI 10.1016/S1369-5266(00)00063-7; Shelden MC, 2003, BIOCHEMISTRY-US, V42, P12941, DOI 10.1021/bi034827s; Shelden MC, 2001, BIOCHEM J, V356, P589, DOI 10.1042/0264-6021:3560589; Shibagaki N, 2002, PLANT J, V29, P475, DOI 10.1046/j.0960-7412.2001.01232.x; SHIBAGAKI N, 2003, SULFUR TRANSPORT ASS, P323; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; SupertiFurga A, 1996, AM J MED GENET, V63, P144, DOI 10.1002/(SICI)1096-8628(19960503)63:1<144::AID-AJMG25>3.0.CO;2-N; Takahashi H, 2000, PLANT J, V23, P171, DOI 10.1046/j.1365-313x.2000.00768.x; Takahashi H., 1999, Plant Physiology, V121, P686; Usami S, 1999, HUM GENET, V104, P188, DOI 10.1007/s004390050933; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; Yoshimoto N, 2002, PLANT J, V29, P465, DOI 10.1046/j.0960-7412.2001.01231.x	34	71	73	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30791	30799		10.1074/jbc.M403248200	http://dx.doi.org/10.1074/jbc.M403248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136568	hybrid			2022-12-27	WOS:000222531900110
J	Xiao, GT; Fong, A; Sun, SC				Xiao, GT; Fong, A; Sun, SC			Induction of p100 processing by NF-kappa B-inducing kinase involves docking I kappa B kinase alpha (IKK alpha) to p100 and IKK alpha-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; NF-KAPPA-B2 P100; MICE DEFICIENT; P50 SUBUNIT; GENE; BAFF; ACTIVATION; PROTEINS; EXPRESSION; PRECURSOR	The processing of the nfkappab2 gene product p100 to generate p52 is a regulated event, which is important for the instrumental function of NF-kappaB. We previously demonstrated that this tightly controlled event is regulated positively by NF-kappaB-inducing kinase (NIK) and its downstream kinase, IkappaB kinase alpha (IKKalpha). However, the precise mechanisms by which NIK and IKKalpha induce p100 processing remain unclear. Here, we show that, besides activating IKKalpha, NIK also serves as a docking molecule recruiting IKKalpha to p100. This novel function of NIK requires two specific amino acid residues, serine 866 and serine 870, of p100 that are known to be essential for inducible processing of p100. We also show that, after being recruited into p100 complex, activated IKKalpha phosphorylates specific serines located in both N- and C-terminal regions of p100 (serines 99, 108, 115, 123, and 872). The phosphorylation of these specific serines is the prerequisite for ubiquitination and subsequent processing of p100 mediated by the beta-TrCP ubiquitin ligase and 26 S proteasome, respectively. These results highlight the critical but different roles of NIK and IKKalpha in regulating p100 processing and shed light on the mechanisms mediating the tight control of p100 processing. These data also provide the first evidence for explaining why overexpression of IKKalpha or its activation by many other stimuli such as tumor necrosis factor and mitogens fails to induce p100 processing.	Rutgers State Univ, Nelson Biol Labs, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Rutgers State University New Brunswick; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Xiao, GT (corresponding author), Rutgers State Univ, Nelson Biol Labs, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.	xiao@biology.rutgers.edu; sxs70@psu.edu			NCI NIH HHS [1R01 CA94922] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; LANOIX J, 1994, ONCOGENE, V9, P841; Liao GX, 2003, ONCOGENE, V22, P4868, DOI 10.1038/sj.onc.1206761; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luftig MA, 2001, J BIOL CHEM, V276, P14602, DOI 10.1074/jbc.C100103200; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; THAKUR S, 1994, ONCOGENE, V9, P2335; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; ZHANG JD, 1994, ONCOGENE, V9, P1931	45	218	231	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30099	30105		10.1074/jbc.M401428200	http://dx.doi.org/10.1074/jbc.M401428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140882	hybrid			2022-12-27	WOS:000222531900030
J	Adachi, T; Pimentel, DR; Heibeck, T; Hou, XY; Lee, YJ; Jiang, BB; Ido, Y; Cohen, RA				Adachi, T; Pimentel, DR; Heibeck, T; Hou, XY; Lee, YJ; Jiang, BB; Ido, Y; Cohen, RA			S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; OXYGEN SPECIES MEDIATE; PROTEIN-KINASE; OXIDATIVE STRESS; REGULATED KINASE; FACTOR RECEPTOR; NADPH OXIDASE; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Angiotensin II (AII) increases production of reactive oxygen species from NAD(P) H oxidase, a response that contributes to vascular hypertrophy. Here we show in cultured vascular smooth muscle cells that S-glutathiolation of the redox-sensitive Cys(118) on the small GTPase, Ras, plays a critical role in AII-induced hypertrophic signaling. AII simultaneously increased the Ras activity and the S-glutathiolation of Ras (GSS-Ras) detected by biotin-labeled GSH or mass spectrometry. Both the increase in activity and GSS-Ras was labile under reducing conditions, suggesting the essential nature of this thiol modification to Ras activation. Overexpression of catalase, a dominant-negative p47(phox), or glutaredoxin-1 decreased GSS-Ras, Ras activation, p38, and Akt phosphorylation and the induction of protein synthesis by AII. Furthermore, expression of a Cys(118) mutant Ras decreased AII-mediated p38 and Akt phosphorylation as well as protein synthesis. These results show that H2O2 from NAD( P) H oxidase forms GSS-Ras on Cys(118) and increases its activity leading to p38 and Akt phosphorylation, which contributes to the induction of protein synthesis. This study suggests that GSS-Ras is a redox-sensitive signaling switch that participates in the cellular response to AII.	Boston Univ, Med Ctr X707, Whitaker Cardiovasc Inst, Vasc Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, Myocardial Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Whitaker Cardiovasc Inst, Diabet & Metab Unit, Boston, MA 02118 USA; Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15260 USA	Boston University; Boston University; Boston University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Adachi, T (corresponding author), Boston Univ, Med Ctr X707, Whitaker Cardiovasc Inst, Vasc Biol Unit, 650 Albany St, Boston, MA 02118 USA.	tadachi@bumc.bu.edu		/0000-0002-1070-6408; Pimentel, David/0000-0002-0537-7195; Ido, Yasuo/0000-0002-3036-9971	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055620] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL55620] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Dodds E, 1999, J NEUROCHEM, V72, P2105, DOI 10.1046/j.1471-4159.1999.0722105.x; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Frank GD, 2000, ENDOCRINOLOGY, V141, P3120, DOI 10.1210/en.141.9.3120; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Hojo Y, 2002, CIRC RES, V91, P712, DOI 10.1161/01.RES.0000037981.97541.25; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Landmesser U, 2002, HYPERTENSION, V40, P511, DOI 10.1161/01.HYP.0000032100.23772.98; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; Teng KK, 1999, J BIOL CHEM, V274, P37315, DOI 10.1074/jbc.274.52.37315; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Williams JG, 2003, P NATL ACAD SCI USA, V100, P6376, DOI 10.1073/pnas.1037299100; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430	29	238	244	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29857	29862		10.1074/jbc.M313320200	http://dx.doi.org/10.1074/jbc.M313320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123696	hybrid			2022-12-27	WOS:000222445300123
J	Chen, OS; Crisp, RJ; Valachovic, M; Bard, M; Winge, DR; Kaplan, J				Chen, OS; Crisp, RJ; Valachovic, M; Bard, M; Winge, DR; Kaplan, J			Transcription of the yeast iron regulon does not respond directly to iron but rather to iron-sulfur cluster biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRATAXIN; MITOCHONDRIAL; PROTEINS; BIOGENESIS; EXPRESSION; TRANSPORT; GENES; NFS1P; CCC1; AFT1	Saccharomyces cerevisiae responds to iron deprivation by increased transcription of the iron regulon, including the high affinity cell-surface transport system encoded by FET3 and FTR1. Here we demonstrate that transcription of these genes does not respond directly to cytosolic iron but rather to the mitochondrial utilization of iron for the synthesis of iron-sulfur (Fe-S) clusters. We took advantage of a mutant form of an iron-dependent enzyme in the sterol pathway (Erg25-2p) to assess cytosolic iron levels. We showed that disruption of mitochondrial Fe-S biosynthesis, which results in excessive mitochondrial iron accumulation, leads to transcription of the iron transport system independent of the cytosolic iron level. There is an inverse correlation between the activity of the mitochondrial Fe-S-containing enzyme aconitase and the induction of FET3. Regulation of transcription by Fe-S biosynthesis represents a mechanism by which cellular iron acquisition is integrated with mitochondrial iron metabolism.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA; Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Indiana University System; Indiana University-Purdue University Indianapolis; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, 50 North 1900 East, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu	Winge, Dennis/G-3611-2010; Valachovic, Martin/O-5962-2017	Valachovic, Martin/0000-0001-7096-9325	NATIONAL CANCER INSTITUTE [R01CA061286, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062104] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA42014, CA 61286] Funding Source: Medline; NIDDK NIH HHS [DK52380] Funding Source: Medline; NIGMS NIH HHS [GM62104] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Crisp RJ, 2003, J BIOL CHEM, V278, P45499, DOI 10.1074/jbc.M307229200; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Kennedy MA, 2001, BBA-GENE STRUCT EXPR, V1517, P177, DOI 10.1016/S0167-4781(00)00246-3; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	24	162	163	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29513	29518		10.1074/jbc.M403209200	http://dx.doi.org/10.1074/jbc.M403209200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123701	hybrid			2022-12-27	WOS:000222445300084
J	Waddell, DS; Liberati, NT; Guo, X; Frederick, JP; Wang, XF				Waddell, DS; Liberati, NT; Guo, X; Frederick, JP; Wang, XF			Casein kinase I epsilon plays a functional role in the transforming growth factor-beta signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATENIN DEGRADATION COMPLEX; TGF-BETA; SUBSTRATE DETERMINANTS; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; CIRCADIAN CLOCK; CULTURED-CELLS; CKI-EPSILON; WNT PATHWAY; PHOSPHORYLATION	The transforming growth factor-beta (TGF-beta) signaling pathway is known to be involved in a wide range of biological events, including development, cellular differentiation, apoptosis, and oncogenesis. The TGF-beta signal is mediated by ligand binding to the type II receptor, leading to the recruitment and activation of the type I receptor, and subsequent activation of a family of intracellular signal transducing proteins called Smads. Here we report a regulatory role for casein kinase Iepsilon (CKIepsilon) in the TGF-beta signaling cascade. We find that CKIepsilon binds to all Smads and the cytoplasmic domains of the type I and type II receptors both in vitro and in vivo. The interaction of CKIepsilon with the type I and type II receptors is independent of TGF-beta stimulation, whereas the CKIepsilon/Smad interaction is transiently disrupted by ligand treatment. Additionally, CKIepsilon is able to phosphorylate the receptor-activated Smads (Smads 1-3 and 5) and the type II receptor in vitro. Transcriptional reporter assays reveal that transient overexpression of wild type CKIepsilon dramatically reduces basal reporter activity but enhances TGF-beta-stimulated transcription. Furthermore, overexpression of a kinase-dead mutant of CKIepsilon inhibits both basal and ligand-induced transcription, whereas inhibition of endogenous CKI catalytic activity with IC261 blocks only TGF-beta-stimulated reporter activity. Finally, knocking down CKIepsilon protein levels results in a significant increase in basal and TGF-beta-induced transcription. These results suggest that CKIepsilon plays a ligand-dependent, differential, and dual regulatory role within the TGF-beta signaling pathway.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Wang, XF (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27710 USA.	wang0011@mc.duke.edu	Waddell, David/AAG-3774-2020; Waddell, David/J-7435-2015	Waddell, David/0000-0001-6749-4461; Waddell, David/0000-0001-6749-4461	NCI NIH HHS [CA83770, CA75368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083770, R01CA075368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Frederick JP, 2002, STRUCTURE, V10, P1607, DOI 10.1016/S0969-2126(02)00914-0; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hall FL, 1996, BIOCHEM J, V316, P303, DOI 10.1042/bj3160303; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Inoue Y, 2004, J INTERF CYTOK RES, V24, P43, DOI 10.1089/107999004772719909; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee C, 2004, MOL CELL BIOL, V24, P584, DOI 10.1128/MCB.24.2.584-594.2004; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Marin O, 2002, BIOCHEMISTRY-US, V41, P618, DOI 10.1021/bi0112309; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Preuss F, 2004, MOL CELL BIOL, V24, P886, DOI 10.1128/MCB.24.2.886-898.2004; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Randall RA, 2004, MOL CELL BIOL, V24, P1106, DOI 10.1128/MCB.24.3.1106-1121.2004; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Tobin AB, 2002, TRENDS PHARMACOL SCI, V23, P337, DOI 10.1016/S0165-6147(02)02043-6; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Warner DR, 2003, FEBS LETT, V539, P167, DOI 10.1016/S0014-5793(03)00155-8; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	67	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29236	29246		10.1074/jbc.M400880200	http://dx.doi.org/10.1074/jbc.M400880200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133026	hybrid			2022-12-27	WOS:000222445300052
J	Zhang, ZH; Rhodes, KJ; Childers, WE; Argentieri, TM; Wang, Q				Zhang, ZH; Rhodes, KJ; Childers, WE; Argentieri, TM; Wang, Q			"Disinactivation" of N-type inactivation of voltage-gated K channels by an erbstatin analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; TYROSINE PHOSPHORYLATION; KINASE INHIBITOR; BETA-SUBUNITS; ASSOCIATION; RECEPTOR; PEPTIDE	In some A-type voltage-gated K channels, rapid inactivation is achieved through the binding of an N-terminal domain of the pore-forming alpha-subunit or an associated beta-subunit to a cytoplasmic acceptor located at or near the channel pore using the ball-and-chain machinery (1-5). This inactivation involving the N terminus is known as N-type inactivation. Here, we describe an erbstatin (Erb) analogue as a small molecule inhibitor of the N-type inactivation in channels of Kv1.4 and Kv1.1+Kvbeta1. We show that this inhibition of inactivation (designated as "disinactivation") is potent and selective for N-type inactivation in heterologous cells (Chinese hamster ovary and Xenopus oocytes) expressing these A-type channels. In Chinese hamster ovary cells, Erb increased the inactivation time constant of Kv1.4 from 86.5 +/- 9.5 to 150 +/- 10 ms (n = 6, p < 0.01). Similarly, Erb increased the inactivation time constant of Kv1.1 + Kv beta 1 from 10 +/- 0.9 to 49.3 +/- 7 ms (n = 7, p < 0.01). The EC50 for disinactivating Kv1.1 + Kvbeta1 was 10.4 +/- 0.9 muM (n = 2-9). Erb had no effect upon another A-channel, Kv4.3, which does not utilize the ball-and-chain mechanism. The mechanism of Erb-induced disinactivation was also investigated. Neither cysteine oxidation nor tyrosine kinase inhibition was involved. The results demonstrate that Erb can be used as a base structure to identify potent, selective small molecule inhibitors of intracellular protein-protein interactions, and that these disinactivators may offer another therapeutic approach to the treatment of seizure disorders.	Wyeth Ayerst Res, Dept Womens Hlth & Bone, Collegeville, PA 19426 USA; Wyeth Ayerst Res, Dept Med Chem, Princeton, NJ 08543 USA; Wyeth Ayerst Res, Dept Neurosci, Princeton, NJ 08543 USA	Pfizer; Pfizer; Pfizer	Wang, Q (corresponding author), Wyeth Ayerst Res, Dept Womens Hlth & Bone, 500 Arcola Rd, Collegeville, PA 19426 USA.	wangq@wyeth.com						COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; Encinar JA, 2002, BIOCHEMISTRY-US, V41, P12263, DOI 10.1021/bi020188u; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; HEINEMANN S, 1994, J PHYSIOL-PARIS, V88, P173, DOI 10.1016/0928-4257(94)90003-5; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISSHIKI K, 1987, J ANTIBIOT, V40, P1207, DOI 10.7164/antibiotics.40.1207; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Murakoshi H, 1997, MOL PHARMACOL, V52, P821, DOI 10.1124/mol.52.5.821; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; PONGS O, 1992, PHYSL REV S4, V72, P69; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Stephens GJ, 1996, PFLUG ARCH EUR J PHY, V431, P435, DOI 10.1007/BF02207283; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; Wang Q, 1999, ANN NY ACAD SCI, V868, P447, DOI 10.1111/j.1749-6632.1999.tb11311.x; Young K. H., 1999, Society for Neuroscience Abstracts, V25, P983; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhang ZH, 2000, PFLUG ARCH EUR J PHY, V440, P784, DOI 10.1007/s004240000360	23	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29226	29230		10.1074/jbc.M403290200	http://dx.doi.org/10.1074/jbc.M403290200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15136567	hybrid			2022-12-27	WOS:000222445300050
J	Hosszu, LLP; Jackson, GS; Trevitt, CR; Jones, S; Batchelor, M; Bhelt, D; Prodromidou, K; Clarke, AR; Waltho, JP; Collinge, J				Hosszu, LLP; Jackson, GS; Trevitt, CR; Jones, S; Batchelor, M; Bhelt, D; Prodromidou, K; Clarke, AR; Waltho, JP; Collinge, J			The residue 129 polymorphism in human prion protein does not confer susceptibility to Creutzfeldt-Jakob disease by altering the structure or global stability of PrP(C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIR GENE INSERTION; NMR STRUCTURE; VARIANT CJD; HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; SCRAPIE; SENSITIVITY; MICE; BSE	There are two common forms of prion protein (PrP) in humans, with either methionine or valine at position 129. This polymorphism is a powerful determinant of the genetic susceptibility of humans toward both sporadic and acquired forms of prion disease and restricts propagation of particular prion strains. Despite its key role, we have no information on the effect of this mutation on the structure, stability, folding, and dynamics of the cellular form of PrP (PrP(C)). Here, we show that the mutation has no measurable effect on the folding, dynamics, and stability of PrP(C). Our data indicate that the 129M/V polymorphism does not affect prion propagation through its effect on PrP(C); rather, its influence is likely to be downstream in the disease mechanism. We infer that the M/V effect is mediated through the conformation or stability of disease-related PrP (PrP(Sc)) or intermediates or on the kinetics of their formation.	UCL, Inst Neurol, Dept Neurodegenerat Dis, MRC,Prion Unit, London WC1N 3BG, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England	University of London; University College London; University of Sheffield	Collinge, J (corresponding author), UCL, Inst Neurol, Dept Neurodegenerat Dis, MRC,Prion Unit, Queen Sq, London WC1N 3BG, England.	j.collinge@prion.ucl.ac.uk		Prodromidou, Kanella/0000-0001-5721-9124; Waltho, Jonathan/0000-0002-7402-5492; Jackson, Graham/0000-0002-3125-2011				Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; FERRIN TE, 1991, J MOL GRAPHICS, V9, P27, DOI 10.1016/0263-7855(91)80030-4; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Haire LF, 2004, J MOL BIOL, V336, P1175, DOI 10.1016/j.jmb.2003.12.059; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PARCHI P, 1996, ANN NEUROL, V39, P669; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Peti W, 2001, J BIOMOL NMR, V19, P153, DOI 10.1023/A:1008307323283; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Whitehead B, 1997, J BIOMOL NMR, V9, P313, DOI 10.1023/A:1018687127330; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zhang YB, 2000, J BIOL CHEM, V275, P33650, DOI 10.1074/jbc.C000483200	61	65	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28515	28521		10.1074/jbc.M313762200	http://dx.doi.org/10.1074/jbc.M313762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123682	hybrid			2022-12-27	WOS:000222265400087
J	Ohnishi, H; Kobayashi, H; Okazawa, H; Ohe, Y; Tomizawa, K; Sato, R; Matozaki, T				Ohnishi, H; Kobayashi, H; Okazawa, H; Ohe, Y; Tomizawa, K; Sato, R; Matozaki, T			Ectodomain shedding of SHPS-1 and its role in regulation of cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; INTEGRIN-ASSOCIATED PROTEIN; NEURAL ADHESION MOLECULE; GROWTH-FACTOR; FOCAL ADHESION; BINDING; SURFACE; KINASE; CD47; GLYCOPROTEIN	SHPS-1 is a transmembrane protein whose cytoplasmic region undergoes tyrosine phosphorylation and then binds the protein-tyrosine phosphatase SHP-2. Formation of the SHPS-1-SHP-2 complex is implicated in regulation of cell migration. In addition, SHPS-1 and its ligand CD47 constitute an intercellular recognition system that contributes to inhibition of cell migration by cell-cell contact. The ectodomain of SHPS-1 has now been shown to be shed from cells in a reaction likely mediated by a metalloproteinase. This process was promoted by activation of protein kinase C or of Ras, and the released ectodomain exhibited minimal CD47-binding activity. Metalloproteinases catalyzed the cleavage of a recombinant SHPS-1-Fc fusion protein in vitro, and the primary cleavage site was localized to the juxtamembrane region of SHPS-1. Forced expression of an SHPS-1 mutant resistant to ectodomain shedding impaired cell migration, cell spreading, and reorganization of the actin cytoskeleton. It also increased the tyrosine phosphorylation of paxillin and FAK triggered by cell adhesion. These results suggest that shedding of the ectodomain of SHPS-1 plays an important role in regulation of cell migration and spreading by this protein.	Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Gunma 3718512, Japan	Gunma University	Matozaki, T (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, 3-39-15 Showa Machi, Gunma 3718512, Japan.	matozaki@showa.gunma-u.ac.jp	Okazawa, Hideki/C-3836-2011; Okazawa, Hideki/E-3055-2010					Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Comu S, 1997, J NEUROSCI, V17, P8702; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Guo L, 2002, MOL CELL PROTEOMICS, V1, P30, DOI 10.1074/mcp.M100020-MCP200; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Manes S, 1999, MOL CELL BIOL, V19, P3125; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; Ohe Y, 2003, BIOCHEM BIOPH RES CO, V308, P719, DOI 10.1016/S0006-291X(03)01454-2; Ohnishi H, 1999, J NEUROCHEM, V72, P1402, DOI 10.1046/j.1471-4159.1999.721402.x; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sato R, 2003, BIOCHEM BIOPH RES CO, V309, P584, DOI 10.1016/j.bbrc.2003.08.031; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; Tanaka Y, 2002, BIOCHEM BIOPH RES CO, V299, P472, DOI 10.1016/S0006-291X(02)02681-5; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	48	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27878	27887		10.1074/jbc.M313085200	http://dx.doi.org/10.1074/jbc.M313085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123722	hybrid			2022-12-27	WOS:000222265400009
J	Scassa, ME; Guberman, AS; Ceruti, JM; Canepa, ET				Scassa, ME; Guberman, AS; Ceruti, JM; Canepa, ET			Hepatic nuclear factor 3 and nuclear factor 1 regulate 5-aminolevulinate synthase gene expression and are involved in insulin repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; BINDING-SITES; FACTOR-I; TRANSCRIPTIONAL REGULATION; GLUCOCORTICOID RESPONSE; AMINOTRANSFERASE GENE; MEDIATES REPRESSION; GLUT4 PROMOTER; FACTOR 3-BETA	Although the negative regulation of gene expression by insulin has been widely studied, the transcription factors responsible for the insulin effect are still unknown. The purpose of this work was to explore the molecular mechanisms involved in the insulin repression of the 5-aminolevulinate synthase ( ALAS) gene. Deletion analysis of the 5'-regulatory region allowed us to identify an insulin-responsive region located at -459 to -354 bp. This fragment contains a highly homologous insulin-responsive (IRE) sequence. By transient transfection assays, we determined that hepatic nuclear factor 3 (HNF3) and nuclear factor 1 (NF1) are necessary for an appropriate expression of the ALAS gene. Insulin overrides the HNF3beta or HNF3beta plus NF1-mediated stimulation of ALAS transcriptional activity. Electrophoretic mobility shift assay and Southwestern blotting indicate that HNF3 binds to the ALAS promoter. Mutational analysis of this region revealed that IRE disruption abrogates insulin action, whereas mutation of the HNF3 element maintains hormone responsiveness. This dissociation between HNF3 binding and insulin action suggests that HNF3beta is not the sole physiologic mediator of insulin-induced transcriptional repression. Furthermore, Southwestern blotting assay shows that at least two polypeptides other than HNF3beta can bind to ALAS promoter and that this binding is dependent on the integrity of the IRE. We propose a model in which insulin exerts its negative effect through the disturbance of HNF3beta binding or transactivation potential, probably due to specific phosphorylation of this transcription factor by Akt. In this regard, results obtained from transfection experiments using kinase inhibitors support this hypothesis. Due to this event, NF1 would lose accessibility to the promoter. The posttranslational modification of HNF3 would allow the binding of a protein complex that recognizes the core IRE. These results provide a potential mechanism for the insulin-mediated repression of IRE-containing promoters.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, RA-1428 Buenos Aires, DF, Argentina	University of Buenos Aires	Canepa, ET (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Mol Biol Lab, Pabellon 2 Piso 4,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.	ecanepa@qb.fcen.uba.ar		Canepa, Eduardo T./0000-0002-4322-1650				Andersson C, 1999, J INTERN MED, V245, P193, DOI 10.1046/j.1365-2796.1999.0448e.x; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Beurton F, 1999, BIOCHEM J, V343, P687, DOI 10.1042/0264-6021:3430687; BISHOP DF, 1990, NUCLEIC ACIDS RES, V18, P7187, DOI 10.1093/nar/18.23.7187; BRODIE MJ, 1977, CLIN SCI MOL MED, V53, P365, DOI 10.1042/cs0530365; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Cha JY, 2001, EXP MOL MED, V33, P59, DOI 10.1038/emm.2001.11; Chaya D, 2001, J BIOL CHEM, V276, P44385, DOI 10.1074/jbc.M108214200; CHOMCZYNSKY P, 1987, ANAL BIOCHEM, V71, P341; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; Cooke DW, 1999, BIOCHEM BIOPH RES CO, V260, P600, DOI 10.1006/bbrc.1999.0959; Czech MP, 2003, P NATL ACAD SCI USA, V100, P11198, DOI 10.1073/pnas.2135308100; Delesque-Touchard N, 2000, J BIOL CHEM, V275, P34173, DOI 10.1074/jbc.M004027200; Dong Y, 2002, EXP CELL RES, V276, P328, DOI 10.1006/excr.2002.5534; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Giono LE, 2001, BIOCHEM J, V353, P307, DOI 10.1042/0264-6021:3530307; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Guberman AS, 2003, J BIOL CHEM, V278, P2317, DOI 10.1074/jbc.M205057200; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Hoodless PA, 2001, GENE DEV, V15, P1257, DOI 10.1101/gad.881501; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; Kappas A, 1995, METABOLIC MOL BASES, P2103; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; Navas MA, 2000, HUM HERED, V50, P370, DOI 10.1159/000022943; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; Park SH, 2001, J BIOL CHEM, V276, P43031, DOI 10.1074/jbc.M107597200; Patel S, 2001, BIOCHEM J, V359, P611, DOI 10.1042/0264-6021:3590611; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; Sadlon TJ, 1999, INT J BIOCHEM CELL B, V31, P1153, DOI 10.1016/S1357-2725(99)00073-4; Sambrook J., 2001, MOL CLONING LAB MANU; Scassa ME, 2001, EXP CELL RES, V271, P201, DOI 10.1006/excr.2001.5386; Scassa ME, 1998, EXP CELL RES, V244, P460, DOI 10.1006/excr.1998.4206; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Shimizu S, 2002, BBA-GENE STRUCT EXPR, V1574, P337, DOI 10.1016/S0167-4781(02)00232-4; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Varone CL, 1996, BIOCHEM CELL BIOL, V74, P271, DOI 10.1139/o96-029; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; Wang DP, 1996, J LIPID RES, V37, P1831; WANG J, 2002, J BIOL CHEM, V275, P14717; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Waxman David J., 1995, P391; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	63	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28082	28092		10.1074/jbc.M401792200	http://dx.doi.org/10.1074/jbc.M401792200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123725	Green Published, hybrid			2022-12-27	WOS:000222265400033
J	Stamatiou, PB; Chan, CC; Monneret, G; Ethier, D; Rokach, J; Powell, WS				Stamatiou, PB; Chan, CC; Monneret, G; Ethier, D; Rokach, J; Powell, WS			5-oxo-6,8,11,14-eicosatetraenoic acid stimulates the release of the eosinophil survival factor granulocyte/macrophage colony-stimulating factor from monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; IN-VITRO; HUMAN-NEUTROPHILS; HUMAN GRANULOCYTES; MONONUCLEAR-CELLS; POTENT STIMULATOR; HUMAN BLOOD; MACROPHAGE; APOPTOSIS; RECEPTOR	Allergic diseases such as asthma are characterized by tissue eosinophilia induced by the combined effects of chemoattractants and cytokines. Lipid mediators are a major class of endogenous chemoattractants, among which 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is the most potent for human eosinophils. In this study, we investigated the effects of 5-oxo-ETE on eosinophil survival by flow cytometry. We found that this compound could promote eosinophil survival in the presence of small numbers of contaminating monocytes, but not in their absence. The conditioned medium from monocytes treated for 24 h with 5-oxo-ETE also strongly promoted eosinophil survival, whereas the medium from vehicle-treated monocytes had no effect. An antibody against the granulocyte/macrophage colony-stimulating factor (GM-CSF) completely blocked the response of eosinophils to the conditioned medium from 5-oxo-ETE-treated monocytes, whereas an antibody against interleukin-5 had no effect. Furthermore, 5-oxo-ETE stimulated the release of GM-CSF from cultured monocytes in amounts compatible with eosinophil survival activity, with a maximal effect being observed after 24 h. This effect was concentration-dependent and could be observed at concentrations in the picomolar range. 5-Oxo-ETE and leukotriene B-4 had similar effects on GM-CSF release at low concentrations, but 5-oxo-ETE induced a much stronger response at concentrations of 10 nM or higher. This is the first report that 5-oxo-ETE can induce the release of any cytokine, suggesting that it could be an important mediator in allergic and other inflammatory diseases due both to its chemoattractant properties and to its potent effects on the synthesis of the survival factor GM-CSF.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	McGill University; Merck & Company; Merck & Company; Florida Institute of Technology; Florida Institute of Technology	Powell, WS (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	william.powell@mcgill.ca	Powell, William/AAE-9000-2020	Rokach, Joshu/0000-0003-1814-7505; Powell, William/0000-0002-8507-4038	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 69835] Funding Source: Medline; NIDDK NIH HHS [DK 44730] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Becler K, 2002, ALLERGY, V57, P1021, DOI 10.1034/j.1398-9995.2002.23620.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bowers RC, 2000, J BIOL CHEM, V275, P29931, DOI 10.1074/jbc.C000502200; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Czech W, 1997, J INVEST DERMATOL, V108, P108, DOI 10.1111/1523-1747.ep12285653; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Guilbert M, 1999, AM J RESP CELL MOL, V21, P97, DOI 10.1165/ajrcmb.21.1.3517; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hevko JM, 2002, J BIOL CHEM, V277, P7037, DOI 10.1074/jbc.M108942200; Hevko JM, 2001, J PHARMACOL EXP THER, V296, P293; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053, DOI 10.1152/ajplung.1997.272.6.L1053; Iversen PO, 1997, AM J RESP CRIT CARE, V156, P1628, DOI 10.1164/ajrccm.156.5.9612097; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; Khanapure SP, 1998, J ORG CHEM, V63, P337, DOI 10.1021/jo9716993; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Meerschaert J, 2000, AM J RESP CELL MOL, V23, P780, DOI 10.1165/ajrcmb.23.6.4171; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; Muro S, 2003, J ALLERGY CLIN IMMUN, V112, P768, DOI 10.1016/S0091-6749(03)01888-8; O'Flaherty JT, 2000, J IMMUNOL, V164, P3345, DOI 10.4049/jimmunol.164.6.3345; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; OFLaherty JT, 1996, J IMMUNOL, V157, P336; Park CS, 1998, EUR RESPIR J, V12, P872, DOI 10.1183/09031936.98.12040872; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; POULIOT M, 1994, J IMMUNOL, V152, P851; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; Powell WS, 2001, J ALLERGY CLIN IMMUN, V107, P272, DOI 10.1067/mai.2001.112847; Powell WS, 1996, J IMMUNOL, V156, P336; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1995, J IMMUNOL, V154, P4123; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; SEEDS EAM, 1995, EUR J PHARM-ENVIRON, V293, P369, DOI 10.1016/0926-6917(95)90057-8; Simon HU, 2000, ALLERGY, V55, P910, DOI 10.1034/j.1398-9995.2000.055010910.x; Sozzani S, 1996, J IMMUNOL, V157, P4664; Stamatiou P, 1998, J CLIN INVEST, V102, P2165, DOI 10.1172/JCI1995; Tohda Y, 1999, CLIN EXP ALLERGY, V29, P1532; Zhang Y, 1996, J LEUKOCYTE BIOL, V59, P847, DOI 10.1002/jlb.59.6.847	49	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28159	28164		10.1074/jbc.M401537200	http://dx.doi.org/10.1074/jbc.M401537200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15136573	hybrid			2022-12-27	WOS:000222265400043
J	Benarroch, D; Egloff, MP; Mulard, L; Guerreiro, C; Romette, JL; Canard, B				Benarroch, D; Egloff, MP; Mulard, L; Guerreiro, C; Romette, JL; Canard, B			A structural basis for the inhibition of the NS5 dengue virus mRNA 2 '-O-Methyltransferase domain by ribavirin 5 '-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEST NILE VIRUS; CRYSTAL-STRUCTURE; DEHYDROGENASE; MECHANISMS	Ribavirin is one of the few nucleoside analogues currently used in the clinic to treat RNA virus infections, but its mechanism of action remains poorly understood at the molecular level. Here, we show that ribavirin 5'-triphosphate inhibits the activity of the dengue virus 2'-O-methyltransferase NS5 domain (NS5MTase(DV)). Along with several other guanosine 5'-triphosphate analogues such as acyclovir, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR), and a series of ribose-modified ribavirin analogues, ribavirin 5'-triphosphate competes with GTP to bind to NS5MTaseDV. A structural view of the binding of ribavirin 5'-triphosphate to this enzyme was obtained by determining the crystal structure of a ternary complex consisting of NS5MTaseDV, ribavirin 5'-triphosphate, and S-adenosyl-L-homocysteine at a resolution of 2.6 Angstrom. These detailed atomic interactions provide the first structural insights into the inhibition of a viral enzyme by ribavirin 5'-triphosphate, as well as the basis for rational drug design of antiviral agents with improved specificity against the emerging flaviviruses.	CNRS, F-13288 Marseille 9, France; Univ Aix Marseille 1, UMR 6098, Ecole Super Ingenieurs Luminy, F-13288 Marseille 9, France; Univ Aix Marseille 2, UMR 6098, Ecole Super Ingenieurs Luminy, F-13288 Marseille 9, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Canard, B (corresponding author), CNRS, Case 925,163 Ave Luminy, F-13288 Marseille 9, France.	bruno@afmb.cnrs-mrs.fr	Benarroch-Popivker, Delphine/T-1990-2019; Benarroch, Delphine/E-9983-2017	Canard, Bruno/0000-0003-4924-1991				Anderson JF, 1999, SCIENCE, V286, P2331, DOI 10.1126/science.286.5448.2331; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALZARINI J, 1993, J BIOL CHEM, V268, P24591; Bisaillon M, 1997, VIROLOGY, V236, P1, DOI 10.1006/viro.1997.8698; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Gallois-Montbrun S, 2003, MOL PHARMACOL, V63, P538, DOI 10.1124/mol.63.3.538; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; Hong Zhi, 2002, Prog Drug Res, V59, P41; Jordan I, 2000, J INFECT DIS, V182, P1214, DOI 10.1086/315847; KOFF WC, 1982, ANTIVIR RES, V2, P69, DOI 10.1016/0166-3542(82)90027-4; KORNBERG A, 1992, DNA REPLICATION, P54; Leyssen P, 2001, VIROLOGY, V279, P27, DOI 10.1006/viro.2000.0723; Matsuo H, 2000, J AM CHEM SOC, V122, P2417, DOI 10.1021/ja9926820; Neyts J, 1996, ANTIVIR RES, V30, P125, DOI 10.1016/0166-3542(96)89697-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATTERSON JL, 1990, REV INFECT DIS, V12, P1139; Prosise GL, 2002, J BIOL CHEM, V277, P50654, DOI 10.1074/jbc.M208330200; ROUSSEL A, 1991, SILICON GRAPHICS DIR, P97; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; Young KC, 2003, HEPATOLOGY, V38, P869, DOI 10.1053/jhep.2003.50445	25	126	136	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35638	35643		10.1074/jbc.M400460200	http://dx.doi.org/10.1074/jbc.M400460200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15152003	hybrid			2022-12-27	WOS:000223303400060
J	Kim, HS; Kang, TS; Hyun, JS; Kang, HS				Kim, HS; Kang, TS; Hyun, JS; Kang, HS			Regulation of penicillin G acylase gene expression in Escherichia coli by repressor PaaX and the cAMP-cAMP receptor protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; PAC GENE; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; PHENYLACETIC ACID; AMIDASE; ACTIVATION; PROMOTER; IDENTIFICATION; MATURATION	The pga gene of Escherichia coli W ATCC11105 encodes a penicillin G acylase whose expression is regulated at both the transcriptional and post-transcriptional level. In this work we have shown that PaaX is the repressor of pga expression, and we have identified its binding consensus as TGATTC(N-27)GAATCA. We conclude that the process of "PAA induction" actually involves relief of pga from repression by PaaX. Other features of the pga promoter have also been characterized. (i) It has a native class III cAMP-receptor protein (CRP)-dependent promoter with two CRP-binding sites. (ii) The downstream CRP-binding site II has higher affinity. (iii) Binding of cAMP-CRP to both sites (I + II) is required for maximal expression. We have also shown that the PaaX-binding site overlaps with the CRP-binding site I. This implies that PaaX and the cAMP-CRP compete for binding to the region around the CRP-binding site I and therefore have antagonistic effects on pga expression.	Seoul Natl Univ, Dept Microbiol, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Kang, HS (corresponding author), Seoul Natl Univ, Dept Microbiol, Sch Biol Sci, San 56-1,Shillim Dong, Seoul 151742, South Korea.	khslab@snu.ac.kr	kang, taesun/AAJ-2957-2020; kang, tae sun/K-2099-2015	kang, taesun/0000-0001-5939-6247; kang, tae sun/0000-0001-5939-6247				BARBERO JL, 1986, GENE, V49, P69, DOI 10.1016/0378-1119(86)90386-0; Beatty CM, 2003, J BACTERIOL, V185, P5148, DOI 10.1128/JB.185.17.5148-5157.2003; BOMSTEIN J, 1965, ANAL CHEM, V37, P576, DOI 10.1021/ac60223a034; Browning DF, 2004, MOL MICROBIOL, V51, P241, DOI 10.1046/j.1365-2958.2003.03824.x; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; Chou CF, 1999, BIOTECHNOL PROGR, V15, P439, DOI 10.1021/bp990036z; Dai MH, 2001, EUR J BIOCHEM, V268, P1298, DOI 10.1046/j.1432-1327.2001.01994.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Diaz E, 2001, MICROBIOL MOL BIOL R, V65, P523, DOI 10.1128/MMBR.65.4.523-569.2001; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Ferrandez A, 2000, J BIOL CHEM, V275, P12214, DOI 10.1074/jbc.275.16.12214; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; GANG DM, 1976, BIOCHIM BIOPHYS ACTA, V425, P110, DOI 10.1016/0005-2787(76)90220-3; Gust B, 2003, P NATL ACAD SCI USA, V100, P1541, DOI 10.1073/pnas.0337542100; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Ignatova Z, 2002, BIOCHEM BIOPH RES CO, V291, P146, DOI 10.1006/bbrc.2002.6420; Jiang L, 1997, GENET ANAL-BIOMOL E, V14, P51, DOI 10.1016/S1050-3862(97)00011-9; Jiang Q. L, 1992, CHIN J BIOTECHNOL, V8, P213; Kasche V, 1999, BBA-PROTEIN STRUCT M, V1433, P76, DOI 10.1016/S0167-4838(99)00155-7; Kim H. G., 1995, THESIS SEOUL NATL U; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee H, 2000, BIOCHEM BIOPH RES CO, V272, P199, DOI 10.1006/bbrc.2000.2729; Lin WJ, 2001, BIOTECHNOL BIOENG, V73, P484, DOI 10.1002/bit.1083; Ljubijankic G, 1992, DNA Seq, V3, P195, DOI 10.3109/10425179209034017; Luengo JM, 2001, MOL MICROBIOL, V39, P1434, DOI 10.1046/j.1365-2958.2001.02344.x; MAHMOOD ZA, 1991, FOLIA MICROBIOL, V36, P444, DOI 10.1007/BF02884063; MARTIN L, 1995, FEMS MICROBIOL LETT, V125, P287, DOI 10.1016/0378-1097(94)00510-X; MAYER H, 1979, PLASMIDS MED ENV COM, P459; MERINO E, 1992, MOL MICROBIOL, V6, P2175, DOI 10.1111/j.1365-2958.1992.tb01391.x; MEYER TL, 1992, FEBS LETT, V307, P62; OH SJ, 1987, GENE, V56, P87; OHASHI H, 1988, APPL ENVIRON MICROB, V54, P2603, DOI 10.1128/AEM.54.11.2603-2607.1988; Oinonen C, 2000, PROTEIN SCI, V9, P2329, DOI 10.1110/ps.9.12.2329; Pan KL, 2003, J BACTERIOL, V185, P3020, DOI 10.1128/JB.185.10.3020-3030.2003; Radoja S, 1999, GENET ANAL-BIOMOL E, V15, P235, DOI 10.1016/S1050-3862(99)00030-3; Roa A, 1997, FEMS MICROBIOL LETT, V151, P9, DOI 10.1016/S0378-1097(97)00117-1; Roa A, 1999, FEMS MICROBIOL LETT, V177, P7, DOI 10.1016/S0378-1097(99)00281-5; Sambrook J., 2001, MOL CLONING LAB MANU; SCHERRER S, 1994, APPL MICROBIOL BIOT, V42, P85; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Stojcevic N, 2001, BIOMOL ENG, V17, P113, DOI 10.1016/S1389-0344(00)00074-5; SUDHAKARAN VK, 1992, PROCESS BIOCHEM, V27, P131, DOI 10.1016/0032-9592(92)87001-W; SZENTIRMAI A, 1964, APPL MICROBIOL, V12, P185, DOI 10.1128/AEM.12.3.185-187.1964; VALLE F, 1986, GENE, V50, P119, DOI 10.1016/0378-1119(86)90316-1; VALLE F, 1991, TRENDS BIOCHEM SCI, V16, P36, DOI 10.1016/0968-0004(91)90014-M; Verhaert RMD, 1997, APPL ENVIRON MICROB, V63, P3412, DOI 10.1128/AEM.63.9.3412-3418.1997; Virden R, 1990, BIOTECHNOL GENET, V8, P189, DOI [10.1080/02648725.1990.10647869, DOI 10.1080/02648725.1990.10647869]; VOJTISEK V, 1975, FOLIA MICROBIOL, V20, P298, DOI 10.1007/BF02878111; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Yang YG, 2000, ACTA BIOCH BIOPH SIN, V32, P163	52	14	16	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33253	33262		10.1074/jbc.M404348200	http://dx.doi.org/10.1074/jbc.M404348200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159386	hybrid			2022-12-27	WOS:000223039700031
J	Spagnolo, L; Toro, I; D'Orazio, M; O'Neill, P; Pedersen, JZ; Oliviero, CG; Rotilio, G; Battistoni, A; Djinovic-Carugo, K				Spagnolo, L; Toro, I; D'Orazio, M; O'Neill, P; Pedersen, JZ; Oliviero, CG; Rotilio, G; Battistoni, A; Djinovic-Carugo, K			Unique features of the sodC-encoded superoxide dismutase from Mycobacterium tuberculosis, a fully functional copper-containing enzyme lacking zinc in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ERYTHROCUPREIN; BINDING SITE; PH; MECHANISM; REFINEMENT; DISTANCE; PROGRAM; ION	The sodC-encoded Mycobacterium tuberculosis superoxide dismutase ( SOD) shows high sequence homology to other members of the copper/zinc-containing SOD family. Its three-dimensional structure is reported here, solved by x-ray crystallography at 1.63-Angstrom resolution. Metal analyses of the recombinant protein indicate that the native form of the enzyme lacks the zinc ion, which has a very important structural and functional role in all other known enzymes of this class. The absence of zinc within the active site is due to significant rearrangements in the zinc subloop, including deletion or mutation of the metal ligands His(115) and His(123). Nonetheless, the enzyme has a catalytic rate close to the diffusion limit; and unlike all other copper/zinc-containing SODs devoid of zinc, the geometry of the copper site is pH-independent. The protein shows a novel dimer interface characterized by a long and rigid loop, which confers structural stability to the enzyme. As the survival of bacterial pathogens within their host critically depends on their ability to recruit zinc in highly competitive environments, we propose that the observed structural rearrangements are required to build up a zinc-independent but fully active and stable copper-containing SOD.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Nazl Fis Mat, I-00133 Rome, Italy; Sincrotrone Trieste, ELETTRA, Struct Biol Lab, I-34012 Trieste, Italy; Ist Nazl Fis Mat, Natl Lab Technol Avanzate & Nanosci, I-34012 Trieste, Italy; MRC, Radiat & Genome Unit, Didcot OX11 0RD, Oxon, England; Univ Pavia, Dept Gen Chem, I-27100 Pavia, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Elettra Sincrotrone Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; MRC Harwell; University of Pavia	Battistoni, A (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	andrea.battistoni@uniroma2.it; kristina.djinovic@elettra.trieste.it	Battistoni, Andrea/A-4778-2016; Spagnolo, Laura/A-4600-2011; Djinovic-Carugo, Kristina/AAW-1167-2021	Battistoni, Andrea/0000-0003-4085-7917; Spagnolo, Laura/0000-0002-0794-566X; Djinovic-Carugo, Kristina/0000-0003-0252-2972				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; Battistoni A, 2003, BIOCHEM SOC T, V31, P1326; Battistoni A, 2001, J BIOL CHEM, V276, P30315, DOI 10.1074/jbc.M010527200; Blencowe DK, 2003, FEMS MICROBIOL REV, V27, P291, DOI 10.1016/S0168-6445(03)00041-X; Bordo D, 1999, J MOL BIOL, V285, P283, DOI 10.1006/jmbi.1998.2267; BORDO D, 2001, HDB METALLOPROTEINS, P1284; Carugo O, 2002, J MOL BIOL, V315, P887, DOI 10.1006/jmbi.2001.5250; Carugo O, 2001, PROTEIN SCI, V10, P1470, DOI 10.1110/ps.690101; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOPER JB, 1995, J MOL BIOL, V246, P531, DOI 10.1006/jmbi.1994.0105; Crow JP, 1997, J NEUROCHEM, V69, P1945; CUDD A, 1982, J BIOL CHEM, V257, P1443; D'Orazio M, 2001, BIOCHEM J, V359, P17, DOI 10.1042/0264-6021:3590017; DeLano W, 2002, PYMOL 0 99; DJINOVIC K, 1992, J MOL BIOL, V226, P227, DOI 10.1016/0022-2836(92)90135-7; Edwards KM, 2001, AM J RESP CRIT CARE, V164, P2213, DOI 10.1164/ajrccm.164.12.2106093; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FIELDEN EM, 1974, BIOCHEM J, V139, P49, DOI 10.1042/bj1390049; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Grishin NV, 1997, J MOL EVOL, V45, P359, DOI 10.1007/PL00006241; Hough MA, 2003, STRUCTURE, V11, P937, DOI 10.1016/S0969-2126(03)00155-2; JOHNSON MS, 1990, J MOL EVOL, V30, P43, DOI 10.1007/BF02102452; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; MCADAM ME, 1977, BIOCHEM J, V167, P271, DOI 10.1042/bj1670271; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Ogihara NL, 1996, BIOCHEMISTRY-US, V35, P2316, DOI 10.1021/bi951930b; ONEILL P, 1988, BIOCHEM J, V251, P41, DOI 10.1042/bj2510041; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PANTOLIANO MW, 1982, J AM CHEM SOC, V104, P1717, DOI 10.1021/ja00370a045; PANTOLIANO MW, 1982, J INORG BIOCHEM, V17, P325, DOI 10.1016/S0162-0134(00)80093-8; PANTOLIANO MW, 1982, J AM CHEM SOC, V104, P6310, DOI 10.1021/ja00387a027; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pesce A, 2000, J MOL BIOL, V302, P465, DOI 10.1006/jmbi.2000.4074; Piddington DL, 2001, INFECT IMMUN, V69, P4980, DOI 10.1128/IAI.69.8.4980-4987.2001; Polticelli F, 1998, PROTEIN SCI, V7, P2354, DOI 10.1002/pro.5560071112; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; Sasin JM, 2003, BIOINFORMATICS, V19, pi252, DOI 10.1093/bioinformatics/btg1035; Shi LB, 2003, P NATL ACAD SCI USA, V100, P241, DOI 10.1073/pnas.0136863100; Stroppolo ME, 1998, BIOCHEMISTRY-US, V37, P12287, DOI 10.1021/bi980563b; Stroppolo ME, 1998, BIOCHEM BIOPH RES CO, V249, P579, DOI 10.1006/bbrc.1998.9199; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VALENTINE JS, 1979, P NATL ACAD SCI USA, V76, P4245, DOI 10.1073/pnas.76.9.4245; Zahrt TC, 2003, MICROBES INFECT, V5, P159, DOI 10.1016/S1286-4579(02)00083-7	59	71	73	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33447	33455		10.1074/jbc.M404699200	http://dx.doi.org/10.1074/jbc.M404699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155722	hybrid			2022-12-27	WOS:000223039700053
J	Boudsocq, F; Kokoska, RJ; Plosky, BS; Vaisman, A; Ling, H; Kunkel, TA; Yang, W; Woodgate, R				Boudsocq, F; Kokoska, RJ; Plosky, BS; Vaisman, A; Ling, H; Kunkel, TA; Yang, W; Woodgate, R			Investigating the role of the little finger domain of Y-family DNA polymerases in low fidelity synthesis and translesion replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SOLFATARICUS P2; SYN THYMINE DIMER; LESION-BYPASS; ERROR-PRONE; CRYSTAL-STRUCTURE; XERODERMA-PIGMENTOSUM; ADAPTIVE MUTATION; ESCHERICHIA-COLI; GENE ENCODES; ETA	Dpo4 and Dbh are Y-family polymerases that originate from two closely related strains of Sulfolobaceae. Quite surprisingly, however, the two polymerases exhibit different enzymatic properties in vitro. For example, Dpo4 can replicate past a variety of DNA lesions, yet Dbh does so with a much lower efficiency. When replicating undamaged DNA, Dpo4 is prone to make base pair substitutions, whereas Dbh predominantly makes single-base deletions. Overall, the two proteins are 54% identical, but the greatest divergence is found in their respective little finger (LF) domains, which are only 41% identical. To investigate the role of the LF domain in the fidelity and lesion-bypassing abilities of Y-family polymerases, we have generated chimeras of Dpo4 and Dbh in which their LF domains have been interchanged. Interestingly, by replacing the LF domain of Dbh with that of Dpo4, the enzymatic properties of the chimeric enzyme are more Dpo4-like in that the enzyme is more processive, can bypass an abasic site and a thymine-thymine cyclobutane pyrimidine dimer, and predominantly makes base pair substitutions when replicating undamaged DNA. The converse is true for the Dpo4-LF-Dbh chimera, which is more Dbh-like in its processivity and ability to bypass DNA adducts and generate single-base deletion errors. Our studies indicate that the unique but variable LF domain of Y-family polymerases plays a major role in determining the enzymatic and biological properties of each individual Y-family member.	NICHD, Sect DNA Replicat Repair & Mutagenesis, Lab Genom Integr, NIH, Bethesda, MD 20892 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Woodgate, R (corresponding author), NICHD, Sect DNA Replicat Repair & Mutagenesis, Lab Genom Integr, NIH, Bethesda, MD 20892 USA.	woodgate@nih.gov	Yang, Wei/ABB-4785-2020; Vaisman, Alexandra/C-3766-2013; Ling, Hong/E-3729-2010; Yang, Wei/D-4926-2011; Kunkel, Thomas A./D-5088-2019	Yang, Wei/0000-0002-3591-2195; Vaisman, Alexandra/0000-0002-2521-1467; Yang, Wei/0000-0002-3591-2195; Kunkel, Thomas A./0000-0002-9900-1788; Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK036119, Z01DK036119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070, ZIAES065070] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Glick E, 2001, EMBO J, V20, P7303, DOI 10.1093/emboj/20.24.7303; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gruz P, 2001, J BIOL CHEM, V276, P47394, DOI 10.1074/jbc.M107213200; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McCulloch SD, 2004, NATURE, V428, P97, DOI 10.1038/nature02352; McDonald JP, 1998, P NATL ACAD SCI USA, V95, P1478, DOI 10.1073/pnas.95.4.1478; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohashi E, 2000, GENE DEV, V14, P1589; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Potapova O, 2002, J BIOL CHEM, V277, P28157, DOI 10.1074/jbc.M202607200; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tompkins JD, 2003, J BACTERIOL, V185, P3469, DOI 10.1128/JB.185.11.3469-3472.2003; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Yeiser B, 2002, P NATL ACAD SCI USA, V99, P8737, DOI 10.1073/pnas.092269199; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	35	109	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32932	32940		10.1074/jbc.M405249200	http://dx.doi.org/10.1074/jbc.M405249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155753	hybrid			2022-12-27	WOS:000222849700113
J	Hsu, JM; Lee, YCG; Yu, CTR; Huang, CYF				Hsu, JM; Lee, YCG; Yu, CTR; Huang, CYF			Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; CELL-CYCLE; F-BOX; MULTISITE PHOSPHORYLATION; HIF-ALPHA; IDENTIFICATION; KINASE; FAMILY; DEGRADATION; EXPRESSION	F-box proteins, components of SCF ubiquitin-ligase complexes, are believed to be responsible for substrate recognition and recruitment in SCF-mediated proteolysis. F-box proteins that have been identified to function in the SCF complexes to date mostly have substrate-binding motifs, such as WD repeats or leucine-rich repeats in their C termini. However, many F-box proteins lack recognizable substrate-binding modules; whether they can function in the SCF complexes remains unclear. We show here that Fbx7, an F-box protein without WD repeats and leucine-rich repeats, is required for the proteasome-mediated proteolysis of the hepatoma upregulated protein (HURP). Depletion of Fbx7 by small interfering RNA leads to depression of HURP ubiquitination and accumulation of HURP abundance. In the SCFFbx7 complex, Fbx7 recruits HURP through its C-terminal proline-rich region in a Cdk1-cyclin B-phosphorylation dependent manner. Mutation of the multiple Cdk1-cyclin B phosphorylation sites on HURP or the proline-rich region of Fbx7 abolishes the association between Fbx7 and HURP. Thus, Fbx7 is a functional adaptor of the SCF complex with a proline-rich region as the substrate-binding module. In addition to Fbx7, data base analyses reveal two putative mammalian proline-rich region-containing F-box proteins, KIAA1783 and RIKEN cDNA 2410015K21. Taken together, these findings further expound the diverse substrate-recognition abilities of the SCF complexes.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Taipei Med Univ, Grad Inst Med Informat, Taipei 110, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Natl Taiwan Univ, Dept Comp Sci & Informat Engn, Taipei 106, Taiwan	National Health Research Institutes - Taiwan; Taipei Medical University; National Yang Ming Chiao Tung University; National Taiwan University	Huang, CYF (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	chiying@nhri.org.tw	Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bassal S, 2001, GENOMICS, V77, P5, DOI 10.1006/geno.2001.6570; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chiu AW, 2002, UROLOGY, V60, P181, DOI 10.1016/S0090-4295(02)01672-2; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Deng MQ, 2000, BIOL REPROD, V62, P873, DOI 10.1095/biolreprod62.4.873; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 2001, CELL, V107, P819, DOI 10.1016/S0092-8674(01)00620-1; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; Ferrell JE, 2001, NATURE, V414, P498, DOI 10.1038/35107180; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang YL, 2003, ANTICANCER RES, V23, P2729; Ilyin GP, 2000, GENOMICS, V67, P40, DOI 10.1006/geno.2000.6211; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Ke PY, 2003, BIOCHEM J, V370, P265, DOI 10.1042/BJ20021335; Kim J, 2002, J BIOL CHEM, V277, P24530, DOI 10.1074/jbc.M201612200; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Malecz N, 1996, J BIOL CHEM, V271, P8203, DOI 10.1074/jbc.271.14.8203; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Thom G, 2003, BIOCHEM J, V370, P91, DOI 10.1042/BJ20021462; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; Tsou AP, 2003, ONCOGENE, V22, P298, DOI 10.1038/sj.onc.1206129; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yoshida Y, 2003, J BIOL CHEM, V278, P43877, DOI 10.1074/jbc.M304157200; ZARRINPAR A, 2003, SCI STKE; Zhao J, 2000, J CELL SCI, V113, P4363; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	47	88	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32592	32602		10.1074/jbc.M404950200	http://dx.doi.org/10.1074/jbc.M404950200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145941	hybrid			2022-12-27	WOS:000222849700076
J	Atshaves, BP; McIntosh, AM; Lyuksyutova, OI; Zipfel, W; Webb, WW; Schroeder, F				Atshaves, BP; McIntosh, AM; Lyuksyutova, OI; Zipfel, W; Webb, WW; Schroeder, F			Liver fatty acid-binding protein gene ablation inhibits branched-chain fatty acid metabolism in cultured primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; NBD-STEARATE UPTAKE; PHYTANIC ACID; RAT-LIVER; PEROXISOME PROLIFERATORS; CYTOPLASMIC DIFFUSION; LIPID-COMPOSITION; MICE LACKING; PPAR-ALPHA; L-FABP	Whereas the role of liver fatty acid-binding protein (L-FABP) in the uptake, transport, mitochondrial oxidation, and esterification of normal straight-chain fatty acids has been studied extensively, almost nothing is known regarding the function of L-FABP in peroxisomal oxidation and metabolism of branched-chain fatty acids. Therefore, phytanic acid ( most common dietary branched-chain fatty acid) was chosen to address these issues in cultured primary hepatocytes isolated from livers of L-FABP gene- ablated (-/-) and wild type (+/+) mice. These studies provided three new insights: First, L-FABP gene ablation reduced maximal, but not initial, uptake of phytanic acid 3.2-fold. Initial uptake of phytanic acid uptake was unaltered apparently due to concomitant 5.3-, 1.6-, and 1.4-fold up-regulation of plasma membrane fatty acid transporter/translocase proteins ( glutamic-oxaloacetic transaminase, fatty acid transport protein, and fatty acid translocase, respectively). Second, L-FABP gene ablation inhibited phytanic acid peroxisomal oxidation and microsomal esterification. These effects were consistent with reduced cytoplasmic fatty acid transport as evidenced by multiphoton fluorescence photobleaching recovery, where L-FABP gene ablation reduced the cytoplasmic, but not membrane, diffusional component of NBD-stearic acid movement 2-fold. Third, lipid analysis of the L-FABP gene- ablated hepatocytes revealed an altered fatty acid phenotype. Free fatty acid and triglyceride levels were decreased 1.9- and 1.6-fold, respectively. In summary, results with cultured primary hepatocytes isolated from L-FABP (+/+) and L- FABP (-/-) mice demonstrated for the first time a physiological role of L- FABP in the uptake and metabolism of branched-chain fatty acids.	Texas A&M Univ, Dept Physiol & Pharmacol, TVMC, College Stn, TX 77843 USA; Cornell Univ, Dept Appl & Engn Phys, Ithaca, NY 14853 USA	Texas A&M University System; Texas A&M University College Station; Cornell University	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, TVMC, College Stn, TX 77843 USA.	Fschroeder@cvm.tamu.edu	Webb, Watt W./B-5905-2011; Zipfel, Warren/B-4059-2016	Zipfel, Warren/0000-0003-2640-329X	NIDDK NIH HHS [DK41402] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atshaves BP, 2004, MOL CELL BIOCHEM, V259, P115, DOI 10.1023/B:MCBI.0000021357.97765.f2; Atshaves BP, 1999, J LIPID RES, V40, P610; Atshaves BP, 2003, J LIPID RES, V44, P1751, DOI 10.1194/jlr.M300141-JLR200; Atshaves BP, 2002, AM J PHYSIOL-CELL PH, V283, pC688, DOI 10.1152/ajpcell.00586.2001; Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; Atshaves BP, 1998, AM J PHYSIOL-CELL PH, V274, pC633, DOI 10.1152/ajpcell.1998.274.3.C633; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown EB, 1999, BIOPHYS J, V77, P2837, DOI 10.1016/S0006-3495(99)77115-8; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; Erol E, 2003, FASEB J, V17, P347, DOI 10.1096/fj.03-0330fje; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; GLATZ JFC, 1995, PROSTAG LEUKOTR ESS, V52, P121, DOI 10.1016/0952-3278(95)90010-1; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; Heyliger CE, 1996, MOL CELL BIOCHEM, V155, P113; Heyliger CE, 1997, MOL CELL BIOCHEM, V176, P281, DOI 10.1023/A:1006817632484; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Huang H, 2004, BIOCHEMISTRY-US, V43, P2484, DOI 10.1021/bi0352318; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; LUXON BA, 1993, AM J PHYSIOL, V265, pG831, DOI 10.1152/ajpgi.1993.265.5.G831; Martin GG, 2003, BIOCHEMISTRY-US, V42, P11520, DOI 10.1021/bi0346749; Martin GG, 2003, J BIOL CHEM, V278, P21429, DOI 10.1074/jbc.M300287200; MARZO A, 1971, CLIN CHEM, V17, P145; McArthur MJ, 1999, J LIPID RES, V40, P1371; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Milliano MT, 2001, HEPATOLOGY, V33, P413, DOI 10.1053/jhep.2001.21999; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG237, DOI 10.1152/ajpgi.1998.275.2.G237; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; PAHAN K, 1995, J LIPID RES, V36, P986; Paulussen R J, 1990, Subcell Biochem, V16, P175; REUBSAET FAG, 1990, FEBS LETT, V267, P229, DOI 10.1016/0014-5793(90)80931-8; Richieri GV, 2000, BIOCHEMISTRY-US, V39, P7197, DOI 10.1021/bi000314z; Schaffer JE, 1995, TRENDS CARDIOVAS MED, V5, P218, DOI 10.1016/1050-1738(95)00102-6; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; Schroeder F, 2001, MOL CELL BIOCHEM, V219, P127, DOI 10.1023/A:1010851130136; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SPENER F, 1989, FEBS LETT, V244, P1, DOI 10.1016/0014-5793(89)81149-4; Steinberg D, 1990, METABOLIC BASIS INHE, P1533; Steinberg D., 1983, METABOLIC BASIS INHE, P731; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Thigpen JE, 1999, ENVIRON HEALTH PERSP, V107, pA182, DOI 10.2307/3434577; Thigpen JE, 1999, LAB ANIM SCI, V49, P530; VEERKAMP JH, 1993, MOL CELL BIOCHEM, V123, P101, DOI 10.1007/BF01076480; Verhoeven NM, 1998, J INHERIT METAB DIS, V21, P697, DOI 10.1023/A:1005476631419; Wahli W, 1999, ADV EXP MED BIOL, V447, P199; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2; Weisiger RA, 1996, COMP BIOCHEM PHYS B, V115, P319, DOI 10.1016/S0305-0491(96)00179-4; Weisiger RA, 1996, HEPATOLOGY, V24, P1288; White AL, 1997, CLIN GENET, V52, P326; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 2000, BIOCHEMISTRY-US, V39, P1469, DOI 10.1021/bi991638u; Wolfrum C, 1999, J LIPID RES, V40, P708; WOODFORD JK, 1993, BIOCHIM BIOPHYS ACTA, V1145, P257, DOI 10.1016/0005-2736(93)90297-D; ZENGERHAIN J, 1992, PROG CLIN BIOL RES, V375, P399	67	84	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30954	30965		10.1074/jbc.M313571200	http://dx.doi.org/10.1074/jbc.M313571200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155724	hybrid			2022-12-27	WOS:000222726800008
J	Cho, YS; Chennathukuzhi, VM; Handel, MA; Eppig, J; Hecht, NB				Cho, YS; Chennathukuzhi, VM; Handel, MA; Eppig, J; Hecht, NB			The relative levels of translin-associated factor X (TRAX) and testis brain RNA-binding protein determine their nucleocytoplasmic distribution in male germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; TB-RBP; MESSENGER-RNAS; CHROMOSOMAL TRANSLOCATIONS; INTERCELLULAR BRIDGES; GENE-EXPRESSION; DNA ENDS; SPERMATOGENESIS; RECOMBINATION; CYTOPLASM	Testis brain RNA-binding protein (TB-RBP), the mouse orthologue of human translin, is an RNA and single-stranded DNA-binding protein abundant in testis and brain. Translin-associated factor X ( TRAX) was identified as a protein that interacts with TB-RBP and is dependent upon TB-RBP for stabilization. Using immunohistochemistry to investigate the subcellular locations of TB-RBP and TRAX during spermatogenesis, both proteins localize in nuclei in meiotic pachytene spermatocytes and in the cytoplasm of subsequent meiotic and post-meiotic cells. An identical subcellular distribution is seen in female germ cells. Western blot analysis of germ cell protein extracts reveals an increased ratio of TRAX to TB-RBP in meiotic pachytene spermatocytes compared with the post-meiotic round and elongated spermatids. Using COS-1 cells and mouse embryonic fibroblasts derived from TB-RBP null mice as model systems to examine the shuttling of TB-RBP and TRAX, we demonstrate that TRAX contains a functional nuclear localization signal and TB-RBP contains a functional nuclear export signal. Coexpression of both proteins in COS-1 cells and TB-RBP-deficient mouse embryonic fibroblasts reveals that the ratio of TRAX to TB-RBP determines their subcellular locations, i.e. increased TRAX to TB-RBP ratios lead to nuclear localizations, whereas TRAX remains in the cytoplasm when TB-RBP levels are elevated. These subcellular distributions require interaction between TB-RBP and TRAX. We propose that the subcellular locations of TB-RBP and TRAX in male germ cells are modulated by the relative ratios of TRAX and TB-RBP.	Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University of Pennsylvania; Pennsylvania Medicine; Jackson Laboratory	Hecht, NB (corresponding author), Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, 1310 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	nhecht@mail.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD033816] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063593] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 33816, HD 28832] Funding Source: Medline; NIGMS NIH HHS [GM63593] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki K, 1999, FEBS LETT, V443, P363, DOI 10.1016/S0014-5793(99)00010-1; Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Braun RE, 2000, INT J ANDROL, V23, P92, DOI 10.1046/j.1365-2605.2000.00027.x; Chennathukuzhi V, 2003, P NATL ACAD SCI USA, V100, P15566, DOI 10.1073/pnas.2536695100; Chennathukuzhi V, 2003, MOL CELL BIOL, V23, P6419, DOI 10.1128/MCB.23.18.6419-6434.2003; Chennathukuzhi VM, 2001, J BIOL CHEM, V276, P13256, DOI 10.1074/jbc.M009707200; Eddy EM, 2002, RECENT PROG HORM RES, V57, P103, DOI 10.1210/rp.57.1.103; Erdemir T, 2002, MOL MICROBIOL, V46, P947, DOI 10.1046/j.1365-2958.2002.03224.x; Erdemir T, 2002, J CELL SCI, V115, P207; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Finkenstadt PM, 2000, J NEUROCHEM, V75, P1754, DOI 10.1046/j.1471-4159.2000.0751754.x; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; Gasca S, 2002, P NATL ACAD SCI USA, V99, P11199, DOI 10.1073/pnas.172383099; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gu W, 1998, MOL REPROD DEV, V49, P219, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;219::AID-MRD1&gt;3.0.CO;2-R; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Han MK, 2002, BIOCHEMISTRY-US, V41, P3468, DOI 10.1021/bi015901e; Harley VR, 2003, P NATL ACAD SCI USA, V100, P7045, DOI 10.1073/pnas.1137864100; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Ishida R, 2002, FEBS LETT, V525, P105, DOI 10.1016/S0014-5793(02)03095-8; Kasai M, 1997, J BIOL CHEM, V272, P11402; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Lee SP, 2001, BIOCHEMISTRY-US, V40, P14081, DOI 10.1021/bi010302t; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MACARA IG, 2001, MOL BIOL REV, V65, P1; Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Morales CR, 1998, DEV BIOL, V201, P113, DOI 10.1006/dbio.1998.8967; Morales CR, 2002, DEV BIOL, V246, P480, DOI 10.1006/dbio.2002.0679; Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Sengupta K, 2002, BIOCHEMISTRY-US, V41, P15315, DOI 10.1021/bi026378m; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Travis AJ, 1998, MOL BIOL CELL, V9, P263, DOI 10.1091/mbc.9.2.263; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; VanLoock MS, 2001, J STRUCT BIOL, V135, P58, DOI 10.1006/jsbi.2001.4383; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vera Y, 2002, J ANDROL, V23, P622; Wu XQ, 1999, BIOCHEMISTRY-US, V38, P11261, DOI 10.1021/bi990573s; Wu XQ, 2000, BIOL REPROD, V62, P720, DOI 10.1095/biolreprod62.3.720; Wu XQ, 1998, NUCLEIC ACIDS RES, V26, P1675, DOI 10.1093/nar/26.7.1675; Wu XQ, 1997, P NATL ACAD SCI USA, V94, P5640, DOI 10.1073/pnas.94.11.5640; Yang SC, 2004, J BIOL CHEM, V279, P12605, DOI 10.1074/jbc.M313133200; Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200	54	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31514	31523		10.1074/jbc.M401442200	http://dx.doi.org/10.1074/jbc.M401442200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138261	hybrid			2022-12-27	WOS:000222726800074
J	Gu, D; Zhou, YZ; Kallhoff, V; Baban, B; Tanner, JJ; Becker, DF				Gu, D; Zhou, YZ; Kallhoff, V; Baban, B; Tanner, JJ; Becker, DF			Identification and characterization of the DNA-binding domain of the multifunctional PutA flavoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE DEHYDROGENASE DOMAIN; FLAVIN REDOX STATE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; CRYSTAL-STRUCTURE; ARC REPRESSOR; ALANINE SUBSTITUTIONS; MET REPRESSOR; MNT REPRESSOR; PLASMID RK2	The PutA flavoprotein from Escherichia coli is a transcriptional repressor and a bifunctional enzyme that regulates and catalyzes proline oxidation. PutA represses transcription of genes putA and putP by binding to the control DNA region of the put regulon. The objective of this study is to define and characterize the DNA binding domain of PutA. The DNA binding activity of PutA, a 1320 amino acid polypeptide, has been localized to N-terminal residues 1 - 261. After exploring a potential DNA-binding region and an N-terminal deletion mutant of PutA, residues 1 - 90 (PutA90) were determined to contain DNA binding activity and stabilize the dimeric structure of PutA. Cell-based transcriptional assays demonstrate that PutA90 functions as a transcriptional repressor in vivo. The dissociation constant of PutA90 with the put control DNA was estimated to be 110 nM, which is slightly higher than that of the PutA-DNA complex (K-d similar to 45 nM). Primary and secondary structure analysis of PutA90 suggested the presence of a ribbon-helix-helix DNA binding motif in residues 1 - 47. To test this prediction, we purified and characterized PutA47. PutA47 is shown to purify as an apparent dimer, to exhibit in vivo transcriptional activity, and to bind specifically to the put control DNA. In gel-mobility shift assays, PutA47 was observed to bind cooperatively to the put control DNA with an overall dissociation constant of 15 nM for the PutA47-DNA complex. Thus, N-terminal residues 1 - 47 are critical for DNA-binding and the dimeric structure of PutA. These results are consistent with the ribbon-helix-helix family of transcription factors.	Univ Nebraska, Dept Biochem, Beadle Ctr N258, Lincoln, NE 68588 USA; Univ Missouri, Dept Chem & Biochem, St Louis, MO 63121 USA; Univ Missouri, Dept Chem, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Nebraska System; University of Nebraska Lincoln; University of Missouri System; University of Missouri Saint Louis; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Becker, DF (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr N258, Lincoln, NE 68588 USA.	dbecker3@unl.edu		ZHOU, Yuzhen/0000-0003-3964-4359; Tanner, John/0000-0001-8314-113X	NCRR NIH HHS [P20 RR017675, P20-RR-01767502] Funding Source: Medline; NIGMS NIH HHS [R01 GM061068, GM65546, R01 GM065546, R01 GM065546-03, GM61068] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065546, R01GM061068] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON JLA, 1983, EUR J BIOCHEM, V134, P77, DOI 10.1111/j.1432-1033.1983.tb07533.x; Becker DF, 2001, BIOCHEMISTRY-US, V40, P4714, DOI 10.1021/bi0019491; Berggrun A, 2001, P NATL ACAD SCI USA, V98, P2301, DOI 10.1073/pnas.041612198; Brown BM, 1999, P NATL ACAD SCI USA, V96, P1983, DOI 10.1073/pnas.96.5.1983; BROWN ED, 1992, J BIOL CHEM, V267, P13086; BROWN ED, 1993, J BIOL CHEM, V268, P8972; CHEN CC, 1985, J MEMBRANE BIOL, V84, P157, DOI 10.1007/BF01872213; CHEN LM, 1991, J BACTERIOL, V173, P783, DOI 10.1128/jb.173.2.783-790.1991; Chivers PT, 1999, PROTEIN SCI, V8, P2494, DOI 10.1110/ps.8.11.2494; Chivers PT, 2000, J BIOL CHEM, V275, P19735, DOI 10.1074/jbc.M002232200; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; DESPICER PO, 1991, J BACTERIOL, V173, P211, DOI 10.1128/jb.173.1.211-219.1991; Golovanov AP, 2003, MOL MICROBIOL, V50, P1141, DOI 10.1046/j.1365-2958.2003.03750.x; Gomis-Ruth FX, 1998, EMBO J, V17, P7404, DOI 10.1093/emboj/17.24.7404; Lee YH, 2003, NAT STRUCT BIOL, V10, P109, DOI 10.1038/nsb885; LING MF, 1994, J MOL BIOL, V243, P950, DOI 10.1006/jmbi.1994.1696; MALOY SR, 1983, J BACTERIOL, V154, P561, DOI 10.1128/JB.154.2.561-568.1983; MENZEL R, 1981, J MOL BIOL, V148, P21, DOI 10.1016/0022-2836(81)90233-3; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; MILLA ME, 1995, BIOCHEMISTRY-US, V34, P3344, DOI 10.1021/bi00010a025; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; MuroPastor AM, 1997, J BACTERIOL, V179, P2788, DOI 10.1128/jb.179.8.2788-2791.1997; Nooren IMA, 1999, NAT STRUCT BIOL, V6, P755; Oberer M, 2002, BIOCHEM J, V361, P41, DOI 10.1042/0264-6021:3610041; OSTROVSKY PC, 1995, GENE DEV, V9, P2034, DOI 10.1101/gad.9.16.2034; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROBERTS RC, 1993, J BIOL CHEM, V268, P27109; Schreiter ER, 2003, NAT STRUCT BIOL, V10, P794, DOI 10.1038/nsb985; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Soto MJ, 2000, J BACTERIOL, V182, P1935, DOI 10.1128/JB.182.7.1935-1941.2000; Straub PF, 1996, APPL ENVIRON MICROB, V62, P221, DOI 10.1128/AEM.62.1.221-229.1996; SUZUKI M, 1995, PROTEIN ENG, V8, P1, DOI 10.1093/protein/8.1.1; Vilchez S, 2000, APPL ENVIRON MICROB, V66, P5221, DOI 10.1128/AEM.66.12.5221-5225.2000; Vinod MP, 2002, BIOCHEMISTRY-US, V41, P6525, DOI 10.1021/bi025706f; WOOD JM, 1981, J BACTERIOL, V146, P895, DOI 10.1128/JB.146.3.895-901.1981; Zhu WD, 2003, BIOCHEMISTRY-US, V42, P5469, DOI 10.1021/bi0272196; Zhu WD, 2002, ARCH BIOCHEM BIOPHYS, V408, P131, DOI 10.1016/S0003-9861(02)00535-0	39	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31171	31176		10.1074/jbc.M403701200	http://dx.doi.org/10.1074/jbc.M403701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155740	Green Accepted, hybrid			2022-12-27	WOS:000222726800034
J	Hsiao, YS; Jogl, G; Tong, L				Hsiao, YS; Jogl, G; Tong, L			Structural and biochemical studies of the substrate selectivity of carnitine acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINED MOLECULAR REPLACEMENT; PALMITOYLTRANSFERASE; MACROMOLECULES; ENZYMOLOGY; TRANSPORT; SYSTEM; MODELS	Carnitine acyltransferases catalyze the exchange of acyl groups between coenzyme A (CoA) and carnitine. They have important roles in many cellular processes, especially the oxidation of long-chain fatty acids, and are attractive targets for drug discovery against diabetes and obesity. These enzymes are classified based on their substrate selectivity for short-chain, medium-chain, or long-chain fatty acids. Structural information on carnitine acetyltransferase suggests that residues Met-564 and Phe-565 may be important determinants of substrate selectivity with the side chain of Met-564 located in the putative binding pocket for acyl groups. Both residues are replaced by glycine in carnitine palmitoyltransferases. To assess the functional relevance of this structural observation, we have replaced these two residues with small amino acids by mutagenesis, characterized the substrate preference of the mutants, and determined the crystal structures of two of these mutants. Kinetic studies confirm that the M564G or M564A mutation is sufficient to increase the activity of the enzyme toward medium-chain substrates with hexanoyl-CoA being the preferred substrate for the M564G mutant. The crystal structures of the M564G mutant, both alone and in complex with carnitine, reveal a deep binding pocket that can accommodate the larger acyl group. We have determined the crystal structure of the F565A mutant in a ternary complex with both the carnitine and CoA substrates at a 1.8-Angstrom resolution. The F565A mutation has minor effects on the structure or the substrate preference of the enzyme.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	tong@como.bio.columbia.edu	Jogl, Gerwald/AAJ-5783-2021	Jogl, Gerwald/0000-0002-5465-5315; Tong, Liang/0000-0002-0563-6468	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067238] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK67238] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COLUCCI WJ, 1988, BIOORG CHEM, V16, P307, DOI 10.1016/0045-2068(88)90018-1; Dall'Acqua W, 2000, PROTEIN SCI, V9, P1; Evans AM, 2003, CLIN PHARMACOKINET, V42, P941, DOI 10.2165/00003088-200342110-00002; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lenhard JM, 2002, ADV DRUG DELIVER REV, V54, P1199, DOI 10.1016/S0169-409X(02)00092-3; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramsay RR, 2003, TRENDS BIOCHEM SCI, V28, P343, DOI 10.1016/S0968-0004(03)00137-3; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; RAMSAY RR, 1987, BIOCHEM J, V244, P271, DOI 10.1042/bj2440271; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X	20	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31584	31589		10.1074/jbc.M403484200	http://dx.doi.org/10.1074/jbc.M403484200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155726	hybrid			2022-12-27	WOS:000222726800081
J	Huang, YM; Chen, SU; Goodman, SD; Wu, SH; Kao, JT; Lee, CN; Cheng, WC; Tsai, KS; Fang, WH				Huang, YM; Chen, SU; Goodman, SD; Wu, SH; Kao, JT; Lee, CN; Cheng, WC; Tsai, KS; Fang, WH			Interaction of nick-directed DNA mismatch repair and loop repair in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NUCLEAR EXTRACTS; SINGLE-STRANDED LOOPS; MAMMALIAN-CELLS; ESCHERICHIA-COLI; HETERODUPLEX DNA; SACCHAROMYCES-CEREVISIAE; REPLICATION FIDELITY; RECOMBINATION; INSTABILITY; CLEAVAGE	In human cells, large DNA loop heterologies are repaired through a nick-directed pathway independent of mismatch repair. However, a 3'-nick generated by bacteriophage fd gene II protein heterology is not capable of stimulating loop repair. To evaluate the possibility that a mismatch near a loop could induce both repair types in human cell extracts, we constructed and tested a set of DNA heteroduplexes, each of which contains a combination of mismatches and loops. We have demonstrated that a strand break generated by restriction endonucleases 3' to a large loop is capable of provoking and directing loop repair. The repair of 3'-heteroduplexes in human cell extracts is very similar to that of 5'-heteroduplex repair, being strand-specific and highly biased to the nicked strand. This observation suggests that the loop repair pathway possesses bidirectional repair capability similar to that of the bacterial loop repair system. We also found that a nick 5' to a coincident mismatch and loop can apparently stimulate the repair of both. In contrast, 3'-nick-directed repair of a G-G mismatch was reduced when in the vicinity of a loop (33 or 46 bp between two sites). Increasing the distance separating the G-G mismatch and loop by 325 bp restored the efficiency of repair to the level of a single base-base mismatch. This observation suggests interference between 3'-nick-directed large loop repair and conventional mismatch repair systems when a mispair is near a loop. We propose a model in which DNA repair systems avoid simultaneous repair at adjacent sites to avoid the creation of double-stranded DNA breaks.	Natl Taiwan Univ, Coll Med, Sch Med Technol, Taipei 10063, Taiwan; Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei 10063, Taiwan; Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 10063, Taiwan; Univ So Calif, Sch Dent, Div Diagnost Sci, Los Angeles, CA 90089 USA	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; University of Southern California	Fang, WH (corresponding author), Natl Taiwan Univ, Coll Med, Sch Med Technol, 7 Chung Shan S Rd, Taipei 10063, Taiwan.	whfang@ha.mc.ntu.edu.tw	Goodman, Steven/C-5732-2013	Wu, Shang-Hsin/0000-0002-6204-7950; KAO, JAU-TSUEN/0000-0003-1918-0366; FANG, WOEI-HORNG/0000-0003-4728-5931; TSAI, KEH-SUNG/0000-0001-8528-1566; CHEN, SHEE-UAN/0000-0001-7592-3238				AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; Bill CA, 2001, MUTAT RES-DNA REPAIR, V485, P255, DOI 10.1016/S0921-8777(01)00065-9; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; Corrette-Bennett SE, 2001, NUCLEIC ACIDS RES, V29, P4134, DOI 10.1093/nar/29.20.4134; Corrette-Bennett SE, 1999, J BIOL CHEM, V274, P17605, DOI 10.1074/jbc.274.25.17605; Fang WH, 2003, J BIOL CHEM, V278, P22446, DOI 10.1074/jbc.M302585200; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; FANG WH, 1993, COLD SPRING HARB SYM, V58, P597, DOI 10.1101/SQB.1993.058.01.066; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GREENSTEIN D, 1989, J BIOL CHEM, V264, P12627; HASTINGS PJ, 1988, GENETIC RECOMBINATIO, P397; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; McCulloch SD, 2003, J BIOL CHEM, V278, P50803, DOI 10.1074/jbc.M309025200; McCulloch SD, 2003, J BIOL CHEM, V278, P3891, DOI 10.1074/jbc.M210687200; MESELSON M, 1988, RECOMBINATION GENETI, P91; MEYER TF, 1979, J BIOL CHEM, V254, P2642; MIRET JJ, 1993, J BIOL CHEM, V268, P3507; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SU SS, 1988, J BIOL CHEM, V263, P6829; Taghian DG, 1998, GENETICS, V148, P1257; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Wang HX, 2003, J BIOL CHEM, V278, P28686, DOI 10.1074/jbc.M302844200; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200; WEISS U, 1989, SOMAT CELL MOLEC GEN, V15, P13, DOI 10.1007/BF01534665; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619; Wierdl M, 1997, GENETICS, V146, P769	37	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30228	30235		10.1074/jbc.M401675200	http://dx.doi.org/10.1074/jbc.M401675200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15151992	hybrid			2022-12-27	WOS:000222531900046
J	Chaumont, S; Jiang, LH; Penna, A; North, RA; Rassendren, F				Chaumont, S; Jiang, LH; Penna, A; North, RA; Rassendren, F			Identification of a trafficking motif involved in the stabilization and polarization of P2X receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; CELL-SURFACE; ION-CHANNEL; MOLECULAR PHYSIOLOGY; ACTIN CYTOSKELETON; POTASSIUM CHANNEL; AMINO-ACIDS; C-TERMINUS; FILAMIN-A; SUBUNIT	Extracellular ATP-gated channels (P2X receptors) define the third major family of ionotropic receptors, and they are expressed widely in nerve cells, muscles, and endocrine and exocrine glands. P2X subunits have two membrane-spanning domains, and a receptor is thought to be formed by oligomerization of three subunits. We have identified a conserved motif in the cytoplasmic C termini of P2X subunits that is necessary for their surface expression; mutations in this motif result in a marked reduction of the receptors at the plasma membrane because of a rapid internalization. Transfer of the motif to a reporter protein (CD4) enhances the surface expression of the chimera, indicating that this motif is likely involved in the stabilization of P2X receptor at the cell surface. In neurons, mutated P2X(2) subunits showed reduced membrane expression and an altered axodendritic distribution. This motif is also present in intracellular regions of other membrane proteins, such as in the third intracellular loop of some G protein-coupled receptors, suggesting that it might be involve in their cellular stabilization and polarization.	CNRS, UPR2580, Lab Gen Fonct, Dept Pharmacol, F-34396 Montpellier, France; Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England	Centre National de la Recherche Scientifique (CNRS); University of Sheffield	Rassendren, F (corresponding author), CNRS, UPR2580, Lab Gen Fonct, Dept Pharmacol, 141 Rue Cardonille, F-34396 Montpellier, France.	far@igh.cnrs.fr	Jiang, Lin-Hua/D-2030-2010; Rassendren, Francois/AAA-6190-2021; penna, aubin/AAD-2550-2019; PENNA, aubin/E-2208-2018; North, Richard/GQA-6156-2022; Jiang, Lin-Hua/AAU-1078-2020	Jiang, Lin-Hua/0000-0001-6398-0411; penna, aubin/0000-0002-1070-5990; PENNA, aubin/0000-0002-1070-5990; Jiang, Lin-Hua/0000-0001-6398-0411; Rassendren, Francois/0000-0003-3320-2461; Chaumont-Dubel, Severine/0000-0001-6860-6891				Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; Denlinger LC, 2003, J IMMUNOL, V171, P1304, DOI 10.4049/jimmunol.171.3.1304; Egan TM, 1998, J NEUROSCI, V18, P2350; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jiang LH, 2001, J BIOL CHEM, V276, P14902, DOI 10.1074/jbc.M011327200; Jiang LH, 2003, J NEUROSCI, V23, P8903; Jones CA, 2004, MOL PHARMACOL, V65, P979, DOI 10.1124/mol.65.4.979; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Kucenas S, 2003, NEUROSCIENCE, V121, P935, DOI 10.1016/S0306-4522(03)00566-9; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Parker KE, 1998, J PHYSIOL-LONDON, V510, P19, DOI 10.1111/j.1469-7793.1998.019bz.x; Radford KM, 1997, J NEUROSCI, V17, P6529; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Sampson LJ, 2003, J BIOL CHEM, V278, P41988, DOI 10.1074/jbc.M307479200; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Smith FM, 1999, J PHYSIOL-LONDON, V520, P91, DOI 10.1111/j.1469-7793.1999.00091.x; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Toth-Zsamboki E, 2002, FEBS LETT, V524, P15, DOI 10.1016/S0014-5793(02)02987-3; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	39	73	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29628	29638		10.1074/jbc.M403940200	http://dx.doi.org/10.1074/jbc.M403940200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126501	hybrid, Green Submitted			2022-12-27	WOS:000222445300099
J	Ray, S; Lu, Y; Kaufmann, SH; Gustafson, WC; Karp, JE; Boldogh, I; Fields, AP; Brasier, AR				Ray, S; Lu, Y; Kaufmann, SH; Gustafson, WC; Karp, JE; Boldogh, I; Fields, AP; Brasier, AR			Genomic mechanisms of p210(BCR-ABL) signaling - Induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PROTEIN-KINASE-C; ABL-MEDIATED RESISTANCE; HEAT-SHOCK PROTEINS; TRANSCRIPTION FACTOR; CELL-DEATH; ACTIVATION; EXPRESSION; GENE; INHIBITION	Chronic myelogenous leukemia (CML) results from a t(9,22) translocation, producing the p210(BCR-ABL) oncoprotein, a tyrosine kinase that causes transformation and chemotherapy resistance. To further understand mechanisms mediating chemotherapy resistance, we identified 556 differentially regulated genes in HL-60 cells stably expressing p210(BCR-ABL) versus those expressing an empty vector using cDNA macro- and oligonucleotide microarrays. These BCR-ABL-regulated gene products play diverse roles in cellular function including apoptosis, cell cycle regulation, intracellular signaling, transcription, and cellular adhesion. In particular, we identified up-regulation of the inducible form of heat shock protein 70 (Hsp70), and further explored the mechanism for its up-regulation. In HL-60/BCR-ABL and K562 cells (expressing p210(BCR-ABL)), abundant cytoplasmic Hsp70 expression was detected by immunoblot analysis. Moreover, cells isolated from bone marrow aspirates of patients in different stages of CML (chronic, aggressive, and blast crisis) express Hsp70. Expression of p210(BCR-ABL) in BCR-ABL negative cells induced transcription of the proximal Hsp70 promoter. Mutational analysis mapped the major p210(BCR-ABL) responsive element to a high affinity 5'(A/T)GATA(A/G)-3' "GATA" response element (GATA-RE) that binds GATA-1 in CML cells. The GATA-RE was sufficient to confer p210(BCR-ABL)- and p185(BCR-ABL)-mediated trans-activation to an inert promoter. Short interfering RNA mediated "knockdown" of Hsp70 expression in K562 cells induced marked sensitivity to paclitaxel-induced apoptosis. Together these findings indicate that BCR-ABL confers chemotherapeutic resistance through intracellular signaling to the GATA-RE element found in the promoter region of the anti-apoptotic Hsp70 protein. We suggest that down-regulation of the GATA-Hsp70 pathway may be useful in the treatment of chemotherapy-resistant CML.	Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, Galveston, TX 77555 USA; Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Mayo Clin, Ctr Comprehens Canc, Jacksonville, FL 32224 USA	University of Texas System; University of Texas Medical Branch Galveston; Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Medical Branch Galveston; Mayo Clinic	Brasier, AR (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, MRB 8-138,301 Univ Blvd, Galveston, TX 77555 USA.	arbrasie@utmb.edu	Ray, Sutapa/D-3272-2012	Ray, Sutapa/0000-0003-4234-2124; Kaufmann, Scott/0000-0002-4900-7145; Brasier, Allan/0000-0002-5012-4090	NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040218, R44AI056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [CA56869] Funding Source: Medline; NIAID NIH HHS [R44 AI056869, AI40218] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; BRASIER AR, 1990, CURRENT PROTOCOLS MO; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DRUKER B, 1992, BLOOD, V79, P2215; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jena N, 2002, CANCER RES, V62, P535; KAUFMANN SH, 1991, CANCER RES, V51, P3534; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salesse S, 2003, MOL CANCER THER, V2, P173; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SIRARD C, 1994, BLOOD, V83, P1575; Snapyan M, 2003, PROTEOMICS, V3, P647, DOI 10.1002/pmic.200300390; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Van Etten RA, 2002, ONCOGENE, V21, P8643, DOI 10.1038/sj.onc.1206091; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Zhang YH, 2001, J VIROL, V75, P9044, DOI 10.1128/JVI.75.19.9044-9058.2001; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	60	50	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35604	35615		10.1074/jbc.M401851200	http://dx.doi.org/10.1074/jbc.M401851200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15155749	hybrid			2022-12-27	WOS:000223303400056
J	Forrest, ST; Barringhaus, KG; Perlegas, D; Hammarskjold, ML; McNamara, CA				Forrest, ST; Barringhaus, KG; Perlegas, D; Hammarskjold, ML; McNamara, CA			Intron retention generates a novel Id3 isoform that inhibits vascular lesion formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL-PROLIFERATION; ATHEROSCLEROTIC PLAQUE RUPTURE; ARTERIAL EXPRESSION; TYROSINE KINASE; GROWTH; PROTEINS; GENE; APOPTOSIS; INJURY; AUTOINHIBITOR	The expression of intron-containing messages has been shown to occur in a variety of diseases including lactic acidosis, Cowden Syndrome, and several cancers. However, it is unknown whether these intron-containing messages result in protein production in vivo. Indeed, intron-containing RNAs are typically retained in the nucleus, targeted for degradation, or are repressed translationally. Here, we show that during vascular lesion formation in rats, an alternative isoform of the helix-loop-helix transcription factor Id3 (Id3a) generated by intron retention is abundantly expressed. We demonstrate that Id3 is expressed early in lesion formation when the proliferative index of the neointima is highest and that Id3 promotes smooth muscle cell (SMC) proliferation and S-phase entry and inhibits transcription of the cell-cycle inhibitor p21(Cip1). Using an Id3a-specific antibody developed by our laboratory, we show that Id3a protein is induced during vascular lesion formation and that Id3a expression peaks late when the proliferative index is low or declining and extensive apoptosis is observed. Furthermore, Id3a fails to promote SMC growth and S-phase entry or to inhibit p21(Cip1) promoter transactivation. In contrast, Id3a stimulates SMC apoptosis and inhibits endogenous Id3 production. Adenoviral delivery of Id3a inhibited lesion formation in balloon-injured rat carotid arteries in vivo. These data describe a novel feedback loop whereby intron retention generates an Id3 isoform that acts to limit SMC growth during vascular lesion formation, providing the first evidence that regulated intron retention can modulate a pathologic process in vivo.	Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Myles H Thaler Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	McNamara, CA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA.	cam8c@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA097095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007355, T32HL007284, P01HL055798, R01HL062522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054335, R01AI034721] Funding Source: NIH RePORTER; NCI NIH HHS [CAA097095] Funding Source: Medline; NHLBI NIH HHS [T32HL007355, T32HL007284, P01 HL55798, R01 HL062522] Funding Source: Medline; NIAID NIH HHS [AI054335, AI34721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bennett MR, 1999, CARDIOVASC RES, V41, P361, DOI 10.1016/S0008-6363(98)00212-0; Braganza DM, 2001, POSTGRAD MED J, V77, P94, DOI 10.1136/pmj.77.904.94; CLOWES AW, 1983, LAB INVEST, V49, P327; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; DUBIN D, 1995, ARTERIOSCL THROM VAS, V15, P1958, DOI 10.1161/01.ATV.15.11.1958; Dytrych L, 1998, J BIOL CHEM, V273, P5794, DOI 10.1074/jbc.273.10.5794; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Goodison S, 1998, AM J PATHOL, V153, P1221, DOI 10.1016/S0002-9440(10)65666-0; HAN DKM, 1995, AM J PATHOL, V147, P267; HANKE H, 1990, CIRC RES, V67, P651, DOI 10.1161/01.RES.67.3.651; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jhabvala-Romero F, 2003, ONCOGENE, V22, P8178, DOI 10.1038/sj.onc.1206912; Justman QA, 2002, J BIOL CHEM, V277, P20618, DOI 10.1074/jbc.M111359200; Kantor B, 1999, Cardiovasc Radiat Med, V1, P48, DOI 10.1016/S1522-1865(98)00005-5; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; Matsumura ME, 2001, ARTERIOSCL THROM VAS, V21, P752, DOI 10.1161/01.ATV.21.5.752; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Mueller C, 2002, CIRCULATION, V105, P2423, DOI 10.1161/01.CIR.0000016047.19488.91; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Suzuki JI, 1997, NAT MED, V3, P900, DOI 10.1038/nm0897-900; Tsukamoto Y, 2001, AM J PATHOL, V158, P1685, DOI 10.1016/S0002-9440(10)64124-7; Wallner K, 2002, ATHEROSCLEROSIS, V161, P75, DOI 10.1016/S0021-9150(01)00627-X	27	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32897	32903		10.1074/jbc.M404882200	http://dx.doi.org/10.1074/jbc.M404882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159391	hybrid			2022-12-27	WOS:000222849700109
J	Takano, A; Isojima, Y; Nagai, K				Takano, A; Isojima, Y; Nagai, K			Identification of mPer1 phosphorylation sites responsible for the nuclear entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN-KINASE-I; DROSOPHILA CLOCK GENE; CKI-EPSILON; DOUBLE-TIME; PERIOD; PROTEINS; MUTATION; ENCODES; CLONING	Casein kinase 1 epsilon (CK1epsilon) is an essential component of the circadian clock in mammals and Drosophila. The phosphorylation of Period (Per) proteins by CK1epsilon is believed to be implicated in their subcellular localization and degradation, but the precise mechanism by which CK1epsilon affects Per proteins has not been determined. In this study, three putative CK1epsilon phosphorylation motif clusters in mouse Per1 (mPer1) were identified, and the phosphorylation status of serine and threonine residues in these clusters was examined. Phosphorylation of residues within a region defined by amino acids 653-663 and in particular of Ser-661 and Ser-663, was identified as responsible for the nuclear translocation of mPer1. Furthermore, phosphorylation of these residues may influence the nuclear translocation of a clock protein complex containing mPer1. These findings indicate that mPer1 phosphorylation is a critical aspect of the circadian clock mechanism.	Osaka Univ, Inst Prot Res, Div Prot Metab, Suita, Osaka 5650871, Japan	Osaka University	Takano, A (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Metab, 3-2 Yamada Oka, Suita, Osaka 5650871, Japan.	atsuko@protein.osaka-u.ac.jp						Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Harmer SL, 2001, ANNU REV CELL DEV BI, V17, P215, DOI 10.1146/annurev.cellbio.17.1.215; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee C, 2004, MOL CELL BIOL, V24, P584, DOI 10.1128/MCB.24.2.584-594.2004; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber EL, 2001, J BIOL CHEM, V276, P45921, DOI 10.1074/jbc.M107726200; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	27	61	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32578	32585		10.1074/jbc.M403433200	http://dx.doi.org/10.1074/jbc.M403433200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15148313	hybrid			2022-12-27	WOS:000222849700074
J	Barros, MH; Johnson, A; Tzagoloff, A				Barros, MH; Johnson, A; Tzagoloff, A			COX23, a homologue of COX17, is required for cytochrome oxidase assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER METALLOCHAPERONE COX17; SACCHAROMYCES-CEREVISIAE; C-OXIDASE; MITOCHONDRIAL-MEMBRANE; PROTEIN; PURIFICATION; EXPRESSION; VECTORS; STRAINS; SHUTTLE	Deletion of reading frame YHR116W of the Saccharomyces cerevisiae nuclear genome elicits a respiratory deficiency. The encoded product, here named Cox23p, is shown to be required for the expression of cytochrome oxidase. Cox23p is homologous to Cox17p, a water-soluble copper protein previously implicated in the maturation of the Cu-A center of cytochrome oxidase. The respiratory defect of a cox23 null mutant is rescued by high concentrations of copper in the medium but only when the mutant harbors COX17 on a high copy plasmid. Overexpression of Cox17p by itself is not a sufficient condition to rescue the mutant phenotype. Cox23p, like Cox17p, is detected in the intermembrane space of mitochondria and in the postmitochondrial supernatant fraction, the latter consisting predominantly of cytosolic proteins. Because Cox23p and Cox17p are not part of a complex, the requirement of both for cytochrome oxidase assembly suggests that they function in a common pathway with Cox17p acting downstream of Cox23p.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Estadual Paulista, Inst Biociencias Botucatu, Dept Genet, BR-18607741 Sao Paulo, Brazil	Columbia University; Instituto de Botanica - Sao Paulo; Universidade Estadual Paulista	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu	Barros, Mario H/B-8118-2012; Barros, Mario/Q-6358-2019	Barros, Mario/0000-0003-2977-9815	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050187, GM 50187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; Beinert H, 1997, EUR J BIOCHEM, V245, P521, DOI 10.1111/j.1432-1033.1997.t01-1-00521.x; Brachmann CB, 1998, YEAST, V14, P115; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Chinenov YV, 2000, J MOL MED, V78, P239, DOI 10.1007/s001090000110; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; Punter FA, 2003, J BIOL CHEM, V278, P30875, DOI 10.1074/jbc.M302358200; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9	29	69	70	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31943	31947		10.1074/jbc.M405014200	http://dx.doi.org/10.1074/jbc.M405014200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145942	hybrid			2022-12-27	WOS:000222726800122
J	Bluher, M; Patti, ME; Gesta, S; Kahn, BB; Kahn, CR				Bluher, M; Patti, ME; Gesta, S; Kahn, BB; Kahn, CR			Intrinsic heterogeneity in adipose tissue of fat-specific insulin receptor knock-out mice is associated with differences in patterns of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NECROSIS-FACTOR-ALPHA; SKELETAL-MUSCLE; DIABETIC MICE; TNF-ALPHA; OBESITY; METABOLISM; ADIPOGENESIS; RAT; DIFFERENTIATION	Mice with a fat-specific insulin receptor knock-out (FIRKO) have reduced adipose tissue mass, are protected against obesity, and have an extended life span. White adipose tissue of FIRKO mice is also characterized by a polarization into two major populations of adipocytes, one small (< 50 mu m) and one large (> 100 mum), which differ with regard to basal triglyceride synthesis and lipolysis, as well as in the expression of fatty acid synthase, sterol regulatory element-binding protein 1c, and CCAAT/enhancer-binding protein alpha (C/EBP-alpha). Gene expression analysis using RNA isolated from large and small adipocytes of FIRKO and control (IR lox/lox) mice was performed on oligonucleotide microarrays. Of the 12,488 genes/expressed sequence tags represented, 111 genes were expressed differentially in the four populations of adipocytes at the p < 0.001 level. These alterations exhibited 10 defined patterns and occurred in response to two distinct regulatory effects. 63 genes were identified as changed in expression depending primarily upon adipocyte size, including C/EBP-alpha, C/EBP-delta, superoxide dismutase 3, and the platelet-derived growth factor receptor. 48 genes were regulated primarily by impairment of insulin signaling, including transforming growth factor beta, interferon gamma, insulin-like growth factor I receptor, activating transcription factor 3, aldehyde dehydrogenase 2, and protein kinase C delta. These data suggest an intrinsic heterogeneity of adipocytes with differences in gene expression related to adipocyte size and insulin signaling.	Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrine, Diabet Unit, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Kahn, CR (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	c.ronald.kahn@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060837] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 60837, R01 DK043051, DK30136] Funding Source: Medline; PHS HHS [45935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Alessi MC, 2000, DIABETES, V49, P1374, DOI 10.2337/diabetes.49.8.1374; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Braiman L, 1999, MOL ENDOCRINOL, V13, P2002, DOI 10.1210/me.13.12.2002; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CUSHMAN SW, 1978, J LIPID RES, V19, P269; ETHERTON TD, 1977, J LIPID RES, V18, P552; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Joffe BI, 2001, LANCET, V357, P1379, DOI 10.1016/S0140-6736(00)04616-X; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; REBUFFESCRIVE M, 1989, METABOLISM, V38, P453, DOI 10.1016/0026-0495(89)90198-4; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tomlinson JW, 2001, ENDOCRINOLOGY, V142, P1982, DOI 10.1210/en.142.5.1982; TOZZO E, 1995, AM J PHYSIOL-ENDOC M, V268, pE956, DOI 10.1152/ajpendo.1995.268.5.E956; Tozzo E, 1997, ENDOCRINOLOGY, V138, P1604, DOI 10.1210/en.138.4.1604; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	31	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31891	31901		10.1074/jbc.M404569200	http://dx.doi.org/10.1074/jbc.M404569200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15131119	hybrid			2022-12-27	WOS:000222726800116
J	Froderberg, L; Houben, ENG; Baars, L; Luirink, J; de Gier, JW				Froderberg, L; Houben, ENG; Baars, L; Luirink, J; de Gier, JW			Targeting and translocation of two lipoproteins in Escherichia coli via the SRP/Sec/YidC pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; OUTER-MEMBRANE LIPOPROTEIN; TRIGGER FACTOR; PRESECRETORY PROTEINS; UBIQUINOL OXIDASE; 4.5S RNA; INSERTION; YIDC; GENE; SECY	In Escherichia coli, two main protein targeting pathways to the inner membrane exist: the SecB pathway for the essentially posttranslational targeting of secretory proteins and the SRP pathway for cotranslational targeting of inner membrane proteins (IMPs). At the inner membrane both pathways converge at the Sec translocase, which is capable of both linear transport into the periplasm and lateral transport into the lipid bilayer. The Sec-associated YidC appears to assist the lateral transport of IMPs from the Sec translocase into the lipid bilayer. It should be noted that targeting and translocation of only a handful of secretory proteins and IMPs have been studied. These model proteins do not include lipoproteins. Here, we have studied the targeting and translocation of two secretory lipoproteins, the murein lipoprotein and the bacteriocin release protein, using a combined in vivo and in vitro approach. The data indicate that both murein lipoprotein and bacteriocin release protein require the SRP pathway for efficient targeting to the Sec translocase. Furthermore, we show that YidC plays an important role in the targeting/translocation of both lipoproteins.	Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; BioCentrum Amsterdam, Dept Microbiol, NL-1081 HV Amsterdam, Netherlands	Stockholm University; University of Amsterdam	de Gier, JW (corresponding author), Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	degier@dbb.su.se	Luirink, Joen/AAB-8658-2021; Houben, Edith N.G./B-2110-2015	Houben, Edith N.G./0000-0002-8805-2002; Froderberg Roth, Linda/0000-0002-2684-3650; Luirink, J./0000-0001-8431-0804				Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bernstein KD, 2001, J BACTERIOL, V183, P2187, DOI 10.1128/JB.183.7.2187-2197.2001; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Drew D, 2003, BBA-BIOMEMBRANES, V1610, P3, DOI 10.1016/S0005-2736(02)00707-1; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; Hashemzadeh-Bonehi L, 1998, MOL MICROBIOL, V30, P676, DOI 10.1046/j.1365-2958.1998.01116.x; HAYASHI S, 1985, J BACTERIOL, V161, P949, DOI 10.1128/JB.161.3.949-954.1985; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LUIRINK J, 1991, MOL MICROBIOL, V5, P393, DOI 10.1111/j.1365-2958.1991.tb02121.x; Ma JX, 1997, BIOCHEMISTRY-US, V36, P11298, DOI 10.1021/bi9709710; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Moore M, 2003, J CELL BIOL, V162, P1245, DOI 10.1083/jcb.200307067; OUDEGA B, 1993, J BACTERIOL, V175, P1543, DOI 10.1128/JB.175.5.1543-1547.1993; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; PETERSON JH, 2003, J BIOL CHEM; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Schierle CF, 2003, J BACTERIOL, V185, P5706, DOI 10.1128/JB.185.19.5706-5713.2003; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Shu W, 2000, J MOL BIOL, V299, P1101, DOI 10.1006/jmbi.2000.3776; Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; SUGAI M, 1992, J BACTERIOL, V174, P2511, DOI 10.1128/jb.174.8.2511-2516.1992; TIAN GL, 1989, J BACTERIOL, V171, P1987, DOI 10.1128/jb.171.4.1987-1997.1989; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; VANDENELZEN PJM, 1983, NUCLEIC ACIDS RES, V11, P2465, DOI 10.1093/nar/11.8.2465; vanderWal FJ, 1995, FEMS MICROBIOL REV, V17, P381, DOI 10.1016/0168-6445(95)00022-4; WATANABE T, 1988, J BACTERIOL, V170, P4001, DOI 10.1128/jb.170.9.4001-4007.1988	56	42	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31026	31032		10.1074/jbc.M403229200	http://dx.doi.org/10.1074/jbc.M403229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140892	Green Published, hybrid			2022-12-27	WOS:000222726800016
J	Kato, Y; Nagata, K; Takahashi, M; Lian, LB; Herrero, JJ; Sudol, M; Tanokura, M				Kato, Y; Nagata, K; Takahashi, M; Lian, LB; Herrero, JJ; Sudol, M; Tanokura, M			Common mechanism of ligand recognition by group II/III WW domains - Redefining their functional classification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH LIGANDS; AMYLOID PRECURSOR PROTEIN; SURFACE-PLASMON RESONANCE; SH3 DOMAINS; STRUCTURAL BASIS; PEPTIDE LIGANDS; BINDING; SPECIFICITY; PROFILIN; COMPLEX	WW domain is a well known protein module that mediates protein to protein interactions by binding to proline-containing ligands. Based on the ligand predilections, the WW domains have been classified into four major groups. Group II and III WW domains have been reported to bind the proline-leucine and proline-arginine motifs, respectively. In the present study, using surface plasmon resonance technique we have shown that these WW domains have almost indistinguishable ligand preferences and kinetic properties. Hence, we propose that Group II and III WW domains should be joined together as one group ( Group II/III). Unlike Group I and IV WW domains, Group II/III WW domains can bind simple polyprolines as well as the proline-leucine and proline-arginine motifs, and they possess two Xaa-proline (where Xaa is any amino acid) binding grooves similar to SH3 domains. Our work assigns Group II and III WW domains to a larger family of polyproline-binding modules and proteins, which includes SH3 domains and profilin. Because polyprolines belong to the most frequently found peptide motifs in several genomes, our study implies the versatile importance of Group II/III WW domains in signaling.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; AxCell Biosci, Newtown, PA 18940 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	University of Tokyo; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tanokura, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amtanok@mail.ecc.u-tokyo.ac.jp		Tanokura, Masaru/0000-0001-5072-2480; Nagata, Koji/0000-0002-4704-0603	NIDDK NIH HHS [DK62345] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK062345] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aasland R, 2002, FEBS LETT, V513, P141, DOI 10.1016/S0014-5793(01)03295-1; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Creamer TP, 1998, PROTEINS, V33, P218, DOI 10.1002/(SICI)1097-0134(19981101)33:2<218::AID-PROT6>3.0.CO;2-E; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hu H, 2004, PROTEOMICS, V4, P643, DOI 10.1002/pmic.200300632; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kato Y, 2002, J BIOL CHEM, V277, P10173, DOI 10.1074/jbc.M110490200; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; Marinaro JA, 1999, FEBS LETT, V450, P240, DOI 10.1016/S0014-5793(99)00499-8; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Oda M, 1999, FEBS LETT, V454, P288, DOI 10.1016/S0014-5793(99)00833-9; Petrella EC, 1996, BIOCHEMISTRY-US, V35, P16535, DOI 10.1021/bi961498d; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V258, P385, DOI 10.1006/bbrc.1999.0639; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Xu GM, 2002, GENOMICS, V79, P87, DOI 10.1006/geno.2001.6684; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; ZARRINPAR A, 2003, SCI STKE, V179, P1	47	58	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31833	31841		10.1074/jbc.M404719200	http://dx.doi.org/10.1074/jbc.M404719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133021	hybrid			2022-12-27	WOS:000222726800110
J	Okubo, S; Hara, F; Tsuchida, Y; Shimotakahara, S; Suzuki, S; Hatanaka, H; Yokoyama, S; Tanaka, H; Yasuda, H; Shindo, H				Okubo, S; Hara, F; Tsuchida, Y; Shimotakahara, S; Suzuki, S; Hatanaka, H; Yokoyama, S; Tanaka, H; Yasuda, H; Shindo, H			NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its interaction with tumor suppressor p53 and A/T-rich DNA oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; JUNCTION RESOLVASE; CRYSTAL-STRUCTURE; NUCLEAR; RECEPTOR; FAMILY; ACTIVATION; ATTACHMENT; UBIQUITIN; PROGRAM	A member of the PIAS ( protein inhibitor of activated STAT) family of proteins, PIAS1, have been reported to serve as an E3-type SUMO ligase for tumor suppressor p53 and its own. It also was proposed that the N-terminal domain of PIAS1 interacts with DNA as well as p53. Extensive biochemical studies have been devoted recently to understand sumoylations and its biological implications, whereas the structural aspects of the PIAS family and the mechanism of its interactions with various factors are less well known to date. In this study, the three-dimensional structure of the N-terminal domain ( residues 1 - 65) of SUMO ligase PIAS1 was determined by NMR spectroscopy. The structure revealed a unique four-helix bundle with a topology of an up-down-extended loop-down-up, a part of which the helix-extended loop-helix represented the SAP (SAF-A/B, Acinus, and PIAS) motif. Thus, this N-terminal domain may be referred to as a four-helix SAP domain. The glutathione S-transferase pull-down assay demonstrated that this domain possesses a binding ability to tumor suppressor p53, a target protein for sumoylation by PIAS1, whereas gel mobility assays showed that it has a strong affinity toward A/T-rich DNA. An NMR analysis of the four-helix SAP domain complexed with the 16-bp-long DNA demonstrated that one end of the four-helix bundle is the binding site and may fit into the minor groove of DNA. The three-dimensional structure and its binding duality are discussed in conjunction with the biological functions of PIAS1 as a SUMO ligase.	Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan; RIKEN Genom Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; SPring 8, RIKEN Harima Inst, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1100033, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Shindo, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan.	shindo@ps.toyaku.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Ahn JS, 2003, J BIOL CHEM, V278, P29121, DOI 10.1074/jbc.M302314200; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Ceschini S, 2001, EMBO J, V20, P6601, DOI 10.1093/emboj/20.23.6601; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kracklauer Martin P, 2003, Mol Cancer, V2, P39, DOI 10.1186/1476-4598-2-39; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Zhang ZM, 2001, J BIOL CHEM, V276, P38231	43	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31455	31461		10.1074/jbc.M403561200	http://dx.doi.org/10.1074/jbc.M403561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133049	hybrid			2022-12-27	WOS:000222726800067
J	Pineda, AO; Carrell, CJ; Bush, LA; Prasad, S; Caccia, S; Chen, ZW; Mathews, FS; Di Cera, E				Pineda, AO; Carrell, CJ; Bush, LA; Prasad, S; Caccia, S; Chen, ZW; Mathews, FS; Di Cera, E			Molecular dissection of Na+ binding to thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN ALPHA-THROMBIN; MONOVALENT CATION SPECIFICITY; ACTIVE-SITE GEOMETRY; SERINE PROTEASES; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; CATALYTIC-ACTIVITY; STRUCTURAL BASIS; DIALKYLGLYCINE DECARBOXYLASE; ANTICOAGULANT ACTIVITY	Na+ binding near the primary specificity pocket of thrombin promotes the procoagulant, prothrombotic, and signaling functions of the enzyme. The effect is mediated allosterically by a communication between the Na+ site and regions involved in substrate recognition. Using a panel of 78 Ala mutants of thrombin, we have mapped the allosteric core of residues that are energetically linked to Na+ binding. These residues are Asp-189, Glu-217, Asp-222, and Tyr-225, all in close proximity to the bound Na+. Among these residues, Asp-189 shares with Asp-221 the important function of transducing Na+ binding into enhanced catalytic activity. None of the residues of exosite I, exosite II, or the 60-loop plays a significant role in Na+ binding and allosteric transduction. X-ray crystal structures of the Na+-free ( slow) and Na+-bound ( fast) forms of thrombin, free or bound to the active site inhibitor H-D-Phe-Pro-Arg-chloromethyl-ketone, document the conformational changes induced by Na+ binding. The slow 3 fast transition results in formation of the Arg-187:Asp-222 ion pair, optimal orientation of Asp-189 and Ser-195 for substrate binding, and a significant shift of the side chain of Glu-192 linked to a rearrangement of the network of water molecules that connect the bound Na+ to Ser-195 in the active site. The changes in the water network and the allosteric core explain the thermodynamic signatures linked to Na+ binding and the mechanism of thrombin activation by Na+. The role of the water network uncovered in this study establishes a new paradigm for the allosteric regulation of thrombin and other Na+-activated enzymes involved in blood coagulation and the immune response.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	enrico@biochem.wustl.edu	Caccia, Sonia/G-5938-2014	Caccia, Sonia/0000-0003-0829-5379	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R29HL049413, R01HL073813, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49413, HL58141, HL73813] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; Banner DW, 1997, THROMB HAEMOSTASIS, V78, P512; BARTUNIK HD, 1989, J MOL BIOL, V210, P813, DOI 10.1016/0022-2836(89)90110-1; Berg DT, 1996, SCIENCE, V273, P1389, DOI 10.1126/science.273.5280.1389; BODE W, 1992, PROTEIN SCI, V1, P426; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Carter WJ, 2004, J BIOL CHEM, V279, P26387, DOI 10.1074/jbc.M402364200; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; Colwell NS, 1998, BIOCHEMISTRY-US, V37, P15057, DOI 10.1021/bi980925f; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dang QD, 1997, J BIOL CHEM, V272, P19649, DOI 10.1074/jbc.272.32.19649; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DEGEN SJF, 1995, THROMB HAEMOSTASIS, V73, P203; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Frisch C, 2001, J MOL BIOL, V308, P69, DOI 10.1006/jmbi.2001.4577; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GELIN BR, 1983, J MOL BIOL, V171, P489, DOI 10.1016/0022-2836(83)90042-6; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Henriksen RA, 1998, BLOOD, V91, P2026, DOI 10.1182/blood.V91.6.2026.2026_2026_2031; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Krem MM, 1998, PROTEINS, V30, P34, DOI 10.1002/(SICI)1097-0134(19980101)30:1<34::AID-PROT3>3.0.CO;2-K; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; Krishnan R, 2000, ACTA CRYSTALLOGR D, V56, P406, DOI 10.1107/S0907444900001487; LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; LANDIS BH, 1981, J BIOL CHEM, V256, P4604; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIU LW, 1991, J BIOL CHEM, V266, P16977; Mann KG, 2003, CHEST, V124, p4S, DOI 10.1378/chest.124.3_suppl.4S; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; McGee M, 2003, ARTERIOSCL THROM VAS, V23, P1921, DOI 10.1161/01.ATV.0000090673.96120.67; MCGRATH ME, 1992, BIOCHEMISTRY-US, V31, P3059, DOI 10.1021/bi00127a005; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN WG, 1995, BIOCHEMISTRY-US, V34, P9277, DOI 10.1021/bi00029a001; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pletnev VZ, 2000, PROTEINS, V41, P8, DOI 10.1002/1097-0134(20001001)41:1<8::AID-PROT30>3.0.CO;2-2; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P1026, DOI 10.1021/bi9620823; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Sanschagrin PC, 1998, PROTEIN SCI, V7, P2054, DOI 10.1002/pro.5560071002; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Sichler K, 2002, J MOL BIOL, V322, P591, DOI 10.1016/S0022-2836(02)00747-7; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; TONEY MD, 1995, J MOL BIOL, V245, P151, DOI 10.1006/jmbi.1994.0014; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P8916, DOI 10.1073/pnas.92.19.8916; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Yu EW, 2001, P NATL ACAD SCI USA, V98, P9517, DOI 10.1073/pnas.161239298; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	101	159	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31842	31853		10.1074/jbc.M401756200	http://dx.doi.org/10.1074/jbc.M401756200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152000	hybrid			2022-12-27	WOS:000222726800111
J	Sol-Foulon, N; Esnault, CC; Percherancier, Y; Porrot, F; Metais-Cunha, P; Bachelerie, F; Schwartz, O				Sol-Foulon, N; Esnault, CC; Percherancier, Y; Porrot, F; Metais-Cunha, P; Bachelerie, F; Schwartz, O			The effects of HIV-1 nef on CD4 surface expression and viral infectivity in lymphoid cells are independent of rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; LIPID RAFTS; DOWN-REGULATION; T-CELLS; PROTEIN PALMITOYLATION; DENDRITIC CELLS; SUBCELLULAR-LOCALIZATION; ENVELOPE GLYCOPROTEIN; MEMBRANE DOMAINS	The HIV-1 Nef protein is a critical virulence factor that exerts multiple effects during viral replication. Nef modulates surface expression of various cellular proteins including CD4 and MHC-I, enhances viral infectivity, and affects signal transduction pathways. Nef has been shown to partially associate with rafts, where it can prime T cells for activation. The contribution of rafts during Nef-induced CD4 down-regulation and enhancement of viral replication remains poorly understood. We show here that Nef does not modify the palmitoylation state of CD4 or its partition within rafts. Moreover, CD4 mutants lacking palmitoylation or unable to associate with rafts are efficiently down-regulated by Nef. In HIV-infected cells, viral assembly and budding occurs from rafts, and Nef has been suggested to increase this process. However, using T cells acutely infected with wild-type or nef-deleted HIV, we did not observe any impact of Nef on raft segregation of viral structural proteins. We have also designed a palmitoylated mutant of Nef (NefG3C), which significantly accumulates in rafts. Interestingly, the efficiency of NefG3C to down-regulate CD4 and MHC-I, and to promote viral replication was not increased when compared with the wild-type protein. Altogether, these results strongly suggest that rafts are not a key element involved in the effects of Nef on trafficking of cellular proteins and on viral replication.	Inst Pasteur, Virus & Immun Grp, CNRS, URA 1930, F-75724 Paris 15, France; Inst Pasteur, Unite Immunol Virale, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Schwartz, O (corresponding author), Inst Pasteur, Virus & Immun Grp, CNRS, URA 1930, 28 Rue Dr Roux, F-75724 Paris 15, France.	schwartz@pasteur.fr	Schwartz, Olivier/AAZ-3765-2021; BACHELERIE, FRANCOISE/F-8823-2013	Schwartz, Olivier/0000-0002-0729-1475; BACHELERIE, FRANCOISE/0000-0002-0399-3277; Sol-Foulon, Nathalie/0000-0002-2643-0311; percherancier, yann/0000-0002-2410-5806				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Alexander M, 2004, J VIROL, V78, P1685, DOI 10.1128/JVI.78.4.1685-1696.2004; Alonso MA, 2001, J CELL SCI, V114, P3957; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Briggs JAG, 2003, J GEN VIROL, V84, P757, DOI 10.1099/vir.0.18779-0; Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003; CINEK T, 1995, IMMUNOGENETICS, V41, P110, DOI 10.1007/BF00182321; Cohen GB, 2000, J BIOL CHEM, V275, P23097, DOI 10.1074/jbc.M000536200; CRISE B, 1992, J BIOL CHEM, V267, P13593; del Real G, 2002, J EXP MED, V196, P293, DOI 10.1084/jem.20020308; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; Ding LM, 2003, J VIROL, V77, P1916, DOI 10.1128/JVI.77.3.1916-1926.2003; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Graham DRM, 2003, J VIROL, V77, P8237, DOI 10.1128/JVI.77.15.8237-8248.2003; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Holm K, 2003, J VIROL, V77, P4805, DOI 10.1128/JVI.77.8.4805-4817.2003; Janardhan A, 2004, PLOS BIOL, V2, P65, DOI 10.1371/journal.pbio.0020006; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004; Lama J, 2000, J VIROL, V74, P9396, DOI 10.1128/JVI.74.20.9396-9402.2000; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Li M, 2002, J VIROL, V76, P11845, DOI 10.1128/JVI.76.23.11845-11852.2002; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Lundquist CA, 2002, J VIROL, V76, P4625, DOI 10.1128/JVI.76.9.4625-4633.2002; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Marechal V, 1998, J VIROL, V72, P2208; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nozawa N, 2003, J VIROL, V77, P3204, DOI 10.1128/JVI.77.5.3204-3216.2003; Ochsenbauer-Jambor C, 2001, J VIROL, V75, P11544, DOI 10.1128/JVI.75.23.11544-11554.2001; Olsen KEP, 1999, J VIROL, V73, P8975, DOI 10.1128/JVI.73.11.8975-8981.1999; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Percherancier Y, 2003, J BIOL CHEM, V278, P3153, DOI 10.1074/jbc.M207371200; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Petit C, 2001, VIROLOGY, V286, P225, DOI 10.1006/viro.2001.0984; Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Rousso I, 2000, P NATL ACAD SCI USA, V97, P13523, DOI 10.1073/pnas.240459697; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349; Sanfridson A, 1997, P NATL ACAD SCI USA, V94, P873, DOI 10.1073/pnas.94.3.873; Schaeffer E, 2001, J VIROL, V75, P2993, DOI 10.1128/JVI.75.6.2993-3000.2001; SCHWARTZ O, 1995, J VIROL, V69, P528, DOI 10.1128/JVI.69.1.528-533.1995; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SCHWARTZ O, 1993, J VIROL, V67, P3274, DOI 10.1128/JVI.67.6.3274-3280.1993; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211; Suomalainen M, 2002, TRAFFIC, V3, P705, DOI 10.1034/j.1600-0854.2002.31002.x; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Tobiume M, 2003, J VIROL, V77, P10645, DOI 10.1128/JVI.77.19.10645-10650.2003; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Venkatesan S, 2003, MOL BIOL CELL, V14, P3305, DOI 10.1091/mbc.e02-11-0714; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Walk SF, 2001, J VIROL, V75, P834, DOI 10.1128/JVI.75.2.834-843.2001; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Wei BL, 2003, CURR HIV RES, V1, P41, DOI 10.2174/1570162033352057; Witte V, 2004, MOL CELL, V13, P179, DOI 10.1016/S1097-2765(04)00004-8; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871; Zhang J, 2000, J VIROL, V74, P4634, DOI 10.1128/JVI.74.10.4634-4644.2000; Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8; Zheng YH, 2003, P NATL ACAD SCI USA, V100, P8460, DOI 10.1073/pnas.1437453100	95	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31398	31408		10.1074/jbc.M401621200	http://dx.doi.org/10.1074/jbc.M401621200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133044	hybrid			2022-12-27	WOS:000222726800061
J	Thornton, C; Tang, KC; Phamluong, K; Luong, K; Vagts, A; Nikanjam, D; Yaka, R; Ron, D				Thornton, C; Tang, KC; Phamluong, K; Luong, K; Vagts, A; Nikanjam, D; Yaka, R; Ron, D			Spatial and temporal regulation of RACK1 function and N-methyl-D-aspartate receptor activity through WD40 motif-mediated dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NMDA RECEPTOR; CRYSTAL-STRUCTURE; SCAFFOLD PROTEIN; GENE-EXPRESSION; BETA; BINDING; INTERACTS; SUBUNIT; ASSOCIATION	Efficient signaling requires accurate spatial and temporal compartmentalization of proteins. RACK1 is a scaffolding protein that fulfils this role through interaction of binding partners with one of its seven WD40 domains. We recently identified the kinase Fyn and the NR2B subunit of the N-methyl-D-Aspartate receptor ( NMDAR) as binding partners of RACK1. Scaffolding of Fyn near its substrate NR2B by RACK1 inhibits Fyn phosphorylation of NR2B and thereby negatively regulates channel function. We found that Fyn and NR2B share the same binding site on RACK1; however, their binding to RACK1 is not mutually exclusive (Yaka, R., Thornton, C., Vagts, A. J., Phamluong, K., Bonci, A., and Ron, D. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 5710 5715). We therefore tested the hypothesis that RACK1 forms a homodimer that allows the simultaneous binding of Fyn and NR2B. We found that RACK1 binds to itself both in vitro and in the brain. Deletion analyses identified a RACK1-RACK1 dimer-binding site within the 4th WD40 repeat, and application of the 4th WD40 repeat or a peptide derivative to hippocampal slices inhibited NMDAR activity. We further found that in hippocampal slices, both RACK1 and NR2B associated with another WD40 protein, the beta-subunit of G protein (Gbeta), previously shown to heterodimerize with RACK1 in vitro ( Dell, E. J., Connor, J., Chen, S., Stebbins, E. G., Skiba, N. P., Mochly- Rosen, D., and Hamm, H. E. ( 2002) J. Biol. Chem. 277, 49888 - 49895). However, activation of the pituitary adenylate cyclase polypeptide ( 1 - 38) G protein-coupled receptor, previously found to induce the dissociation of RACK1 from the NMDAR complex ( Yaka, R., He, D. Y., Phamluong, K., and Ron, D. ( 2003) J. Biol. Chem. 278, 9630 - 9638), attenuated the association of Gbeta with RACK1 and NR2B. Based on these results, we propose that WD40-mediated homo- and heterodimerization of RACK1 mediate the formation of a transient signaling complex that includes the NMDAR, a G protein and Fyn.	Ernest Gallo Res Ctr, Emeryville, CA 94608 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Ron, D (corresponding author), 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	dorit@itsa.ucsf.edu						Angenstein F, 2002, J NEUROSCI, V22, P8827; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chen SH, 2004, J BIOL CHEM, V279, P17861, DOI 10.1074/jbc.M313727200; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dell EJ, 2002, J BIOL CHEM, V277, P49888, DOI 10.1074/jbc.M202755200; Fagni Laurent, 2002, Sci STKE, V2002, pre8, DOI 10.1126/stke.2002.137.re8; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KIELY PA, 2002, J BIOL CHEM, V8, P6; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Liedtke CM, 2004, AM J PHYSIOL-CELL PH, V286, pC1037, DOI 10.1152/ajpcell.00222.2003; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Mourton T, 2001, J BIOL CHEM, V13, P13; Pei L, 2004, J NEUROSCI, V24, P1149, DOI 10.1523/JNEUROSCI.3922-03.2004; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Thornton C, 2003, J BIOL CHEM, V278, P23823, DOI 10.1074/jbc.M302389200; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Wilson SE, 1998, NUCLEIC ACIDS RES, V26, P2457, DOI 10.1093/nar/26.10.2457; Yaka R, 2003, J NEUROSCI, V23, P3623; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	36	62	67	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31357	31364		10.1074/jbc.M402316200	http://dx.doi.org/10.1074/jbc.M402316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140893	hybrid			2022-12-27	WOS:000222726800056
J	Blois, JT; Mataraza, JM; Mecklenbrauker, I; Tarakhovsky, A; Chiles, TC				Blois, JT; Mataraza, JM; Mecklenbrauker, I; Tarakhovsky, A; Chiles, TC			B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; NF-KAPPA-B; TRANSCRIPTION FACTOR; SURFACE-IMMUNOGLOBULIN; FACTOR CREB; SH2 DOMAIN; PKC-DELTA; PHOSPHORYLATION; PATHWAY; BLNK	The cAMP-response element-binding protein ( CREB) is activated by phosphorylation on Ser-133 and plays a key role in the proliferative and survival responses of mature B cells to B cell receptor (BCR) signaling. The signal link between the BCR and CREB activation depends on a phorbol ester (phorbol 12-myristate 13-acetate)-sensitive protein kinase C (PKC) activity and not protein kinase A or calmodulin kinase; however, the identity and role of the PKC(s) activity has not been elucidated. We found the novel PKCdelta (nPKCdelta) activator bistratene A is sufficient to induce CREB phosphorylation in murine splenic B cells. The pharmacological inhibitor Go6976, which targets conventional PKCs and PKC mu, has no effect on CREB phosphorylation, whereas the nPKCdelta inhibitor rottlerin blocks CREB phosphorylation following BCR cross-linking. Bryostatin 1 selectively prevents nPKCdelta depletion by phorbol 12-myristate 13-acetate when coapplied, coincident with protection of BCR-induced CREB phosphorylation. Ectopic expression of a kinase-inactive nPKCdelta blocks BCR-induced CREB phosphorylation in A20 B cells. In addition, BCR-induced CREB phosphorylation is significantly diminished in nPKCdelta-deficient splenic B cells in comparison with wild type mice. Consistent with the essential role for Bruton's tyrosine kinase and phospholipase Cgamma2 in mediating PKC activation, Bruton's tyrosine kinase- and phospholipase Cgamma2-deficient B cells display defective CREB phosphorylation by the BCR. We also found that p90 RSK directly phosphorylates CREB on Ser-133 following BCR cross-linking and is positioned downstream of nPKCdelta. Taken together, these results suggest a model in which BCR engagement leads to the phosphorylation of CREB via a signaling pathway that requires nPKCdelta and p90 RSK in mature B cells.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Rockefeller Univ, Lab Lymphocyte Signaling, New York, NY 10021 USA	Boston College; Rockefeller University	Chiles, TC (corresponding author), Boston Coll, Dept Biol, 414 Higgings Hall, Chestnut Hill, MA 02467 USA.	ChilesT@bc.edu			NIAID NIH HHS [AI34586] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034586, R29AI034586] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amato SF, 1996, J IMMUNOL, V157, P146; Antony P, 2003, EXP CELL RES, V291, P11, DOI 10.1016/S0014-4827(03)00338-0; Barbazuk SM, 1999, IMMUNOL LETT, V69, P259, DOI 10.1016/S0165-2478(99)00090-5; Bhushan A, 2001, EUR J IMMUNOL, V31, P653, DOI 10.1002/1521-4141(200102)31:2<653::AID-IMMU653>3.0.CO;2-D; Cariappa A, 1999, J IMMUNOL, V162, P4417; Cariappa A, 2002, CURR OPIN IMMUNOL, V14, P241, DOI 10.1016/S0952-7915(02)00328-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Craxton A, 1999, ADV IMMUNOL, V73, P79, DOI 10.1016/S0065-2776(08)60786-5; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; FEURSTEIN N, 1996, J IMMUNOL, V156, P4582; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Frissora F, 2003, EUR J IMMUNOL, V33, P907, DOI 10.1002/eji.200323657; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Gubina E, 2001, J IMMUNOL, V167, P4303, DOI 10.4049/jimmunol.167.8.4303; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Ishiai M, 1999, J IMMUNOL, V163, P1746; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1991, J IMMUNOL, V147, P3981; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; MORENO CS, 1995, J IMMUNOL, V155, P4313; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; Stevens S, 2000, J IMMUNOL, V164, P6372, DOI 10.4049/jimmunol.164.12.6372; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Swart JM, 2000, J IMMUNOL, V164, P2311, DOI 10.4049/jimmunol.164.5.2311; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Watters D, 1996, EXP CELL RES, V229, P327, DOI 10.1006/excr.1996.0378; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Xie HJ, 1996, CELL IMMUNOL, V169, P264, DOI 10.1006/cimm.1996.0117; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Zhang CY, 2002, J BIOL CHEM, V277, P48359, DOI 10.1074/jbc.M209329200	62	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30123	30132		10.1074/jbc.M402793200	http://dx.doi.org/10.1074/jbc.M402793200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138267	hybrid			2022-12-27	WOS:000222531900033
J	Chang, WC; Parekh, AB				Chang, WC; Parekh, AB			Close functional coupling between Ca2+ release-activated Ca2+ channels, arachidonic acid release, and leukotriene C-4 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CURRENT I-CRAC; PHOSPHOLIPASE A(2); CALCIUM CURRENT; ADENYLYL CYCLASES; ENTRY; 5-LIPOXYGENASE; DEPLETION; TRANSLOCATION; INACTIVATION	In non-excitable cells, one major route for Ca2+ influx is through store-operated Ca2+ channels in the plasma membrane. These channels are activated by the emptying of intracellular Ca2+ stores, and in some cell types, particularly of hemopoietic origin, store-operated influx occurs through Ca2+ release-activated Ca2+ (CRAC) channels. However, little is known about the downstream consequences of CRAC channel activation. Here, we report that Ca2+ entry through CRAC channels stimulates arachidonic acid production, whereas Ca2+ release from the stores is ineffective even though the latter evokes a robust intracellular Ca2+ signal. We find that arachidonic acid released by Ca2+ entering through CRAC channels is used to synthesize the potent paracrine pro-inflammatory signal leukotriene C-4 (LTC4). Both pharmacological inhibitors of CRAC channels and mitochondrial depolarization, which impairs CRAC channel activity, suppress arachidonic acid release and LTC4 secretion. Thus, arachidonic acid release is preferentially stimulated by elevated subplasmalemmal Ca2+ levels due to open CRAC channels, suggesting that the enzyme is located close to the CRAC channels. Our results also identify a novel role for CRAC channels, namely the activation of a downstream signal transduction pathway resulting in the secretion of LTC4. Finally, mitochondria are key determinants of the generation of both intracellular ( arachidonic acid) and paracrine ( LTC4) signals through their effects on CRAC channel activity.	Univ Oxford, Lab Cellular & Mol Signalling, Dept Physiol, Oxford OX1 3PT, England	University of Oxford	Parekh, AB (corresponding author), Univ Oxford, Lab Cellular & Mol Signalling, Dept Physiol, Parks Rd, Oxford OX1 3PT, England.	anant.parekh@physiol.ox.ac.uk		Chang, Wei-Chiao/0000-0002-8573-5924	Medical Research Council [G0200218] Funding Source: Medline; MRC [G0200218] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Artalejo AR, 1998, PFLUG ARCH EUR J PHY, V436, P934, DOI 10.1007/PL00008088; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; LUO D, 2001, J BIOL CHEM, V274, P31174; Mignen O, 2003, J BIOL CHEM, V278, P40088, DOI 10.1074/jbc.M306365200; Mignen O, 2003, J BIOL CHEM, V278, P10174, DOI 10.1074/jbc.M212536200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; UEDA N, 1986, J BIOL CHEM, V261, P7982; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	35	76	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29994	29999		10.1074/jbc.M403969200	http://dx.doi.org/10.1074/jbc.M403969200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133023	hybrid			2022-12-27	WOS:000222531900017
J	Kulkarni, S; Jackson, SP				Kulkarni, S; Jackson, SP			Platelet factor XIII and calpain negatively regulate integrin alpha(IIb)beta(3) adhesive function and thrombus growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN IIB-IIIA; CYTOPLASMIC DOMAIN; BINDING PROTEIN; CALCIUM SIGNALS; PROCOAGULANT ACTIVITY; STIMULATED PLATELETS; BETA(3) SUBUNIT; CLEAVAGE; AGGREGATION; ACTIVATION	Excessive accumulation of platelets at sites of atherosclerotic plaque rupture leads to the development of arterial thrombi, precipitating clinical events such as the acute coronary syndromes and ischemic stroke. The major platelet adhesion receptor glycoprotein (GP) IIb-IIIa (integrin alpha(IIb)beta(3)) plays a central role in this process by promoting platelet aggregation and thrombus formation. We demonstrate here a novel mechanism down-regulating integrin alpha(IIb)beta(3) adhesive function, involving platelet factor XIII (FXIII) and calpain, which serves to limit platelet aggregate formation and thrombus growth. This mechanism principally occurs in collagen-adherent platelets and is induced by prolonged elevations in cytosolic calcium, leading to dramatic changes in platelet morphology (membrane contraction, fragmentation, and microvesiculation) and a specific reduction in integrin alpha(IIb)beta(3) adhesive function. Adhesion receptor signal transduction plays a major role in the process by sustaining cytosolic calcium flux necessary for calpain and FXIII activation. Analysis of thrombus formation on a type I fibrillar collagen substrate revealed an important role for FXIII and calpain in limiting platelet recruitment into developing aggregates, thereby leading to reduced thrombus formation. These studies define a previously unidentified role for platelet FXIII and calpain in regulating integrin alpha(IIb)beta(3) adhesive function. Moreover, they demonstrate the existence of an autoregulatory feedback mechanism that serves to limit excessive platelet accumulation on highly reactive thrombogenic surfaces.	Box Hill Hosp, Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Box Hill, Vic 3128, Australia	Box Hill Hospital; Monash University	Jackson, SP (corresponding author), Monash Univ, Dept Med, Australian Ctr Blood Dis, Level 5 Clive Ward Bldg,Arnold St, Box Hill, Vic 3128, Australia.	shaun.jackson@med.monash.edu.au		Jackson, Shaun/0000-0002-4750-1991				ARFORS KE, 1968, BRIT MED J, V4, P430, DOI 10.1136/bmj.4.5628.430; ARFORS KE, 1968, BRIT J SURG, V55, P858; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; BAUMGARTNER HR, 1973, MICROVASC RES, V5, P167, DOI 10.1016/0026-2862(73)90069-1; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; COHEN I, 1981, BIOCHIM BIOPHYS ACTA, V676, P137, DOI 10.1016/0304-4165(81)90181-1; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; COX AD, 1994, BLOOD, V83, P1006, DOI 10.1182/blood.V83.4.1006.bloodjournal8341006; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Goncalves I, 2003, J BIOL CHEM, V278, P34812, DOI 10.1074/jbc.M306504200; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Jackson SP, 2003, J THROMB HAEMOST, V1, P1602, DOI 10.1046/j.1538-7836.2003.00267.x; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; Meredith J, 1998, J BIOL CHEM, V273, P19525, DOI 10.1074/jbc.273.31.19525; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; ODA A, 1993, J BIOL CHEM, V268, P12603; OLLGAARD E, 1961, THROMB DIATH HAEMOST, V6, P86; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Schoenwaelder SM, 2000, PLATELETS, V11, P189; TRANZER JP, 1968, EXP BIOL MED, V3, P80; WALKER JH, 1992, BIOCHEM SOC T, V20, P828, DOI 10.1042/bst0200828; WESTER J, 1978, LAB INVEST, V39, P298; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	45	80	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30697	30706		10.1074/jbc.M403559200	http://dx.doi.org/10.1074/jbc.M403559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131115	hybrid			2022-12-27	WOS:000222531900100
J	Bresson, D; Pugniere, M; Roquet, F; Rebuffat, SA; N-Guyen, B; Cerutti, M; Guo, J; McLachlan, SM; Rapoport, B; Estienne, V; Ruf, J; Chardes, T; Peraldi-Roux, S				Bresson, D; Pugniere, M; Roquet, F; Rebuffat, SA; N-Guyen, B; Cerutti, M; Guo, J; McLachlan, SM; Rapoport, B; Estienne, V; Ruf, J; Chardes, T; Peraldi-Roux, S			Directed mutagenesis in region 713-720 of human thyroperoxidase assigns (KFPED717)-K-713 residues as being involved in the B domain of the discontinuous immunodominant region recognized by human autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROID PEROXIDASE; CELL-MEDIATED CYTOTOXICITY; IMMUNOGLOBULIN GENE USAGE; POLYMERASE CHAIN-REACTION; AUTOIMMUNE-DISEASE; CONFORMATIONAL EPITOPES; HASHIMOTOS-THYROIDITIS; 3-DIMENSIONAL MODEL; ANTIBODIES; ANTIGEN	Autoantibodies (aAbs) to thyroid peroxidase (TPO), the hallmark of autoimmune thyroid disease (AITD), recognize conformational epitopes restricted to an immunodominant region (IDR), divided into two overlapping domains A and B. Despite numerous efforts aimed at localizing the IDR and identifying aAb-interacting residues on TPO, only two critical amino acids, Lys(713) and Tyr(772), have been characterized. Precise and complete delineation of the other residues involved in the IDR remains to be defined. By using a recombinant anti-TPO aAb T13, we demonstrated that four regions on TPO are part of the IDR/B; one of them, located between amino acids 713 and 720, is particularly important for the binding of sera from patients suffering from AITD. To precisely define critical residues implicated in the binding of aAb to human TPO, we used directed mutagenesis and expressed the mutants in stably transfected CHO cells. Then we assessed the kinetic parameters involved in the interactions between anti-TPO aAbs and mutants by real-time analysis. We identified (i) the minimal epitope 713-717 recognized by mAb 47 (a reference antibody) and (ii) the amino acids used as contact points for two IDR-specific human monoclonal aAbs TR1.9 (Pro(715) and Asp(717)) and T13 (Lys(713), Phe(714), Pro(715), and Glu(716)). Using a rational strategy to identify complex epitopes on proteins showing a highly convoluted architecture, this study definitively identifies the amino acids Lys(713)-Asp(717) as being the key residues recognized by IDR/B-specific anti-TPO aAbs in AITD.	Fac Pharm Montpellier, Ctr Pharmacol & Biotechnol Sante, CNRS, UMR 5160, F-34093 Montpellier 5, France; INRA, Stn Rech Pathol Comparee, CNRS, FRE 2689, F-30380 St Christol Les Ales, France; Cedars Sinai Res Inst, Autoimmune Dis Unit, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA; Fac Med Marseille, Lab Biochim Endocrinienne & Metab, INSERM, U555, F-13385 Marseille 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); INRAE; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Peraldi-Roux, S (corresponding author), Fac Pharm Montpellier, Ctr Pharmacol & Biotechnol Sante, CNRS, UMR 5160, 15 Ave Charles Flahault,BP 14491, F-34093 Montpellier 5, France.	sylvie.roux@ibph.pharma.univ-montp1.fr	Ruf, Jean/E-3963-2016; Chardès, Thierry/B-5420-2019; PUGNIERE, Martine/AAD-4315-2020; Pugniere, Martine/T-1355-2017	Ruf, Jean/0000-0003-4300-8048; Chardès, Thierry/0000-0002-1836-7439; PUGNIERE, Martine/0000-0002-2049-2909; Pugniere, Martine/0000-0002-2049-2909; Rebuffat, Sandra/0000-0002-1102-4935				Arscott PL, 1996, J BIOL CHEM, V271, P4966; BANGA JP, 1990, AUTOIMMUNITY, V6, P257, DOI 10.3109/08916939008998418; Bes C, 2003, J BIOL CHEM, V278, P14265, DOI 10.1074/jbc.M210694200; Blanchin S, 2002, BIOCHEM BIOPH RES CO, V295, P1118, DOI 10.1016/S0006-291X(02)00827-6; Bresson D, 2003, J BIOL CHEM, V278, P9560, DOI 10.1074/jbc.M211930200; Bresson Damien, 2001, Human Antibodies, V10, P109; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; CHAZENBALK GD, 1993, J CLIN ENDOCR METAB, V77, P1715, DOI 10.1210/jc.77.6.1715; CHIOVATO L, 1993, J CLIN ENDOCR METAB, V77, P1700, DOI 10.1210/jc.77.6.1700; Christen U, 2004, MOL IMMUNOL, V40, P1113, DOI 10.1016/j.molimm.2003.11.014; Czarnocka B, 1997, J CLIN ENDOCR METAB, V82, P2639, DOI 10.1210/jc.82.8.2639; Dai Y, 1999, J IMMUNOL, V162, P6987; Estienne V, 1998, J BIOL CHEM, V273, P8056, DOI 10.1074/jbc.273.14.8056; Estienne V, 2002, INT IMMUNOL, V14, P359, DOI 10.1093/intimm/14.4.359; Estienne V, 1999, J BIOL CHEM, V274, P35313, DOI 10.1074/jbc.274.50.35313; EWINS DL, 1992, AUTOIMMUNITY, V11, P141, DOI 10.3109/08916939209035148; Fairweather D, 2002, NAT IMMUNOL, V3, P338, DOI 10.1038/ni0402-338; FINKE R, 1990, J CLIN ENDOCR METAB, V71, P53, DOI 10.1210/jcem-71-1-53; Flodstrom-Tullberg M, 2003, MICROBES INFECT, V5, P911, DOI 10.1016/S1286-4579(03)00161-8; FRORATH B, 1992, J BIOCHEM-TOKYO, V111, P633, DOI 10.1093/oxfordjournals.jbchem.a123810; Gardas A, 2000, REDOX REP, V5, P237, DOI 10.1179/135100000101535681; Gardas A, 1997, BIOCHEM BIOPH RES CO, V234, P366, DOI 10.1006/bbrc.1997.6600; Guo J, 1997, J CLIN ENDOCR METAB, V82, P925, DOI 10.1210/jc.82.3.925; Guo J, 1998, CLIN EXP IMMUNOL, V111, P408; Guo J, 2002, J BIOL CHEM, V277, P40189, DOI 10.1074/jbc.M205524200; Guo J, 2000, CLIN EXP IMMUNOL, V119, P38, DOI 10.1046/j.1365-2249.2000.01087.x; Guo J, 2001, J IMMUNOL, V166, P1327, DOI 10.4049/jimmunol.166.2.1327; Hendry E, 1999, J ENDOCRINOL, V160, pR13, DOI 10.1677/joe.0.160R013; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobby P, 2000, ENDOCRINOLOGY, V141, P2018, DOI 10.1210/en.141.6.2018; Jones FG, 1999, AUTOIMMUNITY, V30, P157, DOI 10.3109/08916939908993850; Laune D, 1997, J BIOL CHEM, V272, P30937, DOI 10.1074/jbc.272.49.30937; LIBERT F, 1991, J CLIN ENDOCR METAB, V73, P857, DOI 10.1210/jcem-73-4-857; McLachlan S M, 2000, Int Rev Immunol, V19, P587, DOI 10.3109/08830180009088514; Metcalfe RA, 1997, AUTOIMMUNITY, V25, P65, DOI 10.3109/08916939708996272; Nishikawa T, 1996, ENDOCRINOLOGY, V137, P1000, DOI 10.1210/en.137.3.1000; NISHIKAWA T, 1993, ENDOCRINOLOGY, V133, P2496, DOI 10.1210/en.133.6.2496; NISHIKAWA T, 1994, J CLIN ENDOCR METAB, V79, P1648, DOI 10.1210/jc.79.6.1648; PARKES AB, 1994, J CLIN ENDOCR METAB, V79, P395, DOI 10.1210/jc.79.2.395; PORTOLANO S, 1992, J CLIN INVEST, V90, P720, DOI 10.1172/JCI115943; Regner M, 2001, NAT IMMUNOL, V2, P185, DOI 10.1038/85228; Rodien P, 1996, J CLIN ENDOCR METAB, V81, P2595, DOI 10.1210/jc.81.7.2595; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tong JC, 2002, ANN NY ACAD SCI, V958, P182; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; von Herrath MG, 2000, J NEUROIMMUNOL, V107, P154, DOI 10.1016/S0165-5728(00)00227-7; ZANELLI E, 1993, CELL MOL BIOL, V39, P491; ZANELLI E, 1992, CLIN EXP IMMUNOL, V87, P80; Zinkernagel RM, 2002, ANN NY ACAD SCI, V958, P3	50	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39058	39067		10.1074/jbc.M403897200	http://dx.doi.org/10.1074/jbc.M403897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15150267	hybrid			2022-12-27	WOS:000223684100121
J	Zhuo, LS; Hascall, VC; Kimata, K				Zhuo, LS; Hascall, VC; Kimata, K			Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CUMULUS EXTRACELLULAR-MATRIX; SHAP-HYALURONAN COMPLEX; HEAVY-CHAINS; LIGHT-CHAIN; HUMAN-PLASMA; LIMITED PROTEOLYSIS; ALPHA-1-PROTEINASE INHIBITOR; AFFINITY-CHROMATOGRAPHY; RHEUMATOID-ARTHRITIS; FOLLICULAR-FLUID		Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 5600082, Japan; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthopaed Res Ctr ND20, Cleveland, OH 44195 USA	Aichi Medical University; Japan Science & Technology Agency (JST); Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@amugw.aichi-med-u.ac.jp						ANDERSON AJ, 1955, BIOCHEM J, V59, P638, DOI 10.1042/bj0590638; ASTRUP T, 1959, SCAND J CLIN LAB INV, V11, P181, DOI 10.3109/00365515909060431; Atmani F, 1996, EUR J BIOCHEM, V236, P984, DOI 10.1111/j.1432-1033.1996.00984.x; BALDUYCK M, 1986, EUR J BIOCHEM, V158, P417, DOI 10.1111/j.1432-1033.1986.tb09769.x; BECKER A, 1971, ARTHRITIS RHEUM, V14, P764, DOI 10.1002/art.1780140613; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1997, BIOCHEM J, V328, P185; Blom AM, 1999, J BIOL CHEM, V274, P298, DOI 10.1074/jbc.274.1.298; BOURGUIGNON J, 1983, FEBS LETT, V162, P379, DOI 10.1016/0014-5793(83)80791-1; BRATT T, 1993, BIOCHIM BIOPHYS ACTA, V1157, P147, DOI 10.1016/0304-4165(93)90058-G; BRATT T, 1994, FEBS LETT, V354, P57, DOI 10.1016/0014-5793(94)01087-0; Capon C, 2003, BIOCHIMIE, V85, P101, DOI 10.1016/S0300-9084(03)00066-X; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; CHAWLA RK, 1978, J IMMUNOL, V121, P1636; CHEN L, 1994, J BIOL CHEM, V269, P28282; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; DIETL T, 1979, H-S Z PHYSIOL CHEM, V360, P1313, DOI 10.1515/bchm2.1979.360.2.1313; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; Enghild JJ, 1999, BIOCHEMISTRY-US, V38, P11804, DOI 10.1021/bi9908540; FAARVANG HJ, 1965, SCAND J CLIN LAB S83, V17, P1; Fries E, 2000, INT J BIOCHEM CELL B, V32, P125, DOI 10.1016/S1357-2725(99)00125-9; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; GEBHARD W, 1990, BIOL CHEM H-S, V371, P13; HAMERMAN D, 1963, J CLIN INVEST, V42, P1882, DOI 10.1172/JCI104873; HEIDE K, 1965, CLIN CHIM ACTA, V11, P82, DOI 10.1016/0009-8981(65)90093-8; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1357, DOI 10.1515/bchm2.1981.362.2.1357; HUANG L, 1993, J BIOL CHEM, V268, P26725; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; ITOH H, 1994, J BIOL CHEM, V269, P3818; JESSEN TE, 1994, BIOL CHEM H-S, V375, P521, DOI 10.1515/bchm3.1994.375.8.521; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; Kida D, 1999, J RHEUMATOL, V26, P1230; Kobayashi H, 1996, J BIOL CHEM, V271, P11362, DOI 10.1074/jbc.271.19.11362; KOBAYASHI H, 1994, CANCER RES, V54, P844; LAURENT TC, 1987, ACTA OTO-LARYNGOL, P7; Laurent TC, 1998, WENN GR INT, V72, P305; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LINDQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1130, P63, DOI 10.1016/0167-4781(92)90462-9; Mizushima S, 1998, BIOL PHARM BULL, V21, P167; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; OCHIAI H, 1988, CHEM PHARM BULL, V36, P3726; ODUM L, 1991, DAN MED BULL, V38, P68; Odum L, 2002, REPRODUCTION, V124, P249, DOI 10.1530/reprod/124.2.249; Olsen EHN, 1998, BIOCHEMISTRY-US, V37, P408, DOI 10.1021/bi971137d; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; PRATT CW, 1986, ARCH BIOCHEM BIOPHYS, V248, P587, DOI 10.1016/0003-9861(86)90512-6; PRATT CW, 1989, J LEUKOCYTE BIOL, V45, P1; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; PROKSCH GJ, 1973, CLIN BIOCHEM, V6, P200, DOI 10.1016/S0009-9120(73)80027-X; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; SHULMAN R, 1955, J BIOL CHEM, V213, P655; SLOTA A, 1994, BIOL CHEM H-S, V375, P127; SUGIKI M, 1989, ENZYME, V42, P31, DOI 10.1159/000469004; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; Thuveson M, 1999, J BIOL CHEM, V274, P6741, DOI 10.1074/jbc.274.10.6741; TOYODA H, 1993, BIOL PHARM BULL, V16, P945; WACHTER E, 1981, H-S Z PHYSIOL CHEM, V362, P1351, DOI 10.1515/bchm2.1981.362.2.1351; Wilharm E, 1999, J BIOL CHEM, V274, P27331, DOI 10.1074/jbc.274.38.27331; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Yamamoto T, 1996, J BIOCHEM-TOKYO, V120, P145; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Yoneda M, 2000, INT CONGR SER, V1196, P21; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; ZHAO M, 2002, HYALURONAN, V1, P497; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	77	176	186	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38079	38082		10.1074/jbc.R300039200	http://dx.doi.org/10.1074/jbc.R300039200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15151994	hybrid			2022-12-27	WOS:000223684100001
J	Hartshorne, DJ; Ito, M; Erdodi, F				Hartshorne, DJ; Ito, M; Erdodi, F			Role of protein phosphatase type 1 in contractile functions: Myosin phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LIGHT-CHAIN PHOSPHATASE; RHO-ASSOCIATED KINASE; RABBIT SMOOTH-MUSCLE; TARGETING SUBUNIT; BINDING SUBUNIT; IN-VIVO; CARDIAC-HYPERTROPHY; CA2+ SENSITIZATION; MOLECULAR-CLONING; INHIBITOR PROTEIN		Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 514, Japan; Univ Debrecen, Med & Hlth Sci Ctr, Dept Med Chem, H-4026 Debrecen, Hungary	University of Arizona; Mie University; University of Debrecen	Hartshorne, DJ (corresponding author), Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA.	hartshor@ag.arizona.edu	Erdődi, Ferenc/B-3383-2011		NHLBI NIH HHS [HL23615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Aoki H, 2000, NAT MED, V6, P183, DOI 10.1038/72287; Arimura T, 2001, J BIOL CHEM, V276, P6073, DOI 10.1074/jbc.M008566200; Asahi M, 2003, TRENDS CARDIOVAS MED, V13, P152, DOI 10.1016/S1050-1738(03)00037-9; Bannert N, 2003, J BIOL CHEM, V278, P42190, DOI 10.1074/jbc.M306669200; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Borman MA, 2002, J BIOL CHEM, V277, P23441, DOI 10.1074/jbc.M201597200; Cao WS, 2002, AM J PHYSIOL-CELL PH, V283, pC327, DOI 10.1152/ajpcell.00442.2001; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; Cohen PTW, 2002, J CELL SCI, V115, P241; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; Dirksen WP, 2003, J BIOL CHEM, V278, P9722, DOI 10.1074/jbc.M207969200; Dirksen WP, 2000, AM J PHYSIOL-CELL PH, V278, pC589, DOI 10.1152/ajpcell.2000.278.3.C589; Dubois T, 2003, BIOCHEM BIOPH RES CO, V302, P186, DOI 10.1016/S0006-291X(03)00130-X; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; ERDUMLAUTODI F, 1996, BIOCH SMOOTH MUSCLE, P131; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Fujioka M, 1998, GENOMICS, V49, P59, DOI 10.1006/geno.1998.5222; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hayashi Y, 2001, J BIOL CHEM, V276, P39858, DOI 10.1074/jbc.M107302200; Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; Kitazawa T, 2003, J PHYSIOL-LONDON, V546, P879, DOI 10.1113/jphysiol.2002.029306; Liu QR, 2002, J BIOL CHEM, V277, P13312, DOI 10.1074/jbc.M107558200; Mabuchi K, 1999, BBA-PROTEIN STRUCT M, V1434, P296, DOI 10.1016/S0167-4838(99)00182-X; Manganello JM, 2003, J BIOL CHEM, V278, P124, DOI 10.1074/jbc.M209219200; Moorhead G, 1998, FEBS LETT, V438, P141, DOI 10.1016/S0014-5793(98)01276-9; Niiro N, 2003, BIOCHEM J, V369, P117, DOI 10.1042/BJ20021040; Ohki SY, 2001, J MOL BIOL, V314, P839, DOI 10.1006/jmbi.2001.5200; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Skinner JA, 2001, BIOCHEM J, V356, P257, DOI 10.1042/0264-6021:3560257; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Toth A, 2000, EUR J BIOCHEM, V267, P1687, DOI 10.1046/j.1432-1327.2000.01158.x; Totsukawa G, 1999, J CELL BIOL, V144, P735, DOI 10.1083/jcb.144.4.735; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7; Woodsome TP, 2001, J PHYSIOL-LONDON, V535, P553, DOI 10.1111/j.1469-7793.2001.t01-1-00553.x; Wu Y, 2003, J MUSCLE RES CELL M, V24, P499, DOI 10.1023/B:JURE.0000009810.36038.53; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	56	177	183	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37211	37214		10.1074/jbc.R400018200	http://dx.doi.org/10.1074/jbc.R400018200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15136561	hybrid			2022-12-27	WOS:000223554600001
J	Nordlund, HR; Laitinen, OH; Hytonen, VP; Uotila, STH; Porkka, E; Kulomaa, MS				Nordlund, HR; Laitinen, OH; Hytonen, VP; Uotila, STH; Porkka, E; Kulomaa, MS			Construction of a dual chain pseudotetrameric chicken avidin by combining two circularly permuted avidins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE AVIDIN; BIOTIN BINDING; HIGH-AFFINITY; STRUCTURAL CONSEQUENCES; MONOMERIC STREPTAVIDIN; SUBUNIT ASSOCIATION; PROTEINS; COMPLEX; GENE; PERMUTATION	Two distinct circularly permuted forms of chicken avidin were designed with the aim of constructing a fusion avidin containing two biotin-binding sites in one polypeptide. The old N and C termini of wild-type avidin were connected to each other via a glycine/serine-rich linker, and the new termini were introduced into two different loops. This enabled the creation of the desired fusion construct using a short linker peptide between the two different circularly permuted subunits. The circularly permuted avidins (circularly permuted avidin 5 --> 4 and circularly permuted avidin 6 --> 5) and their fusion, pseudotetrameric dual chain avidin, were biologically active, i.e. showed biotin binding, and also displayed structural characteristics similar to those of wild-type avidin. Dual chain avidin facilitates the development of dual affinity avidins by allowing adjustment of the ligand-binding properties in half of the binding sites independent of the other half. In addition, the subunit fusion strategy described in this study can be used, where applicable, to modify oligomeric proteins in general.	Univ Jyvaskyla, Dept Biol & Environm Sci, NanoSci Ctr, FIN-40014 Jyvaskyla, Finland; Univ Kuopio, Dept Mol Med, AI Virtanen Inst, FIN-70211 Kuopio, Finland	University of Jyvaskyla; Finland National Institute for Health & Welfare; University of Eastern Finland	Kulomaa, MS (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, NanoSci Ctr, POB 35, FIN-40014 Jyvaskyla, Finland.	kulomaa@csc.fi	Hytonen, Vesa P./E-8855-2013; Laitinen, Olli H/A-6618-2016; Kulomaa, Markku S/C-9063-2014	Hytonen, Vesa P./0000-0002-9357-1480; Laitinen, Olli H/0000-0002-3751-9952; 				Ahlroth MK, 2000, ANIM GENET, V31, P367, DOI 10.1046/j.1365-2052.2000.00681.x; Airenne KJ, 1997, PROTEIN EXPRES PURIF, V9, P100, DOI 10.1006/prep.1996.0660; ARGARANA CE, 1986, NUCLEIC ACIDS RES, V14, P1871, DOI 10.1093/nar/14.4.1871; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; CHILKOTI A, 1995, BIO-TECHNOL, V13, P1198, DOI 10.1038/nbt1195-1198; Chu V, 1998, PROTEIN SCI, V7, P848; Ding ZL, 2001, NATURE, V411, P59, DOI 10.1038/35075028; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Freitag S, 1999, P NATL ACAD SCI USA, V96, P8384, DOI 10.1073/pnas.96.15.8384; GREEN N. M., 1970, Methods in Enzymology, V18A, P418, DOI 10.1016/0076-6879(71)18342-5; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; Laitinen OH, 2003, J BIOL CHEM, V278, P4010, DOI 10.1074/jbc.M205844200; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Marttila AT, 2003, BIOCHEM J, V369, P249, DOI 10.1042/BJ20020886; Marttila AT, 1998, FEBS LETT, V441, P313, DOI 10.1016/S0014-5793(98)01570-1; Marttila AT, 2000, FEBS LETT, V467, P31, DOI 10.1016/S0014-5793(00)01119-4; McDevitt TC, 1999, BIOTECHNOL PROGR, V15, P391, DOI 10.1021/bp990043n; Nordlund HR, 2003, J BIOL CHEM, V278, P2479, DOI 10.1074/jbc.M210721200; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; Qureshi MH, 2002, PROTEIN EXPRES PURIF, V25, P409, DOI 10.1016/S1046-5928(02)00021-9; Qureshi MH, 2001, J BIOL CHEM, V276, P46422, DOI 10.1074/jbc.M107398200; Reznik GO, 1996, NAT BIOTECHNOL, V14, P1007, DOI 10.1038/nbt0896-1007; Reznik GO, 1998, P NATL ACAD SCI USA, V95, P13525, DOI 10.1073/pnas.95.23.13525; Sanders KE, 2002, BLOOD, V100, P299, DOI 10.1182/blood.V100.1.299; Sano T, 1997, P NATL ACAD SCI USA, V94, P6153, DOI 10.1073/pnas.94.12.6153; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; Shimoboji T, 2001, BIOCONJUGATE CHEM, V12, P314, DOI 10.1021/bc000107b; Uliel S, 2001, PROTEIN ENG, V14, P533, DOI 10.1093/protein/14.8.533; WALLEN MJ, 1995, GENE, V161, P205, DOI 10.1016/0378-1119(95)00187-B; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wilchek M, 1999, BIOMOL ENG, V16, P1	35	34	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36715	36719		10.1074/jbc.M403496200	http://dx.doi.org/10.1074/jbc.M403496200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15131113	hybrid			2022-12-27	WOS:000223453600071
J	Mironova, GD; Negoda, AE; Marinov, BS; Paucek, P; Costa, ADT; Grigoriev, SM; Skarga, YY; Garlid, KD				Mironova, GD; Negoda, AE; Marinov, BS; Paucek, P; Costa, ADT; Grigoriev, SM; Skarga, YY; Garlid, KD			Functional distinctions between the mitochondrial ATP-dependent K+ channel (mitoK(ATP)) and its inward rectifier subunit (mitoKIR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNEL; SULFONYLUREA RECEPTOR; HEART-MITOCHONDRIA; CATION-TRANSPORT; LIGHT-SCATTERING; INNER MEMBRANE; RECONSTITUTION; ACTIVATION; MECHANISM; COA	The ATP-sensitive potassium channel from the inner mitochondrial membrane ( mitoKATP) is a highly selective conductor of K+ ions. When isolated in the presence of nonionic detergent and reconstituted in liposomes, mitoK(ATP) is inhibited with high affinity by ATP (K-1/2 = 20-30 muM). We have suggested that holo-mitoK(ATP) is a heteromultimer consisting of an inwardly rectifying K+ channel (mitoKIR) and a sulfonylurea receptor (Grover, G. J., and Garlid, K. D. ( 2000) J. Mol. Cell. Cardiol. 32, 677-695). Here, we show that a 55-kDa protein isolated by ethanol extraction and reconstituted in bilayer lipid membranes and liposomes is the mitoKIR. This protein, which lacks the sulfonylurea receptor subunit, is inhibited with low affinity by ATP, with K-1/2 similar to 550 muM. ATP inhibition of both mitoKIR and holo-mitoK(ATP) is reversed by UDP (K-1/2 = 10-15 muM). Holo-mitoK(ATP) is opened by cromakalim and diazoxide, and the flux through the open channel is inhibited by glibenclamide and 5-hydroxydecanoate. None of these agents has any effect upon mitoKIR. We have identified two compounds that act specifically on mitoKIR. p-diethylaminoethylbenzoate reverses inhibition of mitoKIR by ATP and ADP at micromolar concentrations and also opens mitoK(ATP) in isolated mitochondria. Tetraphenylphosphonium inhibits K+ flux through both mitoKIR and mitoK(ATP) with the same apparent affinity. These findings support the hypothesis that the 55-kDa mitoKIR is the channel component of mitoK(ATP).	Portland State Univ, Dept Biol, Portland, OR 97207 USA; Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142290, Moscow Region, Russia	Portland State University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics	Garlid, KD (corresponding author), Portland State Univ, Dept Biol, POB 751, Portland, OR 97207 USA.	garlid@pdx.edu	Costa, Alexandre Dias Tavares/ABB-1896-2021; Costa, Alexandre Augusto da/HCJ-0140-2022; Mironova, Galina D/Y-3702-2019	Costa, Alexandre Dias Tavares/0000-0001-8434-2152; Costa, Alexandre Augusto da/0000-0001-7558-5435; Mironova, Galina D/0000-0001-7432-0902; Garlid, Keith/0000-0002-6777-1235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL067842] Funding Source: NIH RePORTER; FIC NIH HHS [TW01116] Funding Source: Medline; NHLBI NIH HHS [HL67842, HL36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Bajgar R, 2001, J BIOL CHEM, V276, P33369, DOI 10.1074/jbc.M103320200; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; Dos Santos P, 2002, AM J PHYSIOL-HEART C, V283, pH284, DOI 10.1152/ajpheart.00034.2002; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; Garlid KD, 2000, BASIC RES CARDIOL, V95, P275, DOI 10.1007/s003950070046; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; Garlid KD, 2001, IUBMB LIFE, V52, P153, DOI 10.1080/15216540152845948; GARLID KD, 1985, J BIOL CHEM, V260, P3434; Garlid KD, 1997, CIRC RES, V81, P1072; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Garlid Keith D., 1996, Biophysical Journal, V70, pA311; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; Grigoriev SM, 1999, BBA-BIOENERGETICS, V1410, P91, DOI 10.1016/S0005-2728(98)00179-0; Grover GJ, 2000, J MOL CELL CARDIOL, V32, P677, DOI 10.1006/jmcc.2000.1111; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLIB MA, 1984, METHOD PHARMACOL, V5, P25; Mironova G. D., 1981, Biophysics, V26, P458; Mironova G D, 1997, Membr Cell Biol, V10, P583; Mironova GD, 1999, J BIOENERG BIOMEMBR, V31, P159, DOI 10.1023/A:1005408029549; MIRONOVA GD, 1996, MEMBR CELL BIOL, V10, P429; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; Paucek P, 1996, J BIOL CHEM, V271, P32084, DOI 10.1074/jbc.271.50.32084; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; YarovYarovoy V, 1997, BBA-BIOENERGETICS, V1321, P128, DOI 10.1016/S0005-2728(97)00051-0; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	43	71	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32562	32568		10.1074/jbc.M401115200	http://dx.doi.org/10.1074/jbc.M401115200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15138282	hybrid			2022-12-27	WOS:000222849700072
J	Estabrook, RA; Lipson, R; Hopkins, B; Reich, N				Estabrook, RA; Lipson, R; Hopkins, B; Reich, N			The coupling of tight DNA binding and base flipping - Identification of a conserved structural motif in base flipping enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HHAI METHYLTRANSFERASE; ESCHERICHIA-COLI; TARGET BASE; CRYSTAL-STRUCTURE; MECHANISM; GLYCOSYLASE; METHYLATION; CATALYSIS; CYTOSINE; DYNAMICS	Val(121) is positioned immediately above the extrahelical cytosine in HhaI DNA C-5-cytosine methyltransferase, and replacement with alanine dramatically interferes with base flipping and catalysis. DNA binding and k(cat) are decreased 10(5)-fold for the Val(121) --> Ala mutant that has a normal circular dichroism spectrum and AdoMet affinity. The magnitude of this loss of function is comparable with removal of the essential catalytic Cys(81). Surprisingly, DNA binding is completely recovered ( increase of 10(5)-fold) with a DNA substrate lacking the target cytosine base (abasic). Thus, interfering with the base flipping transition results in a dramatic loss of binding energy. Our data support an induced fit mechanism in which tight DNA binding is coupled to both base flipping and protein loop rearrangement. The importance of the proximal protein segment ( His(127) Thr(132)) in maintaining this critical interaction between Val(121) and the flipped cytosine was probed with single site alanine substitutions. None of these mutants are significantly altered in secondary structure, AdoMet or DNA affinity, k(methylation), k(inactivation), or k(cat). Although Val(121) plays a critical role in both extrahelical base stabilization and catalysis, its position and mobility are not influenced by individual residues in the adjacent peptide region. Structural comparisons with other DNA methyltransferases and DNA repair enzymes that stabilize extrahelical nucleotides reveal a motif that includes a positively charged or polar side chain and a hydrophobic residue positioned adjacent to the target DNA base and either the 5'- or 3'-phosphate.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Reich, N (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	reich@chem.ucsb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046333] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46333] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1999, J BIOL CHEM, V274, P19269, DOI 10.1074/jbc.274.27.19269; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Banavali NK, 2002, J MOL BIOL, V319, P141, DOI 10.1016/S0022-2836(02)00194-8; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Blumenthal RM, 2001, NAT STRUCT BIOL, V8, P101, DOI 10.1038/84072; Bruice TC, 2002, ACCOUNTS CHEM RES, V35, P139, DOI 10.1021/ar0001665; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOUGLAS KT, 1987, MED RES REV, V7, P441, DOI 10.1002/med.2610070405; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; FERSHT A, 1999, STRUCTURE MECH PROTE, P332; GABBARA S, 1995, BIOCHEMISTRY-US, V34, P8914, DOI 10.1021/bi00027a044; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; Gueron M, 1995, METHOD ENZYMOL, V261, P383; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P3271, DOI 10.1021/bi00227a015; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Huang N, 2003, P NATL ACAD SCI USA, V100, P68, DOI 10.1073/pnas.0135427100; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; Lariviere L, 2002, J MOL BIOL, V324, P483, DOI 10.1016/S0022-2836(02)01091-4; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau EY, 1999, J MOL BIOL, V293, P9, DOI 10.1006/jmbi.1999.3120; Lau EY, 1998, J AM CHEM SOC, V120, P12387, DOI 10.1021/ja9827447; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MI S, 1995, NUCLEIC ACIDS RES, V23, P620, DOI 10.1093/nar/23.4.620; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Perakyla M, 1998, J AM CHEM SOC, V120, P12895, DOI 10.1021/ja981405a; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rozovsky S, 2001, J MOL BIOL, V310, P259, DOI 10.1006/jmbi.2001.4672; Sankpal UT, 2002, NUCLEIC ACIDS RES, V30, P2628, DOI 10.1093/nar/gkf380; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Solstad T, 2003, EUR J BIOCHEM, V270, P929, DOI 10.1046/j.1432-1033.2003.03455.x; Sutcliffe MJ, 2002, EUR J BIOCHEM, V269, P3096, DOI 10.1046/j.1432-1033.2002.03020.x; TAKUSAGAWA F, 1998, S ADENOSYLMETHIONINE, P1; Vilkaitis G, 2000, J BIOL CHEM, V275, P38722, DOI 10.1074/jbc.M005278200; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; Wang PY, 2000, J AM CHEM SOC, V122, P12422, DOI 10.1021/ja001989s; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; WU JC, 1987, J BIOL CHEM, V262, P4778; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	54	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31419	31428		10.1074/jbc.M402950200	http://dx.doi.org/10.1074/jbc.M402950200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143064	hybrid			2022-12-27	WOS:000222726800063
J	Hisanaga, Y; Ago, H; Nakagawa, N; Hamada, K; Ida, K; Yamamoto, M; Hori, T; Arii, Y; Sugahara, M; Kuramitsu, S; Yokoyama, S; Miyano, M				Hisanaga, Y; Ago, H; Nakagawa, N; Hamada, K; Ida, K; Yamamoto, M; Hori, T; Arii, Y; Sugahara, M; Kuramitsu, S; Yokoyama, S; Miyano, M			Structural basis of the substrate-specific two-step catalysis of long chain fatty acyl-CoA synthetase dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE MOVEMENT; FIREFLY LUCIFERASE; ESCHERICHIA-COLI; ACID; ENZYME; ACYLATION; BINDING	Long chain fatty acyl-CoA synthetases are responsible for fatty acid degradation as well as physiological regulation of cellular functions via the production of long chain fatty acyl-CoA esters. We report the first crystal structures of long chain fatty acyl-CoA synthetase homodimer (LC-FACS) from Thermus thermophilus HB8 (ttLC-FACS), including complexes with the ATP analogue adenosine 5'-(beta,gamma-imido) triphosphate (AMP-PNP) and myristoyl-AMP. ttLC-FACS is a member of the adenylate forming enzyme superfamily that catalyzes the ATP-dependent acylation of fatty acid in a two-step reaction. The first reaction step was shown to propagate in AMP-PNP complex crystals soaked with myristate solution. Myristoyl-AMP was identified as the intermediate. The AMP-PNP and the myristoyl-AMP complex structures show an identical closed conformation of the small C-terminal domains, whereas the uncomplexed form shows a variety of open conformations. Upon ATP binding, the fatty acid-binding tunnel gated by an aromatic residue opens to the ATP-binding site. The gated fatty acid-binding tunnel appears only to allow one-way movement of the fatty acid during overall catalysis. The protein incorporates a hydrophobic branch from the fatty acid-binding tunnel that is responsible for substrate specificity. Based on these high resolution crystal structures, we propose a unidirectional Bi Uni Uni Bi Ping-Pong mechanism for the two-step acylation by ttLC-FACS.	RIKEN, Harima Inst SPring, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst SPring, Highthroughput Factory, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst SPring, Structurome Res Grp, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst SPring, Coherent Xray Opt Lab, Sayo, Hyogo 6795148, Japan; Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Kanagawa 2300045, Japan	RIKEN; RIKEN; RIKEN; RIKEN; Osaka University; Yokohama City University	Miyano, M (corresponding author), RIKEN, Harima Inst SPring, Struct Biophys Lab, 8 Kouto, Sayo, Hyogo 6795148, Japan.	ago@spring8.or.jp; miyano@spring8.or.jp	Yokoyama, Shigeyuki/N-6911-2015; Yamamoto, Masaki/B-7844-2015; Miyano, Masashi/R-2785-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Yamamoto, Masaki/0000-0002-1311-1768; Miyano, Masashi/0000-0003-2253-6175; Ago, Hideo/0000-0002-9040-488X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTANA J, 1973, BIOCHEM J, V135, P411, DOI 10.1042/bj1350411; BARTANA J, 1973, BIOCHEM J, V131, P199, DOI 10.1042/bj1310199; BERG P, 1956, J BIOL CHEM, V222, P991; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Black PN, 2000, J BIOL CHEM, V275, P38547, DOI 10.1074/jbc.M006413200; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERSHT A, 1999, STRUCTURE MECH PROTE, P245; Fraisl P, 2004, BIOCHEM J, V377, P85, DOI 10.1042/BJ20031062; Fulda M, 2002, PLANT J, V32, P93, DOI 10.1046/j.1365-313X.2002.01405.x; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; Gulick AM, 2003, BIOCHEMISTRY-US, V42, P2866, DOI 10.1021/bi0271603; GURANOWSKI A, 1994, J BACTERIOL, V176, P2986, DOI 10.1128/JB.176.10.2986-2990.1994; HOSAKA K, 1979, EUR J BIOCHEM, V93, P197, DOI 10.1111/j.1432-1033.1979.tb12811.x; Jogl G, 2004, BIOCHEMISTRY-US, V43, P1425, DOI 10.1021/bi035911a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; Kumasaka T, 2002, STRUCTURE, V10, P1205, DOI 10.1016/S0969-2126(02)00830-4; LAI JCK, 1993, RES COMMUN CHEM PATH, V82, P331; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li ZN, 2001, J GEN VIROL, V82, P1085, DOI 10.1099/0022-1317-82-5-1085; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; May JJ, 2002, P NATL ACAD SCI USA, V99, P12120, DOI 10.1073/pnas.182156699; MISHINA M, 1978, EUR J BIOCHEM, V89, P321, DOI 10.1111/j.1432-1033.1978.tb12533.x; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murakami K, 2001, BIOCHEM J, V353, P231, DOI 10.1042/0264-6021:3530231; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oba Y, 2003, FEBS LETT, V540, P251, DOI 10.1016/S0014-5793(03)00272-2; OBRIEN WJ, 1977, J BACTERIOL, V132, P532, DOI 10.1128/JB.132.2.532-540.1977; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YH, 2001, BIOCHEMISTRY-US, V40, P609, DOI 10.1021/bi002514g; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PHILIPP DP, 1979, J BIOL CHEM, V254, P785; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Saunders C, 1996, BIOCHEM J, V313, P849, DOI 10.1042/bj3130849; SCHOMBURG D, 2001, SPRINGER HDB ENZYMES, V2, P186; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; TAKAO S, 1987, AGR BIOL CHEM TOKYO, V51, P145, DOI 10.1080/00021369.1987.10868004; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Weimar JD, 2002, J BIOL CHEM, V277, P29369, DOI 10.1074/jbc.M107022200; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	56	163	166	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31717	31726		10.1074/jbc.M400100200	http://dx.doi.org/10.1074/jbc.M400100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145952	hybrid			2022-12-27	WOS:000222726800097
J	Hong, M; Zhou, FF; You, GF				Hong, M; Zhou, FF; You, GF			Critical amino acid residues in transmembrane domain 1 of the human organic anion transporter hOAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTAGENESIS; SITE	Human organic anion transporter 1 (hOAT1) belongs to a superfamily of organic anion transporters, which play critical roles in the body disposition of clinically important drugs, including anti-human immunodeficiency virus therapeutics, anti-tumor drugs, antibiotics, anti-hypertensives, and anti-inflammatories. Previously we suggested that the predicted transmembrane domain 1 (TM1) of hOAT1 might be important for its function. In the present study, we examined the role of each residue within TM1 of hOAT1 in substrate recognition and transport. Alanine scanning was used to construct mutants of hOAT1, and the uptake of model substrate para-aminohippurate was studied in COS-7 cells expressing the mutant transporters. This approach led to the discovery of two critical amino acid residues, Leu-30 and Thr-36. A substitution of Leu-30 or Thr-36 with alanine resulted in a complete loss of transport activities. We then further characterized Leu-30 and Thr-36 by mutagenizing these residues to amino acids with different physicochemical properties. Leu-30 was replaced with amino acids with varying sizes of side chains, including glycine, valine, and isoleucine. We showed that progressively smaller side chains at position 30 increasingly impaired hOAT1 function mainly because of the impaired surface expression of the transporter. Thr-36, another critical amino acid in TM1, was replaced by serine and cysteine. Similar to the substitution of Thr-36 by alanine, substitution by serine and cysteine at this position abolished transport activity without affecting the surface expression of the transporter. The fact that Thr-36 cannot be substituted with serine and that the side chains of alanine, serine, and cysteine are smaller than that of threonine by a methyl group indicate that both the methyl group and the hydroxyl group of Thr-36 could be critical for hOAT1 activity. Together we conclude that Leu-30 and Thr-36 play distinct roles in hOAT1 function. Leu-30 is important in targeting the transporter to the plasma membrane. In contrast, Thr-36 is critical for substrate recognition. The present study provided the first molecular evidence that transmembrane domain 1 is a critical determinant of hOAT1 function and may provide important insights into the structure-function relationships of the organic anion transporter family.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	You, GF (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinhuysen Rd, Piscataway, NJ 08854 USA.	gyou@cop.rutgers.edu	Zhou, Fanfan/M-4404-2013; Zhou, Fanfan/J-2327-2019	Zhou, Fanfan/0000-0002-1982-1541; Zhou, Fanfan/0000-0002-1982-1541; Hong, Mei/0000-0001-9219-2844	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060034] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 60034] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Diez-Sampedro A, 2001, J BIOL CHEM, V276, P49188, DOI 10.1074/jbc.M108286200; Ekaratanawong S, 2004, J PHARMACOL SCI, V94, P297, DOI 10.1254/jphs.94.297; Leu YJ, 2003, J BIOL CHEM, V278, P7300, DOI 10.1074/jbc.M206701200; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Witt H, 2002, BIOCHEMISTRY-US, V41, P8557, DOI 10.1021/bi025822i; You GF, 2004, CURR DRUG METAB, V5, P55, DOI 10.2174/1389200043489207; You GF, 2002, MED RES REV, V22, P602, DOI 10.1002/med.10019	8	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31478	31482		10.1074/jbc.M404686200	http://dx.doi.org/10.1074/jbc.M404686200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145940	hybrid			2022-12-27	WOS:000222726800070
J	Munir, S; Xu, GX; Wu, YJ; Yang, B; Lala, PK; Peng, C				Munir, S; Xu, GX; Wu, YJ; Yang, B; Lala, PK; Peng, C			Nodal and ALK7 inhibit proliferation and induce apoptosis in human trophoblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; RECEPTOR SERINE/THREONINE KINASE; CYCLIN-DEPENDENT KINASES; TGF-BETA; EXPRESSION; ACTIVIN; MECHANISM; PATHWAYS; CRIPTO; SMADS	Nodal, a member of the transforming growth factor-beta superfamily, is known to play critical roles in early vertebrate development, but its functions in extraembryonic tissues are unclear. ALK7 is a type I receptor for Nodal. Recently, we demonstrated that Nodal mRNA and several ALK7 transcripts are expressed in human placenta throughout pregnancy (Roberts, H. J., Hu, S., Qiu, Q., Leung, P. C. K., Cannigia, I., Gruslin, A., Tsang, B., and Peng, C. ( 2003) Biol. Reprod. 68, 1719 - 1726). In this study, we determined the role of Nodal and ALK7 in trophoblast cell proliferation and apoptosis. Overexpression of Nodal in normal trophoblast cells (HTR8/ SVneo) and several choriocarcinoma cell lines resulted in a significant decrease in the number of metabolically active cells. The effect of Nodal could be mimicked by constitutively active ALK7 (ALK7-ca), but was blocked by kinase-deficient ALK7. The growth inhibitory effect of Nodal was also blocked by dominant-negative Smad2/3. Overexpression of Nodal and ALK7-ca induced apoptosis in trophoblast cells as determined by Hoechst staining, flow cytometry, and caspase-3 Western blotting. In addition, Nodal and ALK7-ca decreased the number of proliferating cells as measured by bromodeoxyuridine assays. Furthermore, overexpression of Nodal or ALK7-ca increased p27 expression, but reduced the levels of Cdk2 and cyclin D-1. Taken together, this study demonstrates for the first time that Nodal, acting through ALK7 and Smad2/3, inhibits proliferation and induces apoptosis in human trophoblast cells. Our findings also suggest that the Nodal-ALK7 pathway inhibits cell proliferation by inducing G(1) cell cycle arrest and that this effect is mediated in part by the p27-cyclin E/Cdk2 pathway.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada	York University - Canada; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Western University (University of Western Ontario)	Peng, C (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.	cpeng@yorku.ca						Aboagye-Mathiesen G, 1996, Early Pregnancy, V2, P102; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Bondestam J, 2001, CYTOGENET CELL GENET, V95, P157, DOI 10.1159/000059339; Brennan J, 2002, GENE DEV, V16, P2339, DOI 10.1101/gad.1016202; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Donovan J, 2000, BREAST CANCER RES, V2, P116, DOI 10.1186/bcr43; Eimon PM, 2002, DEVELOPMENT, V129, P3089; GRAHAM CH, 1992, BIOL REPROD, V46, P561, DOI 10.1095/biolreprod46.4.561; GRAHAM CH, 1994, EXP CELL RES, V214, P93, DOI 10.1006/excr.1994.1237; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; GRAHAM CH, 1991, J CELL PHYSIOL, V148, P228, DOI 10.1002/jcp.1041480207; GRANA X, 1995, ONCOGENE, V11, P211; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; Jornvall H, 2001, J BIOL CHEM, V276, P5140, DOI 10.1074/jbc.M005200200; Kim BC, 2004, J BIOL CHEM, V279, P28458, DOI 10.1074/jbc.M313277200; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Kumar A, 2001, J BIOL CHEM, V276, P656, DOI 10.1074/jbc.M004649200; Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149; Luo S, 2002, MOL HUM REPROD, V8, P318, DOI 10.1093/molehr/8.4.318; Ma GT, 2001, DEV BIOL, V236, P124, DOI 10.1006/dbio.2001.0334; Massague J, 2000, GENE DEV, V14, P627; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Peng Chun, 2003, J Obstet Gynaecol Can, V25, P834; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Roberts HJ, 2003, BIOL REPROD, V68, P1719, DOI 10.1095/biolreprod.102.013045; Ryden M, 1996, J BIOL CHEM, V271, P30603, DOI 10.1074/jbc.271.48.30603; Schafer KA, 1998, VET PATHOL, V35, P461, DOI 10.1177/030098589803500601; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Watanabe R, 1999, BIOCHEM BIOPH RES CO, V254, P707, DOI 10.1006/bbrc.1998.0118; Wieser R, 2001, CURR OPIN ONCOL, V13, P70, DOI 10.1097/00001622-200101000-00014; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu DN, 2001, MOL CELL ENDOCRINOL, V175, P111, DOI 10.1016/S0303-7207(01)00397-5; Xu GX, 2003, BIOCHEM BIOPH RES CO, V300, P383, DOI 10.1016/S0006-291X(02)02845-0; Xu GX, 2002, BIOCHEM BIOPH RES CO, V294, P1079, DOI 10.1016/S0006-291X(02)00605-8; Xu GX, 2001, BIOCHEM BIOPH RES CO, V287, P47, DOI 10.1006/bbrc.2001.5533; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	48	89	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31277	31286		10.1074/jbc.M400641200	http://dx.doi.org/10.1074/jbc.M400641200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150278	hybrid			2022-12-27	WOS:000222726800047
J	Seow, HA; Penketh, PG; Belcourt, MF; Tomasz, M; Rockwell, S; Sartorelli, AC				Seow, HA; Penketh, PG; Belcourt, MF; Tomasz, M; Rockwell, S; Sartorelli, AC			Nuclear overexpression of NAD(P)H : quinone oxidoreductase 1 in Chinese hamster ovary cells increases the cytotoxicity of mitomycin C under aerobic and hypoxic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR CELLS; DT-DIAPHORASE; REDUCTIVE ACTIVATION; DNA-ADDUCTS; XANTHINE DEHYDROGENASE; NADPH-CYTOCHROME-P-450 REDUCTASE; DRUG-METABOLISM; P-450 REDUCTASE; CROSS-LINKING; BIOACTIVATION	The effects of the subcellular localization of overexpressed bioreductive enzyme NAD(P) H: quinone oxidoreductase 1 (NQO1) on the activity of the antineoplastic agent mitomycin C ( MC) under aerobic and hypoxic conditions were examined. Chinese hamster ovary ( CHO-K1/ dhfr(-)) cells were transfected with NQO1 cDNA to produce cells that overexpressed NQO1 activity in the nucleus (148-fold) or the cytosol (163-fold) over the constitutive level of the enzyme in parental cells. Subcellular localization of the enzyme was confirmed using antibody-assisted immunofluorescence. Nuclear localization of transfected NQO1 activity increased the cytotoxicity of MC over that produced by overexpression in the cytosol under both aerobic and hypoxic conditions, with greater cytotoxicity being produced under hypoxia. The greater cytotoxicity of nuclear localized NQO1 was not attributable to greater metabolic activation of MC but instead was the result of activation of the drug in close proximity to its target, nuclear DNA. A positive relationship existed between the degree of MC-induced cytotoxicity and the number of MC-DNA adducts produced. The findings indicate that activation of MC proximal to nuclear DNA by the nuclear localization of transfected NQO1 increases the cytotoxic effects of MC regardless of the degree of oxygenation and support the concept that the mechanism of action of MC involves alkylation of DNA.	Yale Univ, Sch Med, Dept Pharmacol, Yale Canc Ctr, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Therapeut Radiol, Yale Canc Ctr, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dev Therapeut Program, Yale Canc Ctr, New Haven, CT 06520 USA; CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA	Yale University; Yale University; Yale University; City University of New York (CUNY) System; Hunter College (CUNY)	Sartorelli, AC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Yale Canc Ctr, 333 Cedar St, New Haven, CT 06520 USA.	alan.sartorelli@yale.edu	Rockwell, Sara/B-8458-2009		NCI NIH HHS [CA-80845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; Baumann RP, 2001, CANCER RES, V61, P7770; BEGLEITER A, 1992, MOL PHARMACOL, V41, P677; Belcourt M. F., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P599; Belcourt MF, 1996, BIOCHEM PHARMACOL, V51, P1669, DOI 10.1016/0006-2952(96)00143-8; Belcourt MF, 1998, J BIOL CHEM, V273, P8875, DOI 10.1074/jbc.273.15.8875; Belcourt MF, 1996, P NATL ACAD SCI USA, V93, P456, DOI 10.1073/pnas.93.1.456; Belcourt MF, 1998, ADV ENZYME REGUL, V38, P111, DOI 10.1016/S0065-2571(97)00009-5; BIZANEK R, 1993, CANCER RES, V53, P5127; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; Fisher J., 1982, DEV BIOCHEM, V21, P240; GARGIULO D, 1995, NUCL ACIDS S SER, V34, P169; GUSTAFSON DL, 1992, JNCI-J NATL CANCER I, V84, P1180, DOI 10.1093/jnci/84.15.1180; GUSTAFSON DL, 1992, CANCER RES, V52, P6936; HODNICK WF, 1993, CANCER RES, V53, P4907; Holtz KM, 2003, J BIOL CHEM, V278, P5029, DOI 10.1074/jbc.M209722200; IYER VN, 1963, P NATL ACAD SCI USA, V50, P355, DOI 10.1073/pnas.50.2.355; IYER VN, 1964, SCIENCE, V145, P55, DOI 10.1126/science.145.3627.55; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Jiang HB, 2000, BIOCHEM PHARMACOL, V60, P571, DOI 10.1016/S0006-2952(00)00346-4; Jiang HB, 2001, LIFE SCI, V68, P1677, DOI 10.1016/S0024-3205(01)00959-6; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KENNEDY KA, 1980, CANCER RES, V40, P2356; KEYES SR, 1991, CANCER COMMUN-US, V3, P351, DOI 10.3727/095535491820873812; KEYES SR, 1984, CANCER RES, V44, P5638; KOMIYAMA T, 1979, J PHARMACOBIO-DYNAM, V2, P407, DOI 10.1248/bpb1978.2.407; Kumar GS, 1997, BIOCHEMISTRY-US, V36, P14128, DOI 10.1021/bi971394i; MCHUGH KM, 1988, NUCLEIC ACIDS RES, V16, P4167, DOI 10.1093/nar/16.9.4167; MURRAY RDH, 1982, NATURAL COUMARINS OC, P241; Palom Y, 2001, BIOCHEM PHARMACOL, V61, P1517, DOI 10.1016/S0006-2952(01)00609-8; Palom Y, 1998, ONCOL RES, V10, P509; Palom Y, 2000, CHEM RES TOXICOL, V13, P479, DOI 10.1021/tx000024j; PAN SS, 1988, MOL PHARMACOL, V34, P223; PAN SS, 1984, J BIOL CHEM, V259, P959; Penketh PG, 2001, J BIOL CHEM, V276, P34445, DOI 10.1074/jbc.M104263200; Phillips RM, 2000, CANCER RES, V60, P6384; PRITSOS CA, 1994, ONCOL RES, V6, P477; PRITSOS CA, 1986, CANCER RES, V46, P3528; PRITSOS CA, 1985, ANAL BIOCHEM, V150, P294, DOI 10.1016/0003-2697(85)90513-5; RAUTH AM, 1983, CANCER RES, V43, P4154; SIEGEL D, 1992, BIOCHEMISTRY-US, V31, P7879, DOI 10.1021/bi00149a019; SIEGEL D, 1990, CANCER RES, V50, P7483; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tomasz M, 1997, PHARMACOL THERAPEUT, V76, P73, DOI 10.1016/S0163-7258(97)00088-0; TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANCUROVA I, 1994, BIOCHEM BIOPH RES CO, V205, P529, DOI 10.1006/bbrc.1994.2697; WAKAKI S., 1958, ANTIBIOT AND CHEMOTHER, V8, P228; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YUBISUI T, 1982, J BIOCHEM, V91, P1467, DOI 10.1093/oxfordjournals.jbchem.a133838	51	23	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31606	31612		10.1074/jbc.M404910200	http://dx.doi.org/10.1074/jbc.M404910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155746	hybrid			2022-12-27	WOS:000222726800084
J	Srinivasan, S; Bolick, DT; Hatley, ME; Natarajan, R; Reilly, KB; Yeh, M; Chrestensen, C; Sturgill, TW; Hedrick, CC				Srinivasan, S; Bolick, DT; Hatley, ME; Natarajan, R; Reilly, KB; Yeh, M; Chrestensen, C; Sturgill, TW; Hedrick, CC			Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGGER FIRM ADHESION; VASCULAR ENDOTHELIUM; MONOCYTE ADHESION; MAP KINASE; MONOCYTE/ENDOTHELIAL INTERACTIONS; ATHEROSCLEROTIC LESIONS; FLOW CONDITIONS; TNF-ALPHA; DISEASE; ATHEROGENESIS	We have shown that chronic elevated glucose ( 25 mM) increases monocyte adhesion to human aortic endothelial cells (EC). This increased adhesion is mediated primarily through induction of interleukin (IL)-8 via activation of the transcription factor AP-1 ( Srinivasan, S., Yeh, M., Danziger, E. C., Hatley, M. E., Riggan, A. E., Leitinger, N., Berliner, J. A., and Hedrick, C. C. ( 2003) Circ. Res. 92, 371 - 377). In the current study, we identified the elements in the AP-1 transcriptional complex that are activated by glucose. These elements include c-Jun, c-Fos, and Fra-1. AP-1 is activated by cellular oxidative stress, and we have reported significant production of ROS by high glucose-cultured cells. We examined signaling pathways upstream of AP-1 in EC that lead to AP-1 activation by HG. EC cultured in 25 mM glucose had a 2-fold increase in p38 phosphorylation compared with control normal glucose-cultured EC. Inhibition of the p38 pathway using 5 muM SB203580 significantly reduced glucose-mediated IL-8 mRNA production by 60%. Furthermore, blocking p38 pathway activation using a dominant-negative p38 construct significantly reduced glucose-mediated monocyte adhesion by 50%. Thus, glucose-stimulated monocyte adhesion is primarily regulated through phosphorylation of p38 with subsequent activation of AP-1, leading to IL-8 production. To study this pathway in the setting of diabetes, we used the db/db mouse. P38 phosphorylation was increased in diabetic db/db mice compared with control mice. We found a dramatic elevation in plasma levels of KC, the mouse ortholog of IL-8 in diabetic db/db mice ( 1800 +/- 100 pg/ml KC in db/db versus 300 +/- 75 pg/ml in C57BL/6J control mice, p < 0.0001). Inhibition of the p38 pathway in diabetic db/db mice significantly reduced monocyte adhesion by 50%. Taken together, these data indicate that chronic elevated glucose in diabetes activates the p38 MAP kinase pathway to increase inflammatory IL-8 gene induction and monocyte/endothelial adhesion.	Univ Virginia, Cardiovasc Res Ctr, Div Endocrinol & Metab, Charlottesville, VA 22908 USA; City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet, Duarte, CA 91010 USA; Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Los Angeles; University of Virginia	Hedrick, CC (corresponding author), Univ Virginia, Cardiovasc Res Ctr, Div Endocrinol & Metab, POB 801394,415 Lane Rd,MR5 Rm G123, Charlottesville, VA 22908 USA.	cch6n@virginia.edu	Bolick, David/A-3467-2017; Hedrick, Catherine/D-1106-2012		NHLBI NIH HHS [P01 HL55798-09] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; BERLINER JA, 2001, VASCULAR ADHESION IN, P239; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Conti P, 2001, ALLERGY ASTHMA PROC, V22, P133, DOI 10.2500/108854101778148737; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; GERRITY RG, 1981, AM J PATHOL, V103, P191; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Hatley ME, 2003, J BIOL CHEM, V278, P25369, DOI 10.1074/jbc.M301175200; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Lahti A, 2002, EUR J PHARMACOL, V454, P115, DOI 10.1016/S0014-2999(02)02490-1; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LEY K, 1995, J IMMUNOL, V155, P525; Luscinskas FW, 2000, ANN NY ACAD SCI, V902, P288; McEvoy LM, 1997, J EXP MED, V185, P2069, DOI 10.1084/jem.185.12.2069; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; Reilly KB, 2004, J BIOL CHEM, V279, P9440, DOI 10.1074/jbc.M303857200; REILLY KB, 2003, J BIOL CHEM; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; Shi WB, 2000, CIRC RES, V86, P1078, DOI 10.1161/01.RES.86.10.1078; SOWERS JR, 1995, HYPERTENSION, V26, P869, DOI 10.1161/01.HYP.26.6.869; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Srinivasan S, 2003, CIRC RES, V92, P371, DOI 10.1161/01.RES.0000061714.74668.5C; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Thulaseedharan N, 1995, Indian Heart J, V47, P471; Tkac I, 1997, ARTERIOSCL THROM VAS, V17, P3633, DOI 10.1161/01.ATV.17.12.3633; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; UUSITUPA MIJ, 1990, CIRCULATION, V82, P27, DOI 10.1161/01.CIR.82.1.27; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Yeh M, 2001, ARTERIOSCL THROM VAS, V21, P1585, DOI 10.1161/hq1001.097027; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322	39	52	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31930	31936		10.1074/jbc.M400753200	http://dx.doi.org/10.1074/jbc.M400753200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145956	hybrid			2022-12-27	WOS:000222726800120
J	Buglino, J; Onwueme, KC; Ferreras, JA; Quadri, LEN; Lima, CD				Buglino, J; Onwueme, KC; Ferreras, JA; Quadri, LEN; Lima, CD			Crystal structure of PapA5, a phthiocerol dimycocerosyl transferase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE SYNTHETASE CONDENSATION; CELL-WALL; VIBRIO-CHOLERAE; GENE-CLUSTER; SYNTHASE; BIOSYNTHESIS; ACETYLTRANSFERASE; GENOME; RECONSTITUTION; ATTENUATION	Polyketide-associated protein A5 (PapA5) is an acyltransferase that is involved in production of phthiocerol and phthiodiolone dimycocerosate esters, a class of virulence-enhancing lipids produced by Mycobacterium tuberculosis. Structural analysis of PapA5 at 2.75-resolution reveals a two-domain structure that shares unexpected similarity to structures of chloramphenicol acetyltransferase, dihydrolipoyl transacetylase, carnitine acetyltransferase, and VibH, a non-ribosomal peptide synthesis condensation enzyme. The PapA5 active site includes conserved histidine and aspartic acid residues that are critical to PapA5 acyltransferase activity. PapA5 catalyzes acyl transfer reactions on model substrates that contain long aliphatic carbon chains, and two hydrophobic channels were observed linking the PapA5 surface to the active site with properties consistent with these biochemical activities and substrate preferences. An additional alpha helix not observed in other acyltransferase structures blocks the putative entrance into the PapA5 active site, indicating that conformational changes may be associated with PapA5 activity. PapA5 represents the first structure solved for a protein involved in polyketide synthesis in Mycobacteria.	Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Lima, CD (corresponding author), Sloan Kettering Inst, Struct Biol Program, Box 414,1275 York Ave, New York, NY 10021 USA.	lima@limalab.org	Ferreras, Julian/U-5032-2019	Ferreras, Julian/0000-0003-4189-2917; Lima, Christopher/0000-0002-9163-6092	NIAID NIH HHS [1 F31 AI054326-01] Funding Source: Medline; NIGMS NIH HHS [GM62529] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI054326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062529] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bentley R, 1999, ANNU REV MICROBIOL, V53, P411, DOI 10.1146/annurev.micro.53.1.411; Brennan PJ, 2001, LEPROSY REV, V72, P415; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DECRECYLAGARD V, 1999, COMPREHENSIVE NATURA, V4, P221; DeLano W.L., 2002, PYMOL OPEN SOURCE MO; Dubey VS, 2003, J BACTERIOL, V185, P4620, DOI 10.1128/JB.185.15.4620-4625.2003; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Floss HG, 1999, CURR OPIN CHEM BIOL, V3, P592, DOI 10.1016/S1367-5931(99)00014-9; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keating TA, 2002, NAT STRUCT BIOL, V9, P522, DOI 10.1038/nsb810; Keating TA, 2000, BIOCHEMISTRY-US, V39, P15513, DOI 10.1021/bi001651a; Keating TA, 2000, BIOCHEMISTRY-US, V39, P15522, DOI 10.1021/bi0016523; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIU XD, 1990, BIOCHEMISTRY-US, V29, P8614, DOI 10.1021/bi00489a017; Onwueme KC, 2004, P NATL ACAD SCI USA, V101, P4608, DOI 10.1073/pnas.0306928101; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Quadri LEN, 1999, BIOCHEMISTRY-US, V38, P14941, DOI 10.1021/bi991787c; Quadri LEN, 2000, MOL MICROBIOL, V37, P1, DOI 10.1046/j.1365-2958.2000.01941.x; Rambukkana A, 2002, SCIENCE, V296, P927, DOI 10.1126/science.1067631; Rousseau C, 2003, MICROBIOL-SGM, V149, P1837, DOI 10.1099/mic.0.26278-0; Sirakova TD, 2003, INFECT IMMUN, V71, P3794, DOI 10.1128/IAI.71.7.3794-3801.2003; Sirakova TD, 2003, J BACTERIOL, V185, P2999, DOI 10.1128/JB.185.10.2999-3008.2003; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	42	53	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30634	30642		10.1074/jbc.M404011200	http://dx.doi.org/10.1074/jbc.M404011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123643	hybrid			2022-12-27	WOS:000222531900093
J	Hemers, H; Verrijdt, G; Organe, S; Claessens, F; Heyns, W; Verhoeven, G; Swinnen, JV				Hemers, H; Verrijdt, G; Organe, S; Claessens, F; Heyns, W; Verhoeven, G; Swinnen, JV			Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CANCER CELLS; IN-VIVO; SCAP; EXPRESSION; MECHANISM; PROGESTERONE; MEMBRANES; PROSTATE; PATHWAY	Sterol regulatory element-binding proteins (SREBPs) are transcription regulators that play a pivotal role in intracellular lipid homeostasis. They are synthesized as inactive precursor proteins in the endoplasmic reticulum, where they are retained by SREBP cleavage-activating protein (SCAP), a sterol sensing protein that in turn is linked to a retention protein complex. Low intracellular sterol concentrations weaken the interaction of SCAP with its retention proteins and allow translocation of the SREBP.SCAP complex to the Golgi compartment where SREBP is proteolytically cleaved and activated. Previous studies on the mechanisms by which androgens provoke a coordinated activation of lipogenic pathways in prostate cancer cells have suggested an alternative pathway of activation in which androgens increase the expression of SCAP and favor translocation of the SREBP.SCAP complex to the Golgi apparatus by disturbing the balance between SCAP and its retention proteins. Here we show that the SCAP gene contains an androgen-responsive region located in intron 8. This region interacts directly with the androgen receptor and confers androgen responsiveness to promoter-reporter constructs transfected in LNCaP cells. It contains a noncanonical androgen response element GGAAGAaaaTGTACC that interacts not only with the androgen receptor but also with the glucocorticoid receptor and that also confers glucocorticoid responsiveness. The identification of a steroid response element in intron 8 of the SCAP gene further supports the contention that SCAP is a direct target for steroid hormone action.	Katholieke Univ Leuven, Onderwijs & Navorsing, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Onderwijs & Navorsing, Fac Med, Div Biochem, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Swinnen, JV (corresponding author), Onderwijs & Navorsing, LEGENDO, Herestr 49, B-3000 Louvain, Belgium.	johan.swinnen@med.kuleuven.ac.be	Swinnen, Johannes V/AAA-2214-2022; Claessens, Frank/M-8565-2016	Swinnen, Johannes V/0000-0002-7720-5077; Claessens, Frank/0000-0002-8676-7709				Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHAMBON M, 1989, J STEROID BIOCHEM, V33, P915, DOI 10.1016/0022-4731(89)90240-9; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; Heemers H, 2003, MOL CELL ENDOCRINOL, V205, P21, DOI 10.1016/S0303-7207(03)00205-3; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Jiang F, 2003, ENDOCRINOLOGY, V144, P1257, DOI 10.1210/en.2002-220718; JUDGE SM, 1983, CANCER RES, V43, P4407; Lacasa D, 2001, J BIOL CHEM, V276, P11512, DOI 10.1074/jbc.M008556200; Leake R. E., 1987, STEROID HORMONES PRA, P213; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; Nakajima T, 1999, J HUM GENET, V44, P402, DOI 10.1007/s100380050187; Rosignoli C, 2003, EXP DERMATOL, V12, P480, DOI 10.1034/j.1600-0625.2003.00014.x; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	23	56	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30880	30887		10.1074/jbc.M401615200	http://dx.doi.org/10.1074/jbc.M401615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133039	hybrid			2022-12-27	WOS:000222531900122
J	Hynes, TR; Tang, LN; Mervine, SM; Sabo, JL; Yost, EA; Devreotes, PN; Berlot, CH				Hynes, TR; Tang, LN; Mervine, SM; Sabo, JL; Yost, EA; Devreotes, PN; Berlot, CH			Visualization of g protein beta gamma dimers using bimolecular fluorescence complementation demonstrates roles for both beta and gamma in subcellular targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; ADENYLYL-CYCLASE; CRYSTAL-STRUCTURE; NUCLEAR-LOCALIZATION; SUBUNIT COMPOSITION; PHOSPHOLIPASE-C; SF9 CELLS; RECEPTOR; ALPHA; ASSOCIATION	To investigate the role of subcellular localization in regulating the specificity of G protein betagamma signaling, we have applied the strategy of bimolecular fluorescence complementation (BiFC) to visualize betagamma dimers in vivo. We fused an amino-terminal yellow fluorescent protein fragment to beta and a carboxyl-terminal yellow fluorescent protein fragment to gamma. When expressed together, these two proteins produced a fluorescent signal in human embryonic kidney 293 cells that was not obtained with either subunit alone. Fluorescence was dependent on betagamma assembly in that it was not obtained using beta(2) and gamma(1), which do not form a functional dimer. In addition to assembly, BiFC betagamma complexes were functional as demonstrated by more specific plasma membrane labeling than was obtained with individually tagged fluorescent beta and gamma subunits and by their abilities to potentiate activation of adenylyl cyclase by alpha(s) in COS-7 cells. To investigate isoform-dependent targeting specificity, the localization patterns of dimers formed by pair-wise combinations of three different beta subunits with three different gamma subunits were compared. BiFC betagamma complexes containing either beta(1) or beta(2) localized to the plasma membrane, whereas those containing beta(5) accumulated in the cytosol or on intracellular membranes. These results indicate that the beta subunit can direct trafficking of the gamma subunit. Taken together with previous observations, these results show that the G protein alpha, beta, and gamma subunits all play roles in targeting each other. This method of specifically visualizing betagamma dimers will have many applications in sorting out roles for particular betagamma complexes in a wide variety of cell types.	Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Berlot, CH (corresponding author), Weis Ctr Res, Geisinger Clin, 100 N Acad Ave, Danville, PA 17822 USA.	chberlot@geisinger.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050369, R01GM050369] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50369] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano T, 1999, J BIOL CHEM, V274, P21425, DOI 10.1074/jbc.274.30.21425; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chatterjee TK, 2003, J BIOL CHEM, V278, P30261, DOI 10.1074/jbc.M212687200; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Figler RA, 1997, BIOCHEMISTRY-US, V36, P16288, DOI 10.1021/bi972000q; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Hurowitz EH, 2000, DNA RES, V7, P111, DOI 10.1093/dnares/7.2.111; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Lo W, 1998, BIOTECHNIQUES, V25, P94, DOI 10.2144/98251st05; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Ostrom RS, 2002, MOL PHARMACOL, V61, P473, DOI 10.1124/mol.61.3.473; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; Robishaw JD, 2004, CURR OPIN CELL BIOL, V16, P206, DOI 10.1016/j.ceb.2004.02.007; ROBISHAW JD, 2003, HDB CELL SIGNALING, V2, P623; Rojkova AM, 2003, J BIOL CHEM, V278, P12507, DOI 10.1074/jbc.M207302200; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Schwindinger WF, 2003, J BIOL CHEM, V278, P6575, DOI 10.1074/jbc.M211132200; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Ueda H, 1997, J CELL SCI, V110, P1503; UEDA N, 1994, J BIOL CHEM, V269, P4388; Wang Q, 1999, J BIOL CHEM, V274, P17365, DOI 10.1074/jbc.274.24.17365; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575; Zhou JY, 2003, J PHARMACOL EXP THER, V305, P460, DOI 10.1124/jpet.102.048637	56	85	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30279	30286		10.1074/jbc.M401432200	http://dx.doi.org/10.1074/jbc.M401432200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136579	hybrid			2022-12-27	WOS:000222531900053
J	Pan, YP; Ma, BY; Keskin, O; Nussinov, R				Pan, YP; Ma, BY; Keskin, O; Nussinov, R			Characterization of the conformational state and flexibility of HIV-1 glycoprotein gp120 core domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 RECEPTOR-BINDING; ENVELOPE GLYCOPROTEIN; CRYSTAL-STRUCTURE; VARIABLE REGIONS; ATOMIC-STRUCTURE; NEUTRALIZATION; IDENTIFICATION; ANTIBODY; RETROVIRUS	gp120 is key to the human immunodeficiency virus type 1 viral cell entry. Knowledge of the detailed conformational states of gp120 is crucial to intervention, yet the unbound form is still resistant to structural characterization probably because of its flexibility. Toward this goal, we performed molecular dynamics simulations on the wild type gp120 core domain extracted from its ternary crystal structure and on a modeled mutant, S375W, that experimentally has a significantly different phenotype from the wild type. Although the mutant retained a bound-like conformation, the wild type drifted to a different conformational state. The wild type beta strands 2 and 3 of the bridging sheet were very mobile and partially unfolded, and the organization among the inner and outer domains and beta strands 20 and 21 of the bridging sheet, near the mutation site, was more open than in the bound form, although the overall structure was maintained. These differences were apparently a result of the strengthening of the hydrophobic core in the mutant. This stabilization further explains the experimentally significantly different thermodynamic properties between the wild type and the mutant. Taken together, our results suggest that the free form, although different from the bound state, shares many of the bound structural features. The observed loss of freedom near the binding site, rather than the previously hypothesized more dramatic conformational transition from the unbound to the bound state, appears to be the major contributor to the large entropy cost for the CD4 binding to the wild type.	NCI, Basic Res Program, Sci Applicat Int Corp Frederick Inc, Lab Expt & Computat Biol, Frederick, MD 21702 USA; Koc Univ, Ctr Computat Biol & Bioinformat, TR-34450 Istanbul, Turkey; Koc Univ, Coll Engn, TR-34450 Istanbul, Turkey; Tel Aviv Univ, Sackler Sch Med, Sackler Inst Mol Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Koc University; Koc University; Tel Aviv University; Sackler Faculty of Medicine	Nussinov, R (corresponding author), NCI, Basic Res Program, Sci Applicat Int Corp Frederick Inc, Lab Expt & Computat Biol, Bldg 469,Rm 151, Frederick, MD 21702 USA.	ruthn@ncifcrf.gov	Ma, Buyong/F-9491-2011	Ma, Buyong/0000-0002-7383-719X; Nussinov, Ruth/0000-0002-8115-6415	NATIONAL CANCER INSTITUTE [Z01BC010441] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; Biorn AC, 2004, BIOCHEMISTRY-US, V43, P1928, DOI 10.1021/bi035088i; Boussard C, 2002, EUR J MED CHEM, V37, P883, DOI 10.1016/S0223-5234(02)01412-5; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Keskin O, 2002, BIOPHYS J, V83, P663, DOI 10.1016/S0006-3495(02)75199-0; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McKnight D, 2003, P NATL ACAD SCI USA, V100, P10581, DOI 10.1073/pnas.2035071100; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; Morikita T, 1997, AIDS RES HUM RETROV, V13, P1291, DOI 10.1089/aid.1997.13.1291; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Xiang SH, 2002, J VIROL, V76, P9888, DOI 10.1128/JVI.76.19.9888-9899.2002	42	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30523	30530		10.1074/jbc.M404364200	http://dx.doi.org/10.1074/jbc.M404364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131118	hybrid, Green Submitted			2022-12-27	WOS:000222531900081
J	Stefansson, S; Yepes, M; Gorlatova, N; Day, DE; Moore, EG; Zabaleta, A; McMahon, GA; Lawrence, DA				Stefansson, S; Yepes, M; Gorlatova, N; Day, DE; Moore, EG; Zabaleta, A; McMahon, GA; Lawrence, DA			Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin g are more effective in vivo than their endogenous inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; REACTIVE-CENTER; ALPHA(1)-PROTEINASE INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; PHYSIOLOGICAL RELEVANCE; ESCHERICHIA-COLI; GROWTH-FACTOR; TISSUE-TYPE; LIPOPROTEIN; HEPARIN	Neutrophil elastase and cathepsin G are abundant intracellular neutrophil proteinases that have an important role in destroying ingested particles. However, when neutrophils degranulate, these proteinases are released and can cause irreparable damage by degrading host connective tissue proteins. Despite abundant endogenous inhibitors, these proteinases are protected from inhibition because of their ability to bind to anionic surfaces. Plasminogen activator inhibitor type-1 (PAI-1), which is not an inhibitor of these proteinases, possesses properties that could make it an effective inhibitor of neutrophil proteinases if its specificity could be redirected. PAI-1 efficiently inhibits surface-sequestered proteinases, and it efficiently mediates rapid cellular clearance of PAI-1-proteinase complexes. Therefore, we examined whether PAI-1 could be engineered to inhibit and clear neutrophil elastase and cathepsin G. By introducing specific mutations in the reactive center loop of wild-type PAI-1, we generated PAI-1 mutants that are effective inhibitors of both proteinases. Kinetic analysis shows that the inhibition of neutrophil proteinases by these PAI-1 mutants is not affected by the sequestration of neutrophil elastase and cathepsin G onto surfaces. In addition, complexes of these proteinases and PAI-1 mutants are endocytosed and degraded by lung epithelial cells more efficiently than either the neutrophil proteinases alone or in complex with their physiological inhibitors, alpha(1)-proteinase inhibitor and alpha(1)-anti-chymotrypsin. Finally, the PAI-1 mutants were more effective in reducing the neutrophil elastase and cathepsin G activities in an in vivo model of lung inflammation than were their physiological inhibitors.	JH Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Mol Innovat Inc, Southfield, MI 48034 USA		Stefansson, S (corresponding author), JH Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	StefansS@usa.redcross.org	Yepes, Manuel/C-3576-2011	Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, P01HL054710, R01HL055747, R43HL069624] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55374, HL55747, HL54710, 1 R43 HL69624-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; Belorgey D, 1998, BIOCHEMISTRY-US, V37, P16416, DOI 10.1021/bi981536o; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BIRRER P, 1995, RESPIRATION, V62, P25; BULLEN JJ, 1979, IMMUNOLOGY, V36, P781; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Coakley RJ, 2001, AM J MED SCI, V321, P33, DOI 10.1097/00000441-200101000-00006; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Duranton J, 2000, J BIOL CHEM, V275, P3787, DOI 10.1074/jbc.275.6.3787; Duranton J, 2000, FEBS LETT, V473, P154, DOI 10.1016/S0014-5793(00)01512-X; EDELBERG JM, 1991, J BIOL CHEM, V266, P7488; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Eyles JE, 1999, INT J PHARM, V189, P75, DOI 10.1016/S0378-5173(99)00239-2; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; Forsyth S, 2003, GENOMICS, V81, P336, DOI 10.1016/S0888-7543(02)00041-1; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; IACOVIELLO L, 1995, ARTERIOSCL THROM VAS, V15, P2037, DOI 10.1161/01.ATV.15.11.2037; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KEIJER J, 1991, BLOOD, V78, P401; KEIJER J, 1991, BLOOD, V78, P1254; KISS I, 1989, J BIOL CHEM, V264, P8126; KITZ R, 1962, J BIOL CHEM, V237, P3245; Koehl C, 2003, J BIOL CHEM, V278, P12609, DOI 10.1074/jbc.M210074200; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAURENT P, 1989, BIOCHIM BIOPHYS ACTA, V994, P285, DOI 10.1016/0167-4838(89)90306-3; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; LINZMEIER R, 1993, FEBS LETT, V321, P267, DOI 10.1016/0014-5793(93)80122-B; MALLAMPALLI RK, 1992, IN VITRO CELL DEV-AN, V28A, P181; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; ROSS R, 1989, LANCET, V1, P1179; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHUBEITA HE, 1990, J BIOL CHEM, V265, P18379; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEFANSSON S, 1995, J CELL SCI, V108, P2361; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TAKAHARA H, 1980, J BIOCHEM, V88, P417, DOI 10.1093/oxfordjournals.jbchem.a132988; Tucker HM, 1996, EUR J BIOCHEM, V237, P180, DOI 10.1111/j.1432-1033.1996.0180n.x; Wells MJ, 1999, THROMB HAEMOSTASIS, V81, P325, DOI 10.1055/s-0037-1614472; Welty-Wolf KE, 2001, SEMIN HEMATOL, V38, P35, DOI 10.1016/S0037-1963(01)90145-3; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056	53	24	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29981	29987		10.1074/jbc.M401913200	http://dx.doi.org/10.1074/jbc.M401913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131125	hybrid			2022-12-27	WOS:000222531900015
J	Wondrak, GT; Roberts, MJ; Jacobson, MK; Jacobson, EL				Wondrak, GT; Roberts, MJ; Jacobson, MK; Jacobson, EL			3-hydroxypyridine chromophores are endogenous sensitizers of photooxidative stress in human skin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAILLARD REACTION-PRODUCTS; SINGLET OXYGEN; CROSS-LINKS; ADVANCED GLYCATION; UVA; COLLAGEN; PYRIDOXINE; DAMAGE; IRRADIATION; PROTEINS	Photocarcinogenesis and photoaging are established consequences of chronic exposure of human skin to solar irradiation. Accumulating evidence supports a causative involvement of UVA irradiation in skin photodamage. UVA photodamage has been attributed to photosensitization by endogenous skin chromophores leading to the formation of reactive oxygen species and organic free radicals as key mediators of cellular photooxidative stress. In this study, 3-hydroxypyridine derivatives contained in human skin have been identified as a novel class of potential endogenous photosensitizers. A structure-activity relationship study of skin cell photosensitization by endogenous pyridinium derivatives ( pyridinoline, desmosine, pyridoxine, pyridoxamine, pyridoxal, pyridoxal-5'-phosphate) and various synthetic hydroxypyridine isomers identified 3-hydroxypyridine and N-alkyl-3-hydroxypyridinium cation as minimum phototoxic chromophores sufficient to effect skin cell sensitization toward UVB and UVA, respectively. Photosensitization of cultured human skin keratinocytes ( HaCaT) and fibroblasts (CF3) by endogenous and synthetic 3-hydroxypyridine derivatives led to a dose-dependent inhibition of proliferation, cell cycle arrest in G(2)/M, and induction of apoptosis, all of which were reversible by thiol antioxidant intervention. Enhancement of UVA-induced intracellular peroxide formation and p38 mitogen-activated protein kinase-dependent stress signaling suggest a photooxidative mechanism of skin cell photosensitization by 3-hydroxypyridine derivatives. 3-Hydroxypyridine derivatives were potent photosensitizers of macromolecular damage, effecting protein ( RNase A) photocross-linking and peptide (melittin) photooxidation with incorporation of molecular oxygen. Based on these results, we conclude that 3-hydroxypyridine derivatives comprising a wide range of skin biomolecules, such as enzymatic collagen cross-links, B-6 vitamers, and probably advanced glycation end products in chronologically aged skin constitute a novel class of UVA photosensitizers, capable of skin photooxidative damage.	Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Jacobson, EL (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Coll Pharm, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	elaine.jacobson@pharmacy.arizona.edu			NATIONAL CANCER INSTITUTE [R41CA099469, R01CA043894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038496] Funding Source: NIH RePORTER; NCI NIH HHS [CA43894, CA099469-01A1] Funding Source: Medline; NINDS NIH HHS [NS38496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Aveline BM, 1998, PHOTOCHEM PHOTOBIOL, V68, P266, DOI 10.1562/0031-8655(1998)068<0266:EFRMOC>2.3.CO;2; Bachelor MA, 2004, SEMIN CANCER BIOL, V14, P131, DOI 10.1016/j.semcancer.2003.09.017; Bachelor MA, 2002, ONCOGENE, V21, P7092, DOI 10.1038/sj.onc.1205855; Balakrishnan G, 2000, J PHYS CHEM A, V104, P1834, DOI 10.1021/jp993052n; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Buchczyk DP, 2001, CARCINOGENESIS, V22, P879, DOI 10.1093/carcin/22.6.879; CARBONARE MD, 1992, J PHOTOCH PHOTOBIO B, V14, P105, DOI 10.1016/1011-1344(92)85086-A; Coburn SP, 2003, J INVEST DERMATOL, V120, P292, DOI 10.1046/j.1523-1747.2003.12034.x; Daumer KM, 2000, J BIOL CHEM, V275, P34681, DOI 10.1074/jbc.M002003200; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; deLaat JMT, 1997, EXP DERMATOL, V6, P292; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; FEITELSON J, 1973, J PHYS CHEM-US, V77, P10, DOI 10.1021/j100620a003; FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x; FUJIMOTO D, 1978, BIOCHEM BIOPH RES CO, V84, P52, DOI 10.1016/0006-291X(78)90261-9; Gasparro FP, 2000, ENVIRON HEALTH PERSP, V108, P71, DOI 10.2307/3454633; Gineyts E, 2000, BIOCHEM J, V345, P481, DOI 10.1042/0264-6021:3450481; Gortz V, 2002, MACROMOLECULES, V35, P4258, DOI 10.1021/ma011750b; GUPTASARMA P, 1992, BIOCHEMISTRY-US, V31, P4296, DOI 10.1021/bi00132a021; Harrison GI, 2004, J INVEST DERMATOL, V122, P183, DOI 10.1046/j.0022-202X.2003.22119.x; Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200; Jeanmaire C, 2001, BRIT J DERMATOL, V145, P10, DOI 10.1046/j.1365-2133.2001.04275.x; Kipp C, 1999, PHOTOCHEM PHOTOBIOL, V70, P191, DOI 10.1562/0031-8655(1999)070<0191:TSEPDC>2.3.CO;2; Klotz LO, 2000, METHOD ENZYMOL, V319, P130; Kvam E, 1997, CARCINOGENESIS, V18, P2379, DOI 10.1093/carcin/18.12.2379; LEVY SB, 1992, J AM ACAD DERMATOL, V27, P989, DOI 10.1016/0190-9622(92)70300-5; Liu ZF, 2003, CHEM RES TOXICOL, V16, P232, DOI 10.1021/tx020095d; Luxford C, 1999, BIOCHEM J, V344, P125, DOI 10.1042/0264-6021:3440125; Maeda T, 2000, ARCH DERMATOL RES, V292, P562, DOI 10.1007/s004030000174; Menon EL, 2002, PHOTOCHEM PHOTOBIOL, V75, P565, DOI 10.1562/0031-8655(2002)075<0565:FOSOBU>2.0.CO;2; Metz TO, 2003, ARCH BIOCHEM BIOPHYS, V419, P41, DOI 10.1016/j.abb.2003.08.021; MORTHY PN, 1975, J AM CHEM SOC, V97; Murata Y, 1998, J AM ACAD DERMATOL, V39, P314, DOI 10.1016/S0190-9622(98)70379-2; Nagai R, 2002, J BIOL CHEM, V277, P48905, DOI 10.1074/jbc.M205688200; Ohta BK, 2002, J AM CHEM SOC, V124, P12064, DOI 10.1021/ja0205481; Okano Y, 2001, J DERMATOL SCI, V27, pS11; Ortwerth BJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P666, DOI 10.1111/j.1751-1097.1997.tb01909.x; Pasquali M, 1997, P ASSOC AM PHYSICIAN, V109, P33; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; REIBER H, 1972, BIOCHIM BIOPHYS ACTA, V279, P310, DOI 10.1016/0304-4165(72)90148-1; REISER KM, 1987, BIOCHIM BIOPHYS ACTA, V926, P339, DOI 10.1016/0304-4165(87)90220-0; ROBINS SP, 1983, BIOCHEM J, V215, P167, DOI 10.1042/bj2150167; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SATO K, 1995, J INVEST DERMATOL, V105, P608, DOI 10.1111/1523-1747.ep12323724; SATO K, 1993, J INVEST DERMATOL, V100, P266, DOI 10.1111/1523-1747.ep12469648; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SHWARTZMAN G, 1947, J BIOL CHEM, V167, P345; Tessier FJ, 2003, BIOCHEM J, V369, P705, DOI 10.1042/BJ20020668; Tyrrell RM, 1995, BIOCHEM SOC SYMP, P47, DOI 10.1042/bss0610047; Wang JH, 1996, J PHYS CHEM-US, V100, P16141, DOI 10.1021/jp961295z; Wolken JK, 1999, J AM CHEM SOC, V121, P6010, DOI 10.1021/ja983789a; Wondrak GT, 2003, J INVEST DERMATOL, V121, P578, DOI 10.1046/j.1523-1747.2003.12414.x; Wondrak GT, 2002, J INVEST DERMATOL, V119, P489, DOI 10.1046/j.1523-1747.2002.01788.x; Wondrak GT, 2002, PHOTOCH PHOTOBIO SCI, V1, P355, DOI 10.1039/b202732c; Wondrak GT, 2002, BIOCHEM PHARMACOL, V63, P361, DOI 10.1016/S0006-2952(01)00915-7; Wright A, 2003, FREE RADICAL BIO MED, V34, P637, DOI 10.1016/S0891-5849(02)01361-8; Young AR, 1997, PHYS MED BIOL, V42, P789, DOI 10.1088/0031-9155/42/5/004	61	56	57	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30009	30020		10.1074/jbc.M404379200	http://dx.doi.org/10.1074/jbc.M404379200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133022	hybrid			2022-12-27	WOS:000222531900019
J	Lund, G; Andersson, L; Lauria, M; Lindholm, M; Fraga, MF; Villar-Garea, A; Ballestar, E; Esteller, M; Zaina, S				Lund, G; Andersson, L; Lauria, M; Lindholm, M; Fraga, MF; Villar-Garea, A; Ballestar, E; Esteller, M; Zaina, S			DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE; HISTONE H4; HYPOMETHYLATION; HOMOCYSTEINE; EXPRESSION; DISEASE; CANCER; HYPERCHOLESTEROLEMIA; METHYLTRANSFERASE; TRANSCRIPTION	The present work investigates the occurrence and significance of aberrant DNA methylation patterns during early stages of atherosclerosis. To this end, we asked whether the genetically atherosclerosis-prone APOEnull mice show any changes in DNA methylation patterns before the appearance of histologically detectable vascular lesion. We exploited a combination of various techniques: DNA fingerprinting, in vitro methyl-accepting assay, 5-methylcytosine quantitation, histone post-translational modification analysis, Southern blotting, and PCR. Our results show that alterations in DNA methylation profiles, including both hyper- and hypomethylation, were present in aortas and PBMC of 4-week-old mutant mice with no detectable atherosclerotic lesion. Sequencing and expression analysis of 60 leukocytic polymorphisms revealed that epigenetic changes involve transcribed genic sequences, as well as repeated interspersed elements. Furthermore, we showed for the first time that atherogenic lipoproteins promote global DNA hypermethylation in a human monocyte cell line. Taken together, our results unequivocally show that alterations in DNA methylation profiles are early markers of atherosclerosis in a mouse model and may play a causative role in atherogenesis.	Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Royal Vet & Agr Coll, Dept Plant Biochem, Inst Plant Biol, DK-1871 Frederiksberg, Denmark; Lund Univ, Dept Med, S-20502 Malmo, Sweden; Spanish Natl Canc Ctr, Canc Epigenet Lab, Madrid 28029, Spain	Rigshospitalet; University of Copenhagen; University of Copenhagen; Lund University; Centro Nacional de Investigaciones Oncologicas (CNIO)	Zaina, S (corresponding author), Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark.	silvio.zaina@rh.dk	Fraga, Mario F/H-7824-2017; Ballestar, Esteban/ABG-8561-2020; Zaina, Silvio/C-5255-2017; Lindholm, Marie W/B-8736-2015; Lund, Gertrud/M-3612-2014; Esteller, Manel/L-5956-2014	Fraga, Mario F/0000-0001-8450-2603; Zaina, Silvio/0000-0001-6589-076X; Lindholm, Marie W/0000-0003-4309-3203; Lund, Gertrud/0000-0003-3556-8520; Esteller, Manel/0000-0003-4490-6093; Wikstrom Lindholm, Marie/0000-0002-0975-2394; Ballestar, Esteban/0000-0002-1400-2440; Villar Garea, Ana/0000-0001-8960-1635				AUVERX J, 1991, EXPERIENTIA, V47, P22; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brattstrom L, 2000, AM J CLIN NUTR, V72, P315; Castro R, 2003, CLIN CHEM, V49, P1292, DOI 10.1373/49.8.1292; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Dong CM, 2002, J NUTR, V132, p2406S, DOI 10.1093/jn/132.8.2406S; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11&lt;1677::AID-ELPS1677&gt;3.0.CO;2-Z; Friso S, 2002, J NUTR, V132, p2382S, DOI 10.1093/jn/132.8.2382S; Furano AV, 2000, PROG NUCLEIC ACID RE, V64, P255, DOI 10.1016/S0079-6603(00)64007-2; GOODWIN GH, 1977, BIOCHEM J, V167, P485, DOI 10.1042/bj1670485; GURLEY LR, 1983, ANAL BIOCHEM, V131, P465, DOI 10.1016/0003-2697(83)90200-2; Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158; Hiltunen M, 2002, VASC MED, V7, P5, DOI 10.1191/1358863x02vm418oa; Hiltunen MO, 2003, ARTERIOSCL THROM VAS, V23, P1750, DOI 10.1161/01.ATV.0000092871.30563.41; Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Issa JP, 2002, J NUTR, V132, p2388S, DOI 10.1093/jn/132.8.2388S; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171; Lauria M, 2004, PLANT CELL, V16, P510, DOI 10.1105/tpc.017780; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; LINDHOLM M, 1993, ANN NUTR METAB, V37, P302, DOI 10.1159/000177781; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640; Moghadasian MH, 2001, FASEB J, V15, P2623, DOI 10.1096/fj.01-0463com; Muller K, 2001, J BIOL CHEM, V276, P14271; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Newman PE, 1999, MED HYPOTHESES, V53, P421, DOI 10.1054/mehy.1998.0794; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Panin L. E., 1995, Ukrainskii Biokhimicheskii Zhurnal, V67, P64; Panin L E, 1998, Membr Cell Biol, V11, P631; Panin LE, 2003, J STEROID BIOCHEM, V87, P309, DOI 10.1016/j.jsbmb.2003.09.004; POPESKO P, 1992, COLOUR ATLAS ANATOMY, V2, P105; ReynaLopez GE, 1997, MOL GEN GENET, V253, P703, DOI 10.1007/s004380050374; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Santourlidis S, 1999, PROSTATE, V39, P166; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Schmitt F, 1997, J BIOL CHEM, V272, P1534, DOI 10.1074/jbc.272.3.1534; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; Zaina S, 2002, J BIOL CHEM, V277, P4505, DOI 10.1074/jbc.M108061200; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	53	240	288	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29147	29154		10.1074/jbc.M403618200	http://dx.doi.org/10.1074/jbc.M403618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15131116	Green Published, hybrid			2022-12-27	WOS:000222445300040
J	Pozzi, A; Yan, XX; Macias-Perez, I; Wei, SZ; Hata, AN; Breyer, RM; Morrow, JD; Capdevila, JH				Pozzi, A; Yan, XX; Macias-Perez, I; Wei, SZ; Hata, AN; Breyer, RM; Morrow, JD; Capdevila, JH			Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; CYCLOOXYGENASE-2 OVEREXPRESSION; PROSTANOID RECEPTORS; TRANSGENIC MICE; KNOCKOUT MICE; CANCER CELLS; APC GENE; FACTOR-I; INHIBITION	Cyclooxygenase (COX) and its prostanoid metabolites have been implicated in the control of cell survival; however, their role as mitogens remains undefined. To better understand the role of prostanoids on cell growth, we used mouse colon adenocarcinoma (CT26) cells to investigate the role of prostaglandin E-2 (PGE(2)) in cell proliferation. CT26 cells express both COX1 and COX2 and metabolize arachidonic acid to PGE(2). Treatment with indomethacin, or COX-selective inhibitors, prevents PGE(2) biosynthesis and CT26 cell proliferation. The anti-proliferative effects of COX inhibition are rescued specifically by treatment with PGE(2) or the EP4 receptor-selective agonist PGE(1)-OH via phosphatidylinositol 3-kinase/extracellular signal-regulated kinase (ERK) activation, thus providing a functional link between PGE(2)-induced cell proliferation and EP4-mediated ERK signaling. Indomethacin or COX2 inhibitors, but not COX1 inhibitors, reduced the size and number of CT26-derived tumors in vivo. These inhibitory effects are paralleled by marked declines in the levels of tumor PGE(2), suggesting that their anti-tumor effects are directly associated with the inhibition of COX2 enzymatic activity. The described anti-tumor effects of indomethacin are evident whether it is administered at the time of, or 7 days after, tumor cell injection, suggesting that it has tumor preventive and therapeutic actions. Furthermore, the observation that indomethacin increases the survival rates of tumor-bearing mice, even after withdrawal of the drug, indicates that its effects are long lasting and that it may be potentially useful for the prevention and the clinical management of human cancers.	Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol,Med Ctr N, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vet Affairs Hosp, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Pozzi, A (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol,Med Ctr N, B3109, Nashville, TN 37232 USA.	ambra.pozzi@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA094849, P01CA077839, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R01DK048831, R01DK046205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA94849-01, CA-68485, CA77839] Funding Source: Medline; NIDDK NIH HHS [DK48831, DK46205, P50-DK39261-16] Funding Source: Medline; NIGMS NIH HHS [GM 37922, GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; Bol DK, 2002, CANCER RES, V62, P2516; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Fischer S M, 1980, Adv Prostaglandin Thromboxane Res, V6, P517; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Giardiello FM, 1998, DIGEST DIS SCI, V43, P311; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hansen-Petrik MB, 2002, CANCER RES, V62, P403; Hata AN, 2003, J PHARMACOL EXP THER, V306, P463, DOI 10.1124/jpet.103.050955; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Leahy KM, 2002, CANCER RES, V62, P625; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Mutoh M, 2002, CANCER RES, V62, P28; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Piazza GA, 1997, CANCER RES, V57, P2909; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Raz A, 2002, BIOCHEM PHARMACOL, V63, P343, DOI 10.1016/S0006-2952(01)00857-7; Reese J, 2000, P NATL ACAD SCI USA, V97, P9759, DOI 10.1073/pnas.97.17.9759; Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Wilson JW, 2000, CANCER RES, V60, P4645; Yasumaru M, 2003, CANCER RES, V63, P6726	37	130	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29797	29804		10.1074/jbc.M313989200	http://dx.doi.org/10.1074/jbc.M313989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15123663	hybrid			2022-12-27	WOS:000222445300116
J	Kim, HJ; Kim, JY; Kim, JY; Park, SK; Seo, JH; Kim, JB; Lee, IK; Kim, KS; Choi, HS				Kim, HJ; Kim, JY; Kim, JY; Park, SK; Seo, JH; Kim, JB; Lee, IK; Kim, KS; Choi, HS			Differential regulation of human and mouse orphan nuclear receptor small heterodimer partner promoter by sterol regulatory element binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; RETINOID-X-RECEPTOR; BILE-ACID SYNTHESIS; SHP GENE PROMOTER; TRANSGENIC MICE; LXR-ALPHA; TRANSCRIPTIONAL REGULATION; SYNERGISTIC ACTIVATION; ESTROGEN-RECEPTORS; SYNTHASE PROMOTER	Small heterodimer partner (SHP; NR0B2) is an unusual orphan nuclear receptor that lacks a conventional DNA-binding domain and acts as a modulator of transcriptional activities of a number of nuclear receptors. Herein, we report that the human SHP promoter (hSHP) is activated by sterol regulatory element-binding protein-1 (SREBP-1), which regulates the expression of various genes involved in cholesterol and fatty acid synthesis. Overexpression of SREBP-1 activated the human but not mouse SHP promoter, although SREBP-2 had little effect on the SHP promoter in CV-1 cells. Serial deletion reporter assays revealed that SREBP-1-responsive region is located within the sequences from - 243 to - 120 bp in the hSHP promoter. DNase I footprinting, gel shift assays, and chromatin immunoprecipitation assays demonstrated that SREBP-1 binds directly to the hSHP promoter. Site-directed mutagenesis made it clear that the hSHP promoter activation by SREBP-1 is mostly mediated by the SRE1 ( - 186 to - 195 bp) in the hSHP promoter, which is not conserved in the mouse SHP promoter. Moreover, adenovirus- mediated overexpression of SREBP-1c/ADD-1induced SHP mRNA expression and repressed CYP7A1 expression in HepG2 cells. Finally, we found that a four-nucleotide deletion ( - 195CT-GAdel) in the hSHP promoter, which is reported to be associated with altered body weight and insulin secretion in human, coincides with the SRE1. This mutation strongly decreased both basal and SREBP-1 dependent activities of the hSHP promoter, because of the reduced binding of SREBP-1 to the mutated SRE1. Overall, our results demonstrate a differential regulation of human and mouse SHP promoters by SREBP-1. We propose a possible role of SREBP-1 in the species differential regulation of cholesterol and bile acid homeostasis via a novel mechanism of up-regulation of the hSHP gene expression.	Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea; Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Keimyung Univ, Sch Med, Dept Internal Med, Taegu 700712, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Chonnam National University; Yonsei University; Yonsei University Health System; Keimyung University; Seoul National University (SNU)	Choi, HS (corresponding author), Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Kwangju 500757, South Korea.	hsc@chonnam.ac.kr	Song, Minsun/I-5701-2015	KIM, Jae Bum/0000-0003-2337-6935; Kim, Kyung-sup/0000-0001-8483-8537				Borgius LJ, 2002, J BIOL CHEM, V277, P49761, DOI 10.1074/jbc.M205641200; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chakravarty K, 2004, J BIOL CHEM, V279, P15385, DOI 10.1074/jbc.M309905200; Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; Choi YK, 2003, GENE THER, V10, P559, DOI 10.1038/sj.gt.3301926; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Gobinet J, 2001, BIOCHEMISTRY-US, V40, P15369, DOI 10.1021/bi011384o; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, MOL ENDOCRINOL, V17, P386, DOI 10.1210/me.2002-0246; Guan GM, 1997, J BIOL CHEM, V272, P10295; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Hung CCC, 2003, DIABETES, V52, P1288, DOI 10.2337/diabetes.52.5.1288; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kim HJ, 2003, NUCLEIC ACIDS RES, V31, P6860, DOI 10.1093/nar/gkg906; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Menke JG, 2002, ENDOCRINOLOGY, V143, P2548, DOI 10.1210/en.143.7.2548; Mitchell SMS, 2003, DIABETES, V52, P1276, DOI 10.2337/diabetes.52.5.1276; Moon YA, 2000, J BIOL CHEM, V275, P30280, DOI 10.1074/jbc.M001066200; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seo JB, 2003, MOL ENDOCRINOL, V17, P1522, DOI 10.1210/me.2003-0028; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Wang DP, 1996, J LIPID RES, V37, P1831; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; WANG XD, 1993, J BIOL CHEM, V268, P14497; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	53	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28122	28131		10.1074/jbc.M313302200	http://dx.doi.org/10.1074/jbc.M313302200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123650	hybrid			2022-12-27	WOS:000222265400038
J	Ling, GY; Hauer, CR; Gronostajski, RM; Pentecost, BT; Ding, XX				Ling, GY; Hauer, CR; Gronostajski, RM; Pentecost, BT; Ding, XX			Transcriptional regulation of rat CYP2A3 by nuclear factor 1 - Identification of a novel NFI-A isoform, and evidence for tissue-selective interaction of NFI with the CYP2A3 promoter in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE LOCUS; DNA METHYLATION; GENE-TRANSCRIPTION; OLFACTORY MUCOSA; BINDING SITES; PROTEIN GENE; ACTIVATION; EXPRESSION; ELEMENT; FAMILY	Rat CYP2A3 and its mouse and human orthologs are expressed preferentially in the olfactory mucosa. We found previously that an element in the proximal promoter region of CYP2A3 ( the nasal predominant transcriptional activating (NPTA) element), which is similar to a nuclear factor 1 (NFI)-binding site, is critical for transcriptional activation of CYP2A3 in vitro. We proposed that this element might be important for tissue-selective CYP2A3 expression. The goals of the present study were to characterize NPTA-binding proteins and to obtain more definitive evidence for the role of NFI in the transcriptional activation of CYP2A3. The NPTA-binding proteins were isolated by DNA-affinity purification from rat olfactory mucosa. Mass spectral analysis indicated that isoforms corresponding to all four NFI genes were present in the purified NPTA-binding fraction. Further analysis of NPTA-binding proteins led to the identification of a novel NFI-A isoform, NFI-A-short, which was derived from alternative splicing of the NFI-A transcript. Transient transfection assay showed that NFI-A2, an NFI isoform previously identified in the olfactory mucosa, transactivated the CYP2A3 promoter, whereas NFI-A-short, which lacks the transactivation domain, counteracted the activation. Chromatin immunoprecipitation assays indicated that NFI proteins are associated with the CYP2A3 promoter in vivo, in rat olfactory mucosa, but essentially not in the liver where the CYP2A3 promoter is hypermethylated and CYP2A3 is not expressed. These data strongly support a role for NFI transcription factors in the transcriptional activation of CYP2A3.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA; SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ding, XX (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza,Box 509, Albany, NY 12201 USA.	dingx@wadsworth.org		Hauer, Christoph/0000-0001-8704-2198; Gronostajski, Richard/0000-0003-4264-208X	NICHD NIH HHS [HD 34908] Funding Source: Medline; NIDDK NIH HHS [DK 58401] Funding Source: Medline; NIEHS NIH HHS [ES 07462] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007462] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baumeister H, 1999, MOL BRAIN RES, V72, P65, DOI 10.1016/S0169-328X(99)00210-7; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; Carr BA, 2003, J BIOL CHEM, V278, P15473, DOI 10.1074/jbc.M300319200; Chaudhry AZ, 1999, J BIOL CHEM, V274, P7072, DOI 10.1074/jbc.274.11.7072; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; DING X, 2003, HDB OLFACTION GUSTAT, P51; Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; FERNANDEZSALGUE.P, 1995, PHARMACOGENETICS, V5, P123; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Grunder A, 2003, GENE, V304, P171, DOI 10.1016/S0378-1119(02)01204-0; Grunder A, 2002, MECH DEVELOP, V112, P69, DOI 10.1016/S0925-4773(01)00640-2; Honkakoski P, 1997, DRUG METAB REV, V29, P977, DOI 10.3109/03602539709002240; Kannius-Janson M, 2002, J BIOL CHEM, V277, P17589, DOI 10.1074/jbc.M105979200; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Lin XH, 2003, CANCER RES, V63, P498; Liu YC, 1997, J BIOL CHEM, V272, P10739; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Nakajima M, 2003, TOXICOL LETT, V144, P247, DOI 10.1016/S0378-4274(03)00216-9; Norquay LD, 2003, MOL ENDOCRINOL, V17, P1027, DOI 10.1210/me.2003-0025; Ortiz L, 1999, J BIOL CHEM, V274, P15213, DOI 10.1074/jbc.274.21.15213; Osada S, 1997, J BIOCHEM, V121, P355; Osano K, 2003, EUR J BIOCHEM, V270, P2532, DOI 10.1046/j.1432-1033.2003.03628.x; Steele-Perkins G, 2003, MOL CELL BIOL, V23, P1075, DOI 10.1128/MCB.23.3.1075-1084.2003; Su T, 2002, DRUG METAB DISPOS, V30, P548, DOI 10.1124/dmd.30.5.548; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Wang HJ, 2003, CANCER RES, V63, P8057; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Xie YQ, 2001, BIOCHEM BIOPH RES CO, V289, P1225, DOI 10.1006/bbrc.2001.6084; Zhang JH, 1998, J BIOL CHEM, V273, P23454, DOI 10.1074/jbc.273.36.23454; Zhang JH, 2000, J BIOL CHEM, V275, P8895, DOI 10.1074/jbc.275.12.8895	38	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27888	27895		10.1074/jbc.M403705200	http://dx.doi.org/10.1074/jbc.M403705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123731	hybrid			2022-12-27	WOS:000222265400010
J	Jia, YZ; Qi, C; Kashireddi, P; Surapureddi, S; Zhu, YJ; Rao, MS; Le Roith, D; Chambon, P; Gonzalez, FJ; Reddy, JK				Jia, YZ; Qi, C; Kashireddi, P; Surapureddi, S; Zhu, YJ; Rao, MS; Le Roith, D; Chambon, P; Gonzalez, FJ; Reddy, JK			Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPAR alpha-regulated gene expression in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; NUCLEAR RECEPTORS; BINDING-PROTEIN; EMBRYONIC-DEVELOPMENT; INTERACTING PROTEIN; TRAP220 COMPONENT; LIGAND METABOLISM; BETA-OXIDATION; NORMAL GROWTH; MOUSE-LIVER	Nuclear receptor coactivator PBP (peroxisome proliferator-activated receptor (PPAR)-binding protein) functions as a coactivator for PPARs and other nuclear receptors. PBP serves as an anchor for TRAP ( thyroid hormone receptor-associated proteins)/mediator multi-subunit cofactor transcription complex. Disruption of the PBP/TRAP220 gene results in embryonic lethality around embryonic day 11.5 by affecting placental, cardiac, hepatic, and bone marrow development. Because PPAR isoforms alpha, gamma, and beta/delta function as important regulators of lipid homeostasis in mammals, it becomes important to assess the requirement of coactivator PBP in the regulation of PPAR functions in vivo. Sustained activation of PPARalpha by structurally diverse classes of chemicals of biological importance, designated peroxisome proliferators, leads to proliferation of peroxisomes in liver, induction of PPARalpha target genes including those involved in fatty acid oxidation, and the eventual development of liver tumors. Here, we show that targeted deletion of PBP in liver parenchymal cells, using the Cre-loxP system, results in the near abrogation of PPARalpha ligand-induced peroxisome proliferation and liver cell proliferation, as well as the induction of PPARalpha-regulated genes in PBP-deficient liver cells. In contrast, scattered PBP+/+ hepatocytes in these livers showed DNA synthesis and were markedly hypertrophic with peroxisome proliferation in response to PPARalpha ligands. Chromatin immunoprecipitation data suggest that in PBP conditional null livers, there appears to be reduced association of cofactors, especially of CBP and TRAP150, to the mouse enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase gene promoter. These observations suggest that PBP is required for the stabilization of multiprotein cofactor complexes. In essence, the absence of PBP in hepatocytes in vivo appears to mimic the absence of PPARalpha, indicating that coactivator PBP is essential for PPARalpha-regulated gene expression in liver parenchymal cells.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; NIH, Diabet Branch, Bethesda, MD 20892 USA; Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS INSERM, F-67404 Illkirch Graffenstaden, France; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reddy, JK (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu			NCI NIH HHS [CA104578] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104578, Z01BC005708, ZIABC005708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; CHU RY, 1995, J BIOL CHEM, V270, P29636; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GEHLIN M, 2002, MOL CELL BIOL, V22, P5923; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jain S, 1998, AM J PATHOL, V153, P349, DOI 10.1016/S0002-9440(10)65577-0; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; LASKO M, 1996, P NATL ACAD SCI USA, V93, P5860; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lewis BA, 2003, J CELL SCI, V116, P3667, DOI 10.1242/jcs.00734; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Melnick RL, 2001, ENVIRON HEALTH PERSP, V109, P437, DOI 10.2307/3454700; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Qi C, 1999, J BIOL CHEM, V274, P15775, DOI 10.1074/jbc.274.22.15775; Qi C, 2003, J BIOL CHEM, V278, P25281, DOI 10.1074/jbc.C300175200; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1979, CANCER RES, V39, P152; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 2004, IN PRESS AM J PATHOL; Roeder RG, 2003, NAT MED, V9, P1239, DOI 10.1038/nm938; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Watkins RE, 2003, J MOL BIOL, V331, P815, DOI 10.1016/S0022-2836(03)00795-2; WEGLARZ TC, 1941, CARCINOGENESIS, V25, P107; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 2003, J BIOL CHEM, V278, P1986, DOI 10.1074/jbc.C200634200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	56	94	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24427	24434		10.1074/jbc.M402391200	http://dx.doi.org/10.1074/jbc.M402391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15150259	hybrid			2022-12-27	WOS:000221702500069
J	Yamada, M; Mattaj, IW; Yoneda, Y				Yamada, M; Mattaj, IW; Yoneda, Y			An ATP-dependent activity that releases RanGDP from NTF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSPORT FACTOR-2; GUANINE-NUCLEOTIDE EXCHANGE; PROTEIN IMPORT; PORE COMPLEX; STRUCTURAL BASIS; GTP HYDROLYSIS; GDP-RAN; RCC1; REGULATOR; IDENTIFICATION	The small GTPase Ran functions in several critical processes in eukaryotic cells including nuclear transport, nuclear envelope formation, and spindle formation. A RanGDP-binding protein, NTF2, facilitates translocation of RanGDP through the nuclear pore complex and also acts to stabilize RanGDP against nucleotide exchange. Here, we identify a novel activity that stimulates release of GDP from Ran in the presence of NTF2. Hydrolyzable ATP enhances the GDP dissociation activity, and this enhancement is inhibited by nonhydrolyzable ATP analogues. In contrast, neither hydrolyzable ATP nor nonhydrolyzable ATP analogues affect GDP dissociation from Ran catalyzed by recombinant RCC1 or inhibition of GDP dissociation from Ran by recombinant NTF2. The ATP-dependent RanGDP dissociation activity therefore has the properties of a RanGDP dissociation inhibitor (GDI) displacement factor (RanGDF) where the GDI is NTF2. A protein phosphatase inhibitor mixture stimulates the RanGDF activity, suggesting the activity is regulated by phosphorylation. We propose that the ATP-dependent NTF2 releasing factor may have a role in the RanGDP/GTP cycle.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka, Japan	European Molecular Biology Laboratory (EMBL); Osaka University	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	mattaj@embl-heidelberg.de		Mattaj, Iain/0000-0002-5537-8284				Avis JM, 1996, J CELL SCI, V109, P2423; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Clarkson WD, 1997, J MOL BIOL, V272, P716, DOI 10.1006/jmbi.1997.1255; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; Kunzler M, 2001, J CELL SCI, V114, P3233; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Oki M, 1998, P NATL ACAD SCI USA, V95, P15388, DOI 10.1073/pnas.95.26.15388; Paschal BM, 1997, J BIOL CHEM, V272, P21534, DOI 10.1074/jbc.272.34.21534; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Quimby BB, 2000, J BIOL CHEM, V275, P28575, DOI 10.1074/jbc.M005055200; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stewart M, 2000, J MOL BIOL, V299, P213, DOI 10.1006/jmbi.2000.3733; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; Yamada M, 1998, CURR BIOL, V8, P1339, DOI 10.1016/S0960-9822(07)00566-0	38	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36228	36234		10.1074/jbc.M403101200	http://dx.doi.org/10.1074/jbc.M403101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15155737	hybrid			2022-12-27	WOS:000223453600010
J	Trujillo, M; Budde, H; Pineyro, MD; Stehr, M; Robello, C; Flohe, L; Radi, R				Trujillo, M; Budde, H; Pineyro, MD; Stehr, M; Robello, C; Flohe, L; Radi, R			Trypanosoma brucei and Trypanosoma cruzi tryparedoxin peroxidases catalytically detoxify peroxynitrite via oxidation of fast reacting thiols.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX-SENSITIVE OLIGOMERIZATION; NITRIC-OXIDE SYNTHASE; HUMAN SERUM-ALBUMIN; HYDROGEN-PEROXIDE; MEDIATED CYTOTOXICITY; MACROPHAGE ACTIVATION; LEISHMANIA-CHAGASI; METABOLISM; SUPEROXIDE; PEROXIREDOXINS	Macrophage activation is one of the hallmarks observed in trypanosomiasis, and the parasites must cope with the resulting oxidative burden, which includes the production of peroxynitrite, an unusual peroxo-acid that acts as a strong oxidant and trypanocidal molecule. Cytosolic tryparedoxin peroxidase (cTXNPx) has been recently identified as essential for oxidative defense in trypanosomatids. This peroxiredoxin decomposes peroxides using tryparedoxin (TXN) as electron donor, which in turn is reduced by dihydrotrypanothione. In this work, we studied the kinetics of the reaction of peroxynitrite with the different thiol-containing components of the cytosolic tryparedoxin peroxidase system in T. brucei (Tb) and T. cruzi (Tc), namely trypanothione, TXN, and cTXNPx. We found that whereas peroxynitrite reacted with dihydrotrypanothione and TbTXN at moderate rates (7200 and 3500 M-1 s(-1), respectively, at pH 7.4 and 37 degreesC) and within the range of typical thiols, the second order rate constants for the reaction of peroxynitrite with reduced TbcTXNPx and TccTXNPx were 9 x 10(5) and 7.2 x 10(5) M-1 s(-1) at pH 7.4 and 37 degreesC, respectively. This reactivity was dependent on a highly reactive cTXNPx thiol group identified as cysteine 52. Competition experiments showed that TbcTXNPx inhibited other fast peroxynitrite-mediated processes, such as the oxidation of Mn3+-porphyrins. Moreover, steady-state kinetic studies indicate that peroxynitrite-dependent TbcTXNPx and TccTXNPx oxidation is readily reverted by TXN, supporting that these peroxiredoxins would be not only a preferential target for peroxynitrite reactivity but also be able to act catalytically in peroxynitrite decomposition in vivo.	Univ Republica, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Univ Republica, Fac Med, Ctr Free Rad & Bioomed Res, Montevideo 11800, Uruguay; Tech Univ Carolo Wilhelmina Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany; MOLISA GmbH, D-39106 Magdeburg, Germany	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Braunschweig University of Technology	Radi, R (corresponding author), Univ Republica, Fac Med, Dept Bioquim, Avda Gral Flores 2125, Montevideo 11800, Uruguay.	rradi@fmed.edu.uy	ROBELLO, CARLOS/M-5609-2019	ROBELLO, CARLOS/0000-0001-6985-6171				Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Alvarez MN, 2002, METHOD ENZYMOL, V359, P353; Barr SD, 2003, J BIOL CHEM, V278, P10816, DOI 10.1074/jbc.M212990200; Barr SD, 2001, J BIOL CHEM, V276, P34279, DOI 10.1074/jbc.M104406200; BOHN H, 1989, J CARDIOVASC PHA S11, V14, P6; BOVERIS A, 1977, EXPERIENTIA, V33, P1306, DOI 10.1007/BF01920148; Britto PJ, 2002, J BIOL CHEM, V277, P29018, DOI 10.1074/jbc.M204263200; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Budde H, 2003, BIOL CHEM, V384, P619, DOI 10.1515/BC.2003.069; Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m; CARDONI RL, 1990, CELL IMMUNOL, V128, P11, DOI 10.1016/0008-8749(90)90002-9; Cardoni RL, 1997, AM J TROP MED HYG, V56, P329, DOI 10.4269/ajtmh.1997.56.329; CELENTANO AM, 1992, PARASITE IMMUNOL, V14, P155, DOI 10.1111/j.1365-3024.1992.tb00458.x; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chandrasekar B, 2000, CLIN EXP IMMUNOL, V121, P112, DOI 10.1046/j.1365-2249.2000.01258.x; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; DOCAMPO R, 1986, FED PROC, V45, P2471; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Espenson J. H., 1995, CHEM KINETICS REACTI, P46; Ferrer-Sueta G, 2003, J BIOL CHEM, V278, P27432, DOI 10.1074/jbc.M213302200; Finzi JK, 2004, MOL BIOCHEM PARASIT, V133, P37, DOI 10.1016/j.molbiopara.2003.08.011; Flohe L, 2002, ARCH BIOCHEM BIOPHYS, V397, P324, DOI 10.1006/abbi.2001.2688; FONTECAVE M, 1987, J BIOL CHEM, V262, P12332; GROSSKINSKY CM, 1983, INFECT IMMUN, V39, P1080, DOI 10.1128/IAI.39.3.1080-1086.1983; Guerrero SA, 2000, APPL MICROBIOL BIOT, V53, P410, DOI 10.1007/s002530051634; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; Jaeger T, 2004, ARCH BIOCHEM BIOPHYS, V423, P182, DOI 10.1016/j.abb.2003.11.021; Keita M, 2000, EXP PARASITOL, V95, P19, DOI 10.1006/expr.2000.4505; Kelm M, 1997, J BIOL CHEM, V272, P9922; Konorev EA, 1998, FEBS LETT, V427, P171, DOI 10.1016/S0014-5793(98)00413-X; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MUNOZFERNANDEZ MA, 1992, IMMUNOL LETT, V33, P35, DOI 10.1016/0165-2478(92)90090-B; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Thomson L, 2003, ARCH BIOCHEM BIOPHYS, V412, P55, DOI 10.1016/S0003-9861(02)00745-2; Trujillo M, 2002, ARCH BIOCHEM BIOPHYS, V397, P91, DOI 10.1006/abbi.2001.2619; VINCENDEAU P, 1992, EXP PARASITOL, V75, P353, DOI 10.1016/0014-4894(92)90220-5; VINCENDEAU P, 1999, PROGR HUMAN AFRICAN, P137; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2003, J BIOL CHEM, V278, P31640, DOI 10.1074/jbc.M303035200; Wilkinson SR, 2002, P NATL ACAD SCI USA, V99, P13453, DOI 10.1073/pnas.202422899; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m	54	104	110	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34175	34182		10.1074/jbc.M404317200	http://dx.doi.org/10.1074/jbc.M404317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15155760	hybrid			2022-12-27	WOS:000223134800015
J	Alric, J; Yoshida, M; Nagashima, KVP; Hienerwadel, R; Parot, P; Vermeglio, A; Chen, SWW; Pellequer, JL				Alric, J; Yoshida, M; Nagashima, KVP; Hienerwadel, R; Parot, P; Vermeglio, A; Chen, SWW; Pellequer, JL			Two distinct binding sites for high potential iron-sulfur protein and cytochrome C on the reaction center-bound cytochrome of Rubrivivax gelatinosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; REACTION-CENTER COMPLEX; ELECTRON-TRANSFER; PURPLE BACTERIUM; RHODOPSEUDOMONAS-VIRIDIS; CRYSTAL-STRUCTURE; SUBUNIT; RESOLUTION; SUBSTRATE; HIPIP	The photosynthetic cyclic electron transfer of the purple bacterium Rubrivivax gelatinosus, involving the cytochrome bc(1) complex and the reaction center, can be carried out via two pathways. A high potential iron-sulfur protein (HiPIP) acts as the in vivo periplasmic electron donor to the reaction center (RC)-bound cytochrome when cells are grown under anaerobic conditions in the light, while cytochrome c(8) is the soluble electron carrier for cells grown under aerobic conditions in the dark. A spontaneous reversion of R. gelatinosus C244, a defective mutant in synthesis of the RC-bound cytochrome by insertion of a Km(r) cassette leading to gene disruption with a slow growth rate, restores the normal photosynthetic growth. This revertant, designated C244-P1, lost the Kmr cassette but synthesized a RC-bound cytochrome with an external 77-amino acid insertion derived from the cassette. We characterized the RC-bound cytochrome of this mutant by EPR, time-resolved optical spectroscopy, and structural analysis. We also investigated the in vivo electron transfer rates between the two soluble electron donors and this RC-bound cytochrome. Our results demonstrated that the C244-P1 RC-bound cytochrome is still able to receive electrons from HiPIP, but it is no longer reducible by cytochrome c(8). Combining these experimental and theoretical protein-protein docking results, we conclude that cytochrome c(8) and HiPIP bind the RC-bound cytochrome at two distinct but partially overlapping sites.	CEA Valrho, Ctr Marcoule, DSV, DIEP,SBTN, F-30207 Bagnols Sur Ceze, France; CEA Aix Marseille 2, Lab Genet & Biophys Plantes, CNRS, UMR 6191, F-13288 Marseille, France; UMR 6191 CNRS CEA Aix Marseille 2, CEA Cadarache, Direct Sci Vivant, Dept Ecophysiol Vegetale & Microbiol,Lab Bioenerg, F-13108 St Paul Les Durance, France; Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan	CEA; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; CEA; Tokyo Metropolitan University	Pellequer, JL (corresponding author), CEA Valrho, Ctr Marcoule, DSV, DIEP,SBTN, BP 17171, F-30207 Bagnols Sur Ceze, France.	jlpellequer@cea.fr	Nagashima, Kenji V. P./M-2208-2017; Pellequer, Jean-Luc/L-6855-2013; Parot, Pierre/Q-4444-2019; PAROT, Pierre/B-3959-2012; PAROT, Pierre/C-1742-2017; Alric, Jean/E-3538-2013	Nagashima, Kenji V. P./0000-0002-4526-6625; Pellequer, Jean-Luc/0000-0002-8944-2715; Alric, Jean/0000-0003-3574-2234				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; Axelrod HL, 2002, J MOL BIOL, V319, P501, DOI 10.1016/S0022-2836(02)00168-7; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chen SWW, 2004, CURR MED CHEM, V11, P595, DOI 10.2174/0929867043455891; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Gonzalez A, 2003, ACTA CRYSTALLOGR D, V59, P1582, DOI 10.1107/S0907444903014604; Hochkoeppler A, 1996, P NATL ACAD SCI USA, V93, P6998, DOI 10.1073/pnas.93.14.6998; Kerfeld CA, 1996, BIOCHEMISTRY-US, V35, P7812, DOI 10.1021/bi952731v; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Masuda S, 1999, J BIOL CHEM, V274, P10795, DOI 10.1074/jbc.274.16.10795; Masuda S, 2002, BIOCHEMISTRY-US, V41, P11211, DOI 10.1021/bi0258492; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Menin L, 1999, BIOCHEMISTRY-US, V38, P15238, DOI 10.1021/bi991146h; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESSERSCHMIDT A, 2001, HDB METALLOPROTEINS, V1, P33; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nagashima KVP, 1996, FEBS LETT, V385, P209, DOI 10.1016/0014-5793(96)00382-1; Nagashima KVP, 2002, BIOCHEMISTRY-US, V41, P14028, DOI 10.1021/bi026511a; Nagashima KVP, 1997, PLANT CELL PHYSIOL, V38, P1249, DOI 10.1093/oxfordjournals.pcp.a029112; Nagashima KVP, 1998, PHOTOSYNTH RES, V55, P349, DOI 10.1023/A:1005912810674; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1100, P49; NITSCHKE W, 1989, BIOCHEMISTRY-US, V28, P3161, DOI 10.1021/bi00434a008; Nitschke W., 1995, ANOXYGENIC PHOTOSYNT, P775; Nogi T, 2000, P NATL ACAD SCI USA, V97, P13561, DOI 10.1073/pnas.240224997; Nogi T, 2001, J BIOCHEM-TOKYO, V130, P319, DOI 10.1093/oxfordjournals.jbchem.a002989; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P15779, DOI 10.1021/bi990907d; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P2861, DOI 10.1021/bi982747w; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Roussel A., 1989, SILICON GRAPHICS GEO; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHOEPP B, 1995, BIOCHEMISTRY-US, V34, P11736, DOI 10.1021/bi00037a010; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Venturoli G, 2004, BIOCHEMISTRY-US, V43, P437, DOI 10.1021/bi035384v; VERMEGLIO A, 1989, FEBS LETT, V243, P259, DOI 10.1016/0014-5793(89)80140-1; Vermeglio A, 2002, BIOCHEMISTRY-US, V41, P8868, DOI 10.1021/bi012037h; Yoshida M, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P897; Yoshida MT, 2001, BBA-BIOENERGETICS, V1506, P23, DOI 10.1016/S0005-2728(01)00177-3	46	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32545	32553		10.1074/jbc.M401784200	http://dx.doi.org/10.1074/jbc.M401784200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155756	Green Published, hybrid			2022-12-27	WOS:000222849700070
J	Friedman, YE; O'Brian, MR				Friedman, YE; O'Brian, MR			The ferric uptake regulator (Fur) protein from Bradyrhizobium japonicum is an iron-responsive transcriptional repressor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; BINDING; IDENTIFICATION; IRR; AUTOREGULATION; EXPRESSION; PROMOTER; HEME; GENE	The Fur protein represses transcription of iron-responsive genes in bacteria. The discovery that Fur is a zinc metalloprotein and the use of surrogate metals for Fe2+ for in vitro studies question whether Fur is a direct iron sensor. In the present study, we show that the affinity of Fur from Bradyrhizobium japonicum (BjFur) for its target DNA increases 30-fold in the presence of metal, with a K-d value of about 2 nM. DNase I footprinting experiments showed that BjFur protected its binding site within the irr gene promoter in the presence of Fe2+ but not in the absence of metal, showing that DNA binding is Fe2+-dependent. BjFur did not inhibit in vitro transcription from the irr promoter using purified components in the absence of metal, but BjFur repressed transcription in the presence of Fe2+. Thus, BjFur is an iron-responsive transcriptional repressor in vitro. A regulatory Fe2+-binding site (site 1) and a structural Zn2+-binding site (site 2) inferred from the recent crystal structure of Fur from Pseudomonas aeruginosa are composed of amino acids highly conserved in many Fur proteins, including BjFur. BjFur mutants containing substitutions in site 1 (BjFurS1) or site 2 (BjFurS2) bound DNA with high affinity and repressed transcription in vitro in an Fe2+-dependent manner. Interestingly, only a single dimer of BjFurS2 occupied the irr promoter, whereas the wild type and BjFurS1 displayed one- or two-dimer occupancy. We suggest that the putative functions for metal-binding sites deduced from the structure of P. aeruginosa Fur cannot be extrapolated to bacterial Fur proteins as a whole.	SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	O'Brian, MR (corresponding author), SUNY Buffalo, Dept Biochem, 140 Farber Hall, Buffalo, NY 14214 USA.	mrobrian@buffalo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-067966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Bsat N, 1999, J BACTERIOL, V181, P4299, DOI 10.1128/JB.181.14.4299-4307.1999; de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283; Delany I, 2003, MOL MICROBIOL, V50, P1329, DOI 10.1046/j.1365-2958.2003.03757.x; Delany I, 2002, MOL MICROBIOL, V46, P1107, DOI 10.1046/j.1365-2958.2002.03227.x; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DELORENZO V, 1988, J MOL BIOL, V203, P875, DOI 10.1016/0022-2836(88)90113-1; Escolar L, 1998, J MOL BIOL, V283, P537, DOI 10.1006/jmbi.1998.2119; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; Friedman YE, 2003, J BIOL CHEM, V278, P38395, DOI 10.1074/jbc.M306710200; Hall HK, 1996, J BACTERIOL, V178, P5683, DOI 10.1128/jb.178.19.5683-5691.1996; Hamza I, 1999, J BACTERIOL, V181, P5843, DOI 10.1128/JB.181.18.5843-5846.1999; Hamza I, 1998, J BIOL CHEM, V273, P21669, DOI 10.1074/jbc.273.34.21669; Hamza I, 2000, MICROBIOL-SGM, V146, P669, DOI 10.1099/00221287-146-3-669; Hassett DJ, 1996, J BACTERIOL, V178, P3996, DOI 10.1128/jb.178.14.3996-4003.1996; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Lewin AC, 2002, MICROBIOL-SGM, V148, P2449, DOI 10.1099/00221287-148-8-2449; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; Maxam A M, 1980, Methods Enzymol, V65, P499; OCHSNER UA, 1995, J BACTERIOL, V177, P7194, DOI 10.1128/jb.177.24.7194-7201.1995; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Qi ZH, 1999, P NATL ACAD SCI USA, V96, P13056, DOI 10.1073/pnas.96.23.13056; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; Touati D, 2000, ARCH BIOCHEM BIOPHYS, V373, P1, DOI 10.1006/abbi.1999.1518	25	41	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32100	32105		10.1074/jbc.M404924200	http://dx.doi.org/10.1074/jbc.M404924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15148310	hybrid			2022-12-27	WOS:000222849700015
J	Peng, J; Mao, XO; Stevenson, FF; Hsu, M; Andersen, JK				Peng, J; Mao, XO; Stevenson, FF; Hsu, M; Andersen, JK			The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVIRONMENTAL RISK-FACTORS; N-TERMINAL KINASE; PARKINSONS-DISEASE; C-JUN; PROTEIN-KINASE; CELL-DEATH; SYMPATHETIC NEURONS; SIGNAL-TRANSDUCTION; WELL WATER; EXPOSURE	Environmental exposure to the oxidant-producing herbicide paraquat has been implicated as a risk factor in Parkinson's disease. Although intraperitoneal paraquat injections in mice cause a selective loss of dopaminergic neurons in the substantia nigra pars compacta, the exact mechanism involved is still poorly understood. Our data show that paraquat induces the sequential phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun and the activation of caspase-3 and sequential neuronal death both in vitro and in vivo. These effects are diminished by the specific JNK inhibitor SP600125 and the antioxidant manganese(III) tetrakis (4-benzoic acid) porphyrin in vitro. Furthermore, JNK pathway inhibitor CEP-11004 effectively blocks paraquat-induced dopaminergic neuronal death in vivo. These results suggest that the JNK signaling cascade is a direct activator of the paraquat-mediated nigral dopaminergic neuronal apoptotic machinery and provides a molecular linkage between oxidative stress and neuronal apoptosis.	Buck Inst Age Res, Novato, CA 94945 USA; Univ So Calif, Dept Biol Sci, Program Mol Biol, Los Angeles, CA 90089 USA	Buck Institute for Research on Aging; University of Southern California	Andersen, JK (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	jandersen@buckinstitute.org		Andersen, Julie/0000-0003-1324-4875; Hsu, Mike/0000-0001-7086-1808	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012077] Funding Source: NIH RePORTER; NIEHS NIH HHS [U54 ES12077] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BURKITT MJ, 1993, MOL PHARMACOL, V43, P257; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; CLEJAN L, 1989, BIOCHEM PHARMACOL, V38, P1779, DOI 10.1016/0006-2952(89)90412-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Han MJ, 2003, MOL CELLS, V15, P94; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HERTZMAN C, 1990, AM J IND MED, V17, P349, DOI 10.1002/ajim.4700170307; HUBBLE JP, 1993, NEUROLOGY, V43, P1693, DOI 10.1212/WNL.43.9.1693; JIMENEZJIMENEZ FJ, 1992, MOVEMENT DISORD, V7, P149, DOI 10.1002/mds.870070209; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Maroney AC, 1999, J NEUROCHEM, V73, P1901; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Peng J, 2002, J BIOL CHEM, V277, P44285, DOI 10.1074/jbc.M207407200; Peng J, 2003, IUBMB LIFE, V55, P267, DOI 10.1080/1521654031000121666; PRASAD KN, 1994, IN VITRO CELL DEV-AN, V30A, P596; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Stephenson J, 2000, JAMA-J AM MED ASSOC, V283, P3055, DOI 10.1001/jama.283.23.3055; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298	42	169	179	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32626	32632		10.1074/jbc.M404596200	http://dx.doi.org/10.1074/jbc.M404596200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155744	hybrid			2022-12-27	WOS:000222849700080
J	Zhao, L; Liao, H; Tsai, MD				Zhao, L; Liao, H; Tsai, MD			The catalytic role of aspartate in a short strong hydrogen bond of the Asp(274)-His(32) catalytic dyad in phosphatidylinositol-specific phospholipase C can be substituted by a chloride ion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SERINE PROTEASES; ENZYMATIC CATALYSIS; BACILLUS-CEREUS; ACTIVE-SITE; TRIAD; MECHANISM; HISTIDINE; NMR; CHYMOTRYPSIN	Phosphatidylinositol-specific phospholipase C from Bacillus thuringiensis catalyzes the cleavage of the phosphorus-oxygen bond in phosphatidylinositol. The focus of this work is to dissect the roles of the carboxylate side chain of Asp(274) in the Asp(274)-His(32) dyad, where a short strong hydrogen bond (SSHB) was shown to exist based on NMR criteria. A regular hydrogen bond (HB) was observed in D274N, and no low field proton resonance was detected for D274E and D274A. Comparison of the activity of wild type, D274N, and D274A suggested that the regular HB contributes significantly (similar to4 kcal/mol) to catalysis, whereas the SSHB contributes only an additional 2 kcal/mol. The mutant D274E displays high activity similar to wild type, suggesting that the negative charge is sufficient for the catalytic role of Asp(274). To further support this interpretation and rule out possible contribution of regular HB or SSHB in D274E, we showed that the activity of D274G can be rescued by exogenous chloride ions to a level comparable with that of D274E. Comparison between different anions suggested that the ability of an anion to rescue the activity is due to the size and the charge of the anion not the property as a HB acceptor. In conclusion, a major fraction of the functional role of Asp(274) in the Asp(274)-His(32) dyad can be attributed to a negative charge (as in D274E and D274G-Cl-), and the SSHB in the wild type enzyme provides minimal contribution to catalysis. These results represent novel insight for an Asp-His catalytic dyad and for the mechanism of phosphatidylinositol-specific phospholipase C.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan	Ohio State University; Ohio State University; Ohio State University; Academia Sinica - Taiwan	Tsai, MD (corresponding author), Ohio State Univ, Dept Chem, Columbus, OH 43210 USA.	tsai.7@osu.edu	Tsai, Ming-Daw/G-4689-2019	Tsai, Ming-Daw/0000-0003-1374-0414	NIGMS NIH HHS [GM57568] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ash EL, 1997, SCIENCE, V278, P1128, DOI 10.1126/science.278.5340.1128; Bachovchin WW, 2001, MAGN RESON CHEM, V39, pS199, DOI 10.1002/mrc.951; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; Gassler CS, 1997, BIOCHEMISTRY-US, V36, P12802, DOI 10.1021/bi971102d; Gerlt JA, 1997, CHEM BIOL, V4, P259, DOI 10.1016/S1074-5521(97)90069-7; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P15941, DOI 10.1021/bi961805f; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; Hondal RJ, 1998, BIOCHEMISTRY-US, V37, P4568, DOI 10.1021/bi972646i; Hondal RJ, 1997, BIOCHEMISTRY-US, V36, P6633, DOI 10.1021/bi962866g; HUNKAPILLER MW, 1973, BIOCHEMISTRY-US, V12, P4732, DOI 10.1021/bi00747a028; Kravchuk AV, 2001, BIOCHEMISTRY-US, V40, P5433, DOI 10.1021/bi002372q; Kubiak RJ, 2001, BIOCHEMISTRY-US, V40, P5422, DOI 10.1021/bi002371y; Kubiak RJ, 1999, J AM CHEM SOC, V121, P488, DOI 10.1021/ja9834677; KUMAR A, 1994, PROTEIN SCI, V3, P2082, DOI 10.1002/pro.5560031121; NOEL JP, 1991, BIOCHEMISTRY-US, V30, P11801, DOI 10.1021/bi00115a010; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Poi MJ, 2003, J MOL BIOL, V329, P997, DOI 10.1016/S0022-2836(03)00512-6; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; Ryan M, 2001, BIOCHEMISTRY-US, V40, P9743, DOI 10.1021/bi010958m; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; Stratton JR, 2001, BIOCHEMISTRY-US, V40, P10411, DOI 10.1021/bi015542n; TOBIN JB, 1995, BIOCHEMISTRY-US, V34, P6919, DOI 10.1021/bi00021a002; VOLWERK JJ, 1989, FEMS MICROBIOL LETT, V61, P237, DOI 10.1111/j.1574-6968.1989.tb03629.x; YATES BF, 1988, J AM CHEM SOC, V110, P6327, DOI 10.1021/ja00227a008	29	8	8	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					31995	32000		10.1074/jbc.M404184200	http://dx.doi.org/10.1074/jbc.M404184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155721	hybrid			2022-12-27	WOS:000222849700002
J	Page, JL; Wang, X; Sordillo, LM; Johnson, SE				Page, JL; Wang, X; Sordillo, LM; Johnson, SE			MEKK1 signaling through p38 leads to transcriptional inactivation of E47 and repression of skeletal Myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HELIX-LOOP-HELIX; ACTIVATED PROTEIN-KINASE; MUSCLE GENE-EXPRESSION; MAP KINASE; OXIDATIVE STRESS; AVIAN MYOGENESIS; C2C12 MYOGENESIS; PATHWAYS; DIFFERENTIATION	Activation of the Raf kinase signal transduction pathway in skeletal myoblasts causes a complete cessation of myofiber formation and muscle gene expression. The negative impacts of the signaling pathway are realized through downstream activation of mitogen and extracellular kinase (MEK) phosphorylation-dependent events and MEK-independent signal transmission. MEKK1, a kinase that can physically associate with Raf, may contribute to the MEK-independent signaling in response to elevated Raf activity. Myogenic cells overexpressing activated Raf and kinase-defective MEKK1 remain differentiation-defective, suggesting that MEKK1 does not contribute to the inhibitory actions of Raf. However, constitutive activation of MEKK1 dramatically inhibits biochemical and morphological measures of muscle formation. MEKK1 inhibits MyoD-directed transcriptional activity without altering the ability of the protein to form heterodimers with E2A proteins or bind DNA. By contrast, the transcriptional activity of E47, the preferred dimer partner of the myogenic regulatory factors, is severely compromised by MEKK1-initiated signaling. Inhibition of MEK1/2 and JNK1/2 function did not reinstate E47-directed transcription, indicating that these two downstream kinases likely are not involved in the MEKK1-controlled transcriptional block. Inhibition of p38 signaling overcame the negative effects exerted by MEKK1 on the amino terminus of E47. Closer examination indicates that E47 is phosphorylated in vitro by p38, and deletion analysis predicts that the critical amino acid(s) phosphorylated by p38 lie outside of the minimal transcriptional activation domains. Thus, modification of E47 by p38 likely disrupts higher order protein complex formation that is necessary for muscle gene transcription.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA; Michigan State Univ, Dept Large Anim Clin Sci, E Lansing, MI 48824 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Michigan State University	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, 206 Henning, University Pk, PA 16802 USA.	sej4@psu.edu		Sordillo, Lorraine/0000-0001-8873-3134	NIAMS NIH HHS [1R01 AR048830-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048830] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Becker JR, 2001, EXP CELL RES, V267, P135, DOI 10.1006/excr.2001.5249; Boldt S, 2003, EXP CELL RES, V283, P80, DOI 10.1016/S0014-4827(02)00018-6; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dorman CM, 2000, J BIOL CHEM, V275, P27481; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Johnson SE, 2002, J BIOL CHEM, V277, P28742, DOI 10.1074/jbc.M203680200; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li FQ, 1996, J CELL BIOL, V135, P1043, DOI 10.1083/jcb.135.4.1043; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Mitin N, 2001, ONCOGENE, V20, P1276, DOI 10.1038/sj.onc.1204223; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Puri PL, 2000, GENE DEV, V14, P574; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Sanchez-Perez I, 2002, MOL BIOL CELL, V13, P2933, DOI 10.1091/mbc.E02-01-0022; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Schlesinger TK, 2002, J BIOL CHEM, V277, P10283, DOI 10.1074/jbc.M106885200; Suelves M, 2004, EMBO J, V23, P365, DOI 10.1038/sj.emboj.7600056; Waas WF, 2001, J BIOL CHEM, V276, P5676, DOI 10.1074/jbc.M008787200; Wang X, 2004, J BIOL CHEM, V279, P2528, DOI 10.1074/jbc.M306489200; Winter B, 2000, J CELL SCI, V113, P4211; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	47	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30966	30972		10.1074/jbc.M402224200	http://dx.doi.org/10.1074/jbc.M402224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159407	hybrid			2022-12-27	WOS:000222726800009
J	Alcorn, JF; Wright, JR				Alcorn, JF; Wright, JR			Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC-FIBROSIS; ALVEOLAR MACROPHAGES; BINDING-PROTEIN; STIMULATES PHAGOCYTOSIS; ALKALINE PROTEASE; LUNG; INFECTION; CALCIUM	The alveolar epithelium is lined by surfactant, a lipoprotein complex that both reduces surface tension and mediates several innate immune functions including bacterial aggregation, alteration of alveolar macrophage function, and regulation of bacterial clearance. Surfactant protein-D (SP-D) participates in several of these immune functions, and specifically it enhances the clearance of the pulmonary pathogen Pseudomonas aeruginosa, a common cause of morbidity and mortality in cystic fibrosis (CF) patients. P. aeruginosa secretes a variety of virulence factors including elastase, a zinc-metalloprotease, which degrades both SP-A and SP-D. Here we show that SP-D is cleaved by elastase to produce a stable 35-kDa fragment in a time-, temperature-, and dose-dependent manner. Degradation is inhibited by divalent metal cations, a metal chelator, and the elastase inhibitor, phosphoramidon. Sequencing the SP-D degradation products localized the major cleavage sites to the C-terminal lectin domain. The SP-D fragment fails to bind or aggregate bacteria that are aggregated by intact SP-D. SP-D fragment is observed when normal rat bronchoalveolar lavage (BAL) is treated with Pseudomonas aeruginosa elastase, and SP-D fragments are present in the BAL of CF lung allograft patients. These data show that degradation of SP-D occurs in the BAL environment and that degradation eliminates many normal immune functions of SP-D.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Wright, JR (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	j.wright@cellbio.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051134] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51134] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azghani AO, 2000, LUNG, V178, P181; BRUCE MC, 1985, AM REV RESPIR DIS, V132, P529; Coin D, 1997, FEMS IMMUNOL MED MIC, V18, P175, DOI 10.1016/S0928-8244(97)00037-0; COLLINS JF, 1991, LUNG, V169, P165, DOI 10.1007/BF02714152; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Dong Q, 1998, AM J PHYSIOL-LUNG C, V274, pL97, DOI 10.1152/ajplung.1998.274.1.L97; DORING G, 1983, J INFECT DIS, V147, P744, DOI 10.1093/infdis/147.4.744; Dosanjh AK, 1998, J INTERF CYTOK RES, V18, P851, DOI 10.1089/jir.1998.18.851; Engel LS, 1998, J BIOL CHEM, V273, P16792, DOI 10.1074/jbc.273.27.16792; FICK RB, 1985, J INFECT DIS, V151, P589, DOI 10.1093/infdis/151.4.589; Griese M, 2003, BBA-MOL BASIS DIS, V1638, P157, DOI 10.1016/S0925-4439(03)00063-2; Griese M, 1997, EUR RESPIR J, V10, P1983, DOI 10.1183/09031936.97.10091983; GUYTON AC, 1991, TXB MED PHYSL, P870; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HECK LW, 1990, J IMMUNOL, V144, P2253; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.0.CO;2-W; Hull J, 1997, AM J RESP CRIT CARE, V156, P161, DOI 10.1164/ajrccm.156.1.9609090; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; LAZDUNSKI A, 1990, BIOCHIMIE, V72, P147, DOI 10.1016/0300-9084(90)90140-C; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; LIU PV, 1974, J INFECT DIS, V130, P94; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Mariencheck WI, 2003, AM J RESP CELL MOL, V28, P528, DOI 10.1165/rcmb.2002-0141OC; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; Meyer KC, 2000, CHEST, V118, P164, DOI 10.1378/chest.118.1.164; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; Palaniyar N, 1998, J STRUCT BIOL, V122, P297, DOI 10.1006/jsbi.1998.4004; PERSSON A, 1990, J BIOL CHEM, V265, P5755; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; SCHULTZ DR, 1974, INFECT IMMUN, V10, P128, DOI 10.1128/IAI.10.1.128-135.1974; STOREY DG, 1992, INFECT IMMUN, V60, P4687, DOI 10.1128/IAI.60.11.4687-4694.1992; Tino MJ, 1996, AM J PHYSIOL-LUNG C, V270, pL677, DOI 10.1152/ajplung.1996.270.4.L677; Vanderzwan J, 1998, EUR RESPIR J, V12, P1388, DOI 10.1183/09031936.98.12061388; Yagci A, 2002, MICROBIOLOGICA, V25, P223; Yanagihara K, 2003, J MED MICROBIOL, V52, P531, DOI 10.1099/jmm.0.05154-0	47	92	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30871	30879		10.1074/jbc.M400796200	http://dx.doi.org/10.1074/jbc.M400796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123664	hybrid			2022-12-27	WOS:000222531900121
J	Chen, HH; Mullett, SJ; Stewart, AFR				Chen, HH; Mullett, SJ; Stewart, AFR			Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha(1)-adrenergic activation of gene expression in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; MUSCLE-SPECIFIC TRANSCRIPTION; CAT BINDING-FACTOR; PROTEIN-KINASE-C; SKELETAL-MUSCLE; DROSOPHILA-MELANOGASTER; WING FORMATION; FACTOR RTEF-1; ELEMENTS; TEF-1	Cardiac and skeletal muscle genes are regulated by the transcriptional enhancer factor (TEF-1) family of transcription factors. In skeletal muscle, TEF-1 factors interact with a skeletal muscle-specific cofactor called Vestigial-like 2 (Vgl-2) that is related to the Drosophila protein Vestigial. Here, we characterize Vgl-4, the only member of the Vestigial-like family expressed in the heart. Unlike other members of the Vgl family that have a single TEF-1 interaction domain called the tondu (TDU) motif, Vgl-4 has two TDU motifs in its carboxyl-terminal domain. Like other Vgl factors, Vgl-4 physically interacts with TEF-1 in an immunoprecipitation assay. Vgl-4 functionally interacts with TEF-1 and also with myocyte enhancer factor 2 in a mammalian two-hybrid assay. Overexpression of Vgl-4 in cardiac myocytes interfered with the basal expression and alpha(1)-adrenergic receptor-dependent activation of a TEF-1-dependent skeletal alpha-actin promoter. In cardiac myocytes cultured in serum and in serum-free medium, a myc-tagged Vgl-4 protein was located in the nucleus and cytoplasm but was exported from the nucleus when cells were treated with alpha(1)-adrenergic receptor agonist. A chimeric nuclear-retained Vgl-4 protein inhibited alpha(1)-adrenergic receptor-dependent activation. In contrast, deletion of the TDU motifs of Vgl-4 prevented Vgl-4 nuclear localization, relieved Vgl-4 interference of basal activity, and enhanced alpha(1)-adrenergic up-regulation of the skeletal alpha-actin promoter. Nuclear export of Vgl-4 is dependent on the nuclear exportin CRM-1. These results suggest that Vgl-4 modulates the activity of TEF-1 factors and counteracts alpha(1)-adrenergic activation of gene expression in cardiac myocytes.	Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stewart, AFR (corresponding author), Univ Pittsburgh, Cardiovasc Inst, 1704-3 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	stewartaf@upmc.edu	Stewart, Alexandre F.R./A-5677-2011	Stewart, Alexandre/0000-0003-2673-9164; Chen, Hsiao-Huei/0000-0003-2914-6057				Bate Michael, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1047; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Brown CO, 2004, J BIOL CHEM, V279, P10659, DOI 10.1074/jbc.M301648200; Busk PK, 2002, CARDIOVASC RES, V56, P64, DOI 10.1016/S0008-6363(02)00510-2; Butler AJ, 1999, MOL CELL BIOL, V19, P296; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Halder G, 1998, GENE DEV, V12, P3900, DOI 10.1101/gad.12.24.3900; Halder G, 2001, DEVELOPMENT, V128, P3295; Huey KA, 2003, AM J PHYSIOL-CELL PH, V284, pC738, DOI 10.1152/ajpcell.00389.2002; JACQUEMIN P, 1994, DNA CELL BIOL, V13, P1037, DOI 10.1089/dna.1994.13.1037; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Maeda T, 2002, J BIOL CHEM, V277, P24346, DOI 10.1074/jbc.M201171200; Maeda T, 2002, BIOCHEM BIOPH RES CO, V294, P791, DOI 10.1016/S0006-291X(02)00556-9; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; McLean BG, 2003, J MOL CELL CARDIOL, V35, P461, DOI 10.1016/S0022-2828(03)00049-X; Mielcarek M, 2002, MECH DEVELOP, V119, pS269, DOI 10.1016/S0925-4773(03)00127-8; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Paumard-Rigal S, 1998, DEV GENES EVOL, V208, P440, DOI 10.1007/s004270050201; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Sudarsan V, 2001, DEV CELL, V1, P829, DOI 10.1016/S1534-5807(01)00089-2; Tsika RW, 2002, AM J PHYSIOL-CELL PH, V283, pC1761, DOI 10.1152/ajpcell.00278.2002; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; Vara D, 2003, J BIOL CHEM, V278, P21388, DOI 10.1074/jbc.M212612200; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaudin P, 1999, DEVELOPMENT, V126, P4807; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	43	84	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30800	30806		10.1074/jbc.M400154200	http://dx.doi.org/10.1074/jbc.M400154200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140898	hybrid			2022-12-27	WOS:000222531900111
J	Kong, KY; Kedes, L				Kong, KY; Kedes, L			Cytoplasmic nuclear transfer of the actin-capping protein tropomodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPOMYOSIN-BINDING PROTEIN; INTRANUCLEAR ROD MYOPATHY; CHICK CARDIAC MYOCYTES; POINTED ENDS; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; CYTOSKELETAL PROTEIN; SKELETAL-MUSCLE; MESSENGER-RNA; LEPTOMYCIN-B	Tropomodulin (Tmod) is a cytoskeletal actin-capping protein that interacts with tropomyosin at the pointed end of actin filaments. E-Tmod is an isoform that expresses predominantly in cardiac cells and slow skeletal muscle fibers. We unexpectedly discovered significant levels of Tmod in nuclei and then defined peptide domains in Tmod responsible for nuclear import and export. These domains resemble, and function as, a nuclear export signal (NES) and a pattern 4 nuclear localization signal (NLS). Both motifs are conserved in other Tmod isoforms and across species. Comparisons of wild-type Tmod and Tmod carrying mutations in these peptide domains revealed that Tmod normally traffics through the nucleus. These observations logically presuppose that Tmod functions may include a nuclear role. Indeed, increasing Tmod in the nucleus severely hampered myogenic differentiation and selectively suppressed muscle-specific gene expression (endogenous p21, myosin heavy chain, myogenin, and Tmod) but did not affect endogenous glyceraldehyde-3-phosphate dehydrogenase or expression from a transfected E-GFP vector. These results suggest that, at least in myogenic cells, nuclear Tmod may be involved in the differentiation process.	Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Kedes, L (corresponding author), Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA.	kedes@hsc.usc.edu						Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; Conley CA, 2001, GENOMICS, V73, P127, DOI 10.1006/geno.2000.6501; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Dye CA, 1998, DEVELOPMENT, V125, P1845; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Goebel HH, 1997, NEUROMUSCULAR DISORD, V7, P13, DOI 10.1016/S0960-8966(96)00404-X; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Park M, 1998, MECH DEVELOP, V75, P117, DOI 10.1016/S0925-4773(98)00098-7; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Sakoda T, 1999, J MOL CELL CARDIOL, V31, P2037, DOI 10.1006/jmcc.1999.1035; Skeath JB, 1998, DEVELOPMENT, V125, P1857; SUNG LA, 1994, BIOCHEM BIOPH RES CO, V201, P627, DOI 10.1006/bbrc.1994.1747; SUNG LA, 1992, J BIOL CHEM, V267, P2616; Sussman MA, 1998, CIRC RES, V82, P94; SUSSMAN MA, 1994, CIRC RES, V75, P221, DOI 10.1161/01.RES.75.2.221; SUSSMAN MA, 1994, DEV BRAIN RES, V80, P45, DOI 10.1016/0165-3806(94)90088-4; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; SUSSMAN MA, 1992, EUR J BIOCHEM, V205, P355, DOI 10.1111/j.1432-1033.1992.tb16787.x; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; TemmGrove CJ, 1996, CELL MOTIL CYTOSKEL, V33, P223, DOI 10.1002/(SICI)1097-0169(1996)33:3<223::AID-CM6>3.0.CO;2-B; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Watakabe A, 1996, J CELL SCI, V109, P2299; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Weeks DA, 2003, ULTRASTRUCT PATHOL, V27, P151, DOI 10.1080/01913120309933; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zeng XL, 1999, CELL RES, V9, P61, DOI 10.1038/sj.cr.7290006; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	45	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30856	30864		10.1074/jbc.M302845200	http://dx.doi.org/10.1074/jbc.M302845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15123707	hybrid			2022-12-27	WOS:000222531900119
J	Sheppard, DC; Yeaman, MR; Welch, WH; Phan, QT; Fu, Y; Ibrahim, AS; Filler, SG; Zhang, M; Waring, AJ; Edwards, JE				Sheppard, DC; Yeaman, MR; Welch, WH; Phan, QT; Fu, Y; Ibrahim, AS; Filler, SG; Zhang, M; Waring, AJ; Edwards, JE			Functional and structural diversity in the Als protein family of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; CELL-ADHESION MOLECULE-1; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; ENDOTHELIAL-CELLS; CIRCULAR-DICHROISM; 3-DIMENSIONAL PROFILES; ADHERENCE PROPERTIES; EPITHELIAL-CELLS; GENE FAMILY	The human fungal pathogen Candida albicans colonizes and invades a wide range of host tissues. Adherence to host constituents plays an important role in this process. Two members of the C. albicans Als protein family (Als1p and Als5p) have been found to mediate adherence; however, the functions of other members of this family are unknown. In this study, members of the ALS gene family were cloned and expressed in Saccharomyces cerevisiae to characterize their individual functions. Distinct Als proteins conferred distinct adherence profiles to diverse host substrates. Using chimeric Als5p-Als6p constructs, the regions mediating substrate-specific adherence were localized to the N-terminal domains in Als proteins. Interestingly, a subset of Als proteins also mediated endothelial cell invasion, a previously unknown function of this family. Consistent with these results, homology modeling revealed that Als members contain anti-parallel beta-sheet motifs interposed by extended regions, homologous to adhesins or invasins of the immunoglobulin superfamily. This finding was confirmed using circular dichroism and Fourier transform infrared spectrometric analysis of the N-terminal domain of Als1p. Specific regions of amino acid hypervariability were found among the N-terminal domains of Als proteins, and energy-based models predicted similarities and differences in the N-terminal domains that probably govern the diverse function of Als family members. Collectively, these results indicate that the structural and functional diversity within the Als family provides C. albicans with an array of cell wall proteins capable of recognizing and interacting with a wide range of host constituents during infection.	Univ Calif Los Angeles, Harbor Res & Educ Inst, St Johns Cardiovasc Res Ctr, Div Infect Dis,Dept Med, Torrance, CA 90502 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA; Univ Nevada, Dept Biochem, Reno, NV 89507 USA; Calif State Univ Long Beach, Dept Biol Sci, Long Beach, CA 90840 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Nevada System of Higher Education (NSHE); University of Nevada Reno; California State University System; California State University Long Beach	Sheppard, DC (corresponding author), Univ Calif Los Angeles, Harbor Res & Educ Inst, St Johns Cardiovasc Res Ctr, Div Infect Dis,Dept Med, Torrance, CA 90502 USA.	dsheppard@rei.edu	Sheppard, Donald/B-4637-2008; Filler, Scott G/A-2779-2009	Sheppard, Donald/0000-0001-8877-880X; Filler, Scott G/0000-0001-7278-3700	NCRR NIH HHS [M01 RR00425] Funding Source: Medline; NIAID NIH HHS [1R01 AI054928, R03 AI054531, R01AI-48031, R01 AI19990, P01 AI37194] Funding Source: Medline; NIDCR NIH HHS [5R01 DE13974] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019990, R03AI054531, R01AI048031, R01AI054928, P01AI037194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013974] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bailey DA, 1996, J BACTERIOL, V178, P5353, DOI 10.1128/jb.178.18.5353-5360.1996; Belanger PH, 2002, CELL MICROBIOL, V4, P805, DOI 10.1046/j.1462-5822.2002.00232.x; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; EDWARDS JE, 2000, MANDELL DOUGLAS BENN, P2656; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FILLER SG, 1995, INFECT IMMUN, V63, P976, DOI 10.1128/IAI.63.3.976-983.1995; Fischer D, 1996, FASEB J, V10, P126, DOI 10.1096/fasebj.10.1.8566533; Fu Y, 1998, INFECT IMMUN, V66, P2078, DOI 10.1128/IAI.66.5.2078-2084.1998; Fu Y, 1998, INFECT IMMUN, V66, P1783, DOI 10.1128/IAI.66.4.1783-1786.1998; Fu Y, 2002, MOL MICROBIOL, V44, P61, DOI 10.1046/j.1365-2958.2002.02873.x; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gaur NK, 2002, CELL COMMUN ADHES, V9, P45, DOI 10.1080/15419060212187; Gaur NK, 1997, INFECT IMMUN, V65, P5289, DOI 10.1128/IAI.65.12.5289-5294.1997; Gaur NK, 1999, INFECT IMMUN, V67, P6040, DOI 10.1128/IAI.67.11.6040-6047.1999; GODZIK A, 1995, PROTEIN ENG, V8, P409, DOI 10.1093/protein/8.5.409; GODZIK A, 1993, J COMPUT AID MOL DES, V7, P397, DOI 10.1007/BF02337559; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; GODZIK A, 1992, J MOL BIOL, V227, P227, DOI 10.1016/0022-2836(92)90693-E; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HALVERSON KJ, 1991, J AM CHEM SOC, V113, P6701, DOI 10.1021/ja00017a068; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HEIDEN W, 1993, J COMPUT CHEM, V14, P246, DOI 10.1002/jcc.540140212; Hoyer LL, 1999, INFECT IMMUN, V67, P4251, DOI 10.1128/IAI.67.8.4251-4255.1999; Hoyer LL, 2001, GENETICS, V157, P1555; Hoyer LL, 2001, YEAST, V18, P49, DOI 10.1002/1097-0061(200101)18:1&lt;49::AID-YEA646&gt;3.0.CO;2-M; Hoyer LL, 2001, TRENDS MICROBIOL, V9, P176, DOI 10.1016/S0966-842X(01)01984-9; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kamai Y, 2002, INFECT IMMUN, V70, P5256, DOI 10.1128/IAI.70.9.5256-5258.2002; KELLOGG GE, 1991, J COMPUT AID MOL DES, V5, P545, DOI 10.1007/BF00135313; KLOTZ SA, 1992, CLIN INFECT DIS, V14, P340, DOI 10.1093/clinids/14.1.340; Li F, 2003, EUKARYOT CELL, V2, P1266, DOI 10.1128/EC.2.6.1266-1273.2003; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; LUCINDO NV, 2002, P 102 ANN M AM SOC M, P204; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Phan QT, 2000, INFECT IMMUN, V68, P3485, DOI 10.1128/IAI.68.6.3485-3490.2000; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; ROTROSEN D, 1986, REV INFECT DIS, V8, P73; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sreerama N, 1999, PROTEIN SCI, V8, P370; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; Sundstrom P, 2002, INFECT IMMUN, V70, P3281, DOI 10.1128/IAI.70.6.3281-3283.2002; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Topham C M, 1990, Biochem Soc Symp, V57, P1; Tsuchimori N, 2000, INFECT IMMUN, V68, P1997, DOI 10.1128/IAI.68.4.1997-2002.2000; Viney JL, 1996, J IMMUNOL, V157, P2488; Waring AJ, 1996, PROTEIN PEPTIDE LETT, V3, P177; WELCH W, 1994, BIOCHEMISTRY-US, V33, P6074, DOI 10.1021/bi00186a006; Welch W, 1996, BIOCHEMISTRY-US, V35, P7165, DOI 10.1021/bi9527294; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; Zhang NX, 2003, GENOME RES, V13, P2005, DOI 10.1101/gr.1024903; Zhao H, 2002, HYBRIDOMA HYBRIDOM, V21, P25, DOI 10.1089/15368590252917610; Zhao XM, 2003, MICROBIOL-SGM, V149, P2947, DOI 10.1099/mic.0.26495-0	64	208	235	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30480	30489		10.1074/jbc.M401929200	http://dx.doi.org/10.1074/jbc.M401929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128742	hybrid			2022-12-27	WOS:000222531900076
J	Wang, WQ; Bembenek, J; Gee, KR; Yu, HT; Charbonneau, H; Zhang, ZY				Wang, WQ; Bembenek, J; Gee, KR; Yu, HT; Charbonneau, H; Zhang, ZY			Kinetic and mechanistic studies of a cell cycle protein phosphatase Cdc14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-STEADY-STATE; TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; TRANSITION-STATE; CATALYTIC MECHANISM; PHOSPHOINOSITIDE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; INORGANIC-PHOSPHATE; TUMOR-SUPPRESSOR; SPECIFICITY	The Cdc14 family of protein phosphatases is conserved within eukaryotes and antagonizes the action of cyclin-dependent kinases, thereby promoting mitotic exit and cytokinesis. We performed a detailed kinetic and mechanistic study of the Cdc14 phosphatases with both small molecule aryl phosphates and a physiological protein substrate hCdh1. We found that Cdc14 displays a strong preference for two-ringed aryl phosphates over smaller one-ringed or larger, multi-ringed substrates, a finding that may have important implications for inhibitor design. Results from both leaving group and pH dependence of the Cdc14-catalyzed reaction are consistent with a general acid-independent mechanism for substrates with leaving group pK(a) < 7 and a general acid-dependent mechanism for substrates with leaving group pK(a) > 7. The use of both low and high leaving group pKa substrates, in combination with steady-state and pre-steady-state kinetic techniques enabled the isolation and analysis of both the phosphoenzyme (E-P) formation and hydrolysis step. We established the requirement of general acid catalysis for E-P formation in reactions with high leaving group pKa substrates, and the presence of general base catalysis in E-P hydrolysis. Mutational study of invariant acidic residues in Cdc14 identified Asp(253) as the general acid during E-P formation and the general base in E-P hydrolysis. We also identified several residues including Asp(50), Asp(129), Glu(168), Glu(171), and Asp(177) in the Cdc14 active site cleft that are required for efficient dephosphorylation of hCdh1.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Mol Probes Inc, Eugene, OR 97402 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu		Bembenek, Joshua/0000-0002-0966-2268; Yu, Hongtao/0000-0002-8861-049X	NCI NIH HHS [CA69202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; Cerutti L, 2000, CURR OPIN GENET DEV, V10, P65, DOI 10.1016/S0959-437X(99)00044-1; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; Cueille N, 2001, J CELL SCI, V114, P2649; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Gee KR, 1999, ANAL BIOCHEM, V273, P41, DOI 10.1006/abio.1999.4202; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; Gruneberg U, 2002, J CELL BIOL, V158, P901, DOI 10.1083/jcb.200202054; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P7928, DOI 10.1021/bi970364c; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; KIRBY AJ, 1967, J AM CHEM SOC, V89, P415, DOI 10.1021/ja00978a044; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; McCain DF, 2002, J BIOL CHEM, V277, P11190, DOI 10.1074/jbc.M109636200; Montserat J, 1996, J BIOL CHEM, V271, P7868, DOI 10.1074/jbc.271.13.7868; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Rigas JD, 2001, BIOCHEMISTRY-US, V40, P4398, DOI 10.1021/bi002951v; Rudolph J, 2001, ANAL BIOCHEM, V289, P43, DOI 10.1006/abio.2000.4906; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Trautmann S, 2002, CURR BIOL, V12, pR733, DOI 10.1016/S0960-9822(02)01250-2; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang WQ, 2003, CURR TOP MED CHEM, V3, P739, DOI 10.2174/1568026033452302; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; Zhang ZY, 2003, PROG NUCLEIC ACID RE, V73, P171, DOI 10.1016/S0079-6603(03)01006-7; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	60	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30459	30468		10.1074/jbc.M402217200	http://dx.doi.org/10.1074/jbc.M402217200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15128740	hybrid			2022-12-27	WOS:000222531900073
J	Zhao, Y; Qin, SF; Atangan, LI; Molina, Y; Okawa, Y; Arpawong, HT; Ghosn, C; Xiao, JH; Vuligonda, V; Brown, G; Chandraratna, RAS				Zhao, Y; Qin, SF; Atangan, LI; Molina, Y; Okawa, Y; Arpawong, HT; Ghosn, C; Xiao, JH; Vuligonda, V; Brown, G; Chandraratna, RAS			Casein kinase 1 alpha interacts with retinoid x receptor and interferes with agonist-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR; KINASE-I; ALPHA; ACTIVATION; PHOSPHORYLATION; BINDING; CANCER; CELLS; RXR; CHEMOPREVENTION	Agonists of retinoid X receptors (RXRs), which include the natural 9-cis-retinoic acid and synthetic analogs, are potent inducers of growth arrest and apoptosis in some cancer cells. As such, they are being used in clinical trials for the treatment and prevention of solid tumors and are used to treat cutaneous T cell lymphoma. However, the molecular mechanisms that underlie the anticancer effects of RXR agonists remain unclear. Here, we show that a novel pro-apoptotic pathway that is induced by RXR agonist is negatively regulated by casein kinase 1alpha (CK1alpha). CK1alpha associates with RXR in an agonist-dependent manner and phosphorylates RXR. The ability of an RXR agonist to recruit CK1alpha to a complex with RXR in cells correlates inversely with its ability to inhibit growth. Remarkably, depletion of CK1alpha in resistant cells renders them susceptible to RXR agonist-induced growth inhibition and apoptosis. Our study shows that CK1alpha can promote cell survival by interfering with RXR agonist-induced apoptosis. Inhibition of CK1alpha may enhance the anti-cancer effects of RXR agonists.	Allergan Pharmaceut Inc, Retinoid Res, Dept Biol, Irvine, CA 92612 USA; Allergan Pharmaceut Inc, Retinoid Res, Dept Chem, Irvine, CA 92612 USA; Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England	AbbVie; Allergan; AbbVie; Allergan; University of Birmingham	Chandraratna, RAS (corresponding author), Allergan Pharmaceut Inc, Retinoid Res, Dept Biol, 2525 Dupont Dr, Irvine, CA 92612 USA.	chandraratna_rosh@allergan.com		Qin, Suofu/0000-0002-3323-8846				Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DeGrendele Heather, 2003, Clin Lung Cancer, V4, P210; Duvic M, 2001, J CLIN ONCOL, V19, P2456, DOI 10.1200/JCO.2001.19.9.2456; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gianni M, 2000, CELL DEATH DIFFER, V7, P447, DOI 10.1038/sj.cdd.4400673; Gottardis MM, 1996, CANCER RES, V56, P5566; Gross SD, 1999, J CELL SCI, V112, P2647; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; Klein ES, 2000, J BIOL CHEM, V275, P19401, DOI 10.1074/jbc.M002472200; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lowe M N, 2000, Am J Clin Dermatol, V1, P245, DOI 10.2165/00128071-200001040-00006; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; NAGY L, 1995, MOL CELL BIOL, V15, P3540; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Smith CM, 1997, TRENDS BIOCHEM SCI, V22, P444, DOI 10.1016/S0968-0004(97)01131-6; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Tanaka T, 2004, MOL CELL BIOL, V24, P3972, DOI 10.1128/MCB.24.9.3972-3982.2004; WANG R, 2002, BIOTECHNIQUES, V33, pS88; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wu KD, 2002, CANCER RES, V62, P6376; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200	37	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30844	30849		10.1074/jbc.M404651200	http://dx.doi.org/10.1074/jbc.M404651200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15131121	hybrid			2022-12-27	WOS:000222531900117
J	Mishima, M; Sakai, Y; Itoh, N; Kamiya, H; Furuichi, M; Takahashi, M; Yamagata, Y; Iwai, S; Nakabeppu, Y; Shirakawa, M				Mishima, M; Sakai, Y; Itoh, N; Kamiya, H; Furuichi, M; Takahashi, M; Yamagata, Y; Iwai, S; Nakabeppu, Y; Shirakawa, M			Structure of human MTH1, a nudix family hydrolase that selectively degrades oxidized purine nucleoside triphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; PROTEIN STRUCTURES; DNA GLYCOSYLASE; NMR EXPERIMENTS; MUTT PROTEIN; MUTATIONS; GENE; IDENTIFICATION; 8-OXO-DGTPASE	Oxygen radicals generated through normal cellular respiration processes can cause mutations in genomic and mitochondrial DNA. Human MTH1 hydrolyzes oxidized purine nucleoside triphosphates, such as 8-oxo-dGTP and 2-hydroxy-dATP, to monophosphates, thereby preventing the misincorporation of these oxidized nucleotides during replication. Here we present the solution structure of MTH1 solved by multidimensional heteronuclear NMR spectroscopy. The protein adopts a fold similar to that of Escherichia coli MutT, despite the low sequence similarity between these proteins outside the conserved Nudix motif. The substrate-binding pocket of MTH1, deduced from chemical shift perturbation experiments, is located at essentially the same position as in MutT; however, a pocket-forming helix is largely displaced in MTH1 ( similar to 9 Angstrom) such that the shape of the pocket differs between the two proteins. Detailed analysis of the pocket-forming residues enabled us to identify Asn(33) as one of the key residues in MTH1 for discriminating the oxidized form of purine, and mutation of this residue modifies the substrate specificity. We also show that MTH1 catalyzes hydrolysis of 8-oxo-dGTP through nucleophilic substitution of water at the beta-phosphate.	Kyushu Univ, Med Inst Bioregulat, Dept Immunobiol & Neurosci, Div Neurofunct Genom, Fukuoka 8128582, Japan; JST, CREST, Fukuoka 8128582, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; CNRS, FRE 2230, Fac Sci & Tech, Lab Biocatalyse, F-44322 Nantes 3, France; Univ Nantes, F-44322 Nantes 3, France; Inst Curie, F-91405 Orsay, France; Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan; Osaka Univ, Grad Sch Engn Sci, Osaka 5608531, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2300045, Japan; RIKEN, Genom Sci Ctr, Kanagawa 2300045, Japan	Kyushu University; Japan Science & Technology Agency (JST); Nara Institute of Science & Technology; Hokkaido University; Centre National de la Recherche Scientifique (CNRS); Nantes Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Kumamoto University; Osaka University; Yokohama City University; RIKEN	Nakabeppu, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Immunobiol & Neurosci, Div Neurofunct Genom, Fukuoka 8128582, Japan.	yusaku@bioreg.kyushu-u.ac.jp; shirakawa@tsurumi.yokohama-cu.ac.jp	Kamiya, Hiroyuki/G-2383-2019; Takahashi, Masayuki/AAM-7033-2021; Nakabeppu, Yusaku/A-8902-2011; Sakai, Yasunari/S-7965-2018	Kamiya, Hiroyuki/0000-0001-6866-5322; Nakabeppu, Yusaku/0000-0002-6739-242X; Sakai, Yasunari/0000-0002-5747-8692				ABELLI SB, 2001, NAT STRUCT BIOL, V5, P467; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; BESSHO T, 1993, J BIOL CHEM, V268, P19416; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHENG KC, 1992, J BIOL CHEM, V267, P166; Cordier F, 1999, J AM CHEM SOC, V121, P1601, DOI 10.1021/ja983945d; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1999, J AM CHEM SOC, V121, P2949, DOI 10.1021/ja9902221; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Foster MP, 1998, J BIOMOL NMR, V12, P51, DOI 10.1023/A:1008290631575; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; Fujikawa K, 2001, NUCLEIC ACIDS RES, V29, P449, DOI 10.1093/nar/29.2.449; Furuta A, 2001, NEUROREPORT, V12, P2895, DOI 10.1097/00001756-200109170-00028; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GODDARD TD, 1999, SPARKY3; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Iida T, 2001, NEURO-ONCOLOGY, V3, P73, DOI 10.1093/neuonc/3.2.73; Inoue M, 1998, J BIOL CHEM, V273, P11069, DOI 10.1074/jbc.273.18.11069; Ishibashi T, 2003, EMBO REP, V4, P479, DOI 10.1038/sj.embor.embor838; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; Kang LW, 2003, STRUCTURE, V11, P1015, DOI 10.1016/S0969-2126(03)00154-0; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; Kennedy CH, 1998, FEBS LETT, V429, P17, DOI 10.1016/S0014-5793(98)00505-5; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Massiah MA, 2003, BIOCHEMISTRY-US, V42, P10140, DOI 10.1021/bi030105p; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Pellecchia M, 1997, J MAGN RESON, V124, P274, DOI 10.1006/jmre.1996.1058; Sakai Y, 2002, J BIOL CHEM, V277, P8579, DOI 10.1074/jbc.M110566200; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Shimura-Miura H, 1999, ANN NEUROL, V46, P920, DOI 10.1002/1531-8249(199912)46:6<920::AID-ANA17>3.0.CO;2-R; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Takahashi M, 2002, J MOL BIOL, V319, P129, DOI 10.1016/S0022-2836(02)00163-8; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; Xu P, 2003, J BIOL CHEM, V278, P48422, DOI 10.1074/jbc.M307888200; Yakushiji H, 1997, MUTAT RES-DNA REPAIR, V384, P181, DOI 10.1016/S0921-8777(97)00025-6; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	59	49	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33806	33815		10.1074/jbc.M402393200	http://dx.doi.org/10.1074/jbc.M402393200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15133035	hybrid			2022-12-27	WOS:000223039700090
J	Nishio, M; Fukumoto, S; Furukawa, K; Ichimura, A; Miyazaki, H; Kusunoki, S; Urano, T; Furukawa, K				Nishio, M; Fukumoto, S; Furukawa, K; Ichimura, A; Miyazaki, H; Kusunoki, S; Urano, T; Furukawa, K			Overexpressed GM1 suppresses nerve growth factor (NGF) signals by modulating the intracellular localization of NGF receptors and membrane fluidity in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; LIPID RAFTS; NEUROTROPHIN RECEPTORS; BRAIN GANGLIOSIDES; MAP KINASES; TRK; PROTEIN; CAVEOLAE; RAS; PHOSPHORYLATION	Ganglioside GM1 has been considered to have a neurotrophic factor-like activity. To analyze the effects of endogenously generated GM1, the rat pheochromocytoma cell line PC12 was transfected with the GM1/GD1b/ GA1 synthase gene and showed increased expression levels of GM1. To our surprise, GM1(+)-transfectant cells (GM1(+) cells) showed no neurite formation after stimulation with nerve growth factor (NGF). Autophosphorylation of NGF receptor TrkA and activation of ERK1/2 after NGF treatment were scarcely detected in GM1(+) cells. Binding of I-125-NGF to PC12 cells was almost equivalent between GM1(+) cells and controls. However, dimer formation of TrkA upon NGF treatment was markedly suppressed in GM1(+) cells in both cross-linking analysis with Bis(sulfosuccinimidyl) suberate 3 and I-125-NGF binding assay. The sucrose density gradient fractionation of the cell lysate revealed that TrkA primarily located in the lipid raft fraction moved to the non-raft fraction in GM1(+) cells. p75(NTR) and Ras also moved from the raft to non-raft fraction in GM1(+) cells, whereas flotillin and GM1 persistently resided in the lipid raft. TrkA kinase activity was differentially regulated when GM1 was added to the kinase assay system in vitro, suggesting suppressive/enhancing effects of GM1 on NGF signals based on the concentration. Measurement of fluorescence recovery after photobleaching revealed that the membrane fluidity was reduced in GM1(+) cells. These results suggested that overexpressed GM1 suppresses the differentiation signals mediated by NGF/ TrkA by modulating the properties of the lipid raft and the intracellular localization of NGF receptors and relevant signaling molecules.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528588, Japan; Kinki Univ, Sch Med, Dept Neurol, Osaka 5898511, Japan	Nagoya University; Nagasaki University; Kindai University (Kinki University)	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp		Urano, Takeshi/0000-0003-3383-3554; Fukumoto, Satoshi/0000-0002-5046-6891				Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chen SY, 1996, ALCOHOL, V13, P589; Duchemin AM, 2002, J NEUROCHEM, V81, P696, DOI 10.1046/j.1471-4159.2002.00831.x; Farooqui T, 1997, J NEUROCHEM, V68, P2348; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Ge GX, 2001, BIOCHEM BIOPH RES CO, V282, P511, DOI 10.1006/bbrc.2001.4600; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KARPIAK SE, 1986, CLIN NEUROPHARMACOL, V9, P338; KARPIAK SE, 1984, J NEUROSCI RES, V12, P485, DOI 10.1002/jnr.490120231; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; Masserini M, 2001, BBA-MOL CELL BIOL L, V1532, P149, DOI 10.1016/S1388-1981(01)00128-7; MILJAN EA, 2002, SCI STKE; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Notterpek L, 2003, TRENDS NEUROSCI, V26, P232, DOI 10.1016/S0166-2236(03)00099-7; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; RABIN SJ, 1995, J NEUROCHEM, V65, P347; Rabin SJ, 2002, J BIOL CHEM, V277, P49466, DOI 10.1074/jbc.M203240200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; SCHENGRUND CL, 1990, BRAIN RES BULL, V24, P131, DOI 10.1016/0361-9230(90)90297-D; SCHNEIDER JS, 1992, SCIENCE, V256, P843, DOI 10.1126/science.1350379; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUZUKI K, 1965, J NEUROCHEM, V12, P969, DOI 10.1111/j.1471-4159.1965.tb10256.x; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TERNBERG PW, 1999, NAT CELL BIOL, V1, pE35; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUI Z, 1990, In Vivo (Attiki), V4, P205; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	53	97	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33368	33378		10.1074/jbc.M403816200	http://dx.doi.org/10.1074/jbc.M403816200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15145933	hybrid			2022-12-27	WOS:000223039700044
J	Chaudhary, K; Darling, JA; Fohl, LM; Sullivan, WJ; Donald, RGK; Pfefferkorn, ER; Ullman, B; Roos, DS				Chaudhary, K; Darling, JA; Fohl, LM; Sullivan, WJ; Donald, RGK; Pfefferkorn, ER; Ullman, B; Roos, DS			Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; TRANSITION-STATE ANALOG; ADENOSINE KINASE; ADENINE PHOSPHORIBOSYLTRANSFERASE; PLASMODIUM-FALCIPARUM; CRYSTAL-STRUCTURES; OPPORTUNISTIC INFECTIONS; RECOMBINANT EXPRESSION; SELECTABLE MARKER; EIMERIA-TENELLA	We have exploited a variety of molecular genetic, biochemical, and genomic techniques to investigate the roles of purine salvage enzymes in the protozoan parasite Toxoplasma gondii. The ability to generate defined genetic knockouts and target transgenes to specific loci demonstrates that T. gondii uses two ( and only two) pathways for purine salvage, defined by the enzymes hypoxanthine-xanthine-guanine phosphoribosyltransferase (HXGPRT) and adenosine kinase (AK). Both HXGPRT and AK are single-copy genes, and either one can be deleted, indicating that either one of these pathways is sufficient to meet parasite purine requirements. Fitness defects suggest both pathways are important for the parasite, however, and that the salvage of adenosine is more important than salvage of hypoxanthine and other purine nucleobases. HXGPRT and AK cannot be deleted simultaneously unless one of these enzymes is provided in trans, indicating that alternative routes of functionally significant purine salvage are lacking. Despite previous reports to the contrary, we found no evidence of adenine phosphoribosyltransferase (APRT) activity when parasites were propagated in APRT-deficient host cells, and no APRT ortholog is evident in the T. gondii genome. Expression of Leishmania donovani APRT in transgenic T. gondii parasites yielded low levels of activity but did not permit genetic deletion of both HXGPRT and AK. A detailed comparative genomic study of the purine salvage pathway in various apicomplexan species highlights important differences among these parasites.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Dartmouth Coll Sch Med, Dept Microbiol, Hanover, NH 03755 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	University of Pennsylvania; Dartmouth College; Oregon Health & Science University	Roos, DS (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu	Donald, Robert George Konrad/GNP-4958-2022; Darling, John/B-5451-2014	Darling, John/0000-0002-4776-9533; Roos, David Siker/0000-0001-6725-4089				Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; Bahl A, 2002, NUCLEIC ACIDS RES, V30, P87, DOI 10.1093/nar/30.1.87; Brooks R. G., 1987, Antimicrobial Agents Annual, V2, P297; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CHANG CH, 1980, J BIOL CHEM, V255, P2366; Chiang CW, 1999, J BIOL CHEM, V274, P35255, DOI 10.1074/jbc.274.49.35255; Conner R.L., 1973, P123; DARE E, 1992, EXP CELL RES, V203, P336, DOI 10.1016/0014-4827(92)90007-U; Darling JA, 1999, MOL BIOCHEM PARASIT, V103, P15, DOI 10.1016/S0166-6851(99)00109-7; De Koning HP, 2003, INT J PARASITOL, V33, P821, DOI 10.1016/S0020-7519(03)00091-2; DEJONG JW, 1980, ANAL BIOCHEM, V101, P407, DOI 10.1016/0003-2697(80)90206-7; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Doyle PS, 1998, EXP PARASITOL, V89, P9, DOI 10.1006/expr.1998.4263; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; Fohl LM, 2003, MOL MICROBIOL, V50, P1319, DOI 10.1046/j.1365-2958.2003.03756.x; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; HILL DL, 1967, J CELL PHYSIOL, V69, P321, DOI 10.1002/jcp.1040690308; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; Kissinger JC, 2003, NUCLEIC ACIDS RES, V31, P234, DOI 10.1093/nar/gkg072; KRUG EC, 1989, J BIOL CHEM, V264, P10601; LAFON SW, 1985, MOL BIOCHEM PARASIT, V14, P11, DOI 10.1016/0166-6851(85)90101-X; LANE HC, 1994, ANN INTERN MED, V120, P945, DOI 10.7326/0003-4819-120-11-199406010-00007; LAUGHON BE, 1991, J INFECT DIS, V164, P244, DOI 10.1093/infdis/164.2.244; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; Matrajt M, 2002, MOL BIOCHEM PARASIT, V120, P285, DOI 10.1016/S0166-6851(02)00014-2; MILLER RL, 1983, MOL BIOCHEM PARASIT, V7, P41, DOI 10.1016/0166-6851(83)90115-9; MILLER RL, 1979, J BIOL CHEM, V254, P2346; PEROTTO J, 1971, J PROTOZOOL, V18, P470; PFEFFERKORN ER, 1983, CIBA F SYMP, V99, P74; POLLACK Y, 1985, EXP PARASITOL, V60, P270, DOI 10.1016/0014-4894(85)90031-1; Pongsaensook P, 1997, MUTAT RES-FUND MOL M, V377, P27, DOI 10.1016/S0027-5107(97)00055-9; Puiu D, 2004, NUCLEIC ACIDS RES, V32, pD329, DOI 10.1093/nar/gkh050; QUEEN SA, 1989, BIOCHIM BIOPHYS ACTA, V996, P160, DOI 10.1016/0167-4838(89)90242-2; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SAVARESE TM, 1987, BIOCHEM PHARMACOL, V36, P1881, DOI 10.1016/0006-2952(87)90484-9; Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; Schumacher MA, 1998, EMBO J, V17, P3219, DOI 10.1093/emboj/17.12.3219; SCHWAB JC, 1995, MOL BIOCHEM PARASIT, V70, P59, DOI 10.1016/0166-6851(95)00005-L; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Striepen B, 2004, P NATL ACAD SCI USA, V101, P3154, DOI 10.1073/pnas.0304686101; Striepen B, 2002, P NATL ACAD SCI USA, V99, P6304, DOI 10.1073/pnas.092525699; Sullivan WJ, 1999, MOL BIOCHEM PARASIT, V103, P1, DOI 10.1016/S0166-6851(99)00114-0; THOMAS CB, 1973, J BIOL CHEM, V248, P2529; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; VASANTHAKUMAR G, 1990, GENE, V91, P63, DOI 10.1016/0378-1119(90)90163-L; WANG CC, 1981, P NATL ACAD SCI-BIOL, V78, P6618, DOI 10.1073/pnas.78.11.6618; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	53	80	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31221	31227		10.1074/jbc.M404232200	http://dx.doi.org/10.1074/jbc.M404232200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140885	hybrid			2022-12-27	WOS:000222726800041
J	Dong, MQ; Pinon, DI; Cox, RF; Miller, LJ				Dong, MQ; Pinon, DI; Cox, RF; Miller, LJ			Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; AFFINITY HORMONE-BINDING; PARATHYROID-HORMONE; EXTRACELLULAR DOMAIN; SECRETIN RECEPTOR; SPATIAL APPROXIMATION; DIRECT IDENTIFICATION; CRITICAL DETERMINANTS; PHOTOLABILE RESIDUE; GLUCAGON RECEPTOR	The calcitonin receptor is a member of the class B family of G protein-coupled receptors, which contains numerous potentially important drug targets. Delineation of themes for agonist binding and activation of these receptors will facilitate the rational design of receptor-active drugs. We reported previously that a photolabile residue within the carboxyl-terminal half ( residue 26) and mid-region ( residue 16) of calcitonin covalently label the extracellular amino-terminal domain of this receptor ( Dong, M., Pinon, D. I., Cox, R. F., and Miller, L. J. ( 2004) J. Biol. Chem. 279, 1167 - 1175). Chimeric receptor studies support the importance of this region and suggest important contributions of extracellular loop domains. To examine whether other parts of the ligand may contact those loops, we developed another probe that has its photolabile site of labeling within the amino-terminal half in position 8 of the ligand. This probe was a full agonist (EC50 = 563 +/- 67 pM), stimulating cAMP accumulation in receptor-bearing human embryonic kidney 293 cells in a concentration-dependent manner. It bound specifically and saturably (K-i = 14.3 +/- 1.9 nM) and was able to efficiently label the calcitonin receptor. By purification, specific cleavage, and sequencing of labeled wild-type and mutant calcitonin receptors, the site of attachment was identified as residue Leu(368) within the third extracellular loop of the receptor, a domain distinct from that labeled by previous probes. These data are consistent with a common ligand binding mechanism for receptors in this important family.	Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA	Mayo Clinic; Mayo Clinic Phoenix; GlaxoSmithKline	Dong, MQ (corresponding author), Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Johnson Res Blgd,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	dongmq@mayo.edu			NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chauvin S, 2000, MOL PHARMACOL, V57, P625, DOI 10.1124/mol.57.3.625; DeAlmeida VI, 1998, MOL ENDOCRINOL, V12, P750, DOI 10.1210/me.12.5.750; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; EPAND RM, 1986, BIOCHEMISTRY-US, V25, P1964, DOI 10.1021/bi00356a019; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Hashimoto H, 1997, MOL PHARMACOL, V52, P128, DOI 10.1124/mol.52.1.128; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; Perret J, 2002, BIOCHEM J, V362, P389, DOI 10.1042/0264-6021:3620389; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Pham V, 2004, J BIOL CHEM, V279, P6720, DOI 10.1074/jbc.M307214200; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Pozvek G, 1997, MOL PHARMACOL, V51, P658, DOI 10.1124/mol.51.4.658; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; Runge S, 2003, BRIT J PHARMACOL, V138, P787, DOI 10.1038/sj.bjp.0705120; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sexton PM, 1999, CURR MED CHEM, V6, P1067; SEXTON PM, 1991, MOL NEUROBIOL, V5, P251, DOI 10.1007/BF02935550; Sohn J, 2003, J BIOL CHEM, V278, P47868, DOI 10.1074/jbc.M307751200; Sohn J, 2002, J BIOL CHEM, V277, P50165, DOI 10.1074/jbc.M207646200; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Suva LJ, 1997, J PHARMACOL EXP THER, V283, P876; Sydow S, 1999, EUR J BIOCHEM, V259, P55, DOI 10.1046/j.1432-1327.1999.00007.x; Unson CG, 2002, BIOCHEMISTRY-US, V41, P11795, DOI 10.1021/bi025711j; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200	60	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31177	31182		10.1074/jbc.M404113200	http://dx.doi.org/10.1074/jbc.M404113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155765	hybrid			2022-12-27	WOS:000222726800035
J	Grabar, TB; Cain, BD				Grabar, TB; Cain, BD			Genetic complementation between mutant b subunits in F1F0 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1F0-ATPASE; 2ND STALK; DIMERIZATION DOMAIN; MUTAGENIC ANALYSIS; MEMBRANE DOMAIN; EPSILON-SUBUNIT; F-0 SUBUNITS; H+-ATPASE; F-1-ATPASE; IDENTIFICATION	In Escherichia coli, a parallel homodimer of identical b subunits constitutes the peripheral stalk of F1F0 ATP synthase. Although the two b subunits have long been viewed as a single functional unit, the asymmetric nature of the enzyme complex suggested that the functional roles of each b subunit should not necessarily be considered equivalent. Previous mutagenesis studies of the peripheral stalk suffered from the fact that mutations in the uncF( b) gene affected both of the b subunits. We developed a system to express and study F1F0 ATP synthase complexes containing two different b subunits. Two mutations already known to inactivate the F1F0 ATP synthase complex have been studied using this experimental system. An evolutionarily conserved arginine, b(Arg-36), was known to be crucial for F1F0 ATP synthase function, and the last four C-terminal amino acids had been shown to be important for enzyme assembly. Experiments expressing one of the mutants with a wild type b subunit demonstrated the presence of heterodimers in F1F0 ATP synthase complexes. Activity assays suggested that the heterodimeric F1F0 complexes were functional. When the two defective b subunits were expressed together and in the absence of any wild type b subunit, an active F1F0 ATP synthase complex was assembled. This mutual complementation between fully defective b subunits indicated that each of the two b subunits makes a unique contribution to the functions of the peripheral stalk, such that one mutant b subunit is making up for what the other is lacking.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Cain, BD (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.	bcain@biochem.med.ufl.edu			NIGMS NIH HHS [R01GM43495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altendorf K, 2000, J EXP BIOL, V203, P19; ARIS JP, 1985, J BIOL CHEM, V260, P1207; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Deckers-Hebestreit G, 2000, BBA-BIOENERGETICS, V1458, P364, DOI 10.1016/S0005-2728(00)00087-6; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; Dimroth P, 2000, BBA-BIOENERGETICS, V1458, P374, DOI 10.1016/S0005-2728(00)00088-8; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Fillingame RH, 1999, NOVART FDN SYMP, V221, P218; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; Grabar TB, 2003, J BIOL CHEM, V278, P34751, DOI 10.1074/jbc.M303361200; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Hardy AW, 2003, J BIOENERG BIOMEMBR, V35, P389, DOI 10.1023/A:1027363012727; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Nath Sunil, 2002, Adv Biochem Eng Biotechnol, V74, P65; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Sabbert D, 1997, P NATL ACAD SCI USA, V94, P4401, DOI 10.1073/pnas.94.9.4401; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; Turina P, 2000, J BIOENERG BIOMEMBR, V32, P373, DOI 10.1023/A:1005528003709	36	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31205	31211		10.1074/jbc.M404420200	http://dx.doi.org/10.1074/jbc.M404420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159387	hybrid			2022-12-27	WOS:000222726800039
J	Sheng, SH; Perry, CJ; Kleyman, TR				Sheng, SH; Perry, CJ; Kleyman, TR			Extracellular Zn2+ activates epithelial Na+ channels by eliminating Na+ self-inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; SODIUM-CHANNEL; HISTIDINE-RESIDUES; CONVERTING-ENZYME; GAMMA-SUBUNIT; ALPHA-SUBUNIT; ION CHANNELS; ENAC; HYPERTENSION; BINDING	Inhibition of epithelial Na+ channel ( ENaC) activity by high concentrations of extracellular Na+ is referred to as Na+ self-inhibition. We investigated the effects of external Zn2+ on whole cell Na+ currents and on the Na+ self-inhibition response in Xenopus oocytes expressing mouse alphabetagamma ENaC. Na+ self-inhibition was examined by analyzing inward current decay from a peak current to a steady-state current following a fast switching of a low Na+ (1 mM) bath solution to a high Na+ (110 mM) solution. Our results indicate that external Zn2+ rapidly and reversibly activates ENaC in a dose-dependent manner with an estimated EC50 of 2 muM. External Zn2+ in the high Na+ bath also prevents or reverses Na+ self-inhibition with similar affinity. Zn2+ activation is dependent on extracellular Na+ concentration and is absent in ENaCs containing gammaH239 mutations that eliminate Na+ self-inhibition and in alphaS580Cbetagamma following covalent modification by a sulfhydryl-reactive reagent that locks the channels in a fully open state. In contrast, external Ni2+ inhibition of ENaC currents appears to be additive to Na+ self-inhibition when Ni2+ is present in the high Na+ bath. Pretreatment of oocytes with Ni2+ in a low Na+ bath also prevents the current decay following a switch to a high Na+ bath but rendered the currents below the control steady-state level measured in the absence of Ni2+ pretreatment. Our results suggest that external Zn2+ activates ENaC by relieving the channel from Na+ self-inhibition, and that external Ni2+ mimics or masks Na+ self-inhibition.	Univ Pittsburgh, Div Renal Electrolyte, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sheng, SH (corresponding author), Univ Pittsburgh, Div Renal Electrolyte, Dept Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.	shaohu@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702; Solvi, Cwyn/0000-0003-2517-6179	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Amuzescu B, 2003, PFLUG ARCH EUR J PHY, V446, P69, DOI 10.1007/s00424-002-0998-3; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Buchman AL, 1998, J AM COLL NUTR, V17, P124, DOI 10.1080/07315724.1998.10718737; Campbell JD, 2003, EMBO REP, V4, P1038, DOI 10.1038/sj.embor.7400003; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Cucu D, 2003, J MEMBRANE BIOL, V194, P33, DOI 10.1007/s00232-003-2023-y; Ekmekci OB, 2003, BIOL TRACE ELEM RES, V95, P203, DOI 10.1385/BTER:95:3:203; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GOOD DW, 1984, AM J PHYSIOL, V246, pF609, DOI 10.1152/ajprenal.1984.246.5.F609; Hu JX, 2002, CHEM COMMUN, P1810, DOI 10.1039/b204321c; JACKSON MJ, 1989, ZINC HUMAN BIOL, P1; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Matulef K, 2003, ANNU REV CELL DEV BI, V19, P23, DOI 10.1146/annurev.cellbio.19.110701.154854; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; POCOCK G, 1999, HUMAN PHYSL BASIS ME, P361; Quinteiro-Blondin S, 2001, GEN PHYSIOL BIOPHYS, V20, P331; Reifarth FW, 1999, BBA-BIOMEMBRANES, V1417, P63, DOI 10.1016/S0005-2736(98)00257-0; Riordan JF, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-225; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Schafer JA, 2002, AM J PHYSIOL-RENAL, V283, pF221, DOI 10.1152/ajprenal.00068.2002; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHOLTZ E, 1988, PFLUG ARCH EUR J PHY, V413, P174, DOI 10.1007/BF00582528; Segal A, 2002, FEBS LETT, V515, P177, DOI 10.1016/S0014-5793(02)02464-X; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Song YL, 2003, J GEN PHYSIOL, V122, P511, DOI 10.1085/jgp.200308866; TURNHEIM K, 1991, PHYSIOL REV, V71, P429, DOI 10.1152/physrev.1991.71.2.429; VANDRIESSCHE W, 1985, PHYSIOL REV, V65, P833, DOI 10.1152/physrev.1985.65.4.833; Vasilyev A, 2002, J MEMBRANE BIOL, V185, P237, DOI 10.1007/s00232-001-0126-x; Wagner CA, 2000, CELL PHYSIOL BIOCHEM, V10, P1, DOI 10.1159/000016341; ZOZAYA JLG, 1985, RES COMMUN CHEM PATH, V48, P445; Zozaya JLG, 2000, J HUM HYPERTENS, V14, pS100, DOI 10.1038/sj.jhh.1000995	37	42	45	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31687	31696		10.1074/jbc.M405224200	http://dx.doi.org/10.1074/jbc.M405224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145943	hybrid			2022-12-27	WOS:000222726800094
J	Vyas, S; Juin, P; Hancock, D; Suzuki, Y; Takahashi, R; Triller, A; Evan, G				Vyas, S; Juin, P; Hancock, D; Suzuki, Y; Takahashi, R; Triller, A; Evan, G			Differentiation-dependent sensitivity to apoptogenic factors in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CASPASE ACTIVATION; SYMPATHETIC NEURONS; SERINE-PROTEASE; STRUCTURAL BASIS; APOPTOSIS; DEATH; MITOCHONDRIA; RELEASE; XIAP	We have investigated the role of the mitochondrial pathway during cell death following serum and nerve growth factor (NGF)/dibutyryl cyclic AMP (Bt(2)cAMP) withdrawal in undifferentiated or NGF/Bt(2)cAMP-differentiated PC12 cells, respectively. Holocytochrome c, Smac/DIABLO, and Omi/ HtrA2 are released rapidly following trophic factor deprivation in PC12 cells. Bcl-2 and Akt inhibited this release. The protection, however, persisted longer in differentiated PC12 cells. In differentiated, but not undifferentiated cells, Bcl-2 and Akt also inhibited apoptosis downstream of holocytochrome c release. Thus, undifferentiated PC12 cells showed marked sensitivity to induction of apoptosis by microinjected cytochrome c even in the presence of NGF, Bcl-2, or Akt. In contrast, in differentiated cells these factors suppressed cell death. Consistent with these observations, in vitro processing of procaspase 9 in response to cytochrome c was observed in extracts from undifferentiated but not differentiated cells expressing Akt or Bcl-2. Endogenous caspase 9 was cleaved during cell death, whereas dominant negative caspase 9 inhibited cell death. The results from determining the role of inhibitors of apoptosis (IAPs) suggest that acquisition of inhibition by IAPs is part of the differentiation program. Ubiquitin-DeltaN-AVPI Smac/DIABLO induced cell death in differentiated cells only. c-IAP-2 is unregulated in differentiated cells, whereas X-linked IAP levels decreased in these cells coincident with cell death. Moreover, expressing X-linked IAP rendered undifferentiated cells resistant to microinjected cytochrome c. Overall, the inhibitory regulation, of cell death at the level of release of mitochondrial apoptogenic factors and at post-mitochondrial activation of caspase 9 observed in differentiated PC12 cells, is reduced or absent in the undifferentiated counterparts.	Ecole Normale Super, INSERM, U497, F-75005 Paris, France; INSERM, U419, F-44035 Nantes, France; Canc Res UK, Signal Transduct Lab, London WC2A 3PX, England; RIKEN, Brain Sci Inst, Lab Motor Syst Neurodegenerat, Wako, Saitama 3510198, Japan; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Institut National de la Sante et de la Recherche Medicale (Inserm); Cancer Research UK; RIKEN; University of California System; University of California San Francisco	Vyas, S (corresponding author), Ecole Normale Super, INSERM, U497, 46 Rue Ulm, F-75005 Paris, France.	vyas@wotan.ens.fr	JUIN, Philippe P/H-3636-2014; JUIN, Philippe/Q-1338-2019; Vyas, Sheela/M-4460-2017	JUIN, Philippe P/0000-0002-4997-3888; JUIN, Philippe/0000-0002-4997-3888; TRILLER, Antoine/0000-0002-7530-1233				Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de la Rosa EJ, 2000, TRENDS NEUROSCI, V23, P454, DOI 10.1016/S0166-2236(00)01628-3; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Deshmukh M, 2002, J NEUROSCI, V22, P8018; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; JIN S, 2003, GENE DEV, V17, P1; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; MICHEL PP, 1995, EUR J NEUROSCI, V7, P251, DOI 10.1111/j.1460-9568.1995.tb01061.x; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Potts PR, 2003, J CELL BIOL, V163, P789, DOI 10.1083/jcb.200307130; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Roth KA, 2000, P NATL ACAD SCI USA, V97, P466, DOI 10.1073/pnas.97.1.466; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Stefanis L, 1997, J NEUROCHEM, V69, P1425; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Troy CM, 1997, J NEUROSCI, V17, P1911; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vyas S, 2002, MOL CELL NEUROSCI, V21, P1, DOI 10.1006/mcne.2002.1170; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001	52	34	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30983	30993		10.1074/jbc.M400692200	http://dx.doi.org/10.1074/jbc.M400692200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133027	hybrid			2022-12-27	WOS:000222726800011
J	Wang, YJ; Schattenberg, JM; Rigolo, RM; Storz, P; Czaja, MJ				Wang, YJ; Schattenberg, JM; Rigolo, RM; Storz, P; Czaja, MJ			Hepatocyte resistance to oxidative stress is dependent on protein kinase C-mediated down-regulation of c-Jun/AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATION LOOP SER(744); JUN NH2-TERMINAL KINASE; TYROSINE PHOSPHORYLATION; SENSITIZES HEPATOCYTES; INDUCED APOPTOSIS; TUMOR-NECROSIS; INTACT-CELLS; TNF-ALPHA; EXPRESSION	The prevention of injury from reactive oxygen species is critical for cellular resistance to many death stimuli. Resistance to death from the superoxide generator menadione in the hepatocyte cell line RALA255-10G is dependent on down-regulation of the c-Jun N-terminal kinase (JNK)/AP-1 signaling pathway by extracellular signal-regulated kinase 1/2 (ERK1/2). Because protein kinase C (PKC) regulates both oxidant stress and JNK signaling, the ability of PKC to modulate hepatocyte death from menadione through effects on AP-1 was examined. PKC inhibition with Ro-31-8425 or bisindolylmaleimide I sensitized this cell line to death from menadione. Menadione treatment led to activation of PKCmu, or protein kinase D (PKD), but not PKCalpha/beta, PKCzeta/lambda, or PKCdelta/theta. Menadione induced phosphorylation of PKD at Ser-744/748, but not Ser-916, and translocation of PKD to the nucleus. PKC inhibition blocked menadione-induced phosphorylation of PKD, and expression of a constitutively active PKD prevented death from Ro-31-8425/ menadione. PKC inhibition led to a sustained overactivation of JNK and c-Jun in response to menadione as determined by in vitro kinase assay and immunoblotting for the phosphorylated forms of both proteins. Cell death from PKC inhibition and menadione treatment resulted from c-Jun activation, since death was blocked by adenoviral expression of the c-Jun dominant negative TAM67. PKC and ERK1/2 independently down-regulated JNK/c-Jun, since inhibition of either kinase failed to affect activation of the other kinase, and simultaneous inhibition of both pathways caused additive JNK/c-Jun activation and cell death. Resistance to death from superoxide therefore requires both PKC/PKD and ERK1/2 activation in order to down-regulate proapoptotic JNK/c-Jun signaling.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School	Czaja, MJ (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	czaja@aecom.yu.edu	Schattenberg, Jörn M./C-1301-2013	Schattenberg, Jörn M./0000-0002-4224-4703	NIDDK NIH HHS [DK44234, R01 DK044234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bradham CA, 2001, AM J PHYSIOL-GASTR L, V281, pG1279, DOI 10.1152/ajpgi.2001.281.5.G1279; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; CHOU JY, 1987, CANCER RES, V47, P5415; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; Czaja MJ, 2003, HEPATOLOGY, V37, P1405, DOI 10.1053/jhep.2003.50233; Czaja MJ, 2003, AM J PHYSIOL-GASTR L, V284, pG875, DOI 10.1152/ajpgi.00549.2002; Czaja MJ, 2002, ANTIOXID REDOX SIGN, V4, P759, DOI 10.1089/152308602760598909; Duke RC, 1992, CURR PROT IMMUNOL S3, V17, P1; Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Jones BE, 2000, AM J PHYSIOL-GASTR L, V278, pG693, DOI 10.1152/ajpgi.2000.278.5.G693; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Lee SK, 1998, J BIOL CHEM, V273, P19829, DOI 10.1074/jbc.273.31.19829; LIU H, 2002, AM J PHYSIOL, V2582, pG257; Liu HL, 2002, HEPATOLOGY, V35, P772, DOI 10.1053/jhep.2002.32534; Liu HL, 2000, J BIOL CHEM, V275, P40155, DOI 10.1074/jbc.M001565200; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Meier UT, 1996, J BIOL CHEM, V271, P19376; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; THOR H, 1982, J BIOL CHEM, V257, P2419; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	48	68	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31089	31097		10.1074/jbc.M404170200	http://dx.doi.org/10.1074/jbc.M404170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145937	hybrid			2022-12-27	WOS:000222726800024
J	Cam, JA; Zerbinatti, CV; Knisely, JM; Hecimovic, S; Li, YH; Bu, GJ				Cam, JA; Zerbinatti, CV; Knisely, JM; Hecimovic, S; Li, YH; Bu, GJ			The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR; ALZHEIMERS-DISEASE; GENETIC ASSOCIATION; LRP; ENDOCYTOSIS; BINDING; ALPHA-2-MACROGLOBULIN; POLYMORPHISM; TRAFFICKING; EXPRESSION	The low density lipoprotein (LDL) receptor-related protein 1B (LRP1B) is a newly identified member of the LDL receptor family that shares high homology with the LDL receptor-related protein (LRP). LRP1B was originally described as a putative tumor suppressor in lung cancer cells; however, its expression profile in several regions of adult human brain suggests it may have additional functions in the central nervous system. Since LRP1B has overlapping ligand binding properties with LRP, we investigated whether LRP1B, like LRP, could interact with the beta-amyloid precursor protein (APP) and modulate its processing to amyloid-beta peptides (Abetas). Using an LRP1B minireceptor (mLRP1B4) generated to study the trafficking of LRP1B, we found that mLRP1B4 and APP form an immunoprecipitable complex. Furthermore mLRP1B4 bound and facilitated the degradation of a soluble isoform of APP containing a Kunitz proteinase inhibitor domain but not soluble APP lacking a Kunitz proteinase inhibitor domain. A functional consequence of mLRP1B4 expression was a significant accumulation of APP at the cell surface, which is likely related to the slow endocytosis rate of LRP1B. More importantly, mLRP1B4-expressing cells that accumulated cell surface APP produced less Abeta and secreted more soluble APP. These findings reveal that LRP1B is a novel binding partner of APP that functions to decrease APP processing to Abeta. Consequently LRP1B expression could function to protect against the pathogenesis of Alzheimer's disease.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, Campus Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	bu@kids.wustl.edu	Hecimovic, Silva/T-8091-2017	Hecimovic, Silva/0000-0001-6077-433X	NIA NIH HHS [P50 AG05681] Funding Source: Medline; NINDS NIH HHS [NS41872] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS041872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BU GJ, 1994, J BIOL CHEM, V269, P18521; Bu GJ, 2001, INT REV CYTOL, V209, P79; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x; HECIMOVIC S, 2004, IN PRESS NEUROBIOL D; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; JIN LW, 1994, J NEUROSCI, V14, P5461; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Li YH, 2002, J BIOL CHEM, V277, P42366, DOI 10.1074/jbc.M207705200; Li YH, 2001, MOL NEUROBIOL, V23, P53; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liao A, 1998, HUM MOL GENET, V7, P1953, DOI 10.1093/hmg/7.12.1953; Liu CX, 2000, CANCER RES, V60, P1961; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Marzolo MP, 2000, J NEUROSCI RES, V60, P401, DOI 10.1002/(SICI)1097-4547(20000501)60:3<401::AID-JNR15>3.3.CO;2-C; Narita M, 1997, J NEUROCHEM, V69, P1904; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Qiu ZH, 2001, J NEUROPATH EXP NEUR, V60, P430, DOI 10.1093/jnen/60.5.430; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WavrantDeVrieze F, 1997, NEUROSCI LETT, V227, P68, DOI 10.1016/S0304-3940(97)00304-2; Yamazaki T, 1996, J CELL SCI, V109, P999; ZAGURSKY RJ, 1995, BIOTECHNIQUES, V18, P504; Zerbinatti CV, 2004, P NATL ACAD SCI USA, V101, P1075, DOI 10.1073/pnas.0305803101	41	88	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29639	29646		10.1074/jbc.M313893200	http://dx.doi.org/10.1074/jbc.M313893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15126508	hybrid			2022-12-27	WOS:000222445300100
J	Denissova, NG; Liu, F				Denissova, NG; Liu, F			Repression of endogenous Smad7 by Ski	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; ANAPHASE-PROMOTING COMPLEX; TGF-BETA RECEPTOR; C-SKI; TRANSCRIPTIONAL REPRESSION; MEDIATED REPRESSION; ONCOPROTEIN SKI; ACTIVATED STAT; SNON; ANTAGONIST	The Ski protein has been proposed to serve as a corepressor for Smad4 to maintain a transforming growth factor-beta (TGF-beta)-responsive promoter at a repressed, basal level. However, there have been no reports so far that it indeed acts on a natural promoter. We have previously cloned the human Smad7 promoter and shown that it contains the 8-base pair palindromic Smad-binding element (SBE) necessary for TGF-beta induction. In this report, we have characterized the negative regulation of Smad7 promoter basal activity by Ski. We show that Ski inhibits the Smad7 promoter basal activity in a SBE-dependent manner. Mutation of the SBE abrogates the inhibitory effect of Ski on the Smad7 promoter. Moreover, mutation of the SBE increases the Smad7 promoter basal activity. Using the chromatin immunoprecipitation assay, we further show that Ski together with Smad4 binds to the endogenous Smad7 promoter. Finally, we show that RNAi knockdown of Ski increases Smad7 reporter gene activity in transient transfection assays as well as elevating the endogenous level of Smad7 mRNA. Taken together, our results provide the first evidence that Ski is indeed a corepressor for Smad4, which can inhibit a natural TGF-beta responsive gene at the basal state.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Grad Program Mol & Cellular Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, F (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Ln, Piscataway, NJ 08854 USA.	fangliu@cabm.rutgers.edu						Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Dai P, 2002, GENE DEV, V16, P2843, DOI 10.1101/gad.1017302; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; Frederick JP, 2002, STRUCTURE, V10, P1607, DOI 10.1016/S0969-2126(02)00914-0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; He W, 2002, EMBO J, V21, P2580, DOI 10.1093/emboj/21.11.2580; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ueki N, 2003, J BIOL CHEM, V278, P32489, DOI 10.1074/jbc.C300276200; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang BQ, 2002, AM J PHYSIOL-HEART C, V282, pH1685, DOI 10.1152/ajpheart.00266.2001; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	40	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28143	28148		10.1074/jbc.M404961200	http://dx.doi.org/10.1074/jbc.M404961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15128733	hybrid			2022-12-27	WOS:000222265400041
J	Konishi, A; Aizawa, T; Mohan, A; Korshunov, VA; Berk, BC				Konishi, A; Aizawa, T; Mohan, A; Korshunov, VA; Berk, BC			Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ARREST-SPECIFIC GENE-6; AXL TYROSINE KINASE; ANGIOTENSIN-II; SPLICE VARIANT; IN-VIVO; PROTEIN; INJURY; EXPRESSION; TRANSACTIVATION	Axl, a receptor tyrosine kinase, is involved in cell survival, proliferation, and migration. We have shown that Axl expression increases in the neointima of balloon-injured rat carotids. Because oxidative stress is known to play a major role in remodeling of injured vessels, we hypothesized that H2O2 might activate Axl by promoting autophosphorylation. H2O2 rapidly stimulated Axl tyrosine phosphorylation in rat vascular smooth muscle cells within 1 min that was maximal at 5 min (6-fold). The response to H2O2 was concentration-dependent with EC50 of similar to500 muM. Axl phosphorylation was partly dependent on production of its endogenous ligand, growth arrest gene 6 (Gas6), because Axl-Fc, a fragment of Axl extracellular domain that neutralizes Gas6, inhibited H2O2-induced Axl phosphorylation by 50%. Axl phosphorylation by H2O2 was also attenuated by warfarin, which inhibits Gas6 activity by preventing post-translational modification. In intact vessels Axl was phosphorylated by H2O2, and Axl phosphorylation was inhibited by warfarin treatment in balloon-injured carotids. Akt, a downstream target of Axl, was phosphorylated by H(2)O(2)in Axl(+/+) mouse aorta but significantly inhibited in Axl(-/-) aorta. Intimal proliferation was decreased significantly in a cuff injury model in Axl(-/-) mice compared with Axl(+/+) mice. In summary, Axl is an important signaling mediator for oxidative stress in cultured vascular smooth muscle cells and intact vessels and may represent an important therapeutic target for vascular remodeling and response to injury.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HL 49192, HL 63462] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063462, R01HL049192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1997, CIRCULATION, V96, P1906, DOI 10.1161/01.CIR.96.6.1906; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Fiebeler A, 2004, AM J KIDNEY DIS, V43, P286, DOI 10.1053/j.ajkd.2003.10.016; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, FEBS LETT, V415, P59, DOI 10.1016/S0014-5793(97)01093-4; Hafizi S, 2002, BIOCHEM BIOPH RES CO, V299, P793, DOI 10.1016/S0006-291X(02)02718-3; Hatton MWC, 1998, ARTERIOSCL THROM VAS, V18, P816, DOI 10.1161/01.ATV.18.5.816; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Kalmes A., 2001, ANN NY ACAD SCI, V947, P54; Konishi A, 2003, J BIOL CHEM, V278, P35049, DOI 10.1074/jbc.M304913200; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; Marcandalli P, 1997, FEBS LETT, V415, P56, DOI 10.1016/S0014-5793(97)01094-6; Melaragno MG, 1998, CIRC RES, V83, P697, DOI 10.1161/01.RES.83.7.697; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Nagai K, 2003, J BIOL CHEM, V278, P18229, DOI 10.1074/jbc.M213266200; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; Nakano T, 1997, BIOCHEM J, V323, P387, DOI 10.1042/bj3230387; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; PASTORE CJ, 1995, CIRC RES, V77, P519, DOI 10.1161/01.RES.77.3.519; Pollman MJ, 1999, CIRC RES, V84, P113; Rao GN, 1997, CELL SIGNAL, V9, P181, DOI 10.1016/S0898-6568(96)00139-8; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Saito S, 2002, J BIOL CHEM, V277, P44695, DOI 10.1074/jbc.M208332200; Sata M, 2003, TRENDS CARDIOVAS MED, V13, P249, DOI 10.1016/S1050-1738(03)00106-3; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Uchiyama-Tanaka Y, 2001, KIDNEY INT, V60, P2153, DOI 10.1046/j.1523-1755.2001.00067.x; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X; Yin JL, 2002, TRANSPLANTATION, V73, P657, DOI 10.1097/00007890-200202270-00032	35	71	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28766	28770		10.1074/jbc.M401977200	http://dx.doi.org/10.1074/jbc.M401977200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15123721	hybrid			2022-12-27	WOS:000222265400114
J	Shimaoka, T; Nakayama, T; Hieshima, K; Kume, N; Fukumoto, N; Minami, M; Hayashida, K; Kita, T; Yoshie, O; Yonehara, S				Shimaoka, T; Nakayama, T; Hieshima, K; Kume, N; Fukumoto, N; Minami, M; Hayashida, K; Kita, T; Yoshie, O; Yonehara, S			Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ANTIMICROBIAL ACTIVITY; CXC CHEMOKINES; MICE REVEALS; CUTTING EDGE; ATHEROSCLEROSIS; FRACTALKINE; GALECTIN-3; ADHESION; IMMUNITY	Chemokines are a family of cytokines that induce directed migration of various types of leukocytes through specific interactions with a group of seven transmembrane receptors. Scavenger receptors are a heterogenous family of transmembrane molecules that commonly bind and uptake oxidized low density lipoprotein and bacteria. Here, we show that not only CXC chemokine 16 (CXCL16)/SR-PSOX, a transmembrane chemokine with scavenger receptor activity, but also 12 out of 15 chemokines examined efficiently bound scavenger receptor ligands in competition with cells expressing their specific chemokine receptors. Furthermore both the chemotactic and scavenger receptor activities of SR-PSOX/CXCL16 were similarly impaired in a series of mutants altered in the chemokine domain, indicating that SR-PSOX/CXCL16 binds scavenger receptor ligands as well as CXCR6 using highly overlapping binding motifs. Taken together, chemokines generally have scavenger receptor-like activity through their receptor-binding domain, suggesting a close evolutionary relationship between chemokines and scavenger receptors.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kinki Univ, Sch Med, Dept Microbiol, Osaka 5898511, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kindai University (Kinki University); Kyoto University	Yonehara, S (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Shogoin Kawahara Cho 53, Kyoto 6068507, Japan.	syonehar@virus.kyoto-u.ac.jp	Hieshima, Kunio/AAF-7040-2019	Hieshima, Kunio/0000-0002-7786-4646; Yoshie, Osamu/0000-0003-4353-5809				Alcouffe J, 1999, J LIPID RES, V40, P1200; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Durr M, 2002, INFECT IMMUN, V70, P6515, DOI 10.1128/IAI.70.12.6515-6517.2002; Gotoh O, 1999, ADV BIOPHYS, V36, P159, DOI 10.1016/S0065-227X(99)80007-0; Gough PJ, 2000, MICROBES INFECT, V2, P305, DOI 10.1016/S1286-4579(00)00297-5; Harrison JK, 2001, J BIOL CHEM, V276, P21632, DOI 10.1074/jbc.M010261200; Hieshima K, 2003, J IMMUNOL, V170, P1452, DOI 10.4049/jimmunol.170.3.1452; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Krijgsveld J, 2000, J BIOL CHEM, V275, P20374, DOI 10.1074/jbc.275.27.20374; Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; Mey A, 1996, J IMMUNOL, V156, P1572; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Shimaoka T, 2003, J IMMUNOL, V171, P1647, DOI 10.4049/jimmunol.171.4.1647; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; Shimaoka T, 2004, J LEUKOCYTE BIOL, V75, P267, DOI 10.1189/jlb.1003465; Steinbrecher UP, 1999, BBA-MOL CELL BIOL L, V1436, P279, DOI 10.1016/S0005-2760(98)00127-1; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; Wilbanks A, 2001, J IMMUNOL, V166, P5145, DOI 10.4049/jimmunol.166.8.5145; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zhu WQ, 2001, BIOCHEM BIOPH RES CO, V280, P1183, DOI 10.1006/bbrc.2001.4256; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	28	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26807	26810		10.1074/jbc.C400163200	http://dx.doi.org/10.1074/jbc.C400163200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15128749	hybrid			2022-12-27	WOS:000222120400002
